21
Part 500 to 599
Revised as of April 1, 2002

Food and Drugs
Containing a codification of documents
of general applicability and future effect
As of April 1, 2002

With Ancillaries
Published by
Office of the Federal Register
National Archives and Records Administration
A Special Edition of the Federal Register
# Table of Contents

<table>
<thead>
<tr>
<th>Explanation</th>
<th>v</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title 21:</td>
<td></td>
</tr>
<tr>
<td>Chapter I—Food and Drug Administration, Department of Health and Human Services (Continued)</td>
<td>3</td>
</tr>
<tr>
<td>Finding Aids:</td>
<td></td>
</tr>
<tr>
<td>Material Approved for Incorporation by Reference</td>
<td>539</td>
</tr>
<tr>
<td>Table of CFR Titles and Chapters</td>
<td>541</td>
</tr>
<tr>
<td>Alphabetical List of Agencies Appearing in the CFR</td>
<td>559</td>
</tr>
<tr>
<td>Redesignation Table</td>
<td>569</td>
</tr>
<tr>
<td>List of CFR Sections Affected</td>
<td>571</td>
</tr>
</tbody>
</table>
Cite this Code: CFR

To cite the regulations in this volume use title, part and section number. Thus, 21 CFR 500.23 refers to title 21, part 500, section 23.
Explanation

The Code of Federal Regulations is a codification of the general and permanent rules published in the Federal Register by the Executive departments and agencies of the Federal Government. The Code is divided into 50 titles which represent broad areas subject to Federal regulation. Each title is divided into chapters which usually bear the name of the issuing agency. Each chapter is further subdivided into parts covering specific regulatory areas.

Each volume of the Code is revised at least once each calendar year and issued on a quarterly basis approximately as follows:

- Title 1 through Title 16..............................................................as of January 1
- Title 17 through Title 27 .................................................................as of April 1
- Title 28 through Title 41 ...............................................................as of July 1
- Title 42 through Title 50.............................................................as of October 1

The appropriate revision date is printed on the cover of each volume.

LEGAL STATUS

The contents of the Federal Register are required to be judicially noticed (44 U.S.C. 1507). The Code of Federal Regulations is prima facie evidence of the text of the original documents (44 U.S.C. 1510).

HOW TO USE THE CODE OF FEDERAL REGULATIONS

The Code of Federal Regulations is kept up to date by the individual issues of the Federal Register. These two publications must be used together to determine the latest version of any given rule.

To determine whether a Code volume has been amended since its revision date (in this case, April 1, 2002), consult the “List of CFR Sections Affected (LSA),” which is issued monthly, and the “Cumulative List of Parts Affected,” which appears in the Reader Aids section of the daily Federal Register. These two lists will identify the Federal Register page number of the latest amendment of any given rule.

EFFECTIVE AND EXPIRATION DATES

Each volume of the Code contains amendments published in the Federal Register since the last revision of that volume of the Code. Source citations for the regulations are referred to by volume number and page number of the Federal Register and date of publication. Publication dates and effective dates are usually not the same and care must be exercised by the user in determining the actual effective date. In instances where the effective date is beyond the cut-off date for the Code a note has been inserted to reflect the future effective date. In those instances where a regulation published in the Federal Register states a date certain for expiration, an appropriate note will be inserted following the text.

OMB CONTROL NUMBERS

The Paperwork Reduction Act of 1980 (Pub. L. 96-511) requires Federal agencies to display an OMB control number with their information collection request.
Many agencies have begun publishing numerous OMB control numbers as amendments to existing regulations in the CFR. These OMB numbers are placed as close as possible to the applicable recordkeeping or reporting requirements.

**OBSOLETE PROVISIONS**

Provisions that become obsolete before the revision date stated on the cover of each volume are not carried. Code users may find the text of provisions in effect on a given date in the past by using the appropriate numerical list of sections affected. For the period before January 1, 1986, consult either the List of CFR Sections Affected, 1949–1963, 1964–1972, or 1973–1985, published in seven separate volumes. For the period beginning January 1, 1986, a “List of CFR Sections Affected” is published at the end of each CFR volume.

**INCORPORATION BY REFERENCE**

*What is incorporation by reference?* Incorporation by reference was established by statute and allows Federal agencies to meet the requirement to publish regulations in the Federal Register by referring to materials already published elsewhere. For an incorporation to be valid, the Director of the Federal Register must approve it. The legal effect of incorporation by reference is that the material is treated as if it were published in full in the Federal Register (5 U.S.C. 552(a)). This material, like any other properly issued regulation, has the force of law.

*What is a proper incorporation by reference?* The Director of the Federal Register will approve an incorporation by reference only when the requirements of 1 CFR part 51 are met. Some of the elements on which approval is based are:

(a) The incorporation will substantially reduce the volume of material published in the Federal Register.

(b) The matter incorporated is in fact available to the extent necessary to afford fairness and uniformity in the administrative process.

(c) The incorporating document is drafted and submitted for publication in accordance with 1 CFR part 51.

Properly approved incorporations by reference in this volume are listed in the Finding Aids at the end of this volume.

*What if the material incorporated by reference cannot be found?* If you have any problem locating or obtaining a copy of material listed in the Finding Aids of this volume as an approved incorporation by reference, please contact the agency that issued the regulation containing that incorporation. If, after contacting the agency, you find the material is not available, please notify the Director of the Federal Register, National Archives and Records Administration, Washington DC 20408, or call (202) 523–4534.

**CFR INDEXES AND TABULAR GUIDES**

A subject index to the Code of Federal Regulations is contained in a separate volume, revised annually as of January 1, entitled CFR INDEX AND FINDING AIDS. This volume contains the Parallel Table of Statutory Authorities and Agency Rules (Table I). A list of CFR titles, chapters, and parts and an alphabetical list of agencies publishing in the CFR are also included in this volume.

An index to the text of “Title 3—The President” is carried within that volume.

The Federal Register Index is issued monthly in cumulative form. This index is based on a consolidation of the “Contents” entries in the daily Federal Register.

A List of CFR Sections Affected (LSA) is published monthly, keyed to the revision dates of the 50 CFR titles.

vi
REPUBLICATION OF MATERIAL

There are no restrictions on the republication of material appearing in the Code of Federal Regulations.

INQUIRIES

For a legal interpretation or explanation of any regulation in this volume, contact the issuing agency. The issuing agency’s name appears at the top of odd-numbered pages.

For inquiries concerning CFR reference assistance, call 202-523-5227 or write to the Director, Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408 or e-mail info@fedreg.nara.gov.

SALES

The Government Printing Office (GPO) processes all sales and distribution of the CFR. For payment by credit card, call 202–512–1800, M–F, 8 a.m. to 4 p.m. e.s.t. or fax your order to 202–512–2250, 24 hours a day. For payment by check, write to the Superintendent of Documents, Attn: New Orders, P.O. Box 371954, Pittsburgh, PA 15250–7954. For GPO Customer Service call 202–512–1803.

ELECTRONIC SERVICES


The Office of the Federal Register also offers a free service on the National Archives and Records Administration’s (NARA) World Wide Web site for public law numbers, Federal Register finding aids, and related information. Connect to NARA’s web site at www.nara.gov/fedreg. The NARA site also contains links to GPO Access.

RAYMOND A. MOSLEY,
Director,
Office of the Federal Register.

April 1, 2002.
THIS TITLE

Title 21—FOOD AND DRUGS is composed of nine volumes. The parts in these volumes are arranged in the following order: Parts 1–99, 100–169, 170–199, 200–299, 300–499, 500–599, 600–799, 800–1299 and 1300-end. The first eight volumes, containing parts 1–1299, comprise Chapter I—Food and Drug Administration, Department of Health and Human Services. The ninth volume, containing part 1300 to end, includes Chapter II—Drug Enforcement Administration, Department of Justice, and Chapter III—Office of National Drug Control Policy. The contents of these volumes represent all current regulations codified under this title of the CFR as of April 1, 2002.

Redesignation tables for Chapter I—Food and Drug Administration appear in the Finding Aids section for the volumes containing parts 170–199 and 500–599.
Would you like to know...

if any changes have been made to the Code of Federal Regulations or what documents have been published in the Federal Register without reading the Federal Register every day? If so, you may wish to subscribe to the LSA (List of CFR Sections Affected), the Federal Register Index, or both.

LSA
The LSA (List of CFR Sections Affected) is designed to lead users of the Code of Federal Regulations to amending actions published in the Federal Register. The LSA is issued monthly in cumulative form. Entries indicate the nature of the changes—such as revised, removed, or corrected. $31 per year.

Federal Register Index
The index, covering the contents of the daily Federal Register, is issued monthly in cumulative form. Entries are carried primarily under the names of the issuing agencies. Significant subjects are carried as cross-references. $28 per year.

A finding aid is included in each publication which lists Federal Register page numbers with the date of publication in the Federal Register.

Superintendent of Documents Subscription Order Form

Order Processing Code: YES, send me the following indicated subscriptions for one year:

____ LSA (List of CFR Sections Affected), (LCS) for $31 per year.

____ Federal Register Index (FRSU) $28 per year.

(Includes regular shipping and handling.)

For privacy check box below:

☐ Do not make my name available to other mailers.

Check method of payment:

☐ Check payable to Superintendent of Documents

☐ GPO Deposit Account

☐ VISA ☐ MasterCard

Expiration date)

Credit card No. (must be 20 digits)

Thank you for your order!

Authorized signature

Mail To: Superintendent of Documents
P.O. Box 371954
Pittsburgh, PA 15250-7954

Fax your orders (202) 512-2250
Phone your orders (202) 512-1800
Title 21—Food and Drugs

(This book contains parts 500 to 599)

CHAPTER I—Food and Drug Administration, Department of Health and Human Services (Continued) ........................... 500

CROSS REFERENCES: Animal and Plant Health Inspection Service, Department of Agriculture: See Animals and Animal Products, 9 CFR chapter I.
Food Safety and Inspection Service, Meat and Poultry Inspection, Department of Agriculture: See Animals and Animal Products, 9 CFR chapter III.
U.S. Customs Service, Department of the Treasury: See Customs Duties, 19 CFR chapter I.
Internal Revenue Service, Department of the Treasury: See Internal Revenue, 26 CFR chapter I.
Bureau of Alcohol, Tobacco, and Firearms, Department of the Treasury: See Alcohol, Tobacco Products and Firearms, 27 CFR chapter I.
CHAPTER I—FOOD AND DRUG
ADMINISTRATION, DEPARTMENT OF HEALTH
AND HUMAN SERVICES (CONTINUED)

Editorial Note: For nomenclature changes to chapter I, see 59 FR 14366, Mar. 28, 1994.

SUBCHAPTER E—ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS

<table>
<thead>
<tr>
<th>Part</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>500</td>
<td>General ................................................................. 5</td>
</tr>
<tr>
<td>501</td>
<td>Animal food labeling ............................................. 14</td>
</tr>
<tr>
<td>502</td>
<td>Common or usual names for nonstandardized animal foods .................................................. 31</td>
</tr>
<tr>
<td>509</td>
<td>Unavoidable contaminants in animal food and food-packaging material ................................ 33</td>
</tr>
<tr>
<td>510</td>
<td>New animal drugs ..................................................... 37</td>
</tr>
<tr>
<td>511</td>
<td>New animal drugs for investigational use ................... 52</td>
</tr>
<tr>
<td>514</td>
<td>New animal drug applications ................................... 56</td>
</tr>
<tr>
<td>515</td>
<td>Medicated feed mill license ...................................... 88</td>
</tr>
<tr>
<td>520</td>
<td>Oral dosage form new animal drugs ............................ 92</td>
</tr>
<tr>
<td>522</td>
<td>Implantation or injectable dosage form new animal drugs ..................................................... 213</td>
</tr>
<tr>
<td>524</td>
<td>Ophthalmic and topical dosage form new animal drugs .......................................................... 290</td>
</tr>
<tr>
<td>526</td>
<td>Intramammary dosage forms ...................................... 317</td>
</tr>
<tr>
<td>529</td>
<td>Certain other dosage form new animal drugs ............... 323</td>
</tr>
<tr>
<td>530</td>
<td>Extralabel drug use in animals .................................. 328</td>
</tr>
<tr>
<td>556</td>
<td>Tolerances for residues of new animal drugs in food .......... 334</td>
</tr>
<tr>
<td>558</td>
<td>New animal drugs for use in animal feeds .................... 354</td>
</tr>
<tr>
<td>564</td>
<td>[Reserved]</td>
</tr>
<tr>
<td>570</td>
<td>Food additives .......................................................... 477</td>
</tr>
<tr>
<td>571</td>
<td>Food additive petitions ............................................. 484</td>
</tr>
<tr>
<td>573</td>
<td>Food additives permitted in feed and drinking water of animals ............................................... 489</td>
</tr>
<tr>
<td>579</td>
<td>Irradiation in the production, processing, and handling of animal feed and pet food .................. 506</td>
</tr>
<tr>
<td>582</td>
<td>Substances generally recognized as safe .................... 507</td>
</tr>
<tr>
<td>584</td>
<td>Food substances affirmed as generally recognized as safe in feed and drinking water of animals .... 532</td>
</tr>
<tr>
<td>Part</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>589</td>
<td>Substances prohibited from use in animal food or feed</td>
</tr>
<tr>
<td>590–599</td>
<td>[Reserved]</td>
</tr>
</tbody>
</table>
§ 500.23 Thermally processed low-acid foods packaged in hermetically sealed containers.

The provisions of part 113 of this chapter shall apply to the manufacture, processing or packing of low-acid foods in hermetically sealed containers, and intended for use as food for animals.

[61 FR 37681, July 19, 1996]

§ 500.24 Emergency permit control.

The provisions of part 108 of this chapter shall apply to the issuance of emergency control permits for the manufacturer or packer of thermally processed low-acid foods packaged in hermetically sealed containers, and intended for use as food for animals.

[61 FR 37681, July 19, 1996]

§ 500.25 Anthelmintic drugs for use in animals.

(a) The Commissioner of Food and Drugs has determined that, in order to assure that anthelmintic drugs, including animal feeds bearing or containing such drugs, which do not carry the prescription statement are labeled to provide adequate directions for their effective use, labeling of these anthelmintic drugs shall bear, in addition to other required information, a statement that a veterinarian should be consulted for assistance in the diagnosis, treatment, and control of parasitism.

(b) The label and any labeling furnishing or purporting to furnish directions for use, shall bear conspicuously the following statement: “Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.”
§ 500.26 Timed-release dosage form drugs.

(a) Drugs are being offered in dosage forms that are designed to release the active ingredients over a prolonged period of time. There is a possibility of unsafe overdosage or ineffectual dosage if such products are improperly made and the active ingredients are released at one time, over too short or too long a period of time, or not released at all. Drugs marketed in this form, which are referred to by such terms as timed-release, controlled-release, prolonged-release, sustained-release, or delayed-release drugs, are regarded as new animal drugs within the meaning of section 201(v) of the Federal Food, Drug, and Cosmetic Act.

(b) Timed-release dosage form animal drugs that are introduced into interstate commerce are deemed to be adulterated within the meaning of section 501(a)(5) of the act and subject to regulatory action unless such animal drug is the subject of an approved new animal drug application as required by paragraph (a) of this section.

(c) The fact that the labeling of this kind of drug may claim delayed, prolonged, controlled, or sustained-release of all or only some of the active ingredients does not affect the new animal drug status of such articles. A new animal drug application is required in any such case.

(d) New animal drug applications for timed-release dosage form animal drugs must contain, among other things, data to demonstrate safety and effectiveness by establishing that the article is manufactured using procedures and controls to ensure release of the total dosage at a safe and effective rate. Data submitted in the new animal drug application must demonstrate that the formulation of the drug and the procedures used in its manufacture will ensure release of the active ingredient(s) of the drug at a safe and effective rate and that these release characteristics will be maintained until the expiration date of the drug. When the drug is intended for use in food-producing animals, data submitted must also demonstrate that, with respect to possible residues of the drug, food derived from treated animals is safe for consumption.

§ 500.27 Methylene blue-containing drugs for use in animals.

(a) New information requires a reevaluation of the status of drugs containing methylene blue (tetramethylthionine chloride) for oral use in cats or dogs.

(1)(i) It has been demonstrated that two orally administered urinary antiseptic-antispasmodic preparations that contained methylene blue cause Heinz body hemolytic anemia in cats when used according to label directions. The specific cause of the reaction was determined to be the methylene blue contained in the preparations. The reaction can be severe enough to cause death of treated animals.

(ii) The Heinz body hemolytic anemia reaction to methylene blue has also been demonstrated in dogs under laboratory conditions. The precise mechanism by which methylene blue produces the characteristic erythrocytic inclusion bodies (Heinz bodies) and associated hemolytic anemia is unclear.

(2) The effectiveness of orally administered methylene blue as a urinary antiseptic is open to question. It appears that following oral administration, methylene blue is poorly and erratically absorbed and also slowly and erratically excreted in the urine. Studies
in the dog indicate it is excreted in the urine essentially as leukomethylene blue stabilized in some manner. Methylene blue itself is stepwise demethylated in alkaline solutions (alkaline urine being a frequent consequence of urinary infection) to Azure B, Azure A, and Azure C. The antiseptic efficacy of all of these excretion products is unsubstantiated.

(3) In view of the foregoing, the Commissioner has concluded that animal drugs containing methylene blue for oral use in cats or dogs are neither safe nor generally recognized as effective within the meaning of section 201(v) of the act and are therefore considered new animal drugs. Accordingly, all prior formal and informal opinions expressed by the Food and Drug Administration that such drugs are “not new drugs” or “no longer new drugs” are hereby revoked.

(b) Animal drugs that contain methylene blue for oral use in cats or dogs and not the subject of an approved new animal drug application (NADA) are deemed to be adulterated under the provisions of section 501(a) (5) and/or (6) and/or misbranded under section 502(a) of the act and subject to regulatory action as of April 10, 1978.

(c) Sponsors of animal drugs that contain methylene blue for oral use in cats or dogs and not the subject of an approved new animal drug application (NADA) may submit an application in conformity with §514.1 of this chapter. Such applications will be processed in accordance with section 512 of the act. Submission of an NADA will not constitute grounds for continued marketing of this drug substance until such application is approved.

(d) New animal drug applications required by this regulation pursuant to section 512 of the act shall be submitted to the Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drug Evaluation (HFV-100), 7500 Standish Pl., Rockville, MD 20855.

§ 500.29 Gentian violet for use in animal feed.

The Food and Drug Administration has determined that gentian violet is not generally recognized as safe for use in animal feed and is a food additive subject to section 409 of the Federal Food, Drug, and Cosmetic Act (the act), unless it is intended for use as a new animal drug, in which case it is subject to section 512 of the act. The Food and Drug Administration has determined that gentian violet is not prior sanctioned for any use in animal feed.

§ 500.30 Gentian violet for animal drug use.

The Food and Drug Administration (FDA) has determined that gentian violet is not generally recognized as safe and effective for any veterinary drug use in food animals and is a new animal drug subject to section 512 of the Federal Food, Drug, and Cosmetic Act. FDA has determined that gentian violet is not exempted from new animal drug status under the “grandfather” provisions of the Drug Amendments of 1962 (21 U.S.C. 342).

§ 500.35 Animal feeds contaminated with Salmonella microorganisms.

(a) Investigations by the Food and Drug Administration, the Centers for Disease Control of the U.S. Public Health Service, the Animal Health Division of the Agricultural Research Service, U.S. Department of Agriculture, and by various State public health agencies have revealed that processed fish meal, poultry meal, meat meal, tankage, and other animal byproducts intended for use in animal feed may be contaminated with Salmonella bacteria, an organism pathogenic to man and animals. Contamination of these products may occur through inadequate heat treatment of the product during its processing or through recontamination of the heat-treated product during a time of improper storage or handling subsequent to processing.

(b) Articles used in food for animals are included within the definition of...
§ 500.45 Use of polychlorinated biphenyls (PCB's) in the production, handling, and storage of animal feed.

(a) Polychlorinated biphenyls (PCB's) represent a class of toxic industrial chemicals manufactured and sold under a variety of trade names, including: Aroclor (United States); Phenoclor (France); Colphen (Germany); and Kanaclor (Japan). PCB's are highly stable, heat resistant, and nonflammable chemicals. Industrial uses of PCB's include, or did include in the past, their use as electrical transformer and capacitor fluids, heat transfer fluids, hydraulic fluids, plasticizers, and in formulations of lubricants, coatings, and inks. Their unique physical and chemical properties and widespread, uncontrolled industrial applications have caused PCB's to be a persistent and ubiquitous contaminant in the environment, causing the contamination of certain foods. In addition, incidents have occurred in which PCB's have directly contaminated animal feeds as a result of industrial accidents (leakage or spillage of PCB fluids from plant equipment). These accidents in turn cause the contamination of food intended for human consumption (meat, milk, and eggs). Investigations by the Food and Drug Administration have revealed that heat exchange fluids for certain pasteurization equipment used in processing animal feed contain PCB's. Although heat exchange fluids in such equipment are considered to be in closed systems, leakage has occurred that resulted in direct contamination of animal feed with PCB's and subsequently resulted in the transfer of PCB's to human food produced by animals consuming the contaminated feed. The use of PCB-containing coatings on the inner walls of silos has resulted in the contamination of silage which has in turn caused PCB residues in the milk of dairy cows consuming the contaminated silage. Since PCB's are toxic chemicals, the PCB contamination of food as a result of these and other incidents represent a hazard to public health. It is therefore necessary to place certain restrictions on the industrial uses of PCB's in the production, handling, and storage of animal feed.

(b) The following special provisions are necessary to preclude accidental PCB contamination of animal feed:

(1) Coatings or paints for use on the contact surfaces of feed storage areas may not contain PCB's or any other harmful or deleterious substances likely to contaminate feed.

(2) New equipment or machinery for handling or processing feed in or around an establishment producing animal feed shall not contain PCB's.

(3) On or before Sept. 4, 1973, the management of establishments producing animal feed shall:

(i) Have the heat exchange fluid used in existing equipment or machinery for handling and processing feed sampled and tested to determine whether it contains PCB's, or verify the absence of PCB's in such formulations by other appropriate means. On or before Sept. 4, 1973, any such fluid formulated with PCB's must to the fullest extent possible commensurate with current good manufacturing practices, be replaced with a heat exchange fluid that does not contain PCB's.

(ii) Eliminate to the fullest extent possible commensurate with current good manufacturing practices from the animal feed producing establishment any PCB-containing lubricants for equipment or machinery used for handling or processing animal feed.
§500.46 Hexachlorophene in animal drugs.

(a) The Commissioner of Food and Drugs has determined that there are no adequate data to establish that animal drugs containing hexachlorophene are safe and effective for any animal use other than in topical products for use on non-food-producing animals as part of a product preservative system at a level not to exceed 0.1 percent; that there is no information on the potential risk to humans from exposure to hexachlorophene by persons who apply animal products containing the drug at levels higher than 0.1 percent; and that there is likewise no information on human exposure to animals on which these animal drugs have been used and no information on possible residues of hexachlorophene in edible products of food-producing animals treated with new animal drugs that contain any quantity of hexachlorophene.

(b) Animal drugs containing hexachlorophene for other than preservative use on non-food-producing animals at levels not exceeding 0.1 percent are considered new animal drugs and shall be the subject of new animal drug applications (NADA’s).

(c) Any person currently marketing animal drugs that contain hexachlorophene other than as part of a product preservative system for products used on non-food-producing animals at a level not exceeding 0.1 percent shall submit a new animal drug application, supplement an existing application, or reformulate the product by September 29, 1977. Each application or supplemental application shall include adequate data to establish that the animal drug is safe and effective. If the animal drug is currently subject to an approved new animal drug application, each reformulation shall require an approved supplemental application. The interim marketing of these animal drugs may continue until the application has been approved, until it has been determined that the application is not approvable under the provisions of §514.111 of this chapter, or until an existing approved application has been withdrawn.

(d) After September 29, 1977, animal drugs that contain hexachlorophene other than for preservative use on non-food-producing animals at a level not exceeding 0.1 percent that are introduced into interstate commerce shall be deemed to be adulterated within the meaning of section 501(a)(5) of the act (21 U.S.C. 351(a)(5)) unless such animal drug is the subject of a new animal drug application submitted pursuant to paragraph (c) of this section. Action to withdraw approval of new animal drug applications will be initiated if supplemental new animal drug applications have not been submitted in accordance with this section.

(e) New animal drug applications submitted for animal drugs containing hexachlorophene for use in or on food-
§ 500.50

producing animals shall include adequate data to assure that edible products from treated animals are safe for human consumption under the labeled conditions of use.

[42 FR 37725, July 1, 1977; 42 FR 37975, July 26, 1977]

§ 500.50 Propylene glycol in or on cat food.

The Food and Drug Administration has determined that propylene glycol in or on cat food is not generally recognized as safe and is a food additive subject to section 409 of the Federal Food, Drug, and Cosmetic Act (the act). The Food and Drug Administration also has determined that this use of propylene glycol is not prior sanctioned.

[61 FR 19544, May 2, 1996]

Subpart C—Animal Drug Labeling Requirements

§ 500.51 Labeling of animal drugs; misbranding.

(a) Among the representations on the label or labeling of an animal drug which will render the drug misbranded are any broad statements suggesting or implying that the drug is not safe and effective for use when used in accordance with labeling direction, or suggesting or implying that the labeling does not contain adequate warnings or adequate directions for use. Such statements include, but are not limited to:

(1) Any statement that disclaims liability when the drug is used in accordance with directions for use contained on the label or labeling.

(2) Any statement that disclaims liability when the drug is used under "abnormal" or "unforeseeable" conditions.

(3) Any statement limiting the warranty for the products to a warranty that the drug in the package contains the ingredients listed on the label.

(b) This regulation is not intended to prohibit any liability disclaimer that purports to limit the amount of damages or that sets forth the legal theory under which damages are to be recovered.

(c) Any person wishing to obtain an evaluation of an animal drug liability disclaimer under this regulation may submit it to Division of Compliance, (HFV–230), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. A supplemental NADA providing appropriately revised labeling shall be submitted for any approved new animal drug the labeling of which is not in compliance with this regulation.


§ 500.52 Use of terms such as "tonic", "tone", "toner", or "conditioner" in the labeling of preparations intended for use in or on animals.

(a) The use of terms such as tonic, tone, toner, and similar terms in the labeling of a product intended for use in or on animals implies that such product is capable of a therapeutic effect(s) and causes such a product to be a drug within the meaning of section 201(g) of the Federal Food, Drug, and Cosmetic Act. The unqualified use of such terms in a product's labeling fails to provide adequate directions and indications for use of such product and causes it to be misbranded within the meaning of section 502(a) and (f)(1) of the act. The terms tonic, tone, toner, and similar terms may be used in labeling only when appropriately qualified so as to fully inform the user regarding the intended use(s) of the product.

(b) The unqualified use of the term conditioner and similar terms in the labeling of a product intended for use in or on animals implies that such product is capable of a therapeutic effect(s) and causes such a product to be a drug within the meaning of section 201(g) of the act. The unqualified use of such terms in a product's labeling fails to provide adequate directions and indications for use of such product and causes it to be misbranded within the meaning of section 502(a) and (f)(1) of the act. The term conditioner and similar terms may be used in labeling only when appropriately qualified so as to fully inform the user regarding the intended use(s) of the product. A product labeled as a "conditioner" or with a similar term can be either a food or drug depending upon the manner in
which the term is qualified in the labeling to reflect the product’s intended use.

(c) An article so qualified as to be represented as a drug must be the subject of an approved new animal drug application unless the use of the article under the conditions set forth in its labeling is generally recognized as safe and effective among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs.

§ 500.55 Exemption from certain drug-labeling requirements.

(a) Section 201.105(c) of this chapter provides that in the case of certain drugs for which directions, hazards, warnings, and use information are commonly known to practitioners licensed by law, such information may be omitted from the dispensing package. Under this proviso, the Commissioner of Food and Drugs will offer an opinion, upon written request, stating reasonable grounds therefore on a proposal to omit such information from the dispensing package.

(b) The Commissioner of Food and Drugs has considered submitted material covering a number of drug products and has offered the opinion that the following drugs when intended for those veterinary uses for which they are now generally employed by the veterinary medical profession, should be exempt from the requirements of §201.105(c) of this chapter, provided that they meet the conditions prescribed in this paragraph. Preparations that are not in dosage unit form (for example, solutions) will be regarded as meeting the conditions with respect to the maximum quantity of drug per dosage unit if they are prepared in a manner that enables accurate and ready administration of a quantity of drug not in excess of the stated maximum per dosage unit:

Atropine sulfate. As an injectable for cattle, goats, horses, pigs, and sheep, not in excess of 15 milligrams per dosage unit; as an injectable for cats and dogs, not in excess of 0.6 milligram per dosage unit.

Barbital sodium. For oral use in cats and dogs, not in excess of 30 milligrams per dosage unit.

Epinephrine injection. 1:1,000. For cattle, goats, horses, pigs, and sheep (except as provided in §500.65).

Morphine sulfate. As an injectable for dogs, not in excess of 15 milligrams per dosage unit.

Pentobarbital sodium. For oral use in cats and dogs, not in excess of 100 milligrams per dosage unit.

Phenobarbital sodium. For oral use in cats and dogs, not in excess of 100 milligrams per dosage unit.

Procaine hydrochloride injection. Containing not in excess of 2 percent procaine hydrochloride, with or without epinephrine up to a concentration of 1:50,000. For use in cats, dogs, cattle, goats, horses, pigs, and sheep.

Thyroid. For oral use in dogs, not in excess of 60 milligrams per dosage unit.

Subpart D—Requirements for Specific Animal Drugs

§ 500.65 Epinephrine injection 1:1,000 in 10-milliliter containers for emergency treatment of anaphylactoid shock in cattle, horses, sheep, and swine.

(a) Anaphylactoid reactions in cattle, horses, sheep, and swine occur occasionally from the injection of antibiotics, bacterins, and vaccines. Adequate directions for use of these antibiotics, bacterins, and vaccines can generally be written for use by the laity and thus are available to livestock producers. Epinephrine injection is effective for the treatment of anaphylactoid reactions in animals and would be of value in saving lives of animals if it were readily available at the time of administration of the causative agents. In connection with this problem the Food and Drug Administration has obtained the views of the Advisory Committee on Veterinary Medicine, and other experts, and has concluded that adequate directions for over-the-counter sale of epinephrine injection 1:1,000 can be prepared.

(b) In view of the above, the Commissioner of Food and Drugs has concluded that it is in the public interest to make epinephrine injection 1:1,000 available for sale without a prescription provided that it is packaged in vials not exceeding 10 milliliters and its label bears, in addition to other required information, the following statements in a prominent and conspicuous manner: ‘‘For emergency use only in treating
§ 500.80

anaphylactoid shock. Usual Dosage: Cattle, horses, sheep, and swine—1 cubic centimeter per 100 pounds of body weight. Inject subcutaneously.

(c) The labeling must also bear a description of the symptoms of anaphylactoid shock including glassy eyes, increased salivation, grinding of the teeth, rapid breathing, muscular tremors, staggering gait, and collapse with death following. These symptoms may appear shortly after injection of a bacterin, vaccine, or antibiotic.

Subpart E—Regulation of Carcinogenic Compounds Used in Food-Producing Animals

SOURCE: 52 FR 49586, Dec. 31, 1987, unless otherwise noted.

§ 500.80 Scope of this subpart.

(a) The Federal Food, Drug, and Cosmetic Act requires that sponsored compounds intended for use in food-producing animals be shown to be safe and that food produced from animals exposed to these compounds be shown to be safe for consumption by people. The statute prohibits the use in food-producing animals of any compound found to induce cancer when ingested by people or animals unless it can be determined by methods of examination prescribed or approved by the Secretary (a function delegated to the Commissioner of Food and Drugs under §5.10 of this chapter) that no residue of that compound will be found in the food produced from those animals under conditions of use reasonably certain to be followed in practice. This subpart provides an operational definition of no residue and identifies the steps a sponsor of a compound shall follow to secure the approval of the compound. FDA guidance documents contain the procedures and protocols FDA recommends for the implementation of this subpart. These guidance documents are available from the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. Requests for these guidance documents should be identified with Docket No. 83D–0288.

(b) If FDA concludes on the basis of the threshold assessment that a sponsor shall conduct carcinogenicity testing on the sponsored compound, FDA will also determine whether and to what extent the sponsor shall conduct carcinogenicity testing on metabolites of the sponsored compound. The bioassays that a sponsor conducts must be designed to assess carcinogenicity and to determine the quantitative aspects of any carcinogenic response.

(c) If FDA concludes on the basis of the threshold assessment or at a later time during the approval process that the data show that the sponsored compound and its metabolites should not be subject to this subpart, FDA will continue to consider the compound for approval under the general safety provisions of the act for risks other than cancer.

(d) This subpart does not apply to essential nutrients.


§ 500.82 Definitions.

(a) The definitions and interpretations contained in section 201 of the act apply to those terms when used in this subpart.

(b) The following definitions apply to this subpart:


Essential nutrients means compounds that are found in the tissues of untreated, healthy target animals and not produced in sufficient quantity to support the animal’s growth, development, function, or reproduction, e.g., vitamins, essential minerals, essential amino acids, and essential fatty acids. These compounds must be supplied from external sources.

FDA means the Food and Drug Administration.

Marker residue means the residue selected for assay whose concentration is in a known relationship to the concentration of the residue of carcinogenic concern in the last tissue to deplete to its permitted concentration.
Preslaughter withdrawal period or milk discard time means the time after cessation of administration of the sponsored compound for the residue of carcinogenic concern in the edible product to deplete to the concentration that will satisfy the operational definition of no residue.

Regulatory method means the aggregate of all experimental procedures for measuring and confirming the presence of the marker residue of the sponsored compound in the target tissue of the target animal.

\( R_m \) means the concentration of the marker residue in the target tissue when the residue of carcinogenic concern is equal to \( S_m \) in the last tissue to deplete to its permitted concentration.

Residue means any compound present in edible tissues of the target animal which results from the use of the sponsored compound, including the sponsored compound, its metabolites, and any other substances formed in or on food because of the sponsored compound’s use.

Residue of carcinogenic concern means all compounds in the total residue of a demonstrated carcinogen excluding any compounds judged by FDA not to present a carcinogenic risk.

\( S_m \) means the permitted concentration of residue of carcinogenic concern for a specific edible tissue.

\( S_o \) means the concentration of the test compound in the total diet of test animals that corresponds to a maximum lifetime risk of cancer in the test animals of 1 in 1 million. For the purpose of this subpart, FDA will also assume that this \( S_o \) will correspond to the concentration of residue of carcinogenic concern in the total human diet that represents no significant increase in the risk of cancer to people.

Sponsor means the person or organization proposing or holding an approval by FDA for the use of a sponsored compound.

Sponsored compound means any drug or food additive or color additive proposed for use, or used, in food-producing animals or in their feed.

Target animals means the production class of animals in which a sponsored compound is proposed or intended for use.

Target tissue means the edible tissue selected to monitor for residues in the target animals, including, where appropriate, milk or eggs.

Test animals means the species selected for use in the toxicity tests.

Threshold assessment means FDA’s review of data and information about a sponsored compound to determine whether chronic bioassays in test animals are necessary to resolve questions concerning the carcinogenicity of the compound.

§ 500.84 Operational definition of “no residue”.

(a) On the basis of the results of the chronic bioassays and other information, FDA will determine whether any of the substances tested are carcinogenic.

(b) If FDA concludes that the results of the bioassays do not establish carcinogenicity, then FDA will not subject the sponsored compound to the remainder of the requirements of this subpart.

(c) For each sponsored compound that FDA decides should be regulated as a carcinogen, FDA will analyze the data from the bioassays using a statistical extrapolation procedure.

(1) For each substance tested in separate bioassays, FDA will calculate the concentration of the residue of carcinogenic concern that corresponds to a maximum lifetime risk to the test animal of 1 in 1 million. FDA will designate the lowest value obtained as \( S_o \).

(2) FDA will consider that “no residue” of the compound remains in the edible tissue when conditions of use of the sponsored compound, including any required preslaughter withdrawal period or milk discard time, ensure that the concentration of the residue of carcinogenic concern in the total diet of people will not exceed \( S_o \). Because the total diet is not derived from food-producing animals, FDA will make corrections for food intake. FDA will designate as \( S_m \) the concentration of residue of carcinogenic concern that is permitted in a specific edible product.

§ 500.86 Marker residue and target tissue.

(a) For each edible tissue, the sponsor shall measure the depletion of the
residue of carcinogenic concern until its concentration is at or below \( S_m \).

(b) In one or more edible tissues, the sponsor shall also measure the depletion of one or more potential marker residues until the concentration of the residue of carcinogenic concern is at or below \( S_m \).

(c) From these data, FDA will select a target tissue and a marker residue and designate the concentration of marker residue (\( R_m \)) that the regulatory method must be capable of measuring in the target tissue. FDA will select \( R_m \) such that the absence of the marker residue in the target tissue above \( R_m \) can be taken as confirmation that the residue of carcinogenic concern does not exceed \( S_m \) in each of the edible tissues and, therefore, that the residue of carcinogenic concern in the diet of people does not exceed \( S_o \).

(d) When a compound is to be used in milk- or egg-producing animals, milk or eggs must be the target tissue in addition to the tissue selected to monitor for residues in the edible carcass.

§ 500.88 Regulatory method.

(a) The sponsor shall submit for evaluation and validation a regulatory method developed to monitor compliance with FDA’s operational definition of no residue.

(b) The regulatory method must reliably measure and confirm the identity of the marker residue in the target tissue at concentrations equal to and above \( R_m \).

(c) FDA will publish in the Federal Register the complete regulatory method for measuring the marker residue in the target tissue in accordance with the provisions of sections 409(c)(3)(A), 512(d)(1)(H) and (I), and 721(b)(5)(B) of the act.

§ 500.90 Waiver of requirements.

In response to a petition or on the Commissioner’s own initiative, the Commissioner may waive, in whole or in part, the requirements of this subpart except those provided under § 500.88. A petition for this waiver may be filed by any person who would be adversely affected by the application of the requirements to a particular compound. The petition shall explain and document why the requirements from which a waiver is requested are not reasonably applicable to the compound, and set forth clearly the reasons why the alternative procedures will provide the basis for concluding that approval of the compound satisfies the requirements of the anticancer provisions of the act. If the Commissioner determines that waiver of any of the requirements of this subpart is appropriate, the Commissioner will state the basis for that determination in the regulation approving marketing of the sponsored compound.
§ 501.2 Information panel of package for animal food.

(a) The term information panel as it applies to packaged food means that part of the label immediately contiguous and to the right of the principal display panel is too small to accommodate the necessary information or is otherwise unusable label space, e.g., folded flaps or can ends, and the panel immediately contiguous and to the right of this part of the label may be used.

(2) If the package has one or more alternate principal display panels, the information panel is immediately contiguous and to the right of any principal display panel.

(3) If the top of the container is the principal display panel and the package has no alternate principal display panel,
§ 501.2

16

panel, the information panel is any panel adjacent to the principal display panel.

(b) All information required to appear on the label of any package of food pursuant to §§501.4, 501.5, 501.8 and 501.17 shall appear either on the principal display panel or on the information panel, unless otherwise specified by regulations in this chapter.

(c) All information appearing on the principal display panel or the information panel pursuant to this section shall appear prominently and conspicuously, but in no case may the letters and/or numbers be less than 1⁄16 inch in height unless an exemption pursuant to paragraph (f) of this section is established. The requirements for conspicuousness and legibility shall include the specifications of §§501.15 and 501.105(h) (1) and (2).

(1) Packaged foods are exempt from the type size requirements of this paragraph: Provided, That:

(i) The package is designed such that it has a surface area that can bear an information panel and/or an alternate principal display panel.

(ii) The area of surface available for labeling on the principal display panel of the package as this term is defined in §501.1 is less than 10 square inches.

(iii) The label information includes a full list of ingredients in accordance with regulations in this part.

(iv) The information required by paragraph (b) of this section appears on the single, obvious principal display panel in accordance with the provisions of this paragraph (c) except that the type size is not less than ½ inch in height.

(2) Packaged foods are exempt from the type size requirements of this paragraph: Provided, That:

(i) The package is designed such that it has a total surface area available to bear labeling of less than 12 square inches.

(ii) The label information includes a full list of ingredients in accordance with regulations in this part.

(iii) The information required by paragraph (b) of this section appears on the principal display panel or information panel label in accordance with the provisions of this paragraph (c) except that the type size is not less than 1⁄32 inch in height.

(3) Packaged foods are exempt from the type size requirements of this paragraph: Provided, That:

(i) The package is designed such that it has a single obvious principal display panel as this term is defined in §501.1 and has no other available surface area for an information panel or alternate principal display panel.

(ii) The area of surface available for labeling on the principal display panel of the package as this term is defined in §501.1 is less than 12 square inches and bears all labeling appearing on the package.

(iii) The label information includes a full list of ingredients in accordance with regulations in this part.

(iv) The information required by paragraph (b) of this section appears on the single, obvious principal display panel in accordance with the provisions of this paragraph (c) except that the type size is not less than ½ inch in height.

(e) All information appearing on the information panel pursuant to this section shall appear in one place without other intervening material.

(f) If the label of any package of food is too small to accommodate all of the information required by §§501.4, 501.5, 501.8, and 501.17, the Commissioner may establish by regulation an acceptable alternative method of disseminating such information to the public, e.g., a

VerDate May 15, 2002 09:47 May 15, 2002 Jkt 197067 PO 00000 Frm 00016 Fmt 8010 Sfmt 8010 Y:\SGML\197067T.XXX pfrm17 PsN: 197067T
§ 501.3 Identity labeling of animal food in package form.

(a) The principal display panel of a food in package form shall bear as one of its principal features a statement of the identity of the commodity.

(b) Such statement of identity shall be in terms of:

(1) The name now or hereafter specified in or required by any applicable Federal law or regulation; or, in the absence thereof,

(2) The common or usual name of the food; or, in the absence thereof,

(3) An appropriately descriptive term, or when the nature of the food is obvious, a fanciful name commonly used by the public for such food.

(c) Where a food is marketed in various optional forms (whole, slices, diced, etc.), the particular form shall be considered to be a necessary part of the statement of identity and shall be declared in letters of a type size bearing a reasonable relation to the size of the letters forming the other components of the statement of identity; except that if the optional form is visible through the container or is depicted by an appropriate vignette, the particular form need not be included in the statement. This specification does not affect the required declarations of identity under definitions and standards for foods promulgated pursuant to section 401 of the act.

(d) This statement of identity shall be presented in bold type on the principal display panel, shall be in a size reasonably related to the most prominent printed matter on such panel, and shall be in lines generally parallel to the base on which the package rests as it is designed to be displayed.

(e) Under the provisions of section 402(c) of the Federal Food, Drug, and Cosmetic Act, a food shall be deemed to be misbranded if it is an imitation of another food unless its label bears, in type of uniform size and prominence, the word imitation and, immediately thereafter, the name of the food imitated.

(1) A food shall be deemed to be an imitation and thus subject to the requirements of section 403(c) of the act if it is a substitute for and resembles another food but is nutritionally inferior to that food.

(2) A food that is a substitute for and resembles another food shall not be deemed to be an imitation provided it meets each of the following requirements:

(i) It is not nutritionally inferior to the food for which it substitutes and which it resembles.

(ii) Its label bears a common or usual name that complies with the provisions of §502.5 of this chapter and that is not false or misleading, or in the absence of an existing common or usual name, an appropriately descriptive term that is not false or misleading. The label may, in addition, bear a fanciful name which is not false or misleading.

(iii) A food for which a common or usual name is established by regulation (e.g., in a standard of identity pursuant to section 401 of the act, in a common or usual name regulation and may, in addition, bear a fanciful name which is not false or misleading, and established pursuant to part 502 of this chapter), and which complies with all of the applicable requirements of such regulation(s), shall not be deemed to be an imitation.

(f) A label may be required to bear the percentage(s) of a characterizing ingredient(s) or information concerning the presence or absence of an
§ 501.4 Animal food; designation of ingredients.

(a) Ingredients required to be declared on the label of a food, including foods that comply with standards of identity that require labeling in compliance with this part 501, except those exempted by § 501.100, shall be listed by common or usual name in descending order of predominance by weight on either the principal display panel or the information panel in accordance with the provisions of § 501.2.

(b) The name of an ingredient shall be a specific name and not a collective (generic) name, except that:
   (1) Spices, flavorings, colorings and chemical preservatives shall be declared according to the provisions of § 501.22.
   (2) An ingredient which itself contains two or more ingredients and which has an established common or usual name, conforms to a standard established pursuant to the Meat Inspection or Poultry Products Inspection Acts by the U.S. Department of Agriculture, or conforms to a definition and standard of identity established pursuant to section 401 of the Federal Food, Drug, and Cosmetic Act, shall be designated in the statement of ingredients on the label of such food by either of the following alternatives:
      (i) By declaring the established common or usual name of the ingredient followed by a parenthetical listing of all ingredients contained therein in descending order of predominance except that, if the ingredient is a food subject to a definition and standard of identity established in this chapter, the ingredients required to be declared by the definition and standard of identity need be listed; or
      (ii) By incorporating into the statement of ingredients in descending order of predominance in the finished food, the common or usual name of every component of the ingredient without listing the ingredient itself.

(3) Skim milk, concentrated skim milk, reconstituted skim milk, and nonfat dry milk may be declared as skim milk or nonfat milk.

(4) Milk, concentrated milk, reconstituted milk, and dry whole milk may be declared as milk.

(5) Bacterial cultures may be declared by the word cultured followed by the name of the substrate, e.g., made from cultured skim milk or cultured buttermilk.

(6) Sweetcream buttermilk, concentrated sweetcream buttermilk, reconstituted sweetcream buttermilk, and dried sweetcream buttermilk may be declared as buttermilk.

(7) Whey, concentrated whey, reconstituted whey, and dried whey may be declared as whey.

(8) Cream, reconstituted cream, dried cream, and plastic cream (sometimes known as concentrated milkfat) may be declared as cream.

(9) Butteroil and anhydrous butterfat may be declared as butterfat.

(10) Dried whole eggs, frozen whole eggs, and liquid whole eggs may be declared as eggs.

(11) Dried egg whites, frozen egg whites, and liquid egg whites may be declared as egg whites.

(12) Dried egg yolks, frozen egg yolks, and liquid egg yolks may be declared as egg yolks.

(13) A livestock or poultry feed may be declared by a collective name listed in § 501.110 if it is an animal feed within the meaning of section 201(w) of the act and meets the requirements for the use of a collective name as prescribed in § 501.110 for certain feed ingredients.

(14) [Reserved]

(15) When all the ingredients of a wheat flour are declared in an ingredient statement, the principal ingredient of the flour shall be declared by the name(s) specified in §§ 137.105, 137.200, 137.220, 137.225 of this chapter, i.e., the first ingredient designated in the ingredient list of flour, or bromated flour, or enriched flour, or self-rising flour is flour, white flour, wheat flour, or plain flour; the first ingredient designated in the ingredient list of whole wheat flour is whole wheat flour.
§ 501.8 Labeling of animal food with number of servings.

(a) The label of any package of a food which bears a representation as to the number of servings contained in such package shall bear in immediate conjunction with such statement, and in the same size type as is used for such statement, a statement of the net quantity (in terms of weight, measure, or numerical count) of each such serving; however, such statement may be expressed in terms that differ from the terms used in the required statement of net quantity of contents (for example, cupfuls, tablespoonfuls, etc.) when such differing term is common to cookery and describes a constant quantity. Such statement may not be misleading in any particular. A statement of the number of units in a package is not in itself a statement of the number of servings.

(b) If there exists a voluntary product standard promulgated pursuant to the procedures found in 15 CFR part 10 by the Department of Commerce, quantitatively defining the meaning of the term serving with respect to a particular food, then any label representation as to the number of servings in such packaged food shall correspond with such quantitative definition. (Copies of published standards are available upon request from the National Bureau of Standards, Department of Commerce, Washington, DC 20234.)
§ 501.15 Animal food; prominence of required statements.

(a) A word, statement, or other information required by or under authority of the act to appear on the label may lack that prominence and conspicuousness required by section 403(f) of the act by reason (among other reasons) of:

(1) The failure of such word, statement, or information to appear on the part or panel of the label which is presented or displayed under customary conditions of purchase;

(2) The failure of such word, statement, or information to appear on two or more parts or panels of the label, each of which has sufficient space therefor, and each of which is so designed as to render it likely to be, under customary conditions of purchase, the part or panel displayed;

(3) The failure of the label to extend over the area of the container or package available for such extension, so as to provide sufficient label space for the prominent placing of such word, statement, or information;

(4) Insufficiency of label space (for the prominent placing of such word, statement, or information) resulting from the use of label space for any word, statement, design, or device which is not required by or under authority of the act to appear on the label;

(5) Insufficiency of label space (for the prominent placing of such word, statement, or information) resulting from the use of label space to give materially greater conspicuousness to any other word, statement, or other information or to any design or device; or

(6) Smallness or style of type in which such word, statement, or information appears, insufficient background contrast, obscuring designs or vignettes, or crowding with other written, printed, or graphic matter.

(b) No exemption depending on insufficiency of label space, as prescribed in regulations promulgated under section 403(e) or (1) of the act, shall apply if such insufficiency is caused by:

(1) The use of label space for any word, statement, design, or device which is not required by or under authority of the act to appear on the label;

(2) The use of label space to give greater conspicuousness to any word, statement, or other information that is required by section 403(f) of the act; or

(3) The use of label space for any representation in a foreign language.

(c)(1) All words, statements, and other information required by or under authority of the act to appear on the label or labeling shall appear thereon in the English language: Provided, however, That in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a territory where the predominant language is one other than English, the predominant language may be substituted for English.

(2) If the label contains any representation in a foreign language, all words, statements, and other information required by or under authority of the act to appear on the label shall appear thereon in the foreign language.

(3) If any article of labeling (other than a label) contains any representation in a foreign language, all words, statements, and other information required by or under authority of the act to appear on the label or labeling shall appear on such article of labeling.

§ 501.17 Animal food labeling warning statements.

(a) Self-pressurized containers. (1) The label of a food packaged in a self-pressurized container and intended to be expelled from the package under pressure shall bear the following warning:

Warning Avoid spraying in eyes. Contents under pressure. Do not puncture or incinerate. Do not store at temperature above 120 °F. Keep out of reach of children.

(2) In the case of products intended for use by children, the phrase “except under adult supervision” may be added at the end of the last sentence in the warning required by paragraph (a)(1) of this section.

(3) In the case of products packaged in glass containers, the word “puncture” may be substituted for the word “break” in the warning required by paragraph (a)(1) of this section.

(4) The words “Avoid spraying in eyes” may be deleted from the warning required by paragraph (a)(1) of this section in the case of a product not expelled as a spray.
Food and Drug Administration, HHS

§ 501.22 Animal foods; labeling of spices, flavorings, colorings, and chemical preservatives.

(a)(1) The term artificial flavor or artificial flavoring means any substance, the function of which is to impart flavor, which is not derived from a spice, fruit or fruit juice, vegetable or vegetable juice, edible yeast, herb, bark, bud, root, leaf or similar plant material, meat, fish, poultry, eggs, dairy products, or fermentation products thereof. Artificial flavor includes the substances listed in §§172.515(b) and 582.60 of this chapter except where these are derived from natural sources.

(2) The term spice means any aromatic vegetable substance in the whole, broken, or ground form, except for those substances which have been traditionally regarded as foods, such as onions, garlic and celery; whose significant function in food is seasoning rather than nutritional; that is true to name; and from which no portion of misbranded is any representation that expresses or implies a geographical origin of the food or any ingredient of the food except when such representation is either:

(1) A truthful representation of geographical origin.

(2) A trademark or trade name provided that as applied to the article in question its use is not deceptively misdescriptive. A trademark or trade name comprised in whole or in part of geographical words shall not be considered deceptively misdescriptive if:

(i) Has been so long and exclusively used by a manufacturer or distributor that it is generally understood by the consumer to mean the product of a particular manufacturer or distributor; or

(ii) Is so arbitrary or fanciful that it is not generally understood by the consumer to suggest geographic origin.

(3) A part of the name required by applicable Federal law or regulation.

(4) A name whose market significance is generally understood by the consumer to connote a particular class, kind, type, or style of food rather than to indicate geographical origin.

Subpart B—Specific Animal Food Labeling Requirements

§ 501.22 Animal foods; labeling of spices, flavorings, colorings, and chemical preservatives.

(a)(1) The term artificial flavor or artificial flavoring means any substance, the function of which is to impart flavor, which is not derived from a spice, fruit or fruit juice, vegetable or vegetable juice, edible yeast, herb, bark, bud, root, leaf or similar plant material, meat, fish, poultry, eggs, dairy products, or fermentation products thereof. Artificial flavor includes the substances listed in §§172.515(b) and 582.60 of this chapter except where these are derived from natural sources.

(2) The term spice means any aromatic vegetable substance in the whole, broken, or ground form, except for those substances which have been traditionally regarded as foods, such as onions, garlic and celery; whose significant function in food is seasoning rather than nutritional; that is true to name; and from which no portion of
any volatile oil or other flavoring principle has been removed. Spices include the spices listed in subpart A of part 582 of this chapter, such as the following:

Allspice, Anise, Basil, Bay leaves, Caraway seed, Cardamom, Celery seed, Chervil, Cinnamon, Cloves, Coriander, Cumin seed, Dill seed, Fennel seed, Fenugreek, Ginger, Horseradish, Mace, Marjoram, Mustard flour, Nutmeg, Oregano, Paprika, Parsley, Pepper, black; Pepper, white; Pepper, red; Rosemary, Saffron, Sage, Savory, Star anise seed, Tarragon, Thyme, Turmeric.

Paprika, turmeric, and saffron or other spices which are also colors, shall be declared as *spice and coloring* unless declared by their common or usual name.

(3) The term *natural flavor* or *natural flavoring* means the essential oil, oleoresin, essence or extractive, protein hydrolysate, distillate, or any product of roasting, heating or enzymolysis, which contains the flavoring constituents derived from a spice, fruit or fruit juice, vegetable or vegetable juice, edible yeast, herb, bark, bud, root, leaf or similar plant material, meat, seafood, poultry, eggs, dairy products, or fermentation products thereof, whose significant function in food is flavoring rather than nutritional. Natural flavors, include the natural essence or extractives obtained from plants listed in subpart A of part 582 of this chapter, and the substances listed in §172.510 of this chapter.

(4) The term *artificial color* or *artificial coloring* means any color additive as defined in §70.3(f) of this chapter.

(5) The term *chemical preservative* means any chemical that, when added to food, tends to prevent or retard deterioration thereof, but does not include common salt, sugars, vinegars, spices, or oils extracted from spices, substances added to food by direct exposure thereof to wood smoke, or chemicals applied for their insecticidal or herbicidal properties.

(b) A food which is subject to the requirements of section 403(k) of the act shall bear labeling, even though such food is not in package form.

(c) A statement of artificial flavoring, artificial coloring, or chemical preservative shall be placed on the food, or on its container or wrapper, or on any two or all of these, as may be necessary to render such statement likely to be read by the ordinary individual under customary conditions of purchase and use of such food.

(d) A food shall be exempt from compliance with the requirements of section 403(k) of the act if it is not in package form and the units thereof are so small that a statement of artificial flavoring, artificial coloring, or chemical preservative, as the case may be, cannot be placed on such units with such conspicuousness as to render it likely to be read by the ordinary individual under customary conditions of purchase and use.

(e) A food shall be exempt while held for sale from the requirements of section 403(k) of the act (requiring label statement of any artificial flavoring, artificial coloring, or chemical preservatives) if said food, having been received in bulk containers at a retail establishment, is displayed to the purchaser with either (1) the labeling of the bulk container plainly in view or (2) a counter card, sign, or other appropriate device bearing prominently and conspicuously the information required to be stated on the label pursuant to section 403(k) of the act.

(f) A fruit or vegetable shall be exempt from compliance with the requirements of section 403(k) of the act with respect to a chemical preservative applied to the fruit or vegetable as a pesticide chemical prior to harvest.

(g) A flavor shall be labeled in the following way when shipped to a food manufacturer or processor (but not a consumer) for use in the manufacture of a fabricated food, unless it is a flavor for which a standard of identity has been promulgated, in which case it shall be labeled as provided in the standard:

(1) If the flavor consists of one ingredient, it shall be declared by its common or usual name.

(2) If the flavor consists of two or more ingredients, the label either may declare each ingredient by its common or usual name or may state “All flavor ingredients contained in this product are approved for use in a regulation of the Food and Drug Administration.” Any flavor ingredient not contained in
Food and Drug Administration, HHS

§ 501.22

one of these regulations, and any non-flavor ingredient, shall be separately listed on the label.

(3) In cases where the flavor contains a solely natural flavor(s), the flavor shall be so labeled, e.g., strawberry flavor, banana flavor, or natural strawberry flavor. In cases where the flavor contains both a natural flavor and an artificial flavor, the flavor shall be so labeled, e.g., natural and artificial strawberry flavor. In cases where the flavor contains a solely artificial flavor(s), the flavor shall be so labeled, e.g., artificial strawberry flavor.

(h) The label of a food to which flavor is added shall declare the flavor in the statement of ingredients in the following way:

(1) Spice, natural flavor, and artificial flavor may be declared as spice, natural flavor, or artificial flavor, or any combination thereof, as the case may be.

(2) An incidental additive in a food, originating in a spice or flavor used in the manufacture of the food, need not be declared in the statement of ingredients if it meets the requirements of §501.100(a)(3).

(3) Substances obtained by cutting, grinding, drying, pulping, or similar processing of tissues derived from fruit, vegetable, meat, fish, or poultry, e.g., powdered or granulated onions, garlic powder, and celery powder, are commonly understood by consumers to be food rather than flavor and shall be declared by their common or usual name.

(4) Any salt (sodium chloride) used as an ingredient in food shall be declared by its common or usual name salt.

(5) Any monosodium glutamate used as an ingredient in food shall be declared by its common or usual name monosodium glutamate.

(6) Any pyrrolidine acid or other artificial smoke flavors used as an ingredient in a food may be declared as artificial flavor or artificial smoke flavor. No representation may be made, either directly or implied, that a food flavored with pyrrolidine acid or other artificial smoke flavor has been smoked or has a true smoked flavor, or that a seasoning sauce or similar product containing pyrrolidine acid or other artificial smoke flavor and used to season or flavor other foods will result in a smoked product or one having a true smoked flavor.

(i) If the label, labeling, or advertising of a food makes any direct or indirect representations with respect to the primary recognizable flavor(s), by word, signette, e.g., depiction of a fruit, or other means, or if for any other reason the manufacturer or distributor of a food wishes to designate the type of flavor in the food other than through the statement of ingredients, such flavor shall be considered the characterizing flavor and shall be declared in the following way:

(1) If the food contains no artificial flavor which simulates, resembles or reinforces the characterizing flavor, the name of the food on the principal display panel or panels of the label shall be accompanied by the common or usual name of the characterizing flavor in letters not less than one-half the height of the letters used in the name of the food, except that:

(ii) If none of the natural flavor used in the food is derived from the product whose flavor is simulated, the food in which the flavor is used shall be labeled either with the flavor of the product from which the flavor is derived or as artificially flavored.

(iii) If the food contains both a characterizing flavor from the product whose flavor is simulated and other natural flavor which simulates, resembles or reinforces the characterizing flavor, the food shall be labeled in accordance with the introductory text and paragraph (i)(1)(i) of this section and the name of the food shall be immediately followed by the words with other natural flavor in letters not less than one-half the height of the letters.
used in the name of the characterizing flavor.

(2) If the food contains any artificial flavor which simulates, resembles or reinforces the characterizing flavor, the name of the food on the principal display panel or panels of the label shall be accompanied by the common or usual name(s) of the characterizing flavor, in letters not less than one-half the height of the letters used in the name of the food and the name of the characterizing flavor shall be accompanied by the word(s) \textit{artificial} or \textit{artificially flavored}, in letters not less than one-half the height of the letters in the name of the characterizing flavor.

(3) Wherever the name of the characterizing flavor appears on the label (other than in the statement of ingredients) so conspicuously as to be easily seen under customary conditions of purchase, the words prescribed by this paragraph shall immediately and conspicuously precede or follow such name, without any intervening written, printed, or graphic matter, except:

(i) Where the characterizing flavor and a trademark or brand are presented together, other written, printed, or graphic matter that is a part of or is associated with the trademark or brand may intervene if the required words are in such relationship with the trademark or brand as to be clearly related to the characterizing flavor; and

(ii) If the finished product contains more than one flavor subject to the requirements of this paragraph, the statements required by this paragraph need appear only once in each statement of characterizing flavors present in such food.

(iii) If the finished product contains three or more distinguishable characterizing flavors, or a blend of flavors with no primary recognizable flavor, the flavor may be declared by an appropriately descriptive generic term in lieu of naming each flavor.

(iv) A flavor supplier shall certify, in writing, that any flavor he supplies which is designated as containing no artificial flavor does not, to the best of his knowledge and belief, contain any artificial flavor, and that he has added no artificial flavor to it. The requirement for such certification may be satisfied by a guarantee under section 303(c)(2) of the act which contains such a specific statement. A flavor used shall be required to make such a written certification only where he adds to or combines another flavor with a flavor which has been certified by a flavor supplier as containing no artificial flavor, but otherwise such user may rely upon the supplier’s certification and need make no separate certification. All such certifications shall be retained by the certifying party throughout the period in which the flavor is supplied and for a minimum of 3 years thereafter, and shall be subject to the following conditions:

(i) The certifying party shall make such certifications available upon request at all reasonable hours to any duly authorized officer, or employee of the Food and Drug Administration or any other employee acting on behalf of the Secretary of Health and Human Services. Such certifications are regarded by the Food and Drug Administration as reports to the government and as guarantees or other undertakings within the meaning of section 301(h) of the act and subject the certifying party to the penalties for making any false report to the government under 18 U.S.C. 1001 and any false guarantee or undertaking under section 303(a) of the act. The defenses provided under section 303(c)(2) of the act shall be applicable to the certifications provided for in this section.

(ii) Wherever possible, the Food and Drug Administration shall verify the accuracy of a reasonable number of certifications made pursuant to this section, constituting a representative sample of such certifications, and shall not request all such certifications.

(iii) Where no person authorized to provide such information is reasonably available at the time of inspection, the certifying party shall arrange to have such person and the relevant materials and records ready for verification as soon as practicable; provided that, whenever the Food and Drug Administration has reason to believe that the supplier or user may utilize this period to alter inventories or records, such additional time shall not be permitted. Where such additional time is provided, the Food and Drug Administration may require the certifying party...
Food and Drug Administration, HHS

§ 501.100

Subpart F—Exemptions From Animal Food Labeling Requirements

§ 501.100 Animal food; exemptions from labeling.

(a) The following foods are exempt from compliance with the requirements of section 403(i)(2) of the act (requiring a declaration on the label of the common or usual name of each ingredient when the food is fabricated from two or more ingredients).

(1) An assortment of different items of food, when variations in the items that make up different packages packed from such assortment normally occur in good packing practice and when such variations result in variations in the ingredients in different packages, with respect to any ingredient that is not common to all packages. Such exemption, however, shall be on the condition that the label shall bear, in conjunction with the names of such ingredients as are common to all packages, a statement (in terms that are as informative as practicable and that are not misleading) indicating by name other ingredients which may be present.

(2) A food having been received in bulk containers at a retail establishment, if displayed to the purchaser with either (i) the labeling of the bulk container plainly in view or (ii) a counter card, sign, or other appropriate device bearing prominently and conspicuously the information required to be stated on the label pursuant to section 403(1)(2) of the act.

(3) Incidental additives that are present in a food at insignificant levels and do not have any technical or functional effect in that food. For the purposes of this paragraph (a)(3), incidental additives are:

(i) Substances that have no technical or functional effect but are present in a food by reason of having been incorporated into the food as an ingredient of another food, in which the substance did have a functional or technical effect.

(ii) Processing aids, which are as follows:

(a) Substances that are added to a food during the processing of such food but are removed in some manner from
§ 501.100

the food before it is packaged in its finished form.

(b) Substances that are added to a food during processing, are converted into constituents normally present in the food, and do not significantly increase the amount of the constituents naturally found in the food.

(c) Substances that are added to a food for their technical or functional effect in the processing but are present in the finished food at insignificant levels and do not have any technical or functional effect in that food.

(iii) Substances migrating to food from equipment or packaging or otherwise affecting food that are not food additives as defined in section 201(s) of the act; or if they are food additives as so defined, they are used in conformity with regulations established pursuant to section 409 of the act.

(b) A food repackaged in a retail establishment is exempt from the following provisions of the act if the conditions specified are met.

(1) Section 403(e)(1) of the act (requiring a statement on the label of the name and place of business of the manufacturer, packer, or distributor).

(2) Section 403(g)(2) of the act (requiring the label of a food which purports to be or is represented as one for which a definition and standard of identity has been prescribed to bear the name of the food specified in the definition and standard and, insofar as may be required by the regulation establishing the standard the common names of the optional ingredients present in the food), if the food is displayed to the purchaser with its interstate labeling clearly in view, or with a counter card, sign, or other appropriate device bearing prominently and conspicuously the information required by these provisions.

(3) Section 403(i)(1) of the act (requiring the label to bear the common or usual name of the food), if the food is displayed to the purchaser with its interstate labeling clearly in view, or with a counter card, sign, or other appropriate device bearing prominently and conspicuously the common or usual name of the food, or if the common or usual name of the food is clearly revealed by its appearance.

(c) [Reserved]

(d) Except as provided by paragraphs (e) and (f) of this section, a shipment or other delivery of a food which is, in accordance with the practice of the trade, to be processed, labeled, or repacked in substantial quantity at an establishment other than that where originally processed or packed, shall be exempt, during the time of introduction into and movement in interstate commerce and the time of holding in such establishment, from compliance with the labeling requirements of section 403(c), (e), (g), (h), (i), (j) and (k) of the act if:

(1) The person who introduced such shipment or delivery into interstate commerce is the operator of the establishment where such food is to be processed, labeled, or repacked; or

(2) In case such person is not the operator, such shipment or delivery is made to such establishment under a written agreement, signed by and containing the post office addresses of such person and such operator, and containing such specifications for the processing, labeling, or repacking, as the case may be, of such food in such establishment as will ensure, if such specifications are followed, that such food will not be adulterated or misbranded within the meaning of the act.

(e) Conditions affecting expiration of exemptions.

(1) An exemption of a shipment or other delivery of a food under paragraph (d)(1) of this section shall, at the beginning of the act of removing such shipment or delivery, or any part thereof, from such establishment become void ab initio if the food comprising such shipment, delivery, or part is adulterated or misbranded within the meaning of the act when so removed.

(2) An exemption of a shipment or other delivery of a food under paragraph (d)(2) of this section shall become void ab initio with respect to the
§ 501.105 Declaration of net quantity of contents when exempt.

(a) The principal display panel of a food in package form shall bear a declaration of the net quantity of contents. This shall be expressed in the terms of weight, measure, numerical count, or a combination of numerical count and weight or measure. The statement shall be in terms of fluid measure if the food is liquid, or in terms of weight if the food is solid, semisolid, or viscous, or a mixture of solid and liquid; except that such statement may be in terms of dry measure if the food is a fresh fruit, fresh vegetable, or other dry commodity that is customarily sold by dry measure. If there is a firmly established general consumer usage and trade custom of declaring the contents of a liquid by weight, or a solid, semisolid, or viscous product by fluid measure, it may be used. Whenever the Commissioner determines that an existing practice of declaring net quantity of contents by weight, measure, numerical count, or a combination in the case of a specific packaged food does not facilitate value comparisons by consumers and offers opportunity for consumer confusion, he will by regulation designate the appropriate term or terms to be used for such commodity.

(b) (1) Statements of weight shall be in terms of avoirdupois pound and ounce.

(2) Statements of fluid measure shall be in terms of the U.S. gallon of 231 cubic inches and quart, pint, and fluid ounce subdivisions thereof, and shall:

(i) In the case of frozen food that is sold and consumed in a frozen state, express the volume at the frozen temperature.

(ii) In the case of refrigerated food that is sold in the refrigerated state, express the volume at 40 °F (4 °C).

(iii) In the case of other foods, express the volume at 68 °F (20 °C).

(3) Statements of dry measure shall be in terms of the U.S. bushel of 2,150.42 cubic inches and peck, dry
§ 501.105  quart, and dry pint subdivisions there-

(c) When the declaration of quantity of contents by numerical count does not give adequate information as to the quantity of food in the package, it shall be combined with such statement of weight, measure, or size of the individual units of the foods as will provide such information.

(d) The declaration may contain common or decimal fractions. A common fraction shall be in terms of halves, quarters, eighths, sixteenths, or thirty-seconds; except that if there exists a firmly established general consumer usage and trade custom of employing different common fractions in the net quantity declaration of a particular commodity, they may be employed. A common fraction shall be reduced to its lowest terms; a decimal fraction shall not be carried out to more than two places. A statement that includes small fractions of an ounce shall be deemed to permit smaller variations than one which does not include such fractions.

(e) The declaration shall be located on the principal display panel of the label, and with respect to packages bearing alternate principal panels it shall be duplicated on each principal display panel.

(f) The declaration shall appear as a distinct item on the principal display panel, shall be separated (by at least a space equal to the height of the lettering used in the declaration) from other printed label information appearing above or below the declaration and (by at least a space equal to twice the width of the letter “N” of the style of type used in the quantity of contents statement) from other printed label information appearing to the left or right of the declaration. It shall not include any term qualifying a unit of weight, measure, or count (such as jumbo quart and full gallon) that tends to exaggerate the amount of the food in the container. It shall be placed on the principal display panel within the bottom 30 percent of the area of the label panel in lines generally parallel to the base on which the package rests as it is designed to be displayed: Provided, That on packages having a principal display panel of 5 square inches or less, the requirement for placement within the bottom 30 percent of the area of the label panel shall not apply when the declaration of net quantity of contents meets the other requirements of this part.

(g) The declaration shall accurately reveal the quantity of food in the package exclusive of wrappers and other material packed therewith; provided that in the case of foods packed in containers designed to deliver the food under pressure, the declaration shall state the net quantity of the contents that will be expelled when the instructions for use as shown on the container are followed. The propellant is included in the net quantity declaration.

(h) The declaration shall appear in conspicuous and easily legible boldface print or type in distinct contrast (by typography, layout, color, embossing, or molding) to other matter on the package; except that a declaration of net quantity blown, embossed, or molded on a glass or plastic surface is permissible when all label information is so formed on the surface. Requirements of conspicuousness and legibility shall include the specifications that:

(1) The ratio of height to width (of the letter) shall not exceed a differential of 3 units to 1 unit (no more than 3 times as high as it is wide).

(2) Letter heights pertain to upper case or capital letters. When upper and lower case or all lower case letters are used, it is the lower case letter “o” or its equivalent that shall meet the minimum standards.

(3) When fractions are used, each component numeral shall meet one-half the minimum height standards.

(i) The declaration shall be in letters and numerals in a type size established in relationship to the area of the principal display panel of the package and shall be uniform for all packages of substantially the same size by complying with the following type specifications:

(1) Not less than 1⁄8 inch in height on packages the principal display panel of which has an area of 5 square inches or less.

(2) Not less than 1⁄8 inch in height on packages the principal display panel of which has an area of more than 5 but not more than 25 square inches.
(3) Not less than $\frac{3}{8}$ inch in height on packages the principal display panel of which has an area of more than 25 but not more than 100 square inches.

(4) Not less than $\frac{1}{4}$ inch in height on packages the principal display panel of which has an area of more than 100 square inches, except not less than $\frac{3}{8}$ inch in height if the area is more than 400 square inches.

Where the declaration is blown, embossed, or molded on a glass or plastic surface rather than by printing, typing, or coloring, the lettering sizes specified in paragraphs (i) (1) through (4) of this section shall be increased by $\frac{1}{16}$ of an inch.

(j) On packages containing less than 4 pounds or 1 gallon and labeled in terms of weight or fluid measure:

(1) The declaration shall be expressed both in ounces, with identification by weight or by liquid measure and, if applicable (1 pound or 1 pint or more) followed in parentheses by a declaration in pounds for weight units, with any remainder in terms of ounces or common or decimal fractions of the pound (see examples set forth in paragraphs (m) (1) and (2) of this section), or in the case of liquid measure, in the largest whole units (quarts, quarts and pints, or pints, as appropriate) with any remainder in terms of fluid ounces or common or decimal fractions of the pint or quart (see paragraph (m)(6) of this section).

(2) A declaration of $\frac{3}{4}$ pound avoirdupois weight shall be expressed as Net Wt. 12 oz.

(3) A declaration of 1 quart liquid measure shall be expressed as Net Wt. 32 fl. oz. (1 qt.).

(4) A declaration of $\frac{1}{4}$ quarts liquid measure shall be expressed as Net contents 56 fluid ounces (1 quart 1½ pints) or as Net 56 fluid oz. (1 qt. 1 pt. 8 oz.), but not in terms of quart and ounce such as Net 56 fluid oz. (1 quart 24 ounces).

(5) On a random package, declaration of $\frac{3}{4}$ pound avoirdupois may be expressed as Net Wt. 75 lb.

(6) A declaration of 2½ gallons liquid measure shall be expressed as Net contents 2½ gallons, Net contents 2.5 gallons, or Net contents 2 gallons 2 quarts and not as 2 gallons 4 pints.

(n) For quantities, the following abbreviations and none other may be employed (periods and plural forms are optional):

<table>
<thead>
<tr>
<th>weight wt.</th>
<th>pint pt.</th>
<th>quart qt.</th>
<th>fluid fl.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ounce oz.</td>
<td>pound lb.</td>
<td>gallon gal.</td>
<td></td>
</tr>
</tbody>
</table>

(o) Nothing in this section shall prohibit supplemental statements at locations other than the principal display panel(s) describing in nondeceptive terms the net quantity of contents.
§501.105 provided, that such supplemental statements of net quantity of contents shall not include any term qualifying a unit of weight, measure, or count that tends to exaggerate the amount of the food contained in the package; for example, \textit{jumbo quart} and \textit{full gallon}. Dual or combination declarations of net quantity of contents as provided for in paragraphs (a), (c), and (j) of this section (for example, a combination of net weight plus numerical count, net contents plus dilution directions of a concentrate, etc.) are not regarded as supplemental net quantity statements and may be located on the principal display panel.

(p) A separate statement of the net quantity of contents in terms of the metric system is not regarded as a supplemental statement and an accurate statement of the net quantity of contents in terms of the metric system of weight or measure may also appear on the principal display panel or on other panels.

(q) The declaration of net quantity of contents shall express an accurate statement of the quantity of contents of the package. Reasonable variations caused by loss or gain of moisture during the course of good distribution practice or by unavoidable deviations in good manufacturing practice will be recognized. Variations from stated quantity of contents shall not be unreasonably large.

(r) [Reserved]

(s) On a multiunit retail package, a statement of the quantity of contents shall appear on the outside of the package and shall include the number of individual units, the quantity of each individual unit, and, in parentheses, the total quantity of contents of the multiunit package in terms of avoirdupois or fluid ounces, except that such declaration of total quantity need not be followed by an additional parenthetical declaration in terms of the largest whole units and subdivisions thereof, as required by paragraph (j)(1) of this section. A multiunit retail package may thus be properly labeled: 6–16 oz. bottles—(96 fl. oz.) or 3–16 oz. cans—(net wt. 48 oz). For the purposes of this section, \textit{multiunit retail package} means a package containing two or more individually packaged units of the identical commodity and in the same quantity, intended to be sold as part of the multiunit retail package but capable of being individually sold in full compliance with all requirements of the regulations in this part. Open multiunit retail packages that do not obscure the number of units nor prevent examination of the labeling on each of the individual units are not subject to this paragraph if the labeling of each individual unit complies with the requirements of paragraphs (f) and (i) of this section.

(t) Where the declaration of net quantity of contents is in terms of net weight and/or drained weight or volume and does not accurately reflect the actual quantity of the contents or the product falls below the applicable standard of fill of container because of equipment malfunction or otherwise unintentional product variation, and the label conforms in all other respects to the requirements of this chapter (except the requirement that food falling below the applicable standard of fill of container shall bear the general statement of substandard fill specified in §564.14(b) of this chapter), the mislabeled food product, including any food product that fails to bear the general statement of substandard fill specified in §564.14(b) of this chapter, may be sold by the manufacturer or processor directly to institutions operated by Federal, State or local governments: \textit{Provided, That}:

1. The purchaser shall sign a statement at the time of sale stating that he is aware that the product is mislabeled to include acknowledgement of the nature and extent of the mislabeling, e.g., “Actual net weight may be as low as ___% below labeled quantity” and that any subsequent distribution by him of said product except for his own institutional use is unlawful. This statement shall be kept on file at the principal place of business of the manufacturer or processor for 2 years subsequent to the date of shipment of the product and shall be available to the Food and Drug Administration upon request.

2. The product shall be labeled on the outside of its shipping container with the statement(s):
§ 502.5 General principles.

(a) The common or usual name of a food, which may be a coined term, shall accurately identify or describe, in as simple and direct terms as possible, the basic nature of the food or its characterizing properties or ingredients. The name shall be uniform among all identical or similar products and may not be confusingly similar to the name of Food and Drug Administration, HHS

§ 501.110 Animal feed labeling; collective names for feed ingredients.

(a) An animal feed shall be exempt from the requirements of section 403(i)(2) of the act with respect to its label bearing the common or usual names of the animal feed ingredients listed in paragraph (b) of this section under the following prescribed conditions:

(1) The animal feed is intended solely for livestock and poultry.

(2) The label of the animal feed bears the collective name(s) prescribed in paragraph (b) of this section in lieu of the corresponding common or usual names of the individual feed ingredients contained therein.

(3) The label of the animal feed otherwise conforms to the requirements of section 403(i)(2) of the act.

(b) Each collective name referred to in this paragraph may be used for the purpose of labeling where one or more of the ingredients listed for that collective name are present. The animal feed ingredients listed under each of the collective names are the products defined by the Association of American Feed Control Officials. The collective names are as follows:

(1) Animal protein products include one or more of the following: Animal products, marine products, and milk products.

(2) Forage products include one or more of the following: Alfalfa meals, entire plant meals, hays, and stem meals.

(3) Grain products include one or more of the following: Barley, grain sorghums, maize (corn), oats, rice, rye, and wheat.

(4) Plant protein products include one or more of the following: Algae meals, coconut meals (copra), cottonseed meals, guar meal, linseed meals, peanut meals, safflower meals, soybean meals, sunflower meals, and yeasts.

(5) Processed grain byproducts include one or more of the following: Brans, brewers dried grains, distillers grains, distillers solubles, flours, germ meals, gluten feeds, gluten meals, grits, groats, hominy feeds, malt sprouts, middlings, pearl, polishes, shorts, and wheat mill run.

(6) Roughage products include one or more of the following: Cobs, hulls, husks, pulps, and straw.
§ 502.5 any other food that is not reasonably encompassed within the same name. Each class or subclass of food shall be given its own common or usual name that states, in clear terms, what it is in a way that distinguishes it from different foods.

(1) The common or usual name of a food shall include the percentage(s) of any characterizing ingredient(s) or component(s) when the proportion of such ingredient(s) or component(s) in the food has a material bearing on price or consumer acceptance or when the labeling or the appearance of the food may otherwise create an erroneous impression that such ingredient(s) or component(s) is present in an amount greater than is actually the case. The following requirements shall apply unless modified by a specific regulation in this part.

(i) Not less than one-sixteenth inch in height on packages having a principal display panel with an area of 5 square inches or less and not less than one-eighth inch in height if the area of the principal display panel is greater than 5 square inches; or

(ii) Not less than one-half the height of the largest type appearing in the part of the common or usual name of the food required by paragraph (a) of this section.

(2) The common or usual name of a food shall include a statement of the presence or absence of any characterizing ingredient(s) or component(s) and/or the need for the user to add any characterizing ingredient(s) or component(s) in the food has a material bearing on price or consumer acceptance or when the labeling or the appearance of the food may otherwise create an erroneous impression that such ingredient(s) or component(s) is present when it is not, and consumers may otherwise be misled about the presence or absence of the ingredient(s) or component(s) in the food. The following requirements shall apply unless modified by a specific regulation in this part.

(i) Not less than one-sixteenth inch in height on packages having a principal display panel with an area of 5 square inches or less and not less than one-eighth inch in height if the area of the principal display panel is greater than 5 square inches; or

(ii) Not less than one-half the height of the largest type appearing in the part of the common or usual name of the food required by paragraph (a) of this section.

(c) The common or usual name of a food shall include a statement of the presence or absence of any characterizing ingredient(s) or component(s) in the food. The following requirements shall apply unless modified by a specific regulation in this part.

(1) The presence or absence of a characterizing ingredient or component shall be declared by the words “containing (or contains) ______ percent (or %) ______” or “ ______ percent (or %) ______” with the first blank filled in with the percentage expressed as a whole number not greater than the actual percentage of the ingredient or component named and the second blank filled in with the common or usual name of the ingredient or component. The word “containing” (or “contains”), when used, shall appear on a line immediately below the part of the common or usual name of the food required by paragraph (a) of this section. For each characterizing ingredient or component, the words “ ______ percent (or %) ______” shall appear following or directly below the word “containing” (or “contains”), or directly below the part of the common or usual name of the food required by paragraph (a) of this section when the word “containing” (or “contains”) is not used, in easily legible boldface print or type in distinct contrast to other printed or graphic matter, and in a height not less than the larger of the following alternatives:

(d) A common or usual name of a food may be established by common
Food and Drug Administration, HHS

usage or by establishment of a regulation in this part, in a standard of identity, or in other regulations in this chapter.


§ 502.19 Petitions.

(a) The Commissioner of Food and Drugs, either on his own initiative or on behalf of any interested person who has submitted a petition, may publish a proposal to issue, amend, or revoke, under this part, a regulation prescribing a common or usual name for a food, pursuant to part 10 of this chapter.

(b) If the principal display panel of a food for which a common or usual name regulation is established is too small to accommodate all mandatory requirements, the Commissioner may establish by regulation an acceptable alternative, e.g., a smaller type size. A petition requesting such a regulation, which would amend the applicable regulation, shall be submitted pursuant to part 10 of this chapter.


PART 509—UNAVOIDABLE CONTAMINANTS IN ANIMAL FOOD AND FOOD-PACKAGING MATERIAL

Subpart A—General Provisions

Sec.

509.3 Definitions and interpretations.

509.4 Establishment of tolerances, regulatory limits, and action levels.

509.5 Petitions.

509.6 Added poisonous or deleterious substances.

509.7 Unavoidability.

509.15 Use of polychlorinated biphenyls (PCB’s) in establishments manufacturing food-packaging materials.

Subpart B—Tolerances for Unavoidable Poisonous or Deleterious Substances

509.30 Temporary tolerances for polychlorinated biphenyls (PCB’s).

Subpart C—Regulatory Limits for Added Poisonous or Deleterious Substances [Reserved]

§ 509.4 Establishment of tolerances, regulatory limits, and action levels.

(a) When appropriate under the criteria of §509.6, a tolerance for an added poisonous or deleterious substance, which may be a food additive, may be established by regulation in subpart B of this part under the provisions of section 406 of the act. A tolerance may prohibit any detectable amount of the substance in food.

(b) When appropriate under the criteria of §509.6, and under section 402(a)(1) of the act, a regulatory limit for an added poisonous or deleterious substance, which may be a food additive, may be established by regulation in subpart C of this part under the provisions of sections 402(a)(1) and 701(a) of
§ 509.5

the act. A regulatory limit may prohibit any detectable amount of the substance in food. The regulatory limit established represents the level at which food is adulterated within the meaning of section 402(a)(1) of the act.

(c)(1) When appropriate under the criteria of §509.6, an action level for an added poisonous or deleterious substance, which may be a food additive, may be established to define a level of contamination at which a food may be regarded as adulterated.

(2) Whenever an action level is established or changed, a notice shall be published in the Federal Register as soon as practicable thereafter. The notice shall call attention to the material supporting the action level which shall be on file with the Dockets Management Branch before the notice is published. The notice shall invite public comment on the action level.

(d) A regulation may be established in subpart D of this part to identify a food containing a naturally occurring poisonous or deleterious substance which will be deemed to be adulterated under section 402(a)(1) of the act. These regulations do not constitute a complete list of such foods.


§ 509.6 Added poisonous or deleterious substances.

(a) Use of an added poisonous or deleterious substance, other than a pesticide chemical, that is also a food additive will be controlled by a regulation issued under section 409 of the act when possible. When such a use cannot be approved under the criteria of section 409 of the act, or when the added poisonous or deleterious substance is not a food additive, a tolerance, regulatory limit, or action level may be established pursuant to the criteria in paragraphs (b), (c), or (d) of this section. Residues resulting from the use of an added poisonous or deleterious substance that is also a pesticide chemical will ordinarily be controlled by a tolerance established in a regulation issued under sections 406, 408, or 409 of the act by the U.S. Environmental Protection Agency (EPA). When such a regulation has not been issued, an action level for an added poisonous or deleterious substance that is also a pesticide chemical may be established by the Food and Drug Administration. The Food and Drug Administration will request EPA to recommend such an action level pursuant to the criteria established in paragraph (d) of this section.

(b) A tolerance for an added poisonous or deleterious substance in any food may be established when the following criteria are met:

(1) The substance cannot be avoided by good manufacturing practice.

(2) The tolerance established is sufficient for the protection of the public health, taking into account the extent of which the presence of the substance cannot be avoided and the other ways in which the consumer may be affected by the same or related poisonous or deleterious substances.

(3) No technological or other changes are foreseeable in the near future that might affect the appropriateness of the tolerance established. Examples of changes that might affect the appropriateness of the tolerance include anticipated improvements in good manufacturing practice that would change the extent to which use of the substance is unavoidable and anticipated studies expected to provide significant new toxicological or use data.

(c) A regulatory limit for an added poisonous or deleterious substance in any food may be established when each of the following criteria is met:

(1) The substance cannot be avoided by current good manufacturing practices.
(2) There is no tolerance established for the substance in the particular food under sections 406, 408, or 409 of the act.

(3) There is insufficient information by which a tolerance may be established for the substance under section 406 of the act or technological changes appear reasonably possible that may affect the appropriateness of a tolerance. The regulatory limit established represents the level at which food is adulterated within the meaning of section 402(a)(1) of the act.

(d) An action level for an added poisonous or deleterious substance in any food may be established when the criteria in paragraph (b) of this section are met, except that technological or other changes that might affect the appropriateness of the tolerance are foreseeable in the near future. An action level for an added poisonous or deleterious substance in any food may be established at a level at which the Food and Drug Administration may regard the food as adulterated within the meaning of section 402(a)(1) of the act, without regard to the criteria in paragraph (b) of this section or in section 406 of the act. An action level will be withdrawn when a tolerance or regulatory limit for the same substance and use has been established.

(e) Tolerances will be established under authority appropriate for action levels (sections 306, 402(a), and 701(a) of the act, together with section 408 or 409 of the act, if appropriate) as well as under authority appropriate for tolerances (sections 406 and 701 of the act). In the event the effectiveness of a tolerance is stayed pursuant to section 701(e)(2) of the act by the filing of an objection, the order establishing the tolerance shall be deemed to be an order establishing an action level until final action is taken upon such objection.

§ 509.15  Use of polychlorinated biphenyls (PCB's) in establishments manufacturing food-packaging materials.

(a) Polychlorinated biphenyls (PCB's) represent a class of toxic industrial chemicals manufactured and sold under a variety of trade names, including: Aroclor (United States); Phenoclor (France); Colphen (Germany); and Kanaclor (Japan). PCB's are highly stable, heat resistant, and nonflammable chemicals. Industrial uses of PCB's include, or did include in the past, their use as electrical transformer and capacitor fluids, heat transfer fluids, hydraulic fluids, and plasticizers, and in formulations of lubricants, coatings, and inks. Their unique physical and chemical properties and widespread, uncontrolled industrial applications have caused PCB's to be a persistent and ubiquitous contaminant in the environment, causing the contamination of certain foods. In addition, incidents have occurred in which PCB's have directly contaminated animal feeds as a result of industrial accidents (leakage or spillage of PCB fluids from plant equipment). These accidents in turn caused the contamination of food products intended for human consumption (meat, milk and eggs). Investigations by the Food and Drug Administration...

§ 509.7  Unavoidability.

(a) Tolerances and action levels in this part are established at levels based on the unavoidability of the poisonous or deleterious substance concerned and do not establish a permissible level of contamination where it is avoidable.
§ 509.30

Subpart B—Tolerances for Unavoidable Poisonous or Deleterious Substances

§ 509.30 Temporary tolerances for polychlorinated biphenyls (PCB's).

(a) Polychlorinated biphenyls (PCB’s) are toxic, industrial chemicals. Because of their widespread, uncontrolled industrial applications, PCB’s have become a persistent and ubiquitous contaminant in the environment. As a result, certain foods and animal feeds, principally those of animal and marine origin, contain PCB’s as unavoidable, environmental contaminants. PCB’s are transmitted to the food portion (meat, milk, and eggs) of food producing animals ingesting PCB contaminated animal feed. In addition, a significant percentage of paper food-packaging materials contain PCB’s which may migrate to the packaged food. The source of PCB’s in paper food-packaging materials is primarily of certain types of carbonless copy paper (containing 3 to 5 percent PCB’s) in waste paper stocks used for manufacturing recycled paper. Therefore, temporary tolerances for residues of PCB’s as unavoidable environmental or
industrial contaminants are established for a sufficient period of time following the effective date of this paragraph to permit the elimination of such contaminants at the earliest practicable time. For the purposes of this paragraph, the term polychlorinated biphenyls (PCB’s) is applicable to mixtures of chlorinated biphenyl compounds, irrespective of which mixture of PCB’s is present as the residue. The temporary tolerances for residues of PCB’s are as follows:

(1) 0.2 part per million in finished animal feed for food-producing animals (except the following finished animal feeds: feed concentrates, feed supplements, and feed premixes).

(2) 2 parts per million in animal feed components of animal origin, including fishmeal and other by-products of marine origin and in finished animal feed concentrates, supplements, and premixes intended for food-producing animals.

(3) 10 parts per million in paper food-packaging material intended for or used with finished animal feed and any components intended for animal feeds. The tolerance shall not apply to paper food-packaging material separated from the food therein by a functional barrier which is impermeable to migration of PCB’s.

(b) A compilation entitled ‘Analytical Methodology for Polychlorinated Biphenyls, February 1973’ for determining compliance with the tolerances established in this section is available from the Dockets Management Branch, Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.


Subpart C—Regulatory Limits for Added Poisonous or Deleterious Substances [Reserved]

Subpart D—Naturally Occurring Poisonous or Deleterious Substances [Reserved]
§ 510.3 Definitions and interpretations.

As used in this part:


(b) *Department* means the Department of Health and Human Services.

(c) *Secretary* means the Secretary of Health and Human Services.

(d) *Commissioner* means the Commissioner of Food and Drugs.

(e) *Person* means individuals, partnerships, corporations, and associations.

(f) The definitions and interpretations of terms contained in section 201 of the act shall be applicable to such terms when used in the regulations in this part.

(g) The term *new animal drug* means any drug intended for use for animals other than man, including any drug intended for use in animal feed but not including such animal feed:

1. The composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling thereof; except that such a drug not so recognized shall not be deemed to be a *new animal drug* if at any time prior to June 25, 1938, it was subject to the Food and Drug Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use; or

2. The composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.

(h) The term *animal feed* means an article which is intended for use for food for animals other than man and which is intended for use as a substantial source of nutrients in the diet of the animal, and is not limited to a mixture intended to be the sole ration of the animal.

(i) The newness of an animal drug, including a new animal drug intended for use in or on animal feed, may arise by reason of:

1. The newness for its intended drug use of any substance of which the drug is comprised, in whole or in part, whether it be an active substance or a menstruum, excipient, carrier, coating, or other component; (2) the newness for its intended drug use of a combination of two or more substances, none of which is itself a new animal drug; (3) the newness for its intended drug use of the proportion of a substance in a combination, even though such combination containing such substance in other proportion is not a new animal drug; (4) the newness for its intended drug use in a different species of animal; (5) the newness of its intended drug use in diagnosing, curing, mitigating, treating, or preventing a disease, or to affect a structure or function of the animal body, even though such drug is not a new animal drug when used in another disease or to affect another structure or function of the body; or (6) the newness of a dosage, or method or duration of administration or application, or any other condition of use prescribed, recommended, or suggested in the labeling of such drug, even though such drug or animal feed containing such drug when used in another dosage, or another method or duration of administration or application, or any other condition, is not a new animal drug.

(j) *Animals used only for laboratory research* and *laboratory research animals* mean individual animals or groups of animals intended for use and used solely for laboratory research purposes, regardless of species, and does not include animals intended to be used for any food purposes or animals intended to be kept as livestock.
§ 510.106 Labeling of antibiotic and antibiotic-containing drugs intended for use in milk-producing animals.

Whenever the labeling of an antibiotic drug included in the regulations in this chapter suggests or recommends its use in milk-producing animals, the label of such drugs shall bear either the statement “Warning: Not for use in animals producing milk, since this use
§ 510.110 Antibiotics used in food-producing animals.

(a) The Food and Drug Administration in the interest of fulfilling its responsibilities with regard to protection of the public health has requested an evaluation of the public health aspects of the use of antibiotics in veterinary medical and nonmedical uses. There is particular concern with regard to the potential hazards associated with the extensive use of antibiotics administered to food-producing animals. Accordingly, an ad hoc committee on the Veterinary Medical and Nonmedical Uses of Antibiotics was established by the Food and Drug Administration to study and advise the Commissioner of Food and Drugs on the uses of antibiotics in veterinary medicine and for various nonmedical purposes as such uses may affect the enforcement of the Federal Food, Drug, and Cosmetic Act with respect to their safety and effectiveness.

(b) Based upon an evaluation of the conclusions of said Committee and other relevant material, § 510.112 was published in the Federal Register of August 23, 1966 (31 FR 11141), asking sponsors of drugs containing any antibiotic intended for use in food-producing animals to submit data to establish whether such antibiotic and its metabolites are present as residues in edible tissues, milk, and eggs from treated animals. The data on the residues of antibiotics in milk from intramammary infusion preparations were requested within 60 days and the data on all other products were requested within 180 days following the date of publication of § 510.112 in the Federal Register.

(c) An evaluation of the data now available shows that use of many antibiotic preparations cause residues in edible products of treated animals for varying and, in some cases, for long periods of time following the last administration. Because of the accumulation of new information with regard to the development of resistance of bacteria to antibiotics, the ability of bacteria to transfer this resistance, and the development of sensitivity to antibiotics in humans, unauthorized and unsafe residues of antibiotics cannot be permitted in food obtained from treated animals.

(d) Based on evaluation of information available, including the conclusions of the aforementioned ad hoc Committee, the Commissioner concludes that antibiotic preparations intended for use in food-producing animals, other than topical and ophthalmic preparations, are not generally recognized among qualified experts as having been shown to be safe for their intended use(s) within the meaning of section 201(s) of the Federal Food, Drug, and Cosmetic Act.

(e) Therefore, all exemptions from the provisions of section 409 of the act for use of antibiotics in food-producing animals based on sanctions or approvals granted prior to enactment of the Food Additives Amendment of 1958 (Pub. L. 85–929; 72 Stat. 1784) will be revoked and the uses which are concluded to be safe will be covered by food additive regulations. On those products for which there are inadequate residue data, actions will be initiated to withdraw approval of new-drug applications under the provisions of section 505 of the act. Antibiotic preparations, other than those for topical and ophthalmic application in food-producing animals, which are not covered by food additive regulations will be subject to regulatory action.
§510.300 Records and reports concerning experience with new animal drugs for which an approved application is in effect.

(a) On receiving notification that an application submitted pursuant to §514.1 of this chapter for a new animal drug is approved, the applicant shall establish and maintain such records and make such reports as are specified in this section to facilitate a determination as to whether there may be grounds for suspending or withdrawing approval of the application or whether any applicable regulation should be amended or repealed. The applicant shall maintain adequately organized and indexed files containing full reports of information pertinent to the safety or effectiveness of the new animal drug that have not previously been submitted as part of his application for the drug and which are received or otherwise obtained by him from any source, as follows:

Food and Drug Administration, HHS

§510.112 Antibiotics used in veterinary medicine and for nonmedical purposes; required data.

(a) An ad hoc committee, Committee on the Veterinary Medical and Nonmedical Uses of Antibiotics, was formed by the Food and Drug Administration to study, and advise the Commissioner on, the use of antibiotics in veterinary medicine and for various nonmedical purposes as such uses may affect the enforcement of the Federal Food, Drug, and Cosmetic Act with respect to the safety and effectiveness of such substances. A copy of the report may be obtained from the Food and Drug Administration, Office of Public Affairs, Room 15–05, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857.

(b) On the basis of the report of the Committee and other information, sponsors of drugs containing any antibiotic intended for use in food-producing animals shall submit data for determining whether or not such antibiotics and their metabolites are present as residues in edible tissues, milk, and eggs from treated animals; however, in the case of a drug for which such data have already been submitted and for which a regulation has been promulgated under section 409 of the act, only such data as has been accumulated since the issuance of the regulation need be submitted.

(c) The required data shall be submitted within 180 days of the date of publication of this section in the Federal Register; except that in the case of data on intramammary infusion preparations the data shall be submitted within 90 days of such publication.

(d) Regulatory proceedings including revocation of prior sanctions, or actions to suspend or amend new drug or antibiotic approvals granted prior to passage of the Food Additives Amendment of 1958 (72 Stat. 1784), may be initiated with regard to the continued marketing of any antibiotic preparation on which the required information is not submitted within the period of time prescribed by paragraph (c) of this section.

(e) Questions relating to the acceptability of proposed research protocols and assay methods for determining the amount of antibiotic residues in food should be directed to the Director, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

§ 510.300 21 CFR Ch. I (4–1–02 Edition)

(1) Unpublished reports of clinical or other animal experience, studies, investigations, and tests conducted by the applicant or reported to him by any person involving the new animal drug that is the subject of the application or any related drugs. An adequate summary and bibliography of reports in the scientific literature would ordinarily suffice. (The application must identify at the time of each report submission, each drug he considers related to the subject drug.)

(2) Experience, investigations, studies, or tests involving the chemical or physical properties or any other properties of the new animal drug, such as its behavior or properties in relation to microorganisms, including both the effects of the drug on microorganisms and the effect of microorganisms on the drug.

(3) For information required by this section, adequate identification of its source, when known, including the name and post office address of the person who furnishes such information.

(4) Copies of all mailing pieces and other labeling, and, if it is a prescription new animal drug, all advertising other than that contained in the application used in promoting the drug, and copies of the currently used package labeling that gives full information for use of the drug whether or not such labeling is contained in the application.

(5) Information concerning the quantity of the new animal drug distributed in a manner and form that facilitates estimates of the incidence of any adverse effects reported to be associated with the use of the drug. This does not require disclosure of financial, pricing, or sales data.

(6) Information concerning any previously unreported changes from the conditions described in an application conforming to the conditions of §514.8(a)(5) of this chapter.

(b) The applicant shall submit to the Food and Drug Administration copies of the records and reports described in paragraph (a) of this section, except routine assay and control records, appropriately identified with the new animal drug application(s) to which they relate, as follows:

(1) Immediately upon receipt by the applicant, complete records or reports covering information of the following kinds:

(i) Information concerning a mixup in the new animal drug or its labeling with another article.

(ii) Information concerning any bacteriological or significant physical or other change or deterioration in the new animal drug, or any failure of one or more distributed batches of the drug to meet the specifications established for it in the new animal drug application.

(2) As soon as possible, and in any event within 15 working days of its receipt by the applicant, complete records of reports concerning any information of the following kinds:

(i) Information concerning any unexpected side effects, injury, toxicity, or sensitivity reaction or any unexpected incidence or severity thereof associated with clinical use, studies, investigations, or tests, whether or not determined to be attributable to the new animal drug, except that this requirement shall not apply to the submission of information described in a written communication to the applicant from the Food and Drug Administration as types of information that may be submitted at other designated intervals. Unexpected as used in this subdivision refers to conditions or developments not previously submitted as part of the new animal drug application, or conditions and developments occurring at a rate higher than that shown by information previously submitted as part of the application.

(ii) Information concerning any unusual failure of the new animal drug to exhibit its expected pharmacological activities.

(3) When mailing pieces, any other labeling, and advertising are devised for promotion of the new animal drug, specimens shall be submitted at the time of initial dissemination of such labeling and at the time of initial publication of any advertisement for a prescription drug. Mailing pieces and labeling designed to contain samples of a drug shall be complete except for the omission of the drug.

(4) All the kinds of information described in paragraph (a) of this section, other than that submitted under the provisions of paragraphs (b) (1), (2), and
(3) of this section, shall be submitted as follows unless otherwise ordered in a written communication from the Commissioner:

(i) At intervals within 6 months beginning with the date of approval of the new animal drug application during the first year following such date, and at yearly intervals thereafter.

(ii) Whenever an applicant is required to submit reports under the provisions of paragraph (b)(4)(i) of this section with respect to more than one approved application for preparations containing the same new animal drug so that the same item(s) of information is (are) required to be reported for more than one application, he may elect to submit as a part of the report for one such application all the information common to such applications in lieu of reporting separately and repetitively on each. The applicant shall state when this is done and identify all the new animal drug applications for which the reports are submitted.

(iii) The submitted copies of records and reports shall include all the required information that was received or otherwise obtained by the applicant during the designated intervals.

(5) On written order of the Commissioner, within the time stated in such order or agreed to by the applicant and the Commissioner, any designated records or reports containing the kinds of information described in this section shall be submitted.

(c) The applicant shall, upon request of any properly authorized officer or employee of the Department at reasonable times, permit such officers to have access to and copy and verify any records and reports established and maintained under the provisions of this section.

(d) If the Food and Drug Administration finds that the applicant has failed to establish a system for maintaining required records or has repeatedly or deliberately failed to maintain such records or to make required reports in accordance with the provisions of this section, or that the applicant has refused to permit access to or copying of, or verification of such records or reports, the Commissioner shall give the applicant notice and opportunity for a hearing on the question of whether to withdraw the approval of the application, as provided in §514.200 of this chapter.

(e) Upon written request of the applicant stating reasonable grounds therefor, the Commissioner will make available any information in possession of the Food and Drug Administration of the kinds the applicant is required to maintain under the provisions of this section, except information readily available to the applicant from other sources or information which the Commissioner concludes is confidential.

(f) The applicant required to establish and maintain records and make reports required by this section includes any person whose name appears on the labeling of the drug as its manufacturer, packer, or distributor under an approval or who is engaged in the manufacturing, processing, packing, or labeling of the drug under an approval of the new animal drug application or any supplement to it; however, to avoid unnecessary duplication in the submission of reports, any such applicant's obligation to submit a report may be met by its submission on his behalf, designated as such, by another person responsible for reporting.


§510.301 Records and reports concerning experience with animal feeds bearing or containing new animal drugs for which an approved medicated feed mill license application is in effect.

Records and reports of clinical and other experience with the new animal drug will be maintained and reported, appropriately identified with the new animal drug application(s) to which they relate, to the Center for Veterinary Medicine in duplicate in accordance with the following:

(a) Immediately upon receipt by the applicant, complete records or reports covering information of the following kinds:

(1) Information concerning any mixup in the new animal drug or its labeling with another article.
§ 510.302 Reporting forms.

(a) The information described in §510.300, except that described in paragraphs (b) (1) and (2) of that section, shall be submitted appropriately identified with the new animal drug application or at a rate higher than encountered during such clinical trials.

(b) All adverse experiences with new animal drugs as described in §510.300(b)(2) or §510.301(b) whether or not related to a required periodic report submitted on a Form FD-2301, shall be reported on Form FD-1932 “Adverse Drug Reaction” (except as provided in paragraph (c) of this section). Reports of adverse drug experiences may be submitted initially in the form of a written communication, but any such communication shall be followed promptly (but not necessarily within the prescribed 15 working days) by a completed Form FD-1932. A separate “Adverse Drug Reaction” form should be submitted for each patient where feasible.

(c) In lieu of Form FD-1932 the holder of an approved new animal drug application may submit:

(1) A computerized report if the information contained therein and the sequence in which it is presented are equivalent to that required by Form FD-1932 and the report is submitted in duplicate. Such reports will require initial approval by the Food and Drug Administration prior to use; and

(2) Copies of reports of reactions appearing in the published scientific literature may be submitted.

(d) Forms FD-1932 and FD-2301, with instructions for their use, may be obtained from the Food and Drug Administration, Department of Health and Human Services, Center for Veterinary Medicine, 7500 Standish Pl., Rockville, MD 20855.

§ 510.305 Maintenance of copies of approved medicated feed mill licenses to manufacture animal feed bearing or containing new animal drugs.

Each applicant shall maintain in a single accessible location:

(a) A copy of the approved medicated feed mill license (Form FDA 3448) on the premises of the manufacturing establishment; and

(b) Approved labeling for each Type B and/or Type C feed being manufactured on the premises of the manufacturing establishment or the facility where the feed labels are generated.

[64 FR 63203, Nov. 19, 1999]
Subpart E—Requirements for Specific New Animal Drugs

§510.410 Corticosteroids for oral, injectable, and ophthalmic use in animals; warnings and labeling requirements.

(a) The Food and Drug Administration has received reports of side effects associated with the oral, injectable, and ophthalmic use of corticosteroid animal drugs. The use of these drugs administered orally or by injection has resulted in premature parturition when administered during the last trimester of pregnancy. Premature parturition may be followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids used in dogs, rabbits, and rodents during pregnancy have produced cleft palate in offspring. Use in dogs has resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca. Drugs subject to this section are required to carry the veterinary prescription legend and are subject to the labeling requirements of §201.105 of this chapter.

(b) In view of these potentially serious side effects, the Food and Drug Administration has concluded that the labeling on or within packaged corticosteroid-containing preparations intended for animal use shall bear conspicuously the following warning statement:

Warning: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids used in dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Drugs subject to this section are required to carry the veterinary prescription legend and are subject to the labeling requirements of §201.105 of this chapter.

§510.440 Injectable iron preparations.

There has been an increasing interest in the use of injectable iron compounds for the prevention or treatment of iron-deficiency anemia in animals. Although some such preparations have been shown to be safe, such articles are regarded as new animal drugs within the meaning of the Federal Food, Drug, and Cosmetic Act. Accordingly, an approved new animal drug application is required prior to the marketing of such preparations within the jurisdiction of the act. In addition to the need for demonstrating the safety of such articles, the labeling of such preparations should not only recommend appropriate dosages of iron but also declare the amount (in milligrams) of available iron (Fe) per milliliter of the subject product.

§510.455 New animal drug requirements regarding free-choice administration in feeds.

(a) For the purpose of this section, free-choice administration of animal drugs in feeds involves feeds that are placed in feeding or grazing areas and are not intended to be consumed fully at a single feeding or to constitute the entire diet of the animal. Such methods of administering drugs include, but are not limited to, medicated blocks (agglomerated feed compressed or rendered into a solid mass and cohesive enough to hold its form), mineral mixes, and liquid feed tank supplements (“lick tank” supplements) containing one or more animal drugs. The manufacture of medicated free-choice feeds is subject to the current good manufacturing practice regulations for medicated feeds.

(b) The Food and Drug Administration has concluded that there are questions about the safety and effectiveness of drugs when administered in free-choice feeds. Therefore, such methods of administration cause the drugs so administered to be new animal drugs, for which approved new animal drug applications (NADA’s) are required. (See §510.3(i)). In addition, the exemption from the requirement of an approved medicated feed application provided in §558.4 of this chapter does not apply to any free-choice medicated feed.

(c) An NADA or supplemental NADA for products for free-choice feeding submitted for approval under section 512(b) of the act shall provide for:
§510.515 Animal feeds bearing or containing new animal drugs subject to the provisions of section 512(n) of the act.

Animal feeds that bear or contain penicillin, chlortetracycline, feed grade zinc bacitracin, and bacitracin methylene disalicylate, with or without added suitable nutritive ingredients are exempt from the certification requirements of section 512 of the act provided they are the subject of and in compliance with regulations for their use in this subchapter E, part 558 of this chapter, or any one of the paragraphs of this section:

(a) Where indicated in paragraph (b) of this section it is manufactured with or without one, but only one, of the following ingredients in a quantity, by weight of feed, as hereinafter indicated:

(1) Arsanilic acid: Not less than 0.005 percent and not more than 0.01 percent.

(2) Sodium arsanilate: Not less than 0.005 percent and not more than 0.01 percent.

(3) 3-Nitro-4-hydroxyphenylarsonic acid: Not less than 0.0025 percent and not more than 0.0075 percent except in chicken or turkey feed which shall contain not less than 0.0025 percent and not more than 0.005 percent.

(b) It is intended for use in any one of the following conditions set forth in this paragraph:

(1) It is intended for use solely in the treatment of chronic respiratory disease (air-sac infection), infectious sinusitis, and blue comb (nonspecific infectious enteritis) in poultry and/or bacterial swine enteritis; its labeling bears adequate directions and warnings for such use; and it contains, per ton of feed, the equivalent of 100 grams of

[51 FR 19827, June 3, 1986, as amended at 67 FR 9586, Mar. 4, 2002]
Food and Drug Administration, HHS  
§ 510.600

penicillin. When intended for uses specified in this paragraph, it may also contain, in the amount specified, one, but only one, of the ingredients prescribed by paragraph (a) of this section.

(2) It is intended for use solely in the treatment of chronic respiratory disease (air-sac infection) and infectious sinusitis in poultry; its labeling bears adequate directions and warnings for such use; and it contains not less than 0.1 percent para-aminobenzoic acid or the sodium or potassium salt or para-aminobenzoic acid.

(3) [Reserved]

(c) It is intended for use as follows:

<table>
<thead>
<tr>
<th>Product</th>
<th>Species</th>
<th>Use levels</th>
<th>Indications for use</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Nicarbazin</td>
<td>Chickens</td>
<td>0.01 to 0.02 percent</td>
<td>For use in the prevention of outbreaks of coccidiosis in poultry flocks; growth promotion and feed efficiency. Do.</td>
</tr>
<tr>
<td>2. Nicarbazin Bacitracin methylene disalicylate.</td>
<td>.do</td>
<td>4 to 50 g/ton.</td>
<td>Do.</td>
</tr>
<tr>
<td>3. Nicarbazin Bacitracin methylene disalicylate. 3-Nitro-4-hydroxyphenylarsenic acid.</td>
<td>.do</td>
<td>0.0025 to 0.005 percent.</td>
<td>For use as an aid in the prevention of coccidiosis in poultry flocks; growth promotion and feed efficiency; improving pigmentation.</td>
</tr>
<tr>
<td>4. Nicarbazin Bacitracin methylene disalicylate. 3-Nitro-4-hydroxyphenylarsenic acid.</td>
<td>.do</td>
<td>0.01 to 0.02 percent</td>
<td>Do.</td>
</tr>
<tr>
<td>5. Chlorotetracycline Arsanilic acid.</td>
<td>Swine</td>
<td>10 to 50 g/ton</td>
<td>Enhancement of growth and feed efficiency.</td>
</tr>
</tbody>
</table>

(c) The names, addresses, and drug labeler codes of sponsors of approved new animal drug applications are as follows:

(1) ALPHABETICAL LISTING OF SPONSORS

<table>
<thead>
<tr>
<th>Firm name and address</th>
<th>Drug labeler code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories, North Chicago, IL 60064</td>
<td>000074</td>
</tr>
<tr>
<td>ADM Animal Health &amp; Nutrition Division, 1000 North 30th St., Box 1C, Quincy, IL 62305</td>
<td>017519</td>
</tr>
<tr>
<td>Ag-Mark, Inc., P.O. Box 127, Teachey, NC 28464</td>
<td>024174</td>
</tr>
<tr>
<td>Agri Laboratories, Ltd., P.O. Box 3103, St. Joseph, MO 64503</td>
<td>057561</td>
</tr>
<tr>
<td>Akey, Inc., P.O. Box 607, Lewisburg, OH 45338</td>
<td>017790</td>
</tr>
<tr>
<td>Akzo Nobel Surface Chemistry AB, Box 851, S-44855 Stenungsund, Sweden</td>
<td>063765</td>
</tr>
<tr>
<td>Alanco, Inc., 1500 North Wilmot Rd., suite 293-C, Tucson, AZ 85712</td>
<td>064146</td>
</tr>
<tr>
<td>Alpharma Inc., One Executive Drive, P.O. Box 1399, Fort Lee, NJ 07024</td>
<td>046573</td>
</tr>
<tr>
<td>Altana Inc., 60 Baylis Rd., Melville, NY 11747</td>
<td>025463</td>
</tr>
<tr>
<td>American Cyanamid, Division of American Home Products, P.O. Box 1339, Fort Dodge, IA 50501</td>
<td>010042</td>
</tr>
</tbody>
</table>

(1) ALPHABETICAL LISTING OF SPONSORS—Continued

<table>
<thead>
<tr>
<th>Firm name and address</th>
<th>Drug labeler code</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Pharmaceuticals Partners, Inc., 2045 North Cornell Ave., Melrose Park, IL 60160</td>
<td>063323</td>
</tr>
<tr>
<td>Anika Therapeutics Inc., 236 West Cummings Park, Woburn, MA 01801</td>
<td>060965</td>
</tr>
<tr>
<td>Anthony Products Co., 5660 Peck Rd., Arcadia, CA 91006</td>
<td>000864</td>
</tr>
<tr>
<td>Argent Laboratories, 8702 152d Ave. NE, Redmond, WA 98052</td>
<td>051212</td>
</tr>
<tr>
<td>Ausa International, Inc., R. 8, P.O. Box 324–12, Tyler, TX 75703</td>
<td>059521</td>
</tr>
<tr>
<td>Baxter Healthcare Corp., 95 Spring St., New Providence, NJ 07974</td>
<td>001019</td>
</tr>
<tr>
<td>Bayer Corp., Agriculture Division, Animal Health, P.O. Box 390, Shawnee, Mission, KS 66201</td>
<td>000859</td>
</tr>
<tr>
<td>Berk Pharmaceuticals, Inc., 12720 Dairy Ashford, Sugar Land, TX 77478</td>
<td>062794</td>
</tr>
<tr>
<td>Bimeda, Inc., 288 County Rd. 28, LeSueur, MN 56056–9322</td>
<td>061133</td>
</tr>
<tr>
<td>Biocraft Laboratories, Inc., 92 Route 46, Elmwood Park, NJ 07407</td>
<td>000332</td>
</tr>
<tr>
<td>Bioproducts, Inc., 320 Springside Dr., Suite 300, Fairlawn, OH 44333–2435</td>
<td>051359</td>
</tr>
<tr>
<td>Biopure Corp., 11 Hurley St., Cambridge, MA 02141</td>
<td>063075</td>
</tr>
<tr>
<td>BioScience Division of Milk Specialties Co., Illinois and Water Sts., P.O. Box 276, Dundee, IL 60118</td>
<td>000100</td>
</tr>
<tr>
<td>Blue Ridge Pharmaceuticals, Inc., 4249–105 Piedmont Pkwy, Greensboro, NC 27410</td>
<td>000115</td>
</tr>
<tr>
<td>Boehringer Ingelheim Vetmedica, Inc., 2621 North Belt Highway, St. Joseph, MO 64506–2002</td>
<td>000100</td>
</tr>
<tr>
<td>Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, County Galway, Ireland</td>
<td>010651</td>
</tr>
<tr>
<td>Chemdex, Inc., 12340 Santa Fe Dr., Lenexa, KS 66215</td>
<td>010787</td>
</tr>
<tr>
<td>Combe, Inc., 1101 Westchester Ave., White Plains, NY 10604</td>
<td>035462</td>
</tr>
<tr>
<td>ConAgra Pet Products Co., 3902 Leavenworth St., Omaha, NE 68105</td>
<td>025127</td>
</tr>
<tr>
<td>Contemporary Products, Inc., 378 Elm Springs Rd., Springdale, AR 72764–6067</td>
<td>001263</td>
</tr>
<tr>
<td>Co, Lilly Corporate Center, Indianapolis, IN 46259</td>
<td>032761</td>
</tr>
<tr>
<td>Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland</td>
<td>042774</td>
</tr>
<tr>
<td>Custom Feed Blenders Corp., 540 Hawkeye Ave., Fort Dodge, IA 50501</td>
<td>000071</td>
</tr>
<tr>
<td>Custom Feed Services Corp., 2100 N. 13th St., Norfolk, NE 68021</td>
<td>060965</td>
</tr>
<tr>
<td>Cyanamid Agricultural of Puerto Rico, Inc., P.O. Box 243, Manati, PR 00701</td>
<td>051212</td>
</tr>
<tr>
<td>Delmarva Laboratories, Inc., 2200 Wadestride Rd., P.O. Box 525, Midlothian, VA 23113</td>
<td>001509</td>
</tr>
<tr>
<td>Elanco Animal Health, A Division of Eli Lilly &amp; Co., Lilly Corporate Center, Indianapolis, IN 46259</td>
<td>020191</td>
</tr>
<tr>
<td>Endo Pharmaceuticals, Inc., 223 Wilmington West Chester Pike, Chadds Ford, PA 19317</td>
<td>055442</td>
</tr>
<tr>
<td>Equi Aid Products, Inc., 1517 West Knudsen Dr., Phoenix, AZ 85027</td>
<td>017473</td>
</tr>
<tr>
<td>Evco Pharmaceuticals, Inc., 209, Harding Hwy., Buena, NJ 08310</td>
<td>043781</td>
</tr>
<tr>
<td>Farmland Industries, Inc., Kansas City, MO 64116</td>
<td>046987</td>
</tr>
<tr>
<td>Farnam Companies, Inc., 301 West Osborn, Phoenix, AZ 85013–3928</td>
<td>001715</td>
</tr>
<tr>
<td>Feed Service Co., Inc., 303 Lunden Blvd., P.O. Box 698, Mankato, MN 56001</td>
<td>030841</td>
</tr>
<tr>
<td>John J. Ferrante, 11 Fairway Lane, Trumbull, CT 06611</td>
<td>058034</td>
</tr>
<tr>
<td>First Priority, Inc., 1585 Todd Farm Dr., Elgin, IL 60123</td>
<td>058829</td>
</tr>
<tr>
<td>Fleming Laboratories, Inc., P.O. Box 34384, Charlotte, NC 28234</td>
<td>015565</td>
</tr>
<tr>
<td>Fort Dodge Animal Health, Division of American Cyanamid Co., P.O. Box 1339, Fort Dodge, IA 50501</td>
<td>053501</td>
</tr>
<tr>
<td>Fort Dodge Animal Health, Division of American Home Products Corp., 800 Fifth St. NW, Fort Dodge, IA 50501</td>
<td>000856</td>
</tr>
<tr>
<td>Frey-McNeill Co., Freeport, IL 61032</td>
<td>010439</td>
</tr>
<tr>
<td>Gossen Nutrition, Inc., 1676 Cascade Dr., Marion, OH 43002</td>
<td>050972</td>
</tr>
<tr>
<td>G. C. Hanford Manufacturing Co., P.O. Box 1017, Syracuse, NY 13201</td>
<td>010515</td>
</tr>
<tr>
<td>Halocarbon Laboratories, Division of Halocarbon Products Corp., 887 Kinderkamack Rd., P.O. Box 661, River Ridge, NJ 07661</td>
<td>012164</td>
</tr>
<tr>
<td>Happy Jack, Inc., Snow Hill, NC 28586</td>
<td>003851</td>
</tr>
<tr>
<td>Hess &amp; Clark, Inc., Seventh and Orange Sts., Ashland, OH 44805</td>
<td>050749</td>
</tr>
<tr>
<td>I.M.S. Inc., 13619 Industrial Rd., Omaha, NE 68137</td>
<td>050639</td>
</tr>
<tr>
<td>IMPAX Laboratories, Inc., 30831 Huntwood Ave., Hayward, CA 94544</td>
<td>001115</td>
</tr>
<tr>
<td>International Nutrition, Inc., 7707 T Plaza, Omaha, NE 68127</td>
<td>043733</td>
</tr>
<tr>
<td>Intervet, Inc., P.O. Box 318, 405 State St., Milford, DE 19966</td>
<td>057926</td>
</tr>
<tr>
<td>Ivy Laboratories, Div. of Ivy Animal Health, Inc., 8857 Bond Street, Overland Park, KS 66214</td>
<td>021641</td>
</tr>
<tr>
<td>J. C. Feed Mills, 1050 Sheffield, P.O. Box 224, Waterloo, IA 50704</td>
<td>039741</td>
</tr>
<tr>
<td>Jorgensen Laboratories, Inc., 1450 North Van Buren Ave., Loveland, CO 80538</td>
<td>045087</td>
</tr>
<tr>
<td>K. C. Pharmacal, Inc., 8345 Metloire Dr., Lenexa, KS 66214</td>
<td>038782</td>
</tr>
<tr>
<td>Kerber Milling Co., 152, 1817 E. Main St., Emmetsburg, IA 50536</td>
<td>029341</td>
</tr>
<tr>
<td>Lambert-Kay, A Division of Carter-Wallace, Inc., P.O. Box 1001, Half Acre Rd., Cranbury, NJ 08512–0181</td>
<td>011615</td>
</tr>
<tr>
<td>Lloyd, Inc., 604 W. Thomas Ave., Shenandoah, IA 51601</td>
<td>006960</td>
</tr>
<tr>
<td>Luitpold Pharmaceuticals, Inc., Animal Health Division, Shirley, NY 11967</td>
<td>010797</td>
</tr>
<tr>
<td>M &amp; M Livestock Products Co., Eagle Grove, IA 50533</td>
<td>026282</td>
</tr>
<tr>
<td>Macleod Pharmaceuticals, Inc., 2600 Canton Ct., Fort Collins, CO 80525</td>
<td>058711</td>
</tr>
<tr>
<td>Marsam Pharmaceuticals, LLC, Bldg. 31, 24 Olney Ave., Cherry Hill, NJ 08034</td>
<td>000209</td>
</tr>
<tr>
<td>Medicos Dermatologics, Inc., 8125 North Hayden Rd, Scottsdale, AZ 85259</td>
<td>099207</td>
</tr>
<tr>
<td>Med-Pharmex, Inc., 2727 Thompson Creek Rd., Lakeville, MN 55024</td>
<td>060951</td>
</tr>
<tr>
<td>Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pocatello, ID 83204–1861</td>
<td>051259</td>
</tr>
<tr>
<td>Menard Lab., 3297 Satellite Blvd., Bldg. 500, Dunhu, GA 30096</td>
<td>062240</td>
</tr>
<tr>
<td>Menard Lab., 3297 Satellite Blvd., Bldg. 500, Dunhu, GA 30096</td>
<td>050604</td>
</tr>
<tr>
<td>Mid-Continent Agrimarketing, Inc., 887 Kinderkamack Rd., P.O. Box 661, River Ridge, NJ 07661</td>
<td>045087</td>
</tr>
</tbody>
</table>

21 CFR Ch. I (4–1–02 Edition)
### (1) Alphabetical Listing of Sponsors— Continued

<table>
<thead>
<tr>
<th>Firm name and address</th>
<th>Drug labeler code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monsanto Co., 800 North Lindbergh Blvd., St. Louis, MO 63167</td>
<td>...</td>
</tr>
<tr>
<td>MoorMan’s, Inc., 1000 North 30th St., Quincy, IL 62301-9115</td>
<td>...</td>
</tr>
<tr>
<td>Natchez Animal Supply Co., 201 John R. Junkin Dr., Natchez, MS 39120</td>
<td>...</td>
</tr>
<tr>
<td>Norbrook Laboratories, Ltd., Station Works, Newry BT35 6JP, Northern Ireland</td>
<td>...</td>
</tr>
<tr>
<td>Novartis Animal Health US, Inc., 3200 Northline Ave., suite 300, Greensboro, NC 27408</td>
<td>...</td>
</tr>
<tr>
<td>Nutra-Blend Corp., P.O. Box 465, Neosho, MO 64850</td>
<td>...</td>
</tr>
<tr>
<td>NutriBasics Co., North Highway 71, P.O. Box 1014, Willmar, MN 56201</td>
<td>...</td>
</tr>
<tr>
<td>Nylons Trading Co., Inc., P.O. Box 2, Route 202, Pomona, NY 10970</td>
<td>...</td>
</tr>
<tr>
<td>Orion Corp., Orion Animal, 02800 Espoo, Finland</td>
<td>...</td>
</tr>
<tr>
<td>Orphan Medical, Inc., 13911 Ridgedale Dr., Suite 475, Minnetonka, MN 55305</td>
<td>...</td>
</tr>
<tr>
<td>OVIS International, Inc., 6940 N. Cutter Circle, Suite 317, Portland, OR 97217-3935</td>
<td>...</td>
</tr>
<tr>
<td>Peavey Co., 730 Second Ave. South, Minneapolis, MN 55402</td>
<td>...</td>
</tr>
<tr>
<td>Pegasus Laboratories, Inc., 8809 Ely Rd., Pen- sacola, FL 32514</td>
<td>...</td>
</tr>
<tr>
<td>Pennfield Oil Co., 14040 Industrial Rd., Omaha, NE 68137</td>
<td>...</td>
</tr>
<tr>
<td>Peptech Animal Health Pty, Ltd., 35 – 41 Water- loo Rd., North Ryde, New South Wales 2113, Australia</td>
<td>...</td>
</tr>
<tr>
<td>Pfizer, Inc., 235 East 24th St., New York, NY 10017</td>
<td>...</td>
</tr>
<tr>
<td>Pharmacia &amp; Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 49001-0199</td>
<td>...</td>
</tr>
<tr>
<td>Phibro Animal Health, 710 Rt. 46 East, suite 401, Fairfield, NJ 07004</td>
<td>...</td>
</tr>
<tr>
<td>Phoenix Pharmaceutical, Inc., 421 Easton Rd., P.O. Box 6457 Farleigh Station, St. Joseph, MO 64506-0457</td>
<td>...</td>
</tr>
<tr>
<td>Phoenix Scientific, Inc. 3915 South 48th St. Terrace, P.O. Box 6457, MO 64506-0457</td>
<td>...</td>
</tr>
<tr>
<td>Planatquimica Industrial Ltda., Rua das Magnolias nr. 2405, Jardim das Bandeiras, CEP 13053-120, Campinas, Sao Paulo, Brazil</td>
<td>...</td>
</tr>
<tr>
<td>Pliva d.d., Ulica grada Vukovara 49, 10000 Zagreb, Croatia</td>
<td>...</td>
</tr>
<tr>
<td>PM Resources, Inc., 13001 St. Charles Rock Rd., Bridgeport, MO 63044</td>
<td>...</td>
</tr>
<tr>
<td>Purina Mills, Inc., P.O. Box 66812, St. Louis, MO 63166-6812</td>
<td>...</td>
</tr>
<tr>
<td>Quali-Tech Products, Inc., 318 Lake Hazeline Drive, Chaska, MN 55318</td>
<td>...</td>
</tr>
<tr>
<td>Rhodia Limited, P.O. Box 46, St. Andrews Rd., Avonmouth, Bristol BS11 9YF, England, UK</td>
<td>...</td>
</tr>
<tr>
<td>A. H. Robins Co., P.O. Box 518, Fort Dodge, IA 50501-0518</td>
<td>...</td>
</tr>
<tr>
<td>Roche Vitamins, Inc., 45 Waterview Blvd., Parsippany, NJ 07054-1298</td>
<td>...</td>
</tr>
<tr>
<td>RSN Laboratories, Inc., 501 Fifth St., Bristol, TN 37620</td>
<td>...</td>
</tr>
<tr>
<td>R. P. Scherer North America, P.O. Box 5600, Clearwater, FL 33758</td>
<td>...</td>
</tr>
<tr>
<td>Schering-Plough Animal Health Corp., 1095 Morris Ave., Union, NJ 07083</td>
<td>...</td>
</tr>
<tr>
<td>G. D. Searle LLC, Pharmacia Corp., 4901 Searle Pkwy., Skokie, IL 60077</td>
<td>...</td>
</tr>
</tbody>
</table>

### (2) Alphabetical Listing of Sponsors— Continued

<table>
<thead>
<tr>
<th>Firm name and address</th>
<th>Drug labeler code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seeco Inc., Box 1014, North Highway 71, Willmar, MN 56201</td>
<td>...</td>
</tr>
<tr>
<td>Sioux Biochemical, Inc., 204 Third St. NW, Sioux Center, IA 51250</td>
<td>...</td>
</tr>
<tr>
<td>South St. Paul Feeds, Inc., 500 Farwell Ave., South St. Paul, MN 55075</td>
<td>...</td>
</tr>
<tr>
<td>Southern Micro-Blenders, Inc., 3801 North Hawthorne St., Chattanooga, TN 37406</td>
<td>...</td>
</tr>
<tr>
<td>Springfield Milling Corp., Vigorenna Feeds, Springfield, MA 01518</td>
<td>...</td>
</tr>
<tr>
<td>Squire Laboratories, Inc., 100 Mill St., Revere, MA 02151</td>
<td>...</td>
</tr>
<tr>
<td>Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AZ 85043-4705</td>
<td>...</td>
</tr>
<tr>
<td>Summit Hill Laboratories, P.O. Box 535, Navesink, NJ 07752</td>
<td>...</td>
</tr>
<tr>
<td>Texas Vitamin Co., P.O. Box 18417, 10695 Aledo St., Dallas, TX 75218</td>
<td>...</td>
</tr>
<tr>
<td>Triple “F,” Inc., 10104 Douglas Ave., Des Moines, IA 50322</td>
<td>...</td>
</tr>
<tr>
<td>United Vaccines, A Harlan Sprague Dawley, Inc., P.O. Box 4429, Madison, WI 53711</td>
<td>...</td>
</tr>
<tr>
<td>Vemot, S.p.A., Viale E. Bezzì 24, 20146 Milan, Italy</td>
<td>...</td>
</tr>
<tr>
<td>Veterinary Laboratories, Inc., 12340 Santa Fe Dr., Lenexa, KS 66215</td>
<td>...</td>
</tr>
<tr>
<td>Veterinary Research Associates, Inc., 2817 West Country Rd. 54G, Fort Collins, CO 80524</td>
<td>...</td>
</tr>
<tr>
<td>Veterinary Service, Inc., 416 North Jefferson St., P.O. Box 2467, Modesto, CA 95354</td>
<td>...</td>
</tr>
<tr>
<td>Veterinary Specialties Inc., 387 North Valley Ct., Lenexa, KS 66215</td>
<td>...</td>
</tr>
<tr>
<td>Vetoquinol N.A., Inc., 2000 chemin Georges, Lavaltrie (PQ), Canada J0K 1H0</td>
<td>...</td>
</tr>
<tr>
<td>Virtac AH, Inc., 320 Meacham Blvd., Rt. Worth, TX 76137</td>
<td>...</td>
</tr>
<tr>
<td>Walco International, Inc., 15 West Putnam, Portville, CA 93257</td>
<td>...</td>
</tr>
<tr>
<td>Waterloo Mills Co., 2050 Mitchell Ave., Water- lio, IA 50704</td>
<td>...</td>
</tr>
<tr>
<td>Wayne Feed Division, Continental Grain Co., P.O. Box 459, Libertyville, IL 60048</td>
<td>...</td>
</tr>
<tr>
<td>Webel Feeds, Inc., R.R. 3, Pittsfield, IL 62363</td>
<td>...</td>
</tr>
<tr>
<td>Wellmark International, 1100 East Woodfield Rd., Suite 500, Schaumburg, IL 60173</td>
<td>...</td>
</tr>
<tr>
<td>Wendt Laboratories, Inc., 100 Nancy Dr., Belle Plaine, MN 56011</td>
<td>...</td>
</tr>
<tr>
<td>West Agro., Inc., 11100 N. Congress Ave., Kan- sas City, MO 64153</td>
<td>...</td>
</tr>
<tr>
<td>Western Chemical, Inc., 1269 Lattimore Rd., Ferndale, WA 98248</td>
<td>...</td>
</tr>
<tr>
<td>Wildlife Laboratories, Inc., 3014 Duff Dr., Suite 500, Schaumburg, IL 60173</td>
<td>...</td>
</tr>
<tr>
<td>Wyeth Laboratories, Division American Home Products Corp., P.O. Box 6299, Philadelphia, PA 19191</td>
<td>...</td>
</tr>
<tr>
<td>Yoder Feed, Division of Yoder, Inc., Kalona, IA 52247</td>
<td>...</td>
</tr>
<tr>
<td>Zema Corp., P.O. Box 12803, Research Tri- angle Park, Durham, NC 27709</td>
<td>...</td>
</tr>
</tbody>
</table>
### §510.600 21 CFR Ch. I (4–1–02 Edition)

#### (2) NUMERICAL LISTING OF SPONSORS

<table>
<thead>
<tr>
<th>Drug labeler code</th>
<th>Firm name and address</th>
</tr>
</thead>
<tbody>
<tr>
<td>000008 ..........</td>
<td>Wyeth Laboratories, Division American Home Products Corp., P.O. Box 8299, Philadelphia, PA 19101.</td>
</tr>
<tr>
<td>000069 ..........</td>
<td>Pfizer, Inc., 235 East 42nd St., New York, NY 10017.</td>
</tr>
<tr>
<td>000074 ..........</td>
<td>Abbott Laboratories, North Chicago, IL 60064.</td>
</tr>
<tr>
<td>000093 ..........</td>
<td>Teva Pharmaceuticals USA, 650 Cathill Rd., Sellersville, PA 18960.</td>
</tr>
<tr>
<td>000115 ..........</td>
<td>IMPAX Laboratories, Inc., 30831 Huntwood Rd., suite 500, Schaumburg, IL 60173.</td>
</tr>
<tr>
<td>000209 ..........</td>
<td>Marsam Pharmaceuticals, LLC, Bldg. 31, 24 Olney Ave., Cherry Hill, NJ 08034.</td>
</tr>
<tr>
<td>000842 ..........</td>
<td>Texas Vitamin Co., P.O. Box 18417, 10695 Aledo St., Dallas, TX 75218.</td>
</tr>
<tr>
<td>000856 ..........</td>
<td>Fort Dodge Animal Health, Division of American Home Products Corp., 805 Fifth St. NW., Fort Dodge, IA 50501.</td>
</tr>
<tr>
<td>000857 ..........</td>
<td>Veterinary Laboratories, Inc., 12340 Santa Fe Dr., Lenexa, KS 66215.</td>
</tr>
<tr>
<td>000859 ..........</td>
<td>Bayer Corp., Agriculture Division, Animal Health, P.O. Box 390, Shawnee Mission, KS 66201.</td>
</tr>
<tr>
<td>000896 ..........</td>
<td>Elanco Animal Health, A Division of Eli Lilly &amp; Co., Lilly Corporate Center, Indianapolis, IN 46285.</td>
</tr>
<tr>
<td>001042 ..........</td>
<td>American Cyanamid, Division of American Home Products, P.O. Box 1339, Fort Dodge, IA 50501.</td>
</tr>
<tr>
<td>001049 ..........</td>
<td>First-McNess Co., Freeport, IL 61032.</td>
</tr>
<tr>
<td>001051 ..........</td>
<td>G. C. Hartford Manufacturing Co., P.O. Box 1017, Syracuse, NY 13201.</td>
</tr>
<tr>
<td>011014 ..........</td>
<td>R. P. Scherer North America, P.O. Box 5630, Clearwater, FL 33758.</td>
</tr>
</tbody>
</table>

### (2) NUMERICAL LISTING OF SPONSORS—Continued

<table>
<thead>
<tr>
<th>Drug labeler code</th>
<th>Firm name and address</th>
</tr>
</thead>
<tbody>
<tr>
<td>011615 ..........</td>
<td>Lambert-Key, A Division of Carter-Wallace, Inc., P.O. Box 1001, Half Acre Rd., Cranbury, NJ 08512-0181.</td>
</tr>
<tr>
<td>011722 ..........</td>
<td>Pika d.d., Ulaza grada Vukovara 49, 10000 Zagreb, Croatia</td>
</tr>
<tr>
<td>012164 ..........</td>
<td>Halocarbon Laboratories, Division of Halocarbon Products Corp., 887 Kinderkamack Rd., P.O. Box 661, River Ridge, LA 70661.</td>
</tr>
<tr>
<td>015565 ..........</td>
<td>Fleming Laboratories, Inc., P.O. Box 34384, Charlotte, NC 28234.</td>
</tr>
<tr>
<td>015579 ..........</td>
<td>Wendi Laboratories, Inc., 100 Nancy Dr., Belle Plaine, MN 56011.</td>
</tr>
<tr>
<td>016968 ..........</td>
<td>Quali-Tech Products, Inc., 318 Lake Hazel- time Dr., Chaska, MN 55318.</td>
</tr>
<tr>
<td>017135 ..........</td>
<td>Farmland Companies, Inc., 301 West Osborne, Phoenix, AZ 85013–9028.</td>
</tr>
<tr>
<td>017153 ..........</td>
<td>Squire Laboratories, Inc., 100 Mill St., Revere, MA 02151.</td>
</tr>
<tr>
<td>017287 ..........</td>
<td>Chemdex, Inc., 12340 Santa Fe Dr., Lenexa, KS 66215.</td>
</tr>
<tr>
<td>017473 ..........</td>
<td>Custom Feed Services Corp., 2100 N. 13th St., Norfolk, NE 68701.</td>
</tr>
<tr>
<td>017519 ..........</td>
<td>ADM Animal Health &amp; Nutrition Division, 1000 North 30th St., Box 1C, Quincy, IL 62205–3115</td>
</tr>
<tr>
<td>017790 ..........</td>
<td>Akey, Inc., P.O. Box 607, Lewiston, OH 45338.</td>
</tr>
<tr>
<td>017800 ..........</td>
<td>Purina Mills, Inc., P.O. Box 66812, St. Louis, MO 63166-6812.</td>
</tr>
<tr>
<td>021091 ..........</td>
<td>ConAgra Pet Products Co., 3902 Leavenworth St., Omaha, NE 68105.</td>
</tr>
<tr>
<td>021930 ..........</td>
<td>Moorman’s, Inc., 1000 North 30th St., Quincy, IL 62205–3115.</td>
</tr>
<tr>
<td>024174 ..........</td>
<td>Ag-Mark, Inc., P.O. Box 127, Teachey, NC 27886.</td>
</tr>
<tr>
<td>027344 ..........</td>
<td>Norco Mills of Norfolk, Inc., P.O. Box 56, Norfolk, NE 68701.</td>
</tr>
<tr>
<td>027454 ..........</td>
<td>Nylus Trading Co., Inc., P.O. Box 2, Route 202, Pomona, NY 10970.</td>
</tr>
<tr>
<td>032641 ..........</td>
<td>Kerber Milling Co., Box 152, 1817 E. Main St., Emmetsburg, IA 50536.</td>
</tr>
<tr>
<td>032761 ..........</td>
<td>BioScience Division of Milk Specialties Co., Illinois and Water Sts., P.O. Box 278, Dundee, IL 60118.</td>
</tr>
<tr>
<td>Drug labeler code</td>
<td>Firm name and address</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>033008 ..........</td>
<td>Veterinary Service, Inc., 416 North Jeff erson St., P.O. Box 2467, Modesto, CA 95354.</td>
</tr>
<tr>
<td>034936 ..........</td>
<td>Wayne Feed Division, Continental Grain Co., P.O. Box 459, Libertyville, IL 60048.</td>
</tr>
<tr>
<td>035369 ..........</td>
<td>Yoder Feed Division of Yoder, Inc., Kalona, IA 52247.</td>
</tr>
<tr>
<td>036904 ..........</td>
<td>Sweetlix, LLC, 175 South Main St., suite 150, Salt Lake City, UT 84111.</td>
</tr>
<tr>
<td>037990 ..........</td>
<td>Summit Hill Laboratories, P.O. Box 535, Navesink, NJ 07752.</td>
</tr>
<tr>
<td>039741 ..........</td>
<td>J. C. Feed Mills, 1050 Sheffield, P.O. Box 224, Waterloo, IA 50704.</td>
</tr>
<tr>
<td>043733 ..........</td>
<td>International Nutrition, Inc., 7706 'I' Plaza, Omaha, NE 68127.</td>
</tr>
<tr>
<td>043781 ..........</td>
<td>Cyramid Agricultural de Puerto Rico, Inc., P.O. Box 243, Manati, PR 00701.</td>
</tr>
<tr>
<td>046573 ..........</td>
<td>Alpharma Inc., One Executive Drive, P.O. Box 1399, Fort Lee, NJ 07024.</td>
</tr>
<tr>
<td>046987 ..........</td>
<td>Custom Feed Blenders Corp., 540 Hawk- eye Ave., Fort Dodge, IA 50501.</td>
</tr>
<tr>
<td>049685 ..........</td>
<td>Southern Micro-Blenders, Inc., 3801 North Hawthorne St., Chattanooga, TN 37406.</td>
</tr>
<tr>
<td>049968 ..........</td>
<td>Natchez Animal Supply Co., 201 John R. Junkin Dr., Natchez, MS 39120.</td>
</tr>
<tr>
<td>050568 ..........</td>
<td>Nutra-Blend Corp., P.O. Box 485, Neosho, MO 64850.</td>
</tr>
<tr>
<td>050639 ..........</td>
<td>J.M.S. Inc., 13619 Industrial Rd., Omaha, NE 68137.</td>
</tr>
<tr>
<td>050906 ..........</td>
<td>Zema Corp., P.O. Box 12803, Research Triangle Park, Durham, NC 27709.</td>
</tr>
<tr>
<td>050972 ..........</td>
<td>Gossett Nutrition, Inc., 1676 Cascade Dr., Marion, OH 43302.</td>
</tr>
<tr>
<td>051212 ..........</td>
<td>Argent Laboratories, 6702 152d Ave. NE, Redmond, WA 98052.</td>
</tr>
<tr>
<td>051267 ..........</td>
<td>Cooperative Research Farms, Box 69, Charlotteville, NY 12036.</td>
</tr>
<tr>
<td>051311 ..........</td>
<td>Vetbac Ah, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137.</td>
</tr>
<tr>
<td>051359 ..........</td>
<td>Bioproducts, Inc., 320 Springside Dr., Suite 300, Faribault, OH 44141.</td>
</tr>
<tr>
<td>052483 ..........</td>
<td>Orion Corp., Orioninte 1, 02200 Espoo, Finland.</td>
</tr>
<tr>
<td>053389 ..........</td>
<td>Penfield Oil Co., 14040 Industrial Rd., Omaha, NE 68137.</td>
</tr>
<tr>
<td>053501 ..........</td>
<td>Fort Dodge Animal Health, A Division of American Cyanamid Co., P.O. Box 1339, Fort Dodge, IA 50501.</td>
</tr>
</tbody>
</table>

§510.600

(2) N UMERICAL LISTING OF S PONSORS—Continued

<table>
<thead>
<tr>
<th>Drug labeler code</th>
<th>Firm name and address</th>
</tr>
</thead>
<tbody>
<tr>
<td>051389 ..........</td>
<td>Camping sneakers, 1450 New Highway 71, P.O. Box 1014, Willmar, MN 56201.</td>
</tr>
<tr>
<td>053740 ..........</td>
<td>NutriBasics Co., North Highway 71, P.O. Box 1014, Willmar, MN 56201.</td>
</tr>
<tr>
<td>055529 ..........</td>
<td>Nonbrok Laboratories, Ltd., Station Works, Newby BT35 6JP, Northern Ireland.</td>
</tr>
<tr>
<td>057319 ..........</td>
<td>Phoenix Pharmaceutical, Inc., 4621 Easton Rd., P.O. Box 6457 Farleigh Station, St. Joseph, MO 64506–0457.</td>
</tr>
<tr>
<td>057561 ..........</td>
<td>Agri Laboratories, Ltd., P.O. Box 3103, St. Joseph, MO 64503.</td>
</tr>
<tr>
<td>057926 ..........</td>
<td>Intervet, Inc., P.O. Box 318, 405 State St., Millboro, DE 19966.</td>
</tr>
<tr>
<td>058034 ..........</td>
<td>John J. Ferrante, 11 Fairway Lane, Trumbull, CT 06611.</td>
</tr>
<tr>
<td>058639 ..........</td>
<td>United Vaccines, A Haaran Sprague Dawley, Inc., Co., P.O. Box 4220, Madison, WI 53711.</td>
</tr>
<tr>
<td>058670 ..........</td>
<td>RSR Laboratories, Inc., 501 Fifth St., Bristol, TN 37620.</td>
</tr>
<tr>
<td>058711 ..........</td>
<td>Macleod Pharmaceuticals, Inc., 2600 Canton Dr., Fort Collins, CO 80525.</td>
</tr>
<tr>
<td>058829 ..........</td>
<td>First Priority, Inc., 1585 Todd Farm Dr., Elgin, IL 60123.</td>
</tr>
<tr>
<td>058979 ..........</td>
<td>Delmarva Laboratories, Inc., 220 Wadetrive Rd., P.O. Box 525, Middletown, VA 23113.</td>
</tr>
<tr>
<td>059130 ..........</td>
<td>Phoenix Scientific, Inc. 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506–0457.</td>
</tr>
<tr>
<td>059258 ..........</td>
<td>Rhodia Limited, P.O. Box 46, St Andrews Rd., Avonmouth, Bristol BS11 9YF, England, UK.</td>
</tr>
<tr>
<td>059320 ..........</td>
<td>Vetquinoa N–A., Inc., 2000 chemin Georges, Lavallite (PQ), Canada, J0K 1H0</td>
</tr>
<tr>
<td>059445 ..........</td>
<td>Monsanto Co., 800 North Lindbergh Blvd., St. Louis, MO 63167.</td>
</tr>
<tr>
<td>059521 ..........</td>
<td>Auta International, Inc., Rt. 8, P.O. Box 324–12, Tyler, TX 75703.</td>
</tr>
<tr>
<td>060307 ..........</td>
<td>Minard, Inc., 836 Main St., 2d floor, Buffalo, NY 14202.</td>
</tr>
<tr>
<td>060728 ..........</td>
<td>Picanquima Industrial Ltda, Rua das Magnolias nr. Jardim das Bandeiras, CEP 13053–120, Campinas, Sao Alto, Brazil.</td>
</tr>
<tr>
<td>060951 ..........</td>
<td>Endo Pharmaceuticals, Inc., 223 Wilmington West Chester Pike, Chadds Ford, PA 19317.</td>
</tr>
<tr>
<td>061133 ..........</td>
<td>Bimeda, Inc., 288 County Rd. 28, LeSueur, MN 56058–9322</td>
</tr>
</tbody>
</table>
(2) NUMERICAL LISTING OF SPONSORS—Continued

<table>
<thead>
<tr>
<th>Drug labeler code</th>
<th>Firm name and address</th>
</tr>
</thead>
<tbody>
<tr>
<td>061651</td>
<td>Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, County Galway, Ireland.</td>
</tr>
<tr>
<td>062161</td>
<td>Orphan Medical, Inc., 13911 Ridgeledge Dr., Suite 475, Minnetonka, MN 55305.</td>
</tr>
<tr>
<td>062240</td>
<td>Evi AID Products, Inc., 1517 West Knudsen Dr., Phoenix, AZ 85027.</td>
</tr>
<tr>
<td>062794</td>
<td>Berkel Pharmaceuticals, Inc., 12720 Daisy Ashford, Sugar Land, TX 77478.</td>
</tr>
<tr>
<td>062925</td>
<td>Veterinary Specialties Inc., 387 North Valley Ct., Barrington, IL 60010.</td>
</tr>
<tr>
<td>063075</td>
<td>Biopure Corp., 11 Hurley St., Cambridge, MA 02141.</td>
</tr>
<tr>
<td>063112</td>
<td>Sioux Biochemical, Inc., 204 Third St. NW., Sioux Center, IA 51250.</td>
</tr>
<tr>
<td>063765</td>
<td>Akzo Nobel Surface Chemistry AB, Box 851, S-44485 Stenungsund, Sweden.</td>
</tr>
<tr>
<td>066104</td>
<td>Pepto Animal Health, 710 Rt. 46 East, suite 401, Fairfield, NJ 07004.</td>
</tr>
</tbody>
</table>

[40 FR 13807, Mar. 27, 1975]

EDITORIAL NOTE: For Federal Register citations affecting §510.600, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

PART 511—NEW ANIMAL DRUGS FOR INVESTIGATIONAL USE


§511.1 New animal drugs for investigational use exempt from section 512(a) of the act.

(a) New animal drugs for tests in vitro and in laboratory research animals. (1) A shipment or other delivery of a new animal drug or animal feed bearing or containing a new animal drug intended solely for tests in vitro or in animals used only for laboratory research purposes shall be exempt from section 512 (a) and (m) of the act if it is labeled as follows:

Caution. Contains a new animal drug for investigational use only in laboratory research animals or for tests in vitro. Not for use in humans.

(2) The person distributing or causing the distribution of new animal drugs for tests in vitro or in animals used only for laboratory research purposes under this exemption shall use due diligence to assure that the consignee is regularly engaged in conducting such tests and that the shipment of the new animal drug will actually be used for tests in vitro or in animals used only for laboratory research.

(3) The person who introduced such shipment or who delivered the new animal drug for introduction into interstate commerce shall maintain adequate records showing the name and post office address of the expert or expert organization to whom the new animal drug is shipped and the date, quantity, and batch or code mark of each shipment and delivery for a period of 2 years after such shipment and delivery. Upon the request of a properly authorized employee of the Department at reasonable times, he shall make such records available for inspection and copying.

(4) The exemption allowed in this paragraph shall not apply to any new animal drug intended for in vitro use in the regular course of diagnosing or treating disease, including antibacterial sensitivity discs impregnated with any new animal drug or drugs, which discs are intended for use in determining susceptibility of microorganisms to the new animal drug or drugs.

(b) New animal drugs for clinical investigation in animals. A shipment or other delivery of a new animal drug or an animal feed containing a new animal drug intended for clinical investigational use in animals shall be exempt from section 512(a) and (m) of the act if all the following conditions are met:

(1) The label shall bear the statements:
Caution. Contains a new animal drug for use only in investigational animals in clinical trials. Not for use in humans. Edible products of investigational animals are not to be used for food unless authorization has been granted by the U.S. Food and Drug Administration or by the U.S. Department of Agriculture.

In the case of containers too small or otherwise unable to accommodate a label with sufficient space to bear the caution statements required by paragraph (a) or (b) of this section, the statements may be included on the carton label and other labeling on or within the package from which the new animal drug is to be dispensed.

(2) The person or firm distributing or causing the distribution of the new animal drug or animal feed containing a new animal drug shall use due diligence to assure that the new animal drug or animal feed containing a new animal drug will actually be used for tests in animals and is not used in humans.

(3) The person who introduced such shipment or who delivered the new animal drug or animal feed containing a new animal drug for introduction into interstate commerce shall maintain adequate records showing the name and post office address of the investigator to whom the new animal drug or animal feed containing a new animal drug is shipped and the date, quantity, and batch or code mark of each shipment and delivery for a period of 2 years after such shipment and delivery. Upon the request of a properly authorized employee of the Department at reasonable times, such records shall be made available for inspection and copying.

(4) Prior to shipment of the new animal drug for clinical tests in animals, the sponsor of the investigation shall submit in triplicate to the Food and Drug Administration a “Notice of Claimed Investigational Exemption for a New Animal Drug” including a signed statement containing the following information:

(i) The identity of the new animal drug;

(ii) All labeling and other pertinent information to be supplied to the investigators. When such pertinent information includes nonclinical laboratory studies, the information shall include, with respect to each nonclinical study, either a statement that the study was conducted in compliance with the requirements set forth in part 58 of this chapter, or, if the study was not conducted in compliance with such regulations, a brief statement of the reason for the noncompliance.

(iii) The name and address of each clinical investigator.

(iv) The approximate number of animals to be treated (or if not available, the amount of new animal drug to be shipped).

(v) If the new animal drug is given to food-producing animals, the statement shall contain the following additional information:

(a) A commitment that the edible products from such animals shall not be used for food without prior authorization in accordance with the provisions prescribed in this section.

(b) Approximate dates of the beginning and end of the experiment or series of experiments.

(c) The maximum daily dose(s) to be administered to a given species, the size of animal, maximum duration of administration, method(s) of administration, and proposed withdrawal time, if any.

(vi) If a sponsor has transferred any obligations for the conduct of any clinical study to a contract research organization, a statement containing the name and address of the contract research organization, identification of the clinical study, and a listing of the obligations transferred. If all obligations governing the conduct of the study have been transferred, a general statement of this transfer—in lieu of a listing of the specific obligations transferred—may be submitted.

(5) Authorization for use of edible products derived from a treated food-producing animal may be granted under the provisions of this section and when the following specified conditions are met, except that in the case of an animal administered any unlicensed experimental veterinary biological product regulated under the viruses, serums, toxins statute (21 U.S.C., chapter V, sec. 151 et seq.) the product shall be exempt from the requirements of this section when U.S. Department of Agriculture approval has been obtained.
§ 511.1 as provided in 9 CFR 103.2. Conditional authorization may be granted in advance of identification of the name(s) and address(es) of the clinical investigator(s) as required by paragraph (b)(4)(iii) of this section. Information required for authorization shall include, in addition to all other requirements of this section, the following:

(i) Data to show that consumption of food derived from animals treated at the maximum levels with the minimum withdrawal periods, if any, specified in accordance with paragraph (b)(4)(v)(c) of this section, will not be inconsistent with the public health; or

(ii) Data to show that food derived from animals treated at the maximum levels and with the minimum withdrawal periods, if any, specified in accordance with paragraph (b)(4)(v)(c) of this section, does not contain drug residues or metabolites.

(iii) The name and location of the packing plant where the animals will be processed, except that this requirement may be waived, on request, by the terms of the authorization.

Authorizations granted under this paragraph do not exempt investigational animals and their products from compliance with other applicable inspection requirements. Any person who contests a refusal to grant such authorization shall have an opportunity for a regulatory hearing before the Food and Drug Administration pursuant to part 16 of this chapter.

(6) On written request of the Food and Drug Administration, the sponsor shall submit any additional information reported to or otherwise received by him with respect to the investigation deemed necessary to facilitate a determination whether there are grounds in the interest of public health for terminating the exemption.

(7) The sponsor shall assure himself that the new animal drug is shipped only to investigators who:

(i) Are qualified by scientific training and/or experience to evaluate the safety and/or effectiveness of the new animal drug;

(ii) Shall maintain complete records of the investigations, including complete records of the receipt and disposition of each shipment or delivery of the new animal drug under investigation.

Copies of all records of the investigation shall be retained by the investigator for 2 years after the termination of the investigation or approval of a new animal drug application.

(iii) Shall furnish adequate and timely reports of the investigation to the sponsor.

(8) The sponsor:

(i) Shall retain all reports received from investigators for 2 years after the termination of the investigation or approval of a new animal drug application and make such reports available to a duly authorized employee of the Department for inspection at all reasonable times.

(ii) Shall provide for current monitoring of the investigation by a person qualified by scientific training and experience to evaluate information obtained from the investigation, and shall promptly investigate and report to the Food and Drug Administration and to all investigators any findings associated with use of the new animal drug that may suggest significant hazards pertinent to the safety of the new animal drug.

(iii) Shall not unduly prolong distribution of the new animal drug for investigational use.

(iv) Shall not, nor shall any person acting for or on behalf of the sponsor, represent that the new animal drug is safe or effective for the purposes for which it is under investigation. This requirement is not intended to restrict the full exchange of scientific information.

(v) Shall not commercially distribute nor test-market the new animal drug until a new animal drug application is approved pursuant to section 512(c) of the act.

(9) If the shipment or other delivery of the new animal drug is imported or offered for importation into the United States for clinical investigational use in animals, it shall also meet the following conditions:

(i) The importer of all such shipments or deliveries is an agent of the foreign exporter residing in the United States or the ultimate consignee, which person has, prior to such shipments and deliveries, informed the Food and Drug Administration of his intention to import the new animal drug.
Food and Drug Administration, HHS

§ 511.1

(3) Each “Notice of Claimed Investigational Exemption for a New Animal Drug” and each approved new animal drug application containing data reported by an investigator who has been determined to be ineligible to receive investigational-use new animal drugs will be examined to determine whether he has submitted unreliable data that are essential to the continuation of the investigation or essential to the approval of any new animal drug application.

(4) If the Commissioner determines, after the unreliable data submitted by the investigator are eliminated from consideration, that the data remaining are inadequate to support a conclusion that it is reasonably safe to continue the investigation, he shall first notify the sponsor, who shall have an opportunity for a regulatory hearing before the Food and Drug Administration pursuant to part 16 of this chapter on the question of whether the investigator is entitled to receive investigational new animal drugs.

(5) If the Commissioner determines, after the unreliable data submitted by the investigator are eliminated from consideration, that the data remaining are such that a new animal drug application would not have been approved, he will proceed to withdraw approval of the application in accordance with section 512(e) of the act.

(6) An investigator who has been determined to be ineligible may be reinstated as eligible to receive investigational-use new animal drugs when the Commissioner determines that he has presented adequate assurance that he will employ such new animal drugs solely in compliance with the exempting regulations in this section for investigational-use new animal drugs.

(d) Termination of exemption. If the Commissioner finds that:

(1) The sponsor of the investigation has failed to comply with any of the
conditions for the exemption established under this section, or
(2) The continuance of the investigation is unsafe or otherwise contrary to the public interest or the drug is being or has been used for purposes other than bona fide scientific investigation, he shall first notify the sponsor and invite his immediate correction. If the conditions of the exemption are not immediately met, the sponsor shall have an opportunity for a regulatory hearing before the Food and Drug Administration pursuant of part 16 of this chapter on whether the exemption should be terminated. If the exemption is terminated the sponsor shall recall or have destroyed the unused supplies of the new animal drug.

(e) Statements and requests. “Notice(s) of Claimed Investigational Exemption for a New Animal Drug” and requests for authorization to use investigational animals and their products for food should be addressed to the Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, 7500 Standish Pl., Rockville, MD 20855.

(f) Contract research organizations. (1) For purposes of this part and part 514, contract research organization means a person that assumes, as an independent contractor with the sponsor, one or more of the obligations of a sponsor, e.g., design of a protocol, selection or monitoring of investigations, evaluation of reports, and preparation of materials to be submitted to the Food and Drug Administration.

(2) A sponsor may transfer responsibility for any or all of the obligations set forth in this part to a contract research organization. Any such transfer shall be in writing and, if not all obligations are transferred, shall describe each of the obligations being assumed by the contract research organization. If all obligations are transferred, a general statement that all obligations have been transferred is acceptable. Any obligation not covered by the written description shall be deemed not to have been transferred.

(3) A contract research organization that assumes any obligation of a sponsor shall comply with the specific regulations in this chapter applicable to this obligation and shall be subject to the same regulatory action as a sponsor for failure to comply with any obligation assumed under these regulations. Thus, all references to sponsor in this part apply to a contract research organization to the extent that it assumes one or more obligations of the sponsor.


PART 514—NEW ANIMAL DRUG APPLICATIONS

Subpart A—General Provisions

Sec. 514.1 Applications.
514.3 Definitions.
514.4 Substantial evidence.
514.6 Amended applications.
514.7 Withdrawal of applications without prejudice.
514.8 Supplemental new animal drug applications.
514.11 Confidentiality of data and information in a new animal drug application file.
514.12 Confidentiality of data and information in an investigational new animal drug notice.
514.15 Untrue statements in applications.

Subpart B—Administrative Actions on Applications

514.80 Records and reports concerning experience with approved new animal drugs.
514.100 Evaluation and comment on applications.
514.105 Approval of applications.
514.106 Approval of supplemental applications.
514.110 Reasons for refusing to file applications.
514.111 Refusal to approve an application.
514.115 Withdrawal of approval of applications.
514.116 Notice of withdrawal of approval of application.
514.117 Adequate and well-controlled studies.
514.120 Revocation of order refusing to approve an application or suspending or withdrawing approval of an application.
514.121 Service of notices and orders.

Subpart C—Hearing Procedures

514.200 Contents of notice of opportunity for a hearing.
§ 514.201 Procedures for hearings.

Subparts D—E [Reserved]

Subpart F—Judicial Review

514.205 Judicial review.

Authority: 21 U.S.C. 351, 352, 360b, 371, 379e, 381.

Effective Date Note: At 67 FR 5057, Feb. 4, 2002, the authority for part 514 was revised, effective Aug. 5, 2002. For the convenience of the user, the revised text is set forth as follows:


Source: 40 FR 13825, Mar. 27, 1975, unless otherwise noted.

Subpart A—General Provisions

§ 514.1 Applications.

(a) Applications to be filed under section 512(b) of the act shall be submitted in the form described in paragraph (b) of this section. If any part of the application is in a foreign language, an accurate and complete English translation shall be appended to such part. Translations of literature printed in a foreign language shall be accompanied by copies of the original publication. The application must be signed by the applicant or by an authorized attorney, agent, or official. If the applicant or such authorized representative does not reside or have a place of business within the United States, the application must also furnish the name and post office address of, and must be countersigned by, an authorized attorney, agent, or official residing or maintaining a place of business within the United States. Pertinent information may be incorporated in, and will be considered as part of, an application on the basis of specific reference to such information, including information submitted under the provisions of §511.1 of this chapter, in the files of the Food and Drug Administration; however, the reference must be specific in identifying the information. Any reference to information furnished by a person other than the applicant may not be considered unless its use is authorized in a written statement signed by the person who submitted it.

(b) Applications for new animal drugs shall be submitted in triple copy and assembled in the manner prescribed by paragraph (b)(15) of this section, and shall include the following information:

(1) Identification. Whether the submission is an original or supplemental application; the name and the address of the applicant; the date of the application; the trade name(s) (if one has been proposed) and chemical name(s) of the new animal drug. Upon receipt, the application will be assigned a number NADA , which shall be used for all correspondence with respect to the application.

(2) Table of contents and summary. The application shall be organized in a cohesive fashion, shall contain a table of contents which identifies the data and other material submitted, and shall contain a well-organized summary and evaluation of the data in the following form:

(i) Chemistry:
   (a) Chemical structural formula or description for any new animal drug substance.
   (b) Relationship to other chemically or pharmacologically related drugs.
   (c) Description of dosage form and quantitative composition.

(ii) Scientific rationale and purpose the new animal drug is to serve:
   (a) Clinical purpose.
   (b) Highlights of laboratory studies: The reasons why certain types of studies were done or omitted as related to the proposed conditions of use and to information already known about this class of compounds. Emphasize any unusual or particularly significant pharmacological effects or toxicological findings.
   (c) Highlights of clinical studies: The rationale of the clinical study plan showing why types of studies were done, amended, or omitted as related to laboratory studies and prior clinical experience.
   (d) Conclusions: A short statement of conclusions combining the major points of effectiveness and safety as they relate to the use of the new animal drug.

(3) Labeling. Three copies of each piece of all labeling to be used for the article (total of 9).
§514.1

(i) All labeling should be identified to show its position on, or the manner in which it is to accompany the market package.

(ii) Labeling for nonprescription new animal drugs should include adequate directions for use by the layman under all conditions of use for which the new animal drug is intended, recommended, or suggested in any of the labeling or advertising sponsored by the applicant.

(iii) Labeling for prescription veterinary drugs should bear adequate information for use under which veterinarians can use the new animal drug safely and for the purposes for which it is intended, including those purposes for which it is to be advertised or represented, in accord with §201.105 of this chapter.

(iv) All labeling for prescription or nonprescription new animal drugs shall be submitted with any necessary use restrictions prominently and conspicuously displayed.

(v) Labeling for new animal drugs intended for use in the manufacture of medicated feeds shall include:

(a) Specimens of labeling to be used for such new animal drug with adequate directions for the manufacture and use of finished feeds for all conditions for which the new animal drug is intended, recommended, or suggested in any of the labeling, including advertising, sponsored by the applicant. Ingredient labeling may utilize collective names as provided in §501.110 of this chapter.

(b) Representative labeling proposed to be used for Type B and Type C medicated feeds containing the new animal drug.

(vi) Draft labeling may be submitted for preliminary consideration of an application. Final printed labeling will ordinarily be required prior to approval of an application. Proposed advertising for veterinary prescription drugs may be submitted for comment or approval.

Components and composition. A complete list of all articles used for production of the new animal drug including a full list of the composition of each article:

(i) A full list of the articles used as components of the new animal drug. This list should include all substances used in the synthesis, extraction, or other method of preparation of any new animal drug and in the preparation of the finished dosage form, regardless of whether they undergo chemical change or are removed in the process. Each component should be identified by its established name, if any, or complete chemical name, using structural formulas when necessary for specific identification. If any proprietary name is used, it should be followed by a complete quantitative statement of composition. Reasonable alternatives for any listed component may be specified.

(ii) A full statement of the composition of the new animal drug. The statement shall set forth the name and amount of each ingredient, whether active or not, contained in a stated quantity of the new animal drug in the form in which it is to be distributed (for example, amount per tablet or milliliter) and a batch formula representative of that to be employed for the manufacture of the finished dosage form. All components should be included in the batch formula regardless of whether they appear in the finished product. Any calculated excess of an ingredient over the label declaration should be designated as such and percent excess shown. Reasonable variation may be specified.

(iii) If it is a new animal drug produced by fermentation:

(a) Source and type of microorganism used to produce the new animal drug.

(b) Composition of media used to produce the new animal drug.

(c) Type of precursor used, if any, to guide or enhance production of the antibiotic during fermentation.

(d) Name and composition of preservative, if any, used in the broth.

(e) A complete description of the extraction and purification processes including the names and compositions of the solvents, precipitants, ion exchange resins, emulsifiers, and all other agents used.

(f) If the new animal drug is produced by a catalytic hydrogenation process (such as tetracycline from chlortetracycline), a complete description of each chemical reaction with graphic formulas used to produce the new animal drug, including the names of the catalyst used, how it is removed, and how
the new animal drug is extracted and purified.

(5) Manufacturing methods, facilities, and controls. A full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of the new animal drug. This description should include full information with respect to any new animal drug in sufficient detail to permit evaluation of the adequacy of the described methods of manufacture, processing, and packing, and the described facilities and controls to determine and preserve the identity, strength, quality, and purity of the new animal drug, and the following:

(i) If the applicant does not himself perform all the manufacturing, processing, packaging, labeling, and control operations for any new animal drug, he shall: Identify each person who will perform any part of such operations and designate the part; and provide a signed statement from each such person fully describing, directly or by reference, the methods, facilities, and controls he will use in his part of the operation. The statement shall include a commitment that no changes will be made without prior approval by the Food and Drug Administration, unless permitted under §514.8.

(ii) A description of the qualifications, including educational background and experience, of the technical and professional personnel who are responsible for assuring that the new animal drug has the identity, strength, quality, and purity it purports or is represented to possess, and a statement of their responsibilities.

(iii) A description of the physical facilities including building and equipment used in manufacturing, processing, packaging, labeling, storage, and control operations.

(iv) The methods used in the synthesis, extraction, isolation, or purification of any new animal drug. When the specifications and controls applied to such new animal drugs are inadequate in themselves to determine its identity, strength, quality, and purity, the methods should be described in sufficient detail, including quantities used, times, temperature, pH, solvents, etc., to determine these characteristics. Alternative methods or variations in methods within reasonable limits that do not affect such characteristics of the new animal drug may be specified. A flow sheet and indicated equations should be submitted when needed to explain the process.

(v) Precautions to insure proper identity, strength, quality, and purity of the raw materials, whether active or not, including:

(a) The specifications for acceptance and methods of testing for each lot of raw material.

(b) A statement as to whether or not each lot of raw materials is given a serial number to identify it, and the use made of such numbers in subsequent plant operations.

(vi) The instructions used in the manufacturing, processing, packaging, and labeling of each dosage form of the new animal drug, including:

(a) The method of preparation of the master formula records and individual batch records and the manner in which these records are used.

(b) The number of individuals checking weight or volume of each individual ingredient entering into each batch of the new animal drug.

(c) A statement as to whether or not the total weight or volume of each batch is determined at any stage of the manufacturing process subsequent to making up a batch according to the formula card and, if so, at what stage and by whom it is done.

(d) The precautions used in checking the actual package yield produced from a batch of the new animal drug with the theoretical yield. This should include a description of the accounting for such items as discards, breakage, etc., and the criteria used in accepting or rejecting batches of drugs in the event of an unexplained discrepancy.

(e) The precautions used to assure that each lot of the new animal drug is packaged with the proper label and labeling, including provisions for labeling storage and inventory control.

(f) Any special precautions used in the operations.

(vii) The analytical controls used during the various stages of the manufacturing, processing, packaging, and labeling of the new animal drug, including a detailed description of the
§ 514.1  21 CFR Ch. I (4–1–02 Edition)

collection of samples and the analytical procedures to which they are subjected. The analytical procedures should be capable of determining the active components within a reasonable degree of accuracy and of assuring the identity of such components.

(a) A description of practicable methods of analysis of adequate sensitivity to determine the amount of the new animal drug in the final dosage form should be included. The dosage form may be a finished pharmaceutical product, a Type A medicated article, a Type B or a Type C medicated feed, or a product for use in animal drinking water. Where two or more active ingredients are included, methods should be quantitative and specific for each active ingredient.

(b) If the article is one that is represented to be sterile, the same information with regard to the manufacturing, processing, packaging, and the collection of samples of the drug should be given for sterility controls. Include the standards used for acceptance of each lot of the finished drug.

(viii) An explanation of the exact significance of any batch control numbers used in the manufacturing, processing, packaging, and labeling of the new animal drug, including such control numbers that may appear on the label of the finished article. State whether these numbers enable determination of the complete manufacturing history of the product. Describe any methods used to permit determination of the distribution of any batch if its recall is required.

(ix) Adequate information with respect to the characteristics of and the test methods employed for the container, closure, or other component parts of the drug package to assure their suitability for the intended use.

(x) A complete description of, and data derived from, studies of the stability of the new animal drug in the final dosage form, including information showing the suitability of the analytical methods used. A description of any additional stability studies underway or planned. Stability data for the finished dosage form of the new animal drug in the container in which it is to be marketed, including any proposed multiple dose container, and, if it is to be put into solution at the time of dispensing, for the solution prepared as directed. If the new animal drug is intended for use in the manufacture of Type C medicated feed as defined in §558.3 of this chapter, stability data derived from studies in which representative formulations of the medicated feed articles are used. Similar data may be required for Type B medicated feeds as determined by the Food and Drug Administration on a case-by-case basis. Expiration dates shall be proposed for finished pharmaceutical dosage forms and Type A medicated articles. If the data indicate that an expiration date is needed for Type B or Type C medicated feeds, the applicant shall propose such expiration date. If no expiration date is proposed for Type B or Type C medicated feeds, the applicant shall justify its absence with data.

(xv) Additional procedures employed which are designed to prevent contamination and otherwise assure proper control of the product. An application may be refused unless it includes adequate information showing that the methods used in, and the facilities and controls used for, the manufacturing, processing, and packaging of the new animal drug are adequate to preserve its identity, strength, quality, and purity in conformity with good manufacturing practice and identifies each establishment, showing the location of the plant conducting these operations.

(6) Samples. Samples of the new animal drug and articles used as components and information concerning them may be requested by the Center for Veterinary Medicine as follows:

(i) Each sample shall consist of four identical, separately packaged subdivisions, each containing at least three times the amount required to perform the laboratory test procedures described in the application to determine compliance with its control specifications for identity and assays. Each of the samples submitted shall be appropriately packaged and labeled to preserve its characteristics, to identify the material and the quantity in each subdivision of the sample, and to identify each subdivision with the name of the applicant and the new animal drug application to which it relates. Included are:
Food and Drug Administration, HHS

§ 514.1

(a) A sample or samples of any reference standard and blank used in the procedures described in the application for assaying each new animal drug and other assayed components of the finished new animal drug.

(b) A representative sample or samples of each strength of the finished dosage form proposed in the application and employed in the clinical investigations and a representative sample or samples of each new animal drug from the batch(es) employed in the production of such dosage form.

(c) A representative sample or samples of finished market packages of each strength of the dosage form of the new animal drug prepared for initial marketing and, if any such sample is not from a representative commercial-scale production batch, such a sample from a representative commercial-scale production batch, and a representative sample or samples of each new animal drug from the batch(es) employed in the production of such dosage form, provided that in the case of new animal drugs marketed in large packages the sample should contain only three times a sufficient quantity of the new animal drug to allow for performing the control tests for drug identity and assays.

(ii) The following information shall be included for the samples when requested:

(a) For each sample submitted, full information regarding its identity and the origin of any new animal drug contained therein (including a statement whether it was produced on a laboratory, pilot-plant, or full-production scale) and detailed results of all laboratory tests made to determine the identity, strength, quality, and purity of the batch represented by the sample, including assays.

(b) For any reference standard submitted, a complete description of its preparation and the results of all laboratory tests on it. If the test methods used differed from those described in the application, full details of the methods employed in obtaining the reporting results.

(7) Analytical methods for residues. Applications shall include a description of practicable methods for determining the quantity, if any, of the new animal drug in or on food, and any substance formed in or on food because of its use, and the proposed tolerance or withdrawal period or other use restrictions to ensure that the proposed use of this drug will be safe. When data or other adequate information establish that it is not reasonable to expect the new animal drug to become a component of food at concentrations considered unsafe, a regulatory method is not required.

(i) The kind of information required by this subdivision may include: Complete experimental protocols for determining drug residue levels in the edible products, and the length of time required for residues to be eliminated from such products following the drug's use; residue studies conducted under appropriate (consistent with the proposed usage) conditions of dosage, time, and route of administration to show levels, if any, of the drug and/or its metabolites in test animals during and upon cessation of treatment and at intervals thereafter in order to establish a disappearance curve; if the drug is to be used in combination with other drugs, possible effects of interaction demonstrated by the appropriate disappearance curve or depletion patterns after drug withdrawal under appropriate (consistent with the proposed usage) conditions of dosage, time, and route of administration; if the drug is given in the feed or water, appropriate consumption records of the medicated feed or water and appropriate performance data in the treated animal; if the drug is to be used in more than one species, drug residue studies or appropriate metabolic studies conducted for each species that is food-producing. To provide these data, a sufficient number of birds or animals should be used at each sample interval. Appropriate use of labeled compounds (e.g. radioactive tracers), may be utilized to establish metabolism and depletion curves. Drug residue levels ordinarily should be determined in muscle, liver, kidney, and fat and where applicable, in skin, milk, and eggs (yolk and egg white). As a part of the metabolic studies, levels of the drug or metabolite should be determined in blood where feasible. Samples may be combined where necessary. Where residues are suspected or known
§ 514.1  

to be present in litter from treated animals, it may be necessary to include data with respect to such residues becoming components of other agricultural commodities because of use of litter from treated animals.

(ii) A new animal drug that has the potential to contaminate human food with residues whose consumption could present a risk of cancer to people must satisfy the requirements of subpart E of part 500 of this chapter.

(b) Evidence to establish safety and effectiveness. (i) An application may be refused unless it contains full reports of adequate tests by all methods reasonably applicable to show whether or not the new animal drug is safe and effective for use as suggested in the proposed labeling.

(ii) An application may be refused unless it includes substantial evidence of the effectiveness of the new animal drug as defined in § 514.4.

(iii) An application may be refused unless it contains detailed reports of the investigations, including studies made on laboratory animals, in which the purpose, methods, and results obtained are clearly set forth of acute, subacute, and chronic toxicity, and unless it contains appropriate clinical laboratory results related to safety and efficacy. Such information should include identification of the person who conducted each investigation, a statement of where the investigations were conducted, and where the raw data are available in the application.

(iv) All information pertinent to an evaluation of the safety and effectiveness of the new animal drug received or otherwise obtained by the applicant from any source, including information derived from other investigations or commercial marketing (for example, outside the United States), or reports in the scientific literature, both favorable and unfavorable, involving the new animal drug that is the subject of the application and related new animal drugs shall be submitted. An adequate summary may be acceptable in lieu of a reprint of a published report that only supports other data submitted. Include any evaluation of the safety or effectiveness of the new animal drug that has been made by the applicant's veterinary or medical department, expert committee, or consultants.

(v) If the new animal drug is a combination of active ingredients or animal drugs, an application may be refused unless it includes substantial evidence of the effectiveness of the combination new animal drug as required in § 514.4.

(vi) An application shall include a complete list of the names and post office addresses of all investigators who received the new animal drug. This may be incorporated in whole or in part by reference to information submitted under the provisions of § 511.1 of this chapter.

(vii) Explain any omission of reports from any investigator to whom the investigational new animal drug has been made available. The unexplained omission of any reports of investigations made with the new animal drug by the applicant or submitted to him by an investigator or the unexplained omission of any pertinent reports of investigations or clinical experience received or otherwise obtained by the applicant from published literature or other sources that would bias an evaluation of the safety of the new animal drug or its effectiveness in use, constitutes grounds for the refusal or withdrawal of the approval of an application.

(viii) If a sponsor has transferred any obligations for the conduct of any clinical study to a contract research organization, the application is required to include a statement containing the name and address of the contract research organization, identifying the clinical study, and listing the obligations transferred. If all obligations governing the conduct of the study have been transferred, a general statement of this transfer—in lieu of a listing of the specific obligations transferred—may be submitted.

(ix) If original subject records were audited or reviewed by the sponsor in the course of monitoring any clinical study to verify the accuracy of the case reports submitted to the sponsor, a list identifying each clinical study so audited or reviewed.

(9) Veterinary feed directive. Three copies of a veterinary feed directive (VFD) must be submitted in the format
Food and Drug Administration, HHS

§ 514.1

described under §558.6(a)(4) of this chapter.

(10) Supplemental applications. If it is a supplemental application, full information shall be submitted on each proposed change concerning any statement made in the approved application.

(11) Applicant’s commitment. It is understood that the labeling and advertising for the new animal drug will prescribe, recommend, or suggest its use only under the conditions stated in the labeling which is part of this application and if the article is a prescription new animal drug, it is understood that any labeling which furnishes or purports to furnish information for use or which prescribes, recommends, or suggests a dosage for use of the new animal drug will also contain, in the same language and emphasis, information for its use including indications, effects, dosages, routes, methods, and frequency and duration of administration, any relevant hazards, contraindications, side effects, and precautions contained in the labeling which is part of this application. It is understood that all representations in this application apply to the drug produced until changes are made in conformity with §514.8.

(12) Additional commitments. (i) New animal drugs as defined in §510.3 of this chapter, intended for use in the manufacture of animal feeds in any State will be shipped only to persons who may receive such drugs in accordance with §510.7 of this chapter.

(ii) The methods, facilities, and controls described under item 5 of this application conform to the current good manufacturing practice regulations in subchapter C of this chapter.

(iii) With respect to each nonclinical laboratory study contained in the application, either a statement that the study was conducted in compliance with the good laboratory practice regulations set forth in part 58 of this chapter, or, if the study was not conducted in compliance with such regulations, a brief statement of the reason for the noncompliance.

(13) [Reserved]

(14) Environmental assessment. The applicant is required to submit either a claim for categorical exclusion under §25.30 or §25.33 of this chapter or an environmental assessment under §25.40 of this chapter.

(15) Assembling and binding the application. Assemble and bind an original and two copies of the application as follows:

(i) Bind the original or ribbon copy of the application as copy No. 1.

(ii) Bind two identical copies as copy No. 2 and copy No. 3.

(iii) Identify each front cover with the name of the applicant, new animal drug, and the copy number.

(iv) Number each page of the application sequentially in the upper right hand corner or in another location so that the page numbers remain legible after the application has been bound, and organize the application consistent with paragraphs (b) (1) through (14) of this section. Each copy should bear the same page numbering, whether sequential in each volume or continuous and sequential throughout the application.

(v) Include complete labeling in each of the copies. It is suggested that labeling be identified by date of printing or date of preparation.

(vi) Submit separate applications for each different dosage form of the drug proposed. Repeating basic information pertinent to all dosage forms in each application is unnecessary if reference is made to the application containing such information. Include in each application information applicable to the specific dosage form, such as labeling, composition, stability data, and method of manufacture.

(vii) Submit in folders amendments, supplements, and other correspondence sent after submission of an original application. The front cover of these submissions should be identified with the name of the applicant, new animal drug, copy number, and the new animal drug application number, if known.

(c) When a new animal drug application is submitted for a new animal drug which has a stimulant, depressant, or hallucinogenic effect on the central nervous system, if it appears that the drug has a potential for abuse, the Commissioner shall forward that information to the Attorney General of the United States.

(d) Minor use applications. Applications for minor use new animal drugs:
§ 514.3 Definitions. For the purpose of this section:

(i) **Minor use** means the use of: (a) New animal drugs in minor animal species, or (b) new animal drugs in any animal species for the control of a disease that (1) occurs infrequently or (2) occurs in limited geographic areas.

(ii) **Minor species** means animals other than cattle, horses, swine, chickens, turkeys, dogs, and cats.

(2) **Animal safety, effectiveness, human food safety, and environmental considerations.** Guidance documents for the preparation and submission of data to satisfy the requirements of section 512 of the act regarding animal safety, effectiveness, human food safety, and environmental considerations for new animal drugs intended for a minor use (as defined in paragraph (d)(1)(i) of this section) are available from the Industry Information Staff (HFV–11), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

(i) **Animal safety and effectiveness.** Where the guidance documents do not specifically provide for a particular minor use, the Center for Veterinary Medicine, upon request, will advise interested persons on the effectiveness and animal safety data regarding the minor use that will be needed to satisfy the requirements of section 512 of the act. Where scientifically appropriate, the Center for Veterinary Medicine will allow the use of animal models and the extrapolation of data from a major species to a minor species to satisfy the requirements of the act.

(ii) **Human food safety and environmental considerations.** These guidance documents do not specifically provide for a particular minor use. Therefore, the Center for Veterinary Medicine will, upon request, advise interested persons of the data that will be needed. Where scientifically appropriate, the Center for Veterinary Medicine will allow the extrapolation of data from a major species to a minor species to satisfy the requirements of the act.

[40 FR 13825, Mar. 27, 1975]

Editorial Note: For Federal Register citations affecting §514.1, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.
manufacturing defect is a product defect caused or aggravated by a manufacturing or related process. A manufacturing defect may occur from a single event or from deficiencies inherent to the manufacturing process. These defects are generally associated with product contamination, product deterioration, manufacturing error, defective packaging, damage from disaster, or labeling error. For example, a labeling error may include any incident that causes a distributed product to be mistaken for, or its labeling applied to, another product.

(h) Serious adverse drug experience is an adverse event that is fatal or life-threatening, requires professional intervention, or causes an abortion, stillbirth, infertility, congenital anomaly, prolonged or permanent disability, or disfigurement.

(i) Unexpected adverse drug experience is an adverse event that is not listed in the current labeling for the new animal drug and includes any event that may be symptomatically and pathophysiologically related to an event listed on the labeling, but differs from the event because of greater severity or specificity. For example, under this definition hepatic necrosis would be unexpected if the labeling referred only to elevated hepatic enzymes or hepatitis.

EFFECTIVE DATE NOTE: At 67 FR 5057, Feb. 4, 2002, §514.3 was added, effective Aug. 5, 2002.

§514.4 Substantial evidence.

(a) Definition of substantial evidence. Substantial evidence means evidence consisting of one or more adequate and well-controlled studies, such as a study in a target species, study in laboratory animals, field study, bioequivalence study, or an in vitro study, on the basis of which it could fairly and reasonably be concluded by experts qualified by scientific training and experience to evaluate the effectiveness of the new animal drug involved that the new animal drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof. Substantial evidence shall include such adequate and well-controlled studies that are, as a matter of sound scientific judgment, necessary to establish that a new animal drug will have its intended effect.

(b) Characteristics of substantial evidence—(1) Qualifications of experts. Any study that is intended to be part of substantial evidence of the effectiveness of a new animal drug shall be conducted by experts qualified by scientific training and experience.

(2) Intended uses and conditions of use. Substantial evidence of effectiveness of a new animal drug shall demonstrate that the new animal drug is effective for each intended use and associated conditions of use for and under which approval is sought.

(i) Dose range labeling. Sponsors should, to the extent possible, provide for a dose range because it increases the utility of the new animal drug by providing the user flexibility in the selection of a safe and effective dose. In general, substantial evidence to support dose range labeling for a new animal drug intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease must consist of at least one adequate and well-controlled study on the basis of which qualified experts could fairly and reasonably conclude that the new animal drug will be effective for the intended use at the lowest dose of the dose range suggested in the proposed labeling for that intended use. Substantial evidence to support dose range labeling for a new animal drug intended to affect the structure or function of the body of an animal generally must consist of at least one adequate and well-controlled study on the basis of which qualified experts could fairly and reasonably conclude that the new animal drug will be effective for the intended use at all doses within the range suggested in the proposed labeling for the intended use.

(ii) [Reserved]

(3) Studies—(1) Number. Substantial evidence of the effectiveness of a new animal drug for each intended use and associated conditions of use shall consist of a sufficient number of current adequate and well-controlled studies of sufficient quality and persuasiveness to permit qualified experts:

(A) To determine that the parameters selected for measurement and the
measured responses reliably reflect the effectiveness of the new animal drug;
(B) To determine that the results obtained are likely to be repeatable, and that valid inferences can be drawn to the target animal population; and
(C) To conclude that the new animal drug is effective for the intended use at the dose or dose range and associated conditions of use prescribed, recommended, or suggested in the proposed labeling.

(ii) Types. Adequate and well-controlled studies that are intended to provide substantial evidence of the effectiveness of a new animal drug may include, but are not limited to, published studies, foreign studies, studies using models, and studies conducted by or on behalf of the sponsor. Studies using models shall be validated to establish an adequate relationship of parameters measured and effects observed in the model with one or more significant effects of treatment.

(c) Substantial evidence for combination new animal drugs—(1) Definitions. The following definitions of terms apply to this section:
(i) Combination new animal drug means a new animal drug that contains more than one active ingredient or animal drug that is applied or administered simultaneously in a single dosage form or simultaneously in or on animal feed or drinking water.
(ii) Dosage form combination new animal drug means a combination new animal drug intended for use other than in animal feed or drinking water.
(iii) Antibacterial with respect to a particular target animal species means an active ingredient or animal drug: That is approved in that species for the diagnosis, cure, mitigation, treatment, or prevention of bacterial disease; or that is approved for use in that species for any other use that is attributable to its antibacterial properties. But, antibacterial does not include ionophores or arsenicals intended for use in combination in animal feed or drinking water.
(iv) Appropriate concurrent use exists when there is credible evidence that the conditions for which the combination new animal drug is intended can occur simultaneously.

(2) Combination new animal drugs that contain only active ingredients or animal drugs that have previously been separately approved.
(i) For dosage form combination new animal drugs, except for those that contain a nontopical antibacterial, that contain only active ingredients or animal drugs that have previously been separately approved for the particular uses and conditions of use for which they are intended in combination, a sponsor shall demonstrate:
(A) By substantial evidence, as defined in this section, that any active ingredient or animal drug intended only for the same use as another active ingredient or animal drug in the combination makes a contribution to the effectiveness of the combination new animal drug;
(B) That each active ingredient or animal drug intended for at least one use that is different from all the other active ingredients or animal drugs used in the combination provides appropriate concurrent use for the intended target animal population; and
(C) That the active ingredients or animal drugs are physically compatible and do not have disparate dosing regimens if FDA, based on scientific information, has reason to believe the active ingredients or animal drugs are physically incompatible or have disparate dosing regimens.
(ii) For combination new animal drugs intended for use in animal feed or drinking water that contain only active ingredients or animal drugs that have previously been separately approved for the particular uses and conditions of use for which they are intended in combination, the sponsor shall demonstrate:
(A) By substantial evidence, as defined in this section, that any active ingredient or animal drug intended only for the same use as another active ingredient or animal drug in the combination makes a contribution to the effectiveness of the combination new animal drug;
(B) For such combination new animal drugs that contain more than one antibacterial ingredient or animal drug, by substantial evidence, as defined in this section, that each antibacterial makes a contribution to labeled effectiveness;
(C) That each active ingredient or animal drug intended for at least one use that is different from all other active ingredients or animal drugs used in the combination provides appropriate concurrent use for the intended target animal population; and

(D) That the active ingredients or animal drugs intended for use in drinking water are physically compatible if FDA, based on scientific information, has reason to believe the active ingredients or animal drugs are physically incompatible.

(3) Other combination new animal drugs. For all other combination new animal drugs, the sponsor shall demonstrate by substantial evidence, as defined in this section, that the combination new animal drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling and that each active ingredient or animal drug contributes to the effectiveness of the combination new animal drug.

[64 FR 40756, July 28, 1999]

§ 514.6 Amended applications.

The applicant may submit an amendment to an application that is pending, including changes that may alter the conditions of use, the labeling, safety, effectiveness, identity, strength, quality, or purity of the drug or the adequacy of the manufacturing methods, facilities, and controls to preserve them, in which case the unamended application may be considered as withdrawn and the amended application may be considered resubmitted on the date on which the amendment is received by the Food and Drug Administration. The applicant will be notified of such date.

§ 514.7 Withdrawal of applications without prejudice.

The sponsor may withdraw his pending application from consideration as a new animal drug application upon written notification to the Food and Drug Administration. Such withdrawal may be made without prejudice to a future filing. Upon resubmission, the time limitation will begin to run from the date the resubmission is received by the Food and Drug Administration. The original application will be retained by the Food and Drug Administration although it is considered withdrawn. The applicant shall be furnished a copy at cost on request.

§ 514.8 Supplemental new animal drug applications.

(a)(1) After a new animal drug application is approved, a supplemental new animal drug application may propose changes. A supplemental application may omit statements made in the approved application concerning which no change is proposed. Each supplemental application shall include up-to-date reports of any of the kinds of information required by §510.300(a) of this chapter that has not previously been submitted. A supplemental application shall be accompanied by either a claim for categorical exclusion under §25.30 or §25.33 of this chapter or an environmental assessment under §25.40 of this chapter.

(2) A supplemental new animal drug application shall be submitted for any change beyond the variations provided for in the application, including changes in the scale of production such as from pilot-plant to production batch, that may alter the conditions of use, the labeling, safety, effectiveness, identity, strength, quality, or purity of the new animal drug, or the adequacy of the manufacturing methods, facilities, or controls to preserve them.

(3) If it is a prescription drug, any mailing or promotional piece used after the drug is placed on the market is labeling requiring a supplemental application, unless:

(i) The parts of the labeling furnishing directions, warnings, and information for use of the drug are the same in language and emphasis as labeling approved or permitted; and

(ii) Any other parts of the labeling are consistent with and not contrary to such approved or permitted labeling.

(4) The supplemental application shall be submitted as follows. A communication proposing a change in a new animal drug application should provide for any one of the following kinds of changes:
§514.8

(i) Revision in labeling, such as updating information pertaining to effects, dosages, and side effects and contraindications, which includes information headed “side effects,” “warnings,” “precautions,” and “contraindications.”

(ii) Addition of claim.

(iii) Revision in manufacturing or control procedures; for example, changes in components, composition, method of manufacture, analytical control procedures, package or tablet size, etc.

(iv) Change in manufacturing facilities.

(v) Provision for outside firm to participate in the preparation, distribution, or packaging of a new animal drug (new distributor, packer, supplier, manufacturer, etc.); one firm per submission.

Any number of changes may be submitted at any one time; but if they fall into different categories as listed in paragraphs (a)(4) (i) through (v) of this section, the proposed changes should be covered by separate communications.

Where, however, a change necessitates an overlap in categories, it should be submitted in a single communication. For example, a change in tablet potency would require other changes such as in components, composition, and labeling and should be submitted in a single communication.

(5) The following kinds of changes may be placed into effect without the approval of a supplemental application, if such change is fully described in the next periodic report required under §510.300(b)(4) of this chapter or, when such a report is not required, in a written communication to the Food and Drug Administration within 60 days of the effective date of the change (this does not apply to a change proposed because of any mixup or any bacteriological or significant chemical, physical, or other change or deterioration in the drug or any failure of one or more distributed batches of the drug to meet its specifications):

(i) A different container size for solid oral dosage forms where container and closure are of the same materials as those provided for in the approved application.

(ii) Change in personnel not involving new facilities.

(iii) Change in equipment that does not alter the method of manufacture of a new animal drug.

(iv) Change from one commercial batch size to another without any change in manufacturing procedure.

(v) Change to more stringent specification without altering the method described in the approved application.

(vi) Inclusion of additional specifications and methods without deletion of those described in the approved application.

(vii) Alteration of specifications or methods for inactive ingredients to bring them into compliance with new or revised specifications or methods in an official compendium.

(viii) Initiation of a product identification coding system.

(ix) Addition to labeling of a reasonable expiration date where none was previously used, with related conditions of drug storage when appropriate, except when evidence shows that a significant deterioration of the drug under marketing conditions has occurred which necessitates the immediate submission of a report under §510.300(b)(1) of this chapter. The report or written communication describing such change in labeling should include stability data justifying the expiration date and recommended conditions of storage.

(x) Change from paper labels to direct printing on glass or other kinds of immediate containers without a change in text.

(6) Approval of a supplemental new animal drug application will not be required to provide for an additional distributor to distribute a drug which is the subject of an approved new animal drug application if the conditions described below are met prior to putting such a change into effect. An order may issue refusing approval if any condition is not met or if any of the reasons for refusing or withdrawing approval, as stated in section 512(d) and (e) of the act or §514.110 applies. For the purposes of maintaining records and making reports under the requirements of §510.300 of this chapter, a distributor provided for under this section shall be considered an applicant within
Food and Drug Administration, HHS

§ 514.8

the meaning of §510.300(b) of this chapter. Said conditions are:

(i) A supplemental application is furnished to the Food and Drug Administration to provide for a designated distributor.

(ii) There are no changes from the conditions of the approved application except for a different and suitable proprietary name of the new animal drug (if one is used) and the name and address of the distributor as used on the label and labeling. The name of the distributor shall be accompanied by an appropriate qualifying phrase such as “manufactured for” or “distributed by.”

(iii) A distributor’s statement is furnished to the Food and Drug Administration identifying the category of his operations (for example, wholesaler, retailer) and stating: That he will distribute the new animal drug only under the labeling provided for in the new animal drug application; that any other labeling or advertising for the drug will prescribe, recommend, or suggest its use only under the conditions stated in the labeling provided for in the application; and, if the drug is a prescription article, that he is regularly and lawfully engaged in the distribution or dispensing of prescription drugs.

(iv) Nine copies of the printed labels and other labeling to be used by the distributor are submitted, identified with the new animal drug application number.

(b) When necessary for the safety or effectiveness of the drug, a supplemental new animal drug application shall specify a period of time within which the proposed change will be made.

(c) If a material change is made in the components' composition, manufacturing methods, facilities, or controls, or in the labeling or advertising, from the representations in an approved application for a new animal drug (except changes conforming to the conditions set forth in paragraph (a)(5) and (6) and/or paragraphs (d), (e), (f), and (g) of this section), and the drug is marketed before a supplement is approved for such change, approval of the application may be suspended or withdrawn as provided in section 512(e) of the act.

(d) Changes of the following kinds proposed in supplemental new animal drug applications should be placed into effect at the earliest possible time:

(1) The addition to package labeling, promotional labeling, and prescription drug advertising of additional warning, contraindication, side effect, and precaution information.

(2) The deletion from package labeling, promotional labeling, and drug advertising of false, misleading, or unsupported indications for use or claims for effectiveness.

(3) Changes in the methods, facilities, or controls used for the manufacture, processing, packing, or holding of the new animal drug (other than utilization of establishments not covered by the approval that is in effect) that give increased assurance that the drug will have the characteristics of identity, strength, quality, and purity which it purports or is represented to possess.

(e) The Food and Drug Administration will take no action against a new animal drug or applicant solely because changes of the kinds described in paragraph (d) of this section are placed into effect by the applicant prior to his receipt of a written notice of approval of the supplemental new animal drug application if all the following conditions are met:

(1) The supplemental new animal drug application providing a full explanation of the basis for the changes has been submitted, plainly marked on the mailing cover and on the supplement, “Special new animal drug application Supplement—changes being effected.”

(2) The applicant specifically informs the Food and Drug Administration of the date on which such changes are being effected and submits to the Administration nine printed copies of any revised labeling to be placed in use, identified with the new animal drug application number.

(3) All promotional labeling and all drug advertising are promptly revised consistent with the changes made in the labeling on or within the new animal drug package.

(f) When a supplemental new animal drug application proposes changes only of the kinds described in paragraph (d)
§ 514.8

of this section, and the applicant informs the Food and Drug Administration that the changes are being put into effect, such notification will be regarded as an agreement by the applicant to an extension of the time for formal action on the application.

(g) In addition to changes as permitted by paragraphs (d) and (e) of this section, an applicant may place into effect changes proposed in a supplement to a new animal drug application that became effective prior to October 10, 1962, upon written notification from the Food and Drug Administration that such action is permitted, without approval of the supplemental application, pending the completion of the review of the effectiveness of such drug by the National Academy of Sciences-National Research Council and a determination as to whether there are grounds for refusing approval under section 512(d) of the act or for invoking section 512(e) of the act. The Food and Drug Administration will take no action against a new animal drug or an applicant solely because changes that have been permitted in a written communication are placed into effect by the applicant prior to his receipt of a written notice of approval of the supplemental new animal drug application.

(h) Except as provided in paragraphs (e) and (g) of this section, no provision of this section shall limit the authority of the Secretary or of the Commissioner to suspend or withdraw approval of a new animal drug application in accord with the provisions of section 512(e) of the act or to initiate any other regulatory proceedings with respect to a drug or applicant under provisions of the act.

(i) Changes from the conditions of an approved new animal drug application in accord with the provisions of paragraphs (d), (e), and (g) of this section are permitted on the basis of a temporary deferral of final action on the supplemental application under the provisions of section 512(c), (d), or (e) of the act.

(j) When an applicant receives written notification from the Food and Drug Administration, under the provisions of paragraph (g) of this section, that he may place into effect changes proposed in a supplemental application without approval of the supplemental application, he may within 30 days submit a written request that the Food and Drug Administration process the supplemental application. In such case, the change shall not be put into effect until approved. Within 180 days of the receipt of such written request, the Food and Drug Administration will approve the supplemental application or furnish notice of an opportunity for a hearing under the provisions of section 512(d) or (e), or both, of the act on a proposal to refuse approval of the supplemental application or to withdraw approval of the application and supplements thereto.

(k) A supplement to an application that became effective prior to October 10, 1962, may include a written statement to the effect that a temporary deferral of final action under the provisions of paragraph (d), (e), or (g) of this section is unacceptable to the applicant and that the applicant requests action as provided in section 512(c) of the act. Final action on such supplemental applications will be expedited in accord with applicable provisions of section 512 of the act and regulations in this subchapter E. In such cases, if the applicant places into effect any of the proposed changes prior to his receipt of a written notice of approval of the supplemental new animal drug application, such action may be regarded by the Food and Drug Administration as a basis for invoking the provisions of section 512(e)(1)(D) of the act; that is, the applicant may be furnished notice of an opportunity for a hearing on a proposal to withdraw approval of the application on the ground that the application contains an untrue statement of a material fact related to the changes from the conditions approved in the application.

(l) A supplemental application that contains nonclinical laboratory studies shall include, with respect to each nonclinical study, either a statement that the study was conducted in compliance with the requirements set forth in part 58 of this chapter, or, if the study was not conducted in compliance with such
§514.11 Confidentiality of data and information in a new animal drug application file.

(a) For purposes of this section the NADA file includes all data and information submitted with or incorporated by reference in the NADA, INAD’s incorporated into the NADA, supplemental NADA’s, reports under §§510.300 and 510.301 of this chapter, master files, and other related submissions.

(b) The existence of an NADA file will not be disclosed by the Food and Drug Administration before an approval has been published in the Federal Register before such approval is published, but the Commissioner may, in his discretion, disclose a summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, e.g., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.

(e) After an approval has been published in the Federal Register, the following data and information in the NADA file are immediately available for public disclosure unless extraordinary circumstances are shown:

(1) All safety and effectiveness data and information previously disclosed to the public, as defined in §20.81 of this chapter.

(2) A summary or summaries of the safety and effectiveness data as appropriate for the conditions described in §514.80(b)(5)(iii) are met before putting such a change into effect.

§514.8 Supplemental new animal drug applications.

(a) * * *

(6) Approval of a supplemental new animal drug application will not be required to provide for an additional distributor to distribute a drug which is the subject of an approved new animal drug application if the conditions described in §514.80(b)(5)(ii) are met before putting such a change into effect.

* * * * *

§514.11 Confidentiality of data and information in a new animal drug application file.

(a) For purposes of this section the NADA file includes all data and information submitted with or incorporated by reference in the NADA, INAD’s incorporated into the NADA, supplemental NADA’s, reports under §§510.300 and 510.301 of this chapter, master files, and other related submissions. The availability for public disclosure of any record in the NADA file shall be handled in accordance with the provisions of this section.

(b) The existence of an NADA file will not be disclosed by the Food and Drug Administration before an approval has been published in the Federal Register, unless it has previously been publicly disclosed or acknowledged.

(c) If the existence of an NADA file has not been publicly disclosed or acknowledged, no data or information in the NADA file is available for public disclosure.

(d) If the existence of an NADA file has been publicly disclosed or acknowledged before an approval has been published in the Federal Register, no data or information contained in the file is available for public disclosure before such approval is published, but the Commissioner may, in his discretion, disclose a summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, e.g., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.

(e) After an approval has been published in the Federal Register, the following data and information in the NADA file are immediately available for public disclosure unless extraordinary circumstances are shown:

(1) All safety and effectiveness data and information previously disclosed to the public, as defined in §20.81 of this chapter.

(2) A summary or summaries of the safety and effectiveness data as appropriate for the conditions described in §514.80(b)(5)(iii) are met before putting such a change into effect.

* * * * *

§514.8 Supplemental new animal drug applications.

(a) * * *

(6) Approval of a supplemental new animal drug application will not be required to provide for an additional distributor to distribute a drug which is the subject of an approved new animal drug application if the conditions described in §514.80(b)(5)(ii) are met before putting such a change into effect.

* * * * *

§514.11 Confidentiality of data and information in a new animal drug application file.

(a) For purposes of this section the NADA file includes all data and information submitted with or incorporated by reference in the NADA, INAD’s incorporated into the NADA, supplemental NADA’s, reports under §§510.300 and 510.301 of this chapter, master files, and other related submissions. The availability for public disclosure of any record in the NADA file shall be handled in accordance with the provisions of this section.

(b) The existence of an NADA file will not be disclosed by the Food and Drug Administration before an approval has been published in the Federal Register, unless it has previously been publicly disclosed or acknowledged.

(c) If the existence of an NADA file has not been publicly disclosed or acknowledged, no data or information in the NADA file is available for public disclosure.

(d) If the existence of an NADA file has been publicly disclosed or acknowledged before an approval has been published in the Federal Register, no data or information contained in the file is available for public disclosure before such approval is published, but the Commissioner may, in his discretion, disclose a summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, e.g., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.

(e) After an approval has been published in the Federal Register, the following data and information in the NADA file are immediately available for public disclosure unless extraordinary circumstances are shown:

(1) All safety and effectiveness data and information previously disclosed to the public, as defined in §20.81 of this chapter.

(2) A summary or summaries of the safety and effectiveness data as appropriate for the conditions described in §514.80(b)(5)(iii) are met before putting such a change into effect.

* * * * *

§514.8 Supplemental new animal drug applications.

(a) * * *

(6) Approval of a supplemental new animal drug application will not be required to provide for an additional distributor to distribute a drug which is the subject of an approved new animal drug application if the conditions described in §514.80(b)(5)(ii) are met before putting such a change into effect.

* * * * *

§514.11 Confidentiality of data and information in a new animal drug application file.

(a) For purposes of this section the NADA file includes all data and information submitted with or incorporated by reference in the NADA, INAD’s incorporated into the NADA, supplemental NADA’s, reports under §§510.300 and 510.301 of this chapter, master files, and other related submissions. The availability for public disclosure of any record in the NADA file shall be handled in accordance with the provisions of this section.

(b) The existence of an NADA file will not be disclosed by the Food and Drug Administration before an approval has been published in the Federal Register, unless it has previously been publicly disclosed or acknowledged.

(c) If the existence of an NADA file has not been publicly disclosed or acknowledged, no data or information in the NADA file is available for public disclosure.

(d) If the existence of an NADA file has been publicly disclosed or acknowledged before an approval has been published in the Federal Register, no data or information contained in the file is available for public disclosure before such approval is published, but the Commissioner may, in his discretion, disclose a summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, e.g., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.

(e) After an approval has been published in the Federal Register, the following data and information in the NADA file are immediately available for public disclosure unless extraordinary circumstances are shown:

(1) All safety and effectiveness data and information previously disclosed to the public, as defined in §20.81 of this chapter.

(2) A summary or summaries of the safety and effectiveness data as appropriate for the conditions described in §514.80(b)(5)(iii) are met before putting such a change into effect.

* * * * *

§514.8 Supplemental new animal drug applications.

(a) * * *

(6) Approval of a supplemental new animal drug application will not be required to provide for an additional distributor to distribute a drug which is the subject of an approved new animal drug application if the conditions described in §514.80(b)(5)(ii) are met before putting such a change into effect.

* * * * *

§514.11 Confidentiality of data and information in a new animal drug application file.

(a) For purposes of this section the NADA file includes all data and information submitted with or incorporated by reference in the NADA, INAD’s incorporated into the NADA, supplemental NADA’s, reports under §§510.300 and 510.301 of this chapter, master files, and other related submissions. The availability for public disclosure of any record in the NADA file shall be handled in accordance with the provisions of this section.

(b) The existence of an NADA file will not be disclosed by the Food and Drug Administration before an approval has been published in the Federal Register, unless it has previously been publicly disclosed or acknowledged.

(c) If the existence of an NADA file has not been publicly disclosed or acknowledged, no data or information in the NADA file is available for public disclosure.

(d) If the existence of an NADA file has been publicly disclosed or acknowledged before an approval has been published in the Federal Register, no data or information contained in the file is available for public disclosure before such approval is published, but the Commissioner may, in his discretion, disclose a summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, e.g., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.

(e) After an approval has been published in the Federal Register, the following data and information in the NADA file are immediately available for public disclosure unless extraordinary circumstances are shown:

(1) All safety and effectiveness data and information previously disclosed to the public, as defined in §20.81 of this chapter.

(2) A summary or summaries of the safety and effectiveness data as appropriate for the conditions described in §514.80(b)(5)(iii) are met before putting such a change into effect.

* * * * *

§514.8 Supplemental new animal drug applications.

(a) * * *

(6) Approval of a supplemental new animal drug application will not be required to provide for an additional distributor to distribute a drug which is the subject of an approved new animal drug application if the conditions described in §514.80(b)(5)(ii) are met before putting such a change into effect.

* * * * *

§514.11 Confidentiality of data and information in a new animal drug application file.

(a) For purposes of this section the NADA file includes all data and information submitted with or incorporated by reference in the NADA, INAD’s incorporated into the NADA, supplemental NADA’s, reports under §§510.300 and 510.301 of this chapter, master files, and other related submissions. The availability for public disclosure of any record in the NADA file shall be handled in accordance with the provisions of this section.

(b) The existence of an NADA file will not be disclosed by the Food and Drug Administration before an approval has been published in the Federal Register, unless it has previously been publicly disclosed or acknowledged.

(c) If the existence of an NADA file has not been publicly disclosed or acknowledged, no data or information in the NADA file is available for public disclosure.

(d) If the existence of an NADA file has been publicly disclosed or acknowledged before an approval has been published in the Federal Register, no data or information contained in the file is available for public disclosure before such approval is published, but the Commissioner may, in his discretion, disclose a summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, e.g., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.

(e) After an approval has been published in the Federal Register, the following data and information in the NADA file are immediately available for public disclosure unless extraordinary circumstances are shown:

(1) All safety and effectiveness data and information previously disclosed to the public, as defined in §20.81 of this chapter.

(2) A summary or summaries of the safety and effectiveness data as appropriate for the conditions described in §514.80(b)(5)(iii) are met before putting such a change into effect.
§ 514.12 Confidentiality of data and information in an investigational new animal drug notice.

(a) The existence of an INAD notice will not be disclosed by the Food and Drug Administration unless it has previously been publicly disclosed or acknowledged.

(b) The availability for public disclosure of all data and information in an INAD file shall be handled in accordance with provisions established in §514.11.

§ 514.15 Untrue statements in applications.

Among the reasons why an application for a new animal drug or animal feed bearing or containing a new animal drug may contain an untrue statement of a material fact are:

(a) Differences in:
§ 514.80 Records and reports concerning experience with approved new animal drugs.

The following table outlines the purpose for each paragraph of this section:

<table>
<thead>
<tr>
<th>Purpose</th>
<th>Paragraph and Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>What information must be reported concerning approved NADAs or ANADAs?</td>
<td>514.80(a) Applicability</td>
</tr>
<tr>
<td>What authority does FDA have for requesting records and reports?</td>
<td>514.80(a)(1)</td>
</tr>
<tr>
<td>Who is required to establish, maintain, and report required information relating to experiences with a new animal drug?</td>
<td>514.80(a)(2)</td>
</tr>
<tr>
<td>Is information from foreign sources required?</td>
<td>514.80(a)(3)</td>
</tr>
<tr>
<td>Do applicants of Type A medicated articles have to establish, maintain and report information required under § 514.80?</td>
<td>514.80(a)(4)</td>
</tr>
<tr>
<td>How do the requirements under § 514.80 relate to current good manufacturing practices?</td>
<td>514.80(a)(5)</td>
</tr>
<tr>
<td></td>
<td>514.80(b) Reporting Requirements</td>
</tr>
<tr>
<td>What are the requirements for reporting product/manufacturing defects?</td>
<td>514.80(b)(1) Three-day NADA/ANADA Field Alert Report</td>
</tr>
<tr>
<td></td>
<td>514.80(b)(2) Fifteen-day NADA/ANADA Alert Report</td>
</tr>
<tr>
<td>What are the requirements for followup reporting of serious, unexpected adverse drug experiences?</td>
<td>514.80(b)(2)(i) Initial Report</td>
</tr>
<tr>
<td></td>
<td>514.80(b)(2)(ii) Followup Report</td>
</tr>
<tr>
<td>What are the requirements for reporting increases in the frequency of serious, expected and unexpected, and adverse drug experiences?</td>
<td>514.80(b)(2)(iii) Summary Report of Increased Frequency of Adverse Drug Experience</td>
</tr>
<tr>
<td>What are the requirements for nonapplicants for reporting adverse drug experiences?</td>
<td>514.80(b)(3) Nonapplicant Report</td>
</tr>
</tbody>
</table>
### § 514.80

#### Purpose Paragraph and Title

<table>
<thead>
<tr>
<th>Purpose</th>
<th>Paragraph and Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>What are the general requirements for submission of periodic drug experience reports, e.g., forms to be submitted, submission date and frequency, when is it to be submitted, how many copies? How do I petition to change the date of submission or frequency of submissions?</td>
<td>§514.80(b)(4) Periodic Drug Experience Reports</td>
</tr>
<tr>
<td>What must be submitted in the periodic drug experience reports?</td>
<td>§514.80(b)(4)(i) through (b)(4)(iv)</td>
</tr>
<tr>
<td>What distribution data must be submitted? How should the distribution data be submitted?</td>
<td>§514.80(b)(4)(i) Distribution Data</td>
</tr>
<tr>
<td>What labeling materials should be submitted? How do I report changes to the labeling materials since the last report?</td>
<td>§514.80(b)(4)(ii) Labeling</td>
</tr>
<tr>
<td>What are the requirements for submission of nonclinical laboratory studies?</td>
<td>§514.80(b)(4)(iii) Nonclinical Laboratory Studies and Clinical Data Not Previously Reported</td>
</tr>
<tr>
<td>What are the requirements for submission of clinical laboratory data?</td>
<td>§514.80(b)(4)(iii)(A)</td>
</tr>
<tr>
<td>When must results of clinical trials conducted by or for the applicant be reported?</td>
<td>§514.80(b)(4)(iii)(B)</td>
</tr>
<tr>
<td>How do I report product/manufacturing defects and adverse drug experiences not previously reported to FDA?</td>
<td>§514.80(b)(4)(iv)(A)</td>
</tr>
<tr>
<td>What are the requirements for submitting adverse drug experiences cited in literature?</td>
<td>§514.80(b)(4)(iv)(B)</td>
</tr>
<tr>
<td>What are the requirements for submitting adverse drug experiences in postapproval studies and clinical trials?</td>
<td>§514.80(b)(4)(iv)(C)</td>
</tr>
<tr>
<td>Can FDA request that an applicant submit information at different times than stated specifically in this regulation?</td>
<td>§514.80(b)(5) Other Reporting</td>
</tr>
<tr>
<td>What are the requirements for submission of advertisement and promotional labeling to FDA?</td>
<td>§514.80(b)(5)(ii) Special Drug Experience Report</td>
</tr>
<tr>
<td>What are the requirements for adding a new distributor to the approved application?</td>
<td>§514.80(b)(5)(iii) Distributor's Statement</td>
</tr>
<tr>
<td>What labels and how many labels need to be submitted for review?</td>
<td>§514.80(b)(5)(iii)(A)</td>
</tr>
<tr>
<td>What changes are required and allowed to distributor labeling?</td>
<td>§514.80(b)(5)(iii)(A)(I)</td>
</tr>
<tr>
<td>What are the requirements for making other changes to the distributor labeling?</td>
<td>§514.80(b)(5)(iii)(A)(II)</td>
</tr>
<tr>
<td>What information should be included in each new distributor's signed statement?</td>
<td>§514.80(b)(5)(iii)(B)(I) through (B)(V)</td>
</tr>
<tr>
<td>What are the conditions for submitting information that is common to more than one application? (i.e., can I submit common information to one application?)</td>
<td>§514.80(c) Multiple Applications</td>
</tr>
<tr>
<td>What information has to be submitted to the common application and related application?</td>
<td>§514.80(c)(1) through (c)(4)</td>
</tr>
<tr>
<td>What forms do I need? What are Forms FDA 1932 and 2301? How can I get them? Can I use computer-generated equivalents?</td>
<td>§514.80(d) Reporting Forms</td>
</tr>
<tr>
<td>How long must I maintain Form FDA 1932 and records and reports of other required information, i.e., how long do I need to maintain this information?</td>
<td>§514.80(e) Records to be Maintained</td>
</tr>
<tr>
<td>What are the requirements for allowing access to these records and reports, and copying by authorized FDA officer or employee?</td>
<td>§514.80(f) Access to Records and Reports</td>
</tr>
<tr>
<td>How do I obtain Forms FDA 1932 and 2301? Where do I mail FDA’s required forms, records, and reports?</td>
<td>§514.80(g) Mailing Address</td>
</tr>
<tr>
<td>What happens if the applicant fails to establish, maintain, or make the required reports? What happens if the applicant refuses to allow FDA access to, and/or copying and/or verify records and reports?</td>
<td>§514.80(h) Withdrawal of Approval</td>
</tr>
<tr>
<td>Does an adverse drug experience reflect a conclusion that the report or information constitutes an admission that the drug caused an adverse effect?</td>
<td>§514.80(i) Disclaimer</td>
</tr>
</tbody>
</table>

#### (a) Applicability. (1) Each applicant and nonapplicant must establish and maintain indexed, separate, and complete files containing full records of all
Food and Drug Administration, HHS

§ 514.80

information pertinent to safety or effectiveness of a new animal drug that has not been previously submitted as part of the NADA or ANADA. Such records must include information from domestic, as well as foreign sources.

(2) Each applicant must submit reports of data, studies, and other information concerning experience with new animal drugs to the Food and Drug Administration (FDA) for each approved NADA and ANADA, as required in this section. A nonapplicant must submit data, studies, and other information concerning experience with new animal drugs to the appropriate applicant, as required in this section. The applicant, in turn, must report the nonapplicant’s data, studies, and other information to FDA. Applicants and nonapplicants must submit data, studies, and other information described in this section from domestic, as well as foreign sources.

(3) FDA reviews the records and reports required in this section to facilitate a determination under section 512(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b) as to whether there may be grounds for suspending or withdrawing approval of the NADA or ANADA.

(4) The requirements of this section also apply to any approved Type A medicated article. In addition, the requirements contained in §514.80(b)(1), (b)(2), and (b)(4)(iv) apply to any approved Type A medicated article incorporated in animal feeds.

(5) The records and reports referred to in this section are in addition to those required by the current good manufacturing practice regulations in parts 211, 225, and 226 of this chapter.

(b) Reporting requirements—(1) Three-day NADA/ANADA field alert report.

This report provides information pertaining to product and manufacturing defects that may result in serious adverse drug events. The applicant (or nonapplicant through the applicant) must submit the report to the appropriate FDA District Office or local FDA resident post within 3 working days of first becoming aware that a defect may exist. The information initially may be provided by telephone or other telecommunication means, with prompt written followup using Form FDA 1932 “Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report.” The mailing cover for these reports must be plainly marked “3-Day NADA/ANADA Field Alert Report.”

(2) Fifteen-day NADA/ANADA alert report—(i) Initial report. This report provides information on each serious, unexpected adverse drug event, regardless of the source of the information. The applicant (or nonapplicant through the applicant) must submit the report to FDA within 15 working days of first receiving the information. The report must be submitted on Form FDA 1932, and its mailing cover must be plainly marked “15-Day NADA/ANADA Alert Report.”

(ii) Followup report. The applicant must promptly investigate all adverse drug events that are the subject of 15-day NADA/ANADA alert reports. If this investigation reveals significant new information, a followup report must be submitted within 15 working days of receiving such information. A followup report must be submitted on Form FDA 1932, and its mailing cover must be plainly marked “15-Day NADA/ANADA Alert Report Followup.” The followup report must state the date of the initial report and provide the additional information. If additional information is sought but not obtained within 3 months of the initial report, a followup report is required describing the steps taken and why additional information was not obtained.

(iii) Summary report of increased frequency of adverse drug experience. The applicant must periodically review the incidence of reports of adverse drug experiences to determine if there has been an increased frequency of serious (expected and unexpected) adverse drug events. The applicant must report as soon as possible, but in any case within 15 working days of determining that there is an increased frequency of serious (expected and unexpected) adverse drug events. Summaries of reports of increased frequency of adverse drug events must be submitted in narrative form. The summaries must state the time period on which the increased frequency is based, time period comparisons in determining increased frequency, references to any previously
§ 514.80  submitted Form FDA 1932, the method of analysis, and the interpretation of the results. The summaries must be submitted under separate cover and may not be included, except for reference purposes, in a periodic drug experience report. The applicant must evaluate the increased frequency of serious (expected or unexpected) adverse drug events at least as often as reporting of periodic drug experience reports.

(3) Nonapplicant report. Nonapplicants must forward reports of adverse drug experiences to the applicant within 3 working days of first receiving the information. The applicant must then submit the report(s) to FDA as required in this section. The nonapplicant must maintain records of all nonapplicant reports, including the date the nonapplicant received the information concerning adverse drug experiences, the name and address of the applicant, and a copy of the adverse drug experience report including the date such report was submitted to the applicant. If the nonapplicant elects to also report directly to FDA, the nonapplicant should submit the report on Form FDA 1932 within 15 working days of first receiving the information.

(4) Periodic drug experience report. This report must be accompanied by a completed Form FDA 2301 “Transmittal of Periodic Reports and Promotional Materials for New Animal Drugs.” It must be submitted every 6 months for the first 2 years following approval of an NADA or ANADA and yearly thereafter. Reports required by this section must contain data and information for the full reporting period. The 6-month periodic drug experience reports must be submitted within 30 days following the end of the 6-month reporting period. The yearly periodic drug experience reports must be submitted within 60 days of the anniversary date of the approval of the NADA or ANADA. Any previously submitted information contained in the report must be identified as such. For yearly (annual) periodic drug experience reports, the applicant may petition FDA to change the date of submission or frequency of reporting, and after approval of such petition, file such reports on the new filing date or at the new reporting frequency. Also, FDA may require a report at different times or more frequently. The periodic drug experience report must contain the following:

(i) Distribution data. Information about the distribution of each new animal drug product, including information on any distributor-labeled product. This information must include the total number of distributed units of each size, strength, or potency (e.g., 100,000 bottles of 100 5-milligram tablets; 50,000 10-milliliter vials of 5 percent solution). This information must be presented in two categories: quantities distributed domestically and quantities exported.

(ii) Labeling. Applicant and distributor current package labeling, including package inserts (if any). For large-size package labeling or large shipping cartons, a representative copy must be submitted (e.g., a photocopy of pertinent areas of large feed bags). A summary of any changes in labeling made since the last report (listed by date of implementation) must be included with the labeling or if there have been no changes, a statement of such fact must be included with the labeling.

(iii) Nonclinical laboratory studies and clinical data not previously reported.

(A) Copies of in vitro studies (e.g., mutagenicity) and other nonclinical laboratory studies conducted by or otherwise obtained by the applicant.

(B) Copies of published clinical trials of the new animal drug (or abstracts of them) including clinical trials on safety and effectiveness, clinical trials on new uses, and reports of clinical experience pertinent to safety conducted by or otherwise obtained by the applicant. Review articles, papers, and abstracts in which the drug is used as a research tool, promotional articles, press clippings, and papers that do not contain tabulations or summaries of original data are not required to be reported.

(C) Descriptions of, or if available, prepublication manuscripts relating to completed clinical trials conducted by or otherwise known to the applicant. Supporting information is not to be reported. A study must be submitted no later than 1 year after completion of research.
(iv) **Adverse drug experiences.** (A) Product/manufacturing defects and adverse drug experiences not previously reported under §514.80(b)(1) and (b)(2) must be reported individually on Form FDA 1932.

(B) Reports of adverse drug experiences in the literature must be noted in the periodic drug experience report. A bibliography of pertinent references must be included with the report. Upon FDA’s request, the applicant must provide a full text copy of these publications.

(C) Reports of previously not reported adverse drug experiences that occur in postapproval studies must be reported separately from other experiences in the periodic drug experience report and clearly marked or highlighted.

(5) **Other reporting—** (i) Special drug experience report. Upon written request, FDA may require that the applicant submit a report required under §514.80 at different times or more frequently than the timeframes stated in §514.80.

(ii) **Advertisements and promotional labeling.** The applicant must submit at the time of initial dissemination one set of specimens of mailing pieces and other labeling for prescription and over-the-counter new animal drugs. For prescription new animal drugs, the applicant must also submit one set of specimens of any advertisement at the time of initial publication or broadcast. Mailing pieces and labeling designed to contain product samples must be complete except that product samples may be omitted. Each submission of promotional material must be accompanied by a completed Form FDA 2301.

(iii) **Distributor’s statement.** At the time of initial distribution of a new animal drug product by a distributor, the applicant must submit a special drug experience report accompanied by a completed Form FDA 2301 containing the following:

(A) The distributor’s current product labeling.

(B) The distributor’s labeling must be identical to that in the approved NADA/ANADA except for a different and suitable proprietary name (if used) and the name and address of the distributor. The name and address of the distributor must be preceded by an appropriate qualifying phrase such as “manufactured for” or “distributed by.”

(2) Other labeling changes must be the subject of a supplemental NADA or ANADA as described under §514.8.

(B) A signed statement by the distributor stating:

(1) The category of the distributor’s operations (e.g., wholesale or retail),

(2) That the distributor will distribute the new animal drug only under the approved labeling,

(3) That the distributor will advertise the product only for use under the conditions stated in the approved labeling,

(4) That the distributor will adhere to the records and reports requirements of this section, and

(5) That the distributor is regularly and lawfully engaged in the distribution or dispensing of prescription products if the product is a prescription new animal drug.

(c) **Multiple applications.** Whenever an applicant is required to submit a periodic drug experience report under the provisions of §514.80(b)(4) with respect to more than one approved NADA or ANADA for preparations containing the same new animal drug so that the same information is required to be reported for more than one application, the applicant may elect to submit as a part of the report for one such application (the primary application) all the information common to such applications in lieu of reporting separately and repetitively on each. If the applicant elects to do this, the applicant must do the following:

(1) State when a report applies to multiple applications and identify all related applications for which the report is submitted by NADA or ANADA number.

(2) Ensure that the primary application contains a list of the NADA or ANADA numbers of all related applications.

(3) Submit a completed Form FDA 2301 to the primary application and each related application with reference to the primary application by NADA/ANADA number and submission date for the complete report of the common information.
§ 514.100  Evaluation and comment on applications.

(a) After the filed application has been evaluated, the applicant will be furnished written comment on any apparent deficiencies in the application.

(b) When the description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such new animal drug appears adequate on its face, but it is not feasible to reach a conclusion as to the safety and effectiveness of the new animal drug solely from consideration of this description, the applicant may be notified that an establishment inspection is required to verify their adequacy.

(c) A request for samples of a new animal drug or any edible tissues and byproducts of animals treated with such a drug, shall specify the quantity deemed adequate to permit tests of analytical methods to determine their adequacy for regulatory purposes. The request should be made as early in the 180-day period as possible to assure
Food and Drug Administration, HHS

§ 514.105 Approval of applications.

(a) The Commissioner shall forward for publication in the FEDERAL REGISTER a regulation prescribing the conditions under which the new animal drug may be used, including the name and address of the applicant; the conditions and indications for use covered by the application; any tolerance, withdrawal period, or other use restrictions; any tolerance required for the new animal drug substance or its metabolites in edible products of food-producing animals; and, if such new animal drug is intended for use in animal feed, appropriate purposes and conditions of use (including special labeling requirements) applicable to any animal feed; and such other information the Commissioner deems necessary to assure safe and effective use.

(b) He shall notify the applicant by sending him a copy of the proposed application in accordance with §201.105 of this chapter.

(e) The information contained in an application will be considered insufficient to determine whether a new animal drug is safe and effective for use when there is a refusal or failure upon written notice to furnish inspectors authorized by the Food and Drug Administration an adequate opportunity to inspect the facilities, controls, and records pertinent to the application.

(f) On the basis of preliminary consideration of an application or supplemental application containing typewritten or other draft labeling in lieu of final printed labeling, an applicant may be informed that such application is approvable when satisfactory final printed labeling identical in content to such draft copy is submitted.

(g) When an application has been found incomplete on the basis of a need for the kind of information described in §514.6, such application shall be considered withdrawn without prejudice to future filing on the date of issuance of the letter citing the inadequacies contained in the application, unless within 30 days the sponsor chooses to avail himself of the opportunity for hearing as prescribed by §514.111.

§ 514.105 Approval of applications.

(a) The Commissioner shall forward for publication in the FEDERAL REGISTER a regulation prescribing the conditions under which the new animal drug may be used, including the name and address of the applicant; the conditions and indications for use covered by the application; any tolerance, withdrawal period, or other use restrictions; any tolerance required for the new animal drug substance or its metabolites in edible products of food-producing animals; and, if such new animal drug is intended for use in animal feed, appropriate purposes and conditions of use (including special labeling requirements) applicable to any animal feed; and such other information the Commissioner deems necessary to assure safe and effective use.

(b) He shall notify the applicant by sending him a copy of the proposed application in accordance with §201.105 of this chapter.

(e) The information contained in an application will be considered insufficient to determine whether a new animal drug is safe and effective for use when there is a refusal or failure upon written notice to furnish inspectors authorized by the Food and Drug Administration an adequate opportunity to inspect the facilities, controls, and records pertinent to the application.

(f) On the basis of preliminary consideration of an application or supplemental application containing typewritten or other draft labeling in lieu of final printed labeling, an applicant may be informed that such application is approvable when satisfactory final printed labeling identical in content to such draft copy is submitted.

(g) When an application has been found incomplete on the basis of a need for the kind of information described in §514.6, such application shall be considered withdrawn without prejudice to future filing on the date of issuance of the letter citing the inadequacies contained in the application, unless within 30 days the sponsor chooses to avail himself of the opportunity for hearing as prescribed by §514.111.

§ 514.105 Approval of applications.

(a) The Commissioner shall forward for publication in the FEDERAL REGISTER a regulation prescribing the conditions under which the new animal drug may be used, including the name and address of the applicant; the conditions and indications for use covered by the application; any tolerance, withdrawal period, or other use restrictions; any tolerance required for the new animal drug substance or its metabolites in edible products of food-producing animals; and, if such new animal drug is intended for use in animal feed, appropriate purposes and conditions of use (including special labeling requirements) applicable to any animal feed; and such other information the Commissioner deems necessary to assure safe and effective use.

(b) He shall notify the applicant by sending him a copy of the proposed application in accordance with §201.105 of this chapter.

(e) The information contained in an application will be considered insufficient to determine whether a new animal drug is safe and effective for use when there is a refusal or failure upon written notice to furnish inspectors authorized by the Food and Drug Administration an adequate opportunity to inspect the facilities, controls, and records pertinent to the application.

(f) On the basis of preliminary consideration of an application or supplemental application containing typewritten or other draft labeling in lieu of final printed labeling, an applicant may be informed that such application is approvable when satisfactory final printed labeling identical in content to such draft copy is submitted.

(g) When an application has been found incomplete on the basis of a need for the kind of information described in §514.6, such application shall be considered withdrawn without prejudice to future filing on the date of issuance of the letter citing the inadequacies contained in the application, unless within 30 days the sponsor chooses to avail himself of the opportunity for hearing as prescribed by §514.111.
§ 514.106 Approval of supplemental applications.

(a) Within 180 days after a supplement to an approved application is filed pursuant to §514.8, the Commissioner shall approve the supplemental application in accordance with procedures set forth in §514.105(a)(1) and (2) if he/she determines that the application satisfies the requirements of applicable statutory provisions and regulations.

(b) The Commissioner will assign a supplemental application to its proper category to ensure processing of the application.

(1) Category I. Supplements that ordinarily do not require a reevaluation of any of the safety or effectiveness data in the parent application. Category I supplements include the following:

(i) A corporate change that alters the identity or address of the sponsor of the new animal drug application (NADA).

(ii) The sale, purchase, or construction of manufacturing facilities.

(iii) The sale or purchase of an NADA.

(iv) A change in container, container style, shape, size, or components.

(v) A change in approved labeling (color, style, format, addition, deletion, or revision of certain statements, e.g., trade name, storage, expiration dates, etc).

(vi) A change in promotional material for a prescription drug not exempted by §514.8(a)(3)(i) and (a)(3)(ii).

(vii) Changes in manufacturing processes that do not alter the method of manufacture or change the final dosage form.

(viii) A change in bulk drug shipments.

(ix) A change in an analytical method or control procedures that do not alter the approved standards.

(x) A change in an expiration date.

(xi) Addition of an alternate manufacturer, repackager, or relabeler of the drug product.

(xii) Addition of a new or revised animal production claim.

(xiii) Addition of a new species.

(xiv) A change in the prescription or over-the-counter status of a drug product.

(xv) A change in statements regarding side effects, warnings, precautions, and contraindications, except the addition of approved statements to container, package, and promotional labeling, and prescription drug advertising.

(xvi) A change in the drug withdrawal period prior to slaughter or in the milk discard time.

(xvii) A change in the tolerance for drug residues.

(xviii) A change in analytical methods for drug residues.

(xix) A revised method of synthesis or fermentation of the new drug substance.

(xx) Updating or changes in the manufacturing process of the new drug substance and/or final dosage form (other than a change in equipment that does not alter the method of manufacture of a new animal drug, or a change from one commercial batch size to another without any change in manufacturing procedure), or changes in the methods, facilities, or controls used for
the manufacture, processing, packaging, or holding of the new animal drug (other than use of an establishment not covered by the approval that is in effect) that give increased assurance that the drug will have the characteristics of identity, strength, quality, and purity which it purports or is represented to possess.

§ 514.110 Reasons for refusing to file applications.

(a) The date of receipt of an application for a new animal drug shall be the date on which the application shall be deemed to be filed.

(b) An application for a new animal drug shall not be considered acceptable for filing for any of the following reasons:

1. It does not contain complete and accurate English translations of any pertinent part in a foreign language.

2. Fewer than three copies are submitted.

3. It is incomplete on its face in that it is not properly organized and indexed.

4. On its face the information concerning required matter is so inadequate that the application is clearly not approvable.

5. The new animal drug is to be manufactured, prepared, propagated, compounded, or processed in whole or in part in any State in an establishment that has not been registered or exempted from registration under the provisions of section 510 of the act.

6. The sponsor does not reside or maintain a place of business within the United States and the application has not been countersigned by an attorney, agent, or other representative of the applicant, which representative resides in the United States and has been duly authorized to act on behalf of the applicant and to receive communications on all matters pertaining to the application.

7. The new animal drug is a drug subject to licensing under the animal virus, serum, and toxin law of March 4, 1913 (37 Stat. 832; 21 U.S.C. 151 et seq.). Such applications will be referred to the U.S. Department of Agriculture for action.

§ 514.111 Refusal to approve an application.

(a) The Commissioner shall, within 180 days after the filing of the application, inform the applicant in writing of his intention to issue a notice of opportunity for a hearing on a proposal to refuse to approve the application, if the Commissioner determines upon the basis of the application, or upon the basis of other information before him with respect to a new animal drug, that:

1. The reports of investigations required to be submitted pursuant to section 512(b) of the act do not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof; or

2. The results of such tests show that such drug is unsafe for use under such conditions or do not show that
§ 514.111 21 CFR Ch. I (4–1–02 Edition)

such drug is safe for use under such conditions; or

(3) The methods used in and the facilities and controls used for the manufacture, processing, and packing of such drug are inadequate to preserve its identity, strength, quality, and purity; or

(4) Upon the basis of the information submitted to the Food and Drug Administration as part of the application, or upon the basis of any other information before it with respect to such drug, it has insufficient information to determine whether such drug is safe for use under such conditions. In making this determination the Commissioner shall consider, among other relevant factors:

(i) The probable consumption of such drug and of any substance formed in or on food because of the use of such drug;

(ii) The cumulative effect on man or animal of such drug, taking into account any chemically or pharmacologically related substances;

(iii) Safety factors which, in the opinion of experts qualified by scientific training and experience to evaluate the safety of such drugs, are appropriate for the use of animal experimentation data; and

(iv) Whether the conditions of use prescribed, recommended, or suggested in the proposed labeling are reasonably certain to be followed in practice; or

(5) Evaluated on the basis of information submitted as part of the application and any other information before the Food and Drug Administration with respect to such drug, there is lack of substantial evidence as defined in § 514.4.

(6) Failure to include an appropriate proposed tolerance for residues in edible products derived from animals or a withdrawal period or other restrictions for use of such drug if any tolerance or withdrawal period or other restrictions for use are required in order to assure that the edible products derived from animals treated with such drug will be safe.

(7) Based on a fair evaluation of all material facts, the labeling is false or misleading in any particular; or

(8) Such drug induces cancer when ingested by man or animal or, after appropriate tests for evaluation of the safety of such drug, induces cancer in man or animal, except that this subparagraph shall not apply with respect to such drug if the Commissioner finds that, under the conditions of use specified in proposed labeling and reasonably certain to be followed in practice:

(i) Such drug will not adversely affect the animal for which it is intended; and

(ii) No residue of such drug will be found (by methods of examination prescribed or approved by the Commissioner by regulations) in any edible portion of such animal after slaughter or in any food yielded by, or derived from the living animals.

(9) The applicant fails to submit an adequate environmental assessment under § 25.40 of this chapter or fails to provide sufficient information to establish that the requested action is subject to categorical exclusion under § 25.30 or § 25.33 of this chapter.

(10) The drug fails to satisfy the requirements of subpart E of part 500 of this chapter.

(11) Any nonclinical laboratory study that is described in the application and that is essential to show that the drug is safe for use under the conditions prescribed, recommended, or suggested in its proposed labeling, was not conducted in compliance with the good laboratory practice regulations as set forth in part 58 of this chapter and no reason for the noncompliance is provided or, if it is, the differences between the practices used in conducting the study and the good laboratory practice regulations do not support the validity of the study.

(b) The Commissioner, as provided in § 514.200 of this chapter, shall expeditiously notify the applicant of an opportunity for a hearing on the question of whether such application is approvable, unless by the 30th day following the date of issuance of the letter informing the applicant of the intention to issue a notice of opportunity for a hearing the applicant:

(1) Withdraws the application; or

(2) Waives the opportunity for a hearing; or
(3) Agrees with the Commissioner on an additional period to precede issuance of such notice of hearing.

§514.115 Withdrawal of approval of applications.

(a) The Secretary may suspend approval of an application approved pursuant to section 512(c) of the act and give the applicant prompt notice of his action and afford the applicant the opportunity for an expedited hearing on a finding that there is an imminent hazard to the health of man or of the animals for which such new animal drug or animal feed is intended.

(b) The Commissioner shall notify in writing the person holding an application approved pursuant to section 512(c) of the act and afford an opportunity for a hearing on a proposal to withdraw approval of such application if he finds:

(1) That the application contains any untrue statement of a material fact; or

(2) That the applicant has made any changes from the standpoint of safety or effectiveness beyond the variations provided for in the application unless he has supplemented the application by filing with the Secretary adequate information respecting all such changes and unless there is in effect an approval of the supplemental application, or such changes are those for which written authorization or approval is not required as provided for in §514.8. The supplemental application shall be treated in the same manner as the original application.

(3) That in the case of an application for use of a new animal drug approved or deemed approved pursuant to section 512(c) of the act:

(i) Experience or scientific data show that such drug is unsafe for use under the conditions of use upon the basis of which the application was approved; or

(ii) New evidence not contained in such application or not available to the Secretary until after such application was approved, or tests by new methods, or tests by methods not deemed reasonably applicable when such application was approved, evaluated together with the evidence available to the Secretary when the application was approved, shows that such drug is not shown to be safe for use under the conditions of use upon the basis of which the application was approved or that section 512(d)(1)(H) of the act applies to such drug; or

(iii) On the basis of new information before him with respect to such drug, evaluated together with the evidence available to him when the application was approved, there is a lack of substantial evidence that such drug will have the effect it purports to have or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling thereof.

(4) That any nonclinical laboratory study that is described in the application and that is essential to show that the drug is safe for use under the conditions of use prescribed, recommended, or suggested in its proposed labeling, was not conducted in compliance with the good laboratory practice regulations as set forth in part 58 of this chapter and no reason for the noncompliance is provided or, if it is, the differences between the practices used in conducting the study and the good laboratory practice regulations do not support the validity of the study.

(c) The Commissioner may notify in writing the person holding an application approved pursuant to section 512(c) of the act and afford an opportunity for a hearing on a proposal to withdraw approval of such application if he finds:

(1) That the applicant has failed to establish a system for maintaining required records, or has repeatedly or deliberately failed to maintain such records or to make required reports in accordance with a regulation or order under section 512(l)(1) of the act, or the applicant has refused to permit access to, or copying, or verification of, such records as required by section 512(l)(2) of the act; or

(2) That on the basis of new information before him evaluated together with the evidence before him when the application was approved, the methods used in, or the facilities and controls
§514.116 Notice of withdrawal of approval of application.

When an approval of an application submitted pursuant to section 512 of the act is withdrawn by the Commissioner, he will give appropriate public notice of such action by publication in the FEDERAL REGISTER.

§514.117 Adequate and well-controlled studies.

(a) Purpose. The primary purpose of conducting adequate and well-controlled studies of a new animal drug is to distinguish the effect of the new animal drug from other influences, such as spontaneous change in the course of the disease, normal animal production performance, or biased observation. One or more adequate and well-controlled studies are required to establish, by substantial evidence, that a new animal drug is effective. The characteristics described in paragraphs (b) of this section have been developed over a period of years and are generally recognized as the essentials of an adequate and well-controlled study. Well controlled, as used in the phrase adequate and well controlled, emphasizes an important aspect of adequacy. The Food and Drug Administration (FDA) considers these characteristics in determining whether a study is adequate and well controlled for purposes of section 512 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b). Adequate and well-controlled studies, in addition to providing a basis for determining whether a new animal drug is effective, may also be relied upon to support target animal safety. The report of an adequate and well-controlled study should provide sufficient details of study design, conduct, and analysis to allow critical evaluation and a determination of whether the characteristics of an adequate and well-controlled study are present.

(b) Characteristics. An adequate and well-controlled study has the following characteristics:

1. The protocol for the study (protocol) and the report of the study results (study report) must include a clear statement of the study objective(s).

2. The study is conducted in accordance with an appropriate standard of conduct that addresses, among other issues, study conduct, study personnel, study facilities, and study documentation. The protocol contains a statement acknowledging the applicability of, and intention to follow, a standard of conduct acceptable to FDA. The study report contains a statement describing adherence to the standard.
(3) The study is conducted with a new animal drug that is produced in accordance with appropriate manufacturing practices, which include, but are not necessarily limited to, the manufacture, processing, packaging, holding, and labeling of the new animal drug such that the critical characteristics of identity, strength, quality, purity, and physical form of the new animal drug are known, recorded, and reproducible, to permit meaningful evaluations of and comparisons with other studies conducted with the new animal drug. The physical form of a new animal drug includes the formulation and physical characterization (including delivery systems thereof, if any) of the new animal drug as presented to the animal. The protocol and study report must include an identification number which can be correlated with the specific formulation and production process used to manufacture the new animal drug used in the study.

(4) The study uses a design that permits a valid comparison with one or more controls to provide a quantitative evaluation of drug effects. The protocol and the study report must describe the precise nature of the study design, e.g., duration of treatment periods, whether treatments are parallel, sequential, or crossover, and the determination of sample size. Within the broad range of studies conducted to support a determination of the effectiveness of a new animal drug, certain of the controls listed below would be appropriate and preferred depending on the study conducted:

(i) Placebo concurrent control. The new animal drug is compared with an inactive preparation designed to resemble the new animal drug as far as possible.

(ii) Untreated concurrent control. The new animal drug is compared with the absence of any treatment. The use of this control may be appropriate when objective measurements of effectiveness, not subject to observer bias, are available.

(iii) Active treatment concurrent control. The new animal drug is compared with known effective therapy. The use of this control is appropriate when the use of a placebo control or of an untreated concurrent control would unreasonably compromise the welfare of the animals. Similarity of the new animal drug and the active control drug can mean either that both drugs were effective or that neither was effective. The study report should assess the ability of the study to have detected a difference between treatments. The evaluation of the study should explain why the new animal drugs should be considered effective in the study, for example, by reference to results in previous placebo-controlled studies of the active control.

(iv) Historical control. The results of treatment with the new animal drug are quantitatively compared with experience historically derived from the adequately documented natural history of the disease or condition, or with a regimen (therapeutic, diagnostic, prophylactic) whose effectiveness is established, in comparable animals. Because historical control populations usually cannot be as well assessed with respect to pertinent variables as can concurrent control populations, historical control designs are usually reserved for special circumstances. Examples include studies in which the effect of the new animal drug is self-evident or studies of diseases with high and predictable mortality, or signs and symptoms of predictable duration or severity, or, in the case of prophylaxis, predictable morbidity.

(5) The study uses a method of selecting animals that provides adequate assurances that the animals are suitable for the purposes of the study. For example, the animals can reasonably be expected to have animal production characteristics typical of the class(es) of animals for which the new animal drug is intended, there is adequate assurance that the animals have the disease or condition being studied, or, in the case of prophylactic agents, evidence of susceptibility and exposure to the condition against which prophylaxis is desired has been provided. The protocol and the study report describe the method of selecting animals for the study.

(6) The study uses a method to assign a treatment or a control to each experimental unit of animals that is random and minimizes bias. Experimental units of animals are groups of animals that are comparable with respect to
§ 514.117

pertinent variables such as age, sex, class of animal, severity of disease, duration of disease, dietary regimen, level of animal production, and use of drugs or therapy other than the new animal drug. The protocol and the study report describe the method of assignment of animals to an experimental unit to account for pertinent variables and method of assignment of a treatment or a control to the experimental units. When the effect of such variables is accounted for by an appropriate design, and when, within the same animal, effects due to the test drug can be obtained free of the effects of such variables, the same animal may be used for both the test drug and the control using the controls set forth in paragraph (b)(4) of this section.

(7) The study uses methods to minimize bias on the part of observers and analysts of the data that are adequate to prevent undue influences on the results and interpretation of the study data. The protocol and study report explain the methods of observation and recording of the animal response variables and document the methods, such as "blinding" or "masking," used in the study for excluding or minimizing bias in the observations.

(8) The study uses methods to assess animal response that are well defined and reliable. The protocol and study report describe the methods for conducting the study, including any appropriate analytical and statistical methods, used to collect and analyze the data resulting from the conduct of the study, describe the criteria used to assess response, and, when appropriate, justify the selection of the methods to assess animal response.

(9) There is an analysis and evaluation of the results of the study in accord with the protocol adequate to assess the effects of the new animal drug. The study report evaluates the methods used to conduct, and presents and evaluates the results of, the study as to their adequacy to assess the effects of the new animal drug. This evaluation of the results of the study assesses, among other items, the comparability of treatment and control groups with respect to pertinent variables and the effects of any interim analyses performed.

(c) Field studies. (1) Field conditions as used in this section refers to conditions which closely approximate the conditions under which the new animal drug, if approved, is intended to be applied or administered.

(2) Studies of a new animal drug conducted under field conditions shall, consistent with generally recognized scientific principles and procedures, use an appropriate control that permits comparison, employ procedures to minimize bias, and have the characteristics generally described in paragraph (b) of this section. However, because field studies are conducted under field conditions, it is recognized that the level of control over some study conditions need not or should not be the same as the level of control in laboratory studies. While not all conditions relating to a field study need to be or should be controlled, observations of the conditions under which the new animal drug is tested shall be recorded in sufficient detail to permit evaluation of the study. Adequate and well-controlled field studies shall balance the need to control study conditions with the need to observe the true effect of the new animal drug under closely approximated actual use conditions.

(d) Waiver. The Director of the Center for Veterinary Medicine (the Director) may, on the Director's own initiative or on the petition of an interested person, waive in whole or in part any of the criteria in paragraph (b) of this section with respect to a specific study. A petition for a waiver is required to set forth clearly and concisely the specific criteria from which waiver is sought, why the criteria are not reasonably applicable to the particular study, what alternative procedures, if any, are to be, or have been employed, and what results have been obtained. The petition is also required to state why the studies so conducted will yield, or have yielded, substantial evidence of effectiveness, notwithstanding nonconformance with the criteria for which waiver is requested.

(e) Uncontrolled studies. Uncontrolled studies or partially controlled studies are not acceptable as the sole basis for the approval of claims of effectiveness or target animal safety. Such studies, carefully conducted and documented,
may provide corroborative support of adequate and well-controlled studies regarding effectiveness and may yield valuable data regarding safety of the new animal drug. Such studies will be considered on their merits in light of the characteristics listed here. Isolated case reports, random experience, and reports lacking the details which permit scientific evaluation will not be considered.

§ 514.200 Contents of notice of opportunity for a hearing.

(a) The notice to the applicant of opportunity for a hearing on a proposal by the Commissioner to refuse to approve an application or to withdraw the approval of an application will specify the grounds upon which he proposes to issue his order. On request of the applicant, the Commissioner will explain the reasons for his action. The notice of opportunity for a hearing will be published in the Federal Register and will specify that the applicant has 30 days after issuance of the notice within which he is required to file a written appearance electing whether:

1. To avail himself of the opportunity for a hearing; or
2. Not to avail himself of the opportunity for a hearing.

(b) If the applicant fails to file a written appearance in answer to the notice of opportunity for hearing, his failure will be construed as an election not to avail himself of the opportunity for the hearing, and the Commissioner without further notice may enter a final order.

(c) If the applicant elects to avail himself of the opportunity for a hearing, he is required to file a written appearance requesting the hearing within 30 days after the publication of the notice, giving the reason why the application should not be refused or should not be withdrawn, together with a well-organized and full-factual analysis of the clinical and other investigational data he is prepared to prove in support of his opposition to the Commissioner's proposal. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing there is a genuine and substantial issue of fact that requires a hearing. When it clearly appears from the data in the application and from the reasons and a factual analysis in the request for the hearing that no genuine and substantial issue of fact precludes the refusal to approve the application or the withdrawal of approval of the application (for example, no adequate and well-controlled clinical investigations to support the claims of effectiveness have been identified), the Commissioner will enter an order on this data, stating his findings and conclusions. If a hearing is requested and is justified by the applicant's response to the notice of opportunity for a hearing, the issues will be defined, an Administrative Law Judge will be named, and he shall issue a written notice of the time and place at which the hearing will commence. In the case of denial of approval, such time shall be not more than 90 days after the expiration of such 30 days unless the Administrative Law Judge and the applicant otherwise agree; and, in the case of withdrawal of approval, such time shall be as soon as practicable.

§ 514.120 Revocation of order refusing to approve an application or suspending or withdrawing approval of an application.

The Commissioner, upon his own initiative or upon request of an applicant stating reasonable grounds therefor and if he finds that the facts so require, may issue an order approving an application that previously has had its approval refused, suspended, or withdrawn.

§ 514.121 Service of notices and orders.

All notices and orders under this subchapter E and section 512 of the act pertaining to new animal drug applications shall be served:

(a) In person by any officer or employee of the Department designated by the Commissioner; or

(b) By mailing the order by certified mail addressed to the applicant or respondent at his last known address in the records of the Food and Drug Administration.

Subpart C—Hearing Procedures
§ 514.201

(d) The hearing will be open to the public; however, if the Commissioner finds that portions of the application which serve as a basis for the hearing contain information concerning a method or process entitled to protection as a trade secret, the part of the hearing involving such portions will not be public, unless the respondent so specifies in his appearance.

[40 FR 13825, Mar. 27, 1975, as amended at 43 FR 1941, Jan. 13, 1978]

§ 514.201 Procedures for hearings.

Hearings relating to new animal drugs under section 512(d) and (e) of the act shall be governed by part 12 of this chapter.

[64 FR 63204, Nov. 19, 1999]

Subparts D–E [Reserved]

Subpart F—Judicial Review

§ 514.235 Judicial review.

(a) The transcript and record shall be certified by the Commissioner. In any case in which the Commissioner enters an order without a hearing pursuant to §314.200(g) of this chapter, the request(s) for hearing together with the data and information submitted and the Commissioner’s findings and conclusions shall be included in the record certified by the Commissioner.

(b) Judicial review of an order withdrawing approval of a new drug application, whether or not a hearing has been held, may be sought by a manufacturer or distributor of an identical, related, or similar drug product, as defined in §310.6 of this chapter, in a United States court of appeals pursuant to section 505(h) of the act.

[42 FR 4717, Jan. 25, 1977]

PART 515—MEDICATED FEED MILL LICENSE

Subpart A—Applications

Sec.
515.10 Medicated feed mill license applications.
515.11 Supplemental medicated feed mill license applications.

21 CFR Ch. I (4–1–02 Edition)

Subpart B—Administrative Actions on Licenses

515.20 Approval of medicated feed mill license applications.
515.21 Refusal to approve a medicated feed mill license application.
515.22 Suspension and/or revocation of approval of a medicated feed mill license.
515.23 Voluntary revocation of medicated feed mill license.
515.24 Notice of revocation of a medicated feed mill license.
515.25 Revocation of order refusing to approve a medicated feed mill license application or suspending or revoking a license.
515.26 Services of notices and orders.

Subpart C—Hearing Procedures

515.30 Contents of notice of opportunity for a hearing.
515.31 Procedures for hearings.

Subpart D—Judicial Review

515.40 Judicial review.


SOURCE: 64 FR 63204, Nov. 19, 1999 unless otherwise noted.

Subpart A—Applications

§ 515.10 Medicated feed mill license applications.

(a) Medicated feed mill license applications (Forms FDA 3448) may be obtained from the Public Health Service, Consolidated Forms and Publications Distribution Center, Washington Commerce Center, 3222 Hubbard Rd., Landover, MD 20785, or electronically from the Center for Veterinary Medicine home page at “http://www.fda.gov/cvm”.

(b) A completed medicated feed mill license must contain the following information:

(1) The full business name and address of the facility at which the manufacturing is to take place.

(2) The facility’s FDA registration number as required by section 510 of the Federal Food, Drug, and Cosmetic Act (the act).

(3) The name, title, and signature of the responsible individual or individuals for that facility.

(4) A certification that the animal feeds bearing or containing new animal drugs are manufactured and labeled in
§ 515.21 Refusal to approve a medicated feed mill license application.

(a) The Commissioner of Food and Drugs (the Commissioner) shall within 90 days, or such additional period as may be agreed upon by the Commissioner and the applicant, after the filing of an application under §515.10, inform the applicant in writing of his/her intention to issue a notice of opportunity for a hearing on a proposal to refuse to approve the application, if the Commissioner determines upon the basis of the application, on the basis of a preapproval inspection, or upon the basis of any other information before him that:

(1) The application is incomplete, false, or misleading in any particular; or

(c) Within 30 working days after a supplemental application has been filed, if the Commissioner of Food and Drugs determines that the application provides adequate information respecting the change in ownership and/or postal address of the facility site, then an authorized employee of the Food and Drug Administration designated by the Commissioner shall notify the applicant that it is approved by signing and mailing to the applicant a copy of the Form FDA 3448. Supplemental applications that do not provide adequate information shall be returned to the applicant and all reasons for the return of the application shall be made known to the applicant.

Subpart B—Administrative Actions on Licenses

§ 515.20 Approval of medicated feed mill license applications.

Within 90 days after an application has been filed under §515.10, if the Commissioner of Food and Drugs (the Commissioner) determines that none of the grounds for denying approval specified in section 512(m)(3) of the Federal Food, Drug, and Cosmetic Act (the act) applies, an authorized employee of the Food and Drug Administration designated by the Commissioner shall notify the applicant that it is approved by signing and mailing to the applicant a copy of the Form FDA 3448.
§ 515.22 Suspension and/or revocation of approval of a medicated feed mill license.

(a) The Secretary of Health and Human Services may suspend a medicated feed mill license approved under section 512(m)(2) of the Federal Food, Drug, and Cosmetic Act (the act) and give the person holding the medicated feed mill license application prompt notice of this action and afford the applicant the opportunity for an expedited hearing on a finding that there is an imminent hazard to the health of man or of the animals for which such animal feed is intended.

(b) The Commissioner of Food and Drugs (the Commissioner) shall notify in writing the person holding an application approved under section 512(m)(2) of the act and afford an opportunity for a hearing on a proposal to revoke approval of such application if the Commissioner finds:

1. That the applicant has made any changes that would cause the application to contain any untrue statements of material fact or that would affect the safety or effectiveness of the animal feeds manufactured at the facility unless the applicant has supplemented the application by filing a supplemental application under §515.11.

(c) The Commissioner may notify in writing the person holding an application approved under section 512(m)(2) of the act and afford an opportunity for a hearing on a proposal to revoke approval of such application if the Commissioner finds:

1. That the applicant has failed to establish a system for maintaining required records, or has repeatedly or deliberately failed to maintain such records or to make required reports in accordance with a regulation or order under sections 512(m)(5)(A) or 504(a)(3)(A) of the act, or the applicant has refused to permit access to, or copying, or verification of, such records as required by sections 512(m)(5)(B) or 504(a)(3)(B) of the act; or

2. That on the basis of new information before him, evaluated together with the evidence before him when such license was issued, the methods used in, or the facilities and controls used for, the manufacture, processing, packing, and holding of such animal feed are inadequate to assure and preserve the identity, strength, quality, and purity of the new animal drug therein, and were not made adequate within a reasonable time after receipt of written notice from the Commissioner specifying the matter complained of; or

3. That on the basis of new information before him, evaluated together with the evidence before him when such license was issued, the labeling of any animal feeds, based on a fair evaluation of all material facts, is false or misleading in any particular and was not corrected within a reasonable time after receipt of written notice from the Commissioner specifying the matter complained of; or

4. That on the basis of new information before him, evaluated together with the evidence before him when such license was issued, the facility has manufactured, processed, packed, or
Food and Drug Administration, HHS

§ 515.30 Containing to medicated feed mill licenses shall be served:
(a) In person by any officer or employee of the Department of Health and Human Services designated by the Commissioner of Food and Drugs; or
(b) By mailing the order by certified mail addressed to the applicant or respondent's last known address in the records of the Food and Drug Administration.

Subpart C—Hearing Procedures

§ 515.30 Contents of notice of opportunity for a hearing.

(a) The notice to the applicant of opportunity for a hearing on a proposal by the Commissioner of Food and Drugs (the Commissioner) to refuse to approve a medicated feed mill license application or to revoke the approval of a medicated feed mill license will specify the grounds upon which the Commissioner proposes to issue this order. On request of the applicant, the Commissioner will explain the reasons for the action. The notice of opportunity for a hearing will be published in the FEDERAL REGISTER.

(b) If the applicant fails to file a written appearance in answer to the notice of opportunity for hearing, this failure will be construed as an election not to avail himself of the opportunity for the hearing, and the Commissioner without further notice may enter a final order.

(c) If the applicant elects to avail himself of the opportunity for a hearing, the applicant is required to file a written appearance requesting the hearing within 30 days after the publication of the notice, giving the reason why the application should not be refused or the medicated feed mill license should not be revoked, together with a well-organized and full-factual analysis.
§ 515.31 Procedures for hearings.

Hearings relating to new animal drugs under section 512(m)(3) and (m)(4) of the Federal Food, Drug, and Cosmetic Act (the act) shall be governed by part 12 of this chapter.

Subpart D—Judicial Review

§ 515.40 Judicial review.

The transcript and record shall be certified by the Commissioner of Food and Drugs (the Commissioner). In any case in which the Commissioner enters an order without a hearing under § 314.200(g) of this chapter, the request(s) for hearing together with the data and information submitted and the Commissioner’s findings and conclusions shall be included in the record certified by the Commissioner.

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

Sec. 520.23 Acepromazine maleate tablets.
520.44 Acetazolamide sodium soluble powder.
520.45 Albendazole oral dosage forms.
520.45a Albendazole suspension.
520.45b Albendazole paste.
520.46 Albenzost solution.
520.62 Aminopentamide hydrogen sulphate tablets.
520.82 Aminopropazine fumarate oral dosage forms.
520.82a Aminopropazine fumarate tablets.
520.82b Aminopropazine fumarate, neomycin sulfate tablets.
520.86 Amoxicillin oral dosage forms.
520.88a Amoxicillin trihydrate film-coated tablets.
520.88b Amoxicillin trihydrate for oral suspension.
520.88c Amoxicillin trihydrate oral suspension.
520.88d Amoxicillin trihydrate soluble powder.
520.88e Amoxicillin trihydrate boluses.
520.88f Amoxicillin trihydrate tablets.
520.88g Amoxicillin trihydrate and clavulanate potassium film-coated tablets.
520.88h Amoxicillin trihydrate and clavulanate potassium for oral suspension.
520.90 Ampicillin oral dosage forms.
520.90a Ampicillin capsules.
520.90b Ampicillin trihydrate tablets.
520.90c Ampicillin trihydrate capsules.
520.90d Ampicillin trihydrate for oral suspension.
520.90e Ampicillin trihydrate soluble powder.
520.90f Ampicillin trihydrate boluses.
520.100 Amprolium oral dosage forms.
520.100a Amprolium drinking water.
520.100b Amprolium drench.
520.100c Amprolium crumbles.
520.110 Apramycin sulfate soluble powder.
520.154 Bacitracin oral dosage forms.
520.154a Soluble bacitracin methylene disalicylate.
520.154b Soluble bacitracin methylene disalicylate and streptomycin sulfate oral powder.
520.154c Bacitracin zinc soluble powder.
520.182 Bicyclohexlammonium fumagillin.
520.222 Bunamidine hydrochloride.
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>520.246</td>
<td>Butorphanol tartrate tablets.</td>
</tr>
<tr>
<td>520.260</td>
<td>n-Butyl chloride capsules.</td>
</tr>
<tr>
<td>520.300</td>
<td>Cambendazole oral dosage forms.</td>
</tr>
<tr>
<td>520.300a</td>
<td>Cambendazole suspension.</td>
</tr>
<tr>
<td>520.300b</td>
<td>Cambendazole pellets.</td>
</tr>
<tr>
<td>520.300c</td>
<td>Cambendazole paste.</td>
</tr>
<tr>
<td>520.309</td>
<td>Carprofen.</td>
</tr>
<tr>
<td>520.310</td>
<td>Caramiphen ethanedisulfonate and ammonium chloride tablets.</td>
</tr>
<tr>
<td>520.312</td>
<td>Carnidazole tablets.</td>
</tr>
<tr>
<td>520.314</td>
<td>Cefadroxil tablets.</td>
</tr>
<tr>
<td>520.315</td>
<td>Cefadroxil powder for oral suspension.</td>
</tr>
<tr>
<td>520.390</td>
<td>Chloramphenicol oral dosage forms.</td>
</tr>
<tr>
<td>520.390a</td>
<td>Chloramphenicol tablets.</td>
</tr>
<tr>
<td>520.390b</td>
<td>Chloramphenicol capsules.</td>
</tr>
<tr>
<td>520.390c</td>
<td>Chloramphenicol palmitate oral suspension.</td>
</tr>
<tr>
<td>520.420</td>
<td>Chlorothiazide tablets and boluses.</td>
</tr>
<tr>
<td>520.434</td>
<td>Chlorphenesin carbamate tablets.</td>
</tr>
<tr>
<td>520.445</td>
<td>Chlortetracycline oral dosage forms.</td>
</tr>
<tr>
<td>520.445a</td>
<td>Chlortetracycline bisulfate/sulfamethazine bisulfate soluble powder.</td>
</tr>
<tr>
<td>520.445b</td>
<td>Chlortetracycline powder (chlortetracycline hydrochloride or chlortetracycline bisulfate).</td>
</tr>
<tr>
<td>520.446</td>
<td>Chlortetracycline tablets and boluses.</td>
</tr>
<tr>
<td>520.447</td>
<td>Clindamycin hydrochloride capsules.</td>
</tr>
<tr>
<td>520.452</td>
<td>Clenbuterol syrup.</td>
</tr>
<tr>
<td>520.530</td>
<td>Cythioate oral liquid.</td>
</tr>
<tr>
<td>520.531</td>
<td>Cythioate tablets.</td>
</tr>
<tr>
<td>520.534</td>
<td>Decoquinate.</td>
</tr>
<tr>
<td>520.540</td>
<td>Dexamethasone oral dosage forms.</td>
</tr>
<tr>
<td>520.540a</td>
<td>Dexamethasone powder.</td>
</tr>
<tr>
<td>520.540b</td>
<td>Dexamethasone tablets and boluses.</td>
</tr>
<tr>
<td>520.540c</td>
<td>Dexamethasone chewable tablets.</td>
</tr>
<tr>
<td>520.550</td>
<td>Dextrose/glycine/electrolyte.</td>
</tr>
<tr>
<td>520.563</td>
<td>Diatriozate meglumine and diatriozate sodium oral solution.</td>
</tr>
<tr>
<td>520.580</td>
<td>Dichlorophene and tolenue capsules.</td>
</tr>
<tr>
<td>520.581</td>
<td>Dichlorophene tablets.</td>
</tr>
<tr>
<td>520.600</td>
<td>Dichlorvos.</td>
</tr>
<tr>
<td>520.608</td>
<td>Dicloxacillin sodium monohydrate capsules.</td>
</tr>
<tr>
<td>520.620</td>
<td>Diethylcarbamazine oral dosage forms.</td>
</tr>
<tr>
<td>520.622</td>
<td>Diethylcarbamazine citrate oral dosage forms.</td>
</tr>
<tr>
<td>520.622a</td>
<td>Diethylcarbamazine citrate tablets.</td>
</tr>
<tr>
<td>520.622b</td>
<td>Diethylcarbamazine citrate syrup.</td>
</tr>
<tr>
<td>520.622c</td>
<td>Diethylcarbamazine citrate chewable tablets.</td>
</tr>
<tr>
<td>520.623</td>
<td>Diethylcarbamazine citrate.</td>
</tr>
<tr>
<td>520.763</td>
<td>Dithiazanine iodide oral dosage forms.</td>
</tr>
<tr>
<td>520.763a</td>
<td>Dithiazanine iodide tablets.</td>
</tr>
<tr>
<td>520.763b</td>
<td>Dithiazanine iodide powder.</td>
</tr>
<tr>
<td>520.768c</td>
<td>Dithiazanine iodide and piperazine citrate suspension.</td>
</tr>
<tr>
<td>520.784</td>
<td>Doxylamine succinate tablets.</td>
</tr>
<tr>
<td>520.804</td>
<td>Enalapril tablets.</td>
</tr>
<tr>
<td>520.812</td>
<td>Enrofloxacin tablets.</td>
</tr>
<tr>
<td>520.813</td>
<td>Enrofloxacin oral solution.</td>
</tr>
<tr>
<td>520.816</td>
<td>Epsiprantel tablets.</td>
</tr>
<tr>
<td>520.823</td>
<td>Erythromycin phosphate.</td>
</tr>
<tr>
<td>520.863</td>
<td>Ethylisobutrazine hydrochloride tablets.</td>
</tr>
<tr>
<td>520.870</td>
<td>Etodolac.</td>
</tr>
<tr>
<td>520.903</td>
<td>Febantel oral dosage forms.</td>
</tr>
<tr>
<td>520.903a</td>
<td>Febantel paste.</td>
</tr>
<tr>
<td>520.903b</td>
<td>Febantel suspension.</td>
</tr>
<tr>
<td>520.903c</td>
<td>[Reserved]</td>
</tr>
<tr>
<td>520.903d</td>
<td>Febantel-praziquantel paste.</td>
</tr>
<tr>
<td>520.903e</td>
<td>Febantel tablets.</td>
</tr>
<tr>
<td>520.905</td>
<td>Fenbendazole oral dosage forms.</td>
</tr>
<tr>
<td>520.905a</td>
<td>Fenbendazole suspension.</td>
</tr>
<tr>
<td>520.905c</td>
<td>Fenbendazole paste.</td>
</tr>
<tr>
<td>520.905d</td>
<td>Fenbendazole powder.</td>
</tr>
<tr>
<td>520.905e</td>
<td>Fenbendazole blocks.</td>
</tr>
<tr>
<td>520.906</td>
<td>Flunixin oral dosage forms.</td>
</tr>
<tr>
<td>520.907</td>
<td>Flunixin oral solution.</td>
</tr>
<tr>
<td>520.907a</td>
<td>Flunixin meglumine granules.</td>
</tr>
<tr>
<td>520.907b</td>
<td>Flunixin meglumine paste.</td>
</tr>
<tr>
<td>520.910</td>
<td>Furomamide.</td>
</tr>
<tr>
<td>520.904</td>
<td>Gentamicin sulfate oral dosage forms.</td>
</tr>
<tr>
<td>520.904a</td>
<td>Gentamicin sulfate oral solution.</td>
</tr>
<tr>
<td>520.904b</td>
<td>Gentamicin sulfate pig pump oral solution.</td>
</tr>
<tr>
<td>520.910</td>
<td>Griseofulvin.</td>
</tr>
<tr>
<td>520.912</td>
<td>Haloxon oral dosage forms.</td>
</tr>
<tr>
<td>520.912a</td>
<td>Haloxon drench.</td>
</tr>
<tr>
<td>520.912b</td>
<td>Haloxon boluses.</td>
</tr>
<tr>
<td>520.913</td>
<td>Hetacillin oral dosage forms.</td>
</tr>
<tr>
<td>520.913a</td>
<td>Hetacillin potassium capsules.</td>
</tr>
<tr>
<td>520.913b</td>
<td>Hetacillin potassium oral suspension.</td>
</tr>
<tr>
<td>520.913c</td>
<td>Hetacillin potassium tablets.</td>
</tr>
<tr>
<td>520.913d</td>
<td>Hetacillin potassium oral suspension.</td>
</tr>
<tr>
<td>520.915</td>
<td>Ivermectin liquid.</td>
</tr>
<tr>
<td>520.916</td>
<td>Ivermectin and pyrantel pamoate chewable tablet.</td>
</tr>
<tr>
<td>520.917</td>
<td>Ivermectin sustained-release bolus.</td>
</tr>
<tr>
<td>520.924</td>
<td>Kanamycin sulfa, aminopenamidide hydrogen sulfa, pectin, bismuth subcarbonate, activated attapulgite suspension.</td>
</tr>
<tr>
<td>520.925</td>
<td>Kanamycin sulfa, pectin, bismuth subcarbonate, activated attapulgite tablets.</td>
</tr>
<tr>
<td>520.942</td>
<td>Levamisole hydrochloride oral dosage forms.</td>
</tr>
<tr>
<td>520.942a</td>
<td>Levamisole hydrochloride drench and drinking water.</td>
</tr>
<tr>
<td>520.942b</td>
<td>Levamisole hydrochloride tablet or oblet (bolus).</td>
</tr>
</tbody>
</table>
520.1242c Levamisole hydrochloride and piperazine dihydrochloride.
520.1242d Levamisole resinate.
520.1242e Levamisole hydrochloride effervescent tablets.
520.1242f Levamisole hydrochloride gel.
520.1242g Levamisole resinate and famphur paste.
520.1263 Lincomycin hydrochloride monohydrate oral dosage forms.
520.1263a Lincomycin hydrochloride monohydrate tablets and sirup.
520.1263b Lincomycin hydrochloride monohydrate and spectinomycin sulfate tetrahydrate soluble powder.
520.1263c Lincomycin hydrochloride soluble powder.
520.1284 Sodium liothyronine tablets.
520.1288 Lufenuron tablets.
520.1289 Lufenuron suspension.
520.1310 Marbofloxacin tablets.
520.1320 Mebendazole oral.
520.1326 Mebendazole and trichlorfon oral dosage forms.
520.1326a Mebendazole and trichlorfon powder.
520.1326b Mebendazole and trichlorfon paste.
520.1326c Mebendazole and trichlorfon sustained-release capsules.
520.1330 Meclofenamic acid granules.
520.1331 Meclofenamic acid tablets.
520.1341 Megestrol acetate tablets.
520.1380 Methocarbamol tablets.
520.1390 (S)-methoprene.
520.1408 Methylprednisolone tablets.
520.1409 Methylprednisolone, aspirin tablets.
520.1422 Metoserpate hydrochloride.
520.1430 Mibolerone.
520.1445 Milbemycin oxime tablets.
520.1446 Milbemycin oxime/lufenuron tablets.
520.1448 Monensin oral dosage forms.
520.1448a Monensin blocks.
520.1450 Morantel tartrate oral dosage forms.
520.1450a Morantel tartrate sustained-release trilaminate cylinder/sheet.
520.1451 Moxidectin.
520.1452 Moxidectin gel.
520.1468 Naproxen granules.
520.1484 Neomycin sulfate soluble powder.
520.1485 Neomycin sulfate oral solution.
520.1510 Nitenpyram.
520.1609 Oxytetracycline.
520.1660a Oxytetracycline and carbomycin in combination.
520.1660b Oxytetracycline hydrochloride capsules.
520.1660c Oxytetracycline hydrochloride tablets/boluses.
520.1660d Oxytetracycline hydrochloride soluble powder.
520.1696 Penicillin oral dosage forms.
520.1696a Buffered penicillin powder, penicillin powder with buffered aqueous diluent.
520.1696b Penicillin G potassium in drinking water.
520.1696c Penicillin V potassium for oral solution.
520.1696d Penicillin V potassium tablets.
520.1720 Phenylbutazone oral dosage forms.
520.1720a Phenylbutazone tablets and boluses.
520.1720b Phenylbutazone granules.
520.1720c Phenylbutazone paste.
520.1720d Phenylbutazone gel.
520.1822a Piperazine-carbon disulfide complex oral dosage forms.
520.1822b Piperazine-carbon disulfide complex boluses.
520.1822c Piperazine-carbon disulfide complex with phenothiazine suspension.
520.1833 Piperazine citrate capsules.
520.1834 Piperazine phosphate capsules.
520.1835 Piperazine phosphate with thienium cloxylate tablets.
520.1836 Piperazine monohydrochloride liquid.
520.1837 Piperazine.
520.1849 Poloxalene.
520.1849 Polyoxyethylene (23) lauryl ether blocks.
520.1855 Ponazuril.
520.1870 Praziquantel tablets.
520.1871 Praziquantel/pyrantel pamoate tablets.
520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.
520.1880 Prednisolone tablets.
520.1900 Primidone tablets.
520.1920 Prochlorperazine, isopropamide sustained-release capsules.
520.1921 Prochlorperazine, isopropamide, with neomycin sustained-release capsules.
<table>
<thead>
<tr>
<th>Paragraph</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 520.23</td>
<td>Acepromazine maleate tablets.</td>
</tr>
<tr>
<td>(a) Sponsors.</td>
<td>See drug labeler codes in §510.600(c) of this chapter for identification of sponsors as follows:</td>
</tr>
<tr>
<td>(1)</td>
<td>For No. 000056, use of 5-, 10-, or 25-milligram tablets as in paragraph (b) of this section.</td>
</tr>
<tr>
<td>(2)</td>
<td>For No. 000010, use of 10- or 25-milligram tablets as in paragraph (c) of this section.</td>
</tr>
</tbody>
</table>
§ 520.44 Acetazolamide sodium soluble powder.

(a) Specifications. The drug is in a powder form containing acetazolamide sodium, USP equivalent to 25 percent acetazolamide activity.

(b) Sponsor. See No. 010042 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used in dogs as an aid in the treatment of mild congestive heart failure and for rapid reduction of intraocular pressure.1

(2) It is administered orally at a dosage level of 5 to 15 milligrams per pound of body weight daily.1

(3) For use only by or on the order of a licensed veterinarian.1

§ 520.45 Albendazole oral dosage forms.

§ 520.45a Albendazole suspension.

(a) (1) Specifications. The product contains 11.36 percent albendazole.

(2) Sponsor. See No. 000069 in §510.600 of this chapter.

(3) Related tolerances. See §556.34 of this chapter.

(b) (1) Specifications. The product contains 4.54 or 11.36 percent albendazole.

(2) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(3) Related tolerances. See §556.34 of this chapter.

(c) Conditions of use in cattle—(i) Amount. 4.54 milligrams per pound of body weight (10 milligrams per kilogram).

(ii) Indications for use. For removal and control of the following internal parasites of cattle: Adult liver flukes (Fasciola hepatica); heads and segments of tapeworms (Moniezia benedeni, M. expansa); adult and 4th stage larvae of stomach worms (brown stomach worms including 4th stage inhibited larvae (Ostertagia ostertagi), barberpole worm (Haemonchus contortus, H. placei), small stomach worm (Trichostrongylus axei)); adult and 4th stage larvae of intestinal worms (thread-necked intestinal worm (Nematodirus spathiger, N. helvetianus), small intestinal worm (Cooperia punctata and C. oncophora)); adult stages of intestinal worms (hookworm (Bunostomum phlebotomum), bankrupt worm (Trichostrongylus colubriformis), nodular worm (Oesophagostomum radiatum)); adult and 4th stage larvae of lungworms (Dictyocaulus viviparus).

(iii) Limitations. Administer as a single oral dose using dosing gun or dosing syringe. Do not slaughter within 27 days of last treatment. Do not use in female dairy cattle of breeding age: Do not administer to female cattle during first 45 days of pregnancy or for 45 days after removal of bulls. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(d) (1) Specifications. The product contains 4.55 or 11.36 percent albendazole.

(2) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(3) Related tolerances. See §556.34 of this chapter.

(4) Conditions of use in sheep—(1) Amount. 7.5 milligrams per kilogram of body weight (3.4 milligrams per pound).

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
(i) Indications for use. For removal and control of the following internal parasites of sheep: Adult liver flukes (Fasciola hepatica, Fascioloides magna); heads and segments of common tapeworms (Moniezia expansa) and fringed tapeworm (Thysanosoma actinioide); adult and fourth stage larvae of stomach worms (brown stomach worm (Ostertagia circumcincta and Marshallagia marshallii), barberpole worm (Haemonchus contortus), small stomach worm (Trichostrongylus axei)); adult and fourth stage larvae of intestinal worms (thread-necked intestinal worm (Nematodirus spathiger and N. filicollis), Cooper's worm (Cooperia oncophora), bankrupt worm (Trichostrongylus colubriformis), nodular worm (Oesophagostomum columbianum), and large-mouth bowel worm (Chabertia ovina)); adult and larval stages of lungworms (Dictyocaulus filaria).

(ii) Limitations. Administer as a single oral dose using dosing gun or dosing syringe. Do not slaughter within 7 days of last treatment. Do not administer to ewes during first 30 days of pregnancy or for 30 days after removal of rams. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.48 Altrenogest solution.

(a) Specifications. Each milliliter (mL) of solution contains 2.2 milligrams (mg) altrenogest.

(b) Sponsor. See No. 057926 in §519.600(c) of this chapter.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Amount. 1.0 mL per 110 pounds body weight (0.044 mg per kilogram) daily for 15 consecutive days.

(2) Indications for use. For suppression of estrus in mares.

(3) Limitations. For oral use in horses only; avoid contact with the skin. Do not administer to horses intended for use as food.

§ 520.62 Aminopentamide hydrogen sulphate tablets.

(a) Chemical name. 4-(Dimethylamino)-2-diphenylvaleramide hydrogen sulfate.

(b) Specifications. Each tablet contains 0.2 milligram of the drug.

(c) Sponsor. See No. 000856 in §519.600(c) of this chapter.

(d) Conditions of use. (1) It is intended for use in dogs and cats only for the treatment of vomiting and/or diarrhea,
nausea, acute abdominal visceral spasm, pylorospasm, or hypertrophic gastritis.

Note: Not for use in animals with glaucoma because of the occurrence of mydriasis.

(2) Dosage is administered by oral tablet every 8 to 12 hours, as follows:

<table>
<thead>
<tr>
<th>Weight of animal in pounds</th>
<th>Dosage in milligrams</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 10</td>
<td>0.1</td>
</tr>
<tr>
<td>11 to 20</td>
<td>0.2</td>
</tr>
<tr>
<td>21 to 50</td>
<td>0.3</td>
</tr>
<tr>
<td>51 to 100</td>
<td>0.4</td>
</tr>
<tr>
<td>Over 100</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Dosage may be gradually increased up to a maximum of five times the suggested dosage. Oral administration of tablets may be preceded by subcutaneous or intramuscular use of the injectable form of the drug.

(3) For use only by or on the order of a licensed veterinarian.

[40 FR 13838, March 27, 1975, as amended at 53 FR 27761, July 25, 1988]

§ 520.82 Amoxicillin oral dosage forms.

§ 520.82a Amoxicillin trihydrate film-coated tablets.

(a) Specifications. The drug is in tablet form. Each tablet contains amoxicillin trihydrate equivalent to 50, 100, 150, 200, or 400 milligrams of amoxicillin.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use. (1) Dogs—

(i) Amount. 5 milligrams per pound of body weight, twice a day.

(ii) Indications for use. Treatment of infections of the respiratory tract (tonsillitis, tracheobronchitis), genitourinary tract (cystitis), gastrointestinal tract (bacterial gastroenteritis), and soft tissues (abscesses, lacerations, wounds), caused by susceptible strains of Staphylococcus aureus, Streptococcus spp., Escherichia coli, Proteus mirabilis, and bacterial dermatitis caused by S. aureus, Streptococcus spp., and P. mirabilis.

(2) It is administered for 5 to 7 days or 48 hours after all symptoms have subsided. If no improvement is seen in 5 days, review diagnosis and change therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.88 Amoxicillin oral dosage forms.

§ 520.88a Amoxicillin trihydrate film-coated tablets.

(a) Specifications. Each tablet contains amoxicillin trihydrate equivalent to 50, 100, 150, 200, or 400 milligrams of amoxicillin.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use. (1) Dogs—

(i) Amount. 5 milligrams per pound of body weight, twice a day.

(ii) Indications for use. Treatment of infections of the respiratory tract (tonsillitis, tracheobronchitis), genitourinary tract (cystitis), gastrointestinal tract (bacterial gastroenteritis), and soft tissues (abscesses, lacerations, wounds), caused by susceptible strains of Staphylococcus aureus, Streptococcus spp., Escherichia coli, Proteus mirabilis, and bacterial dermatitis caused by S. aureus, Streptococcus spp., and P. mirabilis.

(2) It is administered for 5 to 7 days or 48 hours after all symptoms have subsided. If no improvement is seen in 5 days, review diagnosis and change therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
(2) Cats—(1) Amount. 50 milligrams (5 to 10 milligrams per pound of body weight) once a day.

(ii) Indications for use. Treatment of infections caused by susceptible organisms as follows: upper respiratory tract due to S. aureus, Streptococcus spp., and E. coli; genitourinary tract (cystitis) due to S. aureus, Streptococcus spp., E. coli, and P. mirabilis; gastrointestinal tract due to E. coli; and skin and soft tissue (abscesses, lacerations, and wounds) due to S. aureus, Streptococcus spp., E. coli, and Pasteurella multocida.

(iii) Limitations. Administer for 5 to 7 days or 48 hours after all symptoms have subsided. If no improvement is seen in 5 days, review diagnosis and change therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37319, Aug. 18, 1992, as amended at 60 FR 55658, Nov. 2, 1995]

§ 520.88b Amoxicillin trihydrate for oral suspension.

(a) Specifications. When reconstituted, each milliliter contains amoxicillin trihydrate equivalent to 50 milligrams of amoxicillin.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(1) Conditions of use—(i) Dogs—(A) Amount. 5 milligrams per pound of body weight twice daily.

(B) Indications for use. Treatment of infections caused by susceptible strains of organisms as follows: respiratory tract (tonsillitis, tracheobronchitis) caused by Staphylococcus aureus, Streptococcus spp., Escherichia coli, and Proteus mirabilis; genitourinary tract (cystitis) caused by S. aureus, Streptococcus spp., E. coli, and P. mirabilis; gastrointestinal tract (bacterial gastroenteritis) caused by S. aureus, Streptococcus spp., E. coli, and P. mirabilis; bacterial dermatitis caused by S. aureus, Streptococcus spp., and P. mirabilis; and soft tissues (abscesses, lacerations, and wounds) caused by S. aureus, Streptococcus spp., E. coli, and P. mirabilis.

(C) Limitations. Use for 5 to 7 days or 48 hours after all symptoms have subsided. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.88c Amoxicillin trihydrate oral suspension.

(a) Specifications. Each 0.8-milliliter dose contains amoxicillin trihydrate equivalent to 40 milligrams of amoxicillin.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.510 of this chapter.

99
§ 520.88d Amoxicillin trihydrate soluble powder.

(a) Specifications. Each gram contains amoxicillin trihydrate equivalent to 115.4 milligrams of amoxicillin.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.38 of this chapter.

(d) Conditions of use. Preruminating calves including veal calves—

(1) Amount. 400 milligrams per 100 pounds of body weight twice daily.

(2) Indications for use. Treatment of bacterial enteritis when due to susceptible Escherichia coli in preruminating calves including veal calves.

(3) Limitations. For oral use in preruminating calves including veal calves only, not for use in other animals which are raised for food production. Treatment should be continued for 48 hours after all symptoms have subsided but not to exceed 5 days. Do not slaughter animals during treatment or for 20 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.88f Amoxicillin trihydrate tablets.

(a) Specifications. Each tablet contains amoxicillin trihydrate equivalent to 50, 100, 200, or 400 milligrams of amoxicillin.

(b) Sponsor. See Nos. 000031 or 000093 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.38 of this chapter.

(d) Conditions of use—

(1) Dogs—

(i) Amount. 5 milligrams per pound of body weight twice a day.

(ii) Indications for use. Treatment of bacterial dermatitis due to Staphylococcus aureus, Streptococcus spp., Staphylococcus spp., and Escherichia coli; and soft tissue infections (abscesses, wounds, lacerations) due to S. aureus, Streptococcus spp., E. coli, Proteus mirabilis, and Staphylococcus spp.

(iii) Limitations. Use for 5 to 7 days or 48 hours after all symptoms have subsided. If no improvement is seen in 5 days, review diagnosis and change therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]
§ 520.88g Amoxicillin trihydrate and clavulanic acid potassium film-coated tablets.

(a) Specifications. Each tablet contains amoxicillin trihydrate and clavulanic acid, equivalent to either 50 milligrams of amoxicillin and 12.5 milligrams clavulanic acid, or 100 milligrams of amoxicillin and 25 milligrams clavulanic acid, or 200 milligrams amoxicillin and 50 milligrams clavulanic acid or 300 milligrams amoxicillin and 75 milligrams clavulanic acid.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 6.25 milligrams (equivalent to 5 milligrams amoxicillin and 1.25 milligrams clavulanic acid) per pound of body weight twice daily.

(ii) Indications for use. Treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of beta-lactamase (penicillinase) Staphylococcus aureus, nonbeta-lactamase Staphylococcus spp., Streptococcus spp., and Escherichia coli. Treatment of periodontal infections due to susceptible strains of aerobic and anaerobic bacteria.

(iii) Limitations. Wounds, abscesses, cellulitis, and superficial/juvenile pyoderma: Treat for 5 to 7 days or for 48 hours after all signs have subsided. If no improvement is seen after 5 days of treatment, discontinue therapy and reevaluate diagnosis. Deep pyoderma may require treatment for 21 days; do not treat for more than 30 days. Not for use in pregnant or breeding animals. Administration for 21 days, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and diagnosis reevaluated. Urinary tract infections may require treatment for 10 to 14 days or longer. The maximum duration of treatment should not exceed 30 days. Safety of use in pregnant or breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37320, Aug. 18, 1992, as amended at 60 FR 55659, Nov. 2, 1995; 63 FR 13121, Mar. 18, 1998]

§ 520.88h Amoxicillin trihydrate and clavulanate potassium for oral suspension.

(a) Specifications. When reconstituted, each milliliter contains amoxicillin trihydrate equivalent to 50 milligrams of amoxicillin with clavulanate potassium equivalent to 12.5 milligrams of clavulanic acid.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 6.25 milligrams (equivalent to 5 milligrams amoxicillin and 1.25 milligrams clavulanic acid) per pound of body weight twice daily.

(ii) Indications for use. Treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of beta-lactamase (penicillinase) producing Staphylococcus aureus, nonbeta-lactamase Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and Escherichia coli. Treatment of periodontal infections due to susceptible strains of aerobic and anaerobic bacteria.

(iii) Limitations. Administer for 5 to 7 days or 48 hours after all symptoms subsided. Deep pyoderma may require 21 days, not to exceed 30 days. If no improvement is seen in 5 days, discontinue therapy and reevaluate the case. Not for use in dogs maintained for breeding. Federal law restricts this
 § 520.90 Amoxicillin oral dosage forms.

§ 520.90a Amoxicillin capsules.

(a) Specifications. Each capsule contains 125 milligrams or 250 milligrams of amoxicillin.

(b) Sponsor. See No. 000008 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Dogs—(a) Amount. 5 to 10 milligrams per pound of body weight, e.g., one 125 mg capsule per 14 to 25 pounds, given 2 to 4 times daily; for animals weighing 6 to 14 pounds, one capsule twice daily.

(ii) Indications for use. Treatment of urinary tract infections (cystitis) due to Proteus spp., hemolytic and non-hemolytic streptococci, beta hemolytic streptococci, and Escherichia coli. In upper respiratory tract infections tracheobronchitis (kennel cough), tonsillitis due to alpha and beta hemolytic streptococci, hemolytic positive staphylococci, E. coli, and Proteus spp. In infections associated with abscesses, lacerations, and wounds due to Staphylococcus spp. and Streptococcus spp.

(ii) Limitations. Bacteriologic studies to determine the causative organisms and their susceptibility to amoxicillin should be performed. Use of the drug is contraindicated in animals with a history of an allergic reaction to any of the penicillins. Amoxicillin is contraindicated in infections caused by penicillinase-producing organisms. Not for use in animals which are raised for food production. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.90b Amoxicillin trihydrate tablets.

(a) Specifications. Each tablet contains amoxicillin trihydrate equivalent to 50 or 100 milligrams of amoxicillin.

(b) Sponsor. See No. 000089 in § 510.600(c) of this chapter.

(c) Conditions of use. Dogs—(a) Amount. 5 milligrams per pound of body weight, at 8-hour intervals, 1 to 2 hours prior to feeding, to be continued 36 to 48 hours after all symptoms have subsided. If no improvement is seen within 5 days, stop treatment, reevaluate diagnosis, and change therapy.

(ii) Indications for use. Oral treatment of infections caused by susceptible organisms as follows: Upper respiratory infections, tonsillitis, and bronchitis due to Streptococcus spp., Staphylococcus spp., Escherichia coli, Proteus mirabilis,
§520.90c Ampicillin trihydrate capsules.

(a) Specifications. Each capsule contains ampicillin trihydrate equivalent to 125, 250, or 500 milligrams of ampicillin.

(b) Sponsor. See No. 055529 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 5 to 10 milligrams per pound of body weight two or three times daily. In severe or acute conditions, 10 milligrams per pound of body weight, three times daily. Administer 1 to 2 hours prior to feeding.

(ii) Indications for use. Treatment of respiratory tract infections (tracheobronchitis and tonsillitis); urinary tract infections (cystitis); bacterial gastroenteritis; generalized infections (septicaemia) associated with abscesses, lacerations, and wounds; and bacterial dermatitis.

(iii) Limitations. The drug may be given as an emergency measure; however, in vitro sensitivity tests on samples collected prior to treatment should be made. Ampicillin is contraindicated for use in infections caused by penicillinase-producing organisms and for use in animals known to be allergic to any of the penicillins. Not for use in animals raised for food production. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37321, Aug. 18, 1992, as amended at 58 FR 61016, Nov. 19, 1993]

§520.90d Ampicillin trihydrate for oral suspension.

(a) Specifications. When reconstituted as directed, each milliliter contains ampicillin trihydrate equivalent to 25 milligrams of ampicillin.

(b) Sponsor. See No. 055529 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 5 to 10 milligrams per pound of body weight orally, 2 or 3 times daily, 1 to 2 hours prior to feeding. In severe or acute conditions, 10 milligrams per pound of body weight 3 times daily.

(ii) Indications for use. Treatment of respiratory tract infections (tracheobronchitis and tonsillitis) due to Escherichia coli, Pseudomonas spp., Proteus spp., Staphylococcus spp., and Streptococcus spp.; urinary tract infections (cystitis) due to E. coli, Staphylococcus spp., Streptococcus spp., and Proteus spp.; bacterial gastroenteritis due to E. coli; generalized infections (septicaemia) associated with abscesses, lacerations, and wounds, due to Staphylococcus and Streptococcus sp.; and bacterial dermatitis due to Staphylococcus.

(iii) Limitations. Duration of treatment is usually 3 to 5 days. Continue treatment 48 hours after the animal’s temperature has returned to normal and all other signs of infection have subsided. If no response is obtained within 3 to 5 days, reevaluate diagnosis and treatment. Appropriate laboratory tests should be conducted, including in vitro culturing and susceptibility tests on samples collected prior to treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cats—(1) Amount. 10 to 30 milligrams per pound of body weight orally, 2 or 3 times daily, 1 to 2 hours prior to feeding.


(iii) Limitations. Duration of treatment is usually 3 to 5 days. Continue treatment 48 hours after the animal’s temperature has returned to normal and all other signs of infection have subsided. If no response is obtained within 3 to 5 days, reevaluate diagnosis and treatment. Appropriate laboratory tests should be conducted, including in vitro culturing and susceptibility tests on samples collected prior to treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


(a) Specifications. Each gram contains ampicillin trihydrate equivalent to 88.2 milligrams of ampicillin.

(b) Sponsor. See No. 055529 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.40 of this chapter.

(d) Conditions of use. Swine—(1) Amount. 5 milligrams of ampicillin per pound of body weight twice daily orally by gavage or in drinking water for up to 5 days.

(ii) Indications for use. Oral treatment of porcine colibacillosis (Escherichia coli) and salmonellosis (Salmonella spp.) infections in swine up to 75 pounds of body weight, and bacterial pneumonia caused by Pasteurella multocida, Staphylococcus spp., and Salmonella spp.

(3) Limitations. For use in swine only. Not for use in other animals which are raised for food production. Treated swine must not be slaughtered for food during treatment and for 24 hours following the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


(a) Specifications. Each bolus contains ampicillin trihydrate equivalent to 400 milligrams of ampicillin.

(b) Sponsor. See No. 055529 in §510.600(c) of this chapter for use as in paragraph (d)(1), 000069 for use as in paragraph (d)(2).

(c) Related tolerances. See §556.40 of this chapter.

(d) Conditions of use. Nonruminating calves—(1) Amount. 5 milligrams per pound of body weight twice daily for up to 5 days.


(ii) Limitations. Treated calves must not be slaughtered for food during treatment and for 15 days after the last treatment. Not for use in other animals raised for food production. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Amount. 5 milligrams per pound of body weight twice daily not to exceed 4 days.

(i) Indications for use. Oral treatment of bacterial enteritis (coli bacillosis) caused by E. coli.

(ii) Limitations. Treated calves must not be slaughtered for food during treatment and for 7 days after the last
§ 520.100b Amprolium oral dosage forms.

§ 520.100a Amprolium drinking water.
(a) Chemical name. 1-(4-Amino-2-n-propyl-5-pyrimidinylmethyl)-2-picolinium chloride hydrochloride.
(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.50 of this chapter.
(d) Conditions of use. It is used in drinking water as follows:
   (1) Chickens and turkeys—(i) Amount. 20 percent soluble powder.
   (ii) Indications for use. Treatment of coccidiosis.
   (iii) Limitations. Administer at the 0.012 percent level in drinking water as soon as coccidiosis is diagnosed and continue for from 3 to 5 days (in severe outbreaks, give amprolium at the 0.024 percent level); continue with 0.006 percent amprolium-mediated water for an additional 1 to 2 weeks; no other source of drinking water should be available to the birds during this time; as sole source of amprolium.
   (2) Calves—(i) Amount. 9.6 percent solution or 20 percent soluble powder.
   (ii) Indications for use. As an aid in the treatment of coccidiosis caused by Eimeria bovis and E. zurnii.
   (b) Limitations. Add 16 fluid ounces of the 9.6 percent solution to each 100 gallons of drinking water; at the usual rate of water consumption, this will provide an intake of approximately 10 milligrams per kilogram (2.2 pounds) of body weight; offer this solution as the only source of water for 5 days; for a satisfactory diagnosis, a microscopic examination of the feces should be done by a veterinarian or diagnostic laboratory before treatment; when treating outbreaks, the drug should be administered promptly after diagnosis is determined; withdraw 24 hours before slaughter.

§ 520.100b Amprolium drench.

(a) Chemical name. 1-(4-Amino-2-n-propyl-5-pyrimidinylmethyl)-2-picolinium chloride hydrochloride.
(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.50 of this chapter.
(d) Conditions of use. It is used for calves as follows:
   (1) Amount. 9.6 percent solution or 20 percent soluble powder.
   (i) Indications for use. As an aid in the treatment of coccidiosis caused by Eimeria bovis and E. zurnii.
   (ii) Limitations. Add 3 fluid ounces of the 9.6 percent solution to 1 pint of water or 3 ounces of the 20 percent soluble powder to each quart of water and with a dose syringe administer 1 fluid ounce of this solution for each 100 pounds of body weight; this will provide a dose of approximately 10 milligrams per kilogram (2.2 pounds) of body weight; administer daily for 5 days; for a satisfactory diagnosis, a microscopic examination of the feces should be done by a veterinarian or diagnostic laboratory before treatment; when treating outbreaks, the drug should be administered promptly after diagnosis is determined; withdraw 24 hours before slaughter.
   (2) Amount. 9.6 percent solution or 20 percent soluble powder.
   (i) Indications for use. As an aid in the prevention of coccidiosis caused by Eimeria bovis and E. zurnii.
§ 520.100c Amprolium crumbles.

(a) Specifications. Amprolium crumbles contain 1.25 percent amprolium.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.50 of this chapter.

(d) Conditions of use. It is top-dressed on or thoroughly mixed in the daily feed ration of calves as follows:

(i) Amount. 1.6 ounces of crumbles per 250 pounds of body weight per day (5 milligrams per kilogram of body weight).

(ii) Indications for use. As an aid in the prevention of coccidiosis caused by Eimeria bovis and E. zurnii.

(ii) Limitations. Administer for 21 consecutive days during periods of exposure or when experience indicates that coccidiosis is likely to be a hazard; withdraw 24 hours before slaughter.

(2) Amount. 3.2 ounces of crumbles per 250 pounds of body weight per day (10 milligrams per kilogram of body weight).

(i) Indications for use. As an aid in the treatment of coccidiosis caused by Eimeria bovis and E. zurnii.

(ii) Limitations. Administer for 5 consecutive days. For satisfactory diagnosis, a microscopic fecal examination should be done by a veterinarian or diagnostic laboratory before treatment. When treating outbreaks, the drug should be administered promptly after diagnosis is determined. Withdraw 24 hours before slaughter. Use as sole source of amprolium.

§ 520.154c Bacitracin zinc soluble powder.

(a) Specifications. Each pound contains the equivalent of not less than 5 grams of bacitracin.

(b) Sponsor. See No. 010042 in §510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 1 level teaspoonful per 10 pounds of body weight three times daily, mixed in a small quantity of liquid or feed.

(2) Indications for use. Treatment of bacterial enteritis caused by pathogens susceptible to bacitracin and streptomycin such as Escherichia coli, Proteus spp., Staphylococcus spp., and Streptococcus spp., and for the symptomatic treatment of associated diarrhea.

(3) Limitations. If no improvement is noted in 2 to 3 days, diagnosis should be reevaluated. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37322, Aug. 18, 1992, as amended at 61 FR 66581, Dec. 18, 1996]

§ 520.154c Bacitracin zinc soluble powder.

(a) Specifications. Each pound contains the equivalent of not less than 5 grams of bacitracin.

(b) Sponsor. See No. 010042 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.70 of this chapter.

(d) Conditions of use. (1) Broiler chickens—(i) Amount. 100 milligrams per gallon in drinking water.

(2) Growing quail—(i) Amount. 400 milligrams per gallon in drinking water.

(3) Swine—(i) Amount. 1 gram per gallon in drinking water.

(ii) Indications for use. Treatment of swine dysentery associated with Treponema hyodysenteriae. Administer continuously for 7 days or until signs of dysentery disappear.

(iii) Limitations. Prepare a fresh solution daily. Treatment not to exceed 14 days. If symptoms persist after 4 to 5 days consult a veterinarian. Not to be given to swine that weigh more than 250 pounds.

(4) Growing quail—(i) Amount. 400 milligrams per gallon in drinking water.

(ii) Indications for use. For prevention of ulcerative enteritis due to Clostridium colinum susceptible to bacitracin methylene disalicylate.

(iii) Limitations. Prepare fresh solution daily. Use as sole source of drinking water.


§ 520.154b Soluble bacitracin methylene disalicylate and streptomycin sulfate oral powder.

(a) Specifications. Each gram contains 200 units of soluble bacitracin methylene disalicylate, streptomycin sulfate equivalent to 20 milligrams of streptomycin, and 850 milligrams of carob flour.

(b) Sponsor. See No. 062925 in §510.600(c) of this chapter.

§ 520.154c Bacitracin zinc soluble powder.

(a) Specifications. Each pound contains the equivalent of not less than 5 grams of bacitracin.

(b) Sponsor. See No. 010042 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.70 of this chapter.

(d) Conditions of use. (1) Broiler chickens—(i) Amount. 100 milligrams per gallon in drinking water.

(2) Growing quail—(i) Amount. 400 milligrams per gallon in drinking water.

(3) Swine—(i) Amount. 1 gram per gallon in drinking water.

(ii) Indications for use. Treatment of necrotic enteritis caused by Clostridium perfringens susceptible to bacitracin methylene disalicylate.

(iii) Limitations. Prepare a fresh solution daily.

(4) Growing quail—(i) Amount. 400 milligrams per gallon in drinking water.

(ii) Indications for use. For prevention of ulcerative enteritis due to Clostridium colinum susceptible to bacitracin methylene disalicylate.

(iii) Limitations. Prepare fresh solution daily. Use as sole source of drinking water.

§ 520.182 Bicyclohexylammonium fumagillin.

(a) Specifications. The drug is a soluble powder containing bicyclohexylammonium fumagillin and appropriate phosphate buffers.

(b) Sponsor. See No. 059620 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used for the prevention of nosema in honey bees.1

(2) It is administered usually in a 2:1 sugar sirup containing a concentration of from 75 to 100 milligrams of fumagillin activity per gallon of sugar sirup.1

(3) Colonies used for package production should be fed medicated sirup as a principal food supply for a month prior to stocking nuclei or shaking packages for market.1

(4) The medicated sirup should not be fed immediately before or during the honey flow.


§ 520.222 Bunamidine hydrochloride.

(a) Chemical name. N,N-Dibutyl-4-(hexyloxy)-1-naphthamidine hydrochloride.

(b) Specifications. The drug is an oral tablet containing 100, 200, or 400 milligrams of bunamidine hydrochloride.

(c) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(d) Conditions of use. (1) The drug is intended for oral administration to dogs for the treatment of the tapeworms Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus, and to cats for the treatment of the tapeworms Dipylidium caninum and Taenia taeniaeformis.

(2) It is administered to cats and dogs at the rate of 25 to 50 milligrams per kilogram of body weight. The drug should be given on an empty stomach and food should not be given for 3 hours following treatment.

(3) Tablets should not be crushed, mixed with food, or dissolved in liquid. Repeat treatments should not be given within 14 days. The drug should not be given to male dogs within 28 days prior to their use for breeding. Do not administer to dogs or cats having known heart conditions.

(4) For use only by or on the order of a licensed veterinarian.

[47 FR 14702, Apr. 6, 1982, as amended at 53 FR 27651, July 26, 1988]

§ 520.246 Butorphanol tartrate tablets.

(a) Specifications. Each tablet contains 1, 5, or 10 milligrams of butorphanol base activity as butorphanol tartrate.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. The drug is used for the treatment of dogs as follows:

(1) Amount. 0.25 milligram of butorphanol base activity per pound of body weight.

(2) Indications for use. For the relief of chronic nonproductive cough associated with tracheo-bronchitis, tracheitis, tonsillitis, laryngitis, and pharyngitis associated with inflammatory conditions of the upper respiratory tract.

(3) Limitations. For oral use in dogs only. Repeat at intervals of 6 to 12 hours as required. If necessary, increase dose to a maximum of 0.5 milligram per pound of body weight. Treatment should not normally be required for longer than 7 days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[47 FR 14702, Apr. 6, 1982, as amended at 53 FR 27651, July 26, 1988]

§ 520.260 n-Butyl chloride capsules.

(a)(1) Specifications. n-Butyl chloride capsules, veterinary contain 272 milligrams or 816 milligrams of n-butyl chloride in each capsule.

(2) Sponsor. See No. 021091 in §510.600(c) of this chapter.

(3) Conditions of use. (i) It is used for the removal of ascarids (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria stenocephala) from dogs and of the ascarid (Toxocara
Food and Drug Administration, HHS

§ 520.260

(i) These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter.

(ii)(a) Animals should not be fed for 18 to 24 hours before being given the drug. Puppies and kittens should be wormed at 6 weeks of age. However, if heavily infested, they may be wormed at 4 or 5 weeks of age. Administration of the drug should be followed in 1/2 to 1 hour with a teaspoonful to a tablespoonful of milk of magnesia or 1 or 2 milk of magnesia tablets. Normal rations may be resumed 4 to 8 hours after treatment. Puppies and kittens should be given a repeat treatment in a week or 10 days. After that they should be treated every 2 months (or as symptoms reappear) until a year old. When the puppy or kitten is a year old, one treatment every 3 to 6 months is sufficient.

(b)(1) Specifications. n-butyl chloride capsules contain 221, 442, 884, or 1,768 milligrams or 4.42 grams of n-butyl chloride in each capsule.1

(ii)(a) Dogs should not be fed for 18 to 24 hours before being given the drug. Administration of the drug should be followed in 1/2 to 1 hour with a mild cathartic. Normal feeding may be resumed 4 to 8 hours after treatment. Animals subject to reinfection may be retreated in 2 weeks.1

(b) The drug is administered orally to dogs. Capsules containing 221 milligrams of n-butyl chloride are administered to dogs weighing under 5 pounds at a dosage level of 1 capsule per 1 1/2 pounds of body weight. Capsules containing 442 milligrams of n-butyl chloride are administered to dogs weighing under 5 pounds at a dosage level of 1 capsule per 2 1/2 pounds body weight. Capsules containing 884 milligrams of n-butyl chloride are administered to dogs as follows: Weighing under 5 pounds, 1 capsule; weighing 5 to 10 pounds, 2 capsules; weighing 10 to 20 pounds, 3 capsules; weighing 20 to 40 pounds, 4 capsules; over 40 pounds, 5 capsules. Capsules containing 1,768 milligrams of n-butyl chloride are administered at a dosage level of 1 capsule per dog weighing 5 to 10 pounds. Capsules containing 4.42 grams of n-butyl chloride are administered at a dosage level of 1 capsule per dog weighing over 40 pounds or over.1

(iii) A veterinarian should be consulted before using in severely debilitated dogs.1

(c)(1) Specifications. n-Butyl chloride capsules, veterinary contain 884 or 1,768 milligrams or 4.42 grams of n-butyl chloride in each capsule.

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter.
§ 520.300

(2) Sponsor. See No. 000115 in § 510.600(c) of this chapter.

(3) Conditions of use. (i) It is used for the removal of ascarids (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria stenocephala) from dogs.

(ii) (a) Dogs should not be fed for 18 to 24 hours before being given the drug. Administration of the drug should be followed in 1/2 to 1 hour with a mild cathartic. Normal rations may be resumed 4 to 8 hours after treatment.

(b) The drug is administered orally to dogs. Capsules containing 884 milligrams of n-butyl chloride are administered to dogs as follows: weighing under 5 pounds, 1 capsule; weighing 5–10 pounds, 2 capsules; weighing 10–20 pounds, 3 capsules; weighing 20–40 pounds, 4 capsules; over 40 pounds, 5 capsules. Capsules containing 1,768 milligrams of n-butyl chloride are administered at a dosage level of 1 capsule per dog to dogs weighing 5–10 pounds and 2 capsules per dog to dogs weighing 20–40 pounds. Capsules containing 4.42 grams of n-butyl chloride are administered at dosage level of 1 capsule per dog to dogs weighing 40 pounds or over.

(iii) A veterinarian should be consulted before using in severely debilitated dogs.


§ 520.300a Cambendazole oral dosage forms.

§ 520.300b Cambendazole pellets.

(a) Specifications. The drug is in feed pellets containing 5.3 percent cambendazole.

(b) Sponsor. No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used in horses for the control of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles (Trichonema, Poteriostomum, Cyclicobrachytus, Craterostomum, Oesophagodontus); roundworms (Parascaris); pinworms (Oxyuris); and threadworms (Strongyloides).

(2) Administer 20 milligrams cambendazole per kilogram body weight (6 ounces per 1,000 pounds) by mixing with normal grain ration given at one feeding. Doses for individual horses should be mixed and fed separately to assure that each horse will consume the correct amount.

(3) For animals maintained on premises where reinfection is likely to occur, re-treatments may be necessary. For most effective results, re-treat in 6 to 8 weeks.

(4) Not for use in horses intended for food.

(5) Caution: Do not administer to pregnant mares during first 3 months of pregnancy.

(6) Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.300c Cambendazole paste.

(a) Specifications. The drug is a paste containing 45 percent cambendazole.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) It is used in horses for the control of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles (Trichonema, Craterostomum, Oesophagodontus); roundworms (Parascaris); pinworms (Oxyuris); and threadworms (Strongyloides).

(2) Administer 20 milligrams cambendazole per kilogram body weight (5 grams per 550 pounds (250 kilograms)) by depositing the paste on the back of the tongue using a dosing gun.

(3) For animals maintained on premises where reinfection is likely to occur, re-treatments may be necessary. For most effective results, re-treat in 6 to 8 weeks.

(4) Not for use in horses intended for food.

(5) Caution: Do not administer to pregnant mares during first 3 months of pregnancy.

(6) Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.309 Carprofen.

(a) Specifications. Each caplet or chewable tablet contains 25, 75, or 100 milligrams (mg) carprofen.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use in dogs—(1) Amount. 2 mg per pound (lb) of body weight once daily or 1 mg/lb twice daily.

(2) Indications for use. For the relief of pain and inflammation associated with osteoarthritis in dogs.

(3) Limitations. Not for use in pigeons intended for human food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism or when severely ill birds do not respond to treatment.


§ 520.310 Caramiphen ethanesulfonate and ammonium chloride tablets.

(a) Specifications. Each tablet contains 10 milligrams of 5stcaramiphen ethanesulfonate and 80 milligrams of ammonium chloride.1

(b) Sponsor. See No. 050856 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. One tablet per 15 to 30 pounds of body weight every 4 to 6 hours.1

(2) Indications for use. For relief of cough.1

[43 FR 55385, Nov. 28, 1978]

§ 520.312 Carnidazole tablets.

(a) Specifications. Each tablet contains 10 milligrams of carnidazole.

(b) Sponsor. See 053923 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Adult pigeons: 1 tablet (10 milligrams); newly weaned pigeons: ½ tablet (5 milligrams).

(2) Indications for use. For treating trichomoniasis (canker) in ornamental and homing pigeons.

(3) Limitations. Not for use in pigeons intended for human food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism or when severely ill birds do not respond to treatment.

[54 FR 32336, Aug. 7, 1989]

§ 520.314 Cefadroxil tablets.

(a) Specifications. 50-, 100-, and 200-milligram tablets for dogs and cats; 1 gram tablet for dogs.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) For use in dogs as follows:

(i) Indications for use. For the treatment of skin and soft tissue infections including cellulitis, pyoderma, dermatitis, wound infections, and abscesses due to susceptible strains of Staphylococcus aureus. For the treatment of

---

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.
§ 520.315

(2) For use in cats as follows:

(i) Indications for use. For treating skin and soft tissue infections including abscesses, wound infections, cellulitis, and dermatitis caused by susceptible strains of Pasteurella multocida, Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus spp.

(ii) Amount. Ten milligrams per pound of body weight, once daily.

(3) Limitations. Discard unused portion of reconstituted product after 14 days. Treatment should continue for 48 hours after animal is afebrile or asymptomatic. If no response after 3 days, discontinue treatment and reevaluate therapy. Not for use in animals raised for food production. Safe use in pregnant or breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.390 Chloramphenicol oral dosage forms.

§ 520.390a Chloramphenicol tablets.

(a)(1) Specifications. Each tablet contains 100, 250, or 500 milligrams, 1 or 2.5 grams of chloramphenicol.

(2) Sponsor. In §510.600(c) of this chapter: No. 000010 for 100-, 250-, and 500-milligram and 1-gram tablets; No. 000656 for 100-, 250-, and 500-milligram tablets; No. 017030 for 100-milligram tablets; No. 000010 for 100-, 250-, and 500-milligram and 1- and 2.5-gram tablets; No. 000669 for 250-milligram tablets.

(3) Conditions of use. Dogs—(i) Amount. 25 milligrams per pound of body weight every 6 hours.
§ 520.390c Chloramphenicol palmitate oral suspension.

(a) Specifications. Each milliliter contains chloramphenicol palmitate equivalent to 30 milligrams of chloramphenicol.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 25 milligrams per pound of body weight every 6 hours. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis.

(2) Indications for use. Treatment of bacterial pulmonary infections, infections of the urinary tract, enteritis, and infections associated with canine distemper caused by susceptible organisms.
§ 520.420 Chlorothiazide tablets and boluses.

(a)(1) Specifications. Each tablet contains 0.25 gram of chlorothiazide.

(2) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. Usual dosage is 5 to 10 milligrams per pound of body weight two or three times daily.1

(ii) Indications for use. For use in dogs for treatment of congestive heart failure and renal edema.1

(iii) Limitations. (a) Dosage must be adjusted to meet the changing needs of the individual animal. In mild and responsive cases, it is suggested that a dose of 5 milligrams per pound of body weight be administered two or three times daily. In moderately edematous and moderately responsive animals, a dose of 7.5 to 10 milligrams per pound of body weight may be administered three times daily. Severe conditions may require higher doses. Certain animals may respond adequately to intermittent therapy; in these cases, the drug may be administered either every other day or for 3 to 5 days each week.

(b) Animals should be regularly and carefully observed for early signs of fluid and electrolyte imbalance. Take appropriate countermeasures if this should occur. Federal law restricts this drug to use by or on the order of a licensed veterinarian.1

(b)(1) Specifications. Each bolus contains 2 grams of chlorothiazide.

(2) Sponsor. See No. 000006 in § 510.600(c) of this chapter.

(3) Conditions of use—(1) Amount. 2 grams once or twice daily for 3 or 4 days.1

(ii) Indications for use. For use in cattle as an aid in reduction of postparturient udder edema.1

(iii) Limitations. Animals should be regularly and carefully observed for early signs of fluid and electrolyte imbalance. Take appropriate countermeasures if this should occur. Milk taken from dairy animals during treatment and for 72 hours (six milkings) after latest treatment must not be used for food. Federal law restrains this drug to use by or on the order of a licensed veterinarian.1


§ 520.434 Chlorphenesin carbamate tablets.

(a) Specifications. Each tablet contains 400 milligrams of chlorphenesin carbamate.

(b) Sponsor. See No. 000009 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 50 milligrams per pound of body weight on first day; 25 milligrams per pound of body weight each following day. Divide total daily dose into 2 or 3 equal doses administer at 12- or 8-hour intervals.

(2) Indications for use. For use as an adjunct to therapy of acute inflammatory and traumatic conditions of skeletal muscles. The drug provides relief of the signs of discomfort associated with myositis, muscle sprains, traumatic injuries, stifle injuries—especially when administered before or after surgery—and intervertebral disc syndrome (can be used concurrently with adrenal corticosteroids).

(3) Limitations. Not recommended for pregnant animals or those with a known hepatic dysfunction. Periodic liver function studies are recommended for animals on prolonged treatment. If no response is evident within 5 days of

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
the beginning of treatment, the diagnosis should be redetermined and appropriate therapy instituted. Not recommended for use with general anesthetics other than the barbiturates. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.445b Chlortetracycline powder (chlortetracycline hydrochloride or chlortetracycline bisulfate).

(a) Specifications. Chlortetracycline powder contains not less than 15 milligrams per gram chlortetracycline hydrochloride, or chlortetracycline bisulfate equivalent to 25.6, 64 or 102.4 grams per pound (56.4, 141 or 226.6 milligrams per gram) chlortetracycline hydrochloride.

(b) Sponsors. See No. 063389 in § 510.600(c) of this chapter for conditions of use as in paragraph (d) of this section; No. 010042 for conditions of use as in paragraph (d)(4) of this section; No. 000010 for conditions of use as in paragraphs (d)(4)(i)(A) and (B) and (d)(4)(ii) through (iv) of this section; Nos. 017519 and 089130 for conditions of use as in paragraphs (d)(4)(i)(A) and (B) and (d)(4)(ii) and (iii) of this section.

(d) Conditions of use. (1) Swine—(A) Amount. Ten milligrams per pound of body weight daily in divided doses.

(2) Use as chlortetracycline hydrochloride in drinking water as follows:

(i) Calves—(A) Amount. Ten milligrams per pound of body weight daily in divided doses.

(ii) Use as chlortetracycline hydrochloride in a drench or drinking water as follows:

(i) Control and treatment of bacterial enteritis (scours) caused by Escherichia coli and bacterial pneumonia (shipping fever) associated with Pasteurella spp., Actinobacillus pleuropneumoniae (Hemophilus spp.), and Klebsiella spp.

(ii) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; administer for not more than 5 days; do not slaughter animals for food within 24 hours of treatment; do not administer this product with milk or milk replacers; a withdrawal period has not been established in preruminating calves; do not use in calves to be processed for veal.

(3) The following uses of chlortetracycline hydrochloride or chlortetracycline bisulfate in drinking water or drench were reviewed by the National...
§ 520.445c

Academy of Sciences/National Research Council (NAS/NRC) and found effective:

(1) Chickens—(A) Amount. 200 to 400 milligrams per gallon.

(1) Indications for use. Control of infectious synovitis caused by Mycoplasma synoviae.

(2) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 14 days; do not slaughter animals for food within 24 hours of treatment; do not use in laying chickens.

(B) Amount. 400 to 800 milligrams per gallon.

(1) Indications for use. Control of chronic respiratory disease and airsac infections caused by Pasteurella multocida susceptible to chlortetracycline.

(2) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 14 days; do not slaughter animals for food within 24 hours of treatment; do not use in laying chickens.

(C) Amount. One thousand milligrams per gallon.

(1) Indications for use. Control of mortality due to fowl cholera caused by Pasteurella multocida and E. coli.

(2) Limitations. See paragraph (d)(4)(1)(A)(2) of this section.

(ii) Growing turkeys—(A) Amount. 400 milligrams per gallon.

(1) Indications for use. Control of infectious synovitis caused by M. synoviae.

(2) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 14 days; do not slaughter animals for food within 24 hours of treatment.

(B) Amount. 25 milligrams per pound of body weight daily.

(1) Indications for use. Control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis).

(2) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 14 days; do not slaughter animals for food within 24 hours of treatment.

(iii) Swine—(A) Amount. 10 milligrams per pound body weight daily in divided doses.

(B) Indications for use. Control and treatment of bacterial enteritis (scours) caused by E. coli and Salmonella spp. and bacterial pneumonia associated with Pasteurella spp., Actinobacillus pleuropneumoniae (Hemophilus spp.), and Klebsiella spp.

(C) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 5 days; for 000010 and 017519 do not slaughter animals for food within 5 days of treatment; for 010042 do not slaughter animals for food within 24 hours of treatment.

(iv) Calves, beef cattle, and nonlactating dairy cattle—(A) Amount. 10 milligrams per pound daily in divided doses.

(B) Indications for use. Control and treatment of bacterial enteritis (scours) caused by E. coli and Salmonella spp. and bacterial pneumonia (shipping fever complex) associated with Pasteurella spp., A. pleuropneumoniae (Hemophilus spp.), and Klebsiella spp.

(C) Limitations. Prepare fresh solution daily; use as a drench; as sole source of chlortetracycline; do not use for more than 5 days; do not slaughter animals for food within 24 hours of treatment; do not use in lactating cattle; do not administer this product with milk or milk replacers; administer 1 hour before or 2 hours after feeding milk or milk replacers; a withdrawal period has not been established in preruminating calves; do not use in calves to be processed for veal.

§ 520.445c Chlortetracycline tablets and boluses.

(a) Specifications. Each tablet/bolus contains 25, 250, or 500 milligrams of chlortetracycline hydrochloride.

(b) Sponsors. See No. 000010 in §510.600(c) of this chapter for the 250-milligram chlortetracycline hydrochloride bolus; see No. 010042 for the 25-milligram tablet and the 500 milligram bolus.
(c) Related tolerances. See §556.150 of this chapter.

(d) National Academy of Sciences/National Research Council NAS/NRC) status. The conditions of use specified in this section were NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified in §514.111 of this chapter but may require bioequivalence and safety information.

(e) Conditions of use. Calves—(1) Amount. One 250 milligram bolus per 50 pounds of body weight twice a day for 3 to 5 days.

(i) Indications for use. Treatment of bacterial enteritis (scours) caused by Escherichia coli and bacterial pneumonia associated with Pasteurella spp., Klebsiella spp., and Hemophilus spp.

(ii) Limitations. Administer bolus directly by mouth or crush and dissolve in milk or water for drenching or bucket feeding; if no improvement is noted after 3 days of treatment, consult a veterinarian; do not use for more than 5 days; do not administer within 24 hours of slaughter.

(2) Amount. One 25 milligram tablet for each 5 pounds of body weight every 12 hours daily for 3 to 5 days.

(i) Indications for use. Control and treatment of bacterial enteritis (scours) caused by E. coli and Salmonella spp., Hemophilus spp., and Klebsiella spp., susceptible to chlorotetracycline.

(ii) Limitations. Administer tablet directly by mouth or crush and dissolve in water for drenching; if no improvement is noted after 3 days of treatment, consult a veterinarian; do not use for more than 5 days; do not administer within 24 hours of slaughter.

(3) Amount. One 500 milligram bolus per 100 pounds of body weight twice a day for 3 to 5 days.

(i) Indications for use. Treatment of bacterial enteritis (scours) caused by E. coli and Salmonella spp., and bacterial pneumonia associated with Pasteurella spp., Hemophilus spp., and Klebsiella spp., susceptible to chlorotetracycline.

(ii) Limitations. Administer directly by mouth or crush and dissolve in water for drenching; if no improvement is noted after 3 days of treatment, consult a veterinarian; do not use for more than 5 days; do not administer within 24 hours of slaughter.

[57 FR 37325, Aug. 18, 1992]

§ 520.446 Clindamycin hydrochloride capsules.

(a) Specifications. Each capsule contains the equivalent of 25, 75, or 150 milligrams of clindamycin as the hydrated hydrochloride salt.

(b) Sponsor. No 00009 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Wounds, abscesses, and dental infections: 2.5 milligrams per pound of body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

(2) Indications for use. For use in dogs for treatment of soft tissue infections (wounds and abscesses), dental infections, and osteomyelitis caused by susceptible strains of Staphylococcus aureus, soft tissue infections (deep wounds and abscesses), dental infections, and osteomyelitis caused by or associated with susceptible strains of Bacteroides fragilis, Bacteroides melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens.

(3) Limitations. Wound infections, abscesses, and dental infections: Do not use more than 4 days if no improvement of acute infection is observed. Osteomyelitis: Do not use for more than 28 consecutive days if no improvement is observed. Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, and horses. Use with caution in animals receiving neuromuscular blocking agents, because clindamycin may potentiate their action. Prescribe with caution in atopic animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.447 Clindamycin hydrochloride liquid.

(a) Specifications. Each milliliter of 8.64 percent alcoholic solution contains the equivalent of 25 milligrams of clindamycin (as the hydrochloride).

(b) Sponsor. See Nos. 000009 and 059130 in §510.600(c) of this chapter for use as in paragraphs (c) and (d) of this section.

(c) Conditions of use in dogs—(1) Amount. Wounds, abscesses, and dental infections: 2.5 milligrams per pound of body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

(2) Indications for use. For use in dogs for treatment of soft tissue infections (wounds and abscesses), dental infections, and osteomyelitis caused by susceptible strains of Staphylococcus aureus and for soft tissue infections (deep wounds and abscesses), dental infections, and osteomyelitis caused by or associated with susceptible strains of Bacteroides fragilis, Bacteroides melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens.

(3) Limitations. Wound infections, abscesses, and dental infections: Do not use for more than 4 days if no improvement of acute infection is observed. Osteomyelitis: Do not use for more than 28 consecutive days if no improvement is observed. Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas, or ruminating animals. Use with caution in animals receiving neuromuscular blocking agents, because clindamycin may potentiate their action. Prescribe with caution in atopic animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.452 Clenbuterol syrup.

(a) Specifications. Each milliliter contains 72.5 micrograms of clenbuterol hydrochloride.

(b) Sponsor. See 000010 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Horses—(i) Amount. Administer orally twice a day (b.i.d.). Initial dose is 0.5 milliliter per 100 pounds body weight (0.8 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1 milliliter per 100 pounds (1.6 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1.5 milliliters per 100 pounds (2.4 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 2.0 milliliters per 100 pounds (3.2 micrograms per kilogram) for 3 days (6 treatments). If no improvement, horse is non-responsive to clenbuterol and treatment should be discontinued.

(ii) Indications for use. Indicated for the management of horses affected with airway obstruction, such as occurs in chronic obstructive pulmonary disease (COPD).

(iii) Limitations. Treat at effective dose for 30 days. At the end of the 30-day treatment period, drug should be
withdrawn. If signs return, the 30-day treatment period may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated. The effect of this drug on breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended. Federal law prohibits the extralabel use of this drug in food animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.455 Clomipramine hydrochloride tablets.

(a) Specifications. Each tablet contains 20, 40, or 80 milligrams of clomipramine hydrochloride.

(b) Sponsor. See No. 058198 in §510.600(c) of this chapter.

(c) Conditions of use—

(1) Amount. 2 to 4 milligrams of clomipramine hydrochloride per kilogram (0.9 to 1.8 milligrams per pound) of body weight per day, administered as a single daily dose or divided twice daily.

(2) Indications for use. For use as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[64 FR 1762, Jan. 12, 1999]

§ 520.462 Clorsulon drench.

(a) Specifications. The drug is a suspension containing 8.5 percent clorsulon (85 milligrams per milliliter).

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use—

(1) Amount. One-quarter fluid ounce per 200 pounds of body weight (7 milligrams per kilogram or 3.2 milligrams per pound of body weight).

(2) Indications for use. For the treatment of immature and adult liver fluke (Fasciola hepatica) infestations in cattle.

(3) Limitations. Using dose syringe, deposit drench over back of tongue. Do not treat cattle within 8 days of slaughter. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.530 Cythioate oral liquid.

(a) Specifications. Each milliliter contains 15 milligrams of cythioate.

(b) Sponsor. See Nos. 000859 and 010042 in §510.600 of this chapter.

(c) Special considerations. Cythioate is a cholinesterase inhibitor. Do not use this product in animals simultaneously with or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, insecticides, pesticides, or chemicals.

(d) Conditions of use—

(1) Amount. 15 milligrams cythioate per 10 pounds of body weight every third day or twice a week.

(2) Indications for use. Dogs, for control of fleas.

(3) Limitations. For oral use in dogs only. Do not use in greyhounds or in animals that are pregnant, sick, under stress, or recovering from surgery. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[49 FR 5614, Feb. 14, 1984]

§ 520.531 Cythioate tablets.

(a) [Reserved]

(b) Sponsors. See No. 000859 in §510.600(c) of this chapter for use of 30- and 90-milligram (mg) tablets and see No. 010042 in §510.600(c) of this chapter for use of 30-mg tablet.

(c) Special considerations. Cythioate is a cholinesterase inhibitor. Do not use this product in animals simultaneously with or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, insecticides, pesticides, or chemicals.

(d) Conditions of use—

(1) Amount. 30 milligrams cythioate per 20 pounds of body weight every third day or twice a week.

(2) Indications for use. Dogs, for control of fleas.

(3) Limitations. For oral use in dogs only. Do not use in greyhounds or in animals that are pregnant, sick, under
§ 520.534 Decoquinate.

(a) Specifications. The drug is a powder containing 0.8 percent decoquinate.

(b) Sponsor. See No. 045773 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.170 of this chapter.

(d) Conditions of use. Calves—

(1) Amount. Feed 22.7 milligrams per 100 pounds of body weight (0.5 milligram per kilogram) per day.

(2) Indications for use. For the prevention of coccidiosis in ruminating and nonruminating calves, including veal calves, caused by Eimeria bovis and E. zuernii.

(3) Limitations. Feed in whole milk at the rate of 22.7 milligrams per 100 pounds body weight daily (0.5 milligram per kilogram) for at least 28 days.

[64 FR 10103, Mar. 2, 1999, as amended at 64 FR 30386, June 8, 1999]

§ 520.540 Dexamethasone oral dosage forms.

§ 520.540a Dexamethasone powder.

(a) Specifications. Dexamethasone powder is packaged in packets containing 10 milligrams of dexamethasone.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use. (1) Dexamethasone powder is indicated in cases where cattle and horses require additional steroid therapy following its parenteral administration. The drug is used as supportive therapy for management of inflammatory conditions such as acute arthritic lameness, and for various stress conditions where corticosteroids are required while the animal is being treated for a specific condition.

(ii) Administered orally, 5 to 10 milligrams for the first day, then 5 milligrams per day as required.

(iii) Do not use in viral infections during the viremic stage. With bacterial infections, appropriate antibacterial therapy should be used.

(iv) Do not use in animals with chronic nephritis and hypercorticalism (cushingoid syndrome), except for emergency therapy.

(v) Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(vi) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b) (1) Specifications. Each bolus is half-scored and contains 10 milligrams of dexamethasone.

(2) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(3) Conditions of use. (i) Dexamethasone bolus is indicated in cases where cattle and horses require additional steroid therapy following its parenteral administration. The drug may be used as supportive therapy for management of inflammatory conditions such as acute arthritic lamenesses, and for various stress conditions where corticosteroids are required while the animal is being treated for a specific condition.

(ii) Administered orally, 5 to 10 milligrams for the first day, then 5 milligrams per day as required.

(iii) Do not use in viral infections during the viremic stage. With bacterial infections, appropriate antibacterial therapy should be used.

(iv) Do not use in animals with chronic nephritis and hypercorticalism (cushingoid syndrome), except for emergency therapy.

(v) Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(vi) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.540b Dexamethasone tablets and boluses.

(a)(1) Specifications. Each tablet contains 0.25 milligram of dexamethasone.

(b)(1) Specifications. Each bolus is half-scored and contains 10 milligrams of dexamethasone.

(2) Sponsor. See Nos. 000061 and 061133 in §510.600(c) of this chapter.

1 CFR Ch. 1 (4–1–02 Edition)
§ 520.550 Dextrose/glycine/electrolyte.

(a) Specifications. The product is distributed in packets each of which contains the following ingredients: sodium chloride 8.82 grams, potassium phosphate 4.20 grams, citric acid anhydrous 0.5 gram, potassium citrate 0.12 gram, aminoacetic acid (glycine) 6.36 grams, and dextrose 44.0 grams.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use. (1) Dextrose/glycine/electrolyte is indicated for use in the control of dehydration associated with diarrhea (scours) in calves. It is used as an early treatment at the first signs of scouring. It may also be used as followup treatment following intravenous fluid therapy.

(2) Dissolve each packet in two quarts of warm water and administer to each calf as follows:

(i) Scouring and/or dehydrated calves. Feed 2 quarts of solution, twice daily for 2 days (four feedings). No milk or milk replacer should be fed during this period. For the next four feedings (days 3 and 4), use 1 quart of solution together with 1 quart of milk replacer. Thereafter, feed as normal.

(ii) Newly purchased calves. Feed 2 quarts of solution instead of milk as the first feed upon arrival. For the next scheduled feeding, use 1 quart of solution mixed together with 1 quart of milk or milk replacer. Thereafter, feed as normal.

§ 520.540c Dexamethasone chewable tablets.

(a) Specifications. Each half-scored tablet contains 0.25 milligram of dexamethasone.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. 0.25 to 1.25 milligrams per day.

(2) Indications for use. Supportive therapy in nonspecific dermatosis and inflammatory conditions in dogs.

(3) Limitations. (i) Administer by free-choice feeding or crumble over food. Administer 0.25 to 1.25 milligrams daily in single or two divided doses until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced by 0.125 milligram per day until maintenance level is achieved.

(ii) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy; and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(iii) Do not use in viral infections. Anti-inflammatory action of corticosteroids may mask signs of infection. Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, except for emergency therapy.

(iv) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.550 Food and Drug Administration, HHS

(3) Conditions of use—(i) Amount. Dogs: Administer orally at 0.25 to 1.25 milligrams per day for up to 7 days. Cats: 0.125 to 0.5 milligram per day for up to 7 days.

(ii) Indications for use. In treatment of dogs and cats as an anti-inflammatory agent.

(iii) Limitations. (a) Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy; and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(b) Do not use in viral infections. Anti-inflammatory action of corticosteroids may mask signs of infections. Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, except for emergency therapy.

(c) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.563 Diatrizoate meglumine and diatrizoate sodium oral solution.

(a) Specifications. Diatrizoate meglumine oral solution is a water soluble radiopaque medium containing 66 percent diatrizoate meglumine and 10 percent diatrizoate sodium.

(b) Sponsor. See No. 053501 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) It is indicated for radiography of the gastrointestinal tract in dogs and cats.

(2) It is administered orally at a dosage level of 0.5 to 1.0 milliliter per pound of body weight by gavage or stomach tube. It is administered rectally at a dosage level of 0.5 to 1.0 milliliter per pound of body weight diluted with 1 part of the drug to 5 parts of water.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[44 FR 12993, Mar. 9, 1979, as amended at 50 FR 41480, Oct. 11, 1985]

§ 520.580 Dichlorophene and toluene capsules.

(a) Specifications. Each soft gelatin capsule contains 50 milligrams of dichlorophene and 60 milligrams of toluene or multiples thereof.1

(b) Sponsor. (1) For single dose only, see 000010, 000061, 000115, 000842, 011615, 017135, 023851, 049968, 059906, and 058670 in § 510.600(c) of this chapter.

(2) For single and multiple dose, see 000010, 000061, and 038782 in § 510.600(c) of this chapter.

(c) Required statement. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism, and before administering to weak or debilitated animals.

(d) Conditions of use—(1) Amount. (i) Single dose of 100 milligrams of dichlorophene and 120 milligrams of toluene per pound of body weight.1

(ii) Divided dose of 100 milligrams of dichlorophene and 120 milligrams of toluene per 5 pounds of body weight (20 and 24 milligrams per pound) daily for 6 days.1

(2) Indications for use. It is used for the removal of ascarids (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala) and as an aid in removing tapeworms (Taenia pisiformis, Dipylidium caninum, and Echinococcus granulosus) from dogs and cats.1

(3) Limitations. Withhold solid foods and milk for at least 12 hours prior to medication and for 4 hours afterward. Repeat treatment in 2 to 4 weeks in animals subject to reinfection.1

[45 FR 10332, Feb. 15, 1980]

EDITORIAL NOTE: For Federal Register citations affecting § 520.580, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

§ 520.581 Dichlorophene tablets.

(a) Specifications. Each tablet contains 1 gram of dichlorophene.

(b) Sponsor. See 023851 in § 510.600(c) of this chapter.

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.
§ 520.600 Dichlorvos.

(a) Chemical name. 2,2-Dichlorvinyl dimethyl phosphate.

(b) [Reserved]

(c) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(d) Related tolerances. See § 556.180 of this chapter.

(e) Conditions of use in swine. (1) It is recommended for the removal and control of sexually mature (adult), sexually immature and/or 4th stage larvae of the whipworm (*Trichuris suis*), nodular worms (*Oesophagostomum* spp.), large round-worm (*Ascaris suum*), and the mature thick stomach worm (*Ascarops strongyline*) occurring in the lumen of the gastrointestinal tract of pigs, boars, and open or bred gilts and sows.

(2) The preparation should be added to the indicated amount of feed as set forth in paragraph (e)(2) of this section and administered shortly after mixing, as follows:

<table>
<thead>
<tr>
<th>Weight of animal in pounds</th>
<th>Pounds of feed to be mixed with each 0.08 ounce of dichlorvos</th>
<th>Pounds of mixed feed to be administered to each pig as a single treatment</th>
<th>Number of pigs to be treated per 0.08 ounce of dichlorvos</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–30</td>
<td>4</td>
<td>0.33</td>
<td>12</td>
</tr>
<tr>
<td>31–40</td>
<td>5</td>
<td>0.56</td>
<td>9</td>
</tr>
<tr>
<td>41–60</td>
<td>6</td>
<td>1.00</td>
<td>6</td>
</tr>
<tr>
<td>61–80</td>
<td>5</td>
<td>1.00</td>
<td>5</td>
</tr>
<tr>
<td>81–100</td>
<td>4</td>
<td>1.00</td>
<td>4</td>
</tr>
<tr>
<td>Adult Gilts, Sows, and Boars</td>
<td>16</td>
<td>4.00</td>
<td>4</td>
</tr>
</tbody>
</table>

(3) Do not use this product on animals either simultaneously or within a few days before or after treatment with or exposure to cholinesterase inhibiting drugs, pesticides, or chemicals. The preparation should be mixed thoroughly with the feed on a clean, impervious surface. Do not allow swine access to feed other than that containing the preparation until treatment is complete. Do not treat pigs with signs of scours until these signs subside or are alleviated by proper medication. Resume normal feeding schedule afterwards. Swine may be retreated in 4 to 5 weeks.

(1) Conditions of use in dogs. (1) For removal of *Toxocara canis* and *Toxascaris leonina* (roundworms), *Ancylostoma caninum* and *Uncinaria stenocephala* (hookworms), and *Trichuris vulpis* (whipworm) residing in the lumen of the gastrointestinal tract.

(2) The drug is in capsule form for direct administration and in pellet form for administration in about one-third of the regular canned dog food ration or in ground meat. Dogs may be treated with any combination of capsules and/or pellets so that the animal receives a single dose equaling 12 to 15 milligrams of the active ingredient per pound of body weight. One-half of the single recommended dosage may be given, and the other half may be administered 8 to 24 hours later. This split dosage schedule should be used in animals which are very old, heavily parasitized, anemic, or otherwise debilitated. The drug should not be used in dogs weighing less than 2 pounds.

(3) In some dogs, efficacy against *Trichurias vulpis* (whipworm) may be erratic. Dogs that do not develop a negative stool for *Trichuris vulpis* ova 10 to 14 days following initial treatment should be re-treated. If a negative stool is not obtained in 10 to 14 days following re-treatment, alternate means of therapy should be considered.

(4) Do not use in dogs infected with *Dirofilaria immitis*.

(5) Do not use with other anthelmintics, taeniacides, antifilarial agents, muscle relaxants, or tranquilizers.

(6) The drug is a cholinesterase inhibitor. Not for use simultaneously or
§ 520.600
within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(7) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(g) Conditions of use in horses when administered in grain. (1) It is recommended for the removal and control of bots (Gastrophilus intestinalis, G. nasalis), large strongyles (Strongylus vulgaris, S. equinus, S. edentatus), small strongyles (of the genera Cyathostomum, Cylicocercus, Cylicocyclus, Cylicodontophorus, Triodontophorus, Poteriostomum, Gyaloccephalus), pinworms (Oxyuris equi), and large roundworm (Parascaris equorum) in horses including ponies and mules. Not for use in foals (sucklings and young weanlings).

(2) For a satisfactory diagnosis, a microscopic fecal examination should be performed by a veterinarian or a diagnostic laboratory prior to worming.

(3) It is administered in the grain portion of the ration at a dosage of 14.2 milligrams to 18.5 milligrams per pound of body weight as a single dose. It may be administered at one-half of the single recommended dosage and repeated 8 to 12 hours later in the treatment of very aged, emaciated or debilitated subjects or those reluctant to consume medicated feed. In suspected cases of severe ascarid infection sufficient to cause concern over mechanical blockage of the intestinal tract, the split dosage should be utilized.

(4) Do not use in horses which are severely debilitated, suffering from diarrhea or severe constipation, infectious disease, toxemia or colic. Do not administer in conjunction with or within 1 week of administration of muscle relaxant drugs, phenothiazine derived tranquilizers or central nervous system depressant drugs. Horses should not be subjected to insecticide treatment for 5 days prior to or after treating with the drug. Do not administer to horses afflicted with chronic alveolar emphysema (heaves) or related respiratory conditions. The product is a cholinesterase inhibitor and should not be used simultaneously or within a few days before or after treatment with or exposure to cholinesterase inhibiting drugs, pesticides or chemicals.

(5) Do not use in animals other than horses, ponies, and mules. Do not use in horses, ponies, and mules intended for food purposes. Do not allow fowl access to feed containing this preparation or to fecal excrement from treated animals.

(h) Conditions of use in horses when administered orally by syringe. (1) It is recommended for the removal and control of first, second, and third instar bots (Gastrophilus intestinalis and G. nasalis), sexually mature and sexually immature (4th stage) ascarids (Parascaris equorum) in horses and foals.

(2) The product is in the form of a gel which is administered directly from a syringe onto the horse's tongue. The product is administered at a dosage level of 20 milligrams of dichlorvos per kilogram of body weight for the removal of bots and ascarids. The same dosage level is repeated every 21 to 28 days for the control of bots and ascarids. For the control of bots only, the repeat dosage is 10 milligrams per kilogram of body weight every 21 to 28 days during bot fly season.

(3) Do not use this product in animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides or chemicals. Do not administer in conjunction with or within 1 week of administration of muscle-relaxant drugs, phenothiazine derived tranquilizers, or central nervous system depressants.

(4) Do not use in horses which are severely debilitated or suffering from diarrhea or severe constipation, infectious disease, toxemia, or colic. Do not administer to horses affected with chronic alveolar emphysema (heaves) or other respiratory conditions.

(5) Do not use in horses intended for food purposes.

(6) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(i) Conditions of use in dogs, cats, puppies, and kittens. (1) Each tablet contains 2, 5, 10, or 20 milligrams of dichlorvos.

(2) It is administered orally at 5 milligrams of dichlorvos per pound of body weight.
(3) Dogs and puppies: Removal and control of intestinal roundworms (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).

(4) Cats and kittens: Removal and control of intestinal roundworms (Toxocara cati and Toxascaris leonina) and hookworms (Ancylostoma tubaeforme and Uncinaria stenocephala).

(5) Dichlorvos is a cholinesterase inhibitor. Do not use simultaneously with or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(6) Do not use in animals under 10 days of age or 1 pound of body weight.

(7) Do not administer to animals showing signs of constipation, mechanical blockage of the intestinal tract, impaired liver function, or recently exposed to or showing signs of infectious disease.

(8) Do not use in dogs or puppies infected with Dirofilaria immitis.

(9) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.608 Diocloxacinil sodium monohydrate capsules.

(a) Specifications. Each capsule contains diocloxacinil sodium monohydrate equivalent to 50, 100, 200, or 500 milligrams of diocloxacinil.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 5 to 10 milligrams per pound of body weight, three times daily. In severe cases, up to 25 milligrams per pound of body weight three times daily.

(2) Indications for use. Treatment of pyoderma (pyogenic dermatitis) due to penicillinase-producing staphylococci sensitive to the drug.

(3) Limitations. For the treatment of dogs only. Continue treatment for 24 to 48 hours after the animal has become afebrile or asymptomatic. Administer 1 to 2 hours before feeding to ensure maximum absorption. Not for use in animals which are raised for food production. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37325, Aug. 18, 1992]

§ 520.620 Diethycarbamazine oral dosage forms.

§ 520.622 Diethycarbamazine citrate oral dosage forms.

§ 520.622a Diethycarbamazine citrate tablets.

(a) Sponsors. (1) See 015579 in § 510.600(c) of this chapter for use of 50, 200, and 400 milligram tablets for prevention of heartworm disease in dogs and as an aid in the treatment of ascarid infections in dogs and cats.

(2) See 053501 in § 510.600(c) of this chapter for use of 100, 200, and 300 milligram tablets for prevention of heartworm disease in dogs and as an aid in the treatment of ascarid infections in dogs.

(3) See 061133 in § 510.600(c) of this chapter for use of 50, 100, 200, 300, or 400 milligram tablets for prevention of heartworm disease in dogs, as an aid in the control of ascarid infections in dogs, and as an aid in the treatment of ascarid infections in dogs and cats.

(4) See 017030 in § 510.600(c) of this chapter for use of 50, 100, 200, 300, and 400 milligram tablets for prevention of heartworm disease in dogs and as an aid in the treatment of ascarid infections in dogs and cats.

(5) See 000081 in § 510.600(c) of this chapter for use of 60, 120, or 180 milligram tablets for prevention of heartworm disease in dogs, as an aid in the control of ascarid infections in dogs, and as an aid in the treatment of ascarid infections in dogs and cats.

(6) See No. 000010 in § 510.600(c) of this chapter for use of 50, 100, 200, 300, or 400 milligram tablets for prevention of heartworm disease in dogs, as an aid in the control of ascarid infections in dogs, and as an aid in the treatment of ascarid infections in dogs and cats.

(b) Conditions of use—(1) Dosage/indications for use. (i) Three milligrams per pound of body weight daily for prevention of heartworm disease (Dirofilaria immitis) in dogs.
§ §520.622b Diethylcarbamazine citrate syrup.

(a)(1) Specifications. Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.

(2) Sponsor. See No. 053501 in §510.600(c) of this chapter.

(b)(3) Conditions of use. (i) The drug is indicated for use in dogs for the prevention of infection with Dirofilaria immitis and T. canis and T. leonina. It is also indicated for treatment of ascariid infections of T. canis and T. leonina in dogs and T. cati in cats.

(ii) For prevention of heartworm and ascariid infections in dogs, the drug may be added to the daily diet at a dosage rate of 3.0 milligrams per pound of body weight per day or given directly by mouth at the same dosage rate. For treatment of ascariid infections in dogs and cats, the drug is administered at a dosage level of 25 to 50 milligrams per pound of body weight preferably administered immediately after feeding.

(iii) Older dogs should be proven negative for the presence of Dirofilaria immitis infection before administration of the drug. Those with proven infection of Dirofilaria immitis should be rendered negative using adulticidal and microfilaricidal drugs before administration of this drug.

(iv) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) Specifications. Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.

(2) Sponsors. (i) See No. 017030 for use as in paragraphs (b)(3)(i)(a) and (b)(3)(i)(c) of this section.

(ii) See No. 017030 for use as in paragraphs (b)(3)(ii) (a) and (c) of this section.

(3) Conditions of use—(1) Amount. 3 milligrams per pound of body weight per day for prevention of heartworm disease and as an aid in control of large roundworms; 25 to 50 milligrams per pound of body weight as an aid in treatment of ascariid infections.

(ii) Indications for use. (a) For prevention of heartworm disease (Dirofilaria immitis) in dogs.

(b) As an aid in control of large roundworms (T. canis) in dogs.

(c) As an aid in treatment of ascariid infections in dogs (T. canis) and cats (T. canis and T. leonina).

(iii) Limitations. The drug may be placed on the daily ration or given directly by mouth. For treatment of ascariid infections, a repeat dose should be given in 10 to 20 days to remove immature worms which may enter the intestine from the lungs after the first dose. Older dogs should be proven negative for presence of Dirofilaria immitis infections before administering the drug. Dogs with established heartworm infections should not receive the drug until they have been converted to a negative status by the use of adulticidal and microfilaricidal drugs.
Inadvertent administration to heartworm-infected dogs may cause adverse reactions due to pulmonary occlusion. Overdosage may cause emesis. For prevention of heartworm disease in heartworm-endemic areas, administration of the drug should start 1 month before the mosquito season and be continued daily throughout the mosquito season and for 2 months thereafter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c)(1) Specifications. Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.

(2) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(3) Conditions of use. (i) The drug is used in dogs between 4 weeks and 8 months of age for the removal of ascarids (Toxocara canis) and in animals over 4 weeks of age for the prevention of heartworm disease (Dirofilaria immitis).

(ii) The drug is administered (a) for removal of ascarids at a dosage of 50 milligrams per pound of body weight divided into two equal doses and administered 8 to 12 hours apart (morning and night), orally or mixed with either dry or wet food, and (b) for prevention of heartworm disease at a dosage of 3 milligrams per pound of body weight daily, orally or in food, in heartworm endemic areas, from the beginning of mosquito activity, during the mosquito season, and for 2 months following the end thereof.

(iii) Dogs older than 8 months of age may be infected with Dirofilaria immitis. Use of the drug is contraindicated in dogs with active D. immitis infections.

(iv) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§520.622c
diethylcarbamazine citrate chewable tablets.

(a) Specifications. Each chewable tablet contains 30, 45, 60, 120, 150, or 180 milligrams of diethylcarbamazine citrate.

(b) Sponsors. See drug listing nos. in §510.600(c) of this chapter for identification of sponsors as follows:

(1) For 015579, use of 30 or 120 milligram tablets as in paragraph (c)(2)(i) of this section.

(2) For 000069, use of 60, 120, or 180 milligram tablets as in paragraph (c)(2)(ii) of this section.

(3) For 061690, use of 45 or 150 milligram tablets as in paragraph (c)(2)(iii) of this section.

(4) For 061133, use of 60-, 120-, or 180-milligram tablets as in paragraph (c)(2)(i) of this section.

(5) For 000061, use of 60-milligram tablets as in paragraph (c)(2)(i) of this section.

(6) For 000010, use of 30, 60, 120, or 180-milligram tablets as in paragraph (c)(2)(i) of this section.

(7) Reserved

(c) Conditions of use—(1) Amount. 3 milligrams per pound of body weight per day for prevention of heartworm disease and control of ascarids; 25 to 50 milligrams per pound of body weight as an aid in treatment of ascarid infections.

(2) Indications for use. (i) For prevention of heartworm disease (Dirofilaria immitis) in dogs; as an aid in control of ascarids (Toxocara canis) in dogs; as an aid in treatment of ascarid (Toxocara canis and Toxascaris leonina) infections in dogs and cats.

(ii) For prevention of infection with Dirofilaria immitis (heartworm disease) in dogs; as an aid in treatment of ascarid (Toxocara canis and Toxascaris leonina) infections in dogs.

(iii) For prevention of heartworm disease (Dirofilaria immitis) in dogs.

(3) Limitations. Tablets are administered orally or pulverized and given in the feed. For treatment of ascarid infections, a repeat dose should be given in 10 to 20 days to remove immature worms which may enter the intestine from the lungs after the first dose. Dogs with established heartworm infections should not receive the drug until they have been converted to a negative status by the use of adulticidal and microfilaricidal drugs. Inadvertent administration to heartworm-infected dogs may cause adverse reactions due to pulmonary occlusion. Overdosage may cause emesis. For prevention of
§ 520.622d **Diethylcarbamazine citrate capsules.**

(a)(1) **Specifications.** Each capsule contains either 12.5, 50, 200, or 400 milligrams of diethylcarbamazine citrate.

(2) **Sponsor.** See 011014 in § 510.600(c) of this chapter.

(3) **Conditions of use—(1) Amount/indications for use.** 3 milligrams per pound of body weight daily for prevention of heartworm disease (*Dirofilaria immitis*) in dogs.

(ii) **Limitations.** Capsules may be administered to the dog directly or added to the daily ration. For oral administration only. Do not treat dogs with established heartworm infections until they have been converted to a negative status by the use of adulticidal and microfilaricidal drugs. Inadvertent administration to heartworm infected dogs may cause adverse reactions due to pulmonary occlusion or shock. For prevention of heartworm disease in heartworm-endemic areas, administration of the drug should begin 1 month before and continue 2 months after the mosquito season. Dogs receiving prophylactic therapy should be examined every 6 months for the presence of microfilariae. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) **Specifications.** Each tablet contains either 60, 120, or 180 milligrams of diethylcarbamazine citrate with 45, 91, or 136 milligrams of oxibendazole, respectively.

(b) **Sponsor.** See 000069 in § 510.600(c) of this chapter.

(c) **Conditions of use in dogs—(1) Amount.** Administer orally to dogs at a dosage level of 6.6 milligrams of diethylcarbamazine citrate per kilogram of body weight (3 milligrams per pound of body weight) and 5.0 milligrams of oxibendazole per kilogram of body weight (2.27 milligrams per pound of body weight).

(2) **Indications for use.** For prevention of infection with *Dirofilaria immitis* (heartworm disease) and *Ancylostoma caninum* (hookworm infection) and for removal and control of *Trichurus vulpis* (whipworm infection) and mature and immature stages of intestinal *Toxocara canis* (ascarid infection).
§ 520.645 Difloxacin.

(a) Specifications. Each tablet contains 11.4, 45.4, or 136 milligrams (mg) of difloxacin hydrochloride.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Dogs—(i) Amount. 5 to 10 mg per kilogram (2.3 to 4.6 mg/pound) of body weight.

(ii) Indications for use. For management of diseases in dogs associated with bacteria susceptible to difloxacin.

(iii) Limitations. Use once a day for 2 to 3 days beyond cessation of clinical signs of disease up to a maximum of 30 days. Federal law prohibits the extra-label use of this drug in food-producing animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

[63 FR 8123, Feb. 18, 1998]

§ 520.763 Dithiazanine iodide oral dosage forms.

§ 520.763a Dithiazanine iodide tablets.

(a) Chemical name. 3-Ethyl-2-[5-(3-ethyl-2-benzothiazolyl)[1,3-pentadienyl]-benzothiazolium iodide.

(b) Specifications. Dithiazanine iodide tablets contain 10 milligrams, 50 milligrams, 100 milligrams, or 200 milligrams of dithiazanine iodide in each tablet.

(c) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(d) Conditions of use. (1) The tablets are administered orally to dogs immediately after feeding using the following dosage schedule for various parasite infestations:

<table>
<thead>
<tr>
<th>Milligrams per pound of body weight</th>
<th>Length of treatment—days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large roundworms (Toxocara canis, Toxascaris leonina)</td>
<td>10</td>
</tr>
<tr>
<td>Hookworms (Ancylostoma caninum, Uncinaria stenocephala)</td>
<td>10</td>
</tr>
<tr>
<td>Whipworms (Trichuris vulpis)</td>
<td>10</td>
</tr>
<tr>
<td>Strongyloides canis, Strongyloides stercoralis</td>
<td>10</td>
</tr>
<tr>
<td>Heartworm microfilariae (Dirofilaria immitis)</td>
<td>3–5</td>
</tr>
</tbody>
</table>

Note: Treatment with dithiazanine iodide for heartworm microfilariae should follow 6 weeks after therapy for adult worms.

(2) The drug is contraindicated in animals sensitive to dithiazanine iodide and should be used cautiously, if at all, in dogs with reduced renal function.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(e) Use for treating dogs for large roundworms, hookworms, whipworms, and strongyloides as provided for in this section has been NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.


§ 520.763b Dithiazanine iodide powder.

(a) Chemical name. 3-Ethyl-2-[5-(3-ethyl-2-benzothiazolyl)[1,3-pentadienyl]-benzothiazolium iodide.

(b) Specifications. Dithiazanine iodide powder contains 200 milligrams of dithiazanine iodide per level standard tablespoon.

(c) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(d) Conditions of use. (1) Dithiazanine iodide powder is administered to dogs by mixing the proper dosage in the dog’s food, using the following dosage schedule for various parasite infestations:

<table>
<thead>
<tr>
<th>Milligrams per pound of body weight</th>
<th>Length of treatment—days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large roundworms (Toxocara canis, Toxascaris leonina)</td>
<td>10</td>
</tr>
</tbody>
</table>
§ 520.763c Dithiazanine iodide and piperazine citrate suspension.

(a) Specifications. Each milliliter of the drug contains 69 milligrams of dithiazanine iodide and 83 milligrams of piperazine base (as piperazine citrate).

(b) Sponsor. See 000010 in § 510.600(c) of this chapter.

(c) NAS/NRC status. The conditions of use are NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.

(d) Conditions of use—(1) Amount. 1 ounce (30 milliliters) per 100 pounds of body weight for the first 500 pounds; 3/4 ounce for each 100 pounds thereafter, up to 1,200 pounds; 10% ounces to animals over 1,200 pounds.

(2) Indications for use. For control of large roundworms, Parascaris equorum; small strongyles; large strongyles, Strongylus vulgaris; and pinworms, Oxyuris equi.

(3) Limitations. Administer by drench or mixed with the daily ration as a single dose. Treatment is recommended in spring and fall. In a heavily infested environment, treatment may be repeated every 30 days. Not for use in horses intended for food purposes. Severely debilitated animals should not be wormed except on the advice of a veterinarian. If the drug is for administration by stomach tube, it shall be labeled: “Federal law restricts this drug to use by or on the order of a licensed veterinarian.”


§ 520.784 Doxylamine succinate tablets.

(a) Specifications. The drug is in tablet form and contains doxylamine succinate as the active drug ingredient.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in conditions in which antihistaminic therapy may be expected to alleviate some signs of disease in horses, dogs, and cats.1

(2) It is administered orally to horses at a dosage level of 1 to 2 milligrams per pound of body weight per day divided into 3 or 4 equal doses. It is administered orally to dogs and cats at a dosage level of 2 to 3 milligrams per pound of body weight per day divided into 3 or 4 equal doses.1

(3) Not for use in horses intended for food.1

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.1


1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter.
§ 520.804 Enalapril tablets.
(a) Specifications. Each tablet contains either 1.0, 2.5, 5.0, 10.0, or 20.0 milligrams of enalapril maleate.
(b) Sponsor. See §510.600(c) of this chapter.
(c) Conditions of use—(1) Dogs—(i) Amount. 0.5 to 1.0 milligram of enalapril maleate per kilogram of body weight per day.
(ii) Indications for use. Treatment of mild, moderate, and severe (modified New York Heart Association Class II, III, IV) heart failure in dogs.
(iii) Limitations. Use 0.5 milligram per kilogram once daily. In the absence of adequate clinical response within a 2-week period, use may be increased to twice daily (a total of 1.0 milligram per kilogram). Enalapril maleate is administered as conjunctive therapy with furosemide and digoxin in the treatment of dilated cardiomyopathy and furosemide with or without digoxin in the treatment of chronic valvular disease. The safety of enalapril for use in breeding dogs has not been established. Use in pregnant bitches is not recommended. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) [Reserved]

§ 520.805 Enrofloxacin tablets.
(a) Specifications. Each tablet contains 22.7, 68.0, or 136.0 milligrams of enrofloxacin.
(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. 5 to 20 milligrams per kilogram (2.27 to 9.07 milligrams per pound) of body weight.
(2) Indications for use. Dogs and cats for management of diseases associated with bacteria susceptible to enrofloxacin.
(3) Limitations. Administer orally as a single dose or divided into 2 equal doses at 12 hour intervals, daily. Administer for at least 2 to 3 days beyond cessation of clinical symptoms, for a maximum of 30 days. Safety in breeding or pregnant cats has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.811 Enrofloxacin oral solution.
(a) Specifications. Each milliliter of concentrate solution contains 32.3 milligrams of enrofloxacin.
(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.228 of this chapter.
(d) Conditions of use. It is used in drinking water as follows:
(1) Chickens and turkeys—(i) Amount. 25 to 50 parts per million of enrofloxacin in drinking water.
(ii) Indications. Chickens: Control of mortality associated with Escherichia coli susceptible to enrofloxacin. Turkeys: Control of mortality associated with E. coli and Pasteurella multocida (fowl cholera) susceptible to enrofloxacin.
(iii) Limitations. Do not use in laying hens producing eggs for human consumption. Administer medicated water continuously as sole source of drinking water for 3 to 7 days. Prepare fresh stock solution daily. Effects on the reproductive function of turkeys have not been determined. Treated animals must not be slaughtered for food within 2 days of the last treatment. Individuals with a history of hypersensitivity to quinolones should avoid exposure to this product. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) [Reserved]

§ 520.812 Epsiprantel tablets.
(a) Specifications. Each tablet contains 12.5, 25, 50, or 100 milligrams of epsiprantel.
(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.
(c) Conditions of use—(1) Dogs—(i) Amount. 2.5 milligrams per pound of body weight.
(2) Cats—(i) Amount. 1.25 milligrams per pound of body weight.
§ 520.823 Erythromycin phosphate.

(a) Specifications. Erythromycin phosphate is the phosphate salt of the antibiotic substance produced by the growth of *Streptomyces erythreus* or the same antibiotic substance produced by any other means. One gram of erythromycin phosphate is equivalent to 0.89 gram of erythromycin master standard.

(b) Sponsor. See No. 061133 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.230 of this chapter.

(d) Conditions of use. It is used in drinking water as follows:

(1) Broiler and replacement chickens—(i) Amount. 0.500 gram per gallon.

(ii) Indications for use. As an aid in the control of chronic respiratory disease due to *Mycoplasma gallisepticum* susceptible to erythromycin.

(iii) Limitations. Administer for 5 days; do not use in replacement pullets over 16 weeks of age; do not use in chickens producing eggs for human consumption; to assure effectiveness, treated birds must consume enough medicated water to provide a therapeutic dosage; solutions older than 3 days should not be used; withdraw 1 day before slaughter.

(2) Replacement chickens and chicken breeders—(i) Amount. 0.500 gram per gallon.

(ii) Indications for use. As an aid in the control of infectious coryza due to *Hemophilus gallinarum* susceptible to erythromycin.

(iii) Limitations. Administer for 7 days; do not use in replacement pullets over 16 weeks of age; do not use in chickens producing eggs for human consumption; to assure effectiveness, treated birds must consume enough medicated water to provide a therapeutic dosage; solutions older than 3 days should not be used; withdraw 1 day before slaughter.

(3) Growing turkeys—(i) Amount. 0.500 gram per gallon.

(ii) Indications for use. As an aid in the control of blue comb (nonspecific infectious enteritis) caused by organisms susceptible to erythromycin.

(iii) Limitations. Administer for 7 days; do not use in turkeys producing eggs for human consumption; to assure effectiveness, treated birds must consume enough medicated water to provide a therapeutic dosage; solutions older than 3 days should not be used; withdraw 1 day before slaughter.

§ 520.863 Ethylisobutrazine hydrochloride tablets.

(a) Specifications. Each tablet contains either 10 milligrams or 50 milligrams of ethylisobutrazine hydrochloride.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) It is administered orally to dogs as a tranquilizer.

(2) It is administered once daily at a dosage level of 2 to 5 milligrams of ethylisobutrazine hydrochloride per pound of body weight.

(3) It is not to be used in conjunction with organophosphates and/or procaine hydrochloride because phenothiazine may potentiate the toxicity of organophosphates and the activity of procaine hydrochloride.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.
§ 520.870 Etodolac.
(a) Specifications. Each tablet contains 150 or 300 milligrams (mg) of etodolac.
(b) Sponsor. See 053501 in §510.600(c) of this chapter.

§ 520.903d (a) Conditions of use—(1) Dogs—(i) Amount. 10 to 15 mg per kilogram (4.5 to 6.8 mg/pound) of body weight per day.
(ii) Indications for use. For the management of pain and inflammation associated with osteoarthritis in dogs.
(iii) Limitations.

§ 520.903 Febantel oral dosage forms.

§ 520.903a Febantel paste.
(a) Chemical name. Dimethyl [(2-[(methoxyacetyl)amino]-4-(phenylthio)phenyl] carbonimidoyl]bis [carbamate].
(b) Specifications. The drug is a paste containing 45.5 percent febantel.
(c) Sponsor. See No. 000859 in §510.600(c) of this chapter.
(d) Conditions of use—(1) Amount. Six milligrams per kilogram (2.73 milligrams per pound) of body weight in horses.
(2) Indications for use. For removal of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); ascarids (Parascaris equorum—sexually mature and immature); pinworms (Oxyurus equi—adult and 4th stage larvae); large strongyles (Strongylus vulgaris, S. edentatus, S. equinus), and the various small strongyles in horses, breeding stallions and mares, pregnant mares, foals, and ponies.
(3) Limitations. Administer by stomach tube or drench, or by mixing well into a portion of the normal grain ration. For animals maintained on premises where reinfection is likely to occur, retreatment may be necessary. For most effective results, retreat in 6 to 8 weeks. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(d) Special considerations. Febantel suspension may be used in combination with trichlorfon oral liquid in accordance with the provisions of §520.2520c, this section, and the following conditions:
(1) Combine 1 part febantel suspension with 5 parts trichlorfon liquid.
(2) Allow animal to consume a portion of daily grain ration; administer mixture by stomach tube at rate of 18 milliliters per 100 pounds of body weight.

§ 520.903c [Reserved]

§ 520.903d Febantel-praziquantel paste.
(a) Specifications. Each gram of paste contains 34 milligrams of febantel and 3.4 milligrams of praziquantel.
(v) Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.903b Febantel suspension.
(a) Specifications. The suspension contains 9.3 percent (2.75 grams per ounce) febantel.
(b) Sponsor. See 000859 in §510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. 3 milliliters per 100 pounds body weight or 1 fluid ounce per 1000 pounds (6 milligrams per kilogram body weight).
(2) Indications for use. For removal of ascarids (Parascaris equorum—adult and sexually immature), pinworms (Oxyurus equi—adult and 4th stage larvae), large strongyles (Strongylus vulgaris, S. edentatus, S. equinus), and the various small strongyles in horses, breeding stallions and mares, pregnant mares, foals, and ponies.

§ 520.903c [Reserved]

§ 520.903 [Reserved]
§ 520.903e

(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount—(i) Dogs and cats (over 6 months of age): 10 milligrams of febantel and 1 milligram of praziquantel per kilogram of body weight (1 gram of paste per 7.5 pounds body weight) administered by mouth or in the food once daily for 3 days.

(ii) Puppies and kittens (less than 6 months of age): 15 milligrams of febantel and 1.5 milligrams of praziquantel per kilogram of body weight (1 gram of paste per 5 pounds body weight) administered by mouth on a full stomach once daily for 3 days.

(2) Indications for use. (i) Dogs and puppies: For removal of hookworms (Ancylostoma caninum and Uncinaria stenocephala), ascarids (Toxocara canis and Toxascaris leonina), and tapeworms (Dipylidium caninum and Taenia pisiformis).

(ii) Cats and kittens: For removal of hookworms (Ancylostoma tubaeforme), ascarids (Toxocara cati) and tapeworms (Dipylidium caninum and Taenia taeniaeformis).

(3) Limitations. Do not use in pregnant animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Special considerations. Consider alternative therapy or use with caution in animals with pre-existing liver or kidney dysfunction.


§ 520.905 Fenbendazole oral dosage forms.

§ 520.905a Fenbendazole suspension.

(a) Specifications. The drug is a suspension containing 10 percent (100 milligrams per milliliter) fenbendazole.

(b) Sponsor. See No. 057926 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.275 of this chapter.

(1) Horses—(i) Amount. 5 milligrams per kilogram (2.3 milligrams per pound) for the control of large strongyles, small strongyles, and pinworms; 10 milligrams per kilogram for the control of ascarids.

(ii) Indications for use. For the control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small strongyles (Cyanthostomum spp., Cylicoclyclus spp., Cylicostephanus spp., Triodontophorus spp.), pinworms (Oxyuris equi), and ascarids (Parascaris equorum) in horses.

(iii) Limitations. Administer orally by dose syringe or suitable plastic syringe. Do not use in horses intended for food. Consult a veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(2) Cattle including dairy cows of breeding age—(i) Amount. Administer orally 5 milligrams per kilogram of body weight (2.3 milligrams per pound).

(ii) Indications for use. For the removal and control of lungworm (Dictyocaulus viviparous); stomach worm (adults)—brown stomach worm (Ostertagia ostertagi); stomach worms (adults and 4th-stage larvae)—barberpole worm (Haemonchus contortus
and small stomach worm (Trichostongylus axei); intestinal worms (adults and 4th-stage larvae)—hookworm (Bunostomum phlebotomum), threadnecked intestinal worm (Nematodirus helvetianus), small intestinal worm (Cooperia punctata and C. oncophora), bankrupt worm (Trichostrongylus colubriformis), and nodular worm (Oesophagostomum radiatum).

(iii) Limitations. Retreatment may be needed after 4 to 6 weeks. Cattle must not be slaughtered within 8 days following last treatment. Consult a veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(b) Beef cattle—(i) Amount. Administer orally 10 milligrams per kilogram of body weight.

(ii) For the removal and control of stomach worm (4th-stage inhibited larvae/type II ostertagiasis), Ostertagia ostertagi, and tapeworm, Moniezia benedeni.

(iii) Limitations. Retreatment may be needed after 4 to 6 weeks. Cattle must not be slaughtered within 8 days following last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(3) Goats—(i) Amount. Administer orally 5 milligrams per kilogram (2.3 milligrams per pound) for the control of large strongyles, small strongyles, and pinworms; 10 milligrams per kilogram for the control of ascarids.

(ii) Indications for use. For the control of infections of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small strongyles, pinworms (Oxyuris equi), and ascarids (Parascaris equorum).

(iii) Limitations. Sprinkle the appropriate amount of drug on a small amount of the usual grain ration. Prepare for each horse individually. Withholding feed or water is not necessary. Retreat in 6 to 8 weeks if required. Do not use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.905b Fenbendazole granules.

(a) Specifications. The drug is in granular form containing 22 percent (222 milligrams per gram) fenbendazole.

(b) Sponsor. See No. 057926 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Horses—(i) Amount. 5 milligrams per kilogram (2.3 milligrams per pound) for the control of large strongyles, small strongyles, and pinworms; 10 milligrams per kilogram for the control of ascarids.

(ii) Indications for use. For the control of infections of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small strongyles, pinworms (Oxyuris equi), and ascarids (Parascaris equorum).

(iii) Limitations. Sprinkle the appropriate amount of drug on a small amount of the usual grain ration. Prepare for each horse individually. Withholding feed or water is not necessary. Retreat in 6 to 8 weeks if required. Do not use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(ii) Indications for use. For the removal of ascarids (Toxocara canis, Toxascaris leonina), hookworms (Ancylostoma caninum, Uncinaria stenocephala), whipworms (Trichuris vulpis), and tapeworms (Taenia pisiformis).

(iii) Limitations. Mix the appropriate amount of drug with a small amount of the usual food; dry dog food may require slight moistening to facilitate mixing. Medicated food must be fully consumed. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 520.905c Fenbendazole paste.

(a) Specifications. The product is an aqueous paste containing 10 percent fenbendazole.

(b) Sponsor. See No. 057926 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.275 of this chapter.

(d) Conditions of use—(1) Horses—(i) Amount. 2.3 milligrams per pound of body weight (one 2.5-gram fenbendazole syringe for a 1,100-pound horse). For foals and weanlings (less than 18 months of age), 4.6 milligrams per pound of body weight (one 2.5-gram fenbendazole syringe for each 550 pounds of body weight).

(ii) Indications for use. For control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small strongyles, pinworms (Oxyuris equi), and ascarids (Parascaris equorum) in horses.

(iii) Limitations. Retreatment at intervals of 6 to 8 weeks may be required. Do not use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(ii) (a) Amount. 4.6 milligrams per pound of body weight (one 2.5-gram fenbendazole syringe for a 550-pound horse) daily for 5 days.

(b) Indications for use. For control of arteritis caused by the fourth stage larvae of Strongylus vulgaris.

(c) Limitations. Treatment should be initiated in the spring and repeated in 6 months. Do not use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of fourth stage larvae of S. vulgaris.

(iii) (a) Amount. 4.6 milligrams per pound of body weight (10 milligrams per kilogram) daily for 5 consecutive days.

(b) Indications for use. For treatment of encysted mucosal cyathostome (small strongyle) larvae including early third stage (hypobiotic), late third stage, and fourth stage larvae in horses.

(c) Limitations. (Consult your veterinarian for assistance in the diagnosis, treatment, and control of encysted mucosal cyathostomes). Do not use in horses intended for food.

(2) Beef and dairy cattle—(1) Amount. Administer orally 5 milligrams per kilogram of body weight (2.3 milligrams per pound).

(ii) Indications for use. For the removal and control of lungworm (Dictyocaulus viviparus), barberpole worm (Haemonchus contortus), brown stomach worm (Ostertagia ostertagi), small stomach worm (Trichostrongylus axei), hookworm (Bunostomum phlebotomum), thread-necked intestinal worm (Nematodirus helvetianus), small intestinal worms (Cooperia punctata and C. oncophora), bankrupt worm (Trichostrongylus colubriformis), and nodular worm (Oesophagostomum radiatum).

(iii) Limitations. Re-treatment may be needed after 4 to 6 weeks. Cattle must...
not be slaughtered within 8 days following last treatment. Consult a veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(e) **Special considerations.**

Fenbendazole paste 10 percent may be used concomitantly with approved forms of trichlorfon for the indications provided in paragraph (d)(1)(i) of this section and for treating infections of stomach bots as provided in §520.2520.

§ 520.905d Fenbendazole powder.

(a) **Specifications.** (1) Each 2-ounce packet contains 2.27 grams (4 percent) of fenbendazole plus other inert ingredients.

(2) Each 4-ounce packet contains 1.7 grams (1.5 percent) of fenbendazole plus other inert ingredients.

(b) **Sponsors.** (1) See No. 057926 in §510.600(c) of this chapter for use of the 4-percent product.

(2) See No. 017800 in §510.600(c) of this chapter for use of the 1.5-percent product.

(c) **Related tolerances.** See §556.275 of this chapter.

(d) **Conditions of use.** It is administered to swine as follows:

(1) **Amount.** 3 milligrams fenbendazole per kilogram body weight per day (1.36 milligrams per pound per day).

(2) **Indications for use.** For removal and control of large roundworms (*Ascaris suum*); lungworms (*Metastrongylus apri*); nodular worms (*Oesophagostomum dentatum, O. quadrirspinulatum*); small stomach worms (*Hydrostrongylus rubidus*); whipworms (*Trichuris suis*); and kidneyworms (*Stephanurus dentatus—mature and immature*).

(3) **Limitations.** Thoroughly mix the contents of the packet(s) with swine ration and administer according to label directions. Feed as sole ration for 3 consecutive days. Can be fed to pregnant sows. No prior withdrawal of feed or water is necessary. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.905e Fenbendazole blocks.

(a) **Specifications.** (1) Each pound of molasses block contains 750 milligrams of fenbendazole.

(2) Each pound of protein block contains 750 milligrams of fenbendazole.

(b) **Sponsor.** See 057926 in §510.600(c) of this chapter.

(c) **Related tolerances.** See §556.275 of this chapter.

(d) **Conditions of use—** (1) **Amount.** 0.1 pound of block per 100 pounds of body weight per day for 3 days. Total dose for the 3-day period is 2.27 milligrams of fenbendazole per pound of body weight for mature cattle.

(2) **Indications for use.** For removal and control of infections of lungworms (*Dictyocaulus viviparus*) and gastrointestinal roundworms (*Haemonchus contortus, Ostertagia ostertagi, Trichostrongylus axei, Bunostomum phlebotomum, Nomadotirus helvetianus, Cooperia oncophora* and *C. punctata, Trichostrongylus colubriformis, and Oesophagostomum radiatum*) in beef cattle.

(3) **Limitations.** Administer free choice of beef cattle on pasture that have become accustomed to nonmedicated block feeding during an adaptation period of 12 to 19 days. Molasses block: Cattle must not be slaughtered within 11 days following last treatment. Protein block: Cattle must not be slaughtered within 16 days following last treatment; do not use in dairy cattle of breeding age. Animals maintained under conditions of constant worm exposure may require retreatment within 6 to 8 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.960 Flumethasone tablets.

(a) **Specifications.** Each tablet contains 0.0625 milligram of flumethasone.

(b) **Sponsor.** See No. 000856 in §510.600(c) of this chapter.
§ 520.970  Flunixin oral dosage forms.

§ 520.970a Flunixin meglumine granules.

(a) Specifications. Each 10-gram package contains flunixin meglumine equivalent to 250 milligrams of flunixin.

(b) Sponsor. No. 000061 in ¶ 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 0.5 milligram of flunixin per pound of body weight (one packet per 500 pounds) per day.

(2) Indications for use. For alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

(3) Limitations. Administer daily dose for up to 5 days by sprinkling on small amount of feed. The effect of this drug on pregnancy has not been determined. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[44 FR 7131, Feb. 6, 1979, as amended at 61 FR 5506, Feb. 13, 1996]

§ 520.970b Flunixin meglumine paste.

(a) Specifications. Each 30-gram syringe contains flunixin meglumine equivalent to 1,500 milligrams of flunixin.

(b) Sponsor. No. 000061 in ¶ 510.600(c) of this chapter.

(c) Conditions of use. Horses—(1) Amount. 0.5 milligram of flunixin per pound of body weight daily.

(2) Indications for use. For alleviation of inflammation and pain associated with musculoskeletal disorders.

(3) Limitations. For oral use only. Treatment should not exceed 5 consecutive days. The effect of this drug on pregnancy has not been determined. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1010 Furosemide.

(a) Specifications. (1) Each tablet contains 12.5 or 50 milligrams (mg) furosemide.

(2) Each bolus contains 2 grams (g) furosemide.

(3) Each packet of powder contains 2 g furosemide.

(4) Each milliliter of syrup contains 10 mg furosemide.

(b) Sponsors. See sponsor numbers in ¶ 510.600(c) of this chapter for use of dosage forms and strengths listed in paragraph (a) of this section for uses as in paragraph (d) of this section.

(1) No. 000010 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of this section.

(2) No. 000093 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i) and (d)(2)(ii)(B) of this section.

(3) No. 057926 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i) and (d)(2)(ii)(B) of this section.
use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of this section; for boluses in paragraph (a)(2) of this section and powder in paragraph (a)(3) of this section for conditions of use in paragraph (d)(1) of this section; and for syrup in paragraphs (a)(4) of this section for conditions of use in paragraphs (d)(2)(i) and (d)(2)(ii)(A).

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use. It is used as follows:

(1) Cattle—(i) Amount. 1 to 2 mg per pound (/lb) body weight using powder, or one 2-g bolus per animal, per day.

(ii) Indications for use. For treatment of physiological parturient edema of the mammary gland and associated structures.

(iii) Limitations. Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment.

(2) Dogs—(i) Amount. 1 to 2 mg/lb body weight, once or twice daily.

(ii) Indications for use—(A) For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

(B) For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency.

(3) Cats—(i) Amount. 1 to 2 mg/lb body weight, once or twice daily.

(ii) Indications for use. For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

[66 FR 47960, Sept. 17, 2001]

§ 520.1044 Gentamicin sulfate oral dosage forms.

§ 520.1044a Gentamicin sulfate oral solution.

(a) Specifications. Each milliliter of aqueous solution contains gentamicin sulfate equivalent to 50 milligrams of gentamicin.

(b) Sponsor. See Nos. 000061 and 051259 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.300 of this chapter.

(d) Conditions of use—(1) Amount. Colibacillosis: 1 milliliter per 2 gallons of drinking water for 3 consecutive days, to provide 0.5 milligram/pound/day; swine dysentery: 1 milliliter per 1 gallon of drinking water for 3 consecutive days, to provide 1.0 milligram/pound/day.

(2) Indications for use. In weanling swine for control and treatment of colibacillosis caused by strains of E. coli sensitive to gentamicin, and in swine for control and treatment of swine dysentery associated with Treponema hyodysenteriae.

(3) Limitations. For use in swine drinking water only. Do not store or offer medicated drinking water in rusty containers since the drug is quickly destroyed in such containers. Medicated drinking water should be prepared daily and be the sole source of drinking water for 3 consecutive days. Treatment may be repeated if dysentery recurs. Do not slaughter treated swine for food for at least 3 days following treatment.


§ 520.1044b Gentamicin sulfate pig pump oral solution.

(a) Specifications. Each milliliter of pig pump oral solution contains gentamicin sulfate equivalent to 4.35 milligrams of gentamicin.

(b) Sponsor. See Nos. 000061 and 059130 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.300 of this chapter.

(d) Conditions of use—(1) Amount. Administer 1.15 milliliters of pig pump oral solution (5 milligrams of gentamicin) orally per pig one time.

(2) Indications for use. In neonatal swine 1 to 3 days of age for control and treatment of colibacillosis caused by strains of E. coli sensitive to gentamicin.

(3) Limitations. For use in neonatal swine only. Do not slaughter treated swine for food for at least 14 days following treatment.

§ 520.1044c Gentamicin sulfate soluble powder.

(a) Specifications. Each gram of gentamicin sulfate soluble powder contains gentamicin sulfate equivalent to 16.7, 66.7, or 333.3 milligrams of gentamicin.

(b) Sponsor. See Nos. 000061 and 057561 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.300 of this chapter.

(d) Conditions of use—(1) Amount. Colibacillosis: gentamicin sulfate equivalent to 25 milligrams of gentamicin per gallon of drinking water for 3 consecutive days, to provide 0.5 milligram per pound of body weight per day; swine dysentery: gentamicin sulfate equivalent to 50 milligrams of gentamicin per gallon of drinking water for 3 consecutive days, to provide 1 milligram per pound of body weight per day.

(2) Indications for use. In weanling swine for control and treatment of coli bacillosis caused by strains of E. coli sensitive to gentamicin, and in swine for control and treatment of swine dysentery associated with Treponema hyodysenteriae.

(3) Limitations. For use in swine drinking water only. Do not store or offer medicated drinking water in rusty containers since the drug is quickly destroyed in such containers. Medicated drinking water should be prepared daily and be the sole source of drinking water for 3 consecutive days. Treatment may be repeated if dysentery recurs. Do not slaughter treated swine for food for at least 10 days following treatment.


§ 520.1100 Griseofulvin.

(a) Chemical name. 7-Chloro-2’4,6-trimethoxy-6-methylspiro [benzofuran-2(3H), 1-[2-cyclohexene]-3,4′-dione.

(b) Specifications. Complies with U.S.P. for griseofulvin microsize.

(c) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(d) Conditions of use. (1) As a soluble powder for horses, it is administered as a drench or as a top dressing on feed. It is used for equine ringworm infection caused by *Trichophyton equinum* or *Microsporum gypseum*. Administer for not less than 10 days a daily dose as follows: Adults, 2.5 grams; yearlings, 1.25 to 2.5 grams; and foals, 1.25 grams. Not for use in horses intended for food. For use only by or on the order of a licensed veterinarian.

(2)(i) Boluses containing 2.5 grams of griseofulvin are used in horses for treating ringworm infection caused by *Trichophyton equinum*. It is administered to adult horses at a level of one bolus per day, to yearlings at one-half to one bolus per day, and to foals at one-half bolus per day. All three dosage levels should be administered for a period of not less than 10 days. In responsive cases, treatment should be continued until all infected areas are proven negative by appropriate culture. Not for use in horses intended for food.

(ii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(3) Dogs and cats: (i) Amount. 125- and 500-milligram tablets administered orally as follows:

(a) Daily (single or divided) dose:

<table>
<thead>
<tr>
<th>Body weight (pounds)</th>
<th>Dosage (milligrams)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 6</td>
<td>625</td>
</tr>
<tr>
<td>6 to 18</td>
<td>125</td>
</tr>
<tr>
<td>18 to 36</td>
<td>250</td>
</tr>
<tr>
<td>36 to 48</td>
<td>375</td>
</tr>
<tr>
<td>48 to 75</td>
<td>500</td>
</tr>
</tbody>
</table>

(b) Weekly (single) dose: If experience indicates that treatment is more effective for the drug given in large doses, administer at intervals of 7 to 10 days, a dose equal to 10 milligrams/pound of body weight x body weight x number of days between treatments. Dosage should be adjusted according to response. Administer additional dose after the animal is free of infection.

(ii) Indications for use. For treatment of fungal infections of the skin, hair, and claws caused by *Trichophyton mentagrophytes, T. rubrum, T. schoenleini, T. sulphureum, T. verrucosum, T. interdigitale, Epidermophyton floccosum, Microsporum gypseum, M. canis, M. audouini*.

(iii) Limitations. For satisfactory diagnosis, a microscopic tissue examination or culture is recommended prior to treatment. Treatment should be continued for 3 to 4 weeks in skin and
§ 520.1120 Haloxon oral dosage forms.

§ 520.1120a Haloxon drench.

(a) Chemical name. 3-Chloro-7-hydroxy-4-methylcoumarin bis (2-chloroethyl) phosphate.

(b) Specifications. Haloxon assay of not less than 96 percent by infrared spectrum at 8.62 microns.

(c) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(d) Special considerations. Do not use any drug, insecticide, pesticide, or other chemical having cholinesterase-inhibiting activity either simultaneously or within a few days before or after treatment with haloxon.

(e) Related tolerances. See §556.310 of this chapter.

(f) Conditions of use. It is used as a drench as follows:

(1) Cattle — (i) Amount. 141.5 grams per packet.

(ii) Indications for use. Control of gastrointestinal roundworms of the genera Haemonchus, Ostertagia, Trichostrongylus and Cooperia.

(iii) Limitations. (a) Dissolve each packet in 32 fluid ounces of water and administer as follows:

<table>
<thead>
<tr>
<th>Weight of animal (pounds)</th>
<th>Dose (fluid ounces)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 100</td>
<td>1/8</td>
</tr>
<tr>
<td>100 to 150</td>
<td>3/4</td>
</tr>
<tr>
<td>150 to 200</td>
<td>1</td>
</tr>
<tr>
<td>200 to 300</td>
<td>11/8</td>
</tr>
<tr>
<td>300 to 450</td>
<td>2</td>
</tr>
<tr>
<td>450 to 700</td>
<td>3</td>
</tr>
<tr>
<td>700 to 1,000</td>
<td>4</td>
</tr>
<tr>
<td>1,000 to 1,200</td>
<td>5</td>
</tr>
<tr>
<td>Over 1,200</td>
<td>6</td>
</tr>
</tbody>
</table>

(b) Do not treat within 1 week of slaughter; do not treat dairy animals of breeding age; animals should be retreated in 3 to 4 weeks.

§ 520.1120b Haloxon boluses.

(a) Chemical name. 3-Chloro-7-hydroxy-4-methylcoumarin bis (2-chloroethyl) phosphate.

(b) Specifications. Each bolus contains 10.1 grams of haloxon.

(c) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.310 of this chapter.

(e) Conditions of use. (1) Haloxon bolus is an anthelmintic used in cattle for the control of gastrointestinal roundworms of the genera Haemonchus, Ostertagia, Trichostrongylus and Cooperia.

(2) It is administered by giving one bolus per approximately 500 pounds body weight (35 to 50 milligrams per kilogram of body weight).

(3) For most effective results, retreat animals in 3 to 4 weeks. If reinfestation is likely to occur, additional re-treatments may be necessary.

(4) Do not use any drug, pesticide or other chemical having cholinesterase inhibiting activity either simultaneously or within a few days before or after treatment with haloxon.

(5) Do not treat dairy animals within one week of slaughter.

(6) Do not treat dairy animals of breeding age or older.

§ 520.1130 Hetacillin oral dosage forms.

§ 520.1130a Hetacillin potassium capsules.

(a) Specifications. Each capsule contains hetacillin potassium equivalent to 50, 100, or 200 milligrams of ampicillin.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. (1) Dogs— (1) Amount. 5 milligrams per pound of body
§ 520.1130b Hetacillin potassium oral suspension.

(a) Specifications. Each milliliter contains hetacillin potassium equivalent to 50 milligrams of ampicillin.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 5 milligrams per pound of body weight twice daily. In severe infections, up to three times daily, or up to 10 milligrams per pound of body weight twice daily. For stubborn urinary tract infections, up to 20 milligrams per pound of body weight twice daily.

(ii) Indications for use. Treatment against strains of organisms susceptible to hetacillin potassium and associated with respiratory tract infections, urinary tract infections, gastrointestinal infections, skin infections, soft-tissue infections, and postsurgical infections.

(iii) Limitations. For use in dogs only. Not for use in animals raised for food production. Continue treatment 48 to 72 hours after the animal has become afebrile or asymptomatic. Administer 1 to 2 hours prior to feeding to ensure maximum absorption. In stubborn infections, therapy may be required for several weeks. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cats—(i) Amount. 50 milligrams twice daily.

(ii) Indications for use. Treatment against strains of organisms susceptible to hetacillin potassium and associated with respiratory tract infections, urinary tract infections, gastrointestinal infections, skin infections, soft-tissue infections, and postsurgical infections.

(iii) Limitations. For use in cats only. Not for use in animals raised for food production. Continue treatment 48 to 72 hours after the animal has become afebrile or asymptomatic. Administer 1 to 2 hours prior to feeding to ensure maximum absorption. In stubborn infections, therapy may be required for several weeks. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37325, Aug. 18, 1992]

§ 520.1130c Hetacillin potassium tablets.

(a) Specifications. Each tablet contains hetacillin potassium equivalent to 50, 100, or 200 milligrams of ampicillin.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 5 milligrams per pound of body weight twice daily. In severe infections, up to three times daily, or up to 10 milligrams per pound of body weight twice daily. For stubborn urinary tract infections, up to 20 milligrams per pound of body weight twice daily.

(ii) Indications for use. Treatment against strains of organisms susceptible to hetacillin potassium and associated with respiratory tract infections, urinary tract infections, gastrointestinal infections, skin infections, soft-tissue infections, and postsurgical infections.

(iii) Limitations. For use in dogs only. Not for use in animals raised for food production. Continue treatment 48 to 72 hours after the animal has become afebrile or asymptomatic. Administer 1 to 2 hours prior to feeding to ensure maximum absorption. In stubborn infections, therapy may be required for several weeks. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37326, Aug. 18, 1992]
infections, up to 20 milligrams per pound of body weight twice daily.

(ii) Indications for use. Oral treatment against strains of organisms sensitive to hetacillin potassium and associated with respiratory tract infections, urinary tract infections, gastrointestinal infections, skin infections, soft tissue infections, and postsurgical infections.

(iii) Limitations. For use in dogs and cats only. Continue treatment for 48 to 72 hours after the animal has become afebrile or asymptomatic. Administer 1 to 2 hours prior to feeding to ensure maximum absorption. In stubborn infections, therapy may be required for several weeks. Not for use in animals which are raised for food production. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cats—(i) Amount. 50 milligrams twice daily.

(ii) Indications for use. Treatment against strains of organisms sensitive to hetacillin potassium and associated with respiratory tract infections, urinary tract infections, gastrointestinal infections, skin infections, soft tissue infections, and postsurgical infections.

(iii) Limitations. For use in dogs and cats only. Continue treatment for 48 to 72 hours after the animal has become afebrile or asymptomatic. Administer 1 to 2 hours prior to feeding to ensure maximum absorption. In stubborn infections, therapy may be required for several weeks. Not for use in animals which are raised for food production. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37326, Aug. 18, 1992]

§ 520.1157 Iodinated casein tablets.

(a) Specifications. Each 1-gram tablet contains 25 milligrams of iodinated casein.

(b) Sponsor. See No. 017762 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 1/5 to 1 tablet per 10 pounds of body weight (equivalent to 0.5 to 2.5 milligrams of iodinated casein per pound of body weight).

(2) Indications for use. For dogs for apparent decreased thyroid activity where the signs are alopecia, scaliness of the skin surface, loss of hair, seborrhea, thickening of the skin, hyperpigmentation, and lethargy.

(3) Limitations. If no response is observed in 30 to 45 days, the drug should be withdrawn and the diagnosis reconsidered. Do not use in the presence of cardiac disease, ischemia, adrenal insufficiency, or nephrosis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[49 FR 22469, May 30, 1984]

§ 520.1158 Iodochlorhydroxyquin boluses.

(a) Specifications. Each bolus contains 10 grams of iodochlorhydroxyquin.

(b) Sponsor. See No. 053501 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 1 bolus (10 grams) daily for a 1,000-pound horse.

(2) Indications for use. For treatment of equine diarrhea.

(3) Limitations. For horses only; not to be administered to food-producing animals. Do not administer to horses intended for use as food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1182 Iron dextran oral suspension.

(a) Specifications. Each 1.8 milliliter contains 100 milligrams of elemental iron as ferric hydroxide in complex with a low molecular weight dextran and 0.2 percent phenol as a preservative.

(b) Sponsor. See 017800 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 100 milligrams of elemental iron to each pig.

(2) Indications for use. Prevention of iron deficiency anemia in baby pigs.

(3) Limitations. Treat each pig within 24 hours of farrowing. Administer 1.8 milliliters orally by automatic dose dispenser.

[45 FR 75199, Nov. 14, 1980]

§ 520.1192 Ivermectin paste.

(a) Specifications. Each milligram of paste contains 0.0187 milligram (1.87 percent) or 0.00153 milligram (0.153 percent) of ivermectin.
§ 520.1193 Ivermectin tablets and chewables.

(a) Specifications. (1) Each tablet or chewable contains 68, 136, or 272 micrograms (mcg) ivermectin.

(2) Each chewable contains 55 or 165 mcg ivermectin.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter, as follows:

(1) No. 050604 for use of tablets or chewables described in paragraph (a)(1) as in paragraph (d)(1) and chewables described in paragraph (d)(2) of this section.

(2) No. 059130 for use of a 1.87 percent paste as in paragraph (d)(1) of this section.

(c) Related tolerances. See §556.344 of this chapter.

(d) Conditions of use.

(1) Horses—(i) Amount. 200 micrograms per kilogram (91 micrograms per pound) of body weight.

(ii) Indications for use. It is used in horses for the treatment and control of large strongyles (adult) (Strongylus equinus), (adult and arterial larval stages) (Strongylus vulgaris), (adult and migrating tissue stages) (Strongylus edentatus), (adult) (Triodontophorus spp.); small strongyles, including those resistant to some benzimidazole class compounds (adult and fourth stage larvae) (Cyathostomum spp., Cylicocyclus spp., Cylicodontophorus spp., Cylicostephanus spp.); pinworms (adult and fourth stage larvae) (Oxyuris equi); ascarids (third- and fourth-stage larvae and adults) (Parascaris equorum); hairworms (adult) (Trichostrongylus axei); large mouth stomach worms (adult) (Habronema muscae); stomach bots (oral and gastric stages) (Gastrophilus spp.); lungworms (adults and fourth stage larvae) (Dictyocaulus arnfieldi); intestinal threadworms (adults) (Strongyloides westeri); summer sores caused by Habronema and Draschia spp. cutaneous third stage larvae; and dermatitis caused by neck threadworm microfilariae (Onchocerca spp.).

(iii) Limitations. For oral use only. Do not use in horses intended for food purposes. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(2) Cattle—(i) Amount. 23 milligrams per 250 pounds of body weight.

(ii) Indications for use. It is used in cattle for the treatment and control of gastrointestinal roundworms (adults and fourth-stage larvae) (Ostertagia ostertagi (including inhibited forms), O. lyrata, Haemonchus placei, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctata, Nematodirus helvetianus, Bunostomum phlebotomum, Strongyloides papillosus (adults only), Oesophagostomum radiatum, Trichuris ovis (adults only)); lungworms (adults and fourth-stage larvae) (Dictyocaulus viviparus); grubs (first, second, and third instars) (Hyoderma bassis, H. lineatum); and sucking lice (Linognathus vituli, Haematopinus eurysternus).

(iv) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Dogs. For use in dogs 6 weeks of age and older as follows:

(i) Amount. 6.0 mcg per kilogram (kg) of body weight (2.72 mcg per pound (lb)); minimum. Up to 25 lb, 68 mcg; 26 to 50 lb, 136 mcg; 51 to 100 lb, 272 mcg; over 100 lb, a combination of the appropriate tablets. Administer at monthly dosing intervals.

(ii) Indications for use. To prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) for 1 month (30 days) after infection.

(2) No. 065274 for use of tablets described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(3) No. 059130 for use of a 1.87 percent paste as in paragraph (d)(1) and chewables described in paragraph (d)(2) of this section.

(4) No. 065274 for use of tablets described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(5) No. 065274 for use of tablets described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(6) No. 065274 for use of tablets described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(7) No. 065274 for use of tablets described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(8) No. 065274 for use of tablets described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(9) No. 065274 for use of tablets described in paragraph (a)(1) as in paragraph (d)(1) of this section.
§ 520.1196 Ivermectin liquid.

(a) Specifications. Each milliliter contains 10 milligrams of ivermectin.

(b) Sponsor. See Nos. 050604, 051259, 058829, and 059130 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 200 micrograms per kilogram of body weight as a single dose by stomach tube or as an oral drench.

(2) Indications for use. For the treatment and control of large strongyles (adult) (Strongylus equinus), (adult and arterial larval stages) (Strongylus vulgaris), (adult and migrating tissue stages) (Strongylus endentatus), (adult) (Triodontophorus spp.); small strongyles, including those resistant to some benzimidazole class compounds (adult and fourth stage larvae) (Cyathostomum spp., Cyclicocyclus spp., Cylicodontophorus spp., Cyclicostephanus spp.); pinworms (adult and fourth stage larvae) (Oxyuris equi); ascarids (third- and fourth-stage larvae and adults) (Parascaris equorum); hairworms (adult) (Trichostongylus axei); large mouth stomach worms (adult) (Habronema muscae); stomach bots (oral and gastric stages) (Gastroophilus spp.); lungworms (adults and fourth stage larvae) (Dictyocaulus arnfieldi); intestinal threadworms (adults) (Strongyloides westeri); summer sores caused by Habronema and Draschia spp. cutaneous third stage larvae; and dermatitis caused by neck threadworm microfilariae (Onchocerca spp.).

(3) Limitations. Do not use in horses intended for food purposes. Federal law restricts this drug to us by or on the order of a licensed veterinarian.


§ 520.1196 Ivermectin and pyrantel pamoate chewable tablet.

(a) Specifications. Each chewable tablet contains 68 micrograms (µg) of ivermectin and 57 milligrams (mg) of pyrantel (as pamoate salt), or 136 µg for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.1197 Ivermectin sustained-release bolus.

(a) Specifications. Each sustained-release bolus contains 1.72 grams of ivermectin.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. A minimum of 6 µg of ivermectin and 5 mg of pyrantel (as pamoate salt) per kilogram (2.72 µg and 2.27 mg per pound) of body weight.

(ii) Indications for use. To prevent canine heartworm disease by eliminating the tissue larval stages of Dirofilaria immitis for up to a month (30 days) after infection and treatment and control of adult ascarids Toxocara canis and Toxascaris leonina, and adult hookworms Ancylostoma caninum, A. braziliense, and Uncinaria stenocephala.

(iii) Limitations. Use monthly. Recommended for dogs 6 weeks of age and older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]


§ 520.1197 Ivermectin sustained-release bolus.

§ 520.1204 Kanamycin sulfate, aminopentamide hydrogen sulfate, pectin, bismuth subcarbonate, activated attapulgite suspension.

(a) Specifications. Each five milliliters of suspension of the drug contains: 100 milligrams of kanamycin as the sulfate, 0.033 milligram of aminopentamide hydrogen sulfate, 25 milligrams of pectin, 250 milligrams of bismuth subcarbonate, and 500 milligrams of activated attapulgite.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is administered orally to dogs for the symptomatic relief of acute bacterial diarrhea caused by kanamycin-susceptible organisms.

(2) Indications. For treatment and control, throughout the grazing season (approximately 130 days), of gastrointestinal roundworms Haemonchus placei, Ostertagia ostertagi (including inhibited fourth-stage larvae), Trichostrongylus axei, T. colubriformis, Cooperia spp., Nematothrius helvetianus, Bunostomum phlebotomum, Oesophagostomum radiatum; lungworms Dictyocaulus viviparus; grubs Hypoderma spp.; sucking lice Linognathus vituli, Solenopotes capillatus; mange mites Psoroptes ovis, Sarcoptes scabiei, and ticks Amblyomma americanum.

(3) Limitations. The bolus was specifically designed for use in cattle; do not use in other animal species. Calves must be ruminating and older than 12 weeks of age. Do not administer to calves weighing less than 275 lb (125 kg). Do not administer a damaged bolus. Because a milk withdrawal time has not been established, do not use in female dairy cattle of breeding age. Do not slaughter cattle within 180 days of treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1205 Kanamycin sulfate, pectin, bismuth subcarbonate, activated attapulgite tablets.

(a) Specifications. Each tablet contains 100 milligrams of kanamycin (as the sulfate), 25 milligrams of pectin,
250 milligrams of bismuth subcarbonate, and 500 milligrams of activated attapulgite.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. One tablet per 44 kilograms (20 pounds) of body weight every 8 hours. Maximum dose 3 tablets every 8 hours. For animals under 22 kilograms (10 pounds) $\frac{1}{2}$ tablet every 8 hours. The initial loading dose should be twice the amount of a single dose.

(2) Indications for use. For the treatment of bacterial enteritis caused by organisms susceptible to kanamycin and the symptomatic relief of associated diarrhea in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[56 FR 8710, Mar. 1, 1991]

§ 520.1242a Levamisole hydrochloride

oral dosage forms.

§ 520.1242a Levamisole hydrochloride
drench and drinking water.

(a) Specifications. Each package contains either 9.075, 11.7, 18.15, 46.8, or 544.5 grams of levamisole hydrochloride.

(b) Sponsors. Approval for sponsors in 21 CFR 510.600(c) for use as in paragraph (d) of this section as follows:

(1) See 043781 for use of 46.8 gram package as in paragraph (d)(1) of this section, for 11.7 and 46.8 gram packages as in paragraph (d)(2) of this section, and for 9.075 and 18.15 gram packages as in paragraph (d)(3) of this section.

(2) See 000061 for use of 46.8 and 544.5 gram packages as in paragraph (d)(1) of this section, for 11.7, 46.8, and 544.5 gram packages as in paragraph (d)(2) of this section, and for 9.075 and 18.15 gram packages as in paragraph (d)(3) of this section.

(3) See 057561 for use of 46.8 and 544.5 gram packages as in paragraphs (d)(1) and (d)(2) of this section.

(c) Related tolerances. See §556.350 of this chapter.

(d) Conditions of use. It is used as an anthelmintic at 0.365 gram per 100 pounds of body weight as follows:

(1) Cattle—(i) Amount. As a single oral dose drench using 46.8 or 544.5 gram packet.

(ii) Indications for use. Anthelmintic effective against the following nematode infections: Stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum), and lungworms (Dictyocaulus).

(iii) Limitations. Conditions of constant helminth exposure may require retreatment within 2 to 4 weeks after the first treatment. Do not slaughter for food within 48 hours of treatment. Not for use in dairy animals of breeding age. Consult your veterinarian before using in severely debilitated animals. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. Prepare solutions for use as follows:

(a) Dissolve contents of 46.8 gram package in water to provide 1 quart (32 fluid ounces) of drench solution and administer as a drench at 1/4 ounce per 100 pounds of body weight as a single oral dose.

(b) Dissolve contents of 46.8 gram package in water to provide 8.75 fluid ounces of concentrate solution and administer as a drench at 2 milliliters per 100 pounds of body weight as a single oral dose by syringe.

(c) Dissolve contents of 544.5 gram package in 3 liters of water and administer as a drench at 2 milliliters per 100 pounds of body weight as a single oral dose.

(2) Sheep—(i) Amount. As a single oral dose drench using 11.7, 46.8, or 544.5 gram packet.

(a) Indications for use. Anthelmintic effective against the following nematode infections: Stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum, Oesophagostomum, Chabertia), and lungworms (Dictyocaulus).

(b) Limitations. Dissolve in 1 gallon (128 fluid ounces) of water and administer as a single drench at 1 ounce (0.365 gram) per 100 pounds of body weight; conditions of constant helminth exposure may require re-treatment within 2 to 4 weeks after the first treatment; do not slaughter for food within 72 hours
§ 520.1242b Levamisole hydrochloride
tablet or oblet (bolus).

(a) Chemical name. (-)-2,3,5,6-
Tetrahydro-6-phenylimidazo [2,1-b] thia-
zole monohydrochloride.

(b) Specifications. Assay of not less
than 99 percent by nonaqueous titra-
tion with 0.1 N potassium isopropoxide;
1 isomer minimum 95 percent pure by
optical rotation.

(c) Sponsor. See Nos. 000061 and 043781
in §510.600(c) of this chapter.

(d) Related tolerances. See §556.350 of
this chapter.

(e) Conditions of use. (1) It is used in
an oblet for cattle as follows:

(i) Amount. 2.19 grams per oblet.

(ii) Indications for use. Anthelmintic
effective against the following nema-
tode infections: Stomach worms
(Haemonchus, Trichostrongylus,
Ostertagia), intestinal worms
(Trichostrongylus, Cooperia,
Nematodirus, Bunostomum,
Oesophagostomum), and lungworms
(Dictyocaulus).

(ii) Amount. 11.7 grams per packet.

(a) Indications for use. See paragraph
(f)(2)(i)(a) of this section.

(b) Limitations. Dissolve in 1 quart (32
fluid ounces) of water and administer
as a drench at 1 ounce (0.365
gram) per 100 pounds of body weight;
dissolve 1 packet in 10 fluid ounces of
water and administer as a single
drench at 1 cubic centimeter (0.036
gram) per 100 pounds of body weight;
conditions of constant helmint exposure
may require re-treatment within 2
to 4 weeks after the first treatment; do
not slaughter for food within 72 hours
of treatment; consult veterinarian before
using in severely debilitated ani-
imals.

(iii) Limitations. Conditions of con-
stant helmint exposure may require
re-treatment within 2 to 4 weeks after
the first treatment. Do not slaughter
for food within 72 hours of treatment.
Consult your veterinarian before using
in severely debilitated animals.
Consult your veterinarian for assistance in
the diagnosis, treatment, and control
of parasitism. Prepare solutions for use
as follows:

(a) Dissolve contents of 11.7 gram
package in 1 quart (32 ounces) of water
and administer as a drench at 1 ounce
per 100 pounds of body weight, or
dissolve in 10 fluid ounces of water
and administer as a drench at 1 milliliter
per 10 pounds of body weight as a single
oral dose.

(b) Dissolve contents of 46.8 gram
package in 128 fluid ounces (1 gallon) of
water and administer as a drench at 1
ounce per 100 pounds of body weight as
a single oral dose.

(c) Dissolve contents of 544.5 gram
package in 3 liters of water and admin-
ister as a drench at 2 milliliters per 100
pounds of body weight as a single oral
dose.

Swine—(i) Amount. 9.075 or 18.15
grams per bottle.

(ii) Indications for use. Anthelmintic
effective against the following nema-
tode infections: Large roundworms
(Ascaris suum), nodular worms
(Oesophagostomum spp.), intestinal
thread worms (Strongyloides ransomi)
and lungworms (Metastrongylus spp.).

(iii) Limitations. Dissolve in water to
provide 9.075 grams per 250 milliliters
or 18.15 grams per 500 milliliters. Add
10 milliliters (2 teaspoons) of this con-
centrate solution to each gallon of
drinking water. Allow 1 gallon of medi-
cated drinking water for each 100
pounds of body weight of pigs to be
treated. No other source of water
should be offered. After pigs have con-
sumed medicated water, resume use of
regular water. Pigs maintained under
conditions of constant exposure to
worms may require re-treatment within
4 to 5 weeks after the first treatment.
Consult your veterinarian before ad-
ministering to sick swine. Consult your
veterinarian for assistance in the diag-
nosis, treatment, and control of para-
sitism. Do not administer within 72
hours of slaughter for food.
Food and Drug Administration, HHS

§ 520.1242d Levamisole hydrochloride and piperazine dihydrochloride.

(a) Specifications. (1) The drug is an aqueous solution which contains in each fluid ounce 0.36 gram of levamisole hydrochloride and piperazine dihydrochloride equivalent to 3.98 grams of piperazine base.

(2) The drug is a soluble powder which when reconstituted with water contains in each fluid ounce 0.45 gram of levamisole hydrochloride and piperazine dihydrochloride equivalent to 5.0 grams of piperazine base.

(b) Sponsor. See No. 043781 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.350 of this chapter.

(d) Conditions of use. It is used as a drench for horses as follows:

(1) Indications for use. An anthelmintic effective against infections of large strongyles (Strongylus vulgaris, S. edentatus), small strongyles (Cylcocercus spp., Cylcoclyclus spp., Cylcodontophoris spp., Cylcocephalurus spp., Cylicotetrapedon spp.), ascarids (Parasacaris equorum), and pinworms (Oxyuris equi).

(2) Limitations. Aqueous solution: administer by stomach tube or drench 1 fluid ounce per 100 pounds of body weight. Reconstituted soluble powder: administer by stomach tube 1 fluid ounce per 125 pounds of body weight. If reinfection occurs, re-treat animals at 6- to 8-week intervals. Do not treat animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1242d Levamisole resinate.

(a) Specifications. The drug is levamisole adsorbed on a resin, in a concentration equivalent to 10 percent levamisole hydrochloride. Each 2.05-ounce (58.1 gram) packet contains levamisole equivalent to 5.806 grams of levamisole hydrochloride.

(b) Sponsor. See No. 043781 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.350 of this chapter.

(d) Conditions of use. In swine it is used as follows:

(1) Amount. The equivalent of 8 milligrams per kilogram of body weight, as a single dose, mixed in the animal’s ration.

(2) Indications for use. For the removal of and control of the following nematode infections: large roundworms (Ascaris suum), nodular worms (Oesophagostomum spp.), lungworms (Metastrongylus spp.), intestinal threadworms (Strongyloces ransomi), and swine kidney worms (Stephanurus dentatum).

(3) Limitations. For pigs from weaning to market weight, mix one 58.1-gram packet of levamisole resinate containing the equivalent of 10-percent levamisole hydrochloride in 40 pounds of feed and administer 1 pound of medicated feed per 40 pounds of body weight as sole ration. For breeding swine, mix 1 packet of the 10-percent resinate in 16 pounds of feed and administer 1 pound of medicated feed per 100 pounds of

§ 520.1242e Levamisole hydrochloride effervescent tablets.

(a) Specifications. Each tablet contains 907 milligrams of levamisole hydrochloride.

(b) Sponsor. See No. 043781 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.350 of this chapter.

(d) Conditions of use. It is used for swine as follows:

(1) Amount. The equivalent of 8 milligrams of levamisole hydrochloride per kilogram of body weight, as a single dose.

(2) Indications for use. See §520.1242f(3)(ii).

(3) Limitations. Withholding water from pigs before treatment is not necessary. Add one tablet for each 2½ gallons of water; mix thoroughly. Allow 1 gallon of medicated water for each 100 pounds body weight of pigs to be treated. No other source of water should be offered. After pigs have consumed medicated water, resume use of regular water. Pigs maintained under conditions of constant worm exposure may require re-treatment within 2 to 4 weeks after the first treatment; do not administer to cattle within 6 days of slaughter for food; do not administer to dairy animals of breeding age; consult veterinarian before using in severely debilitated animals.

(2) Breeding swine—(1) Amount. Eight milligrams per kilogram of body weight (3.6 milligrams per pound) as a single oral dose.

(2) Indications for use. For treating breeding swine infected with the following nematodes: Large roundworms (Ascaris suum), nodular worms (Oesophagostomum spp.), lungworms (Metastrongylus spp.), intestinal threadworms (Strongyloides ransomi), and kidney worms (Stephanurus dentatus).

(iii) Limitations. May require retreatment in 4 to 5 weeks. Do not use within 11 days of slaughter for food. Consult your veterinarian for assistance before using in severely debilitated animals and in the diagnosis, treatment, and control of parasitism. Do not administer within 72 hours of slaughter for food.

[45 FR 6087, Jan. 25, 1980]

§ 520.1242f Levamisole hydrochloride gel.

(a) Specifications. The drug is a gel containing 11.5 percent levamisole hydrochloride.

(b) Sponsor. See No. 043781 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.350 of this chapter.

(d) Conditions of use—(1) Cattle—(i) Amount. Eight milligrams of levamisole hydrochloride per kilogram of body weight, as a single oral dose.

(ii) Indications for use. Anthelmintic effective against the following nematode infections: Stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum), and lungworms (Dictyocaulus).

(iii) Limitations. Conditions of constant helminth exposure may require re-treatment within 2 to 4 weeks after the first treatment; do not administer to cattle within 6 days of slaughter for food; do not administer to dairy animals of breeding age; consult veterinarian before using in severely debilitated animals.

(2) Breeding swine—(1) Amount. Eight milligrams per kilogram of body weight (3.6 milligrams per pound) as a single oral dose.

(ii) Conditions of use. For treating breeding swine infected with the following nematodes: Large roundworms (Ascaris suum), nodular worms (Oesophagostomum spp.), lungworms (Metastrongylus spp.), intestinal threadworms (Strongyloides ransomi), and kidney worms (Stephanurus dentatus).

(iii) Limitations. May require retreatment in 4 to 5 weeks. Do not use within 11 days of slaughter for food. Consult your veterinarian for assistance before using in severely debilitated animals and in the diagnosis, treatment, and control of parasitism.

§ 520.1242g Levamisole resinate and famphur paste.

(a) Chemical name of famphur. O, O-Dimethyl O-p-(dimethylsulfamoyl) phenyl phosphorothioate.

(b) Specifications. The drug is a paste containing 11.6 percent levamisole resinate (50 percent potency) and 23.6 percent famphur.

(c) Sponsor. See 000061 in § 510.600(c) of this chapter.

(d) Special considerations. Do not use any cholinesterase-inhibiting drugs, pesticides, insecticides, or chemicals on cattle simultaneously or within a few days before or after treatment with this product.

(e) Related tolerances. See § 556.350 of this chapter for levamisole and § 556.273 of this chapter for famphur.

§ 520.1263 Lincomycin hydrochloride monohydrate oral dosage forms.

§ 520.1263a Lincomycin hydrochloride monohydrate tablets and sirup.

(a) Specifications. The sirup contains lincomycin hydrochloride equivalent to either 25 milligrams or 50 milligrams of lincomycin.

(b) Sponsor. See No. 000009 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated in infections caused by gram-positive organisms which are sensitive to its action, particularly streptococci and staphylococci.

(2) It is administered orally to dogs and cats at a dosage level of 10 mgs per pound of body weight every 12 hours, or 7 mgs per pound of body weight every 8 hours. Treatment may be continued for periods as long as 12 days if clinical judgment indicates.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1263b Lincomycin hydrochloride monohydrate and spectinomycin sulfate tetrahydrate soluble powder.

(a) Specifications. The spectinomycin sulfate tetrahydrate used in manufacturing the drug is the antibiotic substance produced by the growth of Streptomyces spectabilis or the same antibiotic substance produced by any other means. The quantity of total antibiotic activity cited in this section refers to the equivalent weight of the base activity of the drugs. Lincomycin hydrochloride monohydrate and spectinomycin sulfate tetrahydrate are present in the drug in the ratio of 1 to 2 on the basis of equivalency of lincomycin base to equivalency of spectinomycin base.

(b) Sponsor. See No. 000009 in § 510.600(c) of this chapter.

(c) Related tolerances. See §§ 556.600 and 556.360 of this chapter.

(d) Conditions of use. (1) It is administered in the drinking water of chickens.
§ 520.1263c Lincomycin hydrochloride soluble powder.

(a) Specifications. Each 40-gram packet (1.41 ounce) contains lincomycin hydrochloride equivalent to 16 grams of lincomycin. Each 80-gram packet (2.82 ounces) contains lincomycin hydrochloride equivalent to 32 grams of lincomycin. The 40-gram measuring device contains lincomycin hydrochloride equivalent to 16 grams of lincomycin (the measuring device is packaged with a 32-ounce jar).

(b) Sponsors. Approval for use of 40- and 80-gram packets to Nos. 000009 and 046573 in § 510.600(c) of this chapter. Approval for use of 40- and 80-gram packets and 32-ounce jar to No. 051259 in § 510.600(c) of this chapter. Approval for use of 40-gram packet to No. 046573 in § 510.600(c) of this chapter.

(c) Tolerances. See § 556.360 of this chapter.

(d) Conditions of use—(1) It is used in drinking water for swine as follows:
   (i) Amount. 250 milligrams per gallon.
   (A) Dosage. 3.8 milligrams per pound of body weight per day.
   (B) Indications for use. Treatment of swine dysentery (bloody scours).
   (C) Limitations. Discard medicated drinking water if not used within 2 days. Prepare fresh stock solution daily. Do not use for more than 10 days. If clinical signs of disease have not improved within 6 days, discontinue treatment and reevaluate diagnosis. Not for use in swine weighing more than 250 pounds.
   (ii) [Reserved]

(2) It is used in drinking water for broiler chickens as follows:
   (i) Amount. 64 milligrams per gallon.
   (A) Indications for use. For the control of necrotic enteritis caused by Clostridium perfringens susceptible to lincomycin.
   (B) Limitations. Discard medicated drinking water if not used within 2 days. Prepare fresh stock solution daily. Administer for 7 consecutive days. Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to water containing lincomycin. Not for use in layer and breeder chickens.
   (ii) [Reserved]

§ 520.1284 Sodium liothyronine tablets.

(a) Specifications. Sodium liothyronine tablets consist of tablets intended for oral administration which contain liothyronine at 60 or 120 micrograms per tablet, as the sodium salt.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) It is indicated in cases of hypothyroidism in dogs.

(2) It is administered orally to dogs at levels up to 12.8 micrograms per kilogram of body weight per day. Dosage should be adjusted according to the severity of the condition and the response of the patient. Dosage at the total replacement level (12.8µg per kilogram of body weight) should be considered for initiating therapy and then titrated downward for optimum maintenance effect. Twice daily administration is recommended.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1288 Lufenuron tablets.

(a) Specifications—(1) Dogs. Each tablet contains either 45, 90, 204.9, or 409.8 milligrams (mg) of lufenuron.

(2) Cats. Each tablet contains either 90, 135, 204.9 or 270 mg of lufenuron.
§ 520.1320 Mebendazole oral.

(a) Chemical name. Methyl 5-benzyol-benzimidazole-2-carbamate.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use in horses—

(1) Amount. Minimum of 135 milligrams per 250 pounds of body weight per dose, as an oral powder, paste or suspension.

(2) Indications for use. For control of infections caused by roundworms (Parascaris equorum); large strongyles (Strongylus edentatus, S. equinus, S. vulgaris); small strongyles (Starteria spp., Oesophagostomum spp., Oxyuris spp.); and Tapeworms (Taenia spp., Hymenolepis diminuta) in horses.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.

 § 520.1326 Mebendazole and trichlorfon oral dosage forms.

 § 520.1326a Mebendazole and trichlorfon powder.

(a) Specifications. Each gram of powder contains 83.3 milligrams of mebendazole and 375.0 milligrams of trichlorfon.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. Horses—(1) Amount. 8.8 milligrams of mebendazole and 40 milligrams of trichlorfon per kilogram of body weight.

(2) Indications for use. It is used in horses for the treatment of infections of bots (Gastrophilus intestinalis and G. nasalis), large roundworms (Parascaris equorum), large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small strongyles, and pinworms (Oxyuris equi).

(3) Limitations. Administer orally as an individual dose by stomach tube or thoroughly mixed in the ground grain portion of the ration to be consumed in one feeding. Discard treated feed not consumed. Do not administer more than once every 30 days. Do not treat sick or debilitated animals, foals under 4 months of age, or mares in the last month of pregnancy. Trichlorfon is a cholinesterase inhibitor. Do not administer simultaneously or within a few days before or after treatment with, or exposure to, cholinesterase-inhibiting drugs, pesticides or chemicals. Do not administer intravenous anesthetics, especially muscle relaxants, concurrently. Not for horses intended for food use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1326b Mebendazole and trichlorfon paste.

(a) Specifications. Each gram of paste contains 100 milligrams of mebendazole and 454 milligrams of trichlorfon.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

§ 520.1341 Megestrol acetate tablets.

(a) Specifications. Each tablet contains 5 or 20 milligrams of megestrol acetate.

(b) Sponsor. No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in female dogs for the postponement of estrus and the alleviation of false pregnancy. The drug is administered orally, intact, or crushed and mixed with food as follows:

(i) For the postponement of estrus by proestrus treatment, 1 milligram per pound of body weight per day for 8 days.

(ii) For the postponement of estrus by anestrus treatment, 0.25 milligram per pound of body weight per day for 32 days.

(iii) For alleviation of false pregnancy, 1 milligram per pound of body weight per day for 8 days.

(2) It is administered orally, intact, or crushed and mixed with food as follows:

(i) For the postponement of estrus by proestrus treatment, 1 milligram per pound of body weight per day for 8 days.

(ii) For the postponement of estrus by anestrus treatment, 0.25 milligram per pound of body weight per day for 32 days.

(iii) For alleviation of false pregnancy, 1 milligram per pound of body weight per day for 8 days.

(3) Full dosage regimen must be completed to produce the desired effect.
§ 520.1380 Methocarbamol tablets.

(a) Chemical name. 3-(O-Methoxyphenoxy)-1,2-propanediol 1-carbamate.

(b) Specifications. Each tablet contains 500 milligrams of methocarbamol.

(c) Sponsor. See No. 000031 in §510.600(c) of this chapter.

(d) Conditions of use. (1) The drug is administered to dogs and cats as an adjunct to therapy for acute inflammatory and traumatic conditions of the skeletal muscles in order to reduce muscular spasms.

(2) Dosage is based upon severity of symptoms and response noted. The usual initial dose is 60 milligrams per pound of body weight in two or three equally divided doses followed by 30 to 60 milligrams per pound of body weight each following day, usually not to exceed 14 to 21 days.

(3) For use only by or on the order of a licensed veterinarian.

§ 520.1390 (S)-methoprene.

(a) Specifications. Each capsule contains 154, 308, or 462 milligrams (mg) of (S)-methoprene.

(b) Sponsor. See No. 011536 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Amount. Capsules are given orally, once per week at the recommended minimum dosage of 10 mg of (S)-methoprene per pound of body weight (22 mg/kilograms).

(2) Indications for use. For oral use in dogs, 9 weeks of age and older and 4 pounds body weight or greater, for the prevention and control of flea populations. (S)-methoprene prevents and controls flea populations by preventing the development of flea eggs but does not kill adult fleas. Concurrent use of insecticides may be necessary for adequate control of adult fleas.

[65 FR 20730, Apr. 18, 2000]

§ 520.1408 Methylprednisolone tablets.

(a) Specifications. Each tablet contains 1, 2, or 4 milligrams of methylprednisolone.

(b) Sponsor. See No. 000009 in §510.600(c) of this chapter for use of 1- and 4-milligram tablets; see No. 000010 for use of 1- and 2-milligram tablets.

(c) NAS/NRC status. The conditions of use have been NAS/NRC reviewed and found effective. NADA’s for approval of drugs for these conditions of use need not include effectiveness data specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(d) Special consideration. (1) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(2) Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, or cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind.

(3) Anti-inflammatory action of corticosteroids may mask signs of infection.
(e) Conditions of use—(1) Amount. Dogs and cats: 5 to 15 pounds, 2 milligrams; 15 to 40 pounds, 2 to 4 milligrams; 40 to 80 pounds, 4 to 8 milligrams.

(2) Indications for use. For use in dogs and cats as an anti-inflammatory agent.

(3) Limitations. Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1409 Methylprednisolone, aspirin tablets.

(a) Specifications. Each tablet contains 0.5 milligram of methylprednisolone and 300 milligrams of aspirin.

(b) Sponsor. See No. 000009 in § 510.600(c) of this chapter.

(c) NAS/NRC status. The conditions of use have been NAS/NRC reviewed and found effective. New animal drug applications for approval of drugs for these conditions of use need not include effectiveness data specified by § 514.111 of this chapter, but may require bioequivalency and safety information.

(d) Special considerations. (1) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(2) Systemic therapy with methylprednisolone is contraindicated in animals with tuberculosis, chronic nephritis, peptic ulcer, or Cushingoid syndrome. The presence of diabetes mellitus, osteoporosis, predisposition to thrombophlebitis, hypertension, congestive heart failure, or renal insufficiency necessitates carefully controlled use of corticosteroids.

(3) Anti-inflammatory action of corticosteroids may mask signs of infection.

(2) Indications for use. As an anti-inflammatory and analgesic agent in dogs.

(3) Limitations. Administer total daily dose in divided doses 6 to 10 hours apart, with a light feeding. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Do not administer to cats. Do not overdose. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[48 FR 21566, May 13, 1983]

§ 520.1422 Metoserpate hydrochloride.

(a) Chemical name. Methyl-o-methyl-18-epireserpate hydrochloride.

(b) Sponsor. See No. 000003 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.410 of this chapter.

(d) Conditions of use. It is used in drinking water for replacement chickens as follows:

(1) Amount. 568.5 milligrams per gallon (0.015 percent).

(1) Indications for use. As a tranquilizer for flock treatment of chickens prior to handling.

(1) Limitations. To be used one time as a treatment for replacement chickens up to 16 weeks of age; usual drinking water should be withheld prior to treatment to provide adequate consumption of medicated drinking water; not for use in laying chickens; chickens slaughtered within 72 hours following treatment must not be used for food.

(2) Amount. 2 to 4 milligrams per 2.2 pounds of body weight.

(1) Indications for use. As an aid in control of hysteria.

(1) Limitations. To be used as a treatment for replacement chickens up to 16 weeks of age; usual drinking water should be withheld prior to treatment to provide adequate consumption of medicated drinking water; the drug should be administered at a dosage level of 4 milligrams per 2.2 pounds of body weight followed by 2 treatments
§ 520.1430 Mibolerone.
(a) Specifications. Each milliliter contains 100 micrograms of mibolerone.
(b) Sponsor. See No. 000009 in §510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. 30 micrograms for animals weighing 1 to 25 pounds; 60 micrograms for animals weighing 26 to 50 pounds; 120 micrograms for animals weighing 51 to 100 pounds; 180 micrograms for animals weighing over 100 pounds, German Shepherds, or German Shepherd mix.
(2) Indications for use. For the prevention of estrus (heat) in adult female dogs not intended primarily for breeding purposes.
(3) Limitations. Administer daily, orally or in a small amount of food, at least 30 days before expected initiation of heat, and continue daily as long as desired, but not for more than 24 months. Mibolerone should not be used in bitches before the first estrous period. It is not intended for animals being used primarily for breeding purposes. Use orally in adult female dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1445 Milbemycin oxime tablets.
(a) Specifications—(1) Dogs. Each tablet contains 2.3, 5.75, 11.5, or 23.0 milligrams of milbemycin oxime.
(2) Cats. Each tablet contains 5.75, 11.5, or 23.0 milligrams of milbemycin oxime.
(b) Sponsor. See 058198 in §510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use—(1) Dogs and puppies—(i) Amount. For hookworm, roundworm, and whipworm, use 0.23 milligram per pound of body weight (0.5 milligram per kilogram). For heartworm, use 0.05 milligram per pound of body weight (0.1 milligram per kilogram).
(ii) Indications for use. For prevention of heartworm disease caused by Dirofilaria immitis, control of hookworm infections caused by Ancylostoma caninum, and removal and control of adult roundworm infections caused by Toxocara canis and Toxascaris leonina and whipworm infections caused by Trichuris vulpis in dogs and in puppies 4 weeks of age or greater and 2 pounds of body weight or greater.
(iii) Limitations. Do not use in puppies less than 4 weeks of age and less than 2 pounds of body weight. Administer once a month. First dose given within 1 month after first exposure to mosquitoes and continue regular use until at least 1 month after end of mosquito season. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) Cats and kittens—(i) Amount. 0.91 milligram per pound of body weight (2.0 milligrams per kilogram).
(ii) Indications for use. For prevention of heartworm disease caused by Dirofilaria immitis and the removal of adult Toxocara cati (roundworm) and Ancylostoma tubaeforme (hookworm) infections in cats 6 weeks of age or greater and 1.5 pounds body weight or greater.
(iii) Limitations. Do not use in kittens less than 6 weeks of age or 1.5 pounds body weight. Administer once a month. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 520.1446 Milbemycin oxime/lufenuron tablets.
(a) Specifications—(1) Dogs. Each tablet contains 2.3 milligrams milbemycin oxime/46 milligrams lufenuron, 5.75 milligrams/115 milligrams, 11.5 milligrams/230 milligrams, and 23 milligrams/460 milligrams.
(b) Sponsor. See No. 058198 in §510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use—(1) Dogs and puppies—(i) Amount. For hookworm, roundworm, and whipworm, use 0.23 milligram per pound of body weight (0.5 milligram per kilogram). For heartworm, use 0.05 milligram per pound of body weight (0.1 milligram per kilogram).
(ii) Indications for use. For prevention of heartworm disease caused by Dirofilaria immitis, control of hookworm infections caused by Ancylostoma caninum, and removal and control of adult roundworm infections caused by Toxocara canis and Toxascaris leonina and whipworm infections caused by Trichuris vulpis in dogs and in puppies 4 weeks of age or greater and 2 pounds of body weight or greater.
(iii) Limitations. Do not use in puppies less than 4 weeks of age and less than 2 pounds of body weight. Administer once a month. First dose given within 1 month after first exposure to mosquitoes and continue regular use until at least 1 month after end of mosquito season. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Food and Drug Administration, HHS

§ 520.1448a

(flu) for prevention and control of flea populations, control of adult *Ancylostoma caninum* (hookworm), and removal and control of adult *Toxocara canis, Toxascaris leonina* (roundworm), and *Trichuris vulpis* (whipworm) infections. Lufenuron controls flea populations by preventing the development of flea eggs and does not kill adult fleas. Concurrent use of insecticides may be necessary for adequate control of adult fleas.

(iii) Limitations. Administer tablets once a month, preferably on the same date each time. All dogs in a household should be treated to achieve maximum efficacy. Do not use in dogs less than 4 weeks of age and less than 2 pounds body weight. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]


§ 520.1448 Monensin oral dosage forms.

Monensin, as the base or the sodium salt, contains a minimum of 90 percent monensin activity derived from monensin A and a minimum of 95 percent derived from monensin A plus B. Using thin layer chromatography, the *R*<sub>f</sub> value must be comparable to a reference standard (the *R*<sub>f</sub> value is the distance the spots travel from the starting line divided by the distance the solvent front travels from the starting line). The loss on drying is not more than 10 percent when dried in vacuum at 60 °C for 2 hours.

[55 FR 3586, Feb. 2, 1990]

§ 520.1448a Monensin blocks.

(a)(1) Specifications. Each pound of protein-mineral block contains 400 milligrams of monensin (0.088 percent) as monensin sodium.

(2) Sponsor. See 036904 in §510.600(c) of this chapter.

(3) Related tolerances. See §556.420 of this chapter.

(4) Conditions of use—(i) Amount. 80 to 200 milligrams of monensin (0.2 to 0.5 pound of block) per head per day.

(ii) Indications for use. Increased rate of weight gain.

(iii) Limitations. Block to be fed free choice to pasture cattle (slaughter, stocker, feeder, and dairy and beef replacement heifers). Provide at least one block per five head of cattle. Feed blocks continuously. Do not feed salt or
§ 520.1450 Morantel tartrate oral dosage forms.

§ 520.1450a Morantel tartrate bolus.

(a) Specifications. Each bolus contains 2.2 grams morantel tartrate equivalent to 1.3 grams of morantel base.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.425 of this chapter.

(d) Conditions of use—(1) Amount. One bolus per 500 pounds of body weight (4.4 milligrams per pound of body weight) as a single oral dose. Boluses may be divided in half for more accurate dosing as follows: up to 325 pounds, 1⁄2 bolus; 326 to 600 pounds, 1 bolus; 601 to 900 pounds, 11⁄2 boluses; and 901 to 1,200 pounds, 2 boluses.

(2) Indications for use. For removal and control of mature gastrointestinal nematode infections of cattle including stomach worms (Haemonchus spp., Ostertagia spp., Trichostrongylus spp.), worms of the small intestine (Coopera spp., Trichostrongylus spp., Nematodirus spp.), and worms of the large intestine (Oesophagostomum radiatum).

(3) Limitations. Administer orally with the dosing gun to all cattle that will be grazing the same pasture. Effectiveness of the drug product is dependent upon continuous control of the gastrointestinal parasites for approximately 90 days following administration. Therefore, treated cattle should not be moved to pastures grazed in the same grazing season/calendar year by untreated cattle. Do not administer to cattle within 106 days of slaughter. Consult your veterinarian before administering to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1450b Morantel tartrate cartridge.

(a) Specifications. The drug product consists of a stainless-steel cylinder having both ends closed with polyethylene diffusing discs and containing a morantel tartrate paste. The paste contains 22.7 grams of morantel tartrate equivalent to 13.5 grams of morantel base.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.425 of this chapter.

(d) Conditions of use—(1) Amount. Grazing cattle: Administer 1 cartridge to each animal at the start of the grazing season.

(2) Indications for use. For control of the adult stage of the following gastrointestinal nematode infections in weaned calves and yearling cattle weighing a minimum of 200 pounds: Ostertagia spp., Trichostrongylus axei, Cooperia spp., and Oesophagostomum radiatum.

(3) Limitations. Administer orally with the dosing gun to all cattle that will be grazing the same pasture. Effectiveness of the drug product is dependent upon continuous control of the gastrointestinal parasites for approximately 90 days following administration. Therefore, treated cattle should not be moved to pastures grazed in the same grazing season/calendar year by untreated cattle. Do not administer to cattle within 106 days of slaughter. Consult your veterinarian before administering to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1450c Morantel tartrate sustained-release trilaminate cylinder/sheet.

(a) Specifications. The drug product consists of a trilaminated, perforated, plastic sheet formed into a cylinder having plastic plugs in its ends. The core lamina contains 19.8 grams of morantel tartrate equivalent to 11.8 grams of morantel base.

(b) Sponsor. See 000069 in §510.600(c) of this chapter.
§ 520.1451 Moxidectin.

(a) Specifications. Each tablet contains 30, 68, or 136 micrograms of moxidectin.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Amount. 3 micrograms per kilogram (1.36 micrograms per pound) of body weight.

(2) Indications for use. To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease.

(3) Limitations. Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1452 Moxidectin gel.

(a) Specifications. The gel contains 2 percent moxidectin (20 milligrams per milliliter).

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Amount. 0.4 milligram moxidectin per kilogram (2.2 pounds) of body weight.

(2) Indications for use. Horses and ponies for treatment and control of large strongyles (Strongylus vulgaris (adults and L4/L5 arterial stages), S. edentatus (adult and tissue stages), Triodontophorus brevicauda (adults), T. serratus (adults)); small strongyles (Cyathostomum spp. (adults), Cylcycyclus spp. (adults), Cylcistephanus spp. (adults), Gyalocephalus capilatus (adults), undifferentiated luminal larvae); encysted cyathostomes (late L3 and L4 mucosal cyathostome larvae); ascarids (Parascaris equorum (adults and L4 larval stages)); pinworms (Oxyuris equi (adults and L4 larval stages)); hairworms (Trichostrongylus axei (adults)); large-mouth stomach worms (Habronema muscae (adults)); and horse stomach bots (Gasterophilus intestinalis (2nd and 3rd instars) and G. nasalis (3rd instars)). One dose also suppresses strongyle egg production for 84 days.

(3) Limitations. Not for use in horses and ponies intended for food.


§ 520.1468 Naproxen granules.

(a) Specifications. Naproxen granules contain 50 percent naproxen.

(b) Sponsor. No. 000856 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Horses. The drug is used for the relief of inflammation and associated pain and lameness exhibited with arthritis, as well as myositis and other soft tissue diseases of the musculoskeletal system of the horse.

(2)(i) For oral maintenance therapy following initial intravenous dosage, administer 10 milligrams naproxen per kilogram of animal body weight twice daily as top dressing in the animal’s feed for up to 14 consecutive days. The
§ 520.1484 Neomycin sulfate soluble powder.

(a) Specifications. Neomycin sulfate soluble powder contains 20.3 grams of neomycin sulfate (equivalent to 14.2 grams of neomycin base) per ounce.

(b) Sponsors. See 000009, 051259, and 059130 in §510.600(c) of this chapter for use as in paragraph (d)(1) of this section. See 000009 for use as in paragraphs (d)(1) and (d)(2) of this section.

(c) Related tolerances. See §556.430 of this chapter.

(d) Conditions of use—(1) Cattle (excluding veal calves), swine, sheep, and goats.

(i) Amount. 10 milligrams of neomycin sulfate per pound of body weight per day (22 milligrams per kilogram) in divided doses for a maximum of 14 days.

(ii) Indications for use. For the treatment and control of colibacillosis (bacterial enteritis) caused by Escherichia coli susceptible to neomycin sulfate in cattle (excluding veal calves), swine, sheep, and goats.

(iii) Limitations. Add to drinking water; not for use in liquid supplements. Prepare a fresh solution daily. If symptoms persist after using this preparation for 2 or 3 days, consult a veterinarian. Treatment should continue 24 to 48 hours beyond remission of disease symptoms, but not to exceed a total of 14 consecutive days. Discontinue treatment prior to slaughter as follows: 1 day for cattle, 2 days for sheep, and 3 days for swine and goats.

§ 520.1485 Neomycin sulfate oral solution.

(a) Specifications. Each milliliter contains 200 milligrams of neomycin sulfate (equivalent to 140 milligrams of neomycin base).

(b) Sponsors. See Nos. 000009, 051259, and 059130 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.430 of this chapter.

(d) Conditions of use—(1) Amount. 10 milligrams of neomycin sulfate per pound of body weight per day in divided doses for a maximum of 14 days.

(ii) Indications for use. For the treatment and control of colibacillosis (bacterial enteritis) caused by Escherichia coli susceptible to neomycin in cattle (excluding veal calves), swine, sheep, and goats.

(iii) Limitations. Administer undiluted or in drinking water. Prepare a fresh solution daily. If symptoms persist after using this preparation for 2 or 3 days, consult a veterinarian. Treatment should continue 24 to 48 hours beyond remission of disease symptoms, but not to exceed a total of 14 consecutive days. Discontinue treatment prior to slaughter as follows: 1 day for cattle, 2 days for sheep, and 3 days for swine and goats.
§ 520.1510 Nitenpyram.
(a) Specifications. Each tablet contains 11.4 or 57 milligrams of nitenpyram.
(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use—Dogs and cats—(1) Amount. One tablet given orally, as needed.
(2) Indications for use. For the treatment of flea infestations on dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater.
[65 FR 70662, Nov. 27, 2000]

§ 520.1615 Omeprazole.
(a) Specifications. Each gram of oral paste contains 0.37 gram of omeprazole.
(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use—(1) Amount. For treatment of gastric ulcers, 1.8 milligrams of omeprazole per pound of body weight (4 milligrams per kilogram) once daily for 4 weeks. For prevention of recurrence of gastric ulcers, 0.9 milligram of omeprazole per pound of body weight (2 milligrams per kilogram) once daily for at least an additional 4 weeks.
(2) Indications for use. For treatment and prevention of recurrence of gastric ulcers in horses and foals 4 weeks of age and older.
(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[64 FR 18573, Apr. 15, 1999]

§ 520.1616 Orbifloxacin tablets.
(a) Specifications. Each tablet contains 5.7, 22.7, or 68 milligrams of orbifloxacin.
(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use—(1) Dogs and cats—(i) Amount. 2.5 to 7.5 milligrams per kilogram body weight.
(ii) Indications for use. For management of diseases associated with bacteria susceptible to orbifloxacin.
(iii) Limitations. Administer orally once daily for 2 to 3 days beyond cessation of clinical signs for up to a maximum of 30 days. If no improvement is seen within 5 days, diagnosis should be reevaluated and a different course of therapy considered. Orbifloxacin is contraindicated in immature dogs and cats during the rapid growth phase. Orbifloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) [Reserved]

§ 520.1628 Oxfendazole powder and pellets.
(a) Specifications—(1) Powder for suspension. Each gram of powder contains 7.57 percent oxfendazole.
(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use—(1) Amount. 10 milligrams per kilogram of body weight.
(2) Indications for use. The drug is used in horses for removal of the following gastrointestinal worms: Large roundworms (Parascaris equorum), mature and immature pinworms (Oxyuris equi), large strongyles (Strongylus edentatus, Strongylus vulgaris, and Strongylus equinus), and small strongyles.
(3) Limitations—(1) Powder for suspension. For gravity administration via stomach tube or for positive administration via stomach tube and dose syringe. Discard unused portions of suspension after 24 hours. Mix drug according to directions prior to use. Administer drug with caution to sick or debilitated horses. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(ii) Pellets. The drug is given by sprinkling on the grain portion of the ration. Withholding feed or water prior to administration is not necessary. Administer drug with caution to sick or debilitated horses. Not for use in horses intended for food. Consult your
§ 520.1629 Oxfendazole paste.

(a)(1) Specifications. Each gram of paste contains 0.375 gram oxfendazole (37.5 percent).

(2) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. 10 milligrams per kilogram (2.2 pounds) of body weight.

(ii) Indications for use. The drug is used in horses for removal of the following gastrointestinal worms: Large roundworms (Parascaris equorum), mature and 4th stage larvae pinworms (Oxyuris equi), large strongyles (Strongylus edentatus, S. vulgaris, and S. equinus), and small strongyles.

(iii) Limitations. Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks. Withholding feed or water prior to use is unnecessary. Administer drug with caution to sick or debilitated horses. Not for use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(b)(1) Specifications. Each gram of paste contains 185 milligrams of oxfendazole (18.5 percent).

(2) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(3) Related tolerances. See §556.495 of this chapter.

(4) Conditions of use—(1) Amount. 4.5 milligrams per kilogram of body weight (2.05 milligrams per pound).

(ii) Indications for use. The drug is used in cattle for removal of the following worms: lungworms (Dicyocaulus viviparus—adult, L4); stomach worms: barberpole worms (Haemonchus contortus and H. placei—adult), small stomach worms (Trichostrongylus axei—adult), brown stomach worms (Ostertagia ostertagi—adult, L4, inhibited L4); intestinal worms; nodular worms (Oesophagostomum radiatum—adult), hookworms (Buonostomum phlebotomum—adult), small intestinal worms (Cooperia punctata, C. oncophora, and C. mcmasteri—adult, L4); and tape-worms (Moniezia benedeni—adult).

(iii) Limitations. For use in cattle only. Treatment may be repeated in 4 to 6 weeks. Cattle must not be slaughtered until 11 days after treatment. Do not use in female dairy cattle of breeding age. Consult a veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.1630 Oxfendazole suspension.

(a) Specifications. Each milliliter contains 90.6 or 225.0 milligrams oxfendazole (9.06 or 22.5 percent).

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.495 of this chapter.

(1) Amount. 10 milligrams per kilogram (2.2 pounds) of body weight.

(2) Indications for use. For removal of large roundworms (Parascaris equorum), mature and 4th stage larvae pinworms (Oxyuris equi), large strongyles (Strongylus edentatus, S. vulgaris, and S. equinus), and small strongyles.

(3) Limitations. Administer 9.06 percent suspension by stomach tube or dose syringe. Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks. Withholding feed or water prior to use is unnecessary. Administer drug with caution to sick or debilitated horses. Do not use in horses intended for food. If administered by stomach tube: Federal law restricts this drug to use by or on the order of a licensed veterinarian. If administered by dose syringe only: Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(ii) Indications for use. For the removal and control of: lungworms (Dicyocaulus viviparus—adult, L4); stomach worms: barberpole worms (Haemonchus contortus and H. placei—adult), small stomach worms
(Trichostongylus axei—adult), brown stomach worms (Ostertagia ostertagi—adult, L4, inhibited L4); intestinal worms; nodular worms (Oesophagostomum radiatum—adult), hookworms (Bunostomum phlebotomum—adult), small intestinal worms (Cooperia punctata, C. oncophora, and C. mcmasteri—adult, L4), and tape-worms (Moniezia benedeni—adult).

(iii) Limitations. For use in cattle only. Administer 9.06 percent suspension orally only with a dose syringe, and 22.5 percent suspension either orally with a dose syringe or intraruminally with a rumen injector. Treatment may be repeated in 4 to 6 weeks. Cattle must not be slaughtered until 7 days after treatment. Do not use in lactating dairy cattle. For use of 22.5 percent suspension orally: Consult a veterinarian for assistance in the diagnosis, treatment, and control of parasitism. For use of 22.5 percent suspension orally or intraruminally: Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1631 Oxendazole and trichlorfon paste.

(a) Specifications. Each gram of paste contains 28.5 milligrams of oxendazole and 454.5 milligrams of trichlorfon.

(b) Sponsor. See 000069 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. For use other than for removal of bots (Gasterophilus intestinalis, 2nd and 3rd instars; G. nasalis, 3rd instar) and the following gastrointestinal worms: Large roundworms (Parascaris equorum), pinworms (Oxyuris equi), adult and 4th stage larvae; large strongyles (Strongylus edentatus, S. vulgaris, and S. equinus); and small strongyles.

(2) Indications for use. The drug is used in horses for removal of bots (Gasterophilus intestinalis, 2nd and 3rd instars; G. nasalis, 3rd instar) and the following gastrointestinal worms: Large roundworms (Parascaris equorum), pinworms (Oxyuris equi), adult and 4th stage larvae; large strongyles (Strongylus edentatus, S. vulgaris, and S. equinus); and small strongyles.

(3) Limitations. Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks. Withholding feed or water before use is unnecessary. Administer with caution to sick or debilitated horses. Not for use in horses intended for food. Do not administer to mares during the last month of pregnancy. Trichlorfon is a cholinesterase inhibitor. Do not use this product in animals simultaneously with, or within a few days before or after treatment with or exposure to, cholinesterase-inhibiting drugs, pesticides, or chemicals. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1638 Oxibendazole suspension.

(a) Specifications. The suspension contains 22.7 percent oxibendazole.

(b) Sponsor. See 000069 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. For uses other than for removal and control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris); small strongyles (genera Cylcostephanus, Cylicocyclus, Cyathostomum, Trisodontophorus, Cylcodontophorus, and Gyalocephalus); large roundworms (Parascaris equorum); pinworms (Oxyuris equi) including various larval stages; and threadworms (Strongyloides westeri), 15 milligrams per kilogram of body weight.

(2) Indications for use. For removal and control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris); small strongyles (genera Cylcostephanus, Cylicocyclus, Cyathostomum, Trisodontophorus, Cylcodontophorus, and Gyalocephalus); large roundworms (Parascaris equorum); pinworms (Oxyuris equi) including various larval stages; and threadworms (Strongyloides westeri).

(3) Limitations. Administer orally by syringe. Horses maintained on premises where reinfection is likely to occur should be re-treated in 6 to 8 weeks. Not for use in horses intended for food. Consult a veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1640 Oxibendazole paste.

(a) Specifications. The paste contains 10 percent oxibendazole.

(b) Sponsor. See 000069 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. For use other than for removal and control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris); small strongyles (genera Cylcostephanus, Cylicocyclus, Cyathostomum, Trisodontophorus, Cylcodontophorus, and Gyalocephalus); large roundworms (Parascaris equorum); pinworms (Oxyuris equi) including various larval stages; and threadworms (Strongyloides westeri).
milligrams of oxibendazole per kilogram of body weight; for threadworms, 15 milligrams per kilogram of body weight.

(2) Indications for use. For removal and control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris); small strongyles (species of the genera Cylicostephanus Cylicocycicus, Cyathostomum, Triodontophorus, Cylicodontophorus, and Gyaiocephalus); large roundworms (Parascaris equorum); pinworms (Oxyuris equi) including various larval stages; and threadworms (Strongyloides westeri).

(3) Limitations. Administer by stomach tube in 3 to 4 pints of warm water, or by top dressing or mixing into a portion of the normal grain ration. Prepare individual doses to ensure that each animal receives the correct amount. Horses maintained on premises where reinfection is likely to occur should be re-treated in 6 to 8 weeks. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ §520.1660 Oxytetracycline. § 520.1660a Oxytetracycline and carbomycin in combination.

(a) Specifications. (1) Oxytetracycline: The antibiotic substance produced by growth of Streptomyces rimosus or the same antibiotic substance produced by any other means.

(2) Carbomycin: The antibiotic substance produced by growth of Streptomyces halstedii or the same antibiotic substance produced by any other means.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Special considerations. The quantities of oxytetracycline in paragraph (e) of this section refer to the activity of oxytetracycline hydrochloride and the quantities of carbomycin listed refer to the activity of an appropriate standard.

(d) Related tolerances. See §§ 556.110 and 556.500 of this chapter.

(e) Conditions of use. It is used as oxytetracycline hydrochloride plus carbomycin base in drinking water of chickens as follows:

(1) Amount. 1.0 gram of oxytetracycline and 1.0 gram carbomycin per gallon.

(2) Indications for use. As an aid in the prevention and treatment of complicated chronic respiratory disease (air-sac infection) caused by Mycoplasma gallisepticum and secondary bacterial organisms associated with chronic respiratory disease such as E. coli.

(3) Limitations. Administer for not more than 5 days; not for use in chickens producing eggs for human consumption; withdraw 24 hours before slaughter.

§ §520.1660b Oxytetracycline hydrochloride capsules.

(a) Specifications. The drug is in capsule form with each capsule containing 125 or 250 milligrams of oxytetracycline hydrochloride. Oxytetracycline is the antibiotic substance produced by growth of Streptomyces rimosus or the same antibiotic substance produced by any other means.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) It is used in dogs and cats for the treatment of bacterial pneumonia caused by Brucella bronchiseptica, tonsillitis caused by Streptococcus hemolyticus, bacterial enteritis caused by Escherichia coli, urinary tract infections caused by Escherichia coli, and wound infections caused by Staphylococcus aureus.1

(2) The drug is administered orally to dogs and cats at a dosage level of 25–50 milligrams per pound of body weight per day in divided doses at 12-hour intervals. The drug can be used for continuation of compatible antibiotic therapy following parenteral oxytetracycline administration where rapidly attained, sustained antibiotic blood levels are required. The duration of treatment required to obtain favorable response will depend to some extent on the severity and degree of involvement and the susceptibility of the infectious

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
agent. Clinical response to antibiotic therapy usually occurs within 48 to 72 hours. If improvement is not observed within that period, the diagnosis and course of treatment should be reconsidered. To assure adequate treatment, administration of the drug should continue for at least 48 hours following favorable clinical response.\(^1\)

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.\(^1\)

§ 520.1660c Oxytetracycline hydrochloride tablets/boluses.

(a) Specifications. Each tablet or bolus contains 250, 500, or 1,000 milligrams of oxytetracycline hydrochloride.

(b) Sponsors. For sponsors in § 510.600(c) of this chapter: See 000010 for use of 500 and 1,000 milligram boluses. See 000069 for use of 250 and 500 milligram tablets.

(c) Tolerances. See § 556.500 of this chapter.

(d) Conditions of use in beef and dairy cattle—

(1)(i) Amount. 250 milligrams per 100 pounds of body weight every 12 hours (5 milligrams per pound of body weight daily in two doses).

(ii) Indications for use. For control of bacterial enteritis caused by *Salmonella typhimurium* and *Escherichia coli* (coli bacillosis) and bacterial pneumonia (shipping fever complex, pasteurellosis) caused by *Pasteurella multocida*.

(2)(i) Amount. 500 milligrams per 100 pound of body weight every 12 hours (10 milligrams per pound of body weight daily in two doses).

(ii) Indications for use. For treatment of bacterial enteritis caused by *Salmonella typhimurium* and *Escherichia coli* (coli bacillosis) and bacterial pneumonia (shipping fever complex, pasteurellosis) caused by *Pasteurella multocida*.

(3) Limitations. Dosage should continue until the animal returns to normal and for 24 hours to 48 hours after symptoms have subsided. Treatment should not exceed 4 consecutive days. Do not exceed 500 milligrams per 100 pounds of body weight every 12 hours (10 milligrams per pound daily). For sponsor 000069: Discontinue treatment 7 days prior to slaughter. Not for use in lactating dairy cattle.


§ 520.1660d Oxytetracycline hydrochloride soluble powder.

(a) Specifications. The drug is a soluble powder distributed in packets or pails having several concentrations of oxytetracycline hydrochloride (independent of the various net weights) as follows:

(1) Each 18.14 grams of powder contains 1 gram of oxytetracycline hydrochloride (OTC HCl) (packets: 4, 6.4, and 16 oz.).

(2) Each 4.43 grams of powder contains 1 gram of OTC HCl (packets: 4 and 16 oz.).

(3) Each 1.32 grams of powder contains 1 gram of OTC HCl (packets: 2.39, 4.78, and 9.55 oz.; jars: 2.25 lbs.; and pails: 4.5 lbs.).

(4) Each 2.73 grams of powder contains 1 gram of OTC HCl (packets: 2.46 and 9.87 oz; pail: 3.09 lb).

(5) Each 4.2 grams of powder contains 1 gram of OTC HCl (packets: 3.8 and 15.2 oz; pails: 4.74 and 8.7 lb).

(6) Each 1.32 grams of powder contains 1 gram of OTC HCl (packet: 4.78 oz.; pail: 5 lb).

(7) Each 18.1 grams of powder contains 1 gram of OTC HCl (packet: 6.4 oz.; pails: 2 and 5 lb), each 272.2 grams (9.6 oz) of powder contains 204.8 grams of OTC HCl, each 907.2 grams (2 lb) of powder contains 686 grams of OTC HCl, each 2.26 kilograms (5 lb) of powder contains 1,715 grams of OTC HCl.

(8) Each 135.5-gram packet (4.78 ounce) contains 102.4 grams of OTC HCl. Each 677.5-gram packet (23.9 ounce) contains 512 grams of OTC HCl.

(9) Each 2.73 grams of powder contains 1 gram of OTC HCl (packets: 9.87 and 19.75 oz; pails: 3.09 and 5 lb).

(b) Sponsor. See sponsor numbers in § 510.600(c) of this chapter as follows:

(1) No. 000069 for use of OTC HCl concentrations in paragraphs (a)(1), (a)(2), and (a)(3) of this section in chickens, turkeys, swine, cattle, sheep, and honey bees.

(2) No. 046573 for use of OTC HCl concentration in paragraph (a)(4) of this
(3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 days. Not to be used for more than 14 consecutive days. Use as sole source of drinking water. Do not use in birds producing eggs for human consumption. Withdraw 5 days prior to slaughter those products sponsored by Nos. 000069 and 059130 in §510.600(c) of this chapter. Withdraw 4 days prior to slaughter those products sponsored by No. 000010. Zero-day withdrawal for those products sponsored by Nos. 046573, 053389, 057561, and 061133.

(B)(1) Amount per gallon. 400 milligrams.

(2) Indications for use. Control of infectious synovitis caused by Mycoplasma synoviae susceptible to oxytetracycline.

(3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 days. Not to be used for more than 14 consecutive days. Use as sole source of drinking water. Do not use in birds producing eggs for human consumption. Withdraw 5 days prior to slaughter those products sponsored by Nos. 000069 and 059130 in §510.600(c) of this chapter. Withdraw 4 days prior to slaughter those products sponsored by No. 000010. Zero-day withdrawal for those products sponsored by Nos. 046573, 053389, 057561, and 061133.

(C)(1) Amount. 25 milligrams per pound of body weight.

(2) Indications for use. Growing turkeys. Control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis) susceptible to oxytetracycline.

(3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 days. Not to be used for more than 14 consecutive days. Use as sole source of drinking water. Do not use in birds producing eggs for human consumption. Withdraw 5 days prior to slaughter those products sponsored by Nos. 000069 and 059130 in §510.600(c) of this chapter. Withdraw 4 days prior to slaughter those products sponsored by No. 000010. Zero-day withdrawal for those products sponsored by Nos. 046573, 053389, 057561, and 061133.

(iii) Swine—(A) Amount. 10 milligrams per pound of body weight daily.
§ 520.1696a

(B) Indications for use. Control and treatment of bacterial enteritis caused by Escherichia coli and Salmonella choleraesuis and bacterial pneumonia caused by Pasteurella multocida susceptible to oxytetracycline. For breeding swine: Control and treatment of leptospirosis (reducing the incidence of abortions and shedding of leptospira) caused by Leptospira pomona susceptible to oxytetracycline.

(C) Limitations. Prepare a fresh solution daily. Use as sole source of OTC. Administer up to 14 days; do not use for more than 14 consecutive days; withdraw 5 days prior to slaughter those products sponsored by No. 059130 and zero days those products sponsored by Nos. 046573, 057561, and 061133.

(iv) Calves, beef cattle, and nonlactating dairy cattle—

(A) Amount. 10 milligrams per pound of body weight daily.

(B) Indications for use. Control and treatment of bacterial enteritis caused by E. coli and bacterial pneumonia (shipping fever complex) caused by P. multocida susceptible to oxytetracycline.

(C) Limitations. Prepare a fresh solution daily. Administer up to 14 days. Do not use for more than 14 consecutive days. Use as sole source of oxytetracycline. Do not administer this product with milk or milk replacers. Administer 1 hour before or 2 hours after feeding milk or milk replacers. Withdraw 5 days prior to slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in female dairy cattle 20 months of age or older.

(v) Sheep—

(A) Amount. 10 milligrams per pound of body weight daily.

(B) Indications for use. Control and treatment of bacterial enteritis caused by E. coli and bacterial pneumonia (shipping fever complex) caused by P. multocida susceptible to oxytetracycline.

(C) Limitations. Prepare a fresh solution daily. Administer up to 14 days. Do not use for more than 14 consecutive days. Use as sole source of oxytetracycline. Withdraw 5 days prior to slaughter.

(2) It is used in the food of honey bees as follows:

(i) Amount. 200 milligrams per colony, administered via either a 1:1 sugar syrup (equal parts of sugar and water weight to weight) or dusting with a powdered sugar mixture.

(ii) Indications for use. Control and treatment of American and European foul brood caused by Bacillus larvae susceptible to oxytetracycline.

(iii) Limitations. The drug is administered in 3 applications of sugar syrup or 3 dustings at 4- to 5-day intervals. The drug should be fed early in the spring or fall and consumed by the bees before main honey flow begins to avoid contamination of production honey. Remove at least 6 weeks prior to main honey flow.

[50 FR 32694, Aug. 14, 1985]

EDITORIAL NOTE: For Federal Register citations affecting § 520.1660d, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.
§ 520.1696b Penicillin G potassium in drinking water.

(a) Specifications. When reconstituted, each milliliter contains penicillin G potassium equivalent to 20,000, 25,000, 40,000, 50,000, 80,000, or 100,000 units of penicillin G.

(b) Sponsors. See Nos. 046573, 053501, and 061133 in §510.600(c) of this chapter.

(c) Conditions of use. Turkeys—(1) Amount. 1,500,000 units per gallon drinking water for 5 days.

(2) Indications for use. Treatment of erysipelas caused by Erysipelothrix rhusiopathiae.

(3) Limitations. Prepare concentrated stock solution for use with medication proportioners fresh every 24 hours. Prepare recommended use levels for gravity flow watering system fresh every 12 hours. For best results, treatment should be started at the first sign of infection. Discontinue treatment at least 1 day prior to slaughter. Not for use in turkeys producing eggs for human consumption.


§ 520.1696c Penicillin V potassium for oral solution.

(a) Specifications. When reconstituted, each milliliter contains 25 milligrams (40,000 units) of penicillin V.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) National Academy of Sciences/National Research Council (NAS/NRC) status. The conditions of use were NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

§ 520.1720 Phenylbutazone oral dosage forms.

§ 520.1720a Phenylbutazone tablets and boluses.

(a) Specifications. Each tablet contains 100, 200, or 400 milligrams, or 1
Food and Drug Administration, HHS

§ 520.1720b Phenylbutazone granules.

(a) Specifications. The drug is in granular form. It is packaged to contain either 8 grams of phenylbutazone per package or 1 gram of phenylbutazone per package.

(b) Sponsor. See 000061 in § 510.600(c) for 8-gram package, see 059320 for 1-gram package.

(c) NAS/NRC status. The conditions of use have been NAS/NRC reviewed and found effective. NADA’s for approval of drugs for these conditions of use need not include effectiveness data specified by § 514.111 of this chapter, but may require bioequivalency and safety information.

(d) Conditions of use—(1) Horses—(i) Amount. 1 to 2 grams per 500 pounds of body weight, not to exceed 4 grams, daily, as required.

(ii) Indications. For the treatment of inflammatory conditions associated with the musculoskeletal system.

(iii) Limitations. Administer orally by adding to a portion of the usual grain ration. Use a relatively high dose for the first 48 hours, then gradually reduce to a maintenance level at the lowest level capable of producing the desired clinical response. Treated animals should not be slaughtered for food use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Horses—(i) Amount. One to two grams per 500 pounds weight daily.

(ii) Indications for use. This drug is used for the relief of inflammatory conditions associated with the musculoskeletal system.

(iii) Limitations. Do not exceed a daily dosage of 4 grams per day. Administer at a relatively high dosage level for the first 48 hours and then reduce gradually to a maintenance dosage level with the lowest dosage maintained at the level capable of producing the desired clinical response. Not for use in animals intended for food purposes. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


1 See footnote 1 to § 520.1660b.
§ 520.1720c Phenylbutazone paste.

(a) Specifications. The paste contains 20 percent phenylbutazone.

(b) Sponsor. See 000061 and 010797 in §510.600(c) of this chapter.

(c) NAS/NRC status. The conditions of use are NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(d) Conditions of use in horses—(1) Amount. 1 to 2 grams of phenylbutazone per 500 pounds of body weight, not to exceed 4 grams daily.

(2) Indications for use. For relief of inflammatory conditions associated with the musculoskeletal system.

(3) Limitations. Use a relatively high dose for the first 48 hours, then gradually reduce to a maintenance level of the lowest level capable of producing the desired clinical response. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1720d Phenylbutazone gel.

(a) Specifications. Each 30 grams of gel contains 4 grams of phenylbutazone.

(b) Sponsor. See 061133 in §510.600(c) of this chapter.

(c) NAS/NRC status. The conditions of use are NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified in §514.111 of this chapter, but may require bioequivalency and safety information.

(d) Conditions of use in horses—(1) Amount. 1 to 2 grams of phenylbutazone per 500 pounds of body weight, not to exceed 4 grams daily.

(2) Indications for use. For relief of inflammatory conditions associated with the musculoskeletal system of horses.

(3) Limitations. Use a relatively high dose for the first 48 hours, then gradually reduce to a maintenance level at the lowest level capable of producing the desired clinical response. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1802 Piperazine-carbon disulfide complex oral dosage forms.

§ 520.1802a Piperazine-carbon disulfide complex suspension.

(a) Specifications. Each fluid ounce of suspension contains 7.5 grams of piperazine-carbon disulfide complex. The piperazine-carbon disulfide complex contains equimolar parts of piperazine and carbon disulfide (1 gram contains 530 mgs of piperazine and 470 mgs of carbon disulfide).

(b) Sponsor. See 000009 in §510.600(c) of this chapter.

(c) Conditions of use. Horses and ponies—(1) Amount. One fluid ounce per 100 pounds of body weight.

(2) Indications for use. For removing ascarids (large roundworms, Parascaris equorum), bots (Gastrophilus spp.), small strongyles, large strongyles (Strongyles spp.), and pinworms (Oxyuris equi).

(3) Limitations. Administer by stomach tube or dose syringe after withholding feed overnight or for 8 to 10 hours. Provide water as usual. Resume regular feeding 4 to 6 hours after treatment. Treatment of debilitated or anemic animals is contraindicated. Do not administer to animals that are or were recently affected with colic, diarrhea, or infected with a serious infectious disease. As with most anthelmintics, drastic cathartics and other gastrointestinal irritants should not be administered in conjunction with this drug. Animals in poor condition or heavily parasitized should be given one half the recommended dose and treated again in 2 or 3 weeks. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1802b Piperazine-carbon disulfide complex oral dosage forms.
Food and Drug Administration, HHS

§ 520.1802b Piperazine-carbon disulfide complex boluses.

(a) Specifications. Each bolus contains 20 grams of piperazine-carbon disulfide complex.

(b) Sponsor. See 000009 in §510.600(c) of this chapter.

(c) Conditions of use: Horses and ponies—(1) Amount. For removal of ascarids and small strongyles, 1 bolus (20 grams) per 500 pounds body weight; removal of large strongyles, pinworms, and bots, 1 bolus per 250 pounds body weight.1

(2) Indications for use. For removing ascarids (large roundworms, Parascaris equorum), large strongyles (Strongylus spp.), bots (Gastrophilus spp.), small strongyles, and pinworms (Oxyuris equi).1

(3) Limitations. Withhold feed overnight or for 8 to 10 hours. Give water just before and/or after treatment. Resume regular feeding 4 to 6 hours after treatment. Treatment of debilitated or anemic animals is contraindicated. Do not administer to animals that are or were recently affected with colic, diarrhea, or infected with a serious infectious disease. As with most anthelmintics, drastic cathartics or other gastrointestinal irritants should not be administered in conjunction with this drug. Animals in poor condition or heavily parasitized should be given one half the recommended dose and treated again in 2 or 3 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.1

[45 FR 52782, Aug. 8, 1980]

§ 520.1802c Piperazine-carbon disulfide complex with phenothiazine suspension.

(a) Specifications. Each fluid ounce contains 5 grams of piperazine-carbon disulfide complex and 0.83 gram of phenothiazine.

(b) Sponsor. See 000009 in §510.600(c) of this chapter.

(c) Conditions of use: Horses and ponies—(1) Amount. One fluid ounce per 100 pounds of body weight.

(2) Indications for use. For removing ascarids (large roundworms, Parascaris equorum), bots (Gastrophilus spp.), small strongyles, and large strongyles (Strongylus spp.).

(3) Limitations. See §520.1802b(c)(3).

[45 FR 52782, Aug. 8, 1980]

§ 520.1803 Piperazine citrate capsules.

(a) Specifications. Each capsule contains piperazine citrate equivalent to 140 milligrams of piperazine base in each capsule.

(b) Sponsor. See No. 021091 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 60 milligrams of piperazine phosphate monohydrate per pound of body weight.1

(ii) Cats. It is used for the removal of large roundworms (ascarids) Toxocara mystax and Toxascaris leonina.1

[40 FR 13838, Mar. 27, 1975, as amended at 54 FR 38515, Sept. 19, 1989]

§ 520.1804 Piperazine phosphate capsules.

(a) Specifications. Each capsule contains 120, 300, or 600 milligrams of piperazine phosphate monohydrate.

(b) Sponsor. See No. 050906 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 60 milligrams of piperazine phosphate monohydrate per pound of body weight.1

(2) Indications for use—(1) Dogs. It is used for the removal of large roundworms (ascarids) Toxocara canis and Toxascaris leonina.1

(ii) Cats. It is used for the removal of large roundworms (ascarids) Toxocara mystax and Toxascaris leonina.1

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
§ 520.1805

(3) Limitations. Administer in animal’s food or milk. For animals up to 1 year of age administer every 2 or 3 months; for animals over 1 year old, administer periodically as necessary. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1805 Piperazine phosphate with thenium closylate tablets.

(a) Specifications. Each scored tablet contains the equivalent of 250 milligrams piperazine hexahydrate (as piperazine phosphate) and 125 milligrams thenium (as thenium closylate) or 500 milligrams piperazine hexahydrate (as piperazine phosphate) and 250 milligrams thenium (as thenium closylate).

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer orally to dogs as follows:

<table>
<thead>
<tr>
<th>Animal weight (lb)</th>
<th>375 mg</th>
<th>750 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 but less than 5</td>
<td>½</td>
<td>1</td>
</tr>
<tr>
<td>5 but less than 10</td>
<td>1</td>
<td>1½</td>
</tr>
<tr>
<td>10 or heavier</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

(2) Indications for use. For removal of immature (fourth stage larvae) and adult hookworms (Ancylostoma caninum, A. braziliense, and Uncinia stenocephala) and ascarids (Toxocara canis) from weaned pups and adult dogs.

(3) Limitations. Do not use this product to treat dogs weighing less than 2 pounds, unweaned pups, or pups under 5 weeks of age. Maximum efficacy against hookworms necessitates two doses in 1 day of treatment. The interval between the doses should be not less than 4 hours or more than 24 hours. Administer the first dose in the morning before feeding. Do not permit dog to chew tablet. Feed the dog between doses. Do not feed milk or other fatty foods during treatment. Retreatment may be needed in 7 to 28 days as determined by laboratory fecal examinations or in animals kept in known contaminated quarters. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1806 Piperazine monohydrochloride liquid.

(a) Specifications. The product contains 4.77 percent piperazine monohydrochloride, equivalent to 3.35 percent piperazine base.

(b) Sponsor. See Nos. 017135 and 063765 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. For dogs for the removal of roundworms (Toxocara canis and Toxascaris leonina).

(2) Dosage. Administer 20 to 30 milligrams of piperazine base per pound of body weight as a single dose.

(3) Limitations. Administer by mixing into the animal’s ration to be consumed at one feeding. For animals in heavily contaminated areas, reworm at monthly intervals. Not for use in unweaned pups or animals less than three weeks of age. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1807 Piperazine.

(a) Specifications. A soluble powder or liquid containing piperazine dihydrochloride or dipiperazine sulfate, equivalent to 17, 34, or 230 grams of piperazine per pound or 100 milliliters.

(b) Sponsor. See 015565 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.513 of this chapter.

(d) Conditions of use—(1) Chickens—(i) Amount. 50 milligrams per bird under 6 weeks, 100 milligrams per bird over 6 weeks.

(ii) Indications for use. For removal of large roundworm (Ascaridia spp.).

(iii) Limitations. For use in drinking water or feed. Use as sole source of drinking water. Prepare fresh solution daily. Use as 1-day single treatment. Withdraw 14 days prior to slaughter. Do not use for chickens producing eggs for human consumption. Consult your veterinarian periodically as necessary. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.1846 Polyoxalene.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section.

(d) Conditions of use. (1) For treatment of legume (alfalfa, clover) bloat in cattle. A 53-percent poloxalene top dressing on individual rations of ground feed. Dosage is 1 gram of poloxalene per 100 pounds of body weight daily. If bloat conditions are severe, the dose is doubled. Treatment should be started 2 to 3 days before exposure to bloat-producing conditions. Repeat use of the drug if animals are exposed to bloat-producing conditions for more than 12 hours after the last treatment. Do not exceed the double dose in any 24-hour period.

(2) For control of legume (alfalfa, clover) and wheat pasture bloat in cattle. Administer in molasses block containing 6.6 percent poloxalene, at the rate of 0.8 ounce of block (1.5 grams of poloxalene) per 100 pounds of body weight per day. Provide access to blocks at least 7 days before exposure to bloat-producing conditions.

[§520.1846 Polyoxalene. as amended at 40 FR 48189, Nov. 22, 1975, as amended at 50 FR 48189, Nov. 22, 1985]

§ 520.1846 Polyoxalene.

(a) Specifications. Each molasses-based block contains 2.2 percent polyoxymethylene-23 polyoxyethylene glycol nonionic block polymer.

(b) Sponsor. See No. 050112 in §510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. 2 grams of polyoxymethylene-23 lauryl ether per 100 kilograms of body weight per day (1 pound of block per 500 kilogram (1,100 pound) animal per day).

(2) Indications for use. For reduction of the incidence of bloat (alfalfa and clover) in pastured cattle.

(3) Limitations. Administer free-choice to beef cattle and nonlactating dairy cattle only. Initially, provide one block per five head of cattle. Start treatment 10 to 14 days before exposure to bloat-producing pastures. Do not allow cattle access to other sources of salt while being fed this product. Do not feed this product to animals without adequate forage/roughage consumption.
§ 520.1855 Ponazuril.

(a) Specifications. Each gram of paste contains 150 milligrams (mg) ponazuril.

(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 5 mg per kilogram body weight, daily for 28 days.

(2) Indications for use. For the treatment of equine protozoal myeloencephalitis caused by Sarcocystis neurona.

(3) Limitations. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[66 FR 43774, Aug. 21, 2001]

§ 520.1870 Praziquantel tablets.

(a) Specifications. Each dog tablet contains 34 milligrams (mg) of praziquantel; each cat tablet contains 11.5 or 23 mg of praziquantel.

(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Indications for use. For removal of canine cestodes Dipylidium caninum and Taenia pisiformis. If labeled for use by or on the order of a licensed veterinarian, for removal of the canine cestode Echinococcus granulosus, and for removal and control of the canine cestode Echinococcus multilocularis.

(ii) Dosage. Dogs 5 pounds and under, 1/2 tablet (17 mg); 6 to 10 pounds, 1 tablet (34 mg); 11 to 15 pounds, 1 1/2 tablets (51 mg); 16 to 30 pounds, 2 tablets (68 mg); 31 to 45 pounds, 3 tablets (102 mg); 46 to 60 pounds, 4 tablets (136 mg); over 60 pounds, 5 tablets maximum (170 mg).

(iii) Limitations. Administer directly by mouth or crumbled and in feed. Not intended for use in puppies less than 4 weeks of age. For over-the-counter (OTC) use: Consult your veterinarian before administering tablets to weak or debilitated animals, and for assistance in the diagnosis, treatment, and control of parasitism. For prescription use: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cats—(i) Indications for use. For removal of feline cestodes Dipylidium caninum and Taenia taeniaeformis.

(ii) Dosage. Cats 4 pounds and under, 11.5 mg; 5 to 11 pounds, 23 mg; over 11 pounds, 34.5 mg.

(iii) Limitations. Administer directly by mouth or crumbled and in feed. Not intended for use in kittens less than 6 weeks of age. For OTC use: Consult your veterinarian before administering tablets to weak or debilitated animals, and for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1871 Praziquantel/pyrantel pamoate tablets.

(a) Specifications. Each tablet contains 18.2 milligrams (mg) praziquantel with 72.6 mg pyrantel (as pyrantel pamoate).

(b) Sponsor. See 000859 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Cats—(i) Dosage. 1.5 to 1.9 pounds, 1/4 tablet; 2 to 3 pounds, 1/2 tablet; 4 to 8 pounds, 1 tablet; 9 to 12 pounds, 1 1/2 tablets; 13 to 16 pounds, 2 tablets.

(ii) Indications for use. For removal of tapeworms (Dipylidium caninum and Taenia taeniaeformis), hookworms (Ancylostoma tubaeforme), and large roundworms (Toxocara cati) in cats and kittens.

(iii) Limitations. Not for use in kittens less than 1 month of age or weighing less than 1.5 pounds. May be given directly by mouth or in a small amount of food. Do not withhold food prior to or after treatment. If reinfection occurs, treatment may be repeated. Consult your veterinarian before giving to sick or pregnant animals. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(2) [Reserved]

[58 FR 58652, Nov. 3, 1993]

§ 520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.

(a) Specifications. Each tablet contains either:

(1) Tablet No. 1: 22.7 milligrams praziquantel, 22.7 milligrams pyrantel base, and 113.4 milligrams febantel; or
Food and Drug Administration, HHS

§520.1900

(2) Tablet No. 2: 68 milligrams praziquantel, 68 milligrams pyrantel base, and 340.2 milligrams febantel.

(b) Sponsor. See 000859 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(1) Amount. Administer as a single dose directly by mouth or in a small amount of food as follows:

<table>
<thead>
<tr>
<th>Weight of animal</th>
<th>Number of tablets per dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kilograms</td>
<td>Pounds</td>
</tr>
<tr>
<td>0.9 to 1.8 .......</td>
<td>2 to 4</td>
</tr>
<tr>
<td>2.3 to 3.2 .......</td>
<td>5 to 7</td>
</tr>
<tr>
<td>3.6 to 5.4 .......</td>
<td>8 to 12</td>
</tr>
<tr>
<td>5.9 to 8.2 .......</td>
<td>13 to 18</td>
</tr>
<tr>
<td>8.6 to 11.4 .......</td>
<td>19 to 25</td>
</tr>
<tr>
<td>11.8 to 13.6 .......</td>
<td>26 to 30</td>
</tr>
<tr>
<td>14.1 to 20.9 .......</td>
<td>31 to 44</td>
</tr>
<tr>
<td>20.4 to 27.2 .......</td>
<td>45 to 60</td>
</tr>
<tr>
<td>27.7 to 33.6 .......</td>
<td>61 to 74</td>
</tr>
<tr>
<td>34.0 to 40.9 .......</td>
<td>75 to 90</td>
</tr>
<tr>
<td>41.3 to 47.2 .......</td>
<td>91 to 104</td>
</tr>
<tr>
<td>47.7 to 54.5 .......</td>
<td>105 to 120</td>
</tr>
</tbody>
</table>

(2) Do not use in viral infections. Systemic therapy with prednisolone is contraindicated in animals with peptic ulcer, corneal ulcer, and Cushing syndrome. The presence of diabetes, osteoporosis, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency, and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs but should be kept in mind.

(3) Anti-inflammatory action of corticosteroids may mask signs of infection.

(d) Conditions of use—(1) Amount. Dogs: 2.5 milligrams per 4.5 kilograms (10 pounds) body weight per day. Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved.

(2) Indications for use. For use in dogs as an anti-inflammatory agent.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§520.1900 Primidone tablets.

(a) Specifications. Each tablet contains 50 or 250 milligrams of primidone.

(b) Sponsor. See No. 000010 in §510.600(c) of this chapter for use of 250 milligram tablets; see No. 000856 in §510.600(c) of this chapter for use of 50 and 250 milligram tablets.

(c) Conditions of use in dogs—(1) Amount. Twenty-five milligrams of primidone per pound of body weight (55 milligrams per kilogram of body weight) daily.1

(2) Indications for use. For the control of convulsions associated with idiopathic epilepsy, epileptiform convulsions, viral encephalitis, distemper, and hardpad disease that occurs as a

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
§ 520.1920 Prochlorperazine, isopropamide, with neomycin sustained-release capsules.

(a) Specifications. Each capsule contains either:
(1) Capsule No. 1: 3.33 milligrams of prochlorperazine (as the dimaleate), 1.67 milligrams of isopropamide (as the iodide), and 25 milligrams of neomycin base (as the sulfate); or
(2) Capsule No. 3: 10 milligrams of prochlorperazine (as the dimaleate), 5 milligrams of isopropamide (as the iodide), and 75 milligrams of neomycin base (as the sulfate).

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer capsules orally twice daily to dogs as follows:

<table>
<thead>
<tr>
<th>Animal weight (pounds)</th>
<th>Capsule No. 1</th>
<th>Capsule No. 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 to 20</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>20 to 30</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Over 30</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Over 60</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(2) Indications for use. For treatment of dogs in which infectious bacterial gastroenteritis is associated with emotional stress.

(3) Limitations. Do not continue medication longer than 5 days. Overdosage or prolonged administration may produce nephrotoxicity as manifested by albuminuria, presence of granular casts and depressed urinary output. If it is desirable to administer a vasoconstrictor, norepinephrine is the drug of choice. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1962 Promazine hydrochloride.

(a)(1) Chemical name. 10-[3-(Dimethylamino)propyl]phenothiazine monohydrochloride.

(2) Specifications. Conforms to N.F. XII.

(3) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(4) [Reserved]

(5) Conditions of use. (i) The drug is used for quieting excitable, unruly, or
intractable horses. It is administered at a dosage level of 0.45 to 0.9 milligrams of promazine hydrochloride per pound of body weight mixed with an amount of feed that will be readily consumed.

(ii) Do not use in horses intended for food.

(iii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b) [Reserved]

§ 520.2002 Propiopromazine hydrochloride.

(a) Chemical name. 1-Propanone, 1-[10-(3-(dimethylamino) propyl)-phenothiazine-2-yl]-monohydrochloride.

(b) Specifications. The drug is administered in a chewable tablet containing 10 to 20 milligrams of propiopromazine hydrochloride.

(c) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(d) Conditions of use. (1) The drug is intended for oral administration to dogs as a tranquilizer. It is used as an aid in handling difficult, excited, and unruly dogs, and in controlling excessive kennel barking, car sickness, and severe dermatitis. It is also indicated for use in minor surgery and prior to routine examinations, laboratory procedures, and diagnostic procedures.

(2) It is administered at the rate of 0.5 to 2 milligrams of propiopromazine hydrochloride per pound of body weight once or twice daily depending upon the degree of tranquilization desired.

NOTE: Not for use with organophosphates and/or procaine hydrochloride, as phenothiazine may potentiate the toxicity of organophosphates and the activity of procaine hydrochloride. Overdosage may produce significant depression.

(3) For use only by or on the order of a licensed veterinarian.

§ 520.2004 Pyrantel pamoate chewable tablets.

(a) Specifications. Each tablet contains pyrantel pamoate equivalent to 22.7 or 113.5 milligrams pyrantel base.

(b) Sponsor. See Nos. 017135 and 065274 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Provides at least 2.27 milligrams pyrantel base per pound body weight for dogs weighing more than 5 pounds, and at least 4.54 milligrams of pyrantel base per pound body weight for dogs weighing 5 pounds or less.

(2) Indications for use—(i) In dogs and puppies. For removal of ascarids (Toxocara canis; Toxascaris leonina) and hookworms (Ancylostoma caninum; Uncinaria stenocephala).

(ii) In puppies and adult dogs and in lactating bitches after whelping. To prevent reinfection of Toxocara canis.

(3) Limitations. Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Retreatment of adult dogs may be necessary at monthly intervals as determined by laboratory fecal examinations. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.2042 Pyrantel pamoate tablets.

(a) Specifications. Each tablet contains pyrantel pamoate equivalent to 22.7, 45.4, or 113.5 milligrams of pyrantel base.

(b) Sponsor. See No. 017135 in § 510.600(c) of this chapter.

(c) Conditions of use. It is used for dogs as follows:

(1) Amount. For dogs weighing over 5 pounds, use at least 2.27 milligrams of pyrantel base per pound body weight; for dogs weighing 5 pounds or less, use at least 4.54 milligrams of pyrantel base per pound body weight.

(2) Indications for use. For removal and control of large roundworms (ascarids) (Toxocara canis and Toxascaris leonina), and hookworms
§ 520.2043 Pyrantel pamoate suspension

(Ancylostoma caninum and Uncinaria stenocephala).

(3) Limitations. Administer orally directly or in a small amount of food. To prevent reinfection of T. canis in puppies, lactating bitches after whelping, and adult dogs; treat puppies 2, 3, 4, 6, 8, and 10 weeks of age; treat lactating bitches 2 to 3 weeks after whelping; routinely treat adult dogs monthly. Do not withhold food prior to or after treatment. The presence of these parasites should be confirmed by laboratory fecal examination. A followup fecal examination should be conducted 2 to 4 weeks after first treatment regimen to determine the need for re-treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.2043 Pyrantel pamoate suspension.

(a)(1) Specifications. Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 50 milligrams of pyrantel base per milliliter.

(2) Sponsors. See Nos. 000069 and 059130 in §510.600(c) of this chapter.

(3) Conditions of use. It is used in horses and ponies as follows:

(i) Amount. Equivalent of 3 milligrams of pyrantel base per pound of body weight.

(ii) Indications for use. For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris, Strongylus edentatus, Strongylus equinus), small strongyles, pinworms (Oxyuris), and large roundworms (Parascaris).

(iii) Limitations. Administered as a single dose mixed with the usual grain ration, or by stomach tube, or by dose syringe. Not for use in horses and ponies to be slaughtered for food purposes. When the drug is for administration by stomach tube, it shall be labeled: "Federal law restricts this drug to use by or on the order of a licensed veterinarian." When the drug is not for administration by stomach tube, it shall be labeled: "Consult your veterinarian for assistance in the diagnosis, control, and treatment of parasitism."

(b)(1) Specifications. Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.

(2) Sponsors. See Nos. 000069, 011615, and 059130 for use of 2.27 and 4.54 milligrams per milliliter product. See No. 022851 for use of 4.54 milligrams per milliliter product.

(3) Conditions of use. It is used in puppies and dogs as follows:

(i) Amount. Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.

(ii) Indications for use. To prevent re-infections of Toxocara canis.

(iii) Limitations. Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.2044 Pyrantel pamoate paste.

(a) Specifications. Each milliliter of paste contains 180 milligrams of pyrantel base (as pyrantel pamoate).

(b) Sponsor. See 000069 in §510.600(c) of this chapter.
(c) **Conditions of use.** It is used in horses and ponies as follows:

1. **Amount.** Equivalent of 3 milligrams pyrantel base per pound of body weight.
2. **Indications for use.** For removal and control of infections from the following mature parasites: large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum).
3. **Limitations.** Administer as single dose by depositing paste on dorsum of the tongue using the dose syringe. Not for use in horses intended for food. It is recommended that severely debilitated animals not be treated with this preparation. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.2045 Pyrantel tartrate powder; pyrantel tartrate pellets.

(a) **Specifications.**

1. Pyrantel tartrate powder horse wormer contains 11.3 percent and swine wormer 10.6 percent pyrantel tartrate.
2. Pyrantel tartrate pellets colt and horse wormer contains 1.25 percent pyrantel tartrate.

(b) **Sponsor.**

1. See No. 000069 in § 510.600(c) of this chapter for conditions of use provided for in paragraph (d)(1) of this section.
2. See No. 060594 in § 510.600(c) of this chapter, for conditions of use provided for in paragraph (d)(3) of this section.

(c) **Related tolerances.** See § 556.560 of this chapter.

(d) **Conditions of use.** It is used in: (1) Horses and ponies:

1. For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris, Strongylus edentatus, Strongylus equinus), small strongyles (Trichonema spp., Triodontophorus), pinworms (Oxyuris), and large roundworms (Parascaris).
2. It is administered as a single dose at 0.57 gram of pyrantel tartrate per 100 pounds of body weight mixed with the usual grain ration.
3. It is recommended that severely debilitated animals not be treated with this drug. Do not administer by stomach tube or dose syringe. The drug should be used immediately after the package is opened.
4. Warning: Not for use in horses and ponies to be slaughtered for food purposes.

(2) Swine:

1. For the removal and control of large roundworms (Ascaris suum) and nodular worm (Oesophagostomum) infections.
2. It is added to feed at 0.4 gram pyrantel tartrate per pound of nonpelleted ration. The ration is administered as a single treatment as the sole ration at the rate of 1 pound per 40 pounds of animal weight for animals up to 200 pounds. Animals 200 pounds and over are administered 5 pounds of ration per animal.
3. Fast pigs over night for optimum results. Water should be made available to animals during fasting and treatment periods. Consult veterinarian before using in severely debilitated animals. The drug should be used immediately after the package is opened.
4. Warning: Do not treat within 24 hours of slaughter.

(3) Horses and colts:

1. For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris, Strongylus edentatus, Strongylus equinus), small strongyles (Trichonema spp., Triodontophorus), pinworms (Oxyuris), and large roundworms (Parascaris).
2. It is administered as a single dose at 12.5 milligrams of pyrantel tartrate per 2.2 pounds of body weight mixed with the usual grain ration.
3. It is recommended that severely debilitated animals not be treated with this drug.
4. Warning: Do not use in horses or colts intended for food.

[40 FR 13838, Mar. 27, 1975, as amended at 59 FR 28769, June 3, 1994]

§ 520.2087 Roxarsone soluble powder.

(a) **Specifications.** Each ounce (avoirdupois) of soluble powder contains 21.7 grams of roxarsone (monosodium 3-nitro-4-hydroxyphenylarsonate).

(b) **Sponsor.** See No. 046573 in § 510.600(c) of this chapter.
§ 520.2088 Roxarsone tablets.

(c) Related tolerances. See §556.60 of this chapter.

(d) NAS/NRC status. These conditions of use are NAS/NRC reviewed and found effective. NADA’s for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(e) Conditions of use—(1) Growing chickens and growing turkeys—(i) Amount. 0.002 percent roxarsone in drinking water (one packet per each 250 gallons of drinking water).

(ii) Indications for use. For increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(iii) Limitations. Administer continuously throughout growing period. Withdraw 5 days before slaughter. Use as sole source of organic arsenic.

(2) Swine—(i) Amount. 0.01 percent roxarsone in drinking water (one packet per each 50 gallons of drinking water); or 30 milliliters of a 1.55 percent roxarsone solution (one packet per 3 pints of water) per 50 pounds of body weight as a drench.

(ii) Indications for use. As an aid in the treatment of swine dysentery (hemorrhagic enteritis or bloody scours).

(iii) Limitations. Administer drinking water continuously for not more than 6 days. Administer drench once daily for 1 or 2 days. If no improvement is observed, consult a veterinarian. Treatment may be repeated after 5 days. Withdraw 5 days before slaughter. Use as sole source of organic arsenic.

§ 520.2088 Roxarsone tablets.

(a)(1) Specifications. Each tablet contains 36 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(2) Sponsor. See No. 046573 in §510.600(c) of this chapter.

(3) Related tolerances. See §556.60 of this chapter.

(4) NAS/NRC status. The weight gain, feed efficiency, and pigmentation claims are NAS/NRC reviewed and found effective. NADA’s for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(5) Conditions of use—(1) Growing chickens and growing turkeys—(a) Amount. Dissolve 2 tablets in each gallon of drinking water (0.002 percent roxarsone).

(b) Indications for use. For increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(c) Limitations. Administer continuously throughout growing period. Withdraw 5 days before slaughter. Use as sole source of organic arsenic.

(i) Growing chickens—(a) Amount. Dissolve 8 tablets in each gallon of drinking water (0.008 percent roxarsone).

(b) Indications for use. As an aid in the prevention of coccidiosis due to Eimeria tenella.

(c) Limitations. Administer for not more than 10 consecutive days. Treatment may be repeated after 5 days off medication. Withdraw 5 days before slaughter. Use as sole source of organic arsenic.

(b)(1) Specifications. Each tablet contains 400 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(2) Sponsor. See No. 046573 in §510.600(c) of this chapter.

(3) Related tolerances. See §556.60 of this chapter.

(4) NAS/NRC status. These conditions are NAS/NRC reviewed and found effective. NADA’s for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(5) Conditions of use—(1) Swine—(a) Amount. 1 tablet (400 milligrams) per gallon of drinking water for no more than 6 days, or 1 tablet (400 milligrams) per 2 fluid ounces of warm water per 50 pounds of body weight as a drench once daily for 1 to 2 days.

(b) Indications for use. As an aid in the treatment of swine dysentery (hemorrhagic enteritis or bloody scours).

(c) Limitations. Treatment may be repeated after 5 days off medication. If no improvement is observed, consult a veterinarian. Treated animals must consume enough medicated water to provide a therapeutic dose. Withdraw 5 days before slaughter. Use as sole source of organic arsenic.

(ii) [Reserved]
(c) (1) Specifications. Each tablet contains 72 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(2) Sponsor. See No. 046573 in §510.600(c) of this chapter.

(3) Related tolerances. See §556.60 of this chapter.

(4) Conditions of use in growing chickens and growing turkeys—(1) Amount. 1 tablet in each gallon of drinking water (0.002 percent roxarsone).

(ii) Indications for use. For improved rate of weight gain, improved feed efficiency, and improved pigmentation.

(iii) Limitations. Administer continuously throughout growing period. Do not administer to chickens producing eggs for human consumption. Withdraw 5 days before slaughter. Use as sole source of organic arsenic. Overdosage or the lack of water intake may result in weakness or paralysis of legs.


§520.2089 Roxarsone liquid.

(a) Specifications. Each teaspoon (5 milliliters) of solution contains 72 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(b) Sponsor. See No. 046573 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.60 of this chapter.

(d) Conditions of use in growing chickens and growing turkeys—(1) Amount. 1 teaspoon (5 milliliters) to each gallon of drinking water (0.002 percent roxarsone).

(ii) Indications for use. For improved rate of weight gain, improved feed efficiency, and improved pigmentation.

(iii) Limitations. Administer continuously throughout growing period. Do not administer to chickens producing eggs for human consumption. Withdraw 5 days before slaughter. Use as sole source of organic arsenic. Overdosage or the lack of water intake may result in weakness or paralysis of legs.


§520.2100 Selenium, vitamin E capsules.

(a) Specifications. The capsules contain 2.19 milligrams of sodium selenite (equivalent to 1 milligram of selenium) and 56.2 milligrams of vitamin E (68 I.U.) (as d-alpha tocopheryl acid succinate) or 0.548 milligram of sodium selenite (equivalent to .25 milligram of selenium and 14 milligrams of vitamin E (17 I.U.) (as d-alpha tocopheryl acid succinate).

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is intended for use as an aid in alleviating and controlling inflammation, pain, and lameness associated with certain arthropathies in dogs.

(2) The capsules are administered orally with the larger capsules administered at a dosage level of 1 capsule
per 20 pounds of body weight to a maximum of 5 capsules with the dosage repeated at 3 day intervals until a satisfactory therapeutic response is observed. A maintenance dosage is then administered consisting of 1 capsule per 40 pounds of body weight, with a minimum of 1 capsule per 40 pounds of body weight, with a minimum of 1 capsule, given every 3 days, or 7 days, or longer, as required to maintain improvement or an asymptomatic condition. For dogs under 20 pounds of body weight, the small capsules are administered orally at a dosage level of 1 per 5 pounds of body weight with a minimum of 1 capsule which dosage is repeated at 3 day intervals until a satisfactory response is observed then a maintenance regimen is initiated with 1 capsule per 10 pounds of body weight, minimum of 1 capsule, every 3 days, or 7 days, or longer as required to maintain continued improvement or an asymptomatic condition.

§ 520.2122 Spectinomycin dihydrochloride oral solution.

(a) Specifications. The spectinomycin dihydrochloride pentahydrate used in manufacturing the drug is the antibiotic substance produced by growth of *Streptomyces flavopersicus* (var. Abbott) or the same antibiotic substance produced by any other means. The drug is packaged as an aqueous solution containing 50 milligrams of spectinomycin activity per milliliter.

(b) Sponsors. (1) See No. 059130 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used for the treatment and control of infectious bacterial enteritis (white scours) associated with *E. coli* in pigs under 4 weeks of age. Do not administer within 21 days of slaughter.

§ 520.2123 Spectinomycin dihydrochloride pentahydrate oral dosage forms.

§ 520.2123a Spectinomycin dihydrochloride pentahydrate tablets.

(a) Specifications. The spectinomycin dihydrochloride pentahydrate used in manufacturing the drug is the antibiotic substance produced by growth of *Streptomyces flavopersicus* (var. Abbott) or the same antibiotic substance produced by any other means.

(b) Sponsor. See No. 061133 in §510.600(c) of this chapter.

(c) Special considerations. The quantities of spectinomycin cited in this section refer to the equivalent weight of base activity for the drug.

(d) Conditions of use. (1) The tablets are administered orally to dogs in the treatment of infectious diarrhea and gastroenteritis caused by organisms susceptible to spectinomycin.

(2) The drug is administered orally to provide 10 milligrams per pound of body weight twice daily. The tablets may be placed in the animal’s mouth or crushed and administered in milk or in the feed. Dosage may be continued for 4 consecutive days. Should no improvement be observed, discontinue drug and redetermine diagnosis.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2123b Spectinomycin dihydrochloride pentahydrate soluble powder.

(a) Specifications. The spectinomycin dihydrochloride pentahydrate used in manufacturing the drug is the antibiotic substance produced by growth of *Streptomyces flavopersicus* (var. Abbott) or the same antibiotic substance produced by any other means.

(b) Sponsor. See No. 061133 in §510.600(c) of this chapter.
§ 520.2158a Special considerations. The quantities of spectinomycin cited in this section refer to the equivalent weight of base activity for the drug.

(d) Related tolerances. See §556.600 of this chapter.

(e) Conditions of use. (1) It is administered in the drinking water of growing chickens at 2 grams of spectinomycin per gallon of water as the only source of drinking water for the first 3 days of life and for 1 day following each vaccination. It is administered as an aid in the prevention or control of losses due to CRD associated with M. gallisepticum (PPLO). Do not administer to laying chickens. Do not administer within 5 days of slaughter.

(2) It is administered in the drinking water of floor-raised broiler chickens at 0.5 gram of spectinomycin per gallon of water as the only source of drinking water for the first 3 days of life and for 1 day following each vaccination. It is administered for increased rate of weight gain and improved feed efficiency. Do not administer to laying chickens. Do not administer within 5 days of slaughter.

(3) It is administered in drinking water of broiler chickens at 1 gram of spectinomycin per gallon of water as the only source of drinking water for the first 3 to 5 days of life as an aid in controlling infectious synovitis due to Mycoplasma synoviae. Do not administer to laying chickens. Do not administer within 5 days of slaughter.

§ 520.2150 Stanozolol oral dosage forms.

§ 520.2150a Stanozolol tablets.

(a) Specifications. Each tablet contains 2 milligrams of stanozolol.

(b) Sponsor. No. 000009 in §510.600(c) of this chapter.

(c) Conditions of use. (1) Used as an anabolic steroid treatment in dogs and cats.

(2) Administered orally to cats and small breeds of dogs, ½ to 1 tablet twice daily for several weeks; to large breeds of dogs, 1 to 2 tablets twice daily for several weeks. The tablets may be crushed and administered in feed.

§ 520.2155 Streptomycin/dihydrostreptomycin oral dosage forms.

§ 520.2155a Streptomycin sulfate oral solution.

(a) Specifications. Solution containing 25 percent streptomycin sulfate.

(b) Sponsor. See Nos. 033008 and 055462 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.610 of this chapter.

(d) Conditions of use. Use in drinking water as follows:

(1) Calves and swine—(i) Amount. 10 to 15 milligrams per pound (mg/pound) of body weight (1.0 to 1.5 grams per gallon).

(ii) Indications for use. Treatment of bacterial enteritis caused by Escherichia coli and Salmonella spp. susceptible to streptomycin.

(iii) Limitations. Calves: Do not administer for more than 5 days. Swine: Do not administer for more than 4 days. Prepare fresh solution daily. Calves: Withdraw 2 days before slaughter. As sole source of streptomycin. Warning: Certain strains of bacteria
may develop a tolerance for streptomycin. Consult a veterinarian or animal pathologist for diagnosis.

(2) Chickens—(i) Amount. 10 to 15 mg/pound of body weight (0.6 to 0.9 grams per gallon).

(2) Indications for use. Treatment of nonspecific infectious enteritis caused by organisms susceptible to streptomycin.

(2) Limitations. Chickens: Do not administer for more than 5 days. Withdraw 4 days before slaughter. Do not administer to chickens producing eggs for human consumption. Prepare fresh solution daily. As sole source of streptomycin. Warning: Certain strains of bacteria may develop a tolerance for streptomycin. Consult a veterinarian or animal pathologist for diagnosis.

§ 520.2158b Dihydrostreptomycin tablets.

(a) Specifications. Each tablet contains 37.5 milligrams dihydrostreptomycin (as the sulfate) with 375 milligrams chlorhexidine dihydrochloride.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Related tolerances. See §§ 556.120 and 556.200 of this chapter.

(d) Conditions of use. Calves—(1) Amount. 150 milligrams of dihydrostreptomycin and 1.5 grams of chlorhexidine dihydrochloride per 100 pounds of body weight per day.

(2) Indications for use. Treatment of bacterial scour in calves.

(3) Limitations. Administer orally once a day for 5 days; withdraw 3 days before slaughter.

§ 520.2170 Sulfabromomethazine sodium boluses.

(a) Specifications. Each bolus contains 15 grams of sulfabromomethazine sodium.

(b) Related tolerance. See § 556.620 of this chapter.

(c) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(d) NAS/NRC status. These conditions of use are NAS/NRC reviewed and found effective. NADA’s for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.

(e) Conditions of use. Cattle—(1) Amount. 90 milligrams per pound body weight.

(2) Indications for use. Treatment of necrotic pododermatitis (foot rot) and calf diphtheria caused by Fusobacterium necrophorum; colibacillosis (scours) caused by Escherichia coli; bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) associated with Pasteurella spp.; acute metritis and acute mastitis caused by Streptococcus spp.

(3) Limitations. Administer orally; repeat in 48 hours if necessary; milk taken from animals within 96 hours (8 milkings) of latest treatment must not be used for food; do not administer within 18 days of slaughter; discontinue use if hematuria, crystalluria or severe depression are noticed; if signs persist after 2 or 3 days consult a veterinarian.

§ 520.2158c Dihydrostreptomycin oral suspension.

(a) Specifications. Each milliliter contains 1.25 milligrams dihydrostreptomycin (as the sulfate) with 12.5 milligrams chlorhexidine dihydrochloride.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Related tolerances. See §§ 556.120 and 556.200 of this chapter.

(d) Conditions of use. Calves—(1) Amount. 150 milligrams of dihydrostreptomycin and 1.5 grams of chlorhexidine dihydrochloride per 100 pounds of body weight per day.

(2) Indications for use. Treatment of bacterial scour in calves.

(3) Limitations. Administer orally once a day for 5 days; withdraw 3 days before slaughter.

[57 FR 37327, Aug. 18, 1992]

§ 21 CFR Ch. I (4-1-02 Edition)
§ 520.2184 Sodium sulfachloropyrazine monohydrate.

(a) Chemical name. 2-Sulfamido-6-chloropyrazine, sodium.

(b) Sponsor. See Nos. 010042 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.625 of this chapter.

(d) Conditions of use. It is used in the drinking water of broilers, breeder flocks, and replacement chickens as follows:

(1) Amount. 0.03 percent.

(2) Indications for use. Treatment of coccidiosis.

(3) Limitations. Administer in drinking water for 3 days as sole source of drinking water and sulfonamide medication; withdraw 4 days prior to slaughter; not to be administered to chickens producing eggs for human consumption.


§ 520.2200 Sulfachloropyridazine oral dosage forms.

§ 520.2200a Sulfachloropyridazine bolus.

(a) Chemical name. N′-(6-Chloro-3-pyridazinyl) sulfanilamide.

(b) Specifications. Melting point range: 190 °C to 191 °C.

(c) Sponsor. See No. 053501 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.630 of this chapter.

(e) Conditions of use. It is used in calves as follows:

(1) Amount. 30 to 45 milligrams per pound body weight per day.

(2) Indications for use. Treatment of diarrhea caused or complicated by E. coli (colibacillosis).

(3) Limitations. Administer in a bolus containing 2 grams of sulfachloropyridazine for 1 to 5 days in divided doses twice daily; treated calves must not be slaughtered for food during treatment or for 7 days after the last treatment.

[40 FR 13838, Mar. 27, 1975, as amended at 50 FR 41489, Oct. 11, 1985]

§ 520.2200b Sulfachloropyridazine medicated milk and drinking water.

(a) Chemical name. N′-(6-Chloro-3-pyridazinyl) sulfanilamide.

(b) Specifications. Melting point range: 190 °C to 191 °C.

(c) Sponsor. See No. 053501 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.630 of this chapter.

(e) Conditions of use. It is used as follows:

(1) Calves—(i) Amount. 30 to 45 milligrams per pound body weight per day.

(2) Swine—(i) Amount. 20 to 35 milligrams per pound body weight per day.

(a) Indications for use. Treatment of diarrhea caused or complicated by E. coli (colibacillosis).

(iii) Limitations. Administer as the sodium salt of sulfachloropyridazine in milk or milk-replacer formulations for 1 to 5 days in divided doses twice daily; treated calves must not be slaughtered for food during treatment or for 7 days after the last treatment.

(2) Swine—(i) Amount. 20 to 35 milligrams per pound body weight per day.

(a) Indications for use. Treatment of diarrhea caused or complicated by E. coli (colibacillosis).

(b) Limitations. Administer individually in an oral suspension containing 50 milligrams of sulfachloropyridazine per milliliter in divided doses twice daily for 1 to 5 days; for individual treatment, administer orally in divided doses twice daily; treated swine must not be slaughtered for food during treatment or for 4 days after the last treatment.

[40 FR 13838, Mar. 27, 1975, as amended at 50 FR 41489, Oct. 11, 1985]

§ 520.2200c Sulfachloropyridazine tablets.

(a) Specifications. Sulfachloropyridazine tablets contain 250 milligrams of sulfachloropyridazine per tablet.
§ 520.2220 Sulfadimethoxine oral dosage forms.

§ 520.2220a Sulfadimethoxine oral solution and soluble powder.

(a) Approvals. (1) For oral solution containing 12.5 percent (3.75 grams per ounce) sulfadimethoxine, see Nos. 000010, 000069, 051259, 067561, and 059130 in §510.600(c).

(2) For soluble powder, each package containing the equivalent of 94.6 grams of sulfadimethoxine (as the sodium salt), see Nos. 000069, 051259, 067561, and 059130 in §510.600(c).

(b) Special considerations. Chickens and turkeys that have survived fowl cholera outbreaks should not be kept for replacements or breeders.

(c) Related tolerances. See §556.640 of this chapter.

(d) Conditions of use. The oral solution is administered as a cattle drench or diluted as directed to prepare drinking water. The powder is used to prepare a drench or drinking water. The concentrations and uses of the various solutions are as follows:

(1) Broiler and replacement chickens only. (i) Amount. 1.875 (0.05 percent) grams per gallon.

(ii) Indications for use. Treatment of disease outbreaks of coccidiosis, fowl cholera, and infectious coryza.

(iii) Limitations. Administer for 6 consecutive days; do not administer to chickens over 16 weeks of age; as sole source of drinking water and sulfonamide medication; as sulfadimethoxine solution or sulfadimethoxine soluble sodium salt; withdraw 5 days before slaughter.

(2) Meat-producing turkeys only—(i) Amount. 0.938 (0.025 percent) grams per gallon.

(ii) Indications for use. Treatment of disease outbreaks of coccidiosis and fowl cholera.

(iii) Limitations. Administer for 6 consecutive days; do not administer to turkeys over 24 weeks of age; as sole source of drinking water and sulfonamide medication; as sulfadimethoxine solution or sulfadimethoxine soluble sodium salt; withdraw 5 days before slaughter.

(3) Dairy calves, dairy heifers, and beef cattle only—(i) Amount. 1.18 to 2.36 (0.031 to 0.062 percent) grams per gallon.

(ii) Indications for use. Treatment of shipping fever complex, bacterial pneumonia, calf diphtheria, and foot rot.

(iii) Administer 2.5 grams per 100 pounds of body weight for first day, then 1.25 grams per 100 pounds of body weight per day for the next 4 consecutive days; in drinking water or drench; available as a sulfadimethoxine soluble powder or a 12.5 percent sulfadimethoxine sodium solution (3.75 grams sulfadimethoxine per fluid ounce); if no improvement within 2 to 3 days, reevaluate diagnosis; do not treat beyond 5 days; withdraw 7 days before slaughter.

§ 520.2220b Sulfadimethoxine tablets and boluses.

(a) Sponsors. Approval to firms identified in §510.600(c) of this chapter as follows:

(1) To 000069, approval for use as in paragraphs (d)(1), (d)(2), and (d)(3) of this section.

(2) To 000061, approval for use as in paragraph (d)(2).
§ 520.2220d Sulfadimethoxine-ormetoprim tablets.

(a) Specifications. Each tablet contains 120 milligrams (100 milligrams of sulfadimethoxine and 20 milligrams of ormetoprim), 240 milligrams (200 milligrams of sulfadimethoxine and 40 milligrams of ormetoprim), 600 milligrams (500 milligrams of sulfadimethoxine and 100 milligrams of ormetoprim), or 1200 milligrams (1,000 milligrams of sulfadimethoxine and 200 milligrams of ormetoprim).

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. On the first day of treatment, administer 25 milligrams per pound (55 milligrams per kilogram) of body weight. Then follow with a daily dosage of 12.5 milligrams per pound of body weight. Length of treatment will depend upon clinical response. Continue treatment until patient is asymptomatic for 48 hours. Maintain adequate water intake during the treatment period.

(2) Indications of use. Treatment of skin and soft tissue infections (wounds and abscesses) in dogs caused by strains of *Staphylococcus aureus* and *Escherichia coli* and urinary tract infections caused by *Escherichia coli*.

susceptible to ormetoprim-potentiated sulfadimethoxine.

(3) **Limitations.** Continue treatment until patient is asymptomatic for 48 hours, but do not exceed a total of 21 consecutive days. Maintain adequate water intake during the treatment period. Safety in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2240 Sulfaethoxypyridazine.

§ 520.2240a Sulfaethoxypyridazine drinking water.

(a) **Chemical name.** N′-(6-Ethoxy-3-pyridazinyl) sulfanilamide.

(b) **Specifications.** Melting point range of 180 °C to 186 °C.

(c) **Sponsor.** See No. 010042 in §510.600(c) of this chapter.

(d) **Related tolerances.** See §556.650 of this chapter.

(e) **Conditions of use.** It is used as follows:

(1) **Swine.**

(i) **Amount.** 1.9 to 3.8 grams per gallon (0.05 percent to 0.1 percent).

(ii) **Indications for use.** Treatment of bacterial scours pneumonia enteritis, bronchitis, septicemia accompanying *Salmonella cholerasuis* infection.

(iii) **Limitations.** Administer 3.8 grams per gallon for first day followed by 1.9 grams per gallon for not less than 9 days as sodium sulfaethoxypyridazine; do not treat within 10 days of slaughter; as sole source of sulfanamide; for use by or on the order of a licensed veterinarian.

(2) **Cattle.**

(i) **Amount.** 2.5 grams per gallon (0.066 percent).

(ii) **Indications for use.** Treatment of respiratory infections (pneumonia, shipping fever), foot rot, calf scours; as adjunctive therapy in septicemia accompanying mastitis and metritis.

(iii) **Limitations.** Administer at the rate of 1 gallon per 100 pounds of body weight per day for 4 days; do not treat within 16 days of slaughter; as sole source of sulfanamide; milk that has been taken from animals during treatment and for 72 hours (6 milkings) after latest treatment must not be used for food; for use only by or on the order of a licensed veterinarian.

§ 520.2240b Sulfaethoxypyridazine tablets.

(a) **Chemical name.** N′-(6-Ethoxy-3-pyridazinyl) sulfanilamide.

(b) **Specifications.** Melting point range of 180 °C to 186 °C.

(c) **Sponsor.** See No. 010042 in §510.600(c) of this chapter.

(d) **Related tolerances.** See §556.650 of this chapter.

(e) **Conditions of use.** It is used for cattle as follows:

(1) **Amount.** 2.5 or 15 grams per tablet.

(i) **Indications for use.** Treatment of respiratory infections (pneumonia, shipping fever), foot rot, calf scours; as adjunctive therapy in septicemia accompanying mastitis and metritis.

(ii) **Limitations.** Administer 25 milligrams per pound of animal weight per day for 4 days; do not treat within 16 days of slaughter; as sole source of sulfanamide; milk that has been taken from animals during treatment and for 72 hours (6 milkings) after the latest treatment must not be used for food; for use only by or on the order of a licensed veterinarian.

(2) **Amount.** 15-gram controlled release tablets.

(i) **Indications for use.** Treatment of foot rot and respiratory infections (shipping fever and pneumonia) caused by sulfonamide-susceptible pathogens (*E. coli*, streptococci, staphylococci, *Sphaerophorus necrophorus* and Gram-negative rods including *Pasteurella*); for use prophylactically in cattle during periods of stress for reducing losses due to sulfonamide sensitive disease conditions.

(ii) **Limitations.** Administer 100 milligrams per pound of body weight; do not treat within 16 days of slaughter; as sole source of sulfanamide; not for use in lactating dairy cows; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2260 Sulfamethazine oral dosage forms.

§ 520.2260a Sulfamethazine oblet, tablet, and bolus.

(a)(1) **Sponsor.** See No. 010042 in §510.600(c) of this chapter for use of 2.5-, 5-, and 15-gram sulfamethazine
Food and Drug Administration, HHS

§ 520.2260b Sulfamethazine sustained-release boluses.

(a)(1) Sponsor. See No. 000859 in §510.600(c) of this chapter for use of a 22.5-gram sulfamethazine prolonged-release bolus.

(2) Conditions of use—(i) Amount. Depending on the duration of therapeutic levels desired, administer boluses as a single dose as follows: 3½ days—1 bolus (22.5 grams) per 200 pounds of body weight; 5 days—1 bolus per 100 pounds of body weight.

(ii) Indications for use. Beef and nonlactating cattle for sustained treatment of shipping fever pneumonia caused or complicated by Pasteurella multocida; as an aid in the treatment of foot rot, mastitis, pneumonia, metritis, bacterial enteritis, calf diphtheria, and septicemia when caused or complicated by bacteria susceptible to sulfamethazine.

(iii) Limitations. Cattle that are acutely ill should be treated parenterally with a suitable antibacterial product to obtain immediate therapeutic blood levels; do not slaughter animals for food within 16 days of treatment; do not use in lactating cattle and nonlactating dairy cattle.

(ii)(A) Beef and nonlactating dairy cattle. Treatment of bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) (Pasteurella spp.), colibacillosis (bacterial scours) (Escherichia coli), necrotic pododermatitis (foot rot) (Fusobacterium necrophorum), calf diphtheria (Fusobacterium necrophorum), acute mastitis (Streptococcus spp.), acute metritis (Streptococcus spp.), coccidiosis (Eimeria bovis and Eimeria zurnii), and bacterial pneumonia associated with Pasteurella spp., colibacillosis (bacterial scours) (Escherichia coli), necrotic pododermatitis (foot rot) (Fusobacterium necrophorum), calf diphtheria (Fusobacterium necrophorum), acute mastitis (Streptococcus spp.), acute metritis (Streptococcus spp.), coccidiosis (Eimeria bovis and Eimeria zurnii).

(B) Horses. Treatment of bacterial pneumonia (secondary infections associated with Pasteurella spp.), strangles (Streptococcus equi), and bacterial enteritis (Escherichia coli).

(iii) Limitations. Administer daily until animal’s temperature and appearance are normal. If symptoms persist after using for 2 or 3 days consult a veterinarian. Fluid intake must be adequate. If symptoms persist after 2 or 3 days, consult a veterinarian.

§ 520.2260b Related tolerances in edible products.

See §556.670 of this chapter.
dairy cattle; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) Sponsor. See No. 053501 in § 510.600(c) of this chapter for use of a 27-gram sulfamethazine sustained-release bolus.

(2) Conditions of use—(i) Amount. 27 grams (1 bolus) for each 150 pounds of body weight as a single dose.

(ii) Indications for use. For non lactating cattle for the treatment of infections caused by organisms sensitive to sulfamethazine such as hemorrhagic septicemia (shipping fever complex), bacterial pneumonia, foot rot, and calf diphtheria and as an aid in the control of bacterial diseases usually associated with shipping and handling of cattle.

(iii) Limitations. If no response within 2 to 3 days, reevaluate therapy; do not crush tablets; treated animals must not be slaughtered for food within 28 days after the latest treatment; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c)(1) Sponsor. See No. 061133 in § 510.600(c) of this chapter for use of a 32.1-gram sustained-release bolus.

(2) Conditions of use—(i) Amount. 32.1 grams (1 bolus) per 200 pounds of body weight.

(2) Indications for use. For beef and non lactating dairy cattle for the treatment of diseases caused by sulfamethazine-sensitive organisms as follows: bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) caused by Pasteurella spp., colibacillosis (bacterial scour) caused by E. coli, necrotic pododermatitis (foot rot) and calf diphtheria caused by Fusobacterium necrophorum, and acute mastitis caused by Streptococcus spp.

(iii) Limitations. After 72 hours, all animals should be reexamined for persistence of observable disease signs. If signs are present, consult a veterinarian. It is strongly recommended that a second dose be given to provide for an additional 72 hours of therapy.

1 These conditions are NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information, particularly in more severe cases. The dosage schedule should be used at each 72-hour interval. Animals should not receive more than 2 doses because of the possibility of incurring residue violations. This drug, like all sulfonamides, may cause toxic reactions and irreparable injury unless administered with adequate and continuous supervision; follow dosages carefully. Fluid intake must be adequate at all times throughout the 3-day therapy. Do not use in lactating dairy cattle. Do not treat animals within 12 days of slaughter.

(d)(1) Sponsor. See 000859 in § 510.600(c) of this chapter for use of a 22.5-gram sulfamethazine sustained release bolus.

(2) Conditions of use—(i) Amount. Administer 1 bolus (22.5 grams) per 200 pounds of body weight, as a single dose.

(ii) Indications for use. Beef and non lactating dairy cattle for the prolonged treatment of the following diseases when caused by one or more of the listed pathogenic organisms sensitive to sulfamethazine: bovine respiratory disease complex (shipping fever complex) (Pasteurella spp.), bacterial pneumonia (Pasteurella spp.), necrotic pododermatitis (foot rot) (Fusobacterium necrophorum), colibacillosis (bacterial scour) (Escherichia coli), calf diphtheria (Fusobacterium necrophorum), acute mastitis (Streptococcus spp.) and acute metritis (Streptococcus spp.).

(iii) Limitations. Cattle that are acutely ill should be treated by injection with a suitable antibacterial product to obtain immediate therapeutic blood levels; do not slaughter animals for food within 16 days of treatment; do not use in lactating dairy cattle; if treated animals do not respond within 2 to 3 days, consult a veterinarian.

(e)(1) Sponsor. See No. 061133 in § 510.600(c) of this chapter for use of an 8.02-gram sulfamethazine sustained-release bolus.

(2) Conditions of use—(i) Amount. Administer 2 boluses (8.02 grams per bolus) per 100 pounds of body weight, as a single dose.

(ii) Indications for use. Administer orally to ruminating calves for the prolonged treatment of the following diseases when caused by one or more of
the listed pathogenic organisms sensitive to sulfamethazine: bacterial pneumonia (Pasteurella spp.), colibacillosis (bacterial scour) (E. coli), and calf diphtheria (Fusobacterium necrophorum).

(iii) Limitations. For use in ruminating replacement calves only; 72 hours after dosing all animals should be reexamined for persistence of disease signs; if signs are present, consult a veterinarian; do not slaughter animals for food for at least 12 days after the last dose; this product has not been shown to be effective for nonruminating calves; exceeding two consecutive doses may cause violative tissue residue to remain beyond the withdrawal time; do not use in calves under 1 month of age or calves being fed an all milk diet.

(f)(1) Sponsor. See No. 000010 in §510.600(c) of this chapter for use of a 30-gram sulfamethazine sustained-release bolus.

(2) Conditions of use—(i) Amount. Administer at the rate of 1 bolus (30 grams per bolus) per 200 pounds of body weight, as a single dose.

(ii) Indications for use. Administer orally to beef cattle and nonlactating dairy cattle for treatment of the following diseases when caused by one or more of the listed pathogenic organisms susceptible to sulfamethazine: bacterial pneumonia associated with Pasteurella spp.; colibacillosis (bacterial scour) caused by Escherichia coli; coccidiosis caused by Eimeria bovis and E. zurnii; and calf diphtheria caused by Fusobacterium necrophorum.

(iii) Limitations. Do not use in calves to be slaughtered under 1 month of age or calves being fed an all milk diet. Do not use in female dairy cattle 20 months of age or older. If symptoms persist after 3 days, consult a veterinarian. Do not administer more than 2 consecutive doses. Do not slaughter animals for food for at least 8 days after the last dose. Do not crush bolus.

§ 520.2260c Sulfamethazine sustained-release tablets.

(a) Sponsor. See No. 053501 in §510.600(c) of this chapter for use of an 8.25-gram sulfamethazine sustained-release bolus.

(2) Conditions of use—(i) Amount. Administer at the rate of 1 bolus (8.25 grams per bolus) per 50 pounds of body weight, as a single dose. If signs of disease are significantly reduced, it is recommended that a second dose be given to provide an additional 72 hours of therapy.

(ii) Indications for use. Administer orally to ruminating beef and dairy calves for treatment of the following diseases when caused by one or more of the listed pathogenic organisms susceptible to sulfamethazine: bacterial pneumonia associated with Pasteurella spp.; colibacillosis (bacterial scour) caused by Escherichia coli; coccidiosis caused by Eimeria bovis and E. zurnii; and calf diphtheria caused by Fusobacterium necrophorum.

(iii) Limitations. Do not use in calves to be slaughtered under 1 month of age or calves being fed an all milk diet. Do not use in female dairy cattle 20 months of age or older. If symptoms persist after 3 days, consult a veterinarian. Do not administer more than 2 consecutive doses. Do not slaughter animals for food for at least 8 days after the last dose. Do not crush tablets. Treated animals
must not be slaughtered for food within 18 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2261 Sulfa methazine sodium oral dosage forms.

§ 520.2261a Sulfa methazine sodium drinking water solution.

(a) Sponsors. See Nos. 017800 and 010042 in § 510.600(c) of this chapter for use of a 12.5-percent sulfa methazine sodium solution.

(b) Related tolerances in edible products. See § 556.670 of this chapter.

(c) Conditions of use—(1) Amount. Administer in drinking water to provide: Cattle and swine 112.5 milligrams of sulfa methazine sodium per pound of body weight per day on the first day and 56.25 milligrams per pound of body weight on subsequent days; Chickens, 61 to 89 milligrams of sulfa methazine sodium per pound of body weight per day, and turkeys 53 to 130 milligrams of sulfa methazine sodium per pound of body weight per day, depending upon the dosage, age, and class of chickens or turkeys, ambient temperature, and other factors.

(2) Indications for use. For treatment and control of diseases caused by organisms sensitive to sulfa methazine.

(i) Beef and nonlactating dairy cattle. Treatment of bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) (Pasteurella spp.), colibacillosis (bacterial scours) (Escherichia coli), necrotic pododermatitis (foot rot) (Fusobacterium necrophorum), calf diphtheria (Fusobacterium necrophorum), acute mastitis (Streptococcus spp.), and acute metritis (Streptococcus spp.).

(ii) Swine. Treatment of porcine colibacillosis (bacterial scours) (Escherichia coli), and bacterial pneumonia (Pasteurella spp.).

(iii) Chickens and turkeys. In chickens for control of infectious coryza (Haemophilus gallinarum), coccidiosis (Eimeria tenella, Eimeria necatrix), acute fowl cholera (Pasteurella multocida), and pullorum disease (Salmonella pullorum). In turkeys for control of coccidiosis (Eimeria meleagritnis, Eimeria adenoeides). Medicate as follows: Infectious coryza in chickens, medicate for 2 consecutive days; acute fowl cholera and pullorum disease, in chickens, medicate for 6 consecutive days; coccidiosis, in chickens and turkeys, medicate as in paragraph (c) of this section, then reduce amount of medication to one-half for 4 additional days.

(3) Limitations. Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication from cattle, chickens, and turkeys 10 days prior to slaughter for food. Withdraw medication from swine 15 days before slaughter for food. Not for use in lactating dairy cattle. Do not medicate chickens or turkeys producing eggs for human consumption. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms, but not to exceed a total of 5 consecutive days in cattle or swine. Medicated cattle, swine, chickens, and turkeys must actually consume enough medicated water which provides the recommended dosages.

(d) NAS/NRC status. The conditions of use specified in this section have been reviewed by NAS/NRC and are found effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.

(47 FR 25322, June 11, 1982, as amended at 47 FR 25735, June 15, 1982)

§ 520.2261b Sulfa methazine sodium soluble powder.

(a) Sponsor. See No. 010042 in § 510.600(c) of this chapter for use of a soluble powder composed of 100 percent sulfa methazine sodium.

(b) Related tolerances in edible products. See § 556.670 of this chapter.

(c) Conditions of use—(1) Amount. Administer in drinking water to provide: Chickens 58 to 85 milligrams of sulfa methazine sodium per pound of body weight per day; turkeys 50 to 124 milligrams of sulfa methazine sodium...
per pound of body weight per day; depending upon the dosage, age, and class of chickens or turkeys, ambient temperature, and other factors. Administer to cattle and swine in drinking water, or as a drench, to provide 108 milligrams of sulfamethazine sodium per pound of body weight on the first day and 54 milligrams of sulfamethazine sodium per pound of body weight per day on the second, third, and fourth days of administration.

(2) Indications for use. For treatment and control of disease caused by organisms sensitive to sulfamethazine.

(i) Beef and nonlactating dairy cattle. Treatment of bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) \(\text{(Pasteurella spp.)}\), colibacillosis (bacterial scour) \(\text{(Escherichia coli)}\), necrotic pododermatitis (foot rot) \(\text{(Fusobacterium necrophorum)}\), calf diphtheria \(\text{(Fusobacterium necrophorum)}\), acute mastitis \(\text{(Streptococcus spp.)}\), and acute metritis \(\text{(Streptococcus spp.)}\). (ii) Swine. Treatment of porcine colibacillosis (bacterial scour) \(\text{(Escherichia coli)}\), and bacterial pneumonia \(\text{(Pasteurella spp.)}\).

(iii) Chickens and turkeys. In chickens for control of infectious coryza \(\text{(Haemophilus gallinarum)}\), coccidiosis \(\text{(Eimeria tenella, Eimeria necatrix)}\), acute fowl cholera \(\text{(Pasteurella multocida)}\), and pullorum disease \(\text{(Salmonella pullorum)}\). In turkeys for control of coccidiosis \(\text{(Eimeria meleagrimitis, Eimeria adenoides)}\). Medicate as follows: Infectious coryza in chickens, medicate for 2 consecutive days; acute fowl cholera and pullorum disease in chickens, medicate for 6 consecutive days; coccidiosis in chickens and turkeys, medicate as in paragraph (c) of this section for 2 days, then reduce drug concentration to one-half for 4 additional days.

(3) Limitations. Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication from cattle, chickens, and turkeys 10 days prior to slaughter for food. Withdraw medication from swine 15 days prior to slaughter for food. Not for use in lactating dairy animals. Do not medicate chickens or turkeys producing eggs for human consumption. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms, but not to exceed a total of 5 consecutive days in cattle or swine. Medicated cattle, swine, chickens, and turkeys must actually consume enough medicated water which provides the recommended dosages.

(d) NAS/NRC status. The conditions of use specified in this section have been reviewed by NAS/NRC and are found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

[47 FR 25322, June 11, 1982]

§ 520.2280 Sulfamethizole and methenamine mandelate tablets.

(a) Specifications. Each tablet contains 250 milligrams of sulfamethizole and 250 milligrams of methenamine mandelate.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for the treatment of urinary tract infections in dogs and cats such as cystitis, nephritis, prostatitis, urethritis, and pyelonephritis. It is also used as an aid in the management of complications resulting from surgical manipulations of the urinary tract such as removal of calculi from the bladder, in ureterostomies, and in instrumentation of the urethra and bladder.

(2) It is administered at a dosage level of one tablet for each 20 pounds of body weight given three times per day. The drug should be given until all signs are alleviated. To reduce the possibility of a relapse, it is suggested that therapy be continued for a further period of a week to 10 days.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 50 FR 13561, Apr. 5, 1985]

§ 520.2320 Sulfanitran and aklomide in combination.

(a) Chemical names. (1) Sulfanitran: Acetyl-(p-nitrophenyl)-sulfanilamide.
§ 520.2325 2-Chloro-4-nitrobenzamide.

(b) Specifications. (1) Sulfanitran conforms to the following specifications:
   (i) Melting point range: 260 °C. to 261 °C.
   (ii) Assay (by sodium nitrite titration): 97 to 100.5 percent.
   (iv) Molecular weight: 335.34.
   (v) Soluble in 0.1 N sodium hydroxide, reprecipitating unchanged on acidification.

(2) Aklomide conforms to the following specifications:
   (i) Minimum melting point: 170 °C.
   (ii) Moisture content: Not to exceed 1.0 percent.
   (iii) Purity: Not less than 98 percent on an anhydrous basis.

(c) Sponsor. See No. 053501 in § 510.600(c) of this chapter for identification of the sponsors.

(d) Related tolerances. See §§ 556.30 and 556.680 of this chapter.

(e) Conditions of use. It is used in the drinking water of chickens as follows:
   (1) Amount. 374–747 milligrams of sulfanitran with 477–954 milligrams of aklomide.
   (2) Indications for use. As an aid in the control of outbreaks of coccidiosis caused by E. tenella, E. necatrix, and E. acervulina.

   (3) Limitations. Administer for 2 days at 747 milligrams of sulfanitran per gallon and 954 milligrams of aklomide per gallon, followed by 5 days at 374 milligrams of sulfanitran per gallon and 477 milligrams of aklomide per gallon; do not treat birds over 6 weeks of age; do not administer within 5 days of slaughter; not for laying chickens.

§ 520.2325a Sulfaquinoxaline drinking water.

(a) Sponsor. See § 510.600(c) of this chapter for identification of the sponsors.

(1) To No. 060594 for use of 3.44- and 12.85-percent sulfaquinoxaline sodium solutions as provided for in paragraphs (c)(1), (c)(2), (c)(3), (c)(4)(i), and (c)(4)(ii) of this section.

(2) To No. 060594 for use of 3.44- and 12.85-percent sulfaquinoxaline sodium solutions as provided for in paragraphs (c)(1), (c)(2), (c)(3), (c)(4)(i), and (c)(4)(ii) of this section.

(3) To No. 046573 for use of a 31.92-percent sulfaquinoxaline solution (sodium and potassium salts) as provided for in paragraphs (c)(1), (c)(2), (c)(3), (c)(4)(i), and (c)(4)(ii) of this section.

(4) To No. 053501 for use of a 28.62-percent sulfaquinoxaline sodium solution as provided in paragraphs (c)(1), (c)(2), and (c)(3) of this section.

(b) Related tolerances. See § 556.685 of this chapter.

(c) Conditions of use. It is used in drinking water as follows:
   (1) Chickens. (i) As an aid in the control of outbreaks of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, and E. brunetti.

   (ii) Administer at the 0.04 percent level for 2 or 3 days, skip 3 days then administer at the 0.025 percent level for 2 more days. If bloody droppings appear, repeat treatment at the 0.025 percent level for 2 more days. Do not change litter unless absolutely necessary. Do not give flushing mashes.

   (3) Chickens and turkeys. (i) As an aid in the control of acute fowl cholera caused by Pasteurella multocida susceptible to sulfaquinoxaline and fowl typhoid caused by Salmonella gallinarum susceptible to sulfaquinoxaline.
(i) Administer at the 0.04 percent level for 2 or 3 days. Move birds to clean ground. If disease recurs, repeat treatment. If cholera has become established as the respiratory or chronic form, use feed medicated with sulfamethazine. Poultry which have survived typhoid outbreaks should not be kept for laying house replacements or breeders unless tests show they are not carriers.

(4) Cattle and calves. (i) For the control and treatment of outbreaks of coccidiosis caused by *Eimeria bovis* or *E. zuernii*.

(ii) Administer at the 0.015-percent level for 3 to 5 days in drinking water medicated with sulfamethazine solution.

(iii) In lieu of treatment as provided in paragraph (e)(4)(ii) of this section, administer 1 teaspoon of 25-percent sulfamethazine soluble powder per day for each 125 pounds of body weight for 3 to 5 days in drinking water.

(d) Limitations. Consult a veterinarian or poultry pathologist for diagnosis. May cause toxic reactions unless the drug is evenly mixed in water at dosages indicated and used according to directions. For control of outbreaks of disease, medication should be initiated as soon as the diagnosis is determined. Medicated chickens, turkeys, cattle, and calves must actually consume enough medicated water which provides a recommended dosage of approximately 10 to 45 milligrams per pound per day in chickens, 3.5 to 55 milligrams per pound per day in turkeys, and approximately 6 milligrams per pound per day in cattle and calves depending on the age, class of animal, ambient temperature, and other factors. A withdrawal period has not been established for sulfamethazine in prerninating calves. Do not use in calves to be processed for veal. Not for use in lactating dairy cattle. Do not use in lactating dairy cattle. Do not give to chickens or turkeys producing eggs for human consumption. Make fresh drinking water daily.

§ 520.2330 Sulfisoxazole tablets.

(a) Specifications. Each tablet contains 260 milligrams (4 grains) of sulfisoxazole.

(b) Sponsor. See No. 000656 in §510.600(c) of this chapter.

§ 520.2345  Tetracycline oral dosage forms.

§ 520.2345a  Tetracycline hydrochloride capsules.

(a) Specifications. Each capsule contains 50, 100, 125, 250, or 500 milligrams of tetracycline hydrochloride.

(b) Sponsor. See §510.600(c) of this chapter for identification of the sponsors:

(1) To No. 000009: 250 milligrams per capsule.

(2) To No. 000069: 125, 250, and 500 milligrams per capsule.

(3) To No. 000115: 50, 100, 250, and 500 milligrams per capsule.

(c) Conditions of use. Dogs—(1) Amount. 25 milligrams per pound of body weight per day in divided doses every 6 hours.

(2) Indications for use. Treatment of infections caused by organisms sensitive to tetracycline hydrochloride, such as bacterial gastroenteritis due to *E. coli* and urinary tract infections due to *Staphylococcus* spp. and *E. coli*.

(3) Limitations. Administer orally; continue treatment until symptoms of the disease have subsided and the temperature is normal for 48 hours; not for use in animals raised for food production; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2345b  Tetracycline tablets.

(a) Specifications. Each tablet contains 100, 250, or 500 milligrams of tetracycline (as the hydrochloride).

(b) Sponsor. For 100, 250, or 500 milligrams per tablet, see No. 000069 in §510.600(c) of this chapter. For 250 milligrams per tablet, see No. 000009 in §510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 25 milligrams per pound of body weight per day in divided doses every 6 hours.

(2) Indications for use. Treatment of infections caused by organisms sensitive to tetracycline hydrochloride, such as bacterial gastroenteritis due to *E. coli* and urinary tract infections due to *Staphylococcus* spp. and *E. coli*.

§ 520.2345c  Tetracycline boluses.

(a) Specifications. Each bolus contains 500 milligrams of tetracycline (as the hydrochloride).

(b) Sponsors. See No. 010042 in §510.600(c) of this chapter for use as in paragraph (d)(1) of this section. See No. 000009 in §510.600(c) of this chapter for use as in paragraph (d)(2) of this section.

(c) Related tolerances. See §556.720 of this chapter.

§ 520.2345  Conditions of use—(1) Amount. Administer one tablet orally per 4 pounds of body weight.1

(2) Indications for use. Use in dogs and cats as an aid in treatment of bacterial pneumonia and bacterial enteritis when caused by organisms sensitive to sulfaizoxazole.1

(3) Limitations. Repeat dosage at 24-hour intervals until 2 to 3 days after disappearance of clinical symptoms. (Administration of one-half daily dosage at 12-hour intervals or one-third daily dosage at 8-hour intervals will provide a more constant blood level.) Provide adequate supply of drinking water. If symptoms persist after using this preparation for 2 or 3 days, consult a veterinarian.1

[45 FR 60895, Dec. 29, 1978]
for food within 14 days of treatment; use as sole source of tetracycline.

(iii) National Academy of Sciences/National Research Council (NAS/NRC) status. The conditions of use specified in paragraph (d)(1)(i) of this section were NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified in §514.111 of this chapter, but may require bioequivalency and safety information.

(2) Amount. 10 milligrams per pound of body weight per day in two divided doses.

(i) Indications for use. Treatment of bacterial pneumonia caused by organisms susceptible to tetracycline, bacterial enteritis caused by \textit{E. coli}, and salmonella organisms susceptible to tetracycline.

(ii) Limitations. Administer orally for not more than 5 days; do not slaughter animals for food within 12 days of treatment; use as sole source of tetracycline.

[57 FR 37328, Aug. 18, 1992]

§520.2345d Tetracycline hydrochloride soluble powder.

(a) Sponsors. The following sponsors listed in §510.600(c) of this chapter hold approvals for the drug concentrations (i.e., grams of tetracycline hydrochloride per pound) and conditions of use indicated:

(1) 000010, 046573, 051259, 057561, and 059130 102.4 and 324 grams per pound as in paragraph (d) of this section.

(2) 000069, 25 grams per pound as in paragraphs (d)(3) and (d)(4) of this section.

(3) 010042, 102.4 and 324 grams per pound as in paragraphs (d)(1) and (d)(2) of this section.

(4) 046573, 102.4 and 324 grams per pound as in paragraph (d)(3) of this section.

(b) Related tolerances. See §556.720 of this chapter.

(c) [Reserved]

(d) Conditions of use in drinking water—(1) Calves—(i) Amount. 10 milligrams per pound of body weight per day in divided doses.

(ii) Indications for use. Control and treatment of bacterial enteritis (scours) caused by \textit{Escherichia coli} and bacterial pneumonia (shipping fever complex) associated with \textit{Pasteurella} spp., \textit{Actinobacillus pleuropneumoniae} (\textit{Hemophilus} spp.), and \textit{Klebsiella} spp., susceptible to tetracycline.

(iii) Limitations. Administer for 3 to 5 days; do not slaughter animals for food within 4 days of treatment for sponsor 010042 and within 5 days of treatment for sponsors 046573 and 000010; prepare a fresh solution daily; use as the sole source of tetracycline.

(2) Swine—(i) Amount. 10 milligrams per pound of body weight per day in divided doses.

(ii) Indications for use. Control and treatment of bacterial enteritis (scours) caused by \textit{E. coli} and bacterial pneumonia associated with \textit{Pasteurella} spp., \textit{A. pleuropneumoniae} (\textit{Hemophilus} spp.), and \textit{Klebsiella} spp., susceptible to tetracycline.

(iii) Limitations. Administer for 3 to 5 days; do not slaughter animals for food within 7 days of treatment for sponsor 010042 and within 4 days of treatment for sponsors 046573 and 000010; prepare a fresh solution daily; use as the sole source of tetracycline.

(3) Chickens—(i) Amount. Chronic respiratory disease: 400 to 800 milligrams per gallon. Infectious synovitis: 200 to 400 milligrams per gallon.

(ii) Indications for use. Control of chronic respiratory disease (CRD or air-sac disease) caused by \textit{Mycoplasma gallisepticum} and \textit{E. coli}; control of infectious synovitis caused by \textit{M. synoviae} susceptible to tetracycline.

(iii) Limitations. Administer for 7 to 14 days; do not slaughter for food within 4 days of treatment; not for use in chickens producing eggs for human consumption; prepare a fresh solution daily; use as the sole source of tetracycline.

(4) Turkeys—(i) Amount. For infectious synovitis: 400 milligrams per gallon. For complicating bacterial organisms associated with bluecomb (transmissible enteritis or coronaviral enteritis): 25 milligrams per pound of body weight per day.

(ii) Indications for use. Control of infectious synovitis caused by \textit{M. synoviae}; control of bluecomb complicated by organisms sensitive to tetracycline.
§ 520.2345e Tetracycline oral liquid.

(iii) Limitations. Administer for 7 to 14 days; do not slaughter for food within 4 days of treatment; not for use in turkeys producing eggs for human consumption; prepare a fresh solution daily; use as the sole source of tetracycline.


§ 520.2345f Tetracycline phosphate complex and sodium novobiocin capsules.

(a) Specifications. Each capsule contains the equivalent of 60 milligrams of tetracycline hydrochloride and 60 milligrams of novobiocin.

(b) Sponsor. No. 000009 in §510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 10 milligrams of each antibiotic per pound of body weight (1 capsule for each 6 pounds) every 12 hours.

(2) Indications for use. Treatment of acute or chronic canine respiratory infections such as tonsillitis, bronchitis, and tracheobronchitis when caused by pathogens susceptible to tetracycline and/or novobiocin, such as Staphylococcus spp. and Escherichia coli.

(3) Limitations. Continue treatment for at least 48 hours after the temperature has returned to normal and all evidence of infection has disappeared. As with all antibiotics, appropriate in vitro culturing and susceptibility tests of samples taken before treatment should be conducted. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37329, Aug. 18, 1992]

§ 520.2345g Tetracycline hydrochloride and sodium novobiocin tablets.

(a) Specifications. Each tablet contains the equivalent of 60 milligrams of tetracycline hydrochloride and 60 milligrams of novobiocin, or 180 milligrams of tetracycline hydrochloride and 180 milligrams of novobiocin.

(b) Sponsor. No. 000009 in §510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 10 milligrams of each antibiotic per pound of body weight (one single-strength tablet for each 6 pounds every 6 hours).
or one triple-strength tablet for each 18 pounds).

(2) **Indications for use.** Treatment of acute or chronic canine respiratory infections such as tonsillitis, bronchitis, and tracheobronchitis when caused by pathogens susceptible to tetracycline and/or novobiocin, such as *Staphylococcus* spp. and *Escherichia coli*.

(3) **Limitations.** Continue treatment for at least 48 hours after the temperature has returned to normal and all evidence of infection has disappeared. As with all antibiotics, appropriate in vitro culturing and susceptibility tests of samples taken before treatment should be conducted. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37329, Aug. 18, 1992]

§ 520.2362 Thenium closylate tablets.

(a) **Chemical name.** (N,N-Dimethyl-N-2-phenoxyethyl-N-2′-thenylammonium)-p-chlorobenzene-sulphonate.

(b) **Sponsor.** See No. 000061 in § 510.600(c) of this chapter.

(c) **Conditions of use.** (1) The tablets are administered orally to dogs as a single day treatment of canine ancylostomiasis by the removal from the intestines of the adult forms of the species *Ancylostoma caninum* and *Uncinaria stenocephala* (hookworms). Dogs weighing 10 pounds and over are administered 1 tablet as a single dose. Dogs weighing 5 to 10 pounds are administered one-half tablet twice during a single day. All dosages are given for 1 day only. The treatment should be repeated after 2 or 3 weeks.

(2) Suckling puppies or recently weaned puppies weighing less than 5 pounds should not be treated with the drug. Animals that are severely infected, exhibiting evidence of intestinal hemorrhage, debilitation, and anemia, should be given supportive treatment.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2380 Thiabendazole oral dosage forms.

§ 520.2380a Thiabendazole top dressing and mineral protein feed block.

(a) Chemical name. 2-(4-Thiazolyl)-benzimidazole.

(b) Specifications. Conforms to N.F. XII.

(c) Sponsor. (1) See No. 017800 in §510.600(c) of this chapter for the sponsor of the usage provided by paragraph (e)(1)(ii) of this section.

(2) See No. 050604 in §510.600(c) of this chapter for the sponsor of the usages provided for by paragraph (e)(1)(ii) of this section.

(3) See No. 021930 in §510.600(c) of this chapter for the sponsor of the usage provided for by paragraph (e)(2) of this section.

(d) Related tolerances. See §556.730 of this chapter.

(e) Conditions of use. It is used as follows:

(1) Horses—(i) Route of administration. In feed, as a top dressing.

(a) Amount. 2 grams per 100 pounds of body weight.

(b) Indications for use. For control of large strongyles, small strongyles, pinworms, and threadworms (including members of the genera Strongylus, Cyathostomum, Cylicobrachytus, and related genera, Craterostomum, Oesophagodontus, Poteriostomum, Oxyuris, and Strongyloides).

(c) Limitations. Add to the usual feed of horses mixed into that amount of the feed normally consumed at one feeding. Warning: Not for use in horses intended for food.

(ii) Amount. 2 grams per 100 pounds of body weight.

(1) Indications for use. For control ofascarids of the genus Parascaris.

(2) Limitations. Administer in a single dosage mixed with the normal grain ration given at one feeding. Warning: Not for use in horses intended for food.

(2) Cattle—(i) Route of administration. In feed block.

(a) Amount. 3.3 percent block consumed at the recommended level of 0.11 pound per 100 pounds of body weight per day.

(b) Amount. 4 grams per 100 pounds of body weight.

(1) Indications for use. For control of infections of gastrointestinal roundworms (Trichostrongylus, Haemonchus, Ostertagia and Cooperia).

(c) Limitations. Administer to cattle on pasture or range accustomed to mineral protein block feeding for 3 days. Milk taken from animals during treatment and within 96 hours (8 milkings) after the latest treatment must not be used for food. Do not treat cattle within 3 days of slaughter. For a satisfactory diagnosis, a microscopic fecal examination should be performed by a veterinarian or diagnostic laboratory prior to worming. Animals maintained under conditions of constant worm exposure may require re-treatment within 2 to 3 weeks. Animals that are severely parasitized, sick, or off feed should be isolated and a veterinarian consulted for advice concerning treatment.

§ 520.2380b Thiabendazole drench or oral paste.

(a) Chemical name. 2-(4-Thiazolyl) benzimidazole.

(b) Specifications. Conforms to N.F. XII.

(c) Sponsor. See No. 050604 in §510.600(c) of this chapter for the sponsor of the usages provided for by paragraph (e) of this section.

(d) Related tolerances. See §556.730 of this chapter.

(e) Conditions of use. It is used as follows:

(1) Horses. As a single liquid oral dose, administered as a drench or by stomach tube; or as an oral paste.

(b) Amount. 2 grams per 100 pounds of body weight.

(1) Indications for use. For control of large strongyles, small strongyles, Strongyloides, pinworms of the genera Strongylus, Cyathostomum, Cylicobrachytus and related genera, Craterostomum, Oesophagodontus, Poteriostomum, Oxyuris, and Strongyloides.

(2) Limitations. Administer in a single dosage mixed with the normal grain ration given at one feeding. Warning: Not for use in horses intended for food.

(2) Cattle—(i) Route of administration. In feed. (ii) Amount. 2.2 grams per 100 pounds of body weight.

(1) Indications for use. For control of infections of gastrointestinal roundworms (Trichostrongylus, Haemonchus, Ostertagia and Cooperia).

(2) Limitations. Administer to cattle on pasture or range accustomed to mineral protein block feeding for 3 days. Milk taken from animals during treatment and within 96 hours (8 milkings) after the latest treatment must not be used for food. Do not treat cattle within 3 days of slaughter. For a satisfactory diagnosis, a microscopic fecal examination should be performed by a veterinarian or diagnostic laboratory prior to worming. Animals maintained under conditions of constant worm exposure may require re-treatment within 2 to 3 weeks. Animals that are severely parasitized, sick, or off feed should be isolated and a veterinarian consulted for advice concerning treatment.
(a) **Indications for use.** For the control of infections of large strongyles (*Strongylus vulgaris*, *Strongylus endentatus*), small strongyles (*Cyathostomum, Cylicobrachytus* and related genera, *Craterostomum, Oesophagodontus*, *Poteriostomum*), pinworms (*Oxyuris*), and threadworms (*Strongyloides*).

(b) **Limitations.** Not for use in horses to be slaughtered for food purposes. When administered by stomach tube, for use only by or on the order of a licensed veterinarian. When for use as a liquid oral drench or an oral paste, consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(ii) **Amount.** 4 grams per 100 pounds of body weight.

(a) **Indications for use.** For control of infections of ascardia (*Parascaris*).

(b) **Limitations.** Not for use in horses to be slaughtered for food purposes. When administered by stomach tube, use only by or on the order of a licensed veterinarian. When for use as a liquid oral drench or an oral paste, consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(ii) **Amount.** 5 grams per 100 pounds of body weight.

(a) **Indications for use.** Control of infections of *Cooperia spp.* or severe infections of other species in paragraph (e)(3)(i)(a) of this section.

(b) **Limitations.** For most effective results, severely parasitized animals or those constantly exposed to helminth infection should be re-treated every 2 to 3 weeks. Milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food. Do not treat cattle within 3 days of slaughter. For a satisfactory diagnosis, a microscopic fecal examination should be performed prior to worming.

(ii) **Amount.** 5 grams per 100 pounds of body weight.

(4) **Sheep and goats.** Orally, as a drench.

(i) **Amount.** 3 grams per 100 pounds of body weight.

(ii) **Indications for use.** Control of gastrointestinal roundworms in sheep and goats. (*Trichostrongylus spp.*, *Haemonchus spp.*, *Ostertagia spp.*, *Cooperia spp.*, *Nematodirus spp.*, *Bunostomum spp.*, *Strongyloides spp.*, *Chabertia spp.*, and *Oesophagostomum spp.*); also active from 3 hours to 3 days following treatment against ova and larvae passed by sheep (good activity against *Trichostrongylus colubriformis* and *axei*, *Ostertagia spp.*, *Bunostomum spp.*, *Nematodirus spp.*, and *Strongyloides spp.*; less effective against *Haemonchus contortus* and *Oesophagostomum spp.*).

(iii) **Limitations.** As a single oral dose; do not treat animals within 30 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food; in severe infections in sheep, treatment should be repeated in 2 to 3 weeks.

(5) **Goats.** Orally, as a drench.

(i) **Amount.** 3 grams per 100 pounds of body weight.
§ 520.2380c Thiabendazole bolus.

(a) Chemical name. 2-(4-Thiazolyl) benzimidazole.

(b) Specifications. Conforms to N.F. XII.

(c) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.730 of this chapter.

(e) Conditions of use. It is used as follows:

(1) Cattle. In a bolus.

(i) Amount. 3 grams per 100 pounds of body weight.


(iii) Limitations. As a single oral dose; do not treat animals within 30 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food; treatment should be repeated in 2 to 3 weeks.

(2) Sheep and goats. In a bolus.

(i) Amount. 2 grams per 100 pounds of body weight.

(ii) Indications for use. Control of infections of gastrointestinal roundworms in sheep and goats (genera *Trichostrongylus* spp., *Haemonchus* spp., *Ostertagia* spp., *Cooperia* spp., *Nematodirus* spp., *Bunostomum* spp., *Strongyloides* spp., *Chabertia* spp., and *Oesophagostomum* spp.), also active from 3 hours to 3 days following treatment against ova and larvae passed by sheep (good activity against *T. colubriformis* and *axei*, *Ostertagia* spp., *Bunostomum* spp., *Nematodirus* spp., and *Strongyloides* spp.; less effective against *Haemonchus* contagiosus and *Oesophagostomum* spp.).

(iii) Limitations. As a single oral dose; do not treat animals within 30 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food; in severe infections in sheep, treatment should be repeated in 2 to 3 weeks.

(3) Goats. In a bolus.

(i) Amount. 3 grams per 100 pounds of body weight.


(iii) Limitations. As a single oral dose; do not treat animals within 30 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food; treatment should be repeated in 2 to 3 weeks.

§ 520.2380d Thiabendazole, piperazine citrate suspension.

(a) Specifications. Each fluid ounce of suspension contains 2 grams of thiabendazole and 2.5 grams of piperazine (from piperazine citrate).
Food and Drug Administration, HHS

§ 520.2455  Tiamulin soluble powder.

(a) Specifications. A water-soluble powder containing 45 percent tiamulin

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is administered to horses by stomach tube or as a drench at the rate of 1 fluid ounce of suspension per 100 pounds of body weight for the control of large strongyles, small strongyles, pinworms, Strongyloides and ascarids (including members of the genera Strongylus spp., Cyathostomum spp., Cylicobrachytus spp. and related genera Craterostomum spp., Oesophagodontus spp., Poteriostomum spp., Oxyuris spp., Strongyloides spp., and Parascaris spp.).

(2) Do not use in horses intended to be used for food purposes.

(3) Do not re-treat more than once every 30 days, preferably every 6 to 8 weeks.

(4) Do not treat animals if sick or debilitated; less than 4 months of age; or mares in last month of pregnancy.

(5) Do not administer intravenous anesthetics, especially muscle relaxants, within 2 weeks of use.

(6) Not for animals intended for food use.

(7) Do not use within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(8) If the label bears directions for administration of the drug by stomach tube or drench it shall also bear the statement: Caution; Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2380f  Thiabendazole, piperazine phosphate powder.

(a) Specifications. Each ounce of water dispersible powder contains 6.67 grams of thiabendazole and 8.33 grams of piperazine (as piperazine phosphate).

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 2 grams of thiabendazole and 2.5 grams of piperazine (0.3 ounce of powder) per 100 pounds of body weight.

(2) Indications for use. Treatment of infections of large strongyles (genus Strongylus), small strongyles (genera Cyathostomum, Cylicobrachytus, and related genera Craterostomum, Oesophagodontus, Poteriostomum), pinworms (Oxyuris), threadworms (Strongyloides), and ascarids (Parascaris) in horses.

(3) Limitations. Use a single oral dose. Administer as a drench or by stomach tube suspended in 1 pint of warm water; by dose syringe suspended in ½ ounce of water for each 100 pounds of body weight; or sprinkled over a small amount of daily feed. Not for animals intended for food use. If the label bears directions for administration by stomach tube or drench, it shall also bear the statement “Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian;” if not labeled for use by stomach tube or drench, the label shall bear the statement, “Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.”

used to make a medicated drinking water containing 227 or 677 milligrams of tiamulin per gallon.

(b) **Sponsor.** See No. 000010 in §510.600(c) of this chapter.

(c) **Related tolerances.** See §556.738 of this chapter.

(d) **Conditions of use in swine—(1) Amount.** 3.5 milligrams of tiamulin per pound of body weight for 5 days.

(i) **Indications for use.** For treatment of swine dysentery associated with *Treponema hyodysenteriae* susceptible to tiamulin.

(ii) **Limitations.** Use for 5 consecutive days. Withdraw 3 days before slaughter. Prepare fresh medicated water daily. Not for use in swine over 250 pounds body weight. Use as only source of drinking water. Do not allow consumption of feeds containing polyether ionophores (e.g., monensin, lasalocid, narasin, or salinomycin) as adverse reactions may occur.


§520.2473 **Tioxidazole oral dosage forms.**

§520.2473a **Tioxidazole granules.**

(a) **Specifications.** Each gram of granules contains 200 milligrams of tioxidazole.

(b) **Sponsor.** See No. 000061 in §510.600(c) of this chapter.

(c) **Conditions of use—(1) Horses—(i) Amount.** 5 milligrams per pound of body weight as a single dose.

(ii) **Indications for use.** Removal of mature large strongyles (*Strongylus edentatus*, *S. equinus*, and *S. vulgaris*), mature ascarids (*Parascaris equorum*), mature and immature (4th larval stage) pinworms (*Oxyuris equi*), and mature small strongyles (*Triodontophorus spp.*)

(iii) **Limitations.** For administration with feed: Sprinkle required amount of granules on a small amount of the usual grain ration and mix. Prepare for each horse individually. Withholding of feed or water not necessary. Not for use in horses intended for food. The reproductive safety of tioxidazole in breeding animals has not been determined. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. It is recommended that this drug be administered with caution to sick or debilitated horses.
§ 520.2473b Tioxidazole paste.

(a) Specifications. Each plastic syringe contains 6.25 grams of tioxidazole.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—

(i) Amount. 5 milligrams of tioxidazole per pound of body weight as a single dose.

(ii) Indications for use. Removal of mature large strongyles (Strongylus edentatus, S. equinus, and S. vulgaris), mature ascarids (Parascaris equorum), mature and immature (4th larval stage) pinworms (Oxyuris equi), and mature small strongyles (Triodontophorus spp.).

(iii) Limitations. Administer orally by inserting the nozzle of the syringe through the space between front and back teeth and deposit the required dose on the base of the tongue. Before dosing, make sure the horse’s mouth contains no feed. Not for use in horses intended for food. The reproductive safety of tioxidazole in breeding animals has not been determined. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. It is recommended that this drug be administered with caution to sick or debilitated horses.

(2) [Reserved]


§ 520.2481 Triamcinolone acetonide tablets.

(a) Specifications. Each tablet contains either 0.5 milligram or 1.5 milligrams of the drug.

(b) Sponsor. See Nos. 000010 and 053501 in §510.600(c) of this chapter.

(c) NAS/NRC status. The conditions of use specified in this section are NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(d) Conditions of use. (1) The drug is used as an anti-inflammatory agent for horses.

(2) It is administered at a dosage of 0.005 to 0.01 milligram triamcinolone acetonide per pound of body weight twice daily, sprinkled (top-dressed) on a small portion of feed. Treatment may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear.

(3) The labeling shall comply with the requirements of §510.410 of this chapter.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2520

(3) The labeling shall comply with the requirements of §510.410 of this chapter.

(4) Not for use in horses intended for food.

(5) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2520 Trichlorfon oral dosage forms.

§ 520.2520b Trichlorfon and atropine.

(a) Chemical name. (1) For trichlorfon: O,O-Dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphonate.

(2) For atropine: Atropine N.F.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used for the treatment of Syphacia obvelata (pinworm) in laboratory mice.

(2) It is administered in distilled water as sole source of drinking water continuously for 7 to 14 days at 1.67 grams of trichlorfon and 7.7 milligrams of atropine per liter.

(3) Prepare fresh solution every 3 days. Do not use simultaneously with other drugs, insecticides, pesticides, or chemicals having cholinesterase activity, nor within 7 days before or after treatment with any other cholinesterase inhibitor.

(4) Restricted to use by or on the order of a licensed veterinarian.

§ 520.2520e Trichlorfon boluses.

(a) Specifications. Each bolus contains either 7.3, 10.9, 14.6, or 18.2 g of trichlorfon.

(b) Sponsor. See 000856 in §510.600(c) of this chapter.

(c) Special considerations. Trichlorfon is a cholinesterase inhibitor. Do not use this product on animals simultaneously with, or within 2 weeks before or after treatment with or exposure to neuromuscular depolarizing agents (i.e., succinylcholine) or to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(d) NAS/NRC status. Use of this drug has been NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter.

(e) Conditions of use. (1) Amount. 18.2 milligrams per pound of body weight, except for strongyles use 36.4 milligrams per pound of body weight.

(2) Indications for use. For horses for removal of bots (Gastrothilus nasalis, Gastrothilus intestinalis), large strongyles (Strongylus vulgaris), small strongyles, large roundworms (ascarids, Parascaris equorum), and pinworms (Oxyuris equi).

(3) Limitations. Do not fast horses before or after treatment. Treatment of mares in late pregnancy is not recommended. Surgery or any severe stress should be avoided for at least 2 weeks before or after treatment. Do not administer to sick, toxic, or debilitated horses. Not to be used in horses intended for use as food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2520f Trichlorfon granules.

(a) Specifications. Each package contains either 18.2 or 36.4 g of trichlorfon.

(b) Sponsor. See 000856 in §510.600(c) of this chapter.

(c) Special considerations. Trichlorfon is a cholinesterase inhibitor. Do not use this product on animals simultaneously with, or within 2 weeks before or after treatment with or exposure to neuromuscular depolarizing agents (i.e., succinylcholine) or to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(d) NAS/NRC status. Use of this drug has been NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter.

(e) Conditions of use. (1) Amount. 18.2 milligrams per pound of body weight.

(2) Indications for use. For horses for removal of bots (Gastrothilus nasalis, Gastrothilus intestinalis), large roundworms (ascarids, Parascaris equorum), and pinworms (Oxyuris equi).

(3) Limitations. Do not fast horses before or after treatment. Treatment of mares in late pregnancy is not recommended. Surgery or any severe stress should be avoided for at least 2 weeks before or after treatment. Do not administer to sick, toxic, or debilitated horses. Not to be used in horses intended for use as food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 520.2520g Trichlorfon, phenothiazine, and piperazine dihydrochloride powder.

(a) Specifications. Each 54.10 grams (1.91 ounces) of water dispersible powder contains 9.10 grams of trichlorfon, 6.25 grams of phenothiazine, and the equivalent of 20.0 grams of piperazine base (as piperazine dihydrochloride).

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Special considerations. Labeling shall bear the following statements:

The drug is a cholinesterase inhibitor. Do not use this product in horses simultaneously with, or within 2 weeks before or after treatment with, or exposure to, neuromuscular depolarizing agents (e.g., succinylcholine) or to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(d) Conditions of use—(1) Amount. 18.2 milligrams of trichlorfon, 12.5 milligrams of phenothiazine, and 40.0 milligrams of piperazine base per pound of body weight.

(2) Indications for use. For horses for removal of bots (Gastrophilus nasalis, Gastrophilus intestinalis), large strongyles (Strongylus vulgaris), small strongyles, large roundworms (ascarids, Parascaris equorum), and pinworms (Oxyuris equi).

(3) Limitations. Mix powder and vial contents together in warm water to form suspension. Administer by stomach tube. Do not fast horses before or after treatment. Treatment of mares in late pregnancy is not recommended. Surgery or any severe stress should be avoided for at least 2 weeks before or after treatment. Do not administer to sick, toxic, or debilitated horses. Not to be used in horses intended for use as food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[45 FR 48128, July 18, 1980]

§ 520.2582 Triflupromazine hydrochloride tablets.

(a) Specifications. Each tablet contains either 10 milligrams or 25 milligrams of triflupromazine hydrochloride.

(b) Sponsor. See No. 053501 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in dogs and cats to relieve anxiety and to help control psychomotor overactivity as well as to increase the tolerance of animals to pain and pruritus. The drug is indicated in various office and clinical procedures which require the aid of a tranquilizer, antiemetic, or preanesthetic.

(2) The drug is administered orally to dogs and cats at a dosage level of 1 to 2 milligrams per pound of body weight daily; an initial dosage at the 2-milligram level is suggested followed by daily doses at the 1-milligram level. Frequently, the drug may be withdrawn after 4 to 5 days, with drug effect continuing after withdrawal.

(3) Do not use in conjunction with organophosphates and/or procaine hydrochloride, because phenothiazines may potentiate the toxicity of organophosphates and the activity of procaine hydrochloride.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 50 FR 41489, Oct. 11, 1985]

§ 520.2604 Trimeprazine tartrate and prednisolone tablets.

(a) Specifications. Each tablet contains: trimeprazine tartrate, 5 milligrams; and prednisolone, 2 milligrams.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is administered orally to dogs for the relief of itching regardless of cause; reduction of inflammation commonly associated with most skin disorders of dogs such as eczema, caused by internal disorders, otitis, and dermatitis, allergic, parasitic, pustular and nonspecific. It is also used in dogs as adjunctive therapy in various cough conditions including treatment of "kennel cough" or tracheobronchitis, bronchitis including allergic bronchitis, in
§ 520.2605 Trimeprazine tartrate and prednisolone capsules.

(a) Specifications. Each capsule contains 3.75 milligrams of trimeprazine in sustained released form (as the tartrate) and 2 milligrams of prednisolone (capsule no. 2).

(b) Sponsor. See 000069 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer either capsule orally once daily to dogs as follows:

<table>
<thead>
<tr>
<th>Animal weight (pounds)</th>
<th>Capsule No. 1</th>
<th>Capsule No. 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 10</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>11 to 20</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>21 to 40</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Over 40</td>
<td>6</td>
<td>3</td>
</tr>
</tbody>
</table>

(2) Indications for use. For the relief of itching regardless of cause, reduction of inflammation commonly associated with most skin disorders of dogs such as eczema caused by internal disorders, otitis, and dermatitis (allergic, parasitic, pustular, and nonspecific). It is also used in dogs as adjunctive therapy in various cough conditions including treatment of "kennel cough" or tracheobronchitis, bronchitis including allergic bronchitis, tonsillitis, acute upper respiratory infections, and coughs of nonspecific origin. The product may also be administered to dogs suffering from acute or chronic bacterial infections, provided the infection is controlled by appropriate antibiotic or chemotherapeutic agents.

(3) Limitations. After 4 days, reduce dosage to one-half the initial dose or to an amount sufficient to maintain remission of symptoms. Dosages in individual cases may vary and should be adjusted until proper response is obtained.

(4) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(5) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 56 FR 50653, Oct. 8, 1991; 60 FR 55659, Nov. 2, 1995]
§ 520.2610 Trimethoprim and sulfadiazine tablets.

(a) Specifications. Each tablet contains 30 milligrams (5 milligrams of trimethoprim and 25 milligrams of sulfadiazine), 120 milligrams (20 milligrams of trimethoprim and 100 milligrams of sulfadiazine), 480 milligrams (80 milligrams of trimethoprim and 400 milligrams of sulfadiazine) or 960 milligrams (160 milligrams of trimethoprim and 800 milligrams of sulfadiazine).

(b) Sponsor. See Nos. 000061 and 000856 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in dogs where systemic antibacterial action against sensitive organisms is required, either alone or as an adjunct to surgery or debridement with associated infection. The drug is indicated where control of bacterial infection is required during the treatment of acute urinary tract infections, acute bacterial complications of distemper, acute respiratory tract infections, acute alimentary tract infections, wound infections, and abscesses.

(2) The drug is given orally at 30 milligrams per kilogram of body weight per day (14 milligrams per pound per day), or as follows:

<table>
<thead>
<tr>
<th>Animal body weight (pounds)</th>
<th>Number of tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30 MG TABLETS</td>
</tr>
<tr>
<td>2.2</td>
<td>1</td>
</tr>
<tr>
<td>4.4</td>
<td>2</td>
</tr>
<tr>
<td>6.6</td>
<td>3</td>
</tr>
<tr>
<td>8.8</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>120 MG TABLETS</td>
</tr>
<tr>
<td>10 to 19</td>
<td>2</td>
</tr>
<tr>
<td>20 to 29</td>
<td>3</td>
</tr>
<tr>
<td>30 to 40</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>480 MG TABLETS</td>
</tr>
<tr>
<td>30 to 40</td>
<td>1</td>
</tr>
<tr>
<td>40 to 60</td>
<td>1 1/2</td>
</tr>
<tr>
<td>60 to 80</td>
<td>2</td>
</tr>
<tr>
<td>80 to 110</td>
<td>3</td>
</tr>
<tr>
<td>Over 110</td>
<td>4</td>
</tr>
</tbody>
</table>

(3) The drug is given once daily. Alternatively, especially in severe infections, the initial dose may be followed by one-half the recommended daily dose every 12 hours. If no improvement is seen in 3 days, discontinue therapy and reevaluate diagnosis.

(4) Administer for 2 to 3 days after symptoms have subsided. Do not treat for more than 14 consecutive days.

(5) During long term treatment, periodic platelet counts and white and red blood cell counts are recommended.

(6) The drug should not be used in patients showing marked liver parenchymal damage or blood dyscrasia, nor in those with a history of sulfonamide sensitivity.

(7) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2611 Trimethoprim and sulfadiazine oral paste.

(a) Specifications. Each gram of oral paste contains 400 milligrams (67 milligrams of trimethoprim and 333 milligrams of sulfadiazine).

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter for product to be dosed at 5 grams per 150 pounds of body weight per day. See No. 000061 in §510.600(c) of this chapter for product to be dosed at 3.75 grams per 110 pounds of body weight per day.

(c) Conditions of use—(1) Dosage. (i) 5 grams (335 milligrams of trimethoprim and 1,665 milligrams of sulfadiazine) per 150 pounds (68 kilograms) of body weight per day. (ii) 3.75 grams (250 milligrams of trimethoprim and 1,250 milligrams of sulfadiazine) per 110 pounds (50 kilograms) of body weight per day.

(2) Indications for use. For horses where systemic antibacterial action against sensitive organisms is required during treatment of acute strangles, respiratory infections, acute urogenital infections, and wound infections and abscesses.

(3) Limitations. Administer orally, once a day, as a single dose for 5 to 7 days; daily dose may also be halved and given morning and evening; for acute infection therapy continue treatment 2 to 3 days after clinical signs have subsided; if no improvement of acute infections is seen in 3 to 5 days, reevaluate diagnosis; a complete blood count
§ 520.2612

should be done periodically for prolonged use; not for use in horses intended for food; Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2612 Trimethoprim and sulfadiazine oral suspension.

(a) Specifications. Each milliliter of oral suspension contains 60 milligrams of drug (10 milligrams of trimethoprim and 50 milligrams of sulfadiazine).

(b) Sponsor. See No. 000061 in § 510.600 of this chapter.

(c) Conditions of use. Dogs—(1) Dosage. 1 milliliter (10 milligrams of trimethoprim and 50 milligrams of sulfadiazine) per 5 pounds of body weight.

(2) Indications for use. The drug is used in dogs where systemic antibacterial action against sensitive organisms is required, either alone or as an adjunct to surgery or debridement with associated infection. The drug is indicated where control of bacterial infection is required during the treatment of acute urinary tract infections, acute bacterial complications of distemper, acute respiratory tract infections, acute alimentary tract infections, wound infections, and abscesses.

(3) Limitations. For oral use only. Administer the recommended dose once daily or one-half the recommended daily dose every 12 hours. Administer for 2 to 3 days after symptoms have subsided. If no improvement is seen in 3 days, discontinue therapy and reevaluate diagnosis. A complete blood count should be done periodically with prolonged use. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[58 FR 36135, July 6, 1993, as amended by 64 FR 68289, Dec. 7, 1999]

§ 520.2613 Trimethoprim and sulfadiazine powder.

(a) Specifications. Each gram of powder contains 67 milligrams of trimethoprim and 333 milligrams of sulfadiazine.

(b) Sponsor. See No. 000009 and 058711 in § 510.600(c) of this chapter.

(c) Conditions of use: Horses—(1) Dosage. 3.75 grams of powder per 110 pounds (50 kilograms) of body weight per day.

(2) Indications for use. For control of bacterial infections of horses during treatment of acute strangles, respiratory tract infections, acute urogenital infections, wound infections, and abscesses.

(3) Limitations. Administer orally in a small amount of feed, as a single daily dose, for 5 to 7 days. Continue therapy for 2 to 3 days after clinical signs have subsided. If no improvement is seen in 3 to 5 days, reevaluate diagnosis. A complete blood count should be done periodically with prolonged use. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[58 FR 36135, July 6, 1993, as amended by 64 FR 68289, Dec. 7, 1999]

§ 520.2640 Tylosin.

(a) Specifications. Tylosin is the antibacterial substance produced by growth of Streptomyces fradiae or the same antibacterial substance produced by any other means. Tylosin, present as the tartrate salt, conforms to the appropriate antibacterial standard. Tylosin contains at least 95 percent tylosin as a combination of tylosin A, tylosin B, tylosin C, and tylosin D of which at least 80 percent is tylosin A as determined by a method entitled “Determination of Factor Content in Tylosin by High Performance Liquid Chromatography,” which is incorporated by reference. Copies are available from the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, or available for inspection at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC 20001.

(b) Sponsor. See No. 000986 in § 510.600(c) of this chapter.
(c) Special considerations. The quantities of antibiotic in paragraph (e) of this section refer to the activity of the appropriate standard.

(d) Related tolerances. See § 556.740 of this chapter.

(e) Conditions of use. It is used in drinking water of animals as follows:

(1) Chickens—(i) Amount. 2 grams per gallon.

(ii) Indications for use. Aid in the treatment of chronic respiratory disease (CRD) caused by Mycoplasma gallisepticum sensitive to tylosin in broiler and replacement chickens. For the control of chronic respiratory disease (CRD) caused by Mycoplasma synoviae (CRD) caused by Mycoplasma gallisepticum sensitive to tylosin at time of vaccination or other stress in chickens. For the control of chronic respiratory disease (CRD) caused by Mycoplasma gallisepticum sensitive to tylosin in broiler chickens.

(iii) Limitations. Do not use in layers producing eggs for human consumption; administer from 1 to 5 days as sole source of drinking water; treated chickens should consume enough medicated drinking water to provide 50 milligrams of tylosin per pound of body weight per day; prepare a fresh solution every 3 days; do not administer within 24 hours of slaughter.

(2) Turkeys—(i) Amount. 2 grams per gallon.

(ii) Indications for use. Maintaining weight gains and feed efficiency in the presence of infectious sinusitis caused by Mycoplasma gallisepticum sensitive to tylosin.

(iii) Limitations. Do not use in layers producing eggs for human consumption; administer from 2 to 5 days as sole source of drinking water; treated turkeys should consume enough medicated drinking water to provide 60 milligrams of tylosin per pound of body weight per day; prepare a fresh solution every 3 days; when sinus swelling is present, inject the sinus with tylosin injectable simultaneously with the drinking water treatment; do not administer within 5 days of slaughter.

(3) Swine—(i) Amount. 0.25 gram per gallon.

(ii) Indications for use. For the control and treatment of swine dysentery (bloody scours) caused by pathogens sensitive to tylosin.

(iii) Limitations. As only source of drinking water for 3 to 10 days, depending on the severity of the condition being treated; mix fresh solution daily; medication must be withheld from animals 48 hours prior to slaughter.

Pt. 522

522.540 Dexamethasone injection.
522.542 Dexamethasone-21-isonicotinate suspension.
522.563 Diatrizoate meglumine and diatrizoate sodium injection.
522.575 Diazepam injection.
522.650 Dihydrostreptomycin sulfate injection.
522.690 Dinoprost tromethamine sterile solution.
522.723 Diprenorphine hydrochloride injection.
522.770 Doramectin.
522.775 Doxapram hydrochloride injection.
522.778 Doxycycline hyclate.
522.784 Doxylamine succinate injection.
522.800 Droperidol and fentanyl citrate injection.
522.812 Enrofloxacin solution.
522.820 Erythromycin injection.
522.840 Estradiol.
522.842 Estradiol benzoate and testosterone propionate in combination.
522.850 Estradiol valerate and norgestomet in combination.
522.863 Ethylisobutrazine hydrochloride injection.
522.883 Etorphine hydrochloride injection.
522.900 Euthanasia solution.
522.914 Fenprostalene solution.
522.940 Colloidal ferric oxide injection.
522.970 Flunixin meglumine solution.
522.995 Fluprostenol sodium injection.
522.1002 Follicle stimulating hormone.
522.1010 Furosemide.
522.1020 Gelatin solution.
522.1044 Gentamicin sulfate injection.
522.1077 Gonadorelin injectable.
522.1081 Serum gonadotropin and chorionic gonadotropin.
522.1085 Chorionic gonadotropin for injection; chorionic gonadotropin suspension.
522.1088 Guaifenesin injection.
522.1089 Hemoglobin glutamer-200 (bovine).
522.1090 Hyaluronate sodium injection.
522.1092 Hydrochlorothiazide injection.
522.1094 Imidocarb dipropionate sterile powder.
522.1095 Imidocarb dipropionate solution.
522.1096 Iron dextran complex injection.
522.1097 Iron hydroxymethyl dextran injection.
522.1099 Ivermectin injection.
522.1101 Ivermectin and clorsulon injection.
522.1104 Kanamycin sulfate injection.
522.1122 Ketamine hydrochloride injectable dosage forms.
522.1122a Ketamine hydrochloride injectable dosage forms.
522.1122b Ketamine hydrochloride with promazine hydrochloride and aminopentamide hydrogen sulfate injection.
522.1123 Ketoprofen solution.
522.1125 Ketoprofen solution.
522.1127 Levamisole phosphate injection.
522.1128 Lincomycin injection.
522.1129 Lupenuron suspension.
522.1129a Lupenuron suspension.
522.1129b Lupenuron suspension.
522.1130 Melanotropin implant.
522.1132 Melarsomine dihydrochloride for injection.
522.1137 Mepivacaine hydrochloride injection.
522.1138 Methocarbamol injection.
522.1140 Sterile methylprednisolone acetate suspension.
522.1141 Moxidectin.
522.1142 Nalorphine hydrochloride injection.
522.1143 Naloxone hydrochloride injection.
522.1145 Naltrexone hydrochloride injection.
522.1146 Naproxen for injection.
522.1147 Neomycin sulfate sterile solution.
522.1150 Neostigmine methylsulfate injection.
522.1156 Olate sodium solution.
522.1158 Orgotein for injection.
522.1160 Oxymorphone hydrochloride injection.
522.1160a Oxymorphone hydrochloride injection.
522.1162 Oxzytracycline hydrochloride implantation or injectable dosage forms.
522.1162a Oxytetracycline hydrochloride implantation or injectable dosage forms.
522.1162b Oxytetracycline hydrochloride with lidocaine injection.
522.1163 Oxytocin injection.
522.1169a Penicillin G benzathine and penicillin G procaine sterile suspension.
522.1169b Penicillin G procaine aqueous suspension.
522.1169c Penicillin G procaine in oil.
522.1169d Penicillin G procaine in oil.
522.1170 Sodium pentobarbital injection.
522.1172 Phenylbutazone injection.
522.1173 Pituatory luteinizing hormone for injection.
522.1174 Polysulfated glycosaminoglycan.
522.1175 Sterile pralidoxime chloride.
522.1176 Frazilantel injectable solution.
522.1177 Sterile prednisolone acetate aqueous suspension.
522.1183 Prednisolone sodium phosphate injection, sterile.
522.1184 Prednisolone sodium succinate injection.
522.1185 Prednisolone tertiary butylacetate suspension.
522.1186 Prednisolone tertiary butylacetate suspension.
§ 522.44 Sterile sodium acetazolamide.

(a) Specifications. Sterile sodium acetazolamide contains acetazolamide sodium complying with United States Pharmacopeia as a sterile powder with directions for reconstituting the product with sterile distilled water to furnish a product having a concentration of 100 milligrams acetazolamide activity per milliliter.

(b) Sponsor. See No. 010042 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used as an aid in the treatment of dogs with mild congestive heart failure and for rapid reduction of intraocular pressure.1

(2) It is administered intramuscularly or intraperitoneally to dogs at a level of 5 to 15 milligrams per pound of body weight daily preferably administered in two or more divided doses.1

(3) For use only by or on the order of a licensed veterinarian.1

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
§ 522.46 Alfaprostol.

(a) Specifications. Each milliliter of sterile solution contains 1 milligram of alfaprostol.

(b) Sponsor. No. 055882 in §510.600(c) of this chapter.

(c) Conditions of use. It is used in horses as follows:

(1) Amount. For average mature mares, 6.0 micrograms per kilogram of body weight.

(2) Indications for use. To cause luteolysis in mares with active corpora lutea.

(3) Limitations. For intramuscular or subcutaneous use as a single injection. Not for horses intended for food. Alfaprostol is readily absorbed through the skin and can cause abortion and/or bronchial spasms. Women of child-bearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.56 Amikacin sulfate injection.

(a) Specifications. Each milliliter of sterile aqueous solution contains 50 milligrams of amikacin (as the sulfate).

(b) Sponsor. See Nos. 000856 and 059130 in §510.600(c) of this chapter.

(c) Conditions of use—

(1) Amount. 5 milligrams per pound of body weight twice daily.

(2) Indications for use. The drug is used in dogs for treatment of genito-urinary tract infections (cystitis) caused by susceptible strains of Escherichia coli and Proteus spp. and skin and soft tissue infections caused by susceptible strains of Pseudomonas spp. and E. coli.

(3) Limitations. The drug is administered intramuscularly or subcutaneously. Dosage may be gradually increased up to a maximum of five times the suggested dosage. Following parenteral use dosage may be continued by oral administration of tablets. For use only by or on the order of a licensed veterinarian.


§ 522.62 Aminopentamide hydrogen sulfate injection.

(a) Chemical name. 4-(Dimethylamino)-2,2-diphenylvaleramide hydrogen sulfate.

(b) Specifications. It is sterile and each milliliter of aqueous solution contains 0.5 milligram of the drug.

(c) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(d) Conditions of use. (1) It is intended for use in dogs and cats only for the treatment of vomiting and/or diarrhea, nausea, acute abdominal visceral spasm, pylorospasm, or hypertrophic gastritis.

Note: Not for use in animals with glaucoma because of the occurrence of mydriasis.

(2) Dosage is administered by subcutaneous or intramuscular injection every 8 to 12 hours, as follows:

<table>
<thead>
<tr>
<th>Weight of animal in pounds</th>
<th>Dosage in milligrams</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 10</td>
<td>0.1</td>
</tr>
<tr>
<td>11 to 20</td>
<td>0.2</td>
</tr>
<tr>
<td>21 to 50</td>
<td>0.3</td>
</tr>
<tr>
<td>51 to 100</td>
<td>0.4</td>
</tr>
<tr>
<td>Over 100</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Dosage may not exceed 30 days. Systemic aminoglycoside therapy is contraindicated in dogs with seriously impaired renal function. Not for use in breeding dogs as reproductive studies have not been conducted. Use with extreme caution in dogs in which hearing acuity is required for function. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.82 Aminopropazine fumarate sterile solution injection.

(a) Specifications. Each milliliter of aminopropazine fumarate sterile aqueous solution, veterinary, contains...
§ 522.88 Beta-aminopropionitrile fumarate.

(a) Specifications. Each vial contains 7.0 milligrams of beta-aminopropionitrile fumarate sterile lyophilized powder which is reconstituted for injection with 10 milliliters of sterile physiologic saline, USP.

(b) Sponsor. See No. 064146 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) [Reserved]

§ 522.88 Sterile amoxicillin trihydrate for suspension.

(a)(1) Specifications. Each vial contains 3 grams of amoxicillin as the trihydrate. The powder is reconstituted with sterile water for injection USP to a concentration of 100 or 250 milligrams per milliliter for use as in paragraph (d) of this section.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Related tolerance. See § 556.38 of this chapter.

(d) Conditions of use in dogs and cats—

(1) Amount. 5 milligrams per pound of body weight daily.

(2) Indications for use—(i) Dogs. Treatment of infections caused by susceptible strains of organisms as follows: Respiratory infections (tonsillitis, tracheobronchitis) due to *Staphylococcus aureus*, *Streptococcus* spp., *Escherichia coli*, and *Proteus mirabilis*; genitourinary infections (cystitis) due to *S. aureus*, *Streptococcus* spp., *E. coli*, and *P. mirabilis*; gastrointestinal infections (bacterial gastroenteritis) due to *S. aureus*, *Streptococcus* spp., *E. coli*, and *P. mirabilis*; bacterial dermatitis due to *S. aureus*, *Streptococcus* spp., *E. coli*, and *P. mirabilis*; soft tissue infections (abscesses, lacerations, and wounds), due to *S. aureus*, *Streptococcus* spp., *E. coli*, and *P. mirabilis*.

(ii) Cats. Treatment of infections caused by susceptible strains of organisms as follows: Upper respiratory infections due to *S. aureus*, *Staphylococcus* spp., *Streptococcus* spp., *Hemophilus* spp., *E. coli*, *Pasteurella* spp.,

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §14.111 of this chapter, but may require bioequivalency and safety information.

217
§ 522.90 Ampicillin implantation and injectable dosage forms.

(a) Specifications. Each milliliter contains ampicillin trihydrate equivalent to 200 milligrams of ampicillin.

(1) Sponsor. See No. 053501 in §190.600(c) of this chapter.

(2) Related tolerances. See §556.40 of this chapter.

(b) Conditions of use.—(1) Cattle. (A) Amount. For enteritis: 3 milligrams per pound of body weight, intramuscularly, once or twice daily, for up to 3 days. For pneumonia: 3 milligrams per pound of body weight, intramuscularly, twice daily, for up to 3 days.

(B) Indications for use. Treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella spp. susceptible to ampicillin.

(C) Limitations. Not for use in other animals raised for food production. Treated animals must not be slaughtered for food use during treatment or for 9 days after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Dogs. (A) Amount. 3 to 6 milligrams per pound of body weight intramuscularly, once or twice daily.

(B) Indications for use. Treatment of respiratory tract infections due to E. coli, Pseudomonas spp., Proteus spp., Staphylococcus spp., and Streptococcus spp.; tonsillitis due to E. coli, Pseudomonas spp., Streptococcus spp., and Staphylococcus spp.; generalized infections (septicemia) associated with abscesses, lacerations, and wounds due to Staphylococcus spp. and Streptococcus spp.

(C) Limitations. Continue treatment at least 48 hours after the animal’s temperature has returned to normal and other signs of infection have subsided. Usual treatment is 3 to 5 days. Federal law restricts this drug to use

§ 522.90a Ampicillin trihydrate sterile injectible dosage forms.

(a) Specifications. Each milliliter contains ampicillin trihydrate equivalent to 200 milligrams of ampicillin.

(1) Sponsor. See No. 053501 in §190.600(c) of this chapter.

(2) Related tolerances. See §556.40 of this chapter.

(b) Conditions of use.—(1) Cattle. (A) Amount. For enteritis: 3 milligrams per pound of body weight, intramuscularly, once or twice daily, for up to 3 days. For pneumonia: 3 milligrams per pound of body weight, intramuscularly, twice daily, for up to 3 days.

(B) Indications for use. Treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella spp. susceptible to ampicillin.

(C) Limitations. Not for use in other animals raised for food production. Treated animals must not be slaughtered for food use during treatment or for 9 days after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Dogs. (A) Amount. 3 to 6 milligrams per pound of body weight intramuscularly, once or twice daily.

(B) Indications for use. Treatment of respiratory tract infections due to E. coli, Pseudomonas spp., Proteus spp., Staphylococcus spp., and Streptococcus spp.; tonsillitis due to E. coli, Pseudomonas spp., Streptococcus spp., and Staphylococcus spp.; generalized infections (septicemia) associated with abscesses, lacerations, and wounds due to Staphylococcus spp. and Streptococcus spp.

(C) Limitations. Continue treatment at least 48 hours after the animal’s temperature has returned to normal and other signs of infection have subsided. Usual treatment is 3 to 5 days. Federal law restricts this drug to use
Food and Drug Administration, HHS

§ 522.90b Ampicillin trihydrate for sterile suspension.

(a) Specifications. When reconstituted, each milliliter contains ampicillin trihydrate equivalent to 50, 100, or 250 milligrams of ampicillin.

(b) Sponsor. (1) See 000856 in §510.600(c) of this chapter for use of 50, 100, and 250 milligrams per milliliter ampicillin suspension.

(2) See 010515 in §510.600(c) of this chapter for use of 100 and 250 milligrams per milliliter ampicillin suspension.

(c) Related tolerances. See §556.40 of this chapter.

(d) Conditions of use. (1) Dogs—(i) Amount. 3 milligrams per pound of body weight twice daily.

(ii) Indications for use. Treatment against strains of organisms susceptible to ampicillin and associated with respiratory tract infections, urinary tract infections, gastrointestinal infections, skin infections, soft tissue infections, and postsurgical infections.

(iii) Limitations. Administer by subcutaneous or intramuscular injection. Treatment should be continued for 48 to 72 hours after the animal has become afebrile or asymptomatic. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(ii) Indications for use. Treatment against strains of organisms susceptible to ampicillin and associated with respiratory tract infections, urinary tract infections, gastrointestinal infections, skin infections, soft tissue infections, and postsurgical infections.

(iii) Limitations. Administer by subcutaneous or intramuscular injection. Treatment should be continued for 48 to 72 hours after the animal has become afebrile or asymptomatic. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(iii) Limitations. Administer intramuscularly. If continued treatment is indicated, oral dosage is recommended. As with all antibiotics, appropriate in vitro culturing and susceptibility tests of samples taken before treatment are recommended. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 73330, Aug. 18, 1992, as amended at 60 FR 56659, Nov. 2, 1995]
§ 522.90c Cattle—(i) Amount. 2 to 5 milligrams per pound of body weight once daily by intramuscular injection.


(iii) Limitations. Do not treat cattle for more than 7 days. Milk from treated cows must not be used for food during treatment and for 48 hours (4 milkings) after the last treatment. Cattle must not be slaughtered for food during treatment and for 144 hours (6 days) after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.144 Arsenamide sodium aqueous injection.

(a) Chemical name. [(p-Carbamoylphenyl) arsylene]dithio diacetic acid, sodium salt.

(b) Specifications. The drug is a sterile aqueous solution and each milliliter contains 10.0 milligrams of arsenamide sodium.

(c) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(d) Conditions of use. (1) For the treatment and prevention of canine heartworm disease caused by Dirofilaria immitis.

(2) It is administered intravenously at 0.1 milliliter per pound of body weight (1.0 milliliter for every 10 pounds) twice a day for 2 days. For dogs in poor condition, particularly those with evidence of reduced liver function, a more conservative dosage schedule of 0.1 milliliter per pound of body weight daily for 15 days is recommended.

(3) Restricted to use only by or on the order of a licensed veterinarian.

§ 522.147 Atipamezole hydrochloride.

(a) Specifications. Each milliliter of sterile injectable solution contains 5.0 milligrams of atipamezole hydrochloride.

(b) Sponsor. See No. 052483 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Inject intramuscularly the same volume as that of medetomidine used.

(2) Indications for use. To reverse clinical effects of the sedative and analgesic agent medetomidine hydrochloride.

(3) Limitations. For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in breeding animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37331, Aug. 18, 1992, as amended at 60 FR 56659, Nov. 2, 1995]
§ 522.150 Azaperone injection.

(a) Specifications. Each milliliter of sterile aqueous solution contains 40 milligrams of azaperone.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. Control of aggressiveness when mixing or regrouping weanling or feeder pigs weighing up to 80 pounds.

(2) Dosage. 2.2 milligrams per kilogram (1 milligram per pound).

(3) Limitations. Inject by deep intramuscular injection. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.161 Betamethasone acetate and betamethasone disodium phosphate aqueous suspension.


(b) Specifications. The drug is a sterile aqueous suspension and each cubic centimeter contains: 12 milligrams of betamethasone acetate (equivalent to 10.8 milligrams of betamethasone), 3.9 milligrams of betamethasone disodium phosphate (equivalent to 3 milligrams of betamethasone), 2 milligrams of dibasic sodium phosphate, 5 milligrams of sodium chloride, 0.1 milligram of disodium EDTA, 0.5 milligram of polysorbate 80, 9 milligrams of benzyl alcohol, 5 milligrams of sodium carboxymethylcellulose, 1.8 milligrams of methylparaben, 0.2 milligram of propylparaben, hydrochloric acid and/or sodium hydroxide to adjust pH, and water for injection q.s.

(c) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(d) Conditions of use. It is used or intended for use by intra-articular injection of horses for the treatment of various inflammatory joint conditions; for example, acute and traumatic lameness involving the carpel and fetlock joints. Administer from 2.5 to 5 cubic centimeters per dose. Dose may be repeated when necessary depending upon the duration of relief obtained. Not for use in horses intended for food. For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]

§ 522.163 Betamethasone dipropionate and betamethasone sodium phosphate aqueous suspension.

(a) Specifications. Betamethasone dipropionate and betamethasone sodium phosphate aqueous suspension is a sterile aqueous suspension. Each milliliter of the suspension contains the equivalent of 5 milligrams of betamethasone as betamethasone dipropionate and 2 milligrams of betamethasone as betamethasone sodium phosphate.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs. (i) It is used as an aid in the control of pruritus associated with dermatoses.

(ii) It is administered by intramuscular injection at a dosage of 0.25 to 0.5 milliliter per 20 pounds of body weight, depending on the severity of the condition. Frequency of dosage depends on recurrence of pruritic symptoms. Dosage may be repeated every 3 weeks or when symptoms recur, not to exceed a total of 4 injections.

(2) Horses. (i) It is used as an aid in the control of inflammation associated with various arthropathies.

(ii) It is administered aseptically by intra-articular injection at a dosage of 2.5 to 5 milliliters per joint, depending on the severity of the condition and the joint size. Dosage may be repeated upon recurrence of clinical signs. Injection into the joint cavity should be preceded by withdrawal of synovial fluid.

(iii) Not for use in horses intended for food.

(3) Clinical and experimental data. It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placent, and metritis.
§ 522.204 Boldenone undecylenate injection.

(a) Specifications. Each milliliter contains 25 or 50 milligrams of boldenone undecylenate in a sesame oil base.

(b) Sponsor. See No. 053501 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) It is intended for use as an aid in treating debilitated horses following disease or overwork and overexertion when an improvement in weight, hair coat, or general physical condition is desired. The drug is given only as adjunctive therapy to other specific and supportive therapy for diseases, surgical cases, and traumatic injuries. Optimal results can be expected only when good management and feeding practices are followed.

(2) It is administered intramuscularly at a dosage level of 0.5 milligram per pound of body weight. Treatment may be repeated at 3-week intervals.

(3) For use in horses only. Do not administer to horses intended for use as food. The effectiveness of the drug in stallions and pregnant mares has not been established, nor has the drug been shown not to be teratogenic in pregnant mares; therefore, this drug should not be used in stallions and pregnant mares.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.234 Butamisole hydrochloride.

(a) Specifications. The drug contains 11 milligrams of butamisole per milliliter in a solution consisting of 70 percent propylene glycol, 4 percent benzyl alcohol and distilled water.

(b) Sponsor. See Nos. 000859 and 043781 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Dogs—(i) Amount. 0.025 milligram of butorphanol base activity per pound of body weight (equivalent to 0.5 milliliter per 10 pounds), using 0.5 milligram per milliliter solution.

(ii) Indications for use. For the relief of chronic nonproductive cough associated with tracheo-bronchitis, tracheitis, tonsillitis, laryngitis, and pharyngitis associated with inflammatory conditions of the upper respiratory tract.

(iii) Limitations. For subcutaneous injection in dogs only. Repeat at intervals of 6 to 12 hours as required. If necessary, increase dose to maximum of 0.05 milligram per pound of body weight. Treatment should not normally be required for longer than 7 days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Horses—(i) Amount. 0.05 milligram of butorphanol base activity per pound of body weight (0.1 milligram/kilogram) using 10 milligrams per milliliter solution.
§ 522.313 Ceftiofur sodium powder for injection.

(a) Specifications. Ceftiofur sodium sterile powder for injection is reconstituted to form an aqueous solution containing the equivalent of 50 milligrams ceftiofur per milliliter.

(b) Sponsor. See No. 000009 in § 510.600 of this chapter.

(c) Related tolerances. See § 556.113 of this chapter.

(d) Conditions of use—(1) Cattle—(i) Amount. 0.5 to 1.0 milligram of ceftiofur per pound of body weight intramuscularly or subcutaneously.

(ii) Indications for use. For treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Pasteurella multocida, Actinobacillus pleuropneumoniae, and Haemophilus somnus in beef and dairy cattle. Also, for the treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.

(2) Swine—(i) Amount. 3 to 5 milligrams per kilogram of body weight.

(ii) Indications for use. For treatment of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae,
§ 522.314 Ceftiofur hydrochloride sterile suspension.

(a) Specifications. Each milliliter contains 2.2 milligrams of ceftiofur hydrochloride equivalent to 50 milligrams of ceftiofur.

(b) (i) Indications for use. Treatment of canine respiratory infections associated with *Escherichia coli* and *Proteus mirabilis*.

(ii) Indications for use. Treatment of canine urinary tract infections associated with *Escherichia coli* and *Proteus mirabilis*.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(iv) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.314 Ceftiofur hydrochloride sterile suspension.

(a) Specifications. Each milliliter contains 2.2 milligrams of ceftiofur hydrochloride equivalent to 50 milligrams of ceftiofur.
Food and Drug Administration, HHS

§ 522.380 Chloral hydrate, pentobarbital, and magnesium sulfate sterile aqueous solution.

(a) [Reserved]
(b)(1) Specifications. Chloral hydrate, pentobarbital, and magnesium sulfate sterile aqueous solution contains 42.5 milligrams of chloral hydrate, 8.86 milligrams of pentobarbital, and 21.2 milligrams of magnesium sulfate in each milliliter of sterile aqueous solution containing water, 33.8 percent propylene glycol, and 14.25 percent ethyl alcohol.

(c) Conditions of use. (1) It is used for general anesthesia and as a sedative-relaxant in cattle and horses.

(ii) For intravenous use only. The drug is administered at a dosage level of 20 to 50 milliliters per 100 pounds of body weight for general anesthesia until the desired effect is produced. Cattle usually require a lower dosage on the basis of body weight. When used as a sedative-relaxant, it is administered at a level of one-fourth to one-half of the anesthetic dosage level.

(iii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.390 Chloramphenicol injection.

(a) Specifications. Each milliliter contains 100 milligrams of chloramphenicol.

(b) Sponsor. See Nos. 000069 and 059130 in § 510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 5 to 15 milligrams per pound of body weight, intramuscularly or intravenously, every 6 hours. In severe infections, use 4 to 6 hour treatment intervals the first day. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis.

(ii) For intramuscular use only. Do not inject more than 15 milliliters at each intramuscular injection site. Do not slaughter treated cattle for 48 hours (2 days) after last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.380 Chloral hydrate, pentobarbital, and magnesium sulfate sterile aqueous solution.

(a) [Reserved]
(b)(1) Specifications. Chloral hydrate, pentobarbital, and magnesium sulfate sterile aqueous solution contains 42.5 milligrams of chloral hydrate, 8.86 milligrams of pentobarbital, and 21.2 milligrams of magnesium sulfate in each milliliter of sterile aqueous solution containing water, 33.8 percent propylene glycol, and 14.25 percent ethyl alcohol.

(c) Conditions of use. (1) It is used for general anesthesia and as a sedative-relaxant in cattle and horses.

(ii) For intravenous use only. The drug is administered at a dosage level of 20 to 50 milliliters per 100 pounds of body weight for general anesthesia until the desired effect is produced. Cattle usually require a lower dosage on the basis of body weight. When used as a sedative-relaxant, it is administered at a level of one-fourth to one-half of the anesthetic dosage level.

(iii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.390 Chloramphenicol injection.

(a) Specifications. Each milliliter contains 100 milligrams of chloramphenicol.

(b) Sponsor. See Nos. 000069 and 059130 in § 510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 5 to 15 milligrams per pound of body weight, intramuscularly or intravenously, every 6 hours. In severe infections, use 4 to 6 hour treatment intervals the first day. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis.

(ii) For intramuscular use only. Do not inject more than 15 milliliters at each intramuscular injection site. Do not slaughter treated cattle for 48 hours (2 days) after last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.380 Chloral hydrate, pentobarbital, and magnesium sulfate sterile aqueous solution.

(a) [Reserved]
(b)(1) Specifications. Chloral hydrate, pentobarbital, and magnesium sulfate sterile aqueous solution contains 42.5 milligrams of chloral hydrate, 8.86 milligrams of pentobarbital, and 21.2 milligrams of magnesium sulfate in each milliliter of sterile aqueous solution containing water, 33.8 percent propylene glycol, and 14.25 percent ethyl alcohol.

(c) Conditions of use. (1) It is used for general anesthesia and as a sedative-relaxant in cattle and horses.

(ii) For intravenous use only. The drug is administered at a dosage level of 20 to 50 milliliters per 100 pounds of body weight for general anesthesia until the desired effect is produced. Cattle usually require a lower dosage on the basis of body weight. When used as a sedative-relaxant, it is administered at a level of one-fourth to one-half of the anesthetic dosage level.

(iii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.390 Chloramphenicol injection.

(a) Specifications. Each milliliter contains 100 milligrams of chloramphenicol.

(b) Sponsor. See Nos. 000069 and 059130 in § 510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 5 to 15 milligrams per pound of body weight, intramuscularly or intravenously, every 6 hours. In severe infections, use 4 to 6 hour treatment intervals the first day. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis.

(ii) For intramuscular use only. Do not inject more than 15 milliliters at each intramuscular injection site. Do not slaughter treated cattle for 48 hours (2 days) after last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.460 Cloprostenol sodium.

(a)(1) Specifications. Each milliliter of the aqueous solution contains 263 micrograms of cloprostenol sodium (equivalent to 250 micrograms of cloprostenol) in a sodium citrate, anhydrous citric acid and sodium chloride buffer containing 0.1 percent w/v chlorocresol B.P. as a bactericide.

(b)(1) Specifications. Each milliliter of sterile aqueous solution contains 131.5 micrograms of cloprostenol sodium (equivalent to 125 micrograms of cloprostenol).

(c) [Reserved]

§ 522.468 Colistimethate sodium powder for injection.

(a) Specifications. Each vial contains colistimethate sodium equivalent to 10 grams colistin activity and mannitol to be reconstituted with 62.5 milliliters sterile saline or sterile water for injection. The resulting solution contains colistimethate sodium equivalent to 133 milligrams per milliliter colistin activity.

(b) Sponsor. See No. 046573 in § 510.600(c) of this chapter.

(c) [Reserved]
§ 522.533 Deslorelin acetate.

(a) Specifications. Each implant contains 2.1 milligrams deslorelin acetate.
§ 522.535 Desoxycorticosterone pivalate.

(a) Specifications. Each milliliter of sterile aqueous suspension contains 25 milligrams of desoxycorticosterone pivalate.

(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Dogs—(i) Amount. Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy. Initial dose of 1 milligram per pound (0.45 kilogram) of body weight every 25 days, intramuscularly. Usual dose is 0.75 to 1.0 milligram per pound of body weight every 21 to 30 days.

(ii) Indications for use. For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.

(iii) Limitations. For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

§ 522.536 Detomidine hydrochloride injection.

(a) Specification. Each milliliter of sterile aqueous solution contains 10 milligrams of detomidine hydrochloride.

(b) Sponsor. See No. 052483 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. For sedation, analgesia, or sedation and analgesia: 20 or 40 micrograms per kilogram (0.2 or 0.4 milliliter per 100 kilogram or 220 pounds) by body weight, depending on depth and duration required.

(ii) Indication for use. As a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings.

(3) Limitations. For sedation administer intravenously (IV) or intramuscularly (IM); for analgesia by IV; for both sedation and analgesia by IV. Do not use in horses with pre-existing atrioventricular or sinoauricular block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Do not use in breeding animals. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[54 FR 50365, Dec. 6, 1989; 54 FR 51551, Dec. 15, 1989]
followed by dystocia, fetal death, retained placenta, and metritis.

(iv) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) Specifications. The drug is a sterile aqueous solution. Each milliliter contains either 2.0 milligrams of dexamethasone or 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams dexamethasone).

(2) Sponsor. See number in §510.600(c) of this chapter as follows:
   (i) No. 000864 for use of 2.0 milligrams dexamethasone or 4.0 milligrams dexamethasone sodium phosphate injections.
   (ii) No. 000402 for use of 2.0 milligrams dexamethasone or 4.0 milligrams dexamethasone sodium phosphate injections.

(3) Conditions of use. (i) The drug is used in dogs for the treatment of inflammatory conditions, as supportive therapy in canine posterior paresis, as supportive therapy before or after surgery to enhance recovery of poor surgical risks, and as supportive therapy in nonspecific dermatosis. 1

   (ii) The drug is administered intravenously at 0.25 to 1 milligram initially. The dose may be repeated for 3 to 5 days or until a response is noted. If continued treatment is required, oral therapy may be substituted. When therapy is withdrawn after prolonged use, the daily dose should be reduced gradually over several days. 1

   (iii) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. 1

   (iv) Not for use in horses intended for food.

   (v) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d)(1) Specifications. The drug is a sterile aqueous solution. Each milliliter contains 2.0 milligrams of dexamethasone or 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams of dexamethasone).

(2) Sponsors. See the following numbers in §510.600(c) of this chapter:
   (i) Nos. 000069 and 059130 for intravenous or intramuscular use of 2.0 milligrams dexamethasone injection.
   (ii) No. 000069 for intravenous use of 2.0 milligrams dexamethasone injection.

(3) Conditions of use. (i) The drug is used as an anti-inflammatory agent in dogs, cats, and horses.

   (ii) It is administered intravenously or intramuscularly as follows: dogs—0.25 to 1 milligram; cats—0.125 to 0.5 milligram; horses—2.5 to 5 milligrams.

   (iii) Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.
parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(iv) Not for use in horses intended for food.

(v) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(e)(1) Specifications. The drug is a sterile aqueous solution. Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3 milligrams of dexamethasone).

(2) Sponsor. See No. 059130 in §510.600(c) of this chapter.

(3) Conditions of use. (i) The drug is given for glucocorticoid and anti-inflammatory effect in dogs and horses.

(ii) Administer intravenously as follows: Dogs—0.25 to 1 milligram initially; may be repeated for 3 to 5 days or until response is noted. Horses—2.5 to 5 milligrams. If permanent glucocorticoid effect is required, oral therapy may be substituted. When therapy is to be withdrawn after prolonged use, the daily dose should be reduced gradually over several days.

(iii) Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition following by dystocia, fetal death, retained placenta, and metritis.

(iv) Do not use in viral infections. Anti-inflammatory action of corticosteroids may mask signs of infections. Except when used for emergency therapy, the product is contraindicated in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers.

(v) Not for use in horses intended for food.

(vi) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[41 FR 26265, July 9, 1976]

EDITORIAL NOTE: For Federal Register citations affecting §522.542, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.
Food and Drug Administration, HHS

§ 522.690 Dinoprost tromethamine sterile solution.

(a) Specifications. Each milliliter of sterile solution contains the equivalent of 5 milligrams of dinoprost.

(2) For excretion urography administer 0.5 to 1.0 milliliter per pound of body weight to a maximum of 30 milliliters intravenously. For cystography remove urine, administer 5 to 25 milliliters directly into the bladder via catheter. For urethrography administer 1.0 to 5 milliliters via catheter into the urethra to provide desired contrast delineation. For angiography (including aortography) rapidly inject 3 to 10 milliliters intravascularly into the vascular bed to be delineated. For lymphography slowly inject 1.0 to 10 milliliters directly into the lymph vessel to be delineated. For arthrography slowly inject 0.5 to 1.0 milliliter directly into the joint to be delineated. For discography slowly inject quantity necessary to fill the tract. For delineation of fistulous tracts slowly inject quantity necessary to fill the tract. For delineation of peritoneal hernias inject 0.5 to 1.0 milliliter per pound of body weight directly into the peritoneal cavity.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[58 FR 500, Jan. 6, 1993, as amended at 66 FR 46705, Sept. 7, 2001]

§ 522.650 Dihydrostreptomycin sulfate injection.

(a) Specifications. Each milliliter contains dihydrostreptomycin sulfate equivalent to 500 milligrams of dihydrostreptomycin.

(b) Sponsor. See Nos. 000069 and 055529 in §510.600(c) of this chapter.

(c) National Academy of Sciences/National Research Council (NAS/NRC) status. The conditions of use were NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter but may require bioequivalency and safety information.

(d) Conditions of use—(1) Amount. 5 milligrams per pound of body weight every 12 hours.

(2) Indications for use. Treatment of leptospirosis in dogs and horses due to Leptospira canicola, L. icterohemorrhagiae, and L. pomona; in cattle due to L. pomona; and in swine due to L. pomona; and L. grippotyphosa.

(3) Limitations. Administer by deep intramuscular injection only. Treatment should be continued for 3 to 5 days or until the urine is free of leptospira for at least 72 hours as measured by darkfield microscopic examination. Treatment with subtherapeutic dosages, excessive duration of therapy, or inappropriate use of this antibiotic may lead to the emergence of streptomycin or dihydrostreptomycin resistant organisms. Discontinue use 30 days before slaughter for food. Not for use in animals producing milk because use of the drug will contaminate the milk. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37331, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992]

§ 522.575 Diazepam injection.

(a) Specification. Each milliliter of sterile solution contains 5 milligrams of diazepam.

(b) Sponsor. See 063238 in §510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Indications for use. As a preanesthetic agent to reduce the amount of barbiturate required for short duration anesthesia.

(2) Dosage. Intravenously, 0.2 milligram per kilogram of body weight 3–5 minutes before anesthesia is to be induced using a short acting barbiturate.

(3) Limitations. Not for use in dogs with known sensitivity to benzodiazepines. Safety in animals intended for breeding and pregnant animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[44 FR 12993, Mar. 9, 1979, as amended at 50 FR 41489, Oct. 11, 1985]
§ 522.723 Diprenorphine hydrochloride injection.

(a) Chemical name. N-(Cyclopropylmethyl)-6,7,8,14-tetrahydro-7-alpha-(1-hydroxy-1-methylethyl)-6,14-endoethanonororipavine hydrochloride.

(b) Sponsor. See Nos. 000009 and 059130 in §510.600(c) of this chapter.

(c) Special considerations. Women of child-bearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. Dinoprost tromethamine is readily absorbed through the skin and can cause abortion and bronchospasms. Accidental spillage on the skin should be washed off immediately with soap and water. Use of this product in excess of the approved dose may result in drug residues. Do not administer to pregnant cattle unless abortion is desired. Accidental spillage on the skin should be washed off immediately with soap and water. Use of this product in excess of the approved dose may result in drug residues. Do not administer to pregnant cattle unless abortion is desired. Do not administer intravenously; this may potentiate adverse reactions.

(d) Conditions of use—(1) Mares—(i) Amount. Equivalent of 1 milligram of dinoprost per 100 pounds of body weight.

(ii) Indications. For its luteolytic effect to control timing of estrus in estrous cycling mares and in clinically anestrous mares that have a corpus luteum.

(iii) Limitations. For use once as a single intramuscular injection. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cattle—(i) Amount. 5 milliliters (equivalent to 25 milligrams of dinoprost).

(ii)(a) Indications. For its luteolytic effect to control timing of estrus and ovulation in estrous cycling cattle that have a corpus luteum.

(b) Limitations. For use in beef cattle and nonlactating dairy heifers, as follows: Inject a dose of 5 milliliters intramuscularly either once or twice at a 10- to 12-day interval. With a single injection, cattle should be bred at the usual time relative to estrus. With the two injections, cattle can be bred after the second injection either at the usual time relative to detected estrus or at about 80 hours after the second injection. Estrus is expected to occur 1 to 5 days after injection if a corpus luteum was present. Cattle that do not become pregnant to breeding at estrus on days 1 to 5 after injection will be expected to return to estrus in about 18 to 24 days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(ii)(b) Indications. For treatment of pyometra (chronic endometritis).

(b) Limitations. For intramuscular use as a single injection. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(3) Nonlactating cattle—(i) Amount. Five milliliters intramuscularly as a single injection.

(ii) Indications. For its abortifacient effect in nonlactating cattle.

(iii) Limitations. For intramuscular use only, during first 100 days of gestation. Cattle that abort will abort within 35 days after injection. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Lactating dairy cattle—(i) Amount. Five milliliters intramuscularly as a single injection.

(ii) Indications. For treatment of unobserved (silent) estrus in lactating dairy cattle that have a corpus luteum.

(iii) Limitations. Breed cattle as they are detected in estrus. If estrus has not been observed by 80 hours after injection, breed at 80 hours. If cattle return to estrus breed at the usual time relative to estrus. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(5) Swine—(i) Amount. 2 milliliters (equivalent to 10 milligrams of dinoprost).

(ii) Indications. For parturition induction in swine when injected within 3 days of normal predicted farrowing.

(iii) Limitations. For use in swine as follows: Inject a dose of 2 milliliters intramuscularly within 3 days of predicted farrowing. The response to treatment varies by individual animals with a mean interval from administration to parturition of approximately 30 hours. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Food and Drug Administration, HHS

§ 522.775

(b) Specifications. Each milliliter of diprenorphine hydrochloride injection, veterinary, contains 2 mg of diprenorphine hydrochloride in sterile aqueous solution.

(c) Sponsors. See No. 053923 in § 510.600(c) of this chapter.

(d) Conditions of use. (1) The drug is used for reversing the effects of etorphine hydrochloride injection, veterinary, the use of which is provided for in § 522.883, in wild and exotic animals.

(2) It is administered intramuscularly or intravenously at a suitable dosage level depending upon the species.

(3) For use in wild or exotic animals only. Do not use in domestic food-producing animals. Do not use 30 days before, or during, the hunting season in free-ranging wild animals that might be used for food.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian. Distribution is restricted to veterinarians engaged in zoo and exotic animal practice, wildlife management programs and researchers.

§ 522.770 Doramectin.

(a) Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of doramectin.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.225 of this chapter.

(d) Conditions of use. (1) Cattle—(i) Amount. 200 micrograms per kilogram (10 milligrams per 110 pounds).

(ii) Indications for use. For treatment and control of gastrointestinal roundworms, lungworms, kidney worms, sucking lice, and mange mites.

(iii) Limitations. Administer as a single intramuscular injection. Do not slaughter swine within 24 days of treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 522.775 Doxapram hydrochloride injection.

(a) Specifications. The drug is a sterile aqueous solution containing 20 milligrams doxapram hydrochloride per milliliter.

(b) Sponsor. See No. 000031 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Administer to dogs, cats, and horses to stimulate respiration during and after general anesthesia; to speed awakening and return of reflexes after anesthesia. Administer to neonate dogs and cats to initiate respiration following dystocia or cesarean section; to stimulate respiration following dystocia or cesarean section.

(2) For intravenous use in dogs and cats at a dose of 2½ to 5 milligrams of doxapram hydrochloride per pound of body weight in barbiturate anesthesia, 0.5 mg per lb. in gas anesthesia; for intravenous use in horses at 0.25 mg per lb. of body weight in barbiturate anesthesia, 0.2 mg per lb. in inhalation anesthesia, 0.25 mg per lb. with chloral hydrate with or without magnesium sulfate; for subcutaneous, sublingual, or umbilical vein administration in neonate kittens at 1 to 2 mg. Dosage may be repeated in 15 to 20 minutes if necessary.
§ 522.778

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 17838, Apr. 23, 1975]

§ 522.778 Doxycycline hyclate.

(a) Specifications. Doxycycline hyclate solution contains 8.5 percent doxycycline activity. A syringe of N-methyl-2-pyrrolidone and poly (DL-lactide) mixed with a syringe of doxycycline produces 0.5 milliliter of solution.

(b) Sponsor. See 000009 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use.—(1) Dogs—(i) Amount. Apply subgingivally to periodontal pocket(s) of affected teeth.

(ii) Indications for use. For treatment and control of periodontal disease.

(iii) Limitations. Do not use in dogs less than 1-year old. Use of tetracyclines during tooth development has been associated with permanent discoloration of teeth. Do not use in pregnant bitches. Use of tetracyclines during tooth development has been associated with permanent discoloration of teeth. Do not use in pregnant bitches. Use in breeding dogs has not been evaluated. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.784 Doxylamine succinate injection.

(a) Specifications. Each milliliter of the drug contains 11.36 mg of doxylamine succinate.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in conditions in which antihistaminic therapy may be expected to alleviate some signs of disease in horses, dogs, and cats.1

(2) It is administered to horses at a dosage level of 25 mg per hundred pounds of body weight. It is administered to dogs and cats at a dosage level of 0.5 to 1 mg per pound of body weight. Doses may be repeated at 8 to 12 hours, if necessary, to produce desired effect. Intravenous route is not recommended for dogs and cats and should be injected slowly in horses. Intramuscular and subcutaneous administration should be by divided injection sites.1

(3) Not for use in horses intended for food.1

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.1


§ 522.800 Droperidol and fentanyl citrate injection.

(a) Specifications. Droperidol and fentanyl citrate injection is a sterile solution containing 20 milligrams of droperidol and 0.4 milligram of fentanyl citrate per cubic centimeter.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used in dogs as an analgesic and tranquilizer and for general anesthesia.

(2) It is administered as follows:

(i) For analgesia and tranquilization administer according to response desired, as follows:

(a) Intramuscularly at the rate of 1 cubic centimeter per 15 to 20 pounds of body weight in conjunction with atropine sulfate administered at the rate of 0.02 milligram per pound of body weight, or

(b) Intravenously at the rate of 1 cubic centimeter per 25 to 60 pounds of body weight in conjunction with atropine sulfate administered at the rate of 0.02 milligram per pound of body weight.

(ii) For general anesthesia administer according to response desired, as follows:

(a) Intramuscularly at the rate of 1 cubic centimeter per 40 pounds of body weight in conjunction with atropine sulfate administered at the rate of 0.02 milligram per pound of body weight and followed in 10 minutes by an intravenous administration of sodium pentobarbital at the rate of 3 milligrams per pound of body weight, or

(b) Intravenously at the rate of 1 cubic centimeter per 25 to 60 pounds of body weight in conjunction with atropine sulfate administered at the rate of 0.02 milligram per pound of body weight and followed within 15 seconds

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter.
by an intravenous administration of sodium pentobarbital at the rate of 3 milligrams per pound of body weight.

(3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 64 FR 15684, Apr. 1, 1999]

§ 522.812 Enrofloxacin solution.

(a) Specifications. Each milliliter of sterile solution contains either 22.7 milligrams of enrofloxacin when intended for use in dogs or 100 milligrams of enrofloxacin when intended for use in cattle.

(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

(c) Related tolerance. See § 556.228 of this chapter.

(d) Conditions of use—(1) Dogs—(i) Amount. 2.5 milligrams per kilogram (1.13 milligrams per pound) of body weight as an initial dose only.

(ii) Indications for use. Dogs for management of diseases associated with bacteria susceptible to enrofloxacin.

(iii) Limitations. As a single, intramuscular, initial dose followed by use of tablets twice daily for 2 to 3 days beyond cessation of clinical signs to a maximum of 10 days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cattle—(i) Amount. Single-dose therapy: 7.5 to 12.5 milligrams enrofloxacin per kilogram of body weight (3.4 to 5.7 milliliters per 100 pounds). Multiple-day therapy: 2.5 to 5.0 milligrams per kilogram of body weight (1.1 to 2.3 milliliters per 100 pounds) administered once daily for 3 to 5 days.

(ii) Indications for use. For the treatment of bovine respiratory disease (BRD) associated with Pasteurella haemolytica, P. multocida, and Haemophilus somnus.

(iii) Limitations. For subcutaneous use in cattle only. Do not inject more than 20 milliliters at each site. Do not slaughter within 28 days of last treatment. Do not use in cattle intended for dairy production. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. The effect of enrofloxacin on bovine reproductive performance, pregnancy, and lactation have not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.


§ 522.820 Erythromycin injection.

(a) Sponsor. See 061133 in § 510.600(c) of this chapter.

(b) NAS/NRC status. The conditions of use have been reviewed by NAS/NRC and found effective.

(c) Dogs and cats—(1) Specifications. Each milliliter of polyethylene glycol vehicle contains 100 milligrams of erythromycin base with 2 percent butyl aminobenzoate.

(2) Conditions of use—(i) Amount. 3 to 5 milligrams per pound of body weight, intramuscularly, two to three times daily, for up to 5 days.


(B) Cats. For the treatment of bacterial pneumonia, upper respiratory infections (rhinitis, bronchitis), secondary infections associated with panleukopenia, and bacterial wound infections caused by Staphylococcus spp. and Streptococcus spp., susceptible to erythromycin.

(iii) Limitations. Administer by deep intramuscular injection into the heavy muscles of the neck and limbs. Do not administer intravenously or intraperitoneally. Avoid subcutaneous use. Do not administer from moist or wet syringe. As with all antibiotics, appropriate in vitro culturing and susceptibility testing of samples taken before treatment should be conducted. Do not administer in conjunction with penicillin. As with all antibiotics, excessive continuous use may result in an overgrowth of nonsusceptible organisms. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.840 Estradiol.

(a) Specifications. Each silicone rubber implant contains 25.7 or 43.9 milligrams of estradiol.

(b) Sponsor. See No. 021641 in §510.600(c) of this chapter.

(c) Conditions of use. It is used for implantation in steers and heifers as follows:

(1) Amount. Insert one 25.7-milligram implant every 200 days; insert one 43.9-milligram implant every 400 days.

(2) Specifications. The product is a two-component drug consisting of the following:

(1) An implant containing 6.0 milligrams of norgestomet.

(2) An injectable solution (sesame oil) containing 3.0 milligrams of norgestomet and 5.0 milligrams of estradiol valerate per 2 milliliters.

(3) Limitations. For subcutaneous ear implantation in steers and heifers only. A second implant may be used if desired. No additional effectiveness may be expected from reimplanting in less than 200 days for the 25.7-milligram implant or 400 days for the 43.9-milligram implant. Increased sexual activity (bulling, riding, and excitability) has been reported in implanted animals.

§ 522.842 Estradiol benzoate and testosterone propionate in combination.

(a) Specifications. Each milliliter of nonaqueous, buffered, alcohol base sterile solution contains 200 milligrams of erythromycin base.

(b) Related tolerances. See §556.230 of this chapter.

(c) Conditions of use—(1) Amount. Each milliliter of nonaqueous, buffered, alcohol base sterile solution contains 200 milligrams of erythromycin base.

(d) Related tolerances. See §556.230 of this chapter.

(ii) Indications for use. For the treatment of bovine respiratory disease (shipping fever complex and bacterial pneumonia) associated with Pasteurella multocida susceptible to erythromycin.

(iii) Limitations. For intramuscular use only. Do not use in female dairy cattle over 20 months of age. Do not slaughter treated animals within 6 days of last treatment. To avoid excess trim, do not slaughter within 21 days of last injection.

§ 522.850 Estradiol valerate and norgestomet in combination.

(a) Specifications. The product is a two-component drug consisting of the following:

(1) An implant containing 6.0 milligrams of norgestomet.

(2) An injectable solution (sesame oil) containing 3.0 milligrams of norgestomet and 5.0 milligrams of estradiol valerate per 2 milliliters.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. One implant and 2 milliliters of injection at time of implantation.

(2) Indications for use. For synchronization of estrus/ovulation in cycling beef cattle and non-lactating dairy heifers.

(3) Limitations. Insert implant subcutaneously in the ear only; then immediately inject solution intramuscularly only. Counting the day of implantation as day 1, remove
the implant on day 10. Collect all implants as they are removed and burn them. While animals are restrained for artificial insemination, avoid other treatments such as vaccinations, dipping, pour-on grub and louse prevention, spraying, etc. When inseminating without estrus detection, the entire treated group should start at 48 hours after the last implant has been removed and should be completed within 6 hours. Where estrus detection is preferred, insemination should be approximately 12 hours after first detection of estrus. Those that do not conceive can be re-bred when they return to estrus approximately 17 to 25 days after implant removal. Do not use in cows producing milk for human consumption.

§522.863 Ethylisobutrazine hydrochloride injection.
(a) Specifications. The drug is a sterile aqueous solution. Each milliliter contains 50 milligrams of ethylisobutrazine hydrochloride.
(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.
(c) Conditions of use. (1) It is used in dogs as a tranquilizer.1
(2) It is administered intramuscularly at a dosage level of 2 to 5 milligrams of ethylisobutrazine hydrochloride per pound of body weight for profound tranquilization. It is administered intravenously at a dosage level of 1 to 2 milligrams of ethylisobutrazine hydrochloride per pound of body weight to effect.1
(3) It is not to be used in conjunction with organophosphates and/or procaine hydrochloride because phenothiazines may potentiate the toxicity of organophosphates and the activity of procaine hydrochloride.1

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

§522.900 Euthanasia solution.
(a) [Reserved]
(b)(1) Specifications. Each milliliter of nonsterile solution contains 390 milligrams of pentobarbital sodium and 50 milligrams of phentoyin sodium.
(2) Sponsor. Nos. 000061 and 059079 in §510.600(c) of this chapter.
(3) Conditions of use—(i) Indications for use. For the humane, painless, and rapid euthanasia of dogs.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.1

[40 FR 33592, Sept. 22, 1986; 54 FR 1165, Jan. 12, 1989]
(ii) **Amount.** One milliliter (390 milligrams of pentobarbital sodium and 50 milligrams of phenytoin sodium) for each 10 pounds of body weight.

(iii) **Limitations.** For intravenous injection or intracardiac injection when intravenous use is impractical. Do not use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c)(1) **Specifications.** Each milliliter of nonsterile, aqueous solution contains 400 milligrams of secobarbital sodium and 25 milligrams of dibucaine hydrochloride.

(2) **Sponsor.** See 000033 in §510.600(c) of this chapter.

(3) **Conditions of use**—

(ii) **Indications for use.** To induce rapid, humane, painless euthanasia of dogs.

(ii) **Amount.** For dogs, 1 milliliter for each 10 pounds of body weight.

(iii) **Limitations.** For intravenous injection. Do not use for therapeutic purposes. Do not use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§522.914 Fenprostalene solution.

(a) **Specifications**—

(1) **Cattle.** Each milliliter of sterile solution contains 0.5 milligram of fenprostalene.

(2) **Swine.** Each milliliter of sterile solution contains 0.25 milligram of fenprostalene.

(b) **Sponsor.** See 000856 in §510.600(c) of this chapter.

(c) **Related tolerances.** See §556.277 of this chapter.

(d) **Special considerations.** Labeling shall bear the following statements: Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. It is readily absorbed through the skin and may cause abortion and/ or bronchiospasms. Accidental spillage on the skin should be washed off immediately with soap and water.

(e) **Conditions of use**—

(1) **Cattle**—

(i) **Amount.** 1 milligram (2 milliliters) subcutaneously per animal.

(ii) **Indications for use.** For feedlot heifers to induce abortion when pregnant 150 days or less. For beef or nonlactating dairy cattle for estrus synchronization.

(iii) **Limitations.** Subcutaneous use in cattle only. Feedlot heifers to induce abortion, single dose. Beef or nonlactating dairy cattle for estrus synchronization, a single dose or two doses 11 to 13 days apart. Do not use in pregnant animals unless abortion is desired. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) **Swine**—

(i) **Amount.** 0.25 milligram (1 milliliter) subcutaneously once per animal.

(ii) **Indications for use.** For sows and gilts pregnant at least 112 days for the induction of parturition.

(iii) **Limitations.** Subcutaneous use in swine only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§522.940 Colloidal ferric oxide injection.

(a) **Specifications.** Each milliliter of the drug contains colloidal ferric oxide equivalent to 100 milligrams of iron stabilized with a low-viscosity dextrin and contains 0.5 percent phenol as a preservative.

(b) **NAS/NRC status.** Use of this drug has been NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(c)(1) **Sponsor.** See Nos. 010042 and 017800 in §510.600(c) of this chapter.

(2) **Conditions of use.** It is used in baby pigs as follows:

(i) For the prevention of anemia due to iron deficiency, administer an initial intramuscular injection of 1 milliliter of the drug to each animal at any time between 2 to 5 days of age. Dosage may be repeated at 2 weeks of age.

(ii) For the treatment of anemia due to iron deficiency, administer an
intramuscular injection of from 1 to 2 milliliters of the drug to each animal at any time between 5 to 28 days of age.

§ 522.960b Flumethasone implantation or injectable dosage forms.

§ 522.960a Flumethasone suspension.

(a) Chemical name. 6α,9α-Difluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione.

(b) Specifications. Flumethasone suspension is sterile and each milliliter of the drug contains: 2 milligrams of flumethasone, 20 milligrams of propylene glycol, 9 milligrams of benzyl alcohol (as preservative), 8 milligrams of sodium chloride, 0.02 milligram of polysorbate-80, 0.1 milligram of citric acid, and water for injection q.s.

§ 522.960b Flumethasone acetate injection.

(a) Chemical name. 6-alpha,9-alpha-difluoro - 16 - alpha - methylprednisolone 21-acetate.

(b) Specifications. Flumethasone injection is sterile and contains per cubic
§ 522.960c Flumethasone solution.

(a) Specifications. Each milliliter of sterile aqueous solution contains 0.5 milligram flumethasone.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. It is used as follows:

(1) Horses—(i) Amount. 1.25 to 2.5 milligrams daily, intramuscularly, or intra-articularly.

(ii) Indications for use. It is used for the treatment of musculoskeletal conditions due to inflammation, where permanent structural changes do not exist, e.g., bursitis, carpalitis, osteoarthritis, disc syndrome, and myositis; and allergic states, e.g., hives, urticaria, and insect bites.

(iii) Limitations—(a) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(b) When a long-term therapy is used, the dose should be individually adjusted to the minimum maintenance dose. A protein-rich diet is useful in dogs and cats on long-term therapy to counteract nitrogen loss if it should occur. A small amount of potassium chloride daily in the diet will counteract excessive potassium loss if this is present.

(c) It has been demonstrated that corticosteroids, especially at high dose levels, may result in delayed wound and fracture healing.

(d) Flumethasone may be administered to animals with bacterial diseases provided appropriate antibacterial therapy is administered simultaneously.

(e) The drug is not to be used in horses intended for slaughter for food purposes.

(f) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Dogs—(i) Amount. 0.0625 to 0.25 milligram daily, intravenously, intramuscularly, or subcutaneously; 0.125 to 1.0 milligram daily, intralesionally, depending on the size and location of the lesion; 0.166 to 1.0 milligram daily, intra-articularly, depending on the severity of the condition and the size of the involved joint.

(ii) Indications for use. It is used for the treatment of musculoskeletal conditions due to inflammation of muscles or joints and accessory structures where permanent structural changes do not exist, e.g., arthritis, osteoarthritis, disc syndrome, and myositis (in septic arthritis, appropriate antibacterial therapy should be concurrently administered); certain acute and chronic dermatoses of varying etiology to help control associated pruritus, irritation, and inflammation; otitis externa in conjunction with topical medication; allergic states, e.g., hives, urticaria,

Dosage should be adjusted according to the weight of the animal, the severity of the symptoms, and the response noted. Dosage by injection should not exceed 3 days of therapy. With chronic conditions intramuscular therapy may be followed by oral administration of flumethasone tablets at a daily dose of from 0.0625 to 0.25 milligram per animal.

(3) For use only by or on the order of a licensed veterinarian.

and insect bites; and shock and shock-like states by intravenous administration.

(iii) **Limitations.** See paragraph (c)(1)(iii) of this section.

(3) **Cats**—(i) **Amount.** 0.03125 to 0.125 milligram daily intravenously, intramuscularly, or subcutaneously.

(ii) **Indications for use.** It is used for the treatment of certain acute and chronic dermatoses of varying etiology to help control associated pruritus, irritation, and inflammation.

(iii) **Limitations.** See paragraph (c)(1)(iii) of this section.


§ 522.970 Flunixin meglumine solution.

(a) **Specifications.** Each milliliter of solution contains flunixin meglumine equivalent to 50 milligrams (mg) flunixin.

(b) **Sponsors.** See sponsors in §510.600(c) of this chapter for use as in paragraph (e) of this section.

(1) See Nos. 000061 and 059130 for use as in paragraph (e) of this section.

(2) See Nos. 000859 and 057561 for use as in paragraph (e)(1) of this section.

(c) **Related tolerances.** See §556.286 of this chapter.

(d) **Special considerations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(e) **Conditions of use**—(1) **Horses**—(i) **Amount.** 0.5 mg per pound (/lb) of body weight per day, intravenously or intramuscularly, for up to 5 days.

(ii) **Indications for use.** For alleviation of inflammation and pain associated with musculoskeletal disorders, and alleviation of visceral pain associated with colic.

(iii) **Limitations.** Not for use in horses intended for food.

(2) **Beef cattle and nonlactating dairy cattle**—(i) **Amount.** 1.1 to 2.2 mg/kilogram (0.5 to 1.0 mg/lb) of body weight per day, as a single dose or divided into 2 doses administered at 12-hour intervals, intravenously, for up to 3 days.

(ii) **Indications for use.** For control of pyrexia associated with bovine respiratory disease and endotoxemia. Also indicated for control of inflammation in endotoxemia.

(iii) **Limitations.** Do not slaughter for food use within 4 days of last treatment. Not for use in lactating or dry dairy cows. A withdrawal period has not been established for use in preruminating calves. Do not use in calves to be processed for veal.


§ 522.995 Fluprostenol sodium injection.

(a) **Specifications.** Each milliliter of sterile aqueous solution contains fluprostenol sodium equivalent to 50 micrograms of fluprostenol.

(b) **Sponsor.** See 000859 in §510.600(c) of this chapter.

(c) **Conditions of use**—(1) **Amount.** 0.55 microgram fluprostenol per kilogram of body weight.

(2) **Indications for use.** The drug is used in mares for its luteolytic effect to control the timing of estrus in estrous cycling and in clinically anestrous mares that have a corpus luteum.

(3) **Limitations.** Administer by intramuscular injection only. Warning: Not for use in horses intended for food. For veterinary use only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. In the early stages, women may be unaware of their pregnancies. Fluprostenol is readily absorbed through the skin and can cause abortion and/or bronchospasms. Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.

[44 FR 52191, Sept. 7, 1979, as amended at 47 FR 22992, May 21, 1982]

§ 522.1002 Follicle stimulating hormone.

(a)(1) **Specifications.** Each package contains 2 vials. One vial contains dry, powdered, porcine pituitary gland equivalent to 75 units (NIH–FSH–S1) of follicle stimulating hormone. The other vial contains 10 milliliters of aqueous diluent.
§ 522.1004 Fomepizole.

(a) Specifications. Two vials, one containing 1.5 grams fomepizole (1.5 milliliter of 1.0 gram fomepizole per milliliter sterile aqueous solution), and one vial containing 30 milliliters of 0.9 percent sodium chloride injection USP (as a diluent).

(b)(1) Sponsor. See sponsors in §510.600(c) of this chapter.

(b)(2) Conditions of use in dogs—(1) Amount. 20 milligrams per kilogram initially, 35 milligrams per kilogram at 12 and 24 hours, and 5 milligrams per kilogram at 36 hours.

§ 522.1010 Furosemide.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of furosemide diethanolamine.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) No. 000010 for use as in paragraphs (d)(1) and (d)(2)(ii) of this section.

(2) No. 000864 for use as in paragraph (d)(2)(ii) of this section.

(3) No. 057926 for use as in paragraphs (d)(1), (d)(2)(i), and (d)(3) of this section.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Dogs and cats—(i) Amount. 1.25 to 2.5 mg per pound (/lb) body weight once or twice daily, intramuscularly or intravenously.

(ii) Indications for use. For the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

(B) Limitations. Do not use in horses intended for food.

(ii) Amount. 0.5 mg/lb body weight once or twice daily, intramuscularly or intravenously.

(A) Indications for use. For treatment of acute noninflammatory tissue edema.

(B) Limitations. Do not use in horses intended for food.

(3) Cattle—(i) Amount. 500 mg/animal once daily, intramuscularly or intravenously; or 250 mg/animal twice daily.
§ 522.1044 Gentamicin sulfate injection.

(a) Specifications. Each milliliter of sterile aqueous solution contains gentamicin sulfate equivalent to either 5, 50, or 100 milligrams of gentamicin.

(b) Sponsors. (1) See No. 000061 in § 510.600(c) of this chapter for use of: 5-milligrams-per-milliliter solution in swine as in paragraph (d)(4) of this section, 50-milligrams-per-milliliter solution in dogs and cats as in paragraph (d)(1) of this section, 50- and 100-milligrams-per-milliliter solution in chickens and turkeys as in paragraphs (d)(2) and (d)(3) of this section.

(2) [Reserved]

(3) See No. 000010 for use of 50 milligrams-per-milliliter solution in dogs as in paragraph (d)(5) of this section.

(4) See No. 059130 for use of 100 milligram-per-milliliter solution in turkeys as in paragraph (d)(2) of this section and in chickens as in paragraph (d)(3) of this section.

(c) Related tolerances. See § 556.300 of this chapter.

(d) Conditions of use—(1) Dogs and cats—(i) Amount. Two milligrams of gentamicin per pound of body weight, twice daily on the first day, once daily thereafter, using a 50 milligram-per-milliliter solution.

(ii) Indications for use—(a) Dogs. For the treatment of infections of urinary tract (cystitis, nephritis), respiratory tract (tonsillitis, pneumonia, tracheobronchitis), skin and soft tissue (pyodermatitis, wounds, lacerations, peritonitis).

(b) Cats. For the treatment of infections of urinary tract (cystitis, nephritis), respiratory tract (pneumonitis, pneumonia, upper respiratory tract infections), skin and soft tissue (wounds, lacerations, peritonitis), and as supportive therapy for secondary bacterial infections associated with panleucopenia.

(iii) Limitations. Administer intramuscularly or subcutaneously. If response is not noted after 7 days, the antibiotic sensitivity of the infecting organism should be retested. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Turkeys—(1) Amount. One milligram of gentamicin per 0.2 milliliter dose, using the 50- or 100-milligrams-
§ 522.1055

per-milliliter product diluted with sterile saline to a concentration of 5 milligrams-per-milliliter.

(ii) Indications for use. As an aid in the prevention of early mortality due to Arizona paracolon infections susceptible to gentamicin.

(iii) Limitations. For 1- to 3-day old turkey poults. Administer subcutaneously in the neck. Injected poults must not be slaughtered for food for at least 9 weeks after treatment.

(3) Chickens—(i) Amount. 0.2 milligram of gentamicin per 0.2 milliliter dose, using the 50- or 100-milligram-per-milliliter product diluted with sterile saline to a concentration of 1.0 milligram-per-milliliter.

(ii) Indications for use. In day-old chickens, for prevention of early mortality caused by Escherichia coli, Salmonella typhimurium, and Pseudomonas aeruginosa that are susceptible to gentamicin.

(iii) Limitations. For use in day-old chickens only. Administer aseptically, injecting the diluted product subcutaneously in the neck. Do not slaughter treated animals for food for at least 5 weeks after treatment.

(4) Swine—(i) Amount. 5 milligrams of gentamicin as a single intramuscular dose using 5 milligram-per-milliliter solution.

(ii) Indications for use. In piglets up to 3 days old for treatment of porcine colibacillosis caused by strains of E. coli sensitive to gentamicin.

(iii) Limitations. For single intramuscular dose in pigs up to 3 days of age only. Do not slaughter treated animals for food for at least 40 days following treatment.

(5) Dogs—(i) Amount. 2 milligrams of gentamicin per pound of body weight, twice daily on the first day, then once daily.


(iii) Limitations. Administer intramuscularly or subcutaneously. If no improvement is seen after 3 days, treatment should be discontinued and the diagnosis reevaluated. Treatment not to exceed 7 days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1055 Gleptoferron injection.

(a) Specifications. Each milliliter contains the equivalent of 200 milligrams of elemental iron as gleptoferron (complex of ferric hydroxide and dextran glucoheptonic acid), and 0.5 percent phenol as a preservative.

(b) Sponsor. See 062408 in §510.600(c) of this chapter.

(c) Conditions of use. It is used in baby pigs as follows:

(1) For prevention of iron deficiency anemia, administer 200 milligrams of elemental iron intramuscularly on or before 3 days of age.

(2) For treatment of iron deficiency anemia, administer 200 milligrams of elemental iron intramuscularly.


§ 522.1066 Glycopyrrolate injection.

(a) Specifications. Each milliliter of aqueous solution contains 0.2 milligram of glycopyrrolate.

(b) Sponsor. See No. 000031 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is indicated as a preanesthetic agent in dogs and cats.

(2) It is administered intravenously, intramuscularly, or subcutaneously in dogs and intramuscularly in cats at a dosage level of 5 micrograms per pound of body weight (0.25 milliliter per 10 pounds of body weight).

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(48 FR 21567, May 13, 1983)

§ 522.1077 Gonadorelin injectable.

(a) Specifications. Each milliliter sterile aqueous solution contains 50 micrograms of gonadorelin (as hydrochloride).

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

244
§ 522.1081 Chorionic gonadotropin for injection; chorionic gonadotropin suspension.

(a)(1) Specifications. Chorionic gonadotropin for injection is supplied in vials containing 5,000, 10,000 or 20,000 U.S.P. units of lyophilized powder for reconstitution with the accompanying sterile diluent to a 10 milliliter solution.

(b) Sponsor. See sponsor numbers in §510.600(c) of this chapter, as follows:

(i) Nos. 000402 and 053501 for use of 10,000 U.S.P. units intramuscularly, 2,500 to 5,000 U.S.P. units intravenously, and 500 to 2,500 U.S.P. units intrafollicularly in cattle.

(ii) Nos. 058639 and 063323 for use of 10,000 U.S.P. units intramuscularly and 500 to 2,500 U.S.P. units intrafollicularly in cattle.

(iii) No. 057926 for use of 10,000 U.S.P. units intramuscularly in cattle and finfish.

(3) Related tolerances. See §556.304 of this chapter.

(4) Conditions of use in cattle—

(i) Amount. 10,000 USP units as a single, deep intramuscular injection; 500 to 2,500 USP units for intrafollicular injection; 2,500 to 5,000 USP units intravenously.

(ii) Sows. Delayed return to estrus is most prevalent after the first litter. The effectiveness has not been established after later litters. Delayed return to estrus often occurs during periods of adverse environmental conditions, and sows mated under such conditions may farrow smaller than normal litters.

(iii) Limitations. Dosage may be repeated in 14 days if the animal’s behavior or rectal examination of the ovaries
§ 522.1085  Guaiifenesin sterile powder.  

(a) Specifications. It is a sterile powder containing guaiifenesin.

(b) Sponsor. See No. 000009 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use. (1) The drug is used intravenously in horses as a skeletal muscle relaxant.

(2) Administer rapidly at a dosage of 1 milliliter per pound of body weight.

(3) No to be used in horses intended for food.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[60 FR 27223, May 23, 1995, as amended at 63 FR 29352, May 29, 1998]

§ 522.1125  Hemoglobin glutamer-200 (bovine).  

(a) Specifications. Each 125 milliliter bag contains 13 grams per deciliter of polymerized hemoglobin of bovine origin in modified Lactated Ringer’s Solution. It is a sterile, clear, dark purple solution.

(b) Sponsor. See No. 063075 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use. 

(1) Amount. One-time dose of 10 to 30 milliliters per kilogram of body weight administered intravenously at a rate of up to 10 milliliters per kilogram per hour.

(2) Indications for use. For the treatment of anemia in dogs by increasing systemic oxygen content (plasma hemoglobin concentration) and improving the clinical signs associated with anemia, regardless of the cause of anemia (hemolysis, blood loss, or ineffective erythropoiesis).

(3) Limitations. It is for intravenous use only. Overdosage or an excessive rate of administration (greater than 10 milliliters per kilogram per hour) may result in circulatory overload. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[65 FR 20732, Apr. 18, 2000]

§ 522.1145  Hyaluronate sodium injection.  

(a)(1) Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.

(2) Sponsor. See No. 000009 in §510.600(c).

(3) Conditions of use. 

(1) Amount. Small and medium-size joints (carpal,
Food and Drug Administration, HHS

§ 522.1145

(fetlock)—20 milligrams; larger joint (hock)—40 milligrams.

(ii) Indications for use. Treatment of joint dysfunction in horses due to non-inflammatory synovitis associated with equine osteoarthritis.

(iii) Limitations. For intra-articular injection in horses only. Treatment may be repeated at weekly intervals for a total of three treatments. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) Specifications. Each milliliter of sterile aqueous solution contains 5 milligrams of hyaluronate sodium.

(2) Sponsor. See 055501 in § 510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. Small and medium-size joints (carpal, fetlock)—10 milligrams; larger joint (hock)—20 milligrams.

(ii) Indications for use. Treatment of joint dysfunction in horses due to non-inflammatory synovitis associated with equine osteoarthritis.

(iii) Limitations. For intra-articular injection in horses only. Treatment may be repeated at weekly intervals for a total of four treatments. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c)(1) Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.

(2) Sponsor. See 000856 in § 510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. Intraarticular: 20 milligrams in the carpus or fetlock. Intravenous: 40 milligrams slowly into the jugular vein.

(ii) Indications for use. Treatment of carpal or fetlock joint dysfunction in horses due to noninfectious synovitis associated with equine osteoarthritis.

(iii) Limitations. For intraarticular or intravenous use in horses only. Treatment may be repeated at weekly intervals for a total of three treatments. Not for use in horses intended for food. The safety of use of this drug in breeding animals has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


(2) Sponsor. See 000865 in § 510.600(c).

(3) Conditions of use—(i) Amount. Small and medium-size joints (carpal, fetlock)—22 milligrams; larger joint (hock)—44 milligrams.

(ii) Indications for use. Treatment of joint dysfunction in horses due to noninfectious synovitis associated with equine osteoarthritis.

(iii) Limitations. For intra-articular injection in horses only. Treatment may be repeated at weekly intervals for a total of three treatments. Not for use in horses intended for food. Federal
§ 522.1150 Hydrochlorothiazide injection.

(a) Specifications. Each milliliter contains 25 milligrams of hydrochlorothiazide.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 5 to 10 milliliters (125 to 250 milligrams) intravenously or intramuscularly once or twice a day. After onset of diuresis, treatment may be continued with an orally administered maintenance dose.

(2) Indications for use. For use in cattle as an aid in the treatment of postpartum udder edema.1

(3) Limitations. Animals should be regularly and carefully observed for early signs of fluid and electrolyte imbalance. Take appropriate countermeasures if this should occur. Milk taken from dairy animals during treatment and for 72 hours (6 milkings) after the latest treatment must not be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.1


§ 522.1155 Imidocarb dipropionate sterile powder.

(a) Specifications. Imidocarb dipropionate powder is reconstituted with sterile water. Each milliliter of solution contains 100 milligrams of imidocarb base.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. The drug is used in horses and zebras as follows:

(1) Amount. For Babesia caballi infections, use intramuscularly 2 milligrams of imidocarb base per kilogram of body weight, repeating dosage once after 24 hours. For Babesia equi infections, use 4 milligrams of imidocarb base per kilogram of body weight, repeating dosage four times at 72-hour intervals.

(2) Indications for use. For the treatment of babesiosis (piroplasmosis) caused by Babesia caballi and Babesia equi.

(3) Limitations. Administer intramuscularly in the neck region. Do not inject intravenously. Do not use for other equidae or for animals of other species. Do not use in horses less than 1 year old. Do not use for animals in near-term pregnancies. Imidocarb dipropionate is a cholinesterase inhibitor. Do not use this product simultaneously with or a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals. Do not use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Imidocarb dipropionate is sold only under permit issued by the Director of the National Program Planning Staff, Veterinary Services, APHIS, USDA, to licensed or full-time State, Federal, or military veterinarians.


§ 522.1156 Imidocarb dipropionate solution.

(a) Specifications. Each milliliter of injectable solution contains 120 milligrams of imidocarb.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Dogs—(i) Amount. 6.6 milligrams imidocarb per kilogram (3 milligrams per pound) of body weight.

(2) Indications for use. Treatment of clinical signs of babesiosis and/or demonstrated Babesia organisms in the blood.

(iii) Limitations. Use subcutaneously or intramuscularly. Not for intravenous use. Repeat the dose after 2 weeks for a total of two treatments. Imidocarb is a cholinesterase inhibitor. Do not use simultaneously with or a...
249

Food and Drug Administration, HHS

§ 522.1192 Ivermectin injection.

(a) Specifications. (1) Horses. Each milliliter of sterile aqueous solution contains 0.2 mg of ivermectin. Dosage may be repeated in 10 days to 2 weeks.

(b) Specifications. (1) Cattle. Each milliliter of sterile solution contains 1 mg of ivermectin. Dosage may be repeated in 10 days to 2 weeks.

(c) Specifications. (1) Sheep and goats. Each milliliter of sterile aqueous solution contains 0.2 mg of ivermectin. Dosage may be repeated in 10 days to 2 weeks.

(d) Specifications. (1) Swine. Each milliliter of sterile aqueous solution contains 0.2 mg of ivermectin. Dosage may be repeated in 10 days to 2 weeks.

(e) Specifications. (1) Poultry. Each milliliter of sterile aqueous solution contains 0.2 mg of ivermectin. Dosage may be repeated in 10 days to 2 weeks.

§ 522.1182 Iron dextran complex injection.

(a) Specifications. Each milliliter of sterile solution contains ferric hydroxide dextran complex equivalent to 100 milligrams of elemental iron. It contains 0.5 percent phenol as a preservative.

(b) Grant of temporary registration.

(c) Sponsor. See Nos. 000003 in § 510.600(c) of this chapter.

§ 522.1183 Iron hydrogenated dextran injection.

(a) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(b)–(c) [Reserved]

(d) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(e) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(f) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(g) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(h) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(i) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(j) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(k) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(l) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(m) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(n) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(o) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(p) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(q) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(r) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(s) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(t) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(u) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(v) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(w) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(x) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(y) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.

(z) Specifications. Each milliliter contains 100 milligrams of elemental iron stabilized with a low molecular weight hydrogenated dextran and 0.5 percent phenol as a preservative.
contains 20 milligrams of ivermectin (2 percent).

(2) Cattle, reindeer, swine, and American bison. Each milliliter of sterile aqueous solution contains 10 milligrams of ivermectin (1 percent).

(3) Pigs (70 pounds or less and ranch-raised fakes). Each milliliter of sterile aqueous solution contains 2.7 milligrams of ivermectin (0.27 percent).

(b) Sponsors. See No. 050604 in §510.600(c) of this chapter for use as in paragraph (d) of this section. See No. 051390 in §510.600(c) of this chapter for use as in paragraphs (d)(2), (d)(3), (d)(4), and (d)(6) of this section.

(c) Related tolerances. See §556.344 of this chapter.

(d) Conditions of use—(1) Horses—(i) Amount. 20 milligrams per 100 kilograms (220 pounds) of body weight.

(ii) Indications for use. It is used in horses for the treatment and control of large strongyles (adult) (Strongylus vulgaris, Strongylus edentatus, Triodontophorus spp.), small strongyles (adult and fourth-stage larvae) (Cyathostomum spp., Cylicocyclus spp., Cylicostephanus spp.), pinworms (adult and fourth-stage larvae) (Oxyuris equi), large roundworms (adult) (Parascaris equorum), hairworms (adult) (Trichostrongylus axei), large mouth stomach worms (adult) (Habronema muscae), neck threadworms (microfilariae) (Onchocerca spp.), and stomach bots (Gastrophilus spp.).

(iii) Limitations. For intramuscular use only. Not for intramuscular use. Do not use in female dairy cattle of breeding age. Do not use in other animal species because severe adverse reactions, including fatalities in dogs, may result. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(3) Reindeer—(i) Amount. 10 milligrams per 50 kilograms (110 pounds) body weight.

(ii) Indications for use. It is used in reindeer for treatment and control of warbles (Oedemagena farandii).

(iii) Limitations. For subcutaneous use only. Not for intramuscular use. Do not treat reindeer within 56 days of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Swine—(i) Amount. 300 micrograms per kilogram (2.2 pounds).

(ii) Indications for use. It is used in swine for treatment and control of gastrointestinal roundworms (adults and fourth-stage larvae) (large roundworm, Ascaris suum; red stomach worm, Haemonchus placei, Ostertagia ostertagi (including inhibited larvae), O. lyrata, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctata, C. pectinata, Oesophagostomum radiatum, Nematodirus helvetianus (adults only), N. spathiger (adults only), Bunostomum phlebotomum); lungworms (adults and fourth-stage larvae) (Dictyocaulus viviparus); grubs (first, second, and third instars) (Hypoderma bovis, H. lineatum); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); flies (Psoroptes ovis (syn. Psoroptes communis var. bovis), Sarcoptes scabiei var. bovis). It is also used to control infections of D. viviparum for 28 days after treatment, and O. ostertagi for 21 days after treatment, and H. placei, T. axei, C. punctata, C. oncophora, and Oesophagostomum radiatum for 14 days after treatment.

(iii) Limitations. For subcutaneous injection in the neck of swine only. Do not treat swine within 18 days of slaughter. Do not use in other animal species as severe adverse reactions, including fatalities in dogs, may result.
Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(5) Ranch-raised foxes—(i) Amount. 200 micrograms per kilogram body weight. Repeat in 3 weeks.

(ii) Indications for use. For treatment and control of ear mites (Otodectes cynotis).

(iii) Limitations. For subcutaneous use only. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(6) American bison—(i) Amount. 200 micrograms per kilogram (10 milligrams per 110 pounds) of body weight.

(ii) Indications for use. It is used in American bison for the treatment and control of grubs (Hypoderma bovis). (ii) Limitations. For subcutaneous use. Do not slaughter within 56 days of last treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 522.1193 Ivermectin and clorsulon injection.

(a) Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams (1 percent) of ivermectin and 100 milligrams (10 percent) of clorsulon.

(b) Sponsor. See 050604 in §510.600(c) of this chapter.

(c) Related tolerances. See §§556.163 and 556.344 of this chapter.

(d) Conditions of use—(1) Amount. 1 milliliter (10 milligrams of ivermectin and 100 milligrams of clorsulon) per 50 kilograms (110 pounds).

(2) Indications for use. It is used in cattle for the treatment and control of gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus placei, Oesophagostomum radiatum, Nematodirus helvetianus (adults only), N. springeri (adults only), Bunostomum phlebotomum; lungworms (adults and fourth-stage larvae) (Dictyocaulus viviparus); liver flukes (adults only) (Fasciola hepatica); grubs (parasitic stages) (Hypoderma bovis, H. lineatum); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); mites (Psoroptes ovis (syn. P. communis var. bovis), Sarcoptes scabiei var. bovis). It is also used to control infections of D. viviparum for 28 days after treatment, O. ostertagi for 21 days after treatment, and H. placei, T. axei, C. punctata, C. oncophora, and O. radiatum for 14 days after treatment.

(3) Limitations. For subcutaneous use only. Not for intravenous or intramuscular use. Do not treat cattle within 49 days of slaughter. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age. Do not use in other animal species because severe adverse reactions, including fatalities in dogs, may result. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 522.1204 Kanamycin sulfate injection.

(a) Specifications. Each milliliter of kanamycin sulfate injection veterinary contains either 50 or 200 milligrams of kanamycin.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used in the treatment of bacterial infections due to kanamycin sensitive organisms in dogs and cats.

(2) It is administered subcutaneously or intramuscularly at 5 milligrams per pound of body weight per day in equally divided doses at 12-hour intervals.

(3) Its label shall bear an appropriate expiration date.

(4) Restricted to use by or on the order of a licensed veterinarian.

§ 522.1222 Ketamine hydrochloride injectable dosage forms.

§ 522.1222a Ketamine hydrochloride injection.

(a) [Reserved]
§ 522.1222b Ketamine hydrochloride with promazine hydrochloride and aminopentamide hydrogen sulfate injection.

(a) Chemical name. Ketamine hydrochloride, \((\pm), 2-(o\text{-}chlorophenyl)-2\text{-}(methylamino)\) cyclohexanone hydrochloride, with promazine hydrochloride, 10-\{3\text{-}(dimethylamino)\) propyl\} phenothiazine monohydrochloride, and aminopentamide hydrogen sulfate.

(b) Specifications. The drug is a sterile aqueous solution and each milliliter contains: Ketamine hydrochloride equivalent to 100 milligrams ketamine base activity, 7.5 milligrams of promazine hydrochloride, and 0.0625 milligram of aminopentamide hydrogen sulfate, with 1:10,000 benzethonium chloride.

(c) Sponsor. See Code No. 000856 in §510.600(c) of this chapter.

(d) Special considerations. Store in a cool place. Protect from light. Do not use if precipitate appears.

(e) Conditions of use. (1) It is used in cats as the sole anesthetic agent for ovariohysterectomy and general surgery.

(2) It is administered intramuscularly at a recommended dose from 15 to 20 milligrams ketamine base per pound of body weight, depending on the effect desired.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1225 Ketoprofen solution.

(a) Specifications. Each milliliter of sterile aqueous solution contains 100 milligrams of ketoprofen.

(b) Sponsor. See 000856 in 21 CFR 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 1.0 milligram per pound of body weight once daily for up to 5 days.

(2) Indications for use. For alleviation of inflammation and pain associated with musculoskeletal disorders in horses.

(3) Limitations. For intravenous use only. Do not use in breeding animals. Effects on fertility, pregnancy, or fetal health have not been determined. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[55 FR 40653, Oct. 4, 1990]

§ 522.1228 [Reserved]

§ 522.1244 Levamisole phosphate injection.

(a) Specifications. Each milliliter of sterile aqueous solution contains levamisole phosphate equivalent to 136.5 or 182 milligrams of levamisole hydrochloride (13.65 or 18.2 percent).

(b) Sponsor. See Nos. 000061 and 057561 in §510.600 of this chapter for use of 13.65 percent injection, and see No. 043781 for use of 18.65 and 18.2 percent injection.
(c) **Conditions of use**—(1) **Amount.** 2 milliliters per 100 pounds of body weight, subcutaneously in the neck.

(2) **Indications for use.** (i) The 13.65 percent injection is used as an anthelmintic in cattle for treatment of the following parasites: stomach worms (*Haemonchus, Trichostrongylus, Ostertagia*), intestinal worms (*Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum, Chabertia*), and lungworms (*Dictyocaulus*).

(ii) The 18.2 percent injection is used as an anthelmintic in cattle for treatment of the following parasites: stomach worms (*Haemonchus, Trichostrongylus, Ostertagia*), intestinal worms (*Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum*) and lungworms (*Dictyocaulus*).

(3) **Limitations.** Do not administer more than 10 milliliters per site. Cattle that are severely parasitized or maintained under conditions of constant helminth exposure may require re-treatment within 2 to 4 weeks after first treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. Consult your veterinarian before using in severely debilitated animals or animals under severe stress. Do not administer to cattle within 7 days of slaughter. Do not administer to dairy animals of breeding age.


§ 522.1260 **Lincomycin injection.**

(a) **Specifications.** Each milliliter of sterile aqueous solution contains lincomycin hydrochloride equivalent to 25, 50, 100, or 300 milligrams of lincomycin.

(b) **Sponsor.** See No. 000009 in §510.600(c) of this chapter.

(c) **Special considerations.** When common labeling for use of the drug in dogs, cats, and swine is included with the drug, all such uses are subject to the labeling requirements of §201.105 of this chapter.

(d) **Related tolerances.** See §556.360 of this chapter.

(e) **Conditions of use.** It is used for animals as follows:

(1) **Dogs and cats**—(i) **Amount.** 5 to 10 milligrams per pound of body weight per day.

(ii) **Indications for use.** Infections caused by Gram-positive organisms, particularly streptococci and staphylococci.

(iii) **Limitations.** Administer intramuscularly 10 milligrams per pound of body weight once a day or 5 milligrams per pound of body weight twice daily or intravenously 5 to 10 milligrams per pound of body weight one or two times daily by slow injection. May be diluted with 5 percent glucose in water or normal saline and given as an infusion; as lincomycin hydrochloride monohydrate; for use by or on the order of a licensed veterinarian.

(2) **Swine**—(i) **Amount.** 5 milligrams per pound of body weight per day.

(ii) **Indications for use.** Treatment of infectious arthritis and mycoplasma pneumonia.

(iii) **Limitations.** Administer intramuscularly as a single daily dose for 3 to 7 days; as lincomycin hydrochloride monohydrate: do not treat within 48 hours of slaughter.

[40 FR 13858, Mar. 27, 1975, as amended at 50 FR 31351, Aug. 2, 1985]

§ 522.1289 **Lufenuron suspension.**

(a) **Specifications.** Each milliliter of sterile aqueous suspension contains 10 milligrams of lufenuron.

(b) **Sponsor.** See No. 058198 in §510.600(c) of this chapter.

(c) **Reserved**

(d) **Conditions of use**—(1) **Cats**—(i) **Amount.** 10 milligrams per kilogram (4.5 milligrams per pound) of body weight every 6 months, subcutaneously.

(ii) **Indications for use.** For use in cats 6 weeks of age and older, for control of flea populations. Lufenuron controls flea populations by preventing the development of flea eggs and does not kill adult fleas. Concurrent use of insecticides may be necessary for adequate control of adult fleas.

(iii) **Limitations.** For subcutaneous use in cats only. The safety of this product in reproducing animals has not been established. Do not use in dogs. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.1290 Luprostiol sterile solution.

(a) Specifications. Each milliliter of sterile solution contains 7.5 milligrams of luprostiol.

(b) Sponsor. See No. 057926 in §510.600(c) of this chapter.

(c) Special considerations. Labeling shall bear the following statements: Warning: Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. In the early stages, women may be unaware of their pregnancies. Luprostiol is readily absorbed through the skin and can cause abortion and/or bronchiospasms. Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.

(d) Conditions of use—(1) Amount. 7.5 milligrams per mare.

(2) Indications for use. The drug is used in mares for estrus control and termination of pregnancy.

(3) Limitations. Administer by intramuscular injection only. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1350 Melatonin implant.

(a) Specifications. The drug is a silicone rubber elastomer implant containing 2.7 milligrams of melatonin.

(b) Sponsor. See No. 053923 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. One implant per mink.

(2) Indications for use. For use in healthy male and female kit and adult female mink (Mustela vison) to accelerate the fur priming cycle.

(3) Limitations. For subcutaneous implantation in mink only. Do not implant potential breeding stock. Do not use in food-producing animals.

§ 522.1362 Melarsomine dihydrochloride for injection.

(a) Specifications. The drug consists of a vial of lyophilized powder containing 50 milligrams of melarsomine dihydrochloride which is reconstituted with the provided 2 milliliters of sterile water for injection.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. For asymptomatic to moderate (class 1 to class 2) heartworm disease: 2.5 milligrams per kilogram of body weight (1.1 milligram per pound) twice, 24 hours apart. The series can be repeated in 4 months depending on the response to the first treatment and the condition, age, and use of the dog. For severe (class 3) heartworm disease: Single injection of 2.5 milligrams per kilogram followed, approximately 1 month later,
by 2.5 milligrams per kilogram administered twice, 24 hours apart.

(2) **Indications.** Treatment of stabilized, class 1, 2, and 3 heartworm disease (asymptomatic to mild, moderate, and severe, respectively) caused by immature (4 month-old, stage L₅) to mature adult infections of *Dirofilaria immitis* in dogs.

(3) **Limitations.** Administer only by deep intramuscular injection in the lumbar muscles (L₃-L₅). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use alternate sides with each administration. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Sydrome). Not for use in breeding animals and lactating or pregnant bitches. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[60 FR 49340, Sept. 25, 1995]

§ 522.1372 Mepivacaine hydrochloride injection.

(a) **Specifications.** Each milliliter of sterile aqueous solution contains 20 milligrams of mepivacaine hydrochloride.

(b) **Sponsor.** See No. 000009 in §510.600(c) of this chapter.

(c) **Conditions of use.**

(1) It is intended for use in horses as a local anesthetic for infiltration, nerve block, intra-articular and epidural anesthesia and topical and/or infiltration anesthesia of the laryngeal mucosa prior to ventriculectomy.

(2) It is administered as follows: for nerve block, 3 to 15 milliliters; for epidural anesthesia, 5 to 20 milliliters; for intra-articular anesthesia, 10 to 15 milliliters; for infiltration, as required; for anesthesia of the laryngeal mucosa prior to ventriculectomy, by topical spray, 25 to 40 milliliters, by infiltration, 20 to 50 milliliters.

(3) Not for use in horses intended for food.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1410 Sterile methylprednisolone acetate suspension.

(a) **Specifications.** Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.

(b) **Sponsors.** See Nos. 000009 and 000010 in §510.600(c) of this chapter.

2These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
§ 522.1451 Moxidectin.

(a) Specifications. The drug product consists of two separate vials. One contains 10 percent moxidectin microspheres, and the other contains a vehicle for constitution of the moxidectin microspheres. Each milliliter of constituted, sustained-release suspension contains 3.4 milligrams (mg) of moxidectin.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Amount. 0.17 mg per kilogram body weight (0.0773 mg per pound) as a single subcutaneous injection.

(2) Indications for use. For prevention of heartworm disease caused by Dirofilaria immitis; for treatment of existing larval and adult hookworm (Ancylostoma caninum) infections.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[66 FR 35756, July 9, 2001]

§ 522.1452 Nalorphine hydrochloride injection.

(a) Specifications. Each milliliter of aqueous solution contains 5 milligrams of nalorphine hydrochloride.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. One milligram per 5 pounds; intravenously, intramuscularly, or subcutaneously.

(2) Indications for use. Respiratory and circulatory depression in dogs resulting from overdosage of, or unusual sensitivity to, morphine and certain other narcotics. Not for depression due to any other cause.

(3) Limitations. Successive doses of the drug gradually lose their analgesic effect and eventually induce respiratory depression equal to that of opiates. Therefore, do not exceed therapeutic dosage. Do not mix drug with meperidine solutions because the buffer will cause precipitation. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Food and Drug Administration, HHS

§ 522.1462 Naloxone hydrochloride injection.

(a) Specifications. Naloxone hydrochloride injection is an aqueous sterile solution containing 0.4 milligram of naloxone hydrochloride per milliliter.

(b) Sponsor. See No. 060951 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used as a narcotic antagonist in dogs.

(2) It is administered by intravenous, intramuscular, or subcutaneous injection at an initial dose of 0.04 milligram per kilogram of body weight. When given intravenously, the dosage may be repeated at 2- to 3-minute intervals as necessary. Onset of action by intramuscular or subcutaneous injection is slightly longer than it is by intravenous injection, and repeated doses must be administered accordingly.

(3) For use only by or on the order of a licensed veterinarian.


§ 522.1465 Naltrexone hydrochloride injection.

(a) Specifications. Each milliliter of sterile aqueous solution contains 50 milligrams of naltrexone hydrochloride.

(b) Sponsor. See 053923 in §510.600(c) of this chapter.

(c) Conditions of use in elk and moose—

(1) Amount. 100 milligrams of naltrexone hydrochloride for each milligram of carfentanil citrate administered. One-quarter of the dose should be administered intravenously and three-quarters of the dose should be administered subcutaneously.

(2) Indications for use. As an antagonist to carfentanil citrate immobilization in free-ranging or confined elk and moose (Cervidae).

(3) Limitations. Available data are inadequate to recommend use in pregnant animals. Avoid using during breeding season. Do not use in domestic food-producing animals. Do not use in free-ranging animals for 45 days before or during hunting season. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1468 Naproxen for injection.

(a) Specifications. The drug is a lyophilized powder which is reconstituted with sterile water for injection to form a 10 percent sterile aqueous solution (100 milligrams per milliliter).

(b) Sponsor. See 000856 in §510.600(c) of this chapter.

(c) Conditions of use in horses.

(1) Dosage. Five milligrams per kilogram of body weight intravenously followed by maintenance oral therapy of 10 milligrams per kilogram of body weight twice daily for up to 14 consecutive days.

(2) Indications for use. For the relief of inflammation and associated pain and lameness exhibited with arthritis, as well as myositis and other soft tissue diseases of the musculoskeletal system of the horse.

(3) Limitations. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1484 Neomycin sulfate sterile solution.

(a) Specifications. Each milliliter of sterile aqueous solution contains 50 milligrams of neomycin sulfate (equivalent to 35 milligrams of neomycin base).1

(b) Sponsor. See No. 000009 in §510.600(c) of this chapter.

(c) Conditions of use—

(1) Amount. 5 milligrams per pound of body weight daily divided into portions administered every 6 to 8 hours for 3 to 5 days.1

(2) Indications for use. Administer to dogs and cats for the treatment of acute and chronic bacterial infections due to organisms susceptible to neomycin.1

(3) Limitations. For intramuscular or intravenous use only. Neomycin is not for use parenterally in food-producing animals because of prolonged residues in edible tissues. Labeling shall bear an appropriate expiration date. For use by

1 These claims are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter.
§ 522.1503 Neostigmine methylsulfate injection.

(a) Specifications. Neostigmine methylsulfate injection contains two milligrams of neostigmine methylsulfate in each milliliter of sterile aqueous solution.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is intended for use for treating rumen atony; initiating peristalsis which causes evacuation of the bowel; emptying the urinary bladder; and stimulating skeletal muscle contractions. It is a curare antagonist.

(2) It is administered to cattle and horses at a dosage level of 1 milligram per 100 pounds of body weight subcutaneously. It is administered to sheep at a dosage level of 1 to 1 1/2 milligrams per 100 pounds body weight subcutaneously. It is administered to swine at a dosage level of 2 to 3 milligrams per 100 pounds body weight intramuscularly. These doses may be repeated as indicated.

(3) The drug is contraindicated in mechanical, intestinal or urinary obstruction, late pregnancy, and in animals treated with other cholinesterase inhibitors.

(4) Not for use in animals producing milk, since this use will result in contamination of the milk.

(5) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 50 FR 40966, Oct. 8, 1985]

§ 522.1620 Orgotein for injection.

(a) Specifications. Orgotein for injection is packaged in a vial containing 5 milligrams of orgotein and 10 milligrams of sucrose as lyophilized sterile nonpyrogenic powder with directions for dissolving the contents of the vial in sodium chloride injection, U.S.P.

(b) Sponsor. See No. 024991 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Horses. (i) It is used in the treatment of soft tissue inflammation associated with the musculoskeletal system.

(ii) It is administered by deep intramuscular injection at a dosage level of 5 milligrams every other day for 2 weeks and twice weekly for 2 to 3 more weeks. Severe cases, both acute and chronic, may benefit more from daily therapy initially. Dosage may be continued beyond 5 weeks if satisfactory improvement has not been achieved.

(iii) Not for use in horses intended for food.

(2) Dogs. (i) It is used for the relief of inflammation associated with ankylosing spondylitis, spondylosis, and disc disease. When severe nerve damage is present, response will occur much more slowly, if at all.

(ii) It is administered by subcutaneous injection at a dosage level of 5 milligrams every day for 6 days, and thereafter, every other day for 8 days. In less severe conditions, shorter courses of therapy may be indicated.
Food and Drug Administration, HHS

§ 522.1660 Oxytetracycline injection.

(a) Specifications. Each milliliter of sterile solution contains 200 milligrams of oxytetracycline base.

(b) Sponsor. See 000010, 000069, 011722, 053389, 059130, and 061623 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.500 of this chapter.

(d) Conditions of use. (1) Beef cattle, dairy cattle, and calves including preruminating (veal) calves. (i) Amount. 3 to 5 milligrams of oxytetracycline per pound of body weight per day; 5 milligrams per pound of body weight per day for treatment of anaplasmosis, severe foot-rot, and advanced cases of other indicated diseases; 9 milligrams per pound of body weight as a single dosage where retreatment for anaplasmosis is impractical; 9 milligrams per pound of body weight as single dosage where retreatment of calves and yearlings for bacterial pneumonia is impractical; 9 milligrams per pound of body weight as a single dosage for treatment of infectious bovine keratoconjunctivitis. (ii) Indications for use. Treatment of diseases due to oxytetracycline-susceptible organisms as follows: Pneumonia and shipping fever complex associated with Pasteurella spp. and Haemophilus spp., foot-rot and diphtheria caused by Fusobacterium necrophorum, bacterial enteritis (scours) caused by Escherichia coli, wooden tongue caused by Actinobacillus lignieresii, leptospirosis caused by Leptospira pomona, wound infections and acute metritis caused by Staphylococcus spp. and Streptococcus spp., and infectious bovine keratoconjunctivitis (pink eye) caused by Moraxella bovis. If labeled for use by or on the order of a licensed veterinarian, it may also be used for treatment of anaplasmosis caused by Anaplasma marginale and anthrax caused by Bacillus anthracis. (iii) Limitations. Administer intramuscularly or intravenously at the 3 to 5 milligrams level, intramuscularly at the 9 milligrams level. Sponsors 000010, 053389, and 059130 may also administer subcutaneously at the 3 to 5 milligrams and 9 milligrams levels. Treatment of all diseases should be instituted early and continued for 24 to 48 hours beyond remission of disease symptoms, but not to exceed a total of 4 consecutive days. Consult your veterinarian if no improvement is noted within 48 hours. Do not inject more than 10 milliliters per site in adult cattle, reducing the volume according to age and body size to 1 to 2 milliliters in small calves. Exceeding the highest recommended dose, administering at recommended levels for more than 4 consecutive days, and/or exceeding 10 milliliters intramuscularly per injection site may result in antibiotic residues beyond the withdrawal time. Discontinue treatment at least 28 days.
prior to slaughter. For sponsors 000010, 011722, 053389, 059130, and 061623: Not for use in lactating dairy cattle. For sponsor 000069: Milk taken from animals during treatment and for 96 hours after the last treatment must not be used for food; use subcutaneously with a maximum of 10 milliliters per injection site in adult cattle as well as intramuscularly and intravenously.

(2) Swine—(i) Amount. 3 to 5 milligrams of oxytetracycline per pound of body weight per day; 9 milligrams per pound of body weight as a single dosage where re-treatment for pneumonia is impractical. Sows: Administer once 3 milligrams of oxytetracycline per pound of body weight, approximately 8 hours before farrowing or immediately after completion of farrowing.


(iii) Limitations. Administer intramuscularly. Do not inject more than 5 milliliters per site in adult swine. Discontinue treatment at least 28 days prior to slaughter when provided by 000010, 000069, 011722, 053389, 059130, and 061623.


§ 522.1662 Oxacytetracycline hydrochloride implantation or injectable dosage forms.

§ 522.1662a Oxacytetracycline hydrochloride injection.

(a)(1) Specifications. The drug contains 50 milligrams of oxacytetracycline hydrochloride in each milliliter of sterile solution.

(2) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(3) Conditions of use. (i) The drug is intended for use in beef cattle, beef calves, nonlactating dairy cattle, and dairy calves for treatment of disease conditions caused by one or more of the following oxacytetracycline sensitive pathogens listed as follows: pneumonia and shipping fever complex (Pasteurella spp.; Hemophilus spp.; Klebsiella spp.), bacterial enteritis (scours) (E. coli), foot-rot (Spherothrix necrophorus), diphtheria (Spherothrix necrophorus), wooden tongue (Actinobacillus lignieresii), leptospirosis (Leptospira pomona), and wound infections; acute metritis; traumatic injury (caused by a variety of bacterial organisms such as streptococcal and staphylococcal organisms).

(ii) It is administered by intramuscular injection of 3 to 5 milligrams of oxacytetracycline hydrochloride per pound of body weight per day. Leptospirosis, severe foot-rot and severe forms of the indicated diseases should be treated with 5 milligrams per pound of body weight per day. Treatment should be continued for 24 to 48 hours following remission of disease symptoms; however, not to exceed a total of 4 consecutive days. Only 2 milliliters of the drug should be injected per site in case of calves weighing 100 pounds or less and not more than 10 milliliters should be injected per site in adult cattle.

(iii) Discontinue treatment with the drug at least 20 days prior to slaughter of the animal. When administered to animals within 30 days of slaughter, muscle discoloration may necessitate trimming of injection site and surrounding tissues.

(iv) For use only in beef cattle, beef calves, nonlactating dairy cattle, and dairy calves.

(b)(1) Specifications. Each milliliter of sterile solution contains 50 or 100 milligrams of oxacytetracycline (as oxacytetracycline hydrochloride).

(2) Sponsor. See 000010 in §510.600(c) of this chapter.
anaplasmosis, severe foot-rot, and severe cases of other indicated diseases.

(b) Indications for use. Treatment of diseases due to oxytetracycline-susceptible organisms as follows: Pneumonia and shipping fever complex associated with Pasteurella spp., Hemophilus spp., and Klebsiella spp., foot-rot and diphtheria caused by Sphingomonas necrophorus, bacterial enteritis (scours) caused by Escherichia coli, wooden tongue caused by Actinobacillus lignieresi, leptospirosis caused by Leptospira pomona, and wound infections and acute metritis caused by Staphylococcus spp. and Streptococcus spp. If labeled for use by or on the order of a licensed veterinarian, it may be used for the treatment of anaplasmosis caused by Anaplasma marginale.

(c) Limitations. For 50-milligram-per-milliliter solution, administer intramuscularly or intravenously; for 100-milligram-per-milliliter solution, administer intramuscularly only. Treatment of all diseases should be instituted early and continue for 24 to 48 hours beyond remission of disease symptoms, but not to exceed a total of 4 consecutive days. Consult your veterinarian if no improvement is noted within 48 hours. Do not inject more than 10 milliliters per site in adult cattle, reducing the volume according to age and body size to 0.5 to 2 milliliters in small calves. Exceeding the highest recommended dose of 5 milligrams per pound of body weight, administering at recommended levels for more than 4 consecutive days, and/or exceeding 10 milliliters intramuscularly per injection site may result in antibiotic residues beyond the withdrawal time. Discontinue treatment at least 18 days prior to slaughter. Not for use in lactating dairy cattle.

(ii) Swine—(a) Amount. Three to 5 milligrams of oxytetracycline per pound of body weight per day. Sows: 3 milligrams of oxytetracycline per pound of body weight, approximately 8 hours before farrowing or immediately after completion of farrowing.

(b) Indications for use. For treatment of bacterial enteritis (scours, colibacillosis) caused by Escherichia coli, pneumonia caused by Pasteurella multocida, and leptospirosis caused by Leptospira pomona. Sows: as an aid in control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.

(c) Limitations. Administer intramuscularly. Do not inject more than 5 milliliters per site. Do not use for more than 4 consecutive days. Discontinue treatment at least 26 days before slaughter.

(c)(1) Specifications. The drug contains 50 or 100 milligrams of oxytetracycline hydrochloride in each milliliter of sterile solution.

(2) Sponsor. See No. 000069 in §510.660(c) of this chapter.


(ii) It is administered to cattle at a dosage level of 3 to 5 milligrams per pound of body weight per day. It may be administered intramuscularly or intravenously from a 50 milligram per milliliter solution. It is administered intravenously from a 100 milligram per milliliter solution. Severe foot-rot and the severe forms of the indicated diseases should be treated with 5 milligrams per pound of body weight. Treatment should be continued 24 to 48 hours following remission of disease symptoms, however, not to exceed a total of 4 consecutive days. If no improvement is noted within 24 hours, consult a veterinarian. When injecting the drug intramuscularly, do not inject more than 10 milliliters per site in adult cattle. Reduce the amount injected at each site according to the size of the animal. For very small calves do not use more than 2 milliliters per injection site.

(iii) Not for use in lactating dairy cattle. Discontinue treatment at least
§ 522.1662a

19 days prior to slaughter. When administered intramuscularly within 30 days of slaughter, muscle discoloration may necessitate trimming of the injection site and surrounding tissues.

(d)(1) Specifications. The drug contains 50 milligrams of oxytetracycline hydrochloride in each milliliter of sterile solution.

(2) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(3) Conditions of use. (i) In beef cattle and nonlactating dairy cattle as follows:

(a) It is used for the treatment of pneumonia and shipping fever complex associated with Pasteurella spp. and Hemophilus spp.; foot-rot and diphtheria caused by Spheroophorus necrophorus; bacterial enteritis (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresi; leptospirosis caused by Leptospira pomona; wound infections and acute metritis caused by staphylococcal and streptococcal organisms.

(b) Administer by intravenous or intramuscular injection at 3 to 5 milligrams of oxytetracycline per pound of body weight per day. In the treatment of severe foot-rot and severe forms of the indicated diseases, a dosage level of 5 milligrams per pound of body weight per day is recommended.

(c) If the labeling of the drug bears the statement “Federal law restricts this drug to use by or on the order of a licensed veterinarian,” it may include additional directions for use in beef cattle and nonlactating dairy cattle for the treatment of anaplasmosis caused by Anaplasma marginale, and anthrax caused by Bacillus anthracis in which case the drug is given at 3 to 5 milligrams of oxytetracycline per pound of body weight per day for anthrax, and at 5 milligrams per pound of body weight per day for anaplasmosis.

(ii) In swine as follows:

(a) It is used for the treatment of bacterial enteritis (scours, colibacillosis) caused by Escherichia coli; pneumonia caused by Pasteurella multocida; and leptospirosis caused by Leptospira pomona. Administered to sows as an aid in the control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.

(b) Administer by intramuscular injection at 3 to 5 milligrams of oxytetracycline per pound of body weight per day to swine. Administered to sows at 3 milligrams of oxytetracycline per pound of body weight approximately 8 hours before farrowing or immediately after farrowing.

(iii) In poultry (broilers, turkeys, and breeding chickens) as follows:

(a) It is used for the treatment of air sacculitis (air-sac disease, chronic respiratory disease) caused by Mycoplasma gallisepticum and Escherichia coli; fowl cholera caused by Pasteurella multocida; infectious sinusitis caused by Mycoplasma gallisepticum; and infectious synovitis caused by Mycoplasma synoviae.

(b) Administered subcutaneously to chickens 1 day to 2 weeks of age at 6.25 milligrams of oxytetracycline per bird per day diluted with 1 part of the drug to 3 parts of sterile water; to chickens 2 to 4 weeks of age using the same diluted product at 12.5 milligrams of oxytetracycline per bird; to chickens 4 to 8 weeks of age without dilution at 25 milligrams of oxytetracycline per bird; to chickens 8 weeks of age (broilers and light pullets) at 50 milligrams of oxytetracycline per bird; to adult chickens at 100 milligrams of oxytetracycline per bird.

(c) Administered subcutaneously to turkeys 1 day to 2 weeks of age and 2 to 4 weeks of age at the same dosage as chickens; to turkeys 4 to 6 weeks of age at 50 milligrams of oxytetracycline as the undiluted product per bird; to turkeys 6 to 9 weeks of age at 100 milligrams of oxytetracycline per bird; to turkeys 9 to 12 weeks of age and older at 200 milligrams of oxytetracycline per bird. In light turkey breeds, no more than 25 milligrams per pound of body weight is administered. For the treatment of infectious sinusitis in turkeys, 1/4 to 1/2 milliliter of the drug is injected directly into each swollen sinus depending upon the age of the bird and the severity of the condition. At the time that the sinuses are treated, the drug should also be administered subcutaneously to the birds according...
to the dosage schedule given in paragraph (d)(3)(iii)(c) of this section. If refilling of the sinuses occurs, the treatment may be repeated in 5 to 7 days.

(iv) Treatment of all diseases should be instituted early. Treatment should continue for 24 to 48 hours beyond the remission of disease symptoms, but not exceed a total of 4 consecutive days. If no improvement is noted within 24 to 48 hours, diagnosis and therapy should be reevaluated.

(v) When injecting intramuscularly in adult livestock, do not inject more than 10 milliliters at any one site. The volume administered per injection site should be reduced according to age and body size so that 1 or 2 milliliters are injected in smaller animals such as small calves and young pigs. Intravenous administration is recommended in cattle when daily dosage exceeds 50 milliliters.

(vi) Treatment must be discontinued at least 5 days prior to slaughter for chickens and turkeys and at least 22 days prior to slaughter for cattle and swine. When administered intramuscularly to animals within 30 days of slaughter, muscle discoloration may necessitate trimming of the injection site(s) and surrounding tissues.

(vii) Not for use in lactating dairy animals. Do not administer to laying hens unless the eggs are used for hatching only.

(c) Limitations. Administer intramuscularly. Treatment of all diseases should be instituted early and continue for 24 to 48 hours beyond remission of disease symptoms, but not exceed a total of 4 consecutive days. Consult your veterinarian if no improvement is noted within 48 hours. Do not inject more than 10 milliliters per site in adult cattle, reducing the volume according to age and body size to 1 to 2 milliliters in small calves. Exceeding the highest recommended dose of 5 milligrams per pound of body weight, administering at recommended levels for more than 4 consecutive days, and/or exceeding 10 milliliters intramuscularly per injection site may result in antibiotic residues beyond the withdrawal time. Discontinue treatment at least 5 days prior to slaughter. Not for use in lactating dairy cattle.

(ii) Swine—(a) Amount. 3 to 5 milligrams of oxytetracycline per pound of body weight per day. Sows: 3 milligrams of oxytetracycline per pound of body weight, administered once, approximately 8 hours before farrowing or immediately after completion of farrowing.

(b) Indications for use. For treatment of bacterial enteritis (scours, colibacillosis) caused by Escherichia coli, pneumonia caused by Pasteurella multocida, and leptospirosis caused by Leptospira pomona. Sows: as an aid in control of infections enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.

(c) Limitations. Administer intramuscularly. Do not inject more than 5 milliliters per site in adult swine, reducing the volume according to age and body size to 1 to 2 milliliters in young pigs. Discontinue treatment at least 22 days prior to slaughter.

(f) [Reserved]
§ 522.1662a

(g)(1) Specifications. Each milliliter of sterile solution contains 100 milligrams of oxytetracycline as oxytetracycline hydrochloride.

(2) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(b) Indications for use. For the treatment of diseases due to oxytetracycline-susceptible organisms as follows:

(i) Beef cattle, beef calves, nonlactating dairy cattle, and dairy calves—(a) Amount. 3 to 5 milligrams of oxytetracycline per pound of body weight per day.

(b) Indications for use. For the treatment of pneumonia and shipping fever complex associated with Pasteurella spp., Hemophilus spp., or Klebsiella spp.

(c) Limitations. Administer by intramuscular, intravenous, or subcutaneous injection. In severe forms of the indicated diseases, administer 5 milligrams of oxytetracycline per pound of body weight per day. Continue treatment 24 to 48 hours following remission of disease symptoms, not to exceed a total of 4 consecutive days. If no improvement is noted within 48 hours, consult a veterinarian. Do not inject more than 1 milliliter per site in calves weighing 100 pounds or less. Do not inject more than 10 milliliters per site in calves weighing 100 pounds or more. Do not inject more than 1 milliliter per site in calves weighing 100 pounds or less. Do not inject intramuscularly in adult cattle; no more than 1 milliliter per site in calves weighing 100 pounds or less.

(2) Sponsors. See 000010 in § 510.600(c) of this chapter for use of 50 and 100 milligrams/milliliter solution, and see No. 059130 in § 510.600(c) for use of 100 milligrams/milliliter solution.

(3) Conditions of use—(i) Amount. The drug is used in beef cattle, beef calves, nonlactating dairy cattle, and dairy calves as follows: 3 to 5 milligrams of oxytetracycline hydrochloride per pound of body weight per day; 5 milligrams per pound of body weight per day for treatment of severe forms of the indicated diseases.

(ii) Indications for use. The drug is used for treatment of bacterial pneumonia and shipping fever complex associated with Pasteurella spp.: foot-rot and calf diphtheria caused by Spherophorus necrophorus; bacterial enteritides (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresii; wound infections, acute metritis, and traumatic injury caused by staphylococcal and streptococcal organisms.

(iii) Limitations. Administer 50-milligram-per-milliliter solution intramuscularly; administer 100-milligram-per-milliliter solution intravenously. Continue treatment 24 to 48 hours following remission of disease symptoms, not to exceed a total of 4 consecutive days. If no improvement is noted within 24 to 48 hours, consult a veterinarian for diagnosis and therapy. When injecting the drug intramuscularly, do not inject more than 10 milliliters per site in adult cattle. Reduce the volume administered per injection site according to age and body size. In calves weighing 100 pounds or less, do not inject more than 2 milliliters intramuscularly per site. Discontinue treatment at least 22 days after the last treatment.

Leptospira pomona. Sows: As an aid in control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.

(c) Limitations. Administer intramuscularly. If no improvement is noted within 24 hours, consult a veterinarian. Do not inject more than 5 milliliters per site. Discontinue treatment at least 20 days prior to slaughter.

(2) Conditions of use—(i) Amount. The drug is used in beef cattle, beef calves, nonlactating dairy cattle, and dairy calves as follows: 3 to 5 milligrams of oxytetracycline hydrochloride, 2 milliliters intramuscularly per site. Discontinue treatment at least 22 days after the last treatment.

(ii) Indications for use. The drug is used for the treatment of diseases due to oxytetracycline-susceptible organisms as follows: (a) Amount. 3 to 5 milligrams of oxytetracycline hydrochloride per pound of body weight per day. Continue treatment 24 to 48 hours following remission of disease symptoms, not to exceed a total of 4 consecutive days. If no improvement is noted within 24 hours, consult a veterinarian. Do not inject more than 1 milliliter per site in calves weighing 100 pounds or less. Do not inject more than 10 milliliters per site in calves weighing 100 pounds or more. Do not inject intramuscularly in adult cattle; no more than 1 milliliter per site in calves weighing 100 pounds or less. Do not inject more than 10 milliliters per site in calves weighing 100 pounds or more. Do not inject intramuscularly in adult cattle; no more than 1 milliliter per site in calves weighing 100 pounds or less. Do not inject more than 10 milliliters per site in calves weighing 100 pounds or more.

(2) Sponsors. See No. 000010 in § 510.600(c) of this chapter for use of 50 and 100 milligrams/milliliter solution, and see No. 059130 in § 510.600(c) for use of 100 milligrams/milliliter solution.

(3) Conditions of use—(i) Amount. The drug is used in beef cattle, beef calves, nonlactating dairy cattle, and dairy calves as follows: 3 to 5 milligrams of oxytetracycline hydrochloride per pound of body weight per day; 5 milligrams per pound of body weight per day for treatment of severe forms of the indicated diseases.

(ii) Indications for use. The drug is used for treatment of bacterial pneumonia and shipping fever complex associated with Pasteurella spp.: foot-rot and calf diphtheria caused by Spherophorus necrophorus; bacterial enteritides (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresii; wound infections, acute metritis, and traumatic injury caused by staphylococcal and streptococcal organisms.

(iii) Limitations. Administer 50-milligram-per-milliliter solution intramuscularly; administer 100-milligram-per-milliliter solution intravenously. Continue treatment 24 to 48 hours following remission of disease symptoms, not to exceed a total of 4 consecutive days. If no improvement is noted within 24 to 48 hours, consult a veterinarian for diagnosis and therapy. When injecting the drug intramuscularly, do not inject more than 10 milliliters per site in adult cattle. Reduce the volume administered per injection site according to age and body size. In calves weighing 100 pounds or less, do not inject more than 2 milliliters intramuscularly per site. Discontinue treatment at least 22 days after the last treatment.

Leptospira pomona. Sows: As an aid in control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.

(c) Limitations. Administer intramuscularly. If no improvement is noted within 24 hours, consult a veterinarian. Do not inject more than 5 milliliters per site. Discontinue treatment at least 20 days prior to slaughter.

(2) Conditions of use—(i) Amount. The drug is used in beef cattle, beef calves, nonlactating dairy cattle, and dairy calves as follows: 3 to 5 milligrams of oxytetracycline hydrochloride, 2 milliliters intramuscularly per site. Discontinue treatment at least 22 days after the last treatment.

(ii) Indications for use. The drug is used for the treatment of diseases due to oxytetracycline-susceptible organisms as follows: (a) Amount. 3 to 5 milligrams of oxytetracycline hydrochloride per pound of body weight per day. Continue treatment 24 to 48 hours following remission of disease symptoms, not to exceed a total of 4 consecutive days. If no improvement is noted within 24 hours, consult a veterinarian. Do not inject more than 1 milliliter per site in calves weighing 100 pounds or less. Do not inject more than 10 milliliters per site in calves weighing 100 pounds or more. Do not inject intramuscularly in adult cattle; no more than 1 milliliter per site in calves weighing 100 pounds or less. Do not inject more than 10 milliliters per site in calves weighing 100 pounds or more. Do not inject intramuscularly in adult cattle; no more than 1 milliliter per site in calves weighing 100 pounds or less. Do not inject more than 10 milliliters per site in calves weighing 100 pounds or more.
Food and Drug Administration, HHS

§ 522.1662b

Oxytetracycline hydrochloride with lidocaine injection.

(a) Specifications. The drug contains 50 or 100 milligrams of oxytetracycline hydrochloride and 2 percent lidocaine in each milliliter of sterile aqueous solution.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for use in the treatment of diseases of dogs caused by pathogens sensitive to oxytetracycline hydrochloride including treatment for the following conditions in dogs caused by susceptible microorganisms: Bacterial infections of the urinary tract caused by Hemolytic staphylococcus, Streptococcus spp., Bacterial pulmonary infections caused by Brucella bronchiseptica, Streplococcus pyogenes, Staphylococcus aureus, secondary bacterial infections caused by Micrococcus pyogenes var.

(ii) Indications for use. Treatment of diseases due to oxytetracycline-susceptible organisms as follows: pneumonia and shipping fever complex associated with Pasteurella spp.; foot rot and diphtheria caused by Fusobacterium necrophorum; bacterial enteritis (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresii; leptospirosis caused by Leptospira pomona; acute metritis and wound infections caused by staphylococcal and streptococcal organisms susceptible to oxytetracycline.

(iii) Limitations. Administer by intravenous injection. Treatment should be continued 24 to 48 hours following remission of disease symptoms, not to exceed a total of 4 consecutive days. If no improvement occurs within 24 to 48 hours, reevaluate diagnosis and therapy. Discontinue use at least 19 days prior to slaughter. Not for use in lactating dairy cattle.

(40 FR 13858, Mar. 27, 1975)

EDITORIAL NOTE: For Federal Register citations affecting §522.1662b, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.
albus, Brucella bronchiseptica, Streptococcus spp.

(2) The drug is administered intramuscularly at a recommended daily dosage to dogs at 5 milligrams per pound of body weight administered in divided doses at 6 to 12 hour intervals. Therapy should be continued for at least 24 hours after all symptoms have subsided.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 48 FR 30615, July 5, 1983]

§ 522.1680 Oxytocin injection.


(b) Sponsors. See Nos. 000010, 000856, 000864, 059130, 058639, and 059130 in §510.600(c) of this chapter.

(c) Conditions of use

(1) Amount

(i) Obstetrical. Administer drug intravenously, intramuscularly, or subcutaneously under aseptic conditions as indicated. The following dosages are recommended and may be repeated as conditions require:

<table>
<thead>
<tr>
<th></th>
<th>mL</th>
<th>U.S.P. units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cats</td>
<td>0.25 to 0.5</td>
<td>5 to 10</td>
</tr>
<tr>
<td>Dogs</td>
<td>0.25 to 1.5</td>
<td>5 to 30</td>
</tr>
<tr>
<td>Ewes, Sows</td>
<td>1.5 to 2.5</td>
<td>30 to 50</td>
</tr>
<tr>
<td>Cows, Horses</td>
<td>5.0</td>
<td>100</td>
</tr>
</tbody>
</table>

(ii) Milk letdown. Intravenous administration is desirable. The following dosage is recommended and may be repeated as conditions require:

<table>
<thead>
<tr>
<th></th>
<th>mL</th>
<th>U.S.P. units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cows</td>
<td>0.5 to 1.0</td>
<td>10 to 20</td>
</tr>
<tr>
<td>Sows</td>
<td>0.25 to 1.0</td>
<td>5 to 20</td>
</tr>
</tbody>
</table>

(2) Indications for use. Oxytocin may be used as a uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris. In surgery it may be used postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood. It will contract smooth muscle cells of the mammary gland for milk letdown if the udder is in proper physiological state.

(3) Limitations. Do not use in dystocia due to abnormal presentation of fetus until correction is accomplished. For prepartum usage, full relaxation of the cervix should be accomplished either naturally or by administration of estrogen prior to oxytocin therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1696 Penicillin G procaine implantation and injectable dosage forms.

§ 522.1696a Penicillin G benzathine and penicillin G procaine sterile suspension.

(a) Specifications. Each milliliter of aqueous suspension contains penicillin G benzathine and penicillin G procaine, each equivalent to 150,000 units of penicillin G.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for the conditions of use in paragraph (d) of this section as follows:

(1) Nos. 000008, 000856, 000864, 010515, and 049185 for use as in paragraph (d)(1) of this section.

(2) Nos. 000856 and 049185 for use as in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(2)(ii)(i) of this section.

(3) Nos. 000864, 010515, and 059130 for use as in paragraphs (d)(2)(i), (d)(2)(ii)(B), and (d)(2)(ii)(ii) of this section.

(c) Related tolerances. See §556.510 of this chapter.

(d) Conditions of use—(1) Horses, dogs, and beef cattle—(1) Amount—(A) Beef cattle. 2 milliliters per 150 pounds of body weight intramuscularly or subcutaneously. Repeat dosage in 48 hours.

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bio-equivalency and safety information.
§ 522.1696c Penicillin G procaine aqueous suspension.

(a) Specifications. Each milliliter contains penicillin G procaine equivalent to 300,000 units of penicillin G.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter as follows:

(1) Nos. 010515, 053501, and 059130 for use as in paragraph (d) of this section.

(2) Nos. 000864 and 055529 for use as in paragraph (d)(2) of this section.

(c) Related tolerances. See §556.510 of this chapter.

§ 522.1696c Penicillin G procaine in oil.

(a) Specifications. Each milliliter contains penicillin G procaine equivalent to 300,000 units of penicillin G.

(b) Sponsor. See No. 053501 in §510.600(c) of this chapter.

(c) National Academy of Sciences/National Research Council (NAS/NRC) status. The conditions of use were NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by
§ 522.1698 Pentazocine lactate injection.

(a) Specifications. Each milliliter of sterile aqueous solution contains pentazocine lactate equivalent to 30 milligrams of pentazocine base.

(b) Sponsor. See No. 000009 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Horses—(i) Amount. 0.15 milligram of pentazocine base per pound of body weight per day.

(ii) Indications for use. For symptomatic relief of pain due to colic.

(iii) Limitations. Administer intravenously or intramuscularly. Intravenous injections are given slowly in the jugular vein. In cases of severe pain, a second dose is recommended intramuscularly 10 to 15 minutes after the initial dose at the same level. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Dogs—(i) Amount. 0.75 to 1.50 milligrams of pentazocine base per pound of body weight.

(ii) Indications for use. For amelioration of pain accompanying post-operative recovery, fracture, trauma, and spinal disorders.

(iii) Limitations. Administer intramuscularly only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37333, Aug. 18, 1992]

§ 522.1704 Sodium pentobarbital injection.

(a)(1) Specifications. Sodium pentobarbital injection is sterile and contains in each milliliter 64.8 milligrams of sodium pentobarbital.

(2) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(3) Conditions of use. (i) The drug is indicated for use as a general anesthetic in dogs and cats. Although it may be used as a general surgical anesthetic for horses, it is usually given at a lower dose to cause sedation and hypnosis and may be supplemented with a local anesthetic. It may also be used in dogs for the symptomatic treatment of strychnine poisoning.

(ii) The drug is administered intravenously “to effect”. For general surgical anesthesia, the usual dose is 11 to 13 milligrams per pound of body weight. For sedation, the usual dose is approximately 2 milligrams per pound of body weight. For relieving convulsive seizures in dogs, when caused by strychnine, the injection should be administered intravenously “to effect”. The drug may be given intraperitoneally if desired. However, the results of such injections are less uniform. When given intraperitoneally, it is administered at the same dosage level as for intravenous administration. The dose must be reduced for animals showing under-nourishment, toxemia, shock and similar conditions.

(iii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b) [Reserved]
horses: See sponsor Nos. 000010 and 000864 in §510.600(c) of this chapter.

(3) Approval for use of the 100 milligrams per milliliter drug in dogs and horses: See sponsor No. 000864 in §510.600(c) of this chapter.

(4) Approval for use of the 200 milligrams per milliliter drug in dogs: See sponsor No. 000864 in §510.600(c) of this chapter.

(c) Conditions of use for dogs. (1) It is used for the relief of inflammatory conditions associated with the musculoskeletal system.

(2) It is administered intravenously at a dosage level of 10 milligrams per pound of body weight daily in 3 divided doses, not to exceed 800 milligrams daily regardless of weight. Limit intravenous administration to 2 successive days. Oral medication may follow.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use for horses. (1) It is used for the relief of inflammatory conditions associated with the musculoskeletal system.

(2) It is administered intravenously at a dosage level of 1 to 2 grams per 1,000 pounds of body weight daily in 3 divided doses, not to exceed 4 grams daily. Limit intravenous administration to not more than 5 successive days.

(3) Not for use in animals intended for food.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]

§ 522.1850 Polysulfated glycosaminoglycan.

(a) Specifications. Each 1-milliliter ampule of sterile aqueous solution contains 250 milligrams of polysulfated glycosaminoglycan; each 5-milliliter ampule or vial contains 500 milligrams.

(b) Sponsor. See No. 010797 in §510.600(c) of this chapter.

(c) Conditions of use—horses. (1) Indications for use. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses—

(2) Amount—(i) Intra-articular use (carpal): 250 milligrams once a week for 5 weeks. The joint area must be shaved, cleaned, and sterilized as in a surgical procedure prior to injection. If the joint reacts with excessive inflammation, after intra-articular treatment, cease therapy.

(ii) Intramuscular use (carpal and hock): 500 milligrams every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.

(3) Limitations. Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—dogs—(1) Indications for use. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

(2) Dosage. 2 milligrams per pound of body weight by intramuscular injection.
(3) **Limitations.** Administer intramuscularly twice weekly for up to 4 weeks (maximum of 8 injections). Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1862 Sterile pralidoxime chloride.

(a) **Chemical name.** 2-Formyl-1-methylpyridinium chloride oxime.

(b) **Specifications.** Sterile pralidoxime chloride is packaged in vials. Each vial contains 1 gram of sterile pralidoxime chloride powder and includes directions for mixing this gram with 20 cubic centimeters of sterile water for injection prior to use.

(c) **Sponsor.** See No. 000856 in § 510.600(c) of this chapter.

(d) **Conditions of use.**

(1) It is used in horses, dogs, and cats as an antidote in the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity in horses, dogs, and cats.

(2) It is administered as soon as possible after exposure to the poison. Before administration of the sterile pralidoxime chloride, atropine is administered intravenously at a dosage rate of 0.05 milligram per pound of body weight, followed by administration of an additional 0.15 milligram of atropine per pound of body weight administered intramuscularly. Then the appropriate dosage of sterile pralidoxime chloride is administered slowly intramuscularly. The dosage rate for sterile pralidoxime chloride when administered to horses is 2 grams per horse. When administered to dogs and cats, it is 25 milligrams per pound of body weight. For small dogs and cats, sterile pralidoxime chloride may be administered either intraperitoneally or intramuscularly. A mild degree of atropinization should be maintained for at least 48 hours. Following severe poisoning, a second dose of sterile pralidoxime chloride may be given after 1 hour if muscle weakness has not be relieved.

(3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 49 FR 32961, Aug. 10, 1984]

§ 522.1870 Praziquantel injectable solution.

(a) **Specification.** Each milliliter contains 56.8 milligrams of praziquantel.

(b) **Sponsor.** See 000859 in § 510.600(c) of this chapter.

(c) **Conditions of use—**

(1) **Dogs—**

(i) **Amount.** For dogs 5 pounds and under, 0.3 milliliter (17.0 milligrams); for 6 to 10 pounds, 0.5 milliliter (28.4 milligrams); for 11 to 25 pounds, 1.0 milliliter (56.8 milligrams); if over 25 Pounds, 0.2 milliliter (11.4 milligrams) per 5 pounds body weight to a maximum of 3 milliliters (170.4 milligrams).

(ii) **Indications for use.** For removal of canine cestodes Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus, and removal and control of canine cestode Echinococcus multilocularis.

(iii) **Limitations.** For subcutaneous or intramuscular use; not intended for use in puppies less than 4 weeks of age; Federal law restricts the drug to use by or on the order of a licensed veterinarian.

(2) **Cats—**

(i) **Amount.** For cats under 5 pounds, 0.2 milliliter (11.4 milligrams); 5 to 10 pounds, 0.4 milliliter (22.7 milligrams); 11 pounds and over, 0.6 milliliter (34.1 milligrams) maximum.

(ii) **Indications for use.** For removal of feline cestodes Dipylidium caninum and Taenia taeniaeformis.

(iii) **Limitations.** For subcutaneous or intramuscular injection only. Not intended for use in kittens less than 6 weeks of age. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1881 Sterile prednisolone acetate aqueous suspension.

(a) **Specifications.** Each milliliter of sterile aqueous suspension contains 25 milligrams of prednisolone acetate.

(b) **Sponsor.** See No. 000061 in § 510.600(c) of this chapter.

(c) **NAS/NRC status.** The conditions of use are NAS/NRC reviewed and found
Food and Drug Administration, HHS

§ 522.1884

Effective. Applications for these uses need not include effectiveness data as specified in §514.111 of this chapter but may require bioequivalency and safety information.

(d) Conditions of use. (1) The drug is indicated in the treatment of dogs, cats, and horses for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and post-operatively and for various stress conditions when corticosteroids are required while the animal is being treated for a specific condition.

(2) The drug is administered to horses intra-articularly at a dosage level of 50 to 100 milligrams. The dose may be repeated when necessary. If no response is noted after 3 or 4 days, the possibility must be considered that the condition is unresponsive to prednisolone therapy. The drug is administered to dogs and cats intramuscularly at a dosage level of 10 to 50 milligrams. The dosage may be repeated when necessary. If the condition is of a chronic nature, an oral corticosteroid may be given as a maintenance dosage. The drug may be given intra-articularly to dogs and cats at a dosage level of 5 to 25 milligrams. The dose may be repeated when necessary after 7 days for two or three doses.

(3) The labeling shall comply with the requirements of §510.410 of this chapter for corticosteroids.

(4) Not for use in horses intended for food.

(5) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[52 FR 23032, June 17, 1987]

§ 522.1883 Prednisolone sodium phosphate injection, sterile.

(a) (1) Specifications. Each milliliter contains 20 milligrams of prednisolone sodium phosphate (equivalent to 14.88 milligrams of prednisolone) in sterile aqueous solution.

(2) Sponsor. See No. 000864 in §510.600(c) of this chapter.

(b) [Reserved]

[43 FR 29769, July 11, 1978, as amended at 49 FR 23834, June 8, 1984]

§ 522.1884 Prednisolone sodium succinate injection.

(a) Chemical name. 11 beta, 17, 21-Trihydroxypregna-1, 4-diene-3, 20-dione 21-succinate sodium salt.

(b) Specifications. Each milliliter of prednisolone sodium succinate injection contains: Prednisolone sodium succinate equivalent in activity to 10, 20, or 50 milligrams of prednisolone.

(c) Sponsor. See No. 000009 in §510.600(c) of this chapter for products containing 10, 20, and 50 milligrams equivalent prednisolone activity per milliliter for use in horses, dogs, and cats as provided in paragraphs (d)(1), (2)(i), (ii), and (iii) of this section.
§ 522.1885 Prednisolone tertiary butylacetate suspension.

(a) Specifications. Prednisolone tertiary butylacetate (Pregna-1,4-diene-3,20-dione-11B,17α 21-trioli 21-(3,3, dimethyl butyrate) suspension contains 20 milligrams of prednisolone tertiary butylacetate per milliliter. It is sterile.

(b) Sponsor. See No. 050064 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used as an anti-inflammatory agent in horses, dogs, and cats.1

(2) It is administered to horses intramuscularly at a dosage level of 100 to 300 milligrams and intrasynovially at a dosage level of 50 to 100 milligrams. It is administered intramuscularly to dogs and cats at a dosage level of 1 milligram per 5 pounds of body weight and intrasynovially at a dosage level of 10 to 20 milligrams. Intramuscular re-treatment of horses in 24 to 48 hours may be necessary, depending on the general condition of the animal and the severity and duration of the disease.1

(3) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered late in pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.1

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.1

[40 FR 13858, Mar. 27, 1975, as amended at 62 FR 63271, Nov. 28, 1997]

§ 522.1890 Sterile prednisone suspension.

(a) [Reserved]

(b)(1) Specifications. Each milliliter of sterile aqeous suspension contains 10 to 40 milligrams of prednisone.

(2) Sponsor. See 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(i) Amount. Administer intramuscularly as follows:

(a) Horses. 100 to 400 milligrams, repeating if necessary. If no response is observed after 3 to 4 days of therapy, reevaluate diagnosis.1

(b) Dogs and cats. 0.25 to 1.0 milligram per pound of body weight for 3 to 5 days or until a response is noted. Treatment may be continued with an orally administered dose.1

(ii) Indications for use. It is used for conditions requiring an anti-inflammatory agent.1

(iii) Limitations.1 Do not use in viral infections. Except in emergency therapy, do not use in animals with tuberculosis, chronic nephritis, or
Food and Drug Administration, HHS

§ 522.1940 Progesterone and estradiol benzoate in combination.

(a) [Reserved]

(b) Sponsors. See 000856 in §510.600(c) of this chapter for use as in paragraphs (d)(1)(i)(A), (d)(1)(ii), (d)(1)(iii), (d)(2)(i)(A), (d)(2)(ii), (d)(2)(iii), and (d)(3) of this section. See 021641 in §510.600(c) of this chapter for use as in paragraphs (d)(1) and (d)(2)(i) through (d)(2)(iii)(A) of this section.

(c) Related tolerances. See §§556.240 and 556.540 of this chapter.

(d) Conditions of use. It is used for implantation in animals as follows:

(1) Suckling beef calves—(i) Amount. (A) 100 milligrams of progesterone and 10 milligrams of estradiol benzoate in four pellets per implant dose.

(B) 100 milligrams of progesterone and 10 milligrams of estradiol benzoate in four pellets with 29 milligrams of tylosin tartrate as a local antibacterial in one pellet per implant dose.

(ii) Indications for use. Increased rate of weight gain.

(iii) Limitations. For use in suckling beef calves (at least 45 days of age) up to 400 pounds of body weight. For subcutaneous ear implantation, one dose per animal. Do not use in bull calves intended for reproduction.

(2) Steers—(i) Amount. (A) 200 milligrams of progesterone and 20 milligrams estradiol benzoate in eight pellets per implant dose.

(B) 200 milligrams progesterone and 20 milligrams estradiol benzoate in eight pellets with 29 milligrams tylosin tartrate as a local antibacterial in one pellet per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency.

(iii) Limitations. (A) For animals weighing 400 pounds or more; for subcutaneous ear implantation, one dose per animal.

(B) For additional improvement in rate of weight gain in steers fed in confinement for slaughter, reimplant at approximately day 70.

(3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 50 FR 60653, Oct. 8, 1995; 60 FR 55639, Nov. 2, 1995]

§ 522.1920 Prochlorperazine, isopropamide for injection.

(a) Specifications. Prochlorperazine, isopropamide for injection, veterinary, contains in each milliliter, 6 milligrams of prochlorperazine edisylate (equivalent to 4 milligrams prochlorperazine), and 0.38 milligrams of isopropamide iodide (equivalent to 0.28 milligrams of isopropamide) in buffered aqueous solution.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in dogs and cats in which gastrointestinal disturbances are associated with emotional stress.

(2) Dosage is administered by subcutaneous injection twice daily as follows:

<table>
<thead>
<tr>
<th>Weight of animal in pounds</th>
<th>Dosage in Milliliters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 4</td>
<td>0.25</td>
</tr>
<tr>
<td>5 to 14</td>
<td>0.5–1</td>
</tr>
<tr>
<td>15 to 30</td>
<td>2–3</td>
</tr>
<tr>
<td>30 to 45</td>
<td>3–4</td>
</tr>
<tr>
<td>45 to 60</td>
<td>4–5</td>
</tr>
<tr>
<td>Over 60</td>
<td>6</td>
</tr>
</tbody>
</table>

Following the last injection, administer prochlorperazine and isopropamide sustained release capsules as indicated.

specified by §514.111 of this chapter, but may require bioequivalency and safety information.


§ 522.1940 Progesterone and estradiol benzoate in combination.

(a) [Reserved]

(b) Sponsors. See 000069 in §510.600(c) of this chapter for use as in paragraphs (d)(1)(i)(A), (d)(1)(ii), (d)(1)(iii), (d)(2)(i)(A), (d)(2)(ii), (d)(2)(iii), and (d)(3) of this section. See 021641 in §510.600(c) of this chapter for use as in paragraphs (d)(1) and (d)(2)(i) through (d)(2)(iii)(A) of this section.

(c) Related tolerances. See §§556.240 and 556.540 of this chapter.

(d) Conditions of use. It is used for implantation in animals as follows:

(1) Suckling beef calves—(i) Amount. (A) 100 milligrams of progesterone and 10 milligrams of estradiol benzoate in four pellets per implant dose.

(B) 100 milligrams of progesterone and 10 milligrams of estradiol benzoate in four pellets with 29 milligrams of tylosin tartrate as a local antibacterial in one pellet per implant dose.

(ii) Indications for use. Increased rate of weight gain.

(iii) Limitations. For use in suckling beef calves (at least 45 days of age) up to 400 pounds of body weight. For subcutaneous ear implantation, one dose per animal. Do not use in bull calves intended for reproduction.

(2) Steers—(i) Amount. (A) 200 milligrams of progesterone and 20 milligrams estradiol benzoate in eight pellets per implant dose.

(B) 200 milligrams progesterone and 20 milligrams estradiol benzoate in eight pellets with 29 milligrams tylosin tartrate as a local antibacterial in one pellet per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency.

(iii) Limitations. (A) For animals weighing 400 pounds or more; for subcutaneous ear implantation, one dose per animal.

(B) For additional improvement in rate of weight gain in steers fed in confinement for slaughter, reimplant at approximately day 70.

(3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 50 FR 60653, Oct. 8, 1995; 60 FR 55639, Nov. 2, 1995]
§ 522.1962 Promazine hydrochloride injection.

(a) Specifications. Each milliliter of sterile aqueous solution contains 50 milligrams of promazine hydrochloride.

(b) Sponsor. See No. 000086 in §510.600(c) of this chapter for use as in paragraph (c)(1)(ii) of this section.

(c) Conditions of use. (1)(i) To horses intramuscularly or intravenously at a dosage of 0.2 to 0.5 milligram per pound of body weight and to dogs and cats 1 to 3 milligrams per pound of body weight, every 4 to 6 hours as a tranquilizer, preanesthetic, for minor operative procedures in conjunction with local anesthesia, as adjunctive therapy for tetanus, and as an antiemetic in dogs and cats prior to worming, or to prevent motion sickness in dogs.

(ii) To horses intravenously at a dosage of 0.2 to 0.5 milligram per pound of body weight, as a tranquilizer and preanesthetic.

(2) Not for use in conjunction with organophosphates because their toxicity may be potentiated, nor with procaine hydrochloride as its activity may be increased.

(3) Not for use in horses intended for food.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[46 FR 18962, Mar. 27, 1981]

§ 522.2002 Propiopromazine hydrochloride injection.

(a) Chemical name. 1-Propanone, 1-[10-(3-(dimethylamino) propyl)phenothiazine-2-yl]-, monohydrochloride.

(b) Specifications. Propiopromazine hydrochloride injection contains 5 or 10 milligrams of the drug in each milliliter of sterile aqueous solution.

(c) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(d) Conditions of use. (1) It is administered either intravenously or intramuscularly to dogs and cats for tranquilization at a dosage level of 0.05–0.5 milligram per pound of body weight and is also administered intravenously to dogs and cats as a preanesthetic at a dosage level of 0.25 milligram per pound of body weight.

(2) It is not to be used in conjunction with organophosphates and/or procaine hydrochloride since phenothiazines may potentiate the toxicity of organophosphates and the activity of procaine hydrochloride.

(3) For use only by or on the order of a licensed veterinarian.


§ 522.2005 Propofol injection.

(a) Specifications. The drug is a sterile, nonpyrogenic, oil-in-water emulsion containing 10 milligrams of propofol per milliliter.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter for use as in
paragraphs (c)(1) and (c)(2) of this section. See No. 000074 in §510.600(c) of this chapter for use as in paragraph (c)(1) of this section.

(c) Conditions of use—(1) Dogs. (i) The drug is indicated for use as an anesthetic as follows: As a single injection to provide general anesthesia for procedures lasting up to 5 minutes; for induction and maintenance of general anesthesia using incremental doses to effect; for induction of general anesthesia where maintenance is provided by inhalant anesthetics.

(ii) The drug is administered by intravenous injection as follows: For induction of general anesthesia without the use of preanesthetics the dosage is 5.5 to 7.0 milligrams per kilogram (2.5 to 3.2 milligrams per pound); for the maintenance of general anesthesia without the use of preanesthetics the dosage is 1.1 to 3.3 milligrams per kilogram (0.5 to 1.5 milligrams per pound). The use of preanesthetic medication reduces propofol dose requirements.

(iii) Adequate data concerning safe use of propofol in pregnant and breeding dogs have not been obtained. Doses may need adjustment for geriatric or debilitated patients. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§522.2063 Pyrilamine maleate injection.

(a) Specifications. The drug is a sterile aqueous solution with each milliliter containing 20 milligrams of pyrilamine maleate.

(b) Sponsors. See No. 000061 in §510.600(c) of this chapter for uses in paragraph (c)(2)(i) of this section; see No. 000864 in §510.600(c) of this chapter for uses in paragraph (c)(2)(ii) of this section.

(c) Conditions of use. (1) It is intended for treating horses in conditions in which antihistaminic therapy may be expected to lead to alleviation of some signs of disease.1

(ii) It is administered intramuscularly, subcutaneously, or intravenously. Local injection at the site of insect bites may be indicated in severe cases. Intravenous injections must be given slowly to avoid symptoms of overdosage. Dosage may be repeated every 6 to 12 hours whenever necessary. Horses, 40 to 60 milligrams

---

1These conditions are NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
§ 522.2100 Selenium, vitamin E injection.  

(a)(1) Specifications. The drug is an emulsion containing in each milliliter, 5.48 milligrams sodium selenite (equivalent to 2.5 milligrams selenium), 50 milligrams of vitamin E (68 I.U.) (as d-alpha tocopheryl acetate).  

(2) Sponsor. See No. 000061 in § 510.600(c) of this chapter.  

(3) Conditions of use. (i) The drug is intended for use for the prevention and treatment of selenium-tocopherol deficiency syndrome in horses.  

(ii) The drug is administered intravenously or deep intramuscularly in divided doses in 2 or more sites at a dosage level of 1 milliliter per 20 pounds of body weight. The dosage is repeated at 3 day intervals until a satisfactory therapeutic response is observed. The drug may be used in capsule form for oral maintenance therapy.  

(iii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.  

(c)(1) Specifications. Each milliliter contains 2.19 milligrams of selenite sodium (equivalent to 1 milligram selenium), 50 milligrams vitamin E (68 U.S.P. units).  

(2) Sponsor. See No. 000061 in § 510.600(c) of this chapter.  

(3) Conditions of use. (i) The drug is intended for use as an aid in alleviating and controlling inflammation, pain and lameness associated with certain arthropathies in dogs.  

(ii) The drug is administered subcutaneously or intramuscularly in divided doses in 2 or more sites at a dosage level of 1 milliliter per 20 pounds of body weight with a minimum dosage of 1⁄2 milliliter and a maximum dosage of 5 milliliters. The dosage is repeated at 3 day intervals until a satisfactory therapeutic response is observed. A maintenance regimen is then initiated which consists of 1 milliliter per 40 pounds of body weight with a minimum dosage of 1⁄4 milliliter which is repeated every 3 days or 7 days, or longer, as required to maintain continued improvement or an asymptomatic condition; or the drug may be used in capsule form for oral maintenance therapy.  

(iii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.2112 Sterile sometribove zinc suspension.

(a) Specifications. The drug product consists of a single-dose syringe containing 500 milligrams of sometribove zinc in a sterile, prolonged-release suspension.

(b) Sponsor. See No. 059945 in §510.600(c) of this chapter.

(c) Special considerations. Use may result in reduced pregnancy rates and, in first calf heifers, an increase in days open. Use of the product has also been associated with increases in cystic ovaries and disorders of the uterus during the treatment period. Also, the incidence of retained placenta may be higher following subsequent calving. Treated cows are at an increased risk for clinical mastitis and subclinical mastitis. In some herds, use has been associated with increases in somatic cell counts in milk. Care should be taken to differentiate increased body temperature due to use of this product from an increased body temperature that may occur due to illness. Use may result in an increase in digestive disorders such as indigestion, bloat, and diarrhea. There may be an increase in the number of cows experiencing periods of “off-feed” (reduced feed intake) during treatment. Cows treated with this product may have increased numbers of enlarged hocks and lesions of the knee (carpal region), and second lactation or older cows may have more disorders of the foot region. Use has been associated with reductions in hemoglobin and hematocrit values during treatment. Human warning: Avoid prolonged or repeated contact with eyes and skin.

(d) Conditions of use—(1) Amount. 500 milligrams of sometribove zinc every 14 days beginning during the ninth week after calving and continuing until the end of lactation.

(2) Indications for use. For use in healthy lactating dairy cows to increase the production of marketable milk.

(3) Limitations. For use in lactating dairy cows only. Administer subcutaneously. Safety to replacement bulls born to treated dairy cows has not been established. To minimize injection site blemishes on carcasas at time of slaughter, avoid injections within 2 weeks of expected slaughter. No milk discard or preslaughter withdrawal period is required.

[58 FR 59947, Nov. 12, 1993]
§ 522.2120 Spectinomycin dihydrochloride injection.

(a) Specifications. The spectinomycin dihydrochloride pentahydrate used in manufacturing the drug is the antibiotic substance produced by the growth of Streptomyces flavopersicus (var. Abbott) or the same antibiotic substance produced by any other means. Each milliliter of the drug contains the following amount of spectinomycin activity from spectinomycin dihydrochloride pentahydrate:

1. 5 milligrams when used as provided in paragraph (d)(1) of this section.
2. [Reserved]
3. 100 milligrams when used as provided in paragraphs (d)(2), (3), and (4) of this section.

(b) Sponsor. In §510.600 of this chapter, see No. 059130 for conditions of use as in paragraph (d) of this section, and see No. 000009 for conditions of use as in paragraph (d)(2) and (d)(4) of this section.

(c) Special considerations. The quantity of spectinomycin referred to in this section refers to the equivalent weight of base activity for the drug.

(d) Conditions of use. It is administered as spectinomycin dihydrochloride pentahydrate as follows:

1. Subcutaneously in the treatment of 1-to-3-day-old turkey poult at the rate of 1 to 2 milligrams per poult as an aid in the prevention of mortality associated with Arizona group infection.
2. Subcutaneously in the treatment of 1-to-3-day-old:
   1. Turkey poult at the rate of 5 milligrams per poult as an aid in the control of chronic respiratory disease (CRD) associated with E. coli.
   2. Baby chicks at the rate of 2.5 to 5 milligrams per chick as an aid in the control of mortality and to lessen severity of infections caused by M. synoviae, S. typhimurium, S. infantis, and E. coli.
3. Intramuscularly in the treatment of dogs:
   1. At a dosage level of 2.5 milligrams to 5.0 milligrams per pound of body weight twice daily. Treatment may be continued for 4 days. For treatment of infections caused by gram-negative and gram-positive organisms susceptible to spectinomycin.
   2. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
3. Administer single injection of 0.1 milliliter (10 milligrams) subcutaneously in nape of neck of 1- to 3-day-old turkey poult as an aid in control of airsacculitis associated with M. meleagridis sensitive to spectinomycin.

§ 522.2121 Spectinomycin sulfate solution.

(a) Specifications. Each milliliter of sterile aqueous solution contains spectinomycin sulfate tetrahydrate equivalent to 100 milligrams of spectinomycin.

(b) Sponsor. See 000009 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.600 of this chapter.

(d) Conditions of use—(1) Cattle—(i) Dose. 10 to 15 milligrams per kilogram of body weight, at 24-hour intervals for 3 to 5 consecutive days.
   (ii) Indications for use. For the treatment of bovine respiratory disease (pneumonia) associated with Pasteurella haemolytica, P. multocida, and Haemophilus somnus.
   (iii) Limitations. For subcutaneous injection in the neck. Do not inject more than 50 milliliters at each site. Do not slaughter within 11 days of last treatment. Do not use in female dairy cattle 20 months of age or older. Use in this class of cattle may cause residues in milk. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
   (2) [Reserved]

§ 522.2150 Stanozolol sterile suspension.

(a) Specifications. Each milliliter of sterile suspension contains 50 milligrams of stanozolol.
§ 522.220 Sulfachlorpyridazine.

(a) Chemical name. N\textsuperscript{1}-(6-Chloro-3-pyridazinyl) sulfanilamide.

(b) Specifications. Melting point range 190 °C to 191 °C.

(c) Sponsor. See No. 053501 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.630 of this chapter.

(e) Conditions of use. It is used for injection into calves as follows:

(1) Amount. 30 to 45 milligrams per pound of body weight per day.

(2) Indications for use. Treatment of diarrhea caused or complicated by E. coli (coli bacillosis).

(3) Limitations. Administer as the sodium salt of sulfachlorpyridazine intravenously in aqueous solution for 1 to 5 days in divided doses twice daily; treated calves must not be slaughtered for food during treatment or for 5 days after the last treatment.

§ 522.2220 Sulfadimethoxine injection.

(a)(1) Specifications. Sulfadimethoxine injection containing 400 milligrams per milliliter.

(2) Sponsor. (i) See No. 000069 in §510.600(c) of this chapter for conditions of use as in paragraphs (a)(3)(i) through (a)(3)(iii) of this section.

(ii) See No. 057561 for conditions of use as in paragraph (a)(3) of this section.

(iii) See No. 059130 for use as in paragraph (a)(3)(iii) of this section.

(3) Conditions of use. (i) It is used or intended for use in horses as follows:

(a) For the treatment of respiratory, genitourinary tract, enteric, and soft tissue infections when caused by Streptococci, Staphylococci, Escherichia, Salmonella, Klebsiella, Proteus, or Shigella organisms sensitive to sulfadimethoxine, and in the treatment of canine bacterial enteritis associated with coccidiosis and canine Salmonellosis.

(b) It is administered by intravenous or subcutaneous injection at an initial dose of 55 milligrams per kilogram of body weight followed by 27.5 milligrams per kilogram of body weight every 24 hours.

(c) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(ii) It is used or intended for use in cattle as follows:

(a) For the treatment of shipping fever complex, bacterial pneumonia, calf diphtheria, and foot-rot.

(b) It is administered by intravenous injection at an initial dose of 25 milligrams per pound of body weight followed by 12.5 milligrams per pound of body weight every 24 hours until the animal is asymptomatic for 48 hours.

(c) Milk taken from animals during treatment and for 60 hours (5 milkings) after the latest treatment must not be used for food. Do not administer within 5 days of slaughter.
§ 522.2240  Sulfadimethoxine.

(a) Chemical name. N\(^1\)-(6-Ethoxy-3-pyridazinyl) sulfanilamide.

(b) Specifications. Melting point range of 180 °C to 186 °C.

(c) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.640 of this chapter.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 11011, Mar. 15, 1976]

§ 522.2240  Sulfadimethoxine.

(a) Chemical name. N\(^1\)-(6-Ethoxy-3-pyridazinyl) sulfanilamide.

(b) Specifications. Melting point range of 180 °C to 186 °C.

(c) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.640 of this chapter.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 11011, Mar. 15, 1976]

§ 522.2240  Sulfadimethoxine.

(a) Chemical name. N\(^1\)-(6-Ethoxy-3-pyridazinyl) sulfanilamide.

(b) Specifications. Melting point range of 180 °C to 186 °C.

(c) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.640 of this chapter.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 11011, Mar. 15, 1976]

§ 522.2240  Sulfadimethoxine.

(a) Chemical name. N\(^1\)-(6-Ethoxy-3-pyridazinyl) sulfanilamide.

(b) Specifications. Melting point range of 180 °C to 186 °C.

(c) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.640 of this chapter.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 11011, Mar. 15, 1976]

§ 522.2240  Sulfadimethoxine.

(a) Chemical name. N\(^1\)-(6-Ethoxy-3-pyridazinyl) sulfanilamide.

(b) Specifications. Melting point range of 180 °C to 186 °C.

(c) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(d) Related tolerances. See §556.640 of this chapter.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 11011, Mar. 15, 1976]
§ 522.2340 Sulfomyxin.

(a) Specifications. Sulfomyxin for injection is sterile. It is derived from the antibiotic substance produced by the growth of *Bacillus polymyxa* or is the same substance produced by any other means.

(b) Sponsor. See No. 000069 in § 510.500(c) of this chapter.

(c) Special considerations. The quantities of antibiotic in paragraph (e) of this section refer to the activity of the appropriate standard.

(d) Related tolerances. See § 556.700 of this chapter.

(e) Conditions of use. (1) It is used or intended for use in chickens and turkeys as an aid in the treatment of disease caused or complicated by *E. coli*, such as colibacillosis and complicated chronic respiratory disease.

(2) It is administered by subcutaneous injection as follows:

<table>
<thead>
<tr>
<th>Age of birds in days</th>
<th>Antibiotic activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chickens (units)</td>
</tr>
<tr>
<td></td>
<td>Turkeys (units)</td>
</tr>
<tr>
<td>1 to 14</td>
<td>12,500</td>
</tr>
<tr>
<td>15 to 28</td>
<td>25,000</td>
</tr>
<tr>
<td>29 to 63</td>
<td>50,000</td>
</tr>
<tr>
<td>Over 63</td>
<td>100,000</td>
</tr>
</tbody>
</table>

(3) A second injection may be given 3 days later if symptoms persist.

(4) Not for use in laying hens; do not treat chickens within 5 days of slaughter; do not treat turkeys within 7 days of slaughter.

§ 522.2404 Thialbarbitone sodium for injection.

(a) Specifications. Thialbarbitone sodium for injection when reconstituted with sterile distilled water provides 94 milligrams of thialbarbitone sodium per milliliter of solution.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is administered as a general anesthetic in surgical procedures on dogs, cats, swine, sheep, cattle, and horses. The drug is used for procedures of relatively short duration. However, the period of anesthesia can be lengthened by slower initial injection and supplemental administration during surgery.

(2) It is administered intravenously. The drug is injected slowly to dogs, cats, cattle, sheep, and swine. For horses, it is recommended that a pre-anesthetic sedation be administered to the horse 30 minutes before the drug is administered. The drug is then injected rapidly and completely. The drug is used at the following dosage levels:

<table>
<thead>
<tr>
<th>Species</th>
<th>Weight of animal in pounds</th>
<th>Dosage in milligrams per pound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td>Over 50</td>
<td>14.1</td>
</tr>
<tr>
<td>Do</td>
<td>30–50</td>
<td>18.8</td>
</tr>
<tr>
<td>Do</td>
<td>10–30</td>
<td>23.5</td>
</tr>
<tr>
<td>Do</td>
<td>Under 10</td>
<td>28.2</td>
</tr>
<tr>
<td>Cat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Horse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calves and sheep</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cattle and swine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Horse and swine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Horse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calves and sheep</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cattle and swine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2424 Sodium thiamyl for injection.

(a) Specifications. The drug is a sterile dry powder. It is reconstituted aseptically with sterile distilled water, water for injection, or sodium chloride injection, to a desired concentration of 0.5 to 4 percent sodium thiamyl.

(b) Sponsors. See code Nos. 000010 and 000856 in § 510.500(c) of this chapter.

(c) Conditions of use. (1) It is used as an ultra-short-acting anesthetic in dogs, cats, swine, horses, and cattle.

(2) When diluted aseptically to the desired concentration and administered intravenously to effect, the average single dose is:

(i) Dogs and cats: 8 milligrams per pound of body weight (when used with a preanesthetic, generally one-half the normal dose).

(ii) Horses: Light anesthesia, 1 gram per 500 pounds to 1,100 pounds of body weight; deep anesthesia, 1 gram per 300 pounds of body weight (40 milligrams per 12 pounds of body weight).

(iv) Cattle: Short duration, 20 milligrams per 5 pounds of body weight; longer duration, 40 milligrams per 7 pounds of body weight.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) NAS/NRC status: The conditions of use specified in this paragraph are NAS/NRC reviewed and found effective.
§ 522.2444 Sodium thiopental for injection.

(a) Specifications. The drug contains sodium thiopental sterile powder for dilution with sterile water for injection.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used as an anesthetic for intravenous administration to dogs and cats during short to moderately long surgical procedures.

(2) It is administered as follows:

(i) For total anesthesia, it is given at approximately 10 to 12 milligrams per pound of body weight over a period of 3.5 to 5 minutes.

(ii) When preanesthetic medication is used, it is important to wait at least an hour before administering thiopental and sodium pentobarbital for injection, and the dosage necessary for anesthesia is reduced. Usually 1⁄2 to 2⁄3 the normal amount is adequate.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2444a Sodium thiopental for injection.

(a) Specifications. Each gram of the drug contains 750 milligrams of sodium thiopental and 250 milligrams of sodium pentobarbital sterile powder for dilution with sterile water for injection.

(b) Sponsor. See No. 061133 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used as an anesthetic for intravenous administration to dogs and cats during short to moderately long surgical procedures.

(2) It is administered as follows:

(i) In healthy dogs: An initial intramuscular dosage of 3 to 4.5 milligrams per pound of body weight for diagnostic purposes; 4.5 to 6 milligrams per pound of body weight for minor procedures of short duration such as

§ 522.2447 Tiletamine hydrochloride and zolazepam hydrochloride for injection.

(a) Specifications. Tiletamine hydrochloride and zolazepam hydrochloride for injection when reconstituted with sterile distilled water provides tiletamine hydrochloride and zolazepam hydrochloride equivalent to 50 milligrams of tiletamine base and 50 milligrams of zolazepam base per milliliter of solution.

(b) Sponsor. See No. 000031 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. It is used for restraint or for anesthesia combined with muscle relaxation in cats and in dogs for restraint and minor procedures of short duration (30 minutes) requiring mild to moderate analgesia.

(2) Amount. Expressed as milligrams of the drug combination:

(i) In healthy dogs: An initial intramuscular dosage of 3 to 4.5 milligrams per pound of body weight for diagnostic purposes; 4.5 to 6 milligrams per pound of body weight for minor procedures of short duration such as
repair of lacerations and wounds, castrations, and other procedures requiring mild to moderate analgesia. Supplemental doses when required should be less than the initial dose and the total dose given should not exceed 12 milligrams per pound of body weight. The maximum total safe dose is 13.6 milligrams per pound of body weight.

(ii) In healthy cats: An initial intramuscular dosage of 4.4 to 5.4 milligrams per pound of body weight is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal, and related types of surgery; 4.8 to 5.7 milligrams per pound of body weight for minor procedures requiring mild to moderate analgesia for minor procedures of short duration. Initial dosages of 6.5 to 7.2 milligrams per pound of body weight are recommended for ovariohysterectomy and onychectomy. When supplemental doses are required, such individual supplemental doses should be given in increments that are less than the initial dose and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 milligrams per pound of body weight.

§ 522.2474 Tolazoline hydrochloride injection.

(a) Specifications. Each milliliter contains 100 milligrams of base activity of tolazoline hydrochloride.

(b) Sponsor. See No. 000986 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.735 of this chapter.

(d) Conditions of use—(1) Horses—(i) Amount. Administer slowly by intravenous injection 4 milliliters per 100 kilograms or 4 milliliters per 220 pounds.

(ii) Indications for use. For use in horses when it is desirable to reverse the effects of sedation and analgesia caused by xylazine.

(iii) Limitations. The safety of Tolazine™ has not been established in
pregnant mares, lactating mares, horses intended for breeding, foals, or horses with metabolically unstable conditions. The safety of Tolazine™ has not been evaluated for reversing xylazine used as a preanesthetic to a general anesthetic. This drug is for use in horses only and not for use in food-producing animals. Users with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid accidental exposure to this product.

Accidental spillage on the skin should be washed off immediately with soap and water. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

[61 FR 25785, May 23, 1996]

§ 522.2476 Trenbolone acetate.

(a) [Reserved]

(b) Sponsors. See sponsors in §510.600(c) of this chapter for uses as in paragraph (d) of this section.

(1) No. 021641 for use as in paragraphs (d)(1) and (d)(2) of this section.

(2) No. 057926 for use as in paragraphs (d)(1)(i)(A), (d)(1)(ii), (d)(1)(iii), (d)(2)(i)(A), (d)(2)(ii), and (d)(2)(iii) of this section.

(c) Related tolerances. See §§556.240 and 556.739 of this chapter.

(d) Conditions of use—(1) Steers fed in confinement for slaughter—(i) Amount. Use 126 days prior to slaughter; should be reimplanted once after 63 days.

(A) 140 mg trenbolone acetate (one implant consisting of 7 pellets, each pellet containing 20 mg trenbolone acetate) per implant dose.

(B) 140 mg of trenbolone acetate (one implant consisting of 11 pellets, each of 10 pellets containing 20 mg of trenbolone acetate, and 1 pellet containing 29 mg of tylosin tartrate) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals.

[66 FR 47961, Sept. 17, 2001]

§ 522.2477 Trenbolone acetate and estradiol.

(a) [Reserved]

(b) Sponsors. See sponsors in §510.600(c) of this chapter for uses as in paragraph (d) of this section.

(1) No. 021641 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(B), (d)(1)(ii), (d)(1)(iii), and (d)(3) of this section.


(c) Related tolerances. See §§556.240 and 556.739 of this chapter.

(d) Conditions of use—(1) Steers fed in confinement for slaughter—(i) Amount. (A) 120 milligrams (mg) trenbolone acetate and 24 mg estradiol (one implant consisting of 6 pellets, each pellet containing 20 mg trenbolone acetate and 4 mg estradiol) per implant dose.

(B) 120 mg trenbolone acetate and 24 mg estradiol (one implant consisting of 7 pellets, each of 6 pellets containing 20 mg trenbolone acetate and 4 mg estradiol, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(C) 200 mg trenbolone acetate and 20 mg estradiol (one implant consisting of 10 pellets, each pellet containing 20 mg trenbolone acetate and 2 mg estradiol) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals.
(D) 80 mg trenbolone acetate and 16 mg estradiol (one implant consisting of 4 pellets), or 120 mg trenbolone acetate and 24 mg estradiol (one implant consisting of 6 pellets, each pellet containing 20 mg trenbolone acetate and 4 mg estradiol) per implant dose.

(2) Heifers fed in confinement for slaughter—

(i) Amount.

(A) 140 mg trenbolone acetate and 14 mg estradiol (one implant consisting of 7 pellets, each pellet containing 20 mg trenbolone acetate and 2 mg estradiol) per implant dose for use as in paragraphs (d)(2)(ii)(A) and (d)(2)(ii)(B) of this section.

(B) 80 mg trenbolone acetate and 8 mg estradiol (one implant consisting of 4 pellets, each pellet containing 20 mg trenbolone acetate and 2 mg estradiol) per implant dose for use as in paragraph (d)(2)(ii)(B) of this section.

(C) 200 mg trenbolone acetate and 20 mg estradiol (one implant consisting of 10 pellets, each pellet containing 20 mg trenbolone acetate and 2 mg estradiol) per implant dose for use as in paragraph (d)(2)(ii)(A) of this section.

(ii) Indications for use. (A) For increased rate of weight gain and improved feed efficiency.

(B) For increased rate of weight gain.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals.

(3) Pasture cattle (slaughter, stocker, feeder steers, and heifers)—

(i) Amount.

(A) 40 mg trenbolone acetate and 8 mg estradiol (one implant consisting of 2 pellets, each pellet containing 20 mg trenbolone acetate and 4 mg estradiol) per implant dose.

(B) 40 mg trenbolone acetate and 8 mg estradiol (one implant consisting of 3 pellets, each of 2 pellets containing 20 mg trenbolone acetate and 4 mg estradiol, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(ii) Indications for use. For increased rate of weight gain.

(iii) Limitations. Implant subcutaneously in ear only. Not for use in animals intended for subsequent breeding or in dairy animals.


§ 522.2478 Trenbolone acetate and estradiol benzoate.

(a) Sponsor. See 000856 in § 510.600(c) of this chapter.

(b) Related tolerance. See §§ 556.240 and 556.739 of this chapter.

(c) [Reserved]

(d) Conditions of use—

(1) Steers—

Amount. 200 milligrams of trenbolone acetate and 28 milligrams of estradiol benzoate (one implant consisting of 8 pellets, each pellet containing 25 milligrams of trenbolone acetate and 3.5 milligrams of estradiol benzoate) per animal.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency in steers fed in confinement for slaughter.

(iii) Limitations. Implant subcutaneously in ear only.

(2) Heifers—

Amount. 200 milligrams of trenbolone acetate and 28 milligrams of estradiol benzoate (one implant consisting of 8 pellets, each pellet containing 25 milligrams of trenbolone acetate and 3.5 milligrams of estradiol benzoate) per animal.

(ii) Indications for use. For increased rate of weight gain in heifers fed in confinement for slaughter.

(iii) Limitations. Implant subcutaneously in ear only. Not for dairy or beef replacement heifers.


§ 522.2483 Sterile triamcinolone acetonide suspension.

(a) Specifications. Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide.

(b) Sponsor. See 000010 and 053501 in § 510.600(c) of this chapter.
§ 522.2582 Triflupromazine hydrochloride injection.

(a) Specifications. Triflupromazine hydrochloride injection contains 20 milligrams of triflupromazine hydrochloride in each milliliter of sterile aqueous solution.

(b) Sponsor. See No. 053501 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in dogs, cats, and horses to relieve anxiety and to help control psychomotor overactivity as well as to increase the tolerance of animals to pain and pruritus.

(2) The drug is administered to dogs either intravenously at a dosage level of 0.5 to 1 milligram per pound of body weight daily, or intramuscularly at a dosage level of 1 to 2 milligrams per pound of body weight daily. It is administered to horses intravenously at a dosage level of 2 to 4 milligrams per pound of body weight daily. It is administered to horses intravenously or intramuscularly at a dosage level of 10 to 15 milligrams per 100 pounds of body weight daily to a maximum dose of 100 milligrams.

(iii) Not for use in horses intended for food.

(iv) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(v) Do not use in the treatment of laminitis.

(vi) Intra-articular injection in equine leg injuries may produce osseous metaplasia.

(vii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.2582 Triflupromazine hydrochloride injection.

(c) Conditions of use—(1) Amount—(i) Dogs and cats—(a) Intramuscular or subcutaneous. Single injection of 0.05 to 0.1 milligram (mg.) per pound of body weight in inflammatory, arthritic, or allergic disorders. Single injection of 0.1 mg. per pound of body weight in dermatologic disorders. If symptoms recur, the dose may be repeated, or oral corticosteroid therapy may be instituted.

(b) Intralional. 1.2 to 1.8 mg., divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 mg. and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 mg.

(c) Intra-articular and intrasynovial. Single injection of 1 to 3 mg. dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased, not to exceed 3 mg.

(ii) Horses—(a) Intramuscular or subcutaneous. Single injection of 0.01 to 0.02 mg. per pound of body weight. Usual dose, 12 to 20 mg.

(b) Intra-arterial and intrasynovial. Single injection of 6 to 18 mg. dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased, not to exceed 18 mg.

(2) Indications for use. Treatment of inflammation and related disorders in dogs, cats, and horses; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs and cats.

(3) Limitations. (i) Do not use in viral infections. With bacterial infections, appropriate antibacterial therapy should be used.

(ii) Do not use in animals with tuberculosis, chronic nephritis, or cushingoid syndrome, except for emergency therapy.

1These conditions are NAS/NRC reviewed and are deemed effective. Applications for

2These conditions are NAS/NRC reviewed and are deemed effective. Applications for...
Food and Drug Administration, HHS

§ 522.2610 Trimethoprim and sulfadiazine sterile suspension.

(a)(1) Specifications. Each milliliter of sterile aqueous suspension contains 240 milligrams (40 milligrams of trimethoprim and 200 milligrams of sulfadiazine).

(2) Sponsor. See 000061 and 000856 in §510.600(c) of this chapter.

(b)(1) Specifications. Each milliliter of sterile aqueous suspension contains 480 milligrams (80 milligrams of trimethoprim and 400 milligrams of sulfadiazine (as the sodium salt)).

(2) Sponsor. See 000856 and 011716 in §510.600(c) of this chapter.

(3) Conditions of use—(i) Dosage. Two milliliters (100 milligrams of trimethoprim and 800 milligrams of sulfadiazine) per 100 pounds (45 kilograms) of body weight per day.

(ii) Indications. For horses where systemic anti-bacterial action against sensitive organisms is required during treatment of acute strangles, respiratory tract infections, acute urogenital infections, and wound infections and abscesses.

(iii) Limitations. For intravenous use; administer as single, daily dose for 5 to 7 days; daily dose may also be halved and given morning and evening; continue acute infection therapy 2 to 3 days after clinical signs have subsided; if no improvement of acute infections is seen in 3 to 5 days, reevaluate diagnosis; a complete blood count should be done periodically for prolonged use; not for use in horses intended for food; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2615 Tripelennamine hydrochloride injection.

(a) Specifications. Each milliliter of aqueous solution contains 20 milligrams of tripelennamine hydrochloride.

(b) Sponsor. See Nos. 053501 and 059130 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.741 of this chapter.

(d) Conditions of use—(1) Amount—(i) Dogs, cats, and horses. For intramuscular use only at a dose of 0.5 milligram per pound of body weight.

(ii) Cattle. Administer intravenously or intramuscularly at a dose of 0.5 milligram per pound of body weight.

(2) Indications for use. For use in treating conditions in which antihistaminic therapy may be expected to lead to alleviation of some signs of disease.

(3) Limitations. Do not use in horses intended for food purposes. Treated cattle must not be slaughtered for food.
§ 522.2640 Tylosin injectable dosage forms.

(a) Specifications. Each milliliter of sterile solution of 50 percent propylene glycol with 4 percent benzyl alcohol contains 50 to 200 milligrams of tylosin activity (as tylosin base). Tylosin conforms to the appropriate antibiotic standard. Tylosin contains at least 95 percent tylosin as a combination of tylosin A, tylosin B, tylosin C, and tylosin D of which at least 80 percent is tylosin A as determined by a method entitled “Determination of Factor Content in Tylosin by High Performance Liquid Chromatography,” which is incorporated by reference. Copies are available from the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, or available for inspection at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC 20001.

(b) Sponsors. (1) See No. 000986 in §510.600(c) of this chapter for use in paragraphs (e)(1), (2), and (3) of this section.

(ii) Swine—(i) Amount. 4 milligrams per pound of body weight twice daily.

(ii) Indications for use. Treatment of swine arthritis caused by Mycoplasma hyosynoviae; swine pneumonia caused by Pasteurella spp.; swine erysipelas caused by Erysipelothrix rhusiopathiae; swine dysentery associated with Treponema hyodysenteriae when followed by appropriate medication in the drinking water and/or feed.

(iii) Limitations. Administer intramuscularly for not more than 3 consecutive days. Continue treatment 24 hours after symptoms disappear. Do not inject more than 5 milliliters per site. Do not use in lactating dairy cattle. Use a 50-milligram-per-milliliter solution for calves weighing less than 200 pounds. Do not administer within 21 days of slaughter.

(2) Dogs and cats—(i) Amount. 3 to 5 milligrams per pound of body weight at 12- to 24-hour intervals.

(ii) Indications for use—(a) Dogs. Treatment of upper respiratory infections such as bronchitis, tracheobronchitis, tracheitis, laryngitis, tonsillitis, and pneumonia caused by Staphylococci spp., hemolytic Streptococci spp., and Pasteurella multocida.

§ 522.2640a Tylosin injection.

(a) Specifications. Each milliliter of sterile solution of 50 percent propylene glycol with 4 percent benzyl alcohol contains 50 to 200 milligrams of tylosin activity (as tylosin base). Tylosin conforms to the appropriate antibiotic standard. Tylosin contains at least 95 percent tylosin as a combination of tylosin A, tylosin B, tylosin C, and tylosin D of which at least 80 percent is tylosin A as determined by a method entitled “Determination of Factor Content in Tylosin by High Performance Liquid Chromatography,” which is incorporated by reference. Copies are available from the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, or available for inspection at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC 20001.

(b) Sponsors. (1) See No. 000986 in §510.600(c) of this chapter for use in paragraphs (e)(1), (2), and (3) of this section.

(ii) Swine—(i) Amount. 4 milligrams per pound of body weight twice daily.

(ii) Indications for use. Treatment of swine arthritis caused by Mycoplasma hyosynoviae; swine pneumonia caused by Pasteurella spp.; swine erysipelas caused by Erysipelothrix rhusiopathiae; swine dysentery associated with Treponema hyodysenteriae when followed by appropriate medication in the drinking water and/or feed.

(iii) Limitations. Administer intramuscularly for not more than 3 consecutive days. Continue treatment 24 hours after symptoms disappear. Do not inject more than 5 milliliters per site. Do not administer within 14 days of slaughter. If tylosin medicated drinking water is used as followup treatment for swine dysentery, the animal should thereafter receive feed containing 40 to 100 grams of tylosin per ton for 2 weeks to assure depletion of tissue residues.

(3) Dogs and cats—(i) Amount. 3 to 5 milligrams per pound of body weight at 12- to 24-hour intervals.

(ii) Indications for use—(a) Dogs. Treatment of upper respiratory infections such as bronchitis, tracheobronchitis, tracheitis, laryngitis, tonsillitis, and pneumonia caused by Staphylococci spp., hemolytic Streptococci spp., and Pasteurella multocida.
§ 522.2670 Yohimbine injectable.

(a) Specifications. Each milliliter of sterile aqueous solution contains either 2 or 5 milligrams of yohimbine (as hydrochloride).

(b) Sponsor. See 061690 in §510.600(c) of this chapter for use of 2 milligrams per milliliter solution in dogs.

(c) Conditions of use. (1) The drug is used in horses, wild deer, elk, dogs, and cats to produce sedation, as an analgesic, and a preanesthetic to local anesthesia. It may also be used in horses, dogs, and cats as a preanesthetic to general anesthesia.

(2) It is administered as follows:

(i) To horses from a solution containing 100 milligrams of yohimbine per milliliter, intravenously at 0.5 milligram per pound of body weight, or intramuscularly at 1.0 milligram per pound of body weight.

(ii) To dogs and cats from a solution containing 20 milligrams of yohimbine per milliliter; intravenously at 0.5 milligram per pound of body weight or intramuscularly or subcutaneously at 1.0 milligram per pound of body weight. In dogs over 50 pounds, a dosage of 0.5 mg. per pound administered intramuscularly may provide sufficient sedation and/or analgesia for most procedures.

(iii) To wild deer and elk from a solution containing 100 milligrams of yohimbine (as yohimbine hydrochloride) per milliliter, intramuscularly, by hand syringe or syringe dart, in the heavy muscles of the croup or shoulder as follows:

(a) Fallow deer, 2 to 4 milligrams per pound.

(b) Mule deer, sika deer, and white deer, 1 to 2 milligrams per pound.

(c) Elk, 0.25 to 0.5 milligram per pound.

(3) Not to be administered to food-producing animals.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2670 Yohimbine injectable.

(a) Specifications. Each milliliter of sterile aqueous solution contains either 2 or 5 milligrams of yohimbine (as hydrochloride).

(b) Sponsor. See 061690 in §510.600(c) of this chapter for use of 2 milligrams per milliliter solution in dogs.

(c) Conditions of use. (1) The drug is used in horses, wild deer, elk, dogs, and cats to produce sedation, as an analgesic, and a preanesthetic to local anesthesia. It may also be used in horses, dogs, and cats as a preanesthetic to general anesthesia.

(2) It is administered as follows:

(i) To horses from a solution containing 100 milligrams of yohimbine per milliliter, intravenously at 0.5 milligram per pound of body weight, or intramuscularly at 1.0 milligram per pound of body weight.

(ii) To dogs and cats from a solution containing 20 milligrams of yohimbine per milliliter; intravenously at 0.5 milligram per pound of body weight or intramuscularly or subcutaneously at 1.0 milligram per pound of body weight. In dogs over 50 pounds, a dosage of 0.5 mg. per pound administered intramuscularly may provide sufficient sedation and/or analgesia for most procedures.

(iii) To wild deer and elk from a solution containing 100 milligrams of yohimbine (as yohimbine hydrochloride) per milliliter, intramuscularly, by hand syringe or syringe dart, in the heavy muscles of the croup or shoulder as follows:

(a) Fallow deer, 2 to 4 milligrams per pound.

(b) Mule deer, sika deer, and white deer, 1 to 2 milligrams per pound.

(c) Elk, 0.25 to 0.5 milligram per pound.

(3) Not to be administered to food-producing animals.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2662 Xylazine hydrochloride injection.

(a) Specifications. Xylazine hydrochloride injection is a sterile aqueous solution containing xylazine hydrochloride equivalent to 100 milligrams of xylazine in each milliliter of solution when intended for use in horses, wild deer, and elk, and 20 milligrams of xylazine per milliliter of solution when intended for use in dogs and cats.

(b) Sponsor. See 000856 in §510.600(c) of this chapter for use in horses, wild deer, and elk. See 000859 and 061651 in §510.600(c) of this chapter for use in horses, wild deer, elk, dogs, and cats. See 061690 in §510.600(c) of this chapter for use in horses, wild deer, elk, dogs, and cats. See 000010 in §510.600(c) of this chapter for use in horses only.

(c) Conditions of use. (1) The drug is used in horses, wild deer, elk, dogs, and cats to produce sedation, as an analgesic, and a preanesthetic to local anesthesia. It may also be used in horses, dogs, and cats as a preanesthetic to general anesthesia.

(2) It is administered as follows:

(i) To horses from a solution containing 100 milligrams of xylazine per milliliter, intravenously at 0.5 milligram per pound of body weight, or intramuscularly at 1.0 milligram per pound of body weight.

(ii) To dogs and cats from a solution containing 20 milligrams of xylazine per milliliter; intravenously at 0.5 milligram per pound of body weight or intramuscularly or subcutaneously at 1.0 milligram per pound of body weight. In dogs over 50 pounds, a dosage of 0.5 mg. per pound administered intramuscularly may provide sufficient sedation and/or analgesia for most procedures.

(iii) To wild deer and elk from a solution containing 100 milligrams of xylazine (as xylazine hydrochloride) per milliliter, intramuscularly, by hand syringe or syringe dart, in the heavy muscles of the croup or shoulder as follows:

(a) Fallow deer, 2 to 4 milligrams per pound.

(b) Mule deer, sika deer, and white deer, 1 to 2 milligrams per pound.

(c) Elk, 0.25 to 0.5 milligram per pound.

(3) Not to be administered to food-producing animals.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2662 Xylazine hydrochloride injection.

(a) Specifications. Xylazine hydrochloride injection is a sterile aqueous solution containing xylazine hydrochloride equivalent to 100 milligrams of xylazine in each milliliter of solution when intended for use in horses, wild deer, and elk, and 20 milligrams of xylazine per milliliter of solution when intended for use in dogs and cats.

(b) Sponsor. See 000856 in §510.600(c) of this chapter for use in horses, wild deer, and elk. See 000859 and 061651 in §510.600(c) of this chapter for use in horses, wild deer, elk, dogs, and cats. See 061690 in §510.600(c) of this chapter for use in horses only.

(c) Conditions of use. (1) The drug is used in horses, wild deer, elk, dogs, and cats to produce sedation, as an analgesic, and a preanesthetic to local anesthesia. It may also be used in horses, dogs, and cats as a preanesthetic to general anesthesia.

(2) It is administered as follows:

(i) To horses from a solution containing 100 milligrams of xylazine per milliliter, intravenously at 0.5 milligram per pound of body weight, or intramuscularly at 1.0 milligram per pound of body weight.

(ii) To dogs and cats from a solution containing 20 milligrams of xylazine per milliliter; intravenously at 0.5 milligram per pound of body weight or intramuscularly or subcutaneously at 1.0 milligram per pound of body weight. In dogs over 50 pounds, a dosage of 0.5 mg. per pound administered intramuscularly may provide sufficient sedation and/or analgesia for most procedures.

(iii) To wild deer and elk from a solution containing 100 milligrams of xylazine (as xylazine hydrochloride) per milliliter, intramuscularly, by hand syringe or syringe dart, in the heavy muscles of the croup or shoulder as follows:

(a) Fallow deer, 2 to 4 milligrams per pound.

(b) Mule deer, sika deer, and white deer, 1 to 2 milligrams per pound.

(c) Elk, 0.25 to 0.5 milligram per pound.

(3) Not to be administered to food-producing animals.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2662 Xylazine hydrochloride injection.

(a) Specifications. Xylazine hydrochloride injection is a sterile aqueous solution containing xylazine hydrochloride equivalent to 100 milligrams of xylazine in each milliliter of solution when intended for use in horses, wild deer, and elk, and 20 milligrams of xylazine per milliliter of solution when intended for use in dogs and cats.

(b) Sponsor. See 000856 in §510.600(c) of this chapter for use in horses, wild deer, and elk. See 000859 and 061651 in §510.600(c) of this chapter for use in horses, wild deer, elk, dogs, and cats. See 061690 in §510.600(c) of this chapter for use in horses only.

(c) Conditions of use. (1) The drug is used in horses, wild deer, elk, dogs, and cats to produce sedation, as an analgesic, and a preanesthetic to local anesthesia. It may also be used in horses, dogs, and cats as a preanesthetic to general anesthesia.

(2) It is administered as follows:

(i) To horses from a solution containing 100 milligrams of xylazine per milliliter, intravenously at 0.5 milligram per pound of body weight, or intramuscularly at 1.0 milligram per pound of body weight.

(ii) To dogs and cats from a solution containing 20 milligrams of xylazine per milliliter; intravenously at 0.5 milligram per pound of body weight or intramuscularly or subcutaneously at 1.0 milligram per pound of body weight. In dogs over 50 pounds, a dosage of 0.5 mg. per pound administered intramuscularly may provide sufficient sedation and/or analgesia for most procedures.

(iii) To wild deer and elk from a solution containing 100 milligrams of xylazine (as xylazine hydrochloride) per milliliter, intramuscularly, by hand syringe or syringe dart, in the heavy muscles of the croup or shoulder as follows:

(a) Fallow deer, 2 to 4 milligrams per pound.

(b) Mule deer, sika deer, and white deer, 1 to 2 milligrams per pound.

(c) Elk, 0.25 to 0.5 milligram per pound.

(3) Not to be administered to food-producing animals.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.2680 Zeranol.

(a) Specifications. Each pellet contains 12, 18, or 20 milligrams (mg) zeranol.

(b) Sponsor. See 000061 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.760 of this chapter.

(d) Conditions of use—

(1) Beef cattle—

(i) Amount. 36 mg zeranol (one implant consisting of 3 pellets, each pellet containing 12 mg zeranol) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved food conversion in weaned beef calves, growing beef cattle, feedlot steers, and feedlot heifers.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in bulls intended for reproduction or in dairy animals. Do not use before 1 month of age or after weaning in heifers intended for reproduction.

(2) Feedlot lambs—

(i) Amount. 12 mg zeranol (one implant consisting of 1 pellet containing 12 mg zeranol) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed conversion.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in breeding animals. Do not implant animals within 40 days of slaughter.

(3) Steers fed in confinement for slaughter—

(i) Amount. 72 mg zeranol (one implant consisting of 6 pellets, each pellet containing 12 mg zeranol) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency.

(iii) Limitations. Implant subcutaneously in ear only.

(4) Pasture cattle (slaughter, stocker, feeder steers, and heifers)—

(i) Amount. 138 mg zeranol (one implant consisting of 7 pellets, each of 6 pellets containing 20 mg zeranol and a seventh pellet containing 18 mg zeranol) per implant dose.

(ii) Indications for use. For increased rate of weight gain.

(iii) Limitations. Implant subcutaneously in ear only.
§ 524.86 Amitraz liquid.

(a) Specifications. Amitraz liquid contains 19.9 percent amitraz in an organic solvent.

(b) Sponsor. See No. 000009 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. For dogs for the treatment of generalized demodicosis (Demodex canis).

(2) Amount. One 10.6 milliliter bottle per 2 gallons of warm water (250 parts per million) for each treatment, for a total of 3 to 6 treatments, 14 days apart.
§ 524.154 Bacitracin or bacitracin zinc-neomycin sulfate-polyoxymyxin B sulfate ophthalmic ointment.

(a) Sponsor. To firms identified in §510.600(c) of this chapter as follows:

(1) To 00009; each gram contains 500 units of bacitracin, 3.5 milligrams of neomycin, and 10,000 units of polymyxin B.

(2) To 00061 and 025463; each gram contains 400 units of bacitracin zinc, 3.5 milligrams of neomycin, and 10,000 units of polymyxin B sulfate.

(b) Conditions of use. Dogs and Cats.

(1) Amount. Apply a thin film over the cornea 3 or 4 times daily.

(2) Indications for use. For treating acute or chronic conjunctivitis caused by susceptible organisms.

(3) Limitations. All topical ophthalmic preparations containing corticosteroids with or without an antimicrobial agent are contraindicated in the initial treatment of corneal ulcers. They should not be used until the infection is under control and corneal regeneration is well underway. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.155 Bacitracin zinc-polymyxin B sulfate-neomycin sulfate-hydrocortisone or hydrocortisone acetate ophthalmic ointment.

(a) Sponsor. To firms identified in §510.600(c) of this chapter as follows:

(1) To 00009; each gram contains 500 units of bacitracin, 3.5 milligrams of neomycin, and 10,000 units of polymyxin B sulfate.

(2) To 00061 and 025463; each gram contains 400 units of bacitracin zinc, 3.5 milligrams of neomycin, and 10,000 units of polymyxin B sulfate.

(b) Conditions of use. Dogs and Cats.

(1) Amount. Apply a thin film over the cornea 3 or 4 times daily.

(2) Indications for use. Treatment of superficial bacterial infections of the eyelid and conjunctiva of dogs and cats when due to susceptible organisms.

(3) Limitations. Laboratory tests should be conducted including in vitro culturing and susceptibility tests on samples collected prior to treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.390 Chloramphenicol ophthalmic and topical dosage forms.

§ 524.390a Chloramphenicol ophthalmic ointment.

(a) Specifications. Each gram contains 10 milligrams chloramphenicol in a petrolatum base.

(b) Sponsor. See Nos. 000856 and 025463 in §510.600(c) of this chapter for use as in paragraph (c)(1)(i) of this section. See No. 017030 for use as in paragraph (c)(1)(ii) of this section.

(c) Conditions of use. Dogs and cats.

(1) Amount. Apply as follows:

(i) Every 3 hours around the clock for 48 hours after which night instillations may be omitted.

(ii) Four to six times daily to affected eye for the first 72 hours depending upon the severity of the condition. A small amount of ointment should be placed in the lower conjunctival sac.

(2) Indications for use. Treatment of bacterial conjunctivitis caused by pathogens susceptible to chloramphenicol.

(3) Limitations. Continue treatment for 48 hours (2 days) after eye appears normal. Therapy for cats should not exceed 7 days. Prolonged use in cats may produce blood dyscrasias. If improvement is not noted in a few days a change of therapy should be considered. When infection may be cause of disease, especially in purulent or catarrhal conjunctivitis, attempts should
be made to determine through susceptibility testing, which antibiotics will be effective prior to applying ophthalmic preparations. This chloramphenicol product must not be used in animals producing meat, eggs, or milk. The length of time that residues persist in milk or tissues has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.390b Chloramphenicol ophthalmic solution.
(a) Specifications. Each milliliter contains 5 milligrams of chloramphenicol.
(b) Sponsor. See No. 017030 in §510.600(c) of this chapter.
(c) Conditions of use. Dogs and Cats. (1) Amount. Apply one or two drops, 4 to 6 times a day for the first 72 hours, depending upon the severity of the condition. Intervals between applications may be increased after the first 2 days.
(2) Indications for use. Treatment of bacterial conjunctivitis caused by organisms susceptible to chloramphenicol. Therapy should be continued for 48 hours after the eye appears normal.
(3) Limitations. Therapy for cats should not exceed 7 days, prolonged use in cats may produce blood dyscrasias. As with other antibiotics, prolonged use may result in overgrowth of non-susceptible organisms. If superinfection occurs or if clinical improvement is not noted within a reasonable period, discontinue use and institute appropriate therapy. All topical ophthalmic preparations containing corticosteroids, with or without an antimicrobial agent, are contraindicated in the initial treatment of corneal ulcers. They should not be used until the infection is under control and corneal regeneration is well underway. Chloramphenicol products must not be used in meat-, egg-, or milk-producing animals. The length of time that residues persist in milk or tissues has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.402 Chlorhexidine ointment.
(a) Specifications. The product contains 1-percent chlorhexidine acetate in an ointment base.
(b) Sponsor. See Nos. 000856 and 058829 in §510.600(c) of this chapter.
(c) Conditions of use. Use as a topical antiseptic ointment for surface wounds on dogs, cats, and horses.

§ 524.450 Clotrimazole cream.
(a) Specifications. Each gram contains 10 milligrams of clotrimazole.
(b) Sponsor. See 000859 in §510.600(c).
(c) Conditions of use. Apply ¼-inch ribbon of cream per square inch of lesion once daily for 2 to 4 weeks.

§ 524.390d Chloramphenicol-prednisolone ophthalmic ointment.
(a) Specifications. Each gram contains 10 milligrams of chloramphenicol and 2.5 milligrams of prednisolone acetate.
(b) Sponsor. See No. 017030 in §510.600(c) of this chapter.
(c) Amount. Apply 4 to 6 times daily to the affected eye for the first 72 hours depending upon the severity of the condition. Continue treatment for 48 hours after the eye appears normal.
(2) Indications for use. Treatment of bacterial conjunctivitis and ocular inflammation caused by organisms susceptible to chloramphenicol.
(3) Limitations. Therapy for cats should not exceed 7 days, prolonged use in cats may produce blood dyscrasias. As with other antibiotics, prolonged use may result in overgrowth of non-susceptible organisms. If superinfection occurs or if clinical improvement is not noted within a reasonable period, discontinue use and institute appropriate therapy. All topical ophthalmic preparations containing corticosteroids, with or without an antimicrobial agent, are contraindicated in the initial treatment of corneal ulcers. They should not be used until the infection is under control and corneal regeneration is well underway. Chloramphenicol products must not be used in meat-, egg-, or milk-producing animals. The length of time that residues persist in milk or tissues has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 524.463 Copper naphthenate solution.

(a) Specifications. The drug contains 37.5 percent copper naphthenate in a suitable solvent.

(b) Sponsor. See Nos. 000856 and 017135 in §510.600(c) of this chapter.

(c) Conditions of use—Horses and ponies—(1) Amount. Apply daily to affected hooves until fully healed.

(2) Indications for use. As an aid in treating horses and ponies for thrush caused by organisms susceptible to copper naphthenate.

(3) Limitations. Use on horses and ponies only. Remove debris and necrotic material before applying. Avoid contact around eyes. Do not use on animals that are raised for food production. Do not contaminate feed. Do not allow runoff of excess drug into hair because contact with the drug may cause some hair loss.

[47 FR 4250, Jan. 29, 1982]

§ 524.520 Cuprimyxin cream.

(a) Specifications. The drug contains 0.5 percent cuprimyxin (6-methoxy-1-phenazinol 5, 10-dioxide, cupric complex) in an aqueous cream base.

(b) Sponsor. See No. 063238 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Cuprimyxin is a broad spectrum antibacterial and antifungal cream for the topical treatment of superficial infections in horses, dogs, and cats caused by bacteria, dermatophytes (Trichophyton spp., Microsporum spp.) and yeast (Candida albicans) affecting skin, hair, and external mucosae.

(2) The cream is applied twice daily to affected areas by rubbing into lesions. Treatment should be continued for a few days after clinical recovery to avoid possible relapses.

(3) After application to cutaneous areas, a change in color from dark green to pink is due to the liberation of free myxin from its copper complex.

(4) If no response is seen within seven days, diagnosis and therapy should be reevaluated. If any adverse local reaction is observed after topical application, discontinue treatment.

(5) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.575 Cyclosporine ophthalmic ointment.

(a) Specifications. Each gram of ointment contains 2 milligrams of cyclosporine.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Apply a 1/4-inch strip of ointment to the affected eye(s) every 12 hours.

(2) Indications for use. For management of chronic keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK) in dogs.

(3) Limitations. Place ointment directly on cornea or into the conjunctival sac. Safety of use in puppies, pregnant or breeding animals has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.660 Dimethyl sulfoxide ophthalmic and topical dosage forms.

§ 524.660a Dimethyl sulfoxide solution.

(a) Specifications. Dimethyl sulfoxide contains 90 percent of dimethyl sulfoxide and 10 percent of water.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used or intended for use as a topical application to reduce acute swelling due to trauma:

(i) In horses administered 2 or 3 times daily in an amount not to exceed 100 milliliters per day. Total duration of therapy should not exceed 30 days.

(ii) In dogs administered 3 or 4 times daily in an amount not to exceed 20 milliliters per day. Total duration of therapy should not exceed 14 days.
(2) Not for use in horses and dogs intended for breeding purposes nor in horses slaughtered for food. Other topical medications should only be used when the dimethyl sulfoxide treated area is thoroughly dry. Do not administer by any other route.

(3) For use by or on the order of a licensed veterinarian.

§ 524.660b Dimethyl sulfoxide gel.

(a) Specifications. Dimethyl sulfoxide gel, veterinary contains 90 percent dimethyl sulfoxide in an aqueous gel.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use—

(1) Indications for use. For use on horses and dogs as a topical application to reduce acute swelling due to trauma.

(ii) Dogs. Administer 3 or 4 times daily in an amount not to exceed 20 grams per day. Total duration of therapy should not exceed 14 days.

(3) Limitations. Do not use in horses and dogs intended for breeding purposes nor in horses slaughtered for food. Restricted to topical use on horses and dogs only. Due to rapid penetrating ability of dimethyl sulfoxide, rubber gloves should be worn when applying the drug. No other medications should be present on the skin prior to application of the drug. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.802 Enrofloxacin, silver sulfadiazine emulsion.

(a) Specifications. Each milliliter contains 5 milligrams (mg) enrofloxacin and 10 mg silver sulfadiazine.

(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.

(c) Conditions of use—

(1) Amount. 5 to 10 drops for dogs weighing 35 pounds (lb) or less and 10 to 15 drops for dogs weighing more than 35 lb; applied twice daily for up to 14 days.

(2) Indications for use. For the treatment of otitis externa in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

§ 524.814 Eprinomectin.

(a) Specifications. Each milliliter contains 5 milligrams of eprinomectin.

(b) Sponsor. See No. 000006 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.227 of this chapter.

(d) Conditions of use—Cattle—

(1) Amount. One milliliter (5 milligrams) per 10 kilograms (500 micrograms per kilogram).

(2) Indications for use. The drug is used in beef and dairy cattle for treatment and control of gastrointestinal roundworms, lungworms, eye worms, grubs, biting and sucking lice, horn flies, and mange mites. To control infections and to protect from reinfestation with Cooperia oncophora and Dictyocaulus viviparus for 21 days, Ostertagia ostertagi, C. punctata, and Oesophagostomum radiatum for 28 days, and Haemonchus placei for 35 days after treatment.

(3) Limitations. Administer as a single dose. Do not slaughter cattle within 45 days of latest treatment. Not for use in female dairy cattle 20 months of age or older. Do not use in calves to be processed for veal. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 524.660b Dimethyl sulfoxide gel.

(a) Specifications. Dimethyl sulfoxide gel, veterinary contains 90 percent dimethyl sulfoxide in an aqueous gel.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use—

(1) Indications for use. For use on horses and dogs as a topical application to reduce acute swelling due to trauma.

(ii) Dogs. Administer 3 or 4 times daily in an amount not to exceed 20 grams per day. Total duration of therapy should not exceed 14 days.

(3) Limitations. Do not use in horses and dogs intended for breeding purposes nor in horses slaughtered for food. Restricted to topical use on horses and dogs only. Due to rapid penetrating ability of dimethyl sulfoxide, rubber gloves should be worn when applying the drug. No other medications should be present on the skin prior to application of the drug. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 61 FR 5507, Feb. 13, 1996]
roundworms (Haemonchus placei (adult and L4), Ostertagia ostertagi (adult and L4, including inhibited L4), Trichostrongyulus axei (adult and L4), T. colubriformis (adult and L4), T. longispiralis (adult), Cooperia oncophora (adult and L4), C. punctata (adult and L4), C. surnabada (adult and L4), Nematodirus helvetianus (adult and L4), Bunostomum phlebotomum (adult and L4), Oesophagostomum radiatum (adult and L4), Strongyloides papillosus (adults), Trichuris spp. (adults)); lungworms (Dictyocaulus viviparus, adult and L4); cattle grubs (all parasitic stages, Hypoderma lineatum, H. bovis); lice (Damalinia bovis, Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); mange mites (Choriopotes bovis, Sarcoptes scabiei); and horn flies (Haematobia irritans). Controls and protects from re-infection of D. viviparus for 21 days after treatment and H. irritans for 7 days after treatment.

(3) Limitations. Apply topically along backbone from withers to tailhead. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 524.900 Famphur.

(a) Chemical name. O,O-Dimethyl O-[[p-(dimethylsulfamoyl)phenyl] phosphorothioate.

(b) Specifications. The drug is in liquid form containing 13.2 percent famphur.

(c) Sponsor. See Nos. 000061 and 006594 in §510.600(c) of this chapter.

(d) Special considerations. Do not use on animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(e) Related tolerances. See §556.273 of this chapter.

(f) Conditions of use. (1) The drug is used as a pour-on formulation for the control of grubs and lice in beef and nonlactating cattle.

(ii) It is used at the rate of one-half fluid ounce per 100 pounds of body weight placed on the backline of the animal. Only one application per season should be made for grub control and this will also provide initial control of lice. A second application for lice control may be made if animals become reinfested, but no sooner than 35 days after the first treatment. Proper timing of treatment is important for grub control; cattle should be treated as soon as possible after heel fly activity ceases. Cattle should not be slaughtered within 35 days following a single treatment. If a second application is made for lice control, cattle should not be slaughtered within 45 days of the second treatment. The drug must not be used on lactating dairy cows or dry dairy cows within 21 days of freshening, calves less than 3 months old, animals stressed from castration, over-excitement or dehorning, sick or convalescent animals. Animals may become dehydrated and under stress following shipment. Do not treat until they are in good condition. Brahman and Brahman crossbreeds are less tolerant of cholinesterase-inhibiting insecticides than other breeds. Do not treat Brahman bulls.

(3) Do not slaughter within 35 days after treatment. Swine should be eliminated from area where run-off occurs.


§ 524.920 Fenthion.

(a) Chemical name. O,O-Dimethyl O-[4-(methylthio)-m-tolyl]-phosphorothioate.

(b) Specifications. (1) The drug is in a liquid form containing 3 percent of fenthion.

(2) Sponsor. See No. 000859 in §510.600(c) of this chapter.

(3) Special considerations. Do not use on animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.


(5) Conditions of use. (i) The drug is used as a pour-on formulation for the control of grubs and lice in beef and nonlactating cattle.

(ii) It is used at the rate of one-half fluid ounce per 100 pounds of body weight placed on the backline of the animal. Only one application per season should be made for grub control and this will also provide initial control of lice. A second application for lice control may be made if animals become reinfested, but no sooner than 35 days after the first treatment. Proper timing of treatment is important for grub control; cattle should be treated as soon as possible after heel fly activity ceases. Cattle should not be slaughtered within 35 days following a single treatment. If a second application is made for lice control, cattle should not be slaughtered within 45 days of the second treatment. The drug must not
be used within 28 days of freshening of dairy cattle. If freshening should occur within 28 days after treatment, do not use milk as human food for the balance of the 28-day interval. Do not treat lactating dairy cattle; calves less than 3 months old; or sick, convalescent, or stressed livestock. Do not treat cattle for 10 days before or after shipping, weaning, or dehorning or after exposure to contagious infectious diseases.

(c) **Specifications.** (1) The drug is in a liquid form containing 20 percent fenthion.

(2) **Sponsor.** See No. 000859 in § 510.600(c) of this chapter.

(3) **Special considerations.** Do not use on animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(4) **Related tolerances.** See 40 CFR 180.214.

(5) **Conditions of use.** (i) The drug is used for control of cattle grubs and as an aid in controlling lice on beef cattle and on dairy cattle not of breeding age.

(ii) It is applied as a single application placed on the backline of animals as follows:

<table>
<thead>
<tr>
<th>Weight of animal</th>
<th>Dosage (milliliters)</th>
</tr>
</thead>
<tbody>
<tr>
<td>150 to 300 lb</td>
<td>4</td>
</tr>
<tr>
<td>301 to 600 lb</td>
<td>8</td>
</tr>
<tr>
<td>601 to 900 lb</td>
<td>12</td>
</tr>
<tr>
<td>901 to 1,200 lb</td>
<td>16</td>
</tr>
<tr>
<td>Over 1,200 lb</td>
<td>20</td>
</tr>
</tbody>
</table>

For most effective results, cattle should be treated as soon as possible after heel-fly activity ceases. Host-parasite reactions such as bloat, salivation, staggering and paralysis may sometimes occur when cattle are treated while the common cattle grub (*Hypoderma lineatum*) is in the gullet, or while the northern cattle grub (*H. bovis*) is in the area of the spinal cord. Cattle should be treated before these stages of grub development. Consult your veterinarian, extension livestock specialist, or extension entomologist regarding the timing of treatment. If it is impossible to determine the area from which the cattle came and/or exact stage of the grubs, it is recommended that the cattle receive only a maintenance ration of low-energy feed during the treatment period. This lessens the likelihood of severe bloat which may occur in cattle on full feed when the common grub is killed while in the gullet. A second application is required for animals heavily infested with lice or for those which become reinfested. A second application should be made no sooner than 35 days after the first treatment.

(iii) Do not treat dairy cattle of breeding age; calves less than 3 months old; sick, convalescent, or severely stressed livestock.

(iv) Do not treat cattle for 10 days before or after shipping, weaning, dehorning, or after exposure to contagious or infectious diseases.

(v) Do not slaughter within 45 days of treatment.

(d) **Specifications.** (1) The drug is a solution containing either 5.6 or 13.8 percent fenthion. Each concentration is available in 2 volumes which are contained in single-dose applicators.

(2) **Sponsor.** See No. 000859 in § 510.600(c) of this chapter.

(3) **Special considerations.** Fenthion is a cholinesterase inhibitor. Do not use this product on dogs simultaneously with or within 14 days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals. Do not use on puppies under 10 weeks of age.

(iv) **Related tolerances.** See 40 CFR 180.214.

(5) **Conditions of use.** (i) The drug is used on dogs only.

(ii) **Indications for use.** For flea control on dogs only.

(iii) **Limitations.** Apply the contents of the proper size, single-dose tube directly to one spot on the dog’s skin. Frequency of repeat treatments depends upon rate of flea reinfestations. Do not use more often than once every 2 weeks. Treatment at 2-week intervals is not to exceed 6 months. Do not use on puppies under 10 weeks of age. Do not use on sick, stressed, or convalescing dogs. Safe use in breeding males has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.960 Flumethasone, neomycin sulfate, and polymyxin B sulfate ophthalmic solutions.

(a) Specifications. Each milliliter of ophthalmic preparation contains 0.10 milligram flumethasone, 5.0 milligrams neomycin sulfate (3.5 milligrams neomycin base), and 10,000 units of polymyxin B sulfate, with or without hydroxypropyl methylcellulose.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Conditions of use—

(1) Amount—

(i) Preparation containing hydroxypropyl methylcellulose. Dogs: 1 to 2 drops per eye, every 6 hours.

(ii) Preparation without hydroxypropyl methylcellulose. Dogs and cats: 2 to 3 drops per eye, every 4 hours.

(2) Indications for use. Treatment of the inflammation, edema, and secondary bacterial infections associated with topical ophthalmological conditions of the eye such as corneal injuries, incipient pannus, superficial keratitis, conjunctivitis, acute nongranulomatous anterior uveitis, keratoconjunctivitis, and blepharitis.

(3) Limitations. (i) In treating ophthalmological conditions associated with bacterial infections, the drug is contraindicated in those cases in which microorganisms are not susceptible to the antibiotics incorporated in the drug.

(ii) The drug is contraindicated in infectious tuberculous lesions of the eye, early acute stages of viral diseases of the cornea and conjunctiva, herpes simplex lesions of the eye, and fungal infections of the conjunctiva and eyelids.

(iii) The usual precautions and contraindications for corticosteroids and adrenocorticoids are applicable with this drug. Corticosteroids may inhibit essential inflammatory responses intrinsic to the fundamental healing mechanism. Adrenocorticoid compounds have been reported to cause an increase in intraocular pressure. Intraocular pressure should be checked frequently. Ocular reexaminations should be made at frequent intervals during long-term therapy.

(iv) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.981 Fluocinolone acetonide ophthalmic and topical dosage forms.

§ 524.981a Fluocinolone acetonide cream.

(a) Specifications. The drug contains 0.025 percent fluocinolone acetonide.

(b) Sponsor. See No. 099207 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for the relief of pruritus and inflammation associated with certain superficial acute and chronic dermatoses in dogs. It is used in the treatment of allergic and acute moist dermatitis and for the relief of superficial inflammation caused by chemical and physical abrasions and burns.

(2) A small amount is applied to the affected area two or three times daily.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 40932, July 31, 1997]

§ 524.981b Fluocinolone acetonide solution.

(a) Specifications. The drug contains 0.01 percent fluocinolone acetonide in propylene glycol with citric acid.

(b) Sponsor. See No. 099207 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for the relief of pruritus and inflammation associated with otitis externa and certain superficial acute and chronic dermatoses in the dog. It is also indicated for the relief of pruritus and inflammation associated with acute otitis externa and certain superficial acute and chronic dermatoses in the cat.

(2) A small amount of solution is applied to the affected area 2 or 3 times daily.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 40932, July 31, 1997]
§ 524.961c Fluocinolone acetonide, neomycin sulfate cream.

(a) Specifications. The drug contains 0.025 percent fluocinolone acetonide and 0.5 percent neomycin sulfate (0.35 percent neomycin base).

(b) Sponsor. See No. 099207 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in the relief of pruritus and inflammation associated with superficial acute and chronic dermatoses in dogs. It is used in the treatment of such conditions as allergic and acute moist dermatoses and nonspecific dermatoses in dogs. It is used in the treatment of wound infections in dogs and cats.

(2) A small amount is applied to the infected area two or three times daily.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 40932, July 31, 1997]

§ 524.981d Fluocinolone acetonide, dimethyl sulfoxide solution.

(a) Specifications. Each milliliter of solution contains 0.01 percent fluocinolone acetonide and 20 percent dimethyl sulfoxide with propylene glycol and citric acid.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in dogs for the relief of impaction commonly present in apparently normal anal sacs, for the reversal of inflammatory changes associated with abnormal anal sacs, and to counteract the offensive odor of anal sac secretions.

(2) It is administered by instillation of 1 to 2 milliliters into each anal sac following expression of anal sac contents. It may be necessary to repeat treatment at 60-day intervals to maintain an odor-free state. The total dosage used should not exceed 2 milliliters per anal sac per treatment.

(3) For use only by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 61 FR 5507, July 31, 1997]

§ 524.1005 Furazolidone aerosol powder.

(a) Specifications. The product contains either 4 or 10 percent furazolidone in inert dispersing agent and propel-lant.

(b) Sponsors. (1) See No. 053501 in § 510.600(c) of this chapter for use as in paragraphs (c)(1), (c)(2)(i), (c)(2)(ii), and (c)(3) of this section.

(2) See No. 017135 for use of the 4 percent product as in paragraph (c)(2)(iv) of this section.

(c) Conditions of use—(1) Amount. Hold container about 6 to 12 inches from the eye or affected area and apply only enough powder to impart a light yellow color.
(2) **Indications of use**—(i) Dogs. For treatment or prevention of bacterial infection of superficial wounds, abrasions, lacerations, and pyogenic dermatitis.

(ii) **Horses.** For treatment or prevention of bacterial infection of superficial wounds, abrasions, lacerations, and following firing (heat or electrocautery).

(iii) [Reserved]

(iv) **Horses and ponies.** For treatment or prevention of bacterial infection of superficial wounds, abrasions, and lacerations caused by *Staphylococcus aureus*, *Streptococcus* spp. and *Proteus* spp. sensitive to furazolidone.

(3) **Limitations.** For topical application in horses, ponies, and dogs: Clean affected area thoroughly, apply drug once or twice daily, and repeat treatment as required. Use only as recommended by a veterinarian in treatment of puncture wounds, wounds requiring surgical debridement or suturing, those of a chronic nature involving proud flesh, generalized and chronic infections of the skin, and those skin conditions associated with intense itching. If redness, irritation, or swelling persists or increases, discontinue use and consult a veterinarian. Not for use in horses intended for food.


§ 524.1044 **Gentamicin sulfate ophthalmic and topical dosage forms.**

§ 524.1044a **Gentamicin ophthalmic solution.**

(a) **Specifications.** Each milliliter of sterile aqueous solution contains gentamicin sulfate equivalent to 3 milligrams of gentamicin.

(b) **Sponsor.** See No. 000061 in §510.600(c) of this chapter.

(c) **Conditions of use.** (1) The drug is used in dogs and cats for the topical treatment of infections of the conjunctiva caused by susceptible bacteria.

(ii) Administer 1 or 2 drops into the conjunctival sac 2 to 4 times a day.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.1044b **Gentamicin sulfate, betamethasone valerate otic solution.**

(a) **Specifications.** Each cubic centimeter of solution contains gentamicin sulfate equivalent to 3 milligrams of gentamicin base and betamethasone valerate equivalent to 1 milligram of betamethasone alcohol.

(b) **Sponsor.** See Nos. 000061 and 051259 in §510.600(c) of this chapter.

(c) **Conditions of use.** (1) The drug is used or indicated for use in dogs in the treatment of acute and chronic otitis externa caused by bacteria sensitive to gentamicin; the drug is also used or indicated for use in dogs and cats in the treatment of superficial infected lesions caused by bacteria sensitive to gentamicin.

(2)(i) For the treatment of acute and chronic canine otitis externa caused by bacteria sensitive to gentamicin, the drug is administered by instillation of 3 to 8 drops of solution into the ear canal twice daily for 7 to 14 days. Duration of treatment will depend upon the severity of the condition and the response obtained. The duration of treatment and/or frequency of the dosage may be reduced but care should be taken not to discontinue therapy prematurely. The external ear and ear canal should be properly cleaned and dried before treatment. Remove foreign material, debris, crusted exudates, etc., with suitable nonirritating solutions. Excessive hair should be clipped from the treatment area of the external ear.

(ii) For the treatment of canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin, the lesion and adjacent area should be properly cleaned before treatment. Excessive hair should be removed. A sufficient amount of the drug should be applied to cover the treatment area. The drug should be administered twice daily for 7 to 14 days.

(3) If hypersensitivity to any of the components occurs treatment with this
§ 524.1044c Gentamicin ophthalmic ointment.

(a) Specifications. Each gram of sterile ointment contains gentamicin sulfate equivalent to 3 milligrams of gentamicin.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used on dogs and cats for topical treatment of conjunctivitis caused by susceptible bacteria.

(2) Apply approximately a 1⁄2-inch strip to the affected eye 2 to 4 times a day.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1044d Gentamicin sulfate, betamethasone valerate ointment.

(a) Specifications. Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams of gentamicin base and betamethasone valerate equivalent to 1 milligram of betamethasone.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used or indicated for use in dogs in the treatment of acute and chronic canine otitis externa and canine infected superficial lesions caused by bacteria sensitive to gentamicin.

(2)(i) For the treatment of acute and chronic canine otitis externa the drug is administered by instillation of 3 to 8 drops into the ear canal twice daily for 7 days. The external ear and ear canal should be properly cleaned and dried before treatment. Remove foreign material, debris, crusted exudates, etc., with suitable nonirritating solutions. Excessive hair should be clipped from the treatment area of the external ear.

(ii) For the treatment of canine infected superficial lesions, the lesion and adjacent area should be properly cleaned before treatment. Excessive hair should be removed. A sufficient amount of the drug should be applied to cover the treatment area. The drug should be administered twice daily for 7 to 14 days.

(3) If hypersensitivity to any of the components occurs, treatment should be discontinued and appropriate therapy instituted. Concomitant use of drugs known to induce ototoxicity should be avoided. Observe patients for signs of adrenocorticoid overdosage. The antibiotic susceptibility of the pathogenic organism should be determined prior to use of this preparation. Administration of recommended doses beyond 7 days may result in delayed wound healing. Animals treated longer than 7 days should be monitored closely.

(4) For use by or on the order of a licensed veterinarian.

§ 524.1044e Gentamicin sulfate spray.

(a) Specification. Each milliliter of sterile aqueous solution contains gentamicin sulfate equivalent to 1.07 milligrams of gentamicin.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for the treatment of pink eye in cattle (infectious bovine keratoconjunctivitis) caused by Moraxella bovis.

(2) One actuation of the sprayer delivers 0.7 milliliter containing 0.75 milligram gentamicin. The sprayer should be held upright 3 to 6 inches from the affected eye, with the opening directed towards the eye, and pumped once. It is advisable to treat once a day for up to 3 days.

(3) Conditions other than bacterial infections of the bovine eye and infectious keratoconjunctivitis caused by...
Moraxella bovis may produce similar signs. If conditions persist or increases, discontinue use and consult veterinarian.


§ 524.1044f Gentamicin sulfate, betamethasone valerate topical spray.

(a) Specifications. Each milliliter of spray contains gentamicin sulfate equivalent to 0.57 milligram of gentamicin base and betamethasone valerate equivalent to 0.284 milligram of betamethasone.

(b) Sponsor. See Nos. 000061 and 051259 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in dogs in the treatment of infected superficial lesions caused by bacteria sensitive to gentamicin.

(2) For the treatment of infected superficial lesions, the lesion and adjacent area should be properly cleaned before treatment. Excessive hair should be removed. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. One actuation of the sprayer delivers 0.7 milliliter of the spray. The drug should be administered with two spray actuations 2 to 4 times daily for 7 days.

(3) If hypersensitivity to any of the components occurs, treatment should be discontinued and appropriate therapy instituted. The antibiotic susceptibility of the pathogenic organism should be determined prior to use of this preparation. Administration of recommended doses beyond 7 days may result in delayed wound healing. Animals treated longer than 7 days should be monitored closely.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.1044g Gentamicin sulfate, betamethasone valerate, clotrimazole ointment.

(a) Specifications. Each gram (g) of ointment contains gentamicin sulfate equivalent to 3 milligrams (mg) gentamicin base, betamethasone valerate equivalent to 1 mg betamethasone, and 10 mg clotrimazole.

(b) Sponsor. See 000061 and 051259 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used for the treatment of canine otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis) and/or bacteria susceptible to gentamicin.

(2) For 7.5 or 15 g tube, instill 4 drops of ointment twice daily into the ear canal of dogs weighing less than 30 pounds, instill 8 drops twice daily for dogs weighing 30 pounds or more. For 215 g bottle, instill 2 drops of ointment twice daily into the ear canal of dogs weighing less than 30 pounds, instill 4 drops twice daily for dogs weighing 30 pounds or more. Therapy should continue for 7 consecutive days.

(3) The external ear should be cleaned and dried before treatment. Remove foreign material, debris, crusted exudates, etc., with suitable solutions. Excessive hair should be clipped from the treatment area. If hypersensitivity occurs, treatment should be discontinued and alternate therapy instituted.

(4) Corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(5) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[56 FR 38973, July 21, 1993, as amended at 63 FR 31932, June 11, 1998]

§ 524.1044h Gentamicin sulfate, mometasone furoate, clotrimazole otic suspension.

(a) Specifications. Each gram contains gentamicin sulfate, United States Pharmacopeia (USP) equivalent to 3-
Food and Drug Administration, HHS

§ 524.1200a Ivermectin ophthalmic and topical dosage forms.

(a) Specifications. The drug, which is in a suitable and harmless ophthalmic base, contains 3.5 milligrams of ivermectin activity (as the sulfone) per gram of ointment.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. It is indicated for use in dogs in various eye infections due to ivermectin sensitive bacteria. It is used treating conditions such as conjunctivitis, blepharitis, dacryocystitis, keratitis, and corneal ulcerations and as a prophylactic in traumatic conditions, removal of foreign bodies, and intraocular surgery. Apply a thin film to the affected eye three or four times daily or more frequently if deemed advisable. Treatment should be continued
§ 524.1200b Kanamycin ophthalmic aqueous solution.

(a) Specifications. The drug, which is in an aqueous solution including suitable and harmless preservatives and buffer substances, contains 10 milligrams of kanamycin activity (as the sulfate) per milliliter of solution.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. It is indicated for use in dogs in various eye infections due to kanamycin sensitive bacteria. It is used in treating conditions such as conjunctivitis, blepharitis, dacryocystitis, keratitis, and corneal ulcerations and as a prophylactic in traumatic conditions, removal of foreign bodies, and intraocular surgery. Instill a few drops into the affected eye every 3 hours or more frequently if deemed advisable. Administer as frequently as possible for the first 48 hours, after which the frequency of applications may be decreased. Treatment should be continued for at least 48 hours after the eye appears normal. For use only by or on the order of a licensed veterinarian.

§ 524.1204 Kanamycin sulfate, calcium amphomycin, and hydrocortisone acetate.

(a) Specifications. (1) Calcium amphomycin is the calcium salt of amphomycin. It conforms to the following specifications:

(i) Its potency is not less than 863 micrograms of amphomycin per milligram;

(ii) Its moisture content is not more than 10 percent; and

(iii) Its pH in a 2-percent aqueous suspension is 6.0 to 7.5.

(2) The drug is in a water-miscible ointment or cream base and each gram of ointment or cream contains: 5.0 milligrams of kanamycin activity as the sulfate, 5.0 milligrams of amphomycin activity as the calcium salt, and 10.0 milligrams of hydrocortisone acetate.

(b) Sponsor. See 000061 and 010042 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.350 of this chapter.

(d) Conditions of use. Cattle—(1) Amount. 2.5 milliliters per 110 pounds (10 milligrams of levamisole per kilogram) of body weight as a single dose topically to the back of the animal.

(2) Indications for use. Anthelmintic effective against stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum, Chabertia), and lungworms (Dictyocaulus).
Food and Drug Administration, HHS § 524.1451

(3) Limitations. Conditions of constant helminth exposure may require re-treatment within 2 to 4 weeks after the first treatment. Cattle must not be slaughtered within 9 days following last treatment. Do not administer to dairy animals of breeding age. Do not treat animals before dipping or prior to exposure to heavy rain. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism, and before using in severely debilitated animals.


§ 524.1376 2-Mercaptobenzothiazole solution.

(a) Specifications. The drug contains 1.3 percent 2-mercaptobenzothiazole in a suitable solvent.
(b) Sponsor. See 011509 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. Apply twice daily to affected area.
(2) Indications for use. For dogs as an aid in the treatment of hot spots (moist dermatitis) and as first aid for scrapes and abrasions.
(3) Limitations. Clip hair from affected area before applying. If no improvement is seen within 1 week, consult a veterinarian.


§ 524.1443 Miconazole nitrate cream; miconazole nitrate lotion; miconazole nitrate spray.

(a) Specifications. (1) The cream contains 23 milligrams of miconazole nitrate (equivalent to 20 milligrams of miconazole base) per gram.
(2) The lotion contains 1.15 percent of miconazole nitrate (equivalent to 1 percent miconazole base).
(3) The spray product consists of a dispensing container, sprayer pump assembly, and lotion which contains 1.15 percent of miconazole nitrate (equivalent to 1 percent miconazole base).
(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter for use of cream, lotion, and spray; see No. 051259 in § 510.600(c) of this chapter for use of lotion and spray.
(c) Conditions of use—(1) Miconazole nitrate is an antifungal agent for topical treatment of infections in dogs and cats caused by Microsporum canis, Microsporum gypseum, and Trichophyton mentagrophytes.
(2) Apply once daily by rubbing into or spraying a light covering on the infected site and the immediate surrounding vicinity. Continue treatment for 2 to 4 weeks until infection is completely eradicated as determined by appropriate laboratory examination.
(3) Accurate diagnosis of infecting organism is essential. Identify by microscopic examination of a mounting of infected tissue in potassium hydroxide solution or by culture on an appropriate medium.
(4) If no improvement is observed in 2 weeks, reevaluate diagnosis and therapy.
(5) Avoid contact with eyes since irritation may result.
(6) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.1446 Milbemycin oxime solution.

(a) Specifications. Each tube contains 0.25 milliliter of a 0.1 percent solution of milbemycin oxime.
(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. One tube administered topically into each external ear canal.
(2) Indications for use. For the treatment of ear mite (Otodectes cynotis) infestations in cats and kittens 4 weeks of age and older. Effectiveness is maintained throughout the life cycle of the ear mite.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.1451 Moxidectin.

(a) Specifications. Each milliliter contains 5 milligrams of moxidectin (0.5 percent solution).
(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.
(c) Related tolerances. See § 556.426 of this chapter.
§ 524.1465 Mupirocin ointment.

(a) Specifications. Each gram contains 20 milligrams of mupirocin.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs:

(i) Indications for use. Topical treatment of bacterial infections of the skin, including superficial pyoderma, caused by susceptible strains of Staphylococcus aureus and Staphylococcus intermedius.

(ii) Limitations. Apply twice daily. Treatment should not exceed 30 days. Because of potential hazard of nephrotoxicity due to polyethylene glycol content, care should be exercised in treating deep lesions. Safety of use in pregnant or breeding animals has not been determined. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.1484 Neomycin sulfate ophthalmic and topical dosage forms.

§ 524.1484a Neomycin sulfate ophthalmic ointment.

(a) Specifications. Each gram of the ointment contains 5 milligrams of neomycin sulfate equivalent in activity to 3.5 milligrams of neomycin base.

(b) Sponsor. See No. 017030 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is intended for use in dogs and cats for the treatment of superficial ocular bacterial infections limited to the conjunctival or the anterior segment of the eye.

(2) The drug is applied four times each day.

(3) The drug is applied by inserting the tip of the tube beneath the lower lid and by expressing a small quantity of ointment into the conjunctival sac. The tip of the tube should not come in contact with the eye surface.

(4) Severe infections should be supplemented by systemic therapy.

(5) Prolonged administration of the drug may permit overgrowth of organisms that are not susceptible to neomycin. If new infections due to bacteria or fungi appear during therapy, appropriate measures should be taken.

(6) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 44 FR 19666, Aug. 21, 1979]
myristyl-gamma-picolinium chloride in each gram of the product in a special adherent powder base.

(b) **Sponsor.** See No. 000009 in §510.600(c) of this chapter.

(c) **Conditions of use.** (1) It is used in horses, dogs, and cats in the treatment or adjunctive therapy of certain ear and skin conditions when such conditions are caused by or associated with neomycin-susceptible organisms and/or allergy. In addition the product is indicated as superficial dressing applied to minor cuts, wounds, lacerations, abrasions, and for postsurgical application where reduction of pain and inflammatory response is deemed desirable. The product may be used as a dusting powder following amputation of tails, claws, and dew-claws and following ear trimming, castrating, and such surgical procedures as ovariohysterectomies. The product may also be used in the treatment of acute otitis externa in dogs, acute moist dermatitis and interdigital dermatitis in dogs.

(2) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 43 FR 18172, Apr. 28, 1978]

§524.1484c Neomycin sulfate, isoflupredone acetate, tetracaine hydrochloride ointment.

(a) **Specifications.** The drug contains 5 milligrams of neomycin sulfate (equivalent to 3.5 milligrams of neomycin base), 1 milligram of isoflupredone acetate, and 5 milligrams of tetracaine hydrochloride in each gram of ointment.

(b) **Sponsor.** See No. 000009 in §510.600(c) of this chapter.

(c) **Conditions of use.** (1) It is indicated for treating acute otitis externa in dogs and to a lesser degree, chronic otitis externa in dogs. It also is effective in treating anal gland infections and moist dermatitis in the dog and is a useful dressing for minor cuts, lacerations, abrasions, and post-surgical therapy in the horse, cat, and dog. It may also be used following amputation of dewclaws, tails and claws, following ear trimming and castrating operations.

(2) In treatment of otitis externa and other inflammatory conditions of the external ear canal, a quantity of ointment sufficient to fill the external ear canal may be applied one to three times daily. When used on the skin or mucous membranes, the affected area should be cleansed, and a small amount of the ointment applied and spread or rubbed in gently. The involved area may be treated one to three times a day and these daily applications continued in accordance with the clinical response.

(3) Tetracaine and neomycin have the potential to sensitize. Care should be taken to observe animals being treated for evidence of hypersensitivity or allergy to the drug. If such signs are noted, therapy with the drug should be stopped. Treatment should be limited to the period when local anesthesia is essential to control self-inflicted trauma.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 43 FR 18172, Apr. 28, 1978]

§524.1484d Neomycin sulfate, hydrocortisone acetate, tetracaine hydrochloride ear ointment.

(a) **Specifications.** The product contains 5 milligrams of neomycin sulfate, equivalent to 3.5 milligrams of neomycin base, 5 milligrams of hydrocortisone acetate, and 5 milligrams of tetracaine hydrochloride in each gram of ointment.

(b) **Sponsor.** See No. 000009 in §510.600(c) of this chapter.

(c) **Conditions of use.** (1) It is indicated for treating acute otitis externa and, to a lesser degree, chronic otitis externa in dogs and cats. In treatment of ear canker and other inflammatory conditions of the external ear canal, a quantity of ointment sufficient to fill the external ear canal may be applied one to three times daily.  

(2) Tetracaine and neomycin have the potential to sensitize. Care should be taken to observe animals being treated for evidence of hypersensitivity or allergy to the product. If such signs are noted, therapy with the product should be stopped. Incomplete response or exacerbation of corticosteroid responsive lesions may be due to the presence of...
Non-susceptible organisms or to prolonged use of antibiotic-containing preparations resulting in overgrowth of non-susceptible organisms, particularly Monilia.\footnote{These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.}

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.\footnote{These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.}

(40 FR 13873, Mar. 27, 1975, as amended at 49 FR 21922, May 24, 1984)

§ 524.1484e Neomycin sulfate and polymyxin B sulfate ophthalmic solution.

(a) Specifications. Each milliliter of the ophthalmic preparation contains 5.0 milligrams neomycin sulfate (3.5 milligrams neomycin base), and 10,000 Units of polymyxin B sulfate.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is recommended for the treatment of bacterial infections associated with topical ophthalmological conditions such as corneal injuries, superficial keratitis, conjunctivitis, keratoconjunctivities, and blepharitis in the dog.

(2) The recommended dosage is 1 to 2 drops per eye every 6 hours.

(3) In treating ophthalmological conditions associated with bacterial infections the drug is contraindicated in those cases in which microorganisms are nonsusceptible to the antibiotics incorporated in the drug.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(40 FR 13873, Mar. 27, 1975, as amended at 61 FR 5507, Feb. 13, 1996)

§ 524.1484f Neomycin sulfate, prednisolone acetate, tetracaine hydrochloride eardrops.

(a) Specifications. The product contains 5 milligrams of neomycin sulfate equivalent to 3.5 milligrams of neomycin base, 2.5 milligrams of prednisolone acetate, and 5 milligrams of tetracaine hydrochloride in each milliliter of sterile suspension.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is recommended for use as an aid in the treatment of bacterial, mycotic, and inflammatory dermatoses and otitis externa in dogs and cats.
Food and Drug Administration, HHS

§ 524.1484k Neomycin sulfate, hydrocortisone acetate, sterile ointment.

(a) Specifications. The drug contains 5 milligrams of neomycin sulfate, equivalent to 3.5 milligrams of neomycin base, and 5 milligrams of hydrocortisone acetate in each gram of ointment.1

(b) Sponsor. See 017030 in §510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. 2 to 3 applications daily or as needed.

(2) Indications for use. Indicated for use in dogs and cats for treating acute otitis externa and as adjunctive therapy in management of chronic otitis externa. The product may also be used for treating moist dermatitis in dogs.
§ 524.1580

(3) Limitations. Tetracaine and neomycin have the potential to sensitize. If signs of irritation or sensitivity develop, discontinue use. Prolonged use of this product may result in overgrowth of nonsusceptible organisms. If new infections due to bacteria or fungi appear during therapy, appropriate measures should be taken. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.1580 Nitrofurazone ophthalmic and topical dosage forms.

§ 524.1580a [Reserved]

§ 524.1580b Nitrofurazone ointment.

(a) Specifications. The drug contains 0.2 percent nitrofurazone in a water-soluble base.

(b) Sponsor. See Nos. 000010, 000069, 050749, 023851, 051259, and 061133 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. For prevention or treatment of surface bacterial infections of wounds, burns, skin ulcers, and abscesses after incision.

(2) Limitations. In case of deep or puncture wounds or serious burns, use only as recommended by veterinarian. If redness, irritation, or swelling persists or increases, discontinue use; consult veterinarian. For use only on dogs, cats, and horses (not for food use).


§ 524.1580d [Reserved]

§ 524.1580e Nitrofurazone soluble powder.

(a) Specifications. The drug contains 0.2 percent nitrofurazone in a water-soluble base.

(b) Sponsor. See Nos. 000010, 000069, and 050749 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Apply several times daily to the lesion or affected area from the plastic squeeze bottle.

(2) Indications for use. For prevention or treatment of surface bacterial infections of wounds, burns, skin ulcers, and abscesses after incision.

(3) Limitations. In case of deep or puncture wounds or serious burns, use only as recommended by veterinarian. If redness, irritation, or swelling persists or increases, discontinue use; consult veterinarian. For use only on dogs, cats, and horses (not for food use).


§ 524.1580f Nitrofurazone soluble powder.

(a) Specifications. The drug contains 0.2 percent nitrofurazone in a water-soluble base.

(b) Sponsor. See Nos. 000010, 000069, and 050749 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Apply several times daily to the lesion or affected area from the plastic squeeze bottle.

(2) Indications for use. For prevention or treatment of surface bacterial infections of wounds, burns, skin ulcers, and abscesses after incision.

(3) Limitations. In case of deep or puncture wounds or serious burns, use only as recommended by veterinarian. If redness, irritation, or swelling persists or increases, discontinue use; consult veterinarian. For use only on dogs, cats, and horses (not for food use).


§ 524.1580g Nitrofurazone soluble powder.

(a) Specifications. The drug contains 0.2 percent nitrofurazone in a water-soluble base.

(b) Sponsor. See Nos. 000010, 000069, and 050749 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Apply several times daily to the lesion or affected area from the plastic squeeze bottle.

(2) Indications for use. For prevention or treatment of surface bacterial infections of wounds, burns, skin ulcers, and abscesses after incision.

(3) Limitations. In case of deep or puncture wounds or serious burns, use only as recommended by veterinarian. If redness, irritation, or swelling persists or increases, discontinue use; consult veterinarian. For use only on dogs, cats, and horses (not for food use).


§ 524.1580h Nitrofurazone ointment.

(a) Specifications. The drug contains 0.2 percent nitrofurazone and 0.5 percent butacaine sulfate in a water-soluble base.

(b) Sponsor. See No. 051259 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. For prevention or treatment of surface bacterial infections of ears, wounds, burns, and cutaneous ulcers of dogs, cats, and horses.

(2) Limitations. Apply directly on the lesion with a spatula or first place on a piece of gauze. Use of a bandage is optional. The preparation should remain on the lesion for at least 24 hours. The dressing may be changed several times daily or left on the lesion for a longer period. For use only on dogs, cats, and horses (not for food use).

Food and Drug Administration, HHS

§ 524.1600b Nystatin, neomycin, thiostrepton, and triamcinolone acetonide ophthalmic ointment.

(a) Specifications. Each cubic centimeter of ointment contains: 100,000 units of nystatin; neomycin sulfate equivalent to 2.5 milligrams of neomycin base; 2,500 units of thiostrepton; and 1.0 milligram of triamcinolone acetonide.

(b) Sponsor. See No. 053501 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is recommended for ophthalmic use as an anti-inflammatory, antipruritic, antifungal (Candida albicans), and antibacterial ointment for local therapy in keratitis and conjunctivitis in cats and dogs and for infectious keratoconjunctivitis (pink eye) in cattle.

(2) It is to be administered as follows:

(i) For conjunctivitis and keratitis: Apply one drop of ointment to the affected eye(s) two or three times daily. Treatment may be continued for up to 2 weeks if necessary.

(ii) For bovine infectious keratoconjunctivitis: Apply small line of ointment to the affected eye(s) once daily. Treatment may be continued for up to 2 weeks if necessary.

(iii) Frequency of administration is dependent on the severity of the condition. For mild inflammations, applications may range from once daily to once a week; for severe conditions the drug may be applied as often as two to three times daily. Frequency of treatment may be decreased as improvement occurs.

(3) For use only by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 50 FR 41490, Oct. 11, 1985]
§ 524.1662 Oxytetracycline hydrochloride ophthalmic and topical dosage forms.

§ 524.1662a Oxytetracycline hydrochloride and hydrocortisone spray.

(a) Specifications. Each 3-ounce unit of oxytetracycline hydrochloride and hydrocortisone spray contains 300 milligrams of oxytetracycline hydrochloride and 100 milligrams of hydrocortisone with an inert freon propellant such that a 1-second spray treatment will deliver approximately 2.5 milligrams of oxytetracycline hydrochloride and 0.8 milligram of hydrocortisone.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for relief of discomfort and continued treatment of many allergic, infectious, and traumatic skin conditions. The indications include prevention of bacterial infections in superficial wounds, cuts, and abrasions, treatment of allergic dermatoses, including urticaria, eczemas, insect bites, and cutaneous drug reactions, infections associated with minor burns and wounds, and nonspecific pruritus in dogs and cats.

(2) A small quantity should be sprayed on the affected surface by holding the container about 6 inches from the area to be treated and pressing the nozzle for 1 or 2 seconds. Only sufficient spray to coat the skin thinly is necessary. The application of small amounts at frequent intervals will give best results. Before treating animals with long or matted hair, it may be necessary to clip the affected area or spread the hairs to allow the medication to contact the skin surface. Relief may be noted following the first or second treatment; however, treatment should not be discontinued too soon after the initial favorable response has been obtained.

(3) Keep away from eyes or other mucous membranes; avoid inhaling; use with adequate ventilation; in case of deep or puncture wounds or serious burns, consult a veterinarian.

§ 524.1662b Oxytetracycline hydrochloride, polymyxin B sulfate ophthalmic ointment.

(a) Specifications. Each gram of the ointment contains oxytetracycline hydrochloride equivalent to 5 milligrams of oxytetracycline and 10,000 units of polymyxin B sulfate.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used for the prophylaxis and local treatment of superficial ocular infections due to oxytetracycline- and polymyxin-sensitive organisms. These infections include the following: Ocular infections due to streptococci, rickettsiae, *E. coli*, and *A. aerogenes* (such as conjunctivitis, keratitis, pink-eye, corneal ulcer, and blepharitis in dogs, cats, cattle, sheep, and horses); ocular infections due to secondary bacterial complications associated with distemper in dogs; and ocular infections due to bacterial inflammatory conditions which may occur secondary to other infectious diseases in dogs, cats, cattle, sheep, and horses.

(2) It is administered topically to the eye two to four times daily.

(3) Allergic reactions may occasionally occur. Treatment should be discontinued if reactions are severe. If new infections due to nonsensitive bacteria or fungi appear during therapy, appropriate measures should be taken.

§ 524.1742 *N*-(Mercaptomethyl) phthalimide S-(*O,O*-dimethyl phosphorodithioate) emulsifiable liquid.

(a) Specifications. The emulsifiable liquid contains 11.6 percent *N*-(mercaptomethyl) phthalimide S-(*O,O*-dimethyl phosphorodithioate).

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Methods of application. Methods of application to control the following conditions on beef cattle:

<table>
<thead>
<tr>
<th>To control/method of use</th>
<th>Dilution rate (gal. drug: gal. of water)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grubs:</td>
<td></td>
</tr>
<tr>
<td>Dip</td>
<td>1:60</td>
</tr>
<tr>
<td>Pour-on</td>
<td>1:2</td>
</tr>
<tr>
<td>Spray</td>
<td>1:49</td>
</tr>
</tbody>
</table>

(3) Allergic reactions may occasionally occur. Treatment should be discontinued if reactions are severe. If new infections due to nonsensitive bacteria or fungi appear during therapy, appropriate measures should be taken.
To control/method of use | Dilution rate (gal. drug: gal. of water)
--- | ---
Lice: Dip | 1:60
Pour-on | 1:2 or 1:5
Spray | 1:49 or 1:100
Hornflies: Dip | 1:60
Spray | 1:49 or 1:100
Cattle Ticks: Dip | 1:60 or 1:240
Spray | 1:49
Southern cattle ticks: Dip | 1:60 or 1:240
Spray | 1:49
Scabies mites: Dip | 1:60
Spray | 1:49 or 1:100

(i) Dip vat procedure. (a) Prior to charging vat, empty old contents and thoroughly clean the vat. Dip vats should be calibrated to maintain an accurate dilution. Add water, then drug to the vat according to the dilution rate indicated in the table. Add super phosphate at a rate of 100 pounds per 1,000 gallons of vat solution. Super phosphate is added to control the pH of the solution and ensure vat stability. Super phosphate is usually available at most fertilizer dealers as 0–45–0 or 0–46–0. Stir the dip thoroughly, preferably with a compressed air device; however, any form of thorough mixing is adequate. Re-stir vat contents prior to each use. During the dipping operation, each time the dip's volume is reduced by 1/4 to 3/4 of its initial volume, replenish with water and add the drug at a rate of 1 gallon for each 50 or 200 gallons water added—depending on dilution rate 1:60 or 1:240. Also add super phosphate as necessary to maintain pH between 4.5 and 6.5. Stir well and resume dipping. Repeat replenishment process as necessary. For evaporation, add additional water accordingly. For added water due to rainfall, merely replenish dip with the product according to directions. If overflow occurs, either analyze for drug concentration and adjust accordingly or dispose of vat contents and recharge. Check pH after each addition of water or super phosphate to assure proper pH controls.

(b) Dip maintenance. (1) With use of dip vat tester, dipping may continue as long as the drug concentration is maintained between 0.15 and 0.25 percent, and the dip is not too foul for satisfactory use as indicated by foul odor or excessive darkening (i.e., color changes from beige to very dark brown).

(2) Without use of dip vat tester, vat should be emptied, cleaned, and recharged each time one of the following occurs: When the dip has been charged for 120 days; when the dip becomes too foul for satisfactory use, within the 120-day limit; if the number of animals dipped equals twice the number of gallons of the initial dip volume, within the 120-day limit.

(ii) Spray method. To prepare the spray, mix drug with water according to table and stir thoroughly. Apply the fresh mixture as a high-pressure spray, taking care to wet the skin, not just the hair. Apply to the point of "run-off," about 1 gallon of diluted spray per adult animal. Lesser amounts will permit run-off for younger animals.

(iii) Pour-on method. Dilute the drug with water according to table by slowly adding water to the product while stirring. Apply 1 ounce of the diluted mixture per 100 pounds of body weight (to a maximum of 8 ounces per head) down the center line of the back.

(2) Timing of applications for cattle grub control. For optimum cattle grub control, it is important to treat as soon as possible after the heel fly season, before the grub larvae reach the gullet or spinal canal, as the rapid kill of large numbers of larvae in these tissues may cause toxic side effects, such as bloating, salivation, staggering, and paralysis.

(3) Treatment regimens. (i) Control of scabies mites requires two treatments, 10 to 14 days apart.

(ii) Control of Lone Star Ticks and hornflies requires two treatments, 7 days apart.

(4) Warnings. The drug is a cholinesterase inhibitor. Do not use this drug on animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals. Do not apply within 21 days of slaughter. For use on beef cattle only. Do not treat sick, convalescent, or stressed cattle, or calves less than 3 months old except in Federal or State eradication programs where immediate treatment of all animals in an infested herd is
§ 524.1880 Prednisolone-neomycin sulfate ophthalmic ointment.

(a) Specifications. Prednisolone-neomycin sulfate ophthalmic ointment contains 2 milligrams prednisolone and 5 milligrams neomycin sulfate (equivalent to 3.5 milligrams of neomycin base) in each gram of ointment.

(b) Sponsor. See No. 017030 in §510.600(c) of this chapter.

(c) Conditions of use. The drug is recommended for use in superficial ocular inflammations or infections limited to the conjunctiva or the anterior segment of the eye of cats and dogs, such as those associated with allergic reactions or gross irritants. A small quantity of the ointment should be expressed into the conjunctival sac four times a day for 7 days. After 7 days, if clinical improvement is not noted, re-evaluation of the diagnosis should be considered. All topical ophthalmic preparations containing corticosteroids with or without an antimicrobial agent are contraindicated in the initial treatment of corneal ulcers. They should not be used until the infection is under control and corneal regeneration is well underway. For use only by or on the order of a licensed veterinarian.

§ 524.1881 Prednisolone-acetate ophthalmic and topical dosage forms.

§ 524.1881a [Reserved]

§ 524.1881b Prednisolone-acetate-neomycin sulfate sterile suspension.

(a) Specifications. Prednisolone-acetate-neomycin sulfate sterile suspension contains 2.5 milligrams of prednisolone acetate and 5 milligrams of neomycin sulfate (equivalent to 3.5 milligrams of neomycin base) in each milliliter of sterile suspension.

(b) Sponsor. See No. 000009 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for treating infectious, allergic and traumatic keratitis and conjunctivitis, acute otitis externa, and chronic otitis externa in dogs and cats.

(2) For beginning treatment of acute ocular inflammations 1 or 2 drops may be placed in the conjunctival sac 3 to 6 times during a 24 hour period. When improvement occurs, the dosage may be reduced to 1 drop 2 to 4 times daily. In otitis externa, 2 to 6 drops may be placed in the external ear canal 2 or 3 times daily.

(3) All topical ophthalmic preparations containing corticosteroids with or without an anti-microbial agent are contraindicated in the initial treatment of corneal ulcers. They should not be used until infection is under control and corneal regeneration is well underway.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1883 Prednisolone-sodium phosphate-neomycin sulfate ophthalmic ointment.

(a) Specifications. Prednisolone-sodium phosphate-neomycin sulfate ophthalmic ointment contains prednisolone sodium phosphate equivalent to 2.5 milligrams prednisolone 21-phosphate and 5 milligrams neomycin sulfate (equivalent to 3.5 milligrams of neomycin base) in each gram of ointment.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.
Food and Drug Administration, HHS

§ 524.2098 Selamectin.

(a) Specifications. Each milliliter contains 60 or 120 milligrams of selamectin.

(b) Sponsor. See 000069 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Amount. 2.7 milligrams of selamectin, topically, per pound (6 milligrams per kilogram) of body weight.

(2) Indications for use. Kills adult fleas and prevents flea eggs from hatching for 1 month, and it is indicated for the prevention and control of flea infestations (Ctenocephalides felis), prevention of heartworm disease caused by Dirofilaria immitis, and treatment and control of ear mite (Otodectes cynotis) infestations in dogs and cats. Treatment and control of sarcoptic mange (Sarcoptes scabiei) and control of tick...
§ 524.2101 Selenium disulfide suspension.

(a) Specifications. The product contains 0.9-percent weight in weight (w/w) selenium disulfide (1-percent weight in volume (w/v)).

(b) NAS/NRC status. These conditions are NAS/NRC reviewed and found effective. NADA’s for similar products for these conditions of use need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(c) Sponsors. See 000061, 017135, 023851, and 050604 in §510.600(c) of this chapter.

(1) Indications for use. For use on dogs as a cleansing shampoo and as an agent for removing skin debris associated with dry eczema, seborrhea, and non-specific dermatoses.

(2) Amount. One to 2 ounces per application.

(3) Limitations. Use carefully around scrotum and eyes, covering scrotum with petrolatum. Allow the shampoo to remain for 5 to 15 minutes before thorough rinsing. Repeat treatment once or twice a week. If conditions persist or if rash or irritation develops, discontinue use and consult a veterinarian.

§ 524.2350 Tolnaftate cream.

(a) Specifications. The drug contains 1 percent tolnaftate (2-naphthyl-N-methyl-N-(3-tolyl) thionocarbamate) in an anhydrous cream base.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for treatment of ringworm lesions due to Microsporum canis and Microsporum gypseum in dogs and cats.

(2) A small amount of the cream is applied to the affected areas once or twice a day for 2 to 4 weeks. The areas to be treated are first cleared of exudate and the hair clipped if the areas are not already denuded. The cream is massaged into each lesion and immediate surrounding area until the cream is no longer visible.

(3) If no response is seen after 2 weeks of treatment with the drug the diagnosis should be reviewed.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.2481 Triamcinolone acetonide cream.

(a) Specifications. Triamcinolone acetonide cream contains 0.1 percent triamcinolone acetonide in an aqueous vanishing cream base.

(b) Sponsor. See No. 051259 and 053501 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.

(2) The drug is applied by rubbing into affected areas two to four times daily for 4 to 10 days.

(3) For use only by or on the order of a licensed veterinarian.

§ 524.2620 Liquid crystalline trypsin, Peru balsam, castor oil.

(a)(1) Specifications. The drug is a liquid for direct application or an aerosol preparation formulated so that each gram delivered to the wound site contains 0.12 milligram of crystalline trypsin, 87.0 milligrams of Peru balsam, and 788.0 milligrams of castor oil.

(2) Sponsor. See No. 062794 in §510.600(c) of this chapter.

(b)(1) Specifications. The drug is a liquid for direct application or an aerosol preparation formulated so that each gram delivered to the wound site contains 0.1 milligram of crystalline...
trypsin, 72.5 milligrams of Peru balsam, and 800 milligrams of castor oil.

(2) Sponsor. See No. 017135 in §510.600(c) of this chapter.

(c) Conditions of use. The drug is used as an aid in the treatment of external wounds and assists healing by facilitating the removal of necrotic tissue, exudate and organic debris.


PART 526—INTRAMAMMARY DOSAGE FORMS

Sec.
526.88 Amoxicillin trihydrate for intramammary infusion.
526.363 Cephapirin benzathine.
526.365 Cephapirin sodium for intramammary infusion.
526.464 Cloxacillin intramammary dosage forms.
526.464a Cloxacillin benzathine for intramammary infusion.
526.464b Cloxacillin benzathine for intramammary infusion, sterile.
526.464c Cloxacillin sodium for intramammary infusion.
526.464d Cloxacillin sodium for intramammary infusion, sterile.
526.430 Erythromycin.
526.1130 Hetacillin potassium for intramammary infusion.
526.1590 Novobiocin oil suspension.
526.1696 Penicillin intramammary dosage forms.
526.1696a Penicillin G procaine in oil.
526.1696b Penicillin G procaine-dihydrostreptomycin in soybean oil for intramammary infusion (dry cows).
526.1696c Penicillin G procaine-dihydrostreptomycin sulfate for intramammary infusion (dry cows).
526.1696d Penicillin G procaine-novobiocon for intramammary infusion.
526.1810 Pirlimycin hydrochloride.


§526.88 Amoxicillin trihydrate for intramammary infusion.

(a) Specifications. Each single dose syringe contains amoxicillin trihydrate equivalent to 62.5 milligrams of amoxicillin.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.38 of this chapter.

(d) Conditions of use—Lactating cows—

(1) Amount. One syringe (equivalent to 62.5 milligrams amoxicillin) per quarter.

(2) Indications for use. For the treatment of subclinical infectious bovine mastitis due to Streptococcus agalactiae and Staphylococcus aureus (penicillin sensitive).

(3) Limitations. Administer after milking. Clean and disinfect the teat. Use one syringe per infected quarter every 12 hours for a maximum of 3 doses. Do not use milk taken from treated animals for food purposes within 60 hours (5 milkings) after last treatment. Do not slaughter treated animals for food purposes within 12 days after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37334, Aug. 18, 1992, as amended at 60 FR 55660, Nov. 2, 1995]

§526.363 Cephapirin benzathine.

(a) Specifications. Each 10 milliliter disposable syringe contains 300 milligrams of cephapirin activity (as cephapirin benzathine) in a peanut-oil gel.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.115 of this chapter.

(d) Conditions of use—

(1) Amount. Infuse contents of one syringe into each infected quarter.

(2) Indications for use. Use in dry cows for treatment of mastitis caused by susceptible strains of Streptococcus agalactiae and Staphylococcus aureus.

(3) Limitations. Infuse each infected quarter following last milking or early in the dry period, but no later than 30 days before calving. Milk from treated cows must not be used for food during the first 72 hours after calving. Animals infused with this product must not be slaughtered for food until 42 days after the latest infusion. For use in dry cows only.


§526.365 Cephapirin sodium for intramammary infusion.

(a) Specifications. Each 10-milliliter dose contains 200 milligrams of
§ 526.464  Cephalirin sodium activity in a peanut-oil gel.

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.115 of this chapter.

(d) Conditions of use. (1) The drug is used for the treatment of lactating cows having bovine mastitis caused by susceptible strains of *Streptococcus agalactiae* and *Staphylococcus aureus*.

(2) Administer one dose into each infected quarter immediately after the quarter has been completely milked out. Do not milk out for 12 hours. Repeat once only in 12 hours. If improvement is not noted within 48 hours after treatment, consult your veterinarian.

(3) Milk that has been taken from animals during treatment and for 96 hours after the last treatment must not be used for food. Treated animals must not be slaughtered for food until 4 days after the last treatment.


§ 526.464a  Cloxacillin benzathine for intramammary infusion.

(a) Specifications. Each dose contains cloxacillin benzathine equivalent to 500 milligrams of cloxacillin.

(b) Related tolerances. See §556.165 of this chapter.

(c) Sponsor. See No. 055529 in §510.600(c) of this chapter.

(d) Conditions of use. (1) Administer one dose in each quarter immediately after last milking.

(2) Indications for use. Treatment and prophylaxis of bovine mastitis in non-lactating cows due to *S. agalactiae* and *S. aureus*.

(3) Limitations. For use in dry cows only. Not to be used within 4 weeks (28 days) of calving. Animals infused with this product must not be slaughtered for food use for 4 weeks (28 days) after the latest infusion. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 526.464b  Cloxacillin benzathine for intramammary infusion, sterile.

(a) Specifications. Each 6 milliliter dose contains cloxacillin benzathine equivalent to 500 milligrams of cloxacillin.

(b) Related tolerances. See §556.165 of this chapter.

(c) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(d) Conditions of use. (1) Administer one dose per infected quarter immediately after last milking.

(2) Indications for use. Treatment and prophylaxis of bovine mastitis in non-lactating cows due to *S. agalactiae* and *S. aureus*.

(3) Limitations. For use in dry cows only. Not to be used within 30 days of calving. Milk taken from treated cows prior to 72 hours (6 milkings) after calving must not be slaughtered for food. Animals infused with this drug must not be slaughtered for food from the time of infusion until 72 hours after infusion. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Indications for use. Treatment and prophylaxis of bovine mastitis in non-lactating cows due to *Streptococcus agalactiae* and *Staphylococcus aureus*.

(3) Limitations. For use in dry cows only. Not to be used within 4 weeks (28 days) of calving. Animals infused with this product must not be slaughtered for food use for 4 weeks (28 days) after the latest infusion. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 526.464c Cloxacillin sodium for intramammary infusion, sterile.

(a) Specifications. Each milliliter contains cloxacillin sodium equivalent to 20.0 milligrams of cloxacillin.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.165 of this chapter.

(d) Conditions of use. Lactating cows—

(1) Amount. 10 milliliters (one dose of 200 milligrams) per infected quarter.

(2) Indications for use. Treatment of mastitis in lactating cows due to *Streptococcus agalactiae* and *Staphylococcus aureus*, nonpenicillinase-producing strains.

(3) Limitations. Administer after milking, cleaning, and disinfecting, and as early as possible after detection. Treatment should be repeated at 12-hour intervals for a total of three doses. Milk taken from treated animals within 48 hours (4 milkings) after the latest treatment should not be used for food. Treated animals should not be slaughtered for food within 10 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37335, Aug. 18, 1992, as amended at 60 FR 55660, Nov. 2, 1995]

§ 526.820 Erythromycin.

(a) Specifications. (1) Each 6-milliliter, single-dose, disposable syringe contains 300 milligrams of erythromycin (as the base), 0.45 milligram of butylated hydroxyanisole, and 0.45 milligram of butylated hydroxytoluene.

(2) Each 12-milliliter, single-dose, disposable syringe contains 600 milligrams of erythromycin (as the base), 0.90 milligram of butylated hydroxyanisole, and 0.90 milligram of butylated hydroxytoluene.

(b) Sponsor. See No. 061133 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.165 of this chapter.

(d) Conditions of use. Lactating cows—

(1) Amount. 10 milliliters (one dose of 200 milligrams) per infected quarter.

(2) Indications for use. Treatment of mastitis in lactating cows due to *Streptococcus agalactiae* and *Staphylococcus aureus*, nonpenicillinase-producing strains.

(3) Limitations. Administer after milking, cleaning, and disinfecting, and as early as possible after detection. Treatment should be repeated at 12-hour intervals for a total of three doses. Milk taken from treated animals within 48 hours (4 milkings) after the latest treatment should not be used for food. Treated animals should not be slaughtered for food within 10 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37335, Aug. 18, 1992, as amended at 60 FR 55660, Nov. 2, 1995]
§ 526.1130 Hetacillin potassium for intramammary infusion.

(a) Specifications. Each 10 milliliter syringe contains hetacillin potassium equivalent of 62.5 milligrams of ampicillin.

(b) Sponsor. See No. 000856 in § 510.600(c) of this chapter.

(c) Conditions of use.

(1) Amount. 10 milliliters of hetacillin potassium equivalent to 62.5 milligrams ampicillin into each infected quarter. Repeat at 24-hour intervals until a maximum of three treatments has been given.

(2) Indications for use. Treating acute, chronic, or subclinical bovine mastitis in lactating cows caused by susceptible strains of *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Staphylococcus aureus*, and *Escherichia coli*.

(3) Limitations.

(i) If definite improvement is not noted within 48 hours after treatment, the causal organism should be further investigated. Milk that has been taken from treated animals during treatment and for 72 hours (6 milkings) after the latest treatment must not be used for food. Treated animals must not be slaughtered for food until 10 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(ii) Indications for use. It is used in dry cows for the treatment of mastitis caused by susceptible strains of *Staphylococcus aureus* and *Streptococcus agalactiae*.

(iii) Limitations. Infuse each quarter at the time of drying off, but not less than 30 days prior to calving. Do not slaughter treated animals for food use for 30 days following udder infusion. For udder installation for the treatment of mastitis in dry cows only.

(b)(1) Specifications. Each 10 milliliters of oil suspension contains the equivalent of 150 milligrams of novobiocin (present as sodium novobiocin).

(2) Sponsor. See No. 000009 in § 510.600(c) of this chapter.

(3) Related tolerances. See § 556.460 of this chapter.

(4) Conditions of use—

(i) Amount. Infuse 10 milliliters (equivalent to 150 milligrams of novobiocin) in each quarter after milking. Repeat treatment once after 24 hours.

(ii) Indications for use. Use in lactating cows for treatment of mastitis caused by susceptible strains of *Staphylococcus aureus*.

(iii) Limitations. Do not milk for at least 6 hours after treatment; afterwards, milk at regular intervals. Milk taken from treated animals within 72 hours (6 milkings) after latest treatment must not be used for food. Do not slaughter treated animals for food for 15 days following latest treatment. If redness, swelling, or abnormal milk persists or increases after treatment, discontinue use and consult a veterinarian. For udder instillation in lactating cattle only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 526.1590 Novobiocin oil suspension.

(a)(1) Specifications. Each 10 milliliters of oil suspension contains the equivalent of 400 milligrams of novobiocin (present as sodium novobiocin).

(b) Sponsor. See No. 000009 in § 510.600(c) of this chapter.

(2) Related tolerances. See § 556.460 of this chapter.

(3) Conditions of use.

(1) Amount. In fuse 10 milliliters (equivalent to 400 milligrams of novobiocin) infused in each quarter.

(2) Indications for use. It is used in dry cows for the treatment of mastitis caused by susceptible strains of *Staphylococcus aureus* and *Streptococcus agalactiae*.

(3) Limitations. If definite improvement is not noted within 48 hours after treatment, the causal organism should be further investigated. Milk that has been taken from treated animals during treatment and for 72 hours (6 milkings) after the latest treatment must not be used for food. Treated animals must not be slaughtered for food use for 30 days following udder infusion. For udder installation for the treatment of mastitis in dry cows only.

(b)(1) Specifications. Each 10 milliliters of oil suspension contains the equivalent of 150 milligrams of novobiocin (present as sodium novobiocin).

§ 526.1696 Penicillin intramammary dosage forms.

§ 526.1696a Penicillin G procaine in oil.

(a) Specifications. Each milliliter contains penicillin G procaine equivalent to 100,000 units of penicillin G in peanut, sesame, or soybean oils.

(b) Related tolerances. See § 556.510 of this chapter.
(c) Sponsor. See No. 010515 in §510.600(c) of this chapter.

(1) National Academy of Sciences/National Research Council (NAS/NRC) status. The conditions specified in paragraph (c)(2)(i)(B) of this section were NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(2) Conditions of use. Treating bovine mastitis caused by Streptococcus agalactiae, S. dysgalactiae, and S. uberus in lactating cows as follows:

(i) Three-dose regimen. Administer by intramammary infusion in each infected quarter as follows:

(A) 6-milliliter dose (peanut oil). Treatment may be repeated at 12-hour intervals. Milk that has been taken from animals during treatment and for 44 hours (7 milkings) after the latest treatment must not be used for food. Animals must not be slaughtered for food during treatment or within 4 days after the latest treatment.

(B) 10-milliliter dose (sesame oil). Treatment may be repeated at 12-hour intervals. Milk that has been taken from animals during treatment and for 60 hours (5 milkings) after the latest treatment must not be used for food. Animals must not be slaughtered for food during treatment or within 3 days after the latest treatment.

(ii) Two-dose regimen. 10-milliliter dose (peanut oil). Administer by intramammary infusion in each infected quarter. Treatment may be repeated at intervals of 12 hours. Milk taken from animals during treatment and for 60 hours (5 milkings) after the latest treatment must not be used for food. Animals must not be slaughtered for food during treatment or within 3 days after the latest treatment.

(3) Limitations. Milk that has been taken from animals during treatment and for 60 hours after the latest treatment must not be used for food. Animals must not be slaughtered for food during treatment or within 3 days after the latest treatment.

(e) Sponsor. See No. 010515 (sesame oil) and No. 050604 (peanut oil) in §510.600(c) of this chapter.

(1) NAS/NRC status. The conditions of use were NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(2) Single-dose regimen. One 10-milliliter dose (sesame oil or peanut oil) in each infected quarter at time of drying-off.

(3) Indications of use. Treating bovine mastitis caused by Streptococcus agalactiae in dry cows.

(4) Limitations. Discard all milk for 72 hours (6 milkings) following calving, or later as indicated by the marketable quality of the milk. Animals must not be slaughtered for food within 14 days postinfusion.

§ 526.1696b Penicillin G procaine-dihydrostreptomycin in soybean oil for intramammary infusion (dry cows).

(a) Specifications. Each 10 milliliters of suspension contains penicillin G procaine equivalent to 200,000 units of penicillin G and dihydrostreptomycin sulfate equivalent to 300 milligrams of dihydrostreptomycin.

(b) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(c) Related tolerances. See §§556.200 and 556.510 of this chapter.

(d) Conditions of use. Dairy cows—(1) Amount. One syringe into each quarter at the last milking prior to drying off.

(2) Indications for use. Intramammary treatment of subclinical mastitis in dairy cows at the time of drying off, specifically against infections caused by Staphylococcus aureus and Streptococcus agalactiae.

(3) Limitations. Not to be used within 6 weeks of calving. For use in dry cows.
only. Milk taken from cows within 24 hours (2 milkings) after calving must not be used for food. Animals infused with this drug must not be slaughtered for food within 60 days of treatment nor within 24 hours after calving.

§ 526.1696c Penicillin G procaine-dihydrostreptomycin sulfate for intramammary infusion (dry cows).

(a) Specifications. Each 10 milliliters of suspension contains penicillin G procaine equivalent to 1 million units of penicillin G and dihydrostreptomycin sulfate equivalent to 1 gram of dihydrostreptomycin.

(b) Sponsor. See No. 033392 in §510.600(c) of this chapter.

(c) Related tolerances. See §§556.200 and 556.510 of this chapter.

(d) Conditions of use. Dairy cows—(1) Amount. One syringe per quarter at the last milking prior to drying off.

(2) Indications for use. Intramammary use to reduce the frequency of existing infection and to prevent new infections with *Staphylococcus aureus* in dry cows.

(3) Limitations. Not to be used within 6 weeks of freshening. Not for use in lactating cows. Milk taken from animals within 96 hours (8 milkings) after calving must not be used for feed. Animals infused with this drug must not be slaughtered for food within 60 days from the time of infusion nor within 96 hours after calving. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 526.1696d Penicillin G procaine-novobiocin for intramammary infusion.

(a) Specifications. For lactating cattle: each 10-milliliter dose contains 100,000 units of penicillin G procaine and 150 milligrams of novobiocin as novobiocin sodium. For dry cows: 200,000 units of penicillin G procaine and 400 milligrams of novobiocin as novobiocin sodium.

(b) Sponsor. See No. 000009 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Lactating cows—(i) Amount. 10 milliliters in each infected quarter after milking. Repeat once after 24 hours.

(ii) Indications for use. Treating lactating cows for mastitis caused by susceptible strains of *Staphylococcus aureus*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, and *Streptococcus uberis*.

(3) Limitations. Milk taken from animals during treatment and for 36 hours...
following the last treatment must not be used for food. Treated animals must not be slaughtered for food use for 9 days following the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

Sec. 529.40 Albuterol.
529.400 Chlorhexidine tablets and suspension.

(a) Specifications. A net weight of 6.7 grams of formulated albuterol sulfate is supplied in a pressurized aluminum canister within an actuator system equipped with a detachable nasal delivery bulb.

(b) Approvals. See No. 000010 in §510.600(c) of this chapter for uses as in paragraph (d) of this section.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Amount. Each valve actuation (puff) of the device delivers 120 micrograms (mcg) of albuterol sulfate. One dose is three (3) puffs, totaling 360 mcg.

(2) Indications for use. For the immediate relief of bronchoospasm and bronchoconstriction associated with reversible airway obstruction in horses.

(3) Limitations. Not for use in horses intended for food.

[67 FR 7072, Feb. 15, 2002]

§ 529.50 Amikacin sulfate intrauterine solution.

(a) Specifications. Each milliliter of sterile aqueous solution contains 250 milligrams of amikacin (as the sulfate).

(b) Sponsor. See No. 000856 and 059130 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Two grams (8 milliliters) diluted with 200 milliliters of sterile physiological saline per day for 3 consecutive days.

(2) Indications for use. For treating genital tract infections (endometritis, metritis, and pyometra) in mares when caused by susceptible organisms including E. coli, Pseudomonas spp., and Klebsiella spp.

(3) Limitations. For intrauterine infusion in the horse only. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 529.400 Chlorhexidine tablets and suspension.

(a) Specifications. Each tablet and each 28-milliliter syringe of suspension contain 1 gram of chlorhexidine dihydrochloride.1

(b) Sponsor. See No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Place 1 or 2 tablets deep in each uterine horn; or infuse a solution of 1 tablet dissolved in an appropriate amount of clean boiled water; or infuse one syringe of suspension into the uterus.1

(2) Indications for use. For prevention or treatment of metritis and vaginitis in cows and mares when caused by pathogens sensitive to chlorhexidine dihydrochloride.1

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.
§ 529.469 Competitive exclusion culture.

(a) Specifications. Each packet of lyophilized culture contains either 2,000 or 5,000 doses in frozen pellets to be reconstituted for use.

(1) For 2,000-dose packet, add contents of one 2,000-dose packet of reconstitution powder to 490 milliliters of deionized water. Mix. Add contents of one 2,000-dose packet of lyophilized culture. Mix thoroughly.

(2) For 5,000-dose packet, add contents of one 5,000-dose packet of reconstitution powder to 1,250 milliliters of deionized water. Mix. Add contents of one 5,000-dose packet of lyophilized culture. Mix thoroughly. Allow to stand for 45 minutes before use. Use within 5 hours of reconstitution.

(b) Sponsor. See No. 027681 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use. Chickens—(1) Amount. Apply 25 milliliters of reconstituted culture as a topical spray on each tray of 100 chicks (0.25 milliliter per chick).

(2) Indications for use. For early establishment of intestinal microflora in chickens to reduce Salmonella colonization.

(3) Limitations. Administer as soon as possible after hatch, preferably at less than 1 day of age. Expose chicks to light for at least 5 minutes after spray treatment to encourage preening for oral uptake of the organisms. Provide access to feed and water as soon as possible after treatment. Do not administer antibiotics to treated chickens.

§ 529.1030 Formalin solution.

(a) Specifications. Formalin solution is an aqueous solution containing approximately 37 percent by weight of formaldehyde gas, U.S.P.

(b) Sponsor. Approval to firms identified in §510.600(c) of this chapter for use as indicated:

(1) No. 050378 for use as in paragraphs (d)(1)(iii), (d)(1)(iv), (d)(1)(v), (d)(2)(iii), (d)(2)(iv), (d)(2)(v), and (d)(3).

(2) Nos. 049968 and 051212 for use as in paragraphs (d)(1)(i), (d)(1)(ii), (d)(2)(i), (d)(2)(ii), and (d)(5).

(c) [Reserved]

(d) Conditions of use. It is added to environmental water as follows:

(1) Indications for use. (i) Select finfish. For control of external protozoa Ichthyophthirius spp., Chilodonella spp., Costia spp., Scyphidia spp., Epistylis spp., and Trichodesma spp., and monogenetic trematodes Cleidodiscus spp., Gyrodactylus spp., and Dactylogyrus spp., on salmon, trout, catfish, largemouth bass, and bluegill.

(ii) Select finfish eggs. For control of fungi of the family Saprolegniaceae on salmon, trout, and esocid eggs.

(iii) Penaeid shrimp. For control of external protozoan parasites Bodo spp., Epistylis spp., and Zoothamnium spp.

(iv) All finfish. For control of external protozoa Ichthyophthirius spp., Chilodonella spp., Costia spp., Scyphidia spp., Epistylis spp., and Trichodesma spp., and monogenetic trematodes Cleidodiscus spp., Gyrodactylus spp., and Dactylogyrus spp.
Food and Drug Administration, HHS

§ 529.1044a

(v) All finfish eggs: For control of fungi of the family Saprolegniaceae.

(2) Amount. The drug concentrations required are as follows:

(i) For control of external parasites on select finfish:

<table>
<thead>
<tr>
<th>Fish</th>
<th>Concentration of formalin (microliters per liter)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tanks and raceways (for up to 1 hour)</td>
</tr>
<tr>
<td>Salmon and trout:</td>
<td></td>
</tr>
<tr>
<td>Above 50 °F</td>
<td>Up to 170 ................................ 15-25</td>
</tr>
<tr>
<td>Below 50 °F</td>
<td>Up to 250 .................................. 15-25</td>
</tr>
<tr>
<td>Catfish, largemouth bass, and bluegill.</td>
<td>Up to 250 .................................. 15-25</td>
</tr>
</tbody>
</table>

1 Use the lower concentrations when pond is heavily loaded with fish or phytoplankton.

(ii) For control of fungi of the Saprolegniaceae on salmon, trout, and esocid eggs: Apply in constant flow water supply of incubating facilities for 15 minutes. Concentration of formalin used is 1,000 to 2,000 microliters per liter.

(iii) For control of external protozoan parasites on shrimp:

<table>
<thead>
<tr>
<th>Shrimp</th>
<th>Concentration of formalin (microliters per liter)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tanks and raceways (up to 4 hours daily)</td>
</tr>
<tr>
<td>Penaeid Shrimp ..........</td>
<td>50 to 100 ........................................ 25</td>
</tr>
</tbody>
</table>

1 Treat for up to 4 hours daily. Treatment may be repeated daily until parasite control is achieved. Use the lower concentration when the tanks and raceways are heavily loaded.

2 Single treatment. Treatment may be repeated in 5 to 10 days if needed.

(iv) For control of external parasites on all finfish:

<table>
<thead>
<tr>
<th>Aquatic species</th>
<th>Administer in tanks and raceways for up to 1 hour (microliter/liter or part per million)</th>
<th>Administer in earthen ponds indefinitely (µL per L or ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salmon and trout:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Above 50 °F</td>
<td>Up to 170 ................................ 15 to 25</td>
<td></td>
</tr>
<tr>
<td>Below 50 °F</td>
<td>Up to 250 .................................. 15 to 25</td>
<td></td>
</tr>
<tr>
<td>All other fish</td>
<td>Up to 250 .................................. 15 to 25</td>
<td></td>
</tr>
</tbody>
</table>

1 Use the lower concentration when ponds, tanks, or raceways are heavily loaded with fish or phytoplankton. In this case, formalin should be applied at concentrations of 1,000 to 2,000 µL/L (ppm) for 15 minutes. However, pond treatments for Ichthyophthirius should be made at 2-day intervals until control is achieved. Egg tanks may be treated as often as necessary to prevent growth of fungi. Do not use formalin which has been subjected to temperatures below 40 °F, or allowed to freeze. Do not treat ponds containing striped bass. Treatments in tanks should never exceed 1 hour even if fish show no signs of stress. Do not apply formalin to ponds with water warmer than 27 °C (80 °F), when a heavy bloom of phytoplankton is present, or when the concentration of dissolved oxygen is less than 5 milligrams per liter.


§ 529.1044 Gentamicin sulfate in certain other dosage forms.

§ 529.1044a Gentamicin sulfate intra-uterine solution.

(a) Specifications. Each milliliter of the drug contains 50 or 100 milligrams of gentamicin (as the sulfate) in sterile aqueous solution.

(b) Sponsor. See Nos. 000010, 000061, 000856, 000864, 057561, and 059130 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for use for control of bacterial infections of the uterus in horses (metritis) and as an aid in improving conception in mares with uterine infections caused by bacteria sensitive to gentamicin.

(2) It is administered at a dosage level of 2 to 2.5 grams per day for 3 to 5 days during estrus, each dose being diluted with 200 to 500 milliliters of sterile physiological saline before aseptic infusion into the uterus.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 529.1044b Gentamicin sulfate solution.

(a) Specifications. Each milliliter of solution contains gentamicin sulfate equivalent to 50 milligrams of gentamicin base.

(b) Sponsor. See Nos. 000061 and 051259 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Two to 5 percent of inhaled atmosphere for induction of anesthesia: 0.5 to 2 percent for maintenance of anesthesia.\(^1\)

(2) Indications for use. For nonfood animals for the induction and maintenance of anesthesia.\(^1\)

(3) Limitations. Administered by inhalation. May be administered with either oxygen or a mixture of oxygen and nitrous oxide. Place drug vaporizer between the gas supply and breathing bag to prevent overdosage. Not recommended for obstetrical anesthesia except when uterine relaxation is required. Do not use in pregnant animals; information on possible adverse effects on fetal development is not available. Operating rooms should have adequate ventilation to prevent accumulation of anesthetic gases. Not for use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.\(^1\)

\(^{1}\)These conditions have been reviewed by FDA and found effective. NADA’s for similar products for these conditions of use need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

§ 529.1115 Halothane.

(a) Specifications. The drug is a colorless, odorless, nonflammable, nonexplosive, heavy liquid containing 0.01 percent thymol as a preservative.

(b) Sponsor. See Nos. 000056 and 012164 in §510.600(c) of this chapter.
§ 529.1526 Nifurpirinol capsules.

(a) Specifications. Each capsule contains 3.8 or 7.6 milligrams of nifurpirinol.

(b) Sponsor. See No. 000074 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used for the removal of scar tissue in the teat canal of milk-producing cows.

(2) The labeling bears directions to the user to:

(i) Treat lactating cows initially by inserting dosage and removal of the device;

(ii) Insert second dose and permit device to remain in canal until the next milking; and

(iii) Insert one dose following each milking for not more than 2 days.

(3) Milk that has been drawn from animals within 48 hours of such treatment may not be used for food.

§ 529.2150 Sevoflurane.

(a) Specifications. The drug is a clear, colorless, stable liquid containing no additives or chemical stabilizers.

(b) Sponsor. See No. 000074 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. For induction of surgical anesthesia: 5 to 7 percent sevoflurane with oxygen. For maintenance of surgical anesthesia: 3.7 to 4 percent sevoflurane with oxygen in the absence of premedication and 3.3 to 3.6 percent in the presence of premedication.

(2) Indications for use. For induction and maintenance of general anesthesia in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 529.2464 Ticarcillin powder.

(a) Specifications. Each vial contains ticarcillin disodium equivalent to 6 grams of ticarcillin to be reconstituted with 25 milliliters of sterile water for injection or sterile physiological saline.

(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.
§ 529.2503  

(c) **Conditions of use**—

1. Amount. 6 grams per day, intrauterine, for 3 consecutive days during estrus.

2. **Indications for use.** Horses. Intrauterine treatment of endometritis caused by beta-hemolytic streptococci.

3. **Limitations.** For intrauterine use in horses only. Infuse aseptically. Not for use in horses raised for food production. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37336, Aug. 18, 1992, as amended at 60 FR 55660, Nov. 2, 1995]

§ 529.2503  

**Tricaine methanesulfonate.**

(a) **Chemical name.** Ethyl-m-amino-benzoate methanesulfonate.

(b) **Sponsor.** See Nos. 050378 and 051212 in §510.600(c) of this chapter.

(c) **Conditions of use.**

1. It is used for the temporary immobilization of fish, amphibians, and other aquatic cold-blooded animals (poikilotherms) as an aid in handling during manual spawning (fish stripping), weighing, measuring, marking, surgical operations, transport, photography, and research.

2. It is used as follows:

   (i) For fish the drug is added to ambient water at a concentration of from 15 to 330 milligrams per liter depending upon the degree of anesthetization or sedation desired, the species and size of the fish, and the temperature and softness of the water. Preliminary tests of solutions must be made with small numbers of fish to determine the desired rates of sedation or anesthesia and the appropriate exposure times for the specific lots of fish under prevailing conditions.

   (ii) For amphibians and other aquatic coldblooded animals, the drug is added to ambient water in concentrations of from 1:1000 to 1:20,000 depending upon species and stage of development.

   (iii) Do not use within 21 days of harvesting fish for food. Use in fish intended for food should be restricted to Ictaluridae, Salmonidae, Esoicidae, and Percidae, and water temperature should exceed 10 °C. (50 °F.). In other fish and in cold-blooded animals, the drug should be limited to hatchery or laboratory use.


21 CFR Ch. I (4–1–02 Edition)

**PART 530—EXTRALABEL DRUG USE IN ANIMALS**

**Subpart A—General Provisions**

Sec. 530.1 Scope.  
530.2 Purpose.  
530.3 Definitions.  
530.4 Advertising and promotion.  
530.5 Veterinary records.

**Subpart B—Rules and Provisions for Extralabel Uses of Drugs in Animals**

530.10 Provision permitting extralabel use of animal drugs.  
530.11 Limitations.  
530.12 Labeling.  
530.13 Extralabel use from compounding of approved new animal and approved human drugs.

**Subpart C—Specific Provisions Relating to Extralabel Use of Animal and Human Drugs in Food-Producing Animals**

530.20 Conditions for permitted extralabel animal and human drug use in food-producing animals.  
530.21 Prohibitions for food-producing animals.

530.22 Safe levels and analytical methods for food-producing animals.  
530.23 Procedure for setting and announcing safe levels.  
530.24 Procedure for announcing analytical methods for drug residue quantification.  
530.25 Orders prohibiting extralabel uses for drugs in food-producing animals.

**Subpart D—Extralabel Use of Human and Animal Drugs in Animals Not Intended for Human Consumption**

530.30 Extralabel drug use in nonfood animals.

**Subpart E—Safe Levels for Extralabel Use of Drugs in Animals and Drugs Prohibited From Extralabel Use in Animals**

530.40 Safe levels and availability of analytical methods.  
530.41 Drugs prohibited for extralabel use in animals.


**Source:** 61 FR 57743, Nov. 7, 1996, unless otherwise noted.
Subpart A—General Provisions

§ 530.1 Scope.
This part applies to the extralabel use in an animal of any approved new animal drug or approved new human drug by or on the lawful order of a licensed veterinarian within the context of a valid veterinary-client-patient relationship.

§ 530.2 Purpose.
The purpose of this part is to establish conditions for extralabel use or intended extralabel use in animals by or on the lawful order of licensed veterinarians of Food and Drug Administration approved new animal drugs and approved new human drugs. Such use is limited to treatment modalities when the health of an animal is threatened or suffering or death may result from failure to treat. This section implements the Animal Medicinal Drug Use Clarification Act of 1994 (the AMDUCA) (Pub. L. 103–396).

§ 530.3 Definitions.
(a) Extralabel use means actual use or intended use of a drug in an animal in a manner that is not in accordance with the approved labeling. This includes, but is not limited to, use in species not listed in the labeling, use for indications (disease or other conditions) not listed in the labeling, use at dosage levels, frequencies, or routes of administration other than those stated in the labeling, and deviation from the labeled withdrawal time based on these different uses.
(b) FDA means the U.S. Food and Drug Administration.
(c) The phrase a reasonable probability that a drug’s use may present a risk to the public health means that FDA has reason to believe that use of a drug may be likely to cause a potential adverse event.
(d) The phrase use of a drug may present a risk to the public health means that FDA has information that indicates that use of a drug may cause an adverse event.
(e) The phrase use of a drug presents a risk to the public health means that FDA has evidence that demonstrates that the use of a drug has caused or likely will cause an adverse event.
(f) A residue means any compound present in edible tissues that results from the use of a drug, and includes the drug, its metabolites, and any other substance formed in or on food because of the drug’s use.
(g) A safe level is a conservative estimate of a drug residue level in edible animal tissue derived from food safety data or other scientific information. Concentrations of residues in tissue below the safe level will not raise human food safety concerns. A safe level is not a safe concentration or a tolerance and does not indicate that an approval exists for the drug in that species or category of animal from which the food is derived.
(h) Veterinarian means a person licensed by a State or Territory to practice veterinary medicine.
(i) A valid veterinarian-client-patient relationship is one in which:
(1) A veterinarian has assumed the responsibility for making medical judgments regarding the health of (an) animal(s) and the need for medical treatment, and the client (the owner of the animal or animals or other caretaker) has agreed to follow the instructions of the veterinarian;
(2) There is sufficient knowledge of the animal(s) by the veterinarian to initiate at least a general or preliminary diagnosis of the medical condition of the animal(s); and
(3) The practicing veterinarian is readily available for followup in case of adverse reactions or failure of the regimen of therapy. Such a relationship can exist only when the veterinarian has recently seen and is personally acquainted with the keeping and care of the animal(s) by virtue of examination of the animal(s), and/or by medically appropriate and timely visits to the premises where the animal(s) are kept.

§ 530.4 Advertising and promotion.
Nothing in this part shall be construed as permitting the advertising or promotion of extralabel uses in animals of approved new animal drugs or approved human drugs.

§ 530.5 Veterinary records.
(a) As a condition of extralabel use permitted under this part, to permit FDA to ascertain any extralabel use or
§ 530.10 Provision permitting extralabel use of animal drugs.

An approved new animal drug or human drug intended to be used for an extralabel purpose in an animal is not unsafe under section 512 of the act and is exempt from the labeling requirements of section 502(f) of the act if such use is:

(a) By or on the lawful written or oral order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship; and

(b) In compliance with this part.

§ 530.11 Limitations.

In addition to uses which do not comply with the provision set forth in §530.10, the following specific extralabel uses are not permitted and result in the drug being deemed unsafe within the meaning of section 512 of the act:

(a) Extralabel use in an animal of an approved new animal drug or human drug by a lay person (except when under the supervision of a licensed veterinarian);

(b) Extralabel use of an approved new animal drug or human drug in or on an animal feed;

(c) Extralabel use resulting in any residue which may present a risk to the public health; and

(d) Extralabel use resulting in any residue above an established safe level, safe concentration or tolerance.

§ 530.12 Labeling.

Any human or animal drug prescribed and dispensed for extralabel use by a veterinarian or dispensed by a pharmacist on the order of a veterinarian shall bear or be accompanied by labeling information adequate to assure the safe and proper use of the product. Such information shall include the following:

(a) The name and address of the prescribing veterinarian. If the drug is dispensed by a pharmacy on the order of a veterinarian, the labeling shall include the name of the prescribing veterinarian and the name and address of the dispensing pharmacy, and may include the address of the prescribing veterinarian;

(b) The established name of the drug or, if formulated from more than one active ingredient, the established name of each ingredient;

(c) Any directions for use specified by the veterinarian, including the class/species or identification of the animal or herd, flock, pen, lot, or other group of animals being treated, in which the drug is intended to be used; the dosage,
§ 530.20 Conditions for permitted extralabel animal and human drug use in food-producing animals.

(a) The following conditions must be met for a permitted extralabel use in food-producing animals of approved new animal and human drugs:

(1) There is no approved new animal drug that is labeled for such use and that contains the same active ingredient which is in the required dosage form and concentration, except where a veterinarian finds, within the context of a valid veterinarian-client-patient relationship, that the approved new animal drug is clinically ineffective for its intended use.

(b) Prior to prescribing or dispensing an approved new animal or human drug for an extralabel use in food animals, the veterinarian must:

(i) Make a careful diagnosis and evaluation of the conditions for which the drug is to be used;

(ii) Establish a substantially extended withdrawal period prior to marketing of milk, meat, eggs, or other edible products supported by appropriate scientific information, if applicable;

(iii) Institute procedures to assure that the identity of the treated animal or animals is carefully maintained; and

(iv) Take appropriate measures to assure that assigned timeframes for withdrawal are met and no illegal drug residues occur in any food-producing animal subjected to extralabel treatment.

(b) The following additional conditions must be met for a permitted extralabel use of in food-producing animals an approved human drug, or of an animal drug approved only for use in animals not intended for human consumption:

(1) Such use must be accomplished in accordance with an appropriate medical rationale; and

(2) If scientific information on the human food safety aspect of the use of the drug in food-producing animals is not available, the veterinarian must take appropriate measures to assure
that the animal and its food products will not enter the human food supply.

(c) Extralabel use of an approved human drug in a food-producing animal is not permitted under this part if an animal drug approved for use in food-producing animals can be used in an extralabel manner for the particular use.

§530.21 Prohibitions for food-producing animals.

(a) FDA may prohibit the extralabel use of an approved new animal or human drug or class of drugs in food-producing animals if FDA determines that:

(1) An acceptable analytical method needs to be established and such method has not been established or cannot be established; or

(2) The extralabel use of the drug or class of drugs presents a risk to the public health.

(b) A prohibition may be a general ban on the extralabel use of the drug or class of drugs or may be limited to a specific species, indication, dosage form, route of administration, or combination of factors.

§530.22 Safe levels and analytical methods for food-producing animals.

(a) FDA may establish a safe level for extralabel use of an approved human drug or an approved new animal drug when the agency finds that there is a reasonable probability that an extralabel use may present a risk to the public health. FDA may:

(1) Establish a finite safe level based on residue and metabolism information from available sources;

(2) Establish a safe level based on the lowest level that can be measured by a practical analytical method; or

(3) Establish a safe level based on other appropriate scientific, technical, or regulatory criteria.

(b) FDA may require the development of an acceptable analytical method for the quantification of residues above any safe level established under this part. If FDA requires the development of such an acceptable analytical method, the agency will publish notice of that requirement in the Federal Register.

(c) The extralabel use of an animal drug or human drug that results in residues exceeding a safe level established under this part is an unsafe use of such drug.

(d) If the agency establishes a safe level for a particular species or category of animals and a tolerance or safe concentration is later established through an approval for that particular species or category of animals, the safe level is superseded by the tolerance or safe concentration for that species or category of animals.

§530.23 Procedure for setting and announcing safe levels.

(a) FDA may issue an order establishing a safe level for a residue of an extralabel use of an approved human drug or an approved animal drug. The agency will publish in the Federal Register a notice of the order. The notice will include:

(1) A statement setting forth the agency’s finding that there is a reasonable probability that extralabel use in animals of the human drug or animal drug may present a risk to the public health;

(2) A statement of the basis for that finding; and

(3) A request for public comments.

(b) A current listing of those drugs for which a safe level for extralabel drug use in food-producing animals has been established, the specific safe levels, and the availability, if any, of a specific analytical method or methods for drug residue detection will be codified in §530.40.

§530.24 Procedure for announcing analytical methods for drug residue quantification.

(a) FDA may issue an order announcing a specific analytical method or methods for the quantification of extralabel use drug residues above the safe levels established under §530.22 for extralabel use of an approved human drug or an approved animal drug. The agency will publish in the Federal Register a notice of the order, including the name of the specific analytical method or methods and the drug or drugs for which the method is applicable.
Food and Drug Administration, HHS

§ 530.30 Extralabel drug use in nonfood animals.

(a) Because extralabel use of animal and human drugs in nonfood-producing animals does not ordinarily pose a
§ 530.40  Threat to the public health, extralabel use of animal and human drugs is permitted in nonfood-producing animal practice except when the public health is threatened. In addition, the provisions of §530.20(a)(1) will apply to the use of an approved animal drug.

(b) If FDA determines that an extralabel drug use in animals not intended for human consumption presents a risk to the public health, the agency may publish in the FEDERAL REGISTER a notice prohibiting such use following the procedures in §530.25. The prohibited extralabel drug use will be codified in §530.41.

Subpart E—Safe Levels for Extralabel Use of Drugs in Animals and Drugs Prohibited From Extralabel Use in Animals

§ 530.40  Safe levels and availability of analytical methods.

(a) In accordance with §530.22, the following safe levels for extralabel use of an approved animal drug or human drug have been established: [Reserved]

(b) In accordance with §530.22, the following analytical methods have been accepted by FDA: [Reserved]

§ 530.41  Drugs prohibited for extralabel use in animals.

(a) The following drugs, families of drugs, and substances are prohibited for extralabel animal and human drug uses in food-producing animals.

(1) Chloramphenicol;
(2) Clenbuterol;
(3) Diethylstilbestrol (DES);
(4) Dimetridazole;
(5) Ipronidazole;
(6) Other nitroimidazoles;
(7) Furazolidone.
(8) Nitrofurazone.
(9) Sulfonamide drugs in lactating dairy cattle (except approved use of sulfadimethoxine, sulfabromomethazine, and sulfathiazole); and
(10) Fluoroquinolones; and
(11) Glycopeptides.

(b) The following drugs, families of drugs, and substances are prohibited for extralabel animal and human drug uses in nonfood-producing animals: [Reserved]


PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

Subpart A—General Provisions

Sec. 556.1  General considerations; tolerances for residues of new animal drugs in food.

Subpart B—Specific Tolerances for Residues of New Animal Drugs
§ 556.1 General considerations; tolerances for residues of new animal drugs in food.

(a) Tolerances established in this part are based upon residues of drugs in edible products of food-producing animals treated with such drugs. Consideration of an appropriate tolerance for a drug shall result in a conclusion either that:

(1) Finite residues will be present in the edible products—in which case a finite tolerance is required; or

(2) It is not possible to determine whether finite residues will be incurred but there is reasonable expectation that they may be present—in which case a tolerance for negligible residue is required; or

(3) The drug induces cancer when ingested by man or animal or, after tests which are appropriate for the evaluation of the safety of such drug, has been shown to induce cancer in man or animal; however, such drug will not adversely affect the animals for which it is intended, and no residue of such drug will be found by prescribed methods of analysis in any edible portion of such animals after slaughter or in any food yielded by or derived from the living animal—in which case the accepted method of analysis shall be published or cited, if previously published and available elsewhere, in this part; or

(4) It may or may not be possible to determine whether finite residues will be incurred but there is no reasonable expectation that they may be present—in which case the establishment of a tolerance is not required; or

(5) The drug is such that it may be metabolized and/or assimilated in such form that any possible residue would be indistinguishable from normal tissue constituents—in which case the establishment of a tolerance is not required.

(b) No tolerance established pursuant to paragraph (a)(1) of this section will be set at any level higher than that reflected by the permitted use of the drug.

(c) Any tolerance required pursuant to this section will, in addition to the


SOURCE: 40 FR 13942, Mar. 27, 1975, unless otherwise noted.
§ 556.20 Toxicological considerations, be conditioned on the availability of a practicable analytical method to determine the quantity of residue. Such method must be sensitive to and reliable at the established tolerance level or, in certain instances, may be sensitive at a higher level where such level is also deemed satisfactory and safe in light of the toxicity of the drug residue and of the unlikelihood of such residue exceeding the tolerance.

Subpart B—Specific Tolerances for Residues of New Animal Drugs

§ 556.20 2-Acetylamino-5-nitrothiazole.

A tolerance of 0.1 part per million is established for negligible residues of 2-acetylamino-5-nitrothiazole in the edible tissues of turkeys.

§ 556.30 Aklomide.

Tolerances are established for combined residues of aklomide (2-chloro-4-nitrobenzamide) and its metabolite (4-amino-2-chlorobenzamide) in uncooked edible tissues of chickens as follows:

(a) 4.5 parts per million in liver and muscle.
(b) 3 parts per million in skin with fat.

§ 556.34 Albendazole.

(a) Acceptable daily intake (ADI). The ADI for total residues of albendazole is 5 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle. A tolerance is established for albendazole 2-aminosulfone (marker residue) in liver (target tissue) of 0.2 part per million and in muscle of 0.05 part per million.

(2) Sheep. A tolerance is established for albendazole 2-aminosulfone (marker residue) in liver (target tissue) of 0.25 part per million and in muscle of 0.05 part per million.

§ 556.38 Amoxicillin.

A tolerance of 0.01 part per million is established for negligible residues of amoxicillin in milk and in the uncooked edible tissues of cattle.

§ 556.40 Ampicillin.

A tolerance of 0.01 p/m is established for negligible residues of ampicillin in the uncooked edible tissues of swine and cattle in milk.

§ 556.50 Apramycin.

A tolerance of 0.01 part per million is established for parent apramycin (marker residue) in kidney (target tissue) of swine. The acceptable daily intake (ADI) for total residues of apramycin is 25 micrograms per kilogram of body weight per day.

§ 556.60 Arsenic.

Tolerances for total residues of combined arsenic (calculated as As) in food are established as follows:

(a) In edible tissues and in eggs of chickens and turkeys:
(1) 0.5 part per million in uncooked muscle tissue.
(2) 2 parts per million in uncooked edible by-products.
(3) 0.5 part per million in eggs.
(b) In edible tissues of swine:
(1) 2 parts per million in uncooked liver and kidney.
§ 556.160 Clopidol.

Tolerances for residues of clopidol (3,5-dichloro-2,6-dimethyl-4-pyridinol) in food are established as follows:

(a) In cereal grains, vegetables, and fruits: 0.2 part per million.

(b) In chicken and turkeys: (1) 15 parts per million in uncooked liver and kidney.

(2) 5 parts per million in uncooked muscle.

(c) In cattle, sheep, and goats: (1) 3 parts per million in uncooked kidney.

§ 556.163 Clorsulon.
(a) Acceptable daily intake (ADI). The ADI for total residues of clorsulon is 8 micrograms per kilogram of body weight per day.
(b) Tolerances—(1) Cattle—(i) Kidney (the target tissue). The tolerance for parent clorsulon (the marker residue) is 1.0 part per million.
(ii) Muscle. The tolerance for parent clorsulon (the marker residue) is 0.1 part per million.
(2) Reserved

§ 556.165 Cloxacillin.
A tolerance of 0.01 part per million is established for negligible residues of cloxacillin in the uncooked edible tissues of cattle and in milk.

§ 556.167 Colistimethate.
A tolerance for residues of colistimethate in the edible tissues of chickens is not required.

§ 556.170 Decoquinate.
(a) Acceptable daily intake (ADI). The ADI for total residues of decoquinate is 75 micrograms per kilogram of body weight per day.
(b) Tolerances. Tolerances are established for residues of decoquinate in the uncooked, edible tissues of chickens, cattle, and goats as follows:
(i) 1 part per million (ppm) in skeletal muscle.
(ii) 2 ppm in other tissues.

§ 556.180 Dichlorvos.
A tolerance of 0.1 part per million is established for negligible residues of dichlorvos (2,2-dichlorovinyl dimethyl phosphate) in the edible tissues of swine.
Food and Drug Administration, HHS

§ 556.220

with TiCl₃ in basic solution to an arylamine, presumably 3,5-diaminobenzamide. The reduced fraction is placed on another Dowex-50 column, most of the interfering substances are removed with washings of alcohol and water, and the arylamine residue is eluted with 4N HCl. Colorimetric measurement is made in a 100-millimeter cell at 530 millimicrons after reacting the residue with Bratton-Marshall reagents.

II. Reagents. A. Acetone.

B. Acetyl-(p-nitrophenyl)-sulfanilamide (APNPS) standard—melting point range 264 °C–297 °C. Weigh and transfer 10 milligrams of APNPS to a 100-milliliter flask, dissolve and dilute to volume with acetone.

C. Alumina—activated P-20, 80–200 mesh, Aluminum Co. of America, or equivalent substance.

D. Ammonium sulfamate.

E. Ammonium sulfamate solution 1.25 grams of ammonium sulfamate per 100 milliliters of water. Refrigerate when not in use. Prepare fresh weekly.

F. Cation-exchange resin—Dowex 50W–X8, 200–400 mesh, Baker Analyzed Reagent, or equivalent, prepared as follows:

1. Place 500 grams of resin into a 3-liter beaker.
2. Add 2,000 milligrams of 6N HCl.
3. Heat and stir while on a bath at 80 °C for 6 hours. Discontinue heating and continue stirring overnight.
4. Filter the resin on a Buchner funnel (24 cm.) fitted with Whatman No. 1 paper.
5. Wash the resin bed with four 500-milliliter portions of 6N HCl.
6. Wash the resin bed with 500-milliliter portions of deionized water until the effluent is colorless.
7. Wash the resin bed with three 400-milliliter portions of specially denatured alcohol 3A. Drain thoroughly.
8. Make a slurry of resin in 1,250 milliliters of specially denatured alcohol 3A.

G. Chloroform.

H. Coupling reagent—0.25 gram of N-1-naphthyl-ethylenediamine dihydrochloride per 100 milliliters of water. Refrigerate when not in use. Prepare fresh weekly.

I. 3,5-Dinitrobenzamide (3,5-DNBA standard). Add to boiling specially denatured alcohol 3A until a saturated solution is obtained and treat with activated carbon, filtered, and crystallized by cooling to room temperature. The 3,5-DNBA therefrom is treated a second time with activated carbon and then recrystallized three more times from specially denatured alcohol 3A. The third crystallization is washed with diethyl ether and dried in a vacuum desiccator, melting point range 185 °C–196 °C.

J. Ethyl alcohol—absolute, A.C.S.

K. Eluting reagent A. The formula and volume required in procedure step V–D is dependent on the adsorptive strength of the Al₂O₃. For each lot Al₂O₃, make the following test:

1. Prepare a column (see procedure step V–D for determining formula and volume to eluting reagent A).

2. Transfer 1 milliliter of APNPS standard (100 micrograms per milliliter) in 75 milliliters of chloroform to the column.

3. Wash the column with 100 milliliters of chloroform and discard the eluate.

4. Pass through 100 milliliters of solution consisting of specially denatured alcohol 3A and ethyl alcohol 1:1 (volume to volume). Collect one 50-milliliter and five 10-milliliter portions; these make up the first, second, third, fourth, fifth, and sixth portions of eluate.

5. Place in beakers under a stream of air on a water bath (90 °C) until the solvents are evaporated.

6. Add 10 milliliters of 4N HCl to each, cover with watch glasses and heat (90 °C) for 30 minutes; cool to room temperature.

7. Add the Bratton-Marshall reagents.

8. All fractions show a slight color. Note the portion containing the first significant increase in pink color.

a. If the color increases in the second, third, or fourth portions of eluate, the formula in procedure step V–D is suitable and, depending on the portion, 45, 55, or 65 milliliters, respectively, should be used in procedure step V–D. Thereby, the APNPS is retained on the column and the benzamides are eluted.

b. If the color increases in the first portion, the eluting strength of the reagent is too strong. Return the test, substituting 1:4 (volume to volume) in procedure step V–D. If 1:4 (volume to volume) is too strong, rerun with ethyl alcohol in procedure step V–D. If none of these are suitable, another lot of Al₂O₃ should be used.

c. If the color increases in the fifth or sixth portion, the eluting strength of the reagent is too weak. Rerun the test, substituting in procedure step V–D, respectively, 4:1 (volume to volume), specially denatured alcohol 3A: methyl alcohol, 4:1 (volume to volume), until a suitable formula is found. If none of these are suitable, another lot of Al₂O₃ should be used.

L. Hydrochloric acid, 4N. Add two volumes of water to one volume of HCl.

M. Diatomaceous earth—Hyflo Super Cel, Johns-Manville Co., or equivalent substance.

N. N-1-Naphthylethylenediamine dihydrochloride.

O. Sodium hydroxide solution, 10N. Dissolve 100 grams of sodium hydroxide in water and dilute to 25 milliliters.

P. Sodium nitrite solution—0.25 grams of sodium nitrite per 100 milliliters of water. Refrigerate when not in use. Prepare fresh weekly.

339
§ 556.220

Q. Specially denatured alcohol, formula 3A–100 parts of 190-proof ethyl alcohol plus 5 parts of commercial methyl alcohol.

R. Tитanium(Ⅱ) chloride–20 percent solution.

III. Special apparatus. A. Absorption cells—Beckman No. 75195 matched set of two cylindrical silica cells with 100 millimeter optical length, or equivalent cells.

B. Autotransformer—type 500B, or equivalent. To regulate speed of mixer.

C. Centrifuge.

D. Centrifuge tubes—50-milliliter size with glass stopper.

E. Chromatography tubes—Corning No. 38460, 20 millimeters A 400 millimeters and glass stopper.

F. Evaporator—vacuum, rotary, thin film.

G. Ion-exchange column—as described by Thiegs et al. in "Determination of 3-amino-5-nitro-o-toluamide (ANOT) in chicken tissues" published in "Journal of Agricultural and Food Chemistry" 9, pages 201–204 (1961).

H. Glycerol manostat. For regulating pressure on columns: To Al₂O₃ columns, 15-inch diameter ware.

I. Motor speed control. For regulating speed on 1-quart blender.

J. Volumetric flasks—50 milliliter size, acetic ware.


L. One-quart blender.

M. Water bath (45 °C–50 °C.).

N. Water bath (90 °C.).

IV. Standard curve. A. 1. Weigh 100 milligrams of 3,5-DNBA and transfer to a 1-liter volumetric flask with acetone.

2. Dissolve and dilute with acetone to volume.

3. Dilute 1 milliliter to 100 milliliters.

4. Add 5.0 milliliters of water to each of six centrifuge tubes.

5. Add standard to each of the tubes to contain one of the following amounts: 0.0, 1.0, 2.0, 3.0, 5.0, and 10.0 micrograms of 3,5-DNBA.

B. Prepare each tube for colorimetric measurement as follows:

1. Place the tube in a hot water bath (90 °C.) until 5.0 milliliters remain. Cool to room temperature.

2. While mixing on Vortex mixer, or equivalent, regulated with an autotransformer, add 2 drops of TiCl₃ and 4 drops of 10N NaOH. Continue mixing until chalky-white in appearance.

3. Add 2 milliliters of HCl, mix, and allow to stand for 5 minutes.

4. Transfer to 50-milliliter volumetric flask and dilute with 4N HCl to 40–45 milliliters.

5. Cool to 0 °C.–5 °C. by placing in a freezer or ice bath.

6. Perform the Bratton-Marshall reaction in subdued light as follows:

a. Add 1 milliliter of sodium nitrite reagent, mix, and allow to stand for 1 minute.

b. Add 1 milliliter of ammonium sulfamate reagent, mix, and allow to stand for 1 minute.

c. Add 1 milliliter of coupling reagent, mix, and allow to stand for 10 minutes.

d. Dilute to volume with 4N HCl.

e. Perform colorimetric measurement at 530 millimicrons as follows:

1. Fill two matched 100-millimeter cells with 4N HCl and place into spectrophotometer.

2. Adjust dark current.

3. Adjust to zero absorbance.

4. Replace acid in cell of sample side of compartment with standard to be measured.

5. The standard curve should be run five different times. Plot equivalent concentration in tissue versus mean absorbance at each concentration. If computer is available, a better procedure is to calculate the equation of the standard curve by means of least squares.

V. Procedure. A. Extraction. 1. Mince 350 grams of tissue in a 1-quart blending jar for 3 minutes. Use samples obtained from either freshly killed or quickly frozen birds. The latter should be analyzed as soon as thawed. For fibrous meats (for example, muscle, skin) put through a meat grinder before mincing.

2. Weight 100±0.5 grams of each replicate sample in a 150-milliliter beaker. Analyze each sample in triplicate and average the results. Reproducibility of ±10 percent between such analyses has been obtained.

3. Transfer the sample to a 1-quart blender jar. For kidney and liver tissues, make a slurry with acetone in the weighing beaker. Transfer with several rinses of acetone.

4. Blend the sample for 5 minutes with 250 milliliters of acetone and a 100-milliliter beakerful of diatomaceous earth.

5. Filter through a Buchner funnel containing a wetted Whatman No. 5 filter paper (12.5 cm.) into a 1-liter suction flask.

6. Rinse the blender jar into the funnel with three 25-milliliter portions of acetone.

7. Transfer the pulp and paper from the funnel to the aforementioned blender jar.

8. Add 250 milliliters of chloroform.

9. Blend for 3 minutes.

10. Filter through the aforementioned apparatus of procedure step V. Use rapid filtration of skin and blood samples, prepare funnel by adding diatomaceous earth and tamping evenly over paper to a thickness of 3 to 5 millimeters.

11. Rinse the blender jar into the funnel with three 25-milliliter rinses of chloroform.

B. Phasic separation. 1. Pour the combined filtrates into a 1-liter separatory funnel.

2. Rinse the suction flask twice with 25 milliliters of chloroform.

3. Mix the funnel contents by gently rocking and swirling for 30 seconds.
4. Let stand 10 minutes to allow phases to separate.
   a. The upper (aqueous) phase (30 to 50 milliliters) is not always emulsion-free. Losses from emulsions have not been significant.
   b. If an upper (aqueous) phase does not appear, add an additional 100 milliliters of chloroform and 10 milliliters of water and repeat procedure step V–E3.
5. Withdraw the lower phase into a 1-liter round-bottom flask, and discard upper phase. Withdraw nearly all of the lower phase, let stand for 2 to 3 minutes, then withdraw the remainder.
C. Evaporation. Attach the flask on a thin-film rotary evaporator connected to a vacuum supply, and place in a water bath maintained at 45 °C–50 °C, until an oily residue remains. Do not overheat the sample or allow the sample to go to dryness.
D. Adsorption chromatography. 1. Prepare a chromatography column using a column with calibrated etchings to indicate appropriate adsorbent and solvent levels as follows:
   a. Fill tube to a depth of 60 millimeters with Al₂O₃.
   b. Tap walls gently with hands.
   c. Add anhydrous sodium sulfate to an additional depth of 25 millimeters.
   d. Wet and wash column with 50 milliliters of chloroform.
   i. During chromatography, make each addition to the tube when the liquid level has reached the top of the sodium sulfate layer.
   ii. Increase the percolation rates by applying a slight air pressure to the top of the column.
   2. Transfer the residue from procedure step V–C to the column with four 15-milliliter rinses of chloroform. Then rinse the walls of the tube and sodium sulfate layer with three 5-milliliter portions of chloroform. Percolation rate: 15 to 25 milliliters per minute. No color from sample should be seen in sodium sulfate layer after final rinse.
   3. Wash column with 100 milliliters of chloroform. Discard eluate.
4. Add 75 milliliters of eluting reagent A and collect eluate A in a 250-milliliter beaker three times with 3 milliliters of specially denatured alcohol 3A.
5. Withdraw the lower phase into a 1-liter round-bottom flask, and discard upper phase.
   a. The upper (aqueous) phase (30 to 50 milliliters) is not always emulsion-free. Losses from emulsions have not been significant.
   b. If an upper (aqueous) phase does not appear, add an additional 100 milliliters of chloroform and 10 milliliters of water and repeat procedure step V–E3.
6. Let stand 10 minutes to allow phases to separate.
   a. The upper (aqueous) phase (30 to 50 milliliters) is not always emulsion-free. Losses from emulsions have not been significant.
   b. If an upper (aqueous) phase does not appear, add an additional 100 milliliters of chloroform and 10 milliliters of water and repeat procedure step V–E3.
5. Withdraw the lower phase into a 1-liter round-bottom flask, and discard upper phase. Withdraw nearly all of the lower phase, let stand for 2 to 3 minutes, then withdraw the remainder.
C. Evaporation. Attach the flask on a thin-film rotary evaporator connected to a vacuum supply, and place in a water bath maintained at 45 °C–50 °C, until an oily residue remains. Do not overheat the sample or allow the sample to go to dryness.
D. Adsorption chromatography. 1. Prepare a chromatography column using a column with calibrated etchings to indicate appropriate adsorbent and solvent levels as follows:
   a. Fill tube to a depth of 60 millimeters with Al₂O₃.
   b. Tap walls gently with hands.
   c. Add anhydrous sodium sulfate to an additional depth of 25 millimeters.
   d. Wet and wash column with 50 milliliters of chloroform.
   i. During chromatography, make each addition to the tube when the liquid level has reached the top of the sodium sulfate layer.
   ii. Increase the percolation rates by applying a slight air pressure to the top of the column.
   2. Transfer the residue from procedure step V–C to the column with four 15-milliliter rinses of chloroform. Then rinse the walls of the tube and sodium sulfate layer with three 5-milliliter portions of chloroform. Percolation rate: 15 to 25 milliliters per minute. No color from sample should be seen in sodium sulfate layer after final rinse.
   3. Wash column with 100 milliliters of chloroform. Discard eluate.
4. Add 75 milliliters of eluting reagent A and collect eluate A in a 250-milliliter beaker three times with 3 milliliters of specially denatured alcohol 3A.
5. Withdraw the lower phase into a 1-liter round-bottom flask, and discard upper phase.
   a. The upper (aqueous) phase (30 to 50 milliliters) is not always emulsion-free. Losses from emulsions have not been significant.
   b. If an upper (aqueous) phase does not appear, add an additional 100 milliliters of chloroform and 10 milliliters of water and repeat procedure step V–E3.
6. Let stand 10 minutes to allow phases to separate.
   a. The upper (aqueous) phase (30 to 50 milliliters) is not always emulsion-free. Losses from emulsions have not been significant.
   b. If an upper (aqueous) phase does not appear, add an additional 100 milliliters of chloroform and 10 milliliters of water and repeat procedure step V–E3.
5. Withdraw the lower phase into a 1-liter round-bottom flask, and discard upper phase. Withdraw nearly all of the lower phase, let stand for 2 to 3 minutes, then withdraw the remainder.
C. Evaporation. Attach the flask on a thin-film rotary evaporator connected to a vacuum supply, and place in a water bath maintained at 45 °C–50 °C, until an oily residue remains. Do not overheat the sample or allow the sample to go to dryness.
D. Adsorption chromatography. 1. Prepare a chromatography column using a column with calibrated etchings to indicate appropriate adsorbent and solvent levels as follows:
   a. Fill tube to a depth of 60 millimeters with Al₂O₃.
   b. Tap walls gently with hands.
   c. Add anhydrous sodium sulfate to an additional depth of 25 millimeters.
   d. Wet and wash column with 50 milliliters of chloroform.
   i. During chromatography, make each addition to the tube when the liquid level has reached the top of the sodium sulfate layer.
   ii. Increase the percolation rates by applying a slight air pressure to the top of the column.
   2. Transfer the residue from procedure step V–C to the column with four 15-milliliter rinses of chloroform. Then rinse the walls of the tube and sodium sulfate layer with three 5-milliliter portions of chloroform. Percolation rate: 15 to 25 milliliters per minute. No color from sample should be seen in sodium sulfate layer after final rinse.
   3. Wash column with 100 milliliters of chloroform. Discard eluate.
4. Add 75 milliliters of eluting reagent A and collect eluate A in a 250-milliliter beaker three times with 3 milliliters of specially denatured alcohol 3A.
5. Withdraw the lower phase into a 1-liter round-bottom flask, and discard upper phase.
   a. The upper (aqueous) phase (30 to 50 milliliters) is not always emulsion-free. Losses from emulsions have not been significant.
   b. If an upper (aqueous) phase does not appear, add an additional 100 milliliters of chloroform and 10 milliliters of water and repeat procedure step V–E3.
6. Let stand 10 minutes to allow phases to separate.
   a. The upper (aqueous) phase (30 to 50 milliliters) is not always emulsion-free. Losses from emulsions have not been significant.
   b. If an upper (aqueous) phase does not appear, add an additional 100 milliliters of chloroform and 10 milliliters of water and repeat procedure step V–E3.
5. Withdraw the lower phase into a 1-liter round-bottom flask, and discard upper phase. Withdraw nearly all of the lower phase, let stand for 2 to 3 minutes, then withdraw the remainder.
C. Evaporation. Attach the flask on a thin-film rotary evaporator connected to a vacuum supply, and place in a water bath maintained at 45 °C–50 °C, until an oily residue remains. Do not overheat the sample or allow the sample to go to dryness.
D. Adsorption chromatography. 1. Prepare a chromatography column using a column with calibrated etchings to indicate appropriate adsorbent and solvent levels as follows:
   a. Fill tube to a depth of 60 millimeters with Al₂O₃.
   b. Tap walls gently with hands.
   c. Add anhydrous sodium sulfate to an additional depth of 25 millimeters.
   d. Wet and wash column with 50 milliliters of chloroform.
   i. During chromatography, make each addition to the tube when the liquid level has reached the top of the sodium sulfate layer.
   ii. Increase the percolation rates by applying a slight air pressure to the top of the column.
   2. Transfer the residue from procedure step V–C to the column with four 15-milliliter rinses of chloroform. Then rinse the walls of the tube and sodium sulfate layer with three 5-milliliter portions of chloroform. Percolation rate: 15 to 25 milliliters per minute. No color from sample should be seen in sodium sulfate layer after final rinse.
   3. Wash column with 100 milliliters of chloroform. Discard eluate.
4. Add 75 milliliters of eluting reagent A and collect eluate A in a 250-milliliter beaker three times with 3 milliliters of specially denatured alcohol 3A.
5. Withdraw the lower phase into a 1-liter round-bottom flask, and discard upper phase.
   a. The upper (aqueous) phase (30 to 50 milliliters) is not always emulsion-free. Losses from emulsions have not been significant.
   b. If an upper (aqueous) phase does not appear, add an additional 100 milliliters of chloroform and 10 milliliters of water and repeat procedure step V–E3.
6. Let stand 10 minutes to allow phases to separate.
   a. The upper (aqueous) phase (30 to 50 milliliters) is not always emulsion-free. Losses from emulsions have not been significant.
   b. If an upper (aqueous) phase does not appear, add an additional 100 milliliters of chloroform and 10 milliliters of water and repeat procedure step V–E3.
§ 556.225  Doramectin.

(a) Acceptable daily intake (ADI). The ADI for total residues of doramectin is 0.75 microgram per kilogram of body weight per day.

(b) Tolerances—(1) Cattle. A tolerance of 100 parts per billion is established for parent doramectin (marker residue) in liver (target tissue) and of 30 parts per billion for parent doramectin in muscle.

(2) Swine. A tolerance is established for parent doramectin (marker residue) in liver (target tissue) of 160 parts per billion.

§ 556.227  Eprinomectin.

(a) Acceptable daily intake (ADI). The ADI for total residues of eprinomectin is 10 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle. Tolerances are established for residues of eprinomectin B1a (marker residue) in milk of 12 parts per billion, in liver (target tissue) of 4.8 parts per million, and in muscle of 100 parts per billion.

(2) [Reserved]

§ 556.228  Enrofloxacin.

The acceptable daily intake for enrofloxacin is 3 micrograms per kilogram of body weight per day.

(a) Chickens and turkeys. A tolerance of 0.3 part per million is established for residues of enrofloxacin (marker residue) in muscle (target tissue) of chickens and turkeys.

(b) Cattle. A tolerance of 0.1 part per million for desethylene ciprofloxacin (marker residue) has been established in liver (target tissue) of cattle.

§ 556.230  Erythromycin.

Tolerances for residues of erythromycin in food are established as follows:

(a) 0.1 part per million in uncooked edible tissues of beef cattle and swine.

(b) Zero in milk.

(c) 0.025 part per million in uncooked eggs.

(d) 0.125 part per million (negligible residue) in uncooked edible tissues of chickens and turkeys.

§ 556.240  Estradiol and related esters.

No residues of estradiol, resulting from the use of estradiol or any of the related esters, are permitted in excess of the following increments above the concentrations of estradiol naturally present in untreated animals:

(a) In uncooked edible tissues of heifers, steers, and calves:

(1) 120 parts per trillion for muscle.

(2) 480 parts per trillion for fat.

(3) 360 parts per trillion for kidney.

(4) 240 parts per trillion for liver.

(b) In uncooked edible tissues of lambs:

(1) 120 parts per trillion for muscle.

(2) 600 parts per trillion for fat, kidney, and liver.

§ 556.260  Ethopabate.

Tolerance for residues of ethopabate converted to metaphenetidine are established in the edible tissues of chickens as follows:

(a) 1.5 parts per million in uncooked liver and kidney.

(b) 0.5 part per million in uncooked muscle.

§ 556.270  Ethylenediamine.

A tolerance of zero is established for residues of ethylenediamine in milk.

§ 556.273  Famphur.

Tolerances are established for residues of famphur including its oxygen
§ 556.275 Fenbendazole.

(a) Acceptable daily intake (ADI). The ADI for total residues of fenbendazole is 40 micrograms per kilogram of body weight per day.

(b) Tolerances—

(1) Cattle—(i) Liver (the target tissue). The tolerance for parent fenbendazole (the marker residue) is 0.8 part per million (ppm).

(ii) Muscle. The tolerance for parent fenbendazole (the marker residue) is 0.4 ppm.

(iii) Milk. The tolerance for fenbendazole sulfoxide metabolite (the marker residue in cattle milk) is 0.6 ppm.

(2) Swine—(i) Liver (the target tissue). The tolerance for parent fenbendazole (the marker residue) is 6 ppm.

(ii) Muscle. The tolerance for parent fenbendazole (the marker residue) is 2 ppm.

(3) Turkeys—(i) Liver (the target tissue). The tolerance for fenbendazole sulfone (the marker residue) is 6 ppm.

(ii) Muscle. The tolerance for fenbendazole sulfone (the marker residue) is 2 ppm.

(4) Goats—(i) Liver (the target tissue). The tolerance for parent fenbendazole (the marker residue) is 0.8 ppm.

(ii) Muscle. The tolerance for parent fenbendazole (the marker residue) is 0.4 ppm.

§ 556.277 Fenprostalene.

A tolerance for marker residue of fenprostalene in cattle is not needed. The safe concentrations for the total residues of fenprostalene in the uncooked edible tissues of cattle are 10 parts per billion in muscle, 20 parts per billion in liver, 30 parts per billion in kidney, 40 parts per billion in fat, and 100 parts per billion in the injection site. As used in this section “tolerance” refers to a concentration of a marker residue in the target tissue selected to monitor for total residues of the drug in the target animal, and “safe concentrations” refer to the concentrations of total residues considered safe in edible tissues.

§ 556.283 Florfenicol.

(a) Acceptable daily intake (ADI). The ADI for total residues of florfenicol is 10 micrograms per kilogram of body weight per day.

(b) Cattle. A tolerance of 3.7 parts per million (ppm) for florfenicol amine (marker residue) in liver (target tissue) is established. A tolerance of 0.3 ppm for florfenicol amine in cattle muscle is established.

§ 556.286 Flunixin meglumine.

(a) Acceptable daily intake (ADI). The ADI for total residues of flunixin is 0.72 micrograms per kilogram of body weight per day.

(b) Tolerances. For residues of parent flunixin free acid of 0.125 part per million (ppm) in cattle liver (target tissue) and 0.025 ppm in cattle muscle are established.

§ 556.290 Furazolidone.

A tolerance of zero is established for residues of furazolidone in the uncooked edible tissues of swine.

§ 556.300 Gentamicin sulfate.

(a) A tolerance of 0.1 part per million is established for negligible residues of gentamicin sulfate in the uncooked edible tissues of chickens and turkeys.

(b) Tolerances are established for total residues of gentamicin in edible tissues of swine as follows: 0.1 part per million in muscle, 0.3 part per million in liver, and 0.4 part per million in fat and kidney. A microbiological determinative procedure and an HPLC confirmatory procedure for gentamicin have been developed to assay gentamicin in kidney at 0.4 ppm. Since residues of gentamicin as the parent compound and total residues are equal, the marker (parent drug) residue concentration of 0.4 ppm in kidney corresponds to 0.4 ppm of total residue.
§ 556.304 Gonadotropin.

(a) Acceptable daily intake (ADI). The ADI for residues of total gonadotropins (human chorionic gonadotropin and pregnant mare serum gonadotropin) is 42.25 I.U. per kilogram of body weight per day.

(b) Tolerances. A tolerance for residues of gonadotropin in uncooked edible tissues of cattle or of fish is not required.

[64 FR 48545, Sept. 7, 1999]

§ 556.308 Halofuginone hydrobromide.

The marker residue selected to monitor for total residues of halofuginone hydrobromide in broilers and turkeys is parent halofuginone hydrobromide and the target tissue selected is liver. A tolerance is established in broilers of 0.16 part per million and in turkeys of 0.13 part per million for parent halofuginone hydrobromide in liver. These marker residue concentrations in liver correspond to total residue concentrations of 0.3 part per million in liver. The safe concentrations for total residues of halofuginone hydrobromide in the uncooked edible tissues of broilers and turkeys are 0.1 part per million in muscle, 0.3 part per million in liver, and 0.2 part per million in skin with adhering fat. As used in this section, “tolerance” refers to a concentration of a marker residue in the target tissue selected to monitor for total residues of the drug in the target animal, and “safe concentrations” refers to the concentrations of total residues considered safe in edible tissues.


§ 556.310 Haloxon.

A tolerance of 0.1 part per million is established for negligible residues of haloxon (3-chloro-7-hydroxy-4-methylcoumarin bis(2-chloroethyl) phosphate) in the edible tissues of cattle.

[40 FR 13942, Mar. 27, 1975, as amended at 45 FR 10333, Feb. 15, 1980]

§ 556.320 Hydrocortisone.

A tolerance is established for negligible residues of hydrocortisone (as hydrocortisone sodium succinate or hydrocortisone acetate) in milk at 10 parts per billion.

§ 556.330 Hygromycin B.

A tolerance of zero is established for residues of hygromycin B in or on eggs and the uncooked edible tissues of swine and poultry.

§ 556.344 Ivermectin.

(a) Acceptable daily intake (ADI). The ADI for total residues of ivermectin is 1 microgram per kilogram of body weight per day.

(b) Tolerances—(1) Liver. A tolerance is established for 22,23-dihydroavermectin B₁a (marker residue) in liver (target tissue) as follows:

(i) Cattle. 100 parts per billion.

(ii) Swine. 20 parts per billion.

(iii) Sheep. 30 parts per billion.

(iv) Reindeer. 15 parts per billion.

(v) American bison. 15 parts per billion.

(2) Muscle. Muscle residues are not indicative of the safety of other edible tissues. A tolerance is established for 22,23-dihydroavermectin B₁a (marker residue) in muscle as follows:

(i) Swine. 20 parts per billion.

(ii) Cattle. 10 parts per billion.


§ 556.347 Lasalocid.

(a) Acceptable daily intake (ADI). The ADI for total residues of lasalocid is 10 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle. The tolerance for parent lasalocid (the marker residue) in liver (the target tissue) is 0.7 part per million (ppm).

(2) Chickens—(i) Skin with adhering fat (the target tissue). The tolerance for parent lasalocid (the marker residue) is 1.2 ppm.

(ii) Liver. The tolerance for parent lasalocid (the marker residue) is 0.4 ppm.

(3) Turkeys—(i) Liver (the target tissue). The tolerance for parent lasalocid (the marker residue) is 0.4 ppm.

(ii) Skin with adhering fat. The tolerance for parent lasalocid (the marker residue) is 0.4 ppm.
(4) **Rabbits.** The tolerance for parent lasalocid (the marker residue) in liver (the target tissue) is 0.7 ppm.

(5) **Sheep.** The tolerance for parent lasalocid (the marker residue) in liver (the target tissue) is 1.0 ppm.

§ 556.350 **Levamisole hydrochloride.**

A tolerance of 0.1 part per million is established for negligible residues of levamisole hydrochloride in the edible tissues of cattle, sheep, and swine.

§ 556.360 **Lincomycin.**

(a) **Acceptable daily intake (ADI).** The ADI for total residues of lincomycin is 25 micrograms per kilogram of body weight per day.

(b) **Chickens.** A tolerance for residues of lincomycin in chickens is not required.

(c) **Swine.** Tolerances for lincomycin of 0.6 part per million in liver and 0.1 part per million in muscle are established.

§ 556.375 **Maduramicin ammonium.**

A tolerance is established for residues of maduramicin ammonium in chickens as follows:

(a) A tolerance for maduramicin ammonium (marker residue) in chickens is 0.38 parts per million in fat (target tissue). A tolerance refers to the concentration of marker residues in the target tissue used to monitor for total drug residues in the target animals.

(b) The safe concentrations for total maduramicin ammonium residues in uncooked edible chicken tissues are: 0.34 parts per million in muscle; 0.72 parts per million in liver; 0.48 parts per million in skin; and 0.48 parts per million in fat. A safe concentration refers to the total residue concentration considered safe in edible tissues.

§ 556.380 **Melengestrol acetate.**

A tolerance of 25 parts per billion is established for residues of the parent compound, melengestrol acetate, in fat of cattle.

§ 556.390 **Methylparaben.**

A tolerance of zero is established for residues of methylparaben in milk from dairy animals.

§ 556.400 **Methylprednisolone.**

A tolerance is established for negligible residues of methylprednisolone in milk at 10 parts per billion.

§ 556.410 **Metoserpate hydrochloride.**

A tolerance of 0.02 part per million is established for negligible residues of metoserpate hydrochloride (methyl-o-methyl-18-epireserpate hydrochloride) in uncooked edible tissues of chickens.

§ 556.420 **Monensin.**

(a) **Acceptable daily intake (ADI).** The ADI for total residues of monensin is 12.5 micrograms per kilogram of body weight per day.

(b) **Tolerances—(1) Cattle and goats.** A tolerance of 0.05 part per million is established for negligible residues of monensin in edible tissues of cattle and goats.

(2) **Chickens, turkeys, and quail.** A tolerance for residues of monensin in chickens, turkeys, and quail is not needed.

§ 556.425 **Morantel tartrate.**

A tolerance of 0.7 part per million is established for N-methyl-1,3-propanediamine (MAPA, marker residue) in the liver (target tissue) of cattle and goats. A tolerance for residues of morantel tartrate in milk is not required.

§ 556.426 **Moxidectin.**

(a) **Acceptable daily intake (ADI).** The ADI for total residues of moxidectin is 4 micrograms per kilogram of body weight per day.

(b) **Tolerances—(1) Cattle—(i) Liver (the target tissue).** The tolerance for parent moxidectin (the marker residue) is 200 parts per billion (ppb).

(1) **Muscle.** The tolerance for parent moxidectin (the marker residue) is 50 ppb.
(iii) Milk. The tolerance for parent moxidectin (the marker residue in cattle milk) is 40 ppb.

(2) [Reserved]

[65 FR 36617, June 9, 2000, as amended at 65 FR 76930, Dec. 8, 2000]

§ 556.428 Narasin.

(a) Acceptable daily intake (ADI). The ADI for total residues of narasin is 5 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Chickens (abdominal fat). The tolerance for parent narasin (the marker residue) is 480 parts per billion.

(2) [Reserved]

[66 FR 23589, May 9, 2001]

§ 556.430 Neomycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of neomycin is 6 micrograms per kilogram of body weight per day.

(b) Tolerances. Tolerances are established for residues of parent neomycin in uncooked edible tissues as follows:

(1) Cattle, swine, sheep, and goats. 7.2 parts per million (ppm) in kidney (target tissue) and fat, 3.6 ppm in liver, and 1.2 ppm in muscle.

(2) Turkeys. 7.2 ppm in skin with adhearing fat, 3.6 ppm in liver, and 1.2 ppm in muscle.

(3) Milk. A tolerance is established for residues of parent neomycin of 0.15 ppm.

[64 FR 31498, June 11, 1999]

§ 556.440 Nequinate.

A tolerance of 0.1 part per million is established for negligible residues of nequinate in the uncooked edible tissues of chickens.

§ 556.445 Nicarbazin.

A tolerance of 4 parts per million is established for residues of nicarbazin in uncooked chicken muscle, liver, skin, and kidney.

[42 FR 56729, Oct. 28, 1977]

§ 556.460 Novobiocin.

Tolerances for residues of novobiocin are established at 0.1 part per million in milk from dairy animals and 1 part per million in the uncooked edible tissues of cattle, chickens, turkeys, and ducks.

[47 FR 18590, Apr. 30, 1982]

§ 556.470 Nystatin.

A tolerance of zero is established for residues of nystatin in or on eggs and the uncooked edible tissues of swine and poultry.

§ 556.480 Oleandomycin.

Tolerances are established for negligible residues of oleandomycin in uncooked edible tissues of chickens, turkeys, and swine at 0.15 part per million.

§ 556.490 Ormetoprim.

(a) [Reserved]

(b) Tolerances. A tolerance of 0.1 part per million (ppm) is established for negligible residues of ormetoprim in uncooked edible tissues of chickens, turkeys, ducks, salmonids, catfish, and chukar partridges.

[64 FR 26672, May 17, 1999]

§ 556.495 Oxfendazole.

Cattle: A tolerance is established for total oxfendazole residues in edible cattle tissues based on a marker residue concentration of 0.8 part per million (ppm) fenbendazole in the target liver tissue. A fenbendazole concentration of 0.8 ppm in liver corresponds to a total safe concentration of oxfendazole residues of 1.7 ppm in liver. The safe concentrations of total oxfendazole residues in other uncooked edible cattle tissues are: muscle, 0.84 ppm; kidney, 2.5 ppm; and fat, 3.3 ppm. A tolerance refers to the concentration of marker residue in the target tissue selected to monitor for total drug residue in the target animal. A safe concentration is the total residue considered safe in edible tissue.

[55 FR 46943, Nov. 8, 1990]

§ 556.500 Oxytetracycline.

(a) Acceptable daily intake (ADI). The ADI for total tetracycline residues (chlortetracycline, oxytetracycline, and tetracycline) is 25 micrograms per kilogram of body weight per day.

(b) Beef cattle, dairy cattle, calves, swine, sheep, chickens, turkeys, catfish,
§ 556.510 Penicillin.

Tolerances are established for residues of penicillin and the salts of penicillin in food as follows:

(a) 0.05 part per million (negligible residue) in the uncooked edible tissues of cattle.

(b) Zero in the uncooked edible tissues of chickens, pheasants, quail, swine, and sheep; in eggs; and in milk or in any processed food in which such milk has been used.

(c) 0.01 part per million in the uncooked edible tissues of turkeys.

[40 FR 13942, Mar. 27, 1975, as amended at 43 FR 32749, July 28, 1978]

§ 556.513 Piperazine.

A tolerance of 0.1 part per million piperazine base is established for edible tissues of poultry and swine.

[64 FR 23019, Apr. 29, 1999]

§ 556.515 Pirilimycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of pirilimycin is 0.01 milligram per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for parent pirilimycin (the marker residue) is 0.5 part per million (ppm).

(ii) Muscle. The tolerance for parent pirilimycin (the marker residue) is 0.3 ppm.

(iii) Milk. The tolerance for parent pirilimycin (the marker residue in cattle milk) is 0.4 ppm.

(2) [Reserved]

[65 FR 61061, Oct. 16, 2000]

§ 556.520 Prednisolone.

A tolerance of zero is established for residues of prednisolone in milk from dairy animals.

§ 556.530 Prednisone.

A tolerance of zero is established for residues of prednisone in milk from dairy animals.

§ 556.540 Progesterone.

No residues of progesterone are permitted in excess of the following increments above the concentrations of progesterone naturally present in untreated animals:

(a) In uncooked edible tissues of steers and calves:

(1) 3 parts per billion for muscle.

(2) 12 parts per billion for fat.

(3) 9 parts per billion for kidney.

(4) 6 parts per billion for liver.

(b) In uncooked edible tissues of lambs:

(1) 3 parts per billion for muscle.

(2) 15 parts per billion for fat, kidney, and liver.

[49 FR 13873, Apr. 9, 1984]

§ 556.550 Propylparaben.

A tolerance of zero is established for residues of propylparaben in milk from dairy animals.

§ 556.560 Pyrantel tartrate.

Tolerances are established for residues of pyrantel tartrate in edible tissues of swine as follows:

(a) 10 parts per million in liver and kidney.

(b) 1 part per million in muscle.

§ 556.570 Ractopamine.

(a) Acceptable daily intake (ADI). The ADI for total residues of ractopamine is 1.25 micrograms ractopamine hydrochloride per kilogram of body weight per day.

(b) Tolerances. Swine—Tolerances are established for residues of ractopamine hydrochloride parent (marker residue) in edible swine tissues of 0.05 part per million (ppm) in muscle, and 0.15 ppm in liver (target tissue). Residues of ractopamine in swine muscle are not...
\section*{§ 556.580 Robenidine hydrochloride.}

Tolerances are established for residues of robenidine hydrochloride in edible tissues of chickens as follows:

(a) 0.2 part per million in skin and fat.

(b) 0.1 part per million (negligible residue) in edible tissues other than skin and fat.

\section*{§ 556.590 Salicylic acid.}

A tolerance of zero is established for residues of salicylic acid in milk from dairy animals.

\section*{§ 556.592 Salinomycin.}

(a) \textit{Acceptable daily intake (ADI)}. The ADI for total residues of salinomycin is 0.005 milligram per kilogram of body weight per day.

(b) [Reserved]

\section*{§ 556.597 Semduramicin.}

(a) \textit{Acceptable daily intake (ADI)}. The ADI for total residues of semduramicin is 180 micrograms per kilogram of body weight per day.

(b) \textit{Tolerances}.—(1) \textit{Broiler chickens}. Tolerances are established for residues of parent semduramicin in uncooked edible tissues of 400 parts per billion (ppb) in liver and 130 ppb in muscle.

(2) [Reserved]

\section*{§ 556.600 Spectinomycin.}

(a) \textit{Acceptable daily intake (ADI)}. The ADI for total residues of spectinomycin is 25 micrograms per kilogram of body weight per day.

(b) \textit{Chickens and turkeys}. A tolerance of 0.1 part per million (ppm) for negligible residues of spectinomycin in uncooked edible tissues of chickens and turkeys is established.

(c) \textit{Cattle}. A tolerance of 0 ppm for parent spectinomycin in cattle muscle is established.

\section*{§ 556.610 Streptomycin.}

Tolerances are established for residues of streptomycin in uncooked, edible tissues of chickens, swine, and calves of 2.0 parts per million (ppm) in kidney and 0.5 ppm in other tissues.

\section*{§ 556.620 Sulfabromomethazine sodium.}

Tolerances for residues of sulfabromomethazine sodium in food are established as follows:

(a) In the uncooked edible tissues of cattle at 0.1 part per million (negligible residue).

(b) In milk at 0.01 part per million (negligible residue).

\section*{§ 556.625 Sodium sulfachloropyrazine monohydrate.}

A tolerance of zero is established for residues of sodium sulfachloropyrazine monohydrate in the uncooked edible tissues of chickens.

\section*{§ 556.630 Sulfachloropyridazine.}

A tolerance of 0.1 part per million is established for negligible residues of sulfachloropyridazine in uncooked edible tissues of calves and swine.

\section*{§ 556.640 Sulfadimethoxine.}

(a) [Reserved]

(b) \textit{Tolerances}.—(1) A tolerance of 0.1 part per million (ppm) is established for negligible residues of sulfadimethoxine in uncooked edible tissues of chickens, turkeys, cattle, ducks, salmonids, catfish, and chukar partridges.

(2) A tolerance of 0.01 ppm is established for negligible residues of sulfadimethoxine in milk.

\section*{§ 556.650 Sulfaethoxypyridazine.}

Tolerances for residues of sulfaethoxypyridazine in food are established as follows:
§ 556.660 Sulfamerazine.
A tolerance of zero is established for residues of sulfamerazine (N\textsubscript{1}\textendash[4-methyl-2-pyrimidinyl]sulfanilamide) in the uncooked edible tissues of trout.

§ 556.670 Sulfamethazine.
A tolerance of 0.1 part per million is established for negligible residues of sulfamethazine in the uncooked edible tissues of chickens, turkeys, cattle, and swine.

§ 556.680 Sulfanitran.
A tolerance of zero is established for residues of sulfanitran (acetyl(p-nitrophenyl) sulfanilamide) and its metabolites in the uncooked edible tissues of chickens.

§ 556.685 Sulfadiazine.
A tolerance of 0.1 part per million is established for negligible residues of sulfadiazine in the uncooked edible tissues of chickens, turkeys, calves, and cattle.

§ 556.690 Sulfathiazole.
A tolerance of 0.1 part per million is established for negligible residues of sulfathiazole in the uncooked edible tissues of swine.

§ 556.700 Sulfonylaminodiazine.
A tolerance of zero is established for residues of sulfonylaminodiazine (N-sulfomethylpolymyxin B sodium salt) in uncooked edible tissues from chickens and turkeys.

§ 556.710 Testosterone propionate.
No residues of testosterone, resulting from the use of testosterone propionate, are permitted in excess of the following increments above the concentrations of testosterone naturally present in untreated animals:
(a) In uncooked edible tissues of heifers:
(1) 0.64 part per billion in muscle.
(2) 2.6 parts per billion in fat.
(3) 1.9 parts per billion in kidney.
(4) 1.3 parts per billion in liver.
(b) [Reserved]
[52 FR 27683, July 23, 1987]

§ 556.720 Tetracycline.
(a) Acceptable daily intake (ADI). The ADI for total tetracycline residues (chlortetracycline, oxytetracycline, and tetracycline) is 25 micrograms per kilogram of body weight per day.
(b) Tolerances. Tolerances are established for the sum of tetracycline residues in tissues of calves, swine, sheep, chickens, and turkeys, of 2 parts per million (ppm) in muscle, 6 ppm in liver, and 12 ppm in fat and kidney.
[63 FR 57246, Oct. 27, 1998]

§ 556.730 Thiabendazole.
Tolerances are established at 0.1 part per million for negligible residues of thiabendazole in uncooked edible tissues of cattle, goats, sheep, pheasants, and swine, and at 0.05 part per million for negligible residues in milk.
[40 FR 13942, Mar. 27, 1975, as amended at 49 FR 29958, July 25, 1984]

§ 556.735 Tilmicosin.
(a) Acceptable daily intake (ADI). The ADI for total residues of tilmicosin is 25 micrograms per kilogram of body weight per day.
(b) Tolerances—(1) Cattle. A tolerance is established for residues of parent tilmicosin (marker residue) in liver (target tissue) at 1.2 parts per million (ppm).
(2) Swine. A tolerance is established for residues of parent tilmicosin (marker residue) in liver (target tissue) at 7.5 ppm and in muscle at 0.1 ppm.
[64 FR 13679, Mar. 22, 1999]

§ 556.738 Tiamulin.
A tolerance of 0.6 part per million is established for \textit{8-alpha}-hydroxymutilin (marker compound) in liver (target tissue) of swine.

§ 556.739 Trenbolone.
(a) Acceptable daily intake (ADI). The ADI for total residues of trenbolone is
§ 556.740 Tylosin.

Tolerances are established for residues of tylosin in edible products of animals as follows:

(a) In chickens and turkeys: 0.2 part per million (negligible residue) in uncooked fat, muscle, liver, and kidney.

(b) In cattle: 0.2 part per million (negligible residue) in uncooked fat, muscle, liver, and kidney.

(c) In swine: 0.2 part per million (negligible residue) in uncooked fat, muscle, liver, and kidney.

(d) In milk: 0.05 part per million (negligible residue).

(e) In eggs: 0.2 part per million (negligible residue).

[64 FR 18574, Apr. 15, 1999]

§ 556.741 Tripelennamine.

A tolerance of 200 parts per billion (ppb) is established for residues of tripelennamine in uncooked edible tissues of cattle and 20 ppb in milk.


§ 556.750 Virginiamycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of virginiamycin is 250 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Swine. Tolerances are established for residues of virginiamycin in uncooked edible tissues of 0.4 part per million (ppm) in kidney, skin, and fat, 0.3 ppm in liver, and 0.1 ppm in muscle.

(2) Broiler chickens and cattle. A tolerance for residues of virginiamycin is not required.

[64 FR 48296, Sept. 3, 1999]

§ 556.760 Zeranol.

(a) Acceptable daily intake (ADI). The ADI for total residues of zeranol is 0.00125 milligrams per kilogram of body weight per day.

(b) Tolerances—(1) Cattle. Tolerances for residues of zeranol in edible tissues are not needed.

(2) Sheep. No residues of zeranol may be found in the uncooked edible tissues of sheep as determined by the following method of analysis:

I. Method of Analysis—Zeranol

A gas chromatographic method for the determination of the drug in frozen beef tissues is described. Tissue is frozen and stored in a deep freezer until ready for examination. A weighed portion of wet tissue (with exception of fat) is homogenized and lyophilized to dry solid. The drug is recovered from dry tissue by an extraction with methanol in a Soxhlet extractor. The methanol extract is digested in the presence of hydrochloric acid to hydrolyze conjugates should any be present. Elimination of impurities is brought about by liquid partition transfer successively to chloroform to 1N sodium hydroxide, to carbon tetrachloride, to 1N sodium hydroxide, to ethyl ether, and, finally, to a dry residue. The residue is reacted with a silane mixture to create a volatile derivative which is quantitated by peak area measurements from a flame ionization detector. The drug can be detected at a level of 20 parts per billion with negligible interference from tissues or reagents.

II. Reagents


B. Chloroform, N.F., Fisher Scientific C–296, or equivalent.

C. Chromatograph gases, flow rates adjusted to maximize sensitivity for specific chromatograph.

1. Carrier gas, conventional tank helium.

2. Flame makeup gas.
   a. Oxygen, conventional tank oxygen.
   b. Hydrogen, Linde high purity, or equivalent.

D. Column packing, 3 percent GE SE–52 (Applied Science Laboratories) on P.E. Celite 60–80 mesh (Johns Manville Product No. 154–0008), or equivalent.

E. Ether, anhydrous, Fisher Scientific E–138, or equivalent.

F. Hexamethyldisilazane, Dow-Corning, Peninsular, or equivalent.

G. Hydrochloric acid, analytical reagent grade.

H. Methanol, certified A.C.S., spectranaalyzed, Fisher Scientific A–408, or equivalent.

I. Phosphoric acid, analytical reagent grade.

J. Pyridine, anhydrous, A.C.S. reagent grade.

K. Silating reagent mixture: Pipet 8 milliliters each of pyridine and hexamethyldisilazane and 4 milliliters of trimethylchlorosilane into a clean glass vial with a polyethylene cap and mix thoroughly.
Food and Drug Administration, HHS

§ 556.760

Let stand overnight and decant supernatant liquid into a vial. Cap and store at room temperature for daily use. If kept dry, the reagent is stable for more than a month. Blanks are scanned by gas chromatography on each new bottle of J, F, and N material used in the silating reagent mixture for possible peak interference in the region of zeranol derivative.

L. Sodium chloride, analytical reagent grade.
M. Sodium hydroxide, analytical reagent grade.
N. Trimethylchlorosilane, Dow-Corning, Peninsular, or equivalent.
O. Water, distilled in glass.
P. Zeranol, primary standard.
Q. Solutions.
1. 2N Hydrochloric acid in water.
2. 3N Phosphoric acid in water.
3. 2 percent w/v sodium chloride in water.
4. 1N Sodium hydroxide in water.

III. APPARATUS
A. Extraction assemblies, Soxhlet, improved, standard taper grindings, Pyrex brand glass, 1,000 milliliters capacity, Sargent Catalog S-31265D, or equivalent.
B. Flasks, freeze drying, widemouth, 1,000 milliliters capacity, 24/40 standard taper grindings, Pyrex brand glass, Sargent Catalog S-28975-20-F, or equivalent.
C. Flasks, homogenizing, 250 milliliters, Sargent Catalog S-61716, or equivalent.
D. Funnels, separatory, Squibb stopper, with Teflon stopcock plug, Pyrex brand glass, 250- and 500-milliliter capacities, Sargent Catalog S-35815-20-F or G, or equivalent.
E. Gas chromatograph, F and M Model 5750 with flame ionization detector, or equivalent.
F. Gas chromatography column: Stainless steel tubing, 6 feet by 1/8 inch packed with 3 percent by weight GE SE-52 (Applied Science Laboratories) deposited on P.E. Celite 50-50 mesh (product No. 154-0048), or equivalent. Condition the column by baking for 40-80 hours at 325 °C with a helium flow, but detached from the detector input. Injections of 1-2 microliters of a 50/50 mixture of hexamethyldisilazane and trimethylchlorosilane will help remove active sites in the column.
1. Prepare a TMS derivative of a 1,000-microgram zeranol standard as described in the procedure section. Inject 1-microliter quantities to determine whether the column is responding to the conditioning. After the column shows a response at the 1,000-microgram level, proceed to smaller quantities to optimize conditions. 2. The column and chromatograph must be conditioned to achieve a minimum sensitivity response so that a peak 5 millimeters in height results from an injection of 5 microliter of standard preparation containing 1 microgram of zeranol in the derivative preparation. This criterion must be met before tissue assay is attempted.
3. The column is brought to 250 °C after conditioning and held at that temperature for at least 12 hours before making a run.
G. Heating mantle, electric, Glas-Col. Sargent Catalog S-40866H, or equivalent.
H. Hot plate, with gradient rheostat heat control.
I. Meat grinder, manually operated or equivalent.
J. Steam bath.
K. Syringe, Hamilton Micro Syringe Model 701, 10-microliter capacity, or equivalent.
L. Torsion balance, 0.1 gram sensitivity, 500 grams capacity.
M. Vials, 1-dram glass with plastic tops, Owens-Illinois, Opticlear, or equivalent.
N. Virtis freeze drier, Sargent Catalog S-28881-40, or equivalent.
O. Virtis homogenizing mill, macro, Virtis No. 45, Sargent Catalog S-61700, or equivalent.

IV. STANDARD SOLUTIONS
A. Stock solution A: Accurately weigh 0.1000 gram of zeranol, primary standard, into a 250-milliliter beaker. Dissolve the standard in 80 milliliters of methanol and accurately dilute to 100 milliliters in a volumetric flask with methanol. By preparation, the solution contains 1,000 micrograms per milliliter.
B. Stock solution B: Dilute 10.0 milliliters of stock solution A to 100 milliliters with methanol to provide a standard containing 100 micrograms of the drug per milliliter.
C. Stock solution C: Dilute 5.0 milliliters of stock solution B to 100 milliliters with methanol to provide a standard containing 5 micrograms per milliliter.
D. Stock solution D: Dilute 2.0 milliliters of stock solution C to 100 milliliters with methanol to provide a standard containing 2 micrograms per milliliter.
E. Stock solution E: Dilute 1.0 milliliters of stock solution D to 100 milliliters with methanol to provide a standard containing 1 microgram of zeranol in the derivative preparation. This criterion must be met before tissue assay is attempted.
F. Stock solution F: Dilute 0.1 milliliters of stock solution E to 100 milliliters with methanol to provide a standard containing 0.1 microgram of zeranol in the derivative preparation. This criterion must be met before tissue assay is attempted.

V. PROCEDURE
A. Preparation of glassware: Glassware should be washed in detergent or chromic acid solution to remove contaminants and rinsed in water to remove traces of cleaning agent. Rinse with methanol before using.
B. Preparation of sample.
1. Collect muscle, liver, kidney, and tripe from a freshly sacrificed animal under the cleanest conditions possible.
2. Grind the fresh tissue in a meat grinder, divide into 100-gram portions, and wrap in aluminum foil. Store wrapped tissue in a
§ 556.760

21 CFR Ch. I (4–1–02 Edition)

deep freeze. Fat should be wrapped in foil and stored in deep freeze.

C. Extraction procedure for muscle, liver, kidney, and tripe.

1. Weight 100 grams of partially thawed tissue into a 250-milliliter homogenizing flask, add 60 milliliters of water, and attach to a Virtis ‘45’ Tissue Mill, or equivalent.

2. Mix the materials at 45,000 r.p.m. for 5 minutes to obtain a thin homogenate.

3. Transfer the homogenate to a 1-liter, widemouth, freeze drying flask using 10–20 milliliters of water for a rinse.

4. Place the flask on its side in a nearly horizontal position in a slurry of dry ice and acetone. Rotate the flask on its side as the homogenate cools to set down a uniform frozen solid layer on the wall of the flask.

5. Mount the flask on a Virtis freeze drier, or equivalent, and lyophilize to dry solids. This operation usually requires 20–24 hours. Stopping place.

6. Transfer the solid cake to a clean sheet of paper and crumble by hand to a size convenient for transfer to an extraction thimble.

7. Transfer the solids to a single thickness of paper and add to a size equivalent, and lyophilize to dry solids. Composite the methanol from the extractor and add to the methanol composite. Concentrate to 125 milliliters by boiling on a hot plate.

8. Transfer 600 milliliters of methanol to a 1-liter pot of a Soxhlet extraction assembly and place the thimble in the extractor. Mount a large glass funnel in the neck of the extractor with the stem extending into the thimble. Rinse the 1-liter freeze drying flask using 10–20 milliliters of water for a rinse.

9. Drain the methanol from the thimble. Composite the methanol from the extractor and pot in a 800-milliliter beaker.

10. Rinse the pot with 10 milliliters of methanol and add to the methanol composite. Transfer 50 milliliters of 2N HCl down the pot side wall, and add to methanol composite. Concentrate to 125 milliliters by boiling on a hot plate.

D. Extraction procedure for fat.

1. Cut fat into ¼-inch cubes. The lyophilization of fat is unnecessary since it is essentially water free.

2. Transfer 100 grams of the prepared fat to a 60 x 180-millimeter extraction thimble and extract with 750 milliliters of methanol for 15 hours in the Soxhlet extractor. Extract the thimble with the electric heating mantle so that a fill-empty cycle requires 18–24 minutes.

3. Drain the methanol from the thimble. Composite the methanol from the extractor and pot into a 800-milliliter beaker.

4. Rinse the pot with 10 milliliters of methanol and add to the methanol composite. Transfer 50 milliliters of 2N HCl down the pot side wall, and add to methanol composite. Concentrate to 125 milliliters by boiling on a hot plate.

5. Rinse the pot with 10 milliliters of methanol and add to the methanol composite. Transfer 50 milliliters of 2N HCl down the pot side wall, and add to methanol composite. Concentrate to 125 milliliters by boiling on a hot plate.

6. Add 300 milliliters of water and without shaking allow liquid phase to separate. The zeroanol transfers from the chloroform extract for the first time is accompanied by the appearance of emulsion.

7. Composite the chloroform composite to a 250-milliliter separatory funnel, fitted with a Teflon stopcock, using 10 milliliters of chloroform as a rinse.

8. Composite the chloroform extracts and concentrate to 125 milliliters by evaporation on a steam bath and cool to room temperature.

9. Transfer the chloroform composite to a 250-milliliter separatory funnel, fitted with a Teflon stopcock, using 10 milliliters of chloroform as a rinse.

10. Transfer the chloroform extract to a 250-milliliter separatory funnel, identified by number as 1, with 70 milliliters of chloroform rinse and mix.

11. Perform an extraction by gently inverting the closed funnel and returning the funnel to an upright position.

12. Repeat phase mixing 30 times per extraction.

13. Composite the sodium hydroxide extracts.

14. Wash the sodium hydroxide extract with three 50-milliliter portions of chloroform using the technique as in step 9 and the same 10-minute interval for phase separation. Washing the chloroform removes the emulsion and unwanted impurities from the sodium hydroxide phase.

15. Discard the chloroform washes. Transfer the sodium hydroxide extracts to a 250-milliliter beaker. Rinse each separatory funnel with two 5-milliliter portions of water and add to the sodium hydroxide extract.
Wash each funnel twice with tap water and twice with distilled water before next use.

16. Neutralize the washed sodium hydroxide extract to 8.0 by dropwise addition of 3N phosphoric acid using a pH meter for pH detection.

17. Transfer the pH 8.0 water extract to 250-milliliter separatory funnel using 10 to 20 milliliters of water for a rinse.

18. Extract the solution with three separate 50-milliliter portions of carbon tetrachloride. The zeranol transfers to the lower carbon tetrachloride phase. Use the same 30-count phase-mixing technique as in step 9 and allow the mixture to stand 5 minutes for phase separation.

19. Composite the carbon tetrachloride extracts.

20. Extract the carbon tetrachloride composite with two 20-milliliter portions of 1N sodium hydroxide. Zeranol transfers from carbon tetrachloride to the upper sodium hydroxide phase. After phase mixing, allow the mixture to stand 5 minutes for phase separation.

21. Composite the sodium hydroxide extracts.

22. Wash the extract with two 50-milliliter portions of carbon tetrachloride. Allow the mixture to stand 5 minutes for phase separation. Discard the carbon tetrachloride washes.

23. Transfer the sodium hydroxide extract into a 250-milliliter beaker. Rinse the separatory funnel with two 5-milliliter portions of water and add to the sodium hydroxide extract. Wash each funnel twice with tap water and twice with distilled water before next use. Adjust the sodium hydroxide extract to a pH of 9.5 by dropwise addition of 3N phosphoric acid and transfer to a 250-milliliter separatory funnel using 10-20 milliliters of water for a rinse.

24. Extract the pH 9.5 water solution with three separate 30-milliliter portions of anhydrous ethyl ether. Allow the mixture to stand 5 minutes for phase separation. The zeranol transfers to the upper ether phase.

25. Composite the ether extracts in a 125-milliliter Erlenmeyer flask.

26. Reduce the volume of ether to about 1-2 milliliters by evaporation on a hot plate with low heat while removing vapor from top of flask by vacuum aspiration.

27. Transfer ether residue to a 1 dram glass vial. Rinse down flask side wall with 1-2 milliliters of fresh ether and transfer to the glass vial.

28. Continue evaporation of ether to 0.1 milliliter.

29. Place vial in a vacuum desiccator and evaporate residue at line vacuum and room temperature overnight to dryness.


F. Gas liquid chromatography.

1. Start the gas chromatography and maintain the following operational conditions:
   Carrier gas pressure: 50 p.s.i. at tank.
   Carrier gas flow rate: Sufficient to give zeranol derivative peak a retention time of 4-8 minutes.
   Electrometer range: 105 or 104.
   Detector temperature: 325 °C.
   Injection port temperature: 325 °C.
   Column temperature: 250 °C–280 °C. operate isothermally.
   Recorder sensitivity: 1 millivolt.
   Recorder chart speed: 1 inch per minute.

2. Add 0.2 milliliter of silating reagent to the sample or to the zeranol standard.

3. Stopper the vial and shake vigorously.

4. Warm the vial at 40°–50 °C for a few minutes, then roll the vial on a horizontal plane to insure that all of the interior surfaces of the vial have been in contact with the reagent.

5. Let vial stand for 4 hours or overnight in a warm area (40 °C) to allow reaction to reach completion.

6. Place vial in a small padded centrifuge tube and centrifuge to settle the precipitate and insure that all the liquid is at the bottom of the vial.

7. Inject 1.0-5.0 microliters of clear solution into the chromatograph. At the beginning of the day’s run, make 3-5 injections of a standard to condition the column for that day before taking quantitative data.

8. Run known mixtures at the beginning, middle, and end of the day’s run over the concentration range of samples to be analyzed to compensate for day-to-day sensitivity fluctuations and drift. If four or less samples are to be run, calibrating at the beginning and end of the run is sufficient.

VI. CALCULATIONS

Area values are obtained on known mixtures and samples by multiplying the net peak height by the peak width at half height or by counting squares. Area values obtained on knowns are plotted versus zeranol concentration. Calibration plots indicate a near linear function in the 0-10 microgram range. Area values obtained on samples are converted directly to microgram quantities using the curve. Control tests demonstrated a 70 percent recovery of zeranol from spiked
§ 556.770 Zoalene.

Tolerances are established for residues of zoalene (3,5-dinitro-o-toluamide) and its metabolite 3-amino-5-nitro-o-toluamide in food as follows:

(a) In edible tissues of chickens:
   (1) 6 parts per million in uncooked liver and kidney.
   (2) 3 parts per million in uncooked muscle tissue.

(b) In edible tissues of turkeys: 3 parts per million in uncooked muscle tissue and liver.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

Subpart A—General Provisions

Sec. 558.3 Definitions and general considerations applicable to this part.
558.4 Requirement of a medicated feed mill license.
558.5 New animal drug requirements for liquid Type B feeds.
558.6 Veterinary feed directive drugs.
558.15 Antibiotic, nitrofurazone, and sulfonamide drugs in the feed of animals.

Subpart B—Specific New Animal Drugs For Use in Animal Feeds

558.35 Akloamide.
558.55 Amprolium.
558.56 Amprolium and ethopabate.
558.59 Apramycin.
558.60 Arsanilate sodium.
558.62 Arsanilic acid.
558.76 Bacitracin methylene disalicylate.
558.78 Bacitracin zinc.
558.95 Bambermycin.
558.105 (Reserved).
558.115 Caradox.
558.120 Carbarsone (not U.S.P.).
558.128 Chlortetracycline.
558.140 Chlortetracycline and sulfamethazine.
558.145 Chlortetracycline, procaine penicillin, and sulfamethazine.
558.155 Chlortetracycline, sulfathiazole, penicillin.
558.175 Clopidol.
558.185 Coumaphos.
558.195 Decoquinate.
558.198 Diclazuril.
558.205 Dichlorvos.
558.235 Efrotomycin.
558.248 Erythromycin thiocyanate.
558.254 Fenphur.
558.258 Fenbendazole.
558.265 Halofuginone hydrobromide.
558.274 Hygromycin B.
558.295 Iodinated casein.
558.300 Ivermectin.
558.305 Laidlomycin propionate potassium.
558.311 Lasalocid.
558.315 Levasimole hydrochloride (equivalent).
558.325 Lincomycin.
558.340 Maduramicin ammonium.
558.342 Melengestrol acetate.
558.348 Mibolerone.
558.355 Monensin.
§ 558.3 Definitions and general considerations applicable to this part.

(a) Regulations in this part provide for approved uses of drugs and combinations of drugs in animal feeds. Approved combinations of such drugs are specifically identified or incorporated by cross-reference. Unless specifically provided for by the regulations, a combination of two or more drugs is not approved.

(b) The following definitions apply to terms used in this part:

(1) New animal drugs approved for use in animal feed are placed in two categories as follows:

(i) Category I—These drugs require no withdrawal period at the lowest use level in each species for which they are approved.

(ii) Category II—These drugs require a withdrawal period at the lowest use level for at least one species for which they are approved, or are regulated on a “no-residue” basis or with a zero tolerance because of a carcinogenic concern regardless of whether a withdrawal period is required, or are a veterinary feed directive drug.

(2) A “Type A medicated article” is intended solely for use in the manufacture of another Type A medicated article or a Type B or Type C medicated feed. It consists of a new animal drug(s), with or without carrier (e.g., calcium carbonate, rice hull, corn, gluten) with or without inactive ingredients. The manufacture of a Type A medicated article requires an application approved under §514.165 of this chapter.

(3) A “Type B medicated feed” is intended solely for the manufacture of other medicated feeds (Type B or Type C). It contains a substantial quantity of nutrients including vitamins and/or minerals and/or other nutritional ingredients in an amount not less than 25 percent of the weight. It is manufactured by diluting a Type A medicated article or another Type B medicated feed. The maximum concentration of animal drug(s) in a Type B medicated feed is 200 times the highest continuous use level for Category I drugs and 100 times the highest continuous use level for Category II drugs. The term “highest continuous use level” means the highest dosage at which the drug is approved for continuous use (14 days or more), or, if the drug is not approved for continuous use, it means the highest level used for disease prevention or control. If the drug is approved for multiple species at different use levels, the highest approved level of use would govern under this definition. The manufacture of a Type B medicated feed from a Category II, Type A medicated article requires a medicated feed mill license application approved under §515.20 of this chapter.

(4) A “Type C medicated feed” is intended as the complete feed for the animal or may be fed “top dressed” (added on top of usual ration) or on offered “free-choice” (e.g., supplement) in conjunction with other animal feed. It contains a substantial quantity of nutrients including vitamins, minerals, and/or other nutritional ingredients. It is manufactured by diluting a Type A medicated article or another Type B medicated feed.
medicated article or a Type B medicated feed. A Type C medicated feed may be further diluted to produce another Type C medicated feed. The manufacture of a Type C medicated feed from a Category II, Type A medicated article requires a medicated feed mill license application approved under §515.20 of this chapter.

(5) A Type B or Type C medicated feed manufactured from a drug component (bulk or “drum-run” (dried crude fermentation product)) requires an application approved under §514.105 of this chapter.

(6) A “veterinary feed directive (VFD) drug” is a new animal drug approved under section 512(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for use in or on animal feed. Use of a VFD drug must be under the professional supervision of a licensed veterinarian.

(7) A “veterinary feed directive” is a written statement issued by a licensed veterinarian in the course of the veterinarian’s professional practice that orders the use of a veterinary feed directive (VFD) drug in or on an animal feed. This written statement authorizes the client (the owner of the animal or animals or other caretaker) to obtain and use the VFD drug in or on an animal feed to treat the client’s animals only in accordance with the directions for use approved by the Food and Drug Administration (FDA). A veterinarian may issue a VFD only if a valid veterinarian-client-patient relationship exists, as defined in §530.3(i) of this chapter.

(8) A “medicated feed” means a Type B medicated feed as defined in paragraph (b)(3) of this section or a Type C medicated feed as defined in paragraph (b)(4) of this section.

(9) For the purposes of this part, a “distributor” means any person who distributes a medicated feed containing a VFD drug to another distributor or to the client-recipient of the VFD.

(10) An “animal production facility” is a location where animals are raised for any purpose, but does not include the specific location where medicated feed is made.

(11) An “acknowledgment letter” is a written communication provided to a distributor by a consignee who is not the ultimate user of medicated feed containing a VFD drug. An acknowledgment letter affirms that the consignee will not ship such medicated animal feed to an animal production facility that does not have a VFD, and will not ship such feed to another distributor without receiving a similar written acknowledgment letter.

§558.4 Requirement of a medicated feed mill license.

(a) A feed manufacturing facility must possess a medicated feed mill license in order to manufacture a Type B or Type C medicated feed from a Category II, Type A medicated article.

(b) The manufacture of the following types of feed are exempt from the required license, unless otherwise specified:

(1) Type B or Type C medicated feed using Category I, Type A medicated articles or Category I, Type B or Type C medicated feeds; and

(2) Type B or Type C medicated feed using Category II, Type B or Type C medicated feeds.

(c) The use of Type B and Type C medicated feeds shall also conform to the conditions of use provided for in subpart B of this part and in §§510.515 and 558.15 of this chapter.

(d) This paragraph identifies each drug by category, the maximum level of drug in Type B medicated feeds, and the assay limits for the drug in Type A medicated articles and Type B and Type C medicated feeds, as follows:

<table>
<thead>
<tr>
<th>CATEGORY I</th>
<th>Drug</th>
<th>Assay limits percent(^1) type A</th>
<th>Type B maximum (200x)</th>
<th>Assay limits percent(^1) type B/C(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aklomide</td>
<td>90-110</td>
<td>22.75 g/lb (5.0%)</td>
<td>85-120.</td>
</tr>
<tr>
<td></td>
<td>Amprolium with Ethopabate</td>
<td>94-114</td>
<td>22.75 g/lb (5.0%)</td>
<td>80-120.</td>
</tr>
<tr>
<td></td>
<td>Bacitracin methylene disalicylate</td>
<td>85-115</td>
<td>25.0 g/lb (5.5%)</td>
<td>70-130.</td>
</tr>
</tbody>
</table>
### Category I

<table>
<thead>
<tr>
<th>Drug</th>
<th>Assay limits type A</th>
<th>Type B maximum (200x)</th>
<th>Assay limits type B/C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacitracin zinc</td>
<td>84-115</td>
<td>5.0 g/lb (1.1%)</td>
<td>70-130.</td>
</tr>
<tr>
<td>Bambermycins</td>
<td>90-110</td>
<td>800 g/ton (0.09%)</td>
<td>80-120/70-130.</td>
</tr>
<tr>
<td>Busulfanolate</td>
<td>90-110</td>
<td>9.8 g/lb (2.2%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Chlorotetracycline</td>
<td>85-115</td>
<td>40.0 g/lb (8.8%)</td>
<td>80-115/70-130.</td>
</tr>
<tr>
<td>Coumaphos</td>
<td>95-115</td>
<td>6.0 g/lb (1.3%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Decoquinate</td>
<td>90-105</td>
<td>2.72 g/lb (0.6%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Dichlorvos</td>
<td>100-115</td>
<td>33.0 g/lb (7.3%)</td>
<td>90-120/80-130.</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>90-110</td>
<td>162 g/ml (0.02%)</td>
<td>85-115/70-120.</td>
</tr>
<tr>
<td>Eflornithine</td>
<td>94-113</td>
<td>1.45 g/lb (0.32%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Erythromycin (thiocyanate salt)</td>
<td>85-115</td>
<td>9.25 g/lb (2.04%)</td>
<td>&lt;20 g/ton 70-115/150-200.</td>
</tr>
<tr>
<td>Iodinated casein</td>
<td>85-115</td>
<td>20.0 g/lb (4.4%)</td>
<td>75-125.</td>
</tr>
<tr>
<td>Laidilomycin propionate potassium</td>
<td>90-110</td>
<td>1 g/lb (0.22%)</td>
<td>90-115/85-115.</td>
</tr>
<tr>
<td>Lasalocid</td>
<td>95-115</td>
<td>40.0 g/lb (8.8%)</td>
<td>Type B (cattle and sheep): 80-120. Type C (all): 75-125.</td>
</tr>
<tr>
<td>Lincomycin</td>
<td>90-110</td>
<td>20.0 g/lb (4.4%)</td>
<td>80-130.</td>
</tr>
<tr>
<td>Metranol</td>
<td>90-110</td>
<td>10.0 g/ton (0.0011%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Monein</td>
<td>85-115</td>
<td>40.0 g/lb (8.8%)</td>
<td>Chickens, turkeys, and quail: 75-125. Cattle: 5-10 g/ton 80-120. Sheep: 10-30 g/ton 85-115. Goats 20 g/ton 85-115. Liq. feed: 80-120.</td>
</tr>
<tr>
<td>Narasin</td>
<td>90-110</td>
<td>7.2 g/lb (1.6%)</td>
<td>85-115/75-125.</td>
</tr>
<tr>
<td>Neomycin</td>
<td>95-112</td>
<td>1.83 g/lb (0.4%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Niclosamide</td>
<td>85-120</td>
<td>225 g/lb (49.5%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Nystatin</td>
<td>85-125</td>
<td>5.0 g/lb (1.1%)</td>
<td>75-125.</td>
</tr>
<tr>
<td>Oxytetracycline</td>
<td>85-120</td>
<td>1.25 g/lb (0.25%)</td>
<td>&lt;11.25 g/ton 70-130.</td>
</tr>
<tr>
<td>Oxidized casein</td>
<td>90-120</td>
<td>20.0 g/lb (4.4%)</td>
<td>75-125/85-135.</td>
</tr>
<tr>
<td>Penicillin</td>
<td>80-120</td>
<td>10.0 g/lb (2.2%)</td>
<td>65-135.</td>
</tr>
<tr>
<td>Poloxamine</td>
<td>85-105</td>
<td>1.8 g/lb (0.4%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Salinomycin</td>
<td>95-115</td>
<td>6.0 g/lb (1.3%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Semduramicin</td>
<td>90-110</td>
<td>2.25 g/lb (0.50%)</td>
<td>80-110.</td>
</tr>
<tr>
<td>Trimulin</td>
<td>113.4 g/lb</td>
<td>3.5 g/lb (0.8%)</td>
<td>90-115.</td>
</tr>
<tr>
<td>5 and 10 g'</td>
<td>100-106</td>
<td>10.0 g/lb (2.2%)</td>
<td>70-130.</td>
</tr>
<tr>
<td>Tyllosin</td>
<td>80-120</td>
<td>10.0 g/lb (2.6%)</td>
<td>75-125.</td>
</tr>
<tr>
<td>Virginiamycin</td>
<td>85-115</td>
<td>10.0 g/lb (2.6%)</td>
<td>70-130.</td>
</tr>
<tr>
<td>Zoledene</td>
<td>92-104</td>
<td>11.35 g/lb (2.5%)</td>
<td>85-115.</td>
</tr>
</tbody>
</table>

1 Percent of labeled amount.

2 Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limits, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make Type C medicated feed.

### Category II

<table>
<thead>
<tr>
<th>Drug</th>
<th>Assay limits type A</th>
<th>Type B maximum (100x)</th>
<th>Assay limits type B/C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amprolium</td>
<td>94-114</td>
<td>11.35 g/lb (2.5%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Apramycin</td>
<td>88-112</td>
<td>7.5 g/lb (1.65%)</td>
<td>80-120.</td>
</tr>
<tr>
<td>Arsanilate sodium</td>
<td>90-110</td>
<td>4.5 g/lb (1.0%)</td>
<td>85-115/75-125.</td>
</tr>
<tr>
<td>Arsanilic acid</td>
<td>90-110</td>
<td>4.5 g/lb (1.0%)</td>
<td>85-115/75-125.</td>
</tr>
<tr>
<td>Carbadox</td>
<td>90-110</td>
<td>2.5 g/lb (0.55%)</td>
<td>75-125.</td>
</tr>
<tr>
<td>Carbarsone</td>
<td>93-102</td>
<td>17.0 g/lb (3.74%)</td>
<td>85-115.</td>
</tr>
<tr>
<td>Clopidol</td>
<td>94-106</td>
<td>11.4 g/lb (2.5%)</td>
<td>90-115/80-120.</td>
</tr>
<tr>
<td>Fenbendazole</td>
<td>93-113</td>
<td>8.67 g/lb (1.96%)</td>
<td>75-125.</td>
</tr>
<tr>
<td>Halofuginone hydrobromide</td>
<td>90-115</td>
<td>272 g/ton (0.3%)</td>
<td>75-125.</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>95-105</td>
<td>1,800 g/ton (0.13%)</td>
<td>80-110.</td>
</tr>
<tr>
<td>Levamisole</td>
<td>85-120</td>
<td>113.5 g/lb (25%)</td>
<td>85-125.</td>
</tr>
<tr>
<td>Maduramicin ammonium</td>
<td>90-110</td>
<td>545 g/ton (36%)</td>
<td>80-120.</td>
</tr>
</tbody>
</table>
§ 558.4

21 CFR Ch. I (4–1–02 Edition)

CATEGORY II—Continued

<table>
<thead>
<tr>
<th>Drug</th>
<th>Assay limits percent ¹ Type A</th>
<th>Type B maximum (100x)</th>
<th>Assay limits percent ¹ Type B/C²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morantel tartrate</td>
<td>90–110 66.0 g/lb (14.52%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Neomycin</td>
<td>80–120 7.0 g/lb (1.54%)</td>
<td>70–125</td>
<td></td>
</tr>
<tr>
<td>Oxytetracycline</td>
<td>80–120 10.0 g/lb (2.2%)</td>
<td>70–125</td>
<td></td>
</tr>
<tr>
<td>Neomycin sulfate</td>
<td>80–120 100 g/lb (22.0%)</td>
<td>70–125</td>
<td></td>
</tr>
<tr>
<td>Nicarbazin (granular)</td>
<td>90–110 5.675 g/lb (1.25%)</td>
<td>85–115/75–125</td>
<td></td>
</tr>
<tr>
<td>Nicarbazin (powder)</td>
<td>98–106 5.675 g/lb (1.25%)</td>
<td>85–115/80–120</td>
<td></td>
</tr>
<tr>
<td>Nitosone</td>
<td>90–110 10.5 g/lb (2.2%)</td>
<td>85–100</td>
<td></td>
</tr>
<tr>
<td>Nitrofurazone</td>
<td></td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Nitrofurazone A</td>
<td>85–115 13.6 g/lb (3.0%)</td>
<td>85–125</td>
<td></td>
</tr>
<tr>
<td>Nitrofurazone B</td>
<td>90–110 11.35 g/lb (2.5%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Sulfanitran</td>
<td>90–110 2.7 g/lb (0.5%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Roxarsone</td>
<td>90–110 2.775 g/lb (0.5%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Novobiocin</td>
<td>85–115 17.5 g/lb (3.85%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Naxarne</td>
<td>90–110 36 g/lb (7.9%)</td>
<td>75–125</td>
<td></td>
</tr>
<tr>
<td>Robenidine</td>
<td>95–115 1.5 g/lb (0.33%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Ronnel</td>
<td>85–115 2.7 g/lb (0.6%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Roxarsone</td>
<td>90–110 2.775 g/lb (0.5%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Alkamid</td>
<td>90–110 11.35 g/lb (2.5%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Roxarsone</td>
<td>90–110 2.775 g/lb (0.5%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Clopidol</td>
<td>94–106 11.35 g/lb (2.5%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate</td>
<td>85–115 5.0 g/lb (1.1%)</td>
<td>70–130</td>
<td></td>
</tr>
<tr>
<td>Roxarsone</td>
<td>90–110 2.775 g/lb (0.5%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Methenamine</td>
<td>90–110 5.5 g/lb (1.2%)</td>
<td>75–125</td>
<td></td>
</tr>
<tr>
<td>Sulfadimethoxine</td>
<td>90–110 5.675 g/lb (1.25%)</td>
<td>85–115/75–125</td>
<td></td>
</tr>
<tr>
<td>Omepralim (S/3)</td>
<td>90–110 3.405 g/lb (0.75%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Sulfadimethoxine (S/1)</td>
<td>90–110 17.0 g/lb (3.75%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Sulfathiazole</td>
<td>95–105 5.0 g/lb (11.0%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Sulfamerazine</td>
<td>85–115 18.6 g/lb (4.0%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Sulfathiazole A</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>85–125/70–130.</td>
<td></td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>85–125/70–130.</td>
<td></td>
</tr>
<tr>
<td>Penicillin</td>
<td>85–115 5.0 g/lb (1.1%)</td>
<td>85–125/70–130.</td>
<td></td>
</tr>
<tr>
<td>Sulfamerazine B</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>85–125/70–130.</td>
<td></td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>85–125/70–130.</td>
<td></td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>85–125/70–130.</td>
<td></td>
</tr>
<tr>
<td>Tylosin</td>
<td>80–120 10.0 g/lb (2.2%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Sulfadiazine A</td>
<td>85–115 13.6 g/lb (3.0%)</td>
<td>75–125</td>
<td></td>
</tr>
<tr>
<td>Aklomide</td>
<td>90–110 11.2 g/lb (2.5%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Sulfadiazine B</td>
<td>85–115 13.6 g/lb (3.0%)</td>
<td>75–125</td>
<td></td>
</tr>
<tr>
<td>Aklomide</td>
<td>90–110 11.2 g/lb (2.5%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Roxarsone</td>
<td>90–110 2.715 g/lb (0.60%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Sulfanitran</td>
<td>90–110 13.6 g/lb (3.0%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Aklomide</td>
<td>90–110 11.2 g/lb (2.5%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Roxarsone</td>
<td>90–110 2.715 g/lb (0.60%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Sulfadiazine A</td>
<td>85–115 13.6 g/lb (3.0%)</td>
<td>85–120</td>
<td></td>
</tr>
<tr>
<td>Sulfadiazine B</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>85–125 10.0 g/lb (2.2%)</td>
<td>70–130</td>
<td></td>
</tr>
<tr>
<td>Penicillin</td>
<td>80–120 5.0 g/lb (1.1%)</td>
<td>70–130</td>
<td></td>
</tr>
<tr>
<td>Thiabendazole</td>
<td>94–106 45.4 g/lb (10.0%)</td>
<td>&gt;7% 85–115; &lt;7% 90–110</td>
<td></td>
</tr>
<tr>
<td>Timicosin</td>
<td>90–110 18.2 g/lb (4.0%)</td>
<td>85–115</td>
<td></td>
</tr>
</tbody>
</table>

¹Percent of labeled amount.

²Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limit, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make a Type C medicated feed.

(e) When drugs from both categories are in combination, the Category II requirements will apply to the combination drug product.

[51 FR 7392, Mar. 3, 1986]
§ 558.5 New animal drug requirements for liquid Type B feeds.

(a) Information available to the Commissioner of Food and Drugs shows that certain drugs are unstable when added to some liquid Type B medicated feeds. The demonstrated instability of these drugs gives rise to the question of the stability of other drugs when added to liquid Type B medicated feeds, except where specific approval has been granted for such use. Therefore, the labeling of a drug to provide for its use in a liquid Type B medicated feed causes the drug to be a new animal drug for such use for which an approved new animal drug application is required pursuant to section 512(b) of the Federal Food, Drug, and Cosmetic Act.

(b) The addition of a drug to a liquid Type B medicated feed causes such Type B feed to become an animal feed bearing or containing a new animal drug for which an approved application is required pursuant to section 512(m) of the act.

(c) Each drug product, intended for oral administration to animals, which contains any of the drugs listed in paragraph (d) of this section and which bears labeling for its use in animal feed and/or drinking water shall also include in such labeling the following statement: “FOR USE IN ONLY. NOT FOR USE IN LIQUID TYPE B MEDICATED FEEDS,” the blank being filled in with the words “DRY FEEDS,” “DRINKING WATER,” “DRY FEEDS AND DRINKING WATER” as applicable, unless:

(1) Such drug product is the subject of an approved new animal drug application providing for its use in liquid Type B medicated feeds, or;

(2) The labeling provisions of this paragraph (d) of this section and which include a copy of the product label, a description of the formulation, and information which establishes that the physical, chemical, or other properties of the particular drug product are such that it cannot reasonably be expected to be diverted for use in liquid Type B medicated feeds. Such petitions shall be submitted to the Food and Drug Administration, Center for Veterinary Medicine, 7500 Standish Pl., Rockville, MD 20855.

(d) The labeling provisions of paragraph (c) of this section apply to all forms of bacitracin, oxytetracycline, and chlortetracycline.

(e) For any drug which is the subject of an approved new animal drug application, the labeling provisions of paragraph (c) of this section may be implemented without prior approval as provided for in § 514.6(d) and (e) of this chapter.


§ 558.6 Veterinary feed directive drugs.

(a) What conditions must I meet if I am a veterinarian issuing a veterinary feed directive (VFD)?

(1) You must be appropriately licensed.

(2) You must issue a VFD only within the confines of a valid veterinarian-client-patient relationship (see definition at § 530.3(i) of this chapter).

(3) You must complete the VFD in writing and sign it or it will be invalid.

(4) You must include all of the following information in the VFD or it will be invalid:

(i) You and your client’s name, address and telephone and, if the VFD is faxed, facsimile number.

(ii) Identification and number of animals to be treated/fed the medicated feed, including identification of the species of animals, and the location of the animals.

(iii) Date of treatment, and, if different, date of prescribing the VFD drug.

(iv) Approved indications for use.

(v) Name of the animal drug.

(vi) Level of animal drug in the feed, and the amount of feed required to treat the animals in paragraph (a)(4)(ii) of this section.

(vii) Feeding instructions with the withdrawal time.

(viii) Any special instructions and cautionary statements necessary for use of the drug in conformance with the approval.

(ix) Expiration date of the VFD.

(x) Number of refills (reorders) if necessary and permitted by the approval.
§ 558.6

(x) Your license number and the name of the State issuing the license.

(xi) The statement: “Extra-label use, (i.e., use of this VFD feed in a manner other than as provided for in the VFD drug approval) is strictly prohibited.”

(xii) Any other information required by the VFD drug approval regulation.

(5) You must produce the VFD in triplicate.

(6) You must issue a VFD only for the approved conditions and indications for use of the VFD drug.

(b) What must I do with the VFD if I am a veterinarian?

(1) You must give the original VFD to the feed distributor (directly or through the client).

(2) You must keep one copy of the VFD.

(3) You must give the client a copy of the VFD.

(4) You may send a VFD to the client or distributor by facsimile or other electronic means provided you assure that the distributor receives the original signed VFD within 5 working days of receipt of the facsimile or other electronic order.

(5) You may not transmit a VFD by telephone.

(c) What are the VFD recordkeeping requirements?

(1) The VFD feed distributor must keep the VFD original for 2 years from the date of issuance. The veterinarian and the client must keep their copies for the same period of time.

(2) All involved parties must make the VFD available for inspection and copying by FDA.

(3) All involved parties (the VFD feed distributor, the veterinarian, and the client) must keep VFD’s transmitted by facsimile or other electronic means for a period of 2 years from date of issuance.

(4) All involved parties must have a copy of the VFD before distribution of a VFD feed to the ultimate user.

(d) What are the notification requirements if I am a distributor of animal feed containing a VFD drug?

(1) You must notify FDA only once, by letter, that you intend to distribute animal feed containing a VFD drug.

(i) The notification letter must include the complete name and address of each business site from which distribution will occur.

(ii) A responsible person from your firm must sign and date the notification letter.

(iii) You must submit the notification letter to the Center for Veterinary Medicine, Division of Animal Feeds (HFV-220), 7500 Standish Pl., Rockville, MD 20855, prior to beginning your first distribution.

(iv) You must notify the Center for Veterinary Medicine at the above address within 30 days of any change in name or business address.

(2) If you are a distributor who ships an animal feed containing a VFD drug to another consignee-distributor in the absence of a valid VFD, you must obtain an “acknowledgment letter,” as defined in §558.3(b)(11), from the consignee-distributor. The letter must include a statement affirming that the consignee-distributor has complied with “distributor notification” requirements of paragraph (d)(1) of this section.

(e) What are the additional recordkeeping requirements if I am a distributor?

(1) You must keep records of receipt and distribution of all medicated animal feed containing a VFD drug.

(2) You must keep these records for 2 years from date of receipt and distribution.

(3) You must make records available for inspection and copying by FDA.

(f) What cautionary statements are required for VFD drugs and animal feeds containing VFD drugs? All labeling and advertising must prominently and conspicuously display the following cautionary statement: “Caution: Federal law limits this drug to use under the professional supervision of a licensed veterinarian. Animal feed bearing or containing this veterinary feed directive drug shall be fed to animals only by or upon a lawful veterinarian in the course of the veterinarian’s professional practice.”

[65 FR 76929, Dec. 8, 2000]
Food and Drug Administration, HHS

§ 558.15 Antibiotic, nitrofuran, and sulfonamide drugs in the feed of animals.

(a) The Commissioner of Food and Drugs will propose to revoke currently approved subtherapeutic (increased rate of gain, disease prevention, etc.) uses in animal feed of antibiotic and sulfonamide drugs whether granted by approval of new animal drug applications, master files and/or antibiotic or food additive regulations, by no later than April 20, 1975, or the nitrofuran drugs by no later than September 5, 1975, unless data are submitted which resolve conclusively the issues concerning their safety to man and animals and their effectiveness under specific criteria established by the Food and Drug Administration based on the guidelines included in the report of the FDA task force on the use of antibiotics in animal feeds. All persons or firms previously marketing identical, related, or similar products except the nitrofuran drugs not the subject of an approved new animal drug application must submit a new animal drug application by July 19, 1973, or by December 4, 1973, in the case of nitrofuran drugs, if marketing is to continue during the interim. New animal drug entities with antibacterial activity not previously marketed, now pending approval or submitted for approval prior to, on, or following the effective date of this publication, shall satisfy such criteria prior to approval.

(b) Any person interested in developing data which will support retaining approval for such uses of such antibiotic, nitrofuran, and sulfonamide drugs must submit to the Commissioner the following:

(1) By July 19, 1973, records and reports of completed, ongoing, or planned studies, including protocols, on the tetracyclines, streptomycin, dihydrostreptomycin, the sulfonamides, and penicillin assessing the effect of the subtherapeutic use of the drug in feed on the salmonella reservoir in the target animal as compared to that in nonmedicated controls. Failure to complete the salmonella studies for any of these drugs by that time will be grounds for proceeding to immediately withdraw approval.

(2) By April 20, 1974, data from completed studies on the tetracyclines, streptomycin, dihydrostreptomycin, the sulfonamides, and penicillin assessing the effect of the subtherapeutic use of the drug in feed on the salmonella reservoir in the target animal as compared to that in nonmedicated controls. Failure to complete the salmonella studies for any of these drugs by that time will be grounds for proceeding to immediately withdraw approval.

(3) By April 20, 1975, data satisfying all other specified criteria for safety and effectiveness, including the effect on the salmonella reservoir for any antibiotic or sulfonamide drugs and by September 5, 1975, for the nitrofuran drugs, approved for subtherapeutic use in animal feeds. Drug efficacy data shall be submitted for any feed-use combination product containing such drug and any feed-use single ingredient antibiotic, nitrofuran, or sulfonamide not reviewed by the National Academy of Sciences—National Research Council, Drug Efficacy Study covering drugs marketed between 1938 and 1962.

(4) Progress reports on studies underway every January 1 and July 1 until completion.

(c) Failure on the part of any sponsor to comply with any of the provisions of paragraph (b) of this section for any of the antibacterial drugs included in paragraph (b)(1) of this section, or interim results indicating a health hazard, will be considered as grounds for immediately proceeding to withdraw approval of that drug for use in animal feeds under section 512(l) of the act in the case of failure to submit required records and reports and under section 512(e) where new information shows that such drug is not shown to be safe.

(d) Criteria based upon the guidelines laid down by the task force may be obtained from the Food and Drug Administration, Center for Veterinary Medicine, 7500 Standish Pl., Rockville, MD 20855.

(e) Reports as specified in this section shall be submitted to: Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drug Evaluation (HFV-100), 7500 Standish Pl., Rockville, MD 20855.
§ 558.15  21 CFR Ch. I (4–1–02 Edition)

(f) Following the completion of the requirements of paragraphs (a) and (b) of this section and the studies provided for therein:

(1) Those antibiotic, nitrofurans, and sulfonamide drugs which fail to meet the prescribed criteria for subtherapeutic uses but which are found to be effective for the therapeutic purposes will be permitted in feed only for high-level, short-term therapeutic use and only by or on the order of a licensed veterinarian.

(2) Animal feeds containing antibacterial drugs permitted to remain in use for subtherapeutic purposes shall be labeled to include a statement of the quantity of such drugs.

(g) The submission of applications and data required by paragraphs (a) and (b) of this section is not required for the continued manufacture of any Type A medicated article which is produced solely from a Type A article that is in compliance with the requirements of this section: Provided, That the Type A medicated article contains no drug ingredient whose use in or on animal feed requires an approved application pursuant to section 512(m) of the act and/or where the Type A article is approved by regulation in this part.

(1) The following antibacterial Type A articles manufactured by the designated sponsors are eligible for interim marketing based on their compliance with the requirements of this section:

<table>
<thead>
<tr>
<th>Drug sponsor</th>
<th>Type A article</th>
<th>Species</th>
<th>Use levels</th>
<th>Indications for use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pitman-Moore, Inc.</td>
<td>Bacitracin zinc</td>
<td>Chickens, turkeys, swine, pheasants, quail, and cattle.</td>
<td>Sec. 558.78</td>
<td>Sec. 558.78.</td>
</tr>
<tr>
<td>A. L. Laboratories, Inc</td>
<td>Bacitracin methylene disalicylate</td>
<td>Chicken turkeys, swine, and cattle.</td>
<td>Sec. 558.76</td>
<td>Sec. 558.76.</td>
</tr>
<tr>
<td>Elanco Products Co</td>
<td>Hygromycin B</td>
<td>Chickens and swine.</td>
<td>Sec. 558.274</td>
<td>Sec. 558.274.</td>
</tr>
<tr>
<td>Do</td>
<td>Tylosin</td>
<td>Chickens, swine, and beef cattle.</td>
<td>Sec. 558.625</td>
<td>Sec. 558.625.</td>
</tr>
<tr>
<td>The Upjohn Co</td>
<td>Lincomycin</td>
<td>Chickens, turkeys, and swine.</td>
<td>Sec. 558.325</td>
<td>Sec. 558.325.</td>
</tr>
<tr>
<td>Pfizer, Inc</td>
<td>Oleandomycin</td>
<td>Chickens, turkeys, and swine.</td>
<td>Sec. 558.435</td>
<td>Sec. 558.435.</td>
</tr>
<tr>
<td>Hoechst-Roussel Agri-Vet, Inc.</td>
<td>Bambermycins</td>
<td>Swine</td>
<td>Sec. 558.630</td>
<td>Sec. 558.630.</td>
</tr>
<tr>
<td>Elanco Products Co</td>
<td>Tylosin and sulfamethazine</td>
<td>Chickens, turkeys, swine, and cattle.</td>
<td>Sec. 558.128</td>
<td>Sec. 558.128.</td>
</tr>
<tr>
<td>Merck Sharp &amp; Dohme Research Labs., and Solvay Veterinary, Inc.</td>
<td>Procaine Penicillin</td>
<td>Chickens, turkeys, swine, pheasants, and quail.</td>
<td>Sec. 558.460</td>
<td>Sec. 558.460.</td>
</tr>
<tr>
<td>Pfizer, Inc., PennField Oil Co.</td>
<td>Oxytetracycline</td>
<td>Chickens and swine.</td>
<td>Sec. 558.450</td>
<td>Sec. 558.450.</td>
</tr>
<tr>
<td>American Cyanamid Co.</td>
<td>Chlorotetracycline and sulfadimethoxine</td>
<td>Cattle</td>
<td>Sec. 558.450</td>
<td>Sec. 558.450.</td>
</tr>
<tr>
<td>Sanofi Animal Health, Inc.</td>
<td>Erythromycin</td>
<td>Cattle</td>
<td>Sec. 558.630</td>
<td>Sec. 558.630.</td>
</tr>
<tr>
<td>Hoffman-La Roche, Inc</td>
<td>Sulfadimethoxine and ornidazol</td>
<td>Chickens and turkeys.</td>
<td>Sec. 558.575</td>
<td>Sec. 558.575.</td>
</tr>
<tr>
<td>Pfizer, Inc.</td>
<td>Oxytetracycline and neomycin.</td>
<td>Chickens, turkeys, swine, and calves.</td>
<td>As provided in paragraph (g)(2) of this section.</td>
<td>As provided in paragraph (g)(2) of this section.</td>
</tr>
<tr>
<td>American Cyanamid Co. and Pfizer, Inc.</td>
<td>Chlortetracycline, sulfamethazine, and penicillin.</td>
<td>Swine</td>
<td>Sec. 558.248</td>
<td>Sec. 558.248.</td>
</tr>
<tr>
<td>Boehringer Ingelhein Vetmedica, Inc.</td>
<td>Chlortetracycline, sulfadimethoxine, and penicillin.</td>
<td>As provided in paragraph (g)(2) of this section.</td>
<td>Do.</td>
<td>As provided in paragraph (g)(2) of this section.</td>
</tr>
</tbody>
</table>

362
(2) The following is a list of drug combinations permitted when prepared from antibacterial Type A articles listed in paragraph (g)(1) of this section. Drug combinations listed in subpart B of this part name their sponsors and are incorporated herein by reference since they are safe and effective by contemporary standards, or such sponsors have been notified of any additional safety or efficacy data required on an individual basis:

<table>
<thead>
<tr>
<th>Drug sponsor</th>
<th>Type A article</th>
<th>Species</th>
<th>Use levels</th>
<th>Indications for use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehringer Ingelheim Vetmedica, Inc.</td>
<td>Chlortetracycline and arsanilic acid.</td>
<td>Swine</td>
<td>10 to 50 g/ton and 0.005 to 0.01 percent.</td>
<td>Enhancement of growth and feed efficiency.</td>
</tr>
<tr>
<td>American Cyanamid Co</td>
<td>Chlortetracycline and sulfamethazine.</td>
<td>Cattle</td>
<td>Sec. 558.128</td>
<td>Sec. 558.128.</td>
</tr>
<tr>
<td>Pfizer, Inc., PennField Oil Co., and VPO, Inc.</td>
<td>Oxytetracycline and neomycin base.</td>
<td>Chickens</td>
<td>50 g/ton and 35 to 140 g/ton.</td>
<td>Prevention of diseases from oxytetracycline susceptible organisms during periods of stress. As an aid in the prevention of bacterial enteritis and in the control of neomycin-sensitive organisms associated with bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
<tr>
<td>Do</td>
<td></td>
<td>Chickens</td>
<td>50 to 100 g/ton and 35 to 140 g/ton.</td>
<td>Prevention of early chick mortality due to oxytetracycline-susceptible organisms. As an aid in the prevention of bacterial enteritis and in the control of neomycin-sensitive organisms associated with bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
<tr>
<td>Do</td>
<td></td>
<td>Chickens (first 2 weeks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do</td>
<td></td>
<td>Chickens</td>
<td></td>
<td>To extend period of high egg production, to improve feed efficiency, to improve egg production and feed efficiency in presence of disease and at time of stress. As an aid in maintaining and improving hatchability where birds are suffering stress from moving, vaccinations, culling, extreme temperature changes, and worming; to improve livability of progeny when losses are due to oxytetracycline-susceptible organisms, to improve egg shell quality, prevention of bluecomb (mud fever or nonspecific enteritis). As an aid in the prevention of bacterial enteritis and in the control of neomycin-sensitive organisms associated with bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
<tr>
<td>Do</td>
<td></td>
<td></td>
<td></td>
<td>Prevention of complicated chronic respiratory disease (air-sac infection) and control of complicated chronic respiratory disease by lowering mortality and severity during outbreaks. As an aid in the prevention of bacterial enteritis and in the control of neomycin-sensitive organisms associated with bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
</tbody>
</table>

363
<table>
<thead>
<tr>
<th>Drug sponsor</th>
<th>Type A article</th>
<th>Species</th>
<th>Use levels</th>
<th>Indications for use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do</td>
<td>...............</td>
<td>Turkeys</td>
<td>50 g/ton and 35 to 140 g/ton.</td>
<td>As an aid in the prevention of disease from oxytetracycline susceptible organisms during periods of stress. As an aid in the prevention of bacterial enteritis and in the control of neomycin-sensitive organisms associated with bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
<tr>
<td>Do</td>
<td>...............</td>
<td>do</td>
<td>50 to 100 g/ton and 35 to 140 g/ton.</td>
<td>To extend period of high egg production, to improve egg production, to improve feed efficiency, to improve fertility, to improve egg production and feed efficiency in presence of disease and time of stress; as an aid in maintaining and improving hatchability where birds are suffering from stress, exposure, moving, vaccination, culling, extreme losses due to oxytetracycline-susceptible organisms, and to improve egg shell quality prevention of hexamitiasis. As an aid in the prevention of bacterial enteritis and in the control of neomycin-sensitive organisms associated with bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
<tr>
<td>Do</td>
<td>...............</td>
<td>Turkeys (first 4 weeks)</td>
<td>...............</td>
<td>As an aid in the prevention of early poult mortality due to oxytetracycline-susceptible organisms. As an aid in the prevention of bacterial enteritis and in the control of neomycin-sensitive organisms associated with bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
<tr>
<td>Do</td>
<td>...............</td>
<td>...............</td>
<td>100 to 150 g/ton and 35 to 105 g/ton.</td>
<td>As an aid in reducing mortality in birds which have suffered an attack of airsacculitis (it is recommended, wherever possible, to feed from time of attack to marketing).</td>
</tr>
<tr>
<td>Do</td>
<td>...............</td>
<td>Turkeys</td>
<td>...............</td>
<td>As an aid in the prevention of bacterial enteritis and in the control of neomycin-sensitive organisms associated with bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
<tr>
<td>Do</td>
<td>...............</td>
<td>...............</td>
<td>100 to 200 g/ton and 35 to 140 g/ton.</td>
<td>Control of bluecomb (mud fever or nonspecific enteritis), infectious sinusitis and hexamitiasis, prevention of infectious synovitis. As an aid in the prevention of bacterial enteritis and in the control of neomycin-sensitive organisms associated with bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
<tr>
<td>Do</td>
<td>...............</td>
<td>...............</td>
<td>200 g/ton and 70 to 140 g/ton.</td>
<td>Control of infectious synovitis. For the treatment of bacterial enteritis and bluecomb (mud fever or nonspecific enteritis).</td>
</tr>
</tbody>
</table>
### Food and Drug Administration, HHS

**§ 558.15**

<table>
<thead>
<tr>
<th>Drug sponsor</th>
<th>Type A article</th>
<th>Species</th>
<th>Use levels</th>
<th>Indications for use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do ..........</td>
<td>......do ..........</td>
<td>Swine</td>
<td>50 g/ton and 35 to 140 g/ton.</td>
<td>As an aid in the prevention of bacterial enteritis (scours), baby pig diarrhea (in baby pigs only), vibriotic dysentery, bloody dysentery, and salmonellosis (necrotic or necrotic enteritis).</td>
</tr>
<tr>
<td>Do ..........</td>
<td>......do ..........</td>
<td>......do ..........</td>
<td>50 to 150 g/ton and 70 to 140 g/ton.</td>
<td>As an aid in the maintenance of weight gains and feed consumption in the presence of atrophic rhinitis. As an aid in the treatment of bacterial enteritis.</td>
</tr>
<tr>
<td>Do ..........</td>
<td>......do ..........</td>
<td>......do ..........</td>
<td>8 to 100 mg/gal and 100 to 200 mg/gal reconstituted milk replacer.</td>
<td>As an aid in the prevention of bacterial diarrhea (scours).</td>
</tr>
<tr>
<td>Do ..........</td>
<td>......do ..........</td>
<td>......do ..........</td>
<td>40 to 200 mg/gal and 200 to 400 mg/gal reconstituted milk replacer.</td>
<td>As an aid in the treatment of bacterial diarrhea (scours).</td>
</tr>
<tr>
<td>The Upjohn Co.</td>
<td>Lincomycin, amprolium, and ethopabate.</td>
<td>Chickens</td>
<td>Secs. 558.58 and 558.325.</td>
<td>Secs. 558.58 and 558.325.</td>
</tr>
<tr>
<td>Do ..........</td>
<td>Lincomycin and zoalene.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do ..........</td>
<td>Lincomycin, amprolium, ethopabate, and roxarsone.</td>
<td>Calves</td>
<td>50 g/ton and 35 to 140 g/ton.</td>
<td>As an aid in the prevention of bacterial enteritis (scours).</td>
</tr>
<tr>
<td>Do ..........</td>
<td>Lincomycin, monensin, and roxarsone.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do ..........</td>
<td>Nicarbazin and procarbazine.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do ..........</td>
<td>Nicarbazin and bacitracin methylene disalicylate, and roxarsone.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do ..........</td>
<td>Nicarbazin, bacitracin methylene disalicylate, and roxarsone.</td>
<td>Chickens</td>
<td>0.01 to 0.02 percent and 2.4 to 50 g/ton.</td>
<td>Do.</td>
</tr>
<tr>
<td>Do ..........</td>
<td>Nicarbazin, procarbazine, and roxarsone.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do ..........</td>
<td>Amprolium and bacitracin methylene disalicylate.</td>
<td>Chickens and turkeys.</td>
<td>0.0125 to 0.025 percent and 4 to 50 g/ton.</td>
<td>Secs. 558.55 and 558.76.</td>
</tr>
<tr>
<td>Do ..........</td>
<td>Amprolium, ethopabate, and bacitracin methylene disalicylate.</td>
<td>Chickens</td>
<td>0.0125 to 0.025 percent, 0.0004 percent, and 4 to 50 g/ton.</td>
<td>Secs. 558.58 and 558.76.</td>
</tr>
<tr>
<td>Do ..........</td>
<td>Amprolium, ethopabate, bacitracin methylene disalicylate, and roxarsone.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do ..........</td>
<td>Amprolium and procaine penicillin.</td>
<td>Chickens and turkeys.</td>
<td>0.004 to 0.025 percent and 2.4 to 50 g/ton.</td>
<td>Secs. 558.55 and 558.460.</td>
</tr>
</tbody>
</table>

365
<table>
<thead>
<tr>
<th>Drug sponsor</th>
<th>Type A article</th>
<th>Species</th>
<th>Use levels</th>
<th>Indications for use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do</td>
<td>Amprolium, procaine penicillin, and roxarsone.</td>
<td>Chicks</td>
<td>0.004 to 0.025 percent, 2.4 to 50 g/ton, and 0.0025 to 0.005 percent.</td>
<td>Secs. 558.55, 558.460, and 558.530.</td>
</tr>
<tr>
<td>Do</td>
<td>Amprolium, ethopabate, procaine penicillin, and erythromycin.</td>
<td>do</td>
<td>0.0125 to 0.025 percent, 0.0004 percent, 2.4 to 50 g/ton, and 4.6 to 18.5 g/ton.</td>
<td>Secs. 558.58 and 558.460.</td>
</tr>
<tr>
<td>Do</td>
<td>Amprolium and erythromycin.</td>
<td>do</td>
<td>0.0125 to 0.025 percent and 4.6 to 18.5 g/ton.</td>
<td>Sec. 558.55.</td>
</tr>
<tr>
<td>Do</td>
<td>Amprolium and ethopabate.</td>
<td>do</td>
<td>0.0125 to 0.025 percent, 0.0004 percent, 0.01 percent, and 4.6 to 18.5 g/ton.</td>
<td>Sec. 558.58.</td>
</tr>
<tr>
<td>Do</td>
<td>Amprolium, arsanic acid, and erythromycin.</td>
<td>do</td>
<td>0.0125 to 0.025 percent, 0.004 percent, and 4 to 50 g/ton.</td>
<td>Sec. 558.55.</td>
</tr>
<tr>
<td>Do</td>
<td>Amprolium, ethopabate, and bacitracin methylene disalicylate, and roxarsone.</td>
<td>do</td>
<td>0.0125 percent, 0.004 percent, 5 to 35 g/ton, and 0.00375 percent.</td>
<td>Sec. 558.58.</td>
</tr>
<tr>
<td>Pitman-Moore, Inc.</td>
<td>Bacitracin zinc, amprolium, and ethopabate.</td>
<td>do</td>
<td>4 to 50 g/ton, 0.0125 to 0.025 percent, and 0.0004 percent.</td>
<td>Prevention of coccidiosis. Growth promotion and feed efficiency. Sec.558.78.</td>
</tr>
<tr>
<td>Do</td>
<td>Bacitracin zinc, ethopabate, and roxarsone.</td>
<td>do</td>
<td>4 to 50 g/ton, 0.0125 to 0.025 percent, 0.0004 percent and 0.0025 to 0.005 percent.</td>
<td>Prevention of coccidiosis. Growth promotion and feed efficiency. Improving pigmentation. Sec. 558.78.</td>
</tr>
<tr>
<td>Do</td>
<td>Bacitracin zinc and arsanic acid.</td>
<td>Swine</td>
<td>10 to 50 g/ton and 0.005 to 0.01 percent.</td>
<td>Increased rate of weight gain and improved feed efficiency.</td>
</tr>
<tr>
<td>Merck Sharp &amp; Dohme Research Labs.</td>
<td>Amprolium, ethopabate, procaine penicillin, and roxarsone.</td>
<td>Chicks</td>
<td>0.125 to 0.025 percent, 0.0004 percent, 2.4 to 50 g/ton, and 0.0025 to 0.005 percent.</td>
<td>Secs. 558.58, 558.460 and 558.530.</td>
</tr>
<tr>
<td>A. L. Laboratories, Inc.</td>
<td>Zoalene and bacitracin methylene disalicylate.</td>
<td>Chicks</td>
<td>0.0125 percent and 4 to 50 g/ton.</td>
<td>Sec. 558.680.</td>
</tr>
<tr>
<td>Do</td>
<td>Zoalene, roxarsone, and bacitracin methylene disalicylate.</td>
<td>do</td>
<td>0.0125 percent, 0.005 percent, and 4 to 50 g/ton.</td>
<td>Do.</td>
</tr>
<tr>
<td>Do</td>
<td>Zoalene and bacitracin zinc.</td>
<td>do</td>
<td>0.0125 percent and 4 to 50 g/ton.</td>
<td>Do.</td>
</tr>
<tr>
<td>Do</td>
<td>Zoalene, roxarsone, and bacitracin zinc.</td>
<td>do</td>
<td>0.0125 percent, 0.0025 to 0.005 percent, and 4 to 50 g/ton.</td>
<td>Do.</td>
</tr>
<tr>
<td>Do</td>
<td>Zoalene and penicillin.</td>
<td>do</td>
<td>0.0125 percent and 2.4 to 50 g/ton.</td>
<td>Do.</td>
</tr>
</tbody>
</table>
Subpart B—Specific New Animal Drugs for Use in Animal Feeds

§ 558.35 Aklomide.

(a) Approvals. Type A medicated articles: to 053501 in §510.600(c) of this chapter, as follows:

(1) 50 percent aklomide.

(2) 20 percent sulfanitran and 25 percent aklomide.

(3) 25 percent aklomide, 20 percent sulfanitran, and 5 percent roxarsone.

(4) 50 percent aklomide and 10 percent roxarsone.

(b) Related tolerances. See §556.30 of this chapter.

(c) Conditions of use. It is used in feed for chickens as follows:

(1) Amount per ton. Aklomide, 227 grams (0.025 percent).  

(i) Indications for use. As an aid in the prevention of coccidiosis caused by E. tenella and E. necatrix.

(ii) Limitations. Not to be fed to laying chickens; withdraw 5 days before slaughter.

(2) Amount per ton. Aklomide, 227 grams (0.025 percent) combined with sulfanitran, 181.6 grams (0.02 percent).

(i) Indications for use. As an aid in the prevention of coccidiosis caused by E. tenella, E. necatrix, and E. acervulina.

(ii) Limitations. Not to be fed to laying chickens; withdraw 5 days before slaughter; as sole source of organic arsenic; chickens should have access to drinking water at all times.

(3) Amount per ton. Aklomide, 227 grams (0.025 percent) combined with sulfanitran, 181.6 grams (0.02 percent) + roxarsone, 22.7–45.4 grams (0.0025–0.005 percent).

(i) Indications for use. As an aid in the prevention of coccidiosis caused by E. tenella, E. necatrix, and E. acervulina; growth promotion and feed efficiency; improving pigmentation.

(ii) Limitations. Not to be fed to laying chickens; withdraw 5 days before slaughter; as sole source of organic arsenic; chickens should have access to drinking water at all times.

(4) Amount per ton. Aklomide, 227 grams (0.025 percent) combined with...
roxarsone, 22.7–45.4 grams (0.0025–0.005 percent).

(i) Indications for use. As an aid in the prevention of coccidiosis caused by *E. tenella*, and *E. necatrix*; growth promotion and feed efficiency; improving pigmentation.

(ii) Limitations. Not to be fed to birds laying eggs for human consumption; withdraw 5 days before slaughter; as sole source of organic arsenic; chickens should have access to drinking water at all times.


§ 558.55 Amprolium.

(a) Approvals. Type A medicated articles: 25 percent to 0.50604 in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(b) Special considerations. Do not use in Type B or Type C medicated feeds containing bentonite.

(c) Related tolerances. See § 556.50 of this chapter.

(d) Conditions of use—(1) Calves. It is top-dressed on or thoroughly mixed in the daily feed ration as follows:

(i) Amount. 227 milligrams per 100 pounds (5 milligrams per kilogram) body weight per day.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by *Eimeria bovis* and *E. zurnii*.

(b) Limitations. Administer from a Type B feed containing from 0.05 to 1.25 percent amprolium with the usual amount of feed consumed in 1 day; feed for 21 days during periods of exposure or when experience indicates that coccidiosis is likely to be a hazard; withdraw 24 hours before slaughter; as sole source of amprolium.

(ii) Amount. 454 milligrams per 100 pounds (10 milligrams per kilogram) body weight per day.

(a) Indications for use. As an aid in the treatment of coccidiosis caused by *Eimeria bovis* and *E. zurnii*.

(b) Limitations. Administer from a Type B feed containing from 0.05 to 1.25 percent amprolium with the usual amount of feed consumed in 1 day; feed for 5 days; for a satisfactory diagnosis, a microscopic examination of the feces should be done by a veterinarian or diagnostic laboratory before treatment; when treating outbreaks, the drug should be administered promptly after diagnosis is determined; withdraw 24 hours before slaughter; as sole source of amprolium.

(2) Chickens and turkeys. It is used as follows:

<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amprolium in grams per ton</td>
<td>Combination in grams per ton</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i) 36.3 to 113.5 (0.004% to 0.0125%)</td>
<td></td>
<td>Replacement chickens: development of active immunity to coccidiosis.</td>
<td>Feed as follows—</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Growing conditions</th>
<th>Up to 5 weeks of age</th>
<th>From 5 to 8 weeks of age</th>
<th>Over 8 weeks of age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amprolium grams per ton</td>
<td>Amprolium grams per ton</td>
<td>Amprolium grams per ton</td>
<td></td>
</tr>
<tr>
<td>Severe exposure to coccidiosis.</td>
<td>113.5 (0.0125%)</td>
<td>72.6–113.5 (0.008%–0.0125%)</td>
<td>36.3–113.5 (0.004%–0.0125%)</td>
</tr>
<tr>
<td>Moderate exposure to coccidiosis.</td>
<td>72.6–113.5 (0.008%–0.0125%)</td>
<td>54.5–113.5 (0.006%–0.0125%)</td>
<td>36.3–113.5 (0.004%–0.0125%)</td>
</tr>
<tr>
<td>Slight exposure to coccidiosis.</td>
<td>36.3–113.5 (0.004%–0.0125%)</td>
<td>36.3–113.5 (0.004%–0.0125%)</td>
<td>36.3–113.5 (0.004%–0.0125%)</td>
</tr>
<tr>
<td>Amprolium in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Arsanilate sodium 90</td>
<td>(0.01%)</td>
<td>Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic; feed according to suitable in item (i).</td>
</tr>
<tr>
<td>Arsanilic acid 90</td>
<td>(0.01%)</td>
<td>Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic; feed according to suitable in item (i).</td>
</tr>
<tr>
<td>Arsanilic acid 90</td>
<td>(0.01%) + erythromycin 4.6</td>
<td>Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; withdraw 5 d before slaughter; as sole source of organic arsenic; Feed according to suitable in item (i).</td>
</tr>
<tr>
<td>Arsanilic acid 90</td>
<td>(0.01%) + erythromycin 92.5</td>
<td>1. Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation; as an aid in the prevention of chronic respiratory disease during periods of stress.</td>
<td>Feed for 7 to 14 d; withdraw 5 d before slaughter; as sole source of organic arsenic. Feed according to suitable in item (i).</td>
</tr>
<tr>
<td>Arsanilic acid 90</td>
<td>(0.04%) + erythromycin 185.</td>
<td>Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation; as an aid in the prevention of infectious coryza.</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 5 d before slaughter; as sole source of organic arsenic. Feed according to suitable in item (i).</td>
</tr>
<tr>
<td>Bacitracin 100 to 200</td>
<td></td>
<td>Replacement chickens; development of active immunity to coccidiosis; treatment of chronic respiratory disease (air-sac infection) and blue comb (nonspecific infectious enteritis).</td>
<td>As bacitracin methylene disalicylate or bacitracin zinc. Feed according to suitable in item (i).</td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate 4 to 50</td>
<td></td>
<td>Replacement chickens; development of active immunity to coccidiosis, increased rate of weight gain, and improved feed efficiency.</td>
<td>Feed according to suitable in item (i); bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter..</td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate 50 plus roxarsone 22.7 to 45.4</td>
<td></td>
<td>Replacement chickens; development of active immunity to coccidiosis; as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin; increased rate of weight gain, improved feed efficiency, and improved pigmentation.</td>
<td>Feed according to suitable in entry (i); bacitracin methylene disalicylate and roxarsone as provided by 046573 in §510.600(c) of this chapter..</td>
</tr>
<tr>
<td>Chlortetracycline 100 to 200</td>
<td></td>
<td>Chickens; development of active immunity to coccidiosis; control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption. Feed for 7 to 14 d.</td>
</tr>
<tr>
<td>Amprolium in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-------------------------------</td>
<td>---------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Chlortetracycline 200 to 400</td>
<td>Chickens; development of active immunity to coccidiosis; control of chronic respiratory disease (CRD) and air sac infection caused by <em>M. gallisepticum</em> and <em>E. coli</em> susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption. Feed for 7 to 14 d.</td>
<td>As erythromycin thiocyanate. Feed according to subtable in item (i).</td>
</tr>
<tr>
<td>Erythromycin 4.6 to 18.5</td>
<td>Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency.</td>
<td>Feed for 7 to 14 d; withdraw 24 h before slaughter. Feed according to subtable in item (i).</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; withdraw 24 h before slaughter. Feed according to subtable in item (i).</td>
</tr>
<tr>
<td>Erythromycin 92.5</td>
<td>1. Replacement chickens; development of active immunity to coccidiosis; as an aid in the prevention of infectious coryza. 2. Replacement chickens; development of active immunity to coccidiosis; as an aid in the prevention of chronic respiratory disease during periods of stress.</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 48 h before slaughter. Feed according to subtable in item (i).</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 48 h before slaughter. Feed according to subtable in item (i).</td>
</tr>
<tr>
<td>Erythromycin 185</td>
<td>Replacement chickens; development of active immunity to coccidiosis; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease.</td>
<td>Feed according to subtable in item (i).</td>
<td>Feed according to subtable in item (i).</td>
</tr>
<tr>
<td>Hygromycin B 8 to 12</td>
<td>Replacement chickens; development of active immunity to coccidiosis; control of infestation of large round worms (<em>Ascaris galli</em>), cecal worms (<em>Heterakis gallinae</em>), and capillary worms (<em>Capillaria obsignata</em>).</td>
<td>Feed according to subtable in item (i).</td>
<td>Feed according to subtable in item (i).</td>
</tr>
<tr>
<td>Penicillin 2.4 to 50</td>
<td>Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency.</td>
<td>As procaine penicillin. Feed according to subtable in item (i).</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic. Feed according to subtable in item (i).</td>
</tr>
<tr>
<td>Roxarsone 22.7 to 45.4 (0.0025% to 0.005%).</td>
<td>Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Insertion text</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic. Feed according to subtable in item (i).</td>
</tr>
<tr>
<td>(ii) 72.6 to 113.5 (0.008% to 0.0125%).</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>E. tenella</em> only.</td>
<td>As bacitracin methylene disalicylate, or zinc bacitracin.</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
</tr>
<tr>
<td>Arsanilate sodium 90 (0.01%).</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>E. tenella</em> only; growth promotion and feed efficiency; improving pigmentation.</td>
<td>As bacitracin methylene disalicylate, or zinc bacitracin.</td>
<td>As bacitracin methylene disalicylate, or zinc bacitracin.</td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%).</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>E. tenella</em> only; treatment of chronic respiratory disease (air-sac infection) and blue comb (nonspecific infectious enteritis).</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td>As bacitracin methylene disalicylate, or zinc bacitracin.</td>
</tr>
<tr>
<td>Bacitracin 100 to 200</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>E. tenella</em> only; treatment of chronic respiratory disease (air-sac infection) and blue comb (nonspecific infectious enteritis).</td>
<td>As bacitracin methylene disalicylate, or zinc bacitracin.</td>
<td>As bacitracin methylene disalicylate, or zinc bacitracin.</td>
</tr>
<tr>
<td>Chlortetracycline 100 to 200.</td>
<td>Chickens; prevention of coccidiosis caused by <em>E. tenella</em> only; control of infectious synovitis caused by <em>M. synoviae</em> susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption. Feed for 7 to 14 d.</td>
<td>Do not feed to chickens producing eggs for human consumption. Feed for 7 to 14 d.</td>
</tr>
<tr>
<td>Amprolium in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
</tr>
<tr>
<td>----------------------------</td>
<td>------------------------------</td>
<td>---------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Chlortetracycline 200 to 400</td>
<td>Chicken; prevention of coccidiosis caused by <em>E. tenella</em> only; control of chronic respiratory disease (CRD) and air sac infection caused by <em>M. gallisepticum</em> and <em>E. coli</em> susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption. Feed for 7 to 14 days.</td>
<td></td>
</tr>
<tr>
<td>Hygromycin B 8 to 12</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>Eimeria tenella</em> only; control of infestation of large round worms (<em>Heterakis gallinae</em>), and capillary worms (<em>Capillaria obsignata</em>).</td>
<td>Feed according to subtable in item (i).</td>
<td></td>
</tr>
<tr>
<td>Penicillin 2.4 to 50</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>E. tenella</em> only; growth promotion and feed efficiency.</td>
<td>As procaine penicillin.</td>
<td></td>
</tr>
<tr>
<td>Roxarsone 22.7 to 45.4 (0.0025% to 0.005%).</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>E. tenella</em> only; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Withdraw 5 days before slaughter; as sole source of organic arsenic.</td>
<td></td>
</tr>
<tr>
<td>(iii) 113.5 (0.0125%)</td>
<td>1. Laying chickens; prevention of coccidiosis.  2. Laying chickens; treatment of coccidiosis.</td>
<td>For moderate outbreaks of coccidiosis; administer for 2 weeks.</td>
<td></td>
</tr>
<tr>
<td>Bambermycins 1 to 3 plus roxarsone 22.8 to 34.1 (0.0025% to 0.00375%).</td>
<td>Broiler chickens; as an aid in the prevention of coccidiosis; for increased rate of weight gain, improved feed efficiency, and improved pigmentation.</td>
<td>Feed continuously as the sole source of amprolium and organic arsenic; roxarsone as provided by No. 053501 in §510.600(c) of this chapter, bambermycins as provided by No. 057926; withdraw 5 days before slaughter.</td>
<td></td>
</tr>
<tr>
<td>Bambermycins 1 to 4</td>
<td>Growing turkeys; prevention of coccidiosis; increased rate of weight gain and improved feed efficiency.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(iv) 113.5 to 227 (0.0125% to 0.025%).</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis.  2. Turkeys; prevention of coccidiosis.</td>
<td>Withdraw 5 days before slaughter; as sole source of organic arsenic.</td>
<td></td>
</tr>
<tr>
<td>Arsanilate sodium 90 (0.01%).</td>
<td>Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%).</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation.  2. Turkeys; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

371
<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arsanilic acid 90 (0.01%) plus erythromycin 92.5.</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation; as an aid in the prevention of chronic respiratory disease during periods of stress.</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus erythromycin 185.</td>
<td>2. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation; as an aid in the prevention of respiratory disease.</td>
<td>Feed for 7 to 14 d; withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus erythromycin 4.6 to 18.5.</td>
<td>Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improved pigmentation.</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacitracin 4 to 50</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency.</td>
<td>As bacitracin methylene disalicylate or bacitracin zinc.</td>
<td>012769</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 100 to 200</td>
<td>2. Turkeys; prevention of coccidiosis; growth promotion and feed efficiency.</td>
<td>do</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacitracin plus penicillin 100 to 500 (of combination)</td>
<td>do</td>
<td>Feed contains 50% to 75% of bacitracin but not more than 125 g penicillin; as procaine penicillin; as bacitracin zinc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacitracin 100 to 500</td>
<td>Turkeys; prevention of coccidiosis; treatment of infectious sinusitis, blue comb (mud fever).</td>
<td>As bacitracin zinc</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[^012769]: Official Code Table Reference
<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbarsone 227 to 340.5.</td>
<td>Turkeys; aid in prevention of coccidiosis (E. adenoeides, E. meleagrnitis, and E. galiopavone) and blackhead.</td>
<td>Feed continuously 2 weeks before coccidiosis and blackhead are expected and continue as long as prevention is needed; withdraw 5 days before slaughter; use as sole source of amprolium and organic arsenic; do not use as a treatment for outbreaks of coccidiosis; carbarsone by 046573 in § 510.600(c) of this chapter.</td>
<td>000006</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 100 to 200.</td>
<td>Chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; control of infectious synovitis caused by M. synoviae susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption. Feed for 7 to 14 d.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 200 to 400.</td>
<td>Chickens where immunity to coccidiosis is not desired; control of chronic respiratory disease (CRD) and air sac infection caused by M. gallisepticum and E. coli susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption. Feed for 7 to 14 d.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin 4.6 to 18.5.</td>
<td>Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency.</td>
<td>As erythromycin thiocyanate .......</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin 92.5 .......</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention of chronic respiratory disease during periods of stress.</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; withdraw 24 h before slaughter.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin 185 .......</td>
<td>2. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention of infectious coryza.</td>
<td>Feed for 7 to 14 d; withdraw 24 h before slaughter.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin 185 .......</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease.</td>
<td>Feed for 5 to 8 d, do not use in birds producing eggs for food purposes; withdraw 48 h before slaughter.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hygromycin B 8 to 12</td>
<td>Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; control of infestation of large round worms (Heterakis gallinae) and capillary worms (Capillaria obignata).</td>
<td>Feed according to subtable in item (i).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin 2.4 to 50 ....</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency.</td>
<td>As procaine penicillin ............</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Turkeys; prevention of coccidiosis; growth promotion and feed efficiency.</td>
<td>........................................</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
§ 558.58 Amprolium in grams per ton

<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roxarsone 22.7 to 45.4 (0.0025% to 0.005%).</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(v) 227 (0.025%)</td>
<td>2. Turkeys; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>For severe outbreaks of coccidiosis; administer for 2 weeks.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(3) Pheasants. It is used as follows:

(i) Amount. 0.0175 percent (159 grams per ton).

(ii) Indications for use. For the prevention of coccidiosis in growing pheasants caused by *Eimeria colchici*, *E. duodenalis*, and *E. phasiani*.

(iii) Limitations. Feed continuously as sole ration. Use as sole source of amprolium. Fertility, hatchability, and other reproductive data are not available on amprolium in breeding pheasants. Do not use in feeds containing bentonite.

[41 FR 10985, Mar. 15, 1976]

Editorial Note: For Federal Register citations affecting §558.55, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

§ 558.58 Amprolium and ethopabate.

(a) Approvals. Type A medicated articles:

(1) 25 percent amprolium and 0.8 percent ethopabate; 25 percent amprolium and 8 percent ethopabate; 5 percent amprolium and 0.16 percent ethopabate; 5 percent amprolium and 1.6 percent ethopabate; to 0.0004 percent ethopabate and 0.05 gram per pound bacitracin (as bacitracin methylene disalicylate) to 0.047019.

(2) 0.15 percent amprolium and 0.004 percent ethopabate and 0.05 gram per pound bacitracin (as bacitracin methylene disalicylate) to 0.047019 in §510.600(c) of this chapter.

(b) Special considerations. Do not use in Type B or Type C medicated feeds containing bentonite.

(c) Related tolerances. See §§556.50 and 556.260 of this chapter.

(d) Conditions of use. (1) It is used for chickens as follows:

<table>
<thead>
<tr>
<th>Amprolium and ethopabate in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) Amprolium 113.5 (0.0125 pct) and ethopabate 3.6 (0.0004 pct).</td>
<td>Bambermycins 2 to 3 plus roxarsone 22.8 to 34.1 (0.0025% to 0.00375%).</td>
<td>Broiler chickens as an aid in the prevention of coccidiosis.</td>
<td>Not for laying hens; as sole source of amprolium.</td>
<td></td>
</tr>
<tr>
<td>(ii) Amprolium 113.5 (0.0125%) and ethopabate 3.6 (0.0004%).</td>
<td>Lincomycin 2 to 4</td>
<td>Broiler chickens as an aid in the prevention of coccidiosis; for increased rate of weight gain, improved feed efficiency, and pigmentation.</td>
<td>Feed continuously as the sole ration; as sole source of amprolium and organic arsenic; amprolium and ethopabate as provided by No. 050604 in §510.600(c) of this chapter, roxarsone by No. 046573, bambermycins by No. 057926; withdraw 5 d before slaughter.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Broiler chickens; for increase in rate of weight gain; improved feed efficiency; as an aid in the prevention of coccidiosis.</td>
<td>Not for laying chickens; as lincomycin hydrochloride monohydrate; as sole source of amprolium.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Broiler chickens; for increase in rate of weight gain; improved feed efficiency and pigmentation; as an aid in the prevention of coccidiosis.</td>
<td>Not for laying chickens; as lincomycin hydrochloride monohydrate; withdraw 5 d before slaughter; as sole source of amprolium and organic arsenic.</td>
<td></td>
</tr>
<tr>
<td>Amprolium and ethopabate in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Roxarsone 45.4 (0.005 pct).</td>
<td>Broiler chickens; to aid in prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; for increased rate of weight gain in broiler chickens raised in floor pens.</td>
<td>Do not feed to laying chickens; withdraw 5 d before slaughter; as sole source of amprolium; do not use as a treatment for outbreaks of coccidiosis; feed as sole ration from time chickens are placed on litter until the past the time when coccidiosis is ordinarily a hazard; roxarsone as provided by No. 046573 in §510.600(c) of this chapter; combinations as provided by No. 050604.</td>
<td>Not for chickens over 16 weeks of age.</td>
<td>050604</td>
</tr>
<tr>
<td>(iii) Amprolium 113.5 (0.0125%) and ethopabate 36.3 (0.004%).</td>
<td>Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; as an aid in the prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur.</td>
<td>Not for laying hens; withdraw 5 d before slaughter; as sole source of organic arsenic; as erythromycin thiocyanate.</td>
<td>061133</td>
<td></td>
</tr>
<tr>
<td>Arsanic acid 90 (0.01 pct) plus erythromycin 4.6 to 18.5.</td>
<td>Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improve pigmentation.</td>
<td>Not for chickens over 16 weeks of age; do not feed to laying chickens; as sole source of amprolium; not for use as a treatment for outbreaks of coccidiosis; as bacitracin methylene disalicylate as provided by No. 046573 or bacitracin zinc as provided by No. 046573 in §510.600(c) of this chapter; feed as the sole ration from the time chickens are placed on litter until past the time when coccidiosis is ordinarily a hazard; combination as provided by No. 050604 in §510.600(c) of this chapter.</td>
<td>061133</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 4 to 50 ...</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; to aid in prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; for increased rate of weight gain in broiler chickens raised in floor pens.</td>
<td>Not for chickens over 16 weeks of age; do not feed to laying chickens; as sole source of amprolium; not for use as a treatment for coccidiosis; bacitracin zinc as provided by No. 046573 in §510.600(c) of this chapter; feed as the sole ration from the time chickens are placed on litter until market weight; combination as provided by No. 046573.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>..........</td>
<td>2. Broiler chickens; as an aid in prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; improved feed efficiency.</td>
<td>Not for chickens over 16 weeks of age; do not feed to laying chickens; as sole source of amprolium; not for use as a treatment for coccidiosis; bacitracin zinc as provided by No. 046573 in §510.600(c) of this chapter; feed as the sole ration from the time chickens are placed on litter until market weight; combination as provided by No. 046573.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Amprolium and ethopabate in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>------------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Bacitracin 5 to 35 plus roxarsone 34</td>
<td>Broiler chickens; for increased rate of weight gain and as an aid in the prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur in broiler chickens raised in floor pens.</td>
<td>Do not feed to laying chickens; withdraw 5 d before slaughter; as sole source of amprolium and organic arsenic; do not use as a treatment for outbreaks of coccidiosis; feed as the sole ration from time chickens are placed on litter until past the time when coccidiosis is ordinarily a hazard; amprolium and ethopabate as provided by No. 050604 in §510.600(c) of this chapter; bacitracin methylene disalicylate as provided by No. 046573 or bacitracin zinc as provided by No. 046573 in §510.600(c) of this chapter; roxarsone as provided by No. 046573 in §510.600(c) of this chapter; combination as provided by No. 050604 in §510.600(c) of this chapter.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 20 to 35 plus roxarsone 34</td>
<td>Broiler chickens; for increased rate of weight gain, improved feed efficiency, and as an aid in the prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur in broiler chickens raised in floor pens.</td>
<td>Do not feed to laying chickens; withdraw 5 d before slaughter; as sole source of amprolium and organic arsenic; do not use as a treatment for outbreaks of coccidiosis; feed as the sole ration from time chickens are placed on litter until past the time when coccidiosis is ordinarily a hazard; amprolium and ethopabate as provided by No. 050604 in §510.600(c) of this chapter; bacitracin methylene disalicylate as provided by No. 046573 or bacitracin zinc as provided by No. 046573 in §510.600(c) of this chapter; roxarsone as provided by No. 046573 in §510.600(c) of this chapter; combination as provided by No. 050604 in §510.600(c) of this chapter.</td>
<td>050604</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 10 to 50 plus roxarsone 15.4 to 45.4</td>
<td>Broiler chickens; as an aid in prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; improved feed efficiency.</td>
<td>Do not feed to laying chickens; withdraw 5 d before slaughter; as sole source of amprolium and organic arsenic; do not use as a treatment for outbreaks of coccidiosis; feed as the sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; amprolium and ethopabate as provided by No. 050604 in §510.600(c) of this chapter; bacitracin zinc as provided by No. 046573 roxarsone as provided by No. 046573 combination as provided by No. 046573.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 10 plus roxarsone 30 to 45.4</td>
<td>Broiler chickens; as an aid in prevention of coccidiosis where severe exposure to coccidiosis from <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; improved feed efficiency and improved pigmentation.</td>
<td>do</td>
<td>063238</td>
<td></td>
</tr>
<tr>
<td>Amprolium and ethopabate in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Bambermycins 1 to 3.</td>
<td>Broiler chickens; as an aid in the prevention of coccidiosis where severe exposure to <em>Eimeria acervulina</em>, <em>E. brunetti</em>, and <em>E. maxima</em> is likely to occur; for increased rate of weight gain, and improved feed efficiency.</td>
<td>Feed continuously as the sole ration; as sole source of amprolium, amprolium, ethopabate as provided by No. 057926 in §510.600(c) of this chapter.</td>
<td>Bambermycins as provided by No. 057926 in §510.600(c) of this chapter.</td>
<td>Sponsor</td>
</tr>
<tr>
<td>Bambermycins 1 to 3 plus roxarsone 22.8 to 34.1 (0.0025% to 0.00375%).</td>
<td>Broiler chickens; as an aid in the prevention of coccidiosis where severe exposure to <em>Eimeria acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; for increased rate of weight gain; improved feed efficiency, and improved pigmentation.</td>
<td>Feed continuously as the sole ration; as sole source of amprolium and organic arsenic; amprolium and ethopabate as provided by No. 050604 in §510.600(c) of this chapter, roxarsone by No. 046573 bambermycins by No. 057926. Withdraw 5 days before slaughter.</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>Erythromycin 4.6 to 10.5.</td>
<td>Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency.</td>
<td>Not for laying hens; withdraw 24 hours before slaughter; erythromycin thiocyanate.</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>Virginiamycin, 15.</td>
<td>Broiler chickens, as an aid in the prevention of coccidiosis where severe exposure to <em>Eimeria acervulina</em>, <em>E. brunetti</em>, and <em>E. maxima</em> is likely to occur, for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration, do not feed to laying hens, not for chickens over 16 weeks of age; as sole source of amprolium, amprolium and ethopabate as provided by No. 050604 in §510.600(c), virginiamycin as provided by 066104.</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>Virginiamycin, 5 to 10.</td>
<td>Broiler chickens, as an aid in the prevention of coccidiosis where severe exposure to <em>Eimeria acervulina</em>, <em>E. brunetti</em>, and <em>E. maxima</em> is likely to occur, for increased rate of weight gain.</td>
<td>Not for laying hens.</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>(iv) Amprolium 113.5 to 227 (0.0125% to 0.025%) and ethopabate 3.6 (0.0004%).</td>
<td>For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis.</td>
<td>For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%).</td>
<td>Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>As sole source of organic arsenic; withdraw 5 d before slaughter; not for laying hens.</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus erythromycin 92.5.</td>
<td>1. For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention of chronic respiratory disease during periods of stress; growth promotion and feed efficiency; improving pigmentation. 2. For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention of infectious coryza; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; withdraw 5 d before slaughter; as sole source of organic arsenic; not for laying hens.</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>Amprolium and ethopabate in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Arsanic acid 90 (0.01%) plus erythromycin 185.</td>
<td>For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacitracin 4 to 50 ...</td>
<td>For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency.</td>
<td>As bacitracin methylene disalicylate; not for laying hens.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacitracin 100 to 200.</td>
<td>1. Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; treatment of chronic respiratory disease (air-sac infection) and blue comb (nonspecific infectious enteritis). 2. For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; treatment of chronic respiratory disease (air-sac infection), blue comb (nonspecific infectious enteritis).</td>
<td>As zinc bacitracin, not for laying hens.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacitracin 4 to 50 plus roxarsone 22.7 to 45.4 (0.0025% to 0.005%).</td>
<td>Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>As bacitracin methylene disalicylate; not for laying hens; as sole source of organic arsenic; withdraw 5 d before slaughter.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 100 to 200.</td>
<td>For chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; control of infectious synovitis caused by <em>Mycoplasma synoviae</em> susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption. Feed for 7 to 14 d.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 200 to 400.</td>
<td>For chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; control of chronic respiratory disease (CRD) and air sac infection caused by <em>M. gallisepticum</em> and <em>E. coli</em> susceptible to chlortetracycline.</td>
<td>In low calcium feed containing 0.8% dietary calcium and 1.5% sodium sulfate; feed continuously as sole ration for 7 to 14 d; do not feed to chickens producing eggs for human consumption.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin 92.5 ...</td>
<td>1. For broiler chickens and for replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention of chronic respiratory disease during periods of stress. 2. For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention of infectious coryza.</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; withdraw 24 h before slaughter; not for laying hens.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Feed for 7 to 14 d; withdraw 24 h before slaughter; not for laying hens.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Amprolium and ethopabate in grams per ton | Combination in grams per ton | Indications for use | Limitations | Sponsor |
---|---|---|---|---|
Erythromycin 185 | | For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease. | Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 48 h before slaughter. | |
Penicillin 2.4 to 50 | | For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation. | Not for laying hens; as procaine penicillin. | |
Roxarsone 22.7 to 45.4 (0.0025% to 0.005%). | | Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation. | As sole source of organic arsenic; withdraw 5 d before slaughter; not for laying hens. | |

Erythromycin 185 ... For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease. Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 48 h before slaughter.

Penicillin 2.4 to 50 ... For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation. Not for laying hens; as procaine penicillin.

Roxarsone 22.7 to 45.4 (0.0025% to 0.005%). Broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; growth promotion and feed efficiency; improving pigmentation. As sole source of organic arsenic; withdraw 5 d before slaughter; not for laying hens.

(2) [Reserved]

[41 FR 10990, Mar. 15, 1976]

Editorial Note: For Federal Register citations affecting §558.58, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

§ 558.59 Apramycin.

(a) Approvals. Type A articles to sponsors identified in §510.600(c) of this chapter as follows:

(1) 000986 for 75 grams apramycin (as apramycin sulfate) per pound for use as in paragraph (d)(1) of this section.

(2) [Reserved]

(b) Related tolerances. See §556.60 of this chapter.

(c) Conditions of use. (1) It is used for chickens and turkeys as follows:

(i) Grams per ton. 90 (0.01 percent).

(ii) Indications for use. For growth promotion and feed efficiency; improving pigmentation.

(iii) Limitations. Withdraw 5 days before slaughter; as sole source of organic arsenic.

(2) Arsaniolate may be used in accordance with the provisions of this section in the combinations provided as follows:

(i) Amprolium in accordance with §558.55.

(ii) Zoalene in accordance with §558.68.


§ 558.62 Arsaniolate sodium.

(a) Approvals. Type A medicated articles to sponsors in §510.600(c) of this chapter as follows:

(1) To 015565: 20, 50, and 100 percent for use as in the table in paragraph (c)(1), entry (ii), item 1; entry (ii), item 2; entry (iv); entry (vi); and entry (vii) of this section.

(2) To 015565: 20 percent for use as in paragraph (c)(1), entry (i); entry (ii), item 3 of this section.
(3) To 061133: 90 grams per pound arsanilic acid and 4.6 grams per pound erythromycin equivalents as erythromycin thiocyanate for use as in paragraph (c)(1), entry (v).

(b) Related tolerances. See §556.60 of this chapter.

(c) Conditions of use. (1) It is used as follows:

<table>
<thead>
<tr>
<th>Arsanilic acid in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 45 to 90</td>
<td></td>
<td>1. Growing chickens: For growth promotion and feed efficiency; improving pigmentation.</td>
<td>Withdraw 5 days before slaughter; as sole source of organic arsenic.</td>
<td>015565</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Growing turkeys: For growth promotion and feed efficiency; improving pigmentation.</td>
<td>do</td>
<td>015565</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. Growing swine: For increased rate of weight gain and improved feed efficiency.</td>
<td>do</td>
<td>015565</td>
</tr>
<tr>
<td>(ii) 90</td>
<td></td>
<td>Erythromycin 4.6</td>
<td>As erythromycin thiocyanate; withdraw 5 days before slaughter; as sole source of organic arsenic.</td>
<td>012487</td>
</tr>
<tr>
<td>(iii) Erythromycin 4.6 to 18.5</td>
<td></td>
<td>Chickens: growth promotion and feed efficiency; improving pigmentation.</td>
<td>do</td>
<td>15565</td>
</tr>
<tr>
<td>(iv) Erythromycin 9.25</td>
<td></td>
<td>Chickens: growth promotion and feed efficiency; improving pigmentation.</td>
<td>As erythromycin thiocyanate; withdraw 5 days before slaughter; as sole source of organic arsenic.</td>
<td>012487</td>
</tr>
<tr>
<td>(v) Erythromycin 92.5</td>
<td></td>
<td>1. Chickens: as an aid in the prevention of chronic respiratory disease during periods of stress; growth promotion and feed efficiency; improving pigmentation.</td>
<td>do</td>
<td>015565</td>
</tr>
<tr>
<td>(vi) Erythromycin 185</td>
<td></td>
<td>Chickens: as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease; growth promotion and feed efficiency; improving pigmentation.</td>
<td>As erythromycin thiocyanate; feed for 5 to 8 days; do not use in birds producing eggs for food purposes; withdraw 5 days before slaughter; as sole source of organic arsenic.</td>
<td>15565</td>
</tr>
</tbody>
</table>

(2) Arsanilic acid may be used in accordance with the provisions of this section in the combinations provided as follows:

(i) Amprolium in accordance with §558.55.

(ii) Amprolium and ethopabate in accordance with §558.58.

(iii) Bacitracin and zoalene in accordance with §558.78.

(iv) Bacitracin zinc in accordance with §558.76.

(v) Zoalene in accordance with §558.680.

§558.76 Bacitracin methylene disalicylate.

(a) Approvals. Type A medicated articles: 10, 25, 30, 40, 50, 60, or 75 grams per
Food and Drug Administration, HHS

§ 558.76

pound to 046573 in §510.600(c) of this chapter.

(b) Special considerations. The quantities of antibiotics are expressed in terms of the equivalent amount of antibiotic standard.

(c) Related tolerances. See §556.70 of this chapter.

(d) Conditions of use. (1) It is used as follows:

<table>
<thead>
<tr>
<th>Bacitracin methylene disalicylate in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 4 to 50 ..................................</td>
<td>Chicks, turkeys, and pheasants; increased rate of weight gain and improved feed efficiency(^1)</td>
<td>......................</td>
<td>..................</td>
<td>046573</td>
</tr>
<tr>
<td>(ii) 5 to 20 ..................................</td>
<td>Quail not over 5 weeks of age; increased rate of weight gain and improved feed efficiency(^1)</td>
<td>......................</td>
<td>..................</td>
<td>046573</td>
</tr>
<tr>
<td>(iii) 10 to 25 ................................</td>
<td>Chicks; for increased egg production and improved feed efficiency for egg production.</td>
<td>For first 7 months of production.</td>
<td>...............</td>
<td>046573</td>
</tr>
<tr>
<td>(iv) 10 to 30 ................................</td>
<td>Swine; for increased rate of weight gain and improved feed efficiency.</td>
<td>Swine; for increased rate of weight gain and improved feed efficiency; for treatment of bacterial enteritis caused by Escherichia coli and Salmonella choleraesuis and bacterial pneumonia caused by Pasteurella multocida susceptible to chlortetracycline.</td>
<td>Feed for not more than 14 days to provide 10 milligrams of chlortetracycline per pound of body weight per day, as provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
</tr>
<tr>
<td>(v) [Reserved]</td>
<td>Swine; for control of porcine proliferative enteropathies (ileitis) caused by Lawsonia intracellularis susceptible to chlortetracycline.</td>
<td>Swine; for control of porcine proliferative enteropathies (ileitis) caused by Lawsonia intracellularis susceptible to chlortetracycline.</td>
<td>Feed for not more than 14 days; chlortetracycline and BMD(^\alpha) as provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
</tr>
<tr>
<td>(vi) 50 ..................................</td>
<td>Broiler chickens; as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.</td>
<td>......................</td>
<td>..................</td>
<td>046573</td>
</tr>
<tr>
<td>(vii) 100 to 200 ................................</td>
<td>Replacement chickens; as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.</td>
<td>......................</td>
<td>..................</td>
<td>046573</td>
</tr>
<tr>
<td>(viii) 200 ..................................</td>
<td>Replacement chickens; as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.</td>
<td>......................</td>
<td>..................</td>
<td>046573</td>
</tr>
</tbody>
</table>

\(^1\) Use in his species only.
<table>
<thead>
<tr>
<th>Bacitracin methylene disalicylate in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(x) 200 ..........................................................</td>
<td>..........................</td>
<td>Turkeys; as an aid in the control of transmissible enteritis in growing turkeys complicated by organisms susceptible to bacitracin methylene disalicylate. Quail; for the prevention of ulcerative enteritis in growing quail due to Clostridium colinum susceptible to bacitracin methylene disalicylate.</td>
<td>From Type A medicated articles containing 25, 40, or 50 grams of bacitracin methylene disalicylate. Feed continuously as the sole ration. As the sole ration. Not for use in swine weighing more than 250 pounds. Diagnosis should be confirmed by a veterinarian when results are not satisfactory.</td>
<td>046573</td>
</tr>
<tr>
<td>(xi) 250 ..........................................................</td>
<td>..........................</td>
<td>1. Growing/Finishing Swine: For control of swine dysentery associated with Treponema hyodysenteriae on premises with a history of swine dysentery but where signs of the disease have not yet occurred; or following an approved treatment of the disease condition. 2. Pregnant sows: For control of diarrheal enteritis caused by C. perfringens in suckling piglets.</td>
<td>As the sole ration. Feed to sows from 14 days before through 21 days after farrowing on premises with a history of diarrheal scours. Diagnosis should be confirmed by a veterinarian when results are not satisfactory.</td>
<td>046573</td>
</tr>
</tbody>
</table>

1 These conditions are NAS/NRC reviewed and found effective. Applications for these uses may not require effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(2) It is used as bacitracin methylene disalicylate in feed for animals as follows:

(a) **Amount.** 70 milligrams per head per day.
   (i) **Indications for use.** Feedlot beef cattle; reduction in the number of liver condemnations due to abscesses.
   (ii) **Limitations.** Administer continuously throughout the feeding period.

(b) **Limitations.** Administer continuously throughout the feeding period.

(i) **Amount.** 250 milligrams per head per day.
   (a) **Indications for use.** Feedlot beef cattle; reduction in the number of liver condemnations due to abscesses.
   (b) **Limitations.** Administer continuously for 5 days then discontinue for subsequent 25 days, repeat the pattern during the feeding period.

(3) Bacitracin methylene disalicylate may also be used with:

(a) Amprolium as in §558.55.
(b) Amprolium and ethopabate as in §558.58.
(c) Carbarsone (not USP) as in §558.120.
(d) Decoquinate alone and with roxarsone as in §558.195.
(e) Fenbendazole as in §558.258.
(f) Halofuginone hydrobromide alone and with roxarsone as in §558.265.
(g) Hygromycin B as in §558.274.
(h) Ivermectin as in §558.300.
(i) Lasalocid sodium alone and with roxarsone as in §558.311.
(j) Monensin alone and with roxarsone as in §558.355.
(k) Narasin alone and with roxarsone as in §558.363.
(l) Nicarbazin alone and with roxarsone as in §558.366.
(m) Nitrarsone as in §558.369.
(n) Robenidine alone and with roxarsone as in §558.515.
(o) Salinomycin alone and with roxarsone as in §558.550.
(p) Semduramicin alone and with roxarsone as in §558.555.
(q) Zoalene alone and with arsanilic acid as in §558.680.

[41 FR 10993, Mar. 15, 1976]

EDITORIAL NOTE: For Federal Register citations affecting §558.76, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.
§ 558.78 Bacitracin zinc.

(a) Approvals. To sponsors listed in §510.600(c) of this chapter for use as in paragraph (d) of this section as follows:

(1) No. 046573: 10, 25, 40, and 50 grams per pound as in paragraph (d) of this section.

(2) To 000010: 5 and 50 grams per pound for chickens as in paragraph (d)(1)(i) of this section.

(b) Special considerations. The quantities of antibiotics are expressed in terms of the equivalent amount of antibiotic standard.

(c) Related tolerances. See §556.70 of this chapter.

(d) Conditions of use. (1) It is used as follows:

<table>
<thead>
<tr>
<th>Bacitracin zinc in grams per ton</th>
<th>Combinations in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 4 to 50.......................</td>
<td>..................</td>
<td>Chickens, turkeys, and pheasants; for increased rate of weight gain and improved feed efficiency.</td>
<td>Growing chickens, turkeys, and pheasants.</td>
<td>046573</td>
</tr>
<tr>
<td>(ii) 5 to 20........................</td>
<td>..................</td>
<td>Quail; for increased rate of weight gain and improved feed efficiency.</td>
<td>Growing quail; feed as the Type C feed to starting quail through 5 weeks of age.</td>
<td>046573</td>
</tr>
<tr>
<td>(iii) 10 to 25.....................</td>
<td>..................</td>
<td>Laying chickens; improved feed efficiency and increased egg production.</td>
<td>..............................</td>
<td>046573</td>
</tr>
<tr>
<td>(iv) 10 to 50......................</td>
<td>..................</td>
<td>Swine; increased rate of weight gain and improved feed efficiency.</td>
<td>Growing and finishing swine .......</td>
<td>046573</td>
</tr>
<tr>
<td>(v) 20...............................</td>
<td>..................</td>
<td>Growing-finishing swine; increased rate of weight gain.</td>
<td>In Type C feed ..........</td>
<td>046573</td>
</tr>
<tr>
<td>(vi) 20 to 40.....................</td>
<td>..................</td>
<td>Growing-finishing swine; improved feed efficiency.</td>
<td>Do ..................</td>
<td>046573</td>
</tr>
</tbody>
</table>

(2) It is used in feed for growing cattle at 35 to 70 milligrams per head per day as follows:

(i) To aid in stimulating growth and improving feed efficiency.

(ii) For increased rate of weight gain and improved feed efficiency; see sponsor 046573.

(3) It may be used as approved in combination with:

(i) Amprolium alone and with roxarsone as in §558.55.

(ii) Amprolium and ethopabate alone and with roxarsone as in §558.58.

(iii) Carbamox as in §558.120.

(iv) Clopidol alone and with roxarsone as in §558.175.

(v) Decoquinate alone and with roxarsone as in §558.195.

(vi) Hygromycin B alone and with penicillin as in §558.274.

(vii) Lasalocid sodium alone or with roxarsone as in §558.311.

(viii) Monensin alone and with roxarsone as in §558.355.

(ix) Naracin as in §558.363.

(x) Robenidine as in §558.515.

(xi) Salinomycin alone and with roxarsone as in §558.550.

(xii) Zoalene alone and with arsanilic acid or roxarsone as in §558.680.

[41 FR 10994, Mar. 15, 1976]

EDITORIAL NOTE: For Federal Register citations affecting §558.78, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

§ 558.95 Bambermycins.

(a) Approvals. To sponsors identified by drug labeler codes in §510.600(c) of this chapter for use of bambermycins Type A medicated articles as bambermycins activity per pound in paragraph (d) of this section as follows:

(1) To 057926: 2, 4, and 10 grams for use as in paragraphs (d)(1), (d)(2), (d)(3), and (d)(4) of this section.

(2) To 057926: 0.4 gram for use as in paragraph (d)(2) of this section.

(3) To 011490: 0.4 and 2 grams for use as in paragraph (d)(2) of this section.

(4) To 016968, 017519, and 017790: 0.4 and 2 grams for use as in paragraph (d)(2) and 2 grams for use as in paragraph (d)(3) of this section.

(5) To 057926: 10 grams to make 40 to 800 grams per ton Type B feed for use as in paragraph (d)(4) of this section.
§ 558.95

(b) Special considerations. (1) Bambermycins liquid Type B feeds may be manufactured from dry bambermycins Type A articles. The liquid Type B feeds must have a pH of 3.8 to 7.5, moisture content of 30 to 45 percent.

(2) The expiration date for the liquid Type B feed is 8 weeks after date of manufacture. The expiration date for the dry Type C feed made from the liquid Type B feed is 1 week after date of manufacture.

(c) [Reserved]

(d) Conditions of use—(1) Broiler chickens. It is used as follows:

(i) Amount per ton. 1 to 2 grams.

(a) Indications for use. For increased rate of weight gain and improved feed efficiency.

(b) Limitations. Feed continuously as the sole ration.

(ii) Amount per ton. Bambermycins, 1 to 3 grams plus amprolium, 113.5 grams (.0125 percent) plus ethopabate, 36.3 grams (.004 percent).

(a) Indications for use. As an aid in the prevention of coccidiosis where severe exposure to coccidiosis from E. acervulina, E. maxima, and E. brunetti is likely to occur. For increased rate of weight gain and improved feed efficiency.

(b) Limitations. Feed continuously as the sole ration; as sole source of amprolium; amprolium and ethopabate as provided by No. 050604 in §510.600(c) of this chapter.

(iii) Amount per ton. Bambermycins, 1 to 3 grams plus amprolium, 113.5 grams (.0125 percent) plus ethopabate, 36.3 grams (.004 percent) plus roxarsone, 22.8 to 34.1 grams (.0025–.00375 percent).

(a) Indications for use. As an aid in the prevention of coccidiosis. For increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(b) Limitations. Feed continuously as the sole ration; as sole source of amprolium and organic arsenic; amprolium and ethopabate as provided by No. 050604 in §510.600(c) of this chapter; roxarsone as provided by No. 046573 in §510.600(c) of this chapter. Withdraw 5 days before slaughter.

(iv) Amount per ton. Bambermycins, 1 to 3 grams plus amprolium, 113.5 grams (.0125 percent) plus ethopabate, 3.63 grams (.004 percent) plus roxarsone, 22.8 to 34.1 grams (.0025–.00375 percent).

(a) Indications for use. As an aid in the prevention of coccidiosis. For increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(b) Limitations. Feed continuously as the sole ration; as sole source of amprolium and organic arsenic; amprolium and ethopabate as provided by No. 050604 in §510.600(c) of this chapter; roxarsone as provided by No. 046573 in §510.600(c) of this chapter. With draw 5 days before slaughter.

(v) Amount per ton. Bambermycins, 1 to 3 grams plus amprolium, 113.5 grams (.0125 percent) plus roxarsone, 22.8 to 34.1 grams (.0025–.00375 percent).

(a) Indications for use. As an aid in the prevention of coccidiosis. For increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(b) Limitations. Feed continuously as the sole ration; as sole source of amprolium; amprolium and ethopabate as provided by No. 050604 in §510.600(c) of this chapter; roxarsone as provided by No. 046573 in §510.600(c) of this chapter. Withdraw 5 days before slaughter.

(vi) Amount per ton. Bambermycins, 1 to 2 grams plus monensin, 90 to 110 grams.

(a) Indications for use. For increased rate of weight gain and improved feed efficiency; as an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed continuously as sole ration; as monensin sodium provided by No. 000986 in §510.600(c) of this chapter; as bambermycins provided by No. 057926 in §510.600(c) of this chapter.

(vii) Amount per ton. Bambermycins, 1 gram plus monensin, 90 to 110 grams plus roxarsone, 22.7 to 45.4 grams (.0025 to .005 percent).

(a) Indications for use. For increased rate of weight gain and improved feed efficiency; as an aid in the prevention of coccidiosis caused by E. necatrix, E.
Food and Drug Administration, HHS

§ 558.95


(b) Limitations. Do not feed to laying chickens; feed continuously as sole ration; use as sole source of organic arsenic; withdraw 5 days before slaughter; as monensin sodium provided by No. 000986 in §510.600(c) of this chapter; as bambermycins provided by No. 057926 in §510.600(c) of this chapter; as roxarsone provided by No. 046573 in §510.600(c) of this chapter.

(viii) Amount per ton. Bambermycins, 1 gram plus zoalene, 113.4 grams (0.0125 percent).

(a) Indications for use. As an aid in the prevention and control of coccidiosis; for increased rate of weight gain and improved feed efficiency.

(b) Limitations. Do not feed to chickens over 14 weeks of age; feed continuously as sole ration; zoalene as provided by No. 025700 in §510.600(c) of this chapter.

(ix) Amount per ton. Bambermycins, 1 gram plus zoalene, 113.4 grams (0.0125 percent) plus roxarsone, 22.7 grams (0.0025 percent).

(a) Indications for use. As an aid in the prevention and control of coccidiosis; for increased rate of weight gain and improved feed efficiency.

(b) Limitations. Do not feed to chickens over 14 weeks of age; feed continuously as sole ration; feed as sole source of organic arsenic; withdraw 5 days before slaughter; zoalene as provided by No. 025700, roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(x) [Reserved]

(xi) Amount per ton. Bambermycins 1 to 2 grams, plus monensin 2 to 4 grams, plus salinomycin 40 to 60 grams.

(a) Indications for use. For prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; and improved feed efficiency.

(b) Limitations. See paragraph (b)(1)(vii)(b) of this section.

(xiv) Amount per ton. Bambermycins 1 to 2 grams, plus lasalocid 68 to 113 grams.

(a) Indications for use. For prevention of coccidiosis caused by E. tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima, and for increased rate of weight gain and improved feed efficiency in broiler chickens.

(b) Limitations. For broiler chickens only. Feed continuously as sole ration. Lasalocid as provided by No. 046573 in §510.600(c) of this chapter.

(2) Growing-finishing swine. It is used as follows:

(i) Amount per ton. 2 grams.

(a) Indications for use. For increased rate of weight gain and improved feed efficiency.

(b) Limitations. Feed continuously as sole ration.

(ii) Amount per ton. 2 to 4 grams.

(a) Indications for use. For increased rate of weight gain.

(b) Limitations. Feed continuously as sole ration.
§ 558.95

(3) Growing turkeys. It is used as follows:
   (i) Amount per ton. 1 to 2 grams.
   (a) Indications for use. For improved feed efficiency.
   (b) Limitations. Feed continuously as the sole ration.
   (ii) Amount per ton. 2 grams.
   (a) Indications for use. For increased rate of weight gain and improved feed efficiency.
   (b) Limitations. Feed continuously as sole ration.
   (iii) Amount per ton. Bambermycins, 1 to 4 grams plus amprolium, 113.5 grams (0.025 percent).
   (a) Indications for use. For prevention of coccidiosis; for increased rate of weight gain and improved feed efficiency.
   (b) Limitations. Feed continuously as the sole source of amprolium; amprolium as provided by No. 050604 in §510.600(c) of this chapter.
   (iv) Amount per ton. Bambermycins, 1 or 4 grams plus carbarsone, 227 grams (0.025 percent).
   (a) Indications for use. For increased rate of weight gain and improved feed efficiency (1 gram per ton) or increased rate of weight gain (4 grams per ton); as an aid in the prevention of blackhead.
   (b) Limitations. Feed continuously 2 weeks before blackhead is expected and continue as long as prevention is needed; withdraw 5 days before slaughter; use as sole source of organic arsenic; carbarsone by 046573 in §510.600(c) of this chapter.

(4) Cattle—(i) Amount per ton. 1 to 4 grams.
   (a) Indications for use. For increased rate of weight gain and improved feed efficiency.
   (b) Limitations. Feed only to cattle being fed in confinement for slaughter. Feed continuously to a Type C medicated feed at a rate of 10 to 20 milligrams of bambermycins per head per day. Liquid Type B feeds containing bambermycins may be used in the preparation of dry complete ration Type C feeds.
   (ii) Amount per ton. 2 to 40 grams.
   (a) Indications for use. For increased rate of weight gain.
   (b) Limitations. Feed continuously to pasture cattle (slaughter, stocker, and feeder cattle, and dairy and beef replacement heifers) at a rate of 10 to 20 milligrams of bambermycins per head per day in at least 1 pound and not more than 10 pounds of Type C medicated feed.
   (iii) Used as a free-choice Type C medicated loose mineral feed for pasture cattle (slaughter, stocker, and feeder cattle, and dairy and beef replacement heifers) as follows:
   (a) Specifications.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>International Feed No.</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dehydrated phosphate (20.5% calcium, 18.5% phosphorus)</td>
<td>6–01–080</td>
<td>42.50</td>
</tr>
<tr>
<td>Sodium chloride (sail)</td>
<td>6–04–152</td>
<td>20.10</td>
</tr>
<tr>
<td>Calcium carbonate (38% calcium)</td>
<td>6–01–069</td>
<td>15.24</td>
</tr>
<tr>
<td>Corn distillers dried grains w/solubles</td>
<td>5–26–236</td>
<td>9.57</td>
</tr>
<tr>
<td>Magnesium oxide</td>
<td>6–02–756</td>
<td>5.15</td>
</tr>
<tr>
<td>Vitamin and trace mineral premix *</td>
<td>.......</td>
<td>3.72</td>
</tr>
<tr>
<td>Mineral oil</td>
<td>.......</td>
<td>1.00</td>
</tr>
<tr>
<td>Yeast (primary dehydrated yeast)</td>
<td>7–05–533</td>
<td>0.75</td>
</tr>
<tr>
<td>Bambermycins Type A article (10 g/lb)</td>
<td>6–02–431</td>
<td>0.60</td>
</tr>
<tr>
<td>Iron oxide</td>
<td>6–02–758</td>
<td>0.32</td>
</tr>
<tr>
<td>Magnesium sulfate (67%)</td>
<td>6–02–758</td>
<td>0.21</td>
</tr>
<tr>
<td>Selenium premix (270 mg/lb) *</td>
<td>6–01–720</td>
<td>0.18</td>
</tr>
<tr>
<td>Copper sulfate</td>
<td>6–06–098</td>
<td>0.16</td>
</tr>
</tbody>
</table>

*Content of vitamin/trace mineral premix may be varied. However, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Selenium must comply with 21 CFR 573.920. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7129.18).

(b) Amount per ton. 120 grams.

(c) Indications for use. For increased rate of weight gain.

(d) Limitations. For free-choice feeding to pasture cattle (slaughter, stocker, and feeder). Feed a nonmedicated commercial mineral product for 6 weeks to stabilize consumption between 2.66 and 5.33 ounces per head per day. Feed continuously to provide 10- to 20-milligrams bambermycins per head per day. Each use of this free-
choice Type C medicated feed must be the subject of an approved Form FDA 1900 as required by 21 CFR 510.455.

(iv) Use free-choice Type C medicated feeds for pasture cattle (slaughter, stocker, and feeder cattle, and dairy and beef replacement heifers) as follows:

(a) Amount. Feed continuously to provide 10 to 20 milligrams of bambermycins per head per day.

(b) Indications for use. For increased rate of weight gain.

(c) Limitations. Each use in a free-choice Type C medicated feed must be the subject of an approved new animal drug application (NADA) or supplemental NADA as required by 21 CFR 510.455.

(5) Bambermycins may be used in combination with:

(i) Diclazuril as in §558.198.

(ii) Halofuginone as in §558.265.

(iii) Monensin as in §558.355.

(iv) Narasin alone or with nicarbazin or roxarsone as in §558.363.

(v) Nicarbazin as in §558.366.

[40 FR 13959, Mar. 27, 1975]

EDITORIAL NOTE: For Federal Register citations affecting §558.95, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

§558.105 [Reserved]

§558.115 Carbadox.

(a) Approvals. Type A medicated articles: 2.2 percent (10 grams per pound) to 066104 in §510.600(c) of this chapter.

(b) Related tolerances. See §556.100 of this chapter.

(c) Special considerations. Do not use in Type B or Type C medicated feeds containing bentonite.

(d) Conditions of use. (1) It is used for swine as follows:

(i) Amount per ton. 10–25 grams (0.0011–0.00275 percent).

(ii) Indications for use. For increase in rate of weight gain and improvement of feed efficiency.

(ii) Limitations. Not for use in pregnant swine or swine intended for breeding purposes. Do not feed to swine within 42 days of slaughter.

(2) Amount per ton. 50 grams (0.0055 percent).


§558.120 Carbarsone (not U.S.P.).

(a) Approvals. Type A medicated articles: (1) 37.5 percent to 046573 in §510.600(c) of this chapter.

(2) 25 percent carbarsone and 5 grams per pound bacitracin (as bacitracin methylene disalicylate) to 046573 in §510.600(c) of this chapter.

(b) Related tolerances. See §556.60 of this chapter.

(c) [Reserved]

(d) Conditions of use. (1) It is used for turkeys as follows:

(i) Grams per ton. 227 to 340.5 (0.025 to 0.0375 percent).

(a) Indications for use. As an aid in the prevention of blackhead.
§ 558.128  Chlortetracycline.

(a) Approvals. See sponsors in §510.600(c) of this chapter for Type A medicated articles containing the following concentrations of either chlortetracycline calcium complex equivalent to chlortetracycline hydrochloride or, for products intended for use in milk replacer, chlortetracycline hydrochloride:

(1) Nos. 046573, 053389, and 066104: 50 to 100 grams per pound.

(2) No. 017519: 50 grams per pound.

(b) Related tolerances. See §556.150 of this chapter.

(c) [Reserved]

(d)(1) It is used in feeds as follows:

<table>
<thead>
<tr>
<th>Chlortetracycline amount</th>
<th>Combination</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10 to 50 g/t</td>
<td>1. Chickens; increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to chickens producing eggs for human consumption.</td>
<td>046573.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Growing turkeys; increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to turkeys producing eggs for human consumption.</td>
<td>066104, 046573, 053389.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Growing swine; increased rate of weight gain and improved feed efficiency.</td>
<td></td>
<td>066104, 046573, 053389.</td>
<td></td>
</tr>
<tr>
<td>(ii) 20 to 50 g/t</td>
<td>Growing sheep; increased rate of weight gain and improved feed efficiency.</td>
<td></td>
<td>066104, 046573, 053389.</td>
<td></td>
</tr>
<tr>
<td>(iii) 50 to 100 g/t</td>
<td>Swine; reducing the incidence of cervical lymphadenitis (jaw abscesses) caused by Group E. Streptococci susceptible to chlortetracycline.</td>
<td></td>
<td>066104, 046573, 053389.</td>
<td></td>
</tr>
<tr>
<td>(iv) 100 to 200 g/t</td>
<td>Chickens; control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline.</td>
<td>1. Feed continuously for 7 to 14 d.</td>
<td>046573.</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline amount</td>
<td>Combination</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>(v) 200 g/t</td>
<td></td>
<td>1. Feed continuously for 7 to 14 d; do not feed to chickens producing eggs for human consumption.</td>
<td>Feed continuously for 7 to 14 d; do not feed to turkeys producing eggs for human consumption.</td>
<td>066104, 017519, 046573, 053389.</td>
</tr>
<tr>
<td>(vi) 200 to 400 g/t</td>
<td></td>
<td>1. Chickens; control of chronic respiratory disease (CRD) and air sac infection caused by M. gallisepticum and E. coli susceptible to chlortetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to chickens producing eggs for human consumption.</td>
<td>066104, 017519, 046573, 053389.</td>
</tr>
<tr>
<td>(vi) 400 g/t</td>
<td></td>
<td>1. Turkeys; control of infectious synovitis caused by M. synoviae susceptible to chlortetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to turkeys producing eggs for human consumption.</td>
<td>066104, 017519, 046573, 053389.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Ducks; control and treatment of fowl cholera caused by Pasteurella multocida susceptible to chlortetracycline.</td>
<td>Feed in complete ration to provide from 8 to 28 milligrams per pound of body weight per day depending upon age and severity of disease, for not more than 21 d. Do not feed to ducks producing eggs for human consumption.</td>
<td>063238.</td>
</tr>
<tr>
<td>(vii) 500 g/t</td>
<td></td>
<td>1. Chickens; reduction of mortality due to E. coli infections susceptible to chlortetracycline.</td>
<td>Feed continuously for not more than 14 d.</td>
<td>Do.</td>
</tr>
<tr>
<td>(ix) 10 mg/g of finished feed daily</td>
<td></td>
<td>Psittacine birds (cockatoos, macaws, and parrots) suspected or known to be infected with psittacosis caused by Chlamydia psittaci sensitive to chlortetracycline.</td>
<td>Feed continuously for 45 d; each bird should consume daily an amount of medicated feed equal to one fifth of its body weight. Warning: “Psittacosis, avian chlamydiosis, or ornithosis is a reportable communicable disease, transmissible between wild and domestic birds, other animals, and man. Contact appropriate public health and regulatory officials.”</td>
<td>046573.</td>
</tr>
<tr>
<td>Chlortetracycline amount</td>
<td>Combination</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>(x) 0.1 mg/lb of body weight daily</td>
<td>Calves (up to 250 lb); for increased rate of weight gain and improved feed efficiency</td>
<td>In milk replacers or starter feed; include on labeling the warning: “A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.”</td>
<td>066104, 017519, 046573, 053389</td>
<td></td>
</tr>
<tr>
<td>(xi) 0.5 mg/lb of body weight daily</td>
<td>Beef cattle (over 700 lb); control of active infection of anaplasmosis caused by <em>Anaplasma marginale</em> susceptible to chlortetracycline. Withdraw 48 h prior to slaughter. For sponsor 046573 zero withdrawal time. For sponsor 053389 1 d withdrawal time.</td>
<td>Do.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(xii) 10 mg/lb of body weight</td>
<td>1. Calves, beef and nonlactating dairy cattle; treatment of bacterial enteritis caused by <em>E. coli</em> and bacterial pneumonia caused by <em>P. multocida</em> organisms susceptible to chlortetracycline. Feed approximately 400 g/t, varying with body weight and feed consumption to provide 10 mg/lb per day. Treat for not more than 5 d; in feed including milk replacers; withdraw 10 d prior to slaughter except for 24 h for sponsor 046573; zero withdrawal for sponsor 046573; include on labeling the warning: “A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.”</td>
<td>Do.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Calves (up to 250 lb); treatment of bacterial enteritis caused by <em>E. coli</em> susceptible to chlortetracycline.</td>
<td>In milk replacers or starter feed; include on labeling the warning: “A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Swine; treatment of bacterial enteritis caused by <em>E. coli</em> and <em>S. choleraesuis</em> and bacterial pneumonia caused by <em>P. multocida</em> susceptible to chlortetracycline.</td>
<td>Feed approximately 400 g/t, varying with body weight and feed consumption to provide 10 mg/lb per day. Feed for not more than 14 d; withdraw 5 d prior to slaughter for sponsor 012286.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. Swine; for control of porcine proliferative enteropathies (ileitis) caused by <em>Lawnsonia intracellularis</em> susceptible to chlortetracycline.</td>
<td>Feed for not more than 14 d.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>(xiii) 25 mg lb of body weight</td>
<td>Turkeys; control of complicating bacterial organisms associated with bluecomb (transmissible enteritis; coronaviral enteritis) susceptible to chlortetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to turkeys producing eggs for human consumption.</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td>(xiv) 25 to 70 mg/head/day</td>
<td>Calves (250 to 400 lb); increased rate of weight gain and improved feed efficiency. Include on labeling the warning: “A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.”</td>
<td>066104, 017519, 046573, 053389</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(xv) 70 mg/head/day</td>
<td>Growing cattle (over 400 lb); increased rate of weight gain, improved feed efficiency, and reduction of liver condemnation due to liver abscesses.</td>
<td>......do</td>
<td>Do.</td>
<td></td>
</tr>
</tbody>
</table>
Chlorotetracycline and sulfamethazine.

§ 558.140

(a) Approvals. Type A medicated articles: 35 grams of chlorotetracycline per pound with 7.7 percent (35 grams) of sulfamethazine to 046573 in §510.600(c) of this chapter.

(b) Related tolerances. See §§556.150 and 556.670 of this chapter.

(c) It is used in feed for beef cattle as follows:

1. Amount per head per day. Chlorotetracycline, 350 milligrams plus sulfamethazine, 350 milligrams.

2. Indications for use. Aid in the maintenance of weight gains in the presence of respiratory disease such as shipping fever.

3. Limitations. Feed for 28 days; withdraw 7 days prior to slaughter.

(2) For sponsor 046573: it is used in free-choice cattle feeds such as feed blocks or salt-mineral mixes manufactured from approve Type A articles; such feeds are given to beef cattle and nonlactating dairy cattle to provide a daily intake of 0.5 to 2.0 milligrams of chlorotetracycline per pound of body weight to aid in the control of active infection of anaplasmosis caused by Anaplasma marginale susceptible to chlorotetracycline; the use of these Type A articles to make specific free-choice feed formulations must be approved under section 512(b) of the act and be based on a demonstration of drug stability and consumption which is consistent with the effective dose; the specific free-choice feed formulations approved in this paragraph can be manufactured under section 512(m) of the act.

(3) Chlorotetracycline may be used in accordance with the provisions of this section in the combinations provided as follows:

(i) Amprolium in accordance with §558.35.

(ii) Amprolium plus ethopabate in accordance with §558.58.

(iii) Bacitracin methylene disalicylate in accordance with §558.76.

(iv) Clopidol in accordance with §558.175.

(v) Decoquinate in accordance with §558.195.

(vi) Hygromycin B in accordance with §558.274.

(vii) Monensin in accordance with §558.355.

(viii) Roxarsone and salinomycin in accordance with §558.550.

(ix) Robenidine hydrochloride in accordance with §558.515.

(x) Roxarsone in accordance with §558.530.

(xi) Salinomycin in accordance with §558.550.

(xii) Zoalene in accordance with §558.680.

(xiii) Tiamulin in accordance with §558.600.

[41 FR 10995, Mar. 15, 1976]

EDITORIAL NOTE: For Federal Register citations affecting §558.128, see the List of Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.
§ 558.145 Chlortetracycline, procaine penicillin, and sulfamethazine.

(a) Approvals. Type A medicated articles: (1) 20 grams of chlortetracycline per pound, 4.4 percent (20 grams) of sulfamethazine, and procaine penicillin equivalent in activity to 10 grams of penicillin per pound to Nos. 000010 and 046573 in §510.600(c) of this chapter.

(2) 40 grams of chlortetracycline per pound, 8.8 percent (40 grams) sulfathiazole and procaine penicillin equivalent in activity to 20 grams of penicillin per pound to Nos. 000010 and 046573 in §510.600(c) of this chapter.

(b) Specifications. (1) The antibiotic substance refers to the antibiotic or feed-grade antibiotic.

(2) The antibiotic activities are expressed in terms of the appropriate antibiotic standards.

(3) Type C medicated feed contains in each ton, 100 grams of chlortetracycline, 50 grams of penicillin as procaine penicillin, and 100 grams of sulfamethazine.

(c) Related tolerances. See §§556.150, 556.510, and 556.670 of this chapter.

(d) Conditions of use. (1) It is administered to swine in a Type C feed for reduction of the incidence of cervical abscesses; treatment of bacterial swine enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis and vibrionic dysentery); prevention of these diseases during times of stress; maintenance of weight gains in the presence of atrophic rhinitis; growth promotion and increased feed efficiency in swine weighing up to 75 pounds.

(2) Withdraw 15 days prior to slaughter.

§ 558.155 Chlortetracycline, sulfa-thiazole, penicillin.

(a) Approvals. Type A medicated articles: (1) 20 grams of chlortetracycline hydrochloride, 4.4 percent (20 grams) sulfathiazole, and procaine penicillin equivalent to 10 grams of penicillin per pound to Nos. 000010 and 046573 in §510.600(c) of this chapter.

(2) 40 grams of chlortetracycline hydrochloride, 8.8 percent (40 grams) sulfathiazole and procaine penicillin equivalent in activity to 20 grams of penicillin per pound to Nos. 000010 and 046573 in §510.600(c) of this chapter.

(b) Specifications. (1) The antibiotic substance refers to the antibiotic or feed-grade antibiotic.

(2) The antibiotic activities are expressed in terms of the appropriate antibiotic standards.

(c) Related tolerances. See §§556.150, 556.510, and 556.690 of this chapter.

(d) Conditions of use. It is used for swine as follows:

(1) Amount per ton. Chlortetracycline, 100 grams plus penicillin, 50 grams plus sulfathiazole, 100 grams.

(2) Indications for use. For reduction of incidence of cervical abscesses. Treatment of bacterial enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis and vibrionic dysentery). Maintenance of weight gains in the presence of atrophic rhinitis. Swine 10 pounds of body weight to 6 weeks post-weaning: Increased rate of weight gain and improved feed efficiency. Swine 6 to 16 weeks post-weaning: Increased rate of weight gain.

(3) Limitations. For swine raised in confinement (dry-lot) or on limited pasture. Feed as sole ration. Withdraw 7 days prior to slaughter.

MINIMUM AMOUNT OF TYPE C FEED WHICH THE ANIMAL SHOULD CONSUME

<table>
<thead>
<tr>
<th>Type of feed</th>
<th>Approximate body weight in pounds</th>
<th>Minimum desired daily feed intake in pounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestarter (up to 6 weeks postweaning)</td>
<td>20</td>
<td>1</td>
</tr>
<tr>
<td>Starter (up to 6 weeks postweaning)</td>
<td>50</td>
<td>1½</td>
</tr>
<tr>
<td>Grower (6–16 weeks postweaning)</td>
<td>80</td>
<td>2</td>
</tr>
<tr>
<td>Finisher (6–16 weeks postweaning)</td>
<td>150</td>
<td>3</td>
</tr>
</tbody>
</table>

§ 558.175 Clopidol.

(a) Approvals. Type A medicated articles: (1) 25 percent to 0.11526 in § 510.600(c) of this chapter.

(2) 25 percent of clopidol, 10 percent of roxarsone, and 4, 10, 15, or 25 grams of bacitracin methylene disalicylate per pound to 0.11526 in § 510.600(c) of this chapter.

(b) Related tolerances. See § 556.160 of this chapter.

(c) [Reserved]

(d) Conditions of use. It is used as follows:

(1) Broiler chickens—(i) Amount per ton. Clopidol 113.5 grams (0.0125 percent).


(b) Limitations. Do not feed to chickens over 16 weeks of age.

(ii) Amount per ton. Clopidol, 113.5 grams (0.0125 percent) plus roxarsone, 45.4 grams (0.005 percent).


(b) Limitations. Do not feed to chickens over 16 weeks of age; withdraw 5 days before slaughter; as sole source of organic arsenic.

(iii) Amount per ton. Clopidol, 113.5 grams (0.0125 percent) plus roxarsone, 45.4 grams (0.005 percent) plus bacitracin, 4–25 grams.

(a) Indications for use. Aid in the prevention of coccidiosis caused by E. tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mivati; growth promotion and feed efficiency; improved pigmentation; increased rate of weight gain.

(b) Limitations. Do not feed to chickens over 16 weeks of age; withdraw 5 days before slaughter; as sole source of organic arsenic; as bacitracin methylene disalicylate, provided by No. 046573 in § 510.600(c) of this chapter; or as zinc bacitracin provided by Nos. 046573 and 063238 in § 510.600(c) of this chapter.

(iv) Amount per ton. Clopidol, 113.5 grams (0.0125 percent) plus zinc bacitracin, 5 to 25 grams.

(a) Indications for use. For increased rate of weight gain and improved feed efficiency; aid in the prevention of coccidiosis caused by E. tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mivati.

(b) Limitations. Feed continuously as sole ration. Zinc bacitracin as provided by Nos. 046573 and 063238 of § 510.600(c) of this chapter.

(v) Amount per ton. Clopidol, 113.5 grams (0.0125 percent) plus bacitracin methylene disalicylate, 4 to 50 grams per ton.

(a) Indications for use. For increased rate of weight gain; to aid in the prevention of coccidiosis caused by E. tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mivati.

(b) Limitations. Feed continuously as the sole ration from the time chicks are placed in floor pens until slaughter. Do not feed to chickens over 16 weeks of age. Bacitracin methylene disalicylate as provided by No. 046573 in § 510.600(c) of this chapter.

(vi) Amount per ton. Clopidol, 113.5 grams (0.0125 percent) plus lincomycin, 2–4 grams.

(a) Indications for use. Aid in the prevention of coccidiosis caused by E. tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mivati; increase in rate of weight gain and improved feed efficiency.

(b) Limitations. As lincomycin hydrochloride monohydrate; do not feed to chickens over 16 weeks of age.

(2) Broiler chickens and replacement chickens—(i) Amount per ton. Clopidol, 113.5 or 227 grams (0.0125 or 0.025 percent).


(b) Limitations. Feed up to 16 weeks of age if intended for use as caged layers; feed continuously as the sole ration; withdraw 5 days before slaughter if given at the level of 0.025 percent in feed or reduce level to 0.0125 percent 5 days before slaughter.

(ii) Amount per ton. Clopidol, 113.5 grams (0.0125 percent) plus chlortetracycline 100 to 200 grams.

(a) Indications for use. Aid in the prevention of coccidiosis caused by E. tenella, E. necatrix, E. acervulina, E.
maxima, E. brunetti, and E. mivati; control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline.

(b) Limitations. Feed continuously as sole ration from the time chicks are placed in floor pens for 7 to 14 days.

(3) [Reserved]

(4) Replacement chickens—(i) Amount per ton. Clopidol 113.5 grams (0.0125 percent).


(b) Limitations. For replacement chickens intended for use as caged layers; do not feed to chickens over 16 weeks of age.

(ii) Amount per ton. Clopidol 113.5 grams (0.0125 percent) plus roxarsone 45.4 grams (0.005 percent).

(a) Indications for use. Aid in the prevention of coccidiosis caused by E. tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mivati; growth promotion and feed efficiency; improving pigmentation.

(b) Limitations. For replacement chickens intended for use as caged layers; do not feed to chickens over 16 weeks of age; withdraw 5 days before slaughter; as sole source of organic arsenic.

(5) Turkeys—(i) Amount per ton. Clopidol 113.5 or 227 grams (0.0125 or 0.025 percent).

(ii) Indications for use. Aid in the prevention of leucocytozoosmosis caused by Leucocytozoon smithi.

(iii) Limitations. For turkeys grown for meat purposes only; to be administered continuously in feed at 0.0125 or 0.025 percent clopidol as the sole ration depending upon management practices, degree of exposure, and amount of feed eaten; withdraw medication 5 days before slaughter.

§ 558.185 Coumaphos.

(a) Approvals. Type A medicated articles:

(1) [Reserved]

(2) 1.12 and 11.2 percent to 017800 in §510.600(c) of this chapter for use as in paragraph (d)(1)(ii) of this section.

(b) Special considerations. Adequate directions and warnings for use must be given and shall include a statement that coumaphos is a cholinesterase inhibitor and that animals being treated with coumaphos should not be exposed during or within a few days before or after treatment to any other cholinesterase-inhibiting drugs, insecticides, pesticides, or chemicals.

(c) Related tolerances. See 40 CFR 190.189.

(d) Conditions of use. It is used as follows:

(1) Beef and dairy cattle—(i) Amount. Coumaphos 0.00012 lb. (0.054 gram) per 100 lb. body weight per day.

(a) Indications for use. As an aid in the reduction of fecal breeding flies through control of fly larvae.

(b) Limitations. Feed for the duration of fly season in a Type C feed containing 0.0033 percent or in a feed Type B feed containing not over 0.0066 percent coumaphos; do not feed to animals less than 3 months old; not for use in pelleted feeds.

(ii) Amount. Coumaphos, 0.0002 lb. (0.091 gram) per 100 lb. body weight per day.

(a) Indications for use. As an aid in the reduction of fecal breeding flies through control of fly larvae.

(b) Limitations. Feed 0.0002 lb. (0.091 gram) per 100 lb. body weight per day for 6 consecutive days in the normal grain ration to which the animals are accustomed but not in rations containing more than 0.1 percent coumaphos; do not feed to animals less than 3 months old; do not feed to sick animals or animals under stress, such as those just shipped, dehorned, castrated, or weaned within the last 3 weeks; do not feed in conjunction with oral drenches or with feeds containing phenothiazine. Should conditions warrant, repeat treatment at 30-day intervals.
(2) Laying chickens—(1) Amount. Coumaphos 27.2 grams per ton (0.003 percent).

(ii) Indications for use. For control of capillary worm (*Capillaria obsignata*) and as an aid in control of common roundworm (*Ascaridia galli*) and cecal worm (*Heterakis gallinae*).

(iii) Limitations. In Type C feed; administer continuously as the total feed ration for 14 days; when reinfection occurs, treatment may be repeated but not sooner than 3 weeks after the end of the previous treatment; do not feed to chickens within 10 days of vaccination or other conditions of stress; if birds are maintained on contaminated litter or exposed to infected birds, a second 10 to 14 day treatment is recommended but not sooner than 3 weeks after the end of the previous treatment; as sole medication; if reinfection occurs after production begins, repeat treatment as recommended for laying flocks.

(3) Replacement pullets—(i) Amount. Coumaphos 36.3 grams per ton (0.004 percent).

(ii) Indications for use. For control of capillary worm (*Capillaria obsignata*) and as an aid in control of common roundworm (*Ascaridia galli*) and cecal worm (*Heterakis gallinae*).

(iii) Limitations. In Type C feed; administer before the onset of production; diagnosis by competent personnel is essential; administer continuously as total feed ration for from 10 to 14 days; do not feed to chickens under 8 weeks of age nor within 10 days of vaccination or other conditions of stress; if birds are maintained on contaminated litter or exposed to infected birds, a second 10 to 14 day treatment is recommended but not sooner than 3 weeks after the end of the previous treatment; as sole medication; if reinfection occurs after production begins, repeat treatment as recommended for laying flocks.

§ 558.195 Decoquinate.

(a) Approvals. Type A medicated articles: 6 percent to 046573 in §510.600(c) of this chapter.

(b) Related tolerances in edible products. See §556.170 of this chapter.

(c) Special considerations. (1) Bentonite should not be used in decoquinate feeds.

(2) Type A medicated articles containing 6 percent decoquinate may be used to make dry or liquid Type B cattle (including veal calf), sheep, and goat feeds as in paragraph (d) of this section.

(3) Type A medicated articles containing 6 percent decoquinate may be used to manufacture dry or liquid Type B cattle feeds as indicated in paragraph (d) of this section.

(d) Conditions of use. It is used as follows:

<table>
<thead>
<tr>
<th>Decoquinate in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.6 (0.00149 pct)</td>
<td></td>
<td>Young goats; for the prevention of coccidiosis caused by <em>Eimeria christeri</em> and <em>E. nainakohyakimovei</em>.</td>
<td>Feed at a rate to provide 22.7 mg per 100 lbs of body weight per day (0.5 mg per kilogram); do not feed to goats producing milk for food; feed for at least 28 days during periods of exposure to coccidiosis or when it is likely to be a hazard.</td>
<td>046573</td>
</tr>
<tr>
<td>13.6 (0.0015 pct)</td>
<td></td>
<td>Young sheep; for the prevention of coccidiosis caused by <em>Eimeria ovinaida</em>, <em>E. crandallis</em>, <em>E. parva</em>, <em>E. bakuensis</em>.</td>
<td>Feed Type C feed at a rate to provide 22.7 mg per 100 lbs of body weight (0.5 mg per kg) per day. Feed at least 28 days during periods of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to sheep producing milk for food.</td>
<td>046573</td>
</tr>
<tr>
<td>Decoquinate in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>--------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>13.6 to 27.2 (0.0015 to 0.003 pct.)</td>
<td></td>
<td>Feed Type C feed at a rate to provide 22.7 mg per 100 lb of body weight (0.5 mg per kg) per day. May be prepared from dry or liquid Type B feed containing 0.0125 to 0.5 pct decoquinate. Liquid Type B feed must have a pH range of 5.0 to 6.5 and contain a suspending agent to maintain a viscosity of not less than 500 centipoises. Feed at least 28 days during periods of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to cows producing milk for food.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Monensin 5 to 30</td>
<td></td>
<td>Feed only to cattle fed in confinement for slaughter. Feed continuously as the sole ration to provide 22.7 mg of decoquinate per 100 lb body weight per day and 50 to 360 mg of monensin per head per day. Feed at least 28 days during period of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to animals producing milk for food. Also see (c)(1) of this paragraph and §558.355(d)(8). Monensin as monensin sodium provided by 000986 in §510.600(c) of this chapter.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Monensin 5 to 30; plus tylosin 8 to 10.</td>
<td></td>
<td>Feed only to cattle fed in confinement for slaughter. Feed continuously as the sole ration to provide 22.7 mg of decoquinate per 100 lb body weight per day, 50 to 360 mg of monensin per head per day, and 60 to 90 mg of tylosin per head per day. Feed at least 28 days during period of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to animals producing milk for food. Also see (c)(1) of this paragraph and §558.355(d)(8). Monensin as monensin sodium and tylosin as tylosin phosphate provided by 000986 in §510.600(c) of this chapter.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Decoquinate in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>13.6 to 535.7 (0.0015 to 0.059 pct)</td>
<td>Cattle: prevention of coccidiosis in ruminating and nonruminating calves (including veal calves) and cattle caused by <em>Eimeria bovis</em> and <em>E. zuernii</em>.</td>
<td>Feed Type C feed to provide 22.7 mg decoquinate and 1 g chlortetracycline/100 lb body weight (0.5 mg/kg)/day for not more than 5 days. Type C feed may be prepared from Type B feed containing 535.8 to 5,440 g/ton decoquinate and 6,700 to 80,000 g/ton chlortetracycline. When consumed, feed 22.7 mg decoquinate/100 lb body weight/day for a total of 28 days to prevent coccidiosis. Withdraw 24 hours prior to slaughter. Do not feed to calves to be processed for veal. Do not feed to animals producing milk for food.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>27.2 (0.003 pct)</td>
<td>Broiler chickens; for the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. mivati</em>, <em>E. acervulina</em>, <em>E. maxima</em> and <em>E. brunetti</em>.</td>
<td>Do not feed to laying chickens.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 4 to 50</td>
<td>Broiler chickens; for the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. mivati</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em>, and for increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to laying chickens; feed continuously as sole ration; bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter..</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 10 to 50</td>
<td>Broiler chickens; for the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. mivati</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em>; for increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to laying chickens; feed as sole ration; as zinc bacitracin provided by Nos. 046573 and 011716 in sec. 510.600(c) of this chapter.</td>
<td>046573</td>
<td></td>
</tr>
</tbody>
</table>
### § 558.198 Diclazuril.

(a) **Approvals.** Type A medicated article: 0.2 percent of diclazuril to 0.061 in §510.600(c) of this chapter.

(b) **Related tolerances.** See §556.185 of this chapter.

(c) **Reserved.**

(d) **Conditions of use.**

#### (1) Chickens.

For chickens it is used as follows:

<table>
<thead>
<tr>
<th>Decoquinate in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacitracin methylene disalicylate 50 and roxarsone 22.7–45.4.</td>
<td>Broiler chickens; for prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. mivati</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em>; as an aid in the prevention of necrotic enteritis caused or complicated by <em>Clostridium</em> spp. or other organisms susceptible to bacitracin; for increased rate of weight gain, improved feed efficiency, and improved pigmentation.</td>
<td>Feed continuously as sole ration. Withdraw 5 days before slaughter. Do not feed to laying chickens. Not for use in breeder chickens. Use as sole source of organic arsenic. Poultry should have access to drinking water at all times. Drug overdosage or lack of drinking water may result in leg weakness or paralysis. Decoquinate, bacitracin methylene disalicylate, and roxarsone, as provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 100 to 200.</td>
<td>Chickens; for the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. mivati</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em>; control of infectious synovitis caused by <em>Mycoplasma synoviae</em> susceptible to chlortetracycline.</td>
<td>Do not feed to laying chickens; feed as sole ration; do not feed to chickens producing eggs for human consumption; in low calcium feed containing 0.8 pct. of calcium; feed continuously 7 to 14 days.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 200 to 400.</td>
<td>Chickens; for the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. mivati</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em>; control of chronic respiratory disease (CRD) and air sac infection caused by <em>M. gallisepticum</em> and <em>E. coli</em> susceptible to chlortetracycline.</td>
<td>Do not feed to laying chickens; withdraw 5 days before slaughter; as sole source of organic arsenic.</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Roxarsone 45.4 (0.005 pct.).</td>
<td>Broiler chickens; for the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. mivati</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. brunetti</em>; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Do not feed to laying chickens; feed as sole ration; as lincomycin hydrochloride monohydrate provided by No. 000009 in sec. 510.600(c) of this chapter.</td>
<td>000009, 046573</td>
<td></td>
</tr>
<tr>
<td>Roxarsone 11 to 45 (0.0012–0.005 pct.) plus Bacitracin 12 to 50.</td>
<td>Broiler chickens; for the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. mivati</em>, <em>E. maxima</em>, and <em>E. brunetti</em>; for increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to laying chickens; withdraw 5 days before slaughter; as sole source of organic arsenic; as zinc bacitracin provided by No. 046573 in sec. 510.600(c) of this chapter; as roxarsone provided by No. 046573 in sec. 510.600(c) of this chapter.</td>
<td>046573</td>
<td></td>
</tr>
</tbody>
</table>

*(40 FR 13959, Mar. 27, 1975)*

Editorial Note: For Federal Register citations affecting §558.195, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.
§ 558.205 Dichlorvos.

(a) Approvals. Type A medicated articles: 3.1 and 9.6 percent to 0.00010 in § 510.600(c) of this chapter.

(b) Special considerations. (1) Dichlorvos is to be included in meal or mash or mixed with feed in crumble form only after the crumble feed has been manufactured. Do not mix in feeds to be pelleted nor with pelleted feed. Do not soak the feed or administer as wet mash. Feed must be dry when administered. Do not use in animals other than swine. Do not allow fowl access to feed containing this preparation or to feces from treated animals.

(2) Dichlorvos is a cholinesterase inhibitor. Do not use this product in animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals. If human or animal poisoning should occur, immediately consult a physician or a veterinarian. Atropine is antidotal.

(3) Labeling for Type A articles and Type B feeds must include a statement that containers or materials used in packaging such Type A articles and Type B feeds are not to be reused and all such packaging materials must be destroyed after the product has been used.
§ 558.235  Ectromelia.

(a) Approvals. Type A medicated article: 14.5 grams per pound to 050604 in §510.600(c) of this chapter.

(b) Conditions of use—(1) Swine.

(i) Amount. 3.6 grams per ton.

(A) Indications for use. For improved feed efficiency.

(B) Limitations. Feed continuously as sole ration. Not to be used in swine weighing more than 250 pounds.

(ii) Amount. 3.6 to 14.5 grams per ton.

(A) Indications for use. For increased rate of weight gain.

(B) Limitations. Feed continuously as sole ration. Not to be used in swine weighing more than 250 pounds.

(2) [Reserved]

§ 558.235 Efrothrin.

(a) Approvals. Type A medicated article: 14.5 grams per pound to 050604 in §510.600(c) of this chapter.

(b) Conditions of use—(1) Swine.

(i) Amount. 3.6 grams per ton.

(A) Indications for use. For improved feed efficiency.

(B) Limitations. Feed continuously as sole ration. Not to be used in swine weighing more than 250 pounds.

(ii) Amount. 3.6 to 14.5 grams per ton.

(A) Indications for use. For increased rate of weight gain.

(B) Limitations. Feed continuously as sole ration. Not to be used in swine weighing more than 250 pounds.

(2) [Reserved]

§ 558.248 Erythromycin thiocyanate.

(a) Approvals. Type A medicated articles: (1) 2.2 percent to 061133 in §510.600(c) of this chapter for use as in paragraph (d) of this section.

(2) 5 and 10 percent to 061133 for use in paragraphs (d)(1)(i) and (ii) of this section.

(b) Special considerations. The levels of antibiotic are expressed in terms of erythromycin master standard. One gram of erythromycin thiocyanate is equivalent to 0.925 gram of erythromycin master standard.

(c) Related tolerances. See §556.230 of this chapter.

(d) Condition of use. (1) It is used as follows:

<table>
<thead>
<tr>
<th>Erythromycin thiocyanate in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 4.6 to 18.5</td>
<td>----------------------------</td>
<td>Chickens: growth promotion and feed efficiency</td>
<td>----------------------------</td>
<td>061133</td>
</tr>
</tbody>
</table>
### § 558.254 Famphur.

(a) **Approvals.** Type A medicated articles: 13.2 and 33.3 percent to 000061 in §510.600(c) of this chapter.

(b) **Special considerations.** Famphur is a cholinesterase inhibitor. Do not use this product in animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(c) **Related tolerances.** See §556.273 of this chapter.

(d) **Conditions of use.** It is used in the feed for cattle as follows:

(1) **Amount.** 1.1 milligrams per pound body weight per day.

(2) **Amount.** 2.3 milligrams per pound body weight per day.

### § 558.254 Erythromycin thiocyanate in grams per ton

<table>
<thead>
<tr>
<th>Erythromycin thiocyanate in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ii) 9.25 to 18.5</td>
<td></td>
<td>Turkeys; growth promotion and feed efficiency.</td>
<td>For turkeys not over 12 weeks of age.</td>
<td>061133</td>
</tr>
<tr>
<td>(iii) 9.25 to 64.75</td>
<td></td>
<td>Swine; increase in weight gain, improved feed efficiency in starter pigs (9.25 to 64.75) and grower-finishing pigs (9.25).</td>
<td>Starter ration for animals up to 35 lb body weight.</td>
<td>061133</td>
</tr>
<tr>
<td>(iv) 18.5</td>
<td></td>
<td>Laying chickens; aids in increasing egg production.</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; withdraw 24 h before slaughter.</td>
<td>061133</td>
</tr>
<tr>
<td>(v) 92.5</td>
<td></td>
<td>1. Chickens; as an aid in the prevention of chronic respiratory disease during periods of stress. 2. Chickens; as an aid in the prevention of infectious coryza. 3. Turkeys; as an aid in the prevention of chronic respiratory disease during periods of stress.</td>
<td>Feed for 7 to 14 d; withdraw 24 h before slaughter. Feed for 2 d before stress and 3 to 6 d after stress.</td>
<td>061133</td>
</tr>
<tr>
<td>(vi) 185</td>
<td></td>
<td>1. Chickens; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease. 2. Turkeys; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease.</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 48 h before slaughter. Feed for 5 to 8 d; do not use in birds producing eggs for food purposes.</td>
<td>061133</td>
</tr>
</tbody>
</table>

(2) In feed for feedlot beef cattle at 37 milligrams per head per day as an aid in stimulating growth and improving feed efficiency.

(3) Erythromycin thiocyanate may be used in accordance with the provisions of this section in the combinations provided as follows:

(i) Amprolium in accordance with §558.55.

(ii) Amprolium and ethopabate in accordance with §558.58.

(iii) Arsanilic acid in accordance with §558.62.

(iv) Zoalene in accordance with §558.680.

§ 558.258 Fenbendazole.

(a) Specifications. Type A medicated articles: 4 percent (18.1 grams per pound (g/lb)), 8 percent (36.2 g/lb), and 20 percent (90.7 g/lb) fenbendazole.

(b) Approvals. See No. 057926 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.275 of this chapter.

(d) Special considerations. See §500.25 of this chapter.

(e) Conditions of use—(1) Turkeys.

<table>
<thead>
<tr>
<th>Amount fenbendazole in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.5 (16 parts per million).</td>
<td></td>
<td>Growing turkeys: For the removal and control of gastrointestinal worms: round worms, adult and larvae (Ascaridia dissimilis); cecal worms, adult and larvae (Heterakis gallinarum), an important vector of <em>Histomonas meleagridis</em> (Blackhead).</td>
<td>Feed continuously as the sole ration for 6 days. For growing turkeys only.</td>
<td>057926</td>
</tr>
</tbody>
</table>

(2) Swine.

<table>
<thead>
<tr>
<th>Amount fenbendazole in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10 to 300 (to provide 9 milligrams (mg/kg) of body weight) given over a 3- to 12-day period.</td>
<td></td>
<td>For the removal and control of: Adult stage lungworms (<em>Metastrongylus apri</em> and <em>M. pudendotectus</em>); adult and larvae (L3, 4 stages—liver, lung, intestinal forms) large roundworms (<em>Ascaris suum</em>); adult stage nodular worms (<em>Oesophagostomum dentatum</em>, <em>O. quadrinucleatum</em>); adult stage small stomach worms (<em>Hyostrongylus rubidus</em>); adult and larvae (L2, 3, 4 stages—intestinal mucosal forms) whipworms (<em>Trichuris suis</em>); adult and larve kidney worms (<em>Stephanurus dentatus</em>).</td>
<td>Feed as sole ration.</td>
<td>057926</td>
</tr>
<tr>
<td>(ii) 10 to 80 (to provide 9 mg/kg of body weight).</td>
<td>Lincomycin 20.</td>
<td>As in paragraph (e)(2)(i) of this section; for increased rate of gain in growing-finishing swine.</td>
<td>Feed as sole ration. Do not feed to swine that weigh more than 250 pounds (lbs); lincomycin as provided by 00009 in §510.600(c) of this chapter.</td>
<td>057926</td>
</tr>
<tr>
<td>(iii) 10 to 80 (to provide 9 mg/kg of body weight).</td>
<td>Lincomycin 40.</td>
<td>As in paragraph (e)(2)(i) of this section; for control of swine dysentery in animals on premises with a history of swine dysentery, but where symptoms have not yet occurred.</td>
<td>Feed as sole ration. Do not feed to swine that weigh more than 250 lbs.; lincomycin as provided by 00009 in §510.600(c) of this chapter.</td>
<td>057926</td>
</tr>
<tr>
<td>(iv) 10 to 80 (to provide 9 mg/kg of body weight).</td>
<td>Lincomycin 100.</td>
<td>As in paragraph (e)(2)(i) of this section; for the treatment of swine dysentery.</td>
<td>Feed as sole ration. Do not use within 6 days of slaughter. Do not feed to swine that weigh more than 250 lbs.; lincomycin as provided by 00009 in §510.600(c) of this chapter.</td>
<td>057926</td>
</tr>
<tr>
<td>(v) 10 to 80 (to provide 9 mg/kg of body weight).</td>
<td>Lincomycin 200.</td>
<td>As in paragraph (e)(2)(i) of this section; for reduction in the severity of swine mycoplasmal pneumonia caused by <em>Mycoplasma mycopneumoniae</em>.</td>
<td>Feed as sole ration. Do not use within 6 days of slaughter. Do not feed to swine that weigh more than 250 pound (lb); lincomycin as provided by 00009 in §510.600(c) of this chapter.</td>
<td>057926</td>
</tr>
</tbody>
</table>
(3) Cattle—(i) Conditions of use are as follows:

<table>
<thead>
<tr>
<th>Amount fenbendazole in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) 5 mg/kg body weight (2.27 mg/lb)</td>
<td>------------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>For the removal and control of lungworms (Dictyocaulus viviparus); barberpole worms (Haemonchus contortus); brown stomach worms (Ostertagia ostertagi); small stomach worms (Trichostrongylus axei); hookworms (Bunostomum phlebotomum); thread-necked intestinal worms (Nematodirus helvetianus); small intestinal worms (Coopenia oncophora and C. punctata), bankrupt worms (Trichostrongylus colubriformis), and nodular worms (Oesophagostomum radiatum).</td>
<td>Feed as sole ration for one day. Do not use within 13 days of slaughter.</td>
<td>057926</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
§ 558.265 Amount fenbendazole in grams per ton

<table>
<thead>
<tr>
<th>Amount fenbendazole in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(B) 5 mg/kg body weight (2.27 mg/lb) in a free-choice feed.</td>
<td>.............................</td>
<td>As in paragraph (e)(3)(i)(A) of this section.</td>
<td>Formulate as specified in paragraph (e)(3)(ii) of this section. Feed a total of 5 mg of fenbendazole per kg (2.27 mg/lb) of body weight to cattle over a 3- to 6-day period. Retreatment may be needed after 4 to 6 weeks. Do not slaughter within 13 days following last treatment.</td>
<td>057926</td>
</tr>
</tbody>
</table>

(ii) Formulate for use as a free-choice cattle feed as in paragraph (e)(3)(i)(B) of this section as follows:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent</th>
<th>International feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) Ingredient:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copper sulfate</td>
<td>0.45</td>
<td>6–01–720</td>
</tr>
<tr>
<td>Dried Cane Molasses</td>
<td>3.12</td>
<td>4–04–695</td>
</tr>
<tr>
<td>Monosodium phosphate</td>
<td>31.16</td>
<td>6–04–288</td>
</tr>
<tr>
<td>Salt (sodium chloride)</td>
<td>59.00</td>
<td>6–04–152</td>
</tr>
<tr>
<td>Zinc sulfate</td>
<td>0.76</td>
<td>6–05–556</td>
</tr>
<tr>
<td>Fenbendazole Type A article (20%)</td>
<td>5.51</td>
<td></td>
</tr>
<tr>
<td>(B) Ingredient:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dicalcium phosphate</td>
<td>32.31</td>
<td>6–00–080</td>
</tr>
<tr>
<td>Limestone</td>
<td>17.13</td>
<td>6–02–632</td>
</tr>
</tbody>
</table>

1 The content of any added vitamin and trace mineral may be varied, however, they should be comparable to those used by the firm for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. The amount of selenium must comply with published regulations.

(4) Zoo and wildlife animals.

<table>
<thead>
<tr>
<th>Species/Class</th>
<th>Amount fenbendazole</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) Feral swine (Sus scrofa)</td>
<td>3 mg/kg/day for 3 days.</td>
<td>For the removal and control of kidney worm (Stephanurus dentatus), roundworm (Ascaris suum), nodular worm (Oesophagostomum dentatum).</td>
<td>Use as complete feed. Prior withdrawal of feed or water is not necessary. Retreatment may be required in 6 weeks. Do not use 14 days before or during the hunting season.</td>
<td>057926</td>
</tr>
<tr>
<td>(ii) Ruminants (subfamily Antilopinae, Hippotraginae, Caprinae)</td>
<td>2.5 mg/kg/day for 3 days.</td>
<td>For the removal and control of small stomach worm (Trichostrongylus spp.), thread necked intestinal worm (Nematodirus spp.), barberpole worm (Haemonchus spp.), whipworm (Trichuris spp.).</td>
<td>Use as complete feed. Prior withdrawal of feed or water is not necessary. Retreatment may be required in 6 weeks. Do not use 14 days before or during the hunting season.</td>
<td>057926</td>
</tr>
<tr>
<td>(iii) Rocky mountain bighorn sheep (Ovis c. canadensis)</td>
<td>10 mg/kg/day for 3 days.</td>
<td>For the removal and control of Protostrongylus spp.</td>
<td>Use as complete feed. Prior withdrawal of feed or water is not necessary. Retreatment may be required in 6 weeks. Do not use 14 days before or during the hunting season.</td>
<td>057926</td>
</tr>
</tbody>
</table>

[66 FR 58935, Nov. 26, 2001]
conditions.

(b) Related tolerances. See §556.308 of this chapter.

(c) Conditions of use. (1) It is used in feed for broiler chickens as follows:
   (i) Amount. 2.72 grams per ton.
   (A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima.
   (B) Limitations. Feed continuously as sole ration; withdraw 4 days before slaughter; do not feed to layers; avoid contact with skin, eyes, or clothing; keep out of lakes, ponds, or streams.
   (ii) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus bambermycins 1 to 2 grams.
   (A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; for increased rate of weight gain and improved feed efficiency.
   (B) Limitations. Feed continuously as sole ration; withdraw 5 days before slaughter; do not feed to layers.
   (iii) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus virginiamycin 5 grams.
   (A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; for increased rate of weight gain and improved feed efficiency.
   (B) Limitations. Feed continuously as sole ration; withdraw 6 days before slaughter; do not feed to layers.
   (iv) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus virginiamycin 5 to 15 grams.
   (A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; for increased rate of weight gain.
   (B) Limitations. Feed continuously as sole ration; withdraw 6 days before slaughter; do not feed to layers.
   (v) Amount per ton. Halofuginone hydrobromide 2.72 grams (0.0003 percent) plus bacitracin methylene disalicylate 10 to 50 grams and roxarsone 22.7 to 45.4 grams.
   (A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; for increased rate of weight gain; and for improved feed efficiency.
   (B) Limitations. Feed continuously as sole ration; withdraw 5 days before slaughter; use as sole source of organic arsenic; do not feed to layers; avoid contact with skin, eyes, or clothing; keep out of lakes, ponds, or streams.
   (vi) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus bacitracin methylene disalicylate 10 to 50 grams.
   (A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, E. maxima and for improved feed efficiency.
   (B) Limitations. Feed continuously as sole ration; withdraw 5 days before slaughter; do not feed to layers.
   (vii) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus lincomycin 2 to 4 grams.
   (A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima and for improved feed efficiency.
   (B) Limitations. Feed continuously as sole ration; withdraw 5 days before slaughter; do not feed to layers; avoid contact with skin, eyes, or clothing; keep out of lakes, ponds, or streams.
   (viii) Amount per ton. Halofuginone hydrobromide, 2.72 grams plus roxarsone, 22.7 to 45.4 grams.
   (A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; for increased rate of weight gain, improved feed efficiency, and improved pigmentation.
   (B) Limitations. Feed continuously as sole ration to replacement cage laying chickens until 20 weeks of age. Feed continuously as sole ration to replacement broiler breeder chickens until 16 weeks of age. Use as the sole source of organic arsenic; drug overdose or lack of water intake may result in leg weakness or paralysis. Do not feed to laying chickens or waterfowl. Withdraw 5 days before slaughter.
   (2) It is used in feed for turkeys as follows:
   (i) Amount per ton. 1.36 to 2.72 grams.
§ 558.274 Hygromycin B.

(a) Approvals. (1) Type A medicated articles: 2.4 and 8 grams per pound to 043733 in §510.600(c) of this chapter for use as in paragraph (c) of this section.

(2) 2.4 grams per pound to 043733 in §510.600(c) of this chapter for use in swine feed as in paragraph (c)(1)(ii) of this section.

(3) [Reserved]

(4) 0.6 gram per pound to 017790, 043733, and 050639 in §510.600(c) of this chapter for use in chickens as in paragraph (c)(1)(i) of this section and in swine as in paragraph (c)(1)(ii) of this section.

(5)-(6) [Reserved]
(7) 2.4 grams per pound to 017519 in §510.600(c) of this chapter for use in chickens as in paragraph (c)(1)(i) and in swine as in paragraph (c)(1)(ii) of this section.

(b) Related tolerances. See §556.330 of this chapter.

(c) Conditions of use. (1) It may be used as follows:

<table>
<thead>
<tr>
<th>Hygromycin B in</th>
<th>Combination in</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>grams per ton</td>
<td>grams per ton</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i) 8 to 12</td>
<td></td>
<td>Chickens: control of infestation of large roundworms (Ascaris galli), cecal worms (Heterakis gallinae), and capillary worms (Capillaria obsignata).</td>
<td>Withdraw 3 days before slaughter.</td>
<td>000986, 017519, 017790, 043733, 046573, 050639</td>
</tr>
<tr>
<td>Bacitracin 100</td>
<td></td>
<td>Chickens: control of infestation of large roundworms (Ascaris galli), cecal worms (Heterakis gallinae), and capillary worms (Capillaria obsignata); treatment of chronic respiratory disease (airsac infection), blue comb (nonspecific infectious enteritis),</td>
<td>As bacitracin methylene disalicylate or zinc bacitracin; withdraw 3 days before slaughter.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin plus penicillin (100 to 200 of combination).</td>
<td></td>
<td>Feed containing not less than 25% of penicillin plus not less than 50% of bacitracin; as procaine penicillin plus bacitracin methylene disalicylate; withdraw 3 days before slaughter.</td>
<td>Combination containing not less than 50% nor more than 75% of bacitracin, except that it contains not more than 125 g of penicillin; as procaine penicillin plus zinc bacitracin; withdraw 3 days before slaughter.</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 100 to 200.</td>
<td></td>
<td>Chickens: control of infestation of large roundworms (Ascaris galli), cecal worms (Heterakis gallinae), and capillary worms (Capillaria obsignata); control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption; feed for 7 to 14 days; withdraw 3 days before slaughter.</td>
<td></td>
</tr>
<tr>
<td>Hygromycin B in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>---------------------</td>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>Chlorotetracycline 200 to 400</td>
<td>Chickens; control of infestation of large roundworms (Ascaris galli), cecal worms (Heterakis gallinacea), and capillary worms (Capillaria obsignata); control of chronic respiratory disease (CRD) and air sac infection caused by Mycoplasma gallisepticum and Escherichia coli susceptible to chlorotetracycline.</td>
<td>...do ........................</td>
<td>As procaine penicillin; withdraw 3 days before slaughter.</td>
<td>000986</td>
</tr>
<tr>
<td>Penicillin 100</td>
<td>Chickens; control of infestation of large roundworms (Ascaris galli), cecal worms (Heterakis gallinacea), and capillary worms (Capillaria obsignata); treatment of chronic respiratory disease (ascaric infection), blue comb (nonspecific infectious enteritis).</td>
<td>...do ........................</td>
<td>As tylosin phosphate; withdraw 3 days before slaughter.</td>
<td>000986, 017519, 017790, 043733, 046573, 050639</td>
</tr>
<tr>
<td>Tylosin 4 to 50</td>
<td>Chickens: Control of infestations of large roundworms (Ascaris galli), cecal worms (Heterakis gallinacea), and capillary worms (Capillaria obsignata); growth promotion and feed efficiency.</td>
<td>...do ........................</td>
<td>Withdraw 15 days before slaughter.</td>
<td>000986</td>
</tr>
<tr>
<td>(ii) 12</td>
<td>Swine: control of infestation of large roundworms (Ascaris suis), nodular worms (Oesophagostomum dentatum), and whipworms (Trichuris suis).</td>
<td>...do ........................</td>
<td>Withdraw 15 days before slaughter.</td>
<td>000986, 017519, 017790, 043733, 046573, 050639</td>
</tr>
<tr>
<td>Chlorotetracycline 400.</td>
<td>Swine: control of infestation of large roundworms (Ascaris suis), nodular worms (Oesophagostomum dentatum) and whipworms (Trichuris suis); treatment of bacterial enteritis caused by E. coli and Salmonella choleraesuis and bacterial pneumonia caused by P. multocida susceptible to chlorotetracycline.</td>
<td>...do ........................</td>
<td>Withdraw 15 d before slaughter.</td>
<td>000986</td>
</tr>
<tr>
<td>Tylosin 10 to 100</td>
<td>Swine: Control of infestations of large roundworms (Ascaris suis), nodular worms (Oesophagostomum dentatum), and whipworms (Trichuris suis); growth promotion and feed efficiency.</td>
<td>...do ........................</td>
<td>As tylosin phosphate; withdraw 15 days prior to slaughter; feed continuously as follows.: Animal wt., lbs.: Up to 40.........20 to 100 0 41 to 100.......20 to 40 0 101 to market wt........10 to 20 0</td>
<td>000986</td>
</tr>
</tbody>
</table>

1 Amount of Tylosin (g/t).

(2) Hygromycin B may also be used in combination with:
(i) Amprolium in accordance with §558.55.
(ii) Zoalene in accordance with §558.680.

[41 FR 11000, Mar. 15, 1976]

Editorial Note: For Federal Register citations affecting §558.274, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.
§ 558.300 Ivermectin.

(a) Approvals. (1) Type A medicated articles: 0.6 percent (2.72 grams per pound; 6 grams per kilogram) to 050604 in §510.600(c) of this chapter, and

(2) Type B medicated feeds for swine containing 20 grams per ton lincomycin. Ingestion of transmission of infective larvae may be continued. Not to be fed to swine that weigh more than 250 pounds. Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to feeds containing lincomycin. Ingestion by these species may result in severe gastrointestinal effects. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(b) Related tolerances. See §556.344 of this chapter.

(c) [Reserved]

(d) Conditions of use. It is used in swine feed as follows:

(1) Amount per ton. For weaned, growing-finishing swine, feed 1.8 grams of ivermectin (to provide 0.1 milligram per kilogram of body weight per day). For adult and breeding swine, feed 1.8 to 11.8 grams of ivermectin (to provide 0.1 milligram per kilogram of body weight per day). For adult and breeding swine, may be top-dressed on daily ration for individual treatment at levels of 18.2 to 1180 grams (to provide 0.1 milligram per kilogram of body weight per day).

(2) Amount per pound. For increased milk production in dairy cows. (iii) Limitations. This drug is effective for limited periods of time, and the effectiveness is limited to the declining phase of lactation. Administration must be accompanied with increased feed intake; administration may increase heat sensitivity of the animal.

(3) Amount per pound. 6 grams per kilogram) to 050604 in §510.600(c) of this chapter, and

(ii) Limitations. For use in swine feed only. Feed as only feed for 7 consecutive days. Withdraw 5 days before slaughter. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(ii) Indications for use. For treatment and control of gastrointestinal roundworms (Ascaris suum, adults and fourth-stage larvae; Ascarops strongylinea, adults; Hyostrongylus rubidus, adults and fourth-stage larvae; Oesophagostomum spp., adults and fourth-stage larvae); kidneyworms (Stephanurus dentatus, adults and fourth-stage larvae); lungworms (Metastrongylus spp., adults); threadworms (Strongyloides ransomi, adults and somatic larvae), and prevention of transmission of infective larvae to piglets, via the colostrum or milk, when fed during gestation); lice (Haematopinus suis); and mange mites (Sarcoptes scabiei var. suis).

(i) Indications for use. For increased rate of weight gain and improved feathering in growing ducks.
(Sarcoptes scabiei var. suis). For control of swine dysentery. For use in swine on premises with a history of swine dysentery, but where symptoms have not yet occurred.

(ii) Limitations. For weaned, growing-finishing swine. Feed as only feed for 7 consecutive days. Withdraw 5 days before slaughter. A separate feed containing 40 grams per ton lincomycin may be continued. Not to be fed to swine that weigh more than 250 pounds. Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to feeds containing lincomycin. Ingestion by these species may result in severe gastrointestinal effects. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism.

(4) Amount per ton. 1.8 grams of ivermectin (to provide 0.1 milligram per kilogram of body weight per day) with 100 grams of lincomycin.

(i) Indications for use. For treatment and control of gastrointestinal roundworms (Ascaris suum, adults and fourth-stage larvae; Ascarops strongylina, adults; Hyostrongylus rubidus, adults and fourth-stage larvae; Oesophagostomum spp., adults and fourth-stage larvae), kidneyworms (Stephanurus dentatus, adults and fourth-stage larvae), lungworms (Metastrongylus spp., adults), lice (Haematopinus suis), and mange mites (Sarcoptes scabiei var. suis). Treatment of swine dysentery.

(ii) Limitations. For weaned, growing-finishing swine. Feed as only feed for 7 consecutive days followed by a separate feed containing 200 grams per ton lincomycin for an additional 14 days to complete the lincomycin treatment. Withdraw 6 days before slaughter. Not to be fed to swine that weigh more than 250 pounds. Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to feeds containing lincomycin. Ingestion by these species may result in severe gastrointestinal effects. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(6) Amount per ton. For weaned, growing-finishing pigs, feed 1.8 grams of ivermectin (to provide 0.1 milligram per kilogram of body weight per day), and 10 to 30 or 250 grams of bacitracin methylene disalicylate. For adult and breeding swine, feed 1.8 grams of ivermectin (to provide 0.1 milligram per kilogram of body weight per day), and 10 to 30 or 250 grams of bacitracin methylene disalicylate.

(i) Indications for use. For treatment and control of gastrointestinal roundworms (Ascaris suum, adults and fourth-stage larvae; Ascarops strongylina, adults; Hyostrongylus rubidus, adults and fourth-stage larvae; Oesophagostomum spp., adults and fourth-stage larvae), kidneyworms (Stephanurus dentatus, adults and fourth-stage larvae); lungworms (Metastrongylus spp., adults); threadworms (Strongyloides ransomi, adults and somatic larvae, and prevention of transmission of infective larvae to piglets, via the colostrum or milk, when fed during gestation); lice
§ 558.311 **Lasalocid.**

(a) **Specifications.** A minimum of 90 percent of lasalocid activity is derived from lasalocid A.

(b) **Approvals.** Type A medicated articles approved for sponsors identified in §510.600(c) of this chapter for use as in paragraphs (e)(1) (i), (ii), (iii), (iv), and (x) of this section.
§ 558.311

(2) 15 percent activity to No. 066104 as provided by No. 046573 for use as in paragraph (e)(1)(v) of this section.

(3) 15, 20, 33.1, and 50 percent activity to No. 046573 for use in cattle feeds as in paragraphs (e)(1)(vi), (vii), (ix), (x), (xii), and (xv) of this section, and for use in sheep as in paragraph (e)(1)(viii) of this section.

(4) 15 percent activity to No. 046573 for use in Type C rabbit feeds as in paragraph (e)(1)(xvi) of this section and for use in ruminant free-choice Type C feeds as in paragraphs (e)(2) and (e)(3) of this section.

(5) 15 percent activity to 021930 (Type A article provided by 046573) for use in free-choice vitamin-mineral Type C cattle feeds as in paragraph (e)(1)(xi).

(6) 20 percent activity as a liquid Type A article to No. 046573 for use in cattle feeds as in paragraphs (e)(1)(vi), (e)(1)(vii), (e)(1)(ix), (e)(1)(x), (e)(1)(xii), and (e)(3) of this section, and for use in sheep feeds as in paragraph (e)(1)(viii) of this section.

(7) 20 percent activity to No. 046573 for use as follows:
   (i) Chukar partridges as in paragraph (e)(1)(xiii).
   (ii) Turkeys as in paragraph (e)(1)(xiv).
   (iii) Rabbits as in paragraph (e)(1)(xvi).

(c) Related tolerance. See § 556.347 of this chapter.

(d) Special considerations. (1) Type C cattle and sheep feeds may be manufactured from lasalocid liquid Type B feeds which have a pH of 4.0 to 8.0 and bear appropriate mixing directions as follows:
   (i) For liquid Type B feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.
   (ii) For liquid Type B feeds stored in mechanical, air, or other agitation-type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

(2) A positionally stable lasalocid liquid Type B feed will not be subject to the requirements for mixing directions prescribed in paragraph (d)(1) of this section provided it has a pH of 4.0 to 8.0 and contains a suspending agent(s) sufficient to maintain a viscosity of not less than 300 centipoises per second for 3 months. Form FDA 1900 must indicate the pH and centipoises per second for such lasalocid liquid Type B feed.

(3) If a manufacturer is unable to meet the requirements of paragraph (d)(1) or (2) of this section, the manufacturer may secure approval of a positionally stable liquid Type B feed by (i) either filing a new animal drug application for the product or establishing a master file containing data to support the stability of its product; (ii) authorizing the agency to reference and rely upon the data in the master file to support approval of a supplemental new animal drug application to establish positional stability; and (iii) requesting the sponsor of an approved new animal drug application to file a supplement to provide for use of its lasalocid Type A article in the manufacture of the liquid Type B feed specified in the appropriate master file. If the data demonstrate the stability of the liquid Type B feed described in the master file, the supplement new animal drug application will be approved. Approval of the supplement will not be published in the FEDERAL REGISTER because such approval will not affect or alter conditions or use of the product in the new animal drug application or the regulation. The approval will, however, provide a basis for the individual liquid feed manufacturer to submit, and for the agency to approve, a medicated feed application under section 512(m) of the act for liquid Type B feed. A manufacturer who seeks to market a positionally unstable lasalocid liquid Type B feed with mixing directions different from the standard directions established in paragraph (d)(1) of this section may also follow this procedure.

(4) If adequate information is submitted to show that a particular liquid Type B feed containing lasalocid is stable outside the pH of 4.0 to 8.0, the pH restriction described in paragraphs (d)(1) and (2) of this section may be waived.
(5) Required label statements:

(i) For liquid Type B feed (cattle and sheep): Mix thoroughly with grain and/or roughage prior to feeding. Feeding undiluted, mixing errors, or inadequate mixing (recirculation or agitation) may result in an excess lasalocid concentration which could be fatal to cattle and sheep. Do not allow horses or other equines access to Type A articles or Type B feeds containing lasalocid as ingestion may be fatal. Safety of lasalocid for use in unapproved species has not been established.

(ii) For Type A articles or Type B feeds (cattle and sheep): Feeding undiluted or mixing errors may result in an excess lasalocid concentration which could be fatal to cattle and sheep. Do not allow horses or other equines access to Type A articles or Type B feeds containing lasalocid as ingestion may be fatal. Safety of lasalocid for use in unapproved species has not been established.

(6) Lasalocid Type A medicated articles containing lasalocid dried fermentation residue are for use in cattle and sheep feed only.

(7) Each use in a free-choice Type C cattle feed as in paragraph (e)(1)(xii) of this section must be the subject of an approved NADA or supplemental NADA as provided in §510.455 of this chapter.

(e)(1) Conditions of use. It is used as follows:

<table>
<thead>
<tr>
<th>Lasalocid sodium activity in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td>Roxarsone 45.4 (0.005 pct).</td>
<td>For the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>; and as an aid in the reduction of lesions due to <em>E. tenella</em>; and for increased rate of weight gain and improved feed efficiency.</td>
<td>For broiler or fryer chickens only; feed continuously as sole ration.</td>
<td>046573</td>
</tr>
<tr>
<td>(ii) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td>Roxarsone 45.4 plus bambermycins 1 (0.00011 pct).</td>
<td>For the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>; and as an aid in the reduction of lesions due to <em>E. tenella</em>; and for increased rate of weight gain.</td>
<td>For broiler or fryer chickens only; feed continuously as sole ration.</td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td>Roxarsone 45.4 plus lincomycin 2.0.</td>
<td>For the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>; and as an aid in the reduction of lesions due to <em>E. tenella</em>; and for increased rate of weight gain.</td>
<td>For broiler or fryer chickens only; feed continuously as sole ration; withdraw 5 days before slaughter; roxarsone provided by Nos. 046573 and 011526 in §510.600(c) of this chapter, lincomycin provided by No. 000005.</td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td>Roxarsone 45.4 plus bacitracin 10 to 25.</td>
<td>For the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>; and as an aid in the reduction of lesions due to <em>E. tenella</em>; and for increased rate of weight gain.</td>
<td>For broiler or fryer chickens only; feed continuously as sole ration; withdraw 5 days before slaughter; roxarsone provided by Nos. 046573 and 011526 in §510.600(c) of this chapter, bacitracin methylene disalicylate provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
</tr>
<tr>
<td>Lasalocid sodium activity in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Roxarsone 45.4 plus bacitracin 10 or 30</td>
<td>Roxarsone 45.5 plus bacitracin methylene disalicylate 50</td>
<td>For prevention of coccidiosis caused by <em>E. tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>; as an aid in the reduction of lesions due to <em>E. tenella</em>; and for increased rate of weight gain (10 grams per ton) or improved feed efficiency (30 grams per ton).</td>
<td>For broiler chickens only; feed continuously as sole ration; withdraw 5 days before slaughter; Roxarsone provided by Nos. 046573 and 011526 in §510.600(c) of this chapter. Bacitracin zinc provided by No. 000004.</td>
<td>046573</td>
</tr>
<tr>
<td>(i) 68 (0.0075 percent)</td>
<td>Lincomycin 2 (0.00022 percent).</td>
<td>For prevention of coccidiosis caused by <em>Eimeria necatrix</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>; reduction of lesions due to <em>E. tenella</em>; prevention of necrotic enteritis caused or complicated by <em>Clostridium</em> spp. or other susceptible organisms.</td>
<td>For broiler chickens only; feed continuously as sole ration; withdraw 5 days before slaughter.</td>
<td>046573</td>
</tr>
<tr>
<td>(ii) 68 (0.0075 percent)</td>
<td>Bacitracin 10 to 50</td>
<td>For prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>, and for increased rate of weight gain and improved feed efficiency.</td>
<td>For broiler or fryer chickens only; feed continuously as the sole ration; withdraw 3 days before slaughter; Bacitracin methylene disalicylate provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
</tr>
<tr>
<td>(iii) 68 (0.0075 percent)</td>
<td>Virginiamycin 20</td>
<td>For prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>, and for increased rate of weight gain and improved feed efficiency.</td>
<td>For broiler and fryer chickens only; feed continuously as the sole ration; do not feed to laying chickens; Lasalocid sodium provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
</tr>
<tr>
<td>(iv) 68 (0.0075 percent)</td>
<td>Oxytetracycline 7.5</td>
<td>Cattle; for improved feed efficiency.</td>
<td>In Type C feeds; for cattle fed in confinement for slaughter only; feed continuously in complete feed to provide not less than 100 mg nor more than 360 mg of lasalocid sodium activity per head per day.</td>
<td>046573</td>
</tr>
<tr>
<td>(v) 68 (0.0075 percent) to 113 (0.0125 percent)</td>
<td>Oxytetracycline 7.5</td>
<td>Cattle; for improved feed efficiency and increased rate of weight gain.</td>
<td>In Type C feeds; for cattle fed in confinement for slaughter only; feed continuously in complete feed to provide not less than 250 mg nor more than 360 mg of lasalocid sodium activity per head per day.</td>
<td>046573</td>
</tr>
<tr>
<td>(vi) 68 (0.0075 percent) to 113 (0.0125 percent)</td>
<td>Oxytetracycline 7.5</td>
<td>Cattle; for improved feed efficiency and increased rate of weight gain.</td>
<td>In Type C feeds; for cattle fed in confinement for slaughter only; feed continuously in complete feed to provide not less than 250 mg nor more than 360 mg of lasalocid sodium activity per head per day.</td>
<td>046573</td>
</tr>
<tr>
<td>Lasalocid sodium activity in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>(viii) 20 (0.0022 pct) to 30 (0.0033 pct)</td>
<td></td>
<td>Sheep; for the prevention of coccidiosis caused by Eimeria ovina, E. crandallis, E. ovinaoidalis, E. ninakohlyakimovae, E. parva, and E. intricata.</td>
<td>Feed continuously in complete feed to provide not less than 15 mg nor more than 70 mg of lasalocid sodium activity per head per day depending on body weight. Feed continuously at a rate of not less than 60 mg or more than 300 mg of lasalocid per head per day when on pasture; the drug must be contained in at least 1 pound of feed.</td>
<td>046573</td>
</tr>
<tr>
<td>(ix)</td>
<td>Pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers); for increased rate of weight gain. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day.</td>
<td></td>
<td></td>
<td>046573</td>
</tr>
<tr>
<td>(x) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td>Bacitracin 4 to 50...</td>
<td>Broiler chickens; for prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; and for improved feed efficiency.</td>
<td>For broiler chickens only; feed continuously as sole ration; withdraw 3 days before slaughter; bacitracin methylene disalicylate provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
</tr>
<tr>
<td>(xi) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td>Bacitracin zinc 4 to 50...</td>
<td>Broiler chickens. For prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; and for improved feed efficiency.</td>
<td>Feed continuously as sole ration. Bacitracin zinc and lasalocid sodium as provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
</tr>
<tr>
<td>(xii)</td>
<td>Pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers); for increased rate of weight gain. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day.</td>
<td></td>
<td></td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cattle; for control of coccidiosis caused by Eimeria bovis and Eimeria zuernii.</td>
<td>Feed continuously on a free-choice basis at a rate of not less than 60 mg or more than 300 mg of lasalocid per head per day.</td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>021930</td>
</tr>
<tr>
<td>(xiv) 113 (0.0125 pct)</td>
<td>Chukar partridges; for prevention of coccidiosis caused by Eimeria legionensis.</td>
<td></td>
<td>Feed continuously as sole ration up to 8 weeks of age.</td>
<td>046573</td>
</tr>
<tr>
<td>(xv) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td>Bacitracin 4 to 50...</td>
<td>Growing turkeys; for prevention of coccidiosis caused by E. meleagrismitis, E. gallopavorus, and E. adenoeides.</td>
<td>Feed continuously as sole ration. Bacitracin methylene disalicylate as provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td>Bacitracin methylene disalicylate 4 to 50...</td>
<td>Growing turkeys; for prevention of coccidiosis caused by E. meleagrismitis, E. gallopavorus, and E. adenoeides; for increased rate of weight gain and improved feed efficiency.</td>
<td>Fee continuously as sole ration. Bacitracin methylene disalicylate as provided by No. 046573 in §510.600(c) of this chapter.</td>
<td>046573</td>
</tr>
</tbody>
</table>

415
(2) It is used as a free-choice mineral Type C feed as follows:

(i) Specifications.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent</th>
<th>International feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defluorinated Phosphate (20.5 percent)</td>
<td>35.9</td>
<td>6-01-080</td>
</tr>
<tr>
<td>Calcium, 18.5 percent Phosphorus</td>
<td>20.0</td>
<td>6-04-152</td>
</tr>
<tr>
<td>Calcium Carbonate (38 percent Calcium)</td>
<td>18.0</td>
<td>6-01-069</td>
</tr>
<tr>
<td>Cottonseed Meal</td>
<td>10.0</td>
<td>5-01-061</td>
</tr>
<tr>
<td>Potassium Chloride</td>
<td>3.0</td>
<td>6-03-755</td>
</tr>
<tr>
<td>Selenium Premix (0.02 percent Selenium)</td>
<td>3.0</td>
<td>6-03-755</td>
</tr>
<tr>
<td>Dried Cane Molasses</td>
<td>2.5</td>
<td>6-04-695</td>
</tr>
<tr>
<td>Magnesium Sulfate</td>
<td>1.7</td>
<td>6-02-758</td>
</tr>
<tr>
<td>Vitamin Premix (i)</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>Magnesium Oxide</td>
<td>1.2</td>
<td>6-02-756</td>
</tr>
<tr>
<td>Potassium Sulfate</td>
<td>1.2</td>
<td>6-06-098</td>
</tr>
<tr>
<td>Trace Mineral Premix (ii)</td>
<td>1.04</td>
<td></td>
</tr>
<tr>
<td>Bovatec Premix (68 grams per pound)</td>
<td>1.06</td>
<td></td>
</tr>
</tbody>
</table>

1 Content of the vitamin and trace mineral premixes may be varied; however, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. The amount of selenium and ethylenediamine dihydroiodide (EDDI) must comply with published regulations. For selenium (21 CFR 573.920): up to 120 parts per million in a mixture for free-choice feeding and improved feed efficiency, and for increased rate of weight gain and improved feed efficiency.

(ii) Amount. 1,440 grams per ton (0.16 percent).

(iii) Indications for use. Pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers): for increased rate of weight gain. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day.

(iv) Limitations. For pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers); feed continuously on a free-choice basis at a rate of 60 to 300 milligrams lasalocid per head per day; each use of this Type C free-choice feed must be the subject of an approved FD–1900 as provided in §510.455 of this chapter.

(v) Sponsor. See No. 046573 in §510.600(c) of this chapter.

(3) It is used as a ruminant free-choice liquid Type C feed as follows:

(i) Specifications.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent</th>
<th>International feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cane Molasses</td>
<td>55.167</td>
<td>4–13–241</td>
</tr>
<tr>
<td>Condensed Molasses Fermentation Solubles</td>
<td>24.0</td>
<td>N/A</td>
</tr>
<tr>
<td>50% Urea Solution (23% N)</td>
<td>12.0</td>
<td>N/A</td>
</tr>
<tr>
<td>Ammonium Polyphosphate Solution</td>
<td>1.0</td>
<td>6–08–42</td>
</tr>
<tr>
<td>Phosphoric Acid (54%)</td>
<td>3.0</td>
<td>6–03–707</td>
</tr>
<tr>
<td>Xanthan Gum</td>
<td>0.05</td>
<td>8–15–618</td>
</tr>
<tr>
<td>Water</td>
<td>4.0</td>
<td>N/A</td>
</tr>
<tr>
<td>Trace Mineral Mix (i)</td>
<td>0.5</td>
<td>N/A</td>
</tr>
<tr>
<td>Vitamin Premix (ii)</td>
<td>0.2</td>
<td>N/A</td>
</tr>
<tr>
<td>Bovatec Liquid 20 (90.8 gm/lb)</td>
<td>0.083</td>
<td>N/A</td>
</tr>
</tbody>
</table>

1 Content of vitamin and trace mineral premixes may be varied; however, they should be comparable to those used for other free-choice liquid feeds. Formulation modifications require FDA approval prior to marketing. The amount of selenium and ethylenediamine dihydroiodide (EDDI) must comply with published regulations (for selenium see 21 CFR 573.920; for EDDI see 51 FR 11483, April 3, 1986).

2 To provide 150 gm lasalocid per ton, use 1,652 lb (0.083%) of Bovatec Liquid 20 (90.8 gm/lb). If dry Bovatec-68 (68 gm/lb) is used, use 2,026 lbs per ton (0.11%), replacing molasses.
Food and Drug Administration, HHS

§ 558.315 Levamisole hydrochloride (equivalent).

(a) Approvals. Type A medicated articles: 227 grams per pound to 043781 in §510.600(c) of this chapter.

(b) Related tolerances. See §556.350 of this chapter.

(c) Conditions of use. It is used in Type C medicated feed as follows:

(i) Cattle—(1) Amount per pound. 0.36–3.6 grams (0.08–0.8 percent).

(ii) Indications for use. Treatment of the following gastrointestinal worms and lung worm infections; stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus Cooperia, Nematodirus, Bunostomum, Oesophagostomum), and lungworms (Dictyocaulus).

(iii) Limitations. Administer medicated feed mixed thoroughly in one half the usual amount of morning feed; the medicated feed mix should be consumed within 6 hours; when medicated feed is consumed resume normal feeding; medicated feed is to be fed at the rate of 0.36 gram of levamisole hydrochloride (equivalent) per 100 lb. of body weight; conditions of constant helminth exposure may require retreatment within 2 to 4 weeks after the first treatment; do not slaughter for food within 48 hours of treatment; consult veterinarian before using in severely debilitated animals; do not administer to dairy animals of breeding age; for use in pelleted or meal feeds only; the label shall bear the caution, "Muzzle foam may be observed. However, this reaction will disappear within a few hours. If this condition persists, a veterinarian should be consulted. Follow recommended dosage carefully."

(2) Swine—(1) Amount per pound. 0.36 grams (0.08 percent).

(ii) Indications for use. Treatment of the following nematode infections: large roundworms (Ascaris suum), nodular worms (Oesophagostomum spp.), lungworms (Metastrongylus spp.), intestinal threadworms (Strongyloides ransoni), swine kidney worms (Stephanurus dentatus).

(iii) Limitations. It is recommended that regular feed be withheld overnight and worming feed administered the following morning; dilute supplement with nonmedicated feed as directed; feed the equivalent of 1 lb. of 0.08 percent worming feed per 100 lbs. of body weight of pigs to be treated; may be fed as sole feed or thoroughly mixed with 1 to 2 parts of regular feed prior to feeding; when medicated feed is consumed, resume normal feeding. Pigs maintained under conditions of constant worm exposure may require retreatment within 4 to 5 weeks after the first treatment due to reinfection; do not slaughter for food within 72 hours of treatment; the label shall bear the caution, "Excessive salivation or muzzle foam may be observed. This reaction is occasionally seen and will disappear in a short time after medication. If pigs are infected with mature lungworms, coughing and vomiting may be observed soon after medicated feed is consumed. This reaction is due to the

417
§ 558.325 Lincomycin.

(a) Approvals. Type A articles and Type B feeds approved for sponsors in § 510.600(c) of this chapter for specific uses as in paragraph (c) of this section as follows:

(i) No. 000009: (i) 4 grams per pound as in paragraphs (c)(1) and (3) of this section.

(ii) 20 grams per pound as in paragraphs (c)(1) through (3) of this section.

(iii) 50 grams per pound as in paragraphs (c)(1) and (2) of this section.

(iv) 10 grams per pound as in paragraphs (c)(1) and (2) (i) through (iv) of this section.

(2)–(4) [Reserved]

(5) No. 043733 for 8 and 20 grams per pound as in paragraphs (c)(2) (i) through (iii) of this section.

(6)–(12) [Reserved]

(13) No. 017800 for 2.5 and 8 grams per pound as in paragraphs (c)(2) (i) through (iv) of this section.

(14)–(15) [Reserved]

(b) Related tolerances in edible products. See § 556.360 of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Broilers: Amount per ton. 2 to 4 grams.

(ii) Amount per ton. 2 grams.

(a) Indications for use. For control of necrotic enteritis caused by Clostridium spp. or other susceptible organisms.

(b) Limitations. As lincomycin hydrochloride monohydrate.

(2) Swine—(i) Amount per ton. 40 grams.

(a) Indications for use. For control of swine dysentery.

(b) Limitations. Feed as sole ration; for use in swine on premises with a history of swine dysentery but where symptoms have not yet occurred; not to be fed to swine that weigh more than 250 pounds.

(ii) Amount per ton. 100 grams; 40 grams.

(a) Indications for use. For treatment and control of swine dysentery.

(b) Limitations. Feed 100 grams per ton for 3 weeks or until signs of disease disappear; followed by 40 grams per ton; feed as sole ration; not to be fed to swine that weigh more than 250 pounds.

(3) Lincomycin may also be used for broilers in combination with:

(i) Amprolium, ethopabate, and roxarsone in accordance with §§ 558.58 and 558.530.

(ii) Amprolium and ethopabate in accordance with § 558.58.

(iii) Clopidol in accordance with § 558.175.

(iv) Decoquinate in accordance with § 558.195.

(vi) Zoalene in accordance with § 558.680.

(vii) Monensin in accordance with § 558.355.

(viii) Robenidine hydrochloride in accordance with § 558.515.

(ix) Roxarsone, monensin sodium in accordance with §§ 558.355 and 558.530.

(x) Lasalocid sodium in accordance with § 558.311.

(xi) Nicarbazin and roxarsone as in § 558.366.

(xii) Nicarbazin with or without narasin as in § 558.366.

(xiii) Lasalocid sodium and roxarsone as in § 558.311.
(xiv) Halofuginone in accordance with §558.265.
(xv) Salinomycin with or without roxarsone as in §558.550.
(4) Lincomycin may also be used for swine in combination with:
(i) Pyrantel tartrate as in §558.485.
(ii) Fenbendazole as provided in §558.258.
(iii) Ivermectin as in §558.300.

§558.342 Melengestrol acetate.

(a) Approvals. Dry Type A medicated articles containing 100 or 200 milligrams per pound or liquid Type A article containing 500 milligrams per pound to 000009 in §510.600(c) of this chapter.
(b) Related tolerances. See §556.380 of this chapter.
(c) Special considerations. (1) Type B or C medicated feeds may be manufactured from melengestrol acetate liquid Type A articles or Type B or C medicated feeds which have a pH of 4.0 to 8.0 and bear appropriate mixing directions as follows:
(i) For liquid Type B or C feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.
(ii) For liquid Type B or C feeds stored in mechanical, air, or other agitation type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

(2) A positionally stable melengestrol acetate liquid Type B or C feed will not be subject to the requirements for mixing directions prescribed in paragraphs (c)(1) of this section provided it has a pH of 4.0 to 8.0 and contains a suspending agent(s) sufficient to maintain a viscosity of not less than 300 centipoises per second for 3 months.
(d) Conditions of use. It is used for heifers as follows:
(1) Amount. Melengestrol acetate, 0.25 to 0.50 milligram per head per day.
(i) Indications for use. For increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).
(ii) Limitations: Heifers being fed for slaughter; administer 0.5 to 2.0 pounds per head per day of medicated feed containing 0.125 to 1.0 milligram of melengestrol acetate per pound to provide 0.25 to 0.50 milligram of melengestrol acetate per head per day. Melengestrol acetate as provided by No. 000009 in §510.600(c) of this chapter.
(2) Amount: Melengestrol acetate, 0.25 to 0.40 milligram per head per day, plus monensin (as monensin sodium), 50 to 360 milligrams per head per day.
(i) Indications for use. For increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).
(ii) Limitations: Heifers being fed in confinement for slaughter; add at the rate of 0.5 to 2.0 pounds per head per day a medicated feed (liquid or dry) containing 0.125 to 0.80 milligram of melengestrol acetate per pound to a feed containing 5 to 30 grams of monensin per ton; or, add at the rate of 0.5 to 2.0 pounds per head per day a...
medicated feed (liquid or dry) containing 0.125 to 0.80 milligram of melengestrol acetate plus 25 to 720 milligrams of monensin per pound to a nonmedicated feed to provide 0.25 to 0.40 milligram of melengestrol acetate and 50 to 360 milligrams of monensin per head per day. The liquid medicated feeds must be manufactured in accordance with §558.355(f)(3)(i). Melengestrol acetate and monensin as provided by Nos. 000009 and 000986, respectively, in §510.600(c) of this chapter.

(3) Amount. Melengestrol acetate, 0.25 to 0.50 milligram per head per day in combination with lasalocid (as lasalocid sodium), 100 to 360 milligrams per head per day.

(i) Indications for use. For increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).

(ii) Limitations. Heifers being fed in confinement for slaughter. The liquid medicated feeds are required to be manufactured in accordance with §558.311(d). Add at the rate of 0.5 to 2.0 pounds per head per day a medicated feed (liquid or dry) containing 0.125 to 1.0 milligram of melengestrol acetate per pound to a feed containing 8 to 10 grams of lasalocid per ton; or, add at the rate of 0.5 to 2.0 pounds per head per day a medicated feed (liquid or dry) containing 0.125 to 1.0 milligram of melengestrol acetate plus 25 to 720 milligrams of lasalocid per pound to a ration of nonmedicated feed.

(4) Amount. Melengestrol acetate, 0.25 to 0.50 milligram per head per day, plus tylosin (as tylosin phosphate), 90 milligrams per head per day.

(i) Indications for use. For increased rate of weight gain, improved feed efficiency, suppression of estrus (heat), and reduced incidence of liver abscesses.

(ii) Limitations. Heifers being fed in confinement for slaughter. Melengestrol acetate and tylosin as provided by Nos. 000009 and 000986, respectively, in §510.600(c) of this chapter. To administer 0.25 to 0.50 milligram of melengestrol acetate with 90 milligrams of tylosin per head per day:

(A) Add 0.5 to 2.0 pounds per head per day of a liquid or dry medicated feed containing 0.125 to 1.0 milligram of melengestrol acetate per pound to a medicated feed containing 8 to 10 grams of tylosin per ton; or

(B) Add 0.5 to 2.0 pounds per head per day of a liquid or dry medicated feed containing 0.125 to 1.0 milligram of melengestrol acetate per pound to 4.5 to 18 pounds of a dry medicated feed containing 10 to 40 grams of tylosin per ton; or

(C) Add 0.5 to 2.0 pounds per head per day of a dry medicated feed containing 0.125 to 1.0 millgram of melengestrol acetate (from a dry Type A article) plus 45 to 180 milligrams of tylosin per pound to a ration of nonmedicated feed.

(5) Amount. Melengestrol acetate, 0.25 to 0.50 milligram per head per day, plus monensin (as monensin sodium) at 50 to 360 milligrams per head per day, plus tylosin (as tylosin phosphate), 90 milligrams per head per day.

(i) Indications for use. For increased rate of weight gain, improved feed efficiency, suppression of estrus (heat), and reduced incidence of liver abscesses.

(ii) Limitations. Heifers being fed in confinement for slaughter. Melengestrol acetate as provided by No. 000009 and monensin and tylosin as provided by No. 000986 in §510.600(c) of this chapter. To administer 0.25 to 0.50 milligram of melengestrol acetate to 50 to 360 milligrams of monensin plus 90 milligrams of tylosin per head per day:

(A) Add 0.5 to 2.0 pounds per head per day of a liquid or dry medicated feed containing 0.125 to 1.0 milligram of melengestrol acetate per pound to a medicated feed containing 5 to 30 grams of monensin and 8 to 10 grams of tylosin per ton; or

(B) Add 0.5 to 2.0 pounds per head per day of a liquid or dry medicated feed containing 0.125 to 1.0 milligram of melengestrol acetate plus 25 to 720 milligrams of monensin per pound to 4.5 to
Food and Drug Administration, HHS

§ 558.348

18 pounds of a dry medicated feed containing 10 to 40 grams of tylosin per ton; or

(C) Add 0.5 to 2.0 pounds per head per day of a dry medicated feed containing 0.125 to 1.0 milligram melengestrol acetate (from a dry Type A article), 25 to 600 milligrams of monensin, and 45 to 180 milligrams of tylosin per pound to a ration of nonmedicated feed.

(6) Amount. Melengestrol acetate, 0.25 to 0.50 milligram per head per day, plus lasalocid (as lasalocid sodium), 100 to 360 milligrams per head per day, and tylosin (as tylosin phosphate), 90 milligrams per head per day.

(i) Indications for use. For increased rate of weight gain, improved feed efficiency, suppression of estrus (heat), and reduced incidence of liver abscesses.

(ii) Limitations. Heifers being fed in confinement for slaughter. The liquid medicated feeds are required to be manufactured in accordance with §558.311(d). Lasalocid, melengestrol acetate, and tylosin as provided by Nos. 000009, 000986, and 063238 respectively, in §510.600(c) of this chapter. To administer 0.25 to 0.50 milligram of melengestrol acetate plus 100 to 360 milligrams of lasalocid plus 90 milligrams of tylosin per head per day:

(A) Add 0.5 to 2.0 pounds per head per day of a liquid or dry medicated feed containing 0.125 to 1.0 milligram of melengestrol acetate per pound to a medicated feed containing 10 to 30 grams of lasalocid and 8 to 10 grams of tylosin per ton; or

(B) Add 0.5 to 2.0 pounds per head per day of a liquid or dry medicated feed containing 0.125 to 1.0 milligram of melengestrol acetate plus 50 to 720 milligrams of lasalocid per pound to 4.5 to 18 pounds of a dry medicated feed containing 10 to 40 grams of tylosin per ton; or

(C) Add 0.5 to 2.0 pounds per head per day of a dry pelleted medicated feed containing 0.125 to 1.0 milligram of melengestrol acetate (from a dry Type A article), 50 to 720 milligrams of lasalocid, and 45 to 180 milligrams of tylosin per pound to a ration of nonmedicated feed.

(7) Amount. 0.5 milligram per head per day.

(i) Indications for use. For suppression of estrus (heat).

(ii) Limitation. Heifers intended for breeding. Do not exceed 24 days of feeding. Administer 0.5 to 2.0 pounds per head per day of Type C feed containing 0.25 to 1.0 milligram of melengestrol acetate per pound to provide 0.5 milligram of melengestrol acetate per head per day. Melengestrol acetate as provided by No. 000009 in §510.600(c) of this chapter.

(8) Amount. Melengestrol acetate, 0.25 to 0.5 milligram per head per day, plus oxytetracycline, 75 milligrams per head per day.

(i) Indications for use. For increased rate of weight gain, improved feed efficiency, suppression of estrus (heat), and reduction of liver condemnation due to liver abscesses.

(ii) Limitations. Heifers fed in confinement for slaughter. Add at the rate of 0.5 to 2.0 pounds per head per day a medicated feed (liquid or dry) containing 0.125 to 1.0 milligram of melengestrol acetate per pound to a feed containing 6 to 10 grams of oxytetracycline per ton; or add at the rate of 0.5 to 2.0 pounds per head per day a dry medicated feed containing 0.125 to 1.0 milligram of melengestrol acetate plus 37.5 to 150 milligrams of oxytetracycline per pound to provide 0.25 to 0.5 milligram of melengestrol acetate and 75 milligrams of oxytetracycline per head per day. Liquid melengestrol acetate may not be mixed with oxytetracycline in a common liquid feed supplement. Melengestrol acetate as provided by 000009, oxytetracycline by 000069, in §510.600(c) of this chapter.


§ 558.348 Mibolerone.

(a) Approvals. To No. 000009 in §510.600(c) of this chapter for a canned dog food, each 6½ ounce can containing 30 or 60 micrograms of mibolerone.
§ 558.355  Monensin.

(a) Specifications. Monensin, as the base or the sodium salt, contains a minimum of 90 percent monensin activity derived from monensin A and a minimum of 95 percent derived from monensin A plus B. Using thin layer chromatography, the $R_f$ value must be comparable to a reference standard (the $R_f$ value is the distance the spots travel from the starting line divided by the distance the solvent front travels from the starting line), or, using High Performance Liquid Chromatography, the factor distribution of monensin Factor A or B is calculated as the percentage of total biopotency of all peaks. The loss on drying is not more than 10 percent when dried in vacuum at 60 °C for 2 hours.

(b) Approvals. Approvals for Type A medicated articles containing the specified levels of monensin activity granted to firms identified by sponsor numbers in §510.600(c) of this chapter for the conditions of use indicated in paragraph (f) of this section are as follows:

1. To 000986: 36.3 (for export only), 44, 45, or 60 grams per pound, paragraphs (f)(1)(i) and (4) of this section.
2. To 000986: 110 grams per lb., paragraphs (f)(1)(i), (iii), (iv), (v), (ix), and (x).
3. To 000986: 44 grams per lb. with 18 grams per lb. of roxarsone, 110 grams per lb. with 45 grams per lb. of roxarsone, paragraph (f)(1)(ii).
4. To 000986: 45 and 60 grams per pound, as monensin sodium, paragraph (f)(2) of this section.
5. To 066104: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraphs (f)(1)(xiii), (xx), and (xxi) of this section.
6. To 000986: 45 and 60 grams per pound, as monensin sodium, paragraph (f)(5) of this section.
7. To 000986: 20, 30, 45, 60, 80, and 90.7 grams per pound, as monensin sodium, paragraph (f)(3) of this section.
8. To 046573: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraph (f)(1)(xiv) of this section.
9. To 046573: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraphs (f)(1)(xv) and (xvi) of this section.
10. To 057926: 45 and 60 grams per pound, as monensin sodium, paragraph (f)(1)(xvii) of this section.
11. To 046573: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraphs (f)(1)(xvii), (xviii), (xix), (xxiii), (xxiv), (xxv), (xxvi), and (xxvii) of this section.
12. To 066104: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraph (f)(1)(xviii) of this section.
13. To 021930: 60 and 80 grams per pound, paragraph (f)(3)(v) of this section.
14. To 000986: 60, 80, and 90.7 grams per pound, as monensin sodium, paragraph (f)(6) of this section.
(c) [Reserved]

(d) Special considerations. (1) Type C chicken feed containing monensin as the mycelial cake shall bear an expiration date of 90 days after its date of manufacture.
(2) Type C cattle feeds containing 30 grams or less monensin sodium per ton shall bear an expiration date of 30 days after its date of manufacture.
(3) Type C goat feeds shall bear an expiration date of 30 days after date of manufacture.
(4) [Reserved]

(5) Liquid Type B feeds shall bear an expiration date of 8 weeks after its date of manufacture.

(6) The labeling of all formulations containing monensin shall bear the following caution statement: Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal.

(7) The labeling of all Type A articles and Type B feeds (liquid and dry) containing monensin intended for use in cattle shall bear, in addition to the caution statement in paragraph (d)(6) of this section, the following caution statements:

(i) Monensin medicated cattle feed is safe for use in cattle only. Consumption by unapproved species may result in toxic reactions;

(ii) Feeding undiluted or mixing errors resulting in high concentrations of monensin has been fatal to cattle.

(iii) Must be thoroughly mixed in feeds before use;

(iv) Do not feed undiluted;

(v) Do not exceed the levels of monensin recommended in the feeding directions, as reduced average daily gains may result.

(vi) Do not feed to lactating dairy cows.

(8) The labeling of complete feeds containing monensin intended for use in cattle shall bear the caution statements specified in paragraphs (d)(6) and (7)(i) and (v) of this section.

(9) The labeling of Type A articles containing monensin intended for use in chickens shall bear the caution statements specified in paragraphs (d)(6) and (7) (iii) and (iv) of this section.

(10) The labeling of all Type A articles and Type B feeds (liquid and dry) containing monensin intended for use in goats shall bear the caution statements specified in paragraphs (d)(6) and (d)(10)(i) and (v) of this section.

(e) Related tolerances. See §556.420 of this chapter.

(f) Conditions of use. It is used as follows:

(1) Broiler chickens—(i) Amount per ton. Monensin, 90–110 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; in the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; as monensin or monensin sodium.

(ii) Amount per ton. Monensin, 90–110 grams, plus roxarsone 45.4 grams (0.005 percent).

(a) Indications for use. Growth promotion and feed efficiency, improving pigmentation; as an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; withdraw 5 days before slaughter; as sole source of organic arsenic; as monensin or monensin sodium.


(a) Indications for use. For increased rate of weight gain and improved feed efficiency; as an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed continuously as sole ration; in the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; as bacitracin methylene disalicylate provided by No.
046573 in §510.600(c) of this chapter; as monensin sodium.

(iv) Amount per ton. Monensin, 90–110 grams plus bacitracin, 10 grams.

(a) Indications for use. For increased rate of weight gain and improved feed efficiency; as an aid in the prevention of coccidiosis caused by E. necatriz, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed continuously as sole ration; in the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; as zinc bacitracin provided by No. 046573 in §510.600(c) of this chapter; as monensin sodium.

(v) Amount per ton. Monensin, 90–110 grams plus bacitracin, 10–30 grams.

(a) Indications for use. For improved feed efficiency; as an aid in the prevention of coccidiosis caused by E. necatriz, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed continuously as sole ration; in the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; as zinc bacitracin provided by No. 046573 in §510.600(c) of this chapter; as monensin sodium.

(vi) Amount per ton. Monensin, 90 to 110 grams plus bambermycins, 1 to 2 grams. See §558.95(b)(1)(vi).

(vii) Amount per ton. Monensin, 90 to 110 grams plus bambermycins, 1 gram plus roxarsone, 22.7 to 45.4 grams (.0025 to .005 percent). See §558.95(b)(1)(vii).

(viii) Amount per ton. Monensin, 90 to 110 grams plus oxytetracycline, 200 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by Eimeria necatriz, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; and for the control of complicated chronic respiratory disease (CRD or air-sac infection) caused by Mycoplasma gallisepticum and Escherichia coli.

(b) Limitations. In the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; do not feed to laying chickens; feed continuously as sole ration; as monensin sodium.

(ix) Amount per ton. Monensin, 90–110 grams plus lincomycin, 2 grams.

(a) Indications for use. For increase in rate of weight gain and improved feed efficiency; as an aid in the prevention of coccidiosis caused by E. necatriz, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; to be fed as a sole ration; in the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; as monensin sodium.

(x) Amount per ton. Monensin, 90–110 grams plus lincomycin, 2 grams and roxarsone, 15–45 grams.

(a) Indications for use. For increase in rate of weight gain; as an aid in the prevention of coccidiosis caused by E. necatriz, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; withdraw 5 days before slaughter; as sole source of organic arsenic; as roxarsone provided by No. 046573, §510.600(c) of this chapter; as monensin sodium provided by No. 000986, §510.600(c) of this chapter; as lincomycin provided by No. 000009, §510.600(c) of this chapter; as a combination provided by No. 000986, §510.600(c) of this chapter.

(xi) Amount per ton. Monensin, 90 to 110 grams, plus lincomycin, 2 grams and roxarsone, 15 to 30 grams.

(a) Indications for use. For increase in rate of weight gain, improved feed efficiency, improved pigmentation, and as an aid in the prevention of coccidiosis caused by E. necatriz, E. tenella, E. acervulina, E. brunetti, E. mivati and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; withdraw 5 days before slaughter; as sole source of organic arsenic; as roxarsone provided by No. 046573 in §510.600(c) of this chapter; as monensin sodium provided by No. 000986 in §510.600(c) of this chapter; as lincomycin provided by No. 000986 in §510.600(c) of this chapter; as a combination provided by No. 000009 in §510.600(c) of this chapter.
Food and Drug Administration, HHS

§ 558.355

(xii) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin methylene disalicylate, 10 to 25 grams, and roxarsone, 11.3 to 45.4 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. maxima, and E. mivati; for increased rate of weight gain and for improved feed efficiency.

(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; withdraw 5 days before slaughter; as sole source of organic arsenic; feed must be used within 4 weeks of manufacture; as monensin sodium; as bacitracin zinc provided by No. 046573 in § 510.600 of this chapter; as monensin sodium provided by No. 066104 in § 510.600 of this chapter; as roxarsone provided by No. 046573 in § 510.600(c) of this chapter.

(xiii) Amount per ton. Monensin, 90 to 110 grams, plus 5 grams virginiamycin.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. maxima, and E. mivati; for increased rate of weight gain and improved feed efficiency.

(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; as monensin sodium provided by No. 000986 in § 510.600 of this chapter; as bacitracin methylene disalicylate provided by No. 046573 in § 510.600 of this chapter; as roxarsone provided by No. 046573 in § 510.600(c) of this chapter.

(xiv) Amount per ton. Monensin, 90 to 110 grams, plus 500 grams chlortetraclnyle.

(a) Indications for use. As an aid in the reduction of mortality due to Escherichia coli infections susceptible to such treatment. As an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed for 5 days as the sole ration; withdraw 24 hours before slaughter; in the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; not to be fed continuously for more than 5 days; as monensin sodium; as chlortetraclnyle hydrochloride provided by No. 046573 in § 510.600(c) of this chapter.

(xv) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin zinc, 10 grams, and roxarsone, 15 grams (0.0017 percent).

(a) Indications for use. For increase in rate of weight gain; for the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. maxima, E. brunetti, and E. mivati.

(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; withdraw 5 days before slaughter; as sole source of organic arsenic; feed must be used within 4 weeks of manufacture; as monensin sodium; as bacitracin zinc provided by No. 046573 in § 510.600(c) of this chapter; as roxarsone provided by No. 046573 in § 510.600(c) of this chapter.

(xvi) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin zinc, 4 to 50 grams, and roxarsone, 15 to 45.4 grams (0.0017 percent to 0.005 percent).

(a) Indications for use. For improved feed efficiency; for improved pigmentation by enhancing carotenoid and xanthophyll utilization; for the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. maxima, E. brunetti, and E. mivati.

(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; withdraw 5 days before slaughter; as sole source of organic arsenic; feed must be used within 4 weeks of manufacture; as monensin sodium; as bacitracin zinc provided by No. 046573 in § 510.600(c) of this chapter; as roxarsone provided by No. 046573 in § 510.600(c) of this chapter.

(xvii) Amount per ton. Monensin, 90 to 110 grams, plus bambermycins, 1 to 2 grams plus roxarsone, 22.7 to 45.4 grams (0.0025 to 0.005 percent). See § 558.95(b)(1)(xiii) of this chapter.

(xviii) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin methylene disalicylate, 50 grams, and roxarsone, 22.7 to 34.0 grams (0.0025 percent to .00375 percent).

(a) Indications for use. For increase in rate of weight gain and improved feed efficiency; as an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. maxima, E. brunetti, and E. mivati; as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp or other organisms susceptible to bacitracin methylene disalicylate.
(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; withdraw 5 days before slaughter; as sole source of organic arsenic; as monensin sodium provided by No. 000986 in §510.600(c) of this chapter; bacitracin methylene disalicylate provided by No. 046573 in §510.600(c) of this chapter; as roxarsone provided by No. 046573 in §510.600(c) of this chapter.

(xix) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin methylene disalicylate, 50 grams, and roxarsone, 22.7 to 45.4 grams (0.0025 percent to 0.005 percent).

(a) Indications for use. For increased rate of weight gain; as an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. maxima, E. brunetti, and E. mivati.

(b) Limitations. Do not feed to laying chickens; feed continuously as sole ration; as monensin sodium provided by No. 000986 in §510.600(c) of this chapter; virginiamycin provided by No. 066104 in §510.600 of this chapter.

(xxl) Amount per ton. Monensin, 90 to 110 grams plus oxytetracycline, 500 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. Mivati, and E. maxima; as an aid in the reduction of mortality due to airsacculitis (air-sac infection) caused by Escherichia coli sensitive to oxytetracycline.

(b) Limitations. Feed for 5 days as sole ration. Do not feed to laying chickens. Withdraw 24 hours before slaughter. As monensin sodium provided by No. 000986 in §510.600(c) of this chapter. As mono-alkyl \((C_{16}-C_{18})\) trimethylammonium oxytetracycline provided by No. 066104 in §510.600(c) of this chapter.

(xxii) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin zinc, 4 to 50 grams, and roxarsone, 22.7 to 45.4 grams (0.0025 percent to 0.005 percent).

(a) Indications for use. For improved feed efficiency; as an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. maxima, E. brunetti, and E. mivati.

(b) Limitations. Do not feed to laying chickens; feed continuously as the sole ration; withdraw 5 days before slaughter; as sole source of organic arsenic; as monensin sodium provided by No. 000986 in §510.600(c) of this chapter; bacitracin zinc provided by No. 046573 in §510.600(c) of this chapter; as roxarsone provided by No. 046573 in §510.600(c) of this chapter.

(xxiii) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin methylene disalicylate, 4 to 50 grams.

(a) Indications for use. For increased rate of weight gain and improved feed.
efficiency; as an aid in the prevention of coccidiosis caused by *Eimeria necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*.

(b) **Limitations.** Do not feed to laying chickens; feed continuously as sole ration; in the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; as bacitracin zinc provided by No. 046573 in §510.600(c) of this chapter, as monensin sodium.

(xxvi) **Amount per ton.** Monensin 90 to 110 grams plus bacitracin 100 to 200 grams and roxarsone 22.7 to 34.0 grams.

(a) **Indications for use.** As an aid in the control of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin methylene disalicylate; as an aid in the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*; for increased rate of weight gain and improved feed efficiency.

(b) **Limitations.** For broiler chickens only. Feed continuously as sole ration. Use as sole source of organic arsenic. Withdraw 5 days before slaughter. Do not feed to laying hens. To control necrotic enteritis, start medication at first clinical signs of disease. The dosage range permitted provides for different levels based on the severity of infection. Use continuously for 5 to 7 days or as long as clinical signs persist, then reduce dosage to prevention level. Animals should have access to drinking water at all times. Drug overdosage or lack of water may result in leg weakness. As roxarsone and bacitracin methylene disalicylate provided by No. 046573 in §510.600(c) of this chapter.

(xxviii) **Amount per ton.** Monensin, 90 to 110 grams, plus tylosin phosphate, 4 to 50 grams.

(a) **Indications for use.** As an aid in the prevention of coccidiosis caused by *Eimeria necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*, for increased rate of weight gain, and improved feed efficiency.

(b) **Limitations.** Feed continuously as sole ration. In the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain. Do not feed to laying chickens. As monensin sodium and tylosin phosphate provided by No. 000986 in §510.600(c) of this chapter.

(xxix) **Amount per ton.** Monensin, 90 to 110 grams; plus bacitracin methylene disalicylate, 50 grams.

(a) **Indications for use.** As an aid in the prevention of coccidiosis caused by *E. necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*; and as an aid in the prevention of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin.

(b) **Limitations.** Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. As monensin sodium provided by 000986; bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter.

(XXX) **Amount per ton.** Monensin, 90 to 110 grams; plus bacitracin methylene disalicylate, 100 to 200 grams.

(a) **Indications for use.** As an aid in the prevention of coccidiosis caused by *E. necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*; and
as an aid in the control of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin.

(b) Limitations. Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. To control necrotic enteritis, start medication at first clinical signs of disease; vary dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams per ton). As monensin sodium has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis. Bacitracin methylene disalicylate as provided by No. 046573 in §510.600(c) of this chapter.

(2) Turkeys—(i) Amount per ton. Monensin, 54 to 90 grams.

(a) Indications for use. For the prevention of coccidiosis in turkeys caused by *Eimeria adenoeides*, *E. meleagrimitis*, and *E. gallopavonis*.

(b) Limitations. For growing turkeys only; as monensin sodium; feed continuously as sole ration. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis.

(ii) Amount per ton. Monensin, 54 to 90 grams, and bacitracin methylene disalicylate, 4 to 50 grams.

(a) Indications for use. For prevention of coccidiosis caused by *Eimeria adenoeides*, *E. meleagrimitis*, and *E. gallopavonis*, for increased rate of weight gain, and for improved feed efficiency in growing turkeys.

(b) Limitations. For growing turkeys only; as monensin sodium; feed continuously as sole ration. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis. Bacitracin methylene disalicylate as provided by No. 046573 in §510.600(c) of this chapter.

(iii) Amount per ton. Monensin, 54 to 90 grams, and bacitracin methylene disalicylate, 200 grams.

(a) Indications for use. For the prevention of coccidiosis caused by *Eimeria adenoeides*, *E. meleagrimitis*, and *E. gallopavonis*, and as an aid in the control of transmissible enteritis complicated by organisms susceptible to bacitracin methylene disalicylate.

(b) Limitations. For growing turkeys only; as monensin sodium; feed continuously as sole ration. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis. Bacitracin methylene disalicylate as provided by No. 046573 in §510.600(c) of this chapter.

(iv) Amount per ton. Monensin, 54 to 90 grams, with virginiamycin, 10 to 20 grams.

(a) Indications for use. For the prevention of coccidiosis caused by *Eimeria adenoeides*, *E. meleagrimitis*, and *E. gallopavonis*, and for increased rate of weight gain and improved feed efficiency in growing turkeys.

(b) Limitations. For growing turkeys only. Feed continuously as sole ration. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses, mature turkeys, and guinea fowl has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis. Virginiamycin as provided by No. 066104 in §510.600(c) of this chapter.

(v) Amount per ton. Monensin, 54 to 90 grams, plus bambermycins, 1 to 2 grams.

(a) Indications for use. For the prevention of coccidiosis in turkeys caused by *E. adenoeides*, *E. meleagrimitis*, and *E. gallopavonis*, and for improved feed efficiency in growing turkeys.

(b) Limitations. For growing turkeys only. Feed continuously as sole ration. Some strains of turkey coccidia may be monensin tolerant or resistant.
Monensin may interfere with development of immunity to turkey coccidiosis. Bambermycins as provided by No. 057926 in §510.600(c) of this chapter.

(vi) Amount per ton. Monensin, 54 to 90 grams, plus bambermycins, 2 grams.

(a) Indications for use. For the prevention of coccidiosis in turkeys caused by E. adenoeides, E. melaggregitits, and E. gallopavonis, and for increased rate of weight gain and improved feed efficiency in growing turkeys.

(b) Limitations. For growing turkeys only. Feed continuously as sole ration. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis. Bambermycins as provided by No. 057926 in §510.600(c) of this chapter.


(a) Indications for use. Improved feed efficiency.

(b) Limitations. (1) Feed only to cattle being fed in confinement for slaughter. Feed continuously in complete feed at a rate of 50 to 360 milligrams of monensin per head per day; as monensin sodium. Complete feeds may be manufactured from monensin liquid Type B feeds. The liquid Type B feeds have a pH of 4.3 to 7.1 and their labels must bear appropriate mixing directions. Mixing directions for liquid Type B feeds stored in recirculating tank systems are: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily, as directed in this paragraph, even when Type B feed is not used. Mixing directions for liquid Type B feeds stored in mechanical, air, or other agitation-type tank systems are: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily, as directed in this paragraph, even when Type B feed is not used. The liquid Type B feed must bear directions to mix thoroughly with grain and/or roughage prior to feeding and must bear caution statements as follows: Inadequate mixing, (recirculation or agitation), of liquid Type B feeds has resulted in increased monensin concentration which has been fatal to cattle.

(2) An approved positionally stable monensin liquid Type B feed will not be subject to the requirements for mixing directions and cautionary labeling prescribed in paragraph (f)(3)(i)(b)(1) of this section. A manufacturer may secure approval of a positionally stable liquid Type B feed by (i) either filing an NADA for the product or by establishing a master file containing data to support the stability of its product; (ii) authorizing the agency to reference and rely upon the data in the master file to support approval of a supplemental NADA to establish positional stability; and (iii) requesting No. 000986 in §510.600(c) of this chapter to file a supplemental NADA to provide for the use of its monensin Type A article in the manufacture of the liquid Type B feed specified in the appropriate master file. If the data demonstrate the stability of the liquid Type B feed described in the master file, the agency will approve the supplemental NADA. Approval of the Type B feed need not be published in the Federal Register because approval will not affect or alter the content of the regulation. The approval will, however, provide a basis for the individual liquid feed manufacturer to submit, and for the agency to approve, a medicated feed application under section 512(m) of the act for the liquid Type B feed. A manufacturer who seeks to market a positionally unstable monensin liquid Type B feed with mixing directions different from the standard established in paragraph (f)(3)(i)(b)(1) of this section may also follow this procedure.

(i) Amount per ton. Monensin, 5 to 30 grams, plus tylosin, 8 to 10 grams.

(a) Indications for use. Improved feed efficiency; for reduction of incidence of liver abscesses caused by Fusobacterium necrophorum and Actinomyces (Corynebacterium) pyogenes.

(b) Limitations. Feed only to cattle being fed in confinement for slaughter. Feed continuously as sole ration at the rate of 50 to 360 milligrams of monensin and 60 to 90 milligrams of tylosin per head per day; as monensin sodium; as tylosin phosphate. Combination drug liquid Type B medicated feeds may be used to manufacture dry
Type C medicated feeds and shall conform to mixing instructions as in §558.625 (c).

(iii) Amount per ton. Monensin, 25 to 400 grams.

(a) Indications for use. For increased rate of weight gain; for prevention and control of coccidiosis due to *Eimeria bovis* and *E. zuernii*.

(b) Limitations. Feed to pasture cattle (slaughtering, stocker, feeder, and dairy and beef replacement heifers). For increased rate of weight gain, feed at a rate of 50 to 200 milligrams monensin per head per day in not less than 1 pound of feed or, after the 5th day, feed at a rate of 400 milligrams per head per day every other day in not less than 2 pounds of feed. For prevention and control of coccidiosis, feed at a rate of 0.14 to 0.42 milligram per pound of body weight per day, depending on severity of challenge, up to 200 milligrams per head per day. During first 5 days of feeding, cattle should receive no more than 100 milligrams per day in not less than 1 pound of feed.

(iv) Amount per ton. Monensin, 5 to 30 grams per ton (to provide 50 to 360 milligrams per head per day), plus melengestrol acetate, 0.25 to 1.6 grams per ton (to provide 0.25 to 0.40 milligram per head per day). See §558.342(c)(2).

(a) Indications for use. For increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).

(b) Limitations. Heifers being fed in confinement for slaughter: Administer melengestrol acetate and monensin by: (1) Adding melengestrol acetate from a separate Type B feed containing 0.125 to 0.8 milligram per pound to Type C medicated feeds containing monensin at 5 to 30 grams per ton, (2) adding melengestrol acetate from a separate Type B feed containing 0.125 to 0.8 milligram per pound and monensin from a separate Type B feed containing 50 to 2,200 grams per ton to Type C medicated feeds, (3) adding melengestrol acetate and monensin which are contained in the same dry Type B feed at the ranges in paragraph (f)(3)(iv)(b) (1) and (2) of this section to Type C medicated feeds, or (4) using a liquid Type B feed containing 0.125 to 0.8 milligram melengestrol acetate per pound and 25 to 600 milligrams monensin per pound (50 to 1,200 grams per ton) to make Type C medicated feeds. Type C medicated feeds in paragraph (f)(3)(iv)(b) (1) and (2) of this section may be manufactured from monensin liquid Type B feeds in accordance with paragraph (f)(3)(i)(b) of this section.

(v) Amount. 150 milligrams per pound (0.033 percent).

(a) Indications for use. For increased rate of weight gain and for prevention and control of coccidiosis caused by *Eimeria bovis* and *E. zuernii*.

(b) Limitations. As protein-mineral blocks to be fed free choice to cattle (slaughtering, stocker, feeder, and dairy and beef replacement heifers) on pasture which may require supplemental feed. Provide 50 to 200 milligrams of monensin (0.34 to 1.33 pounds) per head per day, at least 1 block per 10 to 12 head of cattle. Roughage must be available at all times. Do not allow animals access to other protein blocks, salt or mineral, while being fed this product. Do not allow horses or other equines access to formulations containing monensin (ingestion of monensin by equines has been fatal). Block’s effectiveness in cull cows and bulls has not been established. Approval must comply with §510.455 of this chapter.

(vi) Amount per ton. Monensin, 25 to 400 grams.

(a) Indications for use. For improved feed efficiency; for prevention and control of coccidiosis due to *E. bovis* and *E. zuernii*.

(b) Limitations. Feed to mature reproducing beef cattle. Feed as supplemental feed, either hand-fed in a minimum of 1 pound of feed or mixed in a total ration. For improved feed efficiency, feed continuously at a rate of 50 to 200 milligrams monensin per head per day. For prevention and control of coccidiosis, feed at a rate of 0.14 to 0.42 milligram per pound of body weight per day, depending upon severity of challenge, up to a maximum of 200 milligrams per head per day. During first 5 days of feeding, cattle should receive no more than 100 milligrams per head per day.

(vii) Amount per ton. Monensin, 10 to 30 grams.
(a) **Indications for use.** For improved feed efficiency; for prevention and control of coccidiosis due to *E. bovis* and *E. zuernii*.

(b) **Limitations.** For feedlot cattle, feed continuously to provide 50 to 360 milligrams monensin per head per day. For prevention and control of coccidiosis, feed at a rate of 0.14 to 0.42 milligram per pound of body weight per day, depending upon the severity of challenge, up to maximum of 360 milligrams per head per day.

(viii) **Additional combinations.** Monensin may be used for heifers being fed in confinement for slaughter with melengestrol acetate with or without tylosin as in §558.342.

(ix) **Amount.** To make liquid Type B medicated feed containing 400 grams per ton monensin sodium with 150 grams per ton tylosin phosphate used to make a dry Type C medicated feed containing 21.4 to 26.8 grams per ton monensin plus 8 to 10 grams per ton tylosin.

(a) **Indications for use.** Improved feed efficiency; for reduction of incidence of liver abscesses caused by *Fusobacterium necrophorum* and *Actinomyces (Corynebacterium) pyogenes*.

(b) **Limitations.** Feed only to cattle being fed in confinement for slaughter. Feed continuously at the rate of 8.2 to 10.2 kilograms (18 to 22.5 pounds) of Type C medicated feed per head per day to supply 240 milligrams of monensin and 90 milligrams of tylosin per head per day; as monensin sodium; as tylosin phosphate. Do not allow horses or other equines access to feeds containing monensin. Ingestion of monensin by equines has been fatal. Safe use in unapproved species and breeding cattle has not been established. The liquid Type B medicated feed must bear an expiration date of 14 days after date of manufacture. The mixing directions for this liquid Type B medicated feed stored in recirculation or agitation tank systems are: Recirculate or agitate immediately prior to use for not less than 10 minutes, moving at least 1 percent of the tanks contents per minute from the bottom of the tank to the top. Recirculate or agitate as directed daily, even when the Type B medicated feed is not used. Both an approved NADA and an approved medicated feed application are required to make this liquid Type B medicated feed.

(x) **Amount per ton.** Monensin, 1,620 grams as monensin sodium (810 milligrams per pound).

(a) **Indications for use.** For increased rate of weight gain; and for prevention and control of coccidiosis caused by *Eimeria bovis* and *E. zuernii* in pasture cattle (slaughter, stocker, feeder, and dairy and beef replacement heifers).

(b) **Specifications.** Use as free-choice Type C medicated feed formulated as mineral granules as follows:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent</th>
<th>International feed no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monocalcium phosphate (21% phosphorus, 15% calcium)</td>
<td>29.49</td>
<td>6-01-082</td>
</tr>
<tr>
<td>Sodium chloride (salt)</td>
<td>24.25</td>
<td>6-04-152</td>
</tr>
<tr>
<td>Dried cane molasses</td>
<td>20.0</td>
<td>4-04-695</td>
</tr>
<tr>
<td>Ground limestone (33% calcium) or calcium carbonate (38% calcium)</td>
<td>13.75</td>
<td>6-02-632</td>
</tr>
<tr>
<td>Cane molasses</td>
<td>3.0</td>
<td>4-04-696</td>
</tr>
<tr>
<td>Processed grain by-products (as approved by AAFCO)</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>Vitamin/trace mineral premix</td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>Monensin Type A article, 80 grams per pound</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Antidusting oil</td>
<td>1.0</td>
<td></td>
</tr>
</tbody>
</table>

1Content of the vitamin/trace mineral premix may be varied. However, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. The amount of selenium and ethylenediamine dithyrdioxide (EDDI) must comply with the published requirements. (For selenium see 21 CFR 573.520; for EDDI see 51 FR 11483 (April 3, 1986).)

(c) **Limitations.** For free-choice feeding to pasture cattle (slaughter, stocker, feeder, and dairy and beef replacement heifers) at a rate of 50 to 200 milligrams per head per day. During the first 5 days of feeding, cattle should receive no more than 100 milligrams per day. Do not feed additional salt or minerals. Do not mix with grain or other feeds. Monensin is toxic to cattle when
consumed at higher than approved levels. Stressed and/or feed- and/or water-deprived cattle should be adapted to the pasture and to unmedicated mineral supplement before using the monensin mineral supplement. Do not feed to lactating dairy cattle. The product’s effectiveness in cull cows and bulls has not been established. Consumption by unapproved species may result in toxic reactions. A feed manufacturing facility must possess a medication feed mill license issued under § 515.20 of this chapter in order to manufacture this free-choice Type C feed.

§

§ 558.355

E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; for increased rate of weight gain, and improved feed efficiency.

(b) Limitations. Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. As monensin sodium provided by 000986; bacitracin methylene disalicylate as provided by 046573 in § 510.600(c) of this chapter.

(iii) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin methylene disalicylate, 50 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; and as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.

(b) Limitations. Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. As monensin sodium provided by 000986; bacitracin methylene disalicylate as provided by 046573 in § 510.600(c) of this chapter.

(iv) Limitations. Do not feed to laying chickens; feed continuously as sole ration; as monensin sodium; do not feed to chickens over 16 weeks of age.

(v) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin methylene disalicylate, 100 to 200 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; and as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.

(b) Limitations. Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. To control necrotic enteritis, start medication at first clinical signs of disease; vary dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams per ton). As monensin sodium provided by 000986; bacitracin methylene disalicylate as provided by 046573 in § 510.600(c) of this chapter.
(vi) Amount per ton. Monensin, 90 to 110 grams; bacitracin methylene disalicylate, 50 grams; plus roxarsone, 22.7 to 45.4 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatirix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin; and for increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(b) Limitations. Feed continuously as sole ration. Do not feed to laying chickens. Use as sole source of organic arsenic. Do not feed to chickens over 16 weeks of age. Poultry should have access to drinking water at all times. Drug overdosage or lack of water may result in leg weakness or paralysis. Withdraw 5 days before slaughter. As monensin sodium provided by 000986; bacitracin methylene disalicylate and roxarsone as provided by 046573 in §510.600(c) of this chapter.

(vii) Amount per ton. Monensin, 90 to 110 grams; bacitracin methylene disalicylate, 100 to 200 grams; plus roxarsone, 22.7 to 45.4 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatirix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin; and for increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(b) Limitations. Feed continuously as sole ration. To control necrotic enteritis, start medication at first clinical signs of disease; vary bacitracin dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 gramstons). Do not feed to laying chickens. Use as sole source of organic arsenic. Do not feed to chickens over 16 weeks of age. Poultry should have access to drinking water at all times. Drug overdosage or lack of water may result in leg weakness or paralysis. Withdraw 5 days before slaughter. As monensin sodium provided by 000986; bacitracin methylene disalicylate and roxarsone as provided by 046573 in §510.600(c) of this chapter.

(b) Limitations. Feed continuously as sole ration. Use as sole source of organic arsenic. Withdraw 5 days before slaughter. Do not feed to laying chickens. Do not feed to chickens over 16 weeks of age. Poultry should have access to drinking water at all times. Drug overdosage or lack of water may result in leg weakness or paralysis. As monensin sodium provided by 000986; roxarsone as provided by 046573 in §510.600(c) of this chapter.

(5) Bobwhite quail—(i) Amount per ton. Monensin, 73 grams.

(ii) Indications for use. For the prevention of coccidiosis in growing bobwhite quail caused by Eimeria dispersa and E. Lettyae.

(iii) Limitations. Feed continuously as the sole ration; do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin.


(a) Indications for use. For the prevention of coccidiosis caused by Eimeria crandallis, E. christensenii, and E. ninakohlyakimovae.

(b) Limitations. (1) Feed only to goats being fed in confinement. Do not feed to lactating goats. Feed continuously in Type C feed as monensin sodium. Type C feeds may be manufactured from monensin liquid Type B feeds. The liquid Type B feeds have a pH of 4.3 to 7.1 and their labels must bear appropriate mixing directions. Mixing directions for liquid Type B feeds stored in recirculating tank systems are: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily, as directed in this paragraph, even when Type B feed is not used. Mixing directions for

§ 558.355

Food and Drug Administration, HHS
liquid Type B feeds stored in mechanical, air, or other agitation-type tank systems are: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily, as directed in this paragraph, even when Type B feed is not used. The liquid Type B feed must bear directions to mix thoroughly with grain and/or roughage prior to feeding and must bear caution statement as follows: Inadequate mixing (recirculation or agitation) of liquid Type B feeds has resulted in increased monensin concentration which could be fatal to goats.

(2) An approved positionally stable monensin liquid Type B feed will not be subject to the requirements for mixing directions and cautionary labeling prescribed in paragraph (f)(6)(i)(b) of this section. A manufacturer may secure approval of a positionally stable liquid Type B feed by (i) either filing an NADA for the product or by establishing a master file containing data to support the stability of its product; (ii) authorizing the agency to reference and rely upon the data in the master file to support approval of a supplemental NADA to establish positional stability; and (iii) requesting No. 00096 in §510.600(c) of this chapter to file a supplemental NADA to provide for the use of its monensin Type A article in the manufacture of the liquid Type B feed specified in the appropriate master file. If the data demonstrate the stability of the liquid Type B feed described in the master file, the agency will approve the supplemental NADA. Approval of the Type B feed need not be published in the Federal Register because approval will not affect or alter the content of the regulation. The approval will, however, provide a basis for the individual liquid feed manufacturer to submit, and for the agency to approve, a medicated feed application under section 512(m) of the act for the liquid Type B feed. A manufacturer who seeks to market a positionally unstable monensin liquid Type B feed with mixing directions different from the standard established in paragraph (f)(6)(i)(b) of this section may also follow this procedure.

(2) Limitations.

(7) Monensin may also be used in combination with decoquinate alone or with tylosin as in §558.195.

[40 FR 13959, Mar. 27, 1975]

EDITORIAL NOTE: For Federal Register citations affecting §558.355, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

§558.360 Morantel tartrate.

(a) Approvals. Type A medicated articles: 88 grams per pound to 066104 in §510.600(c) of this chapter.

(b) Related tolerances. See §556.425 of this chapter.

(c) Special considerations. (1) Do not use in Type B or Type C medicated feeds containing bentonite.

(2) Consult your veterinarian before using in severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

(d) Conditions of use—(1) Amount. 0.44 to 4.4 grams of morantel tartrate per pound of feed.

(2) Indications for use—(i) Cattle. For removal and control of mature gastrointestinal nematode infections of cattle including stomach worms (Haemonchus spp., Ostertagia spp., Trichostrongylus spp.), worms of the small intestine (Cooperia spp., Trichostrongylus spp., Nematodirus spp.), and worms of the large intestine (Oesophagostomum radiatum).

(ii) Goats. For removal and control of mature gastrointestinal nematode infections of goats including Haemonchus contortus, Ostertagia (Teladorsagia) circumcincta, and Trichostrongylus axei.

(3) Limitations. Feed as a single therapeutic treatment at 0.44 gram of morantel tartrate per 100 pounds of body weight. Fresh water should be available at all times. When medicated feed is consumed, resume normal feeding. Conditions of constant worm exposure may require retreatment in 2 to 4 weeks. Do not treat cattle within 14 days of slaughter; do not treat goats within 30 days of slaughter.

Food and Drug Administration, HHS

§ 558.363 Narasin.

(a) Approvals. Type A medicated articles containing specified levels of narasin approved for sponsors identified in § 510.600(c) of this chapter for use as in paragraph (d) of this section are as follows:

(1) To 000986: 36, 45, 54, 72, and 90 grams per pound, paragraph (d)(1)(i) of this section.

(2) To 000986: 36, 45, 54, 72, and 90 grams per pound, with 10, 20, 50, and 80 percent roxarsone, paragraph (d)(1)(ii) of this section.

(3) To 000986: 36 grams per pound, with 36 grams per pound nicarbazin, paragraph (d)(1)(iii) of this section.

(4) To 057926: 36, 45, 54, 72, and 90 grams per pound, with 2 and 10 grams per pound bambermycins, paragraph (d)(1)(iv) of this section.

(5) To 057926: 45 grams per pound, with 4 and 10 grams per pound bambermycins, and 45.4, 90, and 227 grams per pound roxarsone, paragraph (d)(1)(vii) of this section.

(6) To 046573: 45 grams per pound with 10, 25, 30, 40, 50, 60, or 75 grams per pound bacitracin methylene disalicylate and 45.4, 90, or 227 grams per pound roxarsone, paragraphs (d)(1)(viii) and (d)(1)(ix) of this section.

(7) To 046573: 36, 45, 54, 72, or 90 grams per pound, with 10, 25, 40, or 50 grams per pound bacitracin zinc, paragraph (d)(1)(x) of this section.

(b) Tolerances. See § 556.428 of this chapter.

(c) [Reserved]

(d) Conditions of use. It is used as follows:

(1) Broiler chickens—(i) Amount per ton. Narasin, 54 to 72 grams.


(B) Limitations. For broiler chickens only. Feed continuously as sole ration. Do not feed to laying hens. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these animals has been fatal. Withdraw 5 days before slaughter. The 2 drugs can be combined only at a 1:1 ratio for the 27 to 45 grams per ton range. Only granular nicarbazin as provided by No. 000986 in § 510.600(c) of this chapter may be used in the combination.

(ii) Amount per ton. Narasin, 27 to 45 grams, plus nicarbazin, 27 to 45 grams.

(A) Indications for use. For prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima, and for increased rate of weight gain and improved feed efficiency.

(B) Limitations. For broiler chickens only. Feed continuously as sole ration. May be fatal if fed to adult turkeys, horses, or other equines.

(v) Amount per ton. Narasin, 54 to 72 grams, roxarsone 22.7 to 45.4 grams, and bacitracin methylene disalicylate 10 to 50 grams.

(A) Indications for use. For prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, and E. mivati, for increased rate of weight gain, and for improved feed efficiency.

(B) Limitations. For broiler chickens only. Feed continuously as sole ration.
Withdraw 5 days before slaughter. Do not feed to laying hens. Use as sole source of organic arsenic. Drug overdose or lack of water may result in leg weakness. Do not allow adult turkeys, horses, or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Narasin as provided by 000986, roxarsone by 046573, bacitracin methylene disalicylate by 046573, in §510.600(c) of this chapter.

(vi) **Amount per ton.** Narasin 54 to 72 grams, and bacitracin methylene disalicylate 10 to 50 grams.

(A) **Indications for use.** For the prevention of coccidiosis caused by *Eimeria acervulina*, *E. brunetti*, *E. maxima*, *E. mivati*, *E. necatrix*, and *E. tenella*, for increased rate of weight gain, and for improved feed efficiency.

(B) **Limitations.** For broiler chickens only. Feed continuously as sole ration. Do not feed to laying hens. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these animals has been fatal. Use as sole source of organic arsenic. Poultry should have access to drinking water at all times. Drug overdose or lack of water intake may result in leg weakness or paralysis. Narasin as provided by 000986, bacitracin methylene disalicylate and roxarsone by 046573 in §510.600(c) of this chapter.

(vii) **Amount per ton.** Narasin 54 to 72 grams, bambermycins 1 to 2 grams, and roxarsone 22.7 to 45.4 grams.

(A) **Indications for use.** For prevention of coccidiosis caused by *Eimeria tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*, as an aid in the control of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin, and for increased rate of weight gain, improved feed efficiency, and improved pigmentation in broiler chickens.

(B) **Limitations.** For broiler chickens only. Feed continuously as sole ration. Do not feed to laying hens. Do not allow adult turkeys or horses or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Narasin as provided by 000986, roxarsone by 046573, in §510.600(c) of this chapter.

(ix) **Amount per ton.** Narasin, 54 to 72 grams, and bacitracin methylene disalicylate, 100 to 200 grams, with roxarsone, 22.7 to 45.4 grams.

(A) **Indications for use.** For prevention of coccidiosis caused by *Eimeria necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*, as an aid in the prevention of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin, and for increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(B) **Limitations.** For broiler chickens only. Feed continuously as sole ration. Withdraw 5 days before slaughter. Do not feed to laying hens. Do not allow adult turkeys, horses, or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Use as sole source of organic arsenic. Poultry should have access to drinking water at all times. Drug overdose or lack of water intake may result in leg weakness or paralysis. Narasin as provided by 000986, bacitracin methylene disalicylate and roxarsone by 046573 in §510.600(c) of this chapter.
(x) Amount per ton. Narasin, 54 to 72 grams and bacitracin zinc, 4 to 50 grams.

(A) Indications for use. For the prevention of coccidiosis caused by *Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati,* and *E. maxima,* and for increased rate of weight gain and improved feed efficiency.

(B) Limitations. For broiler chickens only. Feed continuously as sole ration. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Do not feed to laying hens. Withdraw 5 days before slaughter. Narasin and nicarbazin as provided by 000986, bambermycins by 057926 in §510.600(c) of this chapter.

(2) Narasin may also be used for broilers in combination with:

(i) Nicarbazin with lincomycin as in §558.365.

(ii) Nicarbazin and bacitracin methylene disalicylate as in §558.365.

(iii) Bacitracin methylene disalicylate, nicarbazin, and roxarsone as in §558.366.

(iv) Nicarbazin and roxarsone as in §558.366.

§ 558.364 Neomycin sulfate.

(a) Approvals. Type A medicated article: 325 grams per pound to 000009 in §510.600(c) of this chapter.

(b) Related tolerances. See §556.430 of this chapter.

(c) [Reserved]

(d) Conditions of use. Neomycin sulfate is used as follows:
<table>
<thead>
<tr>
<th>Neomycin Sulfate</th>
<th>Combination</th>
<th>Indications for Use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) 250 to 2,250 grams per ton (g/t) of dry type C feed.</td>
<td>Cattle, swine, sheep, and goats. For treatment and control of colibacillosis (bacterial enteritis) caused by Escherichia coli susceptible to neomycin.</td>
<td>To provide 10 milligrams (mg) of neomycin sulfate per pound of body weight per day for a maximum of 14 days. The concentration of neomycin sulfate required in medicated feed must be adjusted to compensate for variation in age and weight of animal, the nature and severity of disease signs, and environmental temperature and humidity, each of which affects feed consumption. If symptoms persist after using for 2 or 3 days, consult a veterinarian. Treatment should continue 24 to 48 hours beyond remission of disease symptoms. Discontinue treatment prior to slaughter as follows: Cattle 1 day, swine 3 days, sheep 2 days, and goats 3 days. A withdrawal period has not been established for use in preruminating calves. Do not use in calves to be processed for veal. A milk discard time has not been established for use in lactating dairy cattle or lactating dairy goats. Do not use in female dairy cattle 20 months of age or older or female dairy goats 12 months of age or older. For use in dry feeds only. Not for use in liquid feed supplements.</td>
<td>000009</td>
<td></td>
</tr>
</tbody>
</table>
(2) 400 to 2,000 g/l of type C milk replacer.

<table>
<thead>
<tr>
<th>Neomycin Sulfate</th>
<th>Combination</th>
<th>Indications for Use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Do.</td>
<td>To provide 10 mg of neomycin sulfate per pound of body weight per day for a maximum of 14 days. Amount consumed will vary depending on animal’s consumption and weight. If symptoms persist after using for 2 or 3 days, consult a veterinarian. Treatment should continue 24 to 48 hours beyond remission of disease symptoms. Discontinue treatment prior to slaughter as follows: Cattle 1 day, swine 3 days, sheep 3 days, and goats 3 days. A withdrawal period has not been established for use in preruminating calves. Do not use in calves to be processed for veal. A milk discard time has not been established for use in lactating dairy cattle or lactating dairy goats. Do not use in female dairy cattle 20 months of age or older or female dairy goats 12 months of age or older. For use in milk replacers only.</td>
<td>00009</td>
<td></td>
</tr>
</tbody>
</table>


§ 558.365 Nequinate.

(a) Approvals. Type A medicated articles: 4 percent to 017800 in §510.600(c) of this chapter.

(b) Related tolerances. See §556.440 of this chapter.

(c) Special considerations. Do not use in Type B or Type C medicated feeds containing bentonite.

(d) Conditions of use. It is used as follows:

(1) Broiler or fryer chickens—(i) Amount per ton. Nequinate, 18.16 grams. (ii) Indications for use. An aid in the prevention of coccidiosis caused by E. tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mivati. (iii) Limitations. Feed continuously as the sole ration; do not feed to chickens over 16 weeks of age.


§ 558.366 Nicarbazin.

(a) Specifications. Type A medicated articles containing 25 percent nicarbazin.
(b) Approvals. See Nos. 000986, 060728, and 066104 in §510.600(c) of this chapter for use as in paragraph (d) of this section.

<table>
<thead>
<tr>
<th>Nicarbazin in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 to 45</td>
<td>Narasin 27 to 45</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, <em>E. mivati</em>.</td>
<td>Feed continuously as sole ration. Withdraw 5 days before slaughter. Do not allow turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Do not feed to laying hens. Narasin and nicarbazin as provided by 000986, bacitracin methylene disalicylate by 046573.</td>
<td>000986</td>
</tr>
<tr>
<td></td>
<td>27 to 45 and bacitracin methylene disalicylate 4 to 50.</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, <em>E. mivati</em>. for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. Withdraw 5 days before slaughter. Do not allow turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Do not feed to laying hens. Use as sole source of organic arsenic. Narasin and nicarbazin as provided by 000986, lincomycin by 000009.</td>
<td>046573</td>
</tr>
<tr>
<td>27 to 45, bacitracin methylene disalicylate 50, and roxarsone 22.7 to 45.4.</td>
<td>Narasin 27 to 45, bacitracin methylene disalicylate 50, and roxarsone 22.7 to 45.4.</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, <em>E. mivati</em>. as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin, for increased rate of weight gain, improved feed efficiency, and improved pigmentation.</td>
<td>Feed continuously as sole ration. Withdraw 5 days before slaughter. Do not allow turkeys, horses, or other equines access to feeds containing lincomycin. Ingestion by these species may result in severe gastrointestinal effects. Narasin and nicarbazin as provided by 000986, lincomycin by 000009.</td>
<td>000986</td>
</tr>
<tr>
<td>27 to 45 and Lincomycin 2 to 4.</td>
<td>Narasin 27 to 45 and Lincomycin 2 to 4.</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, <em>E. mivati</em>. for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. Use as sole source of organic arsenic. Withdraw 5 days before slaughter. Do not allow turkeys, horses, or other equines access to formulations containing lincomycin. Ingestion of narasin by these species has been fatal. Do not feed to laying hens. Use as sole source of organic arsenic. Narasin and nicarbazin as provided by 000986, roxarsone by 046573.</td>
<td>000986</td>
</tr>
<tr>
<td>Nicobarz in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>113.5 (0.0125 pct)</td>
<td>-------------------------------</td>
<td>Chickens; aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 4 days before slaughter.</td>
<td>000986 060728 066104</td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate 30.</td>
<td>Broiler chickens; aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis; for increased rate of weight gain and improved feed efficiency.</td>
<td>For broiler chickens only. Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Discontinue medication 4 days before marketing the birds for human consumption to allow for elimination of the drug from edible tissue. Do not feed to laying hens in production. Nicobarz in as provided by 066104, bacitracin zinc by 046573..</td>
<td>066104</td>
<td></td>
</tr>
<tr>
<td>Bacitracin zinc 4 to 50.</td>
<td>Broiler chickens; aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 4 days before slaughter.</td>
<td>057926</td>
<td></td>
</tr>
<tr>
<td>Bambermycins 1 to 2.</td>
<td>Broiler chickens; aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 4 days before slaughter. Nicobarz in as provided by 066104.</td>
<td>060728 066104</td>
<td></td>
</tr>
<tr>
<td>Lincomycin 2 (0.00044 pct).</td>
<td>Broiler chickens; aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis; for increased rate of weight gain.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 4 days before slaughter.</td>
<td>060728 066104</td>
<td></td>
</tr>
<tr>
<td>Roxarsone 22.7 (0.0025)</td>
<td>do ...............................................</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; as sole source of organic arsenic; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 5 days before slaughter.</td>
<td>060728 066104</td>
<td></td>
</tr>
<tr>
<td>Roxarsone 22.7 (0.0025) plus lincomycin 2 (0.0004).</td>
<td>do ...............................................</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 5 days before slaughter.</td>
<td>060728 066104</td>
<td></td>
</tr>
</tbody>
</table>

441
§ 558.369 Nitarsone.

(a) Approvals. Type A medicated articles: 50 percent to 046573 in § 510.600(c) of this chapter.
(b) Related tolerances. See § 556.60 of this chapter.
(c) [Reserved]
(d) Conditions of use. It is used as follows:
(1) Chickens and turkeys.—(i) Amount. Nitarsone, 0.01875 percent.
(ii) Indications for use. As an aid in the prevention of blackhead.
(iii) Limitations. Early medication is essential to prevent spread of disease. Adequate drinking water must be provided near feeder at all times. The drug is not effective in preventing blackhead in birds infected more than 4 or 5 days. Discontinue use 5 days before slaughtering animals for human consumption to allow elimination of the drug from edible tissues. The drug is dangerous for ducks, geese, and dogs. Overdosage or lack of water may result in leg weakness or paralysis. Use as sole source of arsenic.
(2) Turkeys.—(i) Amount. Nitarsone 0.01875 percent, plus bacitracin methylene disalicylate 4 to 50 grams per ton.
(ii) Indications for use. As an aid in the prevention of blackhead, and for increased rate of weight gain and improved feed efficiency.
(iii) Limitations. For growing turkeys. Feed continuously as sole ration. Early medication is essential to prevent spread of disease. Adequate drinking water must be provided near feeders at all times. Overdosage or lack of water may result in leg weakness or paralysis. The drug is not effective in preventing blackhead in birds infected more than 4 or 5 days. Discontinue use 5 days before slaughtering animals for human consumption to allow elimination of the drug from edible tissues. The drug is dangerous for ducks, geese, and dogs. Use as sole source of arsenic.

§ 558.376 Nitromide and sulfanitran.

(a) Approvals. Type A medicated articles: 25 percent nitromide, 30 percent sulfanitran, with or without 5 percent roxarsone to 053501 in § 510.600(c) of this chapter.
(b) Related tolerances. See §§ 556.220 and 556.680 of this chapter.
(c) Conditions of use. It is used for chickens as follows:
(1) Amount. 227 grams per ton nitromide (0.025 percent) and 272 grams per ton sulfanitran (0.03 percent).
(ii) Indications for use. As an aid in the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, and E. acervulina.
(iii) Limitations. Not to be fed to laying chickens; withdraw 5 days before slaughter; from Type A articles containing not more than 25 percent nitromide and 30 percent sulfanitran.
(2) Amount. 227 grams per ton nitromide (0.025 percent) and 272 grams per ton sulfanitran (0.03 percent), plus 45.4 grams per ton roxarsone (0.005 percent).
(i) Indications for use. Prevention of coccidiosis caused by Eimeria tenella, E. necatrix, and E. acervulina; growth promotion and feed efficiency; improving pigmentation.
(ii) Limitations. Not to be fed to laying chickens; withdraw 5 days before slaughter; from Type A articles containing not more than 25 percent nitromide, 30 percent sulfanitran, and 5 percent roxarsone; as sole source of organic arsenic.

§ 558.415 Novobiocin.

(a) Approvals. Type A medicated articles: 25 grams of activity per pound to 000009 in § 510.600(c) of this chapter. Type B medicated feeds: 17.5 grams per pound to 000009 in § 510.600(c) of this chapter.
(b) Related tolerances. See § 556.460 of this chapter.
(c) Conditions of use. It is used in animal feeds as follows:
(1) **Chickens**—(i) **Amount.** Novobiocin, 6–7 mgs. per lb. body weight per day.  
(a) **Indications for use.** Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin.  
(b) **Limitations.** Administer, as sole ration, feed which contains not less than 200 grams of novobiocin activity per ton of feed; not for laying chickens; feed 5 to 7 days; withdraw 4 days before slaughter.

(i) **Amount.** Novobiocin, 10–14 mgs. per lb. body weight per day.  
(a) **Indications for use.** Treatment of staphylococcal synovitis and generalized staphylococcal infections susceptible to novobiocin.  
(b) **Limitations.** Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(ii) **Amount.** Novobiocin, 4–5 mgs. per lb. body weight per day.  
(a) **Indications for use.** Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin.  
(b) **Limitations.** Administer, as sole ration, feed which contains not less than 200 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(ii) **Amount.** Novobiocin, 5–8 mgs. per lb. body weight per day.  
(a) **Indications for use.** Aid in the control of recurring outbreaks of fowl cholera caused by strains of *Pasteurella multocida* susceptible to novobiocin following initial treatment with 7–8 mgs. per pound body weight per day.  
(b) **Limitations.** Administer, as sole ration, feed which contains not less than 200 grams of novobiocin activity per ton of feed; feed 5 to 7 days; not for laying turkeys; withdraw 4 days before slaughter.

(iii) **Amount.** Novobiocin, 7–8 mgs. per lb. body weight per day.  
(a) **Indications for use.** Treatment of staphylococcal synovitis and generalized staphylococcal infection susceptible to novobiocin; treatment of acute outbreaks of fowl cholera caused by strains of *Pasteurella multocida* susceptible to novobiocin.

(b) **Limitations.** Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; feed 5 to 7 days; not for laying turkeys; withdraw 4 days before slaughter.

(i) **Indications for use.** For treatment of generalized infections, abscesses, or urinary infections caused by staphylococcal or other novobiocin sensitive organisms.

(iii) **Limitations.** Administer, as sole ration, feed which contains not less than 200 grams of novobiocin activity per ton of feed; feed for 7 days.

(iv) **Ducks**—(i) **Amount.** Novobiocin, 100 grams per ton.  
(ii) **Indications for use.** Control of infectious serositis and fowl cholera in ducks caused by *Pasteurella anatipestifer* and *P. multocida*, susceptible to novobiocin.

(iii) **Limitations.** Administer, as sole ration, for 5 to 7 days, continue medication for 14 days if necessary, repeat if reinfection occurs; discontinue use at least 3 days before slaughter; not for use in laying ducks.


## §558.430 Nystatin

(a) **Approvals.** Type A medicated articles: 20 grams of activity per pound to 046573 in §510.600(c) of this chapter.

(b) **Related tolerances.** See §556.470 of this chapter.

(c) **Conditions of use.** It is used for chickens and turkeys as follows:

(1) **Amount.** 50 grams per ton.  
(i) **Indications for use.** Chickens and turkeys; aid in control of crop mycosis and mycotic diarrhea (*Candida albicans*).

(ii) **Limitations.** Growing and laying chickens; growing turkeys.

(2) **Amount.** 100 grams per ton.  
(i) **Indications for use.** Chickens and turkeys; treatment of crop mycosis and mycotic diarrhea (*Candida albicans*).
§ 558.435 Oleandomycin.

(a) Approvals. Type A medicated articles: 5 grams of activity per pound to 066104 in §510.600(c) of this chapter.

(b) Related tolerances. See §556.480 of this chapter.

(c) Special considerations. Do not use bentonite in Type B or Type C medicated feeds containing oleandomycin. Oleandomycin refers to oleandomycin or feed-grade oleandomycin.

(d) Conditions of use. It is used in animal feed as follows:

(1) Chickens and turkeys—(i) Amount per ton. Oleandomycin, 1 to 2 grams.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency for broiler chickens and growing turkeys.

(2) Swine—(i) Amount per ton. Oleandomycin, 5 to 11.25 grams.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency in growing-finishing swine.

§ 558.450 Oxytetracycline.

(a) Approvals. Type A medicated articles:

(1) 10, 20, 30, 50, 100, and 200 grams per pound to 066104 in §510.600(c) of this chapter.

(2) 50 and 100 grams per pound to 053389 in §510.600(c) of this chapter.

(b) Special considerations. (1) In accordance with §558.5 labeling shall bear the statement: “FOR USE IN DRY ANIMAL FEED ONLY. NOT FOR USE IN LIQUID FEED SUPPLEMENTS.”

(2) The articles in paragraph (a)(1) of this section contain an amount of mono-alkyl (C₈–C₁₈) trimethylammonium oxytetracycline expressed in terms of an equivalent amount of oxytetracycline hydrochloride or an amount of oxytetracycline dihydrate base expressed in terms of an equivalent amount of oxytetracycline hydrochloride.

(3) The articles in paragraph (a)(2) of this section contain an amount of mono-alkyl (C₈–C₁₈) trimethylammonium oxytetracycline expressed in terms of an equivalent amount of oxytetracycline hydrochloride.

(c) Related tolerances. See §556.500 of this chapter.

(d)(1) Conditions of use. It is used in feed as follows:

<table>
<thead>
<tr>
<th>Oxytetracycline amount</th>
<th>Combination</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10 to 20 grams per ton (g/ton)</td>
<td>Sheep; increased rate of weight gain and improved feed efficiency.</td>
<td>066104, 053389</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ii) 10 to 50 g/ton</td>
<td>1. Chickens; increased rate of weight gain and improved feed efficiency.</td>
<td>Do.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Growing turkeys; increased rate of weight and improved feed efficiency.</td>
<td>Do.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Swine; increased rate of weight and improved feed efficiency.</td>
<td>Do.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(iii) 100 g/ton</td>
<td>Turkeys; control of hexamitiasis caused by Hexamita meleagridis susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 days (d); do not feed to turkeys producing eggs for human consumption.</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td>Oxytetracycline amount</td>
<td>Combination</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>(iv) 100 to 200 g/ton</td>
<td>Chickens; control of infectious synovitis caused by Mycoplasma synoviae; control of fowl cholera caused by Pasteurella multocida susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to chickens producing eggs for human consumption; in low calcium feed, withdraw 3 d before slaughter.</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td>(v) 200 g/ton</td>
<td>Turkeys; control of infectious synovitis caused by <em>M. synoviae</em> susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; withdraw 5 d before slaughter; do not feed to turkeys producing eggs for human consumption.</td>
<td>066104, 053389</td>
<td></td>
</tr>
<tr>
<td>(vi) 400 g/ton</td>
<td>Chickens; control of chronic respiratory disease (CRD) and air sac infection caused by <em>M. gallisepticum</em> and <em>Escherichia coli</em> susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to chickens producing eggs for human consumption; in low calcium feeds, withdraw 3 d before slaughter.</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td>(vi) 500 g/ton</td>
<td>Chickens; reduction of mortality due to air sacculitis (air-sac-infection) caused by <em>E. coli</em> susceptible to oxytetracycline.</td>
<td>Feed continuously for 5 d; do not feed to chickens producing eggs for human consumption; withdraw 24 hours before slaughter; in low calcium feeds withdraw 3 d before slaughter.</td>
<td>066104, 053389</td>
<td></td>
</tr>
<tr>
<td>(vii) 40 to 60 g/ton</td>
<td>Chickens; reduction of mortality due to air sacculitis (air-sac-infection) caused by <em>E. coli</em> susceptible to oxytetracycline; prevention of coccidiosis caused by <em>E. necatrix</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>.</td>
<td>Feed continuously for 7 to 14 d; do not feed to chickens producing eggs for human consumption; in low calcium feed, withdraw 3 d before slaughter.</td>
<td>066104, 053389</td>
<td></td>
</tr>
<tr>
<td>(viii) 0.05 to 0.1 milligram/pound (mg/lb) of body weight daily.</td>
<td>Calves (up to 250 lb); for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously; in milk replacers or starter feed.</td>
<td>066104, 053389</td>
<td></td>
</tr>
<tr>
<td>(ix) 10 mg/lb of body weight daily.</td>
<td>1. Calves and beef and nonlactating dairy cattle; treatment of bacterial enteritis caused by <em>E. coli</em> and bacterial pneumonia (shipping fever complex) caused by <em>P. multocida</em> susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; in feed or milk replacers; withdraw 5 d before slaughter.</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Calves (up to 250 lb); treatment of bacterial enteritis caused by <em>E. coli</em> susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; in milk replacers or starter feed; withdraw 5 d before slaughter.</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Sheep; treatment of bacterial enteritis caused by <em>E. coli</em> and bacterial pneumonia caused by <em>P. multocida</em> susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; withdraw 5 d before slaughter.</td>
<td>Do.</td>
<td></td>
</tr>
</tbody>
</table>
## TABLE 1—Continued

<table>
<thead>
<tr>
<th>Oxytetracycline amount</th>
<th>Combination</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Swine; treatment of bacterial enteritis caused by <em>E. coli</em> and <em>Salmonella choleraesuis</em> susceptible to oxytetracycline and treatment of bacterial pneumonia caused by <em>P. multocida</em> susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; withdraw 5 d before slaughter.</td>
<td>Do.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Breeding swine; control and treatment of leptospirosis (reducing the incidence of abortion and shedding of leptospires) caused by <em>Leptospira pomona</em> susceptible to oxytetracycline.</td>
<td>Feed continuously for not more than 14 d; withdraw 5 d before slaughter.</td>
<td>Do.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(x) 25 mg/lb of body weight</td>
<td>Turkeys; control of complicating bacterial organisms associated with bluecomb (transmissible enteritis; coronaviral enteritis) susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; withdraw 5 d before slaughter; do not feed to turkeys producing eggs for human consumption.</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td>(xi) 25 mg/head/day</td>
<td>Calves (250 to 400 lb); increased rate of weight gain and improved feed efficiency.</td>
<td>.................................</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td>(xii) 75 mg/head/day</td>
<td>Growing cattle (over 400 lb); increased rate of weight gain; improved feed efficiency, and reduction of liver condemnation due to liver abscesses.</td>
<td>.................................</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td>(xiii) 0.5 to 2.0 g/head/day</td>
<td>Cattle; prevention and treatment of the early stages of shipping fever complex.</td>
<td>Feed 3 to 5 d before and after arrival in feedlots.</td>
<td>Do.</td>
<td></td>
</tr>
<tr>
<td>(xiv) 200 mg/colony</td>
<td>Honey bees; control of American foulbrood caused by <em>Bacillus larvae</em> and European foulbrood caused by <em>Streptococcus pluton</em> susceptible to oxytetracycline.</td>
<td>Remove at least 6 weeks prior to main honey flow.</td>
<td>Do.</td>
<td></td>
</tr>
</tbody>
</table>

(2) It is used in fish feed as follows:

## TABLE 2

<table>
<thead>
<tr>
<th>Oxytetracycline amount</th>
<th>Combination</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 250 mg/kilogram of fish/ d (11.35 g/100 lb of fish/ d).</td>
<td>Pacific salmon for marking of skeletal tissue.</td>
<td>For salmon not over 30 g body weight; administer as sole ration for 4 consecutive days in feed containing oxytetracycline hydrochloride or mono-alkyl (C8–C18) trimethyl ammonium oxytetracycline; fish not to be liberated for at least 7 d following the last administration of medicated feed.</td>
<td>066104</td>
<td></td>
</tr>
</tbody>
</table>
TABLE 2—Continued

<table>
<thead>
<tr>
<th>Oxytetracycline amount</th>
<th>Combination</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ii) 2.5 to 3.75 g/100 lb of fish/d.</td>
<td>1. Salmonids; control of ulcer disease caused by <em>Hemophilus piscium</em>, furunculosis caused by <em>Aeromonas salmonicida</em>, bacterial hemorrhagic septicemia caused by <em>A. liquefaciens</em>, and pseudomonas disease.</td>
<td>Administer as mono-alkyl <em>(C₈–C₁₈)</em> trimethyl ammonium oxytetracycline in mixed ration for 10 d; do not liberate fish or slaughter fish for food for 21 d following the last administration of medicated feed; do not administer when water temperature is below 9°C (48.2°F).</td>
<td>066104</td>
<td></td>
</tr>
<tr>
<td>(iii) 1 g/lb of medicated feed.</td>
<td>Lobsters; control of gaffkemia caused by <em>Aerococcus viridans</em>.</td>
<td>Administer as sole ration for 5 consecutive days in feed containing monoalkyl <em>(C₈–C₁₈)</em> trimethyl ammonium oxytetracycline; withdraw medicated feed 30 d before harvesting lobsters.</td>
<td>066104</td>
<td></td>
</tr>
</tbody>
</table>

(3) Oxytetracycline may be used in accordance with the provisions of this section in the combinations provided as follows:

(i) Robenidine hydrochloride in accordance with §558.515.

(ii) Lasalocid as in §558.311.

(iii) Melengestrol acetate as in §558.342.


$\textbf{§558.460 Penicillin.}$

(a) Specifications. As penicillin procaine G or feed grade penicillin procaine.

(b) Sponsors. Type A medicated articles: To 066104, 100 and 227 grams per pound. To 046573, 100 and 227 grams per pound.

(c) Related tolerances. See §556.510 of this chapter.

(d) Conditions of use. (1) It is used as follows:

<table>
<thead>
<tr>
<th>Penicillin in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 2.4 to 50 ............</td>
<td>..................................</td>
<td>Chickens, turkeys, and pheasants; for increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to poultry producing eggs for human consumption.</td>
<td>000069, 046573.</td>
</tr>
<tr>
<td>(ii) 5 to 20 ............</td>
<td>..................................</td>
<td>Quail; for increased rate of weight gain and improved feed efficiency.</td>
<td>Quail; not over 5 weeks of age.</td>
<td>Do.</td>
</tr>
<tr>
<td>(iii) 10 to 50 ............</td>
<td>..................................</td>
<td>Swine; for increased rate of weight gain and improved feed efficiency.</td>
<td>........................................</td>
<td>Do.</td>
</tr>
</tbody>
</table>
§ 558.464 Penicillin may be used in accordance with the provisions of this section in the combinations provided as follows:

(i) Amprolium in accordance with § 558.55.
(ii) Amprolium plus ethopatbate in accordance with § 558.58.
(iii) Roxarsone and zoalene in accordance with § 558.680.
(iv) Zoalene in accordance with § 558.680.

§ 558.465 Poloxalene free-choice liquid Type C feed.

(a) Approvals. Type A medicated articles: 99.5 percent to 000069 in § 510.600(c) of this chapter.

(b) Conditions of use. (1) For control of legume (alfalfa, clover) and wheat pasture bloat in cattle, use 7.5 grams of poloxalene per pound of liquid Type C feed (1.65 percent weight/weight). Each animal must consume 0.2 pound of Type C feed per 100 pounds of body weight daily for adequate protection. If consumption exceeds 0.2 pound of Type C feed per 100 pounds of body weight daily, cattle should be changed to a Type C feed containing 7.5 grams of poloxalene per pound.

(3) Poloxalene liquid Type A article must be thoroughly blended and evenly distributed into a liquid Type C feed and offered to cattle in a covered liquid Type C feed feeder with lick wheels. The formula for the liquid Type C feed, on a weight/weight basis, is as follows: Ammonium polyphosphate 2.66 percent, phosphoric acid (75 percent) 3.37 percent, sulfuric acid 1.00 percent, water 10.00 percent, and molasses sufficient to make 100.00 percent, vitamins A and D and/or trace minerals may be added. One free-turning lick wheel per 25 head of cattle must be provided.

(4) The medicated liquid Type C feed must be introduced at least 2 to 5 days before legume consumption to custom the cattle to the medicated liquid Type C feed and to lick wheel feedings. If the medicated liquid wheel Type C feed feeding is interrupted, this 2- to 5-day introductory feeding should be repeated.
§ 558.485 Pyrantel tartrate.

(a) Specifications. Type A medicated articles containing 9.6, 19.2, 48, or 80 grams per pound pyrantel tartrate.

(b) Approvals. See sponsors in §510.600(c) of this chapter for uses as in paragraph (e) of this section:

(1) No. 066104: 9.6, 19.2, and 80 grams per pound for use as in paragraph (e)(1) of this section.

(2) No. 001800: 9.6 grams per pound for use as in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(3) Nos. 010439, 011490, 017473, 017519, 017790, 017800, 017825, 043733, 049685, 050568, 050639, and 051359: 9.6 and 19.2 grams per pound for use as in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(4) No. 021676: 19.2 grams per pound for use as in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(5) No. 017800: 19.2 and 48 grams per pound for use as in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(6) Nos. 034936 and 046987: 9.6 and 19.2 grams per pound for use as in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(7) Nos. 000069, 017135, and 062240: 48 grams per pound for use as in paragraph (e)(2) of this section.

(c) Related tolerances. See §556.560 of this chapter.

(d) Special considerations. (1) See §500.25 of this chapter. Consult a veterinarian before using in severely debilitated animals.

(2) Do not mix in Type B or Type C medicated feeds containing bentonite.

(e) Conditions of use. It is used as follows:

(1) Swine—(i) Amount per ton. 96 grams (0.0106 percent).

(A) Indications for use. Aid in the prevention of migration and establishment of large roundworm (Ascaris suum) infections; aid in the prevention of establishment of nodular worm (Oesophagostomum) infections.

(B) Limitations. Feed for 3 days as the sole ration in a Type C feed; withdraw 24 hours prior to slaughter.

(ii) Amount per ton. 800 grams (0.0881 percent).

(A) Indications for use. For the removal and control of large roundworm (Ascaris suum) infections.

(B) Limitations. Feed for 3 days as the sole ration in a Type C feed; withdraw 24 hours prior to slaughter.

(iii) Amount per ton. 800 grams (0.0881 percent).

(A) Indications for use. For the removal and control of large roundworm (Ascaris suum) infections.

(B) Limitations. As sole ration for a single therapeutic treatment in Type C feed; feed at the rate of 1 lb of feed per 40 lb of body weight for animals up to 200 lb, and 5 lb of feed per head for animals 200 lb or over; withdraw 24 hours prior to slaughter.

(iv) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) and carbadox, 50 grams (0.0055 percent).

(A) Indications for use. For control of swine dysentery (vibrionic dysentery, bloody scour or hemorrhagic dysentery); control of bacterial swine enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis); aid in the prevention of migration and establishment of large roundworm (Ascaris suum) infections; aid in the prevention of establishment of nodular worm (Oesophagostomum) infections.

(B) Limitations. Do not feed to swine weighing over 75 pounds; do not feed within 10 weeks of slaughter; consult a veterinarian before feeding to severely debilitated animals; feed continuously as sole ration. Do not use in Type C feeds containing less than 15 percent crude protein.

(v) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) and tylosin, 40 to 100 grams, as tylosin phosphate.

(A) Indications for use. For prevention of swine dysentery (vibrionic); aid in the prevention of migration and establishment of large roundworms (Ascaris suum) infections; aid in the prevention of establishment of nodular worm (Oesophagostomum spp.) infections.

(B) Limitations. Use 100 grams tylosin per ton for at least 3 weeks followed by 40 grams tylosin per ton until market weight; withdraw 24 hours before slaughter. Consult your veterinarian before feeding to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

(vi) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) and
tylosin 40 to 100 grams, as tylosin phosphate.

(A) Indications for use. Treatment and control of swine dysentery (vibrionic); aid in the prevention of migration and establishment of large roundworm (Ascaris suum) infections; aid in the prevention of establishment of nodular worm (Oesophagostomum spp.) infections.

(B) Limitations. Administer tylosin in feed as tylosin phosphate after treatment with tylosin in drinking water as tylosin base; 0.25 grams per gallon in drinking water for 3 to 10 days; 40 to 100 grams tylosin per ton in feed for 2 to 6 weeks; withdraw 24 hours before slaughter. Consult your veterinarian before feeding to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

(vii) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) and lincomycin, 40 grams, as lincomycin hydrochloride monohydrate.

(A) Indications for use. For control of swine dysentery: aid in the prevention of migration and establishment of large roundworm (Ascaris suum) infections; aid in the prevention of establishment of nodular worm (Oesophagostomum spp.) infections.

(B) Limitations. Feed as sole ration; for use in swine on premises with a history of swine dysentery but where symptoms have not yet occurred; not to be fed to swine that weigh more than 250 pounds; withdraw 6 days before slaughter. Consult your veterinarian before feeding to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

(viii) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) and lincomycin, 100 grams, then 40 grams, as lincomycin hydrochloride monohydrate.

(A) Indications for use. For treatment and control of swine dysentery: aid in the prevention of migration and establishment of large roundworm (Ascaris suum) infections; aid in the prevention of establishment of nodular worm (Oesophagostomum spp.) infections.

(B) Limitations. Feed 100 grams per ton 3 weeks or until signs of disease disappear, followed by 40 grams per ton; feed as sole ration; not to be fed to swine that weigh more than 250 pounds; withdraw 6 days before slaughter. Consult your veterinarian before feeding to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

(x) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) and lincomycin, 100 or 40 grams.

(A) Indications for use. For treatment and/or control of swine dysentery; for removal and control of large roundworm (Ascaris suum) infections.

(B) Limitations. Administer in accordance with paragraph (c)(2)(i), (c)(2)(ii), or (c)(2)(iii) of §558.325 and paragraph (e)(3)(i)(B) of this section.

(xi) Amount per ton. Pyrantel tartrate, 800 grams (0.0881 percent) and lincomycin, 100 or 40 grams.

(A) Indications for use. For treatment and/or control of swine dysentery; for removal and control of large roundworm (Ascaris suum) and nodular worm (Oesophagostomum spp.) infections.

(B) Limitations. Administer in accordance with paragraph (c)(2)(i), (c)(2)(ii), or (c)(2)(iii) of §558.325 and paragraph (e)(3)(i)(B) of this section.

(xii) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) and lincomycin, 200 grams as lincomycin hydrochloride monohydrate.

(A) Indications for use. For the reduction in severity of swine mycoplasma pneumonia caused by Mycoplasma
Food and Drug Administration, HHS  § 558.500

hyo pneumoniae; aid in the prevention of migration and establishment of large roundworms (Ascaris suum) infections; aid in the prevention of establishment of nodular worm (Oesophagostomum spp.) infections.

(B) Limitations. Feed as sole ration for 21 days; not to be fed to swine that weigh more than 250 pounds; withdraw 6 days before slaughter; consult your veterinarian before feeding to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

(C) Sponsor. See No. 000009 in §510.600(c) of this chapter.

(2) Horses—(i) Amount. Feed continuously at the rate of 1.2 milligrams per pound (2.64 milligrams per kilogram) of body weight.

(A) Indications for use. Prevention of Strongylus vulgaris larval infections; control of adult large strongyles (S. vulgaris, and S. edentatus), adult and 4th stage larvae small strongyles (Cyathostomum spp., Cylicocyclus spp., Cylicostephanus spp., Cylicodontophorus spp., Poteriostomum spp., and Triodontophorus spp.), adult and 4th stage larvae pinworms (Oxyuris equi), and adult and 4th stage larvae ascarids (Parascaris equorum).

(B) Limitations. Administer either as a top-dress (not to exceed 20,000 grams per ton) or mixed in the horse’s daily grain ration (not to exceed 1,200 grams per ton) during the time that the animal is at risk of exposure to internal parasites. Not for use in horses intended for food. Consult your veterinarian before using in severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

(ii) [Reserved]

[40 FR 13959, Mar. 27, 1975]

EDITORIAL NOTE: For Federal Register citations affecting §558.485, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

§ 558.500 Ractopamine.

(a) Approvals. Type A medicated articles: 9 grams of ractopamine hydrochloride per pound to 000986 in §510.600(c) of this chapter.

(b) [Reserved]

(c) Related tolerances. See §556.570 of this chapter.

(d) Conditions of use—(1) Swine.

<table>
<thead>
<tr>
<th>Ractopamine in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 4.5 ................</td>
<td>..........................</td>
<td>For increased rate of weight gain, improved feed efficiency, and increased carcass leanness.</td>
<td>Feed continuously as sole ration. Feed in a complete ration containing at least 16 percent crude protein to finishing swine from 150 to 240 pounds body weight. Not for use in breeding swine.</td>
<td>000986</td>
</tr>
<tr>
<td>(ii) 4.5 to 18 ....</td>
<td>..........................</td>
<td>For improved feed efficiency and increased carcass leanness.</td>
<td>Feed continuously as sole ration. Feed in a complete ration containing at least 16 percent crude protein to finishing swine from 150 to 240 pounds body weight. Not for use in breeding swine.</td>
<td>000986</td>
</tr>
<tr>
<td>(iii) 4.5 ..........</td>
<td>Tylosin 100 ......</td>
<td>For increased rate of weight gain, improved feed efficiency, and increased carcass leanness; and for prevention and/or control of porcine proliferative enteropathies (ileitis) associated with Lawsonia intracellularis.</td>
<td>Feed continuously as sole ration for 21 days. Feed in a complete ration containing at least 16 percent crude protein to finishing swine from 150 to 240 pounds body weight. Not for use in breeding swine.</td>
<td>000986</td>
</tr>
<tr>
<td>(iv) 4.5 to 18 ....</td>
<td>Tylosin 100 ......</td>
<td>For improved feed efficiency and increased carcass leanness; and for prevention and/or control of porcine proliferative enteropathies (ileitis) associated with Lawsonia intracellularis.</td>
<td>Feed continuously as sole ration for 21 days. Feed in a complete ration containing at least 16 percent crude protein to finishing swine from 150 to 240 pounds body weight. Not for use in breeding swine.</td>
<td>000986</td>
</tr>
</tbody>
</table>
§ 558.515 Robenidine hydrochloride.

(a) Approvals. Type A medicated articles; 30 grams per pound to 046573 in §510.600(c) of this chapter.

(b) Special considerations. Type C feed containing robenidine hydrochloride must be fed within 50 days from the date of manufacture. Do not use in Type B or Type C medicated feeds containing bentonite.

(c) Related tolerances. See §556.580 of this chapter.

(d) Conditions of use. It is used in feed for chickens as follows:

<table>
<thead>
<tr>
<th>Robenidine hydrochloride in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 (0.0033 pct)</td>
<td></td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>.</td>
<td>Feed continuously as sole ration. Do not feed to layers. Withdraw 5 days prior to slaughter.</td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td>Bacitracin (as bacitracin methylene disalicylate) 4 to 30.</td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For improved feed efficiency.</td>
<td>Feed continuously as sole ration. Do not feed to laying chickens. Withdraw 5 days prior to slaughter.</td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td>Bacitracin (as bacitracin methylene disalicylate) 27 to 50.</td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For increased rate of weight gain.</td>
<td>Feed continuously as sole ration. Do not feed to laying chickens. Withdraw 5 days prior to slaughter.</td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td>Bacitracin (as bacitracin methylene disalicylate) 50 and roxarsone 22.7 to 45.4.</td>
<td>For broiler chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For an aid in the prevention of necrotic enteritis caused or complicated by <em>Clostridium</em> spp. or other organisms susceptible to bacitracin. For increased rate of weight gain, improved feed efficiency, and improved pigmentation...</td>
<td>Feed continuously as sole ration. Use as the sole source of organic arsenic; poultry should have access to water at all times; drug overdose or lack of water intake may result in leg weakness or paralysis. Do not feed to laying chickens. Withdraw 5 days prior to slaughter...</td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td>Bacitracin (as bacitracin methylene disalicylate) 100 to 200 and roxarsone 22.7 to 45.4.</td>
<td>For broiler chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. As an aid in the control of necrotic enteritis caused or complicated by <em>Clostridium</em> spp. or other organisms susceptible to bacitracin. For increased rate of weight gain, improved feed efficiency, and improved pigmentation...</td>
<td>To control necrotic enteritis, start medication at first clinical signs of disease; vary bacitracin dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 g/ton). Use as the sole source of organic arsenic; poultry should have access to water at all times; drug overdose or lack of water intake may result in leg weakness or paralysis. Do not feed to laying chickens. Withdraw 5 days prior to slaughter...</td>
<td>046573</td>
</tr>
<tr>
<td></td>
<td>Bacitracin (as bacitracin zinc) 4 to 30.</td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For increased rate of weight gain.</td>
<td>Feed continuously as sole ration. Do not feed to laying chickens. Withdraw 5 days prior to slaughter...</td>
<td>046573</td>
</tr>
</tbody>
</table>
Food and Drug Administration, HHS  § 558.530

<table>
<thead>
<tr>
<th>Robenidine hydrochloride in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. Do not feed to laying chickens. Withdraw 5 days prior to slaughter..</td>
<td>046573</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacitracin (as bacitracin zinc) 27 to 50.</td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For control of chronic respiratory disease (CRD) and air sac infection caused by <em>M. gallisepticum</em> and <em>E. coli</em> susceptible to chlorotetracycline.</td>
<td>Feed continuously as sole ration up to 14 days. Do not feed to chickens producing eggs for human consumption. Withdraw 5 days prior to slaughter..</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Chlorotetracycline 100 to 200.</td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For control of infectious synovitis caused by <em>Mycoplasma synoviae</em> susceptible to chlorotetracycline.</td>
<td>Feed continuously as sole ration up to 14 days. Do not feed to chickens producing eggs for human consumption. Withdraw 5 days prior to slaughter..</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Chlorotetracycline 200 to 400.</td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For control of infectious synovitis caused by <em>Mycoplasma synoviae</em> susceptible to chlorotetracycline.</td>
<td>Feed continuously as sole ration up to 14 days. Do not feed to chickens producing eggs for human consumption. Withdraw 5 days prior to slaughter..</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Chlorotetracycline 500.</td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. As an aid in the reduction of mortality due to <em>E. coli</em> susceptible to chlorotetracycline.</td>
<td>Feed continuously as sole ration up to 5 days. Do not feed to chickens producing eggs for human consumption. Withdraw 5 days prior to slaughter..</td>
<td>000009</td>
<td></td>
</tr>
<tr>
<td>Lincomycin 2 ....</td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For increased rate of weight gain and improved feed efficiency..</td>
<td>Feed continuously as the sole ration. Do not feed to laying hens. Withdraw 5 days before slaughter..</td>
<td>066104</td>
<td></td>
</tr>
<tr>
<td>Oxytetracycline 400.</td>
<td>For broiler chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For control of CRD and air sac infection caused by <em>Mycoplasma gallisepticum</em> and <em>E. coli</em> susceptible to oxytetracycline..</td>
<td>Feed continuously for 7 to 14 days. Do not feed to chickens producing eggs for human consumption. Withdraw 5 days before slaughter..</td>
<td>046573</td>
<td></td>
</tr>
<tr>
<td>Roxarsone 22.5 to 45.4 (0.005 percent),</td>
<td>For broiler and fryer chickens: As an aid in the prevention of coccidiosis caused by <em>E. mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>. For increased rate of weight gain..</td>
<td>Feed continuously as the sole ration. Use as sole source of organic arsenic. Do not feed to layers. Withdraw 5 days prior to slaughter..</td>
<td>046573</td>
<td></td>
</tr>
</tbody>
</table>

§ 558.530 Roxarsone.

(a) Approvals. Type A medicated articles: 10, 20, 50, and 80 percent to 046573 in §510.600(c) of this chapter for use in paragraphs (d)(1) through (d)(4) of this section.

(b) Related tolerances. See §556.60 of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Growing chickens and growing turkeys—(1) Grams per ton. Roxarsone 22.7 and 45.4 (0.0025 to 0.005 percent).

(ii) Indications for use. For increased rate of weight gain, improved feed efficiency, and improved pigmentation.
(iii) Limitations. Withdraw 5 days before slaughter; as sole source of organic arsenic; drug overdose or lack of water may result in leg weakness; feed continuously throughout growing period.

(2) Growing chickens—(i) Grams per ton. Roxarsone, 22.7 to 45.4 (0.0025 to 0.005 percent) plus chlortetracycline, 10 to 50.

(A) Indications for use. For increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(B) Limitations. Do not feed to chickens producing eggs for human consumption; withdraw 5 days before slaughter; as sole source of organic arsenic; drug overdose or lack of water may result in leg weakness; feed continuously throughout growing period.

(ii) Grams per ton. Roxarsone 22.7 to 45.4 (0.0025 to 0.005 percent) plus chlortetracycline 100 to 200.

(A) Indications for use. For increased rate of weight gain, improved feed efficiency, and improved pigmentation; control of infectious synovitis caused by *Mycoplasma synoviae* susceptible to chlortetracycline.

(B) Limitations. See paragraph (d)(2)(i)(B) of this section except feed continuously for 7 to 14 days.

(iii) Grams per ton. Roxarsone 22.7 to 45.4 (0.0025 to 0.005 percent) plus chlortetracycline, 400.

(A) Indications for use. For increased rate of weight gain, improved feed efficiency, and improved pigmentation; control of hexamitiasis caused by *Hexamita meleagrides* susceptible to chlortetracycline. Turkey poults not over 4 weeks of age: Reduction of mortality due to paratyphoid caused by *Salmonella typhimurium* susceptible to chlortetracycline.

(B) Limitations. See paragraph (d)(3)(i)(B) of this section except that the drug should only be fed continuously for 7 to 14 days.

(iv) Amount. Roxarsone 22.7 to 45.4 grams per ton (0.0025 to 0.005 percent) plus chlortetracycline, 25 milligrams per pound of body weight daily.

(A) Indications for use. For increased rate of weight gain, improved feed efficiency, and improved pigmentation; control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis) susceptible to chlortetracycline.

(B) Limitations. See paragraph (d)(3)(i)(B) of this section except that the drug should only be fed continuously for 7 to 14 days.
(4) Growing-finishing swine—(i) Grams per ton. Roxarsone 22.7 to 34.1 (0.0025 to 0.00375 percent).

   (A) Indications for use. For increased rate of weight gain and improved feed efficiency.

   (B) Limitations. Withdraw 5 days before slaughter; as sole source of organic arsenic; feed continuously throughout growing season.

   (ii) Grams per ton. Roxarsone 22.7 to 34.1 (0.0025 to 0.00375 percent) plus chlortetracycline, 400 (to administer 10 milligrams per pound of body weight).

   (A) Indications for use. For increased rate of weight gain and improved feed efficiency; treatment of bacterial enteritis caused by E. coli and S. choleraesuis and bacterial pneumonia caused by P. multocida susceptible to chlortetracycline.

   (B) Limitations. Withdraw 5 days before slaughter; as sole source of organic arsenic; feed for not more than 14 days.

   (iii) Grams per ton. Roxarsone 181.5 (0.02 percent).

   (A) Indications for use. For the treatment of swine dysentery.

   (B) Limitations. Feed for not more than 6 consecutive days; if improvement is not observed, consult a veterinarian; withdraw 5 days before slaughter; as a sole source or organic arsenic; animals must consume enough medicated feed to provide a therapeutic dose.

   (iv) Grams per ton. Roxarsone, 181.5 (0.02 percent) plus chlortetracycline, 10 to 50.

   (A) Indications for use. For the treatment of swine dysentery; increased rate of weight gain and improved feed efficiency.

   (B) Limitations. See paragraph (d)(4)(ii)(B) of this section.

   (v) Grams per ton. Roxarsone, 181.5 (0.02 percent) plus chlortetracycline, 400.

   (A) Indications for use. For the treatment of swine dysentery; treatment of bacterial enteritis caused by E. coli and S. choleraesuis and bacterial pneumonia caused by P. multocida susceptible to chlortetracycline.

   (B) Limitations. See paragraph (d)(4)(iii)(B) of this section.

   (5) Permitted combinations. It may be used in accordance with this section in combination with:

   (i) Aklomide as in §558.35.

   (ii) Amprolium as in §558.55.

   (iii) Amprolium and ethopabate as in §558.58.

   (iv) Bacitracin methylene disalicylate as in §558.76.

   (v) Bacitracin zinc as in §558.78.

   (vi) Bambermycins and bambermycins plus certain anticoccidials as in §558.95.

   (vii) Chlortetracycline as in §558.128.

   (viii) Clopidol as in §558.175.

   (ix) Decoquinate alone or in combination as in §558.195.

   (x) [Reserved]

   (xi) Halofuginone alone or in combination as in §558.265.

   (xii) Lasalocid alone or in combination as in §558.311.

   (xiii) Monensin alone or in combination as in §558.355.

   (xiv) Narasin alone or in combination as in §558.363.

   (xv) Nequinate as in §558.365.

   (xvi) Nicarbazin alone or in combination as in §558.366.

   (xvii) Nitromide and sulfanitran as in §558.376.

   (xviii) Penicillin and zoalene as in §558.680.

   (xix) Robenidine hydrochloride as in §558.515.

   (xx) Salinomycin alone or in combination as in §558.550.

   (xxi) Sulfadimethoxine, ormetoprim as in §558.575.

   (xxii) Zoalene alone or in combination as in §558.680.


§ 558.550 Salinomycin.

(a) Approvals. Type A medicated articles containing 30 or 60 grams of salinomycin activity per pound (as salinomycin sodium biomass) as follows:

   (1) To 046573 in §510.600(c) of this chapter for use as in paragraph (d) of this section.

   (2) To 057926 for use as in paragraphs (d)(1)(i), (d)(1)(ii) through (d)(1)(xvi), and (d)(3)(i) of this section.
§ 558.550

(b)-(c) [Reserved]

(d) Conditions of use. (1) Broilers: It is used as follows:

(i) (a) Amount per ton. Salinomycin 40 to 60 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*.

(c) Limitations. Feed continuously as sole ration. Do not feed to layers. Not approved for use with pellet binders. May be fatal if accidentally fed to adult turkeys or horses. Withdraw 5 days before slaughter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(ii) (a) Amount per ton. Salinomycin 40 to 60 grams and roxarsone 22.7 to 45.4 grams per ton.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati* and for improved feed efficiency.

(c) Limitations. Feed continuously as sole ration. Use as sole source of organic arsenic. Not approved for use with pellet binders. Do not feed to layers. May be fatal if accidentally fed to adult turkeys or horses. Withdraw 5 days before slaughter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(iii) (a) Amount per ton. Salinomycin 40 to 60 grams and bacitracin methylene disalicylate 4 to 30 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati* for increased rate of weight gain and improved feed efficiency.

(c) Limitations. Feed continuously as sole ration. Not approved for use with pellet binders. Do not feed to layers. May be fatal if accidentally fed to adult turkeys or horses. Bacitracin methylene disalicylate as provided by No. 046573 in §510.600(c) of this chapter.

(iv) (a) Amount per ton. Salinomycin 40 to 60 grams and bacitracin zinc 10 to 50 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, and for increased rate of weight gain.

(c) Limitations. Feed continuously as sole ration. Not approved for use with pellet binders. Do not feed to layers. May be fatal if accidentally fed to adult turkeys or horses. Bacitracin zinc as provided by No. 046573 in §510.600(c) of this chapter.

roxarsone combined with salinomycin than to salinomycin alone; for increased rate of weight gain.

(c) Limitations. Feed continuously as sole ration. Use as sole source of organic arsenic. Not approved for use with pellet binders. Do not feed to layers. May be fatal if accidentally fed to adult turkeys or horses. Withdraw 5 days before slaughter. Roxarsone and bacitracin as provided by No. 046573 in §510.600(c) of this chapter.

(v) (a) Amount per ton. Salinomycin 40 to 60 grams per ton with roxarsone 45.4 grams per ton.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati* and for improved feed efficiency.

(c) Limitations. Feed continuously as sole ration. Use as sole source of organic arsenic. Not approved for use with pellet binders. Do not feed to layers. May be fatal if accidentally fed to adult turkeys or horses. Withdraw 5 days before slaughter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(vi) (a) Amount per ton. Salinomycin 40 to 60 grams and bacitracin methylene disalicylate 4 to 50 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati* and for improved feed efficiency.

(c) Limitations. Feed continuously as sole ration. Use as sole source of organic arsenic. Not approved for use with pellet binders. Do not feed to layers. May be fatal if accidentally fed to adult turkeys or horses. Bacitracin MD as provided by No. 046573 in §510.600(c) of this chapter.

(vii) (a) Amount per ton. Salinomycin 40 to 60 grams and bacitracin methylene disalicylate 4 to 50 grams.
(viii) (a) Amount per ton. Salinomycin 40 to 60 grams with roxarsone 45.4 grams and bacitracin zinc 4 to 50 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, including some field strains of *E. tenella* which are more susceptible to roxarsone combined with salinomycin than to salinomycin alone; for increased rate of weight gain and improved feed efficiency.

(c) Limitations. See paragraph (d)(1)(iv)(c) of this section.

(ix) (a) Amount per ton. Salinomycin 40 to 60 grams with roxarsone 34.1 grams and bacitracin zinc 10 to 50 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, and for increased rate of weight gain and improved feed efficiency.

(c) Limitations. Feed continuously as sole ration. Use as sole source of organic arsenic. Do not feed to layers. May be fatal if accidentally fed to adult turkeys or horses. Withdraw 5 days before slaughter. Roxarsone as provided by No. 046573 and bacitracin as provided by No. 046573 in §510.600(c) of this chapter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(x) (a) Amount per ton. Salinomycin 40 to 60 grams and virginiamycin 5 to 15 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, and for improved feed efficiency.

(c) Limitations. Feed continuously as sole ration. Not approved for use with pellet binders. Do not feed to layers. May be fatal if accidentally fed to adult turkeys or horses. Virginiamycin as provided by No. 046573 in §510.600(c) of this chapter.

(xi) (a) Amount per ton. Salinomycin 40 to 60 grams and lincomycin 2 to 4 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati* and for improved feed efficiency.

(c) Limitations. Feed continuously as sole ration. Not approved for use with pellet binders. Do not feed to layers. Do not allow horses, adult turkeys, guinea pigs, rabbits, hamsters, or ruminants access to this feed. Ingestion by these species may result in severe gastrointestinal effects or may be fatal. Lincomycin hydrochloride monohydrate as provided by No. 000009 in §510.600(c) of this chapter.

(xii) (a) Amount per ton. Salinomycin 40 to 60 grams, roxarsone 45.4 grams, and lincomycin 2 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati* that are more susceptible to roxarsone combined with salinomycin than to salinomycin alone, and for improved feed efficiency.

(c) Limitations. Feed continuously as sole ration. Not approved for use with pellet binders. Drug overdose or lack of water may result in leg weakness. Do
not feed to layers. Do not allow horses, adult turkeys, guinea pigs, rabbits, hamsters, or ruminants access to this feed. Ingestion by these species may result in severe gastrointestinal effects or may be fatal. Withdraw 5 days before slaughter. Roxarsone hydrochloride monohydrate as provided by No. 000009 in §510.600(c) of this chapter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(b) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, including some field strains of *E. tenella* which are more susceptible to roxarsone combined with salinomycin than to salinomycin alone; for increased rate of weight gain. Use of 34.1 or 45.4 grams per ton roxarsone is indicated to meet the *E. tenella* challenge which varies with environmental and management conditions.

(c) Limitations. Do not feed to layers. Do not allow horses, adult turkeys, guinea pigs, rabbits, hamsters, or ruminants access to this feed. Ingestion by these species may result in severe gastrointestinal effects or may be fatal. Withdraw 5 days before slaughter. Lincomycin hydrochloride monohydrate as provided by No. 000009 in §510.600(c) of this chapter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(d) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, including some field strains of *E. tenella* which are more susceptible to roxarsone combined with salinomycin than to salinomycin alone; for increased rate of weight gain. Use of 34.1 or 45.4 grams per ton roxarsone is indicated to meet the *E. tenella* challenge which varies with environmental and management conditions.

(e) Limitations. Do not allow horses, adult turkeys, guinea pigs, rabbits, hamsters, or ruminants access to this feed. Ingestion by these species may result in severe gastrointestinal effects or may be fatal. Withdraw 5 days before slaughter. Roxarsone hydrochloride monohydrate as provided by No. 000009 in §510.600(c) of this chapter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(f) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, including some field strains of *E. tenella* which are more susceptible to roxarsone combined with salinomycin than to salinomycin alone; for increased rate of weight gain. Use of 34.1 or 45.4 grams per ton roxarsone is indicated to meet the *E. tenella* challenge which varies with environmental and management conditions.

(g) Limitations. Do not allow horses, adult turkeys, guinea pigs, rabbits, hamsters, or ruminants access to this feed. Ingestion by these species may result in severe gastrointestinal effects or may be fatal. Withdraw 5 days before slaughter. Roxarsone hydrochloride monohydrate as provided by No. 000009 in §510.600(c) of this chapter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(h) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, including some field strains of *E. tenella* which are more susceptible to roxarsone combined with salinomycin than to salinomycin alone; for increased rate of weight gain. Use of 34.1 or 45.4 grams per ton roxarsone is indicated to meet the *E. tenella* challenge which varies with environmental and management conditions.

(i) Limitations. Do not allow horses, adult turkeys, guinea pigs, rabbits, hamsters, or ruminants access to this feed. Ingestion by these species may result in severe gastrointestinal effects or may be fatal. Withdraw 5 days before slaughter. Roxarsone hydrochloride monohydrate as provided by No. 000009 in §510.600(c) of this chapter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(j) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, including some field strains of *E. tenella* which are more susceptible to roxarsone combined with salinomycin than to salinomycin alone; for increased rate of weight gain. Use of 34.1 or 45.4 grams per ton roxarsone is indicated to meet the *E. tenella* challenge which varies with environmental and management conditions.

(k) Limitations. Do not allow horses, adult turkeys, guinea pigs, rabbits, hamsters, or ruminants access to this feed. Ingestion by these species may result in severe gastrointestinal effects or may be fatal. Withdraw 5 days before slaughter. Roxarsone hydrochloride monohydrate as provided by No. 000009 in §510.600(c) of this chapter. Roxarsone as provided by No. 046573 in §510.600(c) of this chapter.

(l) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, including some field strains of *E. tenella* which are more susceptible to roxarsone combined with salinomycin than to salinomycin alone; for increased rate of weight gain. Use of 34.1 or 45.4 grams per ton roxarsone is indicated to meet the *E. tenella* challenge which varies with environmental and management conditions.
roxarsone, 22.7 to 45.4 grams.

(B) Indications for use. For the prevention of coccidiosis caused by *E. tenella*, *E. necatrix*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*, as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin, for increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(C) Limitations. Feed continuously as sole ration. To control necrotic enteritis, start medication at first clinical signs of disease; vary dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams per ton). Do not feed to laying chickens. May be fatal if fed to adult turkeys or to horses. Salinomycin as provided by 046573; bacitracin methylene disalicylate as provided by 046573 in §510.600(c) in this chapter.

(2) Quail—(a) Amount per ton. Salinomycin 50 grams.

(b) Indications for use. For the prevention of coccidiosis caused by *E. dispersa* and *E. lettyae*.

(c) Limitations. Feed continuously as sole ration. Not approved for use with pellet binders. May be fatal if accidentally fed to adult turkeys or horses.

(ii) [Reserved]

(3) Roaster and replacement (breeder and layer) chickens: It is used as follows:

(i) (A) Amount per ton. Salinomycin 40 to 60 grams.

(B) Indications for use. For prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*.

(C) Limitations. Feed continuously as sole ration. Do not feed to laying hens producing eggs for human consumption. Not approved for use with pellet binders. May be fatal if accidentally fed to horses or adult turkeys.

(ii) Amount per ton. Salinomycin, 40 to 60 grams, and bacitracin methylene disalicylate, 4 to 50 grams.

(A) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*; bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter.
(iii) Amount per ton. Salinomycin, 40 to 60 grams, and bacitracin methylene disalicylate, 50 grams.

(A) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, and as an aid in the prevention of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin.

(B) Limitations. Feed continuously as sole ration. To control necrotic enteritis, start medication at first clinical signs of disease; vary dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams per ton). Discontinue use prior to sexual maturity. Do not feed to laying chickens. May be fatal if fed to adult turkeys or to horses. Salinomycin as provided by No. 046573; bacitracin methylene disalicylate as provided by No. 046573 in §510.600(c) of this chapter.

(iv)(A) Amount per ton. Salinomycin, 40 to 60 grams; and roxarsone, 22.7 to 45.4 grams.

(B) Indications for use. For the prevention of coccidiosis caused by *E. tenella*, *E. necatrix*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*, as an aid in the prevention of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin, for increased rate of weight gain, improved feed efficiency, and improved pigmentation.

(C) Limitations. Feed continuously as sole ration. Discontinue use prior to sexual maturity. Do not feed to laying chickens. Use as sole source of organic arsenic. Poultry should have access to drinking water at all times. Drug overdose or lack of water intake may result in leg weakness or paralysis. May be fatal if fed to adult turkeys or to horses. Withdraw 5 days before slaughter. Salinomycin as provided by No. 046573; bacitracin methylene disalicylate and roxarsone as provided by No. 046573 in §510.600(c).

(v) Amount per ton. Salinomycin, 40 to 60 grams; and roxarsone, 22.7 to 45.4 grams.

(A) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, and as an aid in the control of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin.

(B) Limitations. Feed continuously as sole ration. To control necrotic enteritis, start medication at first clinical signs of disease; vary dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams per ton). Discontinue use prior to sexual maturity. Do not feed to laying chickens. May be fatal if fed to adult turkeys or to horses. Salinomycin as provided by No. 046573; bacitracin methylene disalicylate as provided by No. 046573 in §510.600(c) of this chapter.
feed efficiency, and improved pigmentation.

(B) Limitations. Feed continuously as sole ration. Discontinue use prior to sexual maturity. Do not feed to laying chickens. Use as sole source of organic arsenic. Poultry should have access to drinking water at all times. Drug overdosage or lack of water intake may result in leg weakness or paralysis. May be fatal if fed to adult turkeys or to horses. Withdraw 5 days before slaughter. Semduramicin as provided by No. 066104 in §510.600(c) of this chapter, bacitracin methylene disalicylate and roxarsone as provided by No. 046573 as in §558.450.

(4) Permitted combinations. Semduramicin may be used as in this section in combinations as follows:
(i) Bambermycins and roxarsone as in §558.95.
(ii) Bambermycins as in §558.95.
(iii) Oxytetracycline as in §558.450.

§ 558.555 Semduramicin.

(a) Specifications. Type A medicated article containing 22.7 grams per pound (50 grams per kilogram) semduramicin sodium.

(b) Approvals. See No. 066104 in §510.600(c) of this chapter for use as in paragraph (d) of this section.

(c) Related tolerances. See §556.597 of this chapter.


(iii) Limitations. Do not feed to laying hens.

(2) Amount. Semduramicin 22.7 grams with bacitracin methylene disalicylate 10 to 50 grams and roxarsone 45.4 grams per ton.

(i) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. acervulina, E. maxima, E. brunetti, E. necatrix, and E. mivati/E. mitis, and for improved feed efficiency in broiler chickens.

(ii) Limitations. Feed continuously as sole ration. Use within 2 weeks of production. Do not feed to laying hens. Use as sole source of organic arsenic. Roxyarsone as provided by 046573, semduramicin as provided by 066104, bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter.

(3) Amount. Semduramicin 22.7 grams with bacitracin methylene disalicylate 10 to 50 grams per ton.

(i) Indications for use. For the prevention of coccidiosis caused by Eimeria acervulina, E. brunetti, E. maxima, E. mivati/E. mitis, E. necatrix, and E. tenella, and for improved feed efficiency in broiler chickens.

(ii) Limitations. Feed continuously as sole ration. Use within 2 weeks of production. Do not feed to laying hens. Semduramicin as provided by 066104, bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter.

(4) Amount. Semduramicin 22.7 grams with roxarsone 45.4 grams per ton.

(i) Indications for use. For the prevention of coccidiosis caused by Eimeria acervulina, E. brunetti, E. maxima, E. mivati/E. mitis, E. necatrix, and E. tenella, that are more susceptible to semduramicin combined with roxarsone than semduramicin alone.

(ii) Limitations. Feed continuously as sole ration. Withdraw 5 days before slaughter. For broiler chickens only. Do not feed to laying hens. Use as sole source of organic arsenic. Roxyarsone as provided by 046573, semduramicin as provided by 066104 in §510.600(c) of this chapter.

(5) Amount. Semduramicin 22.7 grams with virginiamycin 20 grams per ton.

(i) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. acervulina, E. maxima, E. brunetti, E. necatrix, and E. mivati/mitis, and for prevention of necrotic enteritis caused by Clostridium perfringens susceptible to virginiamycin.
§ 558.575 Sulfadimethoxine, ormetoprim.

(a) Approvals. Type A medicated articles to sponsors as identified in §510.600(c) of this chapter for uses as in paragraph (d) of this section as follows:

(1) 25 percent sulfadimethoxine and 15 percent ormetoprim to 0.0125 percent plus ormetoprim, 68.1 grams (0.0075 percent).—

(b) Limitations. For broiler chickens only. Feed continuously as sole ration. Do not feed to laying hens. Sulfadimethoxine and virginiamycin as provided by 066104 in §510.600(c) of this chapter.

(b) Limitations. For broiler chickens only. Feed continuously as sole ration. Do not feed to laying hens. Sulfadimethoxine and virginiamycin as provided by 066104 in §510.600(c) of this chapter.

(2) 25 percent sulfadimethoxine and 5 percent ormetoprim to 0.0125 percent plus ormetoprim, 68.1 grams (0.0075 percent).—

(c) Related tolerances. See §§556.490 and 556.640 of this chapter.

(1) Broiler chickens—(i) Amount per ton. Sulfadimethoxine, 113.5 grams (0.0125 percent) plus ormetoprim, 68.1 grams (0.0075 percent).

(b) Limitations. Feed as sole ration; withdraw 5 days before slaughter. (ii) Amount per ton. Sulfadimethoxine, 113.5 grams (0.0125 percent) plus ormetoprim, 68.1 grams (0.0075 percent) plus roxarsone, 22.7 grams (0.0025 percent).

(b) Limitations. Withdraw 5 days before slaughter; as sole source of organic arsenic.

(2) Replacement chickens—(i) Amount per ton. Sulfadimethoxine, 113.5 grams (0.0125 percent) plus ormetoprim, 68.1 grams (0.0075 percent) plus roxarsone, 22.7 grams (0.0025 percent).—

(ii) Indications for use. As an aid in the prevention of coccidiosis caused by all Eimeria species known to be pathogenic to chickens, namely, E. tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima, and bacterial infections due to H. gallinarum (infectious coryza), E. coli (coli bacillosis) and P. multocida (fowl cholera).—

(2) Turkeys—(i) Amount per ton. Sulfadimethoxine, 56.75 grams (0.00625 percent) plus ormetoprim, 34.05 grams (0.00375 percent).
(i) **Indications for use.** As an aid in the prevention of coccidiosis caused by all *Eimeria* species known to be pathogenic to turkeys, namely, *E. adenoideides*, *E. gallopavonis*, and *E. meleagrimitis* and bacterial infection due to *P. multocida* (fowl cholera).

(ii) **Limitations.** Do not feed to turkeys producing eggs for food; withdraw 5 days before slaughter.

(4) **Ducks**—(i) **Amount per ton.** Sulfadimethoxine, 227 grams (0.025 percent) plus ormetoprim, 136.2 grams (0.015 percent).

(b) **Limitations.** Feed as sole ration for 7 days; withdraw 5 days before slaughter; medication should be started at the first signs of infection; do not feed to ducks producing eggs for food.

(ii) **Amount per ton.** Sulfadimethoxine, 454 grams (0.05 percent) plus ormetoprim, 272.4 grams (0.03 percent).

(b) **Limitations.** Feed as sole ration for 7 days; withdraw 5 days before slaughter; medication should be started at the first signs of infection; do not feed to ducks producing eggs for food.

(5) **Salmonids**—(i) **Amount.** 50 milligrams of active ingredients per kilogram of body weight per day.

(ii) **Indications of use.** For the control of furunculosis in salmonids (trout and salmon) caused by *Aeromonas salmonicida* strains susceptible to sulfadimethoxine and ormetoprim combination.

(iii) **Limitations.** Administer for 5 consecutive days; withdraw 3 days before slaughter or release as stocker fish.

(7) **Chukar partridges**—(i) **Amount per ton.** Sulfadimethoxine 113.5 grams (0.0125 percent) plus ormetoprim 68.1 grams (0.0075 percent).

(ii) **Indications for use.** For prevention of coccidiosis caused by *Eimeria kofoidi* and *E. legionensis*.

(iii) **Limitations.** Feed continuously to young birds up to 8 weeks of age as sole ration.

§ 558.579 Sulfathoxyppryridazine.

(a) **Approvals.** Type A medicated articles: 5.5 percent for swine, and 5.5 and 11 percent for cattle to 010042 in § 510.600(c) of this chapter.

(b) **Related tolerances.** See § 556.650 of this chapter.

(c) **Conditions of use.** It is used in animal feed as follows:

(1) **Swine**—(i) **Amount.** 25 milligrams per pound body weight per day.

(ii) **Indications for use.** For treatment of bacterial scour, pneumonia, enteritis, bronchitis, septicaemia accompanying *Salmonella choleraesuis* infection.

(iii) **Limitations.** Administer 1.000 grams per ton (0.11 percent) for not less than 4 days nor more than 10 days; do not treat within 10 days of slaughter; as sole source of sulfonamide; for use by or on the order of a licensed veterinarian.

(2) **Cattle**—(i) **Amount.** 25 milligrams per pound body weight per day.

(ii) **Indications for use.** For treatment of respiratory infections (pneumonia, shipping fever), foot rot, calf scour; as adjunctive therapy in septicemia accompanying mastitis and metritis.

(iii) **Limitations.** Administer as a top dressing or in mixed feed for 4 days; do not treat within 16 days of slaughter; as sole source of sulfonamide; milk that has been taken from animals during treatment and for 72 hours (6 milkings) after the latest treatment.
§ 558.582 Sulfamerazine.
(a) Approvals. Type A medicated articles: 99 percent to 046573 in § 510.600(c) of this chapter.
(b) Related tolerances. See § 556.660 of this chapter.
(c) Conditions of use. It is used in fish feed for rainbow trout, brook trout, and brown trout as follows:
(1) Amount. 10 grams of sulfamerazine per 100 pounds of fish per day.
(2) Indications for use. Control of furunculosis.
(3) Limitations. Treat for not more than 14 days; do not treat within 3 weeks of marketing or stocking in stream open to fishing.

§ 558.586 Sulfaquinoxoline.
(a) Approvals. Type A medicated articles: 40 percent to 050749 in § 510.600(c) of this chapter.
(b) [Reserved]
(c) [Reserved]
(d) NAS/NRC status. The conditions of use specified in this section have been reviewed by NAS/NRC and are found effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency information. Applications must be accompanied by a written commitment to undertake the human safety studies required by FDA.
(e) Special considerations. (1) For control of outbreaks of disease, medication should be initiated as soon as the diagnosis is determined. Medicated chickens, turkeys, and rabbits must actually consume enough medicated feed which provides a recommended dose of approximately 3.5 to 60 milligrams per pound per day in chickens, 2.5 to 100 milligrams per pound per day in turkeys, and 2.8 to 68 milligrams per pound per day in rabbits depending upon age and class of animal, ambient temperature, and other factors. Consult a veterinarian or poultry pathologist for diagnosis.
(f) Conditions of use. It is used as follows:
(1) Chickens—(i) Amount. 0.015 percent.
(a) Indications for use. As an aid in preventing outbreaks of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, and E. brunetti under average conditions of exposure.
(b) Limitations. Feed continuously from the time birds are placed on litter and continue past the age when coccidiosis is ordinarily a hazard. If death losses exceed 0.5 percent in a 2-day period, obtain a laboratory diagnosis. If coccidiosis is the cause, use the sulfaquinoxaline levels recommended for control of outbreaks, returning to the original dosage schedule after the outbreak has subsided. Losses may result from intercurrent disease, other conditions affecting drug intake, or variant strains of coccidia species which can contribute to the virulence of coccidiosis under field conditions. Do not treat chickens within 10 days of slaughter. Do not medicate chickens producing eggs for human consumption.
(ii) Amount. 0.0175 percent.
(a) Indications for use. As an aid in preventing outbreaks of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, and E. brunetti where excessive exposure to coccidia is increased due to overcrowding or other management factors.
(b) Limitations. Feed continuously from the time birds are placed on litter and continue past the age when coccidiosis is ordinarily a hazard. If death losses exceed 0.5 percent in a 2-day period, obtain a laboratory diagnosis. If coccidiosis is the cause, use the sulfaquinoxaline levels recommended for control of outbreaks, returning to the original dosage schedule after the outbreak has subsided. Losses may result from intercurrent disease, other conditions affecting drug intake, or variant strains of coccidia species which can contribute to the virulence of coccidiosis under field conditions. Do not treat chickens within 10 days of slaughter. Do not medicate chickens producing eggs for human consumption.
(iii) Amount. 0.1 to 0.05 percent.
Food and Drug Administration, HHS

§ 558.600 Tiamulin.

(a) Specifications. Type A article containing 5, 10, or 113.4 grams of tiamulin (as tiamulin hydrogen fumarate) per pound.

(b) Approvals. See No. 000010 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.738 of this chapter.

(d) Special considerations—(1) Swine being treated with tiamulin should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin, or semduramycin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.

(2) Not for use in swine weighing over 250 pounds.

(3) Use as sole source of tiamulin.

(e) Conditions of use—(1) Swine. It is used as follows:

(a) Indications for use. As an aid in controlling outbreaks of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, and E. brunetti.

(b) Limitations. Feed 0.1 percent for 48 to 72 hours. Mortality should be brought under control. After medication, move birds to clean ground or to a clean house. If disease recurs, use 0.05 percent in feed again for 2 days. Do not treat chickens or turkeys within 10 days of slaughter for feed. Do not medicate chickens or turkeys producing eggs for human consumption.

(ii) [Reserved]

(4) Rabbits—(i) Amount. 0.025 percent.

(a) Indications for use. As an aid in preventing coccidiosis caused by Eimeria stiedae.

(b) Limitations. Treatment to be started after weaning. Feed continuously for 30 days or feed medicated feed for 2 days out of every week until marketing. Do not treat within 10 days of slaughter.

(ii) Amount. 0.05 percent.

(a) Indications for use. As an aid in controlling outbreaks of coccidiosis caused by Eimeria meleagritis and E. adenoeides.

(b) Limitations. Feed 0.0175 percent continuously during time birds are closely confined. May be continued for week to 10 days after flock is transferred to range to reduce danger of an outbreak following moving of the flock. Do not treat turkeys within 10 days of slaughter. Do not medicate turkeys producing eggs for human consumption.

(ii) Amount. 0.05 percent.

(a) Indications for use. As an aid in controlling outbreaks of acute fowl cholera caused by Pasteurella multocida susceptible to sulfaquinoxaline and fowl typhoid caused by Salmonella gallinarum susceptible to sulfaquinoxaline.

(b) Limitations. Feed 0.1 percent for 48 to 72 hours. Mortality should be brought under control. After medication, move birds to clean ground or to a clean house. If disease recurs, use 0.05 percent in feed again for 2 days. Do not treat chickens or turkeys within 10 days of slaughter for feed. Do not medicate chickens or turkeys producing eggs for human consumption.

(ii) [Reserved]

(4) Rabbits—(i) Amount. 0.025 percent.

(a) Indications for use. As an aid in preventing coccidiosis caused by Eimeria stiedae.

(b) Limitations. Treatment to be started after weaning. Feed continuously for 30 days or feed medicated feed for 2 days out of every week until marketing. Do not treat within 10 days of slaughter.

(ii) Amount. 0.05 percent.

(a) Indications for use. As an aid in preventing outbreak of coccidiosis caused by Eimeria meleagritis and E. adenoeides.

(b) Limitations. Feed 0.0175 percent continuously during time birds are closely confined. May be continued for week to 10 days after flock is transferred to range to reduce danger of an outbreak following moving of the flock. Do not treat turkeys within 10 days of slaughter. Do not medicate turkeys producing eggs for human consumption.

(ii) Amount. 0.05 percent.

(a) Indications for use. As an aid in preventing outbreak of coccidiosis caused by Eimeria meleagritis and E. adenoeides.

(b) Limitations. Feed 0.05 percent for 2 days. Follow with 3 days on regular feed and 2 more days on 0.05 percent sulfaquinoxaline feed. Again follow with 3 days on regular feed and 2 more days on 0.05 percent sulfaquinoxaline feed. Continue this schedule if necessary till all signs of the outbreaks have subsided. Do not treat turkeys within 10 days of slaughter. Do not medicate turkeys producing eggs for human consumption.

(3) Chickens and turkeys—(i) Amount. 0.05 or 0.1 percent.

(a) Indications for use. As an aid in the control of acute fowl cholera caused by Pasteurella multocida susceptible to sulfaquinoxaline and fowl typhoid caused by Salmonella gallinarum susceptible to sulfaquinoxaline.
§ 558.615 Tiamulin in grams per ton

<table>
<thead>
<tr>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10</td>
<td>For increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as the sole ration.</td>
<td>000010</td>
</tr>
<tr>
<td>(ii) 35</td>
<td>1. For control of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hydysenteriae susceptible to tiamulin.</td>
<td>Feed continuously as sole ration on premises with a history of swine dysentery but where signs of disease have not yet occurred or following approved treatment of disease. Withdraw 2 days before slaughter.</td>
<td>000010</td>
</tr>
<tr>
<td></td>
<td>2. For control of porcine proliferative enteropathies (ileitis) associated with Lawsonia intracellularis.</td>
<td>Feed continuously as sole ration for not less than 10 days. Withdraw 2 days before slaughter.</td>
<td>000010</td>
</tr>
<tr>
<td>(iii) 35</td>
<td>Chlortetracycline, approximately 400 (varying with body weight and feed consumption to provide 10 milligrams of chlortetracycline per pound of body weight daily).</td>
<td>For treatment of swine bacterial enteritis caused by Escherichia coli and Salmonella choleraesuis and bacterial pneumonia caused by Pasteurella multocida susceptible to chlortetracycline, and control of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hydysenteriae susceptible to tiamulin. Feed continuously as sole ration for 14 days. Use as only source of chlortetracycline. Withdraw 2 days before slaughter.</td>
<td>000010</td>
</tr>
<tr>
<td>(iv) 200</td>
<td>For treatment of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hydysenteriae susceptible to tiamulin.</td>
<td>As chlortetracycline calcium complex. Type A medicated articles containing the equivalent of 50 to 100 grams per pound of chlortetracycline hydrochloride provided by 046573 and 053389 in §510.600(c) of this chapter. Feed continuously as the sole feed for 14 consecutive days. Withdraw feed 7 days before slaughter.</td>
<td>000010</td>
</tr>
</tbody>
</table>

(2) [Reserved]

§ 558.615 Thiabendazole.

(a) Approvals. Dry Type A medicated articles: 22, 44.1, 66.1, and 88.2 percent to 050604 in §510.600(c) of this chapter. The 66.1 percent Type A is solely for the manufacture of cane molasses liquid Type B feed which is mixed in dry feeds. The 88.2 percent Type A is used solely for the manufacture of an aqueous slurry for adding to a Type C dry cattle feed.

(b) Special considerations. Do not use in Type B or Type C medicated feed containing bentonite.

(c) Related tolerances. See §556.730 of this chapter.

(d) Conditions of use. It is used in feed for animals as follows:

(1) Cattle—(i) Amount. 3 grams per 100 lb. body weight.


(b) Limitations. Use 3 grams per 100 lb. body weight at a single dose; may repeat once in 2 to 3 weeks; do not treat animals within 3 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food.

(ii) Amount. 5 grams per 100 lb. body weight.

(a) Indications for use. Control of severe infections of gastrointestinal roundworms (Trichostrongylus spp., Haemonchus spp., Ostertagia spp., Nematodirus spp., Oesophagostomum radiatum); control of infections of Cooperia spp.

(b) Limitations. 5 grams per 100 lb. body weight at a single dose or divided into 3 equal doses, administered 1 dose each day, on succeeding days; may repeat once in 2 to 3 weeks; do not treat animals within 3 days of slaughter;

(2) [Reserved]

67 FR 7268, Feb. 19, 2002

§ 558.615 Thiabendazole.

(a) Approvals. Dry Type A medicated articles: 22, 44.1, 66.1, and 88.2 percent to 050604 in §510.600(c) of this chapter. The 66.1 percent Type A is solely for the manufacture of cane molasses liquid Type B feed which is mixed in dry feeds. The 88.2 percent Type A is used solely for the manufacture of an aqueous slurry for adding to a Type C dry cattle feed.

(b) Special considerations. Do not use in Type B or Type C medicated feed containing bentonite.

(c) Related tolerances. See §556.730 of this chapter.

(d) Conditions of use. It is used in feed for animals as follows:

(1) Cattle—(i) Amount. 3 grams per 100 lb. body weight.


(b) Limitations. Use 3 grams per 100 lb. body weight at a single dose; may repeat once in 2 to 3 weeks; do not treat animals within 3 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food.

(ii) Amount. 5 grams per 100 lb. body weight.

(a) Indications for use. Control of severe infections of gastrointestinal roundworms (Trichostrongylus spp., Haemonchus spp., Ostertagia spp., Nematodirus spp., Oesophagostomum radiatum); control of infections of Cooperia spp.

(b) Limitations. 5 grams per 100 lb. body weight at a single dose or divided into 3 equal doses, administered 1 dose each day, on succeeding days; may repeat once in 2 to 3 weeks; do not treat animals within 3 days of slaughter;

(2) [Reserved]
milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food.

(2) Goats—(i) Amount. 3 grams per 100 lb. body weight.


(iii) Limitations. 3 grams per 100 lb. body weight at a single dose; do not treat animals within 30 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food.

(3) Sheep and goats—(i) Amount. 2 grams per 100 lb. body weight.

(ii) Indications for use. Control of infections of gastrointestinal roundworms (Trichostrongylus spp., Haemonchus spp., Ostertagia spp., Cooperia spp., Nematodirus spp., Bunostomum spp., Strongyloides spp., Chabertia spp., and Oesophagostomum spp.); also active against ova and larvae of T. colubriformis and azei, Ostertagia spp., Nematodirus spp., Strongyloides spp.; less effective against those of Haemonchus contortus and Oesophagostomum spp..

(iii) Limitations. Use 2 grams per 100 lb. body weight at a single dose; do not treat animals within 30 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food.

(4) For swine—(i) Amount. 45.4-908 grams per ton (0.005-0.1 percent).

(ii) Indications for use. Aid in the prevention of infections of large roundworms (genus Ascaris).

(iii) Limitations. Administer continuously feed containing 0.05-0.1 percent thiabendazole per ton for 2 weeks followed by feed containing 0.005-0.02 percent thiabendazole per ton for 8-14 weeks; do not treat animals within 30 days of slaughter.

(5) Pheasants—(i) Amount. 454 grams per ton (0.05 percent) continuously for 2 weeks (14 days).

(ii) Indications for use. For the treatment of gapeworms (Syngamus trachea) in pheasants.

(iii) Limitations. Do not use treated pheasants for food for 21 days after last day of treatment. Fertility, hatchability, and other reproductive data are not available on use in breeding animals.


§ 558.618 Tilmicosin.

(a) Approvals. Type A medicated articles: 90.7 grams of tilmicosin (as tilmicosin phosphate) per pound (200 grams per kilogram) to 000986 in §510.600(c) of this chapter.

(b) Special considerations. Do not use in any feed containing bentonite.

(c) Related tolerances. See §556.735 of this chapter.

(d) Conditions of use. It is used in swine feed as follows:

(1) Amount per ton. 181 grams to 363 grams tilmicosin.

(2) Indications for use. For the control of swine respiratory disease associated with Actinobacillus pleuropneumoniae and Pasteurella multocida.

(3) Limitations. For use in swine feed only. The safety of tilmicosin has not been established in pregnant swine or swine intended for breeding purposes. Do not allow horses or other equine access to feeds containing tilmicosin. Feed continuously as the sole ration for 21-day period, beginning approximately 7 days before an expected disease outbreak. Withdraw 7 days before slaughter. Federal law restricts this drug to use under the professional supervision of a licensed veterinarian. Any animal feed bearing or containing this drug shall be fed to animals only by or upon a lawful veterinary directive (VFD) issued by a licensed veterinarian in the course of the veterinarian’s professional practice. VFD’s for tilmicosin phosphate shall not be refilled.

§ 558.625 Tylosin.

(a) Specifications. Tylosin is the antibiotic substance produced by growth of Streptomyces fradiae or the same antibiotic substance produced by any other means. Tylosin, present as the phosphate salt, conforms to the appropriate antibiotic standard. Tylosin contains at least 95 percent tylosin as a combination of tylosin A, tylosin B, tylosin C, and tylosin D of which at least 80 percent is tylosin A as determined by a method entitled “Determination of Factor Content in Tylosin by High Performance Liquid Chromatography,” which is incorporated by reference. Copies are available from the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, or available for inspection at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC 20001.

(b) Approvals. Type A medicated article levels of tylosin granted to firms as sponsor(s) and identified by drug listing numbers in § 510.600(a) of this chapter for the specific usage indicated in paragraph (f) of this section.

(1) To 000986: 10, 40, 100 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(2) [Reserved]
(3) To 043733: 20 and 40 grams per pound, paragraphs (f)(1)(i) through (vi) of this section.
(4) [Reserved]
(5) To 017800: 0.4, 0.8, 1, and 8 grams per pound, paragraph (f)(1)(vi)(a) of this section; 10 and 40 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(6)–(7) [Reserved]
(8) To 035369: 4 and 10 grams per pound, paragraph (f)(1)(vi)(a) of this section; 10 grams per pound, paragraphs (f)(1)(i) through (vi) of this section.
(9) [Reserved]
(10) To 017519: 0.4, 0.8, and 1.6 grams per pound, paragraph (f)(1)(vi)(a) of this section; 20, 40, and 100 grams per pound, paragraphs (f)(1)(i) through (f)(1)(vi) of this section.
(11) [Reserved]
(12) To 021930: 2 grams per pound, paragraph (f)(1)(vi) of this section; 5, 10, 20, and 40 grams per pound, paragraphs (f)(1)(i) through (vi) of this section.
(52) To 017519: 5, 10, 20, and 40 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(53) [Reserved]
(54) To 046573: 5, 10, 20, and 40 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(55)–(56) [Reserved]
(57) To 028459: 0.4 and 10 grams per pound; paragraph (f)(1)(vi)(a) of this section.
(58)–(59) [Reserved]
(60) To 046987: 5, 10, 20, and 40 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(61) [Reserved]
(62) To 024174: 5, 10, 20, and 40 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(63) To 027190: 2 grams per pound; paragraph (f)(1)(vi)(a) of this section.
(64) To 017473: 10 and 40 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(65)–(76) [Reserved]
(77) To 050639: 5, 10, 20, and 40 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(78)–(79) [Reserved]
(80) To 049685: 5, 10, 20, and 40 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(81)–(82) [Reserved]
(83) To 053389: 5, 10, 20, and 40 grams per pound, paragraph (f) (i) through (vi) of this section.
(84) [Reserved]
(85) To 046726: 10, 40, and 100 grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
(86)–(88) [Reserved]

(c) Special considerations. (1) Type C medicated feeds for cattle may be manufactured from tylosin liquid Type B medicated feeds which have a pH between 4.5 and 6.0 and which bear appropriate mixing directions as follows:

(i) For liquid Type B feeds stored in recirculating tank systems: Recirculate immediately prior to use for no fewer than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.

(ii) For liquid Type B feeds stored in mechanical, air, or other agitation-type tank systems: Agitate immediately prior to use for no fewer than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

(2) Tylosin liquid Type B medicated feeds used to make Type C medicated feeds for cattle may be manufactured from tylosin Type A medicated articles according to the following mixing directions:

(i) Presolubilize tylosin in 50 percent urea for approximately 1 hour prior to adding any feed components or other active ingredients.

(ii) Maintain a pH between 4.5 and 6.0.

(3) Tylosin liquid Type B medicated feeds must bear an expiration date of 8 weeks after the date of manufacture.

(d) [Reserved]

(e) Related tolerances. See §556.740 of this chapter.

§ 558.625

(f) Conditions of use. (1) It is used in animal feeds as follows:

(i) For beef cattle—(a) Amount per ton. 8–10 grams.

(b) Indications for use. For reduction of incidence of liver abscesses caused by Fusobacterium necrophorum and Actinomyces (Corynebacterium) pyogenes.

(c) Limitations. As tylosin phosphate; each animal must receive not more than 90 milligrams per day and not less than 60 milligrams per day; feed continuously as sole ration.

(ii) Broiler chickens—(a) Amount per ton. Tylosin, 800–1000 grams.

(b) Indications for use. To aid in the control of chronic respiratory disease caused by Mycoplasma gallisepticum.

(c) Limitations. As tylosin phosphate; withdraw 5 days before slaughter; administer in feed to chickens 0 to 5 days of age, follow with second administration in feed for 24–48 hours at 3 to 5 weeks of age.
§ 558.630 Tylosin and sulfamethazine.

(1) Indications for use. For increased rate of weight gain and improved feed efficiency.

(2) Limitations. As tylosin phosphate.

(iv) Laying chickens—(a) Amount per ton. Tylosin, 20–50 grams.

(b) Indications for use. For improved feed efficiency.

(c) Limitations. As tylosin phosphate.

(v) Replacement chickens—(a) Amount per ton. Tylosin, 1,000 grams.

(b) Indications for use. To aid in the control of chronic respiratory disease caused by Mycoplasma gallisepticum.

(c) Limitations. As tylosin phosphate; withdraw 5 days before slaughter; administer in feed to chickens 0 to 5 days of age, follow with second administration in feed for 24 to 48 hours at 3 to 5 weeks of age.

(vi) Swine—(a) Amount per ton. Tylosin, 10–100 grams.

(1) Indications for use. For increased rate of weight gain and improved feed efficiency.

(2) Limitations. As tylosin phosphate; continuous use as follows: Grams per ton: 20–100, prestarter or starter; 20–40, grower; 10–20, finisher.

(b) Amount per ton. Tylosin, 40–100 grams.

(1) Indications for use. Prevention of swine dysentery (vibrionic).

(2) Limitations. Use 100 grams per ton for at least 3 weeks followed by 40 grams per ton until market weight; as tylosin phosphate.

(c) Amount per ton. Tylosin, 40–100 grams.

(1) Indications for use. Treatment and control of swine dysentery (vibrionic).

(2) Limitations. Administer in feed as tylosin phosphate after treatment with tylosin in drinking water as tylosin base; 0.25 gram per gallon in drinking water for 3–10 days, 40–100 grams per ton in feed for 2–6 weeks.

(d) Amount per ton. Tylosin, 100 grams.

(1) Indications for use. Maintaining weight gains and feed efficiency in presence of atrophic rhinitis.

(2) Limitations. As tylosin phosphate.

(vi) Pyrantel tartrate in accordance with §558.485.

(e) Amount per ton. Tylosin 100 grams.

(1) Indications for use. Prevention and/or control of procine proliferative enteropathies (ileitis) associated with Lawsonia intracellularis.

(2) Limitations. As tylosin phosphate, administer for 21 days.

(2) Tylosin may also be used in combination with:

(i) Decoquinate and monensin as in §558.195.

(ii) Hygromycin B as in §558.274.

(iii) Melengestrol acetate alone or in combination with certain ionophores as in §558.342.

(iv) Monensin as in §558.356.

(v) Narasin as in §558.363.

(vi) Pyrantel tartrate as in §558.485.

(vii) Ractopamine hydrochloride as in §558.500.

[40 FR 13959, Mar. 27, 1975]

EDITORIAL NOTE: For Federal Register citations affecting §558.625, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

§ 558.630 Tylosin and sulfamethazine.

(a) [Reserved]

(b) Approvals. Type A medicated article levels, a combination of equal amounts of tylosin and sulfamethazine, granted to firms as sponsor(s) and identified by drug listing numbers in §510.600(c) of this chapter for the conditions of use indicated in paragraph (f) of this section.

(1) To 000986: 40 grams per pound each, paragraph (f)(2)(i).

(2) To 000986: 10 grams per pound each, paragraph (f)(2)(i).

(3) To 017519: 10 grams per pound each, paragraph (f)(2)(ii) of this section.

(4) [Reserved]

(5) To 017800: 40 grams per pound each, paragraph (f)(2)(ii) of this section.

(6) To 017139: 4, 10, or 20 grams per pound each, paragraph (f)(2)(ii) of this section.

(7) To 021930: 2 grams per pound each, paragraph (f)(2)(i) of this section; 5, 10, 20, or 40 grams per pound each, paragraph (f)(2)(ii) of this section.

(8) To 017519: 5 or 10 grams per pound each, paragraph (f)(2)(ii) of this section.

(9) [Reserved]

(10) To 010439, 011749, 016968, 017473, 017519, 017790, 02174, 030841, 034936, 035098, 043733, 046573, 046987, 050568,
Food and Drug Administration, HHS

§ 558.635 Virginiamycin.

(a) Approvals. Type A medicated articles. (1) 1.1 percent activity (5 grams per pound), 2.2 percent activity (10 grams per pound), 4.4 percent activity (20 grams per pound), 11 percent activity (50 grams per pound), and 50 percent activity (227 grams per pound) used as in paragraph (d) of this section; and 30 percent activity (336.2 grams per pound) for the manufacture of Type C medicated feed for cattle used as in paragraph (d)(3); to 066104 in §510.600(c) of this chapter.

(2) 2.2 percent activity (10 grams per pound) to 046573, 016968, and 017790 in §510.600(c) of this chapter for use as in paragraphs (d)(1)(iv) and (d)(1)(v) of this section.

(b) Related tolerances. See §556.750 of this chapter.

(c) Special considerations. (1) Not for use in breeding swine over 120 pounds.

(2) Dilute Type A article with at least 10 pounds of a feed ingredient prior to final mixing in 1 ton of Type C feed.

(d) Conditions of use. (1) Swine. It is used as follows:

(i) 100 grams per ton for 2 weeks, for treatment of swine dysentery in non-breeding swine over 120 pounds.

(ii) 100 grams per ton for 2 weeks, 50 grams per ton thereafter, for treatment and control of swine dysentery in swine up to 120 pounds.

(iii) 25 grams per ton, as an aid in control of dysentery in swine up to 120 pounds. For use in animals or on premises with a history of swine dysentery but where symptoms have not yet occurred.

(iv) 10 grams per ton from weaning up to 120 pounds for increased rate of weight gain and improved feed efficiency, followed by 5 grams per ton to market weight for increased rate of weight gain and improved feed efficiency. For continuous use from weaning to market weight.

(v) 10 grams per ton from weaning up to 120 pounds for increased rate of weight gain and improved feed efficiency, followed by 5 to 10 grams per ton to market weight for increased rate of weight gain. For continuous use from weaning to market weight.

(2) Poultry. It is used as follows:

(i) 5 to 15 grams per ton for increased rate of weight gain, for use in broiler chickens, not for use in layers.

(ii) 5 grams per ton for increased rate of weight gain and improved feed efficiency in broiler chickens, not for use in layers.

(iii) 20 grams per ton for prevention of necrotic enteritis caused by Clostridium perfringens susceptible to virginiamycin in broiler chickens; not for use in layers.

(iv) 10 to 20 grams per ton for increased rate of weight gain and improved feed efficiency in growing turkeys.

(3) Cattle. It is used as follows:
§ 558.680  

(i) 16.0 to 22.5 grams per ton to provide 100 to 340 milligrams per head per day for increased rate of weight gain.
(ii) 13.5 to 16.0 grams per ton to provide 85 to 240 milligrams per head per day for reduction of incidence of liver abscesses.
(iii) 11.0 to 16.0 grams per ton to provide 70 to 240 milligrams per head per day for improved feed efficiency.
(iv) Feed continuously as sole ration to cattle fed in confinement for slaughter. Not for use in animals intended for breeding.

(4) Virginiamycin may be used in combination with:
(i) Amprolium and ethopabate as in § 558.58.
(ii) Diclazuril as in § 558.198.
(iii) Halofuginone as in § 558.265.
(iv) Lasalocid as in § 558.311.
(v) Monensin alone or with roxarsone as in § 558.355.
(vi) Salinomycin alone or with roxarsone as in § 558.550.
(vii) Semduramicin as in § 558.555.

(40 FR 13959, Mar. 27, 1975)

EDITORIAL NOTE: For Federal Register citations affecting § 558.635, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and on GPO Access.

§ 558.680  Zoalene.

(a) Specifications. Type A medicated article containing 25 percent zoalene.

(b) Approvals. See No. 046573 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.770 of this chapter.

(d) Conditions of use—(1) Chickens and turkeys:

- **Zoalene in grams/ton**
  - Combination in grams/ton
  - Indications for use
  - Limitations

<table>
<thead>
<tr>
<th>Zoalene in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 36.3–113.5 (0.004–0.0125%)</td>
<td>Replacement chickens; development of active immunity to coccidiosis.</td>
<td>Grower ration not to be fed to birds over 14 weeks of age; as follows:</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Growing conditions</th>
<th>Starter ration Grams per ton</th>
<th>Grower ration Grams per ton</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe exposure</td>
<td>113.5 (0.0125%)</td>
<td>75.4–113.5 (0.0083%–0.0125%)</td>
</tr>
<tr>
<td>Light to moderate exposure</td>
<td>75.4–113.5 (0.0083%–0.0125%)</td>
<td>36.3–75.4 (0.004%–0.0083%)</td>
</tr>
</tbody>
</table>

(2) Arsanilate sodium 90 (0.01%).

- Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation.

(3) Arsanilic acid 90 (0.01%).

- Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation.

(4) Arsanilic acid 90 (0.01%) plus erythromycin 4.6 to 18.5.

- Replacement chickens; growth promotion and feed efficiency; development of active immunity to coccidiosis; improving pigmentation.

- Grower ration not to be fed to birds over 14 weeks of age; as sole source of organic arsenic; feed as in subtable in item (i).

- Grower ration not to be fed to birds over 14 weeks of age; withdraw 5 days (d) before slaughter; as sole source of organic arsenic; feed as in subtable in item (i).

- Grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in subtable in item (i).

- As erythromycin thiocyanate; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in subtable in item (i).
<table>
<thead>
<tr>
<th>Zoalene in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arsanilic acid 90 (0.01%) plus erythromycin 92.5.</td>
<td>1. Replacement chickens; as an aid in the prevention of chronic respiratory disease during periods of stress; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; as erythromycin thiocyanate; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic arsenic; feed as in suitable in item (i).</td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus erythromycin 185.</td>
<td>2. Replacement chickens; as an aid in the prevention of infectious coryza; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Feed for 7 to 14 d; as erythromycin thiocyanate; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic arsenic; feed as in suitable in item (i).</td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus penicillin 2.4 to 50.</td>
<td>Replacement chickens; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease; growth promotion and feed efficiency; improving pigmentation and development of active immunity to coccidiosis.</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
<td></td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate 50</td>
<td>Replacement chickens; development of active immunity to coccidiosis; as an aid in the prevention of necrotic enteritis caused or complicated by <em>Clostridium</em> spp. or other organisms susceptible to bacitracin.</td>
<td>Feed continuously as sole ration as in suitable in this item (i); grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
<td></td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate 100 to 200</td>
<td>Replacement chickens; development of active immunity to coccidiosis; as an aid in the control of necrotic enteritis caused or complicated by <em>Clostridium</em> spp. or other organisms susceptible to bacitracin.</td>
<td>Feed continuously as sole ration as in suitable in this item (i). To control necrotic enteritis, start medication at first clinical signs of disease; vary bacitracin dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams/ton). Bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 100 to 500.</td>
<td>Replacement chickens; treatment of chronic respiratory disease (air-sac infection); blue comb (nonspecific infectious enteritis); development of active immunity to coccidiosis.</td>
<td>As bacitracin zinc; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 100 to 200.</td>
<td>Replacement chickens; development of active immunity to coccidiosis; control of infectious synovitis caused by <em>Mycoplasma synoviae</em> susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 200 to 400.</td>
<td>Replacement chickens; development of active immunity to coccidiosis; control of chronic respiratory disease (CRD) and air sac infection caused by <em>M. gallisepticum</em> and <em>Escherichia coli</em> susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
<td></td>
</tr>
<tr>
<td>Zoalene in grams/ton</td>
<td>Combination in grams/ton</td>
<td>Indications for use</td>
<td>Limitations</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Erythromycin 4.6 to 18.5</td>
<td>Replacement chickens; growth promotion and feed efficiency; development of active immunity to coccidiosis.</td>
<td>As erythromycin thiocyanate; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
<td>Feed for 2 d before stress and 3 to 6 after stress; withdraw 24 hours before slaughter; as erythromycin thiocyanate; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Erythromycin 92.5.</td>
<td>1. Replacement chickens, as an aid in the prevention of chronic respiratory disease during periods of stress; development of active immunity to coccidiosis.</td>
<td>Feed for 7 to 14 d; withdraw 24 h before slaughter; as erythromycin thiocyanate; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdrawn 48 h before slaughter; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Erythromycin 185.</td>
<td>Replacement chickens; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease; development of active immunity to coccidiosis.</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdrawn 48 h before slaughter; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
<td>Grover ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Hygromycin B 8 to 12.</td>
<td>Replacement chickens; development of active immunity to coccidiosis; control of infestation of large round worms (Ascaris galli), cecal worms (Heterakis gallinae) and capillary worms (Capillaria obsoleta).</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Penicillin 2.4 to 50.</td>
<td>Replacement chickens; growth promotion and feed efficiency; development of active immunity to coccidiosis.</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
<td>Grover ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Penicillin 2.4 to 50 plus roxarsone 22.7 to 45.4 (0.0025% to 0.005%).</td>
<td>Replacement chickens; growth promotion and feed efficiency; development of active immunity to coccidiosis; improving pigmentation.</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
<td>Grover ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Roxarsone 22.7 to 45.5 (0.0025% to 0.005%).</td>
<td>Replacement chickens; development of active immunity to coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
<td>Grover ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>(ii) 113.5 (0.0125%).</td>
<td>Broiler chickens; prevention and control of coccidiosis.</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; feed as in suitable in item (i).</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Arsanilate sodium 90 (0.01%).</td>
<td>Broiler chickens; prevention and control of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%).</td>
<td>Broiler chickens; growth promotion and feed efficiency; prevention and control of coccidiosis; improving pigmentation.</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus erythromycin 4.6 to 18.5.</td>
<td>Broiler chickens; growth promotion and feed efficiency; improving pigmentation; control of coccidiosis.</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus erythromycin 92.5.</td>
<td>1. Broiler chickens; as an aid in the prevention of chronic respiratory disease during periods of stress; growth promotion and feed efficiency; improving pigmentation; control of coccidiosis.</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
<td>As procaine penicillin; grower ration not to be fed to birds over 14 weeks of age; withdraw 5 d before slaughter; as sole source of organic arsenic; feed as in suitable in item (i).</td>
</tr>
<tr>
<td>Zoalene in grams/ton</td>
<td>Combination in grams/ton</td>
<td>Indications for use</td>
<td>Limitations</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------</td>
<td>--------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>2. Broiler chickens; prevention and control of coccidiosis; growth promotion and feed efficiency; improving pigmentation; as an aid in the prevention of infectious coryza.</td>
<td>Do.</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; as erythromycin thiochinate; withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus erythromycin 185.</td>
<td>Broiler chickens; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease; prevention and control of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>As procaine penicillin; withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus penicillin 2.4 to 50.</td>
<td>Broiler chickens; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease; prevention and control of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>As bacitracin methylene disalicylate or zinc bacitracin.</td>
<td></td>
</tr>
<tr>
<td>Arsanilic acid 90 (0.01%) plus bacitracin 4 to 50.</td>
<td>Broiler chickens; prevention and control of coccidiosis; improving pigmentation; growth promotion and feed efficiency.</td>
<td>Feed continuously as sole ration. Bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 4 to 50.</td>
<td>Broiler chickens; growth promotion and feed efficiency; prevention and control of coccidiosis.</td>
<td>As bacitracin methylene disalicylate or zinc bacitracin.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 4 to 50 plus roxarsone 22.7 to 45.4 (0.0025 to 0.005%).</td>
<td>Broiler chickens; growth promotion and feed efficiency; prevention and control of coccidiosis; improving pigmentation.</td>
<td>Feed continuously as sole ration. Bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate 50</td>
<td>Broiler chickens; prevention and control of coccidiosis; as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.</td>
<td>Feed continuously as sole ration. To control necrotic enteritis, start medication at first clinical signs of disease; vary bacitracin dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams/ton). Bacitracin methylene disalicylate as provided by 046573 in §510.600(c) of this chapter.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate 100 to 200</td>
<td>Broiler chickens; prevention and control of coccidiosis; as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.</td>
<td>Feed continuously as sole ration.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin 100 to 500.</td>
<td>Broiler chickens; treatment of chronic respiratory disease (air-sac infection); blue comb (nonspecific infectious enteritis); prevention and control of coccidiosis.</td>
<td>As zinc bacitracin.</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 100 to 200</td>
<td>Broiler chickens; prevention and control of coccidiosis; control of infectious synovitis caused by M. synoviae susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption; feed continuously for 7 to 14 d.</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline 200 to 400</td>
<td>Broiler chickens; prevention and control of coccidiosis; control of chronic respiratory disease (CRD) and air sac infection caused by M. gallisepticum and E. coli susceptible to chlortetracycline.</td>
<td>Do not feed to chickens producing eggs for human consumption; feed continuously for 7 to 14 d.</td>
<td></td>
</tr>
<tr>
<td>Zoalene in grams/ton</td>
<td>Combination in grams/ton</td>
<td>Indications for use</td>
<td>Limitations</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------</td>
<td>---------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Erythromycin 4.6 to 18.5</td>
<td>Broiler chickens; growth promotion and feed efficiency; prevention and control of coccidiosis.</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; withdraw 24 h before slaughter; as erythromycin thiocyanate.</td>
<td>As erythromycin thiocyanate.</td>
</tr>
<tr>
<td>Erythromycin 92.5</td>
<td>1. Broiler chickens; as an aid in the prevention of chronic respiratory disease during period of stress; prevention and control of coccidiosis.</td>
<td>Feed for 7 to 14 d; withdraw 24 h before slaughter; as erythromycin thiocyanate.</td>
<td></td>
</tr>
<tr>
<td>Erythromycin 185</td>
<td>Broiler chickens; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease; prevention and control of coccidiosis.</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 48 h before slaughter; as erythromycin thiocyanate.</td>
<td></td>
</tr>
<tr>
<td>Hygromycin B 8 to 12</td>
<td>Broiler chickens; prevention and control of coccidiosis; control of infestation of large round worms (Ascaris galli) cecal worms (Heterakis gallinae) and capillary worms (Capillaria obsignata).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lincomycin 2</td>
<td>Broiler chickens; increase in rate of weight gain; improved feed efficiency; as an aid in the prevention and control of coccidiosis.</td>
<td>Do not feed to laying chickens; to be fed as the sole ration; as lincomycin hydrochloride monohydrate provided by No. 000009 in § 510.600(c) of this chapter.</td>
<td>As procaine penicillin.</td>
</tr>
<tr>
<td>Penicillin 2.4 to 50</td>
<td>Broiler chickens; growth promotion and feed efficiency; prevention and control of coccidiosis.</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic; as procaine penicillin.</td>
<td></td>
</tr>
<tr>
<td>Penicillin 2.4 to 50 plus Roxarsone 22.7 to 45.4 (0.0025 to 0.005%),</td>
<td>Broiler chickens; prevention and control of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
</tr>
<tr>
<td>Roxarsone 22.7 to 45.4 (0.0025 to 0.005%)</td>
<td>Broiler chickens; prevention and control of coccidiosis; growth promotion and feed efficiency; improving pigmentation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(iii) 113.5 to 170.3 (0.0125 to 0.01875%),</td>
<td>Turkeys; prevention and control of coccidiosis.</td>
<td>For turkeys grown for meat purposes only.</td>
<td></td>
</tr>
<tr>
<td>Arsanilate sodium 90 (0.01%).</td>
<td>Turkeys; growth promotion and feed efficiency; improving pigmentation.</td>
<td>For turkeys grown for meat purposes only; not to be fed to laying birds, feed continuously as sole ration until 14 to 16 weeks of age.</td>
<td>For turkeys grown for meat purposes only; feed continuously beginning 2 weeks before blackhead and coccidiosis are expected and continue as long as prevention of blackhead and prevention and control of coccidiosis is needed; withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
</tr>
<tr>
<td>Arsanilic acid 90(0.01%).</td>
<td>do. Turkeys; prevention and control of coccidiosis, and increased rate of weight gain and improved feed efficiency.</td>
<td></td>
<td>Do.</td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate 4–50.</td>
<td>Turkeys; prevention and control of coccidiosis.</td>
<td>For turkeys grown for meat purposes only.</td>
<td></td>
</tr>
<tr>
<td>Carbarsone (not U.S.P.) 277 to 340.5 (0.025% to 0.0375%).</td>
<td>Turkeys; prevention and control of coccidiosis; aid in the prevention of blackhead.</td>
<td>Withdrew 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
</tr>
<tr>
<td>Roxarsone 22.7 to 45.4 (0.0025% to 0.005%).</td>
<td>Turkeys; growth promotion and feed efficiency; improving pigmentation.</td>
<td>Withdraw 5 d before slaughter; as sole source of organic arsenic.</td>
<td></td>
</tr>
</tbody>
</table>
§ 570.3 Definitions.

(a) Secretary means the Secretary of Health and Human Services.

(b) Department means the Department of Health and Human Services.

(c) Commissioner means the Commissioner of Food and Drugs.


(e) Food additives includes all substances not exempted by section 201(s) of the act, the intended use of which results or may reasonably be expected to result, directly or indirectly, either in their becoming a component of food or otherwise affecting the characteristics of food. A material used in the production of containers and packages is subject to the definition if it may reasonably be expected to become a component, or to affect the characteristics, directly or indirectly, of food packed in the container. Affecting the characteristics of food does not include such physical effects, as protecting contents of packages, preserving shape, and preventing moisture loss. If there is no migration of a packaging component from the package to the food, it does not become a component of the food and thus is not a food additive. A substance that does not become a component of food, but that is used, for example, in preparing an ingredient of the food to give a different flavor, texture, or other characteristic in the food, may be a food additive.

(f) Common use in food means a substantial history of consumption of a substance by a significant number of animals in the United States.

(g) The word substance in the definition of the term food additive includes a food or feed or a component of a food or feed consisting of one or more ingredients.

(h) Scientific procedures include those human, animal, analytical, and other scientific studies, whether published or unpublished, appropriate to establish the safety of a substance.

(i) Safe or safety means that there is a reasonable certainty in the minds of
competent scientists that the substance is not harmful under the intended conditions of use. It is impossible in the present state of scientific knowledge to establish with complete certainty the absolute harmlessness of the use of any substance. Safety may be determined by scientific procedures or by general recognition of safety. In determining safety, the following factors shall be considered:

(1) The probable consumption of the substance and of any substance formed in or on food because of its use;

(2) The cumulative effect of the substance in the diet, taking into account any chemically or pharmacologically related substance or substances in such diet;

(3) Safety factors which, in the opinion of experts qualified by scientific training and experience to evaluate the safety of food and food ingredients, are generally recognized as appropriate.

(j) The term nonperishable processed food means any processed food not subject to rapid decay or deterioration that would render it unfit for consumption. Not included are hermetically sealed foods and other processed foods requiring refrigeration.

(k) General recognition of safety shall be determined in accordance with §570.30.

(l) Prior sanction means an explicit approval granted with respect to use of a substance in food prior to September 6, 1958, by the Food Drug and Administration or the United States Department of Agriculture pursuant to the Federal Food, Drug, and Cosmetic Act, the Poultry Products Inspection Act, or the Meat Inspection Act.

(m) Food includes human food, substances migrating to food from food-contact articles, pet food, and animal feed.


§570.6 Opinion letters on food additive status.

(a) Over the years the Food and Drug Administration has given informal written opinions to inquirers as to the safety of articles intended for use as components of, or in contact with, food. Prior to the enactment of the Food Additives Amendment of 1958 (Pub. L. 85-929, Sept. 6, 1958), these opinions were given pursuant to section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act, which reads in part: “A food shall be deemed to be adulterated if it bears or contains any poisonous or deleterious substance which may render it injurious to health”.

(b) Since enactment of the Food Additives Amendment, the Food and Drug Administration has advised such inquirers that an article:

(1) Is a food additive within the meaning of section 201(s) of the act; or

(2) Is generally recognized as safe (GRAS); or

(3) Has prior sanction or approval under that amendment; or

(4) Is not a food additive under the conditions of intended use.

(c) In the interest of the public health, such articles which have been considered in the past by the Food and Drug Administration to be safe under the provisions of section 402(a)(1), or to be generally recognized as safe for their intended use, or to have prior sanction or approval, or not to be food additives under the conditions of intended use, must be reexamined in the light of current scientific information and current principles for evaluating the safety of food additives if their use is to be continued.

(d) Because of the time span involved, copies of many of the letters in which the Food and Drug Administration has expressed an informal opinion concerning the status of such articles may no longer be in the file of the Food and Drug Administration. In the absence of information concerning the names and uses made of all the articles referred to in such letters, their safety of use cannot be reexamined. For this reason all food additive status opinions of the kind described in paragraph (c) of this section given by the Food and Drug Administration are hereby revoked.

(e) The prior opinions of the kind described in paragraph (c) of this section will be replaced by qualified and current opinions if the recipient of each such letter forwards a copy of each to the Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine.
§ 570.18 Tolerances for related food additives.

(a) Food additives that cause similar or related pharmacological effects will be regarded as a class, and in the absence of evidence to the contrary, as
§ 570.19 Pesticide chemicals in processed foods.

When pesticide chemical residues occur in processed foods due to the use of raw agricultural commodities that bore or contained a pesticide chemical in conformity with an exemption granted or a tolerance prescribed under section 408 of the act, the processed food will not be regarded as adulterated so long as good manufacturing practice has been followed in removing any residue from the raw agricultural commodity in the processing (such as by peeling or washing) and so long as the concentration of the residue in the processed food when ready to eat is not greater than the tolerance prescribed for the raw agricultural commodity. But when the concentration of residue in the processed food when ready to eat is higher than the tolerance prescribed for the raw agricultural commodity, the processed food is adulterated unless the higher concentration is permitted by a tolerance obtained under section 409 of the act. For example, if fruit bearing a residue of 7 parts per million of DDT permitted on the raw agricultural commodity is dried and a residue in excess of 7 parts per million of DDT results on the dried fruit, the dehydrated fruit is adulterated unless the higher tolerance for DDT is authorized by the regulations in this part. Food that is itself ready to eat, and which contains a higher residue than allowed for the raw agricultural commodity, may not be legalized by blending or mixing with other foods to reduce the residue in the mixed food below the tolerance prescribed for the raw agricultural commodity.

Subpart B—Food Additive Safety

§ 570.20 General principles for evaluating the safety of food additives.

(a) In reaching a decision on any petition filed under section 409 of the act, the Commissioner will give full consideration to the specific biological properties of the compound and the adequacy of the methods employed to demonstrate safety for the proposed use, and the Commissioner will be guided by the principles and procedures for establishing the safety of food additives stated in current publications of the National Academy of Sciences-National Research Council. A petition will not be denied, however, by reason of the petitioner’s having followed procedures other than those outlined in the publications of the National Academy of Sciences-National Research Council if, from available evidence, the Commissioner finds that the procedures used give results as reliable as, or more reliable than, those reasonably...
to be expected from the use of the outlined procedures. In reaching a decision, the Commissioner will give due weight to the anticipated levels and patterns of consumption of the additive specified or reasonably inferable. For the purposes of this section, the principles for evaluating safety of additives set forth in the above-mentioned publications will apply to any substance that may properly be classified as a food additive as defined in section 201(s) of the act.

(b) Upon written request describing the proposed use of an additive and the proposed experiments to determine its safety, the Commissioner will advise a person who wishes to establish the safety of a food additive whether he believes the experiments planned will yield data adequate for an evaluation of the safety of the additive.

§ 570.30 Eligibility for classification as generally recognized as safe (GRAS).

(a) General recognition of safety may be based only on the views of experts qualified by scientific training and experience to evaluate the safety of substances directly or indirectly added to food. The basis of such views may be either (1) scientific procedures or (2) in the case of a substance used in food prior to January 1, 1958, through experience based on common use in food. General recognition of safety requires common knowledge about the substance throughout the scientific community knowledgeable about the safety of substances directly or indirectly added to food.

(b) General recognition of safety based upon scientific procedures shall require the same quantity and quality of scientific evidence as is required to obtain approval of a food additive regulation for the ingredient. General recognition of safety through scientific procedures shall ordinarily be based upon published studies which may be corroborated by unpublished studies and other data and information.

(c) General recognition of safety through experience based on common use in food prior to January 1, 1958, may be determined without the quantity or quality of scientific procedures required for approval of a food additive regulation. General recognition of safety through experience based on common use in food prior to January 1, 1958, shall ordinarily be based upon generally available data and information. An ingredient not in common use in food prior to January 1, 1958, may achieve general recognition of safety only through scientific procedures.

(d) The food ingredients listed as GRAS in part 582 of this chapter do not include all substances that are generally recognized as safe for their intended use in food. Because of the large number of substances the intended use of which results or may reasonably be expected to result, directly or indirectly, in their becoming a component or otherwise affecting the characteristics of food, it is impracticable to list all such substances that are GRAS. A food ingredient of natural biological origin that has been widely consumed for its nutrient properties in the United States prior to January 1, 1958, without known detrimental effects, which is subject only to conventional processing as practiced prior to January 1, 1958, and for which no known safety hazard exists, will ordinarily be regarded as GRAS without specific inclusion in part 582 of this chapter.

(e) A food ingredient that is not GRAS or subject to a prior sanction requires a food additive regulation promulgated under section 409 of the act before it may be directly or indirectly added to food.

(f) A food ingredient that is listed as GRAS in part 582 of this chapter shall be regarded as GRAS only if, in addition to all the requirements in the applicable regulation, it also meets all of the following requirements:

1. It complies with any applicable specifications, or in the absence of such specifications, shall be of a purity suitable for its intended use.

2. It performs an appropriate function in the food or food-contact article in which it is used.

3. It is used at a level no higher than necessary to achieve its intended purpose in that food or, if used as a component of a food-contact article, at a level no higher than necessary to achieve its intended purpose in that article.
§ 570.35

Affirmation of generally recognized as safe (GRAS) status.

(a) The Commissioner, either on his initiative or on the petition of an interested person, may affirm the GRAS status of substances that directly or indirectly become components of food. (b)(1) If the Commissioner proposes on his own initiative that a substance is entitled to affirmation as GRAS, he will place all of the data and information on which he relies on public file in the office of the Dockets Management Branch and will publish in the FEDERAL REGISTER a notice giving the name of the substance, its proposed uses, and any limitations proposed for purposes other than safety.

(2) The FEDERAL REGISTER notice will allow a period of 60 days during which any interested person may review the data and information and/or file comments with the Dockets Management Branch. Copies of all comments received shall be made available for examination in the Dockets Management Branch’s office.

(c)(1) Persons seeking the affirmation of GRAS status of substances as provided for in §570.30(e), except those subject to the NAS-NRC GRAS list survey (36 FR 20546), shall submit a petition for GRAS affirmation pursuant to part 10 of this chapter. Such petition shall contain information to establish that the GRAS criteria as set forth in §570.30 have been met, in the following form:

(i) Description of the substance, including:

(a) Common or usual name.
(b) Chemical name.
(c) Chemical Abstract Service (CAS) registry number.
(d) Empirical formula.
(e) Structural formula.
(f) Specifications for food grade material, including arsenic and heavy metals. (Recommendation for any change in the Food Chemicals Codex monograph should be included where applicable.)
(g) Quantitative compositions.
(h) Manufacturing process (excluding any trade secrets).
(ii) Use of the substance, including:
(a) Date when use began.
(b) Information and reports or other data on past uses in food.
(c) Foods in which used, and levels of use in such foods, and for what purposes.
(iii) Methods for detecting the substance in food, including:
(a) References to qualitative and quantitative methods for determining the substance(s) in food, including the type of analytical procedures used.
(b) Sensitivity and reproducibility of such method(s).
(iv) Information to establish the safety and functionality of the substance in food. Published scientific literature, evidence that the substance is identical to a GRAS counterpart of natural biological origin, and other data may be submitted to support safety. Any adverse information or consumer complaints shall be included. Complete bibliographic references shall be provided where a copy of the article is not provided.
(v) A statement signed by the person responsible for the petition that to the best of his knowledge it is a representative and balanced submission that includes unfavorable information, as well as favorable information, known to him pertinent to the evaluation of the safety and functionality of the substance.
(vi) If nonclinical laboratory studies are involved, additional information and data submitted in support of filed petitions shall include, with respect to each nonclinical study, either a statement that the study was conducted in compliance with the requirements set forth in part 58 of this chapter, or, if the study was not conducted in compliance with such regulations, a brief statement of the reason for the noncompliance.
(vii) [Reserved]
(viii) A claim for categorical exclusion under §25.30 or 25.32 of this chapter or an environmental assessment under §25.40 of this chapter.
(2) Within 30 days after the date of filing the petition, the Commissioner will place the petition on public file in the Dockets Management Branch and will publish a notice of filing in the Federal Register giving the name of the petitioner and a brief description of the petition including the name of the substance, its proposed use, and any limitations proposed for reasons other than safety. A copy of the notice will be mailed to the petitioner at the time the original is sent to the Federal Register.

(3) The notice of filing in the Federal Register will allow a period of 60 days during which any interested person may review the petition and/or file comments with the Dockets Management Branch. Copies of all comments received shall be made available for examination in the Dockets Management Branch.

(4) The Commissioner will evaluate the petition and all available information including all comments received. If the petition and such information provide convincing evidence that the substance is GRAS as defined in §570.3, he will publish an order in the Federal Register listing the substance in this subchapter E as GRAS.

(5) If, after evaluation of the petition and all available information, the Commissioner concludes that there is a lack of convincing evidence that the substance is GRAS and that it should be considered a food additive subject to section 409 of the act, he shall publish a notice thereof in the Federal Register in accordance with §570.38.

(6) The notice of filing in the Federal Register will request submission of proof of any applicable prior sanction for use of the ingredient under conditions different from those proposed to be determined to be GRAS. The failure of any person to come forward with proof of such an applicable prior sanction in response to the notice of filing will constitute a waiver of the right to assert or rely on such sanction at any later time. The notice of filing will also constitute a proposal to establish a regulation under this subchapter E, incorporating the same provisions, in the event that such a regulation is determined to be appropriate as a result of submission of proof of such an
§ 570.38 Determination of food additive status.

(a) The Commissioner may, in accordance with § 570.35(b)(4) or (c)(5), publish a notice in the Federal Register determining that a substance is not GRAS and is a food additive subject to section 409 of the act.

(b)(1) The Commissioner, on his own initiative or on the petition of any interested person, pursuant to part 10 of this chapter, may issue a notice in the Federal Register proposing to determine that a substance is not GRAS and is a food additive subject to section 409 of the act. Any petition shall include all relevant data and information of the type described in § 571.130(b) of this chapter. The Commissioner will place all of the data and information on which he relies in public file in the Dockets Management Branch and will include in the Federal Register notice the name of the substance, its known uses, and a summary of the basis for the determination.

(2) The Federal Register notice will allow a period of 60 days during which any interested person may review the data and information and/or file comments with the Dockets Management Branch. Copies of all comments shall be made available for examination in the Dockets Management Branch.

(3) The Commissioner will evaluate all comments received. If he concludes that there is a lack of convincing evidence that the substance is GRAS or is otherwise exempt from the definition of a food additive in section 201(s) of the act, he will publish a notice thereof in the Federal Register. If he concludes that there is convincing evidence that the substance is GRAS, he will publish an order in the Federal Register listing the substance in this subchapter E as GRAS.

(c) A Federal Register notice determining that a substance is a food additive shall provide for the use of the additive in food or food-contact surfaces as follows:

(1) It may promulgate a food additive regulation governing use of the additive.

(2) It may promulgate an interim food additive regulation governing use of the additive.

(3) It may require discontinuation of the use of the additive.

(4) It may adopt any combination of the above three approaches for different uses or levels of use of the additive.

(d) If the Commissioner of Food and Drugs is aware of any prior sanction for use of the substance, he will concurrently propose a separate regulation covering such use of the ingredient under this subchapter E. If the Commissioner is unaware of any such applicable prior sanction, the proposed regulation will so state and will require any person who intends to assert or rely on such sanction to submit proof of its existence. Any regulation promulgated pursuant to this section constitutes a determination that excluded uses would result in adulteration of the food in violation of section 402 of the act, and the failure of any person to come forward with proof of such an applicable prior sanction in response to the proposal will constitute a waiver of the right to assert or rely on such sanction at any later time. The notice will also constitute a proposal to establish a regulation under this subchapter E., incorporating the same provisions, in the event that such a regulation is determined to be appropriate as a result of submission of proof of such an applicable prior sanction in response to the proposal.

Subpart B—Administrative Actions on Applications

§ 571.100 Regulation based on petition.
§ 571.102 Effective date of regulation.
§ 571.110 Procedure for objections and hearings.
§ 571.115 Application of the cancer clause of section 409 of the act.
§ 571.130 Procedure for amending and repealing tolerances or exemptions from tolerances.


SOURCE: 41 FR 38647, Sept. 10, 1976, unless otherwise noted.

Subpart A—General Provisions

§ 571.1 Petitions.

(a) Petitions to be filed with the Commissioner under the provisions of section 409(b) of the act shall be submitted in triplicate. If any part of the material submitted is in a foreign language, it shall be accompanied by an accurate and complete English translation. The petition shall state petitioner’s post office address to which published notices or orders issued or objections filed pursuant to section 409 of the act may be sent.

(b) Pertinent information may be incorporated in, and will be considered as part of, a petition on the basis of specific reference to such information submitted to and retained in the files of the Food and Drug Administration. However, any reference to unpublished information furnished by a person other than the applicant will not be considered unless use of such information is authorized in a written statement signed by the person who submitted it. Any reference to published information offered in support of a food-additive petition should be accompanied by reprints or photostatic copies of such references.

(c) Petitions shall include the following data and be submitted in the following form:

<table>
<thead>
<tr>
<th>Name of petitioner</th>
<th>(Date)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post office address</td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td></td>
</tr>
<tr>
<td>Name of food additive and proposed use</td>
<td></td>
</tr>
</tbody>
</table>

Food and Drug Administration, HHS

Food and Drug Administration

CENTER FOR VETERINARY MEDICINE.

Director, Division of Animal Feeds (HFV–220),

7500 Standish Pl., Rockville, MD 20855.

DEAR SIRS: The undersigned, (Name of the food additive and proposed use) submits this petition pursuant to section 409(b)(1) of the Federal Food, Drug, and Cosmetic Act with respect to

A. The name and all pertinent information concerning the food additive, including chemical identity and composition of the food additive, its physical, chemical, and biological properties, and specifications prescribing the minimum content of the desired component(s) and identifying and limiting the reaction byproducts and other impurities. Where such information is not available, a statement as to the reasons why it is not should be submitted.

When the chemical identity and composition of the food additive is not known, the petition shall contain information in sufficient detail to permit evaluation regarding the method of manufacture and the analytical controls used during the various stages of manufacturing, processing, or packing of the food additive which are relied upon to establish that it is a substance of reproducible composition. Alternative methods and controls and variations in methods and controls within reasonable limits that do not affect the characteristics of the substance or the reliability of the controls may be specified.

If the food additive is a mixture of chemicals, the petition shall supply a list of all substances used in the synthesis, extraction, or other method of preparation, regardless of whether they undergo chemical change in the process. Each substance should be identified by its common English name and complete chemical name, using structural formulas when necessary for specific identification. If any proprietary preparation is used as a component, the proprietary name should be followed by a complete quantitative statement of composition. Reasonable alternatives for any listed substance may be specified.

If the petitioner does not himself perform all the manufacturing, processing, and packaging operations for a food additive, the petition shall identify each person who will perform a part of such operations and designate the part.

The petition shall include stability data, and, if the data indicate that it is needed to ensure the identity, strength, quality, or purity of the additive, the expiration date that will be employed.

B. The amount of the food additive proposed for use and the purposes for which it is
§ 571.1 proposed, together with all directions, recommendations, and suggestions regarding the proposed use, as well as specimens of the labeling proposed for the food additive and applicable provisions of the Federal Food, Drug, and Cosmetic Act on the finished food by reason of the use of the food additive. If the additive results in residues which may reasonably be expected to result from the use of packaging material, the petitioner shall show how this may occur and what residues may reasonably be anticipated.

(Typewritten or other draft-labeling copy will be accepted for consideration of the petition, provided a statement is made that final printed labeling identical in content to the draft copy will be submitted as soon as available and prior to the marketing of the food additive.

If the food additive is one for which a tolerance limitation is required to assure its safety, the level of use proposed should be no higher than the amount reasonably required to accomplish the intended physical or other technical effect, even though the safety data may support a higher tolerance.)

C. Data establishing that the food additive will have the intended physical or other technical effect or that it may reasonably be expected to become a component, or to affect the characteristics, directly or indirectly, of food and the amount necessary to accomplish this. These data should include information in sufficient detail to permit evaluation with control data.

D. A description of practicable methods to determine the amount of the food additive in the raw, processed, and/or finished food and of any substance formed in or on such food because of its use. The test proposed shall be one that can be used for food-control purposes and that can be applied with consistent results by any properly equipped and trained laboratory personnel.

E. Full reports of investigations made with respect to the safety of the food additive. (A petition may be regarded as incomplete unless it includes full reports of adequate tests reasonably applicable to show whether or not the food additive will be safe for its intended use. The reports ordinarily should include detailed data derived from appropriate animal and other biological experiments in which the methods used and the results obtained are clearly set forth. The petition shall not omit without explanation any reports of investigations that would bias an evaluation of the safety of the food additive.)

F. Proposed tolerances for the food additive, if tolerances are required in order to ensure its safety. A petitioner may include a proposed regulation.

G. If submitting petition to modify an existing regulation issued pursuant to section 409(c)(1)(A) of the act, full information on each proposed change that is to be made in the original regulation must be submitted. The petition may omit statements made in the original petition concerning which no change is proposed. A supplemental petition must be submitted for any change beyond the variations provided for in the original petition and the regulation issued on the basis of the original petition.

H. The petitioner is required to submit either a claim for categorical exclusion under §25.30 or §25.32 of this chapter or an environmental assessment under §25.40 of this chapter.

Yours very truly,
Petitioner

By __________________ (Indicate authority)

(d) The petitioner will be notified of the date on which his petition is filed, and an incomplete petition, or one that has not been submitted in triplicate, will usually be retained but not filed as a petition under section 409 of the act. The petitioner will be notified in what respects his petition is incomplete.

(e) The petition must be signed by the petitioner or by his attorney or agent, or (if a corporation) by an authorized official.

(f) The data specified under the several lettered headings should be submitted on separate sheets or sets of sheets, suitably identified. If such data have already been submitted with an earlier application, the present petition may incorporate it by specific reference to the earlier. If part of the data have been submitted by the manufacturer of the food additive as a master file, the petitioner may refer to the master file if and to the extent he obtains the manufacturer’s written permission to do so. The manufacturer may authorize specific reference to the data without disclosure to the petitioner. Nothing herein shall prevent reference to published data.

(g) A petition shall be retained but shall not be filed if any of the data prescribed by section 409(b) of the act are lacking or are not set forth so as to be readily understood.

(h) The following data and information in a food additive petition are available for public disclosure, unless extraordinary circumstances are shown, after the notice of filing of the petition is published in the Federal Register or, if the petition is not promptly filed because of deficiencies in it, after the petitioner is informed
that it will not be filed because of the deficiencies involved:

(i) All safety and functionality data and information submitted with or incorporated by reference in the petition.

(ii) A protocol for a test or study, unless it is shown to fall within the exemption established for trade secrets and confidential commercial information in §20.61 of this chapter.

(iii) Adverse reaction reports, product experience reports, consumer complaints, and other similar data and information, after deletion of:

(a) Names and any information that would identify the person using the product.

(b) Names and any information that would identify any third party involved with the report, such as a physician or hospital or other institution.

(iv) A list of all ingredients contained in a food additive, whether or not it is in descending order of predominance. A particular ingredient or group of ingredients shall be deleted from any such list prior to public disclosure if it is shown to fall within the exemption established in §20.61 of this chapter, and a notation shall be made that any such ingredient list is incomplete.

(v) An assay method or other analytical method, unless it serves no regulatory or compliance purpose and is shown to fall within the exemption established in §20.61 of this chapter.

(2) The following data and information in a food additive petition are not available for public disclosure unless they have been previously disclosed to the public as defined in §20.81 of this chapter or they relate to a product or ingredient that has been abandoned and they no longer represent a trade secret or confidential commercial or financial information as defined in §20.61 of this chapter:

(i) Manufacturing methods or processes, including quality control procedures.

(ii) Production, sales, distribution, and similar data and information, except that any compilation of such data and information aggregated and prepared in a way that does not reveal data or information which is not available for public disclosure under this provision is available for public disclosure.

(iii) Quantitative or semiquantitative formulas.

(3) All correspondence and written summaries of oral discussions relating to a food additive petition are available for public disclosure in accordance with the provisions of part 20 of this chapter when the food additive regulation is published in the Federal Register.

(4) For purposes of this regulation, safety and functionality data include all studies and tests of a food additive on animals and humans and all studies and tests on a food additive for identity, stability, purity, potency, performance, and usefulness.

(i)(1) Within 15 days after receipt, the Commissioner will notify the petitioner of acceptance or nonacceptance of a petition, and if not accepted the reasons therefor. If accepted, the date of the notification letter sent to petitioner becomes the date of filing. If the petitioner desires, he may supplement a deficient petition after being notified regarding deficiencies. If the supplementary material or explanation of the petition is deemed acceptable, petitioner shall be notified. The date of such notification becomes the date of filing. If the petitioner does not wish to supplement or explain the petition and requests in writing that it be filed as submitted, the petition shall be filed and the petitioner so notified. The date of such notification becomes the date of filing.

(ii) The Commissioner will publish in the Federal Register within 30 days from the date of filing of such petition, a notice of the filing, the name of the petitioner, and a brief description of the proposal in general terms. In the case of a food additive which becomes a component of food by migration from packaging material, the notice shall include the name of the migratory substance, and where it is different from that of one of the original components, the name of the parent component, the maximum quantity of the migratory substance that is proposed for use in food, and the physical or other technical effect which the migratory substance or its parent component is intended to have in the packaging material. A copy of the notice will be
§ 571.6 Amendment of petition.

After a petition has been filed, the petitioner may submit additional information or data in support thereof. In such cases, if the Commissioner determines that the additional information or data amounts to a substantive amendment, the petition as amended will be given a new filing date, and the time limitation will begin to run anew. If nonclinical laboratory studies are involved, additional information and data submitted in support of filed petitions shall include, with respect to each such study, either a statement that the study was conducted in compliance with the requirements set forth in part 58 of this chapter, or, if the study was not conducted in compliance with such regulations, a brief statement of the reason or the noncompliance.


§ 571.7 Withdrawal of petition without prejudice.

(a) In some cases the Commissioner will notify the petitioner that the petition, while technically complete, is inadequate to justify the establishment of a regulation or the regulation requested by petitioner. This may be due to the fact that the data are not sufficiently clear or complete. In such cases, the petitioner may withdraw the petition pending its clarification or the obtaining of additional data. This withdrawal will be without prejudice to a future filing. Upon refiling, the time limitation will begin to run anew from the date of refiling.

(b) At any time before the order provided for in §571.100(a) has been forwarded to the Federal Register for publication, the petitioner may withdraw the petition without prejudice to a future filing. Upon refiling the time limitation will begin to run anew.

Subpart B—Administrative Actions on Applications

§ 571.100 Regulation based on petition.

(a) The Commissioner will forward for publication in the Federal Register, within 90 days after filing of the petition (or within 180 days if the time is extended as provided for in section 409(c)(2) of the act), a regulation prescribing the conditions under which the food additive may be safely used.
(including, but not limited to, specifications as to the particular food or classes of food in or on which such additive may be used, the maximum quantity that may be used or permitted to remain in or on such food, the manner in which such additive may be added to or used in or on such food, and any directions or other labeling or packaging requirements for such additive deemed necessary by him to assure the safety of such use), and prior to the forwarding of the order to the FEDERAL REGISTER for publication shall notify the petitioner of such order and the reasons for such action; or by order deny the petition, and shall notify the petitioner of such order and of the reasons for such action.

(b) If the Commissioner determines that additional time is needed to study and investigate the petition, he shall by written notice to the petitioner extend the 90-day period for not more than 180 days after the filing of the petition.

§ 571.102 Effective date of regulation.

A regulation published in accordance with § 571.100(a) shall become effective upon publication in the FEDERAL REGISTER.

§ 571.110 Procedure for objections and hearings.

Objections and hearings relating to food additive regulations under section 409(c), (d), or (h) of the act shall be governed by part 12 of this chapter.


§ 571.115 Application of the cancer clause of section 409 of the act.

Food additives intended for use as an ingredient in food for animals that are raised for food production and that have the potential to contaminate human food with residues whose consumption could present a risk of cancer to people must satisfy the requirements of subpart E of part 500 of this chapter.

[52 FR 49588, Dec. 31, 1987]

§ 571.130 Procedure for amending and repealing tolerances or exemptions from tolerances.

(a) The Commissioner, on his own initiative or on the petition of any interested person, pursuant to part 10 of this chapter, may propose the issuance of a regulation amending or repealing a regulation pertaining to a food additive or granting or repealing an exception for such additive.

(b) Any such petition shall include an assertion of facts, supported by data, showing that new information exists with respect to the food additive or that new uses have been developed or old uses abandoned, that new data are available as to toxicity of the chemical, or that experience with the existing regulation or exemption may justify its amendment or repeal. New data shall be furnished in the form specified in § 571.1 for submitting petitions.

§ 573.120 Acrylamide-acrylic acid resin.

Acrylamide-acrylic acid resin (hydrolized polyacrylamide), only for the purposes of this section as described below, may be safely used in accordance with the following prescribed conditions:

(a) The additive is produced by polymerization of acrylamide with partial hydrolysis, or by copolymerization of acrylamide and acrylic acid with the greater part of the polymer being composed of acrylamide units.

(b) The additive meets the following specifications:

1. A minimum molecular weight of 3 million.
2. Viscosity range: 3,000 to 6,000 centipoises at 77 °F in a 1 percent aqueous solution as determined by LVF Brookfield Viscometer or equivalent using a number 6 spindle at 20 r.p.m.
3. Residual acrylamide: Not more than 0.05 percent.

(c) It is used as a thickener and suspending agent in nonmedicated aqueous suspensions intended for addition to animal feeds.

[41 FR 38652, Sept. 10, 1976, as amended at 45 FR 38058, June 6, 1980]

§ 573.130 Aminoglycoside 3′-phosphotransferase II.

The food additive aminoglycoside 3′-phosphotransferase II may be safely used in the development of genetically modified cotton, oilseed rape, and tomatoes in accordance with the following prescribed conditions:

(a) The food additive is the enzyme aminoglycoside 3′-phosphotransferase II (CAS Reg. No. 58943–39–8) which catalyzes the phosphorylation of certain aminoglycoside antibiotics, including kanamycin, neomycin, and gentamicin.

(b) Aminoglycoside 3′-phosphotransferase II is encoded by the kan gene originally isolated from transposon Tn5 of the bacterium Escherichia coli.

(c) The level of the additive does not exceed the amount reasonably required for selection of plant cells carrying the kan gene along with the genetic material of interest.

[59 FR 26711, May 23, 1994]

§ 573.140 Ammoniated cottonseed meal.

The food additive ammoniated cottonseed meal may be safely used in accordance with the following conditions:

(a) The food additive is the product obtained by the treatment of cottonseed meal with anhydrous ammonia until a pressure of 50 pounds per square inch gauge is reached.

(b) It is used or intended for use in the feed of ruminants as a source of protein and/or as a source of non-protein nitrogen in an amount not to exceed 20 percent of the total ration.
§ 573.180 Anhydrous ammonia.

(a) The food additive anhydrous ammonia is applied directly to corn plant material and thoroughly blended prior to ensiling. It is used or intended for use as a source of nonprotein nitrogen in cattle feed in accordance with paragraphs (a)(1), (2), or (3) as follows:

(1)(i) The food additive anhydrous ammonia is applied as a component of an aqueous premix containing 16 to 17 percent ammonia, with molasses, minerals, and not less than 83 percent crude protein. The premix is a source of nonprotein nitrogen and minerals.

(ii) In addition to the requirements of paragraph (b) of this section, the labeling shall bear an expiration date of not more than 10 weeks after date of manufacture; a statement that additional protein should not be fed to lactating dairy cows producing less than 32 pounds of milk per day nor beef cattle consuming less than 1 percent of body weight daily in shelled corn; and a warning not to use additional trace mineral supplementation with treated silage.

(2)(i) The food additive anhydrous ammonia is applied directly to corn plant material for use in dairy or beef cattle rations.

(ii) The anhydrous ammonia is applied at a rate not to exceed the equivalent of 0.35 percent of the corn plant material.

(iii) It is applied to corn plant material containing 30 to 35 percent dry matter.

(iv) It is applied so that 75 to 85 percent of the additive is liquid at ambient pressure.

(3)(i) The food additive anhydrous ammonia is applied after being diluted to a 15 to 30 percent aqueous ammonia solution (by weight).

(ii) The anhydrous ammonia solution is applied at a rate not to exceed anhydrous ammonia equivalent to 0.3 percent of the corn plant material.

(iii) It is applied to corn plant material containing 28 to 38 percent dry matter.

(iv) The silage treated with aqueous ammonia is to be fed to dairy cattle only.

(b) Its labeling shall bear, in addition to the other requirements of the act,
§ 573.200 Condensed animal protein hydrolysate.

(a) Identity. The condensed animal protein hydrolysate is produced from the meat byproducts scraped from cured (salted) hides taken from cattle slaughtered for food consumption. The meat byproduct is hydrolyzed with heat and phosphoric acid.

(b) Specifications. The additive shall conform to the following percent-by-weight specifications:

Moisture, not less than 45 percent nor more than 50 percent.

Protein, not less than 24 percent.

Salt (NaCl), not more than 15 percent.

Phosphorus, not less than 2.25 percent.

(c) Uses. It is used or intended for use as a source of animal protein, phosphorus, and salt (NaCl) as follows:

(1) In poultry and swine feed in an amount not to exceed 5 percent by weight of the feed.

(2) In feed concentrates for cattle in an amount not to exceed 10 percent by weight of the concentrate.

(d) Labeling. The label and labeling shall bear, in addition to the other information required by the act:

(i) The name of the additive.

(ii) The maximum percentage of equivalent crude protein from non-protein nitrogen.

(iii) The statement “Do not feed to animals producing milk for human consumption.”

§ 573.220 Feed-grade biuret.

The food additive feed grade biuret may be safely used in ruminant feed in accordance with the following prescribed conditions:

(a) The food additive is the product resulting from the controlled pyrolysis of urea conforming to the following specifications:

<table>
<thead>
<tr>
<th>Component</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea</td>
<td>15 maximum.</td>
</tr>
<tr>
<td>Cyanuric acid and biuret</td>
<td>30 maximum.</td>
</tr>
<tr>
<td>Mineral oil</td>
<td>0.5 maximum.</td>
</tr>
</tbody>
</table>

(b) It is used in ruminant feeds as a source of nonprotein nitrogen.

(c) To assure safe use of the additive:

(1) The label and labeling of the additive and that of any feed additive supplement, feed additive concentrate, feed additive premix, or complete feed prepared therefrom shall contain, in addition to other information required by the act, the following:

(i) The name of the additive.

(ii) The maximum percentage of equivalent crude protein from non-protein nitrogen.

(iii) The statement “Do not feed to animals producing milk for human consumption.”

(2) The label shall recommend that the diet be balanced to provide adequate nutrients when equivalent crude protein from all forms of nonprotein nitrogen exceed one-third of the total crude protein in the total daily ration.

§ 573.225 1,3-Butylene glycol.

The food additive 1,3-butylene glycol (1,3-butanediol) may be safely used in accordance with the following prescribed conditions:

(a) It complies with the specifications in §173.220(a) of this chapter.

(b) It is intended for use in swine feed as a source of energy.

(c) It is to be thoroughly mixed into feed at levels not to exceed 9 percent of the dry matter of the total ration.

(d) 1,3-Butylene glycol should be mixed in feed with equipment adapted for the addition of liquids, and the feed should be mixed not less than 5 minutes after its addition.

§ 573.240 Calcium periodate.

The food additive calcium periodate may be safely used in accordance with the following prescribed conditions:

(a) The additive is produced by reacting calcium iodate with calcium hydroxide or calcium oxide to form a substance consisting of not less than 60 percent by weight of penta calcium orthoperiodate containing 28 to 31 percent by weight of iodine.
Food and Drug Administration, HHS

§ 573.260 Calcium silicate.

Calcium silicate, including synthetic calcium silicate, may be safely used as an anticaking agent in animal feed, provided that the amount of calcium silicate does not exceed 2 percent.

§ 573.280 Feed-grade calcium stearate and sodium stearate.

Feed-grade calcium stearate and sodium stearate may be safely used in an animal feed in accordance with the following prescribed conditions:

(a) Feed-grade calcium stearate and sodium stearate are the calcium or sodium salts of a fatty acid mixture that is predominately stearic acid. Associated fatty acids, including palmitic acid and minor amounts of lauric, myristic, pentadecanoic, margaric, arachidic, and other fatty acids may be contained in the mixture, but such associated fatty acids in aggregate do not exceed 35 percent by weight of the mixture. The fatty acids may be derived from feed-grade fats or oils.

(b) The additives meet the following specifications:

(1) Unsaponifiable matter does not exceed 2 percent.

(2) They are free of chick-edema factor.

(c) The additives are manufactured so that in aqueous solution they are exposed for 1 hour or longer to temperature in excess of 180 °F.

(d) They are used as anticaking agents in animal feeds in accordance with current good manufacturing practices.

[63 FR 8573, Feb. 20, 1998]

§ 573.300 Choline xanthate.

Choline xanthate may be safely used as a component of animal feed as an added source of choline to supplement the diets of poultry, ruminants, and swine in accordance with good manufacturing practices.

[61 FR 8573, Feb. 20, 1998]

§ 573.310 Crambe meal, heat toasted.

(a) The additive is the seed meal of Crambe abyssinica obtained after the removal of oil from the seed and hull. The oil may be removed by pre-press solvent extraction or by solvent extraction alone. The resulting seed meal is heat toasted.

(b) The additive conforms to the following percent-by-weight specifications: moisture, not more than 11 percent; oil, not more than 4 percent; crude protein, not less than 24 percent; crude fiber, not more than 26 percent; glucosinolate calculated as epi-progoitrin, not more than 4 percent; goitrin, not more than 0.1 percent; nitrile calculated as 1-cyano-2-hydroxy-3-butene, not more than 1.4 percent. At least 50 percent of the nitrogen shall be soluble in 0.5 M sodium chloride. Myrosinase enzyme activity shall be absent.

(c) The additive is used or intended for use in the feed of feedlot cattle as a source of protein in an amount not to exceed 4.2 percent of the total ration.

[46 FR 30082, June 5, 1981]

§ 573.320 Diammonium phosphate.

The food additive diammonium phosphate may be safely used in ruminant feed in accordance with the following prescribed conditions:

(a) The food additive is the product resulting from the neutralization of feeding-phosphoric-acid or defluorinated wet-process phosphoric acid with anhydrous ammonia. It contains not less than 106.25 percent equivalent crude protein (nitrogen X 6.25) and 20 percent phosphorus. It contains not more than the following:

1 part fluorine to 100 parts phosphorus.
75 parts per million or arsenic (as As).
30 parts per million of heavy metals, as lead (Pb).

(b) It is used in ruminant feeds as a source of phosphorus and nitrogen in an amount that supplies not more than 2 percent of equivalent crude protein in the total daily ration.

(c) To assure safe use of the additive, the label and labeling of the additive and that of any feed additive supplement, feed additive concentrate, feed additive premix, or complete feed prepared therefrom shall contain, in addition to other information required by the act, the following:

(1) The name of the additive.
(2) The maximum percentage of equivalent crude protein from the non-protein nitrogen.

(3) If the feed additive premix, feed additive concentrate, or feed additive supplement contains more than 2 percent equivalent crude protein from diammonium phosphate, adequate directions for use and a prominent statement, “Warning—This feed should be used only in accordance with directions furnished on the label.”

§ 573.340 Diatomaceous earth.

(a) Identity. The additive consists of siliceous skeletal material derived from various species of diatoms.

(b) Specifications. The additive shall conform to the following specifications:

Lead, not more than 15 parts per million.
Arsenic (as As), not more than 20 parts per million.
Fluorine, not more than 600 parts per million.

(c) Uses. It is used or intended for use as an inert carrier or anticaking agent in animal feeds in an amount not to exceed 2 percent by weight of the total ration.

§ 573.360 Disodium EDTA.

The food additive disodium EDTA (disodium ethylenediaminetetraacetate) may be safely used in animal feeds, in accordance with the following prescribed conditions:

(a) The food additive contains a minimum of 99 percent disodium ethylenediaminetetraacetate dihydrate (C_{10}H_{14}O_{8}N_{2}Na_2.2H_2O).

(b) It is used to solubilize trace minerals in aqueous solutions, which are then added to animal feeds.

(c) It is used or intended for use in an amount not to exceed 240 parts per million of the additive in finished feed.

(d) To assure safe use of the additive, the label and labeling shall contain:

(1) The name of the additive, ethoxyquin.

(2) A statement of the concentration or strength contained therein.

(3) Adequate use directions to provide for a finished article with the proper concentration of the additive as provided in paragraph (b) of this section, whether or not intermediate premixes are to be used.

(d) The label of any animal feed containing the additive shall, in addition to the other information required by the act, bear the statement “Ethoxyquin, a preservative” or “Ethoxyquin added to retard the oxidative destruction of carotene, xanthophylls, and vitamins A and E.”

§ 573.400 Ethoxyquin in certain dehydrated forage crops.

Ethoxyquin (1,2-dihydro-6-ethoxy-2,2,4-trimethylquinoline) may be safely used in the dehydrated forage crops listed in paragraph (a) of this section when incorporated therein in accordance with the conditions prescribed in this section:

(a) It may be added to dehydrated forage prepared from:

<table>
<thead>
<tr>
<th>Crop</th>
<th>Scientific Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfalfa</td>
<td>Medicago sativa.</td>
</tr>
<tr>
<td>Barley</td>
<td>Hordeum vulgare.</td>
</tr>
<tr>
<td>Clovers:</td>
<td></td>
</tr>
<tr>
<td>Alsike clover</td>
<td>Trifolium hybridum.</td>
</tr>
<tr>
<td>Crimson clover</td>
<td>Trifolium incarnatum.</td>
</tr>
<tr>
<td>Red clover</td>
<td>Trifolium pratense.</td>
</tr>
<tr>
<td>White clover</td>
<td>Trifolium repens.</td>
</tr>
<tr>
<td>White sweetclover</td>
<td>Melilotus alba.</td>
</tr>
<tr>
<td>Yellow sweetclover</td>
<td>Melilotus officinalis.</td>
</tr>
<tr>
<td>Coastal Bermudagrass</td>
<td>Cynodon dactylon.</td>
</tr>
<tr>
<td>Corn</td>
<td>Zea mays.</td>
</tr>
<tr>
<td>Fescue</td>
<td>Festuca sp.</td>
</tr>
</tbody>
</table>

§ 573.380 Ethoxyquin in animal feeds.

Ethoxyquin (1,2-dihydro-6-ethoxy-2,2,4-trimethylquinoline) may be safely used in animal feeds, when incorporated therein in accordance with the following prescribed conditions:

(a) It is intended for use only: (1) As a chemical preservative for retarding oxidation of carotene, xanthophylls, and vitamins A and E in animal feed and fish food and, (2) as an aid in preventing the development of organic peroxides in canned pet food.

(b) The maximum quantity of the additive permitted to be used and to remain in or on the treated article shall not exceed 150 parts per million.

(c) To assure safe use of the additive, the label and labeling of the food additive container and that of any intermediate premixes prepared therefrom shall contain, in addition to other information required by the act:

(1) The name of the additive, ethoxyquin.

(2) A statement of the concentration or strength contained therein.

(3) Adequate use directions to provide for a finished article with the proper concentration of the additive as provided in paragraph (b) of this section, whether or not intermediate premixes are to be used.

(d) The label of any animal feed containing the additive shall, in addition to the other information required by the act, bear the statement “Ethoxyquin, a preservative” or “Ethoxyquin added to retard the oxidative destruction of carotene, xanthophylls, and vitamins A and E.”
Food and Drug Administration, HHS

§ 573.450 Oats, orchardgrass, ryegrass, reed canarygrass, sorghums, sudan grass, wheat, or any mixture of such forage crops, for use only as an animal feed.

(b) Such additive is used only as a chemical preservative for the purpose of retarding oxidative destruction of naturally occurring carotenes and vitamin E in the forage crops.

(c) It is added to the dehydrated forage crops in an oil mixture containing only suitable animal or suitable vegetable oil, prior to grinding and mixing.

(d) The maximum quantity of the additive permitted to be used and to remain in or on the dehydrated forage crop shall not exceed 150 parts per million.

(e) To assure the safe use of the additive, the label of the market package shall contain, in addition to other information required by the act:

(1) The name of the additive as specified in this section.

(2) Directions for the incorporation of the additive in the forage crops, as specified in paragraph (c) of this section, with the directive that only suitable animal or suitable vegetable oils are to be used in the oil mix.

(f) The label of any dehydrated forage crops treated with the additive or the label of an animal-feed supplement containing such treated forage crops, shall, in addition to other information required by the act, bear the following statements:

(1) “Ethoxyquin, a preservative,” or “Ethoxyquin added to retard the oxidative destruction of carotene and vitamin E.”

(2) The statement “For use in animal feed only.”

§ 573.440 Ethylene dichloride.

The food additive ethylene dichloride may be safely used in the manufacture of animal feeds in accordance with the following prescribed conditions:

(a) It is used as a solvent in the extraction processing of animal byproducts for use in animal feeds.

(b) The maximum quantity of the additive permitted to remain in or on the extracted byproducts shall not exceed 300 parts per million.

(c) The extracted animal byproduct is added as a source of protein to a total ration at levels consistent with good feeding practices, but in no event at levels exceeding 13 percent of the total ration.

§ 573.450 Fermented ammoniated condensed whey.

(a) Identity. The product is produced by the Lactobacillus bulgaricus fermentation of whey with the addition of ammonia.

(b) Specifications. The product contains 35 to 55 percent crude protein and not more than 42 percent equivalent crude protein from nonprotein nitrogen sources.

(c) Uses. The product is used as a source of protein and nonprotein nitrogen for cattle.

(d) Limitations. (1) Store in a closed vented tank equipped for agitation. Agitate 5 minutes before using. Do not store at temperature above 110 °F (43 °C).

(2) The maximum level of use of fermented ammoniated condensed whey and equivalent crude protein from all other added forms of nonprotein nitrogen shall not exceed 30 percent of the dietary crude protein.

(3) The additive may be used as follows:

(i) Mixed with grain, roughage, or grain and roughage prior to feeding.

(ii) As a component of free-choice liquid feeds, used to supplement the diets of cattle fed other sources of nutrients, fermented ammoniated condensed whey, or any mixture of such forage crops, for use only as an animal feed.

§ 573.420 Ethyl cellulose.

The food additive ethyl cellulose may be safely used in animal feed in accordance with the following prescribed conditions:

(a) The food additive is a cellulose ether containing ethoxy (OC₂H₅) groups attached by an ether linkage and containing on an anhydrous basis not more than 2.6 ethoxy groups per anhydroglucose unit.

(b) It is used or intended for use as a binder or filler in dry vitamin preparations to be incorporated into animal feed.
§ 573.460 Formaldehyde.

The food additive formaldehyde may be safely used in the manufacture of animal feeds in accordance with the following conditions:

(a)(1) The additive is used, or intended for use, to improve the handling characteristics of animal fat in combination with certain oilseed meals by producing therefrom a dry, free-flowing product as follows:

(i) An aqueous blend of soybean and sunflower meals in a ratio of 3:1, respectively, is mixed with animal fat such that the oilseed meals and animal fat are in a ratio of 3:2. The feed ingredients are those defined by the “Official Publication” of the Association of American Feed Control Officials, Inc., 1976 ed., pages 86, 103, and 109.\(^1\)

(ii) Formaldehyde (37 percent solution) is added to the mixture at a level of 4 percent of the dry matter weight of the oilseed meals and animal fat. This mixture, upon drying, contains not more than 1 percent formaldehyde and not more than 12 percent moisture.

(2) The dried mixture described in paragraph (a) of this section is used, or intended for use, as a component of dry, nonpelleted feeds for beef and nonlactating dairy cattle.

(3) To assure safe use of the additive, in addition to the other information required by the Act, the label and labeling of the dried mixture described in paragraph (a) of this section shall bear:

(i) The name of the additive.

(ii) Adequate directions for use providing that feed as consumed is not to contain more than 25 percent of the mixture.

(b)(1) The food additive is formaldehyde (CAS No. 50–00–0; 37 percent aqueous solution). It is used at a rate of 5.4 pounds (2.5 kilograms) per ton of animal feed or feed ingredient. It is an antimicrobial agent used to maintain complete animal feeds or feed ingredients Salmonella negative for up to 21 days.

(2) To assure safe use of the additive, in addition to the other information required by the Act, the label and labeling shall contain:

(i) The name of the additive.

(ii) A statement that formaldehyde solution which has been stored below 40 °F or allowed to freeze should not be applied to complete animal feeds or feed ingredients.

(iii) Adequate directions for use including a statement that formaldehyde should be uniformly sprayed on and thoroughly mixed into the complete animal feeds or feed ingredients and that the complete animal feeds or feed ingredients so treated shall be labeled as containing formaldehyde. The label must prominently display the statement: “Treated with formaldehyde to maintain feed Salmonella negative. Use within 21 days.”

(iv) The labeling for feed or feed ingredients to which formaldehyde has been added under the provisions of paragraph (b)(1) of this section is required to carry the following statement: “Treated with formaldehyde to maintain feed Salmonella negative. Use within 21 days.”

(3) To assure safe use of the additive, in addition to the other information required by the Act, the label and labeling shall contain:

(i) Appropriate warnings and safety precautions concerning formaldehyde.

(ii) Statements identifying formaldehyde as a poison with potentials for adverse respiratory effects.

(iii) Information about emergency aid in case of accidental inhalation.

(iv) Statements reflecting requirements of applicable sections of the

\(^1\)Copies of the current edition may be obtained from the Treasurer, Donald H. James, West Virginia Department of Agriculture, Capital Complex/Guthrie Center, Charleston, WV 25305.
Food and Drug Administration, HHS

§ 573.540 Hydrolyzed leather meal.

(a) Identity. Hydrolyzed leather meal is produced from leather scraps that are treated with steam for not less than 33 minutes at a pressure of not less than 125 pounds per square inch.

(b) Specifications. The additive shall conform to the following percent-by-weight specifications:

- Moisture, not less than 5 percent nor more than 10 percent.
- Crude protein, not less than 60 percent.

(c) Uses. The additive shall be used as a source of metabolizable energy in animal feed in accordance with good manufacturing and feeding practices.

(d) Limitations. The level of use of the product shall not exceed 15 percent of the total weight of the pet food formulation.

(e) Labeling. The labeling shall bear, in addition to other information required by the Act:

(1) The name of the additive.
(2) Adequate directions for use in accordance with the provisions in paragraph (d) of this section.

[45 FR 22920, Apr. 4, 1980]
§ 573.560 Crude fat, not less than 5 percent.
Crude fiber, not more than 6 percent.
Chromium, not more than 2.75 percent.

(c) Use. It is used or intended for use as a source of protein in swine feeds in an amount not to exceed 1.0 percent by weight of the finished feed.

(d) Labeling. The labels and labeling shall bear, in addition to the other information required by the Act:
(1) The name of the additive, hydrolyzed leather meal.
(2) Adequate directions to provide finished feeds complying with paragraph (c) of this section.

§ 573.560 Iron ammonium citrate.

Iron ammonium citrate may be safely used in animal feed in accordance with the following prescribed conditions:

(a) The additive is the chemical green ferric ammonium citrate.

(b) The additive is used or intended for use as an anticaking agent in salt for animal consumption so that the level of iron ammonium citrate does not exceed 25 parts per million (0.0025 percent) in the finished salt.

(c) To assure safe use of the additive the label or labeling of the additive shall bear, in addition to the other information required by the Act:
(1) The name of the additive.
(2) Adequate directions to provide a final product that complies with the limitations prescribed in paragraph (b) of this section.


Iron-choline citrate complex made by reacting approximately equimolecular quantities of ferric hydroxide, choline, and citric acid may be safely used as a source of iron in animal feed.

§ 573.600 Lignin sulfonates.

Lignin sulfonates may be safely used in animal feeds in accordance with the following prescribed conditions:

(a) For the purpose of this section, the food additive is either one, or a combination of, the ammonium, calcium, magnesium, or sodium salts of the extract of spent sulfite liquor derived from the sulfite digestion of wood or of abaca (Musa textilis) or of sissal (Agave sisalana) in either a liquid form (moisture not to exceed 50 percent by weight) or dry form (moisture not to exceed 6 percent by weight).

(b) It is used or intended for use in an amount calculated on a dry weight basis, as follows:
(1) As a pelleting aid in the liquid or dry form in an amount not to exceed 4 percent of the finished pellets.
(2) As a binding aid in the liquid form in the flaking of feed grains in an amount not to exceed 4 percent of the flaked grain.
(3) As a surfactant in molasses used in feeds, as liquid lignin sulfonate, in an amount not to exceed 11 percent of the molasses.

(4) As a source of metabolizable energy, in the liquid or dry form, in an amount not to exceed 4 percent of the finished feed.

§ 573.620 Menadione dimethylpyrimidinol bisulfite.

The food additive, menadione dimethylpyrimidinol bisulfite, may be safely used in accordance with the following conditions:

(a) The additive is the 2-hydroxy-4,6-dimethylpyrimidinol salt of menadione (C17H18O6N2S).

(b) The additive is used or intended for use as a nutritional supplement for the prevention of vitamin K deficiency as follows:
(1) In chicken and turkey feed at a level not to exceed 2 grams per ton of complete feed.
(2) In the feed of growing and finishing swine at a level not to exceed 10 grams per ton of feed.

(c) To assure safe use, the label and labeling of the additive shall bear adequate directions for use.

§ 573.625 Menadione nicotinamide bisulfite.

The food additive may be safely used as follows:

(a) The additive is 1,2,3,4-tetrahydro-2-methyl-1,4-dioxo-2-naphthalene sulfonic acid with 3-pyridine carboxylic acid amine (CAS No. 73581–79–0).

(b) The additive is used or intended for use as a nutritional supplement for both the prevention of vitamin K deficiency and as a source of supplemental niacin as follows:
Food and Drug Administration, HHS

§ 573.640 Methyl esters of higher fatty acids.

The food additive methyl esters of higher fatty acids may be safely used in animal feeds in accordance with the following prescribed conditions:

(a) The food additive is manufactured by reaction of methyl alcohol with feed-grade fats or oils and consists of not less than 70 percent methyl esters of the following straight-chain monacarboxylic acids: Docosahexanoic acid, eicosapentanoic acid, linoleic acid, myristic acid, oleic acid, palmitic acid, palmitoleic acid, and stearic acid, and lesser amounts of the associated acid esters.

(b) The food additive meets the following specifications:

(1) Free methyl alcohol not to exceed 150 parts per million.

(2) Unsaponifiable matter not to exceed 2 percent.

(3) It is free of chick-edema factor or other factors toxic to chicks, as evidenced during the bioassay method for determining the chick-edema factor as prescribed in paragraph (b)(4)(ii) of this section.

(4) For the purposes of this section:

(i) Unsaponifiable matter shall be determined by the method described in Section 28.081, “Unsaponifiable Residue (20)—Official Final Action” of the “Official Methods of Analysis of the Association of Official Analytical Chemists,” 13th Ed., 1980, p. 451, which is incorporated by reference. Copies are available from the Association of Official Analytical Chemists, 2200 Wilson Blvd., Suite 400, Arlington, VA 22201–3301, or available for inspection at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC 20001. The presence of chick-edema factor shall be determined by a comparison between the mean log of the pericardial fluid volumes of a test group and of a concurrent negative control group. The significance of the difference in pericardial fluid volumes between the test group and the negative control group is determined by calculating a “t” value according to the formula:

\[
t = \frac{\bar{x}_t - \bar{x}_c}{\sqrt{\left(\frac{s_t^2}{n_t}\right) + \left(\frac{s_c^2}{n_c}\right)}}
\]

where:

\(\bar{x}_t\) and \(\bar{x}_c\) are the means of the logs of the pericardial fluid volumes of the test and control groups, respectively;

\(n_t\) and \(n_c\) are the number of chicks in the respective groups;

\(s_t^2\) and \(s_c^2\) are the variances of the test and control groups, respectively.

The variances are calculated as follows:

\[
s^2 = \frac{n(\Sigma x^2) - (\Sigma x)^2}{n(n-1)}
\]

where:

\(\Sigma x\) is the sum of the logs of the pericardial fluid volumes;

\(\Sigma x^2\) is the sum of the squares of the logs of the pericardial fluid volumes for either the test t or control c group data.

The test sample is judged to contain chick-edema factor if the calculated “t” exceeds +1.3 and the mean log of the pericardial fluid volume obtained from the negative control group multiplied by 100 is less than 1.1461.

(iii) “Other factors toxic to chicks” referred to in paragraph (b)(3) of this section shall be determined during the
course of the bioassay test described in paragraph (b)(4)(ii) of this section, on the basis of chick deaths or other abnormalities not attributable to chick-edema factor or to the experimental conditions of the test.

(c) It is used or intended for use as a supplementary source of fat for animal feed.

(d) To assure safe use of the additive, in addition to the other information required by the act:

(1) The label and labeling of the additive, and any feed additive supplement, feed additive concentrate, feed additive premix, or complete feed prepared therefrom shall bear:

(i) The name of the additive.

(ii) The designation "feed grade" in juxtaposition with the name and equally as prominent.

(2) The label or labeling of the additive and any feed additive supplement, feed additive concentrate, feed additive premix, or complete feed prepared therefrom shall bear:

(i) The name of the additive.

(ii) The designation "feed grade" in juxtaposition with the name and equally as prominent.

§ 573.660 Methyl glucoside-coconut oil ester.

Methyl glucoside-coconut oil ester may be safely used in accordance with the following conditions:

(a) The additive meets the specifications prescribed in §172.816 of this chapter.

(b) It is used as a surfactant in molasses intended for use in animal feed at a level not to exceed 320 parts per million.

§ 573.680 Mineral oil.

Mineral oil may be safely used in animal feed, subject to the provisions of this section.

(a) Mineral oil, for the purpose of this section, is that complying with the definition and specifications contained in §172.878 (a) and (b) or in §178.3620(b)(1) (i) and (ii) of this chapter.

(b) It is used in animal feeds for the following purposes:

(1) To reduce dustiness of feeds or mineral supplements.

(2) To serve as a lubricant in the preparation of pellets, cubes, or blocks and to improve resistance to moisture of such pellets, cubes, or blocks.

(3) To prevent the segregation of trace minerals in mineralized salt.

(4) To serve as a diluent carrier in the manufacture of feed grade biuret in accordance with good manufacturing practice.

(5) For the removal of water from substances intended as ingredients of animal feed.

(c) The quantity of mineral oil used in animal feed shall not exceed 3.0 percent in mineral supplements, nor shall it exceed 0.06 percent of the total ration when present in feed or feed concentrates.


§ 573.700 Sodium nitrite.

Sodium nitrite may be safely used in canned pet food containing meat and fish in accordance with the following prescribed conditions:

(a) It is used or intended for use alone as a preservative and color fixative in canned pet food containing fish, meat, and fish and meat byproducts so that the level of sodium nitrite does not exceed 20 parts per million.

(b) To assure safe use of the additive, in addition to the other information required by the act:

(1) The label of the additive shall bear:

(i) The name of the additive.

(ii) A statement of the concentration of the additive in any mixture.

(2) The label or labeling shall bear adequate directions to provide a final product that complies with the limitations prescribed in paragraph (a) of this section.

§ 573.720 Petrolatum.

Petrolatum may be safely used in or on animal feed, subject to the following prescribed conditions:

(a) Petrolatum complies with the specifications set forth in the U.S. Pharmacopeia XVI for white petrolatum or in The National Formulary XII for yellow petrolatum.

(b) Petrolatum meets the following ultraviolet absorbance limits when subjected to the analytical procedure described in §172.865(b) of this chapter.
Ultraviolet absorbance per centimeter path length:

<table>
<thead>
<tr>
<th>Millimicrons</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>280 to 289</td>
<td>0.25</td>
</tr>
<tr>
<td>290 to 299</td>
<td>0.20</td>
</tr>
<tr>
<td>300 to 359</td>
<td>0.14</td>
</tr>
<tr>
<td>360 to 400</td>
<td>0.04</td>
</tr>
</tbody>
</table>

(c) It is used in animal feed for the following purposes:

(1) To reduce dustiness of feeds or mineral supplements.
(2) To serve as a lubricant in the preparation of pellets, cubes, or blocks, and to improve resistance to moisture of such pellets, cubes, or blocks.

(d) The quantity of petrolatum present in animal feeds from the uses specified in paragraph (c) of this section shall not exceed 3 percent in mineral supplements nor shall it exceed 0.06 percent of the total ration when present in feed or feed concentrates.

(e) When used in combination with technical white mineral oil for the uses described in paragraph (c) of this section, the total quantity of combined petrolatum and technical white mineral oil shall not exceed the limits prescribed in paragraph (d) of this section.

(f) Petrolatum may contain any antioxidant permitted in food by regulations issued in accordance with section 409 of the act, in an amount not greater than that required to produce its intended effect.

§ 573.740 Odorless light petroleum hydrocarbons.

Odorless light petroleum hydrocarbons complying with §172.884(a) and (b) of this chapter may be safely used in an amount not in excess of that required as a component of insecticide formulations used in compliance with regulations issued in this part.

§ 573.750 Pichia pastoris dried yeast.

(a) Identity. The food additive Pichia pastoris dried yeast may be used in feed formulations of broiler chickens as a source of protein not to exceed 10 percent by weight of the total formulation.

(b) Specifications. The additive shall conform to the following percent-by-weight specifications:

(1) Crude protein, not less than 60 percent.
(2) Crude fat, not less than 2 percent.
(3) Crude fiber, not more than 2 percent.
(4) Ash, not more than 13 percent.
(5) Moisture, not more than 6 percent.

(c) Use. To ensure safe use, the labeling of the additive and any feed additive supplement, concentrate, or premix prepared therefrom shall bear, in addition to other required information, the name of the additive, directions for use to provide not more than 10 percent by weight of the total ration, and the statement “Caution: Not to be used in layers or other poultry intended for breeding.”

[58 FR 59170, Nov. 8, 1993]

§ 573.760 Poloxalene.

The food additive poloxalene may be safely used in accordance with the following prescribed conditions:

(a) The additive consists of polyoxypropylene-polyoxyethylene glycol nonionic block polymer meeting the following specifications:

(1) Molecular weight range: 2,850–3,150.
(2) Hydroxyl number: 35.7–39.4.
(3) Cloud point (10 percent solution): 42 °C–46 °C.
(4) Structural formula:

\[
\text{HO(CH}_2\text{CH}_2\text{O)}_{11.13}\text{CH}_2\text{CH}_2\text{O)}_{32.36}\text{CH}_2\text{CH}_2\text{O)}_{11.13}\text{H}
\]

(b) In feed as a surfactant for the flaking of feed grains when added to liquid grain conditioner in an amount not to exceed 1.0 percent of the conditioner. The conditioner is added to the feed at a rate of 1 quart per ton of feed.

(c) The label and labeling shall bear, in addition to the other information required by the Act:

(1) The name of the additive.
(2) Adequate directions and warnings for use.

§ 573.780 Polyethylene.

(a) Identity. Polyethylene consists of basic polymers manufactured by the catalytic polymerization of ethylene.

(b) Specifications. (1) For the purposes of this section, polyethylene shall meet
§ 573.800 Polyethylene glycol (400) mono- and dioleate.

(a) The food additive polyethylene glycol (400) mono- and dioleate meets the following specifications: Saponification number, 80-88; acid number, 5.0 maximum; and average molecular weight range, 640-680.

(b) It is used as a processing aid in the production of animal feeds when present as a result of its addition to molasses in an amount not to exceed 250 parts per million of the molasses.

§ 573.820 Polyoxylethylene glycol (400) mono- and dioleates.

The food additive polyoxylethylene glycol (400) mono- and dioleates may be safely used as an emulsifier in milk-replacer formulations.

§ 573.840 Polysorbate 60.

The food additive polysorbate 60 (polyoxyethylene (20) sorbitan mono- stearate) may be safely used in animal feeds in accordance with the following prescribed conditions:

(a) It is used alone or in combination with sorbitan monostearate as an emulsifier in mineral premixes and dietary supplements for animal feeds.

(b) It is used as an emulsifier in milk-replacer formulations for calves.

§ 573.860 Polysorbate 80.

The food additive polysorbate 80 (polyoxyethylene (20) sorbitan monoooleate) may be safely used as an emulsifier in milk-replacer formulations for calves.

§ 573.870 Poly(2-vinylpyridine-co-styrene).

The food additive poly(2-vinylpyridine-co-styrene) may be safely used as nutrient protectant in feed for beef cattle and dairy cattle and replacement dairy heifers when used in accordance with the following conditions:

(a) The additive meets the following specifications:

<table>
<thead>
<tr>
<th>Component/property</th>
<th>Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inherent viscosity</td>
<td>1.0-1.6 deciliter per gram.\textsuperscript{1}</td>
</tr>
<tr>
<td>Styrene moiety</td>
<td>40 percent maximum.</td>
</tr>
<tr>
<td>2-Vinylpyridine moiety</td>
<td>90 percent maximum.</td>
</tr>
<tr>
<td>Residual styrene</td>
<td>200 parts per billion maximum.</td>
</tr>
<tr>
<td>Residual 2-vinylstyrone</td>
<td>200 parts per billion maximum.</td>
</tr>
<tr>
<td>Heavy metals such as lead</td>
<td>&gt;10 parts per million.</td>
</tr>
<tr>
<td>Arsenic</td>
<td>&gt;3 parts per million.</td>
</tr>
</tbody>
</table>

\textsuperscript{1} Inherent viscosity of a 0.25 percent (weight/volume) solution in dimethylformamide.

(b) The additive is used in the manufacture of rumen-stable, abomasum-dispersible nutrient(s) for beef cattle and dairy cattle and replacement dairy heifers such that the maximum use of the additive from all sources does not exceed 5.1 grams per head per day. The additive may be used to protect the following nutrients:

(1) Methionine. The resulting product must contain a maximum of 10 percent poly(2-vinylpyridine-co-styrene) by weight and a minimum of 55 percent methionine by weight. The coated methionine must be established through in vitro tests to be at least 90 percent rumen-stable, of which at least 90 percent is subsequently dispersible under abomasal conditions.

(2) Methionine and lysine. The resulting product must contain a maximum of 10 percent poly(2-vinylpyridine-co-styrene) by weight and a minimum of a
combined total of 55 percent methionine and lysine by weight. The coated methionine and lysine must be established through in vitro tests to be at least 90 percent rumen-stable, of which at least 90 percent is subsequently dispersible under abomasal conditions.

(c) Label and labeling. To ensure safe use of the additive, the label and labeling of the additive and of any feed additive supplement, feed additive concentrate, feed additive premix, or liquid feed supplement prepared therefrom, shall bear, in addition to the other information required by the Federal Food, Drug, and Cosmetic Act, the following:

1. The name of the additive.
2. A statement of the concentration of poly(2-vinylpyridine-co-styrene) in any product or mixture.
3. Adequate directions for the use of the rumen-stable, abomasum-dispersible nutrient(s) products.
4. The following statement: “Warning: Maximum use of poly(2-vinylpyridine-co-styrene) from all sources is not to exceed 5.1 grams per head per day.”

§ 573.880 Normal propyl alcohol.
Normal propyl alcohol may be safely used in feeds and feed supplements for cattle as a source of metabolizable energy. It is incorporated in the feed or feed supplement in an amount which provides not more than 54.5 grams of the additive per head per day.

§ 573.900 Pyrophyllite.
Pyrophyllite (aluminum silicate monohydrate) may be safely used as the sole anticaking aid, blending agent, pelleting aid, or carrier in animal feed when incorporated therein in an amount not to exceed 2 percent in complete animal feed.

§ 573.914 Salts of volatile fatty acids.
(a) Identity. The food additive is a blend containing the ammonium or calcium salt of isobutyric acid and the ammonium or calcium salts of a mixture of 5-carbon acids—isovaleric, 2-methylbutyric, and n-valeric.

(b) Specifications. The additive contains ammonium or calcium salts of volatile fatty acids and shall conform to the following specifications:

<table>
<thead>
<tr>
<th>Components</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ammonium salts of mixed 5-carbon acids</td>
<td>48 to 54 percent.</td>
</tr>
<tr>
<td>Ammonium salt of isobutyric acid</td>
<td>22 to 26 percent.</td>
</tr>
<tr>
<td>Water</td>
<td>26 percent maximum.</td>
</tr>
<tr>
<td>Ammonia</td>
<td>0.3 percent maximum.</td>
</tr>
<tr>
<td>Arsenic</td>
<td>&gt;3 parts per million.</td>
</tr>
<tr>
<td>Heavy metals as lead</td>
<td>&gt;10 parts per million.</td>
</tr>
</tbody>
</table>

(2) Calcium salts:

<table>
<thead>
<tr>
<th>Components</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium salts of mixed 5-carbon acids</td>
<td>58 to 72 percent.</td>
</tr>
<tr>
<td>Calcium salt of isobutyric acid</td>
<td>26 to 34 percent.</td>
</tr>
<tr>
<td>Calcium hydroxide</td>
<td>3 percent maximum.</td>
</tr>
<tr>
<td>Water</td>
<td>14 percent maximum.</td>
</tr>
<tr>
<td>Arsenic</td>
<td>&gt;3 parts per million.</td>
</tr>
<tr>
<td>Heavy metals as lead</td>
<td>&gt;10 parts per million.</td>
</tr>
</tbody>
</table>

(c) Use. The additive is used or intended for use as a source of energy in dairy cattle feed.

(d) Labeling. The label and labeling of the additive in any feed, feed supplement, feed concentrate, feed premix, or liquid feed supplement prepared therefrom shall bear, in addition to other information required by the act, the following:

1. The name of the additive.
2. Adequate directions for use, including statements expressing maximum use levels. For ammonium salts of volatile fatty acids, the statements: “Not to exceed 160 grams per head per day thoroughly mixed in dairy cattle feed as a source of energy.” For calcium salts of volatile fatty acids, the statement: “Not to exceed 135 grams per head per day thoroughly mixed in dairy cattle feed as a source of energy.”

§ 573.920 Selenium.
(a) Public Law 103–354 enacted October 13, 1994 (the 1994 Act), states that FDA shall not implement or enforce the final rule issued on September 13, 1993 (58 FR 47962), in which FDA stayed
§ 573.920  

21 CFR Ch. I (4–1–02 Edition)

the 1987 amendments and any modification of such rule issued after enactment of the 1994 Act; unless the Commissioner of Food and Drugs makes a determination that:

(1) Selenium additives are not essential at levels authorized in the absence of such final rule, to maintain animal nutrition and protect animal health;

(2) selenium at such levels is not safe to the animals consuming the additive;

(3) selenium at such levels is not safe to individuals consuming edible portions of animals that receive the additive;

(4) selenium at such levels does not achieve its intended effect of promoting normal growth and reproduction of livestock and poultry; and

(5) the manufacture and use of selenium at such levels cannot reasonably be controlled by adherence to current good manufacturing practice requirements.

(6) Paragraphs (b) through (g) of this section provide the currently acceptable levels of selenium supplementation.

(b) The food additive selenium is a nutrient administered in animal feed as sodium selenite or sodium selenate or in a controlled-release sodium selenite bolus, as provided in paragraphs (f) and (g) of this section, or as selenium yeast, as provided in paragraph (h) of this section.

(c) It is added to feed as follows:

(1) In complete feed for chickens, swine, turkeys, sheep, cattle, and ducks at a level not to exceed 0.3 part per million.

(2) In feed supplements for limit feeding as follows:

(i) Sheep: At a level not to exceed an intake of 0.7 milligram per head per day.

(ii) Beef cattle: At a level not to exceed an intake of 3 milligrams per head per day.

(3) In salt-mineral mixtures for free-choice feeding as follows:

(i) Sheep: Up to 90 parts per million in a mixture for free-choice feeding at a rate not to exceed an intake of 0.7 milligram per head per day.

(ii) Beef cattle: Up to 120 parts per million in a mixture for free-choice feeding at a rate not to exceed an intake of 3 milligrams per head per day.

(d) The additive shall be incorporated into feed as follows:

(1) It shall be incorporated into each ton of complete feed by adding no less than 1 pound of a premix containing no more than 272.4 milligrams of added selenium per pound.

(2) It shall be incorporated into each ton of salt-mineral mixture for sheep or beef cattle from a premix containing no more than 4.5 grams of added selenium per pound.

(e) The premix manufacturer shall follow good manufacturing practices in the production of selenium premixes. Inventory, production, and distribution records must provide a complete and accurate history of product production. Production controls must assure products to be what they are purported and labeled. Production controls shall include analysis sufficient to adequately monitor quality.

(f) The label or labeling of any selenium premix shall bear adequate directions and cautions for use including this statement: “Caution: Follow label directions. The addition to feed of higher levels of this premix containing selenium is not permitted.”

(g) The additive is orally administered to beef and dairy cattle as an osmotically controlled, constant release bolus containing sodium selenite. Each bolus contains 360 milligrams of selenium as sodium selenite, and delivers 3 milligrams of selenium per day for 120 days. To ensure safe use of the additive:

(1) The osmotically controlled, constant release bolus is for use only in beef and dairy cattle more than 3 months of age or over 200 pounds body weight.

(2) Only one bolus containing 360 milligrams of selenium as sodium selenite is administered orally to each animal in 120 days.

(3) The labeling shall bear the following: “This bolus delivers the maximum daily allowable amount of selenium and shall be the sole source of supplementation. Do not use in areas containing excess selenium. Do not rebolus within 4 months.”

(h) The additive selenium yeast is added to complete feed for chickens at
§ 573.1000 Verxite.

The food additive verxite may be safely used in animal feed in accordance with the following prescribed conditions:

(a) The additive is a magnesium-aluminum-iron silicate conforming to one of the following:
   (1)(i) Verxite granules: The additive contains a minimum of 98 percent of hydrobiotite; it is thermally expanded and has a bulk density of from 5 to 9 pounds per cubic foot.
   (ii) It is used or intended for use:
        (a) In poultry feed at a level not to exceed 5 percent of the weight of the finished feed as a nonnutritive bulking agent for restricting calorie intake in pullet replacement feeds.
        (b) As an anticaking or blending agent, pelleting aid, or nonnutritive carrier for the incorporation of nutrients in poultry, swine, dog, or ruminant feeds, in an amount not to exceed that necessary to accomplish its intended effect and in no case to exceed 1.5 percent of the dog feed or 5 percent of the final feed for other animals.
   (2)(i) Verxite flakes: The additive contains a minimum of 98 percent of hydrobiotite; it has a bulk density of from 20 to 30 pounds per cubic foot.
   (ii) It is used or intended for use as an anticaking or blending agent, pelleting aid, or nonnutritive carrier for the incorporation of nutrients in poultry, swine, dog, or ruminant feeds in an amount not to exceed 1 percent by weight of the final feed for ruminants.
   (3)(i) Verxite grits: The additive contains a minimum of 80 percent of hydrobiotite; it has a bulk density of from 40 to 50 pounds per cubic foot.
   (ii) It is used or intended for use as a partial roughage replacement in ruminant feeds in an amount not to exceed
§ 573.1010 Xanthan gum.

The food additive xanthan gum may be safely used in animal feed as follows:

(a) The food additive is xanthan gum as defined in §172.695 of this chapter and meets all of the specifications thereof.

(b) It is used or intended for use as a stabilizer, emulsifier, thickener, suspending agent, or bodying agent in animal feed as follows:

1. In calf milk replacers at a maximum use level of 0.1 percent, as fed.
2. In liquid feed supplements for ruminant animals at a maximum use level of 0.25 percent (5 pounds per ton).

(c) To assure safe use of the additive:

1. The label of its container shall bear, in addition to other information required by the act, the name of the additive.
2. The label or labeling of the additive container shall bear adequate directions for use.

[49 FR 44630, Nov. 8, 1984]

§ 573.1020 Yellow prussiate of soda.

Yellow prussiate of soda (sodium ferrocyanide decahydrate: Na₄Fe(Ch₃O₁₆)₆·10H₂O) may be safely used as an anticaking agent in salt for animal consumption at a level not to exceed 13 parts per million. The additive contains a minimum of 99.0 percent by weight of sodium ferrocyanide decahydrate.

[41 FR 38657, Sept. 10, 1976; 41 FR 48100, Nov. 2, 1976]
§ 579.40 Ionizing radiation for the treatment of poultry feed and poultry feed ingredients.

Ionizing radiation for the treatment of complete poultry diets and poultry feed ingredients may be safely used as follows:

(a) Energy sources. Ionizing radiation is limited to gamma rays from sealed units of cobalt-60.

(b) Limitation. The ionizing radiation is used for feed or feed ingredients that do not contain drugs.

(c) Use. Ionizing radiation is used as a single treatment for rendering complete poultry diets or poultry feed ingredients salmonella negative as follows:

(1) Minimum dose 2.0 kiloGrays (kGy) (0.2 megarads Mrad); maximum dose 25 kGy (2.5 megarads Mrad). The absorbed dose of irradiation is to be based on initial concentration of salmonella using the relationship that 1.0 kGy (0.1 Mrad) reduces salmonella concentration by one log cycle (one decimal reduction).

(2) Feeds treated by irradiation should be formulated to account for nutritional loss.

(3) If an irradiated feed ingredient is less than 5 percent of the final product, the final product can be irradiated without being considered to be re-irradiated.


PART 582—SUBSTANCES GENERALLY RECOGNIZED AS SAFE

Subpart A—General Provisions

Sec.
582.1 Substances that are generally recognized as safe.
582.10 Spices and other natural seasonings and flavorings.
582.20 Essential oils, oleoresins (solvent-free), and natural extractives (including distillates).
582.30 Natural substances used in conjunction with spices and other natural seasonings and flavorings.
582.40 Natural extractives (solvent-free) used in conjunction with spices, seasonings, and flavorings.
582.50 Certain other spices, seasonings, essential oils, oleoresins, and natural extracts.
582.60 Synthetic flavoring substances and adjuvants.
582.80 Trace minerals added to animal feeds.
582.99 Adjuvants for pesticide chemicals.

Subpart B—General Purpose Food Additives

582.1005 Acetic acid.
582.1009 Adipic acid.
582.1033 Citric acid.
582.1057 Hydrochloric acid.
582.1061 Lactic acid.
582.1069 Malic acid.
582.1073 Phosphoric acid.
582.1077 Potassium acid tartrate.
582.1087 Sodium acid pyrophosphate.
582.1091 Succinic acid.
582.1095 Sulfuric acid.
582.1099 Tartaric acid.
582.1125 Aluminum sulfate.
582.1127 Aluminum ammonium sulfate.
582.1129 Aluminum potassium sulfate.
582.1131 Aluminum sodium sulfate.
582.1135 Ammonium bicarbonate.
582.1137 Ammonium carbonate.
582.1139 Ammonium hydroxide.
582.1141 Ammonium phosphate.
582.1143 Ammonium sulfate.
582.1155 Bentonite.
582.1165 Butane.
582.1191 Calcium carbonate.
582.1193 Calcium chloride.
582.1195 Calcium citrate.
582.1199 Calcium gluconate.
582.1205 Calcium hydroxide.
582.1207 Calcium lactate.
582.1210 Calcium oxide.
582.1217 Calcium phosphate.
582.1235 Caramel.
582.1240 Carbon dioxide.
582.1275 Dextrose.
582.1320 Glycerin.
582.1324 Glyceryl monostearate.
Pt. 582

582.1355 Helium.
582.1366 Hydrogen peroxide.
582.1400 Lecithin.
582.1425 Magnesium carbonate.
582.1431 Magnesium oxide.
582.1480 Methylcellulose.
582.1500 Monoammonium glutamate.
582.1516 Monopotassium glutamate.
582.1540 Nitrogen.
582.1585 Papain.
582.1613 Potassium bicarbonate.
582.1619 Potassium carbonate.
582.1625 Potassium citrate.
582.1631 Potassium hydroxide.
582.1643 Potassium sulfate.
582.1655 Propane.
582.1666 Propylene glycol.
582.1685 Rennet.
582.1711 Silica aerogel.
582.1721 Sodium acetate.
582.1724 Sodium carbonate.
582.1745 Sodium carboxymethylcellulose.
582.1748 Sodium caseinate.
582.1751 Sodium citrate.
582.1763 Sodium hydroxide.
582.1775 Sodium pectinate.
582.1778 Sodium phosphate.
582.1781 Sodium aluminum phosphate.
582.1792 Sodium sesquisilicate.
582.1804 Sodium potassium tartrate.
582.1810 Sodium tripolyphosphate.
582.1973 Beeswax.
582.1975 Bleached beeswax.
582.1978 Carnauba wax.

Subpart C—Anticaking Agents

582.2122 Aluminum calcium silicate.
582.2227 Calcium silicate.
582.2437 Magnesium silicate.
582.2727 Sodium aluminosilicate.
582.2729 Hydrated sodium calcium aluminosilicate.
582.2906 Tricalcium silicate.

Subpart D—Chemical Preservatives

582.3013 Ascorbic acid.
582.3021 Benzoic acid.
582.3041 Erythorbic acid.
582.3081 Propionic acid.
582.3089 Sorbic acid.
582.3109 Thiodipropionic acid.
582.3149 Ascorbyl palmitate.
582.3169 Butylated hydroxyanisole.
582.3173 Butylated hydroxytoluene.
582.3189 Calcium ascorbate.
582.3221 Calcium propionate.
582.3255 Calcium sorbate.
582.3300 Dilauryl thiodipropionate.
582.3336 Gum guaiac.
582.3490 Methylparaben.
582.3616 Potassium bisulfite.
582.3637 Potassium metabisulfite.

Subpart E—Emulsifying Agents

582.4101 Diacetyl tartaric acid esters of mono- and diglycerides of edible fats or oils, or edible fat-forming fatty acids.
582.4105 Mono- and diglycerides of edible fats or oils, or edible fat-forming acids.
582.4321 Monosodium phosphate derivatives of mono- and diglycerides of edible fats or oils, or edible fat-forming fatty acids.
582.4466 Propylene glycol.

Subpart F—Nutrients and/or Dietary Supplements

582.5013 Ascorbic acid.
582.5017 Aspartic acid.
582.5025 Aminoacetic acid.
582.5049 Aminocapric acid.
582.5056 Linoleic acid.
582.5118 Alanine.
582.5145 Arginine.
582.5159 Biotin.
582.5191 Calcium carbonate.
582.5195 Calcium citrate.
582.5201 Calcium glycerophosphate.
582.5210 Calcium oxide.
582.5212 Calcium pantothenate.
582.5217 Calcium phosphate.
582.5223 Calcium pyrophosphate.
582.5230 Calcium sulfate.
582.5245 Carotene.
582.5250 Choline bitartrate.
582.5252 Choline chloride.
582.5260 Copper gluconate.
582.5271 Cysteine.
582.5273 Cystine.
582.5301 Ferric phosphate.
582.5304 Ferric pyrophosphate.
582.5306 Ferric sodium pyrophosphate.
582.5308 Ferrous gluconate.
582.5311 Ferrous lactate.
582.5315 Ferrous sulfate.
582.5361 Histidine.
582.5370 Inositol.
582.5375 Iron reduced.
582.5381 Isoleucine.
582.5406 Leucine.
582.5411 Lysine.
582.5431 Magnesium oxide.
582.5434 Magnesium phosphate.
582.5443 Magnesium sulfate.
582.5446 Manganese chloride.
582.5449 Manganese citrate.
### § 582.1 Substances that are generally recognized as safe

(a) It is impracticable to list all substances that are generally recognized as safe for their intended use. However, by way of illustration, the Commissioner regards such common food ingredients as salt, pepper, sugar, vinegar, baking powder, and monosodium glutamate as safe for their intended use.

(b) For the purposes of this section, good manufacturing or feeding practice shall be defined to include the following restrictions:

1. The quantity of a substance added to animal food does not exceed the amount reasonably required to accomplish its intended physical, nutritional, or other technical effect in food; and

2. The quantity of a substance that becomes a component of animal food as a result of its use in the manufacturing, processing, or packaging of animal food.

Subpart A—General Provisions

#### Subpart B—Ingredients

- Sodium phosphate
- Sodium pyrophosphate
- Tetra sodium pyrophosphate
- Sodium tartrate
- Sodium potassium tartrate
- Sodium thiosulfate
- Sodium tripolyphosphate

#### Subpart G—Sequestrants

- Citric acid
- Sodium acid phosphate
- Tartaric acid
- Calcium acetate
- Calcium chloride
- Calcium citrate
- Calcium diacetate
- Calcium gluconate
- Calcium hexametaphosphate
- Monobasic calcium phosphate
- Calcium phytate
- Dipotassium phosphate
- Disodium phosphate
- Isopropyl citrate
- Monoisopropyl citrate
- Potassium citrate
- Sodium citrate
- Sodium diacetate
- Sodium gluconate
- Sodium hexametaphosphate
- Sodium metaphosphate


#### Source: 41 FR 38657, Sept. 10, 1976, unless otherwise noted.
§ 582.10 Spices and other natural seasonings and flavorings.

Spices and other natural seasonings and flavorings that are generally recognized as safe for their intended use within the meaning of section 409 of the act, are as follows:

<table>
<thead>
<tr>
<th>Common name</th>
<th>Botanical name of plant source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfalfa herb and seed</td>
<td>Medicago sativa L.</td>
</tr>
<tr>
<td>Allspice</td>
<td>Pimenta officinalis Lindl.</td>
</tr>
<tr>
<td>Ambrette seed</td>
<td>Hibiscus abelmoschus L.</td>
</tr>
<tr>
<td>Angelica</td>
<td>Angelica archangelica L. or other spp. of Angelica. Do.</td>
</tr>
<tr>
<td>Angelica root</td>
<td></td>
</tr>
<tr>
<td>Angelica seed</td>
<td>Do.</td>
</tr>
<tr>
<td>Anis, star</td>
<td>Galipé officinalis Hancock.</td>
</tr>
<tr>
<td>Balm (lemongrass)</td>
<td>Pimpinella anisum L.</td>
</tr>
<tr>
<td>Basil, bush</td>
<td>Melissa officinalis L.</td>
</tr>
<tr>
<td>Basil, sweet</td>
<td>Ocimum minimum L.</td>
</tr>
<tr>
<td>Bay</td>
<td>Ocimum basilicum L.</td>
</tr>
<tr>
<td>Bay</td>
<td>Lauris nobilis L.</td>
</tr>
<tr>
<td>Caraway, black (black cumin)</td>
<td>Calendula officinalis L.</td>
</tr>
<tr>
<td>Cardamon (cardamom)</td>
<td>Camomile (chamomile), English or Roman</td>
</tr>
<tr>
<td>Cassia, Chinese</td>
<td>Camomile (chamomile), German or Hungarian</td>
</tr>
<tr>
<td>Cassia, Padang or Batavia</td>
<td>Capers</td>
</tr>
<tr>
<td>Cassia, Saigon</td>
<td>Capsicum frutescens L. or Capsicum annuum L.</td>
</tr>
<tr>
<td>Cayenne pepper</td>
<td>Capsicum frutescens L. or Capsicum annuum L.</td>
</tr>
<tr>
<td>Celery seed</td>
<td>Apium graveolens L.</td>
</tr>
<tr>
<td>Chervil</td>
<td>Anthriscus cerefolium (L.) Hoffm.</td>
</tr>
<tr>
<td>Chives</td>
<td>Allium schoenoprasum L.</td>
</tr>
<tr>
<td>Cinnamon, Ceylon</td>
<td>Cinnamomum zeylanicum Nees.</td>
</tr>
<tr>
<td>Cinnamon, Chinese</td>
<td>Cinnamomum cassia Blume.</td>
</tr>
<tr>
<td>Cinnamon, Saigon</td>
<td>Cinnamomum zeylanicum Nees.</td>
</tr>
<tr>
<td>Clary (clary sage)</td>
<td>Salvia officinalis</td>
</tr>
<tr>
<td>Clover</td>
<td>Triticum spp.</td>
</tr>
<tr>
<td>Cloves</td>
<td>Eugenia caryophyllata Thurb.</td>
</tr>
<tr>
<td>Coriander</td>
<td>Coriandrum sativum L.</td>
</tr>
<tr>
<td>Cumin (cummin)</td>
<td>Cuminum cyminum L.</td>
</tr>
<tr>
<td>Cumin, black (black caraway)</td>
<td>Nigella sativa L.</td>
</tr>
<tr>
<td>Dill</td>
<td>Anethum graveolens L.</td>
</tr>
<tr>
<td>Elder flowers</td>
<td>Sambucus canadensis L.</td>
</tr>
<tr>
<td>Fennel, common</td>
<td>Foeniculum vulgare Mill.</td>
</tr>
</tbody>
</table>
### § 582.20 Essential oils, oleoresins (solvent-free), and natural extractives (including distillates).

Essential oils, oleoresins (solvent-free), and natural extractives (including distillates) that are generally recognized as safe for their intended use, within the meaning of section 409 of the act, are as follows:

<table>
<thead>
<tr>
<th>Common name</th>
<th>Botanical name of plant source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fennel, sweet (finocchio, Florence fennel)</td>
<td>Foeniculum vulgare Mill. var. duce (DC.) Alex.</td>
</tr>
<tr>
<td>Fenugreek</td>
<td>Trigonella foenum-graecum L.</td>
</tr>
<tr>
<td>Galangal (galangal)</td>
<td>Alpinia galanga Blume.</td>
</tr>
<tr>
<td>Garlic</td>
<td>Allium sativum L.</td>
</tr>
<tr>
<td>Geranium</td>
<td>Pelargonium spp.</td>
</tr>
<tr>
<td>Ginger</td>
<td>Zingiber officinalis Rosc.</td>
</tr>
<tr>
<td>Gliricidia</td>
<td>Gliricidia sepium Jacq.</td>
</tr>
<tr>
<td>Holy basil</td>
<td>Ocimum tenuiflorum L.</td>
</tr>
<tr>
<td>Horehound</td>
<td>Marrubium vulgare L.</td>
</tr>
<tr>
<td>Horseradish</td>
<td>Armoracia lapathifolia Gilib.</td>
</tr>
<tr>
<td>Hysop</td>
<td>Hyssopus officinalis L.</td>
</tr>
<tr>
<td>Lavender</td>
<td>Lavandula officinalis Chois.</td>
</tr>
<tr>
<td>Licorice</td>
<td>Glycyrrhiza glabra L. and other spp. of Glycyrrhiza.</td>
</tr>
<tr>
<td>Linden flowers</td>
<td>Tilia spp.</td>
</tr>
<tr>
<td>Mace</td>
<td>Myristica fragrans Houtt.</td>
</tr>
<tr>
<td>Marigold, pot</td>
<td>Calendula officinalis L.</td>
</tr>
<tr>
<td>Marjoram, pot</td>
<td>Majorana hortensis L.</td>
</tr>
<tr>
<td>Mustard, brown</td>
<td>Brassica nigra (L.) Koch.</td>
</tr>
<tr>
<td>Mustard, white</td>
<td>Brassica rapa (L.) Craib.</td>
</tr>
<tr>
<td>Nutmeg</td>
<td>Myristica fragrans Houtt.</td>
</tr>
<tr>
<td>Oregano (oregano, Mexican oregano, Mexican sage, oregano)</td>
<td>Origanum vulgare L.</td>
</tr>
<tr>
<td>Paprika</td>
<td>Capsicum annuum L.</td>
</tr>
<tr>
<td>Parsley</td>
<td>Petroselinum crispum (Mill.) Mansf.</td>
</tr>
<tr>
<td>Pepper, black</td>
<td>Piper nigrum L.</td>
</tr>
<tr>
<td>Pepper, cayenne</td>
<td>Capsicum frutescens L. or Capsicum annuum L.</td>
</tr>
<tr>
<td>Pepper, red</td>
<td>Do.</td>
</tr>
<tr>
<td>Pepper, white</td>
<td>Piper nigrum L.</td>
</tr>
<tr>
<td>Peppermint</td>
<td>Mentha piperita L.</td>
</tr>
<tr>
<td>Poppy seed</td>
<td>Papaver somniferum L.</td>
</tr>
<tr>
<td>Pot marigold</td>
<td>Calendula officinalis L.</td>
</tr>
<tr>
<td>Pot marjoram</td>
<td>Majorana hortensis L.</td>
</tr>
<tr>
<td>Rosemary</td>
<td>Rosmarinus officinalis L.</td>
</tr>
<tr>
<td>Rue</td>
<td>Ruta graveolens L.</td>
</tr>
<tr>
<td>Saffron</td>
<td>Crocus sativus L.</td>
</tr>
<tr>
<td>Sage</td>
<td>Salvia officinalis L.</td>
</tr>
<tr>
<td>Sage, Greek</td>
<td>Salvia trilooba L.</td>
</tr>
<tr>
<td>Savory, summer</td>
<td>Satureja hortensis L. (Satureja).</td>
</tr>
<tr>
<td>Savory, winter</td>
<td>Satureja montana L. (Satureja).</td>
</tr>
<tr>
<td>Sesame</td>
<td>Sesamum indicum L.</td>
</tr>
<tr>
<td>Spearmint</td>
<td>Mentha spicata L.</td>
</tr>
<tr>
<td>Star anise</td>
<td>Illicium verum Jack.</td>
</tr>
<tr>
<td>Tarragon</td>
<td>Artemisia dracunculus L.</td>
</tr>
<tr>
<td>Thyme</td>
<td>Thymus vulgaris L.</td>
</tr>
<tr>
<td>Thyme, wild or creeping</td>
<td>Thymus serpyllum L.</td>
</tr>
<tr>
<td>Turmeric</td>
<td>Curcuma longa L.</td>
</tr>
<tr>
<td>Vanilla</td>
<td>Vanilla planiflora Andr. or Vanilla tahitensis J. W. Moore.</td>
</tr>
<tr>
<td>Zedoary</td>
<td>Curcuma zedoaria Rosc.</td>
</tr>
</tbody>
</table>

### § 582.20 Essential oils, oleoresins (solvent-free), and natural extractives (including distillates).

Essential oils, oleoresins (solvent-free), and natural extractives (including distillates) that are generally recognized as safe for their intended use, within the meaning of section 409 of the act, are as follows:

<table>
<thead>
<tr>
<th>Common name</th>
<th>Botanical name of plant source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfalfa</td>
<td>Medicago sativa L.</td>
</tr>
<tr>
<td>Allspice</td>
<td>Pimenta officinalis Lind.</td>
</tr>
<tr>
<td>Almond, bitter (free from prussic acid)</td>
<td>Prunus amygdalus Batsch, Prunus armeniaca L. or Prunus persica (L.) Batsch.</td>
</tr>
<tr>
<td>Ambrette (seed)</td>
<td>Hibiscus moschatus L.</td>
</tr>
<tr>
<td>Angelica root</td>
<td>Angelica archangelica L.</td>
</tr>
<tr>
<td>Angelica seed</td>
<td>Do.</td>
</tr>
<tr>
<td>Angelica stem</td>
<td>Do.</td>
</tr>
<tr>
<td>Anise</td>
<td>Galipea officinalis Hancock.</td>
</tr>
<tr>
<td>Asafoetida</td>
<td>Ferula asafoetida L. and related spp. of Ferula.</td>
</tr>
<tr>
<td>Balm (lemon balm)</td>
<td>Melissa officinalis L.</td>
</tr>
<tr>
<td>Common name</td>
<td>Botanical name of plant source</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Balsam of Peru</td>
<td>Myroxylon pereneae Klotzsch.</td>
</tr>
<tr>
<td>Basil</td>
<td>Ocimum basilicum L.</td>
</tr>
<tr>
<td>Bay leaves</td>
<td>Laurus nobilis L.</td>
</tr>
<tr>
<td>Bay (myrca oil)</td>
<td>Pimenta racemosa (Mill.) J. W. Moore.</td>
</tr>
<tr>
<td>Bergamot (bergamot orange)</td>
<td>Citrus aurantium L. subsp. bergamia Wright et Am.</td>
</tr>
<tr>
<td>Bitter almond (free from prussic acid)</td>
<td>Prunus amygdalus Batsch, Prunus armeniaca L., or Prunus persica (L.) Batsch.</td>
</tr>
<tr>
<td>Bois de rose</td>
<td>Ambo rosaedora Ducke.</td>
</tr>
<tr>
<td>Cacao</td>
<td>Theobroma cacao L.</td>
</tr>
<tr>
<td>Camomile (chamomile) flowers, Hungarian</td>
<td>Matricaria chamomilla L.</td>
</tr>
<tr>
<td>Camomile (chamomile) flowers, Roman or English</td>
<td>Anthemis nobilis L.</td>
</tr>
<tr>
<td>Cananga</td>
<td>Cananga odorata Hook. f. and Thoms.</td>
</tr>
<tr>
<td>Capsicum</td>
<td>Capsicum frutescens L. and Capsicum annuum L.</td>
</tr>
<tr>
<td>Caraway</td>
<td>Carum carvi L.</td>
</tr>
<tr>
<td>Cardamom seed (cardamon)</td>
<td>Elettaria cardamomum Maton.</td>
</tr>
<tr>
<td>Carob bean</td>
<td>Ceratonia siliqua L.</td>
</tr>
<tr>
<td>Carrot</td>
<td>Daucus carota L.</td>
</tr>
<tr>
<td>Cascarilla bark</td>
<td>Croton elenita Binn.</td>
</tr>
<tr>
<td>Cassia bark, Chinese</td>
<td>Cinnamomum cassia Blume.</td>
</tr>
<tr>
<td>Cassia bark, Padang or Batavia</td>
<td>Cinnamomum burmannii Blume.</td>
</tr>
<tr>
<td>Cassia bark, Saigon</td>
<td>Cinnamomum loureirii Nees.</td>
</tr>
<tr>
<td>Celery seed</td>
<td>Apium graveolens L.</td>
</tr>
<tr>
<td>Cherry, wild, bark</td>
<td>Prunus serotina Ehrh.</td>
</tr>
<tr>
<td>Cherri</td>
<td>Anthriscus cerefolium (L.) Hoffm.</td>
</tr>
<tr>
<td>Chervil</td>
<td>Cichorium intybus L.</td>
</tr>
<tr>
<td>Cinnamon bark, Ceylon</td>
<td>Cinnamomum zeylanicum Nees.</td>
</tr>
<tr>
<td>Cinnamon bark, Chinese</td>
<td>Cinnamomum cassia Blume.</td>
</tr>
<tr>
<td>Cinnamon bark, Saigon</td>
<td>Cinnamomum loureirii Nees.</td>
</tr>
<tr>
<td>Cinnamon leaf, Ceylon</td>
<td>Cinnamomum zeylanicum Nees.</td>
</tr>
<tr>
<td>Cinnamon leaf, Chinese</td>
<td>Cinnamomum cassia Blume.</td>
</tr>
<tr>
<td>Cinnamon leaf, Saigon</td>
<td>Cinnamomum loureirii Nees.</td>
</tr>
<tr>
<td>Citronella</td>
<td>Cymbopogon nardus Rendle.</td>
</tr>
<tr>
<td>Citrus peels</td>
<td>Citrus spp.</td>
</tr>
<tr>
<td>Clary (clary sage)</td>
<td>Salvia sclarea L.</td>
</tr>
<tr>
<td>Clove bud</td>
<td>Eugenia caryophyllata Thurb.</td>
</tr>
<tr>
<td>Clove leaf</td>
<td>Do.</td>
</tr>
<tr>
<td>Clove stem</td>
<td>Do.</td>
</tr>
<tr>
<td>Clover</td>
<td>Trifolium spp.</td>
</tr>
<tr>
<td>Cocoa (decocainized)</td>
<td>Theobroma cacao Lam. and other spp. of Erythrosyrum.</td>
</tr>
<tr>
<td>Coffee</td>
<td>Coffee spp.</td>
</tr>
<tr>
<td>Cola nut</td>
<td>Cola acuminata Schott and Endl., and other spp. of Cola.</td>
</tr>
<tr>
<td>Coriander</td>
<td>Coriandrum sativum L.</td>
</tr>
<tr>
<td>Corn silk</td>
<td>Zea mays L.</td>
</tr>
<tr>
<td>Cumin (cummin)</td>
<td>Cuminum cyminum L.</td>
</tr>
<tr>
<td>Curacao orange peel (orange, bitter peel)</td>
<td>Citrus aurantium L.</td>
</tr>
<tr>
<td>Cusparia bark</td>
<td>Galipcea officinalis Hancock.</td>
</tr>
<tr>
<td>Danedelion</td>
<td>Taraxacum officinale Weber and T. laevigatum DC.</td>
</tr>
<tr>
<td>Dandelion root</td>
<td>Do.</td>
</tr>
<tr>
<td>Dill</td>
<td>Anethum graveolens L.</td>
</tr>
<tr>
<td>Dog grass (quackgrass, triticum)</td>
<td>Agropyron repens (L.) Beauv.</td>
</tr>
<tr>
<td>Elder flowers</td>
<td>Sambucus canadensis L. and S. nigra L.</td>
</tr>
<tr>
<td>Estragole (esdragol, esdragon, tarragon)</td>
<td>Artemisia dracunculus L.</td>
</tr>
<tr>
<td>Estragon (tarragon)</td>
<td>Do.</td>
</tr>
<tr>
<td>Fennel, sweet</td>
<td>Foeniculum vulgare Mill.</td>
</tr>
<tr>
<td>Fenugreek</td>
<td>Trigonella foensum-graecum L.</td>
</tr>
<tr>
<td>Galanga (galangal)</td>
<td>Alpinia officinarum Hance.</td>
</tr>
<tr>
<td>Garlic</td>
<td>Allium sativum L.</td>
</tr>
<tr>
<td>Geranium</td>
<td>Pelargonium spp.</td>
</tr>
<tr>
<td>Geranium, East Indian</td>
<td>Cymbopogon martini Stapf.</td>
</tr>
<tr>
<td>Geranium, rose</td>
<td>Pelargonium graveolens L’Her.</td>
</tr>
<tr>
<td>Ginger</td>
<td>Zingiber officinale Rosc.</td>
</tr>
<tr>
<td>Glycyrrhiza</td>
<td>Glycyrrhiza glabra L. and other spp. of Glycyrrhiza.</td>
</tr>
<tr>
<td>Grapefruit</td>
<td>Citrus paradisi Macf.</td>
</tr>
<tr>
<td>Guava</td>
<td>Psidium spp.</td>
</tr>
<tr>
<td>Hickory bark</td>
<td>Carya spp.</td>
</tr>
<tr>
<td>Horehound (hoarhound)</td>
<td>Marrubium vulgare L.</td>
</tr>
<tr>
<td>Hops</td>
<td>Humulus lupulus L.</td>
</tr>
<tr>
<td>Horsemint</td>
<td>Monarda punctata L.</td>
</tr>
<tr>
<td>Hyssop</td>
<td>Hyssopus officinalis L.</td>
</tr>
<tr>
<td>Immortelle</td>
<td>Helichrysum augustinum DC.</td>
</tr>
<tr>
<td>Jasmine</td>
<td>Jasminum officinale L. and other spp. of Jasminum.</td>
</tr>
<tr>
<td>Juniper</td>
<td>Juniperus communis L.</td>
</tr>
<tr>
<td>Kola nut</td>
<td>Cola acuminata Schott and Endl., and other spp. of Cola.</td>
</tr>
<tr>
<td>Common name</td>
<td>Botanical name of plant source</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Laurel berries</td>
<td>Laurus nobilis L.</td>
</tr>
<tr>
<td>Laurel leaves</td>
<td>Laurus spp.</td>
</tr>
<tr>
<td>Lavender</td>
<td>Lavandula officinalis Chaix.</td>
</tr>
<tr>
<td>Lavender, spike</td>
<td>Lavandula latifolia Vill.</td>
</tr>
<tr>
<td>Lavandin</td>
<td>Hybrids between Lavandula officinalis Chaix and Lavandula latifolia Vill.</td>
</tr>
<tr>
<td>Lemon</td>
<td>Citrus limon (L.) Burm. f.</td>
</tr>
<tr>
<td>Lemon balm (see balm)</td>
<td></td>
</tr>
<tr>
<td>Lemon grass</td>
<td>Cymbopogon citratus DC. and Cymbopogon flexuosus Stapf.</td>
</tr>
<tr>
<td>Lemon peel</td>
<td>Citrus limon (L.) Burm. f.</td>
</tr>
<tr>
<td>Licorice</td>
<td>Glycyrrhiza glabra L. and other spp. of Glycyrrhiza.</td>
</tr>
<tr>
<td>Lime</td>
<td>Citrus aurantifolia Swingle.</td>
</tr>
<tr>
<td>Linden flowers</td>
<td>Tilia spp.</td>
</tr>
<tr>
<td>Locust bean</td>
<td>Ceratonia siliqua L.</td>
</tr>
<tr>
<td>Lupulin</td>
<td>Humulus lupulus L.</td>
</tr>
<tr>
<td>Mace</td>
<td>Myristica fragrans Houtt.</td>
</tr>
<tr>
<td>Malt (extract)</td>
<td>Hordeum vulgare L., or other grains.</td>
</tr>
<tr>
<td>Mandarin</td>
<td>Citrus reticulata Blanco.</td>
</tr>
<tr>
<td>Marjoram, sweet</td>
<td>Majorana hortensis Moench.</td>
</tr>
<tr>
<td>Mate 1</td>
<td>ilix paraguayensis St. Hil.</td>
</tr>
<tr>
<td>Melissa (see balm)</td>
<td>Mentha spp.</td>
</tr>
<tr>
<td>Menthol</td>
<td>Mentha spp.</td>
</tr>
<tr>
<td>Menthyl acetate</td>
<td>Do.</td>
</tr>
<tr>
<td>Molasses (extract)</td>
<td>Saccharum officinarum L.</td>
</tr>
<tr>
<td>Mustard</td>
<td>Brassica spp.</td>
</tr>
<tr>
<td>Naringin</td>
<td>Citrus paradisi Macf.</td>
</tr>
<tr>
<td>Neroli, bigarade</td>
<td>Citrus aurantium L.</td>
</tr>
<tr>
<td>Nutmeg</td>
<td>Myristica fragrans Houtt.</td>
</tr>
<tr>
<td>Onion</td>
<td>Allium cepa L.</td>
</tr>
<tr>
<td>Orange, bitter, flowers</td>
<td>Citrus aurantium L.</td>
</tr>
<tr>
<td>Orange, bitter, peel</td>
<td>Do.</td>
</tr>
<tr>
<td>Orange leaf</td>
<td>Citrus sinensis (L.) Osbeck.</td>
</tr>
<tr>
<td>Orange, sweet</td>
<td>Do.</td>
</tr>
<tr>
<td>Orange, sweet, flowers</td>
<td>Do.</td>
</tr>
<tr>
<td>Orange, sweet, peel</td>
<td>Do.</td>
</tr>
<tr>
<td>Origanum</td>
<td>Origanum spp.</td>
</tr>
<tr>
<td>Palmarosa</td>
<td>Cymbopogon martini Stapf.</td>
</tr>
<tr>
<td>Paprika</td>
<td>Capsicum annuum L.</td>
</tr>
<tr>
<td>Parsley</td>
<td>Petroselinum crispum (Mill.) Mansf.</td>
</tr>
<tr>
<td>Pepper, black</td>
<td>Piper nigrum L.</td>
</tr>
<tr>
<td>Pepper, white</td>
<td>Piper nigrum L.</td>
</tr>
<tr>
<td>Peppermint</td>
<td>Mentha piperita L.</td>
</tr>
<tr>
<td>Peruvian balsam</td>
<td>Myroxylon pereirae Klotzsch.</td>
</tr>
<tr>
<td>Petitgrain</td>
<td>Citrus aurantium L.</td>
</tr>
<tr>
<td>Petitgrain lemon</td>
<td>Citrus limon (L.) Burm. f.</td>
</tr>
<tr>
<td>Petitgrain mandarin or tangerine</td>
<td>Citrus reticulata Blanco.</td>
</tr>
<tr>
<td>Pimento</td>
<td>Pimenta officinalis Lindl.</td>
</tr>
<tr>
<td>Pimento leaf</td>
<td>Pimenta officinalis Lindl.</td>
</tr>
<tr>
<td>Pipsissewa leaves</td>
<td>Chimaphila umbellata Nutt.</td>
</tr>
<tr>
<td>Pomegranate</td>
<td>Punica granatum L.</td>
</tr>
<tr>
<td>Priokly ash bark</td>
<td>Xanthoxylum (or Zanthoxylum) Americanum Mill. or Xanthoxylum clava-herculis L.</td>
</tr>
<tr>
<td>Rose absolute</td>
<td>Rosa alba L., Rosa centifolia L., Rosa damascena Mill., Rosa gallica L., and vars. of these spp.</td>
</tr>
<tr>
<td>Rose (otto of roses, attar of roses)</td>
<td>Do.</td>
</tr>
<tr>
<td>Rose buds</td>
<td>Do.</td>
</tr>
<tr>
<td>Rose flowers</td>
<td>Do.</td>
</tr>
<tr>
<td>Rose fruit (hips)</td>
<td>Do.</td>
</tr>
<tr>
<td>Rose geranium</td>
<td>Pelargonium graveolens L’Hér.</td>
</tr>
<tr>
<td>Rose leaves</td>
<td>Rosa spp.</td>
</tr>
<tr>
<td>Rosemary</td>
<td>Rosmarinus officinalis L.</td>
</tr>
<tr>
<td>Rue</td>
<td>Ruta graveolens L.</td>
</tr>
<tr>
<td>Saffron</td>
<td>Crocus sativus L.</td>
</tr>
<tr>
<td>Sage</td>
<td>Salvia officinalis L.</td>
</tr>
<tr>
<td>Sage, Greek</td>
<td>Salvia officinalis L.</td>
</tr>
<tr>
<td>Sage, Spanish</td>
<td>Salvia lavandulifolia Vahl.</td>
</tr>
<tr>
<td>St. John’s bread</td>
<td>Ceratonia siliqua L.</td>
</tr>
<tr>
<td>Savory, summer</td>
<td>Satureja hortensis L.</td>
</tr>
<tr>
<td>Savory, winter</td>
<td>Satureja montana L.</td>
</tr>
<tr>
<td>Schinus molle</td>
<td>Schinus molle L.</td>
</tr>
<tr>
<td>Sloe berries (blackthorn berries)</td>
<td>Prunus spinosa L.</td>
</tr>
<tr>
<td>Spearmint</td>
<td>Mentha spicata L.</td>
</tr>
<tr>
<td>Spike lavender</td>
<td>Lavandula latifolia Vill.</td>
</tr>
<tr>
<td>Tamarind</td>
<td>Tamarindus indica L.</td>
</tr>
</tbody>
</table>
§ 582.30 Natural substances used in conjunction with spices and other natural seasonings and flavorings.

Natural substances used in conjunction with spices and other natural seasonings and flavorings that are generally recognized as safe for their intended use, within the meaning of section 409 of the act, are as follows:

<table>
<thead>
<tr>
<th>Common name</th>
<th>Botanical name of plant source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tangerine</td>
<td>Citrus reticulata Blanco</td>
</tr>
<tr>
<td>Tannic acid</td>
<td>Nutgalls of Quercus infectoria Oliver and related spp. of Quercus. Also in many other plants.</td>
</tr>
<tr>
<td>Tarragon</td>
<td>Artemisia dracunculus L.</td>
</tr>
<tr>
<td>Thyme</td>
<td>Thea sinensis L.</td>
</tr>
<tr>
<td>Thyme, white</td>
<td>Thymus vulgaris L. and Thymus zygis var. gracilis Boiss.</td>
</tr>
<tr>
<td>Thyme, wild or creeping</td>
<td>Thymus serpyllum L.</td>
</tr>
<tr>
<td>Trilicum (see dog grass)</td>
<td></td>
</tr>
<tr>
<td>Tuberose</td>
<td>Polianthes tuberosa L.</td>
</tr>
<tr>
<td>Vanilla</td>
<td>Canna lutea L.</td>
</tr>
<tr>
<td>Violet flowers</td>
<td>Do.</td>
</tr>
<tr>
<td>Violet leaves</td>
<td>Do.</td>
</tr>
<tr>
<td>Violet leaves absolute</td>
<td>Do.</td>
</tr>
<tr>
<td>Wild cherry bark</td>
<td>Prunus serotina Ehrh.</td>
</tr>
<tr>
<td>Ylang-ylang</td>
<td>Cananga odorata Hook. f. and Thoms.</td>
</tr>
<tr>
<td>Zedoary bark</td>
<td>Curcuma zedoaria Rosc.</td>
</tr>
</tbody>
</table>

§ 582.40 Natural extractives (solvent-free) used in conjunction with spices, seasonings, and flavorings.

Natural extractives (solvent-free) used in conjunction with spices, seasonings, and flavorings that are generally recognized as safe for their intended use, within the meaning of section 409 of the act, are as follows:

<table>
<thead>
<tr>
<th>Common name</th>
<th>Botanical name of plant source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Algae, brown (kelp)</td>
<td>Laminaria spp. and Nereocystis spp.</td>
</tr>
<tr>
<td>Algae, red</td>
<td>Porphyra spp. and Rhodymenia palmata (L.) Grev.</td>
</tr>
<tr>
<td>Dulse</td>
<td>Rhodymenia palmata (L.) Grev.</td>
</tr>
</tbody>
</table>

§ 582.50 Certain other spices, seasonings, essential oils, oleoresins, and natural extracts.

Certain other spices, seasonings, essential oils, oleoresins, and natural extracts that are generally recognized as safe for their intended use, within the meaning of section 409 of the act, are as follows:

<table>
<thead>
<tr>
<th>Common name</th>
<th>Derivation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambergris</td>
<td>Phystester macrocephalus L.</td>
</tr>
<tr>
<td>Castoreum</td>
<td>Castor fiber L. and C. canadensis Kuhl.</td>
</tr>
<tr>
<td>Civet (zibeth, zibet, zibetum)</td>
<td>Civet cats, Viverra civetta Schreber and Viverra zibetha Schreber.</td>
</tr>
<tr>
<td>Cognac oil, white and green</td>
<td>Ethyl oenanthate, so-called.</td>
</tr>
</tbody>
</table>
§ 582.60 Synthetic flavoring substances and adjuvants.

Synthetic flavoring substances and adjuvants that are generally recognized as safe for their intended use, within the meaning of section 409 of the act, are as follows:

- Acetaldehyde (ethanal).
- Acetoin (acetyl methylecarbinol).
- Aconitic acid (equisetic acid, citridic acid, achilleic acid).
- Anethole (parapropenyl anisole).
- Benzaldehyde (benzoic aldehyde).
- N-Butyric acid (butanoic acid).
- d- or l-Carvone (carvol).
- Cinnamaldehyde (cinnamic aldehyde).
- Citral (2,6-dimethyloctadien-2,6-al, geranial, neral).
- Decanal (N-decylaldehyde, capraldehyde, capric aldehyde, aldehyde C-10).
- Diacetyl (2,3-butanedione). Ethyl acetate.
- 3-Methyl-3-phenyl glycidic acid ethyl ester (ethyl-methyl-phenyl-glycidate, so-called strawberry aldehyde, C-16 aldehyde). Ethyl vanillin.
- Eugenol.
- Geranool (3,7-dimethyl-2,6 and 3,6-octadien-1-ol).
- Geranyl acetate (geraniol acetate).
- Glycerol (glyceryl) tributyrate (tributyrin, butyrin).
- Limonene (d-, l-, and dl-).
- Linalool (linalol, 3,7-dimethyl-1,6-octadien-3-ol).
- Linalyl acetate (bergamol).
- 1-Malic acid.
- Methyl anthranilate (methyl-2-aminobenzoate).
- Piperonal (3,4-methylenedioxy-benzaldehyde, heliotropin).
- Vanillin.

§ 582.80 Trace minerals added to animal feeds.

These substances added to animal feeds as nutritional dietary supplements are generally recognized as safe when added at levels consistent with good feeding practice.1

<table>
<thead>
<tr>
<th>Element</th>
<th>Source compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cobalt</td>
<td>Cobalt acetate.</td>
</tr>
<tr>
<td></td>
<td>Cobalt carbonate.</td>
</tr>
<tr>
<td>Copper</td>
<td>Copper chloride.</td>
</tr>
<tr>
<td></td>
<td>Copper carbonate.</td>
</tr>
<tr>
<td></td>
<td>Copper sulfate.</td>
</tr>
<tr>
<td>Iodine</td>
<td>Calcium iodate.</td>
</tr>
<tr>
<td></td>
<td>Calcium iodobehenate.</td>
</tr>
<tr>
<td></td>
<td>Cuprous iodide.</td>
</tr>
<tr>
<td></td>
<td>3,5-Diodosalicylic acid.</td>
</tr>
<tr>
<td></td>
<td>Ethylenediamine dithiodiiodide.</td>
</tr>
<tr>
<td></td>
<td>Potassium iodate.</td>
</tr>
<tr>
<td></td>
<td>Sodium iodate.</td>
</tr>
<tr>
<td></td>
<td>Sodium iodide.</td>
</tr>
<tr>
<td></td>
<td>Thymol iodide.</td>
</tr>
<tr>
<td>Iron</td>
<td>Iron ammonium citrate.</td>
</tr>
<tr>
<td></td>
<td>Iron carbonate.</td>
</tr>
<tr>
<td></td>
<td>Iron chloride.</td>
</tr>
<tr>
<td></td>
<td>Iron glucinate.</td>
</tr>
<tr>
<td></td>
<td>Iron oxide.</td>
</tr>
<tr>
<td></td>
<td>Iron phosphate.</td>
</tr>
<tr>
<td></td>
<td>Iron pyrophosphate.</td>
</tr>
<tr>
<td></td>
<td>Iron sulfate.</td>
</tr>
<tr>
<td></td>
<td>Reduced iron.</td>
</tr>
<tr>
<td>Manganese</td>
<td>Manganese acetate.</td>
</tr>
<tr>
<td></td>
<td>Manganese carbonate.</td>
</tr>
<tr>
<td></td>
<td>Manganese citrate (soluble).</td>
</tr>
<tr>
<td></td>
<td>Manganese chloride.</td>
</tr>
<tr>
<td></td>
<td>Manganese gluconate.</td>
</tr>
<tr>
<td></td>
<td>Manganese orthophosphate.</td>
</tr>
<tr>
<td></td>
<td>Manganese phosphate (dibasic).</td>
</tr>
<tr>
<td></td>
<td>Manganese sulfate.</td>
</tr>
<tr>
<td></td>
<td>Manganese oxide.</td>
</tr>
<tr>
<td>Zinc</td>
<td>Zinc acetate.</td>
</tr>
<tr>
<td></td>
<td>Zinc carbonate.</td>
</tr>
<tr>
<td></td>
<td>Zinc chloride.</td>
</tr>
<tr>
<td></td>
<td>Zinc oxide.</td>
</tr>
<tr>
<td></td>
<td>Zinc sulfate.</td>
</tr>
</tbody>
</table>

§ 582.99 Adjuvants for pesticide chemicals.

Adjuvants, identified and used in accordance with 40 CFR 180.1001(c) and (d), which are added to pesticide use dilutions by a grower or applicator prior to application to the raw agricultural commodity, are exempt from the requirement of tolerances under section 409 of the act.

Subpart B—General Purpose Food Additives

§ 582.1005 Acetic acid.

(a) Product. Acetic acid.
§ 582.1009  Adipic acid.
   (a) Product. Adipic acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1009  Adipic acid.
   (a) Product. Adipic acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1033  Citric acid.
   (a) Product. Citric acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1057  Hydrochloric acid.
   (a) Product. Hydrochloric acid.
   (b) [Reserved]
   (c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used as a buffer and neutralizing agent in accordance with good manufacturing or feeding practice.

§ 582.1061  Lactic acid.
   (a) Product. Lactic acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1069  Malic acid.
   (a) Product. Malic acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1073  Phosphoric acid.
   (a) Product. Phosphoric acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1077  Potassium acid tartrate.
   (a) Product. Potassium acid tartrate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1087  Sodium acid pyrophosphate.
   (a) Product. Sodium acid pyrophosphate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1091  Succinic acid.
   (a) Product. Succinic acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1095  Sulfuric acid.
   (a) Product. Sulfuric acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1099  Tartaric acid.
   (a) Product. Tartaric acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1125  Aluminum sulfate.
   (a) Product. Aluminum sulfate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1127  Aluminum ammonium sulfate.
   (a) Product. Aluminum ammonium sulfate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1129  Aluminum potassium sulfate.
   (a) Product. Aluminum potassium sulfate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1131  Aluminum sodium sulfate.
   (a) Product. Aluminum sodium sulfate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1135 Ammonium bicarbonate.
(a) Product. Ammonium bicarbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1137 Ammonium carbonate.
(a) Product. Ammonium carbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1139 Ammonium hydroxide.
(a) Product. Ammonium hydroxide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1141 Ammonium phosphate.
(a) Product. Ammonium phosphate (mono- and dibasic).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1143 Ammonium sulfate.
(a) Product. Ammonium sulfate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1155 Bentonite.
(a) Product. Bentonite.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1165 Butane.
(a) Product. Butane.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1191 Calcium carbonate.
(a) Product. Calcium carbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1193 Calcium chloride.
(a) Product. Calcium chloride.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1195 Calcium citrate.
(a) Product. Calcium citrate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1199 Calcium gluconate.
(a) Product. Calcium gluconate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1205 Calcium hydroxide.
(a) Product. Calcium hydroxide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1207 Calcium lactate.
(a) Product. Calcium lactate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1210 Calcium oxide.
(a) Product. Calcium oxide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1217 Calcium phosphate.
(a) Product. Calcium phosphate (mono-, di-, and tribasic).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1235 Caramel.
(a) Product. Caramel.
§ 582.1240  Carbon dioxide.
(a) Product. Carbon dioxide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1275  Dextrans.
(a) Product. Dextrans of average molecular weight below 100,000.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1320  Glycerin.
(a) Product. Glycerin.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1324  Glyceryl monostearate.
(a) Product. Glyceryl monostearate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1355  Helium.
(a) Product. Helium.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1366  Hydrogen peroxide.
(a) Product. Hydrogen peroxide.
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used as a bleaching agent in accordance with good manufacturing or feeding practice.

§ 582.1400  Lecithin.
(a) Product. Lecithin.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1425  Magnesium carbonate.
(a) Product. Magnesium carbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1428  Magnesium hydroxide.
(a) Product. Magnesium hydroxide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1431  Magnesium oxide.
(a) Product. Magnesium oxide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1480  Methylcellulose.
(a) Product. U.S.P. methylcellulose, except that the methoxy content shall not be less than 27.5 percent and not more than 31.5 percent on a dry-weight basis.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1500  Monoammonium glutamate.
(a) Product. Monoammonium glutamate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1516  Monopotassium glutamate.
(a) Product. Monopotassium glutamate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1540  Nitrogen.
(a) Product. Nitrogen.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1585  Papain.
(a) Product. Papain.
Food and Drug Administration, HHS

§ 582.1613 Potassium bicarbonate.
(a) Product. Potassium bicarbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1619 Potassium carbonate.
(a) Product. Potassium carbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1625 Potassium citrate.
(a) Product. Potassium citrate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1631 Potassium hydroxide.
(a) Product. Potassium hydroxide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1643 Potassium sulfate.
(a) Product. Potassium sulfate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1655 Propane.
(a) Product. Propane.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1666 Propylene glycol.
(a) Product. Propylene glycol.
(b) Conditions of use. This substance is generally recognized as safe (except in cat food) when used in accordance with good manufacturing or feeding practice.


§ 582.1685 Rennet.
(a) Product. Rennet (rennin).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1711 Silica aerogel.
(a) Product. Silica aerogel as a finely powdered microcellular silica foam having a minimum silica content of 89.5 percent.
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used as a component of antifoaming agents in accordance with good manufacturing or feeding practice.

§ 582.1721 Sodium acetate.
(a) Product. Sodium acetate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1736 Sodium bicarbonate.
(a) Product. Sodium bicarbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1742 Sodium carbonate.
(a) Product. Sodium carbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1745 Sodium carboxymethylcellulose.
(a) Product. Sodium carboxymethylcellulose is the sodium salt of carboxymethylcellulose not less than 99.5 percent on a dry-weight basis, with maximum substitution of 0.95 carboxymethyl groups per anhydroglucose unit, and with a minimum viscosity of 25 centipoises per 2 percent by weight aqueous solution at 25 °C.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 582.1748 Sodium caseinate.
(a) Product. Sodium caseinate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1751 Sodium citrate.
(a) Product. Sodium citrate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1763 Sodium hydroxide.
(a) Product. Sodium hydroxide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1775 Sodium pectinate.
(a) Product. Sodium pectinate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1778 Sodium phosphate.
(a) Product. Sodium phosphate (mono-, di-, and tribasic).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1781 Sodium aluminum phosphate.
(a) Product. Sodium aluminum phosphate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1792 Sodium sesquicarbonate.
(a) Product. Sodium sesquicarbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1804 Sodium potassium tartrate.
(a) Product. Sodium potassium tartrate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1810 Sodium tripolyphosphate.
(a) Product. Sodium tripolyphosphate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1873 Beeswax.
(a) Product. Beeswax (yellow wax).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1875 Bleached beeswax.
(a) Product. Bleached beeswax (white wax).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.1878 Carnauba wax.
(a) Product. Carnauba wax.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

Subpart C—Anticaking Agents

§ 582.2122 Aluminum calcium silicate.
(a) Product. Aluminum calcium silicate.
(b) Tolerance. 2 percent.
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in table salt in accordance with good manufacturing or feeding practice.

§ 582.2227 Calcium silicate.
(a) Product. Calcium silicate.
(b) Tolerance. 2 percent and 5 percent.
§ 582.2437 Magnesium silicate.
   (a) Product. Magnesium silicate.
   (b) Tolerance. 2 percent.
   (c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used at levels not exceeding 2 percent in table salt and 5 percent in baking powder in accordance with good manufacturing or feeding practice.

§ 582.2439 Magnesium silicate.
   (a) Product. Magnesium silicate.
   (b) Tolerance. 2 percent.
   (c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in table salt in accordance with good manufacturing or feeding practice.

§ 582.2727 Sodium aluminosilicate.
   (a) Product. Sodium aluminosilicate (sodium silicoaluminate).
   (b) Tolerance. This substance is generally recognized as safe for use at a level not exceeding 2 percent in accordance with good manufacturing or feeding practice.

§ 582.2729 Hydrated sodium calcium aluminosilicate.
   (a) Product. Hydrated sodium calcium aluminosilicate (sodium calcium silicoaluminate).
   (b) Tolerance. This substance is generally recognized as safe for use at a level not exceeding 2 percent in accordance with good manufacturing or feeding practice.

§ 582.2906 Tricalcium silicate.
   (a) Product. Tricalcium silicate.
   (b) Tolerance. 2 percent.
   (c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in table salt in accordance with good manufacturing or feeding practice.

Subpart D—Chemical Preservatives

§ 582.3013 Ascorbic acid.
   (a) Product. Ascorbic acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3021 Benzoic acid.
   (a) Product. Benzoic acid.
   (b) Tolerance. This substance is generally recognized as safe for use at a level not exceeding 0.1 percent in accordance with good manufacturing or feeding practice.

§ 582.3041 Erythorbic acid.
   (a) Product. Erythorbic acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3081 Propionic acid.
   (a) Product. Propionic acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3089 Sorbic acid.
   (a) Product. Sorbic acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3109 Thiodipropionic acid.
   (a) Product. Thiodipropionic acid.
   (b) Tolerance. This substance is generally recognized as safe for use in food when the total content of antioxidants is not over 0.02 percent of fat or oil content including essential (volatile) oil content of the food, provided the substance is used in accordance with good manufacturing or feeding practice.

§ 582.3149 Ascorbyl palmitate.
   (a) Product. Ascorbyl palmitate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3169 Butylated hydroxyanisole.
   (a) Product. Butylated hydroxyanisole.
   (b) Tolerance. This substance is generally recognized as safe for use in food when the total content of antioxidants is not over 0.02 percent of fat or oil content, including essential (volatile) oil content of food provided the substance is used in accordance with good manufacturing or feeding practice.
§ 582.3173 Butylated hydroxytoluene.
(a) Product. Butylated hydroxytoluene.
(b) Tolerance. This substance is generally recognized as safe for use in food when the total content of antioxidants is not over 0.02 percent of fat or oil content, including essential (volatile) oil content of food provided the substance is used in accordance with good manufacturing or feeding practice.

§ 582.3189 Calcium ascorbate.
(a) Product. Calcium ascorbate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3221 Calcium propionate.
(a) Product. Calcium propionate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3225 Calcium sorbate.
(a) Product. Calcium sorbate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3280 Dilauryl thiodipropionate.
(a) Product. Dilauryl thiodipropionate.
(b) Tolerance. This substance is generally recognized as safe for use in food when the total content of antioxidants is not over 0.02 percent of fat or oil content, including essential (volatile) oil content of the food, provided the substance is used in accordance with good manufacturing or feeding practice.

§ 582.3336 Gum guaiac.
(a) Product. Gum guaiac.
(b) Tolerance. 0.1 percent (equivalent antioxidant activity 0.01 percent).
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in edible fats or oils in accordance with good manufacturing or feeding practice.

§ 582.3490 Methylparaben.
(a) Product. Methylparaben (methyl p-hydroxybenzoate).
(b) Tolerance. This substance is generally recognized as safe for use at a level not exceeding 0.1 percent in accordance with good manufacturing or feeding practice.

§ 582.3616 Potassium bisulfite.
(a) Product. Potassium bisulfite.
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice, except that it is not used in meats or in food recognized as source of vitamin B1.

§ 582.3637 Potassium metabisulfite.
(a) Product. Potassium metabisulfite.
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice, except that it is not used in meats or in food recognized as source of vitamin B1.

§ 582.3640 Potassium sorbate.
(a) Product. Potassium sorbate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3660 Propyl gallate.
(a) Product. Propyl gallate.
(b) Tolerance. This substance is generally recognized as safe for use in food when the total content of antioxidants is not over 0.02 percent of fat or oil content, including essential (volatile) oil content of the food, provided the substance is used in accordance with good manufacturing or feeding practice.

§ 582.3670 Propylparaben.
(a) Product. Propylparaben (propyl p-hydroxybenzoate).
(b) Tolerance. This substance is generally recognized as safe for use at a level not exceeding 0.1 percent in accordance with good manufacturing or feeding practice.
§ 582.3731 Sodium ascorbate.
(a) Product. Sodium ascorbate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3733 Sodium benzoate.
(a) Product. Sodium benzoate.
(b) Tolerance. This substance is generally recognized as safe for use at a level not exceeding 0.1 percent in accordance with good manufacturing or feeding practice.

§ 582.3739 Sodium bisulfite.
(a) Product. Sodium bisulfite.
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice, except that it is not used in meats or in food recognized as source of vitamin B1.

§ 582.3766 Sodium metabisulfite.
(a) Product. Sodium metabisulfite.
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice, except that it is not used in meats or in food recognized as source of vitamin B1.

§ 582.3784 Sodium propionate.
(a) Product. Sodium propionate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3795 Sodium sorbate.
(a) Product. Sodium sorbate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.3798 Sodium sulfite.
(a) Product. Sodium sulfite.
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice, except that it is not used in meats or in food recognized as source of vitamin B1.

§ 582.4505 Mono- and diglycerides of edible fats or oils, or edible fat-forming acids.
(a) Product. Mono- and diglycerides of edible fats or oils, or edible fat-forming acids.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 582.4521 Monosodium phosphate derivatives of mono- and diglycerides of edible fats or oils, or edible fat-forming fatty acids.
(a) Product. Monosodium phosphate derivatives of mono- and diglycerides of edible fats or oils, or edible fat-forming fatty acids.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.4521 Monosodium phosphate derivatives of mono- and diglycerides of edible fats or oils, or edible fat-forming fatty acids.
(a) Product. Monosodium phosphate derivatives of mono- and diglycerides of edible fats or oils, or edible fat-forming fatty acids.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.4666 Propylene glycol.
(a) Product. Propylene glycol.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5013 Ascorbic acid.
(a) Product. Ascorbic acid.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5017 Aspartic acid.
(a) Product. Aspartic acid (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5049 Aminoacetic acid.
(a) Product. Glycine (aminoacetic acid).
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in animal feeds in accordance with good manufacturing or feeding practice.

Subpart F—Nutrients and/or Dietary Supplements

§ 582.5013 Ascorbic acid.
(a) Product. Ascorbic acid.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5017 Aspartic acid.
(a) Product. Aspartic acid (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5049 Aminoacetic acid.
(a) Product. Glycine (aminoacetic acid).
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in animal feeds in accordance with good manufacturing or feeding practice.

§ 582.5065 Linoleic acid.
(a) Product. Linoleic acid prepared from edible fats and oils and free from chick-edema factor.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5118 Alanine.
(a) Product. Alanine (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5145 Arginine.
(a) Product. Arginine (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5159 Biotin.
(a) Product. Biotin.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5191 Calcium carbonate.
(a) Product. Calcium carbonate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5195 Calcium citrate.
(a) Product. Calcium citrate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5201 Calcium glycerophosphate.
(a) Product. Calcium glycerophosphate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5210 Calcium oxide.
(a) Product. Calcium oxide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5212 Calcium pantothenate.
(a) Product. Calcium pantothenate.
(b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5217 Calcium phosphate.
   (a) **Product.** Calcium phosphate (mono-, di-, and tribasic).
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5223 Calcium pyrophosphate.
   (a) **Product.** Calcium pyrophosphate.
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5250 Calcium sulfate.
   (a) **Product.** Calcium sulfate.
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5271 Cysteine.
   (a) **Product.** Cysteine (L-forms).
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5273 Cystine.
   (a) **Product.** Cystine (L- and DL-forms).
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5301 Ferric phosphate.
   (a) **Product.** Ferric phosphate.
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5304 Ferric pyrophosphate.
   (a) **Product.** Ferric pyrophosphate.
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5306 Ferric sodium pyrophosphate.
   (a) **Product.** Ferric sodium pyrophosphate.
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5311 Ferrous lactate.
   (a) **Product.** Ferrous lactate.
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5315 Ferrous sulfate.
   (a) **Product.** Ferrous sulfate.
   (b) **Conditions of use.** This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 582.5361 Histidine.
   (a) Product. Histidine (L- and DL-forms).
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5370 Inositol.
   (a) Product. Inositol.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5375 Iron reduced.
   (a) Product. Iron reduced.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5381 Isoleucine.
   (a) Product. Isoleucine (L- and DL-forms).
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5406 Leucine.
   (a) Product. Leucine (L- and DL-forms).
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5411 Lysine.
   (a) Product. Lysine (L- and DL-forms).
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5431 Magnesium oxide.
   (a) Product. Magnesium oxide.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5434 Magnesium phosphate.
   (a) Product. Magnesium phosphate (dl- and tribasic).
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5443 Magnesium sulfate.
   (a) Product. Magnesium sulfate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5446 Manganese chloride.
   (a) Product. Manganese chloride.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5449 Manganese citrate.
   (a) Product. Manganese citrate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5452 Manganese gluconate.
   (a) Product. Manganese gluconate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5455 Manganese glycerophosphate.
   (a) Product. Manganese glycerophosphate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5458 Manganese hypophosphite.
   (a) Product. Manganese hypophosphite.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5461 Manganese sulfate.
   (a) Product. Manganese sulfate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5464 Manganous oxide.
   (a) Product. Manganous oxide.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
used in accordance with good manufacturing or feeding practice.

§ 582.5470 Mannitol.
(a) Product. Mannitol.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5475 Methionine.
(a) Product. Methionine.
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in animal feeds in accordance with good manufacturing or feeding practice.

§ 582.5477 Methionine hydroxy analog and its calcium salts.
(a) Product. Methionine hydroxy analog and its calcium salts.
(b) [Reserved]
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in animal feeds in accordance with good manufacturing or feeding practice.

§ 582.5530 Niacin.
(a) Product. Niacin.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5535 Niacinamide.
(a) Product. Niacinamide.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5580 D-Pantothenyl alcohol.
(a) Product. D-Pantothenyl alcohol.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5590 Phenylalanine.
(a) Product. Phenylalanine (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5622 Potassium chloride.
(a) Product. Potassium chloride.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5628 Potassium glycerophosphate.
(a) Product. Potassium glycerophosphate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5634 Potassium iodide.
(a) Product. Potassium iodide.
(b) Tolerance. 0.01 percent.
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in table salt as a source of dietary iodine in accordance with good manufacturing or feeding practice.

§ 582.5650 Proline.
(a) Product. Proline (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5676 Pyridoxine hydrochloride.
(a) Product. Pyridoxine hydrochloride.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5695 Riboflavin.
(a) Product. Riboflavin.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5697 Riboflavin-5-phosphate.
(a) Product. Riboflavin-5-phosphate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5701 Serine.
(a) Product. Serine (L- and DL-forms).
§ 582.5772 Sodium pantothenate.
(a) Product. Sodium pantothenate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5778 Sodium phosphate.
(a) Product. Sodium phosphate (mono-, di- , and tribasic).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5835 Sorbitol.
(a) Product. Sorbitol.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5875 Thiamine hydrochloride.
(a) Product. Thiamine hydrochloride.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5878 Thiamine mononitrate.
(a) Product. Thiamine mononitrate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5881 Threonine.
(a) Product. Threonine (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5890 Tocopherols.
(a) Product. Tocopherols.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5892 α-Tocopherol acetate.
(a) Product. α-Tocopherol acetate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5915 Tryptophane.
(a) Product. Tryptophane (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5920 Tyrosine.
(a) Product. Tyrosine (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5925 Valine.
(a) Product. Valine (L- and DL-forms).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5930 Vitamin A.
(a) Product. Vitamin A.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5933 Vitamin A acetate.
(a) Product. Vitamin A acetate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5936 Vitamin A palmitate.
(a) Product. Vitamin A palmitate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.5945 Vitamin B₁₂.
(a) Product. Vitamin B₁₂.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
$582.5950$ Vitamin $D_2$.
   (a) Product. Vitamin $D_2$.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.5953$ Vitamin $D_3$.
   (a) Product. Vitamin $D_3$.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.5985$ Zinc chloride.
   (a) Product. Zinc chloride.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.5988$ Zinc gluconate.
   (a) Product. Zinc gluconate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.5991$ Zinc oxide.
   (a) Product. Zinc oxide.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.5994$ Zinc stearate.
   (a) Product. Zinc stearate prepared from stearic acid free from chick-edema factor.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.5997$ Zinc sulfate.
   (a) Product. Zinc sulfate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

Subpart G—Sequestrants

$582.6033$ Citric acid.
   (a) Product. Citric acid.

$582.6085$ Sodium acid phosphate.
   (a) Product. Sodium acid phosphate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.6099$ Tartaric acid.
   (a) Product. Tartaric acid.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.6185$ Calcium acetate.
   (a) Product. Calcium acetate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.6193$ Calcium chloride.
   (a) Product. Calcium chloride.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.6195$ Calcium citrate.
   (a) Product. Calcium citrate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.6197$ Calcium diacetate.
   (a) Product. Calcium diacetate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

$582.6199$ Calcium gluconate.
   (a) Product. Calcium gluconate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

For the purpose of this subpart, no attempt has been made to designate those sequestrants that may also function as chemical preservatives.
§ 582.6203 Calcium hexametaphosphate.
   (a) Product. Calcium hexametaphosphate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6215 Monobasic calcium phosphate.
   (a) Product. Monobasic calcium phosphate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6219 Calcium phytate.
   (a) Product. Calcium phytate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6285 Dipotassium phosphate.
   (a) Product. Dipotassium phosphate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6290 Disodium phosphate.
   (a) Product. Disodium phosphate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6386 Isopropyl citrate.
   (a) Product. Isopropyl citrate.
   (b) Tolerance. This substance is generally recognized as safe for use at a level not exceeding 0.02 percent in accordance with good manufacturing or feeding practice.

§ 582.6511 Monoisopropyl citrate.
   (a) Product. Monoisopropyl citrate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6625 Potassium citrate.
   (a) Product. Potassium citrate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6751 Sodium citrate.
   (a) Product. Sodium citrate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6754 Sodium diacetate.
   (a) Product. Sodium diacetate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6757 Sodium gluconate.
   (a) Product. Sodium gluconate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6760 Sodium hexametaphosphate.
   (a) Product. Sodium hexametaphosphate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6769 Sodium metaphosphate.
   (a) Product. Sodium metaphosphate.
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6778 Sodium phosphate.
   (a) Product. Sodium phosphate (mono-, di-, and tribasic).
   (b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6787 Sodium pyrophosphate.
   (a) Product. Sodium pyrophosphate.
   (b) Condition of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Food and Drug Administration, HHS

§ 582.6789 Tetra sodium pyrophosphate.
(a) Product. Tetra sodium pyrophosphate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6801 Sodium tartrate.
(a) Product. Sodium tartrate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6804 Sodium potassium tartrate.
(a) Product. Sodium potassium tartrate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6807 Sodium thiosulfate.
(a) Product. Sodium thiosulfate.
(b) Tolerance. 0.1 percent.
(c) Limitations, restrictions, or explanation. This substance is generally recognized as safe when used in salt in accordance with good manufacturing or feeding practice.

§ 582.6810 Sodium tripolyphosphate.
(a) Product. Sodium tripolyphosphate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.6851 Stearyl citrate.
(a) Product. Stearyl citrate.
(b) Tolerance. This substance is generally recognized as safe for use at a level not exceeding 0.15 percent in accordance with good manufacturing or feeding practice.

Subpart H—Stabilizers

§ 582.7115 Agar-agar.
(a) Product. Agar-agar.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7133 Ammonium alginate.
(a) Product. Ammonium alginate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7187 Calcium alginate.
(a) Product. Calcium alginate.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7255 Chondrus extract.
(a) Product. Chondrus extract (carrageenin).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7330 Gum arabic.
(a) Product. Acacia (gum arabic).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7333 Gum ghatti.
(a) Product. Gum ghatti.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7339 Guar gum.
(a) Product. Guar gum.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7343 Locust bean gum.
(a) Product. Locust (carob) bean gum.
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7349 Sterculia gum.
(a) Product. Sterculia gum (karaya gum).
(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 582.7351 Gum tragacanth.

(a) Product. Tragacanth (gum tragacanth).

(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7610 Potassium alginate.

(a) Product. Potassium alginate.

(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

§ 582.7724 Sodium alginate.

(a) Product. Sodium alginate.

(b) Conditions of use. This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.

PART 584—FOOD SUBSTANCES AFFIRMED AS GENERALLY RECOGNIZED AS SAFE IN FEED AND DRINKING WATER OF ANIMALS

Subpart A [Reserved]

Subpart B—Listing of Specific Substances Affirmed as GRAS

Sec.

584.200 Ethyl alcohol containing ethyl acetate.

584.700 Hydrophobic silicas.


Subpart A [Reserved]

Subpart B—Listing of Specific Substances Affirmed as GRAS

§ 584.200 Ethyl alcohol containing ethyl acetate.

The feed additive ethyl alcohol containing ethyl acetate meets the requirement of 27 CFR 212.45, being not less than 92.5 percent ethyl alcohol, each 100 gallons having had added the equivalent of 4.25 gallons of 100 percent ethyl acetate. It is used in accordance with good feeding practices in ruminant feed supplements as a source of added energy.

[46 FR 52333, Oct. 27, 1981]

PART 589—SUBSTANCES PROHIBITED FROM USE IN ANIMAL FOOD OR FEED

Subpart A—General Provisions

Sec.

589.1 Substances prohibited from use in animal food or feed.

Subpart B—Listing of Specific Substances Prohibited From Use in Animal Food or Feed

589.1000 Gentian violet.

589.1001 Propylene glycol in or on cat food.


[61 FR 43453, Aug. 23, 1996]
Food and Drug Administration, HHS


Subpart A—General Provisions

§ 589.1 Substances prohibited from use in animal food or feed.

(a) The substances listed in this part have been prohibited from use in animal food or feed by the Food and Drug Administration because of a determination that they present a potential risk to the public health or have not been shown by adequate scientific data to be safe for use in such food or feed. Use of any of these substances in violation of this part causes the animal food or feed involved to be adulterated and in violation of the Act.

(b) This part includes only a partial list of substances prohibited from use in animal food or feed; it is for easy reference purposes and is not a complete list of substances that may not lawfully be used in such animal food or feed. No substance may be used in animal food or feed unless it meets all applicable requirements of the Act.

(c) The Food and Drug Administration either on its own initiative or on behalf of any interested person who has submitted a petition, may publish a proposal to establish, amend, or repeal a regulation under this part on the basis of new scientific evaluation or information. Any such petition shall include an adequate scientific basis to support the petition, be the form set forth in §571.1 of this chapter, and will be published in the Federal Register for comment if it contains reasonable ground.

[45 FR 28319, Apr. 29, 1980]

Subpart B—Listing of Specific Substances Prohibited From Use in Animal Food or Feed

§ 589.1000 Gentian violet.

The Food and Drug Administration has determined that gentian violet has not been shown by adequate scientific data to be safe for use in animal feed. Use of gentian violet in animal feed causes the feed to be adulterated and in violation of the Federal Food, Drug, and Cosmetic Act (the Act), in the absence of a regulation providing for its safe use as a food additive under section 409 of the Act, unless it is subject to an effective notice of claimed investigational exemption for a food additive under §570.17 of this chapter, or unless the substance is intended for use as a new animal drug and is subject to an approved application under section 512 of the act or an effective notice of claimed investigational exemption for a new animal drug under part 511 of this chapter.

[56 FR 40507, Aug. 15, 1991]

§ 589.1001 Propylene glycol in or on cat food.

The Food and Drug Administration has determined that propylene glycol in or on cat food has not been shown by adequate scientific data to be safe for use. Use of propylene glycol in or on cat food causes the feed to be adulterated and in violation of the Federal Food, Drug, and Cosmetic Act (the Act), in the absence of a regulation providing for its safe use as a food additive under section 409 of the Act, unless it is subject to an effective notice of claimed investigational exemption for a food additive under §570.17 of this chapter, or unless the substance is intended for use as a new animal drug and is subject to an approved application under section 512 of the act or an effective notice of claimed investigational exemption for a new animal drug under part 511 of this chapter.

[61 FR 19544, May 2, 1996]

§ 589.2000 Animal proteins prohibited in ruminant feed.

(a) Definitions—(1) Protein derived from mammalian tissues means any protein-containing portion of mammalian animals, excluding: Blood and blood products; gelatin; inspected meat products which have been cooked and offered for human food and further heat processed for feed (such as plate waste and used cellulose food casings); milk products (milk and milk proteins); and any product whose only mammalian protein consists entirely of porcine or equine protein.
(2) **Renderer** means any firm or individual that processes slaughter byproducts, animals unfit for human consumption, or meat scraps. The term includes persons who collect such materials and subject them to minimal processing, or distribute them to firms other than renderers (as defined here) whose intended use for the products may include animal feed. The term includes renderers that also blend animal protein products.

(3) **Blender** means any firm or individual which obtains processed animal protein from more than one source or from more than one species, and subsequently mixes (blends) or redistributes an animal protein product.

(4) **Feed manufacturer** includes manufacturers of complete and intermediate feeds intended for animals, and includes on-farm in addition to off-farm feed manufacturing and mixing operations.

(5) **Nonmammalian protein** includes proteins from nonmammalian animals.

(6) **Distributor** includes persons who distribute or transport feeds or feed ingredients intended for animals.

(7) **Ruminant** includes any member of the order of animals which has a stomach with four chambers (rumen, reticulum, omasum, and abomasum) through which feed passes in digestion. The order includes, but is not limited to, cattle, buffalo, sheep, goats, deer, elk, and antelopes.

(b) **Food additive status.** The Food and Drug Administration has determined that protein derived from mammalian tissues for use in ruminant feed is a food additive subject to section 409 of the Federal Food, Drug, and Cosmetic Act (the act). The use or intended use in ruminant feed of any material that contains protein derived from mammalian tissues causes the feed to be adulterated and in violation of the act, unless it is the subject of an effective notice of claimed investigational exemption for a food additive under §579.17 of this chapter.

(c) **Requirements for renderers that are not included in paragraph (e) of this section.** (1) Renderers that manufacture products that contain or may contain protein derived from mammalian tissues and that are intended for use in animal feed shall take the following measures to ensure that materials identified in paragraph (b) of this section are not used in the feed of ruminants:

   (i) Label the materials as follows: “Do not feed to cattle or other ruminants”; and

   (ii) Maintain records sufficient to track the materials throughout their receipt, processing, and distribution, and make the copies available for inspection and copying by the Food and Drug Administration.

(2) Renderers described in paragraph (c)(1) of this section will be exempted from the requirements of paragraphs (c)(1)(i) and (c)(1)(ii) of this section if they:

   (i) Use exclusively a manufacturing method that has been validated by the Food and Drug Administration to de-activate the agent that causes transmissible spongiform encephalopathy (TSE) and whose design has been made available to the public;

   (ii) Use routinely a test method that has been validated by the Food and Drug Administration to detect the presence of the agent that causes TSE’s and whose design has been made available to the public. Renderers whose products test positive for agents that cause TSE’s must comply with paragraphs (c)(1)(i) and (c)(1)(ii) of this section. Records of the test results shall be made available for inspection by the Food and Drug Administration; or

   (iii) Use exclusively a method for controlling the manufacturing process that minimizes the risk of the TSE agent entering the product and whose design has been made available to the public and validated by the Food and Drug Administration.

(3) Renderers described in paragraph (c)(1) of this section will be exempted from the requirements of paragraph (c)(1)(ii) of this section if they use a permanent method, approved by FDA, to make a mark indicating that the product contains or may contain protein derived from mammalian tissue. If the marking is by the use of an agent that cannot be detected on visual inspection, the renderer must use an agent whose presence can be detected by a method that has been validated by the Food and Drug Administration and
(d) Requirements for protein blenders, feed manufacturers, and distributors that are not included in paragraph (e) of this section. (1) Protein blenders, feed manufacturers, and distributors that manufacture, blend, process, and distribute products that contain or may contain protein derived from mammalian tissues shall comply with paragraph (c)(1) of this section.

(2) Protein blenders, feed manufacturers, and distributors, shall be exempt from paragraphs (d)(1) of this section if they:

(i) Purchase animal products from renderers that certified compliance with paragraph (c)(2) of this section or purchase such materials from parties that certify that the materials were purchased from renderers that certified compliance with paragraph (c)(2) of this section; or

(ii) Comply with the requirements of paragraph (c)(2) of this section where appropriate.

(3) Protein blenders, feed manufacturers, and distributors, shall be exempt from paragraph (c)(1)(ii) of this section if they:

(i) Purchase animal protein products that are marked in accordance with paragraph (c)(3) of this section or purchase such materials from renderers that certified compliance with paragraph (c)(3) of this section, or purchase such materials from parties that certify that the materials were purchased from renderers that certified compliance with paragraph (c)(3) of this section; or

(ii) Comply with the requirements of paragraph (c)(3) of this section where appropriate.

(4) Pet food products that are sold or are intended for sale at retail and feeds for nonruminant laboratory animals are exempt from the labeling requirements in paragraphs (c) and (d) of this section. However, if the pet food products or feeds for nonruminant laboratory animals are sold or are intended for sale as distressed or salvage items, then such products shall be labeled in accordance with paragraph (c) or (d) of this section, as appropriate.

(5) Copies of certifications as described in paragraphs (d)(2) and (d)(3) of this section, shall be made available for inspection and copying by the Food and Drug Administration.

(e) Requirements for persons that intend to separate mammalian and nonmammalian materials. (1) Renderers, protein blenders, feed manufacturers, distributors, and others that manufacture, process, blend and distribute both products that contain or may contain protein derived from mammalian tissues or feeds containing such products, and protein products from other animal tissues or feeds containing such products, and that intend to keep those products separate shall:

(i) Comply with paragraphs (c)(1) or (d)(1) of this section as appropriate except that the labeling requirement shall apply only to products that contain or may contain protein derived from mammalian tissues or feeds containing such products;

(ii) In the case of a renderer, obtain nonmammalian or pure porcine or pure equine materials only from single-species slaughter facilities;

(iii) Provide for measures to avoid commingling or cross-contamination;

(A) Maintain separate equipment or facilities for the manufacture, processing, or blending of such materials; or

(B) Use clean-out procedures or other means adequate to prevent carry-over of products that contain or may contain protein derived from mammalian tissues into animal protein or feeds that may be used for ruminants; and

(iv) Maintain written procedures specifying the clean-out procedures or other means, and specifying the procedures for separating products that contain or may contain protein derived from mammalian tissue from all other protein products from the time of receipt until the time of shipment.

(2) Renderers, blenders, feed manufacturers, and distributors will be exempted from applicable requirements of paragraph (e)(1) of this section, if they meet the criteria for exemption under paragraphs (c)(2) or (c)(3) of this section, and (d)(2) or (d)(3) of this section.

(f) Requirements for establishments and individuals that are responsible for feeding ruminant animals. Establishments and individuals that are responsible for
§ 589.2000

feeding ruminant animals shall maintain copies of purchase invoices and labeling for all feeds containing animal protein products received, and make the copies available for inspection and copying by the Food and Drug Administration.

(g) Adulteration and misbranding. (1) Animal protein products, and feeds containing such products, that are not in compliance with paragraphs (c) through (f) of this section, excluding labeling requirements, will be deemed adulterated under section 402(a)(2)(C) or 402(a)(4) of the act.

(2) Animal protein products, and feeds containing such products, that are not in compliance with the labeling requirements of paragraphs (c) through (f) of this section will be deemed misbranded under section 403(a)(1) or 403(f) of the act.

(h) Inspection; records retention. (1) Records that are to be made available for inspection and copying, as required by this section, shall be kept for a minimum of 1 year.

(2) Written procedures required by this section shall be made available for inspection and copying by the Food and Drug Administration.


EFFECTIVE DATE NOTE: At 62 FR 30976, June 5, 1997, §589.2000 was added. Paragraph (e)(1)(iv) of this section contains information collection and recordkeeping requirements and will not become effective until approval has been given by the Office of Management and Budget.

PARTS 590–599 [RESERVED]
FINDING AIDS

A list of CFR titles, subtitles, chapters, subchapters and parts and an alphabetical list of agencies publishing in the CFR are included in the CFR Index and Finding Aids volume to the Code of Federal Regulations which is published separately and revised annually.

- Material Approved for Incorporation by Reference
- Table of CFR Titles and Chapters
- Alphabetical List of Agencies Appearing in the CFR
- Redesignation Table
- List of CFR Sections Affected
Material Approved for Incorporation by Reference

(Revised as of April 1, 2002)

The Director of the Federal Register has approved under 5 U.S.C. 552(a) and 1 CFR Part 51 the incorporation by reference of the following publications. This list contains only those incorporations by reference effective as of the revision date of this volume. Incorporations by reference found within a regulation are effective upon the effective date of that regulation. For more information on incorporation by reference, see the preliminary pages of this volume.

21 CFR (PARTS 500 TO 599)

FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES

21 CFR

Academic Press, Inc.
111 Fifth Ave., New York, NY 10003
Method published in “Methods in Hormone Research,” New York, 556.710(b)

AOAC International (Association of Official Analytical Chemists)
481 N. Frederick Ave., Suite 500, Gaithersburg, MD 20877-2417
Telephone: (301) 924–7077
573.640(b)(4)(i)
and (ii)

Note: The following materials are available through the Food and Drug Administration at the addresses indicated.

Center for Food Safety and Applied Nutrition, Food and Drug Administration
200 C St. SW., Washington, DC 20204
Journal of the Association of Official Analytical Chemists:
Weight Method of E. J. Emberg, G. H. Gass and J. M. Curtis, published

Dockets Management Branch (HFA–305), Food and Drug Administration
5600 Fishers Lane, Room 4–62, Rockville, MD 20857
Determination of Factor Content in Tylosin by High Performance
Liquid Chromatography. 520.2640; 522.2640a;
522.2640b;
524.2640; 558.625;
558.630
## Table of CFR Titles and Chapters
(Revised as of April 1, 2002)

### Title 1—General Provisions

| I | Administrative Committee of the Federal Register (Parts 1—49) |
| II | Office of the Federal Register (Parts 50—299) |
| IV | Miscellaneous Agencies (Parts 400—500) |

### Title 2 [Reserved]

### Title 3—The President

| I | Executive Office of the President (Parts 100—199) |

### Title 4—Accounts

| I | General Accounting Office (Parts 1—99) |

### Title 5—Administrative Personnel

| I | Office of Personnel Management (Parts 1—1199) |
| II | Merit Systems Protection Board (Parts 1200—1299) |
| III | Office of Management and Budget (Parts 1300—1399) |
| V | The International Organizations Employees Loyalty Board (Parts 1500—1599) |
| VI | Federal Retirement Thrift Investment Board (Parts 1600—1699) |
| VII | Advisory Commission on Intergovernmental Relations (Parts 1700—1799) |
| VIII | Office of Special Counsel (Parts 1800—1899) |
| IX | Appalachian Regional Commission (Parts 1900—1999) |
| XI | Armed Forces Retirement Home (Part 2100) |
| XIV | Federal Labor Relations Authority, General Counsel of the Federal Labor Relations Authority and Federal Service Impasses Panel (Parts 2400—2499) |
| XV | Office of Administration, Executive Office of the President (Parts 2500—2599) |
| XVI | Office of Government Ethics (Parts 2600—2699) |
| XXI | Department of the Treasury (Parts 3100—3199) |
| XXII | Federal Deposit Insurance Corporation (Part 3201) |
| XXIII | Department of Energy (Part 3301) |
| XXIV | Federal Energy Regulatory Commission (Part 3401) |
Title 5—Administrative Personnel—Continued

XXV Department of the Interior (Part 3501)
XXVI Department of Defense (Part 3601)
XXVIII Department of Justice (Part 3801)
XXIX Federal Communications Commission (Parts 3900–3999)
XXX Farm Credit System Insurance Corporation (Parts 4000–4099)
XXXI Farm Credit Administration (Parts 4100–4199)
XXXIII Overseas Private Investment Corporation (Part 4301)
XXXV Office of Personnel Management (Part 4501)
XL Interstate Commerce Commission (Part 5001)
XLI Commodity Futures Trading Commission (Part 5101)
XLII Department of Labor (Part 5201)
XLIII National Science Foundation (Part 5301)
XLV Department of Health and Human Services (Part 5501)
XLVI Federal Trade Commission (Part 5701)
XLVIII Nuclear Regulatory Commission (Part 5801)
LV Department of Transportation (Part 6001)
LII Export-Import Bank of the United States (Part 6201)
LIII Department of Education (Parts 6300–6399)
LIV Environmental Protection Agency (Part 6401)
LVII General Services Administration (Part 6701)
LVIII Board of Governors of the Federal Reserve System (Part 6801)
LIX National Aeronautics and Space Administration (Part 6901)
LX United States Postal Service (Part 7001)
LXI National Labor Relations Board (Part 7101)
LXII Equal Employment Opportunity Commission (Part 7201)
LXIII Inter-American Foundation (Part 7301)
LXV Department of Housing and Urban Development (Part 7501)
LXVI National Archives and Records Administration (Part 7601)
LXIX Tennessee Valley Authority (Part 7901)
LXI Consumer Product Safety Commission (Part 8101)
LXIII Department of Agriculture (Part 8301)
LXIV Federal Mine Safety and Health Review Commission (Part 8401)
LXVI Federal Retirement Thrift Investment Board (Part 8601)
LXVII Office of Management and Budget (Part 8701)

Title 6 [Reserved]

Title 7—Agriculture

Subtitle A—Office of the Secretary of Agriculture (Parts 0–26)
Subtitle B—Regulations of the Department of Agriculture
Title 7—Agriculture—Continued

I Agricultural Marketing Service (Standards, Inspections, Marketing Practices), Department of Agriculture (Parts 27—209)

II Food and Nutrition Service, Department of Agriculture (Parts 210—299)

III Animal and Plant Health Inspection Service, Department of Agriculture (Parts 300—399)

IV Federal Crop Insurance Corporation, Department of Agriculture (Parts 400—499)

V Agricultural Research Service, Department of Agriculture (Parts 500—599)

VI Natural Resources Conservation Service, Department of Agriculture (Parts 600—699)

VII Farm Service Agency, Department of Agriculture (Parts 700—799)

VIII Grain Inspection, Packers and Stockyards Administration (Federal Grain Inspection Service), Department of Agriculture (Parts 800—899)

IX Agricultural Marketing Service (Marketing Agreements and Orders; Fruits, Vegetables, Nuts), Department of Agriculture (Parts 900—999)

X Agricultural Marketing Service (Marketing Agreements and Orders; Milk), Department of Agriculture (Parts 1000—1199)

XI Agricultural Marketing Service (Marketing Agreements and Orders; Miscellaneous Commodities), Department of Agriculture (Parts 1200—1299)

XIII Northeast Dairy Compact Commission (Parts 1300—1399)

XIV Commodity Credit Corporation, Department of Agriculture (Parts 1400—1499)

XV Foreign Agricultural Service, Department of Agriculture (Parts 1500—1599)

XVI Rural Telephone Bank, Department of Agriculture (Parts 1600—1699)

XVII Rural Utilities Service, Department of Agriculture (Parts 1700—1799)

XVIII Rural Housing Service, Rural Business-Cooperative Service, Rural Utilities Service, and Farm Service Agency, Department of Agriculture (Parts 1800—2099)

XXVI Office of Inspector General, Department of Agriculture (Parts 2600—2699)

XX VII Office of Information Resources Management, Department of Agriculture (Parts 2700—2799)

XXVIII Office of Operations, Department of Agriculture (Parts 2800—2899)

XXIX Office of Energy, Department of Agriculture (Parts 2900—2999)

XXX Office of the Chief Financial Officer, Department of Agriculture (Parts 3000—3099)

XXXI Office of Environmental Quality, Department of Agriculture (Parts 3100—3199)

XXXII Office of Procurement and Property Management, Department of Agriculture (Parts 3200—3299)
XXXIII Office of Transportation, Department of Agriculture (Parts 3300—3399)
XXXIV Cooperative State Research, Education, and Extension Service, Department of Agriculture (Parts 3400—3499)
XXXV Rural Housing Service, Department of Agriculture (Parts 3500—3599)
XXXVI National Agricultural Statistics Service, Department of Agriculture (Parts 3600—3699)
XXXVII Economic Research Service, Department of Agriculture (Parts 3700—3799)
XXXVIII World Agricultural Outlook Board, Department of Agriculture (Parts 3800—3899)
XLI [Reserved]
XLII Rural Business-Cooperative Service and Rural Utilities Service, Department of Agriculture (Parts 4200—4299)

Title 8—Aliens and Nationality

I Immigration and Naturalization Service, Department of Justice (Parts 1—599)

Title 9—Animals and Animal Products

I Animal and Plant Health Inspection Service, Department of Agriculture (Parts 1—199)
II Grain Inspection, Packers and Stockyards Administration (Packers and Stockyards Programs), Department of Agriculture (Parts 200—299)
III Food Safety and Inspection Service, Department of Agriculture (Parts 300—599)

Title 10—Energy

I Nuclear Regulatory Commission (Parts 0—199)
II Department of Energy (Parts 200—699)
III Department of Energy (Parts 700—999)
X Department of Energy (General Provisions) (Parts 1000—1099)
XVII Defense Nuclear Facilities Safety Board (Parts 1700—1799)
XVIII Northeast Interstate Low-Level Radioactive Waste Commission (Part 1800)

Title 11—Federal Elections

I Federal Election Commission (Parts 1—9099)

Title 12—Banks and Banking

I Comptroller of the Currency, Department of the Treasury (Parts 1—199)
Title 12—Banks and Banking—Continued

II Federal Reserve System (Parts 200—299)
III Federal Deposit Insurance Corporation (Parts 300—399)
IV Export-Import Bank of the United States (Parts 400—499)
V Office of Thrift Supervision, Department of the Treasury (Parts 500—599)
VI Farm Credit Administration (Parts 600—699)
VII National Credit Union Administration (Parts 700—799)
VIII Federal Financing Bank (Parts 800—899)
IX Federal Housing Finance Board (Parts 900—999)
XI Federal Financial Institutions Examination Council (Parts 1100—1199)
XIV Farm Credit System Insurance Corporation (Parts 1400—1499)
XV Department of the Treasury (Parts 1500—1599)
XVII Office of Federal Housing Enterprise Oversight, Department of Housing and Urban Development (Parts 1700—1799)
XVIII Community Development Financial Institutions Fund, Department of the Treasury (Parts 1800—1899)

Title 13—Business Credit and Assistance

I Small Business Administration (Parts 1—199)
III Economic Development Administration, Department of Commerce (Parts 300—399)
IV Emergency Steel Guarantee Loan Board (Parts 400—499)
V Emergency Oil and Gas Guaranteed Loan Board (Parts 500—599)

Title 14—Aeronautics and Space

I Federal Aviation Administration, Department of Transportation (Parts 1—199)
II Office of the Secretary, Department of Transportation (Aviation Proceedings) (Parts 200—399)
III Commercial Space Transportation, Federal Aviation Administration, Department of Transportation (Parts 400—499)
V National Aeronautics and Space Administration (Parts 1200—1299)
VI Office of Management and Budget (Parts 1300—1399)

Title 15—Commerce and Foreign Trade

SUBTITLE A—Office of the Secretary of Commerce (Parts 0—29)
SUBTITLE B—Regulations Relating to Commerce and Foreign Trade
I Bureau of the Census, Department of Commerce (Parts 30—199)
II National Institute of Standards and Technology, Department of Commerce (Parts 200—299)
Title 15—Commerce and Foreign Trade—Continued

III International Trade Administration, Department of Commerce (Parts 300—399)
IV Foreign-Trade Zones Board, Department of Commerce (Parts 400—499)
VII Bureau of Export Administration, Department of Commerce (Parts 700—799)
VIII Bureau of Economic Analysis, Department of Commerce (Parts 800—899)
IX National Oceanic and Atmospheric Administration, Department of Commerce (Parts 900—999)
XI Technology Administration, Department of Commerce (Parts 1100—1199)
XIII East-West Foreign Trade Board (Parts 1300—1399)
XIV Minority Business Development Agency (Parts 1400—1499)
SUBTITLE C—REGULATIONS RELATING TO FOREIGN TRADE AGREEMENTS
XX Office of the United States Trade Representative (Parts 2000—2099)
SUBTITLE D—REGULATIONS RELATING TO TELECOMMUNICATIONS AND INFORMATION
XXIII National Telecommunications and Information Administration, Department of Commerce (Parts 2300—2399)

Title 16—Commercial Practices

I Federal Trade Commission (Parts 0—999)
II Consumer Product Safety Commission (Parts 1000—1799)

Title 17—Commodity and Securities Exchanges

I Commodity Futures Trading Commission (Parts 1—199)
II Securities and Exchange Commission (Parts 200—399)
IV Department of the Treasury (Parts 400—499)

Title 18—Conservation of Power and Water Resources

I Federal Energy Regulatory Commission, Department of Energy (Parts 1—399)
III Delaware River Basin Commission (Parts 400—499)
VI Water Resources Council (Parts 700—799)
VIII Susquehanna River Basin Commission (Parts 800—899)
XIII Tennessee Valley Authority (Parts 1300—1399)

Title 19—Customs Duties

I United States Customs Service, Department of the Treasury (Parts 1—199)
II United States International Trade Commission (Parts 200—299)
Chap. 19—Customs Duties—Continued

III International Trade Administration, Department of Commerce (Parts 300—399)

Title 20—Employees' Benefits

I Office of Workers' Compensation Programs, Department of Labor (Parts 1—199)
II Railroad Retirement Board (Parts 200—399)
III Social Security Administration (Parts 400—499)
IV Employees' Compensation Appeals Board, Department of Labor (Parts 500—599)
V Employment and Training Administration, Department of Labor (Parts 600—699)
VI Employment Standards Administration, Department of Labor (Parts 700—799)
VII Benefits Review Board, Department of Labor (Parts 800—899)
VIII Joint Board for the Enrollment of Actuaries (Parts 900—999)
IX Office of the Assistant Secretary for Veterans' Employment and Training, Department of Labor (Parts 1000—1099)

Title 21—Food and Drugs

I Food and Drug Administration, Department of Health and Human Services (Parts 1—1299)
II Drug Enforcement Administration, Department of Justice (Parts 1300—1399)
III Office of National Drug Control Policy (Parts 1400—1499)

Title 22—Foreign Relations

I Department of State (Parts 1—199)
II Agency for International Development (Parts 200—299)
III Peace Corps (Parts 300—399)
IV International Joint Commission, United States and Canada (Parts 400—499)
V Broadcasting Board of Governors (Parts 500—599)
VII Overseas Private Investment Corporation (Parts 700—799)
IX Foreign Service Grievance Board Regulations (Parts 900—999)
X Inter-American Foundation (Parts 1000—1099)
XI International Boundary and Water Commission, United States and Mexico, United States Section (Parts 1100—1199)
XII United States International Development Cooperation Agency (Parts 1200—1299)
XIV Foreign Service Labor Relations Board; Federal Labor Relations Authority; General Counsel of the Federal Labor Relations Authority; and the Foreign Service Impasse Disputes Panel (Parts 1400—1499)
XV African Development Foundation (Parts 1500—1599)
Title 22—Foreign Relations—Continued

XVI Japan-United States Friendship Commission (Parts 1600—1699)

XVII United States Institute of Peace (Parts 1700—1799)

Title 23—Highways

I Federal Highway Administration, Department of Transportation (Parts 1—999)

II National Highway Traffic Safety Administration and Federal Highway Administration, Department of Transportation (Parts 1200—1299)

III National Highway Traffic Safety Administration, Department of Transportation (Parts 1300—1399)

Title 24—Housing and Urban Development

SUBTITLE A—Office of the Secretary, Department of Housing and Urban Development (Parts 0—99)

SUBTITLE B—Regulations Relating to Housing and Urban Development

I Office of Assistant Secretary for Equal Opportunity, Department of Housing and Urban Development (Parts 100—199)

II Office of Assistant Secretary for Housing—Federal Housing Commissioner, Department of Housing and Urban Development (Parts 200—299)

III Government National Mortgage Association, Department of Housing and Urban Development (Parts 300—399)

IV Office of Housing and Office of Multifamily Housing Assistance Restructuring, Department of Housing and Urban Development (Parts 400—499)

V Office of Assistant Secretary for Community Planning and Development, Department of Housing and Urban Development (Parts 500—599)

VI Office of Assistant Secretary for Community Planning and Development, Department of Housing and Urban Development (Parts 600—699) [Reserved]

VII Office of the Secretary, Department of Housing and Urban Development (Housing Assistance Programs and Public and Indian Housing Programs) (Parts 700—799)

VIII Office of the Assistant Secretary for Housing—Federal Housing Commissioner, Department of Housing and Urban Development (Section 8 Housing Assistance Programs, Section 202 Direct Loan Program, Section 202 Supportive Housing for the Elderly Program and Section 811 Supportive Housing for Persons With Disabilities Program) (Parts 800—899)

IX Office of Assistant Secretary for Public and Indian Housing, Department of Housing and Urban Development (Parts 900—999)

X Office of Assistant Secretary for Housing—Federal Housing Commissioner, Department of Housing and Urban Development (Interstate Land Sales Registration Program) (Parts 1700—1799)
Title 24—Housing and Urban Development—Continued

XII Office of Inspector General, Department of Housing and Urban Development (Parts 2000—2099)

XX Office of Assistant Secretary for Housing—Federal Housing Commissioner, Department of Housing and Urban Development (Parts 3200—3899)

XXV Neighborhood Reinvestment Corporation (Parts 4100—4199)

Title 25—Indians

I Bureau of Indian Affairs, Department of the Interior (Parts 1—299)

II Indian Arts and Crafts Board, Department of the Interior (Parts 300—399)

III National Indian Gaming Commission, Department of the Interior (Parts 500—599)

IV Office of Navajo and Hopi Indian Relocation (Parts 700—799)

V Bureau of Indian Affairs, Department of the Interior, and Indian Health Service, Department of Health and Human Services (Part 900)

VI Office of the Assistant Secretary-Indian Affairs, Department of the Interior (Parts 1000—1199)

VII Office of the Special Trustee for American Indians, Department of the Interior (Part 1200)

Title 26—Internal Revenue

I Internal Revenue Service, Department of the Treasury (Parts 1—899)

Title 27—Alcohol, Tobacco Products and Firearms

I Bureau of Alcohol, Tobacco and Firearms, Department of the Treasury (Parts 1—299)

Title 28—Judicial Administration

I Department of Justice (Parts 0—199)

III Federal Prison Industries, Inc., Department of Justice (Parts 300—399)

V Bureau of Prisons, Department of Justice (Parts 500—599)

VI Offices of Independent Counsel, Department of Justice (Parts 600—699)

VII Office of Independent Counsel (Parts 700—799)

VIII Court Services and Offender Supervision Agency for the District of Columbia (Parts 800—899)

IX National Crime Prevention and Privacy Compact Council (Parts 900—999)

XI Department of Justice and Department of State (Parts 1100—1199)
Title 29—Labor

SUBTITLE A—Office of the Secretary of Labor (Parts 0—99)

SUBTITLE B—Regulations Relating to Labor

I National Labor Relations Board (Parts 100—199)

II Office of Labor-Management Standards, Department of Labor (Parts 200—299)

III National Railroad Adjustment Board (Parts 300—399)

IV Office of Labor-Management Standards, Department of Labor (Parts 400—499)

V Wage and Hour Division, Department of Labor (Parts 500—899)

IX Construction Industry Collective Bargaining Commission (Parts 900—999)

X National Mediation Board (Parts 1200—1299)

XII Federal Mediation and Conciliation Service (Parts 1400—1499)

XIV Equal Employment Opportunity Commission (Parts 1600—1699)

XVII Occupational Safety and Health Administration, Department of Labor (Parts 1900—1999)

XX Occupational Safety and Health Review Commission (Parts 2200—2499)

XXV Pension and Welfare Benefits Administration, Department of Labor (Parts 2500—2599)

XXVII Federal Mine Safety and Health Review Commission (Parts 2700—2799)

XL Pension Benefit Guaranty Corporation (Parts 4000—4999)

Title 30—Mineral Resources

I Mine Safety and Health Administration, Department of Labor (Parts 1—199)

II Minerals Management Service, Department of the Interior (Parts 200—299)

III Board of Surface Mining and Reclamation Appeals, Department of the Interior (Parts 300—399)

IV Geological Survey, Department of the Interior (Parts 400—499)

VI Bureau of Mines, Department of the Interior (Parts 600—699)

VII Office of Surface Mining Reclamation and Enforcement, Department of the Interior (Parts 700—999)

Title 31—Money and Finance: Treasury

SUBTITLE A—Office of the Secretary of the Treasury (Parts 0—50)

SUBTITLE B—Regulations Relating to Money and Finance

I Monetary Offices, Department of the Treasury (Parts 51—199)

II Fiscal Service, Department of the Treasury (Parts 200—399)

IV Secret Service, Department of the Treasury (Parts 400—499)

V Office of Foreign Assets Control, Department of the Treasury (Parts 500—599)
Title 31—Money and Finance: Treasury—Continued

VI Bureau of Engraving and Printing, Department of the Treasury (Parts 600—699)

VII Federal Law Enforcement Training Center, Department of the Treasury (Parts 700—799)

VIII Office of International Investment, Department of the Treasury (Parts 800—899)

IX Federal Claims Collection Standards (Department of the Treasury—Department of Justice) (Parts 900—999)

Title 32—National Defense

SUBTITLE A—DEPARTMENT OF DEFENSE

I Office of the Secretary of Defense (Parts 1—399)

V Department of the Army (Parts 400—699)

VI Department of the Navy (Parts 700—799)

VII Department of the Air Force (Parts 800—1099)

SUBTITLE B—OTHER REGULATIONS RELATING TO NATIONAL DEFENSE

XII Defense Logistics Agency (Parts 1200—1299)

XVI Selective Service System (Parts 1600—1699)

XVIII National Counterintelligence Center (Parts 1800—1899)

XX Central Intelligence Agency (Parts 1900—1999)

XX Information Security Oversight Office, National Archives and Records Administration (Parts 2000—2099)

XXI National Security Council (Parts 2100—2199)

XXIV Office of Science and Technology Policy (Parts 2400—2499)

XXVII Office for Micronesian Status Negotiations (Parts 2700—2799)

XXVIII Office of the Vice President of the United States (Parts 2800—2899)

Title 33—Navigation and Navigable Waters

I Coast Guard, Department of Transportation (Parts 1—199)

II Corps of Engineers, Department of the Army (Parts 200—399)

IV Saint Lawrence Seaway Development Corporation, Department of Transportation (Parts 400—499)

Title 34—Education

SUBTITLE A—OFFICE OF THE SECRETARY, DEPARTMENT OF EDUCATION (PARTS 1—99)

SUBTITLE B—REGULATIONS OF THE OFFICES OF THE DEPARTMENT OF EDUCATION

I Office for Civil Rights, Department of Education (Parts 100—199)

II Office of Elementary and Secondary Education, Department of Education (Parts 200—299)

III Office of Special Education and Rehabilitative Services, Department of Education (Parts 300—399)
Title 34—Education—Continued

IV Office of Vocational and Adult Education, Department of Education (Parts 400—499)
V Office of Bilingual Education and Minority Languages Affairs, Department of Education (Parts 500—599)
VI Office of Postsecondary Education, Department of Education (Parts 600—699)
VII Office of Educational Research and Improvement, Department of Education (Parts 700—799)
XI National Institute for Literacy (Parts 1100—1199)
SUBTITLE C—REGULATIONS RELATING TO EDUCATION
XII National Council on Disability (Parts 1200—1299)

Title 35—Panama Canal

I Panama Canal Regulations (Parts 1—299)

Title 36—Parks, Forests, and Public Property

I National Park Service, Department of the Interior (Parts 1—199)
II Forest Service, Department of Agriculture (Parts 200—299)
III Corps of Engineers, Department of the Army (Parts 300—399)
IV American Battle Monuments Commission (Parts 400—499)
V Smithsonian Institution (Parts 500—599)
VII Library of Congress (Parts 700—799)
VIII Advisory Council on Historic Preservation (Parts 800—899)
IX Pennsylvania Avenue Development Corporation (Parts 900—999)
X Presidio Trust (Parts 1000—1099)
XI Architectural and Transportation Barriers Compliance Board (Parts 1100—1199)
XII National Archives and Records Administration (Parts 1200—1299)
XV Oklahoma City National Memorial Trust (Part 1501)
XVI Morris K. Udall Scholarship and Excellence in National Environmental Policy Foundation (Parts 1600—1699)

Title 37—Patents, Trademarks, and Copyrights

I United States Patent and Trademark Office, Department of Commerce (Parts 1—199)
II Copyright Office, Library of Congress (Parts 200—299)
IV Assistant Secretary for Technology Policy, Department of Commerce (Parts 400—499)
V Under Secretary for Technology, Department of Commerce (Parts 500—599)

Title 38—Pensions, Bonuses, and Veterans’ Relief

I Department of Veterans Affairs (Parts 0—99)
Title 39—Postal Service

I United States Postal Service (Parts 1—999)
III Postal Rate Commission (Parts 3000—3099)

Title 40—Protection of Environment

I Environmental Protection Agency (Parts 1—799)
IV Environmental Protection Agency and Department of Justice (Parts 1400—1499)
V Council on Environmental Quality (Parts 1500—1599)
VI Chemical Safety and Hazard Investigation Board (Parts 1600—1699)
VII Environmental Protection Agency and Department of Defense; Uniform National Discharge Standards for Vessels of the Armed Forces (Parts 1700—1799)

Title 41—Public Contracts and Property Management

SUBTITLE B—OTHER PROVISIONS RELATING TO PUBLIC CONTRACTS

50 Public Contracts, Department of Labor (Parts 50–1—50–999)
51 Committee for Purchase From People Who Are Blind or Severely Disabled (Parts 51–1—51–99)
60 Office of Federal Contract Compliance Programs, Equal Employment Opportunity, Department of Labor (Parts 60–1—60–999)
61 Office of the Assistant Secretary for Veterans' Employment and Training Service, Department of Labor (Parts 61–1—61–999)

SUBTITLE C—FEDERAL PROPERTY MANAGEMENT REGULATIONS SYSTEM

101 Federal Property Management Regulations (Parts 101–1—101–99)
102 Federal Management Regulation (Parts 102–1—102–299)
105 General Services Administration (Parts 105–1—105–999)
109 Department of Energy Property Management Regulations (Parts 109–1—109–99)
114 Department of the Interior (Parts 114–1—114–99)
115 Environmental Protection Agency (Parts 115–1—115–99)
128 Department of Justice (Parts 128–1—128–99)

SUBTITLE D—OTHER PROVISIONS RELATING TO PROPERTY MANAGEMENT [RESERVED]

SUBTITLE E—FEDERAL INFORMATION RESOURCES MANAGEMENT REGULATIONS SYSTEM

201 Federal Information Resources Management Regulation (Parts 201–1—201–99) [Reserved]

SUBTITLE F—FEDERAL TRAVEL REGULATION SYSTEM

300 General (Parts 300–1—300–99)
301 Temporary Duty (TDY) Travel Allowances (Parts 301–1—301–99)
302 Relocation Allowances (Parts 302–1—302–99)
303 Payment of Expenses Connected with the Death of Certain Employees (Part 303–70)
Title 41—Public Contracts and Property Management—Continued

304 Payment from a Non-Federal Source for Travel Expenses (Parts 304–1—304–99)

Title 42—Public Health

I Public Health Service, Department of Health and Human Services (Parts 1—199)

IV Centers for Medicare & Medicaid Services, Department of Health and Human Services (Parts 400—499)

V Office of Inspector General—Health Care, Department of Health and Human Services (Parts 1000—1999)

Title 43—Public Lands: Interior

SUBTITLE A—Office of the Secretary of the Interior (Parts 1—199)

SUBTITLE B—Regulations Relating to Public Lands

I Bureau of Reclamation, Department of the Interior (Parts 200—499)

II Bureau of Land Management, Department of the Interior (Parts 1000—9999)

III Utah Reclamation Mitigation and Conservation Commission (Parts 10000—10005)

Title 44—Emergency Management and Assistance

I Federal Emergency Management Agency (Parts 0—399)

IV Department of Commerce and Department of Transportation (Parts 400—499)

Title 45—Public Welfare

SUBTITLE A—Department of Health and Human Services (Parts 1—199)

SUBTITLE B—Regulations Relating to Public Welfare

II Office of Family Assistance (Assistance Programs), Administration for Children and Families, Department of Health and Human Services (Parts 200—299)

III Office of Child Support Enforcement (Child Support Enforcement Program), Administration for Children and Families, Department of Health and Human Services (Parts 300—399)

IV Office of Refugee Resettlement, Administration for Children and Families Department of Health and Human Services (Parts 400—499)

V Foreign Claims Settlement Commission of the United States, Department of Justice (Parts 500—599)

VI National Science Foundation (Parts 600—699)

VII Commission on Civil Rights (Parts 700—799)

VIII Office of Personnel Management (Parts 800—899)
Title 45—Public Welfare—Continued

X Office of Community Services, Administration for Children and Families, Department of Health and Human Services (Parts 1000—1099)
XI National Foundation on the Arts and the Humanities (Parts 1100—1199)
XII Corporation for National and Community Service (Parts 1200—1299)
XIII Office of Human Development Services, Department of Health and Human Services (Parts 1300—1399)
XVI Legal Services Corporation (Parts 1600—1699)
XVII National Commission on Libraries and Information Science (Parts 1700—1799)
XVIII Harry S. Truman Scholarship Foundation (Parts 1800—1899)
XXI Commission on Fine Arts (Parts 2100—2199)
XXIII Arctic Research Commission (Part 2301)
XXIV James Madison Memorial Fellowship Foundation (Parts 2400—2499)
XXV Corporation for National and Community Service (Parts 2500—2599)

Title 46—Shipping

I Coast Guard, Department of Transportation (Parts 1—199)
II Maritime Administration, Department of Transportation (Parts 200—399)
III Coast Guard (Great Lakes Pilotage), Department of Transportation (Parts 400—499)
IV Federal Maritime Commission (Parts 500—599)

Title 47—Telecommunication

I Federal Communications Commission (Parts 0—199)
II Office of Science and Technology Policy and National Security Council (Parts 200—299)
III National Telecommunications and Information Administration, Department of Commerce (Parts 300—399)

Title 48—Federal Acquisition Regulations System

1 Federal Acquisition Regulation (Parts 1—99)
2 Department of Defense (Parts 200—299)
3 Department of Health and Human Services (Parts 300—399)
4 Department of Agriculture (Parts 400—499)
5 General Services Administration (Parts 500—599)
6 Department of State (Parts 600—699)
7 United States Agency for International Development (Parts 700—799)
8 Department of Veterans Affairs (Parts 800—899)
Title 48—Federal Acquisition Regulations System—Continued

9 Department of Energy (Parts 900—999)
10 Department of the Treasury (Parts 1000—1099)
12 Department of Transportation (Parts 1200—1299)
13 Department of Commerce (Parts 1300—1399)
14 Department of the Interior (Parts 1400—1499)
15 Environmental Protection Agency (Parts 1500—1599)
16 Office of Personnel Management Federal Employees Health Benefits Acquisition Regulation (Parts 1600—1699)
17 Office of Personnel Management (Parts 1700—1799)
18 National Aeronautics and Space Administration (Parts 1800—1899)
19 Broadcasting Board of Governors (Parts 1900—1999)
20 Nuclear Regulatory Commission (Parts 2000—2099)
21 Office of Personnel Management, Federal Employees Group Life Insurance Federal Acquisition Regulation (Parts 2100—2199)
23 Social Security Administration (Parts 2300—2399)
24 Department of Housing and Urban Development (Parts 2400—2499)
25 National Science Foundation (Parts 2500—2599)
28 Department of Justice (Parts 2800—2899)
29 Department of Labor (Parts 2900—2999)
34 Department of Education Acquisition Regulation (Parts 3400—3499)
35 Panama Canal Commission (Parts 3500—3599)
44 Federal Emergency Management Agency (Parts 4400—4499)
51 Department of the Army Acquisition Regulations (Parts 5100—5199)
52 Department of the Navy Acquisition Regulations (Parts 5200—5299)
53 Department of the Air Force Federal Acquisition Regulation Supplement (Parts 5300—5399)
54 Defense Logistics Agency, Department of Defense (Part 5452)
57 African Development Foundation (Parts 5700—5799)
61 General Services Administration Board of Contract Appeals (Parts 6100—6199)
63 Department of Transportation Board of Contract Appeals (Parts 6300—6399)
99 Cost Accounting Standards Board, Office of Federal Procurement Policy, Office of Management and Budget (Parts 9900—9999)

Title 49—Transportation

SUBTITLE A—OFFICE OF THE SECRETARY OF TRANSPORTATION (PARTS 1—99)
SUBTITLE B—OTHER REGULATIONS RELATING TO TRANSPORTATION
I Research and Special Programs Administration, Department of Transportation (Parts 100—199)
Title 49—Transportation—Continued

II Federal Railroad Administration, Department of Transportation (Parts 200—299)
III Federal Motor Carrier Safety Administration, Department of Transportation (Parts 300—399)
IV Coast Guard, Department of Transportation (Parts 400—499)
V National Highway Traffic Safety Administration, Department of Transportation (Parts 500—599)
VI Federal Transit Administration, Department of Transportation (Parts 600—699)
VII National Railroad Passenger Corporation (AMTRAK) (Parts 700—799)
VIII National Transportation Safety Board (Parts 800—999)
X Surface Transportation Board, Department of Transportation (Parts 1000—1399)
XI Bureau of Transportation Statistics, Department of Transportation (Parts 1400—1499)
XII Transportation Security Administration, Department of Transportation (Parts 1500—1599)

Title 50—Wildlife and Fisheries

I United States Fish and Wildlife Service, Department of the Interior (Parts 1—199)
II National Marine Fisheries Service, National Oceanic and Atmospheric Administration, Department of Commerce (Parts 200—299)
III International Fishing and Related Activities (Parts 300—399)
IV Joint Regulations (United States Fish and Wildlife Service, Department of the Interior and National Marine Fisheries Service, National Oceanic and Atmospheric Administration, Department of Commerce); Endangered Species Committee Regulations (Parts 400—499)
V Marine Mammal Commission (Parts 500—599)
VI Fishery Conservation and Management, National Oceanic and Atmospheric Administration, Department of Commerce (Parts 600—699)

CFR Index and Finding Aids

Subject/Agency Index
List of Agency Prepared Indexes
Parallel Tables of Statutory Authorities and Rules
List of CFR Titles, Chapters, Subchapters, and Parts
Alphabetical List of Agencies Appearing in the CFR
### Alphabetical List of Agencies Appearing in the CFR

*(Revised as of April 1, 2002)*

<table>
<thead>
<tr>
<th>Agency</th>
<th>CFR Title, Subtitle or Chapter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative Committee of the Federal Register</td>
<td>1, I</td>
</tr>
<tr>
<td>Advanced Research Projects Agency</td>
<td>32, I</td>
</tr>
<tr>
<td>Advisory Commission on Intergovernmental Relations</td>
<td>5, VII</td>
</tr>
<tr>
<td>Advisory Council on Historic Preservation</td>
<td>36, VIII</td>
</tr>
<tr>
<td>African Development Foundation</td>
<td>22, XV</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 57</td>
</tr>
<tr>
<td>Agency for International Development, United States</td>
<td>22, II</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 7</td>
</tr>
<tr>
<td>Agricultural Marketing Service</td>
<td>7, I, IX, X, XI</td>
</tr>
<tr>
<td>Agricultural Research Service</td>
<td>7, V</td>
</tr>
<tr>
<td>Agriculture Department</td>
<td>5, LXXIII</td>
</tr>
<tr>
<td>Agricultural Marketing Service</td>
<td>7, I, IX, X, XI</td>
</tr>
<tr>
<td>Agricultural Research Service</td>
<td>7, V</td>
</tr>
<tr>
<td>Animal and Plant Health Inspection Service</td>
<td>7, III: 9, I</td>
</tr>
<tr>
<td>Chief Financial Officer, Office of</td>
<td>7, XXX</td>
</tr>
<tr>
<td>Commodity Credit Corporation</td>
<td>7, XIV</td>
</tr>
<tr>
<td>Cooperative State Research, Education, and Extension Service</td>
<td>7, XXXIV</td>
</tr>
<tr>
<td>Economic Research Service</td>
<td>7, XXXVII</td>
</tr>
<tr>
<td>Energy, Office of</td>
<td>7, XXIX</td>
</tr>
<tr>
<td>Environmental Quality, Office of</td>
<td>7, XXXI</td>
</tr>
<tr>
<td>Farm Service Agency</td>
<td>7, VII, XVIII</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 4</td>
</tr>
<tr>
<td>Federal Crop Insurance Corporation</td>
<td>7, IV</td>
</tr>
<tr>
<td>Food and Nutrition Service</td>
<td>7, II</td>
</tr>
<tr>
<td>Food Safety and Inspection Service</td>
<td>9, III</td>
</tr>
<tr>
<td>Foreign Agricultural Service</td>
<td>7, XV</td>
</tr>
<tr>
<td>Forest Service</td>
<td>36, II</td>
</tr>
<tr>
<td>Grain Inspection, Packers and Stockyards Administration</td>
<td>7, VIII: 9, II</td>
</tr>
<tr>
<td>Information Resources Management, Office of</td>
<td>7, XXVII</td>
</tr>
<tr>
<td>Inspector General, Office of</td>
<td>7, XXVI</td>
</tr>
<tr>
<td>National Agricultural Library</td>
<td>7, XLI</td>
</tr>
<tr>
<td>National Agricultural Statistics Service</td>
<td>7, XXXVI</td>
</tr>
<tr>
<td>Natural Resources Conservation Service</td>
<td>7, VI</td>
</tr>
<tr>
<td>Operations, Office of</td>
<td>7, XXVIII</td>
</tr>
<tr>
<td>Procurement and Property Management, Office of</td>
<td>7, XXXII</td>
</tr>
<tr>
<td>Rural Business-Cooperative Service</td>
<td>7, XVIII, XLII</td>
</tr>
<tr>
<td>Rural Development Administration</td>
<td>7, XLII</td>
</tr>
<tr>
<td>Rural Housing Service</td>
<td>7, XVIII, XXXV</td>
</tr>
<tr>
<td>Rural Telephone Bank</td>
<td>7, XV</td>
</tr>
<tr>
<td>Rural Utilities Service</td>
<td>7, XVII, XVIII, XLII</td>
</tr>
<tr>
<td>Secretary of Agriculture, Office of</td>
<td>7, Subtitle A</td>
</tr>
<tr>
<td>Transportation, Office of</td>
<td>7, XXXIII</td>
</tr>
<tr>
<td>World Agricultural Outlook Board</td>
<td>7, XXXVIII</td>
</tr>
<tr>
<td>Air Force Department</td>
<td>32, VII</td>
</tr>
<tr>
<td>Federal Acquisition Regulation Supplement</td>
<td>48, 53</td>
</tr>
<tr>
<td>Alcohol, Tobacco and Firearms, Bureau of</td>
<td>27, I</td>
</tr>
<tr>
<td>AMTRAK</td>
<td>49, VII</td>
</tr>
<tr>
<td>American Battle Monuments Commission</td>
<td>36, IV</td>
</tr>
<tr>
<td>American Indians, Office of the Special Trustee</td>
<td>25, VII</td>
</tr>
<tr>
<td>Animal and Plant Health Inspection Service</td>
<td>7, III: 9, I</td>
</tr>
<tr>
<td>Appalachian Regional Commission</td>
<td>5, IX</td>
</tr>
<tr>
<td>Architectural and Transportation Barriers Compliance Board</td>
<td>36, XI</td>
</tr>
</tbody>
</table>

559
<table>
<thead>
<tr>
<th>Agency</th>
<th>CFR Title, Subtitle or Chapter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arctic Research Commission</td>
<td>45, XXIII</td>
</tr>
<tr>
<td>Armed Forces Retirement Home</td>
<td>5, XI</td>
</tr>
<tr>
<td>Army Department</td>
<td>32, V</td>
</tr>
<tr>
<td>Engineers, Corps of</td>
<td>33, II; 36, III</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 51</td>
</tr>
<tr>
<td>Benefits Review Board</td>
<td>20, VII</td>
</tr>
<tr>
<td>Bilingual Education and Minority Languages Affairs, Office of</td>
<td>34, V</td>
</tr>
<tr>
<td>Blind or Severely Disabled, Committee for Purchase From</td>
<td>41, 51</td>
</tr>
<tr>
<td>People Who Are</td>
<td></td>
</tr>
<tr>
<td>Broadcasting Board of Governors</td>
<td>22, V</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 19</td>
</tr>
<tr>
<td>Census Bureau</td>
<td>15, I</td>
</tr>
<tr>
<td>Centers for Medicare &amp; Medicaid Services</td>
<td>42, IV</td>
</tr>
<tr>
<td>Central Intelligence Agency</td>
<td>32, XIX</td>
</tr>
<tr>
<td>Chief Financial Officer, Office of</td>
<td>7, XXX</td>
</tr>
<tr>
<td>Child Support Enforcement, Office of</td>
<td>45, III</td>
</tr>
<tr>
<td>Children and Families, Administration for</td>
<td>45, II, III, IV, X</td>
</tr>
<tr>
<td>Civil Rights, Commission on</td>
<td>45, VII</td>
</tr>
<tr>
<td>Civil Rights, Office for</td>
<td>34, I</td>
</tr>
<tr>
<td>Coast Guard</td>
<td>33, I; 46, I; 49, IV</td>
</tr>
<tr>
<td>Coast Guard (Great Lakes Pilotage)</td>
<td>46, III</td>
</tr>
<tr>
<td>Commerce Department</td>
<td>44, IV</td>
</tr>
<tr>
<td>Census Bureau</td>
<td>15, I</td>
</tr>
<tr>
<td>Economic Affairs, Under Secretary</td>
<td>37, V</td>
</tr>
<tr>
<td>Economic Analysis, Bureau of</td>
<td>15, VIII</td>
</tr>
<tr>
<td>Economic Development Administration</td>
<td>13, III</td>
</tr>
<tr>
<td>Emergency Management and Assistance</td>
<td>44, IV</td>
</tr>
<tr>
<td>Export Administration, Bureau of</td>
<td>15, VII</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 13</td>
</tr>
<tr>
<td>Fishery Conservation and Management</td>
<td>50, VI</td>
</tr>
<tr>
<td>Foreign-Trade Zones Board</td>
<td>15, IV</td>
</tr>
<tr>
<td>International Trade Administration</td>
<td>15, III; 19, III</td>
</tr>
<tr>
<td>National Institute of Standards and Technology</td>
<td>15, II</td>
</tr>
<tr>
<td>National Marine Fisheries Service</td>
<td>50, II, IV, VI</td>
</tr>
<tr>
<td>National Oceanic and Atmospheric Administration</td>
<td>15, IX; 50, II, III, IV, VI</td>
</tr>
<tr>
<td>National Telecommunications and Information</td>
<td>15, XXIII; 47, III</td>
</tr>
<tr>
<td>Administration</td>
<td></td>
</tr>
<tr>
<td>National Weather Service</td>
<td>15, IX</td>
</tr>
<tr>
<td>Patent and Trademark Office, United States</td>
<td>37, I</td>
</tr>
<tr>
<td>Productivity, Technology and Innovation, Assistant Secretory for</td>
<td>37, IV</td>
</tr>
<tr>
<td>Secretary for</td>
<td></td>
</tr>
<tr>
<td>Secretary of Commerce, Office of</td>
<td>15, Subtitle A</td>
</tr>
<tr>
<td>Technology, Under Secretary for</td>
<td>37, V</td>
</tr>
<tr>
<td>Technology Administration</td>
<td>15, XI</td>
</tr>
<tr>
<td>Technology Policy, Assistant Secretary for</td>
<td>37, IV</td>
</tr>
<tr>
<td>Commercial Space Transportation</td>
<td>14, III</td>
</tr>
<tr>
<td>Commodity Credit Corporation</td>
<td>5, XIV</td>
</tr>
<tr>
<td>Commodity Futures Trading Commission</td>
<td>5, XLI; 17, I</td>
</tr>
<tr>
<td>Community Planning and Development, Office of Assistant Secretary for</td>
<td>24, V, VI</td>
</tr>
<tr>
<td>Community Services, Office of</td>
<td>45, X</td>
</tr>
<tr>
<td>Comptroller of the Currency</td>
<td>12, I</td>
</tr>
<tr>
<td>Construction Industry Collective Bargaining Commission</td>
<td>29, IX</td>
</tr>
<tr>
<td>Consumer Product Safety Commission</td>
<td>5, LXI; 16, II</td>
</tr>
<tr>
<td>Cooperative State Research, Education, and Extension Service</td>
<td>7, XXXIV</td>
</tr>
<tr>
<td>Copyright Office</td>
<td>37, II</td>
</tr>
<tr>
<td>Corporation for National and Community Service</td>
<td>46, XII, XXV</td>
</tr>
<tr>
<td>Cost Accounting Standards Board</td>
<td>48, 99</td>
</tr>
<tr>
<td>Council on Environmental Quality</td>
<td>40, V</td>
</tr>
<tr>
<td>Court Services and Offender Supervision Agency for the District of Columbia</td>
<td>28, VIII</td>
</tr>
<tr>
<td>Customs Service, United States</td>
<td>19, I</td>
</tr>
<tr>
<td>Defense Contract Audit Agency</td>
<td>32, I</td>
</tr>
<tr>
<td>Defense Department</td>
<td>5, XXVI; 32, Subtitle A;</td>
</tr>
<tr>
<td></td>
<td>40, VII</td>
</tr>
<tr>
<td>Advanced Research Projects Agency</td>
<td>32, I</td>
</tr>
</tbody>
</table>
Air Force Department 32, VII
Army Department 32, V; 33, II; 36, III, 48, 51
Defense Intelligence Agency 32, I
Defense Logistics Agency 32, I, XII; 48, 54
Engineers, Corps of 33, II; 36, III
Federal Acquisition Regulation 48, 2
National Imagery and Mapping Agency 32, I, II
Navy Department 32, VI; 48, 52
Secretary of Defense, Office of 32, I
Defense Contract Audit Agency 32, I
Defense Intelligence Agency 32, I
Defense Logistics Agency 32, XII; 48, 54
Defense Nuclear Facilities Safety Board 10, XVII
Delaware River Basin Commission 16, III
District of Columbia, Court Services and Offender Supervision Agency for the Drug Enforcement Administration 21, II
East-West Foreign Trade Board 15, XIII
Economic Affairs, Under Secretary 37, V
Economic Analysis, Bureau of 15, VIII
Economic Development Administration 13, III
Economic Research Service 7, XXXVII
Education, Department of 5, LIII
Bilingual Education and Minority Languages Affairs, Office of 34, V
Civil Rights, Office for 34, I
Educational Research and Improvement, Office of 34, VII
Elementary and Secondary Education, Office of 34, II
Federal Acquisition Regulation 48, 34
Postsecondary Education, Office of 34, VI
Secretary of Education, Office of 34, Subtitle A
Special Education and Rehabilitative Services, Office of 34, III
Vocational and Adult Education, Office of 34, IV
Educational Research and Improvement, Office of 34, VII
Elementary and Secondary Education, Office of 34, II
Emergency Oil and Gas Guaranteed Loan Board 13, V
Emergency Steel Guarantee Loan Board 13, IV
Employees’ Compensation Appeals Board 20, IV
Employees Loyalty Board 5, V
Employment and Training Administration 20, V
Employment Standards Administration 20, VI
Endangered Species Committee 50, IV
Energy, Department of 5, XXIII; 10, II, III, X
Federal Acquisition Regulation 48, 9
Federal Energy Regulatory Commission 5, XXIV; 18, I
Property Management Regulations 41, 109
Energy, Office of 7, XXXIX
Engineers, Corps of 33, II; 36, III
Engraving and Printing, Bureau of 31, VI
Environmental Protection Agency 5, LIV; 40, I, IV, VII
Federal Acquisition Regulation 48, 15
Property Management Regulations 41, 115
Environmental Quality, Office of 7, XXXI
Equal Employment Opportunity Commission 5, LXII; 29, XIV
Executive Office of the President 3, I
Administration, Office of 5, XV
Management and Budget, Office of 40, V
National Drug Control Policy, Office of 5, III, LXXVII; 14, VI; 48, 99
National Security Council 32, XXI; 47, 2
Presidential Documents 3
Science and Technology Policy, Office of 32, XXIV; 47, II
Trade Representative, Office of the United States 15, XX
Export Administration, Bureau of 15, VII
<table>
<thead>
<tr>
<th>Agency</th>
<th>CFR Title, Subtitle or Chapter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Export-Import Bank of the United States</td>
<td>5, LI; 12, IV</td>
</tr>
<tr>
<td>Family Assistance, Office of</td>
<td>45, II</td>
</tr>
<tr>
<td>Farm Credit Administration</td>
<td>5, XXXI; 12, VI</td>
</tr>
<tr>
<td>Farm Credit System Insurance Corporation</td>
<td>5, XXX; 12, XIV</td>
</tr>
<tr>
<td>Farm Service Agency</td>
<td>7, VII, XVIII</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 1</td>
</tr>
<tr>
<td>Federal Aviation Administration</td>
<td>14, I</td>
</tr>
<tr>
<td>Commercial Space Transportation</td>
<td>14, III</td>
</tr>
<tr>
<td>Federal Claims Collection Standards</td>
<td>31, IX</td>
</tr>
<tr>
<td>Federal Communications Commission</td>
<td>5, XXIX; 47, I</td>
</tr>
<tr>
<td>Federal Contract Compliance Programs, Office of</td>
<td>41, 60</td>
</tr>
<tr>
<td>Federal Crop Insurance Corporation</td>
<td>7, IV</td>
</tr>
<tr>
<td>Federal Deposit Insurance Corporation</td>
<td>5, XXII; 12, III</td>
</tr>
<tr>
<td>Federal Election Commission</td>
<td>11, I</td>
</tr>
<tr>
<td>Federal Emergency Management Agency</td>
<td>44, I</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 44</td>
</tr>
<tr>
<td>Federal Employees Group Life Insurance Federal Acquisition Regulation</td>
<td>48, 21</td>
</tr>
<tr>
<td>Federal Employees Health Benefits Acquisition Regulation</td>
<td>48, 16</td>
</tr>
<tr>
<td>Federal Energy Regulatory Commission</td>
<td>5, XXIV; 18, I</td>
</tr>
<tr>
<td>Federal Financial Institutions Examination Council</td>
<td>12, XI</td>
</tr>
<tr>
<td>Federal Financing Bank</td>
<td>12, VIII</td>
</tr>
<tr>
<td>Federal Highway Administration</td>
<td>23, I, II</td>
</tr>
<tr>
<td>Federal Home Loan Mortgage Corporation</td>
<td>1, IV</td>
</tr>
<tr>
<td>Federal Housing Enterprise Oversight Office</td>
<td>12, XVII</td>
</tr>
<tr>
<td>Federal Housing Finance Board</td>
<td>12, IX</td>
</tr>
<tr>
<td>Federal Labor Relations Authority and General Counsel of the Federal Labor Relations Authority</td>
<td>5, XIV; 22, XIV</td>
</tr>
<tr>
<td>Federal Law Enforcement Training Center</td>
<td>31, VII</td>
</tr>
<tr>
<td>Federal Management Regulation</td>
<td>41, 102</td>
</tr>
<tr>
<td>Federal Maritime Commission</td>
<td>46, IV</td>
</tr>
<tr>
<td>Federal Mediation and Conciliation Service</td>
<td>29, XII</td>
</tr>
<tr>
<td>Federal Mine Safety and Health Review Commission</td>
<td>5, LXXIV; 29, XXVII</td>
</tr>
<tr>
<td>Federal Motor Carrier Safety Administration</td>
<td>49, III</td>
</tr>
<tr>
<td>Federal Prison Industries, Inc.</td>
<td>29, III</td>
</tr>
<tr>
<td>Federal Procurement Policy Office</td>
<td>48, 99</td>
</tr>
<tr>
<td>Federal Property Management Regulations</td>
<td>41, 101</td>
</tr>
<tr>
<td>Federal Railroad Administration</td>
<td>49, II</td>
</tr>
<tr>
<td>Federal Register, Administrative Committee of</td>
<td>1, I</td>
</tr>
<tr>
<td>Federal Register, Office of</td>
<td>1, II</td>
</tr>
<tr>
<td>Federal Reserve System</td>
<td>12, II</td>
</tr>
<tr>
<td>Board of Governors</td>
<td>5, LVII</td>
</tr>
<tr>
<td>Federal Retirement Thrift Investment Board</td>
<td>5, VI, LXXXVI</td>
</tr>
<tr>
<td>Federal Service Impasses Panel</td>
<td>5, XIV</td>
</tr>
<tr>
<td>Federal Trade Commission</td>
<td>5, XLVII; 16, I</td>
</tr>
<tr>
<td>Federal Transit Administration</td>
<td>49, VI</td>
</tr>
<tr>
<td>Federal Travel Regulation System</td>
<td>41, Subtitle F</td>
</tr>
<tr>
<td>Fine Arts, Commission on</td>
<td>45, XXI</td>
</tr>
<tr>
<td>Fiscal Service</td>
<td>31, II</td>
</tr>
<tr>
<td>Fish and Wildlife Service, United States</td>
<td>50, I, IV</td>
</tr>
<tr>
<td>Fishery Conservation and Management</td>
<td>50, VI</td>
</tr>
<tr>
<td>Food and Drug Administration</td>
<td>21, I</td>
</tr>
<tr>
<td>Food and Nutrition Service</td>
<td>7, II</td>
</tr>
<tr>
<td>Food Safety and Inspection Service</td>
<td>9, III</td>
</tr>
<tr>
<td>Foreign Agricultural Service</td>
<td>7, XV</td>
</tr>
<tr>
<td>Foreign Assets Control, Office of</td>
<td>31, V</td>
</tr>
<tr>
<td>Foreign Claims Settlement Commission of the United States</td>
<td>45, V</td>
</tr>
<tr>
<td>Foreign Service Grievance Board</td>
<td>22, IX</td>
</tr>
<tr>
<td>Foreign Service Impasses Disputes Panel</td>
<td>22, XIV</td>
</tr>
<tr>
<td>Foreign Service Labor Relations Board</td>
<td>22, XIV</td>
</tr>
<tr>
<td>Foreign-Trade Zones Board</td>
<td>15, IV</td>
</tr>
<tr>
<td>Forest Service</td>
<td>36, II</td>
</tr>
<tr>
<td>General Accounting Office</td>
<td>4, I</td>
</tr>
<tr>
<td>General Services Administration</td>
<td>5, LVII; 41, 105</td>
</tr>
<tr>
<td>Contract Appeals, Board of</td>
<td>48, 61</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 5</td>
</tr>
<tr>
<td>Federal Management Regulation</td>
<td>41, 102</td>
</tr>
<tr>
<td>Agency</td>
<td>CFR Title, Subtitle or Chapter</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Federal Property Management Regulation</td>
<td>41, 101</td>
</tr>
<tr>
<td>Federal Travel Regulation System</td>
<td>41, Subtitle F</td>
</tr>
<tr>
<td>General</td>
<td>41, 300</td>
</tr>
<tr>
<td>Payment From a Non-Federal Source for Travel Expenses</td>
<td>41, 304</td>
</tr>
<tr>
<td>Payment of Expenses Connected With the Death of Certain Employees</td>
<td>41, 303</td>
</tr>
<tr>
<td>Geological Survey</td>
<td>30, IV</td>
</tr>
<tr>
<td>Government Ethics, Office of</td>
<td>5, XVI</td>
</tr>
<tr>
<td>Government National Mortgage Association</td>
<td>24, III</td>
</tr>
<tr>
<td>Grain Inspection, Packers and Stockyards Administration</td>
<td>7, VIII: 9, II</td>
</tr>
<tr>
<td>Harry S. Truman Scholarship Foundation</td>
<td>45, XVIII</td>
</tr>
<tr>
<td>Health and Human Services, Department of</td>
<td>5, XLV; 45, Subtitle A</td>
</tr>
<tr>
<td>Centers for Medicare &amp; Medicaid Services</td>
<td>42, IV</td>
</tr>
<tr>
<td>Child Support Enforcement, Office of</td>
<td>45, III</td>
</tr>
<tr>
<td>Children and Families, Administration for</td>
<td>45, II, III, IV, X</td>
</tr>
<tr>
<td>Community Services, Office of</td>
<td>45, X</td>
</tr>
<tr>
<td>Family Assistance, Office of</td>
<td>45, II</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 3</td>
</tr>
<tr>
<td>Food and Drug Administration</td>
<td>21, I</td>
</tr>
<tr>
<td>Human Development Services, Office of</td>
<td>45, XIII</td>
</tr>
<tr>
<td>Indian Health Service</td>
<td>25, V</td>
</tr>
<tr>
<td>Inspector General (Health Care), Office of</td>
<td>42, V</td>
</tr>
<tr>
<td>Public Health Service</td>
<td>42, I</td>
</tr>
<tr>
<td>Refugee Resettlement, Office of</td>
<td>45, IV</td>
</tr>
<tr>
<td>Housing and Urban Development, Department of</td>
<td>5, LXV; 24, Subtitle B</td>
</tr>
<tr>
<td>Community Planning and Development, Office of Assistant Secretary for Human Services, Office of, and Multifamily Housing Assistance</td>
<td>24, V, VI</td>
</tr>
<tr>
<td>Restructuring, Office of</td>
<td>24, XII</td>
</tr>
<tr>
<td>Inspector General, Office of</td>
<td>24, XII</td>
</tr>
<tr>
<td>Public and Indian Housing, Office of Assistant Secretary for Housing, Office of, and Multifamily Housing Assistance</td>
<td>24, IX</td>
</tr>
<tr>
<td>Secretary, Office of</td>
<td>24, Subtitle A, VII</td>
</tr>
<tr>
<td>Housing—Federal Housing Commissioner, Office of Assistant Secretary for Housing, Office of, and Multifamily Housing Assistance</td>
<td>24, II, VIII, X, XX</td>
</tr>
<tr>
<td>Secretary for</td>
<td>24</td>
</tr>
<tr>
<td>Human Development Services, Office of</td>
<td>45, XIII</td>
</tr>
<tr>
<td>Immigration and Naturalization Service</td>
<td>8, I</td>
</tr>
<tr>
<td>Independent Counsel, Office of</td>
<td>28, VII</td>
</tr>
<tr>
<td>Indian Affairs, Bureau of</td>
<td>25, I, V</td>
</tr>
<tr>
<td>Indian Affairs, Office of the Assistant Secretary</td>
<td>25, VI</td>
</tr>
<tr>
<td>Indian Arts and Crafts Board</td>
<td>25, II</td>
</tr>
<tr>
<td>Indian Health Service</td>
<td>25, V</td>
</tr>
<tr>
<td>Information Resources Management, Office of</td>
<td>7, XXVII</td>
</tr>
<tr>
<td>Information Security Oversight Office, National Archives and Records Administration</td>
<td>32, XX</td>
</tr>
<tr>
<td>Inspector General</td>
<td></td>
</tr>
<tr>
<td>Agriculture Department</td>
<td>7, XXVI</td>
</tr>
<tr>
<td>Health and Human Services Department</td>
<td>42, V</td>
</tr>
<tr>
<td>Housing and Urban Development Department</td>
<td>24, XII</td>
</tr>
<tr>
<td>Institute of Peace, United States</td>
<td>22, XVII</td>
</tr>
<tr>
<td>Inter-American Foundation</td>
<td>5, LXIII; 22, X</td>
</tr>
<tr>
<td>Intergovernmental Relations, Advisory Commission on</td>
<td>5, VII</td>
</tr>
<tr>
<td>Interior Department</td>
<td></td>
</tr>
<tr>
<td>American Indians, Office of the Special Trustee</td>
<td>25, VII</td>
</tr>
<tr>
<td>Endangered Species Committee</td>
<td>50, IV</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 14</td>
</tr>
<tr>
<td>Federal Property Management Regulations System</td>
<td>41, 114</td>
</tr>
<tr>
<td>Fish and Wildlife Service, United States</td>
<td>50, 1, IV</td>
</tr>
</tbody>
</table>
Geological Survey 30, IV
Indian Affairs, Bureau of 25, I, V
Indian Affairs, Office of the Assistant Secretary 25, VI
Indian Arts and Crafts Board 25, II
Land Management, Bureau of 43, II
Minerals Management Service 30, II
Mines, Bureau of 30, VI
National Indian Gaming Commission 25, III
National Park Service 36, I
Reclamation, Bureau of 43, I
Secretary of the Interior, Office of 43, Subtitle A
Surface Mining and Reclamation Appeals, Board of 30, III
Surface Mining Reclamation and Enforcement, Office of 30, VII
Internal Revenue Service 26, I
International Boundary and Water Commission, United States and Mexico, United States Section 22, XI
International Development, United States Agency for
Federal Acquisition Regulation 48, 7
International Development Cooperation Agency, United States 22, XII
International Fishing and Related Activities 50, III
International Investment, Office of 31, VIII
International Joint Commission, United States and Canada 22, IV
International Organizations Employees Loyalty Board 5, V
International Trade Administration 15, III; 19, III
International Trade Commission, United States 19, II
Interstate Commerce Commission 5, XL
James Madison Memorial Fellowship Foundation 45, XXIV
Japan–United States Friendship Commission 22, XVI
Joint Board for the Enrollment of Actuaries 20, VII
Justice Department
Drug Enforcement Administration 21, II
Federal Acquisition Regulation 48, 28
Federal Claims Collection Standards 31, IX
Federal Prison Industries, Inc. 28, III
Foreign Claims Settlement Commission of the United States 45, V
Immigration and Naturalization Service 8, I
Offices of Independent Counsel 28, VI
Prisons, Bureau of 28, V
Property Management Regulations 41, 128
Labor Department 5, XLII
Benefits Review Board 20, VII
Employees’ Compensation Appeals Board 20, IV
Employment and Training Administration 20, V
Employment Standards Administration 20, VI
Federal Acquisition Regulation 48, 29
Federal Contract Compliance Programs, Office of 41, 60
Federal Procurement Regulations System 41, 60
Labor-Management Standards, Office of 29, II, IV
Mine Safety and Health Administration 30, I
Occupational Safety and Health Administration 29, XVII
Pension and Welfare Benefits Administration 29, XXV
Public Contracts 41, 60
Secretary of Labor, Office of 29, Subtitle A
Veterans’ Employment and Training Service, Office of the Assistant Secretary 41, 61; 20, IX
Wage and Hour Division 29, V
Workers’ Compensation Programs, Office of 20, I
Labor-Management Standards, Office of 29, II, IV
Land Management, Bureau of 43, II
Legal Services Corporation 45, XVI
Library of Congress 36, VII
Copyright Office 37, II
Management and Budget, Office of 5, III, LXXVII; 14, VI; 48, 99
<table>
<thead>
<tr>
<th>Agency</th>
<th>CFR Title, Subtitle or Chapter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marine Mammal Commission</td>
<td>50, V</td>
</tr>
<tr>
<td>Maritime Administration</td>
<td>46, II</td>
</tr>
<tr>
<td>Merit Systems Protection Board</td>
<td>5, II</td>
</tr>
<tr>
<td>Micronesian Status Negotiations, Office for</td>
<td>32, XXVII</td>
</tr>
<tr>
<td>Mine Safety and Health Administration</td>
<td>30, I</td>
</tr>
<tr>
<td>Minerals Management Service</td>
<td>30, II</td>
</tr>
<tr>
<td>Mines, Bureau of</td>
<td>30, VI</td>
</tr>
<tr>
<td>Minority Business Development Agency</td>
<td>15, XIV</td>
</tr>
<tr>
<td>Miscellaneous Agencies</td>
<td>1, IV</td>
</tr>
<tr>
<td>Monetary Offices</td>
<td>31, I</td>
</tr>
<tr>
<td>Morris K. Udall Scholarship and Excellence in National</td>
<td>36, XVI</td>
</tr>
<tr>
<td>Environmental Policy Foundation</td>
<td></td>
</tr>
<tr>
<td>National Aeronautics and Space Administration</td>
<td>5, LIX; 14, V</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 18</td>
</tr>
<tr>
<td>National Agricultural Library</td>
<td>7, XLI</td>
</tr>
<tr>
<td>National Agricultural Statistics Service</td>
<td>7, XXXVI</td>
</tr>
<tr>
<td>National and Community Service, Corporation for</td>
<td>45, XII, XXV</td>
</tr>
<tr>
<td>National Archives and Records Administration</td>
<td>45, LXVI; 36, XII</td>
</tr>
<tr>
<td>Information Security Oversight Office</td>
<td>32, XX</td>
</tr>
<tr>
<td>National Bureau of Standards</td>
<td>15, II</td>
</tr>
<tr>
<td>National Capital Planning Commission</td>
<td>1, IV</td>
</tr>
<tr>
<td>National Commission for Employment Policy</td>
<td>1, IV</td>
</tr>
<tr>
<td>National Commission on Libraries and Information Science</td>
<td>45, XVII</td>
</tr>
<tr>
<td>National Council on Disability</td>
<td>34, XII</td>
</tr>
<tr>
<td>National Counterintelligence Center</td>
<td>32, XVIII</td>
</tr>
<tr>
<td>National Credit Union Administration</td>
<td>12, VII</td>
</tr>
<tr>
<td>National Crime Prevention and Privacy Compact Council</td>
<td>29, IX</td>
</tr>
<tr>
<td>National Drug Control Policy, Office of</td>
<td>21, III</td>
</tr>
<tr>
<td>National Foundation on the Arts and the Humanities</td>
<td>45, XI</td>
</tr>
<tr>
<td>National Highway Traffic Safety Administration</td>
<td>23, II, III; 49, V</td>
</tr>
<tr>
<td>National Imagery and Mapping Agency</td>
<td>32, I</td>
</tr>
<tr>
<td>National Indian Gaming Commission</td>
<td>25, III</td>
</tr>
<tr>
<td>National Institute for Literacy</td>
<td>34, XI</td>
</tr>
<tr>
<td>National Institute of Standards and Technology</td>
<td>15, II</td>
</tr>
<tr>
<td>National Labor Relations Board</td>
<td>5, LIX; 29, I</td>
</tr>
<tr>
<td>National Marine Fisheries Service</td>
<td>50, II, IV, VI</td>
</tr>
<tr>
<td>National Mediation Board</td>
<td>29, X</td>
</tr>
<tr>
<td>National Oceanic and Atmospheric Administration</td>
<td>15, IX; 50, II, III, IV, VI</td>
</tr>
<tr>
<td>National Park Service</td>
<td>36, I</td>
</tr>
<tr>
<td>National Railroad Adjustment Board</td>
<td>29, III</td>
</tr>
<tr>
<td>National Railroad Passenger Corporation (AMTRAK)</td>
<td>49, VII</td>
</tr>
<tr>
<td>National Science Foundation</td>
<td>5, XLIII; 45, VI</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 25</td>
</tr>
<tr>
<td>National Security Council</td>
<td>32, XXI</td>
</tr>
<tr>
<td>National Security Council and Office of Science and Technology Policy</td>
<td>47, II</td>
</tr>
<tr>
<td>National Telecommunications and Information Administration</td>
<td>15, XXIII; 47, III</td>
</tr>
<tr>
<td>National Transportation Safety Board</td>
<td>49, VIII</td>
</tr>
<tr>
<td>National Weather Service</td>
<td>15, IX</td>
</tr>
<tr>
<td>Natural Resources Conservation Service</td>
<td>7, VI</td>
</tr>
<tr>
<td>Navajo and Hopi Indian Relocation, Office of</td>
<td>25, IV</td>
</tr>
<tr>
<td>Navy Department</td>
<td>32, VI</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 20</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 20</td>
</tr>
<tr>
<td>Occupational Safety and Health Administration</td>
<td>29, XVII</td>
</tr>
<tr>
<td>Occupational Safety and Health Review Commission</td>
<td>29, XX</td>
</tr>
<tr>
<td>Offices of Independent Counsel</td>
<td>29, VI</td>
</tr>
<tr>
<td>Oklahoma City National Memorial Trust</td>
<td>36, XV</td>
</tr>
<tr>
<td>Operations Office</td>
<td>7, XXVIII</td>
</tr>
<tr>
<td>Overseas Private Investment Corporation</td>
<td>5, XXXIII; 22, VII</td>
</tr>
<tr>
<td>Panama Canal Commission</td>
<td>48, 35</td>
</tr>
</tbody>
</table>

565
<table>
<thead>
<tr>
<th>Agency</th>
<th>CFR Title, Subtitle or Chapter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panama Canal Regulations</td>
<td>35, I</td>
</tr>
<tr>
<td>Patent and Trademark Office, United States</td>
<td>37, I</td>
</tr>
<tr>
<td>Payment From a Non-Federal Source for Travel Expenses</td>
<td>41, 304</td>
</tr>
<tr>
<td>Payment of Expenses Connected With the Death of Certain Employees</td>
<td>41, 303</td>
</tr>
<tr>
<td>Peace Corps</td>
<td>22, III</td>
</tr>
<tr>
<td>Pennsylvania Avenue Development Corporation</td>
<td>36, IX</td>
</tr>
<tr>
<td>Pension and Welfare Benefits Administration</td>
<td>29, XXV</td>
</tr>
<tr>
<td>Pension Benefit Guaranty Corporation</td>
<td>29, XL</td>
</tr>
<tr>
<td>Personnel Management, Office of</td>
<td>5, I, XXXV; 45, VIII</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 17</td>
</tr>
<tr>
<td>Federal Employees Group Life Insurance Federal Acquisition Regulation</td>
<td>48, 21</td>
</tr>
<tr>
<td>Federal Employees Health Benefits Acquisition Regulation</td>
<td>48, 16</td>
</tr>
<tr>
<td>Postal Rate Commission</td>
<td>5, XLVI; 39, III</td>
</tr>
<tr>
<td>Postal Service, United States</td>
<td>5, LX; 39, I</td>
</tr>
<tr>
<td>Postsecondary Education, Office of</td>
<td>34, VI</td>
</tr>
<tr>
<td>President’s Commission on White House Fellowships</td>
<td>1, IV</td>
</tr>
<tr>
<td>Presidential Documents</td>
<td>3</td>
</tr>
<tr>
<td>Presidio Trust</td>
<td>36, X</td>
</tr>
<tr>
<td>Prisons, Bureau of</td>
<td>28, V</td>
</tr>
<tr>
<td>Procurement and Property Management, Office of</td>
<td>7, XXXII</td>
</tr>
<tr>
<td>Productivity, Technology and Innovation, Assistant Secretary</td>
<td>37, IV</td>
</tr>
<tr>
<td>Secretary</td>
<td></td>
</tr>
<tr>
<td>Public Contracts, Department of Labor</td>
<td>41, 50</td>
</tr>
<tr>
<td>Public and Indian Housing, Office of Assistant Secretary for</td>
<td>24, IX</td>
</tr>
<tr>
<td>Public Health Service</td>
<td>42, I</td>
</tr>
<tr>
<td>Railroad Retirement Board</td>
<td>26, II</td>
</tr>
<tr>
<td>Reclamation, Bureau of</td>
<td>43, I</td>
</tr>
<tr>
<td>Refugee Resettlement, Office of</td>
<td>45, IV</td>
</tr>
<tr>
<td>Regional Action Planning Commissions</td>
<td>13, V</td>
</tr>
<tr>
<td>Relocation Allowances</td>
<td>41, 302</td>
</tr>
<tr>
<td>Research and Special Programs Administration</td>
<td>49, I</td>
</tr>
<tr>
<td>Rural Business-Cooperative Service</td>
<td>7, XVIII, XLII</td>
</tr>
<tr>
<td>Rural Development Administration</td>
<td>7, XLII</td>
</tr>
<tr>
<td>Rural Housing Service</td>
<td>7, XVIII, XXXV</td>
</tr>
<tr>
<td>Rural Telephone Bank</td>
<td>7, XVI</td>
</tr>
<tr>
<td>Rural Utilities Service</td>
<td>7, XVII, XVIII, XLII</td>
</tr>
<tr>
<td>Saint Lawrence Seaway Development Corporation</td>
<td>33, IV</td>
</tr>
<tr>
<td>Science and Technology Policy, Office of</td>
<td>32, XXIV</td>
</tr>
<tr>
<td>Science and Technology Policy, Office of, and National Security Council</td>
<td>47, II</td>
</tr>
<tr>
<td>Secret Service</td>
<td>31, IV</td>
</tr>
<tr>
<td>Securities and Exchange Commission</td>
<td>17, II</td>
</tr>
<tr>
<td>Selective Service System</td>
<td>32, XVI</td>
</tr>
<tr>
<td>Small Business Administration</td>
<td>13, I</td>
</tr>
<tr>
<td>Smithsonian Institution</td>
<td>36, V</td>
</tr>
<tr>
<td>Social Security Administration</td>
<td>20, III; 48, 23</td>
</tr>
<tr>
<td>Soldiers' and Airmen's Home, United States</td>
<td>5, XI</td>
</tr>
<tr>
<td>Special Counsel, Office of</td>
<td>5, VIII</td>
</tr>
<tr>
<td>Special Education and Rehabilitative Services, Office of</td>
<td>34, III</td>
</tr>
<tr>
<td>State Department</td>
<td>22, 1; 28, XI</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 6</td>
</tr>
<tr>
<td>Surface Mining and Reclamation Appeals, Board of</td>
<td>30, III</td>
</tr>
<tr>
<td>Surface Mining Reclamation and Enforcement, Office of</td>
<td>30, VII</td>
</tr>
<tr>
<td>Surface Transportation Board</td>
<td>49, X</td>
</tr>
<tr>
<td>Susquehanna River Basin Commission</td>
<td>18, VIII</td>
</tr>
<tr>
<td>Technology Administration</td>
<td>15, XI</td>
</tr>
<tr>
<td>Technology Policy, Assistant Secretary for</td>
<td>37, IV</td>
</tr>
<tr>
<td>Technology, Under Secretary for</td>
<td>37, V</td>
</tr>
<tr>
<td>Tennessee Valley Authority</td>
<td>5, L, LXIX; 18, XIII</td>
</tr>
<tr>
<td>Thrift Supervision Office, Department of the Treasury</td>
<td>12, V</td>
</tr>
<tr>
<td>Trade Representative, United States, Office of</td>
<td>15, XX</td>
</tr>
<tr>
<td>Transportation, Department of</td>
<td>5, L</td>
</tr>
<tr>
<td>Coast Guard</td>
<td>33, I; 46, I; 49, IV</td>
</tr>
<tr>
<td>Coast Guard (Great Lakes Pilotage)</td>
<td>46, III</td>
</tr>
<tr>
<td>Commercial Space Transportation</td>
<td>14, III</td>
</tr>
<tr>
<td>Agency</td>
<td>CFR Title, Subtitle or Chapter</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Contract Appeals, Board of</td>
<td>48, 63</td>
</tr>
<tr>
<td>Emergency Management and Assistance</td>
<td>44, IV</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 12</td>
</tr>
<tr>
<td>Federal Aviation Administration</td>
<td>14, I</td>
</tr>
<tr>
<td>Federal Highway Administration</td>
<td>23, I, II</td>
</tr>
<tr>
<td>Federal Motor Carrier Safety Administration</td>
<td>49, III</td>
</tr>
<tr>
<td>Federal Railroad Administration</td>
<td>49, II</td>
</tr>
<tr>
<td>Federal Transit Administration</td>
<td>49, VI</td>
</tr>
<tr>
<td>Maritime Administration</td>
<td>46, II</td>
</tr>
<tr>
<td>National Highway Traffic Safety Administration</td>
<td>23, II, III; 49, V</td>
</tr>
<tr>
<td>Research and Special Programs Administration</td>
<td>49, I</td>
</tr>
<tr>
<td>Saint Lawrence Seaway Development Corporation</td>
<td>33, IV</td>
</tr>
<tr>
<td>Secretary of Transportation, Office of</td>
<td>14, II; 49, Subtitle A</td>
</tr>
<tr>
<td>Surface Transportation Board</td>
<td>49, X</td>
</tr>
<tr>
<td>Transportation Security Administration</td>
<td>49, XII</td>
</tr>
<tr>
<td>Transportation Statistics Bureau</td>
<td>49, XI</td>
</tr>
<tr>
<td>Transportation, Office of</td>
<td>7, XXXIII</td>
</tr>
<tr>
<td>Transportation Security Administration</td>
<td>49, XII</td>
</tr>
<tr>
<td>Transportation Statistics Bureau</td>
<td>49, XI</td>
</tr>
<tr>
<td>Travel Allowances, Temporary Duty (TDY)</td>
<td>41, 301</td>
</tr>
<tr>
<td>Treasury Department</td>
<td>5, XXI; 12, XV; 17, IV; 31, IX</td>
</tr>
<tr>
<td>Alcohol, Tobacco and Firearms, Bureau of</td>
<td>27, I</td>
</tr>
<tr>
<td>Community Development Financial Institutions Fund</td>
<td>12, XVIII</td>
</tr>
<tr>
<td>Comptroller of the Currency</td>
<td>12, I</td>
</tr>
<tr>
<td>Customs Service, United States</td>
<td>19, I</td>
</tr>
<tr>
<td>Engraving and Printing, Bureau of</td>
<td>31, VI</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 10</td>
</tr>
<tr>
<td>Federal Law Enforcement Training Center</td>
<td>31, VII</td>
</tr>
<tr>
<td>Fiscal Service</td>
<td>31, II</td>
</tr>
<tr>
<td>Foreign Assets Control, Office of</td>
<td>31, V</td>
</tr>
<tr>
<td>Internal Revenue Service</td>
<td>26, I</td>
</tr>
<tr>
<td>International Investment, Office of</td>
<td>31, VIII</td>
</tr>
<tr>
<td>Monetary Offices</td>
<td>31, I</td>
</tr>
<tr>
<td>Secret Service</td>
<td>31, IV</td>
</tr>
<tr>
<td>Secretary of the Treasury, Office of</td>
<td>31, Subtitle A</td>
</tr>
<tr>
<td>Thrift Supervision, Office of</td>
<td>12, V</td>
</tr>
<tr>
<td>Truman, Harry S. Scholarship Foundation</td>
<td>45, XVIII</td>
</tr>
<tr>
<td>United States and Canada, International Joint Commission</td>
<td>22, IV</td>
</tr>
<tr>
<td>United States and Mexico, International Boundary and Water Commission, United States Section</td>
<td>22, XI</td>
</tr>
<tr>
<td>Utah Reclamation Mitigation and Conservation Commission</td>
<td>43, III</td>
</tr>
<tr>
<td>Veterans Affairs Department</td>
<td>38, I</td>
</tr>
<tr>
<td>Federal Acquisition Regulation</td>
<td>48, 8</td>
</tr>
<tr>
<td>Veterans’ Employment and Training Service, Office of the Assistant Secretary for Vice President of the United States, Office of</td>
<td>32, XXVIII</td>
</tr>
<tr>
<td>Vocational and Adult Education, Office of</td>
<td>34, IV</td>
</tr>
<tr>
<td>Wage and Hour Division</td>
<td>29, V</td>
</tr>
<tr>
<td>Water Resources Council</td>
<td>18, VI</td>
</tr>
<tr>
<td>Workers’ Compensation Programs, Office of</td>
<td>20, I</td>
</tr>
<tr>
<td>World Agricultural Outlook Board</td>
<td>7, XXXVIII</td>
</tr>
</tbody>
</table>

567
At 53 FR 24666, June 29, 1988, 21 CFR part 561 was redesignated as 40 CFR part 186. The following redesignation table shows the relationship of the CFR section numbers formerly in 21 CFR part 561 and those sections being redesignated as 40 CFR part 186.

<table>
<thead>
<tr>
<th>Old section</th>
<th>New section</th>
</tr>
</thead>
<tbody>
<tr>
<td>561.20</td>
<td>186.100</td>
</tr>
<tr>
<td>561.30</td>
<td>186.150</td>
</tr>
<tr>
<td>561.40</td>
<td>186.200</td>
</tr>
<tr>
<td>561.41</td>
<td>186.250</td>
</tr>
<tr>
<td>561.50</td>
<td>186.300</td>
</tr>
<tr>
<td>561.51</td>
<td>186.350</td>
</tr>
<tr>
<td>561.53</td>
<td>186.375</td>
</tr>
<tr>
<td>561.60</td>
<td>186.4975</td>
</tr>
<tr>
<td>561.65</td>
<td>186.500</td>
</tr>
<tr>
<td>561.66</td>
<td>186.500</td>
</tr>
<tr>
<td>561.67</td>
<td>186.600</td>
</tr>
<tr>
<td>561.70</td>
<td>186.700</td>
</tr>
<tr>
<td>561.80</td>
<td>186.750</td>
</tr>
<tr>
<td>561.91</td>
<td>186.800</td>
</tr>
<tr>
<td>561.92</td>
<td>186.850</td>
</tr>
<tr>
<td>561.93</td>
<td>186.850</td>
</tr>
<tr>
<td>561.95</td>
<td>186.900</td>
</tr>
<tr>
<td>561.96</td>
<td>186.950</td>
</tr>
<tr>
<td>561.97</td>
<td>186.950</td>
</tr>
<tr>
<td>561.98</td>
<td>186.1000</td>
</tr>
<tr>
<td>561.99</td>
<td>186.1000</td>
</tr>
<tr>
<td>561.100</td>
<td>186.1100</td>
</tr>
<tr>
<td>561.110</td>
<td>186.1200</td>
</tr>
<tr>
<td>561.120</td>
<td>186.1250</td>
</tr>
<tr>
<td>561.130</td>
<td>186.1300</td>
</tr>
<tr>
<td>561.140</td>
<td>186.1350</td>
</tr>
<tr>
<td>561.150</td>
<td>186.1400</td>
</tr>
<tr>
<td>561.160</td>
<td>186.1450</td>
</tr>
<tr>
<td>561.170</td>
<td>186.1500</td>
</tr>
<tr>
<td>561.180</td>
<td>186.1550</td>
</tr>
<tr>
<td>561.190</td>
<td>186.1600</td>
</tr>
<tr>
<td>561.191</td>
<td>186.1650</td>
</tr>
<tr>
<td>561.192</td>
<td>186.1700</td>
</tr>
<tr>
<td>561.197</td>
<td>186.1750</td>
</tr>
<tr>
<td>561.200</td>
<td>186.1800</td>
</tr>
<tr>
<td>561.210</td>
<td>186.1850</td>
</tr>
<tr>
<td>561.215</td>
<td>186.1875</td>
</tr>
<tr>
<td>561.220</td>
<td>186.1900</td>
</tr>
<tr>
<td>561.225</td>
<td>186.2000</td>
</tr>
<tr>
<td>561.230</td>
<td>186.2100</td>
</tr>
<tr>
<td>561.232</td>
<td>186.2200</td>
</tr>
<tr>
<td>561.233</td>
<td>186.2250</td>
</tr>
<tr>
<td>561.234</td>
<td>186.2300</td>
</tr>
<tr>
<td>561.235</td>
<td>186.2350</td>
</tr>
<tr>
<td>561.240</td>
<td>186.2400</td>
</tr>
<tr>
<td>561.250</td>
<td>186.2450</td>
</tr>
<tr>
<td>561.253</td>
<td>186.2500</td>
</tr>
<tr>
<td>561.255</td>
<td>186.2550</td>
</tr>
<tr>
<td>561.260</td>
<td>186.2600</td>
</tr>
<tr>
<td>561.263</td>
<td>186.2650</td>
</tr>
<tr>
<td>561.268</td>
<td>186.2700</td>
</tr>
<tr>
<td>561.270</td>
<td>186.2750</td>
</tr>
<tr>
<td>561.273</td>
<td>186.2800</td>
</tr>
<tr>
<td>561.280</td>
<td>186.2850</td>
</tr>
<tr>
<td>561.282</td>
<td>186.3000</td>
</tr>
<tr>
<td>561.283</td>
<td>186.3050</td>
</tr>
<tr>
<td>561.285</td>
<td>186.3100</td>
</tr>
<tr>
<td>561.287</td>
<td>186.3150</td>
</tr>
<tr>
<td>561.290</td>
<td>186.3200</td>
</tr>
<tr>
<td>561.300</td>
<td>186.3250</td>
</tr>
<tr>
<td>561.305</td>
<td>186.3300</td>
</tr>
<tr>
<td>561.310</td>
<td>186.3350</td>
</tr>
<tr>
<td>561.315</td>
<td>186.3400</td>
</tr>
<tr>
<td>561.320</td>
<td>186.3450</td>
</tr>
<tr>
<td>561.325</td>
<td>186.3500</td>
</tr>
<tr>
<td>561.330</td>
<td>186.3550</td>
</tr>
<tr>
<td>561.340</td>
<td>186.3600</td>
</tr>
<tr>
<td>561.350</td>
<td>186.3650</td>
</tr>
<tr>
<td>561.360</td>
<td>186.3700</td>
</tr>
<tr>
<td>561.365</td>
<td>186.3750</td>
</tr>
<tr>
<td>561.370</td>
<td>186.3800</td>
</tr>
<tr>
<td>561.380</td>
<td>186.3850</td>
</tr>
<tr>
<td>561.385</td>
<td>186.4000</td>
</tr>
<tr>
<td>561.390</td>
<td>186.4050</td>
</tr>
<tr>
<td>561.395</td>
<td>186.4100</td>
</tr>
<tr>
<td>561.400</td>
<td>186.4200</td>
</tr>
<tr>
<td>561.410</td>
<td>186.4300</td>
</tr>
<tr>
<td>561.415</td>
<td>186.4350</td>
</tr>
<tr>
<td>561.420</td>
<td>186.4400</td>
</tr>
<tr>
<td>561.425</td>
<td>186.4450</td>
</tr>
<tr>
<td>561.427</td>
<td>186.4500</td>
</tr>
<tr>
<td>561.428</td>
<td>186.4550</td>
</tr>
<tr>
<td>561.429</td>
<td>186.4600</td>
</tr>
<tr>
<td>561.430</td>
<td>186.4650</td>
</tr>
<tr>
<td>561.432</td>
<td>186.4700</td>
</tr>
<tr>
<td>561.434</td>
<td>186.4750</td>
</tr>
<tr>
<td>561.435</td>
<td>186.4800</td>
</tr>
<tr>
<td>561.436</td>
<td>186.4850</td>
</tr>
<tr>
<td>561.437</td>
<td>186.4900</td>
</tr>
<tr>
<td>561.438</td>
<td>186.4950</td>
</tr>
<tr>
<td>561.439</td>
<td>186.5000</td>
</tr>
<tr>
<td>561.440</td>
<td>186.5050</td>
</tr>
<tr>
<td>561.441</td>
<td>186.5100</td>
</tr>
<tr>
<td>561.442</td>
<td>186.5150</td>
</tr>
<tr>
<td>561.443</td>
<td>186.5200</td>
</tr>
<tr>
<td>561.444</td>
<td>186.5250</td>
</tr>
<tr>
<td>561.445</td>
<td>186.5300</td>
</tr>
</tbody>
</table>
List of CFR Sections Affected

All changes in this volume of the Code of Federal Regulations which were made by documents published in the Federal Register since January 1, 1986, are enumerated in the following list. Entries indicate the nature of the changes effected. Page numbers refer to Federal Register pages. The user should consult the entries for chapters and parts as well as sections for revisions.


<table>
<thead>
<tr>
<th>CFR Section</th>
<th>Nature of Change</th>
<th>Effective Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 CFR</td>
<td>Continued</td>
<td></td>
<td>51 FR</td>
</tr>
<tr>
<td>510.305</td>
<td>Introductory text and (a) amended</td>
<td>eff. 5–2–86</td>
<td>1986</td>
</tr>
<tr>
<td>510.505</td>
<td>Removed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>510.520</td>
<td>(a) introductory text amended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>510.600</td>
<td>(c)(1) and (2) tables amended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.580</td>
<td>Effective date corrected to 12–13–85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.600</td>
<td>(c) amended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.905</td>
<td>Added</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.1192</td>
<td>(a) revised; (c)(1) redesignated as (c)(1)(i) and revised; (c)(2) and (3) redesignated as (c)(1)(ii) and (iii); new (c)(2) added</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.1236</td>
<td>(a) revised</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.1242</td>
<td>(d)(1), (2), and (3) redesignated as (d)(1) (i), (ii), and (iii); new (d)(2) added; (d) introductory text redesignated as new (d)(1) heading and revised</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.1326</td>
<td>Redesignated as 520.1326a and heading revised; new 520.1326 added</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.1326a</td>
<td>Redesignated from 520.1326 and heading revised</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.1326b</td>
<td>Added</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.1450a</td>
<td>(d)(3) amended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.1450b</td>
<td>(d) revised</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.1468</td>
<td>(c)(1) revised</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.2043</td>
<td>(b)(4) added</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.2260b</td>
<td>(f) and (g) added</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.2455</td>
<td>(b) amended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.2473a</td>
<td>(c)(1)(ii) corrected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>520.2489</td>
<td>(a) and footnote 1 removed; (b) and (c) redesignated as (a) and (b); new (c) added; (d)(1) and (2) amended; (d)(3) and (4) revised</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
List of CFR Sections Affected

**21 CFR—Continued**

**Chapter I—Continued**

<table>
<thead>
<tr>
<th>Section</th>
<th>Action</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.205</td>
<td>(b) and (c) removed; (d), (e) and (f) redesignated as (b), (c), and (d); (a) added; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.206</td>
<td>(b) and (c) removed; (d), (e) and (f) redesignated as (b), (c), and (d); (a), new (b), and (d)(1) introductory text revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.207</td>
<td>(b) and (c) removed; (d), (e), and (f) redesignated as (b), (c) and (d); (a) and (b) introductory text revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.210</td>
<td>(b) and (c) removed; (d), (e), and (f) redesignated as (b), (c), and (d); (a), new (b), and (d) introductory text revised; eff. 5–2–86</td>
<td>7396</td>
</tr>
<tr>
<td>558.215</td>
<td>(b) and (c) removed; (d), (e) and (f) redesignated as (b), (c) and (d); (a), new (b), and (d)(1) introductory text revised; eff. 5–2–86</td>
<td>7396</td>
</tr>
<tr>
<td>558.219</td>
<td>(b), (c), and (d) removed; (e) redesignated as (b); (a) and new (b)(1) introductory text revised; eff. 5–2–86</td>
<td>7396</td>
</tr>
<tr>
<td>558.220</td>
<td>(b) and (c) removed; (d), (e) and (f) redesignated as (b), (c), and (d); (a) and new (b), and (d) introductory text revised; eff. 5–2–86</td>
<td>7396</td>
</tr>
<tr>
<td>558.221</td>
<td>(a) added; (b), and (c) removed; (d), (e), and (f) redesignated as (b), (c), and (d); (a), new (b), and (d)(1) introductory text revised; eff. 5–2–86</td>
<td>7396</td>
</tr>
<tr>
<td>558.224</td>
<td>(b) and (c) removed; (d), (e) and (f) redesignated as (b), (c), and (d); (a) and new (b), and (d) introductory text revised; eff. 5–2–86</td>
<td>7396</td>
</tr>
<tr>
<td>558.225</td>
<td>(b) and (c) removed; (d), (e) and (f) redesignated as (b), (c), and (d); (a) added; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.226</td>
<td>(b) and (c) removed; (e) and (f) redesignated as (b) and (c); (a) added; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.227</td>
<td>(b) and (c) removed; (d) and (e) redesignated as (b) and (c); (a) added; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.228</td>
<td>(b) and (c) removed; (d) and (e) redesignated as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7396</td>
</tr>
<tr>
<td>558.229</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.230</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.231</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.232</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.233</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.234</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.235</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.236</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.237</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.238</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.239</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7397</td>
</tr>
<tr>
<td>558.240</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) added</td>
<td>7397</td>
</tr>
<tr>
<td>558.241</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) added</td>
<td>7397</td>
</tr>
<tr>
<td>558.242</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) added</td>
<td>7397</td>
</tr>
<tr>
<td>558.243</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) added</td>
<td>7397</td>
</tr>
<tr>
<td>558.244</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) added</td>
<td>7397</td>
</tr>
<tr>
<td>558.245</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) added</td>
<td>7397</td>
</tr>
<tr>
<td>558.246</td>
<td>(b) and (c) removed; (d) and (e) redesigned as (b) and (c); (a) added</td>
<td>7397</td>
</tr>
</tbody>
</table>
### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Changes</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.15</td>
<td>(b), (c), (d), and (f) removed; (e) and (g) redesignated as (b) and (c); (a) and new (c) introductory text revised; eff. 5–2–86</td>
<td>7398</td>
</tr>
<tr>
<td>558.325</td>
<td>(b) and (e) removed; (d) and (f) redesignated as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7398</td>
</tr>
<tr>
<td>558.355</td>
<td>(a), (d) (3) and (4) removed; (a) and new (c)(1) revised; eff. 5–2–86</td>
<td>7398</td>
</tr>
<tr>
<td>558.360</td>
<td>(b)(11) revised; (f)(1)(xxii) added</td>
<td>32631</td>
</tr>
<tr>
<td>558.365</td>
<td>(a), (d) (3) and (4) removed; (b) introductory text and (c) revised; eff. 5–2–86</td>
<td>7398</td>
</tr>
<tr>
<td>558.369</td>
<td>(b)(12) and (f)(1)(xxii) added</td>
<td>10976</td>
</tr>
<tr>
<td>558.370</td>
<td>(b) and (c) removed; (c)(1)(vi) added</td>
<td>6911</td>
</tr>
<tr>
<td>558.375</td>
<td>(b) and (c) removed; (d) and (e) redesignated as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7399</td>
</tr>
</tbody>
</table>

### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Changes</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.380</td>
<td>(b) removed; (c), (d), and (e) redesignated as (b), (c), and (d); (a) and new (c)(1) revised; eff. 5–2–86</td>
<td>7399</td>
</tr>
<tr>
<td>558.383</td>
<td>Added</td>
<td>9005</td>
</tr>
<tr>
<td>558.385</td>
<td>(b) and (c) removed; (d), (e), and (f) redesignated as (b), (c), and (d); (a) and new (c)(1) revised; eff. 5–2–86</td>
<td>7399</td>
</tr>
<tr>
<td>558.386</td>
<td>(b) and (d) removed; (c) and (e) redesignated as (b) and (c); (a) revised; eff. 5–2–86</td>
<td>7399</td>
</tr>
<tr>
<td>558.387</td>
<td>(b) removed; (c) redesignated as (b); (a) revised; eff. 5–2–86</td>
<td>7399</td>
</tr>
<tr>
<td>558.389</td>
<td>(b) and (c) removed; (d), (e), and (f) redesignated as (b), (c), and (d); (a) revised; eff. 5–2–86</td>
<td>7399</td>
</tr>
<tr>
<td>558.390</td>
<td>(a) added; (b) and (c) removed; (d) redesignated as (b); eff. 5–2–86</td>
<td>7399</td>
</tr>
<tr>
<td>558.376</td>
<td>(b) and (c) removed; (d) and (e) redesignated as (b) and (c); (a) added; eff. 5–2–86</td>
<td>7399</td>
</tr>
</tbody>
</table>

### Technical correction

- 21 CFR (4–01 Edition)

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>574</td>
</tr>
</tbody>
</table>
### List of CFR Sections Affected

#### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Chapter I—Continued</th>
<th>51 FR Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.579 (a) added; (b) and (c) removed; (d) and (e) redesignated as (b) and (c); eff. 5–2–86</td>
<td>7400</td>
</tr>
<tr>
<td>558.582 (a) added; (b) and (c) removed; (d) and (e) redesignated as (b) and (c); eff. 5–2–86</td>
<td>7400</td>
</tr>
<tr>
<td>558.586 (b) and (c) removed; heading revised; (a) added; eff. 5–2–86</td>
<td>7400</td>
</tr>
<tr>
<td>558.615 (b) removed; (c), (d), and (e) redesignated as (b), (c), and (d); (a) and new (b) revised; eff. 5–2–86</td>
<td>7400</td>
</tr>
<tr>
<td>558.625 (b)(6) added</td>
<td>5991</td>
</tr>
<tr>
<td>(c) and (d) removed and reserved; (b) introductory text revised; eff. 5–2–86</td>
<td>7400</td>
</tr>
<tr>
<td>(b)(25) amended</td>
<td>7785</td>
</tr>
<tr>
<td>(b)(6) removed</td>
<td>11439</td>
</tr>
<tr>
<td>(b)(87) added</td>
<td>22799</td>
</tr>
<tr>
<td>(b)(88) added</td>
<td>26378</td>
</tr>
<tr>
<td>558.630 (b)(3) and (10) amended</td>
<td>3333</td>
</tr>
<tr>
<td>(b)(10) amended</td>
<td>5992</td>
</tr>
<tr>
<td>(a), (c), and (d) removed; (b) introductory text revised; eff. 5–2–86</td>
<td>7400</td>
</tr>
<tr>
<td>(b)(3) amended</td>
<td>7785</td>
</tr>
<tr>
<td>(b)(10) amended</td>
<td>19829</td>
</tr>
<tr>
<td>(b)(8) and (10) amended</td>
<td>34961</td>
</tr>
<tr>
<td>558.635 (f)(2)(ii) revised</td>
<td>7262</td>
</tr>
<tr>
<td>(a), (c), and (e) (3) and (4) removed; (b) revised; eff. 5–2–86</td>
<td>7400</td>
</tr>
<tr>
<td>(f)(3)(v) added</td>
<td>14990</td>
</tr>
<tr>
<td>558.680 (a) revised; (b) and (c) removed; (d) and (e) redesignated as (b) and (c); eff. 5–2–86</td>
<td>7401</td>
</tr>
<tr>
<td>Corrected</td>
<td>9439</td>
</tr>
<tr>
<td>561.120 Removed</td>
<td>46617</td>
</tr>
<tr>
<td>561.260 (c) removed</td>
<td>1785</td>
</tr>
<tr>
<td>561.370 Removed</td>
<td>46618</td>
</tr>
<tr>
<td>561.432 (c) added</td>
<td>28224</td>
</tr>
<tr>
<td>561.436 Added</td>
<td>13517</td>
</tr>
<tr>
<td>Correctly designated</td>
<td>19169</td>
</tr>
<tr>
<td>561.438 Added</td>
<td>39655</td>
</tr>
<tr>
<td>570 Authority citation revised</td>
<td>5992</td>
</tr>
<tr>
<td>570.12 Removed</td>
<td>5993</td>
</tr>
<tr>
<td>579 Added</td>
<td>5993</td>
</tr>
<tr>
<td>579.22 Correctly designated</td>
<td>8315</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>21 CFR</th>
<th>1987</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter I</td>
<td></td>
</tr>
<tr>
<td>Uniform compliance date 1–1–91</td>
<td>44861</td>
</tr>
<tr>
<td>500.80—500.92 (Subpart E)</td>
<td></td>
</tr>
<tr>
<td>Added</td>
<td>49586</td>
</tr>
<tr>
<td>510 Authority citation revised</td>
<td>20976</td>
</tr>
<tr>
<td>510.600 (c)(1) and (2) tables amended</td>
<td>5455, 7831, 7833, 11041, 11988, 12153, 18691, 18501, 20385, 20597, 25212, 25976, 27801, 32540, 32917, 36022, 36023, 39912, 41295, 41988</td>
</tr>
<tr>
<td>(c)(1) and (2) tables amended; eff. 4–3–87</td>
<td>9295</td>
</tr>
<tr>
<td>Technical correction</td>
<td>10668, 18495, 23397</td>
</tr>
<tr>
<td>511.1 (c)(2) revised; (b)(4)(vi) and (f) added; eff. 6–17–87</td>
<td>8847</td>
</tr>
<tr>
<td>514.1 (b)(8)(vii) and (ix) added; eff. 6–17–87</td>
<td>8847</td>
</tr>
<tr>
<td>(b)(7) introductory text and (ii) revised; OMB number</td>
<td>49588</td>
</tr>
<tr>
<td>514.111 (a)(10) added</td>
<td>49589</td>
</tr>
<tr>
<td>520 Technical correction</td>
<td>10668, 18495</td>
</tr>
<tr>
<td>Heading corrected</td>
<td>28067</td>
</tr>
<tr>
<td>520.23 (a)(2) revised</td>
<td>666</td>
</tr>
<tr>
<td>520.314 (a) revised</td>
<td>11989</td>
</tr>
<tr>
<td>520.540a (b) amended</td>
<td>7832</td>
</tr>
<tr>
<td>520.540b (a)(2) and (b)(2) amended</td>
<td>7832</td>
</tr>
<tr>
<td>520.580 (b)(1) revised</td>
<td>39512</td>
</tr>
<tr>
<td>520.680 Removed</td>
<td>25213</td>
</tr>
<tr>
<td>520.680a Removed</td>
<td>25213</td>
</tr>
<tr>
<td>520.680b Removed</td>
<td>25213</td>
</tr>
<tr>
<td>Correctly designated</td>
<td>27108</td>
</tr>
<tr>
<td>520.970a (b) amended</td>
<td>7832</td>
</tr>
<tr>
<td>520.970b (b) amended</td>
<td>7832</td>
</tr>
<tr>
<td>520.1044a (b) amended</td>
<td>7832</td>
</tr>
<tr>
<td>520.1044b (b) amended</td>
<td>7832</td>
</tr>
<tr>
<td>520.1044c (b) amended</td>
<td>7832</td>
</tr>
<tr>
<td>(a) revised</td>
<td>48675</td>
</tr>
<tr>
<td>520.1100 (c)(1) amended</td>
<td>7832</td>
</tr>
<tr>
<td>520.1193 Added</td>
<td>11942</td>
</tr>
<tr>
<td>520.1195 Added</td>
<td>34637</td>
</tr>
<tr>
<td>520.1242a (f)(2)(i) amended</td>
<td>20598</td>
</tr>
<tr>
<td>520.1341 (b) amended</td>
<td>7832</td>
</tr>
<tr>
<td>520.1448a (b) removed</td>
<td>27197</td>
</tr>
<tr>
<td>(d)(4)(ii) amended</td>
<td>30151</td>
</tr>
<tr>
<td>520.1540 Removed</td>
<td>20597</td>
</tr>
<tr>
<td>520.1600d (e) revised</td>
<td>48094</td>
</tr>
<tr>
<td>520.1720a (b)(5) removed</td>
<td>36023</td>
</tr>
<tr>
<td>520.2041 Added</td>
<td>37937</td>
</tr>
<tr>
<td>520.2100 (b) amended</td>
<td>7832</td>
</tr>
<tr>
<td>(b) corrected</td>
<td>9756</td>
</tr>
<tr>
<td>520.2455 Revised</td>
<td>15718</td>
</tr>
<tr>
<td>520.2473a (b) amended</td>
<td>7832</td>
</tr>
<tr>
<td>Section</td>
<td>Action</td>
</tr>
<tr>
<td>----------</td>
<td>--------</td>
</tr>
<tr>
<td>520.2473b</td>
<td>Added</td>
</tr>
<tr>
<td>522 Technical correction</td>
<td>10668, 18495</td>
</tr>
<tr>
<td>522.56</td>
<td>Added</td>
</tr>
<tr>
<td>(a) corrected</td>
<td>15412</td>
</tr>
<tr>
<td>522.161</td>
<td>(c) amended</td>
</tr>
<tr>
<td>522.163</td>
<td>(b) amended</td>
</tr>
<tr>
<td>522.518</td>
<td>(b) amended</td>
</tr>
<tr>
<td>522.540</td>
<td>(a)(2) amended</td>
</tr>
<tr>
<td>(b)(2) amended</td>
<td>25212</td>
</tr>
<tr>
<td>(e)(2) amended</td>
<td>36023</td>
</tr>
<tr>
<td>522.900</td>
<td>(b) amended</td>
</tr>
<tr>
<td>522.970</td>
<td>(b) amended</td>
</tr>
<tr>
<td>522.1044</td>
<td>(b)(1) amended</td>
</tr>
<tr>
<td>522.1060b</td>
<td>(b) amended</td>
</tr>
<tr>
<td>522.1081</td>
<td>(a)(2)(i) amended</td>
</tr>
<tr>
<td>522.1182</td>
<td>(a)(4)(i) amended</td>
</tr>
<tr>
<td>522.1183</td>
<td>(e)(1) revised</td>
</tr>
<tr>
<td>(e)(1) amended</td>
<td>36023</td>
</tr>
<tr>
<td>522.1258</td>
<td>(b) amended</td>
</tr>
<tr>
<td>522.1660</td>
<td>(c)(1)(i) and (ii) amended</td>
</tr>
<tr>
<td>522.1660a</td>
<td>(e)(1) amended</td>
</tr>
<tr>
<td>(1)(i) amended</td>
<td>36023</td>
</tr>
<tr>
<td>522.1680</td>
<td>(b) revised</td>
</tr>
<tr>
<td>(b) amended</td>
<td>25212, 36023</td>
</tr>
<tr>
<td>522.1704</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>522.1720</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>522.1820</td>
<td>(b) amended</td>
</tr>
<tr>
<td>522.1822</td>
<td>(b) amended</td>
</tr>
<tr>
<td>522.1881</td>
<td>Added</td>
</tr>
<tr>
<td>522.1884</td>
<td>(c) amended</td>
</tr>
<tr>
<td>522.1890</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>522.1940</td>
<td>(d)(2)(iii) amended; (e) added</td>
</tr>
<tr>
<td>522.2065</td>
<td>(b) amended</td>
</tr>
<tr>
<td>522.2100</td>
<td>(a)(2) and (b)(2) amended</td>
</tr>
<tr>
<td>522.2476</td>
<td>Added</td>
</tr>
<tr>
<td>522.2483</td>
<td>(b) amended</td>
</tr>
<tr>
<td>524 Technical correction</td>
<td>10668, 18495</td>
</tr>
<tr>
<td>524.1044a</td>
<td>(b) amended</td>
</tr>
<tr>
<td>524.1044b</td>
<td>(b) amended</td>
</tr>
<tr>
<td>524.1044c</td>
<td>(b) amended</td>
</tr>
<tr>
<td>524.1044d</td>
<td>(b) amended</td>
</tr>
<tr>
<td>524.1044e</td>
<td>(b) amended</td>
</tr>
<tr>
<td>524.1044f</td>
<td>(b) amended</td>
</tr>
<tr>
<td>524.1240</td>
<td>Added</td>
</tr>
<tr>
<td>524.1580b</td>
<td>(b) amended</td>
</tr>
<tr>
<td>524.1580d</td>
<td>(b) and (d)(1) revised</td>
</tr>
<tr>
<td>(b) revised</td>
<td>18691</td>
</tr>
<tr>
<td>(b) amended</td>
<td>36023</td>
</tr>
<tr>
<td>524.2350</td>
<td>(b) amended</td>
</tr>
<tr>
<td>529.1044a</td>
<td>(b) amended</td>
</tr>
<tr>
<td>&quot;Technical correction&quot;</td>
<td>10668, 18495</td>
</tr>
<tr>
<td>529.1044b</td>
<td>(b) amended</td>
</tr>
</tbody>
</table>
**List of CFR SectionsAffected**

### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Initial Text</th>
<th>Amended Text</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.240</td>
<td>(c)(1) introductory text</td>
<td>removed</td>
</tr>
<tr>
<td>558.248</td>
<td>(a)(2) revised; (a)(3), (4), and (5) added; (b) amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.274</td>
<td>(c)(1) introductory text amended</td>
<td>2684</td>
</tr>
<tr>
<td>558.311</td>
<td>(a) through (d) redesignated as (b) through (e); new (a) added; new (e) table amended; new (b), (d), and (e) introductory text revised</td>
<td>2685</td>
</tr>
<tr>
<td>558.325</td>
<td>(c)(1) introductory text and (2) introductory text revised; (c)(3) (i) and (ix) amended</td>
<td>2685</td>
</tr>
<tr>
<td>558.342</td>
<td>(a), (c) introductory text, (1)(ii) and (2)(ii) amended</td>
<td>2685</td>
</tr>
<tr>
<td>558.355</td>
<td>(a) added; (b)(3), (c), (d)(1), (2), (5), (7), and (9), and (f)(1)(ii), (iv), (vi), (vii), (xi) introductory text and (b), (xii), (3)(i)(b)(I) and (2), and (iv)(b) amended</td>
<td>2685</td>
</tr>
<tr>
<td>558.369</td>
<td>(d) introductory text amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.370</td>
<td>(b) introductory text amended</td>
<td>2686</td>
</tr>
</tbody>
</table>

### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Initial Text</th>
<th>Amended Text</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.376</td>
<td>(c) introductory text, (1)(ii) and (2)(ii) amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.415</td>
<td>(a) revised</td>
<td>36402</td>
</tr>
<tr>
<td>558.430</td>
<td>(c) introductory text amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.435</td>
<td>(c) revised</td>
<td>2686</td>
</tr>
<tr>
<td>558.450</td>
<td>(b) and (d)(1) table 1 heading amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.469</td>
<td>(c)(1) introductory text amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.464</td>
<td>(b)(2) amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.465</td>
<td>Heading revised; (b)(1), (2), (3), and (4) amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.495</td>
<td>(a)(26) revised</td>
<td>781</td>
</tr>
<tr>
<td>558.505</td>
<td>(e)(1)(ii), (2)(ii), (3)(ii), (4)(ii), (10)(ii), and (11)(ii) added</td>
<td>2686</td>
</tr>
<tr>
<td>558.515</td>
<td>(b) and (d)(1)(ii) amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.525</td>
<td>(b)(1), (2) (i) and (ii), (d)(1)(ii), (2)(i), (3)(ii), (4)(i) and (5)(ii) amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.526</td>
<td>Heading revised; (a)(1) and (2) amended; (b) removed</td>
<td>2686</td>
</tr>
<tr>
<td>558.530</td>
<td>(a)(1) amended</td>
<td>12521</td>
</tr>
<tr>
<td>558.550</td>
<td>(b)(2) removed</td>
<td>1626</td>
</tr>
<tr>
<td>558.575</td>
<td>(a) revised; (c)(1)(ii) amended</td>
<td>7261</td>
</tr>
<tr>
<td>558.579</td>
<td>(c)(1)(iii) amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.586</td>
<td>(e)(2) removed; (f) amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.600</td>
<td>Added</td>
<td>26956</td>
</tr>
<tr>
<td>558.615</td>
<td>(a), (b), and (d)(5)(ii) amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.625</td>
<td>(b)(42) revised</td>
<td>530</td>
</tr>
<tr>
<td>558.635</td>
<td>(e)(2), (f)(1) introductory text and (2) introductory text amended</td>
<td>2686</td>
</tr>
<tr>
<td>558.680</td>
<td>(c)(1) introductory text revised; (c)(1) table amended</td>
<td>2686</td>
</tr>
</tbody>
</table>

**Page 577**
1988

21 CFR—Continued

Chapter I—Continued

510  Technical correction..........................49823
510.600  (c) (1) and (2) tables amended.............11493,
        28084, 21993, 22927, 25151, 32610,
        39256, 40056, 40057, 40727, 40728,
        40729, 50599, 52682
        Effective date corrected...............39839
        (c)(1) table corrected..................49823
520  Technical correction..........................49823
520.23  (a)(2) amended..........................40727
520.62  (b) amended..........................27851
520.110  (a) revised............................37753
520.246  (b) amended..........................27851
520.314  (b) amended..........................27851
520.315  Added................................27344
520.580  (b)(2) amended..........................21993, 40727
520.622a  (a)(1) amended.........................40056
        (a)(6) amended..........................40727
520.622d  (c)(2) amended..........................40056
520.622c  (b)(1) amended.........................40056
520.623  (a) revised............................45759
520.763a  (c) amended..........................40727
520.763b  (c) amended..........................40727
520.903c  (c)(2)(i) revised......................48533

21 CFR—Continued

Chapter I—Continued

520.905a  (d)(2)(ii) and (iii) redesignated as (d)(2)(i) (A) and (B);
        new (d)(2)(i)(A) revised; new
        (d)(2)(ii)(A) added..........................40058
520.1010a  (b) amended..........................40727
520.1192  (c)(1)(ii) and (iii) amended...........51273
520.1194  Added................................27958
520.1195  (c)(2) and (3) amended...............51273
520.1204  Heading revised; (b) amended...........27851
520.1242g  Added................................23757
520.1330  (c) amended..........................23390
520.1331  (b) amended..........................23390
520.1408  (b) amended..........................40727
520.1801b  Removed..............................48634
520.1900  (b) amended..........................40727
520.2260b  (f)(1) amended........................40727
520.2481  (b) amended..........................40727
520.2611  (b) and (c)(1) revised...............11063
522  Heading correctly revised..................26559
522.23  (e) introductory text amended............40727
522.46  (b) amended..........................40057
522.56  (b) amended..........................27851
522.62  (c) amended..........................27851
522.246  (b) amended..........................27851
522.311  Added................................40057
522.313  Added................................5369
522.480  (a), (b), (c) and (d) heading and (1) through (3) redesignated as (a) (1), (2), (3) and (4)
        heading and (1) through (iii);
        new (a)(4)(i) amended; new (b)
        and (c)(1) added..........................45760
522.844  Removed...............................15812
522.1010  (b) amended..........................40727
522.1044  (b)(3) amended.........................40727
522.1145  (c) added............................19773
        (d) added...............................22297
522.1182  (b)(2)(i) amended......................40727
522.1183  (e)(1) amended.........................40728,
        40729
522.1192  (a)(3) added; (d)(4)(i) revised............11064
        (d)(4)(ii) revised..........................27006
522.1204  (b) amended..........................27851
522.1222a  (c)(2) amended.........................23390
522.1222b  (c)(1) amended.........................27851
522.1222c  (c)(1) amended.........................27851
522.1222d  (c)(2) amended.........................23390
522.1240  (b) amended..........................40727
522.1602a  (k) added............................11494
522.1680  (b) revised..........................40728
      Effective date corrected...............39839

578
## 21 CFR—Continued

### Chapter I—Continued

<table>
<thead>
<tr>
<th>Addition/Removal</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b)(1)(x) and (xi) added</td>
<td>35313</td>
</tr>
<tr>
<td>(b)(1)(xii) added</td>
<td>44010</td>
</tr>
<tr>
<td>558.600 (c)(2)(i) and (ii) revised</td>
<td>39257</td>
</tr>
<tr>
<td>558.635 (f)(2)(iv) added</td>
<td>27852</td>
</tr>
<tr>
<td>(f)(3)(vi) added</td>
<td>35313</td>
</tr>
<tr>
<td>(f)(3)(vi) revised</td>
<td>44010</td>
</tr>
</tbody>
</table>

561 Redesignated as 40 CFR Part 186

Correctly redesignated as 40 CFR Part 186

561.20 (b), (c), and (d) removed | 9435 |
561.55 Removed | 9435 |
561.90 Removed | 9435 |
561.96 (a) added | 1917 |
(c) added | 18837 |
561.98 (b), (c), and (d) removed | 9435 |
561.175 Removed | 9435 |
561.195 Removed | 9435 |
561.197 Existing text designated as (a); (b) added; eff. to 6–30–89 | 23386 |
561.225 (a) table amended | 5307 |
(a) table corrected | 11938, 12940 |
561.231 Removed | 9435 |
561.237 Removed | 9435 |
561.253 (b) removed | 9435 |
561.265 Removed | 9435 |
561.273 (c) removed | 8874 |
561.277 Removed | 8874 |
561.280 (b), (c), and (d) removed | 9435 |
561.281 Removed | 9435 |
561.320 Removed | 9435 |
561.330 Revised | 9435 |
561.371 Removed | 9435 |
561.380 (b) removed | 9435 |
561.395 Removed | 9435 |
561.400 Revised | 23389 |
561.415 Introductory text revised | 23389 |
561.425 Revised | 23389 |
561.430 Table amended | 234, 23389 |
561.432 Revised | 8874 |
561.433 Removed | 8874 |
561.440 Introductory text amended | 20398 |
561.441 Amended | 23107 |
561.443 Added; exp. 2–28–88 | 21 |
Added | 12943 |
561.444 Added | 15813 |
561.445 Added | 23387 |
573.225 Added | 40061 |

## 21 CFR

### 1989

<table>
<thead>
<tr>
<th>Authority Citation</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 Authority citation revised</td>
<td>39637</td>
</tr>
<tr>
<td>500.27 (d) amended</td>
<td>18279</td>
</tr>
<tr>
<td>500.35 (a) amended</td>
<td>18279</td>
</tr>
<tr>
<td>500.49 Authority citation removed</td>
<td>39637</td>
</tr>
<tr>
<td>500.51 (c) amended</td>
<td>18279</td>
</tr>
<tr>
<td>501 Authority citation revised; sectional authority citations removed</td>
<td>39637</td>
</tr>
<tr>
<td>501.3 (e) (3) revised</td>
<td>18279</td>
</tr>
<tr>
<td>501.105 (b)(3) amended</td>
<td>18279</td>
</tr>
<tr>
<td>502 Authority citation revised; sectional authority citations removed</td>
<td>39637</td>
</tr>
<tr>
<td>505 Authority citation revised; sectional authority citations removed</td>
<td>39638</td>
</tr>
<tr>
<td>505.10 Removed</td>
<td>18279</td>
</tr>
<tr>
<td>507 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>508 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>508.5 (a)(1) amended</td>
<td>18279</td>
</tr>
<tr>
<td>508.35 (c) (1) and (2) introductory text, (ii), (j)(1), and (l) amended</td>
<td>18280</td>
</tr>
<tr>
<td>509 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>509.5 Amended</td>
<td>18280</td>
</tr>
<tr>
<td>510 Technical correction</td>
<td>6232, 8880, 25447, 41713</td>
</tr>
<tr>
<td>Authority citation revised; sectional and subpart authority citations removed</td>
<td>39638</td>
</tr>
<tr>
<td>510.3 (g)(2) amended; (g)(3) removed</td>
<td>22741</td>
</tr>
<tr>
<td>510.5 Removed</td>
<td>22741</td>
</tr>
<tr>
<td>510.6 Removed</td>
<td>22741</td>
</tr>
<tr>
<td>510.55 Removed</td>
<td>22741</td>
</tr>
<tr>
<td>510.110 (f) amended</td>
<td>18280</td>
</tr>
<tr>
<td>510.112 (a) and (e) amended</td>
<td>18280</td>
</tr>
<tr>
<td>510.301 Introductory text amended</td>
<td>18280</td>
</tr>
<tr>
<td>510.302 (d) amended</td>
<td>18280</td>
</tr>
<tr>
<td>510.310 (f) amended</td>
<td>18280</td>
</tr>
<tr>
<td>510.350 Removed</td>
<td>22741</td>
</tr>
<tr>
<td>510.510 Removed</td>
<td>22741</td>
</tr>
<tr>
<td>510.520 Removed</td>
<td>22741</td>
</tr>
<tr>
<td>510.521 Removed</td>
<td>22742</td>
</tr>
<tr>
<td>510.690 (c) (1) and (2) tables amended</td>
<td>1163, 1164, 6659, 7406, 17705, 22885, 24901, 25565, 26958, 27328, 32632, 33073, 35114, 38515, 38646, 40657, 41442, 42290, 47678, 50565, 51021</td>
</tr>
<tr>
<td>(c) (1) table corrected</td>
<td>9979</td>
</tr>
</tbody>
</table>
List of CFR Sections Affected

<table>
<thead>
<tr>
<th>21 CFR—Continued</th>
<th>54 FR Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter I—Continued</td>
<td>54 FR Page</td>
</tr>
<tr>
<td>Authority citation revised; sectional and subpart authority citations removed .......... 39638</td>
<td></td>
</tr>
<tr>
<td>511 Authority citation revised ..... 18280, 39638</td>
<td></td>
</tr>
<tr>
<td>Authority citation revised ..... 18280</td>
<td></td>
</tr>
<tr>
<td>514 Technical correction .......... 22742</td>
<td></td>
</tr>
<tr>
<td>Authority citation revised; sectional authority citations removed .......................... 39638</td>
<td></td>
</tr>
<tr>
<td>514.1 (b)(6) introductory text, (d)(2) introductory text, (i), and (ii) amended .......... 18280</td>
<td></td>
</tr>
<tr>
<td>514.11 (e)(2)(ii)(a) and (b) amended .......... 18280</td>
<td></td>
</tr>
<tr>
<td>Heading corrected .............................. 20235</td>
<td></td>
</tr>
<tr>
<td>514.50 Removed .............................. 22742</td>
<td></td>
</tr>
<tr>
<td>514.51 Removed .............................. 22742</td>
<td></td>
</tr>
<tr>
<td>514.55 Removed .............................. 22742</td>
<td></td>
</tr>
<tr>
<td>514.60 Removed .............................. 22742</td>
<td></td>
</tr>
<tr>
<td>514.111 (a)(5)(ii)(a)(6) amended .......... 18280</td>
<td></td>
</tr>
<tr>
<td>514.150 Removed .............................. 22742</td>
<td></td>
</tr>
<tr>
<td>514.155 Removed .............................. 22742</td>
<td></td>
</tr>
<tr>
<td>514.160 Removed .............................. 22742</td>
<td></td>
</tr>
<tr>
<td>520 Technical correction ............ 6233, 9980, 22278</td>
<td></td>
</tr>
<tr>
<td>Effective date corrected ............. 33814</td>
<td></td>
</tr>
<tr>
<td>Authority citation revised; sectional authority citations removed .......................... 39638</td>
<td></td>
</tr>
<tr>
<td>520.45 Added .................. 25115</td>
<td></td>
</tr>
<tr>
<td>520.45a Added ........................... 25115</td>
<td></td>
</tr>
<tr>
<td>520.45b Added ........................... 51385</td>
<td></td>
</tr>
<tr>
<td>520.260 (a)(2) amended .......... 38515</td>
<td></td>
</tr>
<tr>
<td>520.312 Added ........................... 32336</td>
<td></td>
</tr>
<tr>
<td>520.443 Removed ........................... 30205</td>
<td></td>
</tr>
<tr>
<td>520.446 (c) revised .................. 47767</td>
<td></td>
</tr>
<tr>
<td>520.447 (c) revised .................. 47766</td>
<td></td>
</tr>
<tr>
<td>520.580 (b)(1) amended .......... 1164</td>
<td></td>
</tr>
<tr>
<td>(b)(1) revised ............................. 6659</td>
<td></td>
</tr>
<tr>
<td>520.623 (c)(2) revised ............ 3776</td>
<td></td>
</tr>
<tr>
<td>(c)(2) corrected ............................. 6804</td>
<td></td>
</tr>
<tr>
<td>520.812 Added .................. 3444</td>
<td></td>
</tr>
<tr>
<td>520.816 Added .................. 50615</td>
<td></td>
</tr>
<tr>
<td>520.965e (a) and (d)(3) revised ..... 20707</td>
<td></td>
</tr>
<tr>
<td>520.1100 (c) revised; (d)(3) and (4) redesignated as (d)(2) and (3) .......... 30205</td>
<td></td>
</tr>
<tr>
<td>520.1126 Removed .......................... 1686</td>
<td></td>
</tr>
<tr>
<td>520.1139 Section heading and (a) revised .............................. 32337</td>
<td></td>
</tr>
<tr>
<td>520.1236 Removed .......................... 29543</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>21 CFR—Continued</th>
<th>54 FR Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter I—Continued</td>
<td>54 FR Page</td>
</tr>
<tr>
<td>Authority citation revised; sectional and subpart authority citations removed .......... 39638</td>
<td></td>
</tr>
<tr>
<td>520.1242a (f)(2)(i)(a) amended ...... 18280</td>
<td></td>
</tr>
<tr>
<td>520.1242g (f)(3) amended .......... 1353</td>
<td></td>
</tr>
<tr>
<td>520.1600d (d)(3) amended .......... 18280</td>
<td></td>
</tr>
<tr>
<td>520.1720a (b)(4) amended .......... 22865</td>
<td></td>
</tr>
<tr>
<td>520.1760 Removed .......................... 30205</td>
<td></td>
</tr>
<tr>
<td>520.1780 Removed .......................... 30205</td>
<td></td>
</tr>
<tr>
<td>520.1800a (d) removed .......... 1163</td>
<td></td>
</tr>
<tr>
<td>520.1801c Removed .......................... 1163</td>
<td></td>
</tr>
<tr>
<td>520.1803 (b) amended .......... 38515</td>
<td></td>
</tr>
<tr>
<td>520.1840 (c)(4) and (d)(4) added .......... 33501</td>
<td></td>
</tr>
<tr>
<td>520.2080b Removed .......................... 30205</td>
<td></td>
</tr>
<tr>
<td>520.2184 (b) amended .......... 12188</td>
<td></td>
</tr>
<tr>
<td>520.2220d Added .......................... 48593</td>
<td></td>
</tr>
<tr>
<td>520.2260a Revis ed .......... 15751</td>
<td></td>
</tr>
<tr>
<td>(b)(3)(ii)(A) corrected ............... 19283</td>
<td></td>
</tr>
<tr>
<td>520.2260b (b) added ............... 14341</td>
<td></td>
</tr>
<tr>
<td>520.2330 (b)(1)(ii) amended .......... 18280</td>
<td></td>
</tr>
<tr>
<td>520.2560 Removed .......................... 1164</td>
<td></td>
</tr>
<tr>
<td>522 Technical correction .......... 6232</td>
<td></td>
</tr>
<tr>
<td>Authority citation corrected .......... 9590</td>
<td></td>
</tr>
<tr>
<td>Authority citation revised; sectional authorities removed .......... 39638</td>
<td></td>
</tr>
<tr>
<td>522.453 Removed ............... 30205</td>
<td></td>
</tr>
<tr>
<td>522.514 Added ........................... 17706</td>
<td></td>
</tr>
<tr>
<td>522.536 Added ....................... 50965</td>
<td></td>
</tr>
<tr>
<td>Heading and (a) corrected .......... 51551</td>
<td></td>
</tr>
<tr>
<td>522.540 (d)(2)(i) and (e)(2) amended ............... 41442</td>
<td></td>
</tr>
<tr>
<td>522.650 (b) amended ............... 1165</td>
<td></td>
</tr>
<tr>
<td>522.914 (e)(1), (2) and (3) redesignated as (e)(1)(i), (ii), and (iii); (a) and new (e)(1)(i) heading revised; new (e)(2) added .......... 400</td>
<td></td>
</tr>
<tr>
<td>522.1077 Added ....................... 50235</td>
<td></td>
</tr>
<tr>
<td>522.1182 (a)(2) removed ............... 41442</td>
<td></td>
</tr>
<tr>
<td>522.1235 Removed ............... 28545</td>
<td></td>
</tr>
<tr>
<td>522.1462 (b) amended .......... 32632</td>
<td></td>
</tr>
<tr>
<td>522.1662a (f) and (j) removed .......... 41442</td>
<td></td>
</tr>
<tr>
<td>522.1680 (b) amended .......... 41442</td>
<td></td>
</tr>
<tr>
<td>522.1720 (b)(2) amended .......... 41442</td>
<td></td>
</tr>
<tr>
<td>522.1800 Removed ............... 30205</td>
<td></td>
</tr>
<tr>
<td>522.1850 Revis ed .......... 30205</td>
<td></td>
</tr>
<tr>
<td>522.1940 (d)(1)(ii) amended .......... 7406</td>
<td></td>
</tr>
<tr>
<td>522.2063 (b) amended .......... 1164</td>
<td></td>
</tr>
<tr>
<td>522.2220 (c)(2), (3)(i), and (ii) revised; (c)(3)(iv) redesignated as (c)(3)(ii) .......... 30205</td>
<td></td>
</tr>
<tr>
<td>522.2670 Added ....................... 40657</td>
<td></td>
</tr>
<tr>
<td>522.2680 (f)(2)(i)(a) amended .......... 31950</td>
<td></td>
</tr>
<tr>
<td>(f)(3)(ii) removed .......... 31950</td>
<td></td>
</tr>
<tr>
<td>524 Technical correction .......... 6232</td>
<td></td>
</tr>
<tr>
<td>Authority citation revised .......... 39638</td>
<td></td>
</tr>
<tr>
<td>524.1580b (b) revised .......... 39042</td>
<td></td>
</tr>
<tr>
<td>(b) amended .......... 37097</td>
<td></td>
</tr>
<tr>
<td>524.1580c (b) revised .......... 30452</td>
<td></td>
</tr>
</tbody>
</table>
### 21 CFR—Continued

#### Chapter I—Continued

<table>
<thead>
<tr>
<th>CFR Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>524.1600a</td>
<td>(b) revised</td>
</tr>
<tr>
<td>(b) amended</td>
<td>5431</td>
</tr>
<tr>
<td>524.1742</td>
<td>(b) amended</td>
</tr>
<tr>
<td>524.2080</td>
<td>Removed</td>
</tr>
<tr>
<td>525.2101</td>
<td>(c) introductory text amended; (d) removed</td>
</tr>
<tr>
<td>524.2542</td>
<td>Removed</td>
</tr>
<tr>
<td>524.2620</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>526 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529.1030</td>
<td>(b) amended</td>
</tr>
<tr>
<td>529.1810</td>
<td>(c)(1) amended</td>
</tr>
<tr>
<td>Chapter I</td>
<td>21 CFR</td>
</tr>
<tr>
<td>526 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>524.2542</td>
<td>Removed</td>
</tr>
<tr>
<td>524.2620</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>526 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529.1030</td>
<td>(b) amended</td>
</tr>
<tr>
<td>529.1810</td>
<td>(c)(1) amended</td>
</tr>
<tr>
<td>524.2542</td>
<td>Removed</td>
</tr>
<tr>
<td>524.2620</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>526 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529.1030</td>
<td>(b) amended</td>
</tr>
<tr>
<td>529.1810</td>
<td>(c)(1) amended</td>
</tr>
<tr>
<td>524.2542</td>
<td>Removed</td>
</tr>
<tr>
<td>524.2620</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>526 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529.1030</td>
<td>(b) amended</td>
</tr>
<tr>
<td>529.1810</td>
<td>(c)(1) amended</td>
</tr>
<tr>
<td>524.2542</td>
<td>Removed</td>
</tr>
<tr>
<td>524.2620</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>526 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529.1030</td>
<td>(b) amended</td>
</tr>
<tr>
<td>529.1810</td>
<td>(c)(1) amended</td>
</tr>
<tr>
<td>524.2542</td>
<td>Removed</td>
</tr>
<tr>
<td>524.2620</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>526 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529.1030</td>
<td>(b) amended</td>
</tr>
<tr>
<td>529.1810</td>
<td>(c)(1) amended</td>
</tr>
<tr>
<td>524.2542</td>
<td>Removed</td>
</tr>
<tr>
<td>524.2620</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>526 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529.1030</td>
<td>(b) amended</td>
</tr>
<tr>
<td>529.1810</td>
<td>(c)(1) amended</td>
</tr>
<tr>
<td>524.2542</td>
<td>Removed</td>
</tr>
<tr>
<td>524.2620</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>526 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529 Authority citation revised</td>
<td>39638</td>
</tr>
<tr>
<td>529.1030</td>
<td>(b) amended</td>
</tr>
<tr>
<td>529.1810</td>
<td>(c)(1) amended</td>
</tr>
</tbody>
</table>
List of CFR Sections Affected

21 CFR—Continued

Chapter I—Continued

579 Authority citation revised ..........39639
573.920 (a) revised; (f) added ..........14215
(d)(3)(xxv) added .......................29335
(d)(3)(xxiv) added .................33885
573.99 Authority citation revised ..........39639
573.780 (b)(1)(xvi) added ..........26154
(b)(1)(xv) added .......................24901
(b)(1)(xvi) (c) corrected ..........32963
(b)(1)(xv) (d) added ..........32963
(b)(1)(xvi) (e) added ..........32963
573.460 (a)(1) footnote 1 amended .......23076
573.640 (b)(4) (i) and (ii) amended ......18281
573.620 (c)(3)(ii) removed; (c)(3) (i) and (iii) moved ..........39639
573.575 (c)(3)(ii) removed; (c)(3)(i) and (b) redesignated as (c)(3)(ii) and (iii) ..........18281
573.550 (b)(1)(xiii) added ...............21940
(b)(1)(xii) added .......................21940
(b)(1)(xv) added .......................24901
Chapter I

509 Subpart C heading redesignated as Subpart D; new Subpart C heading added ..........20786
509.4 (c) redesignated as (d); heading, (b), and new (d) revised; new (c) added ..........20786
509.6 (c) and (d) redesignated as (d) and (e); (a), new (d) and (e) revised; new (c) added ..........20786
509.7 (b) revised ..........20786
509.8 Removed ..........20787
510.450 Removed ..........32396
510.600 (c)(1) table and (2) table amended ...................14831
514.2 (d) added ...............14831
514.9 Interpretative rule ..........25972
514.106 Added ..........49973
(b)(2)(iii) corrected ..........49973
520.1445 Added ..........25301
520.1448 Amended ..........49888
520.1630 Revised ..........46943
520.1720a (b)(3) added ..........8461
520.1720d (b) amended ..........8462
520.1870 Nomenclature change; (c)(1)(i), (iii), and (2)(iii) revised ..........2234
520.2080a Removed ..........24556
520.2087 (b) amended ..........8460
520.2088 (a)(2) and (b)(2) amended ..........8460
520.2150a (b) amended ..........23076
520.2150b (b) amended ..........23076
520.2260b (c)(1) and (e)(1) amended ..........8462
520.2320 (c) amended ..........8460
509.1870 Nomenclature change; (c)(3) corrected ..........43327
509.575 (c)(3)(ii) removed; (c)(3)(i) and (b) redesignated as (c)(3)(ii) and (iii) ..........18281
509.550 (b)(1)(xiii) added ...............21940
(b)(1)(xii) added .......................21940
(b)(1)(xv) added .......................24901
(b)(1)(xvi) (c) corrected ..........32963
(b)(1)(xv) (d) added ..........32963
(b)(1)(xvi) (e) added ..........32963
509.575 (c)(3)(ii) removed; (c)(3)(i) and (b) redesignated as (c)(3)(ii) and (iii) ..........18281
509.550 (b)(1)(xiii) added ...............21940
(b)(1)(xii) added .......................21940
(b)(1)(xv) added .......................24901
(b)(1)(xvi) (c) corrected ..........32963
(b)(1)(xv) (d) added ..........32963
(b)(1)(xvi) (e) added ..........32963
509.6 (e) amended ..........18281
509.35 (c)(2) and (3) amended ..........18281
509.38 (b)(1) and (2) amended ..........18281
509.575 (c)(3)(ii) removed; (c)(3)(i) and (b) redesignated as (c)(3)(ii) and (iii) ..........18281
509.550 (b)(1)(xiii) added ...............21940
(b)(1)(xii) added .......................21940
(b)(1)(xv) added .......................24901
(b)(1)(xvi) (c) corrected ..........32963
(b)(1)(xv) (d) added ..........32963
(b)(1)(xvi) (e) added ..........32963
509.622a (a)(3) amended ..........8461
509.622c (b)(4) amended ..........8462
(b)(3) amended ..........32616
509.812 (c)(3) amended ..........24226
(c)(2) redesignated as (c)(2)(i); (c)(2)(ii) added; (c)(3) revised ..........43327
509.1263c (d) revised ..........3209
509.1445 Added ..........25301
(c)(3) corrected ..........49888
509.1448 Amended ..........3586
509.1630 Revised ..........46943
509.1720a (b)(3) added ..........8461
509.1720d (b) amended ..........8462
509.1870 Nomenclature change; (c)(1)(i), (iii) and (2)(iii) revised ..........2234
509.2080a Removed ..........24556
509.2087 (b) amended ..........8460
509.2088 (a)(2) and (b)(2) amended ..........8460
509.2150a (b) amended ..........23076
509.2150b (b) amended ..........23076
509.2184 (b) amended ..........8460
509.2260b (c)(1) and (e)(1) amended ..........8462
509.2320 (c) amended ..........8460

589

54 FR

Page

55 FR

Page

21 CFR

1990

Chapter I

509 Subpart C heading redesignated as Subpart D; new Subpart C heading added ..........20786
Subpart D heading redesignated from Subpart C ..........20786
509.4 (c) redesignated as (d); heading, (b), and new (d) revised; new (c) added ..........20786
509.6 (c) and (d) redesignated as (d) and (e); (a), new (d) and (e) revised; new (c) added ..........20786
509.7 (b) revised ..........20786
509.8 Removed ..........20787
510.450 Removed ..........32396
510.600 (c)(1) table and (2) table amended ...................14831
514.2 (d) added ...............14831
514.9 Interpretative rule ..........25972
514.106 Added ..........46052
(b)(2)(iii) corrected ..........49973
520.48 (c)(1) and (3) amended ..........26431
520.260 (b)(2) amended ..........24556
520.540 (b)(2) amended ..........8461
520.580 (b)(1) amended ..........39616
520.622a (a)(3) amended ..........8461
520.622c (b)(4) amended ..........8462
(b)(3) amended ..........32616
520.812 (c)(3) amended ..........24226
(c)(2) redesignated as (c)(2)(i); (c)(2)(ii) added; (c)(3) revised ..........43327
509.1263c (d) revised ..........3209
509.1445 Added ..........25301
(c)(3) corrected ..........49888
509.1448 Amended ..........3586
509.1630 Revised ..........46943
509.1720a (b)(3) added ..........8461
509.1720d (b) amended ..........8462
509.1870 Nomenclature change; (c)(1)(i), (iii), and (2)(iii) revised ..........2234
509.2080a Removed ..........24556
509.2087 (b) amended ..........8460
509.2088 (a)(2) and (b)(2) amended ..........8460
509.2150a (b) amended ..........23076
509.2150b (b) amended ..........23076
509.2184 (b) amended ..........8460
509.2260b (c)(1) and (e)(1) amended ..........8462
509.2320 (c) amended ..........8460
### List of CFR Sections Affected

**21 CFR—Continued**

<table>
<thead>
<tr>
<th>CFR Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chapter I</strong>—Continued</td>
<td></td>
</tr>
<tr>
<td>(b)(3)(ii) added</td>
<td>17599</td>
</tr>
<tr>
<td>558.586 (a) amended</td>
<td>29843</td>
</tr>
<tr>
<td>558.625 (b)(39) amended</td>
<td>8462</td>
</tr>
<tr>
<td>(b)(20) removed</td>
<td>17852</td>
</tr>
<tr>
<td>(b)(47) and (75) removed</td>
<td>19330</td>
</tr>
<tr>
<td>(b)(46) removed</td>
<td>24226</td>
</tr>
<tr>
<td>(b)(69) removed</td>
<td>25972</td>
</tr>
<tr>
<td>(b)(49) and (56) removed</td>
<td>30215</td>
</tr>
<tr>
<td>(f)(2)(ii) added</td>
<td>31829</td>
</tr>
<tr>
<td>(b)(26) and (86) removed</td>
<td>39615</td>
</tr>
<tr>
<td>(b)(82) removed</td>
<td>39616</td>
</tr>
<tr>
<td>558.630 (b)(10) amended</td>
<td>25972</td>
</tr>
<tr>
<td>(b)(8) amended</td>
<td>30215</td>
</tr>
<tr>
<td>(b)(10) amended</td>
<td>39615, 39616</td>
</tr>
<tr>
<td>558.680 (a) amended</td>
<td>4601</td>
</tr>
</tbody>
</table>

| 1991 |

<table>
<thead>
<tr>
<th>CFR Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 CFR</td>
<td></td>
</tr>
<tr>
<td><strong>Chapter I</strong></td>
<td></td>
</tr>
<tr>
<td>500.29 Added</td>
<td>40506</td>
</tr>
<tr>
<td>500.30 Added</td>
<td>40507</td>
</tr>
<tr>
<td>510.515 (a)(4), (5), (11), (15) and (17)(ii) removed; (c) table amended</td>
<td>41912</td>
</tr>
<tr>
<td>510.600 (c)(1) table and (2) table amended</td>
<td>7805, 9623, 9840, 14019, 14641, 16269, 19022, 19023, 19263, 20126, 27196, 37472–37474, 43698, 49410, 49815, 50632, 63875, 64553, 65834</td>
</tr>
<tr>
<td>(c)(1) table amended</td>
<td>8481</td>
</tr>
<tr>
<td>514.106 (a), (b)(1)(ii), (iii), (V), (vi), (viii), (xii), (xiv), (2)(ii), (iv), (ix) and (xiii) corrected</td>
<td>12422</td>
</tr>
<tr>
<td>520 Authority citation corrected</td>
<td>14978</td>
</tr>
<tr>
<td>520.23 (a)(2) amended</td>
<td>37473</td>
</tr>
<tr>
<td>520.45a (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>Corrected</td>
<td>59331</td>
</tr>
<tr>
<td>520.45b (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.182 (b) amended</td>
<td>43699</td>
</tr>
<tr>
<td>520.540c (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.550 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.622c (b)(2) amended; (b)(7) removed</td>
<td>50653</td>
</tr>
<tr>
<td>520.623 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.816 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.950d (c)(4) added</td>
<td>50813</td>
</tr>
<tr>
<td>520.950e Added</td>
<td>50655</td>
</tr>
<tr>
<td>520.1010a (b) amended</td>
<td>37473</td>
</tr>
<tr>
<td>520.1065 Removed</td>
<td>31075</td>
</tr>
<tr>
<td>520.1204 Heading revised; (a) and (c)(2) amended</td>
<td>8710</td>
</tr>
<tr>
<td>520.1205 Added</td>
<td>8710</td>
</tr>
<tr>
<td>520.124 (b) amended</td>
<td>50653</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>21 CFR—Continued</th>
<th>56 FR Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chapter I—Continued</strong></td>
<td></td>
</tr>
<tr>
<td>520.1284 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.1205 (d) introductory text amended</td>
<td>50654</td>
</tr>
<tr>
<td>520.1204 (c)(4)(ii) introductory text amended</td>
<td>5658</td>
</tr>
<tr>
<td>(a)(2) introductory text and (iii) corrected</td>
<td>8710</td>
</tr>
<tr>
<td>520.1284 (d)(2) introductory text and (iii) corrected</td>
<td>8710</td>
</tr>
<tr>
<td>520.1630 (d)(2) introductory text and (iii) corrected</td>
<td>8710</td>
</tr>
<tr>
<td>520.1630 (d)(2) introductory text and (iii) corrected</td>
<td>8710</td>
</tr>
<tr>
<td>520.1638 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.1641 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.1840 (c)(1) and (2) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.1846 (b) amended</td>
<td>9841</td>
</tr>
<tr>
<td>520.1900 (b) amended</td>
<td>37473</td>
</tr>
<tr>
<td>520.1920 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.1921 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.2260a (b)(1) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.2260b (a) amended</td>
<td>50653</td>
</tr>
<tr>
<td>Corrected</td>
<td>59331, 64288</td>
</tr>
<tr>
<td>520.2260c (b)(1) amended</td>
<td>50653</td>
</tr>
<tr>
<td>Corrected</td>
<td>59331, 64288</td>
</tr>
<tr>
<td>520.2804 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.2905 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>520.3103 (d)(1)(ii) and (iii) amended</td>
<td>12119</td>
</tr>
<tr>
<td>522.540 (d)(2)(ii) amended</td>
<td>19022</td>
</tr>
<tr>
<td>(d)(2)(i) amended</td>
<td>50653</td>
</tr>
<tr>
<td>522.562 Removed</td>
<td>31075</td>
</tr>
<tr>
<td>522.900 (a) removed</td>
<td>9623</td>
</tr>
<tr>
<td>522.1081 (a)(2)(ii) amended</td>
<td>14642</td>
</tr>
<tr>
<td>(a)(2)(iii) added</td>
<td>67175</td>
</tr>
<tr>
<td>522.1145 (e) added</td>
<td>50814</td>
</tr>
<tr>
<td>522.1192 (d)(4)(i) revised</td>
<td>14020</td>
</tr>
<tr>
<td>522.1290 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>522.1301 Removed</td>
<td>31075</td>
</tr>
<tr>
<td>522.1680 (b) amended</td>
<td>16002</td>
</tr>
<tr>
<td>522.1720 (b)(2) amended</td>
<td>16002</td>
</tr>
<tr>
<td>(b)(1) amended</td>
<td>19022</td>
</tr>
<tr>
<td>522.1880 (b) amended</td>
<td>19022</td>
</tr>
<tr>
<td>522.1920 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>522.2477 Added</td>
<td>67175</td>
</tr>
<tr>
<td>524.1005 (b)(1) amended</td>
<td>50653</td>
</tr>
<tr>
<td>524.1465 (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>524.1580b (b) amended</td>
<td>37473</td>
</tr>
<tr>
<td>(b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>524.1580c (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>524.1580d (b) amended</td>
<td>37473</td>
</tr>
<tr>
<td>524.1600a (b) amended</td>
<td>50653</td>
</tr>
<tr>
<td>524.2101 (c) introductory text amended</td>
<td>9623</td>
</tr>
<tr>
<td>524.2620 (b)(2) amended</td>
<td>37474</td>
</tr>
<tr>
<td>529.1526 (b) amended</td>
<td>43699</td>
</tr>
<tr>
<td>540.103a (c)(2) amended</td>
<td>50653</td>
</tr>
<tr>
<td>540.103b (c)(2) amended</td>
<td>50653</td>
</tr>
<tr>
<td>540.103c (c)(2) amended</td>
<td>50654</td>
</tr>
<tr>
<td>540.103d (c)(2) amended</td>
<td>50654</td>
</tr>
<tr>
<td>540.103e (c)(2) amended</td>
<td>50654</td>
</tr>
<tr>
<td>540.103g (c)(2) amended</td>
<td>50654</td>
</tr>
<tr>
<td>540.103h (c)(2) amended</td>
<td>50654</td>
</tr>
<tr>
<td>540.107a (c)(2) amended</td>
<td>50654</td>
</tr>
<tr>
<td>540.107e (c)(4)(ii) introductory text amended</td>
<td>50654</td>
</tr>
</tbody>
</table>

| Page | 585 |
List of CFR Sections Affected

21 CFR—Continued  57 FR  Page
Chapter I—Continued  37323
520.390c Added.......................... 37323
(c)(1) corrected................... 42623
520.445 Added.......................... 37323
520.445a Added.......................... 37323
520.445b Added.......................... 37294
(b), (d)(1)(iv)(A) introductory
text and (2)(i)(D)(I) corrected;
d(2)(i)(C) correctly des-
ignated.......................... 42623
520.445c Added.......................... 37325
520.445d Added.......................... 37323
520.608 Added.......................... 37323
520.1130 Added.......................... 37325
520.1130a Added.......................... 37325
520.1130b Added.......................... 37326
520.1130c Added.......................... 37326
520.1242g (c) amended.................. 37652
520.1448b (b) amended.............. 5052
520.1448c Added.......................... 19085
520.1660d (b) revised.............. 26604
520.1660e (b) revised............... 42490
520.1696 Added.......................... 37326
520.1696a Added.......................... 37326
520.1696b Added.......................... 37326
520.1696c Added.......................... 37326
(c) corrected................... 42623
520.1696d Added.......................... 37327
520.1720b (b) amended.............. 3836
520.1806 (b) amended.............. 46163
520.1890 Added.......................... 4718
520.2041 (b) amended.............. 48163
520.2042 (b) amended.............. 48163
520.2087 (b) amended.............. 8577
520.2088 (a)(2) and (b)(2) amend-
ed.......................... 8577
520.2158 Added.......................... 37327
520.2158a Added.......................... 37327
520.2158b Added.......................... 37327
(b) corrected................... 42623
520.2158c Added.......................... 37327
520.2220a (b) amended.............. 32176
520.2345a Added.......................... 37327
520.2345d Added.......................... 3728
520.2345c Added.......................... 37328
(e)(1)(1) corrected................ 42623
520.2345e Added.......................... 37329
520.2345f Added.......................... 37329
520.2345g Added.......................... 37329
520.2345h Added.......................... 37329
520.2471 Added.......................... 12712
520.2100 (a)(1) amended............ 21209
520.22471 Added.......................... 12712
520.22477 (b) corrected........... 5052
524 Heading revised.............. 37333
524.154 Added.......................... 37333
524.155 Added.......................... 37333
524.390 Added.......................... 37333
524.1505 (b)(1) amended........... 31314
526 Heading revised.............. 37334
526.88 Added.......................... 37334
524.646 Added.......................... 37334
526.646a Added.......................... 37333
(c)(2) corrected................ 42623
524.646b Added.......................... 37334
(c)(2) and (3) corrected........ 42623
524.646c Added.......................... 37335
524.646d Added.......................... 37335
524.646e Added.......................... 37335
524.1130 (b) added.............. 37335
524.1550 (c)(1) corrected........ 7652
524.1695 (c)(2) and (3) corrected 42623
524.1145 (d)(3)(ii) corrected........ 2837
524.1145 (d)(2) amended........... 2837
524.645 Added.......................... 37334
524.645d Added.......................... 37334
524.645e Added.......................... 37334
524.645f Added.......................... 37334
524.645g Added.......................... 37334
524.645h Added.......................... 37334
525 Technical correction....... 5286
522 Heading revised.............. 37336
522.88 Added.......................... 37336
522.90 Added.......................... 37330

587
### List of CFR Sections Affected

#### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Page</th>
<th>58 FR</th>
</tr>
</thead>
<tbody>
<tr>
<td>589</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Action</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>520.2041</td>
<td>(b) amended</td>
<td>44611</td>
</tr>
<tr>
<td>520.2042</td>
<td>(c) added</td>
<td>44611</td>
</tr>
<tr>
<td>520.2988</td>
<td>(c) added</td>
<td>65664</td>
</tr>
<tr>
<td>520.2999</td>
<td>Added</td>
<td>65665</td>
</tr>
<tr>
<td>520.2158a</td>
<td>(d)(1) and (2) revised; (d)(3) removed</td>
<td>47211</td>
</tr>
<tr>
<td>520.2220a</td>
<td>Heading, (a), (b) and (e) introductory text revised</td>
<td>6092</td>
</tr>
<tr>
<td>520.2220</td>
<td>(a), (b) and (c) introductory text revised</td>
<td>47211</td>
</tr>
<tr>
<td>520.2345d</td>
<td>(e)(1)(iii)(A), (B), (C), (3)(v)(A), (B) and (C) revised</td>
<td>33331</td>
</tr>
<tr>
<td>520.2455</td>
<td>Heading revised; (d)(2)(i) and (ii) amended</td>
<td>14313</td>
</tr>
<tr>
<td>520.2456</td>
<td>Added</td>
<td>14313</td>
</tr>
<tr>
<td>520.2613</td>
<td>Added</td>
<td>36135</td>
</tr>
<tr>
<td>520.290b</td>
<td>(d)(2)(i) correctly designated</td>
<td>18304</td>
</tr>
<tr>
<td>520.2757</td>
<td>Added</td>
<td>500</td>
</tr>
<tr>
<td>520.2820</td>
<td>Revised</td>
<td>43795</td>
</tr>
<tr>
<td>520.1002</td>
<td>Redesignated from 522.1822 and revised</td>
<td>47377</td>
</tr>
<tr>
<td>520.2197</td>
<td>(c) and (e) added</td>
<td>65665</td>
</tr>
<tr>
<td>520.2197b</td>
<td>(d) introductory text revised</td>
<td>11964</td>
</tr>
<tr>
<td>520.2212</td>
<td>Redesignated as 522.1002</td>
<td>47377</td>
</tr>
<tr>
<td>520.2210</td>
<td>(c) and (e) added</td>
<td>57556</td>
</tr>
<tr>
<td>520.2210</td>
<td>(a), (b) and (e) added</td>
<td>59947</td>
</tr>
</tbody>
</table>

---

### 1994

#### 21 CFR

<table>
<thead>
<tr>
<th>Section</th>
<th>Action</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>500.80</td>
<td>(a) amended</td>
<td>14365</td>
</tr>
<tr>
<td>509.30</td>
<td>(b) amended</td>
<td>14365</td>
</tr>
<tr>
<td>Section</td>
<td>Changes</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>520.1696b</td>
<td>(b)(2) added; (c)(2) amended</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(b) revised</td>
<td></td>
</tr>
<tr>
<td>520.1720</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2045</td>
<td>(b)(2) amended</td>
<td></td>
</tr>
<tr>
<td>520.2520h</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.2520</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.2260c</td>
<td>(a)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260b</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260</td>
<td>(c)(3) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220b</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220c</td>
<td>(c) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220d</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260a</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2155</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.1806</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1872</td>
<td>Added</td>
<td></td>
</tr>
<tr>
<td>520.1962</td>
<td>(b) removed</td>
<td></td>
</tr>
<tr>
<td>520.2045</td>
<td>(b)(2) amended</td>
<td></td>
</tr>
<tr>
<td>520.2015</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.2220a</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1720a</td>
<td>(b)(3) amended</td>
<td></td>
</tr>
<tr>
<td>520.4435b</td>
<td>(a) amended; (b)(4) added; (C) revised; (d)(3) removed; (d)(4)(i)(C) added</td>
<td></td>
</tr>
<tr>
<td>520.5093c</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.905a</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.905b</td>
<td>(c)(3) added</td>
<td></td>
</tr>
<tr>
<td>520.1696d</td>
<td>(a)(4), (b)(2) and (e)(1)(iii)(C) revised</td>
<td></td>
</tr>
<tr>
<td>520.445b</td>
<td>(a)(1) amended; (2), (4)(iii)(B), (C), (iv)(B) and (C) revised; (d)(3) removed; (d)(4)(i)(C) added</td>
<td></td>
</tr>
<tr>
<td>520.531</td>
<td>(a) removed; (b) revised</td>
<td></td>
</tr>
<tr>
<td>520.580</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.804</td>
<td>Added</td>
<td></td>
</tr>
<tr>
<td>520.903c</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.905a</td>
<td>(d)(3) added</td>
<td></td>
</tr>
<tr>
<td>520.905b</td>
<td>(c)(3) added</td>
<td></td>
</tr>
<tr>
<td>520.1872</td>
<td>(b) removed</td>
<td></td>
</tr>
<tr>
<td>520.1806</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1962</td>
<td>(b) revised</td>
<td></td>
</tr>
<tr>
<td>520.2260c</td>
<td>(a)(4) added</td>
<td></td>
</tr>
<tr>
<td>520.2235a</td>
<td>(c)(2) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260c</td>
<td>(a) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260b</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.1962</td>
<td>(b) removed</td>
<td></td>
</tr>
<tr>
<td>520.1806</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1720a</td>
<td>(b)(3) amended</td>
<td></td>
</tr>
<tr>
<td>520.1806</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1872</td>
<td>Added</td>
<td></td>
</tr>
<tr>
<td>520.1962</td>
<td>(b) removed</td>
<td></td>
</tr>
<tr>
<td>520.2045</td>
<td>(b)(2) amended</td>
<td></td>
</tr>
<tr>
<td>520.2155</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.2220a</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260b</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260c</td>
<td>(a)(4) added</td>
<td></td>
</tr>
<tr>
<td>520.2260b</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260c</td>
<td>(a) amended</td>
<td></td>
</tr>
<tr>
<td>520.2325a</td>
<td>(c)(2) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260c</td>
<td>(a) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260b</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260c</td>
<td>(a) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260b</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220c</td>
<td>(c) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220d</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2260a</td>
<td>(b)(1) amended</td>
<td></td>
</tr>
<tr>
<td>520.2155</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.1806</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1872</td>
<td>Added</td>
<td></td>
</tr>
<tr>
<td>520.1962</td>
<td>(b) removed</td>
<td></td>
</tr>
<tr>
<td>520.2045</td>
<td>(b)(2) amended</td>
<td></td>
</tr>
<tr>
<td>520.2155</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.2220a</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1720a</td>
<td>(b)(3) amended</td>
<td></td>
</tr>
<tr>
<td>520.1806</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1872</td>
<td>Added</td>
<td></td>
</tr>
<tr>
<td>520.1962</td>
<td>(b) removed</td>
<td></td>
</tr>
<tr>
<td>520.2045</td>
<td>(b)(2) amended</td>
<td></td>
</tr>
<tr>
<td>520.2155</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.2220a</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1720a</td>
<td>(b)(3) amended</td>
<td></td>
</tr>
<tr>
<td>520.1806</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1872</td>
<td>Added</td>
<td></td>
</tr>
<tr>
<td>520.1962</td>
<td>(b) removed</td>
<td></td>
</tr>
<tr>
<td>520.2045</td>
<td>(b)(2) amended</td>
<td></td>
</tr>
<tr>
<td>520.2155</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.2220a</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1720a</td>
<td>(b)(3) amended</td>
<td></td>
</tr>
<tr>
<td>520.1806</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.1872</td>
<td>Added</td>
<td></td>
</tr>
<tr>
<td>520.1962</td>
<td>(b) removed</td>
<td></td>
</tr>
<tr>
<td>520.2045</td>
<td>(b)(2) amended</td>
<td></td>
</tr>
<tr>
<td>520.2155</td>
<td>Removed</td>
<td></td>
</tr>
<tr>
<td>520.2220a</td>
<td>(b) amended</td>
<td></td>
</tr>
<tr>
<td>520.2220</td>
<td>(b) amended</td>
<td></td>
</tr>
</tbody>
</table>
List of CFR Sections Affected

21 CFR—Continued

Chapter I—Continued

508.35 (c)(1), (2) introductory text and (ii) amended .................. 14481

510.120 Removed .................................. 37882

510.220 (Subpart C) Removed .................. 37882

510.310 Removed .................................. 37882

510.413 Removed .................................. 37882

510.515 (b)(7), (17), (25) and (29) removed; (b)(10) and (13) redesignated as (b)(1) and (2); (c) table added ........................................ 35950

510.600 (c)(1) table and (2) table amended ............ 259, 515, 4755, 5506, 8872, 15703, 17565, 18672, 21075, 24441, 46547, 58630, 58631, 59003, 63710, 63711, 66580, 68146

520 Technical correction.......................... 43964

520.45a (a)(3) amended .......................... 4975

520.82a (b) amended ........................... 8873

520.82b (b) amended ........................... 8873

520.154b (b) amended ........................... 66581

520.222 (c) amended ........................... 8873

520.309 Added ................................... 66581

520.447 (c)(3) amended; (d) added ........................................ 59003

520.500 Removed .................................. 34728

520.580 (b)(2) amended .......................... 34728

520.620a Removed .................................. 34728

520.620b Removed .................................. 34728

520.620c (a) amended ........................... 34728

520.622a (b)(1) revised ........................... 34728

520.622c (b)(5) amended .......................... 8873

520.784 (b) amended ........................... 8873

520.813 Added ................................... 56893

520.863 (b) amended ........................... 8873

520.905a (d)(2) heading revised; (d)(2)(I)(B) amended .......... 29478

520.905c (d)(2) heading revised; (d)(2)(III) amended .......... 29478

520.960 (b) amended ........................... 5506

520.1120a (c) amended ........................... 8873

520.1120b (c) amended ........................... 8873

520.1193 (c)(2) and (3) revised .................. 39868

520.1196 Heading revised: (c)(1)(III) amended .......... 15186

520.1197 Added ................................... 67452

520.1445 (c)(2) amended .......................... 43654

520.1448a (c)(4)(III) amended ............ 24444

520.1468 (b) amended ........................... 5506

520.1484 (b) revised; (c)(3) amended ............... 31027

520.1495 (b) revised; (d)(3) amended ............... 31399

520.1520 Removed .................................. 34728

520.1629 (a)(2) and (b)(2) amended ............... 5506

520.1631 (b) amended ........................... 5506

520.1660d (a)(7) and (b)(5) added ............ 2915

520.1660d (a)(7) revised; (e)(1)(ii)(A)(J), (B)(J), (C)(J), (ii)(C) and (iv)(C) amended .... 52690

520.1720a (b)(1) amended ...................... 8873

520.1720b (b) amended ........................... 8873

520.1720c (b) amended ........................... 8873

520.1805 (b) amended ........................... 8873

520.1872 (c)(1)(ii) amended .................. 29651

520.2002 (c) amended ........................... 5506

520.2022 Removed .................................. 34729

520.2043 (b)(2) revised ........................... 29477

520.2122 (b)(2) amended .......................... 5506

520.2160a Removed .................................. 34728

520.2160b Removed .................................. 34729

520.2160c Removed .................................. 34729

520.2160d Removed .................................. 34729

520.2220a (b)(1) amended ...................... 4875

520.2220b (b) amended ........................... 4875

520.2220c (c) amended ........................... 4875

520.2220d (b) amended ........................... 4875

520.2220e (c)(2) amended ...................... 46719

520.2220f (b)(1) amended ...................... 4875

520.2260b (b)(1) amended ...................... 4875

520.2260c (b)(1) amended ...................... 4875

520.2260d (a) amended ........................... 4875

520.2325a (b) added; (d) removed; (c), (e) and (f) redesignated as (a), (c) and (d); new (a) revised; new (d) amended .......... 24443

21 CFR—Continued

Chapter I—Continued

520.2362 (c) amended ........................... 8873

520.2480 Removed .................................. 34729

520.2520a (b) amended ........................... 34729

520.2520c Removed .................................. 34729

520.2590d Removed .................................. 34729

520.2610 (b) amended .................................. 5506, 8873

520.2611 (b) amended .................................. 5506, 8873

520.2612 (b) amended .................................. 8873

520.2612 Removed .................................. 34729

522.82 (b) amended ........................... 8873

522.147 Added ................................... 48830

522.281 Removed .................................. 34729

522.313 (d)(3)(ii) revised; (d)(4) and (5) redesignated as (d)(5) and (6); new (d)(4) added .................. 35130

522.314 Added ................................... 29479

522.740 Removed .................................. 34729

522.770 Added ................................... 35321

522.784 (b) amended .................................. 8873

593
### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Chapter I—Continued</th>
<th>61 FR Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>522.842 (b) amended..................................</td>
<td>5506</td>
</tr>
<tr>
<td>522.863 (b) amended..................................</td>
<td>8873</td>
</tr>
<tr>
<td>522.889 (c) amended..................................</td>
<td>260</td>
</tr>
<tr>
<td>522.914 (b) amended..................................</td>
<td>5506</td>
</tr>
<tr>
<td>522.955 Added.........................................</td>
<td>42983</td>
</tr>
<tr>
<td>522.960a (c) amended..................................</td>
<td>5506</td>
</tr>
<tr>
<td>522.960b (c) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>522.960c (b) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>522.1004 Added.........................................</td>
<td>68147</td>
</tr>
<tr>
<td>522.1044 (b), (d)(2)(i) and (3)(i) revised..............</td>
<td>24441</td>
</tr>
<tr>
<td>522.1055 (b) amended..................................</td>
<td>19872</td>
</tr>
<tr>
<td>522.1078 (b) amended..................................</td>
<td>37682</td>
</tr>
<tr>
<td>522.1145 (a)(2) amended................................</td>
<td>59003</td>
</tr>
<tr>
<td>522.1155 (b) amended..................................</td>
<td>8873</td>
</tr>
<tr>
<td>522.1182 (a)(4)(i) amended................................</td>
<td>18972</td>
</tr>
<tr>
<td>522.1290 (b) amended..................................</td>
<td>65892</td>
</tr>
<tr>
<td>522.1335 Added.........................................</td>
<td>21075</td>
</tr>
<tr>
<td>522.1468 (b) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>522.1660 (b), (c)(1)(iii) and (2)(iii) amended........</td>
<td>31028, 36281</td>
</tr>
<tr>
<td>522.1720 (b)(1) amended................................</td>
<td>8873</td>
</tr>
<tr>
<td>(b)(1) and (2) revised................................</td>
<td>54339</td>
</tr>
<tr>
<td>522.1850 (c)(1)(i) revised; (c)(2)(i) and (i) amended</td>
<td>54339</td>
</tr>
<tr>
<td>522.1940 (b) and (d)(1)(i) amended.......................</td>
<td>5507</td>
</tr>
<tr>
<td>522.2002 (c) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>522.2005 Added.........................................</td>
<td>66582</td>
</tr>
<tr>
<td>522.2012 (b) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>522.2022 Removed......................................</td>
<td>34729</td>
</tr>
<tr>
<td>522.2120 (b) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>(b) revised; (d)(4) amended................................</td>
<td>31028</td>
</tr>
<tr>
<td>522.2220 (a)(2)(i) amended................................</td>
<td>4875</td>
</tr>
<tr>
<td>522.2474 Added.........................................</td>
<td>25786</td>
</tr>
<tr>
<td>522.2477 (c)(3) added..................................</td>
<td>29480</td>
</tr>
<tr>
<td>(c)(3) heading and (iii) revised........................</td>
<td>41499</td>
</tr>
<tr>
<td>522.2478 Added.........................................</td>
<td>14482</td>
</tr>
<tr>
<td>(a) amended...........................................</td>
<td>29479</td>
</tr>
<tr>
<td>522.2480 Removed......................................</td>
<td>34729</td>
</tr>
<tr>
<td>522.2610 (a)(2) and (b)(2) amended.......................</td>
<td>5507, 8873</td>
</tr>
<tr>
<td>522.2615 (b) amended; (d) removed........................</td>
<td>29480</td>
</tr>
<tr>
<td>522.2662 (b) amended..................................</td>
<td>46548</td>
</tr>
<tr>
<td>524.154 (a)(2) amended................................</td>
<td>8873</td>
</tr>
<tr>
<td>524.155 (a)(1) amended................................</td>
<td>8873</td>
</tr>
<tr>
<td>524.660a (b) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>524.960 (b) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>524.981d (b) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>524.1044b (b) amended..................................</td>
<td>48624</td>
</tr>
<tr>
<td>524.1484e (b) amended..................................</td>
<td>5507</td>
</tr>
<tr>
<td>524.1669a (b) amended................................</td>
<td>69712</td>
</tr>
<tr>
<td>529.810 Removed........................................</td>
<td>34729</td>
</tr>
</tbody>
</table>

### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Chapter I—Continued</th>
<th>61 FR Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>529.810 Removed........................................</td>
<td>34729</td>
</tr>
<tr>
<td>530 Added...............................................</td>
<td>57743</td>
</tr>
<tr>
<td>556.113 Amended.......................................</td>
<td>66583</td>
</tr>
<tr>
<td>556.150 Revised........................................</td>
<td>67453</td>
</tr>
<tr>
<td>556.225 Added...........................................</td>
<td>53221</td>
</tr>
<tr>
<td>556.226 Added...........................................</td>
<td>56893</td>
</tr>
<tr>
<td>556.275 (c) added.......................................</td>
<td>29478</td>
</tr>
<tr>
<td>556.283 Added...........................................</td>
<td>42383</td>
</tr>
<tr>
<td>556.300 (a) amended....................................</td>
<td>24441</td>
</tr>
<tr>
<td>556.430 Revised........................................</td>
<td>31399</td>
</tr>
<tr>
<td>556.500 Revised........................................</td>
<td>67453</td>
</tr>
<tr>
<td>556.600 Revised........................................</td>
<td>31028</td>
</tr>
<tr>
<td>556.685 Added...........................................</td>
<td>24443</td>
</tr>
<tr>
<td>556.720 Revised........................................</td>
<td>67453</td>
</tr>
<tr>
<td>556.735 Revised........................................</td>
<td>68148</td>
</tr>
<tr>
<td>558.4 (d) table amended................................</td>
<td>68148</td>
</tr>
<tr>
<td>558.15 (g)(1) table amended.............................</td>
<td>51589</td>
</tr>
<tr>
<td>558.55 (d)(2) table amended.............................</td>
<td>515, 35950</td>
</tr>
<tr>
<td>558.58 (d)(1) table amended.............................</td>
<td>4875, 18082</td>
</tr>
<tr>
<td>558.76 (d)(3)(xiv) added................................</td>
<td>43451</td>
</tr>
<tr>
<td>558.77 (a)(2), (d)(1) table and (2)(ii) amended.........</td>
<td>18082</td>
</tr>
<tr>
<td>558.85 (b)(3)(iv)(b) amended............................</td>
<td>515</td>
</tr>
<tr>
<td>(b)(1)xiii(b) amended...................................</td>
<td>18082</td>
</tr>
<tr>
<td>(b)(1)xi(b) amended....................................</td>
<td>43655</td>
</tr>
<tr>
<td>(b)(4)(iii) added......................................</td>
<td>43655</td>
</tr>
<tr>
<td>558.120 (a)(1) and (2) amended...........................</td>
<td>515</td>
</tr>
<tr>
<td>(c)(1)(ii)(b) amended..................................</td>
<td>18082</td>
</tr>
<tr>
<td>558.128 (a) amended....................................</td>
<td>18082</td>
</tr>
<tr>
<td>(a), (b) and (c)(1) revised; (c)(2) and (3) removed; (c)(4) and (5) redesigned as (c)(2) and (3).......</td>
<td>35952</td>
</tr>
<tr>
<td>558.140 Added...........................................</td>
<td>35954</td>
</tr>
<tr>
<td>558.145 (a)(1) and (2) amended...........................</td>
<td>18082</td>
</tr>
<tr>
<td>558.155 Heading, (d)(2) and (3) revised..................</td>
<td>2415</td>
</tr>
<tr>
<td>558.175 (c)(2)(ii) revised................................</td>
<td>35954</td>
</tr>
<tr>
<td>558.185 (a)(1) removed..................................</td>
<td>34729</td>
</tr>
<tr>
<td>558.185 (d) table amended...............................</td>
<td>35954</td>
</tr>
<tr>
<td>558.258 (c)(2) introductory text and (3) introductory text revised; (c)(2)(iii) and (3)(iii) amended.........</td>
<td>29478</td>
</tr>
<tr>
<td>558.265 (c)(2)(ii) added................................</td>
<td>21076</td>
</tr>
<tr>
<td>(c)(2)(iii) added......................................</td>
<td>32694</td>
</tr>
<tr>
<td>558.274 (c)(1) table amended............................</td>
<td>35955</td>
</tr>
<tr>
<td>558.300 (a) revised; (c)(2) through (5) added...........</td>
<td>32652</td>
</tr>
<tr>
<td>558.311 (b)(7)(iii) and (e)(1) table corrected ..........</td>
<td>4349</td>
</tr>
<tr>
<td>(b)(2) amended........................................</td>
<td>4875</td>
</tr>
<tr>
<td>558.325 (c)(4)(iii) added................................</td>
<td>32653</td>
</tr>
<tr>
<td>558.340 (a) amended....................................</td>
<td>18082</td>
</tr>
</tbody>
</table>

---

594
### List of CFR Sections Affected

#### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.355</td>
<td>4875</td>
</tr>
<tr>
<td>(b)(5) amended</td>
<td>4875</td>
</tr>
<tr>
<td>(b)(8), (9), (f)(1)(iv)(b), (v)(b), (xiv)(b), (xv)(b), (xvi)(b) amended; (b)(10) added</td>
<td>18082</td>
</tr>
<tr>
<td>(f)(3)(ii)(b) and (v)(b) amended</td>
<td>24444</td>
</tr>
<tr>
<td>(f)(3)(x)(c) amended</td>
<td>51003</td>
</tr>
<tr>
<td>558.366</td>
<td>1832</td>
</tr>
<tr>
<td>(a) revised; (c) table amended</td>
<td>1832</td>
</tr>
<tr>
<td>(c) table amended</td>
<td>14021, 14483</td>
</tr>
<tr>
<td>558.367</td>
<td>34729</td>
</tr>
<tr>
<td>Removed</td>
<td>34729</td>
</tr>
<tr>
<td>558.440</td>
<td>35075</td>
</tr>
<tr>
<td>Revised</td>
<td>35075</td>
</tr>
<tr>
<td>558.445</td>
<td>40933</td>
</tr>
<tr>
<td>Revised</td>
<td>40933</td>
</tr>
<tr>
<td>558.485</td>
<td>35075</td>
</tr>
<tr>
<td>(a)(16) removed</td>
<td>35075</td>
</tr>
<tr>
<td>558.495</td>
<td>63270</td>
</tr>
<tr>
<td>(a) amended</td>
<td>63270</td>
</tr>
<tr>
<td>558.515</td>
<td>51590</td>
</tr>
<tr>
<td>(a), (d)(1)(iii)(A) through (D)</td>
<td>51590</td>
</tr>
<tr>
<td>(a)(2) and new (3) added; new (d)(4) revised; new (d)(2) and new (3) added; new (d)(6)(i)(a) through (d) redesignated as (d)(6)(i)(A) through (B)</td>
<td>35956</td>
</tr>
<tr>
<td>(d)(5)(xxiv) amended</td>
<td>35956</td>
</tr>
<tr>
<td>558.550</td>
<td>18082</td>
</tr>
<tr>
<td>(b)(1)(vii)(c), (ix)(c), (xv)(c) and (xvi)(c) amended</td>
<td>18082</td>
</tr>
<tr>
<td>558.555</td>
<td>24181</td>
</tr>
<tr>
<td>(b)(2)(ii) amended</td>
<td>24181</td>
</tr>
<tr>
<td>(b)(3) added</td>
<td>66584</td>
</tr>
<tr>
<td>558.556</td>
<td>34729</td>
</tr>
<tr>
<td>Removed</td>
<td>34729</td>
</tr>
<tr>
<td>558.582</td>
<td>18082</td>
</tr>
<tr>
<td>(a) amended</td>
<td>18082</td>
</tr>
<tr>
<td>558.618</td>
<td>68148</td>
</tr>
<tr>
<td>Added</td>
<td>68148</td>
</tr>
<tr>
<td>558.625</td>
<td>4875</td>
</tr>
<tr>
<td>(b)(25) amended</td>
<td>4875</td>
</tr>
<tr>
<td>(b)(79) amended</td>
<td>17566</td>
</tr>
<tr>
<td>(b)(72) removed</td>
<td>17566</td>
</tr>
<tr>
<td>(b)(76) removed</td>
<td>17566</td>
</tr>
<tr>
<td>(f)(1)(vi)(e) added</td>
<td>67713</td>
</tr>
<tr>
<td>558.630</td>
<td>34729</td>
</tr>
<tr>
<td>(b)(10) amended</td>
<td>34729</td>
</tr>
<tr>
<td>558.635</td>
<td>30133</td>
</tr>
<tr>
<td>(b)(1) amended</td>
<td>30133</td>
</tr>
<tr>
<td>558.680</td>
<td>35957</td>
</tr>
<tr>
<td>(c)(1) table amended</td>
<td>35957</td>
</tr>
<tr>
<td>550.692</td>
<td>37682</td>
</tr>
<tr>
<td>550.724</td>
<td>37682</td>
</tr>
<tr>
<td>550.730</td>
<td>37682</td>
</tr>
<tr>
<td>(a) introductory text, (1), (2), (b), (c) introductory text, (1)(and) (2) redesignated as (a)(1) introductory text, (1), (ii), (2), (3) introductory text, (1) and (1); new (b) added</td>
<td>15704</td>
</tr>
<tr>
<td>558.625</td>
<td>5</td>
</tr>
<tr>
<td>558.670</td>
<td>5</td>
</tr>
<tr>
<td>Added</td>
<td>5</td>
</tr>
<tr>
<td>558.700</td>
<td>11547</td>
</tr>
<tr>
<td>Added</td>
<td>11547</td>
</tr>
<tr>
<td>558.780</td>
<td>18644</td>
</tr>
<tr>
<td>(b) revised</td>
<td>18644</td>
</tr>
<tr>
<td>558.830</td>
<td>45483</td>
</tr>
<tr>
<td>Added</td>
<td>45483</td>
</tr>
<tr>
<td>558.1001</td>
<td>19544</td>
</tr>
<tr>
<td>Added</td>
<td>19544</td>
</tr>
<tr>
<td>558.1002</td>
<td>19544</td>
</tr>
<tr>
<td>Added</td>
<td>19544</td>
</tr>
<tr>
<td>558.1003</td>
<td>19544</td>
</tr>
<tr>
<td>Added</td>
<td>19544</td>
</tr>
</tbody>
</table>

---

### 21 CFR

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 Authority citation revised</td>
<td>51518</td>
</tr>
<tr>
<td>500.80 (b) amended</td>
<td>66983</td>
</tr>
<tr>
<td>501 Authority citation revised</td>
<td>51518</td>
</tr>
<tr>
<td>502 Authority citation revised</td>
<td>51518</td>
</tr>
<tr>
<td>509 Authority citation revised</td>
<td>51518</td>
</tr>
<tr>
<td>510 Technical correction</td>
<td>23534</td>
</tr>
<tr>
<td>Authority citation revised</td>
<td>51518</td>
</tr>
<tr>
<td>510.351 (c) table corrected; CFR correction</td>
<td>52659</td>
</tr>
<tr>
<td>510.600 (c)(1) table and (2) table amended 7274, 22887, 27691, 29010, 34631, 35075, 38906, 39442, 40931, 48939, 55159, 60781, 61624, 61626, 62241, 63270</td>
<td>14300</td>
</tr>
<tr>
<td>(c)(1) table and (2) table amended; eff. 4–7–97</td>
<td>14300</td>
</tr>
<tr>
<td>Regulation at 62 FR 14300 eff. date corrected to 4–7–97</td>
<td>15751</td>
</tr>
<tr>
<td>511 Technical correction</td>
<td>47760</td>
</tr>
<tr>
<td>Authority citation revised</td>
<td>51518</td>
</tr>
<tr>
<td>511.1 (b)(10) revised</td>
<td>40599</td>
</tr>
<tr>
<td>514 Technical correction</td>
<td>47760</td>
</tr>
<tr>
<td>Authority citation revised</td>
<td>51518</td>
</tr>
<tr>
<td>514.1 (b)(14) revised</td>
<td>40599</td>
</tr>
<tr>
<td>514.8 (a)(1) amended</td>
<td>40600</td>
</tr>
<tr>
<td>514.110 (b)(10) revised</td>
<td>40600</td>
</tr>
<tr>
<td>514.111 (a)(9) revised</td>
<td>40600</td>
</tr>
<tr>
<td>520 Technical correction</td>
<td>35707</td>
</tr>
<tr>
<td>Authority citation revised</td>
<td>51518</td>
</tr>
<tr>
<td>520.23 (a)(2) amended</td>
<td>35075</td>
</tr>
<tr>
<td>520.82a (b) amended</td>
<td>61624</td>
</tr>
<tr>
<td>520.82b (b) amended</td>
<td>61624</td>
</tr>
<tr>
<td>520.88b (c) amended</td>
<td>13302</td>
</tr>
<tr>
<td>520.88d (d) heading and (2) revised; (d)(3) amended</td>
<td>5525</td>
</tr>
<tr>
<td>520.88e (d) heading and (2) revised; (d)(3) amended</td>
<td>5526</td>
</tr>
<tr>
<td>520.88f (b) amended</td>
<td>13302</td>
</tr>
<tr>
<td>520.100a (b) amended</td>
<td>63270</td>
</tr>
<tr>
<td>520.100b (b) amended</td>
<td>63270</td>
</tr>
<tr>
<td>520.100c (b) amended</td>
<td>63270</td>
</tr>
<tr>
<td>520.222 (c) amended</td>
<td>61624</td>
</tr>
<tr>
<td>520.300a (b) amended</td>
<td>63270</td>
</tr>
<tr>
<td>520.300b (b) amended</td>
<td>63270</td>
</tr>
<tr>
<td>520.300c (b) amended</td>
<td>63270</td>
</tr>
<tr>
<td>520.390a (a)(2) amended</td>
<td>35076</td>
</tr>
<tr>
<td>520.420 (a)(2) amended</td>
<td>62270</td>
</tr>
<tr>
<td>520.445b (b) amended; 27681, 35076, 60666</td>
<td>46699</td>
</tr>
<tr>
<td>520.447 (b) revised</td>
<td>46699</td>
</tr>
<tr>
<td>520.462 (b) amended</td>
<td>63270</td>
</tr>
<tr>
<td>520.580 (b)(2) amended</td>
<td>35076, 61624</td>
</tr>
<tr>
<td>520.600 (c) amended</td>
<td>35076</td>
</tr>
<tr>
<td>520.622a (a)(6) amended</td>
<td>35076</td>
</tr>
<tr>
<td>520.622b (c)(2) amended</td>
<td>35076</td>
</tr>
<tr>
<td>(a)(2) amended</td>
<td>38906</td>
</tr>
</tbody>
</table>
21 CFR—Continued

Chapter I—Continued

520.2043 (b)(2) revised....................37712
520.2042b (b)(3) amended..................35076
520.2042c (b) amended ....................61625
520.2042a (c)(2) amended................63271
520.2039d (a)(1) amended; (c) re-
vised..............................39443
520.2039c (b) amended.......................61625
520.2039b (c) amended.....................63271
520.2039a (c)(2) amended................63271
520.2038f (b) amended ....................63271
520.2038d (b) amended....................63271
520.2038c (b) amended....................63271
520.2038b (c) redesignated as (d); new
(b)(2) added..........................36997
520.2038a (b) amended......................61625
520.2037 (b) amended ......................61625
520.2036c (b) amended.......................61625
520.2036b (b) amended......................61625
520.2036a (b) amended......................61625
520.2036 (b) amended ....................61625
520.2035 (b) amended ......................61625
520.2034f (b) amended ....................63271
520.2034d (b) amended....................63271
520.2034c (c) amended....................63271
520.2034b (c) amended.....................63271
520.2034a (c)(2) amended................63271
520.2033b (b) amended......................61625
520.2033a (a)(4) added.....................37712
520.2033 (a)(4) added.......................37712
520.2032 (d) heading revised; (d)(1)
and (h)(1) amended ....................35076
520.2031b (b)(1) amended..................35076
520.2031a (b) amended......................61625
520.2031 (b) amended ....................61625
520.2020 (b)(2) revised....................37712
520.2019b (b) amended......................61625
520.2019a (b) amended......................35076
520.2019 (a)(8) and (b)(6) added ......23356
520.2018b (c)(2) amended ..................35076
520.2018a (b) amended......................61625
520.2018 (b) amended ....................61625
520.2015b (b) amended......................61625
520.2015a (b) amended......................61625
520.2015 (b) amended ....................61625
520.2014b (c) amended ....................61625
520.2014a (c)(2) amended................61625
520.2014 (c)(2) amended ..................61625
520.2013b (b) amended......................61625
520.2013a (b) amended......................61625
520.2013 (b) amended ....................61625
520.2012b (c) redesigned as (d); new
(b)(2) added..........................36997
520.2012a (b) amended......................61625
520.2012 (b) amended ....................61625
520.2011c (b) added .........................61625
520.2011a (b) amended......................61625
520.2011 (b)(1) and (3) revised ........14301
520.2010b (c)(3) amended ..................55160
520.2010a (b) amended......................61625
520.2010 (b) amended ....................61625
520.2009b (b) amended......................61625
520.2009 (b) amended ....................61625
520.2008 (b)(2) revised....................37712
520.2007a (b) amended......................61625
520.2007 (b) amended ....................61625
520.2006b (b) amended......................61625
520.2006a (b) amended......................61625
520.2006 (b) amended ....................61625
520.2005b (b) amended......................61625
520.2005a (b) amended......................61625
520.2005 (b) amended ....................61625
520.2004b (c)(2) amended .................37712
520.2004a (c)(4) amended ................46408
520.2004 (c)(4) amended ..................46408
520.2003b (b) added .........................61625
520.2003a (b) added .........................61625
520.2003 (b) added .........................61625
520.2002 (b) amended ......................61625
520.2001b (b) amended......................61625
520.2001a (b) amended......................61625
520.2001 (b) amended ....................61625
<table>
<thead>
<tr>
<th>CFR Chapter</th>
<th>Page</th>
<th>CFR Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>522.1182</td>
<td>62 FR</td>
<td>Chapter I—Continued</td>
</tr>
<tr>
<td>21</td>
<td>522.1183 (e)(1)</td>
<td>35076</td>
<td>524.981b (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1192 (d)(2)(ii)</td>
<td>35076</td>
<td>524.981c (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1192 (b) amended</td>
<td>14634</td>
<td>524.1044f (b) revised</td>
</tr>
<tr>
<td>21</td>
<td>522.1193 (d)(2)</td>
<td>63271</td>
<td>524.1193 (d)(2) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1193 (b) amended</td>
<td>14302</td>
<td>(b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1222a (c) amended</td>
<td>22888</td>
<td>524.1240 (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1244 (b) amended</td>
<td>61625</td>
<td>524.1443 (b) revised</td>
</tr>
<tr>
<td>21</td>
<td>522.1410 (b) amended</td>
<td>35076</td>
<td>(b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1452 (b) amended</td>
<td>62371</td>
<td>524.1484g (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1465 Added</td>
<td>55161</td>
<td>524.1490b (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1503 (b) amended</td>
<td>61625</td>
<td>524.1498c (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1503 (b) amended</td>
<td>61625</td>
<td>524.1742 (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1660 (c)(1)(iii) corrected</td>
<td>13825</td>
<td>524.1883 (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1662a (g)(3)(i) revised</td>
<td>14303</td>
<td>524.1885 (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>(a)(2), (g)(2) and (b)(2) amended</td>
<td>35076</td>
<td>524 Authority citation revised</td>
</tr>
<tr>
<td>21</td>
<td>522.1680 (b) amended</td>
<td>35076, 38906</td>
<td>529 Authority citation revised</td>
</tr>
<tr>
<td>21</td>
<td>522.1704 (a)(2) amended</td>
<td>61625</td>
<td>529.50 (c)(2) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1720 (b)(2) amended</td>
<td>36906</td>
<td>(b) amended</td>
</tr>
<tr>
<td>21</td>
<td>(b)(1) amended</td>
<td>61625</td>
<td>529.1044a (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1850 (d) added</td>
<td>45158</td>
<td>529.1044b (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1885 (b) amended</td>
<td>63271</td>
<td>529.1115 (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.1940 (d)(1)(iii) amended</td>
<td>63271</td>
<td>529.2090 (a)(1) amended</td>
</tr>
<tr>
<td>21</td>
<td>(d)(2)(iv) removed</td>
<td>8372</td>
<td>530 Authority citation revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2065 (b) amended</td>
<td>61625</td>
<td>530.41 Revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2065 (d) revised</td>
<td>10220</td>
<td>556 Authority citation revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2220 (a)(2)(iii) added</td>
<td>23128</td>
<td>556.52 Revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2222 (c) amended</td>
<td>23128</td>
<td>556.225 Revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2222 (c) amended</td>
<td>23128</td>
<td>556.227 Added</td>
</tr>
<tr>
<td>21</td>
<td>522.2222 (c) amended</td>
<td>23128</td>
<td>556.273 Added</td>
</tr>
<tr>
<td>21</td>
<td>522.2222 (c) amended</td>
<td>23128</td>
<td>556.735 Corrected</td>
</tr>
<tr>
<td>21</td>
<td>522.2222 (c) amended</td>
<td>23128</td>
<td>556.740 Revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2222 (c) amended</td>
<td>23128</td>
<td>556.741 Added</td>
</tr>
<tr>
<td>21</td>
<td>522.2222 (c) amended</td>
<td>23128</td>
<td>558 Technical correction</td>
</tr>
<tr>
<td>21</td>
<td>522.2242 (b) amended</td>
<td>35076</td>
<td>529.1115 (b) amended</td>
</tr>
<tr>
<td>21</td>
<td>522.2242 (b) amended</td>
<td>35076</td>
<td>530 Authority citation revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2247 (d)(1)(ii) revised</td>
<td>35076</td>
<td>530.41 Revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2247 (d)(1)(ii) amended</td>
<td>5526</td>
<td>556 Authority citation revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2247 (a) revised</td>
<td>29014</td>
<td>556.52 Revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2248 (b) amended</td>
<td>29014</td>
<td>556.225 Revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2248 (b) amended</td>
<td>35076</td>
<td>556.227 Added</td>
</tr>
<tr>
<td>21</td>
<td>522.2610 (b)(2) corrected; CFR correction</td>
<td>41272</td>
<td>556.273 Added</td>
</tr>
<tr>
<td>21</td>
<td>(a)(2) amended</td>
<td>61625</td>
<td>556.735 Corrected</td>
</tr>
<tr>
<td>21</td>
<td>522.2615 (c) redesignated as (d); new (c) added; new (d)(3) revised</td>
<td>61625</td>
<td>556.740 Revised</td>
</tr>
<tr>
<td>21</td>
<td>522.2640a (b)(2) amended</td>
<td>35077</td>
<td>556.741 Added</td>
</tr>
<tr>
<td>21</td>
<td>522.2662 (b) amended</td>
<td>35077</td>
<td>568.4 (d) table amended</td>
</tr>
<tr>
<td>21</td>
<td>522.2660 (b) amended</td>
<td>61625</td>
<td>568.55 (a) amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>568.58 (d)(1)(ii) table amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>(d)(1) table amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>558.76 (d)(1)(iv) table amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>(d)(1) table amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>558.78 (a) revised; (d)(1) table amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>558.95 (b) redesignated as (d); (a)(5) and new (b) added;</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>(d)(4)(i)(b) amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>(d)(1)(ii)(b), (iii)(b), (iv)(b), (v)(b) and (3)(iii)(b) amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>558.120 (c) redesignated as (d); new (d)(1)(ii)(b) amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>558.128 (c)(3)(xiii) added</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>(c)(3)(xiv) added</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>(c) redesignated as (d); new (d)(1)(vi), new (xii) and new (xvii) amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>(a)(4) and (d)(1) table amended</td>
</tr>
<tr>
<td>21</td>
<td>524 Authority citation revised</td>
<td>51518</td>
<td>(d)(1) table and (2) amended</td>
</tr>
</tbody>
</table>

597
## List of CFR Sections Affected

### 21 CFR—Continued

<table>
<thead>
<tr>
<th>CFR Section</th>
<th>Action</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>520.1454</td>
<td>(a) amended; (d)(4) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.1447</td>
<td>(b) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.1404</td>
<td>(a) added; (b) and new (d) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.1446</td>
<td>(d)(1)(ii) added</td>
<td>24107</td>
</tr>
<tr>
<td>520.1445</td>
<td>(c) and (d) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.1445(b)</td>
<td>Removed</td>
<td>24107</td>
</tr>
<tr>
<td>520.1484</td>
<td>(b) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.1485</td>
<td>(d)(3) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.1660c</td>
<td>(a) and (b) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.1660d</td>
<td>(a)(3) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.1720a</td>
<td>(b)(3) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.1806</td>
<td>(b) amended</td>
<td>24107</td>
</tr>
<tr>
<td>520.1880</td>
<td>(a) amended</td>
<td>24107</td>
</tr>
<tr>
<td>520.1805</td>
<td>(b) amended</td>
<td>24107</td>
</tr>
<tr>
<td>520.1940</td>
<td>(d)(3) revised</td>
<td>24107</td>
</tr>
<tr>
<td>520.2045</td>
<td>(b) amended</td>
<td>24107</td>
</tr>
<tr>
<td>520.2098</td>
<td>(b) amended</td>
<td>24107</td>
</tr>
<tr>
<td>520.2158a</td>
<td>(b) amended</td>
<td>24107</td>
</tr>
<tr>
<td>520.2220a</td>
<td>(b) revised; (b) removed; (c), (d) and (e) redesignated as (b), (c) and (d)</td>
<td>24107</td>
</tr>
</tbody>
</table>

### 21 CFR—Continued

<table>
<thead>
<tr>
<th>CFR Section</th>
<th>Action</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>520.2345a</td>
<td>(b)(4) removed</td>
<td>24107</td>
</tr>
<tr>
<td>522.84</td>
<td>Added</td>
<td>24107</td>
</tr>
<tr>
<td>522.90b</td>
<td>(b) revised</td>
<td>24107</td>
</tr>
<tr>
<td>522.246</td>
<td>(b) revised</td>
<td>24107</td>
</tr>
<tr>
<td>522.314</td>
<td>(d)(2) added</td>
<td>24107</td>
</tr>
<tr>
<td>522.468</td>
<td>Added</td>
<td>24107</td>
</tr>
<tr>
<td>522.533</td>
<td>Added</td>
<td>24107</td>
</tr>
<tr>
<td>522.535</td>
<td>Added</td>
<td>24107</td>
</tr>
<tr>
<td>Section</td>
<td>Action</td>
<td>Date</td>
</tr>
<tr>
<td>---------</td>
<td>--------</td>
<td>------------</td>
</tr>
<tr>
<td>558.175</td>
<td>(d)(1)(iii)(b) and (iv)(b)</td>
<td>amended</td>
</tr>
<tr>
<td>558.195</td>
<td>(d) table amended</td>
<td>...</td>
</tr>
<tr>
<td>558.274</td>
<td>(a)(6) removed; (o)(1)(b)(iv)(c) table amended</td>
<td>...</td>
</tr>
<tr>
<td>558.300</td>
<td>(c) redesignated as (d); new (d) introductory text added; new (d)(1) revised</td>
<td>...</td>
</tr>
<tr>
<td>558.305</td>
<td>(a) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.311</td>
<td>(e)(1)(ii) table amended</td>
<td>...</td>
</tr>
<tr>
<td>558.325</td>
<td>(c)(3)(xii) revised</td>
<td>...</td>
</tr>
<tr>
<td>558.340</td>
<td>(a) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.342</td>
<td>(d)(3)(ii) and (6)(ii) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.355</td>
<td>(c) removed</td>
<td>...</td>
</tr>
<tr>
<td>558.363</td>
<td>(a) revised; (c) redesignated as (d); new (d)(1)(vii) added</td>
<td>...</td>
</tr>
<tr>
<td>558.366</td>
<td>(c) table amended</td>
<td>...</td>
</tr>
<tr>
<td>558.369</td>
<td>(d)(i) revised</td>
<td>...</td>
</tr>
<tr>
<td>558.374</td>
<td>(b)(ii) added</td>
<td>...</td>
</tr>
<tr>
<td>558.375</td>
<td>(b)(11) and (f)(1)(xv)(b) added</td>
<td>...</td>
</tr>
<tr>
<td>558.380</td>
<td>(c) removed</td>
<td>...</td>
</tr>
<tr>
<td>558.385</td>
<td>(a) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.395</td>
<td>(b)(8), (9), (f)(1)(iv)(b), (v)(b), (xiv)(b), (xv)(b) and (xvi)(b) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.400</td>
<td>(f)(2)(iii) added</td>
<td>...</td>
</tr>
<tr>
<td>558.405</td>
<td>(b)(ii) added</td>
<td>...</td>
</tr>
<tr>
<td>558.410</td>
<td>(a)(6), (d)(1)(viii) and (ix) added</td>
<td>...</td>
</tr>
<tr>
<td>558.415</td>
<td>(d)(2) revised</td>
<td>...</td>
</tr>
<tr>
<td>558.420</td>
<td>(c) table amended</td>
<td>...</td>
</tr>
<tr>
<td>558.425</td>
<td>(c) removed; (d) introductory text revised; (d)(1), (2) and (3) redesignated as (d)(1)(i), (ii) and (iii); (d)(1) heading and (2) added</td>
<td>...</td>
</tr>
<tr>
<td>558.430</td>
<td>(d)(3)(iii) added</td>
<td>...</td>
</tr>
<tr>
<td>558.435</td>
<td>(b) and (c) redesignated as (c) and (d); new (b) added; (d)(1) table revised</td>
<td>...</td>
</tr>
<tr>
<td>558.440</td>
<td>(a)(21) and (25) removed</td>
<td>...</td>
</tr>
<tr>
<td>558.445</td>
<td>(d)(1)(iv)(b) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.450</td>
<td>(a) and (d)(1)(vii)(b) added</td>
<td>...</td>
</tr>
<tr>
<td>558.455</td>
<td>(c) removed; (d)(5)(x) revised</td>
<td>...</td>
</tr>
<tr>
<td>558.460</td>
<td>(a)(1) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.465</td>
<td>(a)(1)(vii)(c), (lx)(c), (xv)(c) and (xvi)(c) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.470</td>
<td>(a) revised; (d)(1)(xv)(c) added</td>
<td>...</td>
</tr>
<tr>
<td>558.475</td>
<td>(a)(3) revised</td>
<td>...</td>
</tr>
<tr>
<td>558.480</td>
<td>(a)(1) and (2) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.485</td>
<td>(a)(1) and (2) amended</td>
<td>...</td>
</tr>
<tr>
<td>558.490</td>
<td>(a)(1) and (2) amended</td>
<td>...</td>
</tr>
</tbody>
</table>
### 21 CFR—Continued

#### Chapter I—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>522.2005</td>
<td>(b) revised; (c)(2) added</td>
</tr>
<tr>
<td>522.2100</td>
<td>(a)(1), (b)(1), (c)(1), (d)(1) and (e)(1) amended</td>
</tr>
<tr>
<td>522.2476</td>
<td>(b) amended; (a)(1) and (2) redesignated as (d)(1)(i)(A) and (2)(i)(A); (d)(1)(ii) and (2)(i)(ii); (d)(1)(iii) and (2)(i)(iii) added</td>
</tr>
<tr>
<td>522.2477</td>
<td>(a) amended; (a), (b) and (c) redesignated as (b), (c) and (d); new (d)(1)(i) redesignated as (d)(1)(i)(A); new (b) revised; (d)(1)(i)(B) added</td>
</tr>
<tr>
<td>522.2478</td>
<td>(c) redesignated as (d); new (d)(1)(i) revised</td>
</tr>
<tr>
<td>522.2680</td>
<td>(d)(3)(ii) amended</td>
</tr>
<tr>
<td>524 Effective date confirmation</td>
<td>26657</td>
</tr>
<tr>
<td>524.770</td>
<td>(d)(2) revised</td>
</tr>
<tr>
<td>524.1081</td>
<td>(a)(3) and (b)(3) redesignated as (a)(4) and (b)(4); (a)(2)(i), (ii), (iii) and new (b)(4)(iii) added; new (a)(3), (5) and new (b)(3) added; (a)(4) heading, (i) and (b)(4) heading revised; (a)(4) footnote removed</td>
</tr>
<tr>
<td>524.1200a</td>
<td>added</td>
</tr>
<tr>
<td>524.1204</td>
<td>(a)(1) removed; (a)(2)(i), (ii), (iii) and (3) redesignated as (a)(2)(i), (ii), (iii) and (2); eff. 5–20–99</td>
</tr>
</tbody>
</table>

---

### 21 CFR—Continued

#### Chapter I—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>522.1092</td>
<td>(d)(2) revised</td>
</tr>
<tr>
<td>522.1093</td>
<td>(d) and (2) amended</td>
</tr>
<tr>
<td>522.1094</td>
<td>(a) amended; eff. 5–20–99</td>
</tr>
<tr>
<td>522.1081</td>
<td>revised; eff. 5–20–99</td>
</tr>
<tr>
<td>522.1192</td>
<td>(d)(2) revised</td>
</tr>
<tr>
<td>522.1193</td>
<td>(d)(2)(ii) added</td>
</tr>
<tr>
<td>522.1194</td>
<td>(d)(2)(ii) and (2)(ii) added</td>
</tr>
<tr>
<td>522.1195</td>
<td>(e)(1) revised; (e)(1)(ii) and (e)(1)(iii) added</td>
</tr>
<tr>
<td>522.1196</td>
<td>(e)(1)(ii) and (e)(1)(iii) added</td>
</tr>
<tr>
<td>522.1197</td>
<td>(e)(1)(ii) and (e)(1)(iii) added</td>
</tr>
<tr>
<td>522.1204</td>
<td>(a) revised; eff. 5–20–99</td>
</tr>
<tr>
<td>522.1205</td>
<td>(b) revised; (c)(2) added</td>
</tr>
<tr>
<td>522.1206</td>
<td>(b) and (d)(2)(iii) amended</td>
</tr>
<tr>
<td>522.1207</td>
<td>(d)(1)(ii) revised</td>
</tr>
<tr>
<td>522.1208</td>
<td>(d)(1)(ii) amended</td>
</tr>
<tr>
<td>522.1209</td>
<td>(d)(1)(ii) revised</td>
</tr>
<tr>
<td>522.1210</td>
<td>(d)(1)(ii) amended</td>
</tr>
<tr>
<td>524.1200a</td>
<td>(a)(1) and (2) designation</td>
</tr>
<tr>
<td>524.1200b</td>
<td>(a)(1) revised; eff. 5–20–99</td>
</tr>
</tbody>
</table>

---

### 21 CFR—Continued

#### Chapter I—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>524 Effective date confirmation</td>
<td>26657</td>
</tr>
<tr>
<td>529.360</td>
<td>(a) amended; eff. 5–20–99</td>
</tr>
<tr>
<td>529.2150</td>
<td>Added</td>
</tr>
<tr>
<td>556.34</td>
<td>Revised</td>
</tr>
<tr>
<td>556.170</td>
<td>Revised</td>
</tr>
<tr>
<td>556.175</td>
<td>Added</td>
</tr>
<tr>
<td>556.304</td>
<td>Added</td>
</tr>
<tr>
<td>556.344</td>
<td>(b)(2)(ii) added</td>
</tr>
<tr>
<td>556.347</td>
<td>Revised</td>
</tr>
<tr>
<td>556.360</td>
<td>Revised</td>
</tr>
<tr>
<td>556.420</td>
<td>Revised</td>
</tr>
<tr>
<td>556.430</td>
<td>Revised</td>
</tr>
<tr>
<td>556.490</td>
<td>Revised</td>
</tr>
<tr>
<td>556.513</td>
<td>Added</td>
</tr>
<tr>
<td>556.597</td>
<td>Added</td>
</tr>
<tr>
<td>556.640</td>
<td>Revised</td>
</tr>
<tr>
<td>556.735</td>
<td>Revised</td>
</tr>
<tr>
<td>556.739</td>
<td>Revised</td>
</tr>
<tr>
<td>556.750</td>
<td>Revised</td>
</tr>
<tr>
<td>558.3</td>
<td>(b)(2) through (5) amended</td>
</tr>
<tr>
<td>558.4</td>
<td>Heading, (a), (b) and (c) revised</td>
</tr>
<tr>
<td>558.15</td>
<td>(g)(1) table and (2) table amended</td>
</tr>
<tr>
<td>558.76</td>
<td>(d)(3)(ix) added</td>
</tr>
<tr>
<td>558.78</td>
<td>(d)(3)(xii) added</td>
</tr>
<tr>
<td>558.85</td>
<td>(d)(1)(xiv) added</td>
</tr>
<tr>
<td>558.2150</td>
<td>Added</td>
</tr>
<tr>
<td>558.265</td>
<td>Revised</td>
</tr>
<tr>
<td>558.300</td>
<td>(d)(1)(ii), (2)(ii), (3)(ii), (4)(ii) and (5)(ii) amended; (d)(6) added</td>
</tr>
<tr>
<td>558.304</td>
<td>Added</td>
</tr>
<tr>
<td>558.311</td>
<td>(b)(4) revised</td>
</tr>
<tr>
<td>558.314</td>
<td>(a)(3) and (b)(3) redesignated as (a)(2)(i), (ii), (iii) and (2); eff. 5–20–99</td>
</tr>
</tbody>
</table>

---

### 21 CFR (4–1–02 Edition)
List of CFR Sections Affected

### 21 CFR—Continued

#### Chapter I—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Amendment Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.325</td>
<td>(c) redesignated as (d); (d)(2)(i)(b), (iii)(b) and (iv)(b) amended</td>
</tr>
<tr>
<td>556.355</td>
<td>(f)(3)(ii)(b) amended</td>
</tr>
<tr>
<td>558.485</td>
<td>(a)(17) removed</td>
</tr>
<tr>
<td>558.530</td>
<td>(d)(5)(xxv) added</td>
</tr>
<tr>
<td>558.555</td>
<td>(b) redesignated as (d); new (b), (c), (d)(5), (6) and (7) added; new (d) heading revised; new (d)(1) introductory text removed</td>
</tr>
<tr>
<td>558.575</td>
<td>(a) revised; (c) redesignated as (d); (d)(2)(ii)(a) amended</td>
</tr>
<tr>
<td>558.590</td>
<td>(a)(i) introductory text and (A) revised; (e)(2)(1)(B) amended</td>
</tr>
<tr>
<td>558.595</td>
<td>(b) added</td>
</tr>
<tr>
<td>558.618</td>
<td>(d)(3) amended</td>
</tr>
<tr>
<td>558.635</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>559.355</td>
<td>(f)(3)(ii)(b) and (f)(3)(ii)(a) added</td>
</tr>
<tr>
<td>559.366</td>
<td>(c) table amended</td>
</tr>
<tr>
<td>559.364</td>
<td>Added</td>
</tr>
<tr>
<td>559.363</td>
<td>(d)(2)(ii) added</td>
</tr>
<tr>
<td>510.300</td>
<td>(a)(4) amended</td>
</tr>
<tr>
<td>510.600</td>
<td>(c)(1) table and (2) table added</td>
</tr>
<tr>
<td>510.660</td>
<td>(c)(1) table and (2) table added</td>
</tr>
<tr>
<td>511.1</td>
<td>(d)(1)(i) added</td>
</tr>
<tr>
<td>511.2</td>
<td>(a)(4) amended</td>
</tr>
</tbody>
</table>
| 21 CFR—Continued

#### Chapter I—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Amendment Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>520.1192</td>
<td>(a) and (b) revised; (c) redesignated as (d); new (c) added</td>
</tr>
<tr>
<td>520.1263c</td>
<td>(b) amended</td>
</tr>
<tr>
<td>520.1390</td>
<td>Added</td>
</tr>
<tr>
<td>520.1485</td>
<td>(b) amended</td>
</tr>
<tr>
<td>520.1510</td>
<td>Added</td>
</tr>
<tr>
<td>520.1696d</td>
<td>(a)(2), (d)(1)(i)(A)(3), (B)(3), (C)(3), and (III)(C) amended</td>
</tr>
<tr>
<td>520.3090</td>
<td>(b) amended</td>
</tr>
<tr>
<td>520.460</td>
<td>(a)(2) and (b)(2) amended</td>
</tr>
<tr>
<td>520.540</td>
<td>(d)(2)(i) and (e)(2) amended</td>
</tr>
<tr>
<td>520.778</td>
<td>(b) amended</td>
</tr>
<tr>
<td>520.1044</td>
<td>(b)(4) amended</td>
</tr>
<tr>
<td>520.1125</td>
<td>(d)(1) and (2) amended</td>
</tr>
<tr>
<td>520.1183</td>
<td>(e)(1) amended</td>
</tr>
<tr>
<td>520.1222a</td>
<td>(c) amended</td>
</tr>
<tr>
<td>520.1244</td>
<td>(b) amended</td>
</tr>
<tr>
<td>520.1662a</td>
<td>(b)(2) amended</td>
</tr>
<tr>
<td>520.1680</td>
<td>(b) amended</td>
</tr>
<tr>
<td>520.2120</td>
<td>(b) amended</td>
</tr>
<tr>
<td>520.22477</td>
<td>(b) revised; (d)(1) heading amended; (d)(1)(i)(C) added</td>
</tr>
<tr>
<td>520.22477</td>
<td>(b) revised; (d)(1) heading amended; (d)(1)(i)(A), (B), (C), (ii), (2)(i), (ii) and (3)(i) revised</td>
</tr>
<tr>
<td>520.22477</td>
<td>(b) amended; (d)(1)(i)(D) added; (d)(2)(i) and (ii) revised</td>
</tr>
<tr>
<td>520.22477</td>
<td>(b) amended; (d)(3)(i) revised</td>
</tr>
<tr>
<td>520.22477</td>
<td>Added</td>
</tr>
<tr>
<td>520.1005</td>
<td>(b)(1) and (c)(3) revised; (c)(2)(iii) removed</td>
</tr>
<tr>
<td>520.1376</td>
<td>(c)(2) amended</td>
</tr>
<tr>
<td>520.1446</td>
<td>Added</td>
</tr>
<tr>
<td>520.1451</td>
<td>(d)(2) and (3) amended</td>
</tr>
<tr>
<td>520.2098</td>
<td>(d)(2) amended</td>
</tr>
<tr>
<td>520.2481</td>
<td>(b) amended</td>
</tr>
<tr>
<td>520.365</td>
<td>(d)(3) amended</td>
</tr>
<tr>
<td>526.1810</td>
<td>Heading and (d)(3) amended</td>
</tr>
<tr>
<td>556.70</td>
<td>Revised</td>
</tr>
<tr>
<td>556.275</td>
<td>Revised</td>
</tr>
<tr>
<td>556.1095</td>
<td>(b)(1)(i) and (3)(ii) added</td>
</tr>
<tr>
<td>556.1095</td>
<td>(b)(3) redesignated as (b)(4); new (b)(3) added</td>
</tr>
<tr>
<td>556.426</td>
<td>Revised</td>
</tr>
<tr>
<td>21 CFR—Continued</td>
<td>65 FR Page</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Chapter I—Continued</td>
<td></td>
</tr>
<tr>
<td>(b) revised ........................................................................................................... 76930</td>
<td></td>
</tr>
<tr>
<td>556.515 Revised ........................................................................................................ 61091</td>
<td></td>
</tr>
<tr>
<td>556.570 Added ............................................................................................................. 4112</td>
<td></td>
</tr>
<tr>
<td>556.592 Added ............................................................................................................. 70791</td>
<td></td>
</tr>
<tr>
<td>558.3 (b)(1)(ii) revised; (b)(6) through (11) added .............................................. 76929</td>
<td></td>
</tr>
<tr>
<td>558.4 (d) table amended ......................................................................................... 4112</td>
<td></td>
</tr>
<tr>
<td>558.6 Added .............................................................................................................. 76929</td>
<td></td>
</tr>
<tr>
<td>558.76 (d)(3)(xxii) added .................................................................................... 41589</td>
<td></td>
</tr>
<tr>
<td>(d)(3)v through (xvii) redesignated as (d)(3)(vi) through (xviii); new (d)(3)(v) added .... 50134</td>
<td></td>
</tr>
<tr>
<td>(d)(3)vii added ................................................................................................... 50915</td>
<td></td>
</tr>
<tr>
<td>(d)(1) table amended ........................................................................................... 54411</td>
<td></td>
</tr>
<tr>
<td>(d)(3)(xxi) added ............................................................................................... 11889</td>
<td></td>
</tr>
<tr>
<td>558.85 (d)(4)(ii) amended .................................................................................. 20734</td>
<td></td>
</tr>
<tr>
<td>(d)(5) introductory text and (i) through (iv) revised .................................... 50134</td>
<td></td>
</tr>
<tr>
<td>(d)(5)(iii) and (iv) redesignated as (d)(5)(iv) and (v); new (d)(5)(iii) added ........ 53582</td>
<td></td>
</tr>
<tr>
<td>(a)(4) amended .................................................................................................. 54148</td>
<td></td>
</tr>
<tr>
<td>558.128 (d)(1)(xxii) table amended ................................................................. 45882</td>
<td></td>
</tr>
<tr>
<td>558.195 (d) table amended .......... 66620, 82913</td>
<td></td>
</tr>
<tr>
<td>558.198 (d) revised ............................................................................................ 50134</td>
<td></td>
</tr>
<tr>
<td>558.258 (c) redesignated as (d); (d)(1)(vi) and (vii) added ................................ 41589</td>
<td></td>
</tr>
<tr>
<td>(d)(1) through (4) redesignated as (d)(2) through (5); new (d)(1) added ............ 50914</td>
<td></td>
</tr>
<tr>
<td>558.265 (c)(1)(viii) and (3)(ii) added .................................................................. 45712</td>
<td></td>
</tr>
<tr>
<td>558.355 (d)(6), (f)(3)(x)(a) and (c) revised ..................................................... 45880</td>
<td></td>
</tr>
<tr>
<td>(f)(1)(xxviii), (2)(v) and (vi) added ...................................................................... 53582</td>
<td></td>
</tr>
<tr>
<td>(f)(4)(ii) and (iii) redesignated as (f)(4)(i)(a) and (b); new (f)(4)(ii) and (iii) added ...... 53583</td>
<td></td>
</tr>
<tr>
<td>(f)(4)(iv) added .................................................................................................. 54412</td>
<td></td>
</tr>
<tr>
<td>(f)(7) added ....................................................................................................... 82913</td>
<td></td>
</tr>
<tr>
<td>55.363 (a)(7) and (d)(1)(x) added ........................................................................... 55894</td>
<td></td>
</tr>
<tr>
<td>(d)(1)(xi) added .................................................................................................. 65271</td>
<td></td>
</tr>
<tr>
<td>558.364 (d) table amended ................................................................................. 45881</td>
<td></td>
</tr>
<tr>
<td>558.366 (c) table amended .................................................................................. 11889</td>
<td></td>
</tr>
<tr>
<td>558.460 (b) amended .......................................................................................... 45880</td>
<td></td>
</tr>
<tr>
<td>558.485 (a)(29) added ....................................................................................... 66621</td>
<td></td>
</tr>
<tr>
<td>558.500 Added .................................................................................................... 4112</td>
<td></td>
</tr>
<tr>
<td>558.515 (c) and (d) revised .............................................................................. 50915</td>
<td></td>
</tr>
<tr>
<td>558.530 (a) and (d)(5) revised; (d)(6) removed .................................................. 45712</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>21 CFR—Continued</th>
<th>65 FR Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter I—Continued</td>
<td></td>
</tr>
<tr>
<td>558.550 (a)(2), (d)(1)(xv)(c) and (xvi)(c) amended; (a)(3) removed; (d)(3)(i), (ii), and (iii) redesignated as (d)(3)(i)(A), (B) and (C); (d)(1)(xxvii), (xxix), new (3)(i) and new (iii) added ........ 41876</td>
<td></td>
</tr>
<tr>
<td>(d)(3)(iv) added .................................................................................................. 45523</td>
<td></td>
</tr>
<tr>
<td>(d)(3)(ii), (iii) and (iv) redesignated as (d)(3)(iv), (vi) and (vii); (a)(3), (d)(1)(xx), (xxi), new (3)(ii), (iii) and (v) added ........................................... 70791</td>
<td></td>
</tr>
<tr>
<td>558.618 (d)(4) removed ...................................................................................... 76930</td>
<td></td>
</tr>
<tr>
<td>558.625 (a) amended; (f)(2)(v)(e) redesignated as (f)(1)(v)(e) ....................... 53582</td>
<td></td>
</tr>
<tr>
<td>(f)(2) revised ..................................................................................................... 65271</td>
<td></td>
</tr>
<tr>
<td>558.635 (d)(4) introductory text and (i) through (vii) revised ...................... 50135</td>
<td></td>
</tr>
<tr>
<td>573.920 (b) revised; (h) added ........................................................................ 35824</td>
<td></td>
</tr>
<tr>
<td>(b) corrected ................................................................................................. 53167</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>21 CFR</th>
<th>66 FR Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter I—Continued</td>
<td></td>
</tr>
<tr>
<td>510.600 (c)(1) table and (2) table amended ..................................... 7578, 13426, 13847, 14073, 15348, 17510, 22117, 22118, 23588, 32739, 36162, 49773, 46306, 46308, 46519, 47960, 56039, 63163, 63164, 63500, 66742</td>
<td></td>
</tr>
<tr>
<td>510.48 Revised ....................................................................................... 47960</td>
<td></td>
</tr>
<tr>
<td>510.309 (a) amended; (d) revised ......................................................... 63165</td>
<td></td>
</tr>
<tr>
<td>510.390a (b)(2) amended ......................................................................... 14073</td>
<td></td>
</tr>
<tr>
<td>510.45b (b) and (d)(4)(iii)(c) amended ..................................................... 35898</td>
<td></td>
</tr>
<tr>
<td>510.47 (b) amended ..................................................................................... 13848</td>
<td></td>
</tr>
<tr>
<td>510.540b (b)(2) amended ........................................................................... 14073</td>
<td></td>
</tr>
<tr>
<td>510.622a (a)(3) amended ........................................................................... 14073</td>
<td></td>
</tr>
<tr>
<td>510.622c (b)(4) amended ........................................................................... 14073</td>
<td></td>
</tr>
<tr>
<td>510.823 (b) amended ................................................................................. 14073</td>
<td></td>
</tr>
<tr>
<td>510.905b (b) amended ............................................................................... 47960</td>
<td></td>
</tr>
<tr>
<td>510.905c (b) amended ............................................................................... 47960</td>
<td></td>
</tr>
<tr>
<td>510.905d (b) amended ............................................................................... 47960</td>
<td></td>
</tr>
<tr>
<td>510.905e (b) amended ............................................................................... 47960</td>
<td></td>
</tr>
<tr>
<td>510.1010 Revised ......................................................................................... 47960</td>
<td></td>
</tr>
<tr>
<td>510.1010a Removed ....................................................................................... 47961</td>
<td></td>
</tr>
<tr>
<td>510.1010b Removed ....................................................................................... 47961</td>
<td></td>
</tr>
<tr>
<td>510.1010c Removed ....................................................................................... 47961</td>
<td></td>
</tr>
<tr>
<td>510.1195 (b) amended ............................................................................... 7579</td>
<td></td>
</tr>
<tr>
<td>(b), (c)(2) and (3) amended; (c) heading and (1) revised .................. 63166</td>
<td></td>
</tr>
<tr>
<td>510.1196 (b) amended ............................................................................... 35756</td>
<td></td>
</tr>
<tr>
<td>510.1310 (a) and (d) revised ................................................................. 46308</td>
<td></td>
</tr>
<tr>
<td>510.1484 (b) amended ............................................................................... 14073</td>
<td></td>
</tr>
<tr>
<td>510.1660d (b)(7) amended ........................................................................... 14073</td>
<td></td>
</tr>
</tbody>
</table>
### 21 CFR—Continued

<table>
<thead>
<tr>
<th>Paragraph</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>524.1195</td>
<td>7578</td>
</tr>
<tr>
<td>524.1446</td>
<td>13849</td>
</tr>
<tr>
<td>524.1451</td>
<td>46370</td>
</tr>
<tr>
<td>524.15800b</td>
<td>14974</td>
</tr>
<tr>
<td>524.2140</td>
<td>42731</td>
</tr>
<tr>
<td>524.2620</td>
<td>46369</td>
</tr>
<tr>
<td>524.2640</td>
<td>22117</td>
</tr>
<tr>
<td>529.1613</td>
<td>17510</td>
</tr>
<tr>
<td>529.1684</td>
<td>35544</td>
</tr>
<tr>
<td>529.1685</td>
<td>62917</td>
</tr>
<tr>
<td>529.175</td>
<td>62917</td>
</tr>
<tr>
<td>529.175</td>
<td>62917</td>
</tr>
<tr>
<td>529.175</td>
<td>62917</td>
</tr>
<tr>
<td>529.175</td>
<td>62917</td>
</tr>
<tr>
<td>529.175</td>
<td>62917</td>
</tr>
<tr>
<td>529.175</td>
<td>62917</td>
</tr>
<tr>
<td>529.175</td>
<td>62917</td>
</tr>
</tbody>
</table>
### List of CFR Sections Affected

#### 21 CFR—Continued

<table>
<thead>
<tr>
<th>CFR Section</th>
<th>Revised/Added</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>514 Authority citation revised</td>
<td></td>
<td>5057</td>
</tr>
<tr>
<td>514.1 OMB number</td>
<td></td>
<td>9586</td>
</tr>
<tr>
<td>514.3 Added; interim</td>
<td></td>
<td>5057</td>
</tr>
<tr>
<td>514.8 (a)(1), (5), and (ix) amended; (a)(6) revised; interim</td>
<td></td>
<td>5057</td>
</tr>
<tr>
<td>514.11 (a) amended; interim</td>
<td></td>
<td>5057</td>
</tr>
<tr>
<td>514.15 (b) amended; interim</td>
<td></td>
<td>5057</td>
</tr>
<tr>
<td>514.80 Added; interim</td>
<td></td>
<td>5057</td>
</tr>
<tr>
<td>520.309 (a) amended; (d)(1) revised</td>
<td></td>
<td>6866</td>
</tr>
<tr>
<td>520.1193 Revised</td>
<td></td>
<td>11230</td>
</tr>
<tr>
<td>520.1660d (a)(6), (d)(1)(ii)(A)(J), (B)(3), (C)(3) and (iii)(C) amended</td>
<td></td>
<td>5469</td>
</tr>
<tr>
<td>522.955 Section heading, (a), (d)(1)(i), (ii) and (iii) revised</td>
<td></td>
<td>6866</td>
</tr>
</tbody>
</table>

#### 21 CFR—Continued

<table>
<thead>
<tr>
<th>CFR Section</th>
<th>Revised/Added</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>522.970 (d) redesignated as (e); new (d) added; (a), (b), new (e)(1)(i), (iii), (2)(i) and (iii) revised</td>
<td></td>
<td>9400</td>
</tr>
<tr>
<td>522.1660d (d)(1)(iii) amended</td>
<td></td>
<td>12471</td>
</tr>
<tr>
<td>522.2477 (d)(2)(i)(C) added</td>
<td></td>
<td>5724</td>
</tr>
<tr>
<td>522.2680 (a), (d)(1)(i), (2)(i), (3)(i) and (ii) revised; (d)(4) added</td>
<td></td>
<td>6867</td>
</tr>
<tr>
<td>524.402 Revised</td>
<td></td>
<td>8860</td>
</tr>
<tr>
<td>529.40 Added</td>
<td></td>
<td>7072</td>
</tr>
<tr>
<td>530.41 (a)(7) and (8) amended</td>
<td></td>
<td>5471</td>
</tr>
<tr>
<td>556.760 (a) and (b) redesignated as (b)(1) and (2); new (b)(1) revised; (a) added</td>
<td></td>
<td>6867</td>
</tr>
<tr>
<td>558.600 Revised</td>
<td></td>
<td>7268</td>
</tr>
<tr>
<td>558.680 (a), (b) and (c) redesignated as (b), (c) and (d); new (a) added; new (b) revised; (d)(1) table amended</td>
<td></td>
<td>6868</td>
</tr>
</tbody>
</table>